<SEC-DOCUMENT>0001824293-25-000050.txt : 20250314
<SEC-HEADER>0001824293-25-000050.hdr.sgml : 20250314
<ACCEPTANCE-DATETIME>20250314170058
ACCESSION NUMBER:		0001824293-25-000050
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250314
DATE AS OF CHANGE:		20250314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GRI Bio, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		25741084

	BUSINESS ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(619) 400-1171

	MAIL ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GRI BIO, Inc.
		DATE OF NAME CHANGE:	20230424

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vallon Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20200910
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ck0001824293-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cc1569ea-7e88-4563-a591-58e791ad305a,g:efa7e1ac-5ebb-4c93-bc1b-10c7aab46343,d:73c3df21d6604995952be1876b1e93fe-->
<html xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ck0001824293="http://www.vallon-pharma.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ck0001824293-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-34">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-35">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-36">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-37">FY</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-31" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-257">0.0333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-32" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-258">0.1429</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-33" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-259">0.0769</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-34" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-260">0.0588</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-34" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-665">0.0588</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ck0001824293-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="closing"><xbrli:measure>ck0001824293:closing</xbrli:measure></xbrli:unit><xbrli:unit id="year"><xbrli:measure>ck0001824293:year</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-29</xbrli:startDate><xbrli:endDate>2024-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-14</xbrli:startDate><xbrli:endDate>2024-06-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-21</xbrli:startDate><xbrli:endDate>2025-02-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-20</xbrli:startDate><xbrli:endDate>2024-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-21</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-20</xbrli:startDate><xbrli:endDate>2024-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-26</xbrli:startDate><xbrli:endDate>2024-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesBCommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD2WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesDWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-21</xbrli:startDate><xbrli:endDate>2024-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:October2024PAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PriorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-21</xbrli:startDate><xbrli:endDate>2024-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ck0001824293:PeripheralEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:GRIOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:GRIOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-13</xbrli:startDate><xbrli:endDate>2022-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-21</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedAndSeriesCWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PriorWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInAugust2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMarch2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInSeptember2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029OneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029TwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:GRIOperationsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:GRIOperationsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ck0001824293:AardvarkTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-22</xbrli:startDate><xbrli:endDate>2023-08-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ck0001824293:StateTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ck0001824293:LocalTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i73c3df21d6604995952be1876b1e93fe_1"></div><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Mark&#160;One)</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal&#160;year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.538%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#168;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-40034</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">GRI BIO, INC.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">82-4369909</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of<br/>incorporation and organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">2223 Avenida de la Playa</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">#208</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">La Jolla</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-13">CA</ix:nonNumeric>&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">92037</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">619</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">400-1170</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:40.334%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.337%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">GRI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: None. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;&#160;Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. &#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).  &#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.317%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Non-accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-26">x</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-27">&#168;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="f-28">&#168;</ix:nonNumeric>  </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-29">&#168;</ix:nonNumeric></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to  &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). &#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#168;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-30">x</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2024 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), the aggregate market value of the registrant&#8217;s common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-31">1.5</ix:nonFraction>&#160;million based on the last reported sale price of the registrant&#8217;s common stock on The Nasdaq Capital Market on June 30, 2024.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 11, 2025, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-32">525,358</ix:nonFraction> shares of the Registrant&#8217;s common stock were outstanding. </span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-33" escape="true"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI BIO, INC.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page&#160;No.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_10">NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_13">RISK FACTOR SUMMARY</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_16">MARKET, INDUSTRY AND OTHER DATA</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:8pt"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_19">PART&#160;I&#160;</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_19">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_19">ITEM&#160;1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_22">BUSINESS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_22">1</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_25">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_25">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_25">&#160;1A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_28">RISK FACTORS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_28">35</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_31">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_31">TEM </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_31">1B.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_31">UNRESOLVED STAFF COMMENTS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_31">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_34">ITEM 1C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_34">CYBERSECURITY</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_34">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_37">ITEM&#160;2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_37">PROPERTIES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_37">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_40">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_40">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_40">&#160;3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_40">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_40">69</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_43">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_43">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_43">&#160;4.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_43">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_43">69</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_46">PART II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_46">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_49">ITEM&#160;5.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_49">MARKET FOR REGISTRAN</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_49">T</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_49">&#8217;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_49">S COMMON </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_49">EQUITY</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_49">, RELATED STOCKHOLDER MATTERS AND ISSUE PURCHASES OF EQUITY SECURITIES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_49">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_52">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_52">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_52">&#160;6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_52">[RESERVED]</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_52">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_55">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_55">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_55">&#160;7.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_55">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION</a>S</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_55">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_85">ITEM&#160;7A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_85">Q</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_85">UANTITATIVE AND QUALITATIVE DISCLO</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_85">S</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_85">URE ABOUT MARKET </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_85">RISK</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_85">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_88">ITEM 8.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_88">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_88">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">&#160;9.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">C</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">HANGES IN AND DISA</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">GREEMEN</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">TS WITH ACCOUNTANTS ON ACCOUNT</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">NG AND FINANCIAL DISCLO</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">SURE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_91">78</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_94">ITEM 9A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_94">CONTROLS AND PROCEDUR</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_94">ES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_94">79</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_97">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_97">TEM</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_97">&#160;9B.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_97">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_97">80</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_100">ITEM 9C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_100">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_100">80</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_103">PART III</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_103">81</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_106">ITEM 10.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_106">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_106">81</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_109">ITEM 11.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_109">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_109">87</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_112">ITEM 12.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_112">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_112">91</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_115">ITEM 13.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_115">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_115">92</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_118">ITEM 14.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_118">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_118">95</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_121">PART IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_121">97</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_124">ITEM 15.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_124">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_124">97</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_127">ITEM 16.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_127">FORM 10-K SUMMARY</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_127">99</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_130">SIGNATURE PAGE</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_130">100</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2024 (Annual Report) contains forward-looking statements that are based on management&#8217;s beliefs and assumptions and on information currently available to management. Some of the statements in the sections captioned &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; and elsewhere in this Annual Report contain forward-looking statements. In some cases, you can identify forward-looking statements by words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our history of losses and need for additional capital to fund our operations, our inability to obtain additional capital on acceptable terms, or at all, our ability to continue as a going concern, and our need to liquidate if we fail to obtain adequate funding, which could result in our stockholders receiving no value for their investment;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to remain listed on The Nasdaq Capital Market;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our limited operating history and the difficulties encountered by a small developing company;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expected restructuring-related cash outlays, including the timing and amount of those outlays;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of initiation of planned clinical trials;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the timing of any planned Investigational New Drug (INDs) or New Drug Applications (NDAs);</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">plans to research, develop, and commercialize current and future product candidates;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability to enter into new collaborations, and to fulfill obligations under any such collaboration agreements;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the clinical utility, potential benefits, and market acceptance of product candidates;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">commercialization, marketing, and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the ability to identify additional products or product candidates with significant commercial potential;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">developments and projections relating to our competitors and their industries;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the impact of government laws and regulations;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to protect our intellectual property position;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">estimates regarding future revenue, expenses, capital requirements, and need for additional financing; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any statements about the effect, or potential effect, of the reverse stock splits, including the February 2025 Reverse Stock Split (as defined below), on the price or trading of our common stock, par value $0.0001 per share (the Common Stock), on The Nasdaq Capital Market; and</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">statements of belief and any statement of assumptions underlying any of the foregoing.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in Part I, Item 1A. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and elsewhere in this Annual Report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Annual Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report to conform these statements to new information, actual results or to changes in our expectations, except as required by law. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read this Annual Report and the documents that we reference in this Annual Report and have filed with the U.S. Securities and Exchange Commission (the SEC) as exhibits to the Annual Report with the understanding that our actual future results, levels of activity, performance, and events and circumstances may be materially different from what we expect.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Annual Report, unless the context requires otherwise, the &#8220;Company,&#8221; &#8220;GRI Bio,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to GRI Bio, Inc.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_13"></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the principal risks described below in Part I, Item 1A. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in this Annual Report on Form 10-K. We believe that the risks described in the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section are material to investors, but other factors not presently known to us or that we currently believe are immaterial may also adversely affect us. The following summary should not be considered an exhaustive summary of the material risks facing us, and it should be read in conjunction with the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section and the other information contained in this Annual Report.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future. We have never been, and may never be, profitable.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations. </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our auditors have expressed substantial doubt about our ability to continue as a going concern, and we may not be able to continue as a going concern if we do not obtain additional financing.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Research and Development and the Pharmaceutical Industry</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our business is highly dependent on the success of our lead product candidate, GRI-0621, and any other product candidates that we may advance into clinical development. All of our product candidates will require significant additional development before we may be able to seek regulatory approval and launch a product commercially.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Clinical development involves a lengthy, complex, and expensive process, with an uncertain outcome. In addition, the results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Commercialization of Our Product Candidates</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Failure to obtain or maintain adequate reimbursement or insurance coverage for our approved product candidates, if any, could limit our ability to market those product candidates and decrease our ability to generate revenue.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Even if we obtain U.S. Food and Drug Administration (FDA) approval of any of our product candidates, if any, we may never obtain approval or commercialize these product candidates outside of the United States, which could limit our ability to realize their full market potential.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We currently have no marketing and sales organization and have no experience as a company in commercializing products. We would have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue from any of our product candidates that may be approved.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our relationships with healthcare providers, physicians, prescribers, purchasers, third-party payors, charitable organizations and patients will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Inadequate funding for the FDA, the SEC and/or other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may enter into license or other collaboration agreements in the future that may impose certain obligations on us. If we fail to comply with our obligations under such future agreements with third parties, we could lose license rights that may be important to our future business.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Third-party claims of intellectual property infringement may be costly and time consuming to defend, and could prevent or delay our product discovery, development and commercialization efforts.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We rely on third parties to conduct our clinical trials, manufacture our product candidates and perform other services. If these third parties do not successfully carry out their contractual duties, meet expected timelines or otherwise conduct the trials as required or perform and comply with regulatory or contractual requirements, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates when expected or at all, and our business could be substantially harmed.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Because we rely on third-party manufacturing and supply vendors, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may in the future seek to enter into collaborations with third parties for the development and commercialization of our product candidates, and our future collaborations will be important to our business. If we are unable to enter into collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Managing Our Business and Operations</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We may be unable to adequately protect our internal information systems, or those used by our CROs, clinical sites, or other contractors or consultants upon which we rely, from cyberattacks, compromises, cybersecurity incidents, or other disruptions, which could result in the compromise of sensitive or proprietary information, lead to operational or service interruption, harm our reputation, and subject us to litigation, fines and other significant financial and legal exposure, and other material and adverse consequences. </span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Financing, our Common Stock and Capital Requirements</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">We expect the stock price of our Common Stock to be highly volatile.</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Future sales and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.</span></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:18.3pt">The February 2025 Reverse Stock Split may have caused our stock price to decline relative to its value before the split and likely has reduced the liquidity of shares of our Common Stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_16"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKET, INDUSTRY AND OTHER DATA</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report contains estimates, projections and other information concerning our industry, our business and the markets for our drug candidates, including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set forth in this Annual Report from our internal estimates and research and from independent industry publications, governmental publications, reports by market research firms or other independent sources that we believe to be reliable sources. In some cases, we do not expressly refer to the sources from which this data is derived. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the industry in which we operate, and our management&#8217;s understanding of industry conditions. While we believe our internal research is reliable, it has not been verified by an independent source. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. We are responsible for all of the disclosure contained in this Annual Report, and we believe these industry publications and third-party research, surveys and studies are reliable. While we are not aware of any misstatements regarding any third-party information presented in this Annual Report, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; in this Annual Report, and elsewhere in this Annual Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="i73c3df21d6604995952be1876b1e93fe_22"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;BUSINESS. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural Killer T (iNKT) cells. GRI-0621 is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, that is approved in the United States for topical treatment of psoriasis and acne. As of December 31, 2024, it has been evaluated in over 1,700 patients as an oral product for up to 52-weeks. We are developing GRI-0621 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung that affects approximately 140,000 people in the United States, with up to 40,000 new cases per year in the United States. Some estimate that IPF affects 3 million people globally. While there are currently two approved therapies for the treatment of lung fibrosis, neither has been associated with improvements in overall survival, and both therapies have been associated with significant side effects leading to poor therapeutic adherence. In preliminary data from our trials to date with GRI-0621, and earlier trials with oral tazarotene, we have observed GRI-0621 to be well-tolerated and to inhibit iNKT cell activity in subjects. We and others have shown that activated iNKT are upregulated in IPF, primary sclerosing cholangitis (PSC), non-alcoholic steatohepatitis (NASH), alcoholic liver disease (ALD), systemic lupus erythematosus disease (SLE), multiple sclerosis (MS), ulcerative colitis (UC) patients, as well as other indications. In these patients activated iNKT cells are correlated with more severe disease. The U.S. Food and Drug Administration (FDA) has cleared our IND application for GRI-0621 for the treatment of IPF and we plan to evaluate GRI-0621 in a randomized, double-blind, multi-center Phase 2a biomarker study, for which we commenced enrollment in December 2023. Based on our current projections, we expect topline results from this trial to be available in the third quarter of 2025. Additionally, on March 1, 2024, we received authorization of our clinical trial application (CTA) from the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the United Kingdom. On September 24, 2024, we received approval from the Australian Human Research Ethics Committee (HREC) to initiate the Phase2a biomarker study evaluating GRI-0621 for the treatment of IPF in Australia, after previously receiving authorization on our CTA from the Australian MHRA. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells. We are developing GRI-0803 for the treatment of autoimmune disorders, with much of our preclinical work in SLE or lupus and MS. In lupus, the immune system mistakenly attacks its own healthy tissues, especially joints and skin, but can affect almost every organ and tissue of the body. The condition can be fatal, and often causes debilitating bouts of fatigue and pain that prevent nearly half of adult patients from working. Lupus affects between 160,000 - 200,000 patients in the United States, with around 80,000 &#8211; 100,000 patients in the United States suffering from kidney nephritis, one of the most serious manifestations of SLE, typically within five years of diagnosis. There is no cure for lupus, but medical interventions and lifestyle changes can help control it. SLE treatment consists primarily of immunosuppressive drugs that inhibit the activity of the immune system. Only two drugs have been approved for lupus in the past 50 years, and new treatment options are sorely needed. Subject to IND clearance, we intend to evaluate GRI-0803 in a Phase 1a and 1b trial initially targeting SLE. We expect to file an IND with respect to this Phase 1a and 1b trial in 2025. We will continue to evaluate indications to select the best fit for further development of the program, but our initial focus is on lupus.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have retained global development and commercialization rights to all of the product candidates in our pipeline. The chart below summarizes key information about our programs. We are also progressing several preclinical and clinical assets that have shown promise in preclinical models associated with disease.</span></div><div style="text-align:center"><img src="ck0001824293-20241231_g1.jpg" alt="Business1a.jpg" style="height:115px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 1. GRI&#8217;s pipeline - GRI-0621 and GRI-0803 </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our initial focus is developing GRI-0621 for the treatment of IPF. GRI-0621 is an oral formulation of tazarotene, a synthetic retinoid acid receptor (RAR) -beta and gamma selective agonist that is approved in the United States for topical treatment of psoriasis and acne. GRI-0621 inhibits the activity of iNKT cells that have been shown to accumulate in IPF patients and other interstitial lung disease patients. We, and others, have shown that activated iNKT cells are overexpressed in IPF, hepatic and other fibrotic conditions and are significantly correlated with advanced disease. We believe GRI-0621 has the potential to treat multiple fibrotic and related diseases, including other pulmonary fibrotic diseases, NASH, ALD, renal fibrosis, acute-on-chronic liver failure, drug-induced liver injury (DILI) and other acute indications. In numerous preclinical studies, inhibiting the activity of iNKT cells significantly reduced inflammation, activation of macrophage populations, transforming growth factor (TGF)-beta and fibrosis. There are currently no therapeutics approved that specifically target iNKT cells.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated GRI-0621 in a pilot Phase 2a trial in 14 hepatically impaired chronic liver disease patients. The study was originally intended to evaluate 60 patients, but we made the administrative decision to halt the study after enrolling 14 patients due to recruitment challenges and updated guidance from the FDA regarding the design of NASH clinical studies. In this limited number of patients, GRI-0621 was observed to be well-tolerated, however, the study was underpowered to meet its endpoints with statistical significance. In December 2023, we commenced enrollment in our Phase 2a trial in IPF patients and we expect topline results from this trial to be available in the third quarter of 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also developing GRI-0803, a novel orally administered activator of dNKT cells, from which we observed therapeutic benefit in multiple models of autoimmunity. We believe GRI-0803 has the potential to treat SLE and related kidney nephritis, MS, autoimmune hepatitis, and other autoimmune disorders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have a library of over 500 novel compounds acquired from JADO Technologies GmbH. The library was designed to mimic the structure and function of GRI-0124 (miltefosine), a potent activator of dNKT cells. GRI-0803 is the lead product candidate selected from the library.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are built upon decades of experience studying the activity of Natural Killer T (NKT) cells and their role in health and disease. Our company was founded by three immunologists, including an internationally recognized leader in NKT cell research who contributed to the initial characterization of NKT subsets, characterized the T cell receptor binding of iNKT and dNKT cells with their respective ligands and identified and characterized the role of iNKT and dNKT cells in inflammatory, fibrotic, and autoimmune disorders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our founders&#8217; and management&#8217;s experience provide unique insights into the activity of NKT cells and their role in chronic inflammatory, fibrotic, and autoimmune disorders. We are led by W. Marc Hertz, Ph.D., our President and Chief Executive Officer, a biotechnology executive who previously served as Chief Executive Officer of Pharmexa, Inc. and Multimeric Biotherapeutics, Inc. and as part of the senior management of Pharmexa A/S. Albert Agro, Ph.D., our Chief Medical Officer, has extensive experience in the biotechnology and pharmaceutical industries and previously held senior positions in global clinical development Boehringer Ingelheim International GmbH and Bayer Inc., as well as executive positions at Cynapsus Therapeutics Inc. (Chief Medical Officer), vTv Therapeutics Inc. (Sr. Vice President Development) and Sublimity Therapeutics Limited (Chief Executive Officer). Dr. Agro maintains a faculty appointment at McMaster University in the Department of Pathology and Molecular Medicine. Vipin Kumar Chaturvedi, Ph.D., our Chief Scientific Officer, is an internationally recognized leader in NKT cell research. GRI&#8217;s technologies are based on his work identifying NKT cell subsets and their differential roles in inflammatory, fibrotic, and autoimmune disease. Dr. Kumar is an Adjunct Professor at the University of California, San Diego, and former Professor of Medicine where he headed the Laboratory of Immune Regulation. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are supported by our board of directors (the Board) and clinical advisory boards and have been funded to date by family offices and leading life sciences investors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to become a leader in developing and commercializing therapeutics that target diseases with significant unmet needs. Our initial focus is on developing product candidates that target the activity of NKT cells and their role in driving dysregulated immune responses. Our strategy is focused on the following key components:</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Efficiently advance the clinical development of GRI-0621 in IPF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to conduct a randomized double-blind placebo-controlled Phase 2a trial in approximately 36 patients with IPF with topline data expected in the third quarter of 2025. This orphan disease is therapeutically underserved, and we believe that GRI-0621 may have the ability to become the first true disease-modifying therapy for these patients. Assuming a positive result in this trial, we plan to initiate a Phase 2b trial that could support an application for conditional approval of GRI-0621 in the European Union (the EU) and could have the potential to be regarded as a registrational trial in the United States. </span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Advance GRI-0803 through Phase 1a/1b studies initially targeting SLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to IND clearance, we intend to evaluate GRI-0803 in a Phase 1a and 1b trial initially targeting SLE. We expect to file an IND with respect to this trial in 2025.</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Leverage our understanding of iNKT and dNKT cells in disease and continue evaluating GRI-0621, GRI-0803, and additional product candidates in subsequent indications</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We intend to expand our leadership as a company dedicated to developing therapies that directly target the biological processes driving dysregulated immune responses. We also intend to selectively pursue business development opportunities to expand our product portfolio and supporting technologies.</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Continue to build a patient-focused company across a broad range of inflammatory, fibrotic and autoimmune diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In building a patient-focused company to address the needs of patients, we will work with clinicians, patient advocacy groups, medical centers of excellence, and medical key opinion leaders to better understand the symptoms and consequences of these diseases, to expeditiously develop and provide better treatments to patients, and to increase awareness of these diseases.</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19pt">Maximize the commercial value of our product candidates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have retained worldwide development and commercial rights for all our product candidates. We intend to commercialize any products in our portfolio for which we receive regulatory approvals in certain rare indications in the United States and the EU with a limited and targeted commercial team. We also intend to retain the flexibility to evaluate strategic collaborations and to seek partners to commercialize our products in other geographies and for our products in highly prevalent indications which require significant investment to build a commercial infrastructure.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NKT Cells and the Immune System </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach is founded on the discovery that NKT cells are a functional link between the innate and adaptive immune systems and that dysregulated immune responses can be reset by regulating the activity of NKT cells to potentially treat a broad array of acute and chronic conditions.</span></div><div style="text-align:center"><img src="ck0001824293-20241231_g2.jpg" alt="Business2a.jpg" style="height:151px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 2. NKT cells are innate-like T cells that bridge the adaptive and innate immune systems.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NKT cells are innate-like T cells that bridge the adaptive and innate immune systems (see Figure 2). They share properties of both NK and T cells, control the expression of key cytokines/chemokines, and are critical regulators of immune responses. iNKT cells are effector T cells that can play a pathogenic role in lung, liver, and autoimmune indications; while dNKT cells are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory T cells that inhibit the activity of iNKT cells, as well as other cell types, and support an anti-inflammatory response. dNKT cells can shift the response from a destructive pro-inflammatory and cytotoxic environment towards an anti-inflammatory and protective environment (see Figure 3) and are critical for minimizing the damage caused by inflammatory responses in certain fibrotic and autoimmune diseases. </span></div><div style="text-align:center"><img src="ck0001824293-20241231_g3.jpg" alt="Business3a.jpg" style="height:195px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 3. iNKT and dNKT cells have opposing roles in controlling inflammation (arrows in the left panel indicate activation and arrows in the right panel indicate inhibition).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repeated activation of iNKT cells can lead to chronic pulmonary diseases and are elevated in patients. Regulating iNKT cell activity has been observed to be therapeutic in animal models of IPF and activated iNKT cells accumulate in the lungs of IPF, NASH and SLE patients, as well as other chronic inflammatory, fibrotic, and autoimmune disease populations.</span></div><div style="text-align:center"><img src="ck0001824293-20241231_g4.jpg" alt="Business4a.jpg" style="height:197px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 4. Activated iNKT cells are increased in PBMC samples from IPF, MASH and SLE patients compared to healthy subjects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current IPF therapies slow the decline in lung function but do not improve overall survival. Regulating iNKT cell activity and their ability to promote macrophage polarization, TGF-beta production, and activation of myofibroblasts suggests they may reduce fibrosis progression and lead to improved survival outcomes in IPF. Activated iNKT cells are significantly upregulated in IPF patients and have the potential to be an important pharmacodynamic biomarker for these patients. We have observed that activated iNKT cells increase in patients with metabolic dysfunction-associated steatohepatitis (MASH) as the disease progresses from healthy individuals to mild non-alcoholic fatty liver disease and advanced MASH and believe iNKT may be a similar biomarker for IPF patients (see Figure 5).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="text-align:center"><img src="ck0001824293-20241231_g5.jpg" alt="Business5a.jpg" style="height:195px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 5. CXCR3+ IFN-gamma+ activated iNKT cells increase in MASH patients as disease progresses from healthy, mild to advanced disease.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In models of pulmonary, renal, and hepatic fibrosis - including IPF, SLE, MASH, ALD, DILI, and autoimmune hepatitis - iNKT cells play an important pathogenic role in mediating tissue damage by rapidly accumulating, becoming activated and secreting cytokines and chemokines for induction of a pro-inflammatory cascade that includes activation of the IL-1beta inflammasome and neutrophil recruitment, differentiation and activation of pro-fibrotic myofibroblasts / hepatic stellate cells, collagen deposition and fibrosis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI has also identified several modulators of dNKT cell activity, including cis-tetracosenoyl sulfatide (sulfatide), certain phospholipids, and GRI-0124. GRI-0803, as well as GRI&#8217;s library of over 500 compounds, are structurally related to GRI-0124. In vivo administration of GRI-0803 and GRI-0124 activates dNKT cells and inhibits the expansion of activated iNKT cells. Together, we believe these data support a model of iNKT inhibitors, such as GRI-0621, and dNKT modulators, such GRI-0803, as well as GRI-0124 and GRI-0729, working together to balance inflammatory immune responses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pulmonary Disease</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPF is a rare life-threatening disease characterized by progressive fibrosis and abnormal scarring that destroys the structure and function of the lungs over time by blocking the movement of oxygen into the bloodstream, leading to their deterioration and destruction. The most common symptoms of IPF are shortness of breath and a dry persistent cough. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Candidate Portfolio</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GRI-0621 for the treatment of IPF</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI-0621 is an oral gel capsule formulation of an FDA-approved topical dermatology product, tazarotene (ethyl 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate), a synthetic RAR-beta and gamma-selective agonist and potent inhibitor of iNKT cells. Tazarotene is approved in topical formulations for psoriasis and acne and has been evaluated in over 1,700 patients as an oral product dosed in subjects for up to 52-weeks. The Company is developing GRI-0621 for the treatment of IPF.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IPF background and market opportunity</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPF is the most common and severe form of progressive pulmonary fibrosis, affecting approximately 140,000 patients in the United States. Up to 40,000 new cases are diagnosed in the United States each year, primarily affecting individuals between the ages of 65 and 70, and prevalence in the United States is expected to rise with an aging population. The median survival is between two to three years after diagnosis, and the average life expectancy for patients with confirmed IPF is between three and five years. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current treatments for IPF and their limitations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some IPF patients with mild or moderate symptoms are treated with either nintedanib, marketed as OFEV by Boehringer Ingelheim Pharmaceuticals, Inc., or pirfenidone, marketed as Esbriet by Genentech USA, Inc. These drugs have been shown to slow progression of decrease in lung function associated with IPF and deterioration of pulmonary function, but neither drug has been associated with improvements in overall survival, and both have been associated with significant side effects. It is estimated that over 60% of patients dosed with nintedanib have diarrhea and approximately 14% experience elevated levels of liver enzymes. Approximately 30% of patients treated with pirfenidone have skin rash, and approximately 9% experience photosensitivity, both of which can lead to dose reductions or discontinuations. Both agents have some efficacy in patients with more advanced disease, but high rates of discontinuations due to adverse events in these frailer patients limit their use. A survey of 290 physicians published by a third-party in 2017 found that over half of IPF patients are not being treated with either agent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for multiple reasons, including physicians not having sufficient confidence in clinical benefit and concerns about safety. A retrospective cohort analysis of prescription records conducted by researchers at the Mayo Clinic and presented in 2019 found that the adoption of pirfenidone and nintedanib by IPF patients was approximately 10% for each therapy, supporting the earlier observation that the majority of IPF patients are not actively being treated. Despite this, total worldwide sales of pirfenidone and nintedanib in 2022 were $4.3 billion combined. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solution - GRI-0621</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing GRI-0621 as an oral gel capsule formulation to treat IPF patients. GRI-0621 is differentiated from current IPF therapies because it is designed to reset the dysfunctional immune response driving disease by inhibiting the activity of iNKT cells, as opposed to targeting a symptom of the disease that is downstream of the dysregulated immune response. GRI-0621 has been evaluated as an oral formulation in approximately 1,700 psoriasis, acne, and liver disease patients and in those patient populations and studies, the molecule was well-tolerated with typical reported adverse events associated with hypervitaminosis A (headache, back pain, foot pain, cheilitis, hyperglycemia, arthralgia, myalgia, joint disorder, nasal dryness, dry skin, rash, and dermatitis). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, animals lacking iNKT cells were observed to be protected from fibrosis in models of IPF, MASH, ALD, autoimmune liver disease, and DILI. Similarly, inhibiting the activity of iNKT cells can protect and/or treat animals from developing fibrosis. Fibrosis is a complex dynamic process involving several signaling molecules, differentiation pathways, and multiple cell types in different tissues. Thus, when the wound repair mechanism goes awry due to chronic inflammation/injury, this results in tissue scarring, stiffness and eventually malfunction. Despite its complexity, scientific literature suggests that there are common biological mechanisms that drive fibrosis in different tissues such as lung, liver, and kidney. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our preclinical studies, GRI-0621 administration in animal models of hepatic fibrosis was observed to inhibit secretion of pro-inflammatory cytokine secretion by iNKT cells (see Figure 6) and maturation and activation of pro-inflammatory Kupffer cells and pro-fibrogenic myofibroblasts/hepatic stellate cells (see Figures 7 and 10).</span></div><div style="text-align:center"><img src="ck0001824293-20241231_g6.jpg" alt="Business6a.jpg" style="height:356px;margin-bottom:5pt;vertical-align:text-bottom;width:403px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">__________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 6. GRI-0621 observed to inhibit in vivo expansion and activation of iNKT cells and inhibits pro-inflammatory cytokines in animal models of fibrosis.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="text-align:center"><img src="ck0001824293-20241231_g7.jpg" alt="Business7a.jpg" style="height:285px;margin-bottom:5pt;vertical-align:text-bottom;width:403px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">__________________</span></div><div style="margin-bottom:8pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 7. GRI-0621 observed to inhibit Kupffer cells and the activation and maturation of myofibroblasts / hepatic stellate cells.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistently, iNKT knock-out (KO) animals that lack iNKT cells were observed to fail to upregulate pro-fibrogenic genes relative to wild type animals (WT) in models of fibrosis (see Figure 8).</span></div><div style="text-align:center"><img src="ck0001824293-20241231_g8.jpg" alt="Business8a.jpg" style="height:291px;margin-bottom:5pt;vertical-align:text-bottom;width:403px"/></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">__________________</span></div><div style="margin-bottom:9pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 8. Inhibition of the key fibrogenic genes, including CTGF, observed in the iNKT-deficient animal model of fibrosis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the most important signaling molecules driving fibrogenesis is TGF-beta. In our models of pulmonary and hepatic, and renal fibrosis, functional inactivation of iNKT cells with iNKT inhibitors or dNKT cell activators led to a significant inhibition of this key mediator of fibrosis (see Figure 9). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="text-align:center"><img src="ck0001824293-20241231_g9.jpg" alt="Business9a.jpg" style="height:242px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">__________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 9. Inhibition of iNKT cells significantly reduced TGF-beta in models of pulmonary and hepatic fibrosis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our preclinical studies, a reduction in pro-inflammatory cytokines, Kupffer cells, activated myofibroblasts, pro-fibrogenic gene expression and the critical soluble mediator of fibrosis, TGF-beta, resulted in reduced collagen deposition and fibrosis in liver and lung models of fibrosis (see Figures 10, 11, and 12).</span></div><div style="text-align:center"><img src="ck0001824293-20241231_g10.jpg" alt="Business10a.jpg" style="height:210px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 10. Hepatic inflammation &amp; steatosis (H&amp;E), myofibroblast activation (anti-SMA) and fibrosis (Sirius Red) were inhibited (left histology panels and upper bar graphs) as well as IFN-gamma, TNF-alpha, and IL-2 (lower bar graphs) following GRI-0621 administration in the choline-deficient L-amino-defined model of MASH.</span></div><div style="text-align:center"><img src="ck0001824293-20241231_g11.jpg" alt="Business11a.jpg" style="height:214px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">__________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 11. iNKT inhibitors observed to prevent inflammation, inflammatory cytokines, and TGF-beta in a bleomycin model of pulmonary fibrosis.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="text-align:center"><img src="ck0001824293-20241231_g12.jpg" alt="Business12a.jpg" style="height:383px;margin-bottom:5pt;vertical-align:text-bottom;width:576px"/></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">__________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 12. GRI-0621 observed to improve lung injury (H&amp;E), myofibroblast activation (a-SMA) and fibrosis (Mason&#8217;s Trichrome and Sirius Red) in a bleomycin treatment model of pulmonary fibrosis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GRI-0621 Pilot Phase 2a Trial in Hepatically Impaired Subjects</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated GRI-0621 in a pilot Phase 2a trial in hepatically impaired chronic liver disease patients. The study was originally intended to evaluate 60 patients, but we made the administrative decision to halt the study after enrolling 14 patients due to recruitment challenges and updated guidance from the FDA regarding the design of non-alcoholic steatohepatitis (NASH) clinical studies. In this limited number of patients, GRI-0621 was observed to be well-tolerated and showed improvements in liver function tests, serum CK-18, and in iNKT cell activity, however, the study was underpowered to meet its endpoints with statistical significance. Adverse events were generally mild and consistent with RAR-beta and gamma agonism (see table below).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ALL-CAUSE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">PLACEBO (n=4)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GRI-0621 4.5mg (n=4)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">GRI-0621 6.0mg (n=5)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SERIOUS TEAEs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRADE 1 TEAEs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRADE 2 TEAEs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRADE 3/4/5 TEAEs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TREATMENT RELATED</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CHELITIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NASEAU</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DRY SKIN</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURITIS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HEADACHE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MYLAGIA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HYPERTENSION</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GASTROENTERITIS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TONSILITIS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CREATINE PHOSPHOKINASE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LACTATE DEHYDROGENASE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">POTASSIUM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0</span></td></tr></table></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*     Grade 2 treatment emergent adverse events (TEAE)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GRI-0621 Manufacturing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party contract manufacturers to manufacture GRI-0621 for preclinical studies and clinical trials, and do not own manufacturing facilities for producing any preclinical study or clinical trial product supplies. We rely on a limited number of suppliers for drug product and engage a single manufacturer to produce our formulated GRI-0621 drug product for clinical studies, as is standard industry practice in early to mid-stage clinical development. If these suppliers are unable to supply to us in the quantities we require, or at all, or otherwise default on their supply obligations to us, we may not be able to obtain alternative supplies from other suppliers on acceptable terms, in a timely manner, or at all.&#160;In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturer or manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GRI-0621 Phase 2a Trial in Patients with IPF</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023 we commenced enrollment for our Phase 2a trial. This trial will be a twelve-week, multicenter, multinational, randomized, placebo-controlled trial in approximately 36 patients with IPF. A 4.5 mg dose will be compared to placebo over twelve weeks of treatment in subjects with a confirmed diagnosis of IPF on background therapy. Subjects will complete a screening visit to evaluate their medical history, present condition, laboratory assessments, comorbidities, and concomitant medications. Based on these findings, subjects will be randomly assigned to one of two treatment arms: 4.5 mg of GRI-0621 or placebo in a 2:1 randomization. Weekly visits out to twelve weeks will evaluate safety, pharmacokinetics, and efficacy/mechanism of action of GRI-0621 as assessed by the activation of iNKT cells from both blood at weeks 6 and 12 and bronchi-alveolar lavage fluid at week 12. As a secondary endpoint, various biomarkers will also be evaluated to support the mechanism of action of GRI-0621. Subjects will be followed for at least two weeks after completion of dosing. Topline data from this trial should be available in the third quarter of 2025. Final results from this trial will be used to determine dose, safety sample size, clinically relevant endpoints, and duration in communication with the FDA in designing the registration program moving forward. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI-0803 for the Treatment of Lupus Nephritis Related to Systemic Lupus Erythematosus</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Systemic Lupus Erythematosus Disease Background</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SLE is the most common type of lupus, affecting between 160,000 - 200,000 patients in the United States, and as many as 24,000 people in the United States are diagnosed with the disease each year. SLE predominantly affects women and often starts between the ages of 15 and 44. SLE is an autoimmune disease in which the immune system attacks its own tissues, causing widespread inflammation and tissue damage in the affected organs. It can affect the joints, skin, brain, lungs, kidneys, and blood vessels. There is no cure for lupus, but medical interventions and lifestyle changes can help control it. While people of all races can have the disease, African American women have a three-times higher number of new cases than white, non-Hispanic women. African American women tend to develop the disease at a younger age than white, non-Hispanic women and develop more serious and life-threatening complications. It is also more common in women of Hispanic, Asian and Native American descent. Adherence to treatment regimens is often a problem, especially among young women of childbearing age. Because SLE treatment may require the use of strong immunosuppressive medications that can have serious side effects, female patients must stop taking the medication before and during pregnancy to protect unborn children from harm.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Treatments for SLE, their Limitations and Lupus Nephritis</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The treatment and management of SLE depends on disease severity and disease manifestations. Hydroxychloroquine plays a central role in the long-term treatment of SLE and is the cornerstone of SLE therapy. Corticosteroids, nonsteroidal anti-inflammatory drugs, and immunosuppressive agents (e.g., azathioprine, cyclophosphamide, cyclosporine, methotrexate, and mycophenolate mofetil) have also been used in the treatment and management of SLE. These treatments are only modestly effective and present safety and/or immune suppression concerns with prolonged use. The B cell-depleting antibody rituximab, while not approved for treatment of SLE, appears to be beneficial in certain subsets of patients.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Two targeted therapies for SLE have been approved by the FDA in the past 50 years, belimumab and anifrolumab. In 2011, the FDA approved belimumab (Benlysta&#174;), an antibody that targets B lymphocyte stimulator, for the treatment of mild to moderate SLE in combination with standard therapy, providing additional clinical validation of the therapeutic benefit of B cell-targeted therapy for autoimmune diseases. However, the modest therapeutic benefit of Benlysta&#174; and delayed onset of disease intervention indicate the need for additional therapeutic strategies to inhibit overactive B cells. In 2021, the first-in-class type 1 interferon receptor antibody, anifrolumab, the first new drug for the disease in a decade, was approved for adults with moderate to severe disease who are receiving standard therapy.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lupus nephritis is a common manifestation of SLE and can lead to irreversible renal impairment. This disease is complex, heterogeneous and involves multiple cell types as well as immune and non-immune mechanisms. Disease progression is characterized by glomerular injury, inflammation, cellular infiltration, and fibrosis. The deposition of immune complexes leads to inflammasome and type I interferon mediated pathways contributing to endothelial dysfunction in conjunction with complement-mediated injury owing to pathogenic antibodies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Solution - GRI-0803</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scientific studies have suggested that iNKT plays an important pathogenic role in kidney diseases, including acute kidney injury, ischemic reperfusion injury and lupus nephritis. Accordingly, iNKT cells were activated in peripheral blood of lupus patients (see Figure 4, above) and in spontaneous models of lupus. Notably, activation of dNKT leads to a dendritic cell-mediated inhibition of iNKT cells. In our preclinical studies, a dNKT activating molecule, GRI-0803, was observed to inhibit both murine and human iNKT cells. Oral administration of GRI-0803, a dNKT activating molecule, was observed to inhibit lupus nephritis and to significantly improve overall survival. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a weekly oral administration of GRI-0803 in a spontaneous model of lupus nephritis significant inhibition of pro-inflammatory cytokines, including IL-17 and IL-6 (see Figure 13) was observed. Other fibrogenic molecules, including TGF-beta, were also observed to be inhibited leading to blocking of collagen deposition and renal fibrosis (see Figure 14). This was observed to be accompanied by inhibition of cellular infiltration (including B cells and T cells) into the kidney and glomerular pathology. Furthermore, following GRI-0803 administration, significant inhibition of pathogenic anti-dsDNA antibodies, and proteinuria as measured in urine (see Figures 15 and 16) was observed. Additionally, GRI-0803 was observed to block activation of plasmacytoid dendritic cells and type I interferon signaling pathway genes involved in renal injury. Inhibition of renal disease was reflected in the improvement of overall survival of proteinuria-free animals.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lipocalin 2 (LCN2) is a glycoprotein secreted by several immune cells and promotes pro-inflammatory immune responses in autoimmune diseases and suggested to be an indicator of the severity of lupus nephritis. Interestingly, among other inflammatory genes, significant inhibition of LCN2 expression in the kidney was observed in animals orally treated with GRI-0803 in comparison to that in the control group (see Figure 13).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="text-align:center"><img src="ck0001824293-20241231_g13.jpg" alt="Business13a.jpg" style="height:268px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">__________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 13. Inhibition of several key pro-inflammatory, fibrotic and kidney disease promoting genes in a spontaneous lupus model observed following oral administration of GRI-0803.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="ck0001824293-20241231_g14.jpg" alt="Business14a.jpg" style="height:301px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">__________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 14. GRI-0803 administration observed to inhibit inflammatory cellular infiltration (H&amp;E), glomerular pathology (PAS), and kidney fibrosis (Trichrome) in a spontaneous lupus model. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="text-align:center"><img src="ck0001824293-20241231_g15.jpg" alt="Business15a.jpg" style="height:223px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 15. Observed inhibition anti-dsDNA antibodies in serum and increased overall survival in a lupus model following treatment with GRI-0803.</span></div><div style="text-align:center"><img src="ck0001824293-20241231_g16.jpg" alt="Business16a.jpg" style="height:254px;margin-bottom:5pt;vertical-align:text-bottom;width:489px"/></div><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">__________________</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Figure 16. Significant inhibition of proteinuria in urine and spontaneously occurring lupus nephritis observed in animals orally treated with GRI-0803. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GRI-0803 Manufacturing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party contract manufacturers to manufacture GRI-0803 for preclinical studies, and do not own manufacturing facilities for producing any preclinical study product supplies. We rely on a single or limited number of suppliers for drug product and engage a single manufacturer to produce our formulated GRI-0803 drug product for clinical studies, as is standard industry practice in early to mid-stage clinical development. If these suppliers are unable to supply to us in the quantities we require, or at all, or otherwise default on their supply obligations to us, we may not be able to obtain alternative supplies from other suppliers on acceptable terms, in a timely manner, or at all.&#160;In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturer or manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GRI-0803 Phase 1 Trial</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to initiate a Phase 1 trial upon completion of the toxicology program for GRI-0803. Assuming positive results, we anticipate filing an IND in 2025. The Single Ascending Dose (SAD) trial will be run in healthy volunteers. Up to six doses will be evaluated in cohorts of 12 subjects with 10 receiving a dose of GRI-0803 and two receiving placebo. The safety in each cohort will be evaluated with an Independent Safety Review Board (ISRB) along with the GRI clinical management. After completion of the first cohort, subsequent cohorts will begin within two weeks of dosing the previous cohort. Pharmacokinetics </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and safety will be the primary endpoint of the SAD trial. The completion of this trial should take approximately three months from when the first cohort is dosed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Multiple Ascending Dose (MAD) trial will begin upon the completion of Dose 3 in the SAD trial based on the recommendation of the ISRB. The MAD trial will examine four doses of GRI-0803 with doses dependent on the results of the SAD. A total of 10 subjects will be in each cohort: eight on GRI-0803 and two on placebo. Cohorts will be dosed for four weeks with two weeks of safety follow up post dosing with the first two cohorts being in healthy subjects and the two highest doses will be completed in patients with SLE. Safety and multi-dose pharmacokinetics will be the primary endpoint of the MAD trial. Exploratory outcomes will be examined in the third and fourth cohorts and will include several biomarkers (e.g., cytokines) as well as NKT cell activation markers. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competitive Landscape</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and biopharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our management team, clinical capabilities, research and development experience and scientific knowledge provide us with competitive advantages, we face increasing competition from many different sources, including biotechnology and biopharmaceutical companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are several large biotechnology and biopharmaceutical companies that are currently pursuing the development of products for the treatment of conditions GRI is also targeting, or may target in the future, including IPF, SLE, MS, UC, PSC and MASH. While we know of no other companies currently in clinical development targeting NKT cells as a method of treating any of the above conditions, companies that we are aware of that are targeting the treatment of these diseases include large companies with significant financial resources such as:</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IPF</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - AstraZeneca PLC, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline plc, Endeavor Biomedicines, Inc., Guangzhou JOYO Pharma Co., Ltd., InSilico Medicine Hong Kong Ltd., Pliant Therapeutics, Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., United Therapeutics Corp. and Vicore Pharma Holding AB.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SLE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Astellas Pharma Inc., AstraZeneca PLC, Aurinia Pharmaceuticals Inc., Biogen Inc., Bristol-Myers Squibb Co., Gilead Sciences, Inc., GlaxoSmithKline plc, Johnson &amp; Johnson, Nektar Therapeutics, Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A. and UCB S.A. Additional smaller companies with significant resources include Anthera Pharmaceuticals, Inc., Aurinia Pharmaceuticals Inc., ImmuPharma PLC, Kezar Life Sciences, Inc., Vera Therapeutics, Inc. and Viela Bio, Inc.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of our product candidates are likely to be efficacy, safety, cost, and convenience. Many of our competitors, either alone or with their collaborators, have significantly greater resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing, and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect the proprietary technology and information commercially or strategically important to our business. We seek to obtain and maintain, patent rights intended to cover the technologies incorporated into, or used to produce, our therapeutic candidates, the compositions of matter of our therapeutic candidates and their methods of use and manufacture, as well as other inventions that are important to our business. We also seek to obtain strategic or commercially valuable patent rights in the United States and other jurisdictions.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To cover our proprietary technologies and our current pipeline of proprietary products and related methods, such as methods of use, we have filed patent applications representing six patent families. As of February 28, 2025, our patent estate included 12 issued United States patents, two United States pending non-provisional patent applications, 75 issued foreign patents and 10 foreign patent applications currently pending in various foreign jurisdictions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we own one patent family with claims directed to GRI-0621, and related methods of using the same to treat diseases, e.g. inflammatory conditions. Three United States and 22 foreign patents (Australia, Brazil, Canada, China, Europe (validated in nine countries), Hong Kong, Japan, South Korea, Mexico, and Russia) were granted in this family. Patent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">applications in this family are pending in multiple jurisdictions, including, for example, the European Patent Organization and China. Patents in this patent family are expected to expire in 2032, absent any patent term adjustments or extensions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own one patent family with claims directed to GRI-0803 and related methods of using the same to treat diseases. Three United States and nine foreign patents (Canada, Europe (validated in seven countries), and Hong Kong) were granted in this family. Patent applications in this family are pending in the United States and European Patent Organization. Patents in this patent family are expected to expire in 2032, absent any patent term adjustment or extension. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we own one patent family relating to GRI-0729 and related methods of using the same to treat diseases. Four United States and 13 foreign patents (Canada, Europe (validated in 11 countries), and Hong Kong) have been granted in this family. Patents in this patent family are expected to expire in 2032, absent any patent term adjustment or extension. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own one patent family with claims directed to GRI-0124 and related methods of using the same to treat diseases. Fourteen foreign patents (Taiwan, Australia, China, Europe (validated in seven countries), Hong Kong, Israel, Mexico and Russia) were granted in this family. Patent applications in this family are pending, for example, in the United States, United Arab Emirates, Brazil, China, Japan, Russia, Canada, Hong Kong and South Korea. Patents in this patent family are expected to expire in 2035, absent any patent term adjustment or extension. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually assess and refine our intellectual property strategy as we develop new technologies and therapeutic candidates. As our business evolves, we may, among other activities, file additional patent applications in pursuit of our intellectual property strategy, to adapt to competition or to seize potential opportunities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the laws of the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing of a non-provisional patent application. However, the term of United States patents may be extended for delays incurred due to compliance with the FDA requirements or by delays encountered during prosecution that are caused by the United States Patent and Trademark Office (USPTO). For example, the Hatch-Waxman Act, permits a patent term extension for FDA-approved drugs of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our therapeutic candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those therapeutic candidates. We intend to seek patent term extensions in any jurisdiction where these are available and where we also have a patent that may be eligible; however there is no guarantee that the applicable authorities, including the USPTO and FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we expect to rely on data exclusivity, market exclusivity, patent term adjustment and patent term extensions when available. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation and Product Approval</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, clinical trials, testing, manufacture (including any manufacturing changes), authorization, pharmacovigilance, adverse event reporting, recalls, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products and product candidates such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">United States Government Regulation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions brought by the FDA and the Department of Justice (DOJ), or other governmental entities, such as the FDA&#8217;s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil and/or criminal penalties. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a new drug may be marketed in the United States generally involves the following: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">completion of nonclinical and preclinical studies, such as laboratory tests, potentially animal studies and formulation studies, in compliance with FDA regulations for Good Laboratory Practices (GLPs) and other applicable regulations; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">approval by an IRB covering each clinical site before a trial may be initiated; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">performance of adequate and well-controlled human clinical trials in accordance with good clinical practices (GCPs) to establish the safety and efficacy of the proposed drug product for each indication; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">submission to the FDA of an NDA with payment of application user fees, if applicable, and FDA acceptance of that NDA; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">satisfactory completion of an FDA advisory committee review, if applicable; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing practices (cGMPs) and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">satisfactory completion of audits of clinical trial sites conducted by FDA to assure compliance with GCPs and the integrity of clinical data; and </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">FDA review and approval of the NDA.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Studies</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical or nonclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as potential animal studies to assess potential safety and efficacy. The Consolidated Appropriations Act for 2023, signed into law on December 29, 2022, (P.L. 117-328) amended the FDCA to specify that nonclinical testing for drugs may, but is not required to, include in vivo animal testing. According to the amended language, a sponsor may fulfill nonclinical testing requirements by completing various in vitro assays (e.g., cell-based assays, organ chips, or microphysiological systems), in silico studies (i.e., computer modeling), other human or non-human biology-based tests (e.g., bioprinting), or in vivo animal tests.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical tests intended for submission to the FDA to support the safety of a product candidate must be conducted in compliance with GLP regulations and the U.S. Department of Agriculture&#8217;s Animal Welfare Act. A drug sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available ex-U.S. clinical data or relevant literature, among other things, to the FDA as part of an IND. Some nonclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the IND to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial (unless the consent requirement has been waived by an IRB) along with the requirement to ensure that the data and results reported from the clinical trials are credible and accurate. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the criteria for determining subject eligibility, the dosing plan, the parameters to be used in monitoring safety, the procedure for timely reporting of adverse events, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB must review and approve the plan for any clinical trial before it commences.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information about certain clinical trials and clinical trial results must be submitted within specific timeframes to the National Institutes of Health for public dissemination on the Clinicaltrials.gov registry. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the non-compliant </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">party from receiving future grant funds from the federal government. The government has brought enforcement actions against clinical trial sponsors that fail to comply with such requirements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. During Phase 1 clinical trials, sufficient information about the investigational drug&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 2:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The product candidate is administered to a larger, but still limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted indications and to determine dosage tolerance and optimal dosage. Phase 2 clinical trials are typically well-controlled and closely monitored.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Phase 3:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. Phase 3 clinical trials usually involve a larger number of participants than a Phase 2 clinical trial. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as &#8220;Phase 4&#8221; clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of &#8220;Phase 4&#8221; clinical trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are inherently uncertain, and Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Moreover, a given clinical trial may combine the elements of more than one phase and a company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted and reviewed. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate&#8217;s safety and efficacy such that it can be used, alone or with other pivotal or non-pivotal trials, to support regulatory approval. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need. In recent years, the FDA has been increasingly willing to exercise regulatory flexibility when determining the types, amount, and timing of data submissions to support the demonstration of a &#8220;substantial evidence of effectiveness,&#8221; which is the legal standard applicable to new drug approvals and is discussed further below. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress also recently amended the FDCA in order to require sponsors of a Phase 3 clinical trial, or other &#8220;pivotal study&#8221; of a new drug to support marketing authorization, to design and submit a diversity action plan for such clinical trial. The action plan must include the sponsor&#8217;s diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. Sponsors must submit a diversity action plan to the FDA by the time the sponsor submits the relevant clinical trial protocol to the agency for review. The FDA may grant a waiver for some or all of the requirements for a diversity action plan. If the FDA objects to a sponsor&#8217;s diversity action plan or otherwise requires significant changes to be made, it could potentially delay initiation of the relevant clinical trial.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interactions with FDA During the Clinical Development Program</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. Progress reports detailing the results of clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Specifically, sponsors may meet with the FDA prior to the submission of an IND (pre-IND meeting), at the end of Phase 2 clinical trial (EOP2 meeting) and before an NDA is submitted (pre-NDA meeting). Meetings at other times may also be requested. These meetings provide an opportunity for the sponsor to share information about the data gathered to date with the FDA and for the FDA to provide advice on the next phase of development. For example, at an EOP2, a sponsor may discuss its Phase 2 clinical results and present its plans for the pivotal Phase 3 clinical trial(s) that it believes will support the approval of the new product. Such meetings may be conducted in person, via teleconference/videoconference or written response only with minutes reflecting the questions that the sponsor posed to the FDA and the agency&#8217;s responses. The FDA has indicated that its </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">responses, as conveyed in meeting minutes and advice letters, only constitute recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acceptance of NDAs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#8217;s chemistry, manufacturing, controls, safety updates, patent information, abuse information and proposed labeling, are submitted to the FDA as part of an application requesting approval to market the product candidate for one or more indications. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of a drug product. The fee required for the submission and review of an application under the Prescription Drug User Fee Act (PDUFA) is substantial, and the sponsor of an approved application is also subject to an annual program fee assessed based on eligible prescription drug products. These fees are typically adjusted annually, and exemptions and waivers may be available under certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the applicant is a small business submitting its first human therapeutic application for review. Congress is required to re-authorize the agency&#8217;s user fee programs every five years, and current legislative provisions supporting the PDUFA program are set to expire on September 30, 2027.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of all applications within 60 days of receipt and must inform the sponsor at that time or before whether an application is sufficiently complete to permit substantive review. In pertinent part, the FDA&#8217;s regulations state that an application &#8220;shall not be considered as filed until all pertinent information and data have been received&#8221; by the FDA. In the event that the FDA determines that an application does not satisfy this standard, it will issue a Refuse to File (RTF) determination to the applicant. Typically, an RTF will be based on administrative incompleteness, such as clear omission of information or sections of required information; scientific incompleteness, such as omission of critical data, information or analyses needed to evaluate safety and efficacy or provide adequate directions for use; or inadequate content, presentation, or organization of information such that substantive and meaningful review is precluded. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review of NDAs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the current PDUFA goals and policies agreed to by the FDA, the agency has ten months from the filing date in which to complete its initial review of a standard application that is a new molecular entity, and six months from the filing date for an application with &#8220;priority review.&#8221; The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. Despite these review goals, the NDA review process can be very lengthy and it is not uncommon for FDA review of an application to extend beyond the PDUFA target action date. Most innovative drug products (other than biological products) obtain FDA marketing approval pursuant to an NDA submitted under Section 505(b)(1) of the FDCA, commonly referred to as a traditional or &#8220;full NDA.&#8221; In 1984, with passage of the Hatch-Waxman Act that established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs based on an innovator or &#8220;reference&#8221; product, Congress also enacted Section 505(b)(2) of the FDCA, which provides a hybrid pathway combining features of a traditional NDA and a generic drug application. Section 505(b)(2) enables the applicant to rely, in part, on the FDA&#8217;s prior findings of safety and efficacy data for an existing product, or published literature, in support of its application. Section 505(b)(2) NDAs may provide an alternate path to FDA approval for new or improved formulations or new uses of previously approved products that would require new clinical data to demonstrate safety or effectiveness. Section 505(b)(2) permits the filing of an NDA in which the applicant relies, at least in part, on information from studies made to show whether a drug is safe or effective that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. A Section 505(b)(2) applicant may eliminate or reduce the need to conduct certain preclinical or clinical studies, if it can establish that reliance on studies conducted for a previously-approved product is scientifically appropriate. The FDA may also require companies to perform additional studies or measurements, including nonclinical and clinical studies, to support the change from the approved product. The types of studies and extent of data necessary to establish the safety and/or effectiveness of the new product, such as the effects of changing the drug&#8217;s route of administration from topical to oral, are scientifically driven and determined on a case-by-case basis. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new indication for which the Section 505(b)(2) NDA applicant has submitted data.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its review of an application, the FDA will typically submit information requests to the applicant and set deadlines for responses thereto. The FDA will also conduct a pre-approval inspection of the manufacturing facilities for the new </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product to determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMPs and are adequate to assure consistent production of the product within required specifications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND and GCP requirements and the integrity of the clinical data submitted to the FDA. To ensure compliance with cGMPs and GCPs by its employees and third-party contractors, an applicant may incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control. The FDA generally accepts data from foreign clinical trials in support of an NDA if the trials were conducted under an IND. If a foreign clinical trial is not conducted under an IND, the FDA nevertheless may accept the data in support of an NDA if the study was conducted in accordance with GCPs and the FDA is able to validate the data through an on-site inspection, if deemed necessary. Although the FDA generally requests that marketing applications be supported by some data from domestic clinical trials, the FDA may accept foreign data as the sole basis for marketing approval if (1) the foreign data are applicable to the United States population and United States medical practice, (2) the studies were performed by clinical investigators with recognized competence, and (3) the data may be considered valid without the need for an on-site inspection or, if the FDA considers the inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA may refer an application, including applications for novel product candidates which present difficult questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from clinical trials are not always conclusive, and the FDA or its advisory committee may interpret data differently than the sponsor interprets the same data. The FDA may also re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process or delay, limit or prevent regulatory approval. The FDA may not grant approval on a timely basis, or at all.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a risk evaluation and mitigation strategy (REMS) if it determines that a REMS is necessary to ensure that the benefits of the drug product outweigh its risks and to assure the safe use of the product. The REMS could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS and the FDA will not approve the application without a REMS.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Decisions on NDAs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews an application to determine, among other things, whether the product is safe and whether it is effective for its intended use(s), with the latter determination being made on the basis of substantial evidence. The term &#8220;substantial evidence&#8221; is defined under the FDCA as &#8220;evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the product involved, on the basis of which it could fairly and responsibly be concluded by such experts that the product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has interpreted this evidentiary standard to require at least two adequate and well-controlled clinical investigations to establish effectiveness of a new product. Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard. This approach was subsequently endorsed by Congress in 1998 with legislation providing, in pertinent part, that &#8220;If [the FDA] determines, based on relevant science, that data from one adequate and well-controlled clinical investigation and confirmatory evidence (obtained prior to or after such investigation) are sufficient to establish effectiveness, the FDA may consider such data and evidence to constitute substantial evidence.&#8221; This modification to the law recognized the potential for the FDA to find that one adequate and well controlled </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical investigation with confirmatory evidence, including supportive data outside of a controlled trial, is sufficient to establish effectiveness. In December 2019, the FDA issued draft guidance further explaining the studies that are needed to establish substantial evidence of effectiveness. In September 2023, the agency supplemented and expanded the recommendations in the 2019 &#8220;substantial evidence of effectiveness&#8221; draft guidance with a second draft guidance entitled &#8220;Demonstrating Substantial Evidence of Effectiveness Based on One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence.&#8221; The second document complements the first by providing further detail on the use of data drawn from one or more sources (e.g., clinical data, mechanistic data, animal data) in order to support the results of one adequate and well-controlled clinical investigation and provides examples of types of data that could be considered confirmatory evidence. Due to the case-by-case nature of such determinations, the FDA continues to emphasize the need for sponsors to engage early with the agency if they intend to establish substantial evidence of effectiveness with one adequate and well-controlled clinical investigation plus confirmatory evidence.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a Complete Response Letter (CRL) or an approval letter. To reach this determination, the FDA must determine that the drug is effective and that its expected benefits outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the product&#8217;s safety and efficacy in the NDA. This assessment is also informed by other factors, including: the severity of the underlying condition and how well patients&#8217; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks. In connection with this assessment, the FDA review team will assemble all individual reviews and other documents into an &#8220;action package,&#8221; which becomes the record for FDA review. The review team then issues a recommendation, and a senior FDA official makes a decision.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time- consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the applicant an additional six-month extension to respond. The FDA has committed to reviewing resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. That is, the approval will be limited to the conditions of use (e.g., patient population, indication) described in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Special FDA Expedited Review Programs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to designate certain products for expedited development or review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation, and priority review designation. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides additional opportunities for interaction with the FDA&#8217;s review team and may allow for a rolling review of NDA components before the completed application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. In addition, fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging in the clinical trial process. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, with the enactment of the FDA Safety and Innovation Act (FDASIA) in 2012, Congress created a new regulatory program for therapeutic candidates designated by the FDA as &#8220;breakthrough therapies&#8221; upon a request made by the IND sponsors. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA must take certain actions with respect to breakthrough therapies, such as holding timely meetings with and providing advice to the product sponsor, intended to expedite the development and review of an application for approval of a breakthrough therapy.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, the FDA may designate a product for priority review if it is a drug that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the proposed drug represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months for an NDA for a new molecular entity from the date of filing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, breakthrough therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval process.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerated Approval Pathway</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a product studied for its safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, meaning that it may be approved on (i) the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or (ii) on an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM) and that is reasonably likely to predict an effect on IMM or other clinical benefits, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on IMM or other clinical endpoints, and the drug may be subject to expedited withdrawal procedures. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. All promotional materials for drug products being considered and approved under the accelerated approval program are subject to prior review by the FDA.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long-term clinical benefit of a drug.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of drugs for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. In addition, as part of the Consolidated Appropriations Act for 2023, Congress provided FDA additional statutory authority to mitigate potential risks to patients from continued marketing of ineffective drugs previously granted accelerated approval. Under these amendments to the FDCA, the agency may require a sponsor of a product granted accelerated approval to have a confirmatory trial underway prior to approval. The sponsor must </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also submit progress reports on a confirmatory trial every six months until the trial is complete, and such reports will be published on FDA&#8217;s website. Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during post-marketing studies, would allow the FDA to withdraw approval of the drug. Congress also recently amended the law to give FDA the option of using expedited procedures to withdraw product approval if the sponsor&#8217;s confirmatory trial fails to verify the claimed clinical benefits of the product. All promotional materials for drug products being considered and approved under the accelerated approval program are subject to prior review by the FDA. Prior to the recent statutory amendments enacted by Congress, several oncology sponsors voluntarily withdrew specific indications for their drug products that were being marketed pursuant to accelerated approval. More recently, in February 2024 the FDA announced its first use of the law&#8217;s amended procedures to withdraw an accelerated approval following the drug&#8217;s confirmatory study failing to verify clinical benefit. Scrutiny of the accelerated approval pathway is likely to continue in the coming years and may lead to further legislative and/or administrative changes in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Approval Requirements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. Certain modifications to the product, including changes in indications or manufacturing processes or facilities, may require the applicant to develop additional data or conduct additional preclinical studies and clinical trials to support the submission to FDA. As previously noted, there also are continuing, annual user fee requirements for any marketed products, as well as new application fees for supplemental applications with clinical data. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMPs include requirements relating to the organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and some state agencies and are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other laws. Changes to the manufacturing process are strictly regulated and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers. Accordingly, manufacturers must continue to expend time, money, and effort in production and quality control to maintain compliance with cGMPs and other aspects of quality control and quality assurance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates the marketing, labeling, advertising and promotion of drug products that are placed on the market. A product cannot be commercially promoted before it is approved, and approved drugs may generally be promoted only for their approved indications and for use in patient populations described in the product&#8217;s approved labeling. Promotional claims must also be consistent with the product&#8217;s FDA-approved label, including claims related to safety and effectiveness. The government closely scrutinizes the promotion of prescription drugs in specific contexts such as direct-to-consumer advertising, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. Although physicians may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The FDA has recently published a draft guidance outlining modernized recommendations for how drug manufacturers can share truthful, scientifically sound, and clinically relevant information on unapproved uses with health care providers.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences of regulatory non-compliance include, among other things:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on, or suspensions of, the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of production processes, including the shutdown of manufacturing facilities or production lines or the imposition of new manufacturing requirements; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or other enforcement letters or clinical holds on post-approval clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated modification of promotional materials and labeling and the issuance of corrective information; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties; or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA) which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act (the DSCSA) was enacted in 2013 with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the United States. The DSCSA mandated and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a 10-year period that was designed to culminate in November 2023. However, the FDA announced a one-year &#8220;stabilization period&#8221; until November 2024, followed by trading partner-specific exemptions through specified dates in 2025, to accommodate additional time that trading partners in the pharmaceutical supply chain needed in order to fully implement DSCSA requirements for electronic drug tracing at the package level.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. For example, FDA released proposed regulations in February 2022 to amend the national standards for licensing of wholesale drug distributors by the states; establish new minimum standards for state licensing third-party logistics providers; and create a federal system for licensure for use in the absence of a State program, each of which is mandated by the DSCSA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Exclusivity and Approval of Follow-on Products</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Exclusivity </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to enacting Section 505(b)(2) of the FDCA as part of the Hatch-Waxman Amendments to the FDCA, Congress also established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (ANDA) to the agency. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, bioequivalence, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are &#8220;abbreviated&#8221; because they cannot include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support of such applications, a generic manufacturer must rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug (RLD).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, the strength of the drug and the conditions of use of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to an RLD if &#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221; Unlike the 505(b)(2) NDA pathway that permits a follow-on applicant to conduct and submit data from additional clinical trials or nonclinical studies in order to support the proposed change(s) to the reference product, the ANDA regulatory pathway does not allow applicants to submit new clinical data other than bioavailability or bioequivalence data. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider a therapeutically equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. Given the importance of such Orange Book designations to the practice of pharmacy, Congress recently directed FDA to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">perform therapeutic equivalence evaluations for certain 505(b)(2) drugs no later than six months after approval when the applicant requests such an evaluation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As part of the NDA review and approval process, applicants are required to list with the FDA each patent that has claims that cover the applicant&#8217;s product or method of therapeutic use. Upon approval of a new drug, each of the patents listed in the application for the drug is then published in the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential follow-on competitors in support of approval of an ANDA or 505(b)(2) NDA. FDA&#8217;s role in this process is purely &#8220;ministerial&#8221; and it does not review or assess the claims within each patent to determine whether they cover the drug product or its approved method of use. Patents that may fall outside the scope of what the FDCA and FDA&#8217;s implementing regulations define as needing to be listed by the NDA holder are periodically challenged by competitors and other stakeholders, either through FDA&#8217;s administrative challenge process or in the court system as anticompetitive or unfair behavior. In particular, the Federal Trade Commission (FTC) issued a policy statement in September 2023 indicating that it would be scrutinizing the &#8220;improper&#8221; submission of patents for listing in the Orange Book on the basis that such listings may harm competition from cheaper generic alternatives and keep brand prices artificially high. The FTC followed that action in November 2023 by publicly calling out over 100 &#8220;improper&#8221; patent listings made by ten large pharmaceutical companies and initiating an FDA administrative process with respect to those patents. The controversy regarding the appropriateness of listing such patents has led to numerous lawsuits alleging anticompetitive conduct by biopharmaceutical companies. It is unclear whether the FTC, under the Trump Administration, will continue to prioritize the policy issue of &#8220;improper&#8221; patent listings or whether Congress may take any legislative actions related to this issue.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an ANDA applicant submits its application to the FDA, it is required to certify to the FDA concerning any patents listed for the reference product in the FDA&#8217;s Orange Book. Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is invalid or will not be infringed by the new product. Moreover, to the extent that the Section 505(b)(2) NDA applicant is relying on studies conducted for an already approved product, the applicant also is required to certify to the FDA concerning any patents listed for the NDA-approved product in the Orange Book to the same extent that an ANDA applicant would. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the follow-on applicant does not challenge the innovator&#8217;s listed patents, the FDA will not approve the ANDA or 505(b)(2) application until all the listed patents claiming the referenced product have expired. A certification that the new product will not infringe the already approved product&#8217;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the follow-on applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA or 505(b)(2) NDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA or 505(b)(2) applicant. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivities listed in the Orange Book for the referenced product have expired. The Hatch-Waxman Amendments to the FDCA provided a five-year period of non-patent data exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity (NCE). For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA or 505(b)(2) NDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA also provides for a period of three years of data exclusivity if an NDA or NDA supplement includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as new indications, dosage forms, route of administration or combination of ingredients. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs or 505(b)(2) NDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product; rather, this three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA from approving follow-on applications for drugs containing the original active ingredient. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Five-year and three-year exclusivity also will not delay the submission or approval of a traditional NDA filed under Section 505(b)(1) of the FDCA; however, an applicant submitting a traditional NDA would be required to conduct or obtain a right of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation and Exclusivity</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects either (i) fewer than 200,000 individuals in the United States, or (ii) more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Legislative proposals to revise or revoke the second option available for a product candidate to receive an orphan designation, the so-called &#8220;cost recovery&#8221; pathway, are periodically considered by Congress. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use will be disclosed publicly by the FDA; the posting will also indicate whether a drug is no longer designated as an orphan drug. Recent court cases have challenged the FDA&#8217;s approach to determining the scope of orphan drug exclusivity; however, at this time the agency continues to apply its long-standing interpretation of the governing regulations and has stated that it does not plan to change any orphan drug implementing regulations. Congress may also act to amend the law in this area at some point in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More than one product candidate may receive an orphan drug designation for the same indication, and the same product candidate can be designated for more than one qualified orphan indication. The benefits of orphan drug designation include research and development tax credits and exemption from FDA prescription drug user fees. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process if or when an NDA for the product candidate is filed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product that has orphan drug designation subsequently receives the first FDA approval for the indication for which it has such designation, the product is entitled to orphan product exclusivity, which means that for seven years, the FDA may not approve any other marketing applications for the same drug for the same indication, except under limited circumstances described further below. Orphan exclusivity does not block the approval of a different drug for the same rare disease or condition, nor does it block the approval of the same drug for different conditions. As a result, the FDA can still approve different drugs for use in treating the same indication or disease. Additionally, if a drug designated as an orphan product receives marketing approval for an indication broader than what was designated, it may not be entitled to orphan drug exclusivity.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan exclusivity will not bar approval of another product with the same drug for the same condition under certain circumstances, including if a subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety or a major contribution to patient care, or if the company with orphan drug exclusivity cannot assure the availability of sufficient quantities of the drug to meet the needs of persons with the disease or condition for which the drug was designated. The FDA is now required to publish a summary of the clinical superiority findings when a drug is eligible for orphan product exclusivity on the basis of a demonstration of clinical superiority.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA has finalized guidance indicating that it does not expect to grant any additional orphan drug designation to products for pediatric subpopulations of common diseases. Nevertheless, FDA intends to still grant orphan drug designation to a drug that otherwise meets all other criteria for designation when it prevents, diagnoses or treats either (i) a rare disease that includes a rare pediatric subpopulation, (ii) a pediatric subpopulation that constitutes a valid orphan subset, or (iii) a rare disease that is, in fact, a different disease in the pediatric population as compared to the adult population.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent Term Extension</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent claiming a prescription drug for which FDA approval is granted may be eligible for a limited patent term extension under the FDCA, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review provided that certain statutory and regulatory requirements are met. The length of the patent term extension is related to the length of time the drug is under regulatory review while the patent is in force. The restoration period granted on a patent covering a new FDA-regulated medical product is typically one-half the time between the date a clinical investigation on human beings is begun and the submission date of an application for premarket approval of the product, plus the time between the submission date of an application for approval of the product and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">sought can only be extended in connection with one of the marketing approvals. The USPTO reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Exclusivity</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Best Pharmaceuticals for Children Act (BPCA), certain therapeutic candidates may obtain an additional six months of exclusivity if the sponsor submits information requested in writing by the FDA, referred to as a &#8220;Written Request,&#8221; relating to the use of the active moiety of the product candidate in children. The data do not need to show the product to be effective in the pediatric population studied; rather, the additional protection is granted if the pediatric clinical trial is deemed to have fairly responded to the FDA&#8217;s Written Request. Although the FDA may issue a Written Request for studies on either approved or unapproved indications, it may only do so where it determines that information relating to that use of a product candidate in a pediatric population, or part of the pediatric population, may produce health benefits in that population. The issuance of a Written Request does not require the sponsor to undertake the described trials.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Congress periodically considers enacting new incentives or mandates applicable to pediatric drug development, and the regulatory requirements applicable to pediatric drug developers may change in the future. For example, bipartisan legislation introduced in the House of Representatives during the last congressional session (2023-2024) would have increased funding for pediatric trials; mandated that drugs for rare diseases be studied in children; and granted FDA authority to assess penalties against companies that do not complete required pediatric studies.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other U.S. Healthcare Laws and Regulations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing, sales, promotion and other activities following product approval may also be subject to regulation by other regulatory authorities in the United States in addition to the FDA. Depending on the nature of the product, those authorities may include the Centers for Medicare &amp; Medicaid Services (CMS), other divisions of the Department of Health and Human Services (HHS), the DOJ, the FTC, the Drug Enforcement Administration, the Occupational Safety and Health Administration, and state and local governments.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in the United States, sales and marketing for prescription biopharmaceutical products must comply with state and federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute (AKS), which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by imprisonment, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, the Patient Protection and Affordable Care Act (ACA), among other things, amended the intent requirement of the federal AKS and two of the five criminal healthcare fraud statutes created by Health Insurance Portability and Accountability Act (HIPAA). A person or entity no longer needs to have actual knowledge of these two provisions in the statute or specific intent to violate them; specifically with respect to the prohibition on executing or attempting to execute a scheme or artifice to defraud or to fraudulently obtain money or property of any healthcare benefit program and the prohibition on disposing of assets to enable a person to become eligible for Medicaid. Moreover, the government may now assert that a claim including items or services resulting from a violation of the federal AKS constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. There also are federal transparency requirements under the Physician Payments Sunshine Act that require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to CMS information related to payments and other transfers of value to physicians, teaching hospitals, and certain advanced non-physician healthcare practitioners and physician ownership and investment interests. Prescription drug products also must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines, or the relevant compliance guidance promulgated by the federal government, in addition to requiring drug manufacturers to report information related to payments to physicians and other healthcare providers or </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing expenditures to the extent that those laws impose requirements that are more stringent than the Physician Payments Sunshine Act. State, federal, and foreign laws, including the Federal Trade Commission Act, also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Regulation Outside the United States</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to regulations in the United States, we will be subject to a variety of foreign regulations that govern, among other things, clinical trials and any commercial sales and distribution of our products, if approved, either directly or through distribution partners. Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities in foreign countries or economic areas, such as the EU, Canada, and the United Kingdom, among other foreign countries, before we may commence clinical trials or market products in those countries or areas. The foreign regulatory approval process includes all of the risks associated with the FDA approval described above, and the time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Some foreign jurisdictions have a drug product approval process similar to that in the United States, which requires the submission of a clinical trial application much like the IND prior to the commencement of clinical studies. In Europe, for example, a CTA must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. To obtain regulatory approval of a medicinal product candidate under EU regulatory systems, we would be required to submit a Marketing Authorisation Application (MAA), which is similar to the NDA, except that, among other things, there are country-specific document requirements. For countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, and recently the United Kingdom, the requirements governing the conduct of clinical trials, product approval, pricing and reimbursement vary from country to country. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. Moreover, some nations may not accept clinical studies performed for United States approval to support approval in their countries or require that additional studies be performed on natives of their countries. In addition, in certain foreign markets, the pricing of drug products is subject to government control and reimbursement may in some cases be unavailable or insufficient. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2020, the United Kingdom is no longer a member state of the EU, and therefore a separate marketing authorization application and approval will be required to market a medicinal product in the United Kingdom. The MHRA is the United Kingdom&#8217;s standalone pharmaceutical regulator.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trials and Regulation of Medicinal Products in Europe</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, medicinal products can be marketed in the EU only if a marketing authorization from the competent regulatory agencies has been obtained. Similar to the United States, the various phases of preclinical and clinical research in the EU are subject to significant regulatory controls. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the European Clinical Trials Directive, a system for the approval of clinical trials in the EU has been implemented through national legislation of the member states. Under this system, an applicant must obtain approval from the competent national authority of a EU member state in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial after a competent ethics committee has issued a favorable opinion. Clinical trial applications must be accompanied by an investigational medicinal product dossier with supporting information prescribed by the European Clinical Trials Directive and corresponding national laws of the member states and further detailed in applicable guidance documents. In April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation), was adopted and became effective on January 31, 2022. The Clinical Trials Regulation is directly applicable in all the EU Member States, repealing the prior Clinical Trials Directive 2001/20/EC. The extent to which ongoing clinical trials will be governed by the Clinical Trials Regulation will depend on the duration of the individual clinical trial; if a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial. In addition, use of the new EU-wide application procedure being implemented via the Clinical Trial Information System (CTIS) became mandatory for new clinical trial application submissions as of February 1, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single entry point; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain marketing approval of a drug in the EU, an applicant must submit a MAA either under a centralized or decentralized procedure. The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU member states, Iceland, Lichtenstein and Norway. The centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products (such as gene-therapy, somatic cell-therapy or tissue-engineered medicines) and products with a new active substance indicated for the treatment of certain diseases. For products with a new active substance indicated for the treatment of certain diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the European Medicines Agency (EMA) is 210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee for Medicinal Products for Human Use (CHMP). Accelerated assessment might be granted by the CHMP in exceptional cases, when a medicinal product is expected to be of a major public health interest, particularly from the point of view of therapeutic innovation. The timeframe for the evaluation of an MAA under the accelerated assessment procedure is of 150 days, excluding stop-clocks.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized procedure is available to applicants who wish to market a product in specific EU member states where such product has not received marketing approval in any EU member states before. The decentralized procedure provides for an applicant to apply to one-member state to assess the application (the reference member state) and specifically list other member states in which it wishes to obtain approval (concerned member states). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, only products for which marketing authorizations have been granted may be promoted. A marketing authorization is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the EU market (in case of centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, even if authorized to be marketed in the EU, prescription medicines may only be promoted to healthcare professionals, not the general public. All promotion should be in accordance with the particulars listed in the summary of product characteristics. Promotional materials must also comply with various laws, and codes of conduct developed by pharmaceutical industry bodies in the EU which govern (among other things) the training of sales staff, promotional claims and their justification, comparative advertising, misleading advertising, endorsements, and (where permitted) advertising to the general public. Failure to comply with these requirements could lead to the imposition of penalties by the competent authorities of the EU member states. The penalties could include warnings, orders to discontinue the promotion of the drug product, seizure of promotional materials, fines and possible imprisonment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the European Commission issued a proposal that will revise and replace the existing general pharmaceutical legislation. If adopted and implemented as currently proposed, these revisions will significantly change several aspects of drug development and approval in the EU.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of New Drugs in the United Kingdom</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom left the EU on January 31, 2020 (commonly referred to as &#8220;Brexit&#8221;), with a transitional period that expired on December 31, 2020. The United Kingdom and the EU entered into a trade agreement known as the Trade and Cooperation Agreement, which went into effect on January 1, 2021. We are currently evaluating the potential impacts on our business of the Trade and Cooperation Agreement and guidance issued to date by the United Kingdom&#8217;s MHRA regarding the requirements for licensing and marketing medicinal products in the United Kingdom. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of medicinal products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to such products and the approval of product candidates in the United Kingdom. Such outcomes could make it more difficult and expensive for us to do business in Europe, complicate our clinical, manufacturing and regulatory strategies and impair our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to obtain and maintain regulatory approval for, and, if approved, commercialize, our products and product candidates in Europe.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">More recently, in March 2023, the United Kingdom government and the European Commission reached agreement on a regulatory framework to replace the Northern Ireland Protocol, referred to as the Windsor Framework. Effective as of January 1, 2025, the Windsor Framework introduced new rules for the regulation of pharmaceutical products in the United Kingdom. The MHRA is now responsible for approving all medicines intended to be marketed in the United Kingdom as a whole (i.e., Great Britain and Northern Ireland). Thus, the EMA is no longer involved in approving medicines intended for sale in Northern Ireland.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation of Medicinal Products in Canada</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Canada is the Canadian federal authority that regulates, evaluates and monitors the safety, effectiveness, and quality of drugs and other therapeutic products available to Canadians. Health Canada&#8217;s regulatory process for review, approval and regulatory oversight of products is similar to the regulatory process conducted by the FDA. To initiate clinical testing of a product candidate in human subjects in Canada, a CTA must be filed with and approved by Health Canada. In addition, all federally regulated trials must be approved and monitored by research ethics boards. The review boards study and approve study-related documents and monitor trial data.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to being given market authorization for a drug product, a manufacturer must present substantive scientific evidence of a product&#8217;s safety, efficacy and quality as required by the Food and Drugs Act (Canada) and its associated regulations, including the Food and Drug Regulations. This information is usually submitted in the form of a New Drug Submission (NDS). Health Canada reviews the submitted information, sometimes using external consultants and advisory committees, to evaluate the potential benefits and risks of a drug. If after of the review, the conclusion is that the patient benefits outweigh the risks associated with the drug, the drug is issued a Drug Identification Number (DIN), followed by a Notice of Compliance (NOC), which permits the market authorization holder (i.e., the NOC and DIN holder) to market the drug in Canada. Drugs granted an NOC may be subject to additional post-market surveillance and reporting requirements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All establishments engaged in the fabrication, packaging/labeling, importation, distribution, and wholesale of drugs and operation of a testing laboratory relating to drugs are required to hold a Drug Establishment License to conduct one or more of the licensed activities unless expressly exempted under the Food and Drug Regulations. The basis for the issuance of a Drug Establishment License is to ensure the facility complies with cGMPs as stipulated in the Food and Drug Regulations and as determined by cGMP inspection conducted by Health Canada. An importer of pharmaceutical products manufactured at foreign sites must also be able to demonstrate that the foreign sites comply with cGMPs, and such foreign sites are included on the importer&#8217;s Drug Establishment License.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory obligations and oversight continue following the initial market approval of a pharmaceutical product. For example, every market authorization holder must report any new information received concerning adverse drug reactions, including timely reporting of serious adverse drug reactions that occur in Canada and any serious unexpected adverse drug reactions that occur outside of Canada. The market authorization holder must also notify Health Canada of any new safety and efficacy issues that it becomes aware of after the launch of a product.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical Coverage, Pricing and Reimbursement &amp; Healthcare Reform</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products, if approved for marketing, will depend, in part, on the availability and extent of coverage and reimbursement by third-party payors, such as government health programs, including Medicare and Medicaid, commercial insurance and managed healthcare organizations. These third-party payors are increasingly challenging the price and limiting the coverage and reimbursement amounts for medical products and services. There may be significant delays in obtaining coverage and reimbursement for approved products, and coverage may be more limited than the purposes for which the product is approved by the FDA or regulatory authorities in other countries. It is time-consuming and expensive to seek reimbursement from third-party payors. Moreover, eligibility for reimbursement does not imply that any product will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new products, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the product and the clinical setting in which it is used, may be based on payments allowed for lower-cost products that are already reimbursed and may be incorporated into existing payments for other services. Net prices for products may be reduced by mandatory discounts or rebates required by third-party payors and by any future relaxation of laws that presently restrict imports of products from countries where they may be sold at lower prices than in the United States. In the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies, but they also have their own methods and approval process apart from Medicare coverage and reimbursement determinations. Accordingly, one third-party payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the containment of healthcare costs has become a priority for federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payor to not cover our product candidates could reduce physician usage of the product candidate and have a material adverse effect on our sales, results of operations and financial condition. Moreover, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate pharmacy benefits managers (PBMs) and other members of the healthcare and pharmaceutical supply chain, an important decision that has led to further and more aggressive efforts by states in this area. The FTC in mid-2022 also launched sweeping investigations into the practices of the PBM industry, and published interim reports with its findings in mid-2024 and January 2025, that could lead to additional federal and state legislative or regulatory proposals targeting such entities&#8217; operations, pharmacy networks, or financial arrangements ,including in the current 2025-2026 congressional session. Indeed both the U.S. Congress and state legislatures are increasingly scrutinizing the industry and proposing novel regulatory approaches to address various perceived public policy concerns. For example, during the previous congressional session, numerous bipartisan PBM reforms were considered in both the Senate and the House of Representatives; they include diverse legislative proposals such as eliminating rebates; divorcing service fees from the price of a drug, discount, or rebate; prohibiting spread pricing; limiting administrative fees; requiring PBMs to report formulary placement rationale; promoting transparency. Significant efforts to change the PBM industry as it currently exists in the United States may affect the entire pharmaceutical supply chain and the business of other stakeholders, including biopharmaceutical product developers like us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, in August 2022, President Biden signed into the law the Inflation Reduction Act of 2022 (the IRA). Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. A manufacturer of drugs covered by Medicare Parts B or D must now pay a rebate to the federal government if their drug product&#8217;s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting for payment year 2026, CMS is negotiating drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. CMS has begun to implement these new authorities entering into agreements to conduct price negotiations with pharmaceutical manufacturers in October 2023 and ultimately announcing the first round of negotiated prices for the first 10 drugs in August 2024; those negotiated &#8220;maximum fair prices&#8221; will be effective as of January 1, 2026 (payment year 2026). CMS is currently engaged in its second round of negotiations and published the next 15 drugs selected for negotiation in January 2025. However, the impact of this program on the biopharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints.The outcome of such ongoing lawsuits, as well as potential legislative changes enacted by Congress or programmatic changes implemented at CMS by the Trump Administration, may impact the IRA drug price negotiation program in the future.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, in the EU, the sole legal instrument at the EU level governing the pricing and reimbursement of medicinal products is Council Directive 89/105/EEC (the Price Transparency Directive). The aim of the Price Transparency Directive is to ensure that pricing and reimbursement mechanisms established in the EU Member States are transparent and objective, do not hinder the free movement of and trade in medicinal products in the EU, and do not hinder, prevent or distort competition on the market. The Price Transparency Directive does not provide any guidance concerning the specific criteria on the basis of which pricing and reimbursement decisions are to be made in the individual EU Member States, nor does it have any direct consequence for pricing or reimbursement levels in the individual EU Member States. The EU Member States are free to restrict the range of medicinal products for which their national health insurance systems provide reimbursement, and to control the prices and/or reimbursement levels of medicinal products for human use. A EU Member State may approve a specific price or level of reimbursement for the medicinal product, or alternatively adopt a system of direct or indirect controls on the profitability of the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company responsible for placing the medicinal product on the market, including volume-based arrangements, caps and reference pricing mechanisms. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Technology Assessment (HTA) of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU Member States, including France, Germany, Ireland, Italy and Sweden. The HTA process in the EU Member States is governed by the national laws of these countries. HTA is the procedure according to which the assessment of the public health impact, therapeutic impact, and the economic and societal impact of the use of a given medicinal product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual medicinal products as well as their potential implications for the healthcare system. Those elements of medicinal products are compared with other treatment options available on the market. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these medicinal products by the competent authorities of individual EU Member States. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product vary between the EU Member States. For example, EU Member States that have not yet developed HTA mechanisms could rely to some extent on the HTA performed in countries with a developed HTA framework when adopting decisions concerning the pricing and reimbursement of a specific medicinal product. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately from cost containment efforts, in the United States and some foreign jurisdictions, there also have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates or restrict or regulate post-approval activities. For example, in April 2023 the European Commission issued a proposal for anew Directive and a new Regulation, which will revise and replace the existing general pharmaceutical legislation. If adopted and implemented as currently proposed, these revisions will significantly change several aspects of drug development and approval in the EU. The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our current or future product candidates. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Privacy and the Protection of Personal Information</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to laws and regulations governing data privacy and the protection of personal information including health information. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues which will continue to affect our business. In the United States, we may be subject to state security breach notification laws, state laws protecting the privacy of health and personal information and federal and state consumer protections laws that regulate the collection, use, disclosure and transmission of personal information. These laws overlap and often conflict, and each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues. If we fail to comply with applicable laws and regulations, we could be subject to penalties or sanctions, including criminal penalties. Our customers and research partners must comply with laws governing the privacy and security of health information, including HIPAA and state health information privacy laws. If we knowingly obtain health information that is protected under HIPAA, called &#8220;protected health information,&#8221; our customers or research collaborators may be subject to enforcement, and we may have direct liability for the unlawful receipt of protected health information or for aiding and abetting a HIPAA violation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the California Confidentiality of Medical Information Act imposes restrictive requirements regulating the use and disclosure of health information and other personally identifiable information. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other federal and state laws establish additional requirements for protecting the privacy and security of health information that is not protected by HIPAA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, Washington state recently passed the &#8220;My Health My Data&#8221; Act, which will regulate &#8220;consumer health data,&#8221; which is defined as &#8220;personal information that is linked or reasonably linkable to a consumer and that identifies a consumer&#8217;s past, present, or future physical or mental health.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The &#8220;My Health My Data&#8221; Act provides exemptions for personal data used or shared in connection with certain research activities, including data subject to 45 C.F.R. Parts 46, 50 and 56.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notably, the &#8220;My Health My Data&#8221; Act contains a private right of action.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Nevada recently enacted a consumer health data privacy bill, SB 370, which also regulates &#8220;consumer health data&#8221; and shares many similarities with Washington&#8217;s &#8220;My Health My Data&#8221; Act, and Connecticut recently amended its comprehensive privacy law to include heightened regulation of &#8220;consumer health data.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional states may adopt health-specific privacy laws that could impact our business activities and our collection and handling of health-related data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More broadly, various state laws regulate the processing of personal information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, California has enacted the California Consumer Privacy Act (CCPA), which went into effect in January of 2020. The CCPA gives California residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well as a private right of action for data breaches that may increase data breach litigation. Although the CCPA includes exemptions for certain categories of health information, the law may increase our compliance costs and potential liability with respect to other personal information we collect about California residents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in 2020, California voters passed the California Privacy Rights Act (CPRA), which went into full effect on January 1, 2023. The CPRA significantly amended the CCPA, potentially resulting in further uncertainty, additional costs and expenses in an effort to comply and additional potential for harm and liability for failure to comply. Among other things, the CPRA established a new regulatory authority, the California Privacy Protection Agency, which is tasked with enacting new regulations under the CPRA and has expanded enforcement authority. In addition to California, more U.S. states are enacting similar legislation, increasing compliance complexity and increasing risks of failures to comply.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, comprehensive privacy laws in Virginia, Colorado, Connecticut, and Utah all took effect, and laws in Montana, Oregon, and Texas took effect during 2024. Laws in a number of other US states took effect, or are set to take effect, in 2025, in 2026, and beyond.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional U.S. states have proposals under consideration, all of which are likely to increase our regulatory compliance costs and risks, exposure to regulatory enforcement action, and other liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Numerous other countries have, or are developing, laws governing the collection, use and transmission of personal information as well.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, the European Parliament and the Council of the European Union adopted a comprehensive general data privacy framework called the General Data Protection Regulation (GDPR) which went into effect in May 2018, and implemented a broad data protection framework that expanded the scope of EU data protection law, and applies to entities located inside and outside of the EU that process, or control the processing of, personal data relating to individuals located in the EU, including clinical trial data. The GDPR, which is wide-ranging in scope, imposes several requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals, the security and confidentiality of the personal data, data breach notification, and the use of third-party processors in connection with the processing of the personal data. In particular, medical or health data, and genetic and biometric data used to uniquely identify an individual are all classified as &#8220;special category&#8221; data under the GDPR and are subject to heightened restrictions and compliance obligations. Further, EU member states have a broad right to impose additional conditions &#8211; including restrictions &#8211; on these data categories. This is because the GDPR allows EU member states to derogate from the requirements of the GDPR mainly in regard to specific processing situations (including special category data and processing for scientific or statistical purposes). As EU member states continue to reframe their national legislation to harmonize with the GDPR, we will need to monitor compliance with all relevant EU member states&#8217; laws and regulations, including where permitted derogations from the GDPR are introduced. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relatedly, following Brexit and the expiry of the Brexit transition period, which ended on December 31, 2020, the EU GDPR has been implemented in the United Kingdom (as the UK GDPR). The UK GDPR sits alongside the United Kingdom Data Protection Act 2018 which implements certain derogations in the EU GDPR into United Kingdom law. Under the UK GDPR, companies not established in the United Kingdom but who process personal data in relation to the offering of goods or services to individuals in the United Kingdom , or to monitor their behavior will be subject to the UK GDPR &#8211; the requirements of which are (at this time) largely aligned with those under the GDPR and as such, may lead to similar compliance and operational costs with potential fines of up to &#163;17.5 million or 4% of global turnover.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers of personal data to certain countries outside of the EU and the UK are also highly regulated under the GDPR and UK GDPR.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the GDPR only permits exports of personal data outside of the EU to &#8220;non-adequate&#8221; countries where there is a suitable data transfer mechanism in place to safeguard personal data (e.g., the EU Commission approved Standard Contractual Clauses or certification under the newly-adopted Data Privacy Framework). On July 16, 2020, the Court of Justice of the EU (CJEU), issued a landmark opinion in the case Maximilian Schrems vs. Facebook (Case C-311/18) (Schrems II). This decision calls into question certain data transfer mechanisms as between the EU member states and the U.S. The CJEU is the highest court in Europe and the Schrems II decision heightened the burden to assess U.S. national security laws on their business, and future actions of EU data protection authorities are difficult to predict at this time. While the Data Privacy Framework was meant to address the concerns raised by the CJEU in Schrems II, it will likely be subject to future legal challenges. Consequently, there is some risk of any data transfers from the EU being halted. If we have to rely on third parties to carry out services for us, including processing personal data on our behalf, we are required under GDPR to enter into contractual arrangements to flow down or help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause customers to lose trust in us, which would have an adverse impact on our reputation and business. Any contractual arrangements requiring the processing of personal data from the EU to us in the U.S. will require greater scrutiny and assessments as required under Schrems II and may have an adverse impact on cross-border transfers of personal data or increase costs of compliance.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Applicable data privacy and data protection laws may conflict with each other, and by complying with the laws or regulations of one jurisdiction, we may find that we are violating the laws or regulations of another jurisdiction. Despite our efforts, we may not have fully complied in the past and may not in the future. That could require us to incur significant expenses, which could significantly affect our business. Failure to comply with data protection laws may expose us to risk of enforcement actions taken by data protection authorities or other regulatory agencies, private rights of action in some jurisdictions, and potential significant penalties if we are found to be non-compliant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the number of government investigations related to data security incidents and privacy violations continue to increase and government investigations typically require significant resources and generate negative publicity, which could harm our business and reputation.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">United States Foreign Corrupt Practices Act</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, the Foreign Corrupt Practices Act of 1977, as amended (FCPA), prohibits offering to pay, paying, promising to pay, or authorizing the payment of money or anything of value to a foreign official in order to influence any act or decision of the foreign official in his or her official capacity or to secure any other improper advantage in order to obtain or retain business for or with, or in order to direct business to, any person. The prohibitions apply not only to payments made to &#8220;any foreign official,&#8221; but also those made to &#8220;any foreign political party or official thereof,&#8221; to &#8220;any candidate for foreign political office&#8221; or to any person, while knowing that all or a portion of the payment will be offered, given, or promised to anyone in any of the foregoing categories. &#8220;Foreign officials&#8221; under the FCPA include officers or employees of a department, agency, or instrumentality of a foreign government. The term &#8220;instrumentality&#8221; is broad and can include state-owned or state-controlled entities. Importantly, United States authorities deem most healthcare professionals and other employees of foreign hospitals, clinics, research facilities and medical schools in countries with public healthcare and/or public education systems to be &#8220;foreign officials&#8221; under the FCPA. When we interact with foreign healthcare professionals and researchers in testing and marketing our products abroad, should any of our product candidates receive foreign regulatory approval in the future, we must have policies and procedures in place sufficient to prevent us and agents acting on our behalf from providing any bribe, gift or gratuity, including excessive or lavish meals, travel or entertainment in connection with marketing our products and services or securing required permits and approvals. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Environmental, Health and Safety Regulation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous federal, state and local environmental, health and safety (EHS) laws and regulations relating to, among other matters, safe working conditions, product stewardship, environmental protection, and handling or disposition of products, including those governing the generation, storage, handling, use, transportation, release, and disposal of hazardous or potentially hazardous materials, medical waste, and infectious materials that may be handled by our partner research laboratories. Some of these laws and regulations also require us to obtain licenses or permits to conduct our operations. If we fail to comply with such laws or obtain and comply with the applicable permits, we could face substantial fines or possible revocation of our permits or limitations on our ability to conduct our operations. Certain of our development and manufacturing activities may involve, from time to time, use of hazardous materials, and we believe we are in compliance with the applicable environmental laws, regulations, permits, and licenses. However, we cannot ensure that EHS liabilities will not develop in the future. EHS laws and regulations are complex, change frequently and have tended to become more stringent over time. Although the costs to comply with applicable laws and regulations, have not been material, we cannot predict the impact on our business of new or amended laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced, nor can we ensure we will be able to obtain or maintain any required licenses or permits.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 7, 2025 we had four employees, of which three were full-time employees and one was part-time. We believe the intellectual capital of our current and future employees and consultants is an impactful driver of our business and is key to our future prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI&#8217;s Corporate Information</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc. (Vallon) was incorporated under the laws of the State of Delaware in January 2018, and completed its organization, formation and initial capitalization activities effective in June 2018. GRI Bio Operations, Inc. (GRI Operations), formerly known as GRI Bio, Inc., was incorporated under the laws of the State of Delaware in May 2009 under the name Glycoregimmune, Inc., and amended its certificate of incorporation to change its name to GRI Bio, Inc. on July 29, 2015.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to that Agreement and Plan of Merger, dated as of December 13, 2022, as amended on February 17, 2023 (the Merger Agreement), by and among Vallon, GRI Operations and Vallon Merger Sub, Inc., a Delaware corporation </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and wholly owned subsidiary of the Company (Merger Sub), Merger Sub was merged with and into GRI (the Merger), with GRI surviving the Merger as a wholly owned subsidiary of the Company. In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 2223 Avenida De La Playa #208, La Jolla, CA 92037. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file our annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, proxy and information statements, and other information with the SEC under the Securities Exchange Act of 1934, as amended (the Exchange Act). You can read our SEC filings at the SEC&#8217;s website.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains an internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">http://www.sec.gov.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.gribio.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The information contained in, and that can be accessed through, our website is not incorporated into and is not part of this Annual Report. </span></div><div style="margin-bottom:9pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not applicable to emerging growth companies. These exemptions include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about our executive compensation arrangements;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more, (b) December 31, 2026, the last day of the fiscal year following the fifth anniversary of the completion of the IPO, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i73c3df21d6604995952be1876b1e93fe_28"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Careful consideration should be given to the following risk factors, in addition to the other information contained in this Annual Report and in our other public filings, in evaluating our company and business. Investing in our securities involves a high degree of risk. If any of the following risks actually occurs, our business, financial condition, results of operations and future growth prospects would likely be materially and adversely affected and the trading price of our securities could decline. Our actual results could differ materially from those anticipated in the forward looking statements as a result of factors that are described below and elsewhere in this Annual Report.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future. We have never been, and may never be, profitable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net losses since our inception and have financed our operations principally through equity and debt financing. We continue to incur significant research and development and other expenses related to our ongoing operations. Our net loss was $8.2 million and $13.0 million for the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $39.7 million. We have devoted substantially all of our resources and efforts to research and development, and we expect that it will be several years, if ever, before we generate revenue from product sales. Even if we receive marketing approval for and commercialize one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses in order to develop and, if approved, market additional potential product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant losses for the foreseeable future, and we anticipate that our expenses will increase substantially if, and as, we:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our lead product candidate, GRI-0621, and our other product candidates through clinical development, and, if successful, later-stage clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discover and develop new product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance our preclinical development programs into clinical development;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">further develop manufacturing processes and manufacture our product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">experience delays or interruptions to preclinical studies, clinical trials, our receipt of services from our third-party service providers on whom we rely, or our supply chain due to pandemics, supply chain and labor shortages, labor strikes, work stoppages or boycotts, natural disasters and geopolitical conflicts, such as the conflicts in Ukraine and the Middle East;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize GRI-0621, our other product candidates and any future product candidates, if approved;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase the amount of research and development activities to identify and develop product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire additional clinical development, quality control, scientific and management personnel;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development and manufacturing efforts and our operations as a public company;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">invest in or in-license other technologies or product candidates; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to build out our organization to engage in such activities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To become and remain profitable, we must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, marketing, and selling products for which we may </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business, or continue our operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs, future commercialization efforts or other operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developing biotechnology and biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive, and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our planned clinical trials of GRI-0621, GRI-0803 and any other product candidates that we may develop or seek regulatory approvals for and, if approved, launch and commercialize. In particular, we do not expect to be able to continue our clinical trials or development efforts without raising additional funds. We also expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce, or eliminate one or more of our research and drug development programs or future commercialization efforts.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had approximately $5.0 million in cash and cash equivalents and an accumulated deficit of approximately $39.7 million. If we secure additional funds, we expect to devote substantial financial resources to our planned activities, particularly as we conduct our clinical trials of GRI-0621 and GRI-0803, advance our discovery programs and continue our product development efforts.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the second quarter of 2025. We have based these estimates on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. Our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will require additional funding to recommence development of our product candidates. Our spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development, and assuming approval, marketing and commercialization activities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will need to raise additional funds in the near term in order to maintain compliance with Nasdaq&#8217;s continued listing requirements and continue operations. However, additional funding may not be available on acceptable terms, if at all. Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Further, to the extent that we raise additional capital through the sale of Common Stock or securities convertible or exchangeable into Common Stock, our stockholders&#8217; ownership interest will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional capital through marketing and distribution arrangements or collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also may be required to seek collaborators for any of our product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Market volatility resulting from inflation, pandemics, geopolitical events or other financial markets factors could also adversely impact our ability to access capital as and when needed.&#160;If we are unable to secure adequate additional funding, we will need to reevaluate our operating plans and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, relinquish rights to our technology on less favorable terms than we would otherwise choose or cease operations entirely. These actions could materially impact our business, results of operations, our future prospects and the value of shares of our Common Stock, and as a result, our stockholders may receive no value for their investment. In addition, attempting to secure additional financing diverts the time and attention of management from day-to-day activities and distract from our discovery and product development efforts. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our auditors have expressed substantial doubt about our ability to continue as a going concern, and we may not be able to continue as a going concern if we do not obtain additional financing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred losses since inception and, to date, have financed our operations by issuing equity and debt securities. We anticipate that we will continue to incur losses and generate negative operating cash flows in the foreseeable future as we continue to develop our drug candidates and that we will require additional funding to support our planned operating activities. The report of our independent registered public accounting firm on our financial statements as of and for the year ended December&#160;31, 2024 includes an explanatory paragraph indicating that there is substantial doubt about our ability to continue as a going concern. Until such time, if ever, in which we can generate substantial product revenue, we expect we may continue to fund our operations and capital funding needs through equity offerings, debt financings or other capital sources, including strategic licensing, collaboration or other similar agreements. As stated above, if we are unable to secure adequate additional funding, we will need to reevaluate our operating plans and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our technology on less favorable terms than it would otherwise choose. These actions could materially impact our business, results of operations, our future prospects and the value of shares of our Common Stock, and, as a result, our stockholders may receive no value for their investment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Research and Development and the Pharmaceutical Industry</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is highly dependent on the success of our lead product candidate, GRI-0621, and any other product candidates that we may advance into clinical development. All of our product candidates will require significant additional development before we may be able to seek regulatory approval and launch a product commercially.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have no products that are approved for commercial sale and may never be able to develop marketable products. Because GRI-0621 is our lead product candidate, if GRI-0621 encounters safety or efficacy problems, additional development delays, regulatory issues or other problems, our development plans and business would be significantly harmed. Before we can generate any revenue from sales of our lead product candidate, GRI-0621, GRI-0803 or any of our other product candidates, we must undergo additional clinical development, regulatory review, and approval in one or more jurisdictions. These efforts will require substantial investment, and we may not have the financial resources to continue development of our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience setbacks that could delay or prevent regulatory approval of, or the extent of regulatory protection or our ability to commercialize, our product candidates, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">product-related side effects experienced by subjects in our clinical trials or by individuals using drugs or therapeutics similar to our product candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">further delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials, including any regulatory requirements for certain outcomes be measured during product development or to support market authorization;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays in enrolling subjects in clinical trials, including due to pandemics, labor shortages or other geopolitical events;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">high drop-out rates of subjects from clinical trials; </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">challenges manufacturing our product candidates to regulatory requirements in a cost effective manner;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">greater than anticipated clinical trial costs;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">inability to compete with other therapies;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">failure to secure or maintain orphan designation in some jurisdictions;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">poor efficacy of our product candidates during clinical trials;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular; or</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">varying interpretations of data by the FDA and similar foreign regulatory agencies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and our manufacturing, marketing, distribution and sales efforts or that of any future collaborator. Delays in regulatory approvals or our failure to obtain regulatory approvals would harm our business, prospects and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy, complex, and expensive process, with an uncertain outcome. In addition, the results of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive nonclinical studies and clinical trials that our product candidates are safe and effective in humans for their intended use(s). Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. In particular, the general approach for FDA approval of a new drug is dispositive data from two well-controlled, Phase 3 clinical trials of the relevant drug in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product candidate can fail at any stage of testing, even after observing promising signals of activity in earlier preclinical studies or clinical trials. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. In general, most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of GRI-0621, GRI-0803 or any of our other product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including:</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical studies or clinical trials may show the product candidates to be less effective than expected (e.g., a clinical trial could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">development of competing products in the same disease state;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing costs, formulation issues, pricing or reimbursement issues, or other factors that make a product candidate uneconomical; and</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proprietary rights of others and their competing products and technologies that may prevent one of our product candidates from being commercialized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, Congress amended the FDCA to require sponsors of a Phase 3 clinical trial, or other &#8220;pivotal study&#8221; of a new drug to support marketing authorization, to design and submit a diversity action plan for such clinical trial. The action plan must describe appropriate diversity goals for enrollment, as well as a rationale for the goals and a description of how the sponsor will meet them. Although none of our product candidates has reached Phase 3 of clinical development, we must submit a diversity action plan to the FDA by the time we submit a Phase 3 trial, or pivotal study, protocol to the agency for review, unless we are able to obtain a waiver for some or all of the requirements for a diversity action plan. It is unknown at this time how the diversity action plan may affect the planning and timing of any future Phase 3 trial for our product candidates. However, initiation of such trials may be delayed if the FDA objects to our proposed diversity action plans for any future Phase 3 trial for our product candidates, and we may experience difficulties recruiting a diverse population of patients in attempting to fulfill the requirements of any approved diversity action plan.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the standards that the FDA and comparable foreign regulatory authorities use when regulating our product candidates require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations. Examples of such regulations include future legislation or administrative action, or changes in FDA policy during the period of product development and FDA regulatory review. We cannot predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. For example, in April 2023 the European Commission issued a proposal for a new directive and a new regulation, which will revise and replace the existing general pharmaceutical legislation. If adopted and implemented as currently proposed, these revisions will significantly change several aspects of drug development and approval in the EU.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also require a panel of experts, referred to as an advisory committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the advisory committee, although not binding on the FDA, may have a significant impact on the agency&#8217;s decision-making process and our ability to obtain approval of any product candidates that we develop.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we seek to conduct clinical trials in foreign countries or pursue marketing approvals in foreign jurisdictions, we must comply with numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the United States and vice versa. Our competitors also may obtain FDA or regulatory approval from comparable foreign regulatory authorities for their product candidates more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter additional difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and qualifying patients to participate in clinical studies of our product candidates is critical to our success. The timing of completion of our clinical studies depends in part on the speed at which we can recruit patients to participate in testing our product candidates, and we may experience delays in our clinical trials if we again encounter difficulties in enrollment. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient eligibility and exclusion criteria defined in the protocol;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness or availability of patients to participate in our trials;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity of patients to trial sites;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the design of the trial;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of competing commercially available therapies and other competing product candidates&#8217; clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain patient informed consents; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish new sites in accordance with applicable regulatory requirements; and</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, when we evaluated GRI-0621 in a pilot Phase 2a trial in hepatically impaired chronic liver disease patients, the study was originally intended to evaluate 60 patients but due to recruitment challenges and updated guidance from the FDA regarding the design of NASH clinical studies we made the administrative decision to halt the study after enrolling 14 patients. In addition, we previously expected topline results from our Phase 2a trial for GRI-0621 to be available in the fourth quarter of 2024 and this has since been delayed to the third quarter of 2025 primarily as a result of delayed enrollment. Enrollment in this trial continues to be somewhat unpredictable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we are initially developing GRI-0621 for the treatment of IPF, which is an orphan indication. As a result, we have and may again encounter difficulties enrolling subjects in our clinical trials of GRI-0621 due, in part, to the small size of this patient population or the burden of safety labs included in the clinical protocol. In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition may reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, timely enrollment in clinical trials is reliant on clinical trial sites which may be adversely affected by global health matters, including, among other things, pandemics, supply and labor shortages and geopolitical events. These delays and potential delays to development timelines may adversely affect our business, prospects and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we publicly disclose interim, preliminary or topline data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analysis of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, topline or preliminary results of clinical trials we report may differ from final results reported for those studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final, complete data are available.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. There can be no guarantee that a favorable interim analysis will result in a favorable final result at the completion of the clinical trial.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Likewise, in light of the fact that our evaluation of GRI-0621 in a pilot Phase 2a trial in hepatically impaired chronic liver disease patients was originally intended to evaluate 60 patients and that we made the administrative decision to halt the study after enrolling 14 patients due to recruitment challenges and updated guidance from the FDA regarding the design of NASH clinical studies, our disclosure that GRI-0621 was observed to be well-tolerated and showed improvements in liver function tests, serum CK-18, and in iNKT cell activity in this limited number of patients is qualified by the fact that the study was underpowered to meet its endpoints with statistical significance. Our observations from this pilot Phase 2a trial may not be indicative of results from any potential future preclinical studies or clinical trials.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in regulatory requirements, FDA guidance or unanticipated events during our preclinical studies and clinical studies of our product candidates may occur, which may result in changes to preclinical or clinical study protocols or additional preclinical or clinical study requirements, which could result in increased costs to us and could delay our development timeline.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulatory requirements, FDA guidance or unanticipated events during our preclinical studies and clinical studies may force us to amend preclinical studies and clinical study protocols. The FDA or comparable foreign regulatory authorities may also impose additional preclinical studies and clinical study requirements. Amendments or changes to our clinical study protocols, including changes to endpoints, would require resubmission to the FDA or comparable foreign regulatory authorities and IRBs for review and approval, which may increase the cost or delay the timing or successful completion of clinical studies. Similarly, amendments to our preclinical studies may increase the cost or delay the timing or successful completion of those </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">preclinical studies. If we experience delays completing, or if we terminate, any of our preclinical or clinical studies, or if we are required to conduct additional preclinical or clinical studies, the commercial prospects for our product candidates may be harmed and our ability to recognize product revenue will be delayed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of testing GRI-0621, GRI-0803 and any of our other product candidates in clinical trials and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. As an oral formulation of an active ingredient that has previously been approved by FDA only for topical administration, in particular, GRI-0621 may be subject to the identification of new serious adverse events as it is administered to larger numbers of research subjects in order to evaluate its safety/effectiveness in chronic use indications and in new patient populations. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even a successful defense of these claims would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">inability to bring a product candidate to the market;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">decreased demand for our products;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">injury to our reputation;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">withdrawal of clinical trial participants and inability to continue clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">initiation of investigations by regulators;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">fines, injunctions or criminal penalties;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">costs to defend the related litigation;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">diversion of management&#8217;s time and our resources;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">substantial monetary awards to trial participants;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">loss of revenue;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">exhaustion of any available insurance and our capital resources;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the inability to commercialize any product candidate, if approved; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">decline in our share price.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We may be unable to obtain, or may obtain on unfavorable terms, clinical trial insurance in amounts adequate to cover any liabilities from any of our clinical trials. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to utilize the FDA&#8217;s Section 505(b)(2) pathway for our lead product candidate, and if that pathway is not available, the development of our product candidate will likely take significantly longer, cost significantly more and entail significantly greater complexity and risk than currently anticipated, and, in any case, may not be successful.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to develop and seek approval for GRI-0621, and potentially other candidates that we may develop, pursuant to the FDA&#8217;s 505(b)(2) pathway. If the FDA determines that we may not use this regulatory pathway, then we would need to seek regulatory approval via a &#8220;full&#8221; or &#8220;stand-alone&#8221; NDA under Section 505(b)(1) of the FDCA. This would require us to conduct additional clinical trials, provide additional safety and efficacy data and other information, and meet additional standards for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory approval including possibly nonclinical data. If this were to occur, the time and financial resources required to obtain FDA approval, as well as the development complexity and risk associated with these programs, would likely substantially increase, which could have a material adverse effect on our business and financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Price Competition and Patent Term Restoration Act of 1984, informally known as the Hatch-Waxman Act, added Section 505(b)(2) to the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies and information that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2), if applicable to certain of our product candidates under the FDCA, would allow an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved compounds. Such an approach could expedite the development programs for GRI-0621. In addition, although 505(b)(2) applicants have significant flexibility in the types of studies, data, and information they may submit in a 505(b)(2) NDA to support the requirements for NDA approval, establish a favorable benefit-risk profile for the new drug product, and demonstrate the new drug&#8217;s substantial evidence of effectiveness for its proposed intended use(s), the applicant bears the burden of establishing a scientific bridge between its drug product and each listed drug that the applicant seeks to rely upon and that the studies it is proposing to conduct are scientifically justified. If the FDA disagrees with the applicant&#8217;s proposed development plan for the follow-on drug product, it may require the sponsor to perform additional studies or measurements, including nonclinical and clinical studies, to support the change from the approved product. FDA also may request or require studies to incorporate additional clinical endpoints than what the sponsor proposes. The extent of data necessary to establish the safety and/or effectiveness of the new product, such as the effects of changing the drug&#8217;s route of administration from topical to oral, are therefore scientifically driven and determined on a case-by-case basis. There can be no assurance that the studies and clinical trials we propose to FDA to establish the safety and effectiveness of GRI-0621 for the treatment of IPF, or any future candidates we may develop using the 505(b)(2) NDA pathway, will be deemed sufficient to support all of the differences between our product candidate and the relevant listed drug. For example, we may be required to collect more safety data than we anticipate in order to gain approval of an oral formulation of an active ingredient that has previously been approved by FDA only for topical administration.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged, or if Congress were to amend the statute to alter the currently available regulatory pathway, the FDA may change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs referenced in a Section 505(b)(2) NDA. Even if we are able to utilize the Section 505(b)(2) regulatory pathway for one or more of our candidates, there is no guarantee this would ultimately lead to faster product development or earlier approval.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, any delay resulting from our inability to pursue the FDA&#8217;s 505(b)(2) pathway could result in new competitive products reaching the market more quickly than our GRI-0621 product candidate, which may have a material adverse impact our competitive position and prospects. Even if we are allowed to pursue the FDA&#8217;s 505(b)(2) pathway, we cannot assure you that GRI-0621 or any of our future product candidates will receive the requisite approvals for commercialization.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval of Our Product Candidates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek Fast Track designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, a product sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a product candidate, we may not receive it from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular time frame. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review. Maintaining compliance with ongoing regulatory requirements may result in significant additional expense to us, and any failure to maintain such compliance could subject us to penalties and cause our business to suffer.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved, we will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and their facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMPs and applicable electronic package-level tracing requirements. We and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of one or more of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. If our original marketing approval for a product candidate was obtained through an accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial in order to confirm the clinical benefit for that product. An unsuccessful post-marketing clinical trial or failure to complete such a trial could result in the withdrawal of marketing approval.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we hope to obtain marketing approval. The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is not inconsistent with the labeling, and the FDA has recently published a draft guidance with recommendations for how drug manufacturers can share scientifically sound and clinically relevant information on unapproved uses with health care providers so long as such presentations are not promotional. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates (or with drugs that contain the same active ingredients as our product candidates), including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div><span><br/></span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">new requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">fines, warning letters or holds on clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">suspension or revocation of drug product approvals;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">voluntary or mandatory product recalls and related publicity requirements;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">total or partial suspension of production;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">product seizure or detention or refusal to permit the import or export of our product candidates; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">injunctions, consent decrees, or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adverse side effects caused by any drugs that contain the same active ingredients as or may otherwise be similar in nature to our product candidates could delay or prevent marketing approval of our product candidates or limit the commercial profile of an approved label for our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law would be expected to require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products and our value and our operating results would be adversely affected. In addition, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Commercialization of our Product Candidates</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if a product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if GRI-0621, GRI-0803 or any other product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients and third-party payors, such as Medicare and Medicaid programs and managed care organizations, and others in the medical community. In addition, the availability of coverage by third-party payors may be affected by existing and future health care reform measures designed to reduce the cost of health care. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including:</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">efficacy and potential advantages compared to alternative treatments;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to offer our products, if approved, for sale at competitive prices;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">convenience and ease of administration compared to alternative treatments;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recommendations with respect to our product candidates in guidelines published by various scientific organizations applicable to us and our product candidates;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing and distribution support;</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to obtain sufficient third-party coverage and adequate reimbursement; and</span></div><div style="margin-bottom:8pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects, as well as the language and scope of any labeled warnings (including boxed warnings), precautions, or contraindications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that out products are safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. If government and other third-party payors do not provide coverage and adequate reimbursement levels for any products we commercialize, market acceptance and commercial success would be reduced.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain or maintain adequate reimbursement or insurance coverage for our approved product candidates, if any, could limit our ability to market those product candidates and decrease our ability to generate revenue.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing, coverage, and reimbursement of our approved products, if any, must be sufficient to support our commercial efforts and other development programs, and the availability and adequacy of coverage and reimbursement by third-party payors, including governmental and private insurers, are essential for most patients to be able to afford medical treatments. Sales of our approved products, if any, will depend substantially, both domestically and abroad, on the extent to which the costs of our approved products, if any, will be paid for or reimbursed by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or government payors and private payors. If coverage and reimbursement are not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available, or are available only in limited amounts, we may have to subsidize or provide products for free or we may not be able to successfully commercialize our products.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by the CMS, an agency within HHS, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel product candidates such as ours and what reimbursement codes our product candidates may receive if approved.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of prescription drugs. In many countries, the prices of drugs are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products, if any. Accordingly, in markets outside the United States, the potential revenue may be insufficient to generate commercially reasonable revenue and profits.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and private payors in the United States and abroad to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new drugs and, as a result, they may not cover or provide adequate payment for our products, if any. We expect to experience pricing pressures in connection with drugs due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, and prescription drugs in particular, has and is expected to continue to increase in the future. As a result, profitability of our products, if any, may be more difficult to achieve even if any of them receive regulatory approval.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize these product candidates outside of the United States, which could limit our ability to realize their full market potential.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties, and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently have no marketing and sales organization and have no experience as a company in commercializing products. We would have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue from any of our product candidates that may be approved.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no internal sales, marketing, or distribution capabilities. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our sales, marketing and distribution capabilities would adversely impact the commercialization of any product candidates that may obtain approval. We may also choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over these third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing any approved product candidates that we may have, either on our own or through </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, physicians, prescribers, purchasers, third-party payors, charitable organizations and patients will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the AKS and the federal False Claims Act, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute pharmaceutical products. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. See the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business &#8212; Government Regulation and Product Approval &#8212; Other U.S. Healthcare Laws and Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from other aspects of its business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. Any action for violation of these laws, even if successfully defended, could cause significant legal expenses and divert management&#8217;s attention from the operation of the business. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example, changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or discontinuation of our products; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. See the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business &#8212; Government Regulation and Product Approval &#8212; Pharmaceutical Coverage, Pricing and Reimbursement &amp; Healthcare Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad, including in Canada and Europe, to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Most recently, in August 2022, President Biden signed into the law the IRA which </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">among other things, contains multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Among other things, the IRA has multiple provisions that may impact the prices of drug products that are both sold into the Medicare program and throughout the United States. A manufacturer of drugs or biological products covered by Medicare Parts B or D must now pay a rebate to the federal government if their drug product&#8217;s price increases faster than the rate of inflation. This calculation is made on a drug product by drug product basis and the amount of the rebate owed to the federal government is directly dependent on the volume of a drug product that is paid for by Medicare Parts B or D. Additionally, starting for payment year 2026, CMS is negotiating drug prices annually for a select number of single source Part D drugs without generic or biosimilar competition. CMS will also negotiate drug prices for a select number of Part B drugs starting for payment year 2028. If a drug product is selected by CMS for negotiation, it is expected that the revenue generated from such drug will decrease. CMS has begun to implement these new authorities and entered into the first set of agreements with pharmaceutical manufacturers to conduct price negotiations in October 2023 and ultimately announcing the first round of negotiated prices for the first 10 drugs in August 2024; those negotiated &#8220;maximum fair prices&#8221; will be effective as of January 1, 2026 (payment year 2026). CMS is currently engaged in its second round of negotiations and published the next 15 drugs selected for negotiation in January 2025. However, the IRA&#8217;s impact on the biopharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. The outcome of such ongoing lawsuits, as well as potential legislative changes enacted by Congress or programmatic changes implemented at CMS by the Trump Administration, may impact the IRA drug price negotiation program in the future.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, financial condition, results of operations and prospects. In addition, the U.S. Supreme Court held unanimously in December 2020 that federal law does not preempt the states&#8217; ability to regulate PBMs and other members of the health care and pharmaceutical supply chain, an important decision that has led to further and more aggressive efforts by states in this area.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FTC in mid-2022 also launched sweeping investigations into the practices of the PBM industry, and published interim reports with its findings in mid-2024 and January 2025, that could lead to additional federal and state legislative or regulatory proposals targeting such entities&#8217; operations, pharmacy networks, or financial arrangements, including in the current 2025-2026 congressional session. Both the U.S. Congress and state legislatures are increasingly scrutinizing the industry and proposing novel regulatory approaches to address various perceived public policy concerns. Significant efforts to change the PBM industry as it currently exists in the United States may affect the entire pharmaceutical supply chain and the business of other stakeholders, including biopharmaceutical product developers like us. Further, in September 2023, the FTC issued a policy statement articulating its view that certain &#8220;improper&#8221; patent listings by drug developers in FDA&#8217;s Orange Book represent an unfair trade practice and indicated that industry should be prepared for potential enforcement actions based on its analysis. The FTC followed that action in November 2023 by publicly calling out over 100 &#8220;improper&#8221; patent listings made by ten large pharmaceutical companies and initiating an FDA administrative process with respect to those patents. The controversy regarding the appropriateness of listing such patents has led to numerous lawsuits alleging anticompetitive conduct by biopharmaceutical companies. It remains to be seen whether the FTC under the Trump Administration will continue to prioritize the policy issue of &#8220;improper&#8221; patent listings or whether Congress may take any legislative actions related to this issue. Accordingly, regulatory and government interest in biopharmaceutical industry business practices continues to expand and pose a risk of uncertainty.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. Additionally, we expect to experience pricing pressures in connection with the sale of any future approved product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inadequate funding for the FDA, the SEC and/or other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including from December 22, 2018 through January 25, 2019, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC, and other government employees and stop critical activities. If a prolonged government shutdown or slowdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. There have been U.S. government shutdowns historically, and recent government shutdowns have been threatened; it is often unclear how long a shutdown will last and what impacts it may have on the federal agencies that have jurisdiction over our various operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, three decisions from the U.S. Supreme Court issued in July 2024 may lead to an increase in litigation against regulatory agencies that could create uncertainty and thus negatively impact our business. The first decision overturned established precedent that required courts to defer to regulatory agencies&#8217; interpretations of ambiguous statutory language. The second decision overturned regulatory agencies&#8217; ability to impose civil penalties in administrative proceedings. The third decision extended the statute of limitations within which entities may challenge agency actions. These cases may result in increased litigation by industry against regulatory agencies, including but not limited to the FDA and SEC, and may impact how such agencies choose to pursue enforcement and compliance actions. However, the specific, lasting effects of these decisions, which may vary within different judicial districts and circuits, is unknown. We also cannot predict the extent to which FDA and SEC regulations, policies, and decisions may become subject to increasing legal challenges, delays, and changes.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other matters, United States. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, Trade Laws) prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase in time. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations; environmental damage resulting in costly clean-up; and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of specified materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry hazardous waste insurance coverage.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business depends in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our product candidates, their respective components, synthetic intermediates, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities and whether a court would issue an injunctive remedy. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. The patenting process is subject to numerous risks and there can be no assurance that we will be successful in obtaining patents for which we have applied. In addition, we may not pursue, obtain, or maintain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and biopharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability, or scope thereof, which may result in such patents being narrowed, invalidated, or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our technology, including our product candidates, or prevent others from designing around our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that we were the first to file any patent application related to our technology, including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that we were the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. Furthermore, for U.S. applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. Similarly, for U.S. applications in which at least one claim is not entitled to a priority date before March 16, 2013, derivation proceedings can be instituted to determine whether the subject matter of a patent claim was derived from a prior inventor&#8217;s disclosure.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent or patent application claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, would adequately protect our product candidates, or would be found by a court to be infringed by a competitor&#8217;s technology or product. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities and consider that we are free to operate in relation to our product candidates, but our competitors may obtain issued claims, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including in patents we consider to be unrelated, which block our efforts or may potentially result in our product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights or will design around the claims of patents that may issue that cover our products.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may enter into license or other collaboration agreements in the future that may impose certain obligations on us. If we fail to comply with our obligations under such future agreements with third parties, we could lose license rights that may be important to our future business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our efforts to expand our pipeline of product candidates, we may enter into certain licenses or other collaboration agreements pertaining to the in-license of rights to additional product candidates. Such agreements may impose various diligence, milestone payment, royalty, insurance, or other obligations on us. If we fail to comply with these obligations, our licensor or collaboration partners may have the right to terminate the relevant agreement, in which event we would not be able to develop or market the products covered by such licensed intellectual property.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the sublicensing of patent and other rights under our collaborative development relationships;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">the priority of invention of patented technology.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may have limited control over the maintenance and prosecution of these in-licensed patents and patent applications, or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding, or defense activities may be less vigorous than had we conducted them ourselves.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party claims of intellectual property infringement may be costly and time consuming to defend, and could prevent or delay our product discovery, development and commercialization efforts.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and biopharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation, inter partes review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">developing our product candidates. As the biotechnology and biopharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies, or methods.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Common Stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition, and prospects. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be third-party patents of which we are currently unaware with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment that encompass the composition, use or manufacture of our product candidates. There may be currently pending patent applications of which we are currently unaware which may later result in issued patents that our product candidates or their use or manufacture may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patent were held by a court of competent jurisdiction to cover our product candidates, intermediates used in the manufacture of our product candidates or our materials generally, aspects of our formulations or methods of manufacture or use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in the biotechnology and biopharmaceutical industries, we employ individuals who were previously employed at universities or other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Common Stock. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Others may claim an ownership interest in our intellectual property, which could expose us to litigation and have a significant adverse effect on our prospects. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third-party may claim an ownership interest in one or more of our or our licensors&#8217; patents or other proprietary or intellectual property rights. A third-party could bring legal actions against us and seek monetary damages and/or enjoin clinical testing, manufacturing and marketing of the affected product or products. While we are presently unaware of any claims or assertions by third parties with respect to our patents or other intellectual property, we cannot guarantee that a third-party will not assert a claim or an interest in any of such patents or intellectual property. If we become involved in any litigation, it could consume a substantial portion of our resources and cause a significant diversion of effort by our technical and management personnel. If any of these actions are successful, in addition to any potential liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product, in which case we may be required to pay substantial royalties or grant cross-licenses to our patents. We cannot predict whether any such license will be available on commercially acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product candidate or be forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases that may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates may also require specific formulations to work effectively and efficiently, and these rights may be held by others. We may develop products containing our compounds and pre-existing biotechnology and biopharmaceutical compounds. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, or challenging the patent rights of others, which could be expensive, time-consuming and unsuccessful.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors or other third parties such as chemical and reagent suppliers may infringe our patents or the patents of our current or future licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question or for other reasons. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may choose to challenge the patentability of claims in a third-party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-examination, inter partes review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#8217;s patent in patent opposition proceedings in the European Patent Office (EPO) or other foreign patent offices. The costs of these opposition proceedings could be substantial and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent offices, we may be exposed to litigation by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and in-licensed issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent or first to file a patent application covering the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our owned and in-licensed patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned by or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate in an interference or derivation proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference or derivation proceeding involving a U.S. patent application on inventions owned by or in-licensed to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our Common Stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on our owned and in-licensed issued patents and patent applications are or will be due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In certain circumstances, even inadvertent noncompliance events may permanently and irrevocably jeopardize patent rights. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO (or foreign patent offices).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one of our licensors initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earliest patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, results of operations, financial condition and prospects. We own pending patent applications covering our proprietary technologies or our product candidates that if issued as patents are expected to expire from 2032 through 2035, without taking into account any possible patent term adjustments or extensions. However, we cannot be assured that the USPTO, EPO or other relevant foreign patent offices will grant any of these patent applications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States or in foreign jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March 16, 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On March 16, 2013, under the Leahy-Smith America Invents Act (the America Invents Act), the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third-party that files a patent application in the USPTO on or after March 16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third-party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third-party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third-party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third-party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our owned or in-licensed issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of biotechnology and biopharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited foreign intellectual property rights and may not be able to protect and enforce our intellectual property rights throughout the world.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited intellectual property rights outside the United States. Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of, and may require a compulsory license to, patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain patent term extension and data exclusivity or similar non-U.S. legislation extending the term of protection covering any product candidates we may develop, our business may be materially harmed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Depending upon the timing, duration, and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permit a patent term extension of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failure to exercise due diligence during the testing phase or regulatory review process, failure to apply within applicable deadlines, failure to apply prior to expiration of relevant patents, or otherwise failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. In addition, within the EU, regulatory protections afforded to medicinal products such as data exclusivity, marketing protection, market exclusivity for orphan indications and pediatric extensions are currently under review and could be curtailed in future years. If we are unable to obtain patent term extension or the term of any such extension is less than we request, or if data exclusivity or other regulatory protections are reduced, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical trials, manufacture our product candidates and perform other services. If these third parties do not successfully carry out their contractual duties, meet expected timelines or otherwise conduct the trials as required or perform and comply with regulatory or contractual requirements, we may not be able to successfully complete clinical development, obtain regulatory approval or commercialize our product candidates when expected or at all, and our business could be substantially harmed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely upon third-party CROs to conduct, monitor and manage our clinical programs. We rely on these parties for execution of clinical trials and we manage and control only some aspects of their activities. We remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with all applicable laws, regulations and guidelines, including those required by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, or any of our CROs or vendors, fail to comply with applicable laws, regulations or guidelines, or as otherwise required, the results </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot be assured that our CROs or other vendors will meet these requirements, or that upon inspection by any regulatory authority, such regulatory authority will determine that efforts, including any of our clinical trials, comply with applicable requirements. Our failure to comply with these laws, regulations or guidelines may require us to repeat clinical trials, which would be costly and delay the regulatory approval process.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminates, or they otherwise are subject to quarantines, shelter-in-place orders, shutdowns or other restrictions and must scale back their operations unexpectedly we may not be able to enter into arrangements with alternative CROs in a timely manner or do so on commercially reasonable terms. In addition, our CROs may not prioritize our clinical trials relative to those of other customers, and any turnover in personnel or delays in the allocation of CRO employees by the CRO may negatively affect our clinical trials. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, our clinical trials may be delayed or terminated, and we may not be able to meet our current plans with respect to our product candidates. CROs also may involve higher costs than anticipated, which could negatively affect our financial condition and operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on third-party manufacturers to produce our clinical-stage product candidates, and their responsibilities often include purchasing from third-party suppliers the materials necessary to produce our product candidates for our clinical trials and regulatory approval. There are a limited number of suppliers for some of the raw materials that we expect to use to manufacture our product candidates, and we may not be able to identify alternative suppliers to prevent a possible disruption of the manufacture of our product candidates for our clinical trials, and, if approved, ultimately for commercial sale. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we generally do not expect to begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the trial, any significant delay or discontinuity in the supply of a product candidate, or the raw materials or other material components in the manufacture of the product candidate, could delay completion of our clinical trials and potential timing for regulatory approval of our product candidates, which would harm our business and results of operations. We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our product candidates and our current costs to manufacture our product candidates may not be commercially feasible. As a result, we may never be able to develop a commercially viable product.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our reliance on third-party manufacturers exposes us to the following additional risks:</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to identify manufacturers to manufacture our product candidates on acceptable terms or at all, because the number of qualified potential manufacturers is limited. Following NDA approval, a change in the manufacturing site could require additional approval from the FDA. This approval would require new testing and compliance inspections;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party manufacturers might be forced to scale back or terminate operations as a result of labor shortages, inflation, natural disasters or geopolitical conflicts, which could harm our ability to conduct ongoing and future clinical trials of our product candidates;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our future third-party manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our product candidates;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">drug manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMPs and other government regulations and corresponding foreign standards, and we do not have control over third-party manufacturers&#8217; compliance with these regulations and standards;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">if any third-party manufacturer makes improvements in the manufacturing process for our products, we may not own or be able to license, or we may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates; and</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party manufacturers could breach or terminate their agreements with us.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could delay our clinical trials, the approval, if any, of our product candidates, or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we rely on third parties to perform release testing on our product candidates prior to delivery to subjects in our clinical trials. If these tests are not appropriately conducted and test data are not reliable, subjects in our clinical trials, or patients treated with our product candidates, if any are approved in the future, could be put at risk of serious harm, which could result in product liability suits.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, consultants or vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants or vendors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA; manufacturing standards; federal and state healthcare fraud and abuse laws and regulations; or laws that require the true, complete and accurate reporting of financial information or data. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could result in regulatory sanctions and serious harm to our reputation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter misconduct by our employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished potential profits and future earnings, and curtailment of our operations, any of which could adversely affect our business, financial condition, results of operations or prospects.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we rely on third-party manufacturing and supply vendors, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party contract manufacturers to manufacture our product candidates for preclinical studies and clinical trials. We do not own manufacturing facilities for producing any clinical trial product supplies. There can be no assurance that our preclinical and clinical development product supplies will not be limited or interrupted, or that they will be of satisfactory quality or continue to be available at acceptable prices. The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMPs. In the event that any of our manufacturers fails to comply with these requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills or technology to a back-up or alternative supplier, or we may not be able to transfer such skills or technology at all. Furthermore, a manufacturer may possess technology related to the manufacture of our product candidate that such manufacturer owns independently. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on a sole supplier for the manufacture of GRI-0621. If this supplier is unable to supply to us in the quantities we require, or at all, or otherwise defaults on their supply obligations to us, we may not be able to obtain alternative supplies from other suppliers on acceptable terms, in a timely manner, or at all. Moreover, in the event this supplier breaches its contracts with us, our legal remedies associated with such a breach may be insufficient to compensate us for any damages we may suffer. In addition, if we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturer or manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for GRI-0621, GRI-0803 or any other product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may in the future seek to enter into collaborations with third parties for the development and commercialization of our product candidates, and our future collaborations will be important to our business. If we are unable to enter into collaborations, or if these collaborations are not successful, our business could be adversely affected. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A part of our strategy is to consider partnerships in indications and geographies where we believe partners can add significant commercial and/or development capabilities. Further, we do not yet have any capability for commercialization. Accordingly, we have and may in the future enter into collaborations with other companies to provide us with important technologies and funding for our programs and technology. Any future collaborations we enter into may pose a number of risks, including that collaborators have significant discretion in determining the efforts and resources that they will apply and may not perform their obligations as expected, collaborators may not provide us with timely and accurate information regarding development progress and activity under any future license agreement, which could adversely impact our ability to report progress to our investors and otherwise plan development of our product candidates, we may have disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive and collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborators for our product candidates, and the negotiation process is time-consuming and complex. In order for us to successfully establish a collaboration for one or more of our product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Collaborations are complex and time-consuming to negotiate and document. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into future collaborations or do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates, bring them to market and generate revenue from sales of drugs or continue to develop our technology, and our business may be materially and adversely affected. Even if we are successful in our efforts to establish new strategic collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. Any delay in entering into new strategic collaboration agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Managing Our Business and Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to develop current product candidates or identify and develop new product candidates will be impaired, could result in loss of markets or market share and could make us less competitive.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biotechnology and biopharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific, and medical personnel. We are highly dependent on our management, scientific and medical personnel, including W. Marc Hertz, our President and Chief Executive Officer, Vipin Kumar Chaturvedi, our Chief Scientific Officer and Albert Agro, our Chief Medical Officer. We have modified our employment arrangements with Dr. Agro. On June 16, 2024, our board of directors approved an amendment to Dr. Agro&#8217;s employment agreement, which reduced Dr. Agro's service for us to at least 70 hours per month. Dr. Agro may devote the balance of his time to other consulting or employment activities. The loss of the services of any of our executive officers, other key employees and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our operations at our facility in La Jolla, California. This region is headquarters to many other biotechnology companies, biopharmaceutical companies, and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Our key employees are at-will employees, which means that any of our employees could leave our employment at any time, with or without notice. There is no guarantee that any &#8220;key person&#8221; insurance policy we have or may enter into would adequately compensate us for the loss of any key employee. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior scientific and medical personnel.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract and retain management and other key personnel, we may be unable to successfully develop or commercialize our product candidates or otherwise implement our business plan.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry has experienced a high rate of turnover in recent years. Our ability to compete in the highly competitive biopharmaceuticals industry depends upon our ability to attract, retain, and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing, and management skills and experience. We may not be able to attract or retain qualified personnel in the future due, in part, to the intense competition for a limited number of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies against which we will compete have greater financial and other resources, different risk profiles, and a longer history in the industry. Our competitors may provide higher compensation, more diverse opportunities, and/or better opportunities for career advancement. Any or all of these competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize our product candidates and to grow our business and operations as currently contemplated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to adequately protect our internal information systems, or those used by our CROs, clinical sites, or other contractors or consultants upon which we rely, from cyberattacks, compromises, cybersecurity incidents, or other disruptions,compromises, cybersecurity incidents, or other disruptions, which could result in the compromise of sensitive or proprietary information, lead to operational or service interruption, harm our reputation, and subject us to litigation, fines and other significant financial and legal exposure, and other material and adverse consequences. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we, and the third parties upon which we rely, process sensitive or proprietary information and as a result, we and the third parties upon which we rely face a variety of evolving threats which could cause material cybersecurity incidents.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our implementation of security measures, our internal computer systems and those of our CROs, clinical sites, and other collaborators, contractors, or consultants upon which we rely are vulnerable to cyberattacks, computer viruses, malware, bugs, worms, or other malicious code, software or hardware failures, loss of data or other information technology assets, phishing or other unauthorized access, natural disasters, terrorism, war, and telecommunication and electrical failures, and other similar threats. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer &#8220;hackers,&#8221; threat actors, &#8220;hacktivists,&#8221; organized criminal threat actors, personnel, such as through theft or misuse, sophisticated nation states, and nation-state-supported actors. In particular, ransomware attacks, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including those from organized criminal threat actors, nation-states and nation-state supported actors, are becoming increasingly prevalent and severe and can lead to significant interruptions, delays, or outages in our operations, loss of data, including significant extra expenses to restore data or systems, reputational loss and the diversion of funds. To alleviate the negative impact of a ransomware attack, it may be preferable to make payments to the threat actor(s), but we may be unwilling or unable to do so, including, for example, if applicable laws or regulations prohibit such payments.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some threat actors also now engage and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors, for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we, the third parties upon which we rely, and our customers may be vulnerable to a heightened risk of these attacks, including retaliatory cyber-attacks that could materially disrupt our systems and operations. In addition to experiencing a cybersecurity incident, third parties may gather, collect, or infer sensitive information about us from public sources, data brokers, or other means that reveals competitively sensitive details about our organization and could be used to undermine our competitive advantage or research and development activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, remote work has become more common and has increased risks to our information technology systems and data, as our employees utilize network connections, computers and devices outside our premises or network, including working at home, while in transit and in public locations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we take steps to detect and remediate vulnerabilities, we may not be able to detect and remediate all vulnerabilities because the threats and techniques used to exploit such vulnerabilities change frequently and are often sophisticated in nature. Therefore, such vulnerabilities could be exploited but may not be detected until after a cybersecurity incident has occurred, if at all. Further, we may experience delays in developing and deploying remedial measures designed to address any such identified vulnerabilities. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on third-party service providers and critical business information technology systems that we or our third-party service providers operate to process, transmit and store confidential, sensitive, and proprietary information in our day-to-day operations. We also rely on third-party service providers to assist with our clinical trials, provide other products or services, or otherwise to operate our research and development activities. Our ability to monitor these third parties&#8217; information security practices is limited, and these third parties may not have adequate information security measures in place. If our third-party service providers experience a cybersecurity incident or other interruption, we could experience adverse consequences. While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award. In addition and in general, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that third parties and infrastructure in our supply chain or our third-party partners&#8217; supply chains have not been compromised or that they do not contain exploitable defects or bugs that could result in a breach of or disruption to our information technology systems, including our services, or the third-party information technology systems that support us and our services.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the previously identified or similar threats could cause a cybersecurity incident or other interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss, alteration, encryption, disclosure of, or access to our sensitive data or our information technology systems, or those of the third parties upon whom we rely. A cybersecurity incident or other interruption could materially and adversely disrupt our ability, and that of third parties upon whom we rely, to conduct clinical trials and our research and development activities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs related to significant cybersecurity breaches or disruptions could be material and cause us to incur significant expenses. If the information technology systems of our CROs, clinical sites, and other contractors and consultants become subject to disruptions or cybersecurity incidents, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our operations, financial loss, a loss of our trade secrets or other proprietary information and damage to our reputation and otherwise negatively impact us. For example, the loss of clinical trial data from ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or cybersecurity incident were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential, sensitive, or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Applicable data privacy and security obligations may require us to notify relevant stakeholders, regulatory authorities, and other individuals of cybersecurity incidents, and take other remedial measures. Such disclosures and measures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. Any such event could also result in legal claims or proceedings, liability under laws that protect the privacy of personal information and significant regulatory penalties, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and damage to our reputation and a loss of confidence in us and our ability to conduct clinical trials, which could delay the clinical development of our product candidates.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster, including earthquakes, outbreak of disease or other natural disasters.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our current operations are located in our facilities in La Jolla, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemic, power shortage, telecommunication failure or other natural or manmade accident or incident that results in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Some of these natural events may be exacerbated by climate change. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption or disruption of our business operations, all of which could have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented or interrupted us from using all or a significant portion of our headquarters, damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disaster recovery and business continuity plans and procedures we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of any failure or inadequacy of our disaster recovery and business continuity plans and procedures, which, could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at reasonable levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of our insurance coverage will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed or delayed.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics in regions where it or third parties on which it relies have significant manufacturing facilities, concentrations of clinical trial sites, or other business operations. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business could be adversely affected by the effects of health pandemics or epidemics in regions where it has concentrations of clinical trial sites or other business operations, and could cause significant disruption in the operations of third-party manufacturers and CROs upon whom it relies. Such pandemics or epidemics may negatively impact productivity, disrupt business and delay clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of any restrictions and other limitations placed on our ability to conduct business in the ordinary course as a result of any such pandemic or epidemic. These and similar disruptions in operations could negatively impact our business, operating results and financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quarantines, stay at home and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, may impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain. While many of these materials may be obtained by more than one supplier, restrictions resulting from any pandemic may disrupt our supply chain or limit our ability to obtain sufficient materials for our product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance may not provide adequate levels of coverage against claims which may adversely affect our financial condition.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain insurance that we believe is adequate for businesses of our size and type. However, there are types of losses that we believe are not economically reasonable to insure or that cannot be insured against.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that we may be subject to securities litigation in the future, including potential class action or stockholder derivative actions. Our indemnification agreements with our directors and certain officers, as well as Delaware General Corporation Law (DGCL), may require us, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. Without Director and Officer insurance, the amounts we would pay to defend any such litigation or indemnify our officers and directors should they be subject to legal action based on their service to us could have a material adverse effect on our financial condition, results of operations and liquidity.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock, Financing and Capital Requirements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect the stock price of our Common Stock to be highly volatile.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of shares of our Common Stock has been and is likely to continue to be subject to significant fluctuations. Market prices for securities of biotechnology and other life sciences companies historically have been particularly volatile subject even to large daily price swings. Some of the factors that may cause the market price of shares of our Common Stock to fluctuate include, but are not limited to:</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain timely regulatory approvals for future product candidates, and delays or failures to obtain such approvals;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with the listing requirements of The Nasdaq Capital Market and any delisting or potential delisting of shares of our Common Stock; </span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of product candidates, if approved, to achieve commercial success;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issues in manufacturing future product candidates;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of current and any future clinical trials;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the entry into, or termination of, or breach by partners of key agreements, including key commercial partner agreements;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation of, material developments in, or conclusion of any litigation to enforce or defend any intellectual property rights or defend against the intellectual property rights of others;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of any dilutive equity financings and significant issuances of equity securities;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships or capital commitments;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to elicit meaningful stock analyst coverage and downgrades of our stock by analysts; </span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with our obligations pursuant to our registration rights agreements; and</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the loss of key employees.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the stock markets in general have experienced substantial volatility in the biotechnology industry that has often been unrelated to the operating performance of individual companies or a certain industry segment. These broad market fluctuations may also adversely affect the trading price of our Common Stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation. In addition, such securities litigation often has ensued after a reverse merger or other merger and acquisition activity of the type engaged by us. Such litigation, if brought, could impact negatively our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales and issuances of our securities could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations, including research and development, increased marketing, hiring new personnel, commercializing our products, and continuing activities as an operating public company. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell shares of our Common Stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell Common Stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there were a total of (i) 420 shares of Common Stock directly or indirectly underlying the Series B-1 common warrants (the Series B-1 Common Warrants) and Series B-2 common warrants (the Series B-2 Common Warrants, and together with the Series B-1 Common Warrants, the Series B Common Warrants), (ii) 257,154 shares of Common Stock directly or indirectly underlying the Series C-1 common warrants (the Series C-1 Common Warrants) and Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants), (iii) 89,678 shares of Common Stock directly or indirectly underlying the Series D-1 common warrants (the Series D-1 Common Warrants) and Series D-2 common warrants (the Series D-2 Common Warrants, and together with the Series D-1 Common Warrants, the Series D Common Warrants), (iv) 12,171 shares of Common Stock underlying other outstanding warrants to purchase Common Stock, (v) 62 shares of Common Stock issuable upon the exercise of vested outstanding options under the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan), (vi) an additional 80 shares of Common Stock issuable upon the exercise of options that remain subject to vesting as of that date and (vii) 114 options available for future issuance under the A&amp;R 2018 Plan. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not receive any proceeds from the exercise of warrants to the extent exercised on a cashless basis. The holders of these securities or their affiliates have and may sell large amounts of our Common Stock in the open market or in privately negotiated transactions, which, in the past and again may result in a lower trading price of our Common Stock and substantial dilution to our stockholders. Additionally, the registration and availability of such a significant number of shares of Common Stock for trading in the public market has and may increase the volatility in our stock price or put significant downward pressure on the price of our Common Stock. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not anticipate paying any dividends in the foreseeable future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current expectation is that we will retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of the shares of our Common Stock will be our stockholders&#8217; sole source of gain, if any, for the foreseeable future.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives. In addition, if we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses under the Exchange Act, the Sarbanes-Oxley Act of 2002, as amended (SOX) and other applicable securities rules and regulations. In addition, we are subject to the rules of Nasdaq and The Nasdaq Capital Market.</span></div><div style="margin-bottom:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These rules impose various requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial controls and appropriate corporate governance practices. Our management and other personnel have devoted and will continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and regulations make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In addition, the listing requirements of The Nasdaq Capital Market require that we satisfy certain corporate governance requirements relating to director independence, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel need to devote a substantial amount of time to ensure that we comply with all of these requirements. As a result, it may be difficult for us to attract and retain qualified persons to serve on our Board, our Board committees or as executive officers.</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SOX requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. As a result, we are required to periodically perform an evaluation of our internal controls over financial reporting to allow management to report on the effectiveness of those controls, as required by Section 404 of SOX (Section 404). Additionally, our independent auditors may be required to perform a similar evaluation and report on the effectiveness of our internal controls over financial reporting. These efforts to comply with Section 404 and related regulations have required, and continue to require, the commitment of significant financial and managerial resources. B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ased on management&#8217;s processes and assessment, as described under Item 9A. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,&#8221; management has concluded that, as of December 31, 2024, our internal control over financial reporting was not effective as a result of material weakness related to inaccurate computation of the non-cash deemed dividend associated with the pre-pricing of the Series B Common Warrants in the Warrant Pricing Transaction (as defined below) in accordance with applicable GAAP guidance. While we anticipate remediating this material weakness, and maintaining the integrity of our internal controls over financial reporting and all other aspects of Section 404, we cannot be certain that additional material weaknesses will not be identified when we test the effectiveness of our control systems in the future or that our remediation efforts will be or remain successful. If additional material weaknesses are identified, we could be subject to sanctions or investigations by the SEC, or other regulatory authorities, which would require additional financial and management resources, costly litigation or a loss of public confidence in our internal controls, which could have an adverse effect on the market price of our stock. Notwithstanding this material weakness, we believe that our financial statements contained in this Annual Report on Form 10-K fairly present our financial position, results of operations and cash flows for the periods covered by this report in all material respects.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently take advantage of reduced disclosure and governance requirements applicable to smaller reporting companies, which could result in our Common Stock being less attractive to investors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a public float of less than $250.0 million and therefore qualify as a smaller reporting company under the rules of the SEC. As a smaller reporting company, we are able to take advantage of reduced disclosure requirements, such as simplified executive compensation disclosures and reduced financial statement disclosure requirements in our SEC filings. Decreased disclosures in our SEC filings due to our status as a smaller reporting company may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our Common Stock less attractive if we rely on these exemptions. If some investors find our Common Stock less attractive as a result, there may be a less active trading market for our Common Stock and our stock price may be more volatile. We may take advantage of the reporting exemptions applicable to a smaller reporting company until we are no longer a smaller reporting company, which status would end once we have a public float greater than $250.0 million. In that event, we could still be a smaller reporting company if our annual revenues were below $100.0 million and we have a public float of less than $700.0 million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We also take advantage of reduced disclosure and governance requirements applicable to emerging growth companies, which could result in our Common Stock being less attractive to investors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. Emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. As an emerging growth company, we are not being required to comply with the auditor attestation requirements of Section 404, we have reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and we are exempt from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Additionally, as an emerging growth company, we have elected to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As such, our financial statements may not be comparable to companies that comply with public company effective dates. We cannot predict if investors will find our stock less attractive because we may rely on these provisions. If some investors find our stock less attractive as a result, there may be a less active trading market for our shares and our stock price may be more volatile.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement filed under the Securities Act of 1933, as amended (the Securities Act)) declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, will not adopt the new or revised standard until the time private companies are required to adopt the new or revised standard. This may make comparison of our financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accountant standards used.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will remain an emerging growth company until the earliest of (i) the end of the fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700 million as of the end of the second fiscal quarter, (ii) the end of the fiscal year in which we have total annual gross revenues of $1.235 billion or more during such fiscal year, (iii) the date on which we issue more than $1 billion in non-convertible debt in a three-year period, or (iv) the end of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement filed under the Securities Act (December 31, 2026).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A delisting of our Common Stock from Nasdaq could adversely affect our ability to raise additional capital through the public or private sale of equity securities and our investors&#8217; ability to dispose of, or obtain accurate quotations as to the market value of, our Common Stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules of The Nasdaq Capital Market require that we maintain a closing price for shares of our Common Stock of at least $1.00 per share (the Minimum Bid Price Rule) and that we meet other requirements for continued listing which include, among other things, requirements that we maintain a market value of listed securities of at least $35 million or, alternatively, stockholders&#8217; equity of at least $2.5 million, or, alternatively, annual net income from continuing operations of at least $500 thousand as described in applicable listing requirements. As of the date of this Annual Report, the market value of our listed securities was less than $35 million, and we had not earned net income in excess of $500 thousand. We will need to raise a substantial amount of capital in the near term to maintain compliance with The Nasdaq Capital Market&#8217;s $2.5 million equity requirement and these efforts may not be successful.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 10, 2024, we received a letter (the Letter) from the Staff of Nasdaq indicating that we no longer met the Minimum Bid Price Rule set forth in Nasdaq Listing Rule 5550(a)(2) because the closing bid price for our Common Stock was less than $1.00 for the 30 consecutive business days prior thereto. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 19, 2025, we filed an amendment to our Charter to implement a reverse split of our Common Stock at a ratio of one-for-seventeen (the February 2025 Reverse Stock Split) to attempt to regain compliance with the Minimum Bid Price Rule. Subsequently, on March 10, 2025, we received a letter from the Staff indicating that we were once again in compliance with the Minimum Bid Price Rule. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, we may fail to maintain long-term compliance with the Minimum Bid Price Rule. We previously effected two reverse stock splits in 2024 prior to receiving the Letter from Nasdaq in September 2024. If we again fail to comply with the Minimum Bid Price Rule, we will not be able to again complete a reverse stock split in compliance with applicable Nasdaq rules in the near term. If we are unable to comply with a listing requirement of The Nasdaq Capital Market, including the Minimum Bid Price Rule, shares of our Common Stock would likely be delisted.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our Common Stock is delisted by Nasdaq, our Common Stock may be eligible to trade on the OTC Markets or another over-the-counter market, but a delisting, threatened delisting or trading on these markets would likely result in it being more difficult for us to raise additional capital through the public or private sale of equity securities and for investors to dispose of, or obtain accurate quotations as to the market value of, our Common Stock. In addition, there can be no assurance that our Common Stock would be eligible for trading on any such alternative exchange or markets.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless our Common Stock is listed on a national securities exchange, such as The Nasdaq Capital Market, our Common Stock may also be subject to the regulations and restrictions regarding trading in &#8220;penny stocks,&#8221; which are those securities trading for less than $5.00 per share, and that are not otherwise exempted from the definition of a penny stock under other exemptions provided for in the applicable regulations. These requirements and regulations could severely limit the liquidity of securities in the secondary market because fewer brokers or dealers would likely to be willing to undertake related compliance activities. If our Common Stock is not listed on a national securities exchange, the rules and restrictions regarding penny stock transactions may limit an investor&#8217;s ability to sell to a third-party and our trading activity in the secondary market may be reduced.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these or the above circumstances could adversely affect our business, results of operation, prospects and the value of shares of our Common Stock. A delisting for this reason or any other reason could materially affect our ability to raise capital, adversely affect our business and the price of our Common Stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The February 2025 Reverse Stock Split may have caused our stock price to decline relative to its value before the split and likely has reduced the liquidity of shares of our Common Stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We legally effected the February 2025 Reverse Stock Split on February 21, 2025 and on February 24, 2025, our Common Stock began trading on a post-split basis. It cannot be assured that the February 2025 Reverse Stock Split will result in any sustained proportionate increase in the market price of our Common Stock, which is dependent upon many factors, including our business and financial performance, general market conditions, and prospects for future success, which are unrelated to the number of shares of our Common Stock outstanding. It is not uncommon for the market price of a company&#8217;s common stock to decline in the period following a reverse stock split.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2025 Reverse Stock Split may have caused a decline in the value of our outstanding Common Stock. Additionally, the trading volume of our shares following the reverse stock splits completed since 2023 has varied, and shares of our Common Stock have been less liquid as a result of these reverse stock splits. It is likely that the liquidity of the shares of our Common Stock was affected adversely by the February 2025 Reverse Stock Split given the reduced number of shares outstanding following the February 2025 Reverse Stock Split. There can be no assurance that the liquidity of our Common Stock will increase, especially if the market price of our Common Stock does not increase.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Following a reverse stock split, the resulting market price of our Common Stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements of those investors. Consequently, the trading liquidity of our Common Stock may not improve.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that a higher market price of our Common Stock may help generate greater or broader investor interest, there can be no assurance that a reverse stock split, including the recently completed February 2025 Reverse Stock Split, will result in a share price that will attract new investors, including institutional investors. In addition, there can be no assurance that the market price of our Common Stock will satisfy or continue to satisfy the investing requirements of those investors. As a result, the trading liquidity of our Common Stock may not necessarily improve. The primary intent for the February 2025 Reverse Stock Split was to increase the price of our Common Stock in order to help us meet the Minimum Bid Price Rule pursuant to Nasdaq listing requirements. It cannot be assured that a reverse stock split, including the February 2025 Reverse Stock Split, will result in any sustained proportionate increase in the market price of our Common Stock, which is dependent </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">upon many factors, including our business and financial performance, general market conditions, and prospects for future success, which are unrelated to the number of shares of our Common Stock outstanding. It is not uncommon for the market price of a company&#8217;s common stock to decline in the period following a reverse stock split such as occurred following the reverse stock splits completed since 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal, state and local income taxation are constantly under review by the Internal Revenue Service (IRS), the U.S. Treasury Department, and other governmental bodies. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our Common Stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An active trading market for our Common Stock may not develop and our stockholders may not be able to resell their shares of Common Stock for a profit, if at all.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An active trading market for our shares of Common Stock may never develop or be sustained. If an active market for our Common Stock does not develop or is not sustained, it may be difficult for our stockholders to sell their shares at an attractive price or at all.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If equity research analysts do not publish research or reports, continue to publish reports or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our Common Stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may not elect to provide research coverage of our Common Stock or may elect to discontinue coverage of our Common Stock, and such lack of research coverage may adversely affect the market price of our Common Stock. We do not have any control over the analysts, or the content and opinions included in their reports. The price of our Common Stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research or discontinue coverage of our Common Stock. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our Common Stock could decrease, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become a defendant in one or more stockholder derivative or class-action litigations, and any such future lawsuit may adversely affect our business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our officers and directors may become defendants in one or more future stockholder derivative actions or other class-action lawsuits. These lawsuits would divert our management&#8217;s attention and resources from our ordinary business operations, and we would likely incur significant expenses associated with their defense (including, without limitation, substantial attorneys&#8217; fees and other fees of professional advisors and potential obligations to indemnify current and former officers and directors who are or may become parties to such actions). If these lawsuits do arise, we may be required to pay material damages, consent to injunctions on future conduct and/or suffer other penalties, remedies or sanctions. In addition, any such future stockholder lawsuits could adversely impact our reputation, our ability to continue to develop our product candidates, thereby harming our ability to generate revenue. Accordingly, the ultimate resolution of these matters could have a material adverse effect on our business, financial condition, results of operation and cash flow and, consequently, could negatively impact the trading price of our Common Stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation documents and Delaware law may inhibit a takeover that stockholders consider favorable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions of our amended and restated certificate of incorporation and our amended and restated bylaws and applicable provisions of Delaware law may delay or discourage transactions involving an actual or potential change in control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. The provisions in our amended and restated certificate of incorporation and amended and restated bylaws:</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">do not provide for cumulative voting rights;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that all vacancies may be filled only by the affirmative vote of a majority of directors then in office, even if less than a quorum;</span></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal claims; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:31.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide that the federal district courts of the United States of American will be the exclusive forum for legal claims under the Securities Act.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section 203 of the DGCL may limit our ability to engage in any business combination with a person who beneficially owns 15% or more of our outstanding voting stock unless certain conditions are satisfied. This restriction lasts for a period of three years following the share acquisition. These provisions may have the effect of entrenching our management team and may deprive stockholders&#8217; of the opportunity to sell their shares to potential acquirers at a premium over prevailing prices. This potential inability to obtain a control premium could reduce the price of our common stock. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our amended and restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claim for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, and employees to our or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. We believe these provisions provide increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, these provisions may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in the amended and restated certificate of incorporation to be inapplicable or unenforceable in such action. This choice of forum provision does not preclude or contract the scope of exclusive federal jurisdiction for any actions brought under the Exchange Act. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction, and we do not intend for the exclusive forum provision to apply to Exchange Act claims. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act. Additionally, this choice of forum provision will not apply to claims as to which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction. The choice of forum provision in the amended and restated certificate of incorporation does not have the effect of causing our stockholders to have waived our obligation to comply with the federal securities laws and the rules and regulations thereunder.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i73c3df21d6604995952be1876b1e93fe_31"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS.</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_34"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1C.&#160;&#160;&#160;&#160;CYBERSECURITY.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-38" continuedAt="f-38-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the critical importance of maintaining the trust and confidence of patients, business partners and employees toward our business and are committed to protecting the confidentiality, integrity and availability of our business operations and systems. Our Board is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-39" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-40">In general, we seek to address cybersecurity risks through a comprehensive approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.</ix:nonNumeric></ix:nonNumeric></span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><ix:continuation id="f-38-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy; Effect of Risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to cybersecurity such as unauthorized access, cybersecurity attacks and other security incidents, including as perpetrated by hackers and unintentional damage or disruption to hardware and software systems, loss of data, and misappropriation of confidential information. To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity program to ensure our systems are effective and prepared for information security risks, including regular oversight of our programs for security monitoring for internal and external threats to ensure the confidentiality and integrity of our information assets. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. As discussed in more detail under &#8220;Cybersecurity Governance&#8221; below, our Board provides oversight of our cybersecurity risk management and strategy processes, which are led by our Chief Financial Officer.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incident response plan coordinates the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, which include processes to triage, assess severity for, escalate, contain, investigate and remediate the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-41">Our processes also address <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-42">cybersecurity threat risks associated with our use of third-party service providers</ix:nonNumeric> who have access to employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers</ix:nonNumeric>.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, in Item 1A. under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">We may be unable to adequately protect our internal information systems, or those used by our CROs, clinical sites, or other contractors or consultants upon which we rely,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">from cyberattacks, compromises, cybersecurity incidents, or other disruptions, which could result in the compromise of sensitive or proprietary information, lead to operational or service interruption, harm our reputation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">and subject us to litigation, fines and other significant financial and legal exposure, and other adverse consequences,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; which disclosures are incorporated by reference herein.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-43">In the last three fiscal years, we have not experienced any material cybersecurity incidents and the expenses we have incurred from cybersecurity incidents were immaterial. This includes penalties and settlements, of which there were none.</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity Governance; Management</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-44" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-45" escape="true">Cybersecurity is an important part of our risk management processes and an area of focus for our Board and management. Our Board is responsible for the oversight of risks from cybersecurity threats.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-47" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-46" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Board receives periodic updates from management about our cybersecurity threat risk management and strategy processes. Additionally, upon detection of a cybersecurity threat, our Board receives an update from management of our cybersecurity threat risk management and strategy processes, as well as the steps management has taken to respond to such identified cybersecurity threat. Our Board also receive prompt and timely information regarding any cybersecurity incident that meets establishing reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed</span></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-50" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-49" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-48" escape="true">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, is managed by our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-51">Chief Financial Officer</ix:nonNumeric> and supported by consultants with experience in managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs as needed.</ix:nonNumeric></ix:nonNumeric> As discussed above, <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-52">the Chief Financial Officer reports to our Board about material cybersecurity threat risks.</ix:nonNumeric></span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2.&#160;&#160;&#160;&#160;PROPERTIES.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive offices are located at 2223 Avenida de La Playa #208, La Jolla, CA 92037, where we lease approximately 1,100 square feet of office space under a lease that expires in March 2027. We believe that our facilities are adequate to meet our current needs.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_40"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition. </span></div><div id="i73c3df21d6604995952be1876b1e93fe_43"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i73c3df21d6604995952be1876b1e93fe_49"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information and Holders</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Stock is currently listed on The Nasdaq Capital Market under the symbol &#8220;GRI.&#8221; As of March 14, 2025, there were 525,358 shares of Common Stock held by approximately 13 stockholders of record and no shares of preferred stock outstanding. </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance Under Equity Compensation Plans</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part III, Item 12. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for information relating to our equity compensation plans.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of Equity Securities By the Issuer and Affiliated Purchasers</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not declared or paid any cash or other dividends on our Common Stock, and we do not expect to declare or pay any cash or other dividends in the foreseeable future.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_52"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;[</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RESERVED.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">]</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div id="i73c3df21d6604995952be1876b1e93fe_55"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and related notes beginning on page F-1 of this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled &#8220;Item 1A. Risk Factors&#8221; and &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained herein.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_58"></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our lead product candidate, GRI-0621, is an oral inhibitor of iNKT cells. GRI-0621 is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, that is approved in the United States for topical treatment of psoriasis and acne. As of December 31, 2024, it has been evaluated in over 1,700 patients as an oral product for up to 52-weeks. We are developing GRI-0621 for the treatment of severe fibrotic lung diseases such as IPF, a life-threatening progressive fibrotic disease of the lung that affects approximately 140,000 people in the United States, with up to 40,000 new cases per year in the United States. Some estimate that IPF affects 3 million people globally. While there are currently two approved therapies for the treatment of lung fibrosis, neither has been associated with improvements in overall survival, and both therapies have been associated with significant side effects leading to poor therapeutic adherence. In preliminary data from our trials to date with GRI-0621, and earlier trials with oral tazarotene, we have observed GRI-0621 to be well-tolerated and to inhibit iNKT cell activity in subjects. We and others have shown that activated iNKT are upregulated in IPF, PSC, MASH, ALD, SLE, MS, UC patients, as well as other indications. In these patients activated iNKT cells are correlated with more severe disease. The FDA has cleared our IND application for GRI-0621 for the treatment of IPF and we plan to evaluate GRI-0621 in a randomized, double-blind, multi-center Phase 2a biomarker study, for which we commenced enrollment in December 2023. Based on our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">current projections, we expect topline results from this trial to be available in the third quarter of 2025. Additionally, on March 1, 2024, we received authorization of our CTA from the United Kingdom MHRA to initiate the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the United Kingdom. On September 24, 2024, we received approval from the HREC to initiate the Phase2a biomarker study evaluating GRI-0621 for the treatment of IPF in Australia, after previously receiving authorization on our CTA from the Australian MHRA. </span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of dNKT cells. We are developing GRI-0803 for the treatment of autoimmune disorders, with much of our preclinical work in SLE or lupus and MS. In lupus, the immune system mistakenly attacks its own healthy tissues, especially joints and skin, but can affect almost every organ and tissue of the body. The condition can be fatal, and often causes debilitating bouts of fatigue and pain that prevent nearly half of adult patients from working. Lupus affects between 160,000 &#8211; 200,000 patients in the United States, with around 80,000 &#8211; 100,000 patients in the United States suffering from kidney nephritis, one of the most serious manifestations of SLE, typically within five years of diagnosis. There is no cure for lupus, but medical interventions and lifestyle changes can help control it. SLE treatment consists primarily of immunosuppressive drugs that inhibit the activity of the immune system. Only two drugs have been approved for lupus in the past 50 years, and new treatment options are sorely needed. Subject to IND clearance, we intend to evaluate GRI-0803 in a Phase 1a and 1b trial initially targeting SLE. We expect to file an IND with respect to this Phase 1a and 1b trial in 2025. We will continue to evaluate indications to select the best fit for further development of the program, but our initial focus is on lupus.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Splits</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 11, 2025, our stockholders approved the February 2025 Reverse Stock Split within a range of not less than one-for-two and not more than one-for-23 and our Board subsequently approved the February 2025 Reverse Stock Split at the ratio of one-for-17. Following these approvals, we filed an amendment to our Charter with the Secretary of State of the State of Delaware to effect the February 2025 Reverse Stock Split as of 4:01 p.m. Eastern Time on February 21, 2025. Shares of our Common Stock began trading on a post-split basis on February 24, 2025. The February 2025 Reverse Stock Split had the effect of reducing the aggregate number of outstanding shares of Common Stock from 8,933,366 shares on a pre-reverse split basis to a total of 525,358 shares outstanding on a post-reverse split basis.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously, on January 29, 2024, we effected a reverse stock split of our Common Stock at a ratio of one-for-seven, and on June 17, 2024, we effected a reverse stock split of our Common Stock at a ratio of one-for-13. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise noted, all financial information, share numbers, option numbers, warrant numbers, other derivative security numbers and exercise prices appearing in this Annual Report have been adjusted to give effect to the reverse stock splits described herein.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2024 Repricing Letter Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 21, 2024, we entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of our issued and outstanding Series B-1 Common Warrants and Series B-2 Common Warrants to purchase an aggregate of 44,842 shares of our Common Stock, offering these Holders the opportunity to exercise all of their Series B Common Warrants for cash at an exercise price equal to $17.00 per share. In addition, these Holders received new unregistered Series D-1 Common Warrants exercisable for up to an aggregate of 44,839 shares of Common Stock and new unregistered Series D-2 Common Warrants exercisable for up to an aggregate of 44,839 shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $17.00 per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We refer to this transaction as the &#8220;Warrant Repricing Transaction.&#8221;</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">H.C. Wainwright &amp; Co., LLC (Wainwright) acted as the exclusive placement agent for the Warrant Repricing Transaction pursuant to an engagement agreement between us and Wainwright, dated as of October 21, 2024. In addition to a cash fee, management fee, and reimbursement of certain accountable and non-accountable expenses, we also issued to Wainwright or its designees warrants to purchase up to an aggregate of 3,140 shares of Common Stock (the PA Warrants) as compensation for its placement agent services. The PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $21.25 per share.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, we entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which we issued and sold, in a public offering (the June 2024 Offering), (i) 3,529 shares (the June 2024 Shares) of Common Stock, (ii) 125,047 pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of 125,047 shares of Common Stock, (iii) 128,577 Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of 128,577 shares of Common Stock, and (iv) 128,577 Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants) exercisable for an aggregate of 128,577 shares of Common Stock. The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $31.11 (less $0.0017 for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants have been exercised in full. Each Series C-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 and expires on September 6, 2029. Each Series C-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 and expires on March 6, 2026. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent in the June 2024 Offering. Pursuant to an engagement agreement, we issued to Wainwright, or its designees, warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,002 shares of Common Stock (the June 2024 PA Warrants)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The June 2024 PA Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$38.89</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, will expire on June 26, 2029 and are currently exercisable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, we entered into an At The Market Offering Agreement (the Sales Agreement) with Wainwright, pursuant to which we may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0 million of our Common Stock from time to time through Wainwright as our sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we have sold 325,618 shares of our Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3.6 million of gross proceeds and net proceeds of $3.5 million, after deducting commissions to the sales agent and other ATM Offering related expenses. On December 20, 2024, we filed a prospectus supplement to our registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that we may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $0.3 million, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3.6 million that were sold under the ATM Offering through December 20, 2024, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, we entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which we issued and sold, in a public offering, (i) 1,495 shares (the February 2024 Shares) of Common Stock, (ii) 21,131 pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 Common Warrants exercisable for an aggregate of 22,631 shares of Common Stock, and (iv) 22,631 Series B-2 Common Warrants exercisable for an aggregate of 22,631 shares of Common Stock. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Annual Report as the February 2024 Warrants. The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $243.10 (less $0.0221 for each February 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2024 Pre-Funded Warrants have been exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 and expires on February 6, 2029. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 and expires on August 6, 2026. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the February 2024 Shares and the February 2024 Warrants pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants was reduced to par, or $0.0001 per share, pursuant to the terms of the Series A-1 Warrants. All of the Series A-1 Warrants have been exercised in full.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasdaq Compliance - Bid Price Deficiency</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules of The Nasdaq Capital Market require that we maintain a closing price for shares of our Common Stock of at least $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). On September 10, 2024, we received the Letter from the Staff of Nasdaq, indicating that we no longer met the Minimum Bid Price Rule because the closing bid price for our Common Stock was less than $1.00 for the 30 consecutive business days prior thereto. Subsequently, on March 10, 2025, we received a letter from the Staff indicating that we were once again in compliance with the Minimum Bid Price Rule. </span></div><div id="i73c3df21d6604995952be1876b1e93fe_61"></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC Topic 718). ASC Topic 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. We account for forfeitures as incurred. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of option shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of our common stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in our Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective. If any assumptions change, our stock-based compensation expense could be materially different in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These assumptions used in our Black-Scholes option-pricing model are estimated as follows:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  Due to the lack of sufficient company-specific historical data, the expected term of employee options is determined using the &#8220;simplified&#8221; method, as prescribed in SEC&#8217;s Staff Accounting Bulletin (SAB) No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option. The expected term of nonemployee options is equal to the contractual term. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The expected volatility is based on a weighted-average of our historical volatility and the historical volatilities of similar entities within our industry which were commensurate with the expected term assumption as described in SAB No. 107. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Risk-Free Interest Rat</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e.  The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Expected Dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  The expected dividend yield is 0% because we have not historically paid, and do not expect for the foreseeable future to pay, a dividend on our common stock.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for leases in accordance with Accounting Standards Update (ASU) 2016-02,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and ASU 2018-10,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements to Topic 842, Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ASU 2018-11,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842): Targeted Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, both of which clarify and enhance the certain amendments made in ASU 2016-02. The ASUs increase transparency and comparability among entities by recognizing lease assets and lease liabilities on the balance sheet for all leases and disclosing key information about lease arrangements. We entered into one lease for office space which we determined was an operating lease.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_64"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses have consisted primarily of costs related to our development program for our lead product candidate GRI-0621. These expenses include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead-related expenses and travel-related expenses for our research and development personnel; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expenses incurred under agreements with contract research organizations, contract manufacturing organizations and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities as well as consultants that support the implementation of our clinical and nonclinical studies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our direct research and development expenses are tracked by product candidate, we do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates as these costs are deployed across multiple programs. We expect our research and development expenses to increase over the next several years as we conduct our planned clinical and preclinical activities for our product candidates.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to corporate matters.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our general and administrative expenses will continue to increase as we incur costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors&#8217; and officers&#8217; insurance, legal and accounting costs and investor relations costs, as well as an increase in personnel expenses as we hire additional personnel.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precludes the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were measured at fair value upon issuance using a Black-Scholes valuation model and are recorded as a liability on the consolidated balance sheet. The fair value of the May 2022 Warrants is measured at each reporting date and changes in fair value are recognized in the consolidated statements of operations in the period of change. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2023, we entered into Asset Purchase Agreement (the Aardvark Agreement) with Aardvark Therapeutics, Inc. (Aardvark), pursuant to which Aardvark agreed to purchase (i) our license agreement with Medice Arzneimittel P&#369;tter GmbH &amp; Co. KG, dated January 6, 2020, (ii) certain patents related to our ADAIR product candidate, and (iii) files (of contract manufacturing and FDA correspondence) for a formulation described in IND No. 133072, ADAIR for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy, filed with the United States FDA. Under the terms of the Aardvark Agreement, we received an upfront cash payment of $0.3 million, which was recognized as other income. We are also eligible to receive potential additional milestone payments contingent upon Aardvark achieving certain future ADAIR regulatory and sales milestones. Other than the upfront payment, we do not anticipate the receipt of any milestone payments from Aardvark in the near term, which potential milestone payments may or may not be achieved, paid or received in the future.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income (Expense), net</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of amortization of debt discounts, debt issuance costs and interest expense related to the senior secured notes in the aggregate principal amount of up to approximately $3.3 million (the Bridge Notes) purchased pursuant to that certain Securities Purchase Agreement, dated December 13, 2022, with Altium Growth Fund LP (Altium) (the Equity SPA). Interest income consists of interest earned on our cash and cash equivalents held with institutional banks.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2024-03). The amendments in ASU 2024-03 require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, for all public entities. Early adoption is permitted. We are currently evaluating the impact of this update on our consolidated financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. We are currently evaluating the impact of this update on our consolidated financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, FASB issued ASU 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-06 represent changes to clarify or improve disclosure and presentation requirements of a variety of topics in the Codification and align those requirements with the SEC&#8217;s regulation. For entities subject to the SEC&#8217;s existing disclosure requirements, the effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. We are currently evaluating the impact of this update and its effective dates but do not expect the update to have a material effect on our consolidated financial statements.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_70"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company Status</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of any fiscal year for so long as either (1) the market value of our shares of Common Stock held by non-affiliates does not equal or exceed $250.0 million as of the prior June 30th, or (2) our annual revenues did not equal or exceed $100.0 million during such completed fiscal year and the market value of our shares of Common Stock held by non-affiliates did not equal or exceed $700.0 million as of the prior June 30th. To the extent we take advantage of any reduced disclosure obligations, it may make comparison of our financial statements with other public companies difficult or impossible.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not applicable to emerging growth companies. These exemptions include:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about our executive compensation arrangements;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more, (b) December 31, 2026, the last day of the fiscal year following the fifth anniversary of the completion of Vallon&#8217;s initial public offering, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2024 and 2023</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth our results of operations for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023 (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,768&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,235&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,235)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,387)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">250&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income (expense), net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,082)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,207)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,037)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $3.8 million and $3.2 million for the years ended December&#160;31, 2024 and 2023, respectively. The $0.6 million increase in research and development expenses was primarily due to increases of $0.7 million in expenses related to the registration development program of GRI-0621, offset by a $0.1 million decrease in personnel expense.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $4.5 million and $8.2 million for the years ended December&#160;31, 2024 and 2023, respectively. The $3.7 million decrease was primarily due to a decrease of $3.4 million in accounting, legal, investment banking and other fees as a result of the Merger and the cost of being a public company, a decrease of $0.4 million in personnel costs, and a decrease $0.1 million in consulting expenses, offset by an increase of $0.1 million in insurance expense and an increase of $0.1 million in other general and administrative expenses. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Income</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income was $0.3 million for the year ended December&#160;31, 2023 as a result of payments received under the terms of the Aardvark Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Warrant Liability </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of $0.2 million represents a decrease in the fair value of the warrants outstanding during the year ended December&#160;31, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income (Expense), net</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $25,000 for the year ended December&#160;31, 2024. Interest expense, net, was $2.1 million for the year ended December&#160;31, 2023 and related to the Bridge Notes. </span></div><div id="i73c3df21d6604995952be1876b1e93fe_76"></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $8.2 million and $13.0 million for the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $39.7 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our working capital requirements to date through the issuance of common stock, warrants, convertible notes and promissory notes. As of December&#160;31, 2024, we had $5.0 million in cash and cash equivalents. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,799&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024 and 2023, $8.6 million and $9.0 million were used in operating activities, respectively. The $0.4 million decrease was primarily due to a $4.8 million decrease in our net loss and a decrease of $1.0 million in cash used for prepaid and other expenses and operating lease liabilities, offset by a $2.3 million net decrease in non-cash adjustments, including stock based compensation expense and the amortization of debt discounts and debt issuance costs, and a $3.2 million increase in cash used for the payment of accounts payable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $8,000 for the year ended December&#160;31, 2023, which was related to the purchase of computer equipment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $11.8 million during the year ended December&#160;31, 2024 and was primarily related to $9.5 million of proceeds from the February 2024 Purchase Agreement and the June 2024 Purchase Agreement, $3.6 million of proceeds from the ATM Offering and $0.8 million of proceeds from the exercise of certain Series B Common Warrants. These proceeds were offset by $2.0&#160;million in stock issuance costs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $10.8 million for the year ended December&#160;31, 2023 and was primarily due to of $12.3&#160;million of proceeds from the Equity SPA, $1.3&#160;million of proceeds from the funding of the second tranche of the Bridge Notes and $0.9&#160;million of cash acquired in the connection with the Merger. These proceeds were offset by $3.0&#160;million in costs associated with the Merger, the payment of $0.2&#160;million of debt issuance costs related to the Bridge Notes and $0.5&#160;million of stock issuance costs related the Equity SPA. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2024 Repricing Letter Agreements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the transactions contemplated by the October 2024 Repricing Letter Agreements, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Overview &#8212; October 2024 Repricing Letter Agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; The net proceeds from the exercise of certain Series B Common Warrants were $0.6&#160;million after deducting placement agent fees and offering expenses of $0.2&#160;million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the transactions contemplated by the June 2024 Securities Purchase Agreement, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Overview &#8212; June 2024 Securities Purchase Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; The net proceeds from the offering were $3.2&#160;million, after deducting placement agent fees and offering expenses of $1.1&#160;million. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the May 2024 At the Market Offering, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Overview &#8212; May 2024 At The Market Offering.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; As of December&#160;31, 2024, we have sold 325,618 shares of our Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3.6 million of gross proceeds and net proceeds of $3.5 million, after deducting commissions to the sales agent and other ATM Offering related expenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the transactions contemplated by the February 2024 Securities Purchase Agreement, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Overview &#8212; February 2024 Securities Purchase </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; The net proceeds from the offering were $4.4&#160;million, after deducting placement agent fees and offering expenses of $1.1&#160;million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, we entered into the Equity SPA with GRI Operations and Altium pursuant to which Altium agreed to invest $12.3&#160;million in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations common stock immediately prior to the consummation of the Merger for net proceeds of $11.7&#160;million, after deducting offering expenses of $0.5&#160;million.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses were $8.2 million and $13.0 million for the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, we had $5.0 million in cash and an accumulated deficit of $39.7 million. We expect to devote substantial financial resources to our planned activities, particularly as we prepare for, initiate, and conduct our planned clinical trials of GRI-0621 and GRI-0803, advance our discovery programs and continue our product development efforts. In addition, we expect to incur additional costs associated with operating as a public company. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the second quarter of 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We intend to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed on acceptable terms, or at all, even if our research and development efforts are successful. If we are unable to secure adequate additional funding when needed or on acceptable terms, we will need to reevaluate our operating plans and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our technology on less favorable terms than we would otherwise choose or cease operations entirely. These actions could materially impact our business, results of operations and future prospects and the value of shares of our Common Stock. In addition, attempting to secure additional financing may divert the time and attention of management from day-to-day activities and distract from our discovery and product development efforts. As a result, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue unless and until we successfully complete development, obtain regulatory approval for and successfully commercialize our current, or any future, product candidates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 1A. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; of this Annual Report for additional risks associated with our substantial capital requirements.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_79"></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Other Commitments</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts in the normal course of business with third-party contract organizations for clinical trials, preclinical studies, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice and therefore we believe that our non-cancelable obligations under these agreements are not material.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_82"></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any off-balance sheet transactions. We have no guarantees or obligations other than those which arise out of normal business operations.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_85"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_88"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The financial statements required pursuant to this item are incorporated by reference herein from the applicable information included in Item 15. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Exhibits, Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; of this Annual Report and are presented beginning on page F-1.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_91"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to a company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Additionally, in designing disclosure controls and procedures, our management was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer (our principal executive officer) and our Chief Financial Officer (our principal financial officer) evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a 15(e) and 15d 15(e) under the Exchange Act, as of the end of the period covered by this Annual Report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of December&#160;31, 2024 due to the material weakness described below.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting to provide reasonable assurance of the reliability of financial reporting and of the preparation of financial statements for external reporting purposes, in accordance with GAAP. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;internal control over financial reporting&#8221; as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act is defined as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers, or persons performing similar functions, and effected by the company&#8217;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and disposition of assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with the authorization of its management and directors; and (3) provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on its financial statements. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies and procedures included in such controls may deteriorate.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our management has assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2024. In making this assessment, management used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring. Management&#8217;s assessment included documentation, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting. A material weakness in an internal control is defined as a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on management&#8217;s processes and assessment, as described above, management has concluded that, as of December&#160;31, 2024, our internal control over financial reporting was not effective as a result of a material weakness. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This material weakness related to the inaccurate computation of the non-cash deemed dividend associated with the pre-pricing of the Series B Common Warrants in the Warrant Repricing Transaction in accordance with applicable GAAP guidance. This inaccurate computation, if it had remained undetected, would have resulted in a single-digit percentage error in the amount of the net loss attributable to holders of our Common Stock used to compute basic and diluted net loss per share of Common Stock. The amounts presented in our balance sheets, statements of changes in stockholders&#8217; equity (deficit) and statements of cash flows were not affected. This adjustment was corrected prior to the finalization of this Annual Report on Form 10-K and no restatements of any prior periods are required.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has implemented a plan to remediate this material weakness which includes the continued engagement of third-party professionals with appropriate expertise in accounting and reporting under GAAP and SEC regulations who have adequate experience related to non-recurring debt and equity transactions and the enhanced documentation related to the accounting treatment for such transactions and who will assist in reviewing the attendant calculations. Management is refining our processes for communicating with our auditor as to when our financial statements and related materials have passed through the Company&#8217;s internal control processes.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding this material weakness, we believe that our financial statements contained in this Annual Report on Form 10-K fairly present our financial position, results of operations and cash flows for the periods covered by this report in all material respects.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firm</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for &#8220;emerging growth companies.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as disclosed above with respect to the plan to remediate the material weakness, there have been no changes in our internal control over financial reporting during the quarter ended December&#160;31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations of Effectiveness of Control</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. The design of any control system is based, in part, upon the benefits of the control system relative to its costs. Control systems can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. In addition, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_97"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B.&#160;&#160;&#160;&#160;OTHER INFORMATION.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rule 10b5-1 Trading Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended December&#160;31, 2024, none of our directors or officers <ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-53"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-54">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-55"><ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-56">terminated</ix:nonNumeric></ix:nonNumeric> a &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408 of Regulation S-K.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_100"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i73c3df21d6604995952be1876b1e93fe_106"></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10.&#160;&#160;&#160;&#160; DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE MANAGEMENT.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information about our directors and our executive officers as of February 28, 2025.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.587%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Age</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Executive Officers</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W. Marc Hertz, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">55</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Leanne Kelly</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Financial Officer</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vipin Kumar Chaturvedi, Ph.D.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Scientific Officer</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Albert Agro, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Chief Medical Officer</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Non-Employee Directors </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">David Szekeres</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Director, Chair of the Board</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">David Baker</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">61</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Camilla V. Simpson, M.Sc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Director</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Roelof Rongen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Director</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of the audit committee.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of the compensation committee.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Member of the nominating and corporate governance committee.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">W. Marc Hertz, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, has served as our President and Chief Executive Officer and as a member of our Board since April 2023. He co-founded GRI Operations in 2009 and served as Chief Executive Officer and chairperson of its board of directors since its inception. In addition to his management positions, Dr. Hertz previously served on the boards of directors of GemVax AS from 2005 to 2009, Evozym Biologics Inc., from 2014 to 2018, and currently serves on the board of directors of Multimeric Biotherapeutics, a privately-held research and development biotechnology company, since 2008. Dr. Hertz has also held several senior positions at companies in the biotechnology industry since 1998. Dr. Hertz received his undergraduate degree in biology from Bowdoin College and his Ph.D. in immunology and microbiology from the University of Colorado Medical School. We believe Dr. Hertz&#8217;s service as GRI Operations&#8217; co-founder and Chief Executive Officer and his extensive experience in the biotechnology industry qualifies him to serve as a member of our Board.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leanne Kelly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Chief Financial Officer since the closing of the Merger in April 2023. She brings over 20 years of experience leading private and publicly-traded companies across life sciences, technology and e-commerce sectors with a foundation in public accounting. From May 2021 until the closing of the Merger, she served as the Chief Financial Officer of Vallon. From 2016 to 2021, she served as the Controller and Executive Director of Global Financial Reporting at OptiNose, Inc., a multi-million dollar revenue specialty pharmaceutical company. Over the course of her career, she has held Senior Vice President of Finance, Controller and Chief Financial Officer positions in private and public companies such as Flower Orthopedics, Iroko Pharmaceuticals, LLC, and Genaera Corporation. Ms. Kelly began her career as an auditor with KPMG LLP. While serving in those roles, Ms. Kelly's work included multi-million dollar financings, M&amp;A diligence and support. She also has experience in financial oversight, internal and external financial reporting, forecasting, and financial analysis, as well as investor and public relations. Ms. Kelly also serves on the Board of Directors of Windtree Therapeutics, Inc., a publicly-traded biotechnology company, a position she has held since January 2025. Ms. Kelly received her Bachelor of Science degree in Business Economics with a concentration in Accounting from Lehigh University and is a licensed CPA (inactive status) in the state of Pennsylvania.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vipin Kumar Chaturvedi, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has served as our Chief Scientific Officer since April 2023. He co-founded GRI Operations in 2009 and, since its inception and until the date of the Merger, served as a member of its board of directors and as chairperson of its scientific advisory board. Dr. Chaturvedi served as GRI Operations&#8217; Chief Scientific Officer from 2009 to 2017 and from 2022 to April 2023. Dr. Chaturvedi has served as a Professor of Medicine, Laboratory of Immune Regulation at the University of California, San Diego since April 2015. In 2015, Dr. Chaturvedi co-founded Simomics, UK, a simulation software company and served as a non-executive director from 2015 to July 2022. Additionally, Dr. Chaturvedi has served on the board of directors of Vidur Discoveries, LLC, a consulting company, since 2009. Dr. Chaturvedi obtained his undergraduate degree in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">biology from the Kanpur University, India, his master&#8217;s in biochemistry, molecular biology and immunology from the Institute of Medical Education &amp; Research, India, and his Ph.D. in biochemistry from the Indian Institute of Science, India.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Albert Agro, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as our Chief Medical Officer since April 2023. He co-founded GRI Operations in 2009 and served as a consultant to GRI Operations with the title Chief Medical Officer from August 2017 until April 2023. Dr. Agro has been serving as the Chief Executive Officer of Jocasta Neuroscience Inc., a publicly-traded biotechnology company since June of 2024. He has also served as President and Chief Executive Officer of Columbia Therapeutics Inc. since April 2021 and has over 20 years of experience in the biotechnology and pharmaceutical industries having held several senior clinical and development positions, including Chief Executive Officer of Sublimity Therapeutics Inc. from March 2018 to April 2021 and Chief Medical Officer at Cynapsus from June 2012 to September 2016. Dr. Agro received his Ph.D. in immunology from the Department of Medicine at McMaster University. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">David Szekeres</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> has served as a member of our Board since April 2023. Mr. Szekeres currently serves as the President of Connect Biopharma Holdings Limited, a publicly-traded, U.S.-headquartered global clinical-stage biopharmaceutical company. He has more than two decades of experience in the global life sciences industry as a finance and business development executive, deal maker, legal counsel and board member. Mr. Szekeres joined Heron Therapeutics, Inc. in March 2016 and served as Chief Operating Officer and Head of Finance until August 2023. Prior to this, he served as Chief Business Officer, Principal Financial &amp; Accounting Officer and General Counsel at Regulus Therapeutics Inc. from 2014 to 2016. Mr. Szekeres also served as head of Mergers and Acquisitions at Life Technologies Corporation from 2008 through its acquisition by Thermo Fisher Scientific in February 2014. Mr. Szekeres currently serves on the board of directors at Sanford Burnham Prebys, CureMatch, and Animantis, and as an executive advisory board member at Colossal Biosciences. He served on the board of directors of Edico Genome Inc. from March 2014 until its acquisition by Illumina in 2018 and Patara Pharma from October 2014 until its acquisition by Roivant Sciences in 2018. Mr. Szekeres received his undergraduate degree in criminology, law and society from the University of California, Irvine and his J.D. from Duke University School of Law. We believe that Mr. Szekeres&#8217;s extensive experience as an executive and serving on other boards of directors in the biotechnology and biotherapeutics industry qualifies him to serve on our Board.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">David Baker</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Board from January 15, 2019 until August 23, 2019, and upon the consummation of the initial public offering of our Common Stock on February 12, 2021, he was again appointed as a director. He previously served as Vallon&#8217;s President and Chief Executive Officer from January 15, 2019 until April 12, 2023. Mr. Baker has also been serving as the President and Consultant of DB Biopharma Consulting LLC, a life science consulting company, since April 2023. He previously served as the Interim Chief Executive Officer and Chief Commercial Officer of Alcobra Ltd. (now known as Arcturus), where he oversaw the development of ADAIR. Prior to joining Alcobra Ltd., he worked at Shire Pharmaceuticals for 10 years, including as Vice President of Commercial Strategy and New Business in the Neuroscience Business Unit. In that role, Mr. Baker led the commercial assessment of neuroscience licensing opportunities, managed commercial efforts on pipeline central nervous system (CNS) products, and led the long-term strategic planning process. Previously, he served as Global General Manager for Shire&#8217;s Vyvanse&#174; where he led the launch of Vyvanse and led global expansion efforts including successful establishment of a partnership in Japan and launches in Canada and Brazil. Prior to that, Mr. Baker served as Vice President of Marketing for all of Shire&#8217;s ADHD products. From 1990 through 2004, Mr. Baker worked at Merck &amp; Co., where he held positions of increasing responsibility in marketing, sales, market research, and business development. In addition to his knowledge and experience with CNS medications, Mr. Baker&#8217;s expertise includes therapeutics for osteoporosis, migraine, and hyperlipidemia. He has been directly involved with the marketing of five medications with annual sales in excess of $1.0 billion each. Mr. Baker graduated Magna Cum Laude with a bachelor&#8217;s degree in Economics and Computer Science from Duke University. He earned a Master of Business Administration in Marketing from Duke&#8217;s Fuqua School of Business. Mr. Baker also serves on the board of directors of Benchworks, Inc., a private healthcare advertising agency. We believe that Mr. Baker&#8217; service as Vallons&#8217;s President and Chief Executive Officer and his extensive expertise in the biotechnology industry qualifies him to serve as a member of our Board.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Roelof Rongen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Board since April 2023. He is a serial entrepreneur, company builder and Research and Development/Commercial Development leader with extensive experience across many therapeutic areas and functions. Mr. Rongen has served as Chief Executive Officer of Adolore BioTherapeutics, gene-therapy company, since July 2022, Founder/Chief Executive Officer of Innovative Molecules since June 2019, and Managing Member of AsteRx Pharma Consulting since September 2018. In 2012, he founded and progressed Matinas BioPharma (omega-3 and lipid-crystal nano-particle drug delivery) into a public company (NYSE:MTNB) until his departure in March 2018. Mr. Rongen was integral to the development and commercialization of products such as Humira&#174; and Lovaza&#174;. Prior to founding Matinas BioPharma, Mr. Rongen served as Executive Vice President at Trygg Pharma from 2010 to 2012 where he facilitated Norway&#8217;s Aker Group&#8217;s entry into the prescription omega-3 business, and ultimate sale to FMC. Before Aker, Mr. Rongen was VP for IP and Portfolio Management at Reliant Pharmaceuticals (acquired by GlaxoSmithKline) where he in-licensed Lovaza&#174; and led development </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and pre-launch activities. Earlier in his career, Mr. Rongen was Global Product Director for Humira&#174; and other Immunology Programs at BASF Pharma (acquired by Abbott/Abbvie). Mr. Rongen started his professional career as a management consultant at Arthur D. Little&#8217;s Technology Innovation Management practice and as a biotechnology/pharmaceutical consultant at The Wilkerson Group (acquired by IBM). Mr. Rongen received a Master of Science in Engineering in Molecular Sciences (with Biotechnology/Bio-Process Technology focus) from Wageningen University in the Netherlands and a Master of Business Administration from the Kellogg Business School at Northwestern University. We believe that Mr. Rongen&#8217;s experience in the biopharmaceutical industry qualifies him to serve on our Board.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Camilla V. Simpson, M.Sc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has served as a member of our Board since April 2023. She has served as a member of Spruce Biosciences board of directors since October 2017. Since April 2021, Ms. Simpson has been Chief Executive Officer of Zehna Therapeutics, an early stage biotechnology company and a spin-out from the Cleveland Clinic. Since April 2019, Ms. Simpson has been the Managing Member and President of Rare Strategic, LLC where she provides strategic advice and consulting services to biotechnology companies. Ms. Simpson joined the board of directors of Dyve Biosciences in December 2020. From April 2017 to April 2019, Ms. Simpson was SVP, Head of Product Portfolio Development at BioMarin where she was responsible for corporate and Research and Development governance, program leadership, project management, competitive intelligence, portfolio strategy, and business analytics. From October 2014 to April 2017, Ms. Simpson was Group Vice President Global Regulatory Affairs at BioMarin, and from March 2014 to October 2014, Ms. Simpson was Vice President Regulatory Affairs EU at BioMarin. She also spent 12 years at Shire, where after multiple roles of increasing responsibility, ultimately held the position of Vice President of Regulatory Affairs Early Development and Business Development. Ms. Simpson holds a Bachelor of Science from University College Galway, Ireland, a Bachelors of Science (Honors) from Kingston University, United Kingdom, and an Master of Science with distinction from University of London, UK. We believe that Ms. Simpson&#8217;s extensive experience serving as an executive, director and consultant in the biotechnology industry qualifies her to serve as a member of our Board.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Family Relationships</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no family relationship between any director, executive officer or person nominated to become a director or executive officer.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Composition</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that the number of directors on our Board shall be determined from time to time by resolution of the Board or our stockholders, and the current size of our Board is five members.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws also provide that our directors may be removed from office with or without cause by vote of the holders of a majority of the shares of stock entitled to vote in the election of directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future executive officers and significant employees serve at the discretion of our Board. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board is divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the directors whose terms then expire will be subject to re-election to serve until the third annual meeting following re-election. As a result, only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our directors are divided among the three classes as follows:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the Class I director is David Baker, and his term expires at the annual meeting of stockholders to be held in 2027;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the Class II directors are Roelof Rongen and Camilla V. Simpson, M.Sc., and their term expires at the annual meeting of stockholders to be held in 2025; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">the Class III directors are W. Marc Hertz, Ph.D., and David Szekeres, and their term expires at the annual meeting of stockholders to be held in 2026.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that only our Board can fill vacancies on the Board, including due to increases in the size of the Board. Any additional directorships resulting from an increase in the authorized number of directors would be placed among the three classes so that, as nearly as possible, each class consists of one-third of the authorized number of directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Independence </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the listing requirements of The Nasdaq Capital Market, independent directors must comprise a majority of a listed company&#8217;s board of directors within 12 months from the date of listing. In addition, subject to specified exceptions, each </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">member of a listed company&#8217;s audit, compensation and nominating and corporate governance committees must be independent within 12 months from the date of listing. Audit committee members must also satisfy additional independence criteria, including those set forth in Rule 10A-3 under the Exchange Act and compensation committee members must also satisfy the independence criteria set forth in Rule 10C-1 under the Exchange Act. A director will only qualify as an &#8220;independent director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In order to be considered independent for purposes of Rule 10A-3 under the Exchange Act, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any other board committee: (1) accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries, other than compensation for board service; or (2) be an affiliated person of the listed company or any of its subsidiaries. In order to be considered independent for purposes of Rule 10C-1, the board of directors must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether a director has a relationship to such company which is material to that director&#8217;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: the source of compensation of the director, including any consulting advisory or other compensatory fee paid by such company to the director, and whether the director is affiliated with the company or any of its subsidiaries or affiliates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has determined that all members of the Board, except W. Marc Hertz, Ph.D. and David Baker, are independent directors, including for purposes of the rules of The Nasdaq Capital Market and the SEC. In making such independence determination, our Board considered the relationships that each non-employee director has with us and all other facts and circumstances that our Board deemed relevant in determining their independence, including the beneficial ownership of our capital stock by each non-employee director. The composition and functioning of our Board and each of our committees comply with all applicable requirements of The Nasdaq Capital Market and the rules and regulations of the SEC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committees of the Board of Directors </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has the ability to establish committees and has established an audit committee, a compensation committee and a nominating and corporate governance committee and may establish other committees to facilitate the management of our business. Members serve on these committees until their resignation or until otherwise determined by our Board. Our Board and its committees set meeting schedules throughout the year and can also hold special meetings and act by written consent from time to time, as appropriate.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The committees regularly report on their activities and actions to the full Board. Each member of each committee of our Board qualifies as an independent director in accordance with the listing standards of The Nasdaq Capital Market. Each committee of our Board has a written charter that was approved by our Board.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Copies of each charter are posted on our website at www.gribio.com under the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section. Information contained on our website is not incorporated by reference into this Annual Report. We have included our website address in this Annual Report on Form 10-K solely as an inactive textual reference.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our audit committee are Roelof Rongen, Camilla V. Simpson, M.Sc., and David Szekeres, who is the chairperson of the audit committee.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee assists our Board with its oversight of the integrity of our financial statements; our compliance with legal and regulatory requirements; the qualifications, independence and performance of the independent registered public accounting firm; the design and implementation of our financial risk assessment and risk management. Among other things, our audit committee is responsible for reviewing and discussing with our management the adequacy and effectiveness of our disclosure controls and procedures. Our audit committee also discusses with our management and independent registered public accounting firm the annual audit plan and scope of audit activities, scope and timing of the annual audit of our financial statements, and the results of the audit, quarterly reviews of our financial statements and, as appropriate, initiates inquiries into certain aspects of our financial affairs.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee is responsible for establishing and overseeing procedures for the receipt, retention and treatment of any complaints regarding accounting, internal accounting controls or auditing matters, as well as for the confidential and anonymous submissions by our employees of concerns regarding questionable accounting or auditing matters. In addition, our audit committee has direct responsibility for the appointment, compensation, retention and oversight of the work of our independent registered public accounting firm. Our audit committee has sole authority to approve the hiring and discharging of our independent registered public accounting firm, all audit engagement terms and fees and all permissible non-audit </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">engagements with the independent auditor. Our audit committee reviews and oversees all related person transactions in accordance with our policies and procedures.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each member of our audit committee is independent under the rules and regulations of the SEC and the listing standards of The Nasdaq Capital Market applicable to audit committee members. Our Board has determined that David Szekeres qualifies as an audit committee financial expert within the meaning of SEC regulations and meets the financial sophistication requirements of The Nasdaq Capital Market listing standards. In making this determination, our Board has considered Mr. Szekeres&#8217; prior experience, business acumen and independence. Both our independent registered public accounting firm and management periodically meets privately with our audit committee.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the composition and functioning of our audit committee complies with all applicable requirements of Section 404 of SOX, and all applicable SEC and The Nasdaq Capital Market rules and regulations. We intend to comply with future requirements to the extent they become applicable to us.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our compensation committee are David Szekeres and Camilla V. Simpson, M.Sc., who is the chairperson of the compensation committee.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each member of our compensation committee is independent under the rules and regulations of the SEC and the listing standards of The Nasdaq Capital Market applicable to compensation committee members. Our compensation committee assists our Board with its oversight of the forms and amount of compensation for our executive officers (including officers reporting under Section 16 of the Exchange Act), the administration of our equity and non-equity incentive plans for employees and other service providers and certain other matters related to our compensation programs. Our compensation committee, among other responsibilities, evaluates the performance of our Chief Executive Officer and, in consultation with him, evaluates the performance of our other executive officers (including officers reporting under Section 16 of the Exchange Act). Our compensation committee also administers our A&amp;R 2018 Plan. The compensation committee is responsible for the determination of the compensation of our Chief Executive Officer, and will conduct its decision making process with respect to that issue without the Chief Executive Officer present.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee has adopted the following processes and procedures for the consideration and determination of executive and director compensation:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Evaluating, recommending, approving, and reviewing executive officer and director compensation arrangements, plans, policies, and programs;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Administering our cash-based and equity-based compensation plans; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">Making recommendations to our Board regarding any other Board responsibilities relating to executive compensation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nominating and Corporate Governance Committee </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The members of our nominating and corporate governance committee are Camilla V. Simpson, M.Sc. and Roelof Rongen, who is the chairperson of the nominating and corporate governance committee.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each member of our nominating and corporate governance committee is independent under the rules and regulations of the SEC and the listing standards of The Nasdaq Capital Market, applicable to nominating and corporate governance committee members. Our nominating and corporate governance committee&#8217;s responsibilities include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">evaluating and making recommendations to the full Board as to the composition, organization and governance of our Board and its committees;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">evaluating and making recommendations as to director candidates;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">evaluating current Board members&#8217; performance;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">developing continuing education programs for directors, as needed;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">overseeing the process for the dissemination of information to the Board and its committees;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">reviewing its own performance and the nominating and corporate governance committee charter annually;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">overseeing the process for chief executive officer and other executive officer succession planning; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19pt">developing and recommending governance guidelines for the Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Corporate Governance Matters</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Nominations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No material changes have been made to the procedures by which stockholders may recommend nominees to our Board.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board Leadership Structure and Role of the Board in Risk Oversight </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board is responsible for the control and direction of the Company. At present, the Board has elected to separate the positions of chairperson and Chief Executive Officer. Dr. Hertz will serve as Chief Executive Officer of the Company and as a member of the Board. Mr. Szekeres will serve as the chairperson of the Board. The Board believes that this structure will serve the Company well by maintaining a link between management, through Dr. Hertz&#8217;s membership on the Board, and the non-executive directors led by Mr. Szekeres in his role as a non-executive chairperson.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the key functions of our Board is informed oversight of our risk management process. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through the various standing committees of our Board that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure and our audit committee has the responsibility to consider and discuss our major financial risk exposures facing the Company and the steps management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. Our nominating and corporate governance committee monitors the effectiveness of our corporate governance practices, including whether such practices are successful in preventing illegal or improper liability-creating conduct. Our compensation committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No member of our compensation committee has ever been an executive officer or employee of the Company. None of our officers currently serves, or has served during the last completed fiscal year, on any other entity&#8217;s board of directors, compensation committee or other committee that serves an equivalent function as our compensation committee and that has one or more officers who serves as a member of our Board or compensation committee.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Code of Business Conduct and Ethics </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a written Code of Business Conduct and Ethics (the Code of Conduct) applicable to all of our employees, executive officers and directors. The Code of Conduct covers fundamental ethical and compliance-related principles and practices such as accurate accounting records and financial reporting, avoiding conflicts of interest, the protection and use of our property and information and compliance with legal and regulatory requirements. Our Code of Conduct is available on the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investors &#8212; Corporate Governance&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of our website at www.gribio.com and will be made available to stockholders without charge, upon request, by writing to the Corporate Secretary at 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our nominating and corporate governance committee is responsible for overseeing our Code of Conduct and must approve any waivers of the Code of Conduct for employees, executive officers or directors. We intend to disclose any future amendments to, or waivers from, our Code of Conduct in a Current Report on Form 8-K within four business days of the waiver or amendment, unless website posting or the issuance of a press release of such amendments or waivers is then permitted by Nasdaq rules.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insider Trading Policy</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain an Insider Trading Policy that, among other things, generally prohibits all persons who are aware of material information about the Company that is not generally known or available to the public, including our officers, directors and employees, from engaging in transactions involving our shares without first obtaining pre-clearance of the transaction by following the procedures described in the Insider Trading Policy. This includes short sales, hedging of share ownership positions, and transactions involving derivative securities relating to our shares. This policy is included as Exhibit 19 to this Annual Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11.&#160;&#160;EXECUTIVE COMPENSATION.&#160;</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an emerging growth company, we are required to disclose the compensation earned by or paid to our named executive officers for the last two completed fiscal years.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.016%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.780%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Name and Principal Position</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Salary ($)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Bonus ($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Option</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Awards ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Non-Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Incentive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Compensation ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">All Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Compensation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">W. Marc Hertz, Ph.D.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">458,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">158,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">617,224&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">404,447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">381,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">785,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Leanne M. Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">342,417&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">50,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">76,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">469,420&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">304,063&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">114,437&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">118,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9,367&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">646,617&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Vipin Kumar Chaturvedi, Ph.D.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">342,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">76,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">419,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Chief Scientific Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">214,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">79,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">302,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Reflects the aggregate grant date fair value of stock options granted during the fiscal year calculated in accordance with FASB ASC Topic 718. These amounts do not necessarily correspond to the actual value that may be realized by the executive in connection with the option awards. The assumptions made in valuing the option awards reported in this column are described in the Company&#8217;s audited consolidated financial statements (Note 3. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and Note 11.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Stock Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">) included in this Annual Report.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amounts in this column represent performance bonuses earned by the named executive officers in the year shown based upon the achievement of pre-established performance objectives. See &#8220;Executive Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Elements of Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Bonuses and Non-Equity Incentive Plan Compensation&#8221; below. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amounts in this column include group term life insurance premiums paid on behalf of the named executive officers. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pursuant to her employment agreement, Ms. Kelly was paid a retention bonus of $50,000 on April 21, 2024, the first anniversary of the Closing.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Pursuant to her employment agreement, Ms. Kelly was paid a sign on bonus of $100,000 at the Closing.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amounts reflect matching contributions to the named executive officer&#8217;s accounts under the Vallon SIMPLE IRA plan, in addition to group term life insurance premiums paid on the named executive officer&#8217;s behalf.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The amounts reflect consulting fees paid to Dr. Chaturvedi prior to April 21, 2023, the date of his employment with the Company, in addition to group term life insurance premiums paid on the named executive officer&#8217;s behalf.</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Elements of Compensation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Base Salaries</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Effective August 1, 2024, the base salaries of Dr. Hertz, Ms. Kelly and Dr. Chaturvedi were increased to $575,900, $384,300 and $384,300, respectively. From January 1, 2024 through July 31, 2024, the base salaries of Dr. Hertz, Ms. Kelly and Dr. Chaturvedi were $375,000, $312,500 and $312,500, respectively.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bonuses and Non-Equity Incentive Plan Compensation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Hertz, Ms. Kelly and Dr. Chaturvedi are each eligible to receive a discretionary annual performance bonus with a target bonus equal to 55%, 40% and 40% of their then current base salary, respectively. For the fiscal year ended December 31, 2024, based on the achievement level of performance objectives, the Board awarded an annual performance bonus of $158,373 to Dr. Hertz and $76,860 to each of Ms. Kelly and Dr. Chaturvedi. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to annual performance bonuses and pursuant to her employment agreement, on the first anniversary of the Closing in April 2024, Ms. Kelly was paid a retention bonus of $50,000.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Option Awards Granted During 2024</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although no option awards were granted to our named executive officers in 2024, in January 2025 the Board granted an aggregate of 34,319 options to Dr. Hertz and 14,402 options to each Ms. Kelly and Dr. Chaturvedi, of which an aggregate of 12,727 vested at the time of grant. The unvested options are subject to stockholder approval, a portion of which will vest immediately upon receipt of such approval and the remaining unvested options will vest following such approval on a quarterly vesting schedule over three years from the date of grant, subject to the holder&#8217;s continued service to the Company. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qualified Retirement Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not maintain any retirement, deferred compensation, pension, or profit-sharing plans.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into an employment agreement with each of our named executive officers. The employment agreements provide that the executive will receive a base salary and be eligible to receive an annual cash bonus contingent upon the attainment of certain company milestones and/or individual objectives. Pursuant to the employment agreements, each executive's base salary and target bonus will be reviewed periodically by our compensation committee or Board. The employment agreements also provide for certain termination benefits, which are described below in the section entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Payments Upon a Termination or Change in Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our named executive officers are also entitled to participate in all of our retirement and group welfare plans, subject to the terms and conditions applicable to such plans. Further, each named executive officer's employment agreement contains restrictive covenants relating to non-disclosure of confidential information, mutual non-disparagement and assignment of inventions provisions. The employment agreement with Ms. Kelly also include non-competition and non-solicitation provisions.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential Payments Upon a Termination or Change in Control</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to those potential payments described below, regardless of the manner in which a named executive officer&#8217;s service terminates, that named executive officer is entitled to receive compensation amounts earned during his or her term of service, including unpaid salary and other accrued benefits, as applicable. In addition, each named executive officer is entitled to receive certain benefits upon the Company&#8217;s termination of his or her employment without cause or his or her resignation for good reason.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">W. Marc Hertz, Ph.D.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to his employment agreement with us, if Dr. Hertz&#8217;s employment were terminated by us without cause or terminated by Dr. Hertz for good reason, in either case not in connection with a change in control, then Dr. Hertz would be entitled to the following severance benefits:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continued base salary for a period of 12 months, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided he was employed for at least six months during that year; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">subsidized premiums for COBRA continuation coverage for a period of 12 months (or such earlier date that he obtains alternative coverage).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to his employment agreement with us, if Dr. Hertz&#8217;s employment were terminated by us without cause or terminated by Dr. Hertz for good reason, in either case within the one-year period following a change in control transaction, then Dr. Hertz would be entitled to the following severance benefits:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a lump sum payment equal to 18 months of his annual base salary, plus a lump sum payment equal to 150% of his target bonus, without proration, for the fiscal year of termination;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">subsidized premiums for COBRA continuation coverage for a period of 18 months (or such earlier date that he obtains alternative coverage); and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#8220;target&#8221; performance level, and any stock options remaining outstanding for their full term.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leanne Kelly</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to her employment agreement with us, if Ms. Kelly&#8217;s employment were terminated by us without cause or terminated by Ms. Kelly for good reason, in either case not in connection with a change in control, then Ms. Kelly would be entitled to the following severance benefits:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continued base salary for a period of nine months, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided she was employed for at least six months during that year; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">subsidized premiums for COBRA continuation coverage for a period of nine months (or such earlier date that she obtains alternative coverage).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to her employment agreement with us, if Ms. Kelly&#8217;s employment were terminated by us without cause or terminated by Ms. Kelly for good reason, in either case within the one-year period following a change in control transaction, then Ms. Kelly would be entitled to the following severance benefits:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">a lump sum payment equal to 12 months of her annual base salary, plus a lump sum payment equal to 100% of her target bonus, without proration, for the fiscal year of termination;</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">subsidized premiums for COBRA continuation coverage for a period of 12 months (or such earlier date that she obtains alternative coverage); and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#8220;target&#8221; performance level, and any stock options remaining outstanding for their full term.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vipin Kumar Chaturvedi, Ph.D.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to his employment agreement with us, if Dr. Chaturvedi&#8217;s employment were terminated by us without cause or terminated by Dr. Chaturvedi for good reason, in either case not in connection with a change in control, then Dr. Chaturvedi would be entitled to the following severance benefits:</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">continued base salary for a period of nine months, plus a pro-rated bonus for the year of termination, based on actual performance results for the entire year, and provided he was employed for at least six months during that year; and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">subsidized premiums for COBRA continuation coverage for a period of nine months (or such earlier date that he obtains alternative coverage).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to his employment agreement with us, if Dr. Chaturvedi&#8217;s employment were terminated by us without cause or terminated by Dr. Chaturvedi for good reason, in either case within the one-year period following a change in control transaction, then Dr. Chaturvedi would be entitled to the following severance benefits:</span></div><div style="padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10pt">a lump sum payment equal to 12 months of his annual base salary, plus a lump sum payment equal to 100% of his target bonus, without proration, for the fiscal year of termination;<br/></span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">subsidized premiums for COBRA continuation coverage for a period of 12 months (or such earlier date that he obtains alternative coverage); and</span></div><div style="margin-bottom:8pt;padding-left:22.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">accelerated vesting of all outstanding stock-based awards held by the executive as of the date of termination, with any performance awards deemed satisfied at the &#8220;target&#8221; performance level, and any stock options remaining outstanding for their full term.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the outstanding stock option awards as of December&#160;31, 2024, held by our named executive officers, on an award-by-award basis, setting forth the total number of shares underlying each stock option award that are (i) exercisable, but not yet exercised, (ii) unexercisable and not yet exercised, and (iii) total aggregate amount underlying each award.</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Option Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of Securities Underlying Unexercised, Options (#) Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Number of Securities Underlying Unexercised, Options (#) Unexercisable</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Option Exercise Price ($)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Option Expiration Date</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Leanne Kelly</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">36</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,351.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9/22/2033</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The stock options award vested 25% on the first anniversary of the vesting start date (September 22, 2023) and vests 2.083% (1/48th of such shares) for each subsequent month that the executive remains employed with us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Drs. Hertz and Chaturvedi had no outstanding option or stock awards as of December&#160;31, 2024, and are therefore not included in this table.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Compensation and Compensation Table</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our director compensation program is designed to enhance our ability to attract and retain highly qualified directors and to align their interests with the long-term interests of our stockholders. The program generally includes a cash component, which is designed to compensate non-employee directors for their service on our Board and an equity component, which is designed to align the interests of non-employee directors and stockholders. Directors who are employees of the Company receive no additional compensation for their service on our Board.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee annually reviews compensation paid to our non-employee directors and makes recommendations for adjustments, as appropriate, to the full Board. As part of this annual review, the compensation committee considers the significant time commitment and skill level required by each non-employee director in serving on our Board and its various committees. The compensation committee seeks to maintain a market competitive director compensation program and benchmarks our director compensation program against those maintained by our peer group.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated non-employee director compensation program provides that each non-employee Board member will receive the following compensation:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An annual cash retainer of $40,000 for service on the Board, an annual cash retainer of $7,500 for service on the audit committee, an annual cash retainer of $6,000 for service on the compensation committee and an annual cash retainer of $5,000 for service on the nominating and corporate governance committee, which the non-employee director may instead elect to receive any of the annual retainers in an award of a stock option in lieu of cash.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Non-employee directors who are first appointed or elected to the Board will receive an initial stock option grant to purchase a number of shares of our Common Stock equal to the quotient obtained by dividing $100,000 by the closing price of our Common Stock on the date of such director&#8217;s initial election or appointment, which generally will vest in quarterly installments over three years.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">A non-employee director who (i) is serving on the Board as of the date of any annual meeting of our stockholders after August 10, 2023 and has been serving as a non-employee director for at least six months as of the date of such meeting, and (ii) will continue to serve as a non-employee director immediately following such meeting, shall be automatically granted an option grant to purchase a number of shares of Common Stock equal to the quotient obtained by dividing $50,000 by the closing price of the Common Stock on the date of such annual meeting, which generally will vest in quarterly installments over one year. Notwithstanding the foregoing,the directors did not receive stock options on the date of the 2024 annual meeting of our stockholders, and in lieu thereof, in January 2025, the directors, other than the chairman of the Board, received options to purchase an aggregate of 23,328 shares of Common Stock and the chairman of the Board received options to purchase 13,331 shares of Common Stock, of which an aggregate of 8,401 vested at the time of grant. The unvested options are subject to stockholder approval, a portion of which will vest immediately upon receipt of such approval and the remaining unvested options will vest following such approval on a quarterly vesting schedule over three years from the date of grant, subject to the holder&#8217;s continued service to the Company. </span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to any other consideration received, our amended and restated non-employee director compensation program provides that non-employee Board members serving as a chairperson will receive the following additional consideration:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The audit committee chairperson will receive an additional annual retainer of $15,000.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The compensation committee chairperson will receive an additional annual retainer of $12,000.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The nominating and corporate governance committee chairperson will receive an additional annual retainer of $10,000.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Board chairperson will receive an additional annual retainer of $30,000.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-employee director may instead elect to receive annual retainer for serving as a chairperson in an award of a stock option in lieu of cash.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director Compensation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information on compensation paid to our non-employee directors in 2024:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fees Earned or Paid in Cash ($)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Option Awards ($)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Baker</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Roelof Rongen</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camilla V. Simpson, M.Sc.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Szekeres</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Policies and Procedures Related to the Grant of Certain Equity Awards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We do not purposefully time our grants to coincide or be near in time to the release of material non-public information (MNPI). However, from time to time, we may grant options close in time to the release of MNPI to the extent those options are being granted upon the hiring of new executive officers and in connection with annual grants being made as part of our director compensation policy, upon appointment of a new director and on an annual basis at each annual meeting.</span></div><div><span><br/></span></div><div id="i73c3df21d6604995952be1876b1e93fe_112"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12.&#160;&#160;&#160;&#160;SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information known to us regarding beneficial ownership of our capital stock as of February&#160;28, 2025 for:</span></div><div style="margin-bottom:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">each person or group of affiliated persons known by us to be the beneficial owner of more than five percent of our capital stock;</span></div><div style="margin-bottom:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">each of our named executive officers;</span></div><div style="margin-bottom:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">each of our directors; and</span></div><div style="margin-bottom:8pt;padding-left:37.4pt;text-indent:-10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.5pt">all of our executive officers, and directors as a group.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power, and includes securities that the individual or entity has the right to acquire, such as through the exercise of stock options, within 60&#160;days of February&#160;28, 2025. Except as noted by footnote, and subject to community property laws where applicable, we believe, based on the information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to all common stock shown as beneficially owned by them.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The&#160;percentage of beneficial ownership in the table below is based on 525,358 shares of Common Stock deemed to be outstanding as of February&#160;28, 2025.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock Beneficially Owned</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name and Address of Beneficial Owner</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Shares of Beneficial Ownership</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Percentage of Total Common Stock</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Directors and Named Executive Officers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W. Marc Hertz, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,880</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leanne Kelly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,569</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vipin Kumar Chaturvedi, Ph.D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,659</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Baker</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,796</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Roelof Rongen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,795</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camilla V. Simpson, M.Sc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,795</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Szekeres</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,068</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">All directors and executive officers as a group (8 persons)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,673</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Represents beneficial ownership of less than one percent of our outstanding common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Except as otherwise noted below,&#160;the address of the beneficial owner is c/o GRI Bio, Inc. 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 249 shares of Common Stock and (ii) 7,631 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of February&#160;28, 2025.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 2,569 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of February&#160;28, 2025.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) 111 shares of Common Stock and (ii) 2,548 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of February&#160;28, 2025.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 1,796 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of February&#160;28, 2025.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 1,795 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of February&#160;28, 2025.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of 3,068 shares of Common Stock issuable pursuant to stock options exercisable within 60 days of February&#160;28, 2025.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(8)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Consists of (i) the shares of Common Stock described in footnotes (2) through (6) above and (ii) 111 shares of Common Stock held by Albert Agro, Ph.D.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding our equity compensation plans as of December&#160;31, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.625%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.266%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a))</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Plan category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(c)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation plans approved by security holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,376.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity compensation plans not approved by security holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">The number of shares of our Common Stock authorized under the A&amp;R 2018 Plan automatically increases on January 1st of each year until the expiration of the A&amp;R 2018 Plan, in an amount equal to four percent of the total number of shares of our Common Stock outstanding on December 31st of the preceding calendar year, subject to the discretion of our Board or compensation committee to determine a lesser number of shares shall be added for such year.</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Includes shares of our common stock under the A&amp;R 2018 Plan. For a description of this plan, refer to Note 11. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Stock Based Compensation&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to the financial statements included in this Annual Report.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the A&amp;R 2018 Plan. The A&amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving the amendment to the A&amp;R 2018 Plan (i) to increase the aggregate number of shares by 109 shares to 140 shares of Common Stock for issuance as awards under the A&amp;R 2018 Plan, (ii) to increase the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of incentive stock options under the A&amp;R 2018 Plan to 1,723 shares, (iii) to extend the term of the A&amp;R 2018 Plan through January 1, 2033, (iv) to prohibit any action that would be treated as a &#8220;repricing&#8221; of an award without further approval by the stockholders of Company, and (v) to revise the limits on awards to non-employee directors as follows: the aggregate grant date fair value of shares granted to any non-employee director under the A&amp;R 2018 Plan and any other cash compensation paid to any non-employee director in any calendar year may not exceed $0.75 million; increased to $1.0 million in the year in which such non-employee director initially joins the Board.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R 2018 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock, performance units, performance shares, RSUs, and other stock-based awards to our employees, directors, and consultants. The purpose of the A&amp;R 2018 Plan is to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to our employees, directors and consultants, and to promote the success of our business. The A&amp;R 2018 Plan provides for an annual increase on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, equal to the less over (x) 4% of the aggregate number of shares outstanding on the final day of the immediately preceding calendar year, and (y) such smaller number of shares as is determined by the Board. The A&amp;R 2018 Plan further authorizes the administrator to amend the exercise price and terms of certain awards thereunder.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_115"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13.&#160;&#160;&#160;&#160;CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of each transaction or series of similar transactions since January 1, 2022, to which we have been a party that:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The amount involved exceeded or exceeds $120,000 or is greater than 1% of our total assets as of December&#160;31, 2024, 2023 and 2022; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our directors or executive officers, any holder of 5% of our capital stock or any member of their immediate family had or will have a direct or indirect material interest.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TEP Convertible Promissory Note</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, GRI Operations and TEP Biotech, LLC (&#8220;TEP&#8221;) entered into a convertible note and warrant purchase agreement pursuant to which TEP agreed to fund up to $5.0 million to GRI Operations in exchange for a convertible promissory note (the &#8220;TEP Note&#8221;) and a warrant to purchase up to 16 shares of GRI Operations common stock at an exercise price of $0.01 per share. The TEP Note was secured by GRI Operations&#8217; assets and accrues simple interest on the outstanding principal balance at a rate of 12% per annum. The total outstanding principal and accrued interest balance was initially due on the earlier of GRI Operations&#8217; next financing (as defined therein) and May 2, 2020 (the &#8220;Maturity Date&#8221;).</span></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendments to TEP Note</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, GRI Operations and TEP amended the TEP Note. In lieu of TEP funding the second $2.5 million tranche, TEP made a first additional advance of $0.5 million to GRI Operations in exchange for a convertible promissory note, a warrant to purchase up to 11 shares of GRI Operations common stock at an exercise price of $0.01 per share, and the assignment of GRI Operations&#8217; rights under a certain call option agreement. The call option agreement, which was entered into in 2015, provided GRI Operations with the right to repurchase up to 25 shares of GRI Operations common stock held by the counterparty for $41,366.78 per share at any time before April 1, 2025.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Maturity Date was extended to August 31, 2020, and in March 2021, TEP agreed to forbear on its available right to exercise remedies on account of GRI Operations&#8217; failure to pay the past due principal and accrued interest balance until October 31, 2021.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, GRI Operations and TEP further amended the TEP Note, and TEP agreed to make a second additional advance of $0.5 million to GRI Operations in exchange for a convertible promissory note with separate, modified conversion options.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, GRI Operations and TEP further amended the TEP Note, and TEP agreed to make a third additional advance of $125,000 to GRI Operations in exchange for a convertible promissory note and a warrant to purchase up to 1 share of GRI Operations common stock at an exercise price of $0.01 per share.</span></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion of TEP Note</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, in connection with the execution of the Merger Agreement, the TEP Note converted in full into 100 shares of GRI Operations common stock pursuant to a conversion agreement executed by GRI and TEP. Upon conversion, TEP became a beneficial owner of more than 5% of GRI Operations common stock.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Financing</span></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Purchase Agreement (Bridge Financing)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the execution of the Merger Agreement, in December 2022, GRI Operations entered into the Bridge SPA with Altium. Pursuant to the Bridge SPA, GRI Operations issued to Altium the Bridge Notes and warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="f-57">809</ix:nonFraction> shares of GRI Operations&#8217; common stock (the &#8220;Bridge Warrants&#8221;). As a result of the Merger, at the Effective Time, the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants have since been fully exercised on a cashless basis.</span></div><div style="margin-bottom:8pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Purchase Agreement (Equity Financing)</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, in connection with the of execution the Merger Agreement in December 2022, the Company, GRI Operations and Altium entered into the Equity SPA. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued 4,387 shares of GRI Operations common stock (the &#8220;Initial Shares&#8221;) to Altium and 17,549 shares of GRI Operations common stock (the &#8220;Additional Shares&#8221;) into escrow with an escrow agent. At the Closing, pursuant to the Merger, the Initial Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="f-58">164</ix:nonFraction> shares of Common Stock and the Additional Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="ck0001824293:ConversionOfStockAdditionalSharesConverted" scale="0" id="f-59">656</ix:nonFraction> shares of Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, we and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of Common Stock issued in exchange for the Additional Shares. Pursuant to the Equity SPA, we issued to Altium on May 8, 2023 (i) Series A-1 Warrants to purchase 820 shares of Common Stock with an initial exercise price of $20,899.97 per share, (ii) Series A-2 Warrants to purchase 738 shares of Common Stock with an initial exercise price of $22,802.78per share, and (iii) Series T Warrants to purchase (x) 526 shares of Common Stock at an exercise price of $18,997.16 per share and (y) if the Series T Warrants are exercised in full by paying the Aggregate Exercise Price in cash, an additional amount of Series A-1 Warrants and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Series A-2 Warrants, each to purchase 526 shares of Common Stock at their respective exercise price (collectively, the &#8220;Equity Warrants&#8221;). All of the Equity Warrants have since been fully exercised or forfeited. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the transactions described herein, Altium became a holder of greater than 5% of our Common Stock.</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment agreements with each of our executive officers. See Item 11. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Grants</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have granted stock options to each of our executive officers and members of our Board. See Item 11. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification and Limitation on Liability</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 145 of the DGCL (Section 145) authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys&#8217; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted provisions in our amended and restated certificate of incorporation and our amended and restated bylaws that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for:</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any breach of the director&#8217;s duty of loyalty to us or our stockholders;</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">any transaction from which the director derived an improper personal benefit.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our amended and restated bylaws provide that:</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">we will advance reasonable expenses, including attorneys&#8217; fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into indemnification agreements with each of our directors and officers. These agreements provide that we will indemnify each of our directors, our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#8217; fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person&#8217;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#8217;s or officer&#8217;s services as a director referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policies and Procedures for Related Party Transactions</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a written policy that requires all future transactions between us and any director, executive officer, holder of 5% or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of them, or any other related persons, as defined in Item 404 of Regulation S-K, or their affiliates, in which the amount involved is equal to or greater than the threshold amount proscribed by Item 404 of Regulation S-K, be approved in advance by our Audit Committee. Any request for such a transaction must first be presented to our Audit Committee for review, consideration and approval. In approving or rejecting any such proposal, our Audit Committee is to consider the relevant facts and circumstances available and deemed relevant to the Audit Committee, including, but not limited to, the extent of the related party&#8217;s interest in the transaction, and whether the transaction is on terms no less favorable to us than terms we could have generally obtained from an unaffiliated third party under the same or similar circumstances.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director Independence</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 10. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors, Executive Officers and Corporate Governance Management &#8212; Director Independence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Committees of our Board of Directors</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which operates pursuant to a written charter adopted by our Board. See Item 10. &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors, Executive Officers and Corporate Governance Management &#8212; Committees of the Board of Directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div id="i73c3df21d6604995952be1876b1e93fe_118"></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:43.2pt;text-indent:-43.2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14.&#160;&#160;&#160;&#160;PRINCIPAL ACCOUNTANT FEES AND SERVICES.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-60">Sadler, Gibb &amp; Associates LLC</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-61">Draper, Utah</ix:nonNumeric>, Auditor Firm ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-62">3627</ix:nonNumeric>. </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents aggregate fees incurred for Sadler, Gibb &amp; Associates LLC services during the years ended December&#160;31, 2024 and 2023 by us.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Audit Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">194,325&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Audit Related Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Tax Fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All Other Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> (4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">194,325&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">156,323&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.68pt">Audit Fees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">represent the aggregate fees billed for professional services rendered by our independent registered public accounting firm for the audit of our annual financial statements, review of financial statements included in our quarterly reports or services that are normally provided in connection with statutory and regulatory filings or engagements for those fiscal years as well as the issuance of consents in connection with registration statement filings with the SEC and comfort letters in connection with securities offerings.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.68pt">Audit Related Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> represent the aggregate fees billed for assurance and related professional services rendered by our independent registered public accounting firm that are reasonably related to the performance of the audit or review of our financial statements and are not reported under "Audit Fees." </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.68pt">Tax Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> represent the aggregate fees billed for professional services rendered by our independent registered public accounting firm for tax compliance, tax advice and tax planning services.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:8.68pt">All Other Fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> represent the aggregate fees billed for all other products and services rendered by our independent registered public accounting firm other than the services reported in the other categories</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The audit committee will approve in advance the engagement and fees of the independent registered public accounting firm for all audit services and non-audit services, based upon independence, qualifications and, if applicable, performance. The audit committee may form and delegate to subcommittees of one or more members of the audit committee the authority to grant pre-approvals for audit and permitted non-audit services, up to specific amounts. All audit services provided by Sadler, Gibb &amp; Associates LLC for the periods presented were approved by our audit committee and ratified by our Board.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pre-Approval of Audit and Non-Audit Services</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee has adopted policies and procedures relating to the approval of all audit and non-audit services that are to be performed by our independent registered public accounting firm. These policies and procedures generally provide that we will not engage our registered public accounting firm to render audit or non-audit services unless the service is specifically </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved in advance by our audit committee or the engagement is entered into pursuant to one of the pre-approval procedures described below.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our audit committee may pre-approve specified types of services that are expected to be provided to us by our independent registered public accounting firm during the next twelve months. Any such pre-approval is detailed as to the particular service or type of services to be provided and is also generally subject to a maximum dollar amount.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with requirements of the SEC and the Public Company Accounting Oversight Board regarding auditor independence, our audit committee is responsible for the appointment, compensation and oversight of the work of our independent registered public accounting firm. In recognition of this responsibility, our audit committee, or the chairperson if such approval is needed between meetings of the audit committee, pre-approves all audit and permissible non-audit services provided by the independent registered public accounting firm. These services may include audit services, audit-related services, tax services and other services.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i73c3df21d6604995952be1876b1e93fe_124"></div><div style="-sec-extract:summary;margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15.&#160;&#160;&#160;&#160; EXHIBITS, FINANCIAL STATEMENT SCHEDULES.</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">The following documents are filed as part of this report:</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Financial&#160;Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The financial statements of the Company, together with the report thereon of Sadler, Gibb &amp; Associates LLC, an independent registered public accounting firm, are included in this Annual Report beginning on page F-1.</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Financial Statement&#160;Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See (b) below.</span></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Exhibits</span></div><div style="margin-bottom:8pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed in the Exhibit&#160;Index below are filed or incorporated by reference as part of this Annual Report.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.662%"/><td style="width:0.1%"/><td style="width:0.0%"/><td style="width:0.238%"/><td style="width:0.0%"/><td style="width:1.0%"/><td style="width:22.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit&#160;No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Filed Herewith</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Date </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">File Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.1&#9651;</span></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit21-8xk121222.htm">Agreement and Plan of Merger, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit21-8xk121222.htm">by and among the Company, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit21-8xk121222.htm">Vallon</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit21-8xk121222.htm">, and Vallon Merger Sub, Inc.</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit21-8xk121222.htm">dated as of December 13, 2022</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/13/22</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1824293/000162828023004948/val-20230224.htm#ie46b68ab5ec64379b510f065cb272cf5_7864">Amendment to Agreement and Plan of Merger, by and among the Company, Vallon, and Vallon Merger Sub, Inc., dated as of February 17, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/24/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.1</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="gri-202410k_ex31.htm">Amended and Restated Certificate of Incorporation, as amended</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="gri-202410k_ex31.htm">.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.2</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429323000129/gribioinc-amendedandrestat.htm">Amended and Restated Bylaws</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/26/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.1</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000110465921008880/tm2030737d10_ex4-1.htm">Specimen Common Stock Certificate.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-249636</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.2&#9651;</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit44-8xk121222.htm">Registration Rights Agreement,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit44-8xk121222.htm"> by and between Vallon and the investor party thereto</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit44-8xk121222.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit44-8xk121222.htm"> dated December 13, 2022</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit44-8xk121222.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/13/22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001824293/000162828022014382/ex41_ladenburg-vlonxrdmay2.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001824293/000162828022014382/ex41_ladenburg-vlonxrdmay2.htm">orm of Common </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001824293/000162828022014382/ex41_ladenburg-vlonxrdmay2.htm">Stock Purchase Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5/13/22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.4</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429322000066/formofwarrantamendment.htm">Form of Amendment No. 1 to Common Stock Purchase Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">07/26/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.5</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit42-8xk121222.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit42-8xk121222.htm">Equity </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit42-8xk121222.htm">Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/13/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.6</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit43-8xk121222.htm">Form of Exchange Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/13/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.7</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit46-sx4.htm">Form of Senior Secured Note of GRI Bio Operations, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/23/22</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.8</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">Warrant to Purchase</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm"> Stock issued to TEP</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">B</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">i</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">t</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">e</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">c</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">h</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">L</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">L</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">C</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit48-sx4.htm">, dated as of November 2, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/23/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.9</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit49-sx4.htm">Warrant to Purchase</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit49-sx4.htm"> Stock issued to TEP Biotech, LLC, dated as of December 3, 2019.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/23/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.10</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit410-sx4.htm">Warrant to Purchase</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit410-sx4.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit410-sx4.htm">Stock issued to TEP Biotech, LLC, dated as of July 7, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/23/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.11</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit411-sx4.htm">Warrant to Purchase</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit411-sx4.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit411-sx4.htm">Stock issued to Oppel Greeff, dated as of July 7, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/23/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.12</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828023001687/exhibit418-sx4a.htm">Form of Amendment to 2022 Warrant to Purchase Stock.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/30/23</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.13</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024002622/exhibit425-sx1a.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024002622/exhibit425-sx1a.htm">orm of Series B-1 Common Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/31/24</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-276025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.14</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024002622/exhibit426-sx1a.htm">Form of Series B-2 Common Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/31/24</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-276025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.15</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit44-8xkjune2024.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit44-8xkjune2024.htm">orm of P</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit44-8xkjune2024.htm">lacement A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit44-8xkjune2024.htm">ge</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit44-8xkjune2024.htm">nt</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit44-8xkjune2024.htm"> Warrant</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/26/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-280323</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.16</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit42-8xkjune2024.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit42-8xkjune2024.htm">orm of </a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Series C-1 Common Warrant</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit42-8xkjune2024.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/26/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-280323</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.17</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit43-8xkjune2024.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024030244/exhibit43-8xkjune2024.htm">orm of Series C-2 Common Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/26/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-280323</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.18</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex43-formofplacementagentw.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex43-formofplacementagentw.htm">orm of Placement A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex43-formofplacementagentw.htm">ge</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex43-formofplacementagentw.htm">nt Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/22/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.19</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex41-formofseriesdx1warrant.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex41-formofseriesdx1warrant.htm">orm of Se</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex41-formofseriesdx1warrant.htm">ries D-1 Common Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/22/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.20</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex42-formofseriesdx2warrant.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex42-formofseriesdx2warrant.htm">orm of Series D-2 Common Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/22/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.21</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="gri-202410k_ex428.htm">Description of Securities.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.1#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/ex108_argribioinc2018eip.htm">A&amp;R 2018 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/21/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.2#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000110465920117717/tm2030737d4_ex10-6.htm">Form of Nonqualified Stock Option Agreement under the Company&#8217;s A&amp;R 2018 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-249636</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.3#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000110465920117717/tm2030737d4_ex10-7.htm">Form of Incentive Stock Option Agreement under the Company&#8217;s A&amp;R 2018 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-249636</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.4#</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit1038-sx4.htm">GRI Bio Operations, Inc. 2015 Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/23/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.5</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000110465920125904/tm2030737d6_ex10-15.htm">License Agreement, by and between the Company and MEDICE Arzneimittel Putter GmbH &amp; Co. KG, dated as of January 6, 2020.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/23/20</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-249636</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.6&#9651;</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022014382/ex102_vlonspa6.htm">Form of Securities Purchase Agreement. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">05/13/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.7&#9651;</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429322000066/amendmentno1tospa.htm">Amendment No.  1 to Securities Purchase Agreement, by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429322000066/amendmentno1tospa.htm">Vallon </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429322000066/amendmentno1tospa.htm">and each purchaser identified on the signature pages thereto, dated as of July 25, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">07/26/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.662%"/><td style="width:0.1%"/><td style="width:0.0%"/><td style="width:0.238%"/><td style="width:0.0%"/><td style="width:1.0%"/><td style="width:22.811%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.060%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.775%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.863%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.867%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.8#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit1035-sx4.htm">Consulting and Clinical Advisory Board Agreement, by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit1035-sx4.htm">the Company </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit1035-sx4.htm">and Rohit Loomba, M.D., dated as of June 3, 2016.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/23/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.9#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit1036-sx4.htm">Consulting and Scientific Advisory Board Agreement, by and between </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit1036-sx4.htm">the Company </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022032519/exhibit1036-sx4.htm">and Vipin Kumar Chaturvedi, personally or through Vidur Discoveries LLC, dated as of October 31, 2018.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/23/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.10</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit104-8xk121222.htm">Securities Purchase Agreement, by and between the Company and Altium Growth Fund, LP, dated as of December 13, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/13/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.11</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828022031808/exhibit105-8xk121222.htm">Securities Purchase Agreement, by and among the Company, Vallon and Altium Growth Fund, LP, dated as of December 13, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/13/22</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.12</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000162828023006542/val-20230306.htm#ie46b68ab5ec64379b510f065cb272cf5_7871">Omnibus Amendment to Securities Purchase Agreements, by and among the Company, GRI Bio Operations, Inc., and Altium Growth Fund, LP, dated as of February 17, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/06/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.13&#9651;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001824293/000182429324000033/gri-202310xk_ex1026.htm">Lease Agreement, by and between La Jolla Shores Plaza, LLC and GRI Bio Operations, Inc., dated as of March 2, 2018, for that property located at 2223 Avenida de la Playa, Suite 208, La Jolla, California, 92037, as amended on February 16, 2021 and February 20, 2024.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">03/28/24</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.14#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828023040629/exhibit1028-sx1.htm">Amended and Restated Non-Employee Director Compensation Program.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/04/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-274972</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.15#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/ex101_formofindemnificatio.htm">Form of Indemnification Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/21/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.16#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828023004948/exhibit1040-sx4a3.htm">Employment Agreement, by and between GRI Bio Operations, Inc. and Marc Hertz, Ph.D., dated as of February 20, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/24/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.17#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828023004948/exhibit1041-sx4a3.htm">Employment Agreement, by and between GRI Bio Operations, Inc. and Leanne M.  Kelly, dated as of February 20, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/24/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.18#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828023004948/exhibit1042-sx4a3.htm">Employment Agreement, by and between GRI Bio Operations, Inc. and Vipin Kumar Chaturvedi, dated as of February 20, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-4/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">02/24/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-268977</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.19#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/ex109_separationagreementb.htm">Separation Agreement, by and between the Company and David Baker, dated as of April 21, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">04/21/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.20#</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429323000147/ex106_aagroemploymentagree.htm">Employment Agreement, by and between the Company and Albert Agro, Ph.D., dated as of July 1, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">08/14/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.21&#9651;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429323000159/ex101_gri-aardvarkagreemen.htm">Asset Purchase Agreement, by and between the Company and Aardvark Therapeutics, Inc., dated as of August 22, 2023.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">08/23/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.22&#9651;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024002622/exhibit1037-sx1a.htm">Form of Securities Purchase Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/31/24</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-276025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.23</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024002622/exhibit1038-sx1a.htm">Form of Placement Agent Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">01/31/24</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-276025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.24&#9651;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024029968/exhibit1038-sx1a2024.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024029968/exhibit1038-sx1a2024.htm">orm of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024029968/exhibit1038-sx1a2024.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024029968/exhibit1038-sx1a2024.htm">ecurities Purchase Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828024029968/exhibit1038-sx1a2024.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">06/26/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-280323</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.25</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex101-formofrepricinglette.htm">F</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex101-formofrepricinglette.htm">orm of Repricing Letter Agreement.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000141/ex101-formofrepricinglette.htm"> </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10/22/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10.26</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000052/exhibit101_atmagreement.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000052/exhibit101_atmagreement.htm">t The Market Offering Agreement, dated May 20, 2024, by and between GRI Bio, Inc. and H.C. Wainwright &amp; Co.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429324000052/exhibit101_atmagreement.htm">, LLC </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">8-K</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5/20/24</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="gri-202410k_ex19.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-63">Insider Trading Policy.</ix:nonNumeric> </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">21.1</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000162828023040629/exhibit211-sx1.htm">Subsidiaries</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">S-1/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">12/04/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">333-274972</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="gri-202410k_ex231.htm">Consent of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24.1</span></div></td><td colspan="3" style="padding:0 1pt"><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba79f9c02a34174ab9583f212438dec_1575">Powers of Attorney for directors and certain executive officers (contained on the signature page)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ibba79f9c02a34174ab9583f212438dec_1575">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31.1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="gri-202410k_ex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">31.2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="gri-202410k_ex312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15a-14(a) under the Exchange Act</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="gri-202410k_ex321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">32.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="gri-202410k_ex322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429323000170/ex103_gri-clawbackpolicyse.htm">Clawback Policy.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">11/14/23</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.INS</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Instance Document </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.SCH</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.CAL</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.DEF</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.LAB</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Label Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">101.PRE</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Unless otherwise indicated, exhibits are filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#9651;&#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Indicates a management contract or any compensatory plan, contract or arrangement.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;The certification attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</span></div><div id="i73c3df21d6604995952be1876b1e93fe_127"></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the Registrant has duly caused this Annual Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.783%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.432%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.485%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI BIO, INC.</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March 14, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ W. Marc Hertz</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name: W. Marc Hertz, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title: President and Chief Executive Officer</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span id="ibba79f9c02a34174ab9583f212438dec_1575"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES AND POWER OF ATTORNEY</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints W. Marc Hertz, Ph.D. and Leanne Kelly as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto and all documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or his or her or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ W. Marc Hertz, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President, Chief Executive Officer and Director</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Executive Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 14, 2025</span></td></tr><tr style="height:17pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W. Marc Hertz, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Leanne Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Principal Financial and Accounting Officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 14, 2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leanne Kelly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Szekeres</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director, Chair of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 14, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Szekeres</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ David Baker</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 14, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">David Baker</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Roelof Rongen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 14, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Roelof Rongen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Camilla V. Simpson, M.Sc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 14, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camilla V. Simpson, M.Sc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:8pt;margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:91.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_136">Report of Independent Registered Public Accounting Firm, Sadler Gibb PCAOB ID NO: 3627</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_136">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_139">Consolidated Balance Sheets as of December 31, 2024 and December 31, 2023</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_139">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_145">Consolidated Statements of Operations for the years ended December 31, 2024 and 2023</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_145">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_151">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) for the years ended December 31, 2024 and 2023</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_151">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_154">Consolidated Statements of Cash Flows for the years ended December 31, 2024 and 2023</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_154">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_157">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_157">7</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:8pt;margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Shareholders of GRI Bio, Inc.:</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opinion on the Financial Statements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of GRI Bio, Inc. (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated statements of operations, changes in stockholders&#8217; equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Explanatory Paragraph Regarding Going Concern</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Basis for Opinion</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">/s/ Sadler, Gibb &amp; Associates, LLC</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2022.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Draper, UT</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;14, 2025</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_139"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-64">5,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-65">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-66">587</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">1,126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">5,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">2,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-70">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-71">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-72">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-73">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-74">5,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-75">2,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities and stockholders' equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="f-76">897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-78">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:WarrantLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-80">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ck0001824293:WarrantLiabilityCurrent" scale="3" id="f-81">3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-82">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-83">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">1,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-86">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-88">1,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-89">2,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commitments and contingencies (Note 13)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-90"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-8" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-91"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders' equity:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-92"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-93">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-94"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-95">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-96"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-97">525,485</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-98"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-99">2,909</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2024 and 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-101">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in-capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-102">43,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-103">31,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-104">39,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-105">31,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders' equity</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-106">4,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-107">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.37pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders' equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-108">5,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-109">2,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:72.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.390%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.753%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-110">3,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-111">3,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-112">4,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-113">8,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-114">8,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-115">11,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-116">8,235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-117">11,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="f-118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-119">250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-120">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-121">182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Interest income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-122">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-123">2,082</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-124">8,207</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-125">13,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;Deemed dividend on Series B Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RedeemablePreferredStockDividends" format="ixt:num-dot-decimal" scale="3" id="f-126">1,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RedeemablePreferredStockDividends" format="ixt:fixed-zero" scale="3" id="f-127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss available to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-128">10,118</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-129">13,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share attributable to common stockholders, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-130"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-131">55.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" format="ixt:num-dot-decimal" scale="0" id="f-132"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" format="ixt:num-dot-decimal" scale="0" id="f-133">5,018.09</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-134"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-135">183,278</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-136"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-137">2,598</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.590%"><tr><td style="width:1.0%"/><td style="width:39.240%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.881%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.255%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.955%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.801%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.418%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.887%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional<br/>Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Equity (Deficit)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="f-138">646</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-140">16,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-141">18,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-142">1,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-143">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-144">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Restricted stock vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="f-145">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Warrant issuance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-146">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-147">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Warrant exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise" format="ixt:num-dot-decimal" scale="0" id="f-148">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueWarrantExercises" scale="3" id="f-149">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueWarrantExercises" scale="3" id="f-150">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock in pre-closing financing</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing" scale="0" id="f-151">785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing" format="ixt:num-dot-decimal" scale="3" id="f-152">11,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing" format="ixt:num-dot-decimal" scale="3" id="f-153">11,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock for settlement of bridge note</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt" scale="0" id="f-154">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-155">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-156">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock for reverse recapitalization expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" scale="0" id="f-157">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-158">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-159">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock to Vallon stockholders in reverse recapitalization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization" scale="0" id="f-160">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-161">2,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-162">2,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-163">13,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-164">13,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-165">2,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-166">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-167">31,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">31,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-169">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-170">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-171">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Fractional share adjustment</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment" scale="0" id="f-172">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Warrant exercise</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise" format="ixt:num-dot-decimal" scale="0" id="f-173">191,946</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueWarrantExercises" scale="3" id="f-174">666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueWarrantExercises" scale="3" id="f-175">666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of common stock</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-176">330,642</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="f-177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-178">11,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-179">11,166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-180">8,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-181">8,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Balance, December 31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-182">525,485</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-184">43,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-185">39,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-186">4,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_154"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="margin-bottom:8pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-187">8,207</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-188">13,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-189">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-190">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of debt discounts and issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:fixed-zero" scale="3" id="f-191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-192">2,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-193">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-194">388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-195">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-196">182</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:OperatingLeaseRightOfUseAssetPeriodicAddition" scale="3" id="f-197">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-198">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-199">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-200">547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-201">387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-202">2,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-203">479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-204">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-205">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-206">57</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-207">8,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-208">8,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-210">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-211">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-212">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Advances from employees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ProceedsFromAdvancesFromEmployees" format="ixt:fixed-zero" scale="3" id="f-213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:ProceedsFromAdvancesFromEmployees" scale="3" id="f-214">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Repayment of advances from employees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:RepaymentOfAdvancesFromEmployees" format="ixt:fixed-zero" scale="3" id="f-215">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:RepaymentOfAdvancesFromEmployees" scale="3" id="f-216">195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of bridge promissory note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="f-217">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-218">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Proceeds from issuance of common stock in financing transactions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-219">9,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-220">12,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock under ATM facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-221">3,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.8pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Proceeds from warrant exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-223">762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-224">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Payment for fractional shares in connection with reverse stock split</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:PaymentForFractionalSharesReverseStockSplit" scale="3" id="f-225">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:PaymentForFractionalSharesReverseStockSplit" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.8pt;text-align:left;text-indent:-22.51pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash acquired in reverse recapitalization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:CashAcquiredInReverseRecapitalization" format="ixt:fixed-zero" scale="3" id="f-227">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:CashAcquiredInReverseRecapitalization" scale="3" id="f-228">941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-0.01pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Payment of reverse recapitalization costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:PaymentOfReverseRecapitalizationCosts" format="ixt:fixed-zero" scale="3" id="f-229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:PaymentOfReverseRecapitalizationCosts" format="ixt:num-dot-decimal" scale="3" id="f-230">2,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Payment of deferred stock issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-231">2,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-232">517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-234">150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 29.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-235">11,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-236">10,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-237">3,220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-238">1,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-239">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-240">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash and cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-241">5,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-242">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Supplemental disclosure or noncash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of stock for repayment of bridge loan</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuedForRepaymentOfNotesPayable" format="ixt:fixed-zero" scale="3" id="f-243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:StockIssuedForRepaymentOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-244">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Recognition of debt discount and additional paid-in-capital for warrants issued in connection with promissory notes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-245">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" scale="3" id="f-246">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net liabilities acquired in connection with reverse recapitalization</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" format="ixt:fixed-zero" scale="3" id="f-247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-248">3,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Debt and deferred stock issuance costs included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" scale="3" id="f-250">226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of stock for payment of reverse recapitalization costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts" format="ixt:fixed-zero" scale="3" id="f-251">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts" format="ixt:num-dot-decimal" scale="3" id="f-252">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Issuance of warrants for payment of stock issuance costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:WarrantsIssued" scale="3" id="f-253">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="ck0001824293:WarrantsIssued" scale="3" id="f-254">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_157"></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div><div id="i73c3df21d6604995952be1876b1e93fe_160"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.  <ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-255" continuedAt="f-255-1" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span><ix:continuation id="f-255-1" continuedAt="f-255-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></ix:continuation></div><ix:continuation id="f-255-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT I) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Merger with Vallon Pharmaceuticals, Inc.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to an Agreement and Plan of Merger, dated as of December 13, 2022, as amended on February 17, 2023 (the Merger Agreement), by and among the Company, GRI Bio Operations, Inc., formerly known as GRI Bio, Inc. (GRI Operations), and Vallon Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Merger Sub), Merger Sub was merged with and into GRI Operations (the Merger), with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company (Note 4). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and amended its bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Splits</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, and immediately prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-30" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-256">0.0001</ix:nonFraction>(Common Stock), at a ratio of one-for thirty (the April 2023 Reverse Stock Split). On January 29, 2024, the Company effected a reverse stock split of its common stock at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 14, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split). On February 21, 2025, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen (the February 2025 Reverse Stock Split and together with the April 2023 Reverse Stock Split, the January 2024 Reverse Stock Split and the June 2024 Reverse Stock Split, the Reverse Stock Splits).Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, GRI Operations. All Common Stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio (as defined below) and the Reverse Stock Splits for all periods presented, to the extent applicable.</span></div></ix:continuation><div id="i73c3df21d6604995952be1876b1e93fe_169"></div><div style="margin-bottom:8pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.  <ix:nonNumeric contextRef="c-1" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="f-261" continuedAt="f-261-1" escape="true">LIQUIDITY</ix:nonNumeric></span></div><ix:continuation id="f-261-1" continuedAt="f-261-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-262">39,740</ix:nonFraction> in accumulated deficit through December&#160;31, 2024. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of December&#160;31, 2024, the Company had cash of approximately $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-263">5,028</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, the Company, GRI Operations and Altium Growth Fund, LP (Altium) entered into a Securities Purchase Agreement, dated December 13, 2022 (the Equity SPA), pursuant to which Altium agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-264">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes (as defined below) in return for the issuance of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-261-2" continuedAt="f-261-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of GRI Operations common stock (GRI Operations Common Stock) immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued <ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-265">4,387</ix:nonFraction> shares of GRI Operations Common Stock (the Initial Shares) to Altium and <ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="ck0001824293:CommonStockHeldIntoEscrowAccount" format="ixt:num-dot-decimal" scale="0" id="f-266">17,549</ix:nonFraction> shares of GRI Operations Common Stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-267">11,704</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-268">546</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="f-269">164</ix:nonFraction> shares of the Company&#8217;s Common Stock and the Additional Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="ck0001824293:ConversionOfStockAdditionalSharesConverted" scale="0" id="f-270">656</ix:nonFraction> shares of the Company&#8217;s Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Company&#8217;s Common Stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into a securities purchase agreement (the Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering, (i) <ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-271">1,495</ix:nonFraction> shares (the February 2024 Shares) of Common Stock, (ii) <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-272">21,131</ix:nonFraction> pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-273">21,131</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-274">22,631</ix:nonFraction> Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-275">22,631</ix:nonFraction> shares of Common Stock, and (iv) <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-276">22,631</ix:nonFraction> Series B-2 common warrants (the Series B-2 Common Warrants, and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-277">22,631</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-278">4,389</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-279">1,110</ix:nonFraction>. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Annual Report on Form 10-K for the year ended December 31, 2024 (Annual Report) as the &#8220;February 2024 Warrants.&#8221; The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-280">one</ix:nonFraction> February 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-281">one</ix:nonFraction> February 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-282">one</ix:nonFraction> Series B-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-283">one</ix:nonFraction> Series B-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-41" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-284">243.10</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-285">0.0221</ix:nonFraction> for each February Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2024 Pre-Funded Warrants have been exercised in full. Each Series B-1 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-286">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-43" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-287">243.10</ix:nonFraction> and expires on February 6, 2029. Each Series B-2 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-288">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-289">243.10</ix:nonFraction> and expires on August 6, 2026. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the securities pursuant to the Purchase Agreement, the exercise price of the Series A-1 Warrants was reduced to par, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-290">0.0001</ix:nonFraction>, per share pursuant to the terms of the Series A-1 Warrants. As of December&#160;31, 2024, all of the Series A-1 Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="6" id="f-291">10.0</ix:nonFraction>&#160;million shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of <ix:nonFraction unitRef="number" contextRef="c-46" decimals="3" name="ck0001824293:SaleOfStockAgentCompensationPercentage" scale="-2" id="f-292">3.0</ix:nonFraction>% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company has sold <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-293">325,618</ix:nonFraction> shares of Common Stock in the ATM Offering at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-48" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-294">11.07</ix:nonFraction> per share, raising $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-295">3,605</ix:nonFraction> of gross proceeds and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-296">3,467</ix:nonFraction>, after deducting commissions to the sales agent and other ATM Offering related expenses. On December 20, 2024, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" scale="3" id="f-297">322</ix:nonFraction>, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-298">3,605</ix:nonFraction> that were sold under the ATM Offering through December&#160;31, 2024, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering (the June 2024 Offering), (i) <ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-299">3,529</ix:nonFraction> shares (the June 2024 Shares) of Common Stock, (ii) <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-300"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-301">125,047</ix:nonFraction></ix:nonFraction> pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-302">125,047</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-303">128,577</ix:nonFraction> Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-304">128,577</ix:nonFraction> shares of Common Stock, and (iv) <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-305">128,577</ix:nonFraction> Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-306">128,577</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-307">3,172</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-308">1,057</ix:nonFraction>. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Annual Report as the &#8220;June 2024 Warrants.&#8221; The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-309">one</ix:nonFraction> June 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-310">one</ix:nonFraction> June 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-311">one</ix:nonFraction> Series C-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-312">one</ix:nonFraction> Series C-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-313">31.11</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-314">0.0017</ix:nonFraction> for each June 2024 Pre-Funded Warrant).</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-261-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants have been exercised in full. Each Series C-1 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-315">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-316">31.11</ix:nonFraction> and expires on September 6, 2029. Each Series C-2 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-317">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-318">31.11</ix:nonFraction> and expires on March 6, 2026. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the June 2024 Offering. Pursuant to an engagement agreement (the June 2024 Engagement Agreement) with Wainwright, dated as of May 3, 2024, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-319">9,002</ix:nonFraction> shares of Common Stock (the June 2024 PA Warrants)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The June 2024 PA Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-58" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-320">38.89</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, will expire on June 26, 2029 and are exercisable beginning after September 6, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 21, 2024, the Company entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of its issued and outstanding Series B Common Warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-321">44,842</ix:nonFraction> shares of its Common Stock, offering these Holders the opportunity to exercise all of their Series B Common Warrants for cash at a reduced exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-59" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-322">17.00</ix:nonFraction> per share. In addition, these Holders received new unregistered Series D-1 Warrants (the Series Common D-1 Warrants) exercisable for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-323">44,839</ix:nonFraction> shares of Common Stock and new unregistered Series D-2 Common Warrants (the Series D-2 Common Warrants and, together with the Series D-1 Common Warrants, the Series D Common Warrants) exercisable for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-61" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-324">44,839</ix:nonFraction> shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-325">17.00</ix:nonFraction> per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We refer to this transaction as the &#8220;Warrant Repricing Transaction.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pursuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to <ix:nonFraction unitRef="number" contextRef="c-63" decimals="INF" name="ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds" scale="-2" id="f-326">7.0</ix:nonFraction>% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to <ix:nonFraction unitRef="number" contextRef="c-63" decimals="INF" name="ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds" scale="-2" id="f-327">1.0</ix:nonFraction>% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="ck0001824293:SaleOfStockReimbursementOfAccountableExpenses" format="ixt:num-dot-decimal" scale="0" id="f-328">25,000</ix:nonFraction> and non-accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses" format="ixt:num-dot-decimal" scale="0" id="f-329">10,000</ix:nonFraction>. The Company has also issued to Wainwright or its designees warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-64" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-330">3,140</ix:nonFraction> shares of Common Stock (the October 2024 PA Warrants). The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-64" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-331">21.25</ix:nonFraction> per share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross proceeds to the Company from the exercise of the Series B Common Warrants were $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-332">762</ix:nonFraction> prior to deducting placement agent fees and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="ck0001824293:ClassOfWarrantOrRightOfferingCost" scale="3" id="f-333">154</ix:nonFraction>. The issuance under the Repricing Letter Agreements represented $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-334">1,911</ix:nonFraction> in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#8217;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div></ix:continuation><div id="i73c3df21d6604995952be1876b1e93fe_172"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-335" continuedAt="f-335-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-335-1" continuedAt="f-335-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-336" escape="true">References in this Annual Report to &#8220;authoritative guidance&#8221; is meant to refer to accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-337" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly-owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-335-2" continuedAt="f-335-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-338" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-339" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of December&#160;31, 2024 and 2023 included investment in money market funds.&#160;The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashFDICInsuredAmount" scale="3" id="f-340">250</ix:nonFraction> by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="3" id="f-341">4,521</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:CashUninsuredAmount" format="ixt:num-dot-decimal" scale="3" id="f-342">1,217</ix:nonFraction> at December&#160;31, 2024 and 2023, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-343" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&#160;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&#160;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs that are generally unobservable inputs and not corroborated by market data.&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At December&#160;31, 2024, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the statement of operations for the year ended December&#160;31, 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-344" continuedAt="f-344-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-344-1">Property and equipment are stated at cost. The Company commences depreciation when the asset is placed in service. Computers and peripheral equipment are depreciated on a straight-line method over useful lives of <ix:nonNumeric contextRef="c-66" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-345"><ix:nonNumeric contextRef="c-67" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-346">three years</ix:nonNumeric></ix:nonNumeric>.</ix:continuation>&#160;</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-335-3" continuedAt="f-335-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-347" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to use, or control the use of, identified property, plant, or equipment for a period of time in exchange for consideration. Lease right-of-use (ROU) assets and lease liabilities recognized in the accompanying balance sheet represent the right to use an underlying asset for the lease term and an obligation to make lease payments arising from the lease respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the Company recognizes an ROU asset and a lease liability for its operating leases, except its short-term operating leases with original lease terms of twelve months or less. The ROU asset is initially measured at cost, which primarily comprises the initial amount of the lease liability plus any lease prepayments. The lease liability is initially measured at the present value of the lease payments not yet paid, discounted using an estimate of the Company&#8217;s incremental borrowing rate for a collateralized loan with a similar amount and terms as the underlying lease in a similar economic environment. That discount rate is used because the interest rate implicit in the Company&#8217;s lease contracts is typically not readily determinable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease modifications that grant the right to use an existing leased asset for an additional period of time are not accounted for as separate contracts; however, the lease term, classification, discount rate, and measurement of the remaining consideration due under the contract are reassessed upon execution of such modifications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-348" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the May 2022 Warrants (Note 10) in accordance with ASC 815-40, and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the accompanying consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with changes in fair value recognized in the accompanying consolidated statements of operations in the period of change. The derivative liabilities will ultimately be converted into the Common Stock when the warrants are exercised, or will be extinguished upon expiry of the warrant term. Upon exercise, the intrinsic value of the shares issued is transferred to stockholders&#8217; equity. The difference between the intrinsic value of the stock issued and the fair value of the warrant is recorded as gain or loss on the exchange in the accompanying consolidated statements of operations in the period of exercise.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-349" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-350" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's Common Stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-351" continuedAt="f-351-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-335-4"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-351-1">benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-352" escape="true"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;As the Company had a net loss in each of the years ended December&#160;31, 2024 and 2023, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-353" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-354">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-69" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="f-355">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-70" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-356">359,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-357">1,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-358">359,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-359">1,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-360" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2024-03). The amendments in ASU 2024-03 require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, for all public entities. Early adoption is permitted. Management is currently evaluating the impact of this update on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-09). The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. Management is currently evaluating the impact of this update on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, FASB issued ASU 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-06)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-06 represent changes to clarify or improve disclosure and presentation requirements of a variety of topics in the Codification and align those requirements with the SEC&#8217;s regulation. For entities subject to the Security and Exchange Commission&#8217;s (SEC) existing disclosure requirements, the effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited.</span><span style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. Management is currently evaluating the impact of this update and its effective dates but does not expect the update to have a material effect on the Company&#8217;s financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_181"></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.  <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-361" continuedAt="f-361-1" escape="true">MERGER WITH VALLON.</ix:nonNumeric></span></div><ix:continuation id="f-361-1" continuedAt="f-361-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into GRI Operations, with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Effective Time:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each share of GRI Operations Common Stock outstanding immediately prior to the Effective Time, including any shares of GRI Operations Common Stock issued pursuant to the Equity SPA, automatically converted solely into the right to receive a number of shares of the Company&#8217;s Common Stock equal to <ix:nonFraction unitRef="number" contextRef="c-72" decimals="4" name="ck0001824293:CommonStockExchangeRatio" scale="0" id="f-362">0.0374</ix:nonFraction> (the Exchange Ratio).</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Each option to purchase shares of GRI Operations Common Stock (each, a GRI Operations Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the GRI Operations Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#8217;s Common Stock, and the Company assumed the GRI Operations Plan and each such GRI Operations Option in accordance with the terms of the GRI Operations Plan (the Assumed Options). The number of shares of Common Stock subject to each Assumed Option was determined by multiplying (i) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Common Stock. The per share exercise price for the Common Stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each warrant to purchase shares of GRI Operations Common Stock (the GRI Operations Warrants) outstanding immediately prior to the Effective Time was assumed by the Company and converted into a warrant to purchase shares of Common Stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Common Stock; (ii) the number of shares of Common Stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Common Stock; and (iii) the per share exercise price for shares of Common Stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of GRI Operations Common Stock subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Bridge Warrants (Note 9) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="f-363">272</ix:nonFraction> shares of the Company&#8217;s Common Stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants and have an initial exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-364">22,787.31</ix:nonFraction> per share. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All rights with respect to GRI Operations restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s Common Stock. The term, exercisability, vesting schedule and other provisions of the GRI Operations restricted stock awards otherwise remained unchanged.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI Operations was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i) the equity holders of GRI Operations immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately <ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="ck0001824293:CommonStockOwnershipPercentage" scale="-2" id="f-365">85</ix:nonFraction>% of the outstanding shares of the Company&#8217;s Common Stock and the Company&#8217;s stockholders immediately prior to the Merger owned approximately <ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="ck0001824293:CommonStockOwnershipPercentage" scale="-2" id="f-366">15</ix:nonFraction>% of the outstanding shares of the Company&#8217;s Common Stock </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-361-2" continuedAt="f-361-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) GRI Operations held the majority (4 out of 5) of board seats of the combined company, and (iii) GRI Operations&#8217; management held the majority of key positions in the management of the combined company.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-367" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="f-368">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="f-369">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-370">4,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" sign="-" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-371">2,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plus: Transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-372">2,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net liabilities assumed plus transaction costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" sign="-" name="ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-373">5,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-361-3">In addition to the transaction costs noted above, at the Effective Time, <ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" scale="0" id="f-374">19</ix:nonFraction> shares of the Common Stock were issued to GRI Operations&#8217; financial advisor for services related to the Merger.</ix:continuation> </span></div><div id="i73c3df21d6604995952be1876b1e93fe_184"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-375" continuedAt="f-375-1" escape="true">FAIR VALUE MEASUREMENTS.</ix:nonNumeric></span></div><ix:continuation id="f-375-1" continuedAt="f-375-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the year ended December&#160;31, 2024 and 2023.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-375-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-376" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2024:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="ck0001824293:WarrantLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="ck0001824293:WarrantLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="ck0001824293:WarrantLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2023:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="ck0001824293:WarrantLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="ck0001824293:WarrantLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="ck0001824293:WarrantLiabilityFairValueDisclosure" scale="3" id="f-382">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-383" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes is the fair value of the Level 3 liability:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-384">3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in valuation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-385">3</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-386">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-387" continuedAt="f-387-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.429%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-388">166.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-389">2.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-390">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-87" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-391">4.26</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i73c3df21d6604995952be1876b1e93fe_190"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.  <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-392" continuedAt="f-392-1" escape="true">PROPERTY AND EQUIPMENT.</ix:nonNumeric></span></div><ix:continuation id="f-392-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-393" escape="true"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-394">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-395">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-396">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-397">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-398">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-399">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-400">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-401">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:9pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-402">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-403">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-404"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-405">4</ix:nonFraction></ix:nonFraction> in each of the years ended December&#160;31, 2024 and 2023.</span></div></ix:continuation><div id="i73c3df21d6604995952be1876b1e93fe_193"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.  <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-406" continuedAt="f-406-1" escape="true">LEASES.</ix:nonNumeric></span></div><ix:continuation id="f-406-1" continuedAt="f-406-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office facilities under an operating lease agreement. The lease agreement requires fixed monthly rental payments as well as payments for variable monthly utilities and operating costs throughout the lease term. The Company evaluates renewal options at lease inception on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-406-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants.</span></div><ix:nonNumeric contextRef="c-1" name="ck0001824293:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-407" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the operating lease assets and liabilities recognized on the Company's consolidated balance sheets:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.916%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.919%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance Sheet Line Item</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-408">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-409">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-410">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-411">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-412">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-414">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-415">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-416" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments are due as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-417">60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-418">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-419">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="f-420">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-421">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiability" scale="3" id="f-422">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-423">62</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-424">59</ix:nonFraction> for each of the years ended December&#160;31, 2024 and 2023, respectively. Operating lease costs are included within selling, general and administrative expenses on the consolidated statements of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-425">59</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="f-426">58</ix:nonFraction> for the years ended December&#160;31, 2024 and 2023, respectively. This amount is included in operating activities in the consolidated statements of cash flows.</span></div></ix:continuation><div id="i73c3df21d6604995952be1876b1e93fe_196"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-427" continuedAt="f-427-1" escape="true">ACCRUED EXPENSES.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-428" escape="true"><ix:continuation id="f-427-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="f-429">342</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="f-430">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="f-431">12</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="f-432">441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Payroll and related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-433">337</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-434">736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-435">691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-436">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i73c3df21d6604995952be1876b1e93fe_199"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-437" continuedAt="f-437-1" escape="true">PROMISSORY NOTES.</ix:nonNumeric></span></div><ix:continuation id="f-437-1" continuedAt="f-437-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Financing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, GRI Operations entered into a Securities Purchase Agreement, dated as of December 13, 2022 (Bridge SPA), with Altium, pursuant to which GRI Operations issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-438">3,333</ix:nonFraction>, in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-439">2,500</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were issued in <ix:nonFraction unitRef="closing" contextRef="c-92" decimals="INF" name="ck0001824293:DebtInstrumentNumberOfClosings" format="ixt-sec:numwordsen" scale="0" id="f-440">two</ix:nonFraction> closings: (i) the first closing for $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-441">1,667</ix:nonFraction> in aggregate principal amount (in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-442">1,250</ix:nonFraction>) closed on December 14, 2022; and (ii) the second closing for $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-443">1,667</ix:nonFraction> in aggregate principal amount (in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-444">1,250</ix:nonFraction>) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#8217;s assets. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-437-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the funding of each tranche, Altium received warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="f-445">809</ix:nonFraction> shares of the Common Stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-446">2,057.51</ix:nonFraction> per share, were exercisable at any time on or after the applicable issuance date and had a term of <ix:nonNumeric contextRef="c-5" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-447">60</ix:nonNumeric> months from the date all shares underlying the Bridge Warrants were freely tradable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-448">1,250</ix:nonFraction> of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-449">679</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-450">571</ix:nonFraction>, respectively. The $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-451">1,250</ix:nonFraction> of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-452">718</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-453">532</ix:nonFraction>, respectively. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered into the Equity SPA (Note 10) pursuant to which Altium agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-454">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations&#8217; Common Stock immediately prior to the consummation of the Merger. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-101" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-455">22,787.31</ix:nonFraction> per share subject to adjustments for splits and recapitalization events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="f-456">294</ix:nonFraction> of which $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-457">90</ix:nonFraction> was incurred during the year ended December&#160;31, 2023 related to its issuance of debt under the Bridge SPA. Interest expense stemming from amortization of debt discounts and issuance costs was $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-458">2,104</ix:nonFraction> for the year ended December&#160;31, 2023.</span></div></ix:continuation><div id="i73c3df21d6604995952be1876b1e93fe_205"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-459" continuedAt="f-459-1" escape="true">STOCKHOLDERS EQUITY.</ix:nonNumeric></span></div><ix:continuation id="f-459-1" continuedAt="f-459-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Purchase Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered the Equity SPA pursuant to which Altium agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-460">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations Common Stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued the Initial Shares to Altium and the Additional Shares into escrow with an escrow agent for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-461">11,704</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-462">546</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" id="f-463">164</ix:nonFraction> shares of the Common Stock and the Additional Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="ck0001824293:ConversionOfStockAdditionalSharesConverted" scale="0" id="f-464">656</ix:nonFraction> shares of the Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Common Stock issued in exchange for the Additional Shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell (i) <ix:nonFraction unitRef="shares" contextRef="c-37" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-465">1,495</ix:nonFraction> February 2024 Shares, (ii) <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-466">21,131</ix:nonFraction> February 2024 Pre-Funded Warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-467">21,131</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-468">22,631</ix:nonFraction> Series B-1 Common Warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-469">22,631</ix:nonFraction> shares of Common Stock and (iv) <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-470">22,631</ix:nonFraction> Series B-2 Common Warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-471">22,631</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-472">4,389</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-473">1,110</ix:nonFraction>. The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-474">one</ix:nonFraction> February 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-475">one</ix:nonFraction> February 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-476">one</ix:nonFraction> Series B-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-477">one</ix:nonFraction> Series B-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-41" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-478">243.10</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-42" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-479">0.0221</ix:nonFraction> for each February 2024 Pre-Funded Warrant).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The February 2024 Pre-Funded Warrants have been exercised in full. Each Series B-1 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-43" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-480">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-43" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-481">243.10</ix:nonFraction> and expires on February 6, 2029. Each Series B-2 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-482">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-483">243.10</ix:nonFraction> and expires on August 6, 2026. The February 2024 Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-484">4,279</ix:nonFraction> is included in additional paid in capital. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-459-2" continuedAt="f-459-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the amount paid for the February 2024 Pre-Funded Warrants approximates their fair value. <ix:continuation id="f-387-1" continuedAt="f-387-2">The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:</ix:continuation></span></div><ix:continuation id="f-387-2" continuedAt="f-387-3"><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-105" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-485">156.3</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="year" contextRef="c-106" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-486">1.63</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-487">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-488">4.65</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants issued in connection with the Merger was reduced to par, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-45" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-489">0.0001</ix:nonFraction>, per share pursuant to the terms of the Series A-1 Warrants. All of the Series A-1 Warrants have been exercised in full.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="6" id="f-490">10.0</ix:nonFraction>&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of <ix:nonFraction unitRef="number" contextRef="c-46" decimals="3" name="ck0001824293:SaleOfStockAgentCompensationPercentage" scale="-2" id="f-491">3.0</ix:nonFraction>% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company has sold <ix:nonFraction unitRef="shares" contextRef="c-47" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-492">325,618</ix:nonFraction> shares of Common Stock in the ATM Offering at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-48" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-493">11.07</ix:nonFraction> per share, raising $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-494">3,605</ix:nonFraction> of gross proceeds and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-495">3,467</ix:nonFraction>, after deducting commissions to the sales agent and other ATM Offering related expenses. On December 20, 2024, we filed a prospectus supplement to our registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that we may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" scale="3" id="f-496">322</ix:nonFraction>, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-497">3,605</ix:nonFraction> that were sold under the ATM Offering through December 20, 2024, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company issued and sold, in the June 2024 Offering, (i) <ix:nonFraction unitRef="shares" contextRef="c-50" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-498">3,529</ix:nonFraction> June 2024 Shares, (ii) <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-499">125,047</ix:nonFraction> June 2024 Pre-Funded Warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-500">125,047</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-501">128,577</ix:nonFraction> Series C-1 Common Warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-502">128,577</ix:nonFraction> shares of Common Stock, and (iv) <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-503">128,577</ix:nonFraction> Series C-2 Common Warrants, exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-504">128,577</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-505">3,172</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-506">1,057</ix:nonFraction>. The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-507">one</ix:nonFraction> June 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-51" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-508">one</ix:nonFraction> June 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-52" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-509">one</ix:nonFraction> Series C-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-510">one</ix:nonFraction> Series C-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-511">31.11</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-55" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-512">0.0017</ix:nonFraction> for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants have been exercised in full. Each Series C-1 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-513">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-56" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-514">31.11</ix:nonFraction> and expires on September 6, 2029. Each Series C-2 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-515">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-516">31.11</ix:nonFraction> and expires on March 6, 2026. The June 2024 Pre-Funded Warrants and the Series C Common Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-517">2,908</ix:nonFraction> is included in additional paid in capital.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the June 2024 Engagement Agreement, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, June 2024 PA Warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-518">9,001</ix:nonFraction> shares of Common Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The June 2024 PA Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-519">38.89</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share and will expire on June 26, 2029. The June 2024 PA Warrants were classified as equity and the fair value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="f-520">229</ix:nonFraction> is included in additional paid in capital.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-459-3" continuedAt="f-459-4"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the amount paid for the June 2024 Pre-Funded Warrants approximates their fair value. <ix:continuation id="f-387-3" continuedAt="f-387-4">The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants, and the Placement Agent Warrants with the following weighted-average assumptions:</ix:continuation></span></div><ix:continuation id="f-387-4" continuedAt="f-387-5"><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-113" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-521">159.1</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="year" contextRef="c-114" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-522">1.65</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-115" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-523">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-524">4.92</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2024 Repricing Letter Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 21, 2024, the Company entered into the Repricing Letter Agreements with certain Holders of its issued and outstanding Series B Common Warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-525">44,842</ix:nonFraction> shares of its Common Stock, offering these Holders the opportunity to exercise all of their Series B Common Warrants for cash at a reduced exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-117" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-526">17.00</ix:nonFraction> per share. In addition, these Holders received new unregistered Series D-1 Common Warrants exercisable for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-527">44,839</ix:nonFraction> shares of Common Stock and new unregistered Series D-2 Common Warrants exercisable for up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-61" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-528">44,839</ix:nonFraction> shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-529">17.00</ix:nonFraction> per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rsuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to <ix:nonFraction unitRef="number" contextRef="c-63" decimals="INF" name="ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds" scale="-2" id="f-530">7.0</ix:nonFraction>% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to <ix:nonFraction unitRef="number" contextRef="c-63" decimals="INF" name="ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds" scale="-2" id="f-531">1.0</ix:nonFraction>% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="ck0001824293:SaleOfStockReimbursementOfAccountableExpenses" format="ixt:num-dot-decimal" scale="0" id="f-532">25,000</ix:nonFraction> and non-accountable expenses of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses" format="ixt:num-dot-decimal" scale="0" id="f-533">10,000</ix:nonFraction>. The Company has also issued to Wainwright or its designees the October 2024 PA Warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-534">3,140</ix:nonFraction> shares of Common Stock. The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-118" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-535">21.25</ix:nonFraction> per share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to the Company from the exercise of the Series B Common Warrants were $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="ck0001824293:ProceedsFromWarrantExercisesNetOfOfferingExpense" scale="3" id="f-536">609</ix:nonFraction> after deducting placement agent fees and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="ck0001824293:ClassOfWarrantOrRightOfferingCost" scale="3" id="f-537">154</ix:nonFraction>. The issuance under the Repricing Letter Agreements represented $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="3" id="f-538">1,911</ix:nonFraction> in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.</span></div><ix:continuation id="f-387-5"><div style="margin-bottom:9pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Series D-1 Common Warrants, the Series D-2 Common Warrants, and the October 2024 PA Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-119" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-539">174.4</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="year" contextRef="c-120" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-540">1.65</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-121" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-541">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-542">4.16</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-459-4"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-543" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had the following warrants outstanding to purchase common stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-544">210</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-545">243.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-546">9</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-547">464,100.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-548">128,577</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-549">31.11</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-550">44,839</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-551">17.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-552">16</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-553">43,548.05</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-554">1</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-555">0.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-556">3</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-557">94,970.33</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-558">210</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-130" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-559">243.10</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-560">9,002</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-131" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-561">38.8875</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-562">128,577</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-132" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-563">31.11</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-564">44,839</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-565">17.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-566">3,140</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-567">21.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 2029</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><div id="i73c3df21d6604995952be1876b1e93fe_208"></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-568" continuedAt="f-568-1" escape="true">STOCK BASED COMPENSATION.</ix:nonNumeric></span></div><ix:continuation id="f-568-1" continuedAt="f-568-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Operations adopted the GRI Operations Plan, which provided GRI Operations with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Upon completion of the Merger, the Company assumed the GRI Operations Plan and <ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="f-569">57</ix:nonFraction> outstanding and unexercised options issued thereunder, and ceased granting awards under the GRI Operations Plan. As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-570">no</ix:nonFraction> options remain outstanding under the GRI Operations Plan. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan had previously been approved by the Company&#8217;s board of directors, subject to stockholder approval. The A&amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving an amendment to the A&amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" id="f-571">109</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="f-572">140</ix:nonFraction> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s Common Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for issuance as awards under the A&amp;R 2018 Plan, (ii) to extend the term of the A&amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#8220;repricing&#8221; of an award without further approval by the stockholders of Company and (iv) to revise the limits on awards to non-employee directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;R 2018 Plan generally have a contractual life of up to <ix:nonNumeric contextRef="c-139" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-573">10</ix:nonNumeric> years. As of December&#160;31, 2024, awards granted under the A&amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="f-574">142</ix:nonFraction> shares of the Company's Common Stock were outstanding and <ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="f-575">256</ix:nonFraction> shares of the Company&#8217;s Common Stock were reserved for issuance under the A&amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;R 2018 Plan may be increased pursuant to the A&amp;R 2018 Plan&#8217;s &#8220;evergreen&#8221; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed <ix:nonFraction unitRef="number" contextRef="c-140" decimals="2" name="ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" scale="-2" id="f-576">4</ix:nonFraction>% of the aggregate number of shares of the Company&#8217;s Common Stock outstanding on the final day of the immediately preceding calendar year.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-577" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the GRI Operations Plan and the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and nine months ended December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.316%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-578">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-579">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-580">148</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-581">388</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-582">148</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-583">388</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-568-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-584" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the year ended December&#160;31, 2024:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="f-585">142</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-586">4,376.92</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-587">9.63</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="3" id="f-588">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-589">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-590">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="f-591">142</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-592">4,376.92</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-593">8.63</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="f-594">62</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-595">5,475.38</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-596">8.57</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested and expected to vest at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="f-597">142</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-598">4,376.92</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-599">8.63</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, all of the outstanding and exercisable stock options were out of the money and therefore had <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="f-600">no</ix:nonFraction> intrinsic value. At December&#160;31, 2024, the unrecognized compensation cost related to unvested stock options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="f-601">240</ix:nonFraction>. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of <ix:nonNumeric contextRef="c-145" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durwordsen" id="f-602">two years</ix:nonNumeric>. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="f-603">141</ix:nonFraction> stock options to employees and non-employees during the year ended December&#160;31, 2023. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-604" continuedAt="f-604-1" escape="true">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-604-1"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.873%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-146" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-605">129.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-146" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-606">5.84</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-146" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-607">0.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-146" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-608">4.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of common stock on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-147" decimals="2" name="us-gaap:SharePrice" format="ixt:num-dot-decimal" scale="0" id="f-609">3,298.42</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-610">No</ix:nonFraction> equity-based awards were granted during the year ended December&#160;31, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected term of options is determined using the "simplified" method, as prescribed in SEC's SAB No. 107, Share Based Payment (SAB No. 107), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company's lack of sufficient historical data. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility is based on a weighted average of the Company's historical volatility and the volatilities of similar entities within the Company's industry which were commensurate with the expected term assumption as described in SAB No. 107.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate is based on the interest rate payable on US Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected dividend yield is <ix:nonFraction unitRef="number" contextRef="c-145" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-611">0</ix:nonFraction>% because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</span></div></ix:continuation><div id="i73c3df21d6604995952be1876b1e93fe_217"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.  <ix:nonNumeric contextRef="c-1" name="us-gaap:AssetAcquisitionTextBlock" id="f-612" continuedAt="f-612-1" escape="true">ASSET PURCHASE AGREEMENT.</ix:nonNumeric></span></div><ix:continuation id="f-612-1" continuedAt="f-612-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2023, the Company entered into Asset Purchase Agreement (the Aardvark Agreement) with Aardvark Therapeutics, Inc. (Aardvark), pursuant to which Aardvark agreed to purchase (i) the Company&#8217;s license agreement with Medice Arzneimittel P&#369;tter GmbH &amp; Co. KG, dated January 6, 2020, (ii) certain patents related to the Company&#8217;s ADAIR product candidate, and (iii) files (of contract manufacturing and FDA correspondence) for a formulation described in IND No. 133072, ADAIR for the Treatment of </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-612-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADHD and Narcolepsy, filed with the United States Food and Drug Administration. Under the terms of the Aardvark Agreement, the Company received an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="f-613">250</ix:nonFraction>, which was recognized as other income. The Company is also eligible to receive potential additional milestone payments contingent upon Aardvark achieving certain future ADAIR regulatory and sales milestones. Other than the upfront payment, the Company does not anticipate the receipt of any milestone payments from Aardvark in the near term, which potential milestone payments may or may not be achieved, paid or received in the future.</span></div></ix:continuation><div id="i73c3df21d6604995952be1876b1e93fe_223"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-614" continuedAt="f-614-1" escape="true">COMMITMENTS AND CONTINGENCIES.</ix:nonNumeric></span></div><ix:continuation id="f-614-1" continuedAt="f-614-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with each of its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation and Release Agreement</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-614-2">In connection with the resignation of David Baker, the Company&#8217;s former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for <ix:nonNumeric contextRef="c-149" name="ck0001824293:COBRABenefitsPaymentPeriod" format="ixt-sec:durmonth" id="f-615">18</ix:nonNumeric> months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to <ix:nonFraction unitRef="number" contextRef="c-149" decimals="INF" name="ck0001824293:PercentageOfTargetBonus" scale="-2" id="f-616">150</ix:nonFraction>% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</ix:continuation> </span></div><div id="i73c3df21d6604995952be1876b1e93fe_226"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-617" continuedAt="f-617-1" escape="true">INCOME TAX.</ix:nonNumeric></span></div><ix:continuation id="f-617-1" continuedAt="f-617-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-618" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected income tax benefit at the federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-619">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-620">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State and local taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-621">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-622">8.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-deductible items and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-623">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-624">12.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-625">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-626">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-627">26.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-628">18.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" id="f-629">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" format="ixt:fixed-zero" scale="-2" id="f-630">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-631">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-9" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:76.5pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i73c3df21d6604995952be1876b1e93fe_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:8pt;text-align:center"><span><br/></span></div></div><ix:continuation id="f-617-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-633" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-634">14,537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-635">12,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="f-636">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="f-637">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accruals and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="f-638">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="f-639">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-640">1,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-641">1,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:fixed-zero" scale="3" id="f-642">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="f-643">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation - Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="f-644">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-645">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization - Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" scale="3" id="f-646">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-648">16,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-649">14,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-651">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-652">16,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-653">14,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-655">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2024 and 2023. The Company increased its valuation allowance by approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="3" id="f-656">2,163</ix:nonFraction> for the&#160;year ended December&#160;31, 2024. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had federal, state and local net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-657">52,369</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-658">58,254</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-659">5,563</ix:nonFraction>, respectively; $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="ck0001824293:OperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-660">46,245</ix:nonFraction> of the federal net operating loss carryforwards do not expire and the remaining $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="ck0001824293:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-661">6,124</ix:nonFraction> begin to expire in 2029. The state losses also begin to expire in 2029. The local net operating losses begin to expire in 2024. Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (IRC), these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the IRC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of Sections&#160;382 and 383 of the IRC, certain substantial changes in the Company&#8217;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the US federal jurisdiction as well as California, Pennsylvania and Philadelphia. The tax years 2021 to 2024 remain open to examination by the major jurisdictions in which the Company is subject to tax. Fiscal years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early years, which have been carried forward and may be audited in subsequent years when utilized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2024 and 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:fixed-zero" scale="0" id="f-662"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:fixed-zero" scale="0" id="f-663">no</ix:nonFraction></ix:nonFraction> unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#8217;s uncertain tax positions yet to be determined would be related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</span></div></ix:continuation><div id="i73c3df21d6604995952be1876b1e93fe_235"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-664" continuedAt="f-664-1" escape="true">SUBSEQUENT EVENTS.</ix:nonNumeric></span></div><ix:continuation id="f-664-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recapitalization</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2025, the Company effected the February 2025 Reverse Stock Split. Stockholders&#8217; equity and all references to share and per share amounts in the accompanying financial statements have been retroactively adjusted to reflect the one-for-seventeen reverse stock split for all periods presented.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>gri-202410k_ex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6b241a41439d4b81a8a1bf05c90c6b04_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 3.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Delaware</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The First State</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF &#8220;VALLON PHARMACEUTICALS, INC.&#8221;, FILED IN THIS OFFICE ON THE TENTH DAY OF FEBRUARY, A.D. 2021, AT 1&#58;14 O&#8217;CLOCK P.M.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6705195 8100 Authentication&#58; 202482772</font><img alt="image_02.jpg" src="image_02.jpg" style="height:97px;margin-bottom:5pt;vertical-align:text-bottom;width:242px"><img alt="image_1.jpg" src="image_1.jpg" style="height:134px;margin-bottom:5pt;vertical-align:text-bottom;width:144px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SR# 20210402453 Date&#58; 02-10-21</font></div><div style="margin-bottom:24pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may verify this certificate online at corp.delaware.gov&#47;authver.shtml</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALLON PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a Delaware corporation)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The present name of the corporation is Vallon Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The Corporation was incorporated under its present name by the filing of its original certificate of incorporation (as heretofore amended, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Original Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) with the Secretary of State of the State of Delaware on January 11, 2018. This Amended and Restated Certificate of Incorporation of the Corporation (as the same may be amended and&#47;or restated from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which amends, restates and integrates the provisions of the Original Certificate of Incorporation, was duly adopted in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of die State of Delaware and by the written consent of the stockholders in accordance with Section 228 of the General Corporation Law of the State of Delaware. The Original Certificate of Incorporation of the Corporation is hereby amended and restated to read in its entirety as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE I<br>NAME</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The name of the corporation is Vallon Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE II<br>AGENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The address of the Corporation&#8217;s registered office in the State of Delaware is c&#47;o The Corporation Trust Company, 1209 Orange Street in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE III<br>PURPOSE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IV<br>STOCK</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authorized Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total number of shares which the Corporation shall have authority to issue is 260,000,000, of which 250,000,000 shall be designated as Common Stock, par value $0.0001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and 10,000,000 shall be designated as Preferred Stock, par value $0.0001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Each holder of Common Stock, as such, shall be entitled to one vote for each share of Common Stock held of record by such holder on all matters on which stockholders generally are entitled to vote&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate of Incorporation, including any certificate of designations relating to any series of Preferred Stock (each hereinafter referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to this Certificate of Incorporation (including any Preferred Stock Designation).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State of Delaware</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Secretary of State</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Division of Corporations</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delivered 01&#58;14 PM 02&#47;10&#47;2021</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the rights of the holders of any outstanding series of Preferred Stock, the holders of shares of Common Stock shall be entitled to receive dividends to the extent permitted by law when, as and if declared by the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liquidation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Upon the dissolution, liquidation or winding up of the Corporation, subject to the rights of the holders of any outstanding series of Preferred Stock, the holders of shares of Common Stock shall be entitled to receive the assets of the Corporation available for distribution to its stockholders ratably in proportion to the number of shares held by them.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Preferred Stock may be issued from time to time in one or more series. Subject to limitations prescribed by law and the provisions of this Article IV (including any Preferred Stock Designation), the Board of Directors is hereby authorized to provide by resolution and by causing the filing of a Preferred Stock Designation for the issuance of the shares of Preferred Stock in one or more series, and to establish from time to time the number of shares to be included in each such series, and to fix the designations, powers, preferences, and relative, participating, optional or other rights, if any, and the qualifications, limitations or restrictions, if any, of the shares of each such series.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Class Vote on Changes in Authorized Number of Shares of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subject to the rights of the holders of any outstanding series of Preferred Stock, the number of authorized shares of Common Stock or Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of at least a majority of the voting power of the stock outstanding and entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the DGCL.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE V<br>BOARD OF DIRECTORS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Number</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as otherwise provided for or fixed pursuant to the provisions of Article IV hereof (including any Preferred Stock Designation), the Board of Directors shall consist of such number of directors as shall be determined from time to time solely by resolution adopted by the affirmative vote of a majority of the total number of directors then authorized.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Classification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Except as may be otherwise provided with respect to directors elected by the holders of any series of Preferred Stock provided for or fixed pursuant to the provisions of Article IV hereof (including any Preferred Stock Designation) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the Board of Directors shall be divided into three classes, designated Class I, Class II and Class III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class I directors shall initially serve until the first annual meeting of stockholders following the initial effectiveness of this Section 5.2&#59; Class II directors shall initially serve until the second annual meeting of stockholders following the initial effectiveness of this Section 5.2&#59; and Class III directors shall initially serve until the third annual meeting of stockholders following the initial effectiveness of this Section 5.2. Commencing with the first annual meeting of stockholders following the initial effectiveness of this Section 5.2, directors of each class the term of which shall then expire shall be elected to hold office for a three-year term and until the election and qualification of their respective successors in office. The Board of Directors is authorized to assign members of the Board of Directors already in office to Class I, Class II or Class III, with such assignment becoming effective as of the initial effectiveness of this Section 5.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Subject to the rights of the holders of any outstanding series of Preferred Stock, and unless otherwise required by law, newly created directorships resulting from any increase in the authorized number of directors and any vacancies in the Board of Directors resulting from death, resignation, retirement, disqualification, removal from office or other cause shall be filled solely by the affirmative vote of a majority of the remaining directors then in office (other than any director elected by a separate vote of the holders of one or more outstanding series of Preferred Stock), even though less than a quorum of the Board of Directors. Any director so chosen shall hold office until the next election of the class for which such director shall have been chosen and until his or her successor shall have been duly elected and qualified. No decrease in the authorized number of directors shall shorten the term of any incumbent director.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Any director elected by the stockholders generally may be removed from office at any time, but only for cause and only by the affirmative vote of at least 66 2&#47;3% of the voting power of the stock outstanding and entitled to vote thereon.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;During any period when the holders of any series of Preferred Stock have the right to elect additional directors as provided for or fixed pursuant to the provisions of Article IV hereof (including any Preferred Stock Designation), and upon commencement and for the duration of the period during which such right continues&#58; (i) the then otherwise total authorized number of directors of the Corporation shall automatically be increased by such number of directors that the holders of any series of Preferred Stock have a right to elect, and the holders of such Preferred Stock shall be entitled to elect the additional directors so provided for or fixed pursuant to said provisions&#59; and (ii) each Preferred Stock Director shall serve until such Preferred Stock Director&#8217;s successor shall have been duly elected and qualified, or until such director&#8217;s right to hold such office terminates pursuant to said provisions, whichever occurs earlier, subject to his or her earlier death, disqualification, resignation or removal. Except as otherwise provided for or fixed pursuant to the provisions of Article IV hereof (including any Preferred Stock Designation), whenever the holders of any series of Preferred Stock having such right to elect additional directors are divested of such right pursuant to said provisions, the terms of office of all Preferred Stock Directors elected by the holders of such Preferred Stock, or elected to fill any vacancies resulting from the death, resignation, disqualification or removal of such additional directors, shall forthwith terminate (in which case such Preferred Stock Director shall cease to be qualified as a director and shall cease to be a director) and the total authorized number of directors of the Corporation shall be automatically reduced accordingly.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.3&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Except as otherwise required by the DGCL or as provided in this Certificate of Incorporation (including any Preferred Stock Designation), the business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.4&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Election&#58; Annual Meeting of Stockholders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Ballot Not Required</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The directors of the Corporation need not be elected by written ballot unless the Bylaws of the Corporation so provide.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Advance notice of nominations for the election of directors, and of business other than nominations, to be proposed by stockholders for consideration at a meeting of stockholders of the Corporation shall be given in the manner and to the extent provided in or contemplated by the Bylaws of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The annual meeting of stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, if any, either within or without the State of Delaware, on such date, and at such time as the Board of Directors shall fix.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VI<br>STOCKHOLDER ACTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise provided for or fixed with respect to actions required or permitted to be taken solely by holders of Preferred Stock pursuant to the provisions of Article IV hereof (including any Preferred Stock Designation), no action that is required or permitted to be taken by the stockholders of the Corporation may be effected by consent of stockholders in lieu of a meeting of stockholders.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VII<br>SPECIAL MEETINGS OF STOCKHOLDERS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise required by law, and except as otherwise provided for or fixed pursuant to the provisions of Article IV hereof (including any Preferred Stock Designation), a special meeting of the stockholders of the Corporation may be called at any time only by the Board of Directors. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting by or at the direction of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE VIII<br>EXISTENCE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation shall have perpetual existence.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE IX<br>AMENDMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Certificate of Incorporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Corporation reserves the right at any time, and from time to time, to amend, alter, change or repeal any provision contained in this Certificate of Incorporation (including any Preferred Stock Designation), and other provisions authorized by the laws of the State of Delaware at the time in force may be added or inserted, in the manner now or hereafter prescribed by the laws of the State of Delaware, and all powers, preferences and rights of any nature conferred upon stockholders, directors or any other persons by and pursuant to this Certificate of Incorporation (including any Preferred Stock Designation) in its present form or as hereafter amended are granted subject to this reservation&#59; provided, however, that except as otherwise provided in this Certificate of Incorporation (including any provision of a Preferred Stock Designation) that provides for a greater or lesser vote and in addition to any other vote required by law, the affirmative vote of at least 66 2&#47;3% of the voting power of the stock outstanding and entitled to vote thereon, voting together as a single </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">class, shall be required to adopt, amend or repeal, or adopt any provision inconsistent with Section 5.2(c) of Article V of this Certificate of Incorporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment of Bylaws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware, but subject to the terms of any series of Preferred Stock then outstanding, the Board of Directors is expressly authorized to adopt, amend or repeal the Bylaws of the Corporation. Except as otherwise provided in this Certificate of Incorporation (including the terms of any Preferred Stock Designation that require an additional vote) or the Bylaws of the Corporation, and in addition to any requirements of law, the affirmative vote of at least 66 2&#47;3% of the voting power of the stock outstanding and entitled to vote thereon, voting together as a single class, shall be required for the stockholders to adopt, amend or repeal, or adopt any provision inconsistent with, any provision of the Bylaws of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE X<br>LIABILITY OF DIRECTORS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">No Personal Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. To the fullest extent permitted by the DGCL as the same exists or as may hereafter be amended, no director of the Corporation shall be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Amendment or Repeal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any amendment, alteration or repeal of this Article X that adversely affects any right of a director shall be prospective only and shall not limit or eliminate any such right with respect to any proceeding involving any occurrence or alleged occurrence of any action or omission to act that took place prior to such amendment, alteration or repeal.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARTICLE XI<br>FORUM FOR ADJUDICATION OF DISPUTES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Forum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Unless the Corporation consents in writing to the selection of an alternative forum, (A) (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of a fiduciary duty owed by any current or former director, officer, other employee or stockholder of the Corporation to the Corporation or the Corporation&#8217;s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL, this Certificate of Incorporation or the Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv) any action asserting a claim governed by the internal affairs doctrine of the law of the State of Delaware shall, to the fullest extent permitted by law, be exclusively brought in the Court of Chancery of the State of Delaware or, if such court does not have subject matter jurisdiction thereof, the federal district court of the State of Delaware&#59; and (B) the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring or holding any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Article XI.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.2&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enforceability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If any provision of this Article XI shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provision in any other circumstance and of the remaining provisions of this Article XI (including, without limitation, each portion of any sentence of this Article XI containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities or circumstances shall not in any way be affected or impaired thereby.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;The remainder of this page has been intentionally left blank.&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the Corporation has caused this Amended and Restated Certificate of Incorporation to be signed by the undersigned officer of the Corporation this 5th day of February, 2021.</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALLON PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47;David Baker&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:1.5pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; David Baker</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Chief Executive Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i6b241a41439d4b81a8a1bf05c90c6b04_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALLON PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Pursuant to Section 242 of the General Corporation Law of the State of Delaware)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), does hereby certify as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;That a resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section 242 of the General Corporation Law of the State of Delaware setting forth an amendment to the Amended and Restated Certificate of Incorporation of the Corporation and declaring said amendment to be advisable and that such amendment be submitted to the stockholders of the Corporation for their consideration, as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; That, effective at 10&#58;00 a.m. Eastern time on April 21, 2023, Section 4.1 of Article IV of the Amended and Restated Certificate of Incorporation of the Corporation be and hereby is deleted in its entirety and the following is inserted in lieu thereof&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Section 4.1 Authorized Stock. The total number of shares which the Corporation shall have authority to issue is 260,000,000, of which 250,000,000 shall be designated as Common Stock, par value $0.0001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; and 10,000,000 shall be designated as Preferred Stock, par value $0.0001 per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective at 10&#58;00 a.m. Eastern time on April 21, 2023 (the &#8220;Reverse Stock Split Effective Time&#8221;), a one-for-30 reverse stock split of the Corporation&#8217;s Common Stock shall become effective, pursuant to which each 30 shares of Common Stock outstanding and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Reverse Stock Split Effective Time shall be reclassified and combined into one (1) validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Reverse Stock Split Effective Time and shall represent one share of Common Stock from and after the Reverse Stock Split Effective Time (such reclassification and combination of shares, the &#8220;Reverse Stock Split&#8221;). No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Reverse Stock Split Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Reverse Stock Split Effective Time, shall be entitled to receive a cash payment equal to the fraction of a share of Common Stock to which such holder would otherwise be entitled multiplied by the fair value per share of the Common Stock immediately prior to the Reverse Stock Split Effective Time as determined by the Board of Directors of the Corporation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each stock certificate that, immediately prior to the Reverse Stock Split Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall, from and after the Reverse Stock Split Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Reverse Stock Split Effective Time into which the shares formerly represented by such certificate have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Reverse Stock Split Effective Time)&#59; provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Reverse Stock Split </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;That, at a special meeting of stockholders of the Corporation, the aforesaid amendment was duly adopted by the stockholders of the Corporation.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;That the aforesaid amendment was duly adopted in accordance with the applicable provisions of Section 242 of the General Corporation Law of the State of Delaware.</font></div><div style="margin-bottom:12pt;padding-left:18pt;padding-right:18pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Remainder of Page Intentionally Left Blank&#59; Signature Page Follows&#93;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, this Certificate of Amendment has been executed by a duly authorized officer of the Corporation on this 21st day of April, 2023.</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALLON PHARMACEUTICALS, INC.</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; David Baker&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:1.5pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; David Baker</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; Chief Executive Officer</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><div id="i6b241a41439d4b81a8a1bf05c90c6b04_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vallon Pharmaceuticals, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), does hereby certify that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FIRST&#58; Effective at 10&#58;02 a.m. Eastern time on April 21, 2023, Article I of the Amended and Restated Certificate of Incorporation be, and it hereby is, amended and restated in its entirety as follows&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;ARTICLE I</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NAME</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The name of the corporation is GRI Bio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECOND&#58; This Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Corporation was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware and shall be effective at 10&#58;02 a.m. Eastern time on April 21, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the undersigned has caused this Certificate of Amendment to be duly executed this 21st day of April, 2023.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VALLON PHARMACEUTICALS, INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; W. Marc Hertz</font></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; President and Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certified that&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FIRST</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The name of the corporation is </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SECOND</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The Amended and Restated Certificate of Incorporation of the Corporation, as amended to date, is hereby further amended by striking Section 4.1 of Article IV in its entirety and by substituting in lieu of the following&#58;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Section 4.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authorized Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total number of shares which the Corporation shall have authority to issue is 260,000,000 shares, of which (a) 250,000,000 shall be designated as Common Stock, $0.0001 par value per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and (b) 10,000,000 shall be designated Preferred Stock, $0.0001 par value per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective at 4&#58;01 p.m. Eastern Time on January 29, 2024 (the &#8220;Reverse Stock Split Effective Time&#8221;), a one-for-seven reverse stock split of the Corporation&#8217;s Common Stock shall become effective, pursuant to which each seven (7) shares of Common Stock outstanding and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Reverse Stock Split Effective Time shall be reclassified and combined into one (1) validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Reverse Stock Split Effective Time and shall represent one share of Common Stock from and after the Reverse Stock Split Effective Time (such reclassification and combination of shares, the &#8220;Reverse Stock Split&#8221;). No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Reverse Stock Split Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Reverse Stock Split Effective Time, shall be entitled to receive a cash payment equal to the fraction of a share of Common Stock to which such holder would otherwise be entitled multiplied by the fair value per share of the Common Stock immediately prior to the Reverse Stock Split Effective Time as determined by the Board of Directors of the Corporation.</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each stock certificate that, immediately prior to the Reverse Stock Split Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall, from and after the Reverse Stock Split Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Reverse Stock Split Effective Time into which the shares formerly represented by such certificate have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Reverse Stock Split Effective Time)&#59; provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Reverse Stock Split Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified.&#8221;</font></div><div style="margin-bottom:10pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">THIRD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; The amendment of the Amended and Restated Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.748%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">GRI BIO, INC.</font></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; W. Marc Hertz</font></td></tr><tr><td colspan="12" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; President and Chief Executive Officer</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certified that&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FIRST</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  The name of the corporation is </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SECOND</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  The Amended and Restated Certificate of Incorporation of the Corporation, as amended to date, is hereby further amended by striking Section 4.1 of Article IV in its entirety and by substituting in lieu of the following&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Section 4.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authorized Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total number of shares which the Corporation shall have authority to issue is 260,000,000 shares, of which (a) 250,000,000 shall be designated as Common Stock, $0.0001 par value per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and (b) 10,000,000 shall be designated Preferred Stock, $0.0001 par value per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred&#160;Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective at 4&#58;01 p.m. Eastern Time on June 17, 2024 (the &#8220;Reverse Stock Split Effective Time&#8221;), a one-for-thirteen reverse stock split of the Corporation&#8217;s Common Stock shall become effective, pursuant to which each thirteen (13) shares of Common Stock outstanding and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Reverse Stock Split Effective Time shall be reclassified and combined into one (1) validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Reverse Stock Split Effective Time and shall represent one share of Common Stock from and after the Reverse Stock Split Effective Time (such reclassification and combination of shares, the &#8220;Reverse Stock Split&#8221;). No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Reverse Stock Split Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Reverse Stock Split Effective Time, shall be entitled to receive a cash payment equal to the fraction of a share of Common Stock to which such holder would otherwise be entitled multiplied by the fair value per share of the Common Stock immediately prior to the Reverse Stock Split Effective Time as determined by the Board of Directors of the Corporation.</font></div><div style="margin-bottom:6pt;padding-left:36pt;padding-right:18pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each stock certificate that, immediately prior to the Reverse Stock Split Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall, from and after the Reverse Stock Split Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Reverse Stock Split Effective Time into which the shares formerly represented by such certificate have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Reverse Stock Split Effective Time)&#59; provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Reverse Stock Split Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">THIRD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;  The amendment of the Amended and Restated Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI BIO, INC.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; W. Marc Hertz</font></div><div style="margin-bottom:1.5pt;margin-top:1.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; W. Marc Hertz</font></div><div style="margin-bottom:1.5pt;margin-top:2.65pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title&#58; President and Chief Executive Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE OF AMENDMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AMENDED AND RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certified that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">FIRST</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The name of the corporation is GRI Bio, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">SECOND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Amended and Restated Certificate of Incorporation of the Corporation, as amended to date, is hereby further amended by striking Section 4.1 of Article IV in its entirety and by substituting in lieu of the following&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Section 4.1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authorized Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The total number of shares which the Corporation shall have authority to issue is 260,000,000 shares, of which (a) 250,000,000 shall be designated as Common Stock, $0.0001 par value per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Common Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and (b) 10,000,000 shall be designated Preferred Stock, $0.0001 par value per share (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective at 4&#58;01 p.m. Eastern Time on February 21, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reverse Stock Split Effective Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), a one-for-seventeen reverse stock split of the Corporation&#8217;s Common Stock shall become effective, pursuant to which each seventeen (17) shares of Common Stock outstanding and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Reverse Stock Split Effective Time shall be reclassified and combined into one (1) validly issued, fully paid and nonassessable share of Common Stock automatically and without any action by the holder thereof upon the Reverse Stock Split Effective Time and shall represent one share of Common Stock from and after the Reverse Stock Split Effective Time (such reclassification and combination of shares, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Reverse Stock Split</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). No fractional shares of Common Stock shall be issued as a result of the Reverse Stock Split and, in lieu thereof, upon surrender after the Reverse Stock Split Effective Time of a certificate which formerly represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time, any person who would otherwise be entitled to a fractional share of Common Stock as a result of the Reverse Stock Split, following the Reverse Stock Split Effective Time, shall be entitled to receive a cash payment equal to the fraction of a share of Common Stock to which such holder would otherwise be entitled multiplied by the fair value per share of the Common Stock immediately prior to the Reverse Stock Split Effective Time as determined by the Board of Directors of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each stock certificate that, immediately prior to the Reverse Stock Split Effective Time, represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall, from and after the Reverse Stock Split Effective Time, automatically and without the necessity of presenting the same for exchange, represent that number of whole shares of Common Stock after the Reverse Stock Split Effective Time into which the shares formerly represented by such certificate have been reclassified (as well as the right to receive cash in lieu of fractional shares of Common Stock after the Reverse Stock Split Effective Time)&#59; provided, however, that each person of record holding a certificate that represented shares of Common Stock that were issued and outstanding immediately prior to the Reverse Stock Split Effective Time shall receive, upon surrender of such certificate, a new certificate evidencing and representing the number of whole shares of Common Stock after the Reverse Stock Split Effective Time into which the shares of Common Stock formerly represented by such certificate shall have been reclassified.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">THIRD</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amendment of the Amended and Restated Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI BIO, INC.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; W. Marc Hertz, Ph.D.&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name. W. Marc Hertz, Ph.D.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title. President and Chief Executive Officer</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.28
<SEQUENCE>3
<FILENAME>gri-202410k_ex428.htm
<DESCRIPTION>EX-4.28
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2a20e06cb3fe4547ab980f1c81949c2b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 4.28</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">The following summary of the material terms of the capital stock of GRI Bio, Inc. (formerly Vallon Pharmaceuticals, Inc.) is not intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to our amended and restated certificate of incorporation, as amended (&#8220;Amended and Restated Certificate of Incorporation&#8221;) and our amended and restated bylaws (&#8220;Amended and Restated Bylaws&#8221;) described herein, each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit is a part, and certain provisions of Delaware law.  We urge you to read each of our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws described herein in their entirety for a complete description of the rights and preferences of our securities.  Unless the context requires otherwise, all references to &#8220;we&#8221;, &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and &#8220;GRI&#8221; in this section refer solely to GRI Bio, Inc. (formerly Vallon Pharmaceuticals, Inc.) and not to our subsidiary, GRI Bio Operations, Inc. </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our authorized capital stock consists of 250,000,000 shares of common stock, par value $0.0001 per share (&#8220;Common Stock&#8221;), and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The holders of Common Stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders.  The holders of Common Stock do not have any cumulative voting rights.  Holders of Common Stock are entitled to receive ratably any dividends declared by the Company&#8217;s board of directors (the &#8220;Board&#8221;) out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock.  Our Common Stock has no preemptive rights, conversion rights, or other subscription rights or redemption or sinking fund provisions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the event of our liquidation, dissolution or winding up, holders of Common Stock are entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof.  These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Common Stock.  The issuance of our preferred stock could adversely affect the voting power of holders of Common Stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation.  In addition, the issuance of preferred stock could have the effect of delaying, deferring or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">preventing a change in control of the Company or other corporate action.  No shares of preferred stock are issued or outstanding, and we have no present plan to issue any shares of preferred stock.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Anti-Takeover Effects of our Amended and Restated Certificate of Incorporation, Amended and Restated Bylaws and Delaware Law</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of the Company and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with the Board rather than pursue non-negotiated takeover attempts.  These provisions include the items described below.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Board Composition and Filling Vacancies</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our Amended and Restated Certificate of Incorporation provides for the division of the Board into three classes serving staggered three-year terms, with one class being elected each year.  Our Amended and Restated Certificate of Incorporation provides that directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the shares then entitled to vote at an election of directors.  Furthermore, any vacancy on the Board, however occurring, including a vacancy resulting from an increase in the size of the Board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum.  The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of the Board.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">No Written Consent of Stockholders</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our Amended and Restated Certificate of Incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting.  This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our Amended and Restated Bylaws or removal of directors by our stockholders without holding a meeting of stockholders.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Meetings of Stockholders</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws provide that only the Company&#8217;s chief executive officer, chairperson of the Board and a majority of the members of the Board then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders.  Our Amended and Restated Bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Advance Notice Requirements</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our Amended and Restated Bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders.  These procedures provide that notice of stockholder proposals must be timely given in writing to the Company&#8217;s corporate secretary prior to the meeting at which the action is to be taken.  Generally, to be timely, notice must be received at the Company&#8217;s principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year.  Our Amended and Restated Bylaws specify the requirements as to form and content of all notices to stockholders.  These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any amendment of our Amended and Restated Certificate of Incorporation must first be approved by a majority of the Board, and if required by law or our Amended and Restated Certificate of Incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to removal of our directors, and the amendment of our Amended and Restated Bylaws must be approved by not less than 66 2&#47;3% of the outstanding shares entitled to vote on the amendment.  Our Amended and Restated Bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in our Amended and Restated Bylaws&#59; and may also be amended by the affirmative vote of 66 2&#47;3% of the outstanding shares entitled to vote on the amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our Amended and Restated Certificate of Incorporation provides for 10,000,000 authorized shares of preferred stock.  The existence of authorized but unissued shares of preferred stock may enable the Board to discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest or otherwise.  For example, if in the due exercise of its fiduciary obligations, the Board were to determine that a takeover proposal is not in the best interests of our stockholders, the Board could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group.  In this regard, our Amended and Restated Certificate of Incorporation grants the Board broad power to establish the rights and preferences of authorized and unissued shares of preferred stock.  The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of Common Stock.  The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Choice of Forum</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our Amended and Restated Certificate of Incorporation provides that unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claim for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers, and employees to the Company or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law (the &#8220;DGCL&#8221;), our Amended and Restated Certificate of Incorporation or our Amended and Restated Bylaws or (iv) any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery of the State of Delaware having personal jurisdiction over the indispensable parties named as defendants therein.  This choice of forum provision does not preclude or contract the scope of exclusive federal jurisdiction for any actions brought under the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).  Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder.  As a result, the exclusive forum provision will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction, and we do not intend for the exclusive forum provision to apply to Exchange Act claims.  Section 22 of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.  Accordingly, there is uncertainty as to whether a court would enforce such a forum selection provision as written in connection with claims arising under the Securities Act.  Additionally, this choice of forum provision will not apply to claims as to which the Court of Chancery of the State of Delaware does not have subject matter jurisdiction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our Amended and Restated Certificate of Incorporation further provides that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, our Amended and Restated Certificate of Incorporation provides that any person or entity purchasing or otherwise acquiring any interest in shares of our Common Stock is deemed to have notice of and consented to the foregoing provisions&#59; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.  The enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 203 of the Delaware General Corporation Law</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We are subject to the provisions of Section 203 of the DGCL.  In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">becomes an interested stockholder, unless the business combination is approved in a prescribed manner.  Under Section 203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;before the stockholder became interested, the board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;at or after the time the stockholder became interested, the business combination was approved by the board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 203 defines a business combination to include&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;any merger or consolidation involving the corporation and the interested stockholder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Listing</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our Common Stock is listed on The Nasdaq Capital Market under the trading symbol &#8220;GRI.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Our transfer agent and registrar for our Common Stock is Broadridge Corporate Issuer Solutions, Inc.  The transfer agent and registrar&#8217;s address is 51 Mercedes Way, Edgewood, NY 11717.</font><img alt="image_0.jpg" src="image_0.jpg" style="height:33px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19
<SEQUENCE>4
<FILENAME>gri-202410k_ex19.htm
<DESCRIPTION>EX-19
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie4684fbada8a4b82ae7cb6d98e641f56_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 19</font></div></div><div style="margin-bottom:12pt;padding-right:375.85pt"><img alt="image_0a.jpg" src="image_0a.jpg" style="height:59px;margin-bottom:5pt;vertical-align:text-bottom;width:118px"></div><div style="margin-top:1.1pt;padding-left:63pt;padding-right:63pt;text-align:center;text-indent:-57.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:13.65pt">INSIDER TRADING AND SECURITIES LAW COMPLIANCE POLICY </font></div><div style="margin-top:1.1pt;padding-left:63pt;padding-right:63pt;text-align:center;text-indent:-57.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:13.65pt">OF </font></div><div style="margin-top:1.1pt;padding-left:63pt;padding-right:63pt;text-align:center;text-indent:-57.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:13.65pt">GRI BIO, INC.</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:13.80pt">Adopted by the Board of Directors on November 6, 2020</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BACKGROUND</font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors of GRI Bio, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) has adopted this Insider Trading and Securities Law Compliance Policy relating to the trading of GRI securities as well as the securities of publicly-traded companies with whom GRI has a business relationship. The terms &#8220;GRI,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; mean GRI Bio, Inc. and all of its subsidiaries.</font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state securities laws prohibit the purchase or sale of a company&#8217;s securities by persons who are aware of material information about that company that is not generally known or available to the public. These laws also prohibit persons who are aware of such material nonpublic information from disclosing this information to others who may trade. Companies and their controlling persons are also subject to liability if they fail to take reasonable steps to prevent insider trading by company personnel.</font></div><div style="margin-bottom:14.4pt;padding-right:10.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important that you understand the breadth of activities that constitute illegal insider trading and the resulting consequences, which can be severe. This policy is applicable to all trading of our securities. Both the U.S. Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and the Nasdaq investigate and are very effective at detecting insider trading. The SEC and U.S. Attorneys pursue insider trading violations vigorously. Cases have been successfully prosecuted against trading by employees through foreign accounts, trading by family members and friends and trading involving only a small number of shares.</font></div><div style="margin-bottom:14.4pt;padding-right:10.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This policy is designed to prevent insider trading or allegations of insider trading and protect our reputation for integrity and ethical conduct. It is your obligation to understand and comply with this policy. Should you have any questions regarding this policy, please contact our principal executive officer, principal accounting officer, principal financial officer, corporate secretary, or such other individual(s) designated by the Chairman of the Company&#8217;s board of directors (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BASIC POLICY &#47; ADDITIONAL RESTRICTIONS ON RESTRICTED PERSONS</font></div><div style="margin-bottom:14.4pt;padding-right:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No director, officer, employee, consultant or agent (or their family members and members of their household) of GRI and its subsidiaries and affiliates may trade on the basis of material nonpublic information or engage in any other action to take advantage of, or pass on to others, that information. To avoid even the appearance of impropriety, additional restrictions on trading our securities apply to our directors, executive officers and certain other persons identified by us from time to time and who have been notified that they have been so identified (collectively with our directors and executive officers, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). For the purposes of this policy, the term &#8220;Restricted Persons&#8221; shall also include any person, regardless of title or job description, who works in any of the following roles or departments&#58;</font></div><div style="margin-bottom:14.4pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Chief executive officer&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Chief financial officer&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:14.4pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Principal accounting officer&#59; </font></div><div style="margin-bottom:14.4pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Chief medical officer&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Chief commercial officer</font></div><div style="margin-bottom:14.4pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Senior Vice President of Regulatory and Project Management&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Senior Vice President of Commercial Operations&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Accounting Department&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Investor Relations Department&#59; and</font></div><div style="margin-bottom:14.4pt;padding-left:36pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Business Development Department.</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;Transactions in our securities by Restricted Persons are subject to pre-clearance.  See &#8220;Regular Blackout Periods,&#8221; &#8220;Special Blackout Periods&#8221; and &#8220;Pre-Clearance Provisions.&#8221; </font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SCOPE OF POLICY</font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This policy applies to directors, officers, employees, consultants, contractors, advisors, and agents of GRI and its subsidiaries and affiliates. The same restrictions that apply to you apply to your family members who reside with you, anyone else who lives in your household and any family members who do not live in your household but whose transactions in our securities are directed by you or are subject to your influence or control (such as parents or children who consult with you before they trade in securities). You are responsible for making sure that the purchase or sale of any security covered by this policy by any such person complies with this policy.</font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Companies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The prohibition on insider trading in this policy is not limited to trading in our securities. It includes trading in the securities of other firms, such as our customers or suppliers and those with which we may be negotiating major transactions, such as an acquisition, investment or sale. Information that is not material to GRI may nevertheless be material to one of those other firms.</font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The trading covered by this policy includes purchases and sales of our common stock (including initial elections, changes in elections or reallocation of funds relating to 401(k) plan or Simple IRA accounts), derivative securities relating to our common stock (such as options for our common stock, put and call options and convertible debentures), preferred stock, warrants and debt securities (debentures, bonds and notes). Loans, pledges, gifts, charitable donations and other contributions of our securities are also subject to this policy.</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEFINITION OF MATERIAL NONPUBLIC INFORMATION</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Material Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Information is material if there is a substantial likelihood that a reasonable investor would consider it important in deciding whether to buy, hold or sell a security. Any information that could reasonably be expected to affect the price of the security is material. Common examples of material information are&#58; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial results, projections of future earnings or losses, or other earnings guidance&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Earnings that are inconsistent with the consensus expectations of the investment community or any earnings guidance released by GRI&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Communications with government agencies and pending regulatory actions&#59; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Discovery or development of product candidates&#59; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Significant write-downs in assets or increases in reserves&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Significant changes in the Company&#8217;s prospects&#59; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Proposals, plans or agreements, even if preliminary in nature, involving mergers, acquisitions, divestitures, recapitalizations, strategic alliances, licensing arrangements, potential tender offers or proxy fights, contract awards or cancellations, or purchases or sales of substantial assets&#59; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Notice of issuance of patents&#59; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Partner or collaborator relationships&#59; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Change in management or the board of directors&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Extraordinary borrowings&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Major changes in accounting methods or policies&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Major events regarding our securities, including the declaration of a stock split, the offering of additional securities&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Material clinical trial or regulatory updates&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Developments regarding significant litigation or government agency investigations&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial liquidity problems&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Cybersecurity or data privacy risks and incidents, including vulnerabilities and breaches&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Actual or threatened major litigation, or a significant development with respect to such litigation&#59; and</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;New major contracts, material agreements, licenses, orders, suppliers, customers or finance sources, or the loss or termination thereof.</font></div><div style="margin-bottom:14.4pt;padding-left:3.6pt;padding-right:10.8pt;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This list is not exhaustive&#59; other types of information may also be material. Both positive and negative information can be material. Because trading that receives scrutiny will be evaluated after the fact with the benefit of hindsight, questions concerning the materiality of particular information should be resolved in favor of materiality.</font></div><div style="margin-bottom:14.4pt;padding-left:3.6pt;padding-right:10.8pt;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Material information is not limited to historical facts but may also include projections and forecasts. With respect to a future event, such as a merger, acquisition or introduction of a new product, the point at which negotiations or product development are determined to be material is determined by balancing the probability that the event will occur against the magnitude of the effect the event would have on a company's operations or stock price should it occur. Thus, information concerning an event that would have a large effect on stock price, such as a merger, clinical trial, or regulatory update, may be material even if the possibility that the event will occur is relatively small. When in doubt about whether particular nonpublic information is material, you should presume it is material. </font></div><div style="margin-bottom:14.4pt;padding-left:3.6pt;padding-right:10.8pt;text-indent:36.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If you are unsure whether information is material, you should either consult a Compliance Officer before making any decision to disclose such information (other than to persons who need to know it) or to trade in or recommend securities to which that information relates or assume that the information is material.</font></div><div style="margin-bottom:14.4pt;padding-left:3.6pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Nonpublic Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Insider trading prohibitions come into play only when you possess information that is material and &#8220;nonpublic.&#8221; Nonpublic information is information that is not generally known or available to the public. </font></div><div style="margin-bottom:14.4pt;padding-left:3.6pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fact that information has been disclosed to a few members of the public does not make it public for insider trading purposes. In addition, a common misconception is that material information loses its &#8220;nonpublic&#8221; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:14.4pt;padding-left:3.6pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">status as soon as a press release is issued disclosing the information. In fact, information is considered to be available to the public only when it has been released broadly to the marketplace (such as by a press release or an SEC filing) and the investing public has had time to absorb the information fully. As a general rule, after nonpublic information is publicly disseminated, two full trading days must elapse before such information loses its status as nonpublic information.</font></div><div style="margin-bottom:14.4pt;padding-left:3.6pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonpublic information may include&#58;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-14.4pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;information available to a select group of analysts or brokers or institutional investors&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-14.4pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-14.4pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;undisclosed facts that are the subject of rumors, even if the rumors are widely circulated&#59; and</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-14.4pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-14.4pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;information that has been entrusted to the Company on a confidential basis until a public announcement of the information has been made and enough time has elapsed for the market to respond to a public announcement of the information (normally one trading day).</font></div><div style="margin-bottom:14.4pt;padding-left:3.6pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As with questions of materiality, if you are not sure whether information is considered public, you should either consult with a Compliance Officer or assume that the information is nonpublic and treat it as confidential.</font></div><div style="margin-bottom:14.4pt;padding-left:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">V.&#160;&#160;&#160;&#160;RESTRICTIONS ON PURCHASES, SALES AND TIPPING</font></div><div style="margin-bottom:14.4pt;padding-left:3.6pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Trading on Inside Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You may not trade in our securities, directly or indirectly (through family members or other persons or entities), if you are aware of material nonpublic information relating to GRI. Similarly, you may not trade in the securities of any other company, directly or indirectly, if you are aware of material nonpublic information about that company which you obtained in the course of your relationship with GRI.</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Tipping</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You may not pass material nonpublic information on to others or recommend to anyone the purchase or sale of any securities when you are aware of such information. This practice, known as &#8220;tipping,&#8221; also violates the securities laws and can result in the same civil and criminal penalties that apply to insider trading, even though you did not trade and did not gain any benefit from another&#8217;s trading.</font></div><div style="margin-bottom:14.4pt;padding-right:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Short Sales</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You may not engage in any short sales of our securities (sales of securities that are not then owned), including a &#8220;sale against the box&#8221; (a sale with delayed delivery).</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Hedging Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Certain forms of hedging or monetization transactions relating to our securities (such as zero-cost collars and forward sale contracts) could involve the establishment of a short position in our securities and limit or eliminate your ability to profit from an increase in the value of our securities. Therefore, you are prohibited from engaging in any hedging or monetization transactions involving our securities.</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Publicly-Traded Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You may not engage in transactions in publicly-traded or other third-party options relating to our securities, such as puts, calls and other derivative securities, on an exchange, in any other organized market or otherwise.</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Limit Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You are prohibited from placing limit orders for our securities that remain effective after the day on which they are placed (such as &#8220;good until cancelled&#8221; orders).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Margin Accounts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You are prohibited from holding our securities in a margin account, except that securities held in a margin account prior to the date of adoption of this policy and&#47;or approved in writing by a Compliance Officer shall be permitted.</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regular Blackout Periods Applicable to Restricted Persons</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In addition to the general policy prohibiting trading while in possession of material nonpublic information, all Restricted Persons, and all family members of such persons and members of their household, are also prohibited from purchasing or selling our securities during the period beginning on the last day of each fiscal quarter and ending after the passage of one full trading day after earnings have been publicly released with respect to such quarter or fiscal year (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">regular blackout period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Special Blackout Periods</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. From time to time, GRI may also prohibit our Restricted Persons and potentially a larger group of employees, consultants and agents from trading our securities because of material developments known to GRI and not yet disclosed to the public (each, a&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">special blackout period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). The existence of a special blackout period will not be announced, other than to those who are aware of the event giving rise to the special blackout. If, however, a person subject to a special blackout period requests permission to trade in our securities during such period, a Compliance Officer will inform the requesting person of the existence of a special blackout period, without disclosing the reason for the special blackout. Any person made aware of the existence of a special blackout period shall not disclose the existence of the blackout to any other person.</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Open Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If you have any open orders during any regular or special blackout period, it is your responsibility to cancel these orders with your broker. If you have an open order and it executes after the commencement of any regular or special blackout period, it is a violation of our insider trading policy and may also be a violation of the insider trading laws.</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:3.6pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">No Safe Harbor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For those persons who are subject to blackout periods, the existence of such blackouts shall </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> be considered a safe harbor for trading during other periods, and all of our officers, directors, other employees and agents should use good judgment at all times. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, occasions may arise when individuals covered by this policy become aware prior to the blackout period that earnings for that quarter are likely to exceed, or fall below, market expectations to an extent that is material. In such a case, the general policy against trading on inside information would still prohibit trading even though the time period is not within the blackout period or even if you are not a Restricted Person subject to the blackout periods. If you have any questions about whether you are permitted to trade in our securities at any particular time, you should contact a Compliance Officer. </font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VII.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRE-CLEARANCE PROVISIONS APPLICABLE TO RESTRICTED PERSONS</font></div><div style="margin-bottom:14.4pt;padding-right:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help prevent inadvertent violations of the federal securities laws and avoid even the appearance of trading on the basis of inside information, the following pre-clearance provisions are applicable to our Restricted Persons.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:14.4pt;padding-right:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All Restricted Persons, together with their immediate family members and other members of their household (including any entities over which such person has control), shall not engage in any transaction involving our securities (including a stock plan transaction such as an option exercise, or a gift, loan, pledge, contribution to a trust, 401(k) or Simple IRA transfer or any other transfer) without first obtaining pre-clearance of the transaction from a Compliance Officer in accordance with the following procedures&#58;</font></div><div style="margin-bottom:14.4pt;padding-left:54pt;padding-right:7.2pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No Restricted Person may, directly or indirectly, purchase or sell (or otherwise make any transfer, gift, pledge or loan of) any Company security at any time without first obtaining prior approval from a Compliance Officer. </font></div><div style="margin-bottom:14.4pt;padding-left:54pt;padding-right:7.2pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:54pt;padding-right:7.2pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Requests for pre-clearance should be submitted to a Compliance Officer at least two business days in advance of the proposed transaction. </font></div><div style="margin-bottom:14.4pt;padding-left:54pt;padding-right:7.2pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:54pt;padding-right:7.2pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Compliance Officer shall record the date each request is received and the date and time each request is approved or disapproved. </font></div><div style="margin-bottom:14.4pt;padding-left:54pt;padding-right:7.2pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:54pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No Compliance Officer is under any obligation to approve a transaction submitted for pre-clearance and may determine not to permit the transaction. </font></div><div style="margin-bottom:14.4pt;padding-left:54pt;padding-right:7.2pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:54pt;padding-right:7.2pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Unless revoked, a grant of permission will normally remain valid until the close of trading five business days following the date on which it was granted, but regardless may not be exercised if material nonpublic information is obtained during that time. If the transaction does not occur during such period, pre-clearance of the transaction must be re-requested.</font></div><div style="margin-bottom:14.4pt;padding-left:54pt;padding-right:7.2pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:54pt;padding-right:7.2pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No Compliance Officer may trade in our securities unless our Chief Executive Officer has approved the trade in accordance with the procedures set forth herein.</font></div><div style="margin-bottom:14.4pt;padding-right:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When requesting pre-clearance, please provide the following information to the Compliance Officer&#58; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:7.2pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Whether you believe may be aware of any material non-public information about GRI&#59; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:7.2pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:7.2pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Whether you have effected any non-exempt &#8220;opposite-way&#8221; transactions within the past six months&#59;</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:7.2pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:7.2pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Whether you intend to purchase or sell, and whether such transaction will be conducted through in the open market or otherwise&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:7.2pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:7.2pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Approximate timing and number of shares that you intend to purchase or sell&#59; and</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:7.2pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;padding-right:7.2pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;That you will notify the Compliance Officer promptly upon the completion of the pre-cleared transaction.</font></div><div style="margin-bottom:14.4pt;padding-right:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These procedures also apply to transactions by such person&#8217;s spouse, other persons living in such person&#8217;s household and minor children and to transactions by entities over which such person exercises control.</font></div><div style="margin-bottom:14.4pt;padding-right:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clearance is not required for purchases and sales of securities under an Approved 10b5-1 Plan (as defined below). With respect to any purchase or sale under an Approved 10b5-1 Plan, the third-party effecting transactions on behalf of the Restricted Person should be instructed to send duplicate confirmations of all such transactions to a Compliance Officer.</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIII.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCEPTIONS </font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Approved Rule 10b5-1 Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Trades in our securities that are executed pursuant to an Approved 10b5-1 Plan (as defined below) are not subject to the prohibition on trading on the basis of material nonpublic information contained in this policy or the restrictions relating to pre-clearance procedures and blackout periods. Rule 10b5-1 provides an affirmative defense from insider trading liability under the federal securities laws for trading plans that meet certain requirements. In general, a 10b5-1 plan must be entered into before you are aware of material nonpublic information. You may not adopt a 10b5-1 plan during any regular or special blackout period. Note that once the Approved 10b5-1 Plan is adopted, you must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. The plan must either specify (including by formula) the amount, pricing and timing of transactions in advance or delegate discretion on those matters to an independent third party. </font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this Policy, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approved 10b5-1 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) means a pre-existing written plan, contract, instruction, or arrangement under Rule 10b5-1 under the Securities Exchange Act of 1934 that&#58; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) &#160;&#160;&#160;&#160;has been reviewed and approved in writing at least one month in advance of any trades thereunder by a Compliance Officer (or, if revised or amended, such revisions or amendments have been reviewed and approved by a Compliance Officer at least one month in advance)&#59; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) &#160;&#160;&#160;&#160;was entered into in good faith at a time when the you were not in possession of material nonpublic information about the Company&#59; and</font></div><div style="margin-bottom:14.4pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) &#160;&#160;&#160;&#160;gives a third party the discretionary authority to execute such purchases and sales, outside the control of the Covered Person, so long as such third party does not possess any material nonpublic information about the Company&#59; or explicitly specifies the security or securities to be purchased or sold, the number of shares, the prices and&#47;or dates of transactions, or other formula(s) describing such transactions.</font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Option Exercises</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. You may exercise stock options where cash is paid for the exercise price and tax withholding obligation, and in turn receive shares, and you may surrender shares to the Company in payment of the exercise price or in satisfaction of any tax withholding obligations. However, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">you may not sell any securities so acquired </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(either outright or in connection with a &#8220;cashless&#8221; exercise transaction through a broker) or otherwise settle </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the option during a regular or special blackout period or any time that you are aware of material nonpublic information. If you choose to exercise and hold the shares, you will be responsible at that time for any taxes due. </font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Employee Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This policy does not apply to&#58; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Acquisitions or dispositions of the Company&#8217;s common stock under the Company&#8217;s 401(k) or other individual account plan that are made pursuant to standing instructions not entered into or modified while you were aware of material nonpublic information or were subject to a regular or special blackout period (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that this policy does apply to sales of the Company&#8217;s securities purchased received pursuant to such plan)&#59; </font></div><div style="margin-bottom:14.4pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;other purchases of securities from the Company (including purchases under any employee stock purchase plan) or sales of securities to the Company&#59; and</font></div><div style="margin-bottom:14.4pt;padding-left:72pt"><font><br></font></div><div style="margin-bottom:14.4pt;padding-left:72pt;text-indent:-18pt"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;bona fide gifts, unless you have reason to believe that the recipient intends to sell the securities while you are aware of material nonpublic information or you are subject to a regular or special blackout period.</font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Special Circumstances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Notwithstanding anything to the contrary contained herein, you may request that any regular blackout period or special blackout period be waived by the Company&#8217;s principal executive officer, principal financial officer, or principal accounting officer (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clearing Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), provided that you affirm in writing that you do not have any material non-public information. Any such waivers shall be in the sole discretion of the Clearing Officer, shall be limited in scope and duration, and may be revoked at any time. </font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Underwritten Public Offerings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Nothing in this policy is intended to limit the ability of any person to sell the Company&#8217;s securities as a selling stockholder in an underwritten public offering pursuant to an effective registration statement in accordance with applicable securities law.</font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For clarity, please be reminded that the following are subject to this policy, including any regular and special blackout periods&#58; (a) any &#8220;cashless&#8221; exercise of stock options or other equity awards&#59; (b) any market sale of the Company&#8217;s securities for the purpose of generating the cash needed to pay the exercise price of any stock option or equity award or other derivative security&#59; (c) the sale of any shares issued on the exercise of stock options or other equity award elections made under 401(k) plans to (i) increase or decrease the percentage of periodic contributions that will be allocated to the Company&#8217;s securities, (ii) make an intra-plan transfer of an existing account balance into or out of the Company&#8217;s securities, (iii) borrow money against a 401(k) plan account if the loan will result in a liquidation of all or some of the Company&#8217;s securities in the account, and (iv) pre-pay any loan if the pre-payment will result in an allocation of loan proceeds to the Company&#8217;s securities&#59; (d) elections to participate in or increase participation in an employee stock purchase plan and to a participant&#8217;s sale of the Company&#8217;s securities purchased pursuant to such plan&#59; and (e)&#160;elections to participate in or increase participation in any dividend reinvestment plan, voluntary purchases of the Company&#8217;s securities that result from additional contributions a participant chooses to make under such plan, and a participant&#8217;s sale of the Company&#8217;s securities purchased pursuant to such plan.</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IX.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POST-TERMINATION TRANSACTIONS</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If you are aware of material nonpublic information when you terminate employment or services, you may not trade in our securities until that information has become public or is no longer material. In addition, if you are </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to a blackout period at the time of your termination of employment or services, the restrictions on trading in our securities will not cease to apply until the expiration of such blackout period.</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">X.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNAUTHORIZED DISCLOSURE</font></div><div style="margin-bottom:14.4pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining the confidentiality of our information is essential for competitive, security and other business reasons, as well as to comply with securities laws. You should treat all information you learn about GRI or its business plans in connection with your employment as confidential and proprietary to us. Inadvertent disclosure of confidential or inside information may expose us and you to significant risk of investigation and litigation.</font></div><div style="margin-bottom:14.4pt;padding-right:7.2pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing and nature of our disclosure of material information to outsiders is subject to legal rules, including the SEC&#8217;s Regulation FD, the breach of which could result in substantial liability to you, us and our management. Accordingly, it is important that responses to inquiries about us by the press, financial analysts, investors or others in the financial community be made on our behalf only through authorized individuals.</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XI.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERSONAL RESPONSIBILITY</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;You should remember that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">the ultimate responsibility for adhering to this policy and avoiding improper trading rests with you</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> If you violate this policy, GRI may take disciplinary action, including dismissal for cause.</font></div><div style="margin-bottom:14.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XII.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ADDITIONAL INFORMATION FOR DIRECTORS AND SECTION 16 OFFICERS</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Officers and directors have additional obligations under the federal securities laws, most notably the obligations to report their share ownership and transactions, and to forfeit the profits on any purchases and sales of Company stock within a six-month period under Section 16(b) of the Securities Exchange Act of 1934.  Short sales by such persons are also prohibited under Section 16(c).  </font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon becoming an officer or director, a person must report his or her holdings of equity securities of the Company on a Form 3, and any transaction in such securities (including purchases, sales, gifts, award or exercise of stock options) must be reported to the SEC within two business days on a Form 4.  Late filing of these reports must be reported by the Company in its periodic reports filed with the SEC. Consequently, it is critical that such transactions be reported to the Company&#8217;s Compliance Officers immediately so that proper reports can be timely prepared and filed. </font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> While the Company may assist you in the assessing your obligations under Section 16 and coordinate the filing of your Section 16 reports,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">such legal responsibilities and obligations are ultimately yours</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should also understand that compliance with the obligations described above does not excuse violation of the laws against trading on material inside information which apply to any single transaction regardless of whether or not it is reported on Form 4 or subject to the recapture of profits under Section 16(b).</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIII.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PENALTIES FOR NONCOMPLIANCE</font></div><div style="margin-bottom:14.4pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Penalties for trading on or communicating material nonpublic information can be severe, both for individuals involved in such unlawful conduct and their employers and supervisors, and may include jail terms, criminal fines, civil penalties and civil enforcement injunctions. Given the severity of the potential penalties, compliance with this Policy is absolutely mandatory. If you believe that you may have violated this Policy or any federal or state laws governing insider trading or tipping, or you know of the possibility of any such violation by any person, you must report such matter immediately to a Compliance Officer. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:14.4pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Civil and Criminal Penalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A person who violates insider trading laws by engaging in transactions in a company's securities when he or she has material nonpublic information can be sentenced to a substantial jail term and required to pay a criminal penalty of several times the amount of profits gained or losses avoided.</font></div><div style="margin-bottom:14.4pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a person who tips others may also be liable for transactions by the tippees to whom he or she has disclosed material nonpublic information. Tippers can be subject to the same penalties and sanctions as the tippees, and the SEC has imposed large penalties even when the tipper did not profit from the transaction.</font></div><div style="margin-bottom:14.4pt;padding-right:18pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC can also seek substantial civil penalties from any person who, at the time of an insider trading violation, &#34;directly or indirectly controlled the person who committed such violation,&#34; which would apply to the Company and&#47;or management and supervisory personnel. These control persons may be held liable for up to the greater of $1 million or three times the amount of the profits gained or losses avoided. Even for violations that result in a small or no profit, the SEC can seek penalties from a company and&#47;or its management and supervisory personnel as control persons.</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Controlling Person Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. If we fail to take appropriate steps to prevent illegal insider trading, we may have &#8220;controlling person&#8221; liability for a trading violation and be subject to civil penalties of up to the greater of $1 million and three times the profit gained or loss avoided as well as a criminal penalty of up to $25 million. The civil penalties can extend personal liability to our directors, officers and other supervisory personnel if they fail to take appropriate steps to prevent insider trading.</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Company-Imposed Penalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Failure to comply with this policy may also subject you to sanctions imposed by GRI, including dismissal for cause, whether or not your failure to comply with this policy results in a violation of law. Any exceptions to this policy, if permitted, may only be granted by a Compliance Officer and must be provided before any activity contrary to the above requirements takes place.</font></div><div style="margin-bottom:14.4pt;padding-right:3.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">XIV.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ASSISTANCE</font></div><div style="margin-bottom:14.4pt;padding-right:10.8pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Your compliance with this policy is of the utmost importance both for you and GRI. If you have any questions about this policy or its application to any proposed transaction, you may obtain additional guidance from any Compliance Officer. Do not try to resolve uncertainties on your own, as the rules relating to insider trading are often complex, not always intuitive and carry severe consequences.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>gri-202410k_ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i833723c1f1434964b4d20cbd3647d48e_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:112%;text-decoration:underline">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">La Jolla, CA</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the inclusion in the Registration Statements on Form S-1 (Nos. 333-274972 and 333-276205), Form S-3 (Nos. 333-279348 and 333-283234) and Form S-8 (No. 333-284149)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of GRI Bio, Inc. (&#8220;the Company&#8221;), of our report dated March&#160;14, 2025, on our audits of the consolidated financial statements of GRI Bio, Inc. as of December 31, 2024 and 2023, and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March&#160;14, 2025. Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company&#8217;s ability to continue as a going concern.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#47;s&#47; Sadler, Gibb &#38; Associates, LLC</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sadler, Gibb &#38; Associates, LLC</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Draper, UT</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;14, 2025</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>gri-202410k_ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if1d382834498444d89b6cd4a400c5faf_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, W. Marc Hertz, Ph.D., certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K for the year ended December&#160;31, 2024 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:8pt;margin-top:10pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 14, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">W. Marc Hertz, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>gri-202410k_ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if7b75ea4468346f5910f6917cfeaa610_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Leanne Kelly, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K for the year ended December 31, 2024 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"> All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March 14, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne Kelly</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leanne Kelly</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>gri-202410k_ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i9b64bf96f2fc45588476366f91cd797b_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, W. Marc Hertz, Ph.D., President and Chief Executive Officer of GRI Bio, Inc. (the Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2024 (the Annual Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">W.Marc Hertz, Ph.D.</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>gri-202410k_ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia924f8e604514a2e9a8481a45afe91b3_1"></div><div style="min-height:45pt;width:100%"><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Leanne Kelly, Chief Financial Officer of GRI Bio, Inc. (the Company), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2024 (the Annual Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.357%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne Kelly</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leanne Kelly</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>ck0001824293-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cc1569ea-7e88-4563-a591-58e791ad305a,g:efa7e1ac-5ebb-4c93-bc1b-10c7aab46343-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ck0001824293="http://www.vallon-pharma.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vallon-pharma.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vallon-pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.vallon-pharma.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952154 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquityDeficit" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit">
        <link:definition>9952155 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITY" roleURI="http://www.vallon-pharma.com/role/LIQUIDITY">
        <link:definition>9952157 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLON" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLON">
        <link:definition>9952159 - Disclosure - MERGER WITH VALLON</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>9952160 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>9952161 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.vallon-pharma.com/role/LEASES">
        <link:definition>9952162 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES">
        <link:definition>9952163 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROMISSORYNOTES" roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTES">
        <link:definition>9952164 - Disclosure - PROMISSORY NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952165 - Disclosure - STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>9952166 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETPURCHASEAGREEMENT" roleURI="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT">
        <link:definition>9952167 - Disclosure - ASSET PURCHASE AGREEMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952168 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAX" roleURI="http://www.vallon-pharma.com/role/INCOMETAX">
        <link:definition>9952169 - Disclosure - INCOME TAX</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS">
        <link:definition>9952170 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONTables" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables">
        <link:definition>9955513 - Disclosure - MERGER WITH VALLON (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9955514 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>9955515 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.vallon-pharma.com/role/LEASESTables">
        <link:definition>9955516 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables">
        <link:definition>9955517 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9955518 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9955519 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXTables" roleURI="http://www.vallon-pharma.com/role/INCOMETAXTables">
        <link:definition>9955520 - Disclosure - INCOME TAX (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
        <link:definition>9955521 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITYDetails" roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails">
        <link:definition>9955522 - Disclosure - LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails">
        <link:definition>9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails">
        <link:definition>9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails">
        <link:definition>9955525 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails">
        <link:definition>9955526 - Disclosure - MERGER WITH VALLON - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails">
        <link:definition>9955527 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1">
        <link:definition>9955527 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails">
        <link:definition>9955528 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails">
        <link:definition>9955529 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails">
        <link:definition>9955530 - Disclosure - FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
        <link:definition>9955531 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails">
        <link:definition>9955532 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails" roleURI="http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails">
        <link:definition>9955533 - Disclosure - LEASES - Schedule of Operating Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofFutureMinimumLeasePaymentsDetails" roleURI="http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails">
        <link:definition>9955534 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1">
        <link:definition>9955534 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/LEASESNarrativeDetails">
        <link:definition>9955535 - Disclosure - LEASES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>9955536 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROMISSORYNOTESBridgeFinancingDetails" roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails">
        <link:definition>9955537 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9955538 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
        <link:definition>9955539 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails">
        <link:definition>9955540 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9955541 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9955542 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails">
        <link:definition>9955543 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails">
        <link:definition>9955544 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ASSETPURCHASEAGREEMENTDetails" roleURI="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails">
        <link:definition>9955545 - Disclosure - ASSET PURCHASE AGREEMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9955546 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails" roleURI="http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails">
        <link:definition>9955547 - Disclosure - INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXComponentsofDeferredTaxesDetails" roleURI="http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails">
        <link:definition>9955548 - Disclosure - INCOME TAX- Components of Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails">
        <link:definition>9955549 - Disclosure - INCOME TAX - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9955550 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ck0001824293_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ck0001824293_WarrantLiabilityCurrent" abstract="false" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ChangeInFairValueOfWarrantLiability" abstract="false" name="ChangeInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ThroughFinancingMember" abstract="true" name="ThroughFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" abstract="false" name="OperatingLeaseRightOfUseAssetPeriodicAddition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ProceedsFromAdvancesFromEmployees" abstract="false" name="ProceedsFromAdvancesFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_RepaymentOfAdvancesFromEmployees" abstract="false" name="RepaymentOfAdvancesFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PaymentForFractionalSharesReverseStockSplit" abstract="false" name="PaymentForFractionalSharesReverseStockSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_CashAcquiredInReverseRecapitalization" abstract="false" name="CashAcquiredInReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PaymentOfReverseRecapitalizationCosts" abstract="false" name="PaymentOfReverseRecapitalizationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedForRepaymentOfNotesPayable" abstract="false" name="StockIssuedForRepaymentOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" abstract="false" name="DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" abstract="false" name="NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" abstract="false" name="DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" abstract="false" name="StockIssuedForPaymentOfReverseRecapitalizationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantsIssued" abstract="false" name="WarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" abstract="false" name="StockIssuedDuringPeriodSharesFractionalShareAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" abstract="false" name="StockIssuedDuringPeriodSharesWarrantExercise" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" abstract="false" name="StockIssuedDuringPeriodValueWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" abstract="false" name="StockIssuedDuringPeriodSharesPreClosingFinancing" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" abstract="false" name="StockIssuedDuringPeriodValuePreClosingFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" abstract="false" name="StockIssuedDuringPeriodSharesSettlementOfDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" abstract="false" name="StockIssuedDuringPeriodValueSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" abstract="false" name="StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" abstract="false" name="StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodSharesReverseRecapitalization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodValueReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ck0001824293_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesB1CommonWarrantsMember" abstract="true" name="SeriesB1CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesB2CommonWarrantsMember" abstract="true" name="SeriesB2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesA1WarrantsMember" abstract="true" name="SeriesA1WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_SeriesC1CommonWarrantsMember" abstract="true" name="SeriesC1CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesC2CommonWarrantsMember" abstract="true" name="SeriesC2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PriorWarrantsMember" abstract="true" name="PriorWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesD1WarrantsMember" abstract="true" name="SeriesD1WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesD2WarrantsMember" abstract="true" name="SeriesD2WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesDWarrantsMember" abstract="true" name="SeriesDWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_June2024PAWarrantsMember" abstract="true" name="June2024PAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesBCommonWarrantsMember" abstract="true" name="SeriesBCommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_October2024PAWarrantsMember" abstract="true" name="October2024PAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_CommonStockHeldIntoEscrowAccount" abstract="false" name="CommonStockHeldIntoEscrowAccount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsOfferingExpenses" abstract="false" name="StockIssuanceCostsOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ConversionOfStockAdditionalSharesConverted" abstract="false" name="ConversionOfStockAdditionalSharesConverted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" abstract="false" name="SaleOfStockNumberOfSecuritiesIssuedPerTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_SaleOfStockMaximumValueOfSharesOffered" abstract="false" name="SaleOfStockMaximumValueOfSharesOffered" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockAgentCompensationPercentage" abstract="false" name="SaleOfStockAgentCompensationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockAggregateCashFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" abstract="false" name="SaleOfStockManagementFeePercentageOfGrossProceeds" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" abstract="false" name="SaleOfStockReimbursementOfAccountableExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" abstract="false" name="SaleOfStockReimbursementOfNonAccountableExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ClassOfWarrantOrRightOfferingCost" abstract="false" name="ClassOfWarrantOrRightOfferingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PeripheralEquipmentMember" abstract="true" name="PeripheralEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ExchangeWarrantsMember" abstract="true" name="ExchangeWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_GRIOperationsMember" abstract="true" name="GRIOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_CommonStockExchangeRatio" abstract="false" name="CommonStockExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ck0001824293_CommonStockOwnershipPercentage" abstract="false" name="CommonStockOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantLiabilityFairValueDisclosure" abstract="false" name="WarrantLiabilityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantLiabilityMember" abstract="true" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_BridgeSecuritiesPurchaseAgreementMember" abstract="true" name="BridgeSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_BridgeWarrantsMember" abstract="true" name="BridgeWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentAggregatePurchasePrice" abstract="false" name="DebtInstrumentAggregatePurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentNumberOfClosings" abstract="false" name="DebtInstrumentNumberOfClosings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ck0001824293_PreFundedAndSeriesCWarrantsMember" abstract="true" name="PreFundedAndSeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" abstract="false" name="ProceedsFromWarrantExercisesNetOfOfferingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" abstract="true" name="SeriesB1CommonAndSeriesB2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" abstract="true" name="SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember" abstract="true" name="SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInAugust2025Member" abstract="true" name="WarrantsExpiringInAugust2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInFebruary2026Member" abstract="true" name="WarrantsExpiringInFebruary2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInMarch2026Member" abstract="true" name="WarrantsExpiringInMarch2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2026Member" abstract="true" name="WarrantsExpiringInApril2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInMay2027Member" abstract="true" name="WarrantsExpiringInMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJuly2027Member" abstract="true" name="WarrantsExpiringInJuly2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2028Member" abstract="true" name="WarrantsExpiringInApril2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInFebruary2029Member" abstract="true" name="WarrantsExpiringInFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJune2029Member" abstract="true" name="WarrantsExpiringInJune2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInSeptember2029Member" abstract="true" name="WarrantsExpiringInSeptember2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInOctober2029OneMember" abstract="true" name="WarrantsExpiringInOctober2029OneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInOctober2029TwoMember" abstract="true" name="WarrantsExpiringInOctober2029TwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_GRIOperationsPlanMember" abstract="true" name="GRIOperationsPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" abstract="true" name="AmendedAndRestated2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_AardvarkTherapeuticsIncMember" abstract="true" name="AardvarkTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_FormerChiefExecutiveOfficerMember" abstract="true" name="FormerChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_COBRABenefitsPaymentPeriod" abstract="false" name="COBRABenefitsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_PercentageOfTargetBonus" abstract="false" name="PercentageOfTargetBonus" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_StateTaxAuthorityMember" abstract="true" name="StateTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_LocalTaxAuthorityMember" abstract="true" name="LocalTaxAuthorityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>ck0001824293-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cc1569ea-7e88-4563-a591-58e791ad305a,g:efa7e1ac-5ebb-4c93-bc1b-10c7aab46343-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7b34a44a-a7fd-4905-b897-be12c5eba6af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_26f63472-ec88-4bae-b966-25b734ce280c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7b34a44a-a7fd-4905-b897-be12c5eba6af" xlink:to="loc_us-gaap_Liabilities_26f63472-ec88-4bae-b966-25b734ce280c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7a668621-4deb-4c39-b7cf-468213c39e32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7b34a44a-a7fd-4905-b897-be12c5eba6af" xlink:to="loc_us-gaap_StockholdersEquity_7a668621-4deb-4c39-b7cf-468213c39e32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4ca477ab-a91a-4ab7-9c1b-a1244418e3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7b34a44a-a7fd-4905-b897-be12c5eba6af" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4ca477ab-a91a-4ab7-9c1b-a1244418e3d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_29e4cc5e-980e-4609-a61a-fabb36791124" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffb8d424-1629-417c-a5e0-034b5489eb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_29e4cc5e-980e-4609-a61a-fabb36791124" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ffb8d424-1629-417c-a5e0-034b5489eb4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_398243dd-4498-448e-ba72-39987f5aad7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_29e4cc5e-980e-4609-a61a-fabb36791124" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_398243dd-4498-448e-ba72-39987f5aad7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f208783e-5ac0-4c4a-9ca9-85532cddd83d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityCurrent_94075142-e052-46aa-8c97-901f5bbd19cb" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f208783e-5ac0-4c4a-9ca9-85532cddd83d" xlink:to="loc_ck0001824293_WarrantLiabilityCurrent_94075142-e052-46aa-8c97-901f5bbd19cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_088376ef-d41e-4f26-9f1e-d3f0dc0c4c68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f208783e-5ac0-4c4a-9ca9-85532cddd83d" xlink:to="loc_us-gaap_AccountsPayableCurrent_088376ef-d41e-4f26-9f1e-d3f0dc0c4c68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c8309cd-7c89-47a1-9b6b-89267b45d6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f208783e-5ac0-4c4a-9ca9-85532cddd83d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2c8309cd-7c89-47a1-9b6b-89267b45d6cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4b4d78eb-52bf-457a-9fe5-5dd769dee9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f208783e-5ac0-4c4a-9ca9-85532cddd83d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4b4d78eb-52bf-457a-9fe5-5dd769dee9e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2696179b-0d6d-45e8-bfbe-fb9fe4f2be46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1ee38481-d53a-43ff-ad08-de28d16b94ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2696179b-0d6d-45e8-bfbe-fb9fe4f2be46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1ee38481-d53a-43ff-ad08-de28d16b94ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6de71ecc-a33b-4e9e-bbfc-0ea083b589c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2696179b-0d6d-45e8-bfbe-fb9fe4f2be46" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6de71ecc-a33b-4e9e-bbfc-0ea083b589c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e55d5f5d-87b9-48d1-8b58-fc89dd5c644f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_2696179b-0d6d-45e8-bfbe-fb9fe4f2be46" xlink:to="loc_us-gaap_AssetsCurrent_e55d5f5d-87b9-48d1-8b58-fc89dd5c644f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f5b09d7e-8c41-4dcd-bd6a-1219f1e4b92e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_6fc3fb57-e382-48a2-95ea-9c8a38049b50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f5b09d7e-8c41-4dcd-bd6a-1219f1e4b92e" xlink:to="loc_us-gaap_CommonStockValueOutstanding_6fc3fb57-e382-48a2-95ea-9c8a38049b50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0bb4cd39-3c9f-4683-ab4d-0ebacb9057e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f5b09d7e-8c41-4dcd-bd6a-1219f1e4b92e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_0bb4cd39-3c9f-4683-ab4d-0ebacb9057e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_03dd562e-4dff-45c6-b09b-73fdee4ec268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f5b09d7e-8c41-4dcd-bd6a-1219f1e4b92e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_03dd562e-4dff-45c6-b09b-73fdee4ec268" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_743bb6ae-efa5-4430-8803-5e885d15f017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_809b9260-f587-427a-a687-e10d863b8055" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_743bb6ae-efa5-4430-8803-5e885d15f017" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_809b9260-f587-427a-a687-e10d863b8055" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7910e8d9-6357-44cb-966e-f56c71790bae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_743bb6ae-efa5-4430-8803-5e885d15f017" xlink:to="loc_us-gaap_LiabilitiesCurrent_7910e8d9-6357-44cb-966e-f56c71790bae" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9883be42-5cfb-498f-bcd5-fbeb4eaac650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_1fa5c2c7-3410-4d71-8246-7a34c42828dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9883be42-5cfb-498f-bcd5-fbeb4eaac650" xlink:to="loc_us-gaap_OperatingExpenses_1fa5c2c7-3410-4d71-8246-7a34c42828dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ad4da51f-0a83-461c-a843-aefb4bbd6823" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c8f6c732-615e-4e45-a029-08e0b4d57b02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ad4da51f-0a83-461c-a843-aefb4bbd6823" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_c8f6c732-615e-4e45-a029-08e0b4d57b02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8182293d-2423-4b76-84e0-11feb8b3ee06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ad4da51f-0a83-461c-a843-aefb4bbd6823" xlink:to="loc_us-gaap_OperatingIncomeLoss_8182293d-2423-4b76-84e0-11feb8b3ee06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f20cd044-16b0-495b-974f-43842b0462d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ad4da51f-0a83-461c-a843-aefb4bbd6823" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f20cd044-16b0-495b-974f-43842b0462d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_0a4c305f-7db2-421a-b65a-c7f476dd20c2" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ad4da51f-0a83-461c-a843-aefb4bbd6823" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_0a4c305f-7db2-421a-b65a-c7f476dd20c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f5ef1c11-ea5a-4a35-aaae-1bdc96b25b63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_889310c5-4e85-4296-a561-b237bef00915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f5ef1c11-ea5a-4a35-aaae-1bdc96b25b63" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_889310c5-4e85-4296-a561-b237bef00915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8f35a94c-7ae1-4c2e-a8a0-3515d37453aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f5ef1c11-ea5a-4a35-aaae-1bdc96b25b63" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8f35a94c-7ae1-4c2e-a8a0-3515d37453aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b72b2924-a0bb-41a9-bb21-8b60d899b854" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockDividends_4851b8eb-b3f0-463a-84cf-352706ed7626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b72b2924-a0bb-41a9-bb21-8b60d899b854" xlink:to="loc_us-gaap_RedeemablePreferredStockDividends_4851b8eb-b3f0-463a-84cf-352706ed7626" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_88d46738-53f0-4426-96ee-8f040bbb0583" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_b72b2924-a0bb-41a9-bb21-8b60d899b854" xlink:to="loc_us-gaap_NetIncomeLoss_88d46738-53f0-4426-96ee-8f040bbb0583" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_469d21cf-5e18-4e65-8876-19069f420e59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0410a649-6169-4e3a-b64d-31bcde037725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_469d21cf-5e18-4e65-8876-19069f420e59" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0410a649-6169-4e3a-b64d-31bcde037725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_dedba1c5-8b90-4ae3-84ac-48d51a73e814" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_dedba1c5-8b90-4ae3-84ac-48d51a73e814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6a9cfd77-a62c-40d8-b3ea-514c84363bdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_us-gaap_Depreciation_6a9cfd77-a62c-40d8-b3ea-514c84363bdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_daa031d3-0876-40dd-b706-1811e9ac8f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_us-gaap_ShareBasedCompensation_daa031d3-0876-40dd-b706-1811e9ac8f73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_01acf770-2ddd-464b-b9b9-fcb2b7b5c447" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_01acf770-2ddd-464b-b9b9-fcb2b7b5c447" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_9e6b2388-8a14-490d-b6d0-2ec8353fad8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_9e6b2388-8a14-490d-b6d0-2ec8353fad8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_39d40724-37e5-4db3-ac44-171a85cad923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_39d40724-37e5-4db3-ac44-171a85cad923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a79c794e-5857-47ec-aa46-e040f745a993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a79c794e-5857-47ec-aa46-e040f745a993" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_013fdc73-df93-4577-8727-aa82c85ab5ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_us-gaap_NetIncomeLoss_013fdc73-df93-4577-8727-aa82c85ab5ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fc2427e2-1374-4db2-bead-816177133537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fc2427e2-1374-4db2-bead-816177133537" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_18b746c6-7a34-45cd-9448-2120133c24f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_18b746c6-7a34-45cd-9448-2120133c24f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_4eda26be-cacf-4800-8182-e2b9b647c0d6" xlink:href="ck0001824293-20241231.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b0671a3e-feb7-4a4a-9ff6-6fc3c4ce7c2f" xlink:to="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_4eda26be-cacf-4800-8182-e2b9b647c0d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_d661883a-5857-4446-998f-6982f7373cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_d661883a-5857-4446-998f-6982f7373cb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CashAcquiredInReverseRecapitalization_135b9625-76e2-4b62-b809-52e990400501" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CashAcquiredInReverseRecapitalization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:to="loc_ck0001824293_CashAcquiredInReverseRecapitalization_135b9625-76e2-4b62-b809-52e990400501" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5ff4219e-ca94-42e0-ae4c-cd1d25033e73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_5ff4219e-ca94-42e0-ae4c-cd1d25033e73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_ce948499-9fd3-4f4e-b237-d9737c84d051" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:to="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_ce948499-9fd3-4f4e-b237-d9737c84d051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2dc92137-28bb-404a-a97f-718c149bcedd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2dc92137-28bb-404a-a97f-718c149bcedd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_305511ba-31c5-41ee-a3fd-4cfdfd65fbcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_305511ba-31c5-41ee-a3fd-4cfdfd65fbcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_3869795e-55f0-4c4f-bf0e-4bfe3adeb39f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:to="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_3869795e-55f0-4c4f-bf0e-4bfe3adeb39f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_9510fb0b-d189-49d8-94d1-2c25a4b9146d" xlink:href="ck0001824293-20241231.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:to="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_9510fb0b-d189-49d8-94d1-2c25a4b9146d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_57fd7a78-1697-4a81-90a9-bca8598d8116" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_57fd7a78-1697-4a81-90a9-bca8598d8116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_c9cd6430-d7f6-4298-9470-78e61fe84ac8" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_562a0876-da1c-4e04-8869-b845759a0c7c" xlink:to="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_c9cd6430-d7f6-4298-9470-78e61fe84ac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4d21736-875a-4f74-ab96-c8ec970de820" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ecb726aa-631b-4254-8bdd-f1a96d983102" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4d21736-875a-4f74-ab96-c8ec970de820" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ecb726aa-631b-4254-8bdd-f1a96d983102" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b59b7217-dd5d-4ea9-b03a-5d116551dfe6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4d21736-875a-4f74-ab96-c8ec970de820" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b59b7217-dd5d-4ea9-b03a-5d116551dfe6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2dbb89ca-27b1-49b4-8645-28e0cfd6d680" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_d4d21736-875a-4f74-ab96-c8ec970de820" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_2dbb89ca-27b1-49b4-8645-28e0cfd6d680" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f60a4607-81fd-41ac-a386-1cea91a4c6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_1b8bbe00-2836-461c-8a45-99d46f2a47ec" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f60a4607-81fd-41ac-a386-1cea91a4c6f3" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_1b8bbe00-2836-461c-8a45-99d46f2a47ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_edafb8b2-e624-495b-b392-f07c38b171ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f60a4607-81fd-41ac-a386-1cea91a4c6f3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_edafb8b2-e624-495b-b392-f07c38b171ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_b072f75a-9599-451a-955a-26495f2a3452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f60a4607-81fd-41ac-a386-1cea91a4c6f3" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_b072f75a-9599-451a-955a-26495f2a3452" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d76f0e65-c139-43e3-926f-fcb6fc15adfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_fe42e74e-8e92-45a8-a47b-bb9766f18698" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d76f0e65-c139-43e3-926f-fcb6fc15adfa" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_fe42e74e-8e92-45a8-a47b-bb9766f18698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_d70d95b1-c054-4191-9c97-ef3dfdd16f93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_d76f0e65-c139-43e3-926f-fcb6fc15adfa" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_d70d95b1-c054-4191-9c97-ef3dfdd16f93" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4cacbe34-99f4-4c08-8438-3b2719b7c4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d414eb1c-427f-4351-b806-f3f17785c65b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4cacbe34-99f4-4c08-8438-3b2719b7c4d4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d414eb1c-427f-4351-b806-f3f17785c65b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_645661bc-5add-4990-bc08-a80bffe8eb89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4cacbe34-99f4-4c08-8438-3b2719b7c4d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_645661bc-5add-4990-bc08-a80bffe8eb89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_35be8611-91bd-4628-9c54-88be10af63c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4148a1e2-2ed5-4af1-ad43-62e4ca36f1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_35be8611-91bd-4628-9c54-88be10af63c9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4148a1e2-2ed5-4af1-ad43-62e4ca36f1fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c3c459af-ff83-4a2c-99e0-4bec8dbc4b44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_35be8611-91bd-4628-9c54-88be10af63c9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c3c459af-ff83-4a2c-99e0-4bec8dbc4b44" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e6fe777f-dcb9-4d0f-861c-c618535d3728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4d5f839c-4914-40f4-b001-07c1052124fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e6fe777f-dcb9-4d0f-861c-c618535d3728" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4d5f839c-4914-40f4-b001-07c1052124fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ad215363-4c99-4a7a-9320-401674ef0c85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e6fe777f-dcb9-4d0f-861c-c618535d3728" xlink:to="loc_us-gaap_OperatingLeaseLiability_ad215363-4c99-4a7a-9320-401674ef0c85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3298f756-8163-4635-85bf-96cc72cd9452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_55100593-8f2d-43b5-813a-c0d497407a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3298f756-8163-4635-85bf-96cc72cd9452" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_55100593-8f2d-43b5-813a-c0d497407a9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_76eccd46-007d-46b8-9b6c-c2a9abf6199f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3298f756-8163-4635-85bf-96cc72cd9452" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_76eccd46-007d-46b8-9b6c-c2a9abf6199f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6b0e66fa-aeff-4891-93d1-e37c644cffcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3298f756-8163-4635-85bf-96cc72cd9452" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6b0e66fa-aeff-4891-93d1-e37c644cffcc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e6748da7-219b-44f2-82c8-a8bcfb0f4ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_73a4b263-c2d7-4aea-abc4-21b0b36dc0e4" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e6748da7-219b-44f2-82c8-a8bcfb0f4ce4" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_73a4b263-c2d7-4aea-abc4-21b0b36dc0e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_7e4c96fc-3622-4aa0-ae1b-a77df7ef8283" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e6748da7-219b-44f2-82c8-a8bcfb0f4ce4" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_7e4c96fc-3622-4aa0-ae1b-a77df7ef8283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_19dccaec-f326-45f3-aa2b-d4eee791925d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e6748da7-219b-44f2-82c8-a8bcfb0f4ce4" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_19dccaec-f326-45f3-aa2b-d4eee791925d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7314e4cd-45c0-4d5d-9e64-8d058fca910c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_703bb48a-3ae4-41e4-8f9b-bd9b81446693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7314e4cd-45c0-4d5d-9e64-8d058fca910c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_703bb48a-3ae4-41e4-8f9b-bd9b81446693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_cef15847-621d-4e12-acab-fd930a15daa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7314e4cd-45c0-4d5d-9e64-8d058fca910c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_cef15847-621d-4e12-acab-fd930a15daa1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2ade063c-2993-4def-ab84-3752867186fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7314e4cd-45c0-4d5d-9e64-8d058fca910c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_2ade063c-2993-4def-ab84-3752867186fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d1ce1ee5-1e19-4cb1-8781-a4d378c02915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7314e4cd-45c0-4d5d-9e64-8d058fca910c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d1ce1ee5-1e19-4cb1-8781-a4d378c02915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f9f83d81-b16b-46fd-88a5-a8a7ffeacd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7314e4cd-45c0-4d5d-9e64-8d058fca910c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_f9f83d81-b16b-46fd-88a5-a8a7ffeacd9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_556b334a-94ac-4f9f-b3f1-4c86a3325a94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7314e4cd-45c0-4d5d-9e64-8d058fca910c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_556b334a-94ac-4f9f-b3f1-4c86a3325a94" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#INCOMETAXComponentsofDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f04cd177-7ddc-42ba-8990-43b091710c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_3800d3af-a565-4d67-97dd-ac979a39933a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f04cd177-7ddc-42ba-8990-43b091710c0c" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_3800d3af-a565-4d67-97dd-ac979a39933a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bdc5a2d1-b21a-4199-92e4-5d1cc47075fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f04cd177-7ddc-42ba-8990-43b091710c0c" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bdc5a2d1-b21a-4199-92e4-5d1cc47075fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_259ba903-573a-4842-95c8-0a89d33fa62e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f04cd177-7ddc-42ba-8990-43b091710c0c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_259ba903-573a-4842-95c8-0a89d33fa62e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_9e77a8d3-fda8-414a-9a55-4d6b58b0bb94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f04cd177-7ddc-42ba-8990-43b091710c0c" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_9e77a8d3-fda8-414a-9a55-4d6b58b0bb94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_81513166-4710-439d-bd4b-d9c5545090b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f04cd177-7ddc-42ba-8990-43b091710c0c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_81513166-4710-439d-bd4b-d9c5545090b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6f9c64b9-9480-4b28-82af-98903ffbf212" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f04cd177-7ddc-42ba-8990-43b091710c0c" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_6f9c64b9-9480-4b28-82af-98903ffbf212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_f1da463a-f2c2-4548-9f7c-417ecbcbeeca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_f04cd177-7ddc-42ba-8990-43b091710c0c" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_f1da463a-f2c2-4548-9f7c-417ecbcbeeca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_860eeda3-6643-49fe-a3ba-1ceade6514ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_dc93d62e-6398-4997-be26-85cd342bb04e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_860eeda3-6643-49fe-a3ba-1ceade6514ed" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_dc93d62e-6398-4997-be26-85cd342bb04e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_029ae02a-46ec-4c2f-94ea-e6ed3327fcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_860eeda3-6643-49fe-a3ba-1ceade6514ed" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_029ae02a-46ec-4c2f-94ea-e6ed3327fcdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_14d94dfc-43d6-4c7e-bae0-e3ef7b7e3e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_860eeda3-6643-49fe-a3ba-1ceade6514ed" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_14d94dfc-43d6-4c7e-bae0-e3ef7b7e3e82" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>ck0001824293-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cc1569ea-7e88-4563-a591-58e791ad305a,g:efa7e1ac-5ebb-4c93-bc1b-10c7aab46343-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5840644a-f518-4a19-b45a-a391bd4427eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_StatementTable_5840644a-f518-4a19-b45a-a391bd4427eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4bc47a4f-2fe0-4a2f-9316-fa1ae5eaf6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5840644a-f518-4a19-b45a-a391bd4427eb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4bc47a4f-2fe0-4a2f-9316-fa1ae5eaf6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4bc47a4f-2fe0-4a2f-9316-fa1ae5eaf6c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4bc47a4f-2fe0-4a2f-9316-fa1ae5eaf6c7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4bc47a4f-2fe0-4a2f-9316-fa1ae5eaf6c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5aad9e58-579a-409f-a7bf-46941bc2975d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4bc47a4f-2fe0-4a2f-9316-fa1ae5eaf6c7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5aad9e58-579a-409f-a7bf-46941bc2975d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember_b6dd1be2-720d-4da2-a80e-3234bbf4c985" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5aad9e58-579a-409f-a7bf-46941bc2975d" xlink:to="loc_ck0001824293_ThroughFinancingMember_b6dd1be2-720d-4da2-a80e-3234bbf4c985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_dfaf5102-899b-4dc6-96a9-7fc3ee75ca7f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5aad9e58-579a-409f-a7bf-46941bc2975d" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_dfaf5102-899b-4dc6-96a9-7fc3ee75ca7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b86cbb13-092f-49d8-b026-e7dfea0156fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b86cbb13-092f-49d8-b026-e7dfea0156fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d5247fae-cbc0-4aa6-ab76-5d4b7e1bee96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b86cbb13-092f-49d8-b026-e7dfea0156fa" xlink:to="loc_us-gaap_NetIncomeLoss_d5247fae-cbc0-4aa6-ab76-5d4b7e1bee96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b86cbb13-092f-49d8-b026-e7dfea0156fa" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1f46da3c-fc5e-48fc-b6ca-cd006dc44f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_Depreciation_1f46da3c-fc5e-48fc-b6ca-cd006dc44f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7772d2bf-c4f2-4d90-8aa8-fc04f1f2496c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7772d2bf-c4f2-4d90-8aa8-fc04f1f2496c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_28450150-dfd6-4e25-9daf-59d3f4509a51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_ShareBasedCompensation_28450150-dfd6-4e25-9daf-59d3f4509a51" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_12d9ce6d-1777-4795-a3e5-871b5186ec6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_12d9ce6d-1777-4795-a3e5-871b5186ec6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f9191651-5998-440b-ac99-0f882f34afae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f9191651-5998-440b-ac99-0f882f34afae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_c808a2f2-c44f-4ca8-9bd6-88d5579a0349" xlink:href="ck0001824293-20241231.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_c808a2f2-c44f-4ca8-9bd6-88d5579a0349" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c644b9fe-8603-4b76-af62-ded27174c868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c644b9fe-8603-4b76-af62-ded27174c868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_754d78cd-d5d5-4a71-85b6-4baf16ab16d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_754d78cd-d5d5-4a71-85b6-4baf16ab16d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_84f95ed8-1c2f-4e91-afbd-fb86e3f5acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_84f95ed8-1c2f-4e91-afbd-fb86e3f5acfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ab3707a3-2c7a-48d0-9190-b881a5df8399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ab3707a3-2c7a-48d0-9190-b881a5df8399" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_380c07bd-7f24-468a-a286-10075ebc4e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_380c07bd-7f24-468a-a286-10075ebc4e5f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca21e0a0-db70-4dfa-b933-70241038a6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca21e0a0-db70-4dfa-b933-70241038a6b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8431e3cb-3e68-4504-a0b8-d40f3164ed13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca21e0a0-db70-4dfa-b933-70241038a6b8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8431e3cb-3e68-4504-a0b8-d40f3164ed13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af16bfe1-ad42-4e35-9493-4a270ab91329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca21e0a0-db70-4dfa-b933-70241038a6b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af16bfe1-ad42-4e35-9493-4a270ab91329" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_0e8ed517-715e-44c1-9096-96fbc56ab6b9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_0e8ed517-715e-44c1-9096-96fbc56ab6b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_d71c8ae0-cdf6-4f31-89c6-1251dc259678" xlink:href="ck0001824293-20241231.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_d71c8ae0-cdf6-4f31-89c6-1251dc259678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_f1744c99-b527-4b65-acaf-56fb8b806085" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_f1744c99-b527-4b65-acaf-56fb8b806085" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c0a5630-88c8-40b4-a7a9-c5534da427b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c0a5630-88c8-40b4-a7a9-c5534da427b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_16560b52-0532-40d1-b250-348ed41d2436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_16560b52-0532-40d1-b250-348ed41d2436" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_09072766-6f00-4b91-a290-340ddaef902f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_09072766-6f00-4b91-a290-340ddaef902f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CashAcquiredInReverseRecapitalization_4489991a-7c8d-4d30-80f4-b748e282ab31" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CashAcquiredInReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_ck0001824293_CashAcquiredInReverseRecapitalization_4489991a-7c8d-4d30-80f4-b748e282ab31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_28744bfa-7e20-4935-b9fe-39205a119f61" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_28744bfa-7e20-4935-b9fe-39205a119f61" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0f331a12-bd85-4dcd-aa0b-06d715aa6ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0f331a12-bd85-4dcd-aa0b-06d715aa6ad9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_94e9c7af-d61c-445d-a4db-0ea5d3aaee43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_94e9c7af-d61c-445d-a4db-0ea5d3aaee43" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_122cd3b0-39ee-40ba-96ac-f66470170742" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_122cd3b0-39ee-40ba-96ac-f66470170742" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd6d4c04-bb62-488f-ba9b-248b187ccd94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd6d4c04-bb62-488f-ba9b-248b187ccd94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_345d4217-9f26-495a-a486-4dfb255bbfef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_345d4217-9f26-495a-a486-4dfb255bbfef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7070683b-1e75-471a-af61-6962a708a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_9e760a63-7f2a-4ff1-ab48-581702b4d19e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedForRepaymentOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_9e760a63-7f2a-4ff1-ab48-581702b4d19e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_73b60712-fd5d-4775-87c3-4b287f7e0811" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_73b60712-fd5d-4775-87c3-4b287f7e0811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_b993a50a-94c6-4ec3-b529-ba6576f10d87" xlink:href="ck0001824293-20241231.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_b993a50a-94c6-4ec3-b529-ba6576f10d87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_ee3c77f4-3551-4964-b8fe-d663598dd380" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_ee3c77f4-3551-4964-b8fe-d663598dd380" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_00df2c82-3101-4a48-8563-777c8ee668c0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_00df2c82-3101-4a48-8563-777c8ee668c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued_6c9a7374-d772-42c6-b4ec-0c0d6b33c2b6" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_WarrantsIssued_6c9a7374-d772-42c6-b4ec-0c0d6b33c2b6" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ConsolidatedStatementsofChangesinStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ba1b3920-b234-41aa-bb32-6a6d04ddf3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c01251c8-6a74-40cc-a8dd-2ed70be6a651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ba1b3920-b234-41aa-bb32-6a6d04ddf3b2" xlink:to="loc_us-gaap_StatementTable_c01251c8-6a74-40cc-a8dd-2ed70be6a651" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_83f2c124-176b-42ae-b710-3a5d4e9a1c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c01251c8-6a74-40cc-a8dd-2ed70be6a651" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_83f2c124-176b-42ae-b710-3a5d4e9a1c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_83f2c124-176b-42ae-b710-3a5d4e9a1c81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83f2c124-176b-42ae-b710-3a5d4e9a1c81" xlink:to="loc_us-gaap_EquityComponentDomain_83f2c124-176b-42ae-b710-3a5d4e9a1c81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_44eb3e6c-9e84-4dfe-af45-0ad10abb1dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83f2c124-176b-42ae-b710-3a5d4e9a1c81" xlink:to="loc_us-gaap_EquityComponentDomain_44eb3e6c-9e84-4dfe-af45-0ad10abb1dc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b4cabbd8-0ea3-402f-9a72-61b6f54f6669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_44eb3e6c-9e84-4dfe-af45-0ad10abb1dc9" xlink:to="loc_us-gaap_CommonStockMember_b4cabbd8-0ea3-402f-9a72-61b6f54f6669" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_194b7a6e-51c1-4da9-9ce7-64926b7fdb02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_44eb3e6c-9e84-4dfe-af45-0ad10abb1dc9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_194b7a6e-51c1-4da9-9ce7-64926b7fdb02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ff7e6c41-9360-4753-8c22-cabf5f5bc07e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_44eb3e6c-9e84-4dfe-af45-0ad10abb1dc9" xlink:to="loc_us-gaap_RetainedEarningsMember_ff7e6c41-9360-4753-8c22-cabf5f5bc07e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ba1b3920-b234-41aa-bb32-6a6d04ddf3b2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5b1e533b-1179-4209-aa89-90da74e854c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5b1e533b-1179-4209-aa89-90da74e854c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5768dc54-2c1a-4a8b-a553-2fef902f7069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_StockholdersEquity_5768dc54-2c1a-4a8b-a553-2fef902f7069" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aab1b453-8d9f-4ba1-8346-923cb27baf31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aab1b453-8d9f-4ba1-8346-923cb27baf31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_cd22c160-0b42-46ce-8514-cd98009e5263" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_cd22c160-0b42-46ce-8514-cd98009e5263" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_954d2016-d8f5-4ac8-bb35-2bbc3b7d4c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_954d2016-d8f5-4ac8-bb35-2bbc3b7d4c42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_66a38797-8842-4123-8bf6-fc13b20982b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_66a38797-8842-4123-8bf6-fc13b20982b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a9ee33b9-cb09-4a53-a8d8-c2e530ec868e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a9ee33b9-cb09-4a53-a8d8-c2e530ec868e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_39be0c7a-203b-4fed-9d2a-124c89124196" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_39be0c7a-203b-4fed-9d2a-124c89124196" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_492db8df-bc13-43d2-910d-7d3c37aba5b1" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_492db8df-bc13-43d2-910d-7d3c37aba5b1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_749e2143-74de-4e33-bb9b-a0ef0920409a" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_749e2143-74de-4e33-bb9b-a0ef0920409a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_b206d342-fdac-4714-802f-35bdab488e49" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_b206d342-fdac-4714-802f-35bdab488e49" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_83b861c2-131f-4b70-989a-26b4b011fba4" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_83b861c2-131f-4b70-989a-26b4b011fba4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_66ee02f7-0613-4ca8-b923-eeeef1f91d22" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_66ee02f7-0613-4ca8-b923-eeeef1f91d22" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_ff3facef-a89a-45ea-87d5-3986b254335c" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_ff3facef-a89a-45ea-87d5-3986b254335c" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_a57018c8-f43a-4987-9ebf-10bfa835dc89" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_a57018c8-f43a-4987-9ebf-10bfa835dc89" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_d6617792-e478-4357-ac40-8448e1ebbb9e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_d6617792-e478-4357-ac40-8448e1ebbb9e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_fec001fd-407d-451a-8d46-2d31a4c5932e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_fec001fd-407d-451a-8d46-2d31a4c5932e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_262e09ac-3fe8-46d4-a654-9f49e8384631" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_262e09ac-3fe8-46d4-a654-9f49e8384631" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fa97332e-d715-4ed3-b07e-acc04d008767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_NetIncomeLoss_fa97332e-d715-4ed3-b07e-acc04d008767" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f2252218-adc6-4529-9d75-9a503a4940d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7360f175-4e6d-4dc3-992c-3aab33c1d18f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dd871ae6-6ce4-44a7-b817-9c9d330dd3df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_79272619-5518-4b38-bf84-c6ad4b80162a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd871ae6-6ce4-44a7-b817-9c9d330dd3df" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_79272619-5518-4b38-bf84-c6ad4b80162a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_98f87b28-1a74-4986-8a4d-e04f25125422" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_79272619-5518-4b38-bf84-c6ad4b80162a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_98f87b28-1a74-4986-8a4d-e04f25125422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_98f87b28-1a74-4986-8a4d-e04f25125422_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_98f87b28-1a74-4986-8a4d-e04f25125422" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_98f87b28-1a74-4986-8a4d-e04f25125422_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_425d2371-7807-4c2b-8150-eaf7717740d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_98f87b28-1a74-4986-8a4d-e04f25125422" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_425d2371-7807-4c2b-8150-eaf7717740d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_629f7c0b-999c-4937-90d7-28e6895e8fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_425d2371-7807-4c2b-8150-eaf7717740d9" xlink:to="loc_us-gaap_SubsequentEventMember_629f7c0b-999c-4937-90d7-28e6895e8fcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2142bdbe-fb6f-4d86-b8bc-c2aa3a9e10a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd871ae6-6ce4-44a7-b817-9c9d330dd3df" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2142bdbe-fb6f-4d86-b8bc-c2aa3a9e10a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_c1cb7e02-5e7b-466f-b8d6-4664984e7679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd871ae6-6ce4-44a7-b817-9c9d330dd3df" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_c1cb7e02-5e7b-466f-b8d6-4664984e7679" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LIQUIDITYDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_467cd538-8532-41b2-bcc8-72f27df58e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_467cd538-8532-41b2-bcc8-72f27df58e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_467cd538-8532-41b2-bcc8-72f27df58e2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_467cd538-8532-41b2-bcc8-72f27df58e2d" xlink:to="loc_us-gaap_RelatedPartyDomain_467cd538-8532-41b2-bcc8-72f27df58e2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b1ee222e-f7e4-4af0-8a34-b4f7b0227754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_467cd538-8532-41b2-bcc8-72f27df58e2d" xlink:to="loc_us-gaap_RelatedPartyDomain_b1ee222e-f7e4-4af0-8a34-b4f7b0227754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_3bf923e2-9ff0-4b35-ba19-2fe244e66a90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b1ee222e-f7e4-4af0-8a34-b4f7b0227754" xlink:to="loc_us-gaap_InvestorMember_3bf923e2-9ff0-4b35-ba19-2fe244e66a90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e56d2d9f-54d0-451a-9561-b1fdc7be619b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e56d2d9f-54d0-451a-9561-b1fdc7be619b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e56d2d9f-54d0-451a-9561-b1fdc7be619b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e56d2d9f-54d0-451a-9561-b1fdc7be619b" xlink:to="loc_us-gaap_EquityComponentDomain_e56d2d9f-54d0-451a-9561-b1fdc7be619b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08014082-e8c6-43e1-b4b0-265fa0ca9c46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e56d2d9f-54d0-451a-9561-b1fdc7be619b" xlink:to="loc_us-gaap_EquityComponentDomain_08014082-e8c6-43e1-b4b0-265fa0ca9c46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e1c53fed-ec84-4a8a-b7d5-6dd5f099ee79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_08014082-e8c6-43e1-b4b0-265fa0ca9c46" xlink:to="loc_us-gaap_CommonStockMember_e1c53fed-ec84-4a8a-b7d5-6dd5f099ee79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_956b11cd-e0f2-45e7-baef-18c49c0b5e15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_956b11cd-e0f2-45e7-baef-18c49c0b5e15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_956b11cd-e0f2-45e7-baef-18c49c0b5e15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_956b11cd-e0f2-45e7-baef-18c49c0b5e15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_956b11cd-e0f2-45e7-baef-18c49c0b5e15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad054b6c-9319-41c0-9be2-33c639006ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_956b11cd-e0f2-45e7-baef-18c49c0b5e15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad054b6c-9319-41c0-9be2-33c639006ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_668329e2-1ea3-40ea-b032-8ced12b2d217" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad054b6c-9319-41c0-9be2-33c639006ae5" xlink:to="loc_ck0001824293_PublicOfferingMember_668329e2-1ea3-40ea-b032-8ced12b2d217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_52f93b8e-e675-4eda-9615-da120cc6aa92" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad054b6c-9319-41c0-9be2-33c639006ae5" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_52f93b8e-e675-4eda-9615-da120cc6aa92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_fd8b97f5-3a20-441c-bb22-5abcfbf491a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_fd8b97f5-3a20-441c-bb22-5abcfbf491a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_fd8b97f5-3a20-441c-bb22-5abcfbf491a5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fd8b97f5-3a20-441c-bb22-5abcfbf491a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_fd8b97f5-3a20-441c-bb22-5abcfbf491a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fd8b97f5-3a20-441c-bb22-5abcfbf491a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_a5e3a5d6-3175-4e91-a487-0231b977b117" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_a5e3a5d6-3175-4e91-a487-0231b977b117" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_2bbc82fd-f082-45d8-a275-9b9ea504ebf9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_2bbc82fd-f082-45d8-a275-9b9ea504ebf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_93ddd4d6-e9ab-4c99-b718-f02bd1d0dda0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_93ddd4d6-e9ab-4c99-b718-f02bd1d0dda0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_75a3bdc6-3d83-431d-bac4-7641f84b4bbb" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_75a3bdc6-3d83-431d-bac4-7641f84b4bbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_5c465584-5bf1-47ce-ac93-a2ba17530f02" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_5c465584-5bf1-47ce-ac93-a2ba17530f02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_e5ebcbe7-047d-40ff-8fee-ca9dcbb29c9e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_e5ebcbe7-047d-40ff-8fee-ca9dcbb29c9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PriorWarrantsMember_39babd5b-df36-47d7-8650-42603e39028f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PriorWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_PriorWarrantsMember_39babd5b-df36-47d7-8650-42603e39028f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember_2d162b2d-feae-48ec-939c-e464649c7165" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesD1WarrantsMember_2d162b2d-feae-48ec-939c-e464649c7165" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember_b0eda515-0ac6-4a14-9709-6f3c230b8eb6" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesD2WarrantsMember_b0eda515-0ac6-4a14-9709-6f3c230b8eb6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember_4f5ae273-1bd2-4ac9-817d-d4b1c6cdb330" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesDWarrantsMember_4f5ae273-1bd2-4ac9-817d-d4b1c6cdb330" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember_db7b1324-3739-483a-9dd6-b48c1551c063" xlink:href="ck0001824293-20241231.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_June2024PAWarrantsMember_db7b1324-3739-483a-9dd6-b48c1551c063" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember_25c31739-0213-410a-b081-92b6d26c70e8" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesBCommonWarrantsMember_25c31739-0213-410a-b081-92b6d26c70e8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_October2024PAWarrantsMember_50d37763-5e31-4f62-91b6-34167da69bc6" xlink:href="ck0001824293-20241231.xsd#ck0001824293_October2024PAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_October2024PAWarrantsMember_50d37763-5e31-4f62-91b6-34167da69bc6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbc3c82c-2b5f-487c-b856-8d8dc02cfae6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_srt_RangeAxis_cbc3c82c-2b5f-487c-b856-8d8dc02cfae6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbc3c82c-2b5f-487c-b856-8d8dc02cfae6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cbc3c82c-2b5f-487c-b856-8d8dc02cfae6" xlink:to="loc_srt_RangeMember_cbc3c82c-2b5f-487c-b856-8d8dc02cfae6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d976d178-c613-43e5-80d1-3f1815fa6646" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cbc3c82c-2b5f-487c-b856-8d8dc02cfae6" xlink:to="loc_srt_RangeMember_d976d178-c613-43e5-80d1-3f1815fa6646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_55c13ae6-2288-40f5-9d31-fb5986a41d01" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d976d178-c613-43e5-80d1-3f1815fa6646" xlink:to="loc_srt_WeightedAverageMember_55c13ae6-2288-40f5-9d31-fb5986a41d01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fba6a1a-58ee-429d-a171-4e5b210f863d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fba6a1a-58ee-429d-a171-4e5b210f863d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d7be121-0219-4ac3-8a92-364a92adc6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d7be121-0219-4ac3-8a92-364a92adc6b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_5c1d4224-d93c-4572-b800-21bd6e058a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_5c1d4224-d93c-4572-b800-21bd6e058a9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4ed5763d-8de1-4d18-b8f4-56b554e2e1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_CommonStockSharesIssued_4ed5763d-8de1-4d18-b8f4-56b554e2e1f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_62d6abff-3415-4104-9667-292855e1aeb5" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_62d6abff-3415-4104-9667-292855e1aeb5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cbc6b4fd-ad11-4dba-9ec8-6f758b85adbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cbc6b4fd-ad11-4dba-9ec8-6f758b85adbb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_42345052-24b1-4993-b25a-b5eba3561caf" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_42345052-24b1-4993-b25a-b5eba3561caf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_40a79879-1381-4018-ae72-3f32bd8d7174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_40a79879-1381-4018-ae72-3f32bd8d7174" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_a4b8e1b3-2dc1-48ed-86a7-2cd134a68cb3" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_a4b8e1b3-2dc1-48ed-86a7-2cd134a68cb3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fdc1ecec-b823-4288-8595-92ff11937fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fdc1ecec-b823-4288-8595-92ff11937fd3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_651d98ee-e20c-4033-a7dd-562b2ed7524a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_651d98ee-e20c-4033-a7dd-562b2ed7524a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6b1d59ea-5614-4c72-9328-dce5f072411e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6b1d59ea-5614-4c72-9328-dce5f072411e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_17f1434a-9a5e-4fc8-b9cd-442f9558ae34" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_17f1434a-9a5e-4fc8-b9cd-442f9558ae34" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e34a5d56-7fa3-4fc2-9e84-45d7e2e8d7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e34a5d56-7fa3-4fc2-9e84-45d7e2e8d7e1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_de6a95e9-0286-4030-b8fe-27b5305b47ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_de6a95e9-0286-4030-b8fe-27b5305b47ab" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_9fdd7a0f-0e1b-4fd3-80eb-1beccf3feae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_9fdd7a0f-0e1b-4fd3-80eb-1beccf3feae3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_2786898f-cd8e-4180-9cbe-21cb4d02904e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_2786898f-cd8e-4180-9cbe-21cb4d02904e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_d750fff5-cdb7-4fd2-a129-5e19fd8951b0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_d750fff5-cdb7-4fd2-a129-5e19fd8951b0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_96194dab-d597-4222-a1ef-fffae5dfc53b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_96194dab-d597-4222-a1ef-fffae5dfc53b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_94260dde-76f8-4c1b-912c-a4368de6f266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_94260dde-76f8-4c1b-912c-a4368de6f266" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_76e6c9bd-46bd-4fcd-ac66-78f286b30b6c" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_76e6c9bd-46bd-4fcd-ac66-78f286b30b6c" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_33286b95-81e1-4d42-9859-9dc2f07df715" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_33286b95-81e1-4d42-9859-9dc2f07df715" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_ba7628fb-9e3c-487f-9e03-e9e2bb992b56" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_ba7628fb-9e3c-487f-9e03-e9e2bb992b56" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_a072f5b8-4569-4095-9877-76283c52ed76" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_a072f5b8-4569-4095-9877-76283c52ed76" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_81421229-23f1-4fc9-a5e0-57a8e8ac6f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_81421229-23f1-4fc9-a5e0-57a8e8ac6f4d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_2d7b4dea-9012-492a-9634-8312f11d10d9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_2d7b4dea-9012-492a-9634-8312f11d10d9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d4e76d3e-3d26-480b-9864-ef4ade4aad31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d4e76d3e-3d26-480b-9864-ef4ade4aad31" xlink:type="arc" order="26"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b8cff0e-508e-45fb-b198-eda11f742930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_63462edc-2ca6-4d2c-9b75-ac687884799b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b8cff0e-508e-45fb-b198-eda11f742930" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_63462edc-2ca6-4d2c-9b75-ac687884799b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c3d8c4f-6317-4923-b4a0-f9e9d04f88ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_63462edc-2ca6-4d2c-9b75-ac687884799b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c3d8c4f-6317-4923-b4a0-f9e9d04f88ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6c3d8c4f-6317-4923-b4a0-f9e9d04f88ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c3d8c4f-6317-4923-b4a0-f9e9d04f88ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6c3d8c4f-6317-4923-b4a0-f9e9d04f88ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2457e3dd-8263-4222-8d62-a41ba2b28b29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c3d8c4f-6317-4923-b4a0-f9e9d04f88ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2457e3dd-8263-4222-8d62-a41ba2b28b29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_92c6d919-601a-4ffa-a9bc-dbd8ce186717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2457e3dd-8263-4222-8d62-a41ba2b28b29" xlink:to="loc_us-gaap_ComputerEquipmentMember_92c6d919-601a-4ffa-a9bc-dbd8ce186717" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PeripheralEquipmentMember_1a048954-cfb0-41d9-abda-d6dda9065dcd" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PeripheralEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2457e3dd-8263-4222-8d62-a41ba2b28b29" xlink:to="loc_ck0001824293_PeripheralEquipmentMember_1a048954-cfb0-41d9-abda-d6dda9065dcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3568001f-a409-482c-8f0d-4ef17ff46493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b8cff0e-508e-45fb-b198-eda11f742930" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3568001f-a409-482c-8f0d-4ef17ff46493" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_55d4635d-d2ff-4994-8a68-33db0d70b8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_545adace-bf93-4a8d-886b-05f181863c61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_55d4635d-d2ff-4994-8a68-33db0d70b8ca" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_545adace-bf93-4a8d-886b-05f181863c61" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5433652-08fd-412d-b956-ae061af114c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_545adace-bf93-4a8d-886b-05f181863c61" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5433652-08fd-412d-b956-ae061af114c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5433652-08fd-412d-b956-ae061af114c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5433652-08fd-412d-b956-ae061af114c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5433652-08fd-412d-b956-ae061af114c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ff905b8-84d3-4520-9c49-72698d56477b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5433652-08fd-412d-b956-ae061af114c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ff905b8-84d3-4520-9c49-72698d56477b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_59c56e49-82a8-4aa5-aa6c-e90c3cfd0164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ff905b8-84d3-4520-9c49-72698d56477b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_59c56e49-82a8-4aa5-aa6c-e90c3cfd0164" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_16418cce-9bcc-4411-9d71-8f0251203d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ff905b8-84d3-4520-9c49-72698d56477b" xlink:to="loc_us-gaap_WarrantMember_16418cce-9bcc-4411-9d71-8f0251203d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6b11f813-521a-4bc9-9529-20c05e30949c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_55d4635d-d2ff-4994-8a68-33db0d70b8ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6b11f813-521a-4bc9-9529-20c05e30949c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#MERGERWITHVALLONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0e6e3169-17cd-4981-97b0-284805b7da62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0e6e3169-17cd-4981-97b0-284805b7da62" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_dea6e6ff-4b10-452c-9087-5b410ea605c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0e6e3169-17cd-4981-97b0-284805b7da62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_dea6e6ff-4b10-452c-9087-5b410ea605c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_dea6e6ff-4b10-452c-9087-5b410ea605c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dea6e6ff-4b10-452c-9087-5b410ea605c0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_dea6e6ff-4b10-452c-9087-5b410ea605c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4b6a7b86-c200-4ed8-a229-ed9a7128bceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dea6e6ff-4b10-452c-9087-5b410ea605c0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4b6a7b86-c200-4ed8-a229-ed9a7128bceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_ed1e55ea-59f8-4d90-be7a-67bb04dd2e55" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4b6a7b86-c200-4ed8-a229-ed9a7128bceb" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_ed1e55ea-59f8-4d90-be7a-67bb04dd2e55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d9b5e821-df57-4179-8f3e-eabdd77f17ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0e6e3169-17cd-4981-97b0-284805b7da62" xlink:to="loc_dei_LegalEntityAxis_d9b5e821-df57-4179-8f3e-eabdd77f17ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d9b5e821-df57-4179-8f3e-eabdd77f17ba_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d9b5e821-df57-4179-8f3e-eabdd77f17ba" xlink:to="loc_dei_EntityDomain_d9b5e821-df57-4179-8f3e-eabdd77f17ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1364b7da-6cea-41fc-9caf-e4436677d16b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d9b5e821-df57-4179-8f3e-eabdd77f17ba" xlink:to="loc_dei_EntityDomain_1364b7da-6cea-41fc-9caf-e4436677d16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsMember_c1ca93e4-32af-4a13-a747-5ef1b0303263" xlink:href="ck0001824293-20241231.xsd#ck0001824293_GRIOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1364b7da-6cea-41fc-9caf-e4436677d16b" xlink:to="loc_ck0001824293_GRIOperationsMember_c1ca93e4-32af-4a13-a747-5ef1b0303263" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockExchangeRatio_bb97cff1-c7da-4528-9cac-c7e7e7ba66f0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CommonStockExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_ck0001824293_CommonStockExchangeRatio_bb97cff1-c7da-4528-9cac-c7e7e7ba66f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e50efa50-a5f9-43c4-897b-78805c0b3cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e50efa50-a5f9-43c4-897b-78805c0b3cd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a3ea75dc-eae3-442b-8c36-4c277de9bd21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a3ea75dc-eae3-442b-8c36-4c277de9bd21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage_109230bc-e885-4591-9118-acea300566f9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_ck0001824293_CommonStockOwnershipPercentage_109230bc-e885-4591-9118-acea300566f9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_4c90f0c9-5472-4674-81f5-e072691af72f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_4c90f0c9-5472-4674-81f5-e072691af72f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ddd26183-b4d0-44e2-8a56-5794a2e55578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ddd26183-b4d0-44e2-8a56-5794a2e55578" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3ef461ae-8fdf-4fa7-89bb-44497164479c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ddd26183-b4d0-44e2-8a56-5794a2e55578" xlink:to="loc_dei_LegalEntityAxis_3ef461ae-8fdf-4fa7-89bb-44497164479c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3ef461ae-8fdf-4fa7-89bb-44497164479c_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_3ef461ae-8fdf-4fa7-89bb-44497164479c" xlink:to="loc_dei_EntityDomain_3ef461ae-8fdf-4fa7-89bb-44497164479c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5c77e232-82f1-4b00-acb2-bfa7e5575588" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_3ef461ae-8fdf-4fa7-89bb-44497164479c" xlink:to="loc_dei_EntityDomain_5c77e232-82f1-4b00-acb2-bfa7e5575588" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsMember_74a077ba-4390-4362-bf1c-87fb12261972" xlink:href="ck0001824293-20241231.xsd#ck0001824293_GRIOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5c77e232-82f1-4b00-acb2-bfa7e5575588" xlink:to="loc_ck0001824293_GRIOperationsMember_74a077ba-4390-4362-bf1c-87fb12261972" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c94e851f-3dbd-4913-8f80-2dd793294e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c94e851f-3dbd-4913-8f80-2dd793294e0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2436dc12-aadc-42da-87c6-ff5949c98e30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2436dc12-aadc-42da-87c6-ff5949c98e30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_b1039285-914f-4bf5-8391-3af7ae842302" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_b1039285-914f-4bf5-8391-3af7ae842302" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b367ee1-6137-4f11-bcb2-caa5029e1fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b367ee1-6137-4f11-bcb2-caa5029e1fcc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_5b78d1cf-7bba-4d1d-b7b7-5e9be4da904f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_5b78d1cf-7bba-4d1d-b7b7-5e9be4da904f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_c68f7eac-76eb-4112-85fb-d8468857a0bf" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_c68f7eac-76eb-4112-85fb-d8468857a0bf" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e97bdac0-59c9-471a-abed-605140c4dc69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b82066a7-9af0-4816-bf71-70f07f725e08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e97bdac0-59c9-471a-abed-605140c4dc69" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b82066a7-9af0-4816-bf71-70f07f725e08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29d9b44c-09fb-4cbf-a208-f3b0a37ea68c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b82066a7-9af0-4816-bf71-70f07f725e08" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29d9b44c-09fb-4cbf-a208-f3b0a37ea68c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_29d9b44c-09fb-4cbf-a208-f3b0a37ea68c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29d9b44c-09fb-4cbf-a208-f3b0a37ea68c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_29d9b44c-09fb-4cbf-a208-f3b0a37ea68c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cc09061-af08-4687-bd88-bf9b13e5fcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29d9b44c-09fb-4cbf-a208-f3b0a37ea68c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cc09061-af08-4687-bd88-bf9b13e5fcaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_56f64f38-657f-4987-b496-67b0f1507643" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cc09061-af08-4687-bd88-bf9b13e5fcaa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_56f64f38-657f-4987-b496-67b0f1507643" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2a20a591-90f7-4a1b-b94e-402c7be0c17e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cc09061-af08-4687-bd88-bf9b13e5fcaa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2a20a591-90f7-4a1b-b94e-402c7be0c17e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_43ab8589-a483-4572-b6fb-ac4985a430e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cc09061-af08-4687-bd88-bf9b13e5fcaa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_43ab8589-a483-4572-b6fb-ac4985a430e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cadb54f2-cdf9-4dce-b817-963ec7772061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e97bdac0-59c9-471a-abed-605140c4dc69" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cadb54f2-cdf9-4dce-b817-963ec7772061" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityFairValueDisclosure_1985f087-2035-4ffe-b5ee-40f1ea3ff0cb" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cadb54f2-cdf9-4dce-b817-963ec7772061" xlink:to="loc_ck0001824293_WarrantLiabilityFairValueDisclosure_1985f087-2035-4ffe-b5ee-40f1ea3ff0cb" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e4a3176e-5d9e-40d4-a305-19aaaf503ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_60cc3e42-e067-44a0-bfb9-c3cabce8531b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e4a3176e-5d9e-40d4-a305-19aaaf503ec9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_60cc3e42-e067-44a0-bfb9-c3cabce8531b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_40743f7c-8ed0-4835-86cd-79f339fdcc78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_60cc3e42-e067-44a0-bfb9-c3cabce8531b" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_40743f7c-8ed0-4835-86cd-79f339fdcc78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_40743f7c-8ed0-4835-86cd-79f339fdcc78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_40743f7c-8ed0-4835-86cd-79f339fdcc78" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_40743f7c-8ed0-4835-86cd-79f339fdcc78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8199a083-58ba-4428-a183-29d7f1caa9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_40743f7c-8ed0-4835-86cd-79f339fdcc78" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8199a083-58ba-4428-a183-29d7f1caa9ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember_4cd3461d-a9b1-4af3-bfe3-81589dc7b004" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8199a083-58ba-4428-a183-29d7f1caa9ab" xlink:to="loc_ck0001824293_WarrantLiabilityMember_4cd3461d-a9b1-4af3-bfe3-81589dc7b004" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c3bbd8d3-4a24-4446-bf70-1d1688c3818f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e4a3176e-5d9e-40d4-a305-19aaaf503ec9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c3bbd8d3-4a24-4446-bf70-1d1688c3818f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7e094f57-64eb-443d-ba9c-9208bcc9a97d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c3bbd8d3-4a24-4446-bf70-1d1688c3818f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7e094f57-64eb-443d-ba9c-9208bcc9a97d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_26c65138-a73e-495c-ae9a-1fdf6160dc78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c3bbd8d3-4a24-4446-bf70-1d1688c3818f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_26c65138-a73e-495c-ae9a-1fdf6160dc78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_293d18d7-0b91-4ee4-80e2-be7b6fdab4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9e380ad5-e8b2-4514-849f-c825638f54b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3c87b016-f841-41ff-881f-9a2d9d2247a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9e380ad5-e8b2-4514-849f-c825638f54b5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3c87b016-f841-41ff-881f-9a2d9d2247a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76e2ee2d-867e-40be-8e82-109a51ff8121" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3c87b016-f841-41ff-881f-9a2d9d2247a4" xlink:to="loc_srt_RangeAxis_76e2ee2d-867e-40be-8e82-109a51ff8121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_76e2ee2d-867e-40be-8e82-109a51ff8121_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_76e2ee2d-867e-40be-8e82-109a51ff8121" xlink:to="loc_srt_RangeMember_76e2ee2d-867e-40be-8e82-109a51ff8121_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be47446e-4ec9-42f6-8c07-40eeb4a9c8fd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_76e2ee2d-867e-40be-8e82-109a51ff8121" xlink:to="loc_srt_RangeMember_be47446e-4ec9-42f6-8c07-40eeb4a9c8fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_56816149-d8cf-4665-b4a2-1aa5c76fb9d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_be47446e-4ec9-42f6-8c07-40eeb4a9c8fd" xlink:to="loc_srt_WeightedAverageMember_56816149-d8cf-4665-b4a2-1aa5c76fb9d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e4802ee2-7ba8-451f-9b7f-68c343308da3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3c87b016-f841-41ff-881f-9a2d9d2247a4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e4802ee2-7ba8-451f-9b7f-68c343308da3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e4802ee2-7ba8-451f-9b7f-68c343308da3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e4802ee2-7ba8-451f-9b7f-68c343308da3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e4802ee2-7ba8-451f-9b7f-68c343308da3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e4802ee2-7ba8-451f-9b7f-68c343308da3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_eede9158-7d66-49bc-ac13-79295168a79a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_eede9158-7d66-49bc-ac13-79295168a79a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_f7dd7fcc-1406-4f1c-8a21-f42a716e9c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_f7dd7fcc-1406-4f1c-8a21-f42a716e9c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_801bffc8-1896-4185-b150-adfbcba1a740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_801bffc8-1896-4185-b150-adfbcba1a740" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_fac63426-0fd9-4130-9d2b-3fbdc1e35825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_fac63426-0fd9-4130-9d2b-3fbdc1e35825" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_c0d268b1-c390-4456-92d3-4311e7a39060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9e380ad5-e8b2-4514-849f-c825638f54b5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_c0d268b1-c390-4456-92d3-4311e7a39060" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b83598e2-a031-44ff-841f-7937256ade25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2bc372c-afb7-4cba-b34d-d38e8ad7ac23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b83598e2-a031-44ff-841f-7937256ade25" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2bc372c-afb7-4cba-b34d-d38e8ad7ac23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_572cc00b-6f4c-4fa9-8e30-39802653a956" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2bc372c-afb7-4cba-b34d-d38e8ad7ac23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_572cc00b-6f4c-4fa9-8e30-39802653a956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_572cc00b-6f4c-4fa9-8e30-39802653a956_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_572cc00b-6f4c-4fa9-8e30-39802653a956" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_572cc00b-6f4c-4fa9-8e30-39802653a956_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_004d9cec-f3b1-4209-9b09-928073e91ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_572cc00b-6f4c-4fa9-8e30-39802653a956" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_004d9cec-f3b1-4209-9b09-928073e91ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_60cbf7c6-8648-45a5-9f1d-c098bc1cf42b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_004d9cec-f3b1-4209-9b09-928073e91ee8" xlink:to="loc_us-gaap_ComputerEquipmentMember_60cbf7c6-8648-45a5-9f1d-c098bc1cf42b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c7d0189e-b1b6-4d39-ba62-859997c4682a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_004d9cec-f3b1-4209-9b09-928073e91ee8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c7d0189e-b1b6-4d39-ba62-859997c4682a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_298bb488-884f-4711-ab52-1a9d0f05ba8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b83598e2-a031-44ff-841f-7937256ade25" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_298bb488-884f-4711-ab52-1a9d0f05ba8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2d2b5bbf-d9dd-4080-a003-987fc60c8cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b83598e2-a031-44ff-841f-7937256ade25" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2d2b5bbf-d9dd-4080-a003-987fc60c8cb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c0360152-e16b-4aea-a38a-71dfcc0d4da9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b83598e2-a031-44ff-841f-7937256ade25" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c0360152-e16b-4aea-a38a-71dfcc0d4da9" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#PROMISSORYNOTESBridgeFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b3cc9cbe-3029-4c55-b1a3-f2b29695c045" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b3cc9cbe-3029-4c55-b1a3-f2b29695c045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b3cc9cbe-3029-4c55-b1a3-f2b29695c045_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b3cc9cbe-3029-4c55-b1a3-f2b29695c045" xlink:to="loc_us-gaap_RelatedPartyDomain_b3cc9cbe-3029-4c55-b1a3-f2b29695c045_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_23a39684-d895-4f8f-9a86-cbde7ff8cdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b3cc9cbe-3029-4c55-b1a3-f2b29695c045" xlink:to="loc_us-gaap_RelatedPartyDomain_23a39684-d895-4f8f-9a86-cbde7ff8cdcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_1af86d6d-91c2-4922-be41-c849b3068a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_23a39684-d895-4f8f-9a86-cbde7ff8cdcd" xlink:to="loc_us-gaap_InvestorMember_1af86d6d-91c2-4922-be41-c849b3068a25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a612b41c-6bcf-47aa-ae4f-9bc3ba08083f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:to="loc_us-gaap_DebtInstrumentAxis_a612b41c-6bcf-47aa-ae4f-9bc3ba08083f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a612b41c-6bcf-47aa-ae4f-9bc3ba08083f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_a612b41c-6bcf-47aa-ae4f-9bc3ba08083f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a612b41c-6bcf-47aa-ae4f-9bc3ba08083f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_69c8264a-bd22-477d-8e2e-7ccb1d71f230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_a612b41c-6bcf-47aa-ae4f-9bc3ba08083f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_69c8264a-bd22-477d-8e2e-7ccb1d71f230" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_030c9716-6b77-4510-86ad-8b152139b6cd" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69c8264a-bd22-477d-8e2e-7ccb1d71f230" xlink:to="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_030c9716-6b77-4510-86ad-8b152139b6cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e9e86bb5-2412-4abb-ac59-6a6c8e4a4569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e9e86bb5-2412-4abb-ac59-6a6c8e4a4569" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_e9e86bb5-2412-4abb-ac59-6a6c8e4a4569_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e9e86bb5-2412-4abb-ac59-6a6c8e4a4569" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_e9e86bb5-2412-4abb-ac59-6a6c8e4a4569_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2f544de2-40da-4741-8a6b-a005d5400e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e9e86bb5-2412-4abb-ac59-6a6c8e4a4569" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2f544de2-40da-4741-8a6b-a005d5400e9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_95043c4a-b633-40e9-8d50-1c3faf40d3c7" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2f544de2-40da-4741-8a6b-a005d5400e9b" xlink:to="loc_ck0001824293_BridgeWarrantsMember_95043c4a-b633-40e9-8d50-1c3faf40d3c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_9b8225c8-22ad-4725-a1dd-39c6b1fc3220" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2f544de2-40da-4741-8a6b-a005d5400e9b" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_9b8225c8-22ad-4725-a1dd-39c6b1fc3220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b24710c3-cb62-45cd-aadc-40dcfab30e49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b24710c3-cb62-45cd-aadc-40dcfab30e49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_4b486c6b-45ad-4093-b68f-2cf3f99235e7" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_4b486c6b-45ad-4093-b68f-2cf3f99235e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings_162ccedb-a419-49ee-a88c-64815b359480" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_ck0001824293_DebtInstrumentNumberOfClosings_162ccedb-a419-49ee-a88c-64815b359480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_087ac18d-12df-4a85-ac0e-dbe72d595a14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_087ac18d-12df-4a85-ac0e-dbe72d595a14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45a8720e-5bd8-4ec6-825c-cbb21e89bafe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45a8720e-5bd8-4ec6-825c-cbb21e89bafe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7f49c7f3-ef1f-4480-959b-41eb78f8fc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7f49c7f3-ef1f-4480-959b-41eb78f8fc4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_9fb9ff8f-fb32-4a5c-9b96-c07419758cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_9fb9ff8f-fb32-4a5c-9b96-c07419758cb5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_9ee47f27-e61a-4b38-8f7c-198a09ea07fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_9ee47f27-e61a-4b38-8f7c-198a09ea07fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e088f1a9-82d5-4049-ad26-70b5d8205b25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e088f1a9-82d5-4049-ad26-70b5d8205b25" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5319dc7d-a11e-4f0d-b5f6-2de9462105bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5319dc7d-a11e-4f0d-b5f6-2de9462105bf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_85b2fabb-5474-4327-9f15-9366b9052f52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_85b2fabb-5474-4327-9f15-9366b9052f52" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c374fe92-5ddd-4be6-bb87-04a4a93a0f63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c374fe92-5ddd-4be6-bb87-04a4a93a0f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c374fe92-5ddd-4be6-bb87-04a4a93a0f63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c374fe92-5ddd-4be6-bb87-04a4a93a0f63" xlink:to="loc_us-gaap_RelatedPartyDomain_c374fe92-5ddd-4be6-bb87-04a4a93a0f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7ab4581e-0a6c-43eb-8dd6-4b7d2b1bb435" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c374fe92-5ddd-4be6-bb87-04a4a93a0f63" xlink:to="loc_us-gaap_RelatedPartyDomain_7ab4581e-0a6c-43eb-8dd6-4b7d2b1bb435" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_627ada3d-9885-479f-852b-20f5d633ae94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7ab4581e-0a6c-43eb-8dd6-4b7d2b1bb435" xlink:to="loc_us-gaap_InvestorMember_627ada3d-9885-479f-852b-20f5d633ae94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_53707d90-5ed7-44c9-87b9-b2f9f022f4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_53707d90-5ed7-44c9-87b9-b2f9f022f4ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_53707d90-5ed7-44c9-87b9-b2f9f022f4ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_53707d90-5ed7-44c9-87b9-b2f9f022f4ac" xlink:to="loc_us-gaap_EquityComponentDomain_53707d90-5ed7-44c9-87b9-b2f9f022f4ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c5cf851-49bd-4a25-9d95-b8eb0a1d04a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_53707d90-5ed7-44c9-87b9-b2f9f022f4ac" xlink:to="loc_us-gaap_EquityComponentDomain_9c5cf851-49bd-4a25-9d95-b8eb0a1d04a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7f3c6d73-4367-4ca8-98c1-e0a8d13e9c50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9c5cf851-49bd-4a25-9d95-b8eb0a1d04a1" xlink:to="loc_us-gaap_CommonStockMember_7f3c6d73-4367-4ca8-98c1-e0a8d13e9c50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_06f0f71a-579b-431b-b008-4b01c85efcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9c5cf851-49bd-4a25-9d95-b8eb0a1d04a1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_06f0f71a-579b-431b-b008-4b01c85efcbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3ed768b5-e3b2-4602-b728-a4f28f7d4bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3ed768b5-e3b2-4602-b728-a4f28f7d4bd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ed768b5-e3b2-4602-b728-a4f28f7d4bd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3ed768b5-e3b2-4602-b728-a4f28f7d4bd5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3ed768b5-e3b2-4602-b728-a4f28f7d4bd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58bc84c3-d1ae-4340-899f-03f588c41525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3ed768b5-e3b2-4602-b728-a4f28f7d4bd5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58bc84c3-d1ae-4340-899f-03f588c41525" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_b469a2b2-3b12-47ca-b70e-fb1640a2627d" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58bc84c3-d1ae-4340-899f-03f588c41525" xlink:to="loc_ck0001824293_PublicOfferingMember_b469a2b2-3b12-47ca-b70e-fb1640a2627d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_c987e29f-79c2-4344-ae27-82ca436645d4" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58bc84c3-d1ae-4340-899f-03f588c41525" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_c987e29f-79c2-4344-ae27-82ca436645d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_34dacc10-d034-4f12-a784-f324454264d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_34dacc10-d034-4f12-a784-f324454264d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_34dacc10-d034-4f12-a784-f324454264d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_34dacc10-d034-4f12-a784-f324454264d4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_34dacc10-d034-4f12-a784-f324454264d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_34dacc10-d034-4f12-a784-f324454264d4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_7cfeb793-39ec-4688-bee0-7046b909cdcf" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_7cfeb793-39ec-4688-bee0-7046b909cdcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_be746661-58d6-4659-af4a-345a34191367" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_be746661-58d6-4659-af4a-345a34191367" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_f6e3c5d6-60f0-4b0e-8a4b-a517c592eb10" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_f6e3c5d6-60f0-4b0e-8a4b-a517c592eb10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_bdd25a3b-d897-4855-a255-06fd54fbcfa9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_bdd25a3b-d897-4855-a255-06fd54fbcfa9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_03fb955e-4ec1-4a06-8732-6915671575f9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_03fb955e-4ec1-4a06-8732-6915671575f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_3ca78e3d-a5ca-42a9-a0c3-d5a537dc5126" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_3ca78e3d-a5ca-42a9-a0c3-d5a537dc5126" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_cf974f56-d4fb-4d44-ae8b-33229b579f77" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_cf974f56-d4fb-4d44-ae8b-33229b579f77" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember_c08cdf1d-aae2-43c1-8a19-6500675ab3ee" xlink:href="ck0001824293-20241231.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_June2024PAWarrantsMember_c08cdf1d-aae2-43c1-8a19-6500675ab3ee" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PriorWarrantsMember_982abc2e-26f6-42e5-ad15-4552733598ad" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PriorWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_PriorWarrantsMember_982abc2e-26f6-42e5-ad15-4552733598ad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember_3fbb2b43-7172-4900-aeba-b270dde6f998" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesD1WarrantsMember_3fbb2b43-7172-4900-aeba-b270dde6f998" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember_617576fe-f33c-44ab-b071-efff88c7a456" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesD2WarrantsMember_617576fe-f33c-44ab-b071-efff88c7a456" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember_e9ce450e-4736-47c0-be4d-4c4ac9938e68" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesDWarrantsMember_e9ce450e-4736-47c0-be4d-4c4ac9938e68" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17ff2281-2077-40a4-97fe-04406e0320e7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_srt_RangeAxis_17ff2281-2077-40a4-97fe-04406e0320e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17ff2281-2077-40a4-97fe-04406e0320e7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17ff2281-2077-40a4-97fe-04406e0320e7" xlink:to="loc_srt_RangeMember_17ff2281-2077-40a4-97fe-04406e0320e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea58fd3d-d165-42e1-ad92-3cb15c10c644" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17ff2281-2077-40a4-97fe-04406e0320e7" xlink:to="loc_srt_RangeMember_ea58fd3d-d165-42e1-ad92-3cb15c10c644" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_bf429d62-7807-4043-b49f-08d74049644d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ea58fd3d-d165-42e1-ad92-3cb15c10c644" xlink:to="loc_srt_WeightedAverageMember_bf429d62-7807-4043-b49f-08d74049644d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_788cba92-e0a6-4ff8-850d-8117c0a8bef9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_788cba92-e0a6-4ff8-850d-8117c0a8bef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5a827193-1e35-4b37-9be1-0ad54cfd103c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5a827193-1e35-4b37-9be1-0ad54cfd103c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_1b605878-f408-4a72-a267-4770fa7b5985" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_1b605878-f408-4a72-a267-4770fa7b5985" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_f1d74c25-9893-45c9-a4b8-786e2edb5645" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_f1d74c25-9893-45c9-a4b8-786e2edb5645" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_11cfa2ed-cdb3-42a1-8826-363a43e78193" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_11cfa2ed-cdb3-42a1-8826-363a43e78193" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5bd18047-fed9-4a16-b8f4-f4a6cdeed3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5bd18047-fed9-4a16-b8f4-f4a6cdeed3bc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f53866bb-99e1-40e1-ba62-0538dfe00a32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f53866bb-99e1-40e1-ba62-0538dfe00a32" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6b248d1e-f6ed-410a-a7a7-317177fa9d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6b248d1e-f6ed-410a-a7a7-317177fa9d3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_24e55be2-556a-43fa-a300-bfb1fc524d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_24e55be2-556a-43fa-a300-bfb1fc524d9c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_6c89cf14-6dfa-4a5d-ac44-5768024b613f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_6c89cf14-6dfa-4a5d-ac44-5768024b613f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_9be42273-58fe-45b7-a2bc-a4e49f7fe49d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_9be42273-58fe-45b7-a2bc-a4e49f7fe49d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41c15a5e-bf6e-467f-b84a-d967a7bad2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41c15a5e-bf6e-467f-b84a-d967a7bad2d6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_41c86509-4cd5-4067-8933-7635bca5c059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_41c86509-4cd5-4067-8933-7635bca5c059" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e8c5b1c3-6b0d-460f-b765-5748ed0de9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e8c5b1c3-6b0d-460f-b765-5748ed0de9b1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_8233730c-4529-4251-b1d5-967ef1376271" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_8233730c-4529-4251-b1d5-967ef1376271" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_8bdd7beb-2754-440c-863d-94ffaee57bf2" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_8bdd7beb-2754-440c-863d-94ffaee57bf2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_cdba2d01-c120-49b1-b3a3-35c356e966e0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_cdba2d01-c120-49b1-b3a3-35c356e966e0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_46cda79d-1859-4559-bddd-7e063e84e120" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_46cda79d-1859-4559-bddd-7e063e84e120" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_baf1cdbc-6680-407d-beab-6bb0512e54cb" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_baf1cdbc-6680-407d-beab-6bb0512e54cb" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_bfb1b33f-1afd-477b-a1a8-2b1dc090e456" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_bfb1b33f-1afd-477b-a1a8-2b1dc090e456" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_cbfdb703-b03e-4e70-ac1e-2aeb5ff15538" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_cbfdb703-b03e-4e70-ac1e-2aeb5ff15538" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_609248ae-0ef9-4bcb-9048-0000d38b769e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_609248ae-0ef9-4bcb-9048-0000d38b769e" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_29010216-7a83-4100-a1e2-ce2201265f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_29010216-7a83-4100-a1e2-ce2201265f19" xlink:type="arc" order="22"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e347a376-321b-41df-9b21-bd9387adb910" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e347a376-321b-41df-9b21-bd9387adb910" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_baee52d5-70f4-474c-a9f0-d9281558678e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:to="loc_srt_RangeAxis_baee52d5-70f4-474c-a9f0-d9281558678e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_baee52d5-70f4-474c-a9f0-d9281558678e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_baee52d5-70f4-474c-a9f0-d9281558678e" xlink:to="loc_srt_RangeMember_baee52d5-70f4-474c-a9f0-d9281558678e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_516994d7-5651-4efc-9114-be05595da765" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_baee52d5-70f4-474c-a9f0-d9281558678e" xlink:to="loc_srt_RangeMember_516994d7-5651-4efc-9114-be05595da765" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_1ac862ce-08c0-4295-8d0a-d273dd346f44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_516994d7-5651-4efc-9114-be05595da765" xlink:to="loc_srt_WeightedAverageMember_1ac862ce-08c0-4295-8d0a-d273dd346f44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_07e5b269-b859-4ead-9b94-351680ef8ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_07e5b269-b859-4ead-9b94-351680ef8ebd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_07e5b269-b859-4ead-9b94-351680ef8ebd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_07e5b269-b859-4ead-9b94-351680ef8ebd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_07e5b269-b859-4ead-9b94-351680ef8ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_08129385-88a3-475b-ad8e-c9a033f16c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_07e5b269-b859-4ead-9b94-351680ef8ebd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_08129385-88a3-475b-ad8e-c9a033f16c0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_52d65e99-2a6e-4e60-9c5c-f1a908cb80ea" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_08129385-88a3-475b-ad8e-c9a033f16c0d" xlink:to="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_52d65e99-2a6e-4e60-9c5c-f1a908cb80ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_3fd6aa1f-bb22-4bd5-bd4f-024dcc0f7f02" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_08129385-88a3-475b-ad8e-c9a033f16c0d" xlink:to="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_3fd6aa1f-bb22-4bd5-bd4f-024dcc0f7f02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember_9f500cc6-f649-4a2b-8726-e3b2aa81cde7" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_08129385-88a3-475b-ad8e-c9a033f16c0d" xlink:to="loc_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember_9f500cc6-f649-4a2b-8726-e3b2aa81cde7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7c27a41e-851a-4845-b0d4-e2741a955017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7c27a41e-851a-4845-b0d4-e2741a955017" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7c27a41e-851a-4845-b0d4-e2741a955017_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7c27a41e-851a-4845-b0d4-e2741a955017" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7c27a41e-851a-4845-b0d4-e2741a955017_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7c27a41e-851a-4845-b0d4-e2741a955017" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_d405dfe0-0bfa-4296-b6dc-149e9cee2395" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_d405dfe0-0bfa-4296-b6dc-149e9cee2395" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_b6594a7f-b2e0-4389-8a7b-1f97cfa4296e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_b6594a7f-b2e0-4389-8a7b-1f97cfa4296e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_11bfe669-dd41-4144-9d0e-851a76e6645f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_11bfe669-dd41-4144-9d0e-851a76e6645f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a4fd6ca9-f3fe-4d50-9dec-8c9a6a1fb7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a4fd6ca9-f3fe-4d50-9dec-8c9a6a1fb7b6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_772a6b16-a6b0-48fe-b55c-18d9dcef6368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e347a376-321b-41df-9b21-bd9387adb910" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_772a6b16-a6b0-48fe-b55c-18d9dcef6368" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_130e5db9-0743-4e22-a171-ae363c6eb3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4e7104aa-ac63-4641-a5f3-c2563211dc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_130e5db9-0743-4e22-a171-ae363c6eb3a7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4e7104aa-ac63-4641-a5f3-c2563211dc3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_70a200dd-4cad-4777-aae9-c03fe2b97ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4e7104aa-ac63-4641-a5f3-c2563211dc3d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_70a200dd-4cad-4777-aae9-c03fe2b97ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_70a200dd-4cad-4777-aae9-c03fe2b97ce6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_70a200dd-4cad-4777-aae9-c03fe2b97ce6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_70a200dd-4cad-4777-aae9-c03fe2b97ce6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_70a200dd-4cad-4777-aae9-c03fe2b97ce6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member_52c7fe9a-1e08-4d75-8eee-30575af722a1" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInAugust2025Member_52c7fe9a-1e08-4d75-8eee-30575af722a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_d2842271-cca6-4ade-a88e-b37e6a7e6976" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_d2842271-cca6-4ade-a88e-b37e6a7e6976" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMarch2026Member_6d65c3ae-91c4-4e0c-b523-c18be05b425b" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInMarch2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInMarch2026Member_6d65c3ae-91c4-4e0c-b523-c18be05b425b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2026Member_b8c57737-3477-4181-b704-db3492e8f243" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInApril2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2026Member_b8c57737-3477-4181-b704-db3492e8f243" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_49f3336b-a42a-4230-8eb7-bacd359fed7b" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_49f3336b-a42a-4230-8eb7-bacd359fed7b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_ff0e7962-2860-4ed7-a933-ef493f4a48b0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_ff0e7962-2860-4ed7-a933-ef493f4a48b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_e2b1283b-b0d4-44dd-9710-afee2955c1d9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_e2b1283b-b0d4-44dd-9710-afee2955c1d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_1ecb9857-1996-4ae7-8e28-25ae1b43a10f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_1ecb9857-1996-4ae7-8e28-25ae1b43a10f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member_95296b96-cd16-4382-ac59-2e95fc8d718f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2029Member_95296b96-cd16-4382-ac59-2e95fc8d718f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_a0aa65be-84e0-43eb-ac35-2831c46eda14" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInSeptember2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_a0aa65be-84e0-43eb-ac35-2831c46eda14" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_6c24bdea-6580-48ac-895c-cd30041e95f1" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInOctober2029OneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_6c24bdea-6580-48ac-895c-cd30041e95f1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_57305734-8b5e-430b-b806-a948a37de639" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInOctober2029TwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_57305734-8b5e-430b-b806-a948a37de639" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_abf87f97-1200-4305-af13-14c9ae5015d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_130e5db9-0743-4e22-a171-ae363c6eb3a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_abf87f97-1200-4305-af13-14c9ae5015d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_61de5a7d-018d-4e57-aa5a-41349bdecd12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_130e5db9-0743-4e22-a171-ae363c6eb3a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_61de5a7d-018d-4e57-aa5a-41349bdecd12" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47a68cc5-7449-49c2-8825-a1dd7f53c173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:to="loc_us-gaap_PlanNameAxis_47a68cc5-7449-49c2-8825-a1dd7f53c173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_47a68cc5-7449-49c2-8825-a1dd7f53c173_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_47a68cc5-7449-49c2-8825-a1dd7f53c173" xlink:to="loc_us-gaap_PlanNameDomain_47a68cc5-7449-49c2-8825-a1dd7f53c173_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a646cc03-c654-4705-ac85-a5405b13112e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_47a68cc5-7449-49c2-8825-a1dd7f53c173" xlink:to="loc_us-gaap_PlanNameDomain_a646cc03-c654-4705-ac85-a5405b13112e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsPlanMember_3c531a12-90d4-4bf5-aa9d-c37053b9c460" xlink:href="ck0001824293-20241231.xsd#ck0001824293_GRIOperationsPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a646cc03-c654-4705-ac85-a5405b13112e" xlink:to="loc_ck0001824293_GRIOperationsPlanMember_3c531a12-90d4-4bf5-aa9d-c37053b9c460" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_6dc68eb8-cc84-4070-bdf6-e611be1c6b23" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a646cc03-c654-4705-ac85-a5405b13112e" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_6dc68eb8-cc84-4070-bdf6-e611be1c6b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_af803000-b093-4751-bf88-68b469f477bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:to="loc_us-gaap_AwardTypeAxis_af803000-b093-4751-bf88-68b469f477bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af803000-b093-4751-bf88-68b469f477bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_af803000-b093-4751-bf88-68b469f477bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_af803000-b093-4751-bf88-68b469f477bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee75cfc3-6d47-41b9-ae5b-fb0e63cdbf08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_af803000-b093-4751-bf88-68b469f477bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee75cfc3-6d47-41b9-ae5b-fb0e63cdbf08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f6f37f07-b7f7-4663-a493-c281dabb81ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee75cfc3-6d47-41b9-ae5b-fb0e63cdbf08" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f6f37f07-b7f7-4663-a493-c281dabb81ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4bde8413-6914-4320-9f00-a6b45f2966a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:to="loc_srt_RangeAxis_4bde8413-6914-4320-9f00-a6b45f2966a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4bde8413-6914-4320-9f00-a6b45f2966a8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4bde8413-6914-4320-9f00-a6b45f2966a8" xlink:to="loc_srt_RangeMember_4bde8413-6914-4320-9f00-a6b45f2966a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1dedb631-5651-4ac9-b45a-11113a3fd1bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4bde8413-6914-4320-9f00-a6b45f2966a8" xlink:to="loc_srt_RangeMember_1dedb631-5651-4ac9-b45a-11113a3fd1bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1108ed24-7f62-4906-aca7-e49555e0bf29" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1dedb631-5651-4ac9-b45a-11113a3fd1bb" xlink:to="loc_srt_MaximumMember_1108ed24-7f62-4906-aca7-e49555e0bf29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_950975a5-4055-428a-84cb-8289091ed8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_950975a5-4055-428a-84cb-8289091ed8a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a92f38a8-b4d2-46e7-a1c6-c4171ac1d94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a92f38a8-b4d2-46e7-a1c6-c4171ac1d94d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44c0fa92-7023-418b-9e11-48acd0d19666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44c0fa92-7023-418b-9e11-48acd0d19666" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_198ac894-56fd-4b3b-961b-24f257822c68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_198ac894-56fd-4b3b-961b-24f257822c68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_36287e4c-302f-4681-876b-cadf87926260" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_36287e4c-302f-4681-876b-cadf87926260" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_cbf00094-1785-4616-90ea-8cf67971c717" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_cbf00094-1785-4616-90ea-8cf67971c717" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b9c90b15-7045-4d86-a075-0cc8bc65137e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b9c90b15-7045-4d86-a075-0cc8bc65137e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86493196-a0d7-43f5-b5eb-9c3d8926b477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86493196-a0d7-43f5-b5eb-9c3d8926b477" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c3649af-f719-41b4-8325-3c8fabe06b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c3649af-f719-41b4-8325-3c8fabe06b9d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5681877b-fabd-43e6-8479-2758ca609662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5681877b-fabd-43e6-8479-2758ca609662" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c80166b-8b3d-4179-84b9-06ea9e488b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c80166b-8b3d-4179-84b9-06ea9e488b72" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_65e1ba22-231a-4577-9ccb-99eafb27a545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3e30aa58-90f7-4204-8b49-b9c6892685f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_65e1ba22-231a-4577-9ccb-99eafb27a545" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3e30aa58-90f7-4204-8b49-b9c6892685f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3dfd30c0-faa9-408c-b22b-d0cb1e025366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3e30aa58-90f7-4204-8b49-b9c6892685f3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3dfd30c0-faa9-408c-b22b-d0cb1e025366" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3dfd30c0-faa9-408c-b22b-d0cb1e025366_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3dfd30c0-faa9-408c-b22b-d0cb1e025366" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3dfd30c0-faa9-408c-b22b-d0cb1e025366_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bd060480-9ca3-48c9-b61e-502c4ee509ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3dfd30c0-faa9-408c-b22b-d0cb1e025366" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bd060480-9ca3-48c9-b61e-502c4ee509ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6096838c-874b-40a5-be20-03c08c8d2738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bd060480-9ca3-48c9-b61e-502c4ee509ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6096838c-874b-40a5-be20-03c08c8d2738" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_fa31d4d8-5ec7-43c7-8158-b03e982f4ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bd060480-9ca3-48c9-b61e-502c4ee509ad" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_fa31d4d8-5ec7-43c7-8158-b03e982f4ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b905b9d-9115-4d0e-9f52-c4becd930dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_65e1ba22-231a-4577-9ccb-99eafb27a545" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b905b9d-9115-4d0e-9f52-c4becd930dc5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe0acfd1-4916-493b-81b1-7e8c52a1f9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe0acfd1-4916-493b-81b1-7e8c52a1f9d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c7eb95aa-94c5-404c-917a-155a3e39629f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe0acfd1-4916-493b-81b1-7e8c52a1f9d8" xlink:to="loc_us-gaap_AwardTypeAxis_c7eb95aa-94c5-404c-917a-155a3e39629f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7eb95aa-94c5-404c-917a-155a3e39629f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c7eb95aa-94c5-404c-917a-155a3e39629f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7eb95aa-94c5-404c-917a-155a3e39629f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05c4a7c5-05b2-497a-9a09-457199877d61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c7eb95aa-94c5-404c-917a-155a3e39629f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05c4a7c5-05b2-497a-9a09-457199877d61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35303a5a-f0a0-4e4c-9bab-cfec57b12138" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05c4a7c5-05b2-497a-9a09-457199877d61" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35303a5a-f0a0-4e4c-9bab-cfec57b12138" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7685865e-f6cf-4c15-a01a-41fc5fb38777" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7685865e-f6cf-4c15-a01a-41fc5fb38777" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_416e6df0-872f-4ffc-93c4-430904dc006a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_416e6df0-872f-4ffc-93c4-430904dc006a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b98c1d91-0727-4411-9125-af1cf8534276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b98c1d91-0727-4411-9125-af1cf8534276" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_49dbbcc1-2664-4062-9c68-2196e9745ece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_49dbbcc1-2664-4062-9c68-2196e9745ece" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ea9ce262-f0e0-4f66-8771-964fe85b63b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_SharePrice_ea9ce262-f0e0-4f66-8771-964fe85b63b7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ASSETPURCHASEAGREEMENTDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fe8f3bcb-c311-4cf9-b677-7d7c76b61c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_aead575e-80f5-4113-b460-016bd55c9bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f3bcb-c311-4cf9-b677-7d7c76b61c9e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_aead575e-80f5-4113-b460-016bd55c9bd7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9e41de7-2452-401e-8910-225d9d119009" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_aead575e-80f5-4113-b460-016bd55c9bd7" xlink:to="loc_srt_CounterpartyNameAxis_a9e41de7-2452-401e-8910-225d9d119009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9e41de7-2452-401e-8910-225d9d119009_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a9e41de7-2452-401e-8910-225d9d119009" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9e41de7-2452-401e-8910-225d9d119009_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a7209c-864d-4aff-8127-5fb247479959" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a9e41de7-2452-401e-8910-225d9d119009" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a7209c-864d-4aff-8127-5fb247479959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AardvarkTherapeuticsIncMember_7a556339-6415-469a-a15b-925b41876ca6" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AardvarkTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a7209c-864d-4aff-8127-5fb247479959" xlink:to="loc_ck0001824293_AardvarkTherapeuticsIncMember_7a556339-6415-469a-a15b-925b41876ca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_654653db-b72d-44ea-b8ca-892d43ac8898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f3bcb-c311-4cf9-b677-7d7c76b61c9e" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_654653db-b72d-44ea-b8ca-892d43ac8898" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b4768071-e022-4f95-9f6a-f8a08f2dfe94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d1033d35-e5f9-4c4e-942e-bdfcf3be0c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4768071-e022-4f95-9f6a-f8a08f2dfe94" xlink:to="loc_us-gaap_LossContingenciesTable_d1033d35-e5f9-4c4e-942e-bdfcf3be0c4e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d67c2966-bc90-4a46-a419-001863e6a07c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_d1033d35-e5f9-4c4e-942e-bdfcf3be0c4e" xlink:to="loc_srt_TitleOfIndividualAxis_d67c2966-bc90-4a46-a419-001863e6a07c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d67c2966-bc90-4a46-a419-001863e6a07c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_d67c2966-bc90-4a46-a419-001863e6a07c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d67c2966-bc90-4a46-a419-001863e6a07c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ab3b7b1-c0e8-4a72-b1f2-d41d63a9bfe7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_d67c2966-bc90-4a46-a419-001863e6a07c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ab3b7b1-c0e8-4a72-b1f2-d41d63a9bfe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_d7f64ec9-6a54-4f25-960a-56b0b5e0f19b" xlink:href="ck0001824293-20241231.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ab3b7b1-c0e8-4a72-b1f2-d41d63a9bfe7" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_d7f64ec9-6a54-4f25-960a-56b0b5e0f19b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_598bbea8-ee5a-4842-83ab-62d1bd4e81ce" xlink:href="ck0001824293-20241231.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4768071-e022-4f95-9f6a-f8a08f2dfe94" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_598bbea8-ee5a-4842-83ab-62d1bd4e81ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_cc0c708e-6e6b-4c5e-a383-e8b6c8ded699" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4768071-e022-4f95-9f6a-f8a08f2dfe94" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_cc0c708e-6e6b-4c5e-a383-e8b6c8ded699" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#INCOMETAXNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_58006ed3-b30b-49ec-8bf0-ddbec3b59ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_58006ed3-b30b-49ec-8bf0-ddbec3b59ee3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_71a344b5-577a-48fd-845d-deb5950d3214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_58006ed3-b30b-49ec-8bf0-ddbec3b59ee3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_71a344b5-577a-48fd-845d-deb5950d3214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_71a344b5-577a-48fd-845d-deb5950d3214_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_71a344b5-577a-48fd-845d-deb5950d3214" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_71a344b5-577a-48fd-845d-deb5950d3214_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_aa794df1-c212-4f0c-b2c7-f214dd01ecc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_71a344b5-577a-48fd-845d-deb5950d3214" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_aa794df1-c212-4f0c-b2c7-f214dd01ecc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_d017dcce-f4ea-4c01-a79d-f12655b7cc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aa794df1-c212-4f0c-b2c7-f214dd01ecc6" xlink:to="loc_us-gaap_DomesticCountryMember_d017dcce-f4ea-4c01-a79d-f12655b7cc23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StateTaxAuthorityMember_e06e5cc7-5364-4ba2-9a36-611946e08d23" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StateTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aa794df1-c212-4f0c-b2c7-f214dd01ecc6" xlink:to="loc_ck0001824293_StateTaxAuthorityMember_e06e5cc7-5364-4ba2-9a36-611946e08d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LocalTaxAuthorityMember_ee8f18a9-b9f6-4aa9-a3eb-c8534519e027" xlink:href="ck0001824293-20241231.xsd#ck0001824293_LocalTaxAuthorityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aa794df1-c212-4f0c-b2c7-f214dd01ecc6" xlink:to="loc_ck0001824293_LocalTaxAuthorityMember_ee8f18a9-b9f6-4aa9-a3eb-c8534519e027" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d633b655-5333-4818-b1a9-4b02553a087e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d633b655-5333-4818-b1a9-4b02553a087e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1c07bb35-0de6-48c4-ba60-68e4660972d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1c07bb35-0de6-48c4-ba60-68e4660972d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration_fa0b7f66-26cf-4ba5-91b8-c8d31b697771" xlink:href="ck0001824293-20241231.xsd#ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration_fa0b7f66-26cf-4ba5-91b8-c8d31b697771" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration_dd8b4fc0-cca0-430a-b47b-808c0da579fd" xlink:href="ck0001824293-20241231.xsd#ck0001824293_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration_dd8b4fc0-cca0-430a-b47b-808c0da579fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e0bffd91-0078-42cf-8c59-67b59dee79b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e0bffd91-0078-42cf-8c59-67b59dee79b4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3452b0d6-1429-41b0-8520-fdfbd1ff38db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a321b070-afc2-4eb2-b168-48b033ad7ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_3452b0d6-1429-41b0-8520-fdfbd1ff38db" xlink:to="loc_us-gaap_SubsequentEventTable_a321b070-afc2-4eb2-b168-48b033ad7ab2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_aba401a1-6233-40c1-8d2e-c87c172b4c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_a321b070-afc2-4eb2-b168-48b033ad7ab2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_aba401a1-6233-40c1-8d2e-c87c172b4c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_aba401a1-6233-40c1-8d2e-c87c172b4c4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_aba401a1-6233-40c1-8d2e-c87c172b4c4c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_aba401a1-6233-40c1-8d2e-c87c172b4c4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4988cd89-72eb-4856-b63f-b1ebff55d8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_aba401a1-6233-40c1-8d2e-c87c172b4c4c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4988cd89-72eb-4856-b63f-b1ebff55d8e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cea9c2e2-2677-499b-8727-0c7a860372ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4988cd89-72eb-4856-b63f-b1ebff55d8e4" xlink:to="loc_us-gaap_SubsequentEventMember_cea9c2e2-2677-499b-8727-0c7a860372ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_77f3411c-cbb6-48b1-9eaa-47bca81037b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_3452b0d6-1429-41b0-8520-fdfbd1ff38db" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_77f3411c-cbb6-48b1-9eaa-47bca81037b0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>ck0001824293-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cc1569ea-7e88-4563-a591-58e791ad305a,g:efa7e1ac-5ebb-4c93-bc1b-10c7aab46343-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_37434c9c-5788-4567-af6e-f202a8f5a321_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for reverse recapitalization expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3d931d17-9a95-4a12-a8fc-0f40c83e5229_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_bad450f6-cbf8-40c6-bf4c-983f88b23fd7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85f77270-4793-440e-b2a8-29ba9d0f3fc8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7695a1d3-e133-4251-99d1-a3338c1cc0e4_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_49b7f9b9-0c85-47d1-9837-b3eb7fbe1591_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesD1WarrantsMember_9823a4fd-405a-45e5-9267-f2dfcb66ad1e_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesD1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D-1 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesD1WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesD1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D-1 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesD1WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesD1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D-1 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesD1WarrantsMember" xlink:to="lab_ck0001824293_SeriesD1WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_22108f53-87a6-47c9-adea-9af25732e30d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_27898268-b60c-4b90-9f43-5032c79f57c8_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would affect effective tax rate if recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_f0d625d7-abfa-4590-9601-37ce2b0f76b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ed47a44c-f699-4e38-b2e6-1046bca4129a_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost_38b0eb69-d679-4bb7-ac20-0eeda703c7d2_terseLabel_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, offering cost</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost_label_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Offering Cost</link:label>
    <link:label id="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost_documentation_en-US" xlink:label="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Offering Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:to="lab_ck0001824293_ClassOfWarrantOrRightOfferingCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_5b1ffd81-f362-4db8-ab23-eb0afa4f38ff_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock placed into escrow (in shares)</link:label>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_label_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Held Into Escrow Account</link:label>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Held Into Escrow Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:to="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_916625b6-3e6e-4429-a3b6-13469420425b_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-2 common warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesB2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_9204d779-b1ff-4d28-8bd7-3a5870905c36_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for settlement of bridge note (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Settlement Of Debt</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Settlement Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_e3abf4c9-3704-4099-9d67-2c7820f53780_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_abbe3a77-3228-436c-b99d-e68b563a06f5_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, exchange ratio</link:label>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_label_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Exchange Ratio</link:label>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockExchangeRatio" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CommonStockExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockExchangeRatio" xlink:to="lab_ck0001824293_CommonStockExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_698a0c50-b955-4e7b-a896-75b6fb549eda_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_25058dc4-f662-4464-bc4c-4c731f803b76_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock for repayment of bridge loan</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_label_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued For Repayment Of Notes Payable</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued For Repayment Of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedForRepaymentOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:to="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_885a14cc-e36d-44b3-9650-7cb4f8b7b6e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e495e2f7-2f9d-4b58-b551-d2cc01b0920d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_f1415f05-7069-4450-be03-08112bedf59b_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_49e72849-e235-42f8-a71f-2df2706bdfc2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_186b25dd-4096-4c74-8c44-0f94e9bf8b90_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_23b6352a-ead7-45f0-b621-b7fe52027db1_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b4d879cc-2fc8-4776-a964-1b1aa1202132_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_f5f878b6-b09f-43c2-a4a4-258e2a99f708_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_f8aaac8b-621f-4640-b0ed-dbf6150e153e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInSeptember2029Member_48c72bf7-0404-4221-9a04-79eee0faa0fa_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In September 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInSeptember2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In September 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInSeptember2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In September 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInSeptember2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInSeptember2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_5d78f796-0e55-47b8-b24d-b5661b78699d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c128c920-2b58-4ce3-8998-778e05248899_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_53f4f9af-d05f-4662-9d7c-8540c3853a97_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8a3fd3d0-f365-41d0-b251-8381f4b5fbb6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_d1504486-593a-4f0f-ae5a-a9b7dd999577_terseLabel_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net liabilities acquired in connection with reverse recapitalization</link:label>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Liabilities Assumed In Connection With Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Liabilities Assumed In Connection With Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:href="ck0001824293-20241231.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:to="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_d3f04d3c-4267-4314-aef1-04bda96e686f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7435cecc-2187-4094-9a8d-cff6d87a0fb0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_5f38e7a9-b74b-48a6-bf88-e46d1bc2f4c6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_08137e03-eb3b-4c0d-8d1b-b8e450ef57a5_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in pre-closing financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Pre-closing Financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Pre-closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_b4b21a53-fa56-4f9d-b28a-72b91c27198b_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f69338f9-cd55-4dc1-9809-16b0edf4e0cf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7469fde9-c7e9-4a79-8207-4f5620bd55a7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_04f4950b-2921-4273-8e89-4863c5c50e5a_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_f0eda71c-2213-44d9-91b1-976d305703e1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2a02dc8e-bdb5-4194-b9fd-199fc709c0a6_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b9f0ef8b-e200-4521-b263-8506a15d8a6f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_3485a70e-e43d-4e9f-80c0-1c93aff352a5_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_c577bf43-0c7b-4ca8-a333-aa9fd118f422_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - Federal</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_392ebd32-28ea-4542-9e2c-43e87e2f8897_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_c372b22a-894a-4400-8720-23e2d4746cdb_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of advances from employees</link:label>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_label_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment Of Advances From Employees</link:label>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_documentation_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayment Of Advances From Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:href="ck0001824293-20241231.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:to="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a37ae84b-63ee-46f2-af08-120b9ffcfcf2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_8f1d67cd-6eb7-44b6-ab9b-aaec9e134ea3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3ddb656c-9478-4aea-880a-d2411dd55cbf_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_967afeae-b8fe-48e5-9dcf-80ab34a35cf7_terseLabel_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge SPA</link:label>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridge Securities Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:to="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_c97e964d-4788-498f-aaa6-6333dff1af1f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_f94716b2-e273-4687-860a-7526ebdb9cea_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c5d95ac4-e3ee-42f1-acc6-2d7be4d5c5b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_eddcf037-94f9-44a5-a07e-addbbfa02fe3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_4954d25c-cc84-4b3b-869a-96020116cb3e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_feda987a-c771-4545-8113-6f9c7c3aaf59_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_dde40191-079b-48f4-9b71-b8a249f9a3c6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_941c764b-3ffa-4a38-8371-e1a1ab8292ee_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_222fbde5-01b9-4e94-b177-c5ab84db8ee9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_af66c46d-2b5e-421b-b322-3eae21ee563a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance, increase</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3a58185f-5e3b-41d8-bf65-fc55f6f80495_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fb4b80c2-ce7a-4401-853a-a463787abee5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_83455faf-7bb1-48d9-815b-0f04c32babd0_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_08f4da8d-f75e-46fd-8c0e-88f6ed7dbea7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0333faa6-a0ec-4621-a5be-4770ea88edb3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_212a5226-0d37-4366-a1f8-32809634c4d7_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for reverse recapitalization expenses (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8d505694-179f-4d25-9fd6-73bbc73f94c8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_57efedcf-c940-4b73-b84c-658f45f7f1a2_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b878ea0f-56ec-4e73-813e-8d6bf7558edf_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_aba51c28-5704-4447-aefe-c89da9fc53d7_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_88d6fc94-d28b-4509-810a-dac01e6f395f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_43d7f75d-0685-436e-bbc8-f823d72d7103_verboseLabel_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_label_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantLiabilityMember" xlink:to="lab_ck0001824293_WarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa283650-6f31-48ce-8eb5-a41911a2e162_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_48b7850c-e8a4-4333-8ab5-408247dd7920_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2026Member_0f68f3b3-6520-457b-baa2-73ccccf5d06c_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2026Member" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInApril2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d5a1fb0f-8137-4401-8e03-8dd89317e443_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_5bb6f7bc-76a8-42d2-b5a2-7884f5694fd5_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Uninsured cash balances</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_e214d973-0e85-4855-b714-4dd85b2a5719_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_ca7dcc57-74cd-467e-bc31-be36223564da_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_26761851-bc6e-437e-9727-51f03a3334df_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d4e23e8e-5c86-4943-b119-2e357280d33b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_acba89f3-0a0a-484a-9787-f71ebefe1810_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_0de75442-29da-46d4-8b70-f5b258ba9b63_terseLabel_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net liabilities assumed plus transaction costs</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_label_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_documentation_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:to="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_c334739d-bb9a-41c3-a71f-bdf67d88d798_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_d2f288de-5c7e-49c4-a957-c589bf1185f5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a1094b5d-3acd-4a8b-ac64-b2ab091851b1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_46547447-0f55-4a96-be22-ba2a42d2a428_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_928b7283-d961-44ce-9fdb-0d0df637dafb_negatedLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Fractional share adjustment (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Fractional Share Adjustment</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Fractional Share Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_08fd1353-e493-48d1-a250-2cd5af2578b5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e19d2fac-02c0-410a-b61b-5fd295882513_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_478173c1-57c6-485e-836b-89af0df4403e_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9dd1cd77-281f-44f9-b6f4-0b275034f0b3_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7e3f100a-c6a0-48eb-be42-bed5fbdc1835_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_360b910a-d465-441b-99e9-a104db75066c_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt and deferred stock issuance costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs and Financing Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs and Financing Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:to="lab_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c82c4872-0ac5-41f7-9f3f-b43cfa77584b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_dcdfc65d-1e24-4817-ab46-47f0226d956e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a8ecd466-dac5-41a8-98ac-c9969112e1e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_9d27da82-f2d4-4541-86bb-c781de1cf09b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_8e4e29c3-0068-41ec-a7cb-56cd863b89bc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_72e73366-51a4-4a97-ba29-8a32ab9da1d4_terseLabel_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of target bonus (as a percent)</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_label_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_documentation_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PercentageOfTargetBonus" xlink:to="lab_ck0001824293_PercentageOfTargetBonus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2f939fce-1826-49fc-9b35-f81a3ca644cd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_c090c991-c421-4fec-ae15-7502eab30da8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_07a739e6-5b40-4777-8e63-07362c4b5054_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_ea50835e-b307-421a-8229-bbf1df33f3d7_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_96070d6b-fc9b-410b-915b-b95fe90e9f4a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal and state net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_86067f6c-e247-4630-a64a-b7c88a1f7bbb_verboseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computers</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_edb79456-2061-40a6-85f6-527860ed3a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesD2WarrantsMember_a382fc8e-95bf-4c8e-94f3-ed643bf9c318_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesD2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D-2 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesD2WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesD2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D-2 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesD2WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesD2WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D-2 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesD2WarrantsMember" xlink:to="lab_ck0001824293_SeriesD2WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyCommittedCapital_9bb9a123-1f2f-4d6d-be74-72f429a11afd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in cash</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyCommittedCapital_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Company, Committed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyCommittedCapital" xlink:to="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b2c2e3fb-6714-44e5-8a38-971f8730e79d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_9f911efc-70f6-43e0-a06a-d73f6f78ffa3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_4433c992-e9c1-4965-83e9-7bb926b3dc7b_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:to="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_54b1881c-1b2b-4f4c-8358-413feb8974ca_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_39ee8750-764c-4b07-930e-748adb9c6e09_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_6f62717c-1a0e-45bb-b40e-e2ae1421b915_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_916a2d6c-f486-4d5b-9c8c-2a979b50cf25_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0492ecfc-9660-433e-b882-54a05c32f230_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_9bb0ebbe-b020-478d-8030-1b4f652176ce_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ff0f175b-c06e-4485-a54b-eb39a08d5641_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3a67da2b-80fe-4076-b6e4-36f4d7b70e8b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8b9eb311-ee7e-4acf-a905-e9d3e21bb0a6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization - Federal</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7a50576c-985b-43e1-b0b7-dc87b314c4f1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c3ccef1c-df7d-4eb2-bc46-a90f56f29070_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0c9fa128-2cca-44d4-927e-1c36177641ee_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_129fcaf1-0c25-4feb-b082-a10308eed77e_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_e6d4fda2-7284-4e85-b04f-83317af8eaf3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_905e34a6-ac75-459e-abec-dcd00bc334eb_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_79f43185-fb2f-427c-8621-f41abc1cb9be_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_d5b638e4-58dc-4072-94f6-6aee784758b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities:</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_9e9183da-0720-46e8-a3b7-305e7666965a_terseLabel_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prefunded Warrants</link:label>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PreFundedWarrantsMember" xlink:to="lab_ck0001824293_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_be879a21-18fc-4a0c-94c2-bb3c03cbe736_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_75518254-f445-4bc4-b6f0-1bb0ec5bda6a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_95fe5fe5-fd07-465d-a0af-847529682a4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_GRIOperationsMember_fd171dc0-9ffa-4124-82b7-0c829cad15f6_terseLabel_en-US" xlink:label="lab_ck0001824293_GRIOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GRI Operations</link:label>
    <link:label id="lab_ck0001824293_GRIOperationsMember_label_en-US" xlink:label="lab_ck0001824293_GRIOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GRI Operations [Member]</link:label>
    <link:label id="lab_ck0001824293_GRIOperationsMember_documentation_en-US" xlink:label="lab_ck0001824293_GRIOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GRI Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_GRIOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_GRIOperationsMember" xlink:to="lab_ck0001824293_GRIOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_0698c31c-ea49-480b-8394-ed397e996ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_0d02ca46-45f6-4dbf-8392-fa0905240b64_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage in common stock (as a percent)</link:label>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_label_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Ownership Percentage</link:label>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockOwnershipPercentage" xlink:to="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ffe361f2-4404-436e-a898-c8252a36e9c3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_4ab35b93-4962-4bab-b856-ef427c6f654f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AuditInformationAbstract_3c95baa6-7a5f-43ec-ad36-05368288b99d_terseLabel_en-US" xlink:label="lab_ck0001824293_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ck0001824293_AuditInformationAbstract_label_en-US" xlink:label="lab_ck0001824293_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ck0001824293_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ck0001824293_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AuditInformationAbstract" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AuditInformationAbstract" xlink:to="lab_ck0001824293_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_e3d19996-20fc-422f-81b4-8005b02684f0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_fe1b8d40-ac5d-43c0-aad5-53ddb4732d4c_terseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advances from employees</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Advances From Employees</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Advances From Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:to="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesDWarrantsMember_eedb5e42-a137-49b2-aad7-0c2933183b7b_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesDWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesDWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesDWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesDWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesDWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesDWarrantsMember" xlink:to="lab_ck0001824293_SeriesDWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_11c5813a-89ec-49fa-90ee-c108c9547ccf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_e9ccd322-2b6f-442d-aa14-9518adba93e9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_b7956c27-1537-49a6-9eb3-a4c87a6dab87_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercise</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f090b7a8-3196-4e2a-8633-6c8edd76b255_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d54888e9-0a18-4b35-b930-6bf6fab7004f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_44854ff8-74ea-443d-b06a-1a485dd13233_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a5746fc3-06cb-419b-a298-982ffd550714_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_f5e87ea4-eb4b-445c-9cf1-4914ec969ba0_terseLabel_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding</link:label>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_label_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</link:label>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_documentation_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:to="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0d515ed9-4c93-4f47-a885-8a7c377d8dbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_9cc56630-ac42-4241-8e72-c889b5d14674_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4f2376e7-2b96-4682-83aa-db79b5bd226d_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_13098534-622c-49a9-a0f4-fb68698813e1_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_e1aa25e4-214a-41da-951c-669a44a1c0ec_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5178d337-7f99-4b05-a9c3-1287eecba371_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_6b1a19d8-67e4-4a8b-9f28-478ecfeaeee9_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock for payment of reverse recapitalization costs</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_label_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued For Payment Of Reverse Recapitalization Costs</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued For Payment Of Reverse Recapitalization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:to="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0e7e67a0-2863-402f-aa7d-04f995e6c1a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_d905aef3-6fb8-4cae-b293-528aec0685c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_October2024PAWarrantsMember_6c690802-e918-4bec-a87a-daa901d4bc2a_terseLabel_en-US" xlink:label="lab_ck0001824293_October2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">October 2024 PA Warrants</link:label>
    <link:label id="lab_ck0001824293_October2024PAWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_October2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">October 2024 PA Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_October2024PAWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_October2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">October 2024 PA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_October2024PAWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_October2024PAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_October2024PAWarrantsMember" xlink:to="lab_ck0001824293_October2024PAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_010d5eec-afa9-4173-a737-3c5218e63f58_terseLabel_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares converted into common stock (in shares)</link:label>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_label_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Additional Shares Converted</link:label>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_documentation_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Additional Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:to="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4dd1689f-5c6f-4bb7-90f6-b45d3de4a239_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_2742bc42-6761-43e3-9b65-89d780ed75b3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MERGER WITH VALLON</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_8c3be5ed-3ed6-4982-8e56-6db24fe928e5_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_be72a703-f39e-43c5-b4d2-d461886d07c8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesBCommonWarrantsMember_6e163b59-0959-439d-81bc-7fe8470e9a19_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesBCommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesBCommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesBCommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesBCommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_30306a04-4c19-4ebb-aab8-136996993d00_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_39ddefb6-4f90-4349-ba23-fcf340383e3d_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, maximum value of shares offered</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Value Of Shares Offered</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Value Of Shares Offered</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:to="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_968c6f37-cdf4-4a13-b2b2-0fdd16be311c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrant shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_bd0842d5-895a-4577-a2ed-2490ae816b91_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f89f70e5-33e2-4fa3-b2ed-88230375a78b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_af0245c7-0c93-43e5-862d-6d94a8143f21_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9a652a44-6cb7-4c7e-92a0-08c89b557685_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0cc11bc2-3ebc-4f4c-bcd6-5b43edad8aca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_c1097a4e-d370-40c8-a622-492b5f550595_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6e5be01d-c948-4bc2-ad46-9d64d8438ee6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_2ceb2104-d378-4a10-ac73-e41fdd4f630c_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Aggregate Purchase Price</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Aggregate Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:to="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_2dcfdf9e-16b3-4137-9e9a-c9cbc6de8ceb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_fb91259b-3db5-489a-b3ce-509167468392_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_16b6b771-23ca-458c-86ba-6e84afa2564f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_3dfdab1d-30f3-4874-813c-225a58400dc0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_93839ab6-f46a-46f6-8843-3051dec3a221_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c9d56ff8-60f9-4cea-b2dd-64e9df61962f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_9d15ff54-e061-421b-981e-d50407f0f098_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_June2024PAWarrantsMember_8404982a-9eba-4b31-b429-2d28e7c99fd0_terseLabel_en-US" xlink:label="lab_ck0001824293_June2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">June 2024 PA Warrants</link:label>
    <link:label id="lab_ck0001824293_June2024PAWarrantsMember_c27d6115-1648-4d5b-99c1-385674d672a0_verboseLabel_en-US" xlink:label="lab_ck0001824293_June2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">June 2024 PA Warrants</link:label>
    <link:label id="lab_ck0001824293_June2024PAWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_June2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June 2024 PA Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_June2024PAWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_June2024PAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">June 2024 PA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_June2024PAWarrantsMember" xlink:to="lab_ck0001824293_June2024PAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_e9b3b1fd-e8c2-4b47-a967-afbfa3486540_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_d0d022a6-fa42-4390-8c48-7619ec90f05e_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_738607f3-44f7-47f8-b279-a798a6d1c5e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrants Outstanding to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_3f345686-bc85-4440-b6f6-0cdae4ffb035_terseLabel_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Warrants</link:label>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridge Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BridgeWarrantsMember" xlink:to="lab_ck0001824293_BridgeWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_cfc3d417-9c44-4ed4-8e54-246031d4505f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_49cb5afb-8cd2-4d9b-923c-d0953ce0765e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock_f4eff3f5-020a-49c7-93e3-c827565d6c35_terseLabel_en-US" xlink:label="lab_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Lease Assets and Liabilities</link:label>
    <link:label id="lab_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_589664a7-618b-4faf-9375-e116c84c28dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_18dc260e-8146-40b1-9ecc-011cff9247dd_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant issuance</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_40f6820d-5ab0-4f9e-a5ad-903d86ef1577_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure or noncash activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AardvarkTherapeuticsIncMember_87172962-f3f5-47a3-9ac6-61fbadbdf452_terseLabel_en-US" xlink:label="lab_ck0001824293_AardvarkTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aardvark Therapeutics, Inc.</link:label>
    <link:label id="lab_ck0001824293_AardvarkTherapeuticsIncMember_label_en-US" xlink:label="lab_ck0001824293_AardvarkTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aardvark Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_ck0001824293_AardvarkTherapeuticsIncMember_documentation_en-US" xlink:label="lab_ck0001824293_AardvarkTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aardvark Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AardvarkTherapeuticsIncMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AardvarkTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AardvarkTherapeuticsIncMember" xlink:to="lab_ck0001824293_AardvarkTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0345fab5-5f1b-4b90-bfb0-c188ad84dc3f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation, weighted average amortization period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_09b002bb-5f77-49ae-8fba-1ca961963a28_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantLiabilityFairValueDisclosure_a4fdb82a-6dce-4e54-a4ec-24fc2bd212f1_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityFairValueDisclosure_documentation_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:to="lab_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_82b076f3-81ca-4eba-90da-7879b2754964_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2b4ceed5-a168-4838-87e7-79165c7b8518_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_be94d730-086a-4ddc-af46-81dba0f32b4b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ec22e692-8fe6-41b7-9ca6-3531a885a7c5_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_d3a5c106-0c59-4013-8e5f-84a4dc3aa269_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e5b2ac8d-091b-4e33-ace5-105141baec56_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_c209c6f3-0812-4f0c-94d1-b1288702ddc1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c669a366-bf1e-4021-89e4-cb2842bb9b69_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_1b45b2fe-ad83-4bd8-925f-d0a56de25f99_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1fe7a417-0169-467f-bc7b-00b57b0221aa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_74c2d524-c5e1-4155-af26-b4ca5c516cf3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_00a21e2c-daef-4bed-ab01-c45515d10060_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_86a2afa4-7554-49c8-9e9b-0490d60e1e03_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_f0085886-7efa-4dd0-8e59-2e6e7f77298d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income (expense), net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_f3651065-639e-4eda-8795-0468f36c9fde_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of bridge promissory note</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_6c0b547c-08e5-4b43-8f6d-684786140972_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_4d7a1b11-625d-413f-be16-c491e72a09ec_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_a0f4c04f-0229-4b1e-a3a5-83293d54004e_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesC1CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_a17329bb-f31c-470e-bb46-a82666b6d438_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.0001 par value; 250,000,000 shares authorized; 525,485 and 2,909 shares issued and outstanding as of December&#160;31, 2024 and 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_d10352ae-6b2c-4d34-97ea-6b8bea9624d0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_529084c5-0f86-4d8f-be89-5a6abcdc9197_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_44888e09-9efa-49cd-8c3b-d63871b90240_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_98cb2e3e-7833-4046-8d3a-1d48765ed3c8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_a0d40b88-6504-481a-a87b-6b173d61b9ef_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember_aaf22ae5-6028-4848-8756-91af83706528_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, One</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, One [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInOctober2029OneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:to="lab_ck0001824293_WarrantsExpiringInOctober2029OneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration_c9299efa-9186-4820-8171-14846c6ba604_terseLabel_en-US" xlink:label="lab_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:label id="lab_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="ck0001824293-20241231.xsd#ck0001824293_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_9cddd3a2-d2a4-45e6-9023-afe122434bdd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_051e18c8-8335-46dc-89c2-a47cf7bc172a_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_77ce4f4d-b2be-4989-973a-c9f88283e3db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_5d8c68d8-8092-4c3c-9d0a-63175f29b8aa_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to Vallon stockholders in reverse recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8135d100-d0fa-4958-9890-b34ce1adb156_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8274525e-fbca-4921-9dee-9c214a13342e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value as of December 31, 2023</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_285920f3-557c-42d0-a3de-e520834534bd_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance as of December 31, 2024</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_809df87c-97da-49fc-8c58-b3a9384dff2c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_db871651-d7b6-4d30-bded-e708cd44c4bc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_68b80578-0a59-4051-be97-b5cabc5ed3a5_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in pre-closing financing (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Pre-closing Financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Pre-closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_01aaff40-8ad9-4442-bade-6cf90f2583b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_9703ba18-a863-47f2-a029-861083b8d90f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_01d5974c-214e-49ad-904e-0e9e1cf35bba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_446c8b7a-0b3b-43b8-80aa-e27748ab8f2f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_25e671c5-3461-4baf-b7a7-d30c40a87d39_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_37938a26-a3fd-427d-807d-6209ef0413f9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_1e52b440-9561-47d7-bb4e-63cd9a9bceb8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_58512834-6f8d-431d-9c21-388d1aca0ba1_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e0578842-dd94-4411-8d6b-580ab90044c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16374922-b20d-418a-8e5a-cd75c5f682e5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_652f1749-41cb-4794-beaf-5f89bf491753_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_f1521103-dbe9-49b7-a89e-bc9f7d8e4579_terseLabel_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_label_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_documentation_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:to="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_b00e0d96-12db-45fb-9090-dc2f42ac5815_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activity of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_93aba31b-d139-46ed-acce-04b9ef3a9a53_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of closings</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Closings</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Closings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentNumberOfClosings" xlink:to="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_3596b047-4c3e-4ce2-a5bb-55f0b4f76d0b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected income tax benefit at the federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_88438849-cfbd-4f89-802d-65582c6edc13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_7733e147-da91-479b-9528-276d13a42c15_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of reverse recapitalization costs</link:label>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_label_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Reverse Recapitalization Costs</link:label>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_documentation_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Of Reverse Recapitalization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:to="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_85cb9d9f-73ef-45f3-a7b0-ca74e503b4b2_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:to="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_d9b20877-fa1c-4ced-aedb-6326ca58ab63_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_0d5874b2-827a-4a5a-bad7-6feb8006f97c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_bf0f3417-369d-46ac-95d1-3d9726fc91d4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_dfed9c7e-5767-42d2-9181-edcdb5e30719_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_b07c92a1-438b-4d36-b5af-6129178833ca_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_123fd08f-f829-4c0c-b0ed-ce04a069dade_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_0f3acec6-d3f8-43ab-b4e5-d905a4be5aa8_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIQUIDITY</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2587867a-b9bc-49a3-9b16-5aadfc650edf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_a9aaca73-d437-4046-bfc6-e47ccb2a1754_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f7dd738d-f398-4fe2-93d2-4df60302ea6a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c52a61ff-cc25-41a7-a9b5-4980359b5348_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_43ef5be0-5563-4a89-90c1-eec691009a62_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StateTaxAuthorityMember_d68842f0-d599-4aea-95ba-aae133abebe6_terseLabel_en-US" xlink:label="lab_ck0001824293_StateTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_ck0001824293_StateTaxAuthorityMember_label_en-US" xlink:label="lab_ck0001824293_StateTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State Tax Authority [Member]</link:label>
    <link:label id="lab_ck0001824293_StateTaxAuthorityMember_documentation_en-US" xlink:label="lab_ck0001824293_StateTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">State Tax Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StateTaxAuthorityMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StateTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StateTaxAuthorityMember" xlink:to="lab_ck0001824293_StateTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember_602e0ab4-44bf-4aac-8bdd-ac0f7ddc2a56_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, Two</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, Two [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In October 2029, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInOctober2029TwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:to="lab_ck0001824293_WarrantsExpiringInOctober2029TwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_LocalTaxAuthorityMember_eb2f37b7-f4d3-48f8-b59d-719f4f6b82dd_terseLabel_en-US" xlink:label="lab_ck0001824293_LocalTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local</link:label>
    <link:label id="lab_ck0001824293_LocalTaxAuthorityMember_label_en-US" xlink:label="lab_ck0001824293_LocalTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Tax Authority [Member]</link:label>
    <link:label id="lab_ck0001824293_LocalTaxAuthorityMember_documentation_en-US" xlink:label="lab_ck0001824293_LocalTaxAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Local Tax Authority</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LocalTaxAuthorityMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_LocalTaxAuthorityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_LocalTaxAuthorityMember" xlink:to="lab_ck0001824293_LocalTaxAuthorityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_2532f4cc-daf3-4774-92f1-bb0ae409b4b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Plus: Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8bcff647-784c-498e-930b-8be5d03d8cac_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_eea11ff7-45c9-479a-abd2-dc745fcebe51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_bb4096d0-86d3-403c-97d4-a5b0ea72bcfb_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_b630029e-eb5f-4cf4-a433-6449855771f7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_16bc42de-fc58-466d-84c6-cf7092c44d76_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7a2c163b-5e4c-45b7-a5f5-7f4b936d3170_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_50106087-54fe-414c-9e18-027564d57228_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_d5d33516-d8a4-4cb9-a4fc-5dae9ec241b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_feed115d-9b35-42cb-bdbe-1b4f3d2871be_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of accountable expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Accountable Expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Accountable Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:to="lab_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PriorWarrantsMember_52616f04-c70e-4bd1-b5f7-cbe37ea42e90_terseLabel_en-US" xlink:label="lab_ck0001824293_PriorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Warrants</link:label>
    <link:label id="lab_ck0001824293_PriorWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_PriorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_PriorWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_PriorWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prior Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PriorWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PriorWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PriorWarrantsMember" xlink:to="lab_ck0001824293_PriorWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_190a7195-3363-41ab-a6da-60dd6c746154_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_315939e5-708d-43a1-ae18-a21420cd5dec_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_1ee6adc4-4399-476f-ba46-0488f9c3ce57_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_07761e33-e2b1-48f0-9a57-77bdf09e71dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term&#160;(years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aba3326e-0777-48ca-b967-3d1b70a4476f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_7b4d767d-7fcb-4d37-9c26-9c2e4f3c309d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3220fa9e-0aa1-496f-9bb6-8968a0bdd75b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c962c7dd-3854-4bc7-b07f-f79cc56a7208_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_819273fc-ce9d-4752-bfa8-d4bec462dfbb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_c38ceae4-91dc-4e31-92eb-eddba3a57f36_terseLabel_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FDIC insured amount</link:label>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_5b6e7950-a6cd-4661-814f-f4c8dfa5b5be_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_466c01ba-baca-405d-af94-33d47b7732ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_4f87861e-372e-4e14-9031-287202fefd02_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_b4e93d15-f0cf-4e81-b48c-e56b20349a1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of deferred stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9b5a2f65-3ca8-43b1-95ca-367aee565c89_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_e6fe334b-9dea-47e5-9559-4b70f6fb1ca4_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c7afee99-2fd6-4b94-b22b-0baa4806f569_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_b037b3aa-71b9-482a-8256-c3cd0d0542fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of common stock on grant date (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_GRIOperationsPlanMember_988993a2-10bf-4967-a37d-95848fbab9ae_terseLabel_en-US" xlink:label="lab_ck0001824293_GRIOperationsPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Plan</link:label>
    <link:label id="lab_ck0001824293_GRIOperationsPlanMember_label_en-US" xlink:label="lab_ck0001824293_GRIOperationsPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GRI Operations Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_GRIOperationsPlanMember_documentation_en-US" xlink:label="lab_ck0001824293_GRIOperationsPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GRI Operations Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsPlanMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_GRIOperationsPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_GRIOperationsPlanMember" xlink:to="lab_ck0001824293_GRIOperationsPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_75defd32-0935-4727-b4f5-1af66c47d549_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fb8fc1ab-f1f3-4d08-897c-05c47a668f00_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_d163fdcb-ac59-490e-8d46-1acd85317f99_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0bd66398-8231-47af-8fa3-9b69c8b872f7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ef922e5e-4774-4aa2-adff-9833b0cb9ce5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ccaab7e3-ff72-4789-9a71-b51707bc23bc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0cb13737-1fa1-44a9-809c-85bc1bd7473c_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_6d1cd533-17c8-4f3d-bd3c-3d64851b68ec_terseLabel_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COBRA benefits, payment period (in months)</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_label_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_documentation_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:href="ck0001824293-20241231.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:to="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_b6a32155-90a8-4d9b-9f8b-f83b524bce70_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses:</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMarch2026Member_0ba3933c-752e-4b1a-a034-2004543df60a_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In March 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMarch2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In March 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMarch2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In March 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInMarch2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInMarch2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_8f7df4b9-bd9b-4ac3-9df3-fb7e4d65f7d7_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reimbursement of non-accountable expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Non-Accountable Expenses</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Reimbursement Of Non-Accountable Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:to="lab_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a1189e2c-afd2-49df-98b6-045072f508a1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_162fdb6c-163c-4886-a13d-8560d33cb790_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7a97aa20-baf0-4a28-843b-fc0935178978_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_819c095b-75fe-44b2-9086-3bc868265ac6_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-1 Common And Series B-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-1 Common And Series B-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-1 Common And Series B-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_3ed1e3fd-ae96-431b-a23c-4291ad3f5ca2_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_81e2fc8b-eaab-4ed5-8ce4-46129c16c100_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in valuation</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b184554a-4df3-4a9f-acd5-a21efc1cdace_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_4722cf15-4c2c-483f-9bf6-d1adcff1332d_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_715a5204-487c-4496-8012-2e364612019b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9ce9e106-101b-4c5e-a120-7249a02e2b53_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c798f67f-1053-4909-bb99-4ddc61f2efb2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_9c9bad7a-9e61-48ac-96e2-a9bd38e1400e_negatedLabel_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:to="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemablePreferredStockDividends_0137d7ef-0130-4a36-8383-0d6acba8ac2e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend on Series B Warrants</link:label>
    <link:label id="lab_us-gaap_RedeemablePreferredStockDividends_label_en-US" xlink:label="lab_us-gaap_RedeemablePreferredStockDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Preferred Stock Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemablePreferredStockDividends" xlink:to="lab_us-gaap_RedeemablePreferredStockDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_fe664379-4167-48c5-a241-64f1383a69e3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5ae6b3fa-0dbf-4299-9de3-5824d46e62ab_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1e558f89-fab8-4f41-bbbc-809da323d3cd_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PeripheralEquipmentMember_1e46c0a6-626a-402d-9853-f2f9708e9d8c_terseLabel_en-US" xlink:label="lab_ck0001824293_PeripheralEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peripheral Equipment</link:label>
    <link:label id="lab_ck0001824293_PeripheralEquipmentMember_label_en-US" xlink:label="lab_ck0001824293_PeripheralEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peripheral Equipment [Member]</link:label>
    <link:label id="lab_ck0001824293_PeripheralEquipmentMember_documentation_en-US" xlink:label="lab_ck0001824293_PeripheralEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Peripheral Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PeripheralEquipmentMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PeripheralEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PeripheralEquipmentMember" xlink:to="lab_ck0001824293_PeripheralEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4f2a2fb9-cb47-496d-bc9c-9be16a695fdb_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_e325757a-b5ce-470b-be8f-92745be6cba1_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_0eca52b4-8076-43da-a80a-f38d4b7e46f3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals and other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration_5e0767fa-557b-4aa6-9a3a-e589dbd23c89_terseLabel_en-US" xlink:label="lab_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, not subject to expiration</link:label>
    <link:label id="lab_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:label id="lab_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="ck0001824293-20241231.xsd#ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d2960923-7f3f-44ac-b075-e1ec21cd22b0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_17b68447-5ad1-4164-a5b6-5c5d37888fe9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_dee0c3cb-ce75-44b7-a83b-85aa1ab9135a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_17c3d4de-da6d-4461-891a-da6834b272a8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_e34ed540-00dc-4b33-a169-0c4eee2f574b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_3716477c-816c-49c5-b880-4734d2e65f5c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_9ed77fd6-4333-473b-ba49-c3dffccecdd8_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_ab5b35ff-03fb-4c21-b3f9-bf6e6261e89d_verboseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_f3f9a215-4157-469b-a1eb-8b15bc89496a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_e9829d43-2ffc-47d7-b69e-803ba8858315_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_66873b9f-5865-46be-a11e-b4f680e2691e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAX</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3acbe05d-da11-4585-8920-04faf5d418ef_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_210df534-19af-425b-ac33-dec5403b3c4e_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_47f5f09e-1d32-4b4c-8738-c17c70fd7ad9_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:to="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_4afbbb20-2e06-4b28-bc46-bc0b0bfb23ad_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_8db669c2-fccc-4e4c-832a-47c48e1f185a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_110e5d6f-c4a4-4820-b3f8-666818924325_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_dafdea79-6f3b-4e34-bcca-bab6e13bcb9c_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesA1WarrantsMember" xlink:to="lab_ck0001824293_SeriesA1WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b31f5acc-dffe-4c5c-aa4e-673dcbdde0a3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e1e03ac4-6adc-41a3-b3c1-5158a1be93cd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_1a2700b9-1ff1-4013-b348-6883d16ed0d8_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, aggregate cash fee, percentage of gross proceeds</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:to="lab_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_4296d126-82cc-42fa-86f9-a006944521b6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_d055dd90-b09b-45e1-a287-b8c95c83218b_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, agent compensation, percentage</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Compensation, Percentage</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Compensation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:to="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_78cfc52f-ba4f-4552-b685-e81b9881409c_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition of debt discount and additional paid-in-capital for warrants issued in connection with promissory notes</link:label>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_label_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</link:label>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_documentation_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:to="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_244d3454-6c81-4329-b421-fabf6035b955_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bc1962c1-727a-4922-bb01-fe1e62cf49ca_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_4dd993aa-7ca5-4c61-ac2d-520032b46316_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management fee, percentage of gross proceeds</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:to="lab_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_7ded655a-df12-492f-99bf-ea4b1b8c90f0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_63cc1aa3-d375-487c-9f66-451466c52b6a_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a8520717-7088-463d-820d-a7c184595a56_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROMISSORY NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd937ff8-2b94-45ad-b32d-c10a188d26ef_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_82fb27a3-8e64-4121-ab96-5582b08eb20e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8ec06055-927f-4764-9187-cbcaa95ac9a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c79cc194-25e9-4c21-acd6-15115f3058f5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_87f5e058-0fdd-4c44-81ab-0c1d5f070b90_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_0fca7b49-54e6-477b-ba7f-db55ed2aadb6_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CashAcquiredInReverseRecapitalization_7fccfa67-4bf2-49f3-b61f-954597c8540a_terseLabel_en-US" xlink:label="lab_ck0001824293_CashAcquiredInReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash acquired in reverse recapitalization</link:label>
    <link:label id="lab_ck0001824293_CashAcquiredInReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_CashAcquiredInReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired In Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_CashAcquiredInReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_CashAcquiredInReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Acquired In Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CashAcquiredInReverseRecapitalization" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CashAcquiredInReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CashAcquiredInReverseRecapitalization" xlink:to="lab_ck0001824293_CashAcquiredInReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_012cb15a-7310-4d2f-b7b4-62fbdffe0a71_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_22141143-c854-47dc-abeb-1cd4e5a2484d_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_9f3a5b6d-fd64-4846-9c90-d5bdaff34b24_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-1 common warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesB1CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_76a35db4-0aae-47fd-9e23-377c323de06f_terseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercise, net of offering cost</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Warrant Exercises, Net Of Offering Expense</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Warrant Exercises, Net Of Offering Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:to="lab_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_ef3c69b0-f2d1-4c5e-929d-c7b250de5d8a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_88f777c6-826e-4eae-8f97-ea28557d7f69_terseLabel_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer [Member]</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:to="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PublicOfferingMember_de372d9a-9ded-47bf-a565-e60c95958785_terseLabel_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_ck0001824293_PublicOfferingMember_label_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_ck0001824293_PublicOfferingMember_documentation_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PublicOfferingMember" xlink:to="lab_ck0001824293_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsIssued_bc0291a6-8260-47a2-ae88-8da0288a0552_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants for payment of stock issuance costs</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssued_label_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssued_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsIssued" xlink:to="lab_ck0001824293_WarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8aed6976-b162-4317-8e73-79c3cb8dc0c1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local taxes, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_9c2fc4ae-9ff8-4de3-9310-dd38df2032aa_terseLabel_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">A&amp;R 2918 Plan</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:to="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_b9f69ec8-dff1-4dd4-901e-0313ba31c99b_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember_bf7f4faa-3086-4bf6-a7db-74731fea7dd5_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series D-1 Common Warrants, Series D-2 Common Warrants, And PA Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series D-1 Common Warrants, Series D-2 Common Warrants, And PA Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series D-1 Common Warrants, Series D-2 Common Warrants, And PA Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember" xlink:to="lab_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantLiabilityCurrent_6c082dc8-e931-4b86-900c-c60e73cd4901_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityCurrent_label_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability, Current</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityCurrent_documentation_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityCurrent" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantLiabilityCurrent" xlink:to="lab_ck0001824293_WarrantLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b3782b45-466c-434d-bb6a-0031fd6c382c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit_067dc93b-ce19-471c-9932-6c17c5e3a4a3_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment for fractional shares in connection with reverse stock split</link:label>
    <link:label id="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit_label_en-US" xlink:label="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Fractional Shares, Reverse Stock Split</link:label>
    <link:label id="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit_documentation_en-US" xlink:label="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Fractional Shares, Reverse Stock Split</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:to="lab_ck0001824293_PaymentForFractionalSharesReverseStockSplit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71d49e8b-2511-459b-9b7e-0b1bb316e740_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_6f304ad3-8706-4ff4-92fb-0328b84bcbb4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f1b8cacf-904c-4fe6-a0d7-44efd21884b5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_61ba7048-c818-4faf-80de-de23f766d204_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ca0f00ae-3486-4d2b-883a-3f6ff9d0ac9a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_00049b0c-f2cf-4f83-9d3e-eb61a0604697_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_ec22e500-1302-4dc6-9731-fbd2b8eeed38_netLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock in financing transaction / under ATM facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8a7650d4-1902-4df7-8656-59ef5b2bfb7d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock in financing transactions</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0336232e-f4c2-4382-ac97-6a9a6ec9bc8d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dde06732-88d1-477f-ada8-d4d900b232c6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock awards, contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_068e5fc7-0c4a-45da-aad9-1278fafd8d07_terseLabel_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange Warrants</link:label>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ExchangeWarrantsMember" xlink:to="lab_ck0001824293_ExchangeWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d6c71ad4-f04f-4d13-a7db-bdc9ab822f7d_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss available to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_9747c4f2-32f9-4d79-8219-1b74d14bed2c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible items and other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_396ea38d-0749-4842-b8a7-144e0652e761_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_3422fc56-70e4-4e57-b914-766db2a92afb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_1189304d-7b5f-4e70-9e16-320ca5d25a26_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_12e12cd1-5625-416b-9190-1377fb01b97b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_78ae8d5a-f6e3-40e8-b684-0aa750656f5f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c61a592f-2449-40b3-bd9a-529237da7872_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_046ed8b1-f8ec-4d9b-8ec7-3a3d2f51a7e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_2116872f-f258-4c17-b792-b9d726875c54_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 13)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7c7b5514-ea47-4e47-ac05-8191ba94ae1c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_4234bd22-aec1-49fd-8cad-05e3ca74dcdf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Federal Statutory Income Tax Rate to the Effective Income tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_461d9567-4b8d-48c3-8ef2-ba294e816c84_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSET PURCHASE AGREEMENT</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_6a2c2929-3a7c-436e-8a79-8526662c8e8a_terseLabel_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Through Financing</link:label>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_label_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Through Financing [Member]</link:label>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_documentation_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Through Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ThroughFinancingMember" xlink:to="lab_ck0001824293_ThroughFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_a345d285-057a-4e9f-add0-70f3b89c96f9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_c5b34f23-2253-40c6-9657-89cbd64c41ff_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97f21d1b-25c2-40ac-9a83-f110599c879e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c478992b-0384-4aa4-a746-e2bba581f187_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price per Share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_4ca98c37-bd0b-4806-b34a-acd291cc37e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_941145d8-de31-4e51-bd4c-921915cd7623_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for settlement of bridge note</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Settlement Of Debt</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Settlement Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_988f0ff2-9703-490b-886e-d7b74e14d001_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ab1fdf32-41f5-4f92-8150-cb4a443765d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7610d972-9604-483a-bfd9-a741463ec330_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_ae659073-5682-4f13-a5e6-c461af6594fe_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities issued (in shares)</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Securities Issued Per Transaction</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Securities Issued Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:to="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_20509898-d702-468d-ba74-7de79e4ba388_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants not settleable in cash, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_851ff153-3f1e-4330-bcf8-f3fe455ed8dd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_23fa3be7-cb78-460a-8b71-6bd834e307a8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_8824fce2-0473-44f0-bc4c-e26708da2333_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_458093b6-8624-40c7-ba5c-f3e2a3da0e24_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f88ee528-70d9-44e8-9b07-7554f1501067_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7e68f074-5b4d-44eb-9e29-6fc298a5893b_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_edf08d4a-35db-496e-b985-f4b2bd7245f5_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_b3034982-e6c8-4d5a-95ec-f269e496dd56_negatedLabel_en-US" xlink:label="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in operating lease right of use assets</link:label>
    <link:label id="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_label_en-US" xlink:label="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Periodic Addition</link:label>
    <link:label id="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_documentation_en-US" xlink:label="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Periodic Addition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:href="ck0001824293-20241231.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:to="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_2c29510b-5acb-45a0-ab9f-400930452e79_terseLabel_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants</link:label>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:to="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_c8259529-b797-4ce1-8581-76ae038b044a_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_feb3f932-7bf9-41a1-a31d-ee358d89add4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_55462ee9-8d24-4766-8770-1513718299f4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f68783e2-5dc1-4d88-ae65-7903097a73af_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a6ed2d6a-708d-487a-9470-5c9c0e5db395_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_08c5c2e1-b793-43ed-b688-0da7b12b71b2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a6682d6c-7265-493c-ad93-a39364c81380_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_9831ec9b-e4aa-49db-b0a0-a38d26d57e71_terseLabel_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AtTheMarketOfferingMember" xlink:to="lab_ck0001824293_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9ec944e4-9015-4e88-9b80-4a6078643f39_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9f36a6db-639a-48ff-8c4a-4616fe5a991a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8d3dc0ef-8be9-4416-9c32-71890178f12d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_dbf93afd-57bc-4ee3-b973-0455371a74a5_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesC2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_77c2e166-65d9-46cd-abb5-83aeb56103b3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_d6a44e72-dd0f-458f-89b6-cf026108beed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Net Liabilities Assumed in the Merger</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0191082c-2782-4d08-8414-42e18214cc50_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_461770fa-5ff2-4c6c-98dd-d11522c15de1_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_5d468afa-3f12-4169-a97e-bdbb8ce75efd_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJune2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5060a724-c6db-4dac-b62a-6905b8223037_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_7a2381d9-c862-4f94-878e-ebc2e3ac9dda_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_427434d1-6ac6-4095-829a-9b2b63d7d7c1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_274f961a-f47b-4239-a8b2-1df71b6f40ab_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2bb73b8c-1110-41e7-b4bf-375cdf9d0759_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c602c763-6723-4c8a-b461-169fa2ca2f7c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_50a5ea38-47ec-4f0e-9843-c5d5e6ab8420_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront cash payment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_49aa8efd-e731-44a2-8a8a-80bcdd64e718_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d0b677d-95f7-47d1-ad3d-6562d5a4db9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b452988f-3e51-4be6-bdbe-47fabf8321b5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d5d01b94-b993-47a3-944b-82ba21b078fa_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_cf210aea-b4e2-4162-9330-f0a4ec1074a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_a7d272ba-3cec-40d6-84cb-d03dc9b8bd6b_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>ck0001824293-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:cc1569ea-7e88-4563-a591-58e791ad305a,g:efa7e1ac-5ebb-4c93-bc1b-10c7aab46343-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/Cover" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_2f72e7b8-62fd-4820-b737-8a1c15219f56" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_DocumentType_2f72e7b8-62fd-4820-b737-8a1c15219f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_204b9110-c23e-40e9-b94f-92dbe324bf0a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_DocumentAnnualReport_204b9110-c23e-40e9-b94f-92dbe324bf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_973212f8-f3d0-40a9-bbac-4f0b81ace64e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_DocumentPeriodEndDate_973212f8-f3d0-40a9-bbac-4f0b81ace64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_570b8d00-c833-4f77-be77-a48262c78f03" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_CurrentFiscalYearEndDate_570b8d00-c833-4f77-be77-a48262c78f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6883a8d5-f613-488c-86da-dc9fb50e0f12" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_DocumentTransitionReport_6883a8d5-f613-488c-86da-dc9fb50e0f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_99039f5a-3500-40c6-9115-990ecf9d131c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityFileNumber_99039f5a-3500-40c6-9115-990ecf9d131c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a4a52b79-1a3a-4c5c-bc2a-921fe596cf5e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityRegistrantName_a4a52b79-1a3a-4c5c-bc2a-921fe596cf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9c767735-1c10-4173-a6d2-76f0a5e5b4ea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9c767735-1c10-4173-a6d2-76f0a5e5b4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_dccc2dda-a134-4e59-95e6-479b0582ad09" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityTaxIdentificationNumber_dccc2dda-a134-4e59-95e6-479b0582ad09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a8f9781d-30ed-41eb-b52c-7989a119b891" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityAddressAddressLine1_a8f9781d-30ed-41eb-b52c-7989a119b891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_9988ba4d-0023-4a9c-80fc-96bf083a0928" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityAddressAddressLine2_9988ba4d-0023-4a9c-80fc-96bf083a0928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_b95c7688-f39e-458b-985e-1041377f1a6b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityAddressCityOrTown_b95c7688-f39e-458b-985e-1041377f1a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a2422ced-46f6-4e9d-9895-89789b1475bb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityAddressStateOrProvince_a2422ced-46f6-4e9d-9895-89789b1475bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fb6e6b9d-05da-4b89-a0f3-6cda0cbf6553" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityAddressPostalZipCode_fb6e6b9d-05da-4b89-a0f3-6cda0cbf6553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_08f8be59-9c39-413c-a7b2-a3f6e6833a04" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_CityAreaCode_08f8be59-9c39-413c-a7b2-a3f6e6833a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ad349d1b-de23-4ea5-b5d7-ec77aa1e703b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_LocalPhoneNumber_ad349d1b-de23-4ea5-b5d7-ec77aa1e703b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_cb79d665-a107-4d0a-8746-20155b481f49" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_Security12bTitle_cb79d665-a107-4d0a-8746-20155b481f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_7c75120b-42e8-4c08-89f7-d300aae2dca4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_TradingSymbol_7c75120b-42e8-4c08-89f7-d300aae2dca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_13063c21-d7c6-4415-a8e9-31622233a5be" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_SecurityExchangeName_13063c21-d7c6-4415-a8e9-31622233a5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f6ae69ea-a0ef-4208-b784-1fe54ace7bc7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f6ae69ea-a0ef-4208-b784-1fe54ace7bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_4e602250-26b9-4165-89c8-060eaa7fde82" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityVoluntaryFilers_4e602250-26b9-4165-89c8-060eaa7fde82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_2172c97c-a7d6-44bf-97f1-c7108e9bd75e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityCurrentReportingStatus_2172c97c-a7d6-44bf-97f1-c7108e9bd75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b1264f6d-03b4-4709-a0d8-3083294f221a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityInteractiveDataCurrent_b1264f6d-03b4-4709-a0d8-3083294f221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1762dac3-907e-47eb-a9b8-dc0574dadfa8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityFilerCategory_1762dac3-907e-47eb-a9b8-dc0574dadfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_da9804b0-fd99-4d6b-9585-ef6f466cd34a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntitySmallBusiness_da9804b0-fd99-4d6b-9585-ef6f466cd34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_57fc710d-a484-4d02-853e-f6b3a199a662" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityEmergingGrowthCompany_57fc710d-a484-4d02-853e-f6b3a199a662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_7e2768a6-aff4-491c-a3dc-a9884975ce4c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityExTransitionPeriod_7e2768a6-aff4-491c-a3dc-a9884975ce4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_5db93390-2a23-4d35-9777-320f42060c5e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_IcfrAuditorAttestationFlag_5db93390-2a23-4d35-9777-320f42060c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_fef21e74-578b-49b3-b52c-24bcd569d0b6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_fef21e74-578b-49b3-b52c-24bcd569d0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e29cab5b-ebfe-4be4-93e0-68414bb2c49a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityShellCompany_e29cab5b-ebfe-4be4-93e0-68414bb2c49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_975079c5-1344-4dc8-b452-44b77ea80faf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityPublicFloat_975079c5-1344-4dc8-b452-44b77ea80faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_282d0f4a-31b8-4961-951e-430913efdc15" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_282d0f4a-31b8-4961-951e-430913efdc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_564e58cf-4135-4167-8675-e33b0b980617" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_564e58cf-4135-4167-8675-e33b0b980617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c9fc0a72-4542-45dd-bf8c-3fd1f9c18537" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_EntityCentralIndexKey_c9fc0a72-4542-45dd-bf8c-3fd1f9c18537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_f7a64fce-ffeb-4d9d-b618-2d2b28b65b96" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_AmendmentFlag_f7a64fce-ffeb-4d9d-b618-2d2b28b65b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_de8cecfa-c76c-4b63-8cf4-22b7c89a8117" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_DocumentFiscalYearFocus_de8cecfa-c76c-4b63-8cf4-22b7c89a8117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e7ebe301-0fa5-420b-823d-9b72cf9a0b35" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e9a729af-db0d-4f80-b7a4-e1abdad42e5e" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e7ebe301-0fa5-420b-823d-9b72cf9a0b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/AuditInformation" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AuditInformationAbstract_a8623944-1201-4f7b-bb7b-7a13b7d74374" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_7ccb4fa7-e968-42fa-8b1c-6421ebd0f7ca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_AuditInformationAbstract_a8623944-1201-4f7b-bb7b-7a13b7d74374" xlink:to="loc_dei_AuditorName_7ccb4fa7-e968-42fa-8b1c-6421ebd0f7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_274ab706-95e7-4e20-90a8-4d46d4e0bba5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_AuditInformationAbstract_a8623944-1201-4f7b-bb7b-7a13b7d74374" xlink:to="loc_dei_AuditorLocation_274ab706-95e7-4e20-90a8-4d46d4e0bba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_88123b7f-3417-4a46-95ee-bf5a738e51e2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ck0001824293_AuditInformationAbstract_a8623944-1201-4f7b-bb7b-7a13b7d74374" xlink:to="loc_dei_AuditorFirmId_88123b7f-3417-4a46-95ee-bf5a738e51e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_a431e551-e053-4f1d-b960-ba21788bad11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_77a3ce98-6ae3-445b-beba-d3a79f5302d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a431e551-e053-4f1d-b960-ba21788bad11" xlink:to="loc_us-gaap_AssetsAbstract_77a3ce98-6ae3-445b-beba-d3a79f5302d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_07a5cbd7-ecaf-4163-9860-ec4aab39949c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_77a3ce98-6ae3-445b-beba-d3a79f5302d0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_07a5cbd7-ecaf-4163-9860-ec4aab39949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3369359f-bd7f-4cff-83bb-fb21593b22d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07a5cbd7-ecaf-4163-9860-ec4aab39949c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3369359f-bd7f-4cff-83bb-fb21593b22d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c173f472-05ac-40cd-b81e-63a6d47f0628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07a5cbd7-ecaf-4163-9860-ec4aab39949c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c173f472-05ac-40cd-b81e-63a6d47f0628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_425ee922-58a4-4ba5-a415-d44d94a2f795" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07a5cbd7-ecaf-4163-9860-ec4aab39949c" xlink:to="loc_us-gaap_AssetsCurrent_425ee922-58a4-4ba5-a415-d44d94a2f795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7c6a6b20-75da-4076-a770-93f4262c60cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_77a3ce98-6ae3-445b-beba-d3a79f5302d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7c6a6b20-75da-4076-a770-93f4262c60cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2b2159cc-fdb1-4672-b98b-483c58ad3ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_77a3ce98-6ae3-445b-beba-d3a79f5302d0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2b2159cc-fdb1-4672-b98b-483c58ad3ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8d535728-993d-4de1-8ab2-b01437913320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_77a3ce98-6ae3-445b-beba-d3a79f5302d0" xlink:to="loc_us-gaap_Assets_8d535728-993d-4de1-8ab2-b01437913320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64a4289d-7dbd-44f0-bdf9-e0b0a11b28b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_a431e551-e053-4f1d-b960-ba21788bad11" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64a4289d-7dbd-44f0-bdf9-e0b0a11b28b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_92ab9d5e-c337-42f9-b739-e05cc91b92ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64a4289d-7dbd-44f0-bdf9-e0b0a11b28b9" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_92ab9d5e-c337-42f9-b739-e05cc91b92ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_de47b17d-64d5-4850-b550-54d1f5aef8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92ab9d5e-c337-42f9-b739-e05cc91b92ec" xlink:to="loc_us-gaap_AccountsPayableCurrent_de47b17d-64d5-4850-b550-54d1f5aef8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6a6dea6d-56d0-4309-bfaf-794241c6ce16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92ab9d5e-c337-42f9-b739-e05cc91b92ec" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6a6dea6d-56d0-4309-bfaf-794241c6ce16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityCurrent_aedca6ec-ebb6-443c-94bd-fad4172ef63f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92ab9d5e-c337-42f9-b739-e05cc91b92ec" xlink:to="loc_ck0001824293_WarrantLiabilityCurrent_aedca6ec-ebb6-443c-94bd-fad4172ef63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_64fd259b-f44f-4430-ac2b-05bff52c40b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92ab9d5e-c337-42f9-b739-e05cc91b92ec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_64fd259b-f44f-4430-ac2b-05bff52c40b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e3d122f3-db62-45df-93ce-f5b43efbd3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_92ab9d5e-c337-42f9-b739-e05cc91b92ec" xlink:to="loc_us-gaap_LiabilitiesCurrent_e3d122f3-db62-45df-93ce-f5b43efbd3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a0ca1c9b-fcbf-411e-af62-52e1ffbbd1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64a4289d-7dbd-44f0-bdf9-e0b0a11b28b9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a0ca1c9b-fcbf-411e-af62-52e1ffbbd1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_22df576f-407d-4bc7-b7ac-a039d82aa7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64a4289d-7dbd-44f0-bdf9-e0b0a11b28b9" xlink:to="loc_us-gaap_Liabilities_22df576f-407d-4bc7-b7ac-a039d82aa7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e2148e8c-9c25-4486-9949-c30d1860c327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64a4289d-7dbd-44f0-bdf9-e0b0a11b28b9" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e2148e8c-9c25-4486-9949-c30d1860c327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_64be0454-fa75-4308-9cdc-64d741e1510a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64a4289d-7dbd-44f0-bdf9-e0b0a11b28b9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_64be0454-fa75-4308-9cdc-64d741e1510a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_692b121d-9862-474a-a1f3-4b5bcc773e8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64be0454-fa75-4308-9cdc-64d741e1510a" xlink:to="loc_us-gaap_CommonStockValueOutstanding_692b121d-9862-474a-a1f3-4b5bcc773e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df2ed6c7-d85c-46a3-bf52-78586918a8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64be0454-fa75-4308-9cdc-64d741e1510a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_df2ed6c7-d85c-46a3-bf52-78586918a8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f06fc1d-d7f1-4c04-b230-ee5bdfe9edbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64be0454-fa75-4308-9cdc-64d741e1510a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f06fc1d-d7f1-4c04-b230-ee5bdfe9edbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c213e3a3-0415-43e8-a07f-bcaf4261a38a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_64be0454-fa75-4308-9cdc-64d741e1510a" xlink:to="loc_us-gaap_StockholdersEquity_c213e3a3-0415-43e8-a07f-bcaf4261a38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0476ea2b-b20b-4a46-bffe-de71995cfde5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_64a4289d-7dbd-44f0-bdf9-e0b0a11b28b9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0476ea2b-b20b-4a46-bffe-de71995cfde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3ac87c69-4d46-40ad-879b-6c27b361587c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d5e07fdc-d8aa-4b76-8027-320a7e88fa17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3ac87c69-4d46-40ad-879b-6c27b361587c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d5e07fdc-d8aa-4b76-8027-320a7e88fa17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_319acbf9-4ebd-428a-a160-a4d70d4d8264" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3ac87c69-4d46-40ad-879b-6c27b361587c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_319acbf9-4ebd-428a-a160-a4d70d4d8264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7e430436-abf1-49e2-b404-44a451da6a38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3ac87c69-4d46-40ad-879b-6c27b361587c" xlink:to="loc_us-gaap_CommonStockSharesIssued_7e430436-abf1-49e2-b404-44a451da6a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_171d212e-48c2-4a48-947a-0a1108bb8aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3ac87c69-4d46-40ad-879b-6c27b361587c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_171d212e-48c2-4a48-947a-0a1108bb8aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_15b284cb-81ec-4e57-b997-ddd73e930898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_15b284cb-81ec-4e57-b997-ddd73e930898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f2ac7d0d-7818-4380-9a89-d7cd6e21a880" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15b284cb-81ec-4e57-b997-ddd73e930898" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f2ac7d0d-7818-4380-9a89-d7cd6e21a880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_55e16a88-0eae-4278-95a7-70c6039d54d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15b284cb-81ec-4e57-b997-ddd73e930898" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_55e16a88-0eae-4278-95a7-70c6039d54d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_01933c53-f24d-4038-97ff-cee9ba00760e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_15b284cb-81ec-4e57-b997-ddd73e930898" xlink:to="loc_us-gaap_OperatingExpenses_01933c53-f24d-4038-97ff-cee9ba00760e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bf22548d-c67f-48dc-80ba-90945fba9b08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_OperatingIncomeLoss_bf22548d-c67f-48dc-80ba-90945fba9b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0a9d3cc7-c2c8-4394-a253-56f9bbfe75e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0a9d3cc7-c2c8-4394-a253-56f9bbfe75e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_fd800197-a256-4e5d-acf3-f5d11b3b4ab4" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_fd800197-a256-4e5d-acf3-f5d11b3b4ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_27c6d997-71e1-473f-a096-11aac64e331b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_27c6d997-71e1-473f-a096-11aac64e331b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_18c2ca6b-cf6b-4309-8c75-fbccb42e5d25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_NetIncomeLoss_18c2ca6b-cf6b-4309-8c75-fbccb42e5d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemablePreferredStockDividends_92576cb0-4e4d-4ff0-90f2-1cb446cd059f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_RedeemablePreferredStockDividends_92576cb0-4e4d-4ff0-90f2-1cb446cd059f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_210e6e38-a579-48a0-bd3c-4fa5b1926560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_210e6e38-a579-48a0-bd3c-4fa5b1926560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_83157ba4-81ca-49d8-8a0b-ddc0ba7403a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_EarningsPerShareBasic_83157ba4-81ca-49d8-8a0b-ddc0ba7403a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_33c70bb3-4c02-468f-a951-19f512ba0e13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_33c70bb3-4c02-468f-a951-19f512ba0e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_93496c30-cd9f-45a6-8507-5464d9227177" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_93496c30-cd9f-45a6-8507-5464d9227177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_38d6f1af-ca52-4fc1-a1b7-1d6c3a8c06cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2b99afe9-3cdc-46af-82a0-34dcc735054e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_38d6f1af-ca52-4fc1-a1b7-1d6c3a8c06cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_257a930e-7ee3-4fbb-9ded-b72baffb15f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5840644a-f518-4a19-b45a-a391bd4427eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_257a930e-7ee3-4fbb-9ded-b72baffb15f2" xlink:to="loc_us-gaap_StatementTable_5840644a-f518-4a19-b45a-a391bd4427eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4bc47a4f-2fe0-4a2f-9316-fa1ae5eaf6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5840644a-f518-4a19-b45a-a391bd4427eb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4bc47a4f-2fe0-4a2f-9316-fa1ae5eaf6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5aad9e58-579a-409f-a7bf-46941bc2975d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4bc47a4f-2fe0-4a2f-9316-fa1ae5eaf6c7" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5aad9e58-579a-409f-a7bf-46941bc2975d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember_b6dd1be2-720d-4da2-a80e-3234bbf4c985" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5aad9e58-579a-409f-a7bf-46941bc2975d" xlink:to="loc_ck0001824293_ThroughFinancingMember_b6dd1be2-720d-4da2-a80e-3234bbf4c985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_dfaf5102-899b-4dc6-96a9-7fc3ee75ca7f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_5aad9e58-579a-409f-a7bf-46941bc2975d" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_dfaf5102-899b-4dc6-96a9-7fc3ee75ca7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5840644a-f518-4a19-b45a-a391bd4427eb" xlink:to="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b86cbb13-092f-49d8-b026-e7dfea0156fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b86cbb13-092f-49d8-b026-e7dfea0156fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d5247fae-cbc0-4aa6-ab76-5d4b7e1bee96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b86cbb13-092f-49d8-b026-e7dfea0156fa" xlink:to="loc_us-gaap_NetIncomeLoss_d5247fae-cbc0-4aa6-ab76-5d4b7e1bee96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b86cbb13-092f-49d8-b026-e7dfea0156fa" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_1f46da3c-fc5e-48fc-b6ca-cd006dc44f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_Depreciation_1f46da3c-fc5e-48fc-b6ca-cd006dc44f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7772d2bf-c4f2-4d90-8aa8-fc04f1f2496c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7772d2bf-c4f2-4d90-8aa8-fc04f1f2496c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_28450150-dfd6-4e25-9daf-59d3f4509a51" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_ShareBasedCompensation_28450150-dfd6-4e25-9daf-59d3f4509a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_12d9ce6d-1777-4795-a3e5-871b5186ec6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_12d9ce6d-1777-4795-a3e5-871b5186ec6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f9191651-5998-440b-ac99-0f882f34afae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_f9191651-5998-440b-ac99-0f882f34afae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_c808a2f2-c44f-4ca8-9bd6-88d5579a0349" xlink:href="ck0001824293-20241231.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_c808a2f2-c44f-4ca8-9bd6-88d5579a0349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c644b9fe-8603-4b76-af62-ded27174c868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c644b9fe-8603-4b76-af62-ded27174c868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_754d78cd-d5d5-4a71-85b6-4baf16ab16d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_754d78cd-d5d5-4a71-85b6-4baf16ab16d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_84f95ed8-1c2f-4e91-afbd-fb86e3f5acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_84f95ed8-1c2f-4e91-afbd-fb86e3f5acfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ab3707a3-2c7a-48d0-9190-b881a5df8399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4d29ab2c-557f-4910-abb5-058e35910081" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ab3707a3-2c7a-48d0-9190-b881a5df8399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_380c07bd-7f24-468a-a286-10075ebc4e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e4b9e080-da6d-4200-8cba-852808d64a1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_380c07bd-7f24-468a-a286-10075ebc4e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca21e0a0-db70-4dfa-b933-70241038a6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca21e0a0-db70-4dfa-b933-70241038a6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8431e3cb-3e68-4504-a0b8-d40f3164ed13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca21e0a0-db70-4dfa-b933-70241038a6b8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8431e3cb-3e68-4504-a0b8-d40f3164ed13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af16bfe1-ad42-4e35-9493-4a270ab91329" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ca21e0a0-db70-4dfa-b933-70241038a6b8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af16bfe1-ad42-4e35-9493-4a270ab91329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_0e8ed517-715e-44c1-9096-96fbc56ab6b9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_0e8ed517-715e-44c1-9096-96fbc56ab6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_d71c8ae0-cdf6-4f31-89c6-1251dc259678" xlink:href="ck0001824293-20241231.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_d71c8ae0-cdf6-4f31-89c6-1251dc259678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_f1744c99-b527-4b65-acaf-56fb8b806085" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_f1744c99-b527-4b65-acaf-56fb8b806085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c0a5630-88c8-40b4-a7a9-c5534da427b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1c0a5630-88c8-40b4-a7a9-c5534da427b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_16560b52-0532-40d1-b250-348ed41d2436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_16560b52-0532-40d1-b250-348ed41d2436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_09072766-6f00-4b91-a290-340ddaef902f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PaymentForFractionalSharesReverseStockSplit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_ck0001824293_PaymentForFractionalSharesReverseStockSplit_09072766-6f00-4b91-a290-340ddaef902f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CashAcquiredInReverseRecapitalization_4489991a-7c8d-4d30-80f4-b748e282ab31" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CashAcquiredInReverseRecapitalization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_ck0001824293_CashAcquiredInReverseRecapitalization_4489991a-7c8d-4d30-80f4-b748e282ab31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_28744bfa-7e20-4935-b9fe-39205a119f61" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_28744bfa-7e20-4935-b9fe-39205a119f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_0f331a12-bd85-4dcd-aa0b-06d715aa6ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_0f331a12-bd85-4dcd-aa0b-06d715aa6ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_94e9c7af-d61c-445d-a4db-0ea5d3aaee43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_94e9c7af-d61c-445d-a4db-0ea5d3aaee43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_122cd3b0-39ee-40ba-96ac-f66470170742" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_822fe2d6-90b0-4160-bcfb-e11d12ccc9a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_122cd3b0-39ee-40ba-96ac-f66470170742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd6d4c04-bb62-488f-ba9b-248b187ccd94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd6d4c04-bb62-488f-ba9b-248b187ccd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_345d4217-9f26-495a-a486-4dfb255bbfef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_345d4217-9f26-495a-a486-4dfb255bbfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7070683b-1e75-471a-af61-6962a708a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7070683b-1e75-471a-af61-6962a708a45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1ad32417-f308-4124-80fb-87ce08f7e563" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_9e760a63-7f2a-4ff1-ab48-581702b4d19e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedForRepaymentOfNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_9e760a63-7f2a-4ff1-ab48-581702b4d19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_73b60712-fd5d-4775-87c3-4b287f7e0811" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_73b60712-fd5d-4775-87c3-4b287f7e0811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_b993a50a-94c6-4ec3-b529-ba6576f10d87" xlink:href="ck0001824293-20241231.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_b993a50a-94c6-4ec3-b529-ba6576f10d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_ee3c77f4-3551-4964-b8fe-d663598dd380" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid_ee3c77f4-3551-4964-b8fe-d663598dd380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_00df2c82-3101-4a48-8563-777c8ee668c0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_00df2c82-3101-4a48-8563-777c8ee668c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued_6c9a7374-d772-42c6-b4ec-0c0d6b33c2b6" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_982836d4-6428-4cf7-9cbf-c1a00c93e920" xlink:to="loc_ck0001824293_WarrantsIssued_6c9a7374-d772-42c6-b4ec-0c0d6b33c2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ConsolidatedStatementsofChangesinStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d84fd03a-2e12-44b9-916a-ed0316153164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c01251c8-6a74-40cc-a8dd-2ed70be6a651" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d84fd03a-2e12-44b9-916a-ed0316153164" xlink:to="loc_us-gaap_StatementTable_c01251c8-6a74-40cc-a8dd-2ed70be6a651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_83f2c124-176b-42ae-b710-3a5d4e9a1c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c01251c8-6a74-40cc-a8dd-2ed70be6a651" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_83f2c124-176b-42ae-b710-3a5d4e9a1c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_44eb3e6c-9e84-4dfe-af45-0ad10abb1dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83f2c124-176b-42ae-b710-3a5d4e9a1c81" xlink:to="loc_us-gaap_EquityComponentDomain_44eb3e6c-9e84-4dfe-af45-0ad10abb1dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b4cabbd8-0ea3-402f-9a72-61b6f54f6669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_44eb3e6c-9e84-4dfe-af45-0ad10abb1dc9" xlink:to="loc_us-gaap_CommonStockMember_b4cabbd8-0ea3-402f-9a72-61b6f54f6669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_194b7a6e-51c1-4da9-9ce7-64926b7fdb02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_44eb3e6c-9e84-4dfe-af45-0ad10abb1dc9" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_194b7a6e-51c1-4da9-9ce7-64926b7fdb02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ff7e6c41-9360-4753-8c22-cabf5f5bc07e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_44eb3e6c-9e84-4dfe-af45-0ad10abb1dc9" xlink:to="loc_us-gaap_RetainedEarningsMember_ff7e6c41-9360-4753-8c22-cabf5f5bc07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ba1b3920-b234-41aa-bb32-6a6d04ddf3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c01251c8-6a74-40cc-a8dd-2ed70be6a651" xlink:to="loc_us-gaap_StatementLineItems_ba1b3920-b234-41aa-bb32-6a6d04ddf3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ba1b3920-b234-41aa-bb32-6a6d04ddf3b2" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5b1e533b-1179-4209-aa89-90da74e854c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5b1e533b-1179-4209-aa89-90da74e854c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5768dc54-2c1a-4a8b-a553-2fef902f7069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_StockholdersEquity_5768dc54-2c1a-4a8b-a553-2fef902f7069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aab1b453-8d9f-4ba1-8346-923cb27baf31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_aab1b453-8d9f-4ba1-8346-923cb27baf31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_cd22c160-0b42-46ce-8514-cd98009e5263" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_cd22c160-0b42-46ce-8514-cd98009e5263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_954d2016-d8f5-4ac8-bb35-2bbc3b7d4c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_954d2016-d8f5-4ac8-bb35-2bbc3b7d4c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_66a38797-8842-4123-8bf6-fc13b20982b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_66a38797-8842-4123-8bf6-fc13b20982b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a9ee33b9-cb09-4a53-a8d8-c2e530ec868e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_a9ee33b9-cb09-4a53-a8d8-c2e530ec868e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_39be0c7a-203b-4fed-9d2a-124c89124196" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_39be0c7a-203b-4fed-9d2a-124c89124196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_492db8df-bc13-43d2-910d-7d3c37aba5b1" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_492db8df-bc13-43d2-910d-7d3c37aba5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_749e2143-74de-4e33-bb9b-a0ef0920409a" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_749e2143-74de-4e33-bb9b-a0ef0920409a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_b206d342-fdac-4714-802f-35bdab488e49" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_b206d342-fdac-4714-802f-35bdab488e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_83b861c2-131f-4b70-989a-26b4b011fba4" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_83b861c2-131f-4b70-989a-26b4b011fba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_66ee02f7-0613-4ca8-b923-eeeef1f91d22" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_66ee02f7-0613-4ca8-b923-eeeef1f91d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_ff3facef-a89a-45ea-87d5-3986b254335c" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_ff3facef-a89a-45ea-87d5-3986b254335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_a57018c8-f43a-4987-9ebf-10bfa835dc89" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_a57018c8-f43a-4987-9ebf-10bfa835dc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_d6617792-e478-4357-ac40-8448e1ebbb9e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_d6617792-e478-4357-ac40-8448e1ebbb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_fec001fd-407d-451a-8d46-2d31a4c5932e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_fec001fd-407d-451a-8d46-2d31a4c5932e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_262e09ac-3fe8-46d4-a654-9f49e8384631" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_262e09ac-3fe8-46d4-a654-9f49e8384631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fa97332e-d715-4ed3-b07e-acc04d008767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_NetIncomeLoss_fa97332e-d715-4ed3-b07e-acc04d008767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f2252218-adc6-4529-9d75-9a503a4940d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f2252218-adc6-4529-9d75-9a503a4940d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7360f175-4e6d-4dc3-992c-3aab33c1d18f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d018fbe3-e29a-49a1-a384-39c06cb0dd14" xlink:to="loc_us-gaap_StockholdersEquity_7360f175-4e6d-4dc3-992c-3aab33c1d18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62a8aacc-9c0c-4cff-87d9-a8bea208ed3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_7c51d3e6-e9d3-4ece-b9a9-0eb9518ed156" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62a8aacc-9c0c-4cff-87d9-a8bea208ed3a" xlink:to="loc_us-gaap_NatureOfOperations_7c51d3e6-e9d3-4ece-b9a9-0eb9518ed156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LIQUIDITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cfe2634c-15f8-4011-9c0f-b2830d57516b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_1f3e3a59-5b55-4060-ad57-a18aae4fc91b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cfe2634c-15f8-4011-9c0f-b2830d57516b" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_1f3e3a59-5b55-4060-ad57-a18aae4fc91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b6e23222-0e62-442c-9471-c63c5e1e4aab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2fdb1ade-2ad6-4dd6-9e1a-11ea47318d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6e23222-0e62-442c-9471-c63c5e1e4aab" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2fdb1ade-2ad6-4dd6-9e1a-11ea47318d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLON" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#MERGERWITHVALLON"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLON" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_dee9596b-4f01-4662-b5a9-2142fc6cb9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_10c0e758-6198-48a6-9e03-a7142b7f3013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_dee9596b-4f01-4662-b5a9-2142fc6cb9f4" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_10c0e758-6198-48a6-9e03-a7142b7f3013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ce199020-ad4e-46c1-a8cc-4504d28814cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_75e11189-18df-4a68-9fae-c8943b02e779" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ce199020-ad4e-46c1-a8cc-4504d28814cd" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_75e11189-18df-4a68-9fae-c8943b02e779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_be20512f-db28-4b34-9569-70e87284a2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_61468e9d-5d4b-4ed7-b08b-062d30d5b4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_be20512f-db28-4b34-9569-70e87284a2fa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_61468e9d-5d4b-4ed7-b08b-062d30d5b4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASES" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_99927d93-fba3-470e-830a-57f09a32249b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_f155e9a5-4261-4e91-951d-7aafbe61d2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_99927d93-fba3-470e-830a-57f09a32249b" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_f155e9a5-4261-4e91-951d-7aafbe61d2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_ba12d206-caf7-47ad-92aa-803572ad5449" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e3f43c6d-64e8-41d0-8095-4a75ad1b6ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_ba12d206-caf7-47ad-92aa-803572ad5449" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_e3f43c6d-64e8-41d0-8095-4a75ad1b6ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTES" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#PROMISSORYNOTES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a308e5fd-d722-4410-a982-6fd66a37b528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_cc929b7c-7144-4c75-8305-bb7490657c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a308e5fd-d722-4410-a982-6fd66a37b528" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_cc929b7c-7144-4c75-8305-bb7490657c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f8f03117-853d-4d23-85ad-e15026ea657a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a7a6607a-ebb3-45b2-ab02-77bb5c95d5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f8f03117-853d-4d23-85ad-e15026ea657a" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a7a6607a-ebb3-45b2-ab02-77bb5c95d5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69cc9f12-5075-4f02-baab-c6e48ba66137" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bb7eab24-3c9c-47e9-8c82-9d330ceef5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_69cc9f12-5075-4f02-baab-c6e48ba66137" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_bb7eab24-3c9c-47e9-8c82-9d330ceef5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ASSETPURCHASEAGREEMENT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d9037a03-f92e-41d1-96e6-004c2700962d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_c1f32736-1b86-430c-a267-2f9a4870f7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d9037a03-f92e-41d1-96e6-004c2700962d" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_c1f32736-1b86-430c-a267-2f9a4870f7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe4234b5-dec1-4860-a390-1f3d399201e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_654c717f-fedd-4ff8-8f29-87e49064244e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fe4234b5-dec1-4860-a390-1f3d399201e6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_654c717f-fedd-4ff8-8f29-87e49064244e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAX" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#INCOMETAX"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAX" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5336a8a6-1af4-424b-8c21-95869b350a2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f2cd3a75-5d21-405c-ae49-ca04a2cfe1db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5336a8a6-1af4-424b-8c21-95869b350a2b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f2cd3a75-5d21-405c-ae49-ca04a2cfe1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_853031dc-05b7-4dbc-b4d7-38d078fb260e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9c5830ec-7ead-448c-bf8c-4ed2a8d3762f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_853031dc-05b7-4dbc-b4d7-38d078fb260e" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9c5830ec-7ead-448c-bf8c-4ed2a8d3762f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0b385709-e6d6-420d-9f03-fe77873034cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0b385709-e6d6-420d-9f03-fe77873034cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_db92b808-5e51-48bc-b4c5-b53a48b5740d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_db92b808-5e51-48bc-b4c5-b53a48b5740d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_2def523b-f813-49fc-898d-b3626d387312" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_UseOfEstimates_2def523b-f813-49fc-898d-b3626d387312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_11b105c5-5287-49f5-a763-b1e6904c3b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_11b105c5-5287-49f5-a763-b1e6904c3b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_e6abeddb-196b-4a0b-819a-eed34dc6bb64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_e6abeddb-196b-4a0b-819a-eed34dc6bb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7221352b-8c4e-414c-bf6b-450943d5503c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7221352b-8c4e-414c-bf6b-450943d5503c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_ba523774-8781-4e53-be62-5ed22e267add" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_ba523774-8781-4e53-be62-5ed22e267add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_bcc7505a-b6b5-4028-a58f-c1770dd7f50e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_bcc7505a-b6b5-4028-a58f-c1770dd7f50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_52f09562-cf2a-4717-8684-074971454f32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_52f09562-cf2a-4717-8684-074971454f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_688282b7-87fe-4afc-a1d2-3ef1eb36e51b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_688282b7-87fe-4afc-a1d2-3ef1eb36e51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_a5943bb2-f699-478c-bcf0-51fcc1b4ff0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_a5943bb2-f699-478c-bcf0-51fcc1b4ff0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7ffbfbde-0a53-48a5-bd92-9fda12ad46a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7ffbfbde-0a53-48a5-bd92-9fda12ad46a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f85d5585-f522-4715-ab81-cbbea8bf4509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4853584d-5aa4-4c72-81f5-4f052735a9c1" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f85d5585-f522-4715-ab81-cbbea8bf4509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9c54b682-06e1-41c1-a3db-697cbcfbd091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_459caca6-09cb-45d7-b14b-4f4b5c54c8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9c54b682-06e1-41c1-a3db-697cbcfbd091" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_459caca6-09cb-45d7-b14b-4f4b5c54c8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#MERGERWITHVALLONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_59460f07-13d3-4e2f-94b9-986283329a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_63651fef-08fe-4b4a-8147-b706187d1e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_59460f07-13d3-4e2f-94b9-986283329a34" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_63651fef-08fe-4b4a-8147-b706187d1e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dbf90d8c-25b8-46ed-b87f-abe90a1c58c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_cc17912d-707c-4b5b-b602-925c710563a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbf90d8c-25b8-46ed-b87f-abe90a1c58c7" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_cc17912d-707c-4b5b-b602-925c710563a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a9892fba-0910-4841-83cf-a7b4c7b7b888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbf90d8c-25b8-46ed-b87f-abe90a1c58c7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a9892fba-0910-4841-83cf-a7b4c7b7b888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_706fe4f3-3bd6-4f41-9b01-73da0bbc69c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbf90d8c-25b8-46ed-b87f-abe90a1c58c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_706fe4f3-3bd6-4f41-9b01-73da0bbc69c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57a3c7f2-b8f3-4e99-b852-acb0bcc4cac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_da91e424-1abe-4382-8345-e0775d53852e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57a3c7f2-b8f3-4e99-b852-acb0bcc4cac1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_da91e424-1abe-4382-8345-e0775d53852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESTables" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f5b20dee-5939-43f5-a57b-047a21f80aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock_7f52a358-009b-4352-8bab-430a9d28a5f7" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f5b20dee-5939-43f5-a57b-047a21f80aa3" xlink:to="loc_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock_7f52a358-009b-4352-8bab-430a9d28a5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8a4f3c6a-0479-4898-ba5b-939cd5246787" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f5b20dee-5939-43f5-a57b-047a21f80aa3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8a4f3c6a-0479-4898-ba5b-939cd5246787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_540735c3-9f0c-4bc1-88a0-335d6dcb4ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b9780153-b183-4c39-a408-ad236b698ced" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_540735c3-9f0c-4bc1-88a0-335d6dcb4ce1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_b9780153-b183-4c39-a408-ad236b698ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0d1eb21e-a6c7-48b4-87d3-b5addc1d2dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5a17b98b-32a7-424e-9450-68052c3afcde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0d1eb21e-a6c7-48b4-87d3-b5addc1d2dd5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_5a17b98b-32a7-424e-9450-68052c3afcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_b38a0375-7b23-4ca0-89f2-fc43f20dfa8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0d1eb21e-a6c7-48b4-87d3-b5addc1d2dd5" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_b38a0375-7b23-4ca0-89f2-fc43f20dfa8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_700e8f3f-e643-42cb-81fb-2af981dd5201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_681ffda9-3fc8-4e79-a147-940873e0d45b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_700e8f3f-e643-42cb-81fb-2af981dd5201" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_681ffda9-3fc8-4e79-a147-940873e0d45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_9aee726a-e038-4d1f-8a85-8b12796abde6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_700e8f3f-e643-42cb-81fb-2af981dd5201" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_9aee726a-e038-4d1f-8a85-8b12796abde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cfe01d8a-ac29-4eac-94e1-05f546cbf71f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_700e8f3f-e643-42cb-81fb-2af981dd5201" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cfe01d8a-ac29-4eac-94e1-05f546cbf71f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXTables" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#INCOMETAXTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4a1f23a1-cc27-481d-8bca-6baaaeed3e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_21ff2e13-4720-4882-9ec6-e54009d7854d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a1f23a1-cc27-481d-8bca-6baaaeed3e5e" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_21ff2e13-4720-4882-9ec6-e54009d7854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b2b71efc-96dc-4a2f-b0e2-165152ce574c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a1f23a1-cc27-481d-8bca-6baaaeed3e5e" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b2b71efc-96dc-4a2f-b0e2-165152ce574c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ed6efb-aa43-46f6-bf47-131259f46efa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_79272619-5518-4b38-bf84-c6ad4b80162a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ed6efb-aa43-46f6-bf47-131259f46efa" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_79272619-5518-4b38-bf84-c6ad4b80162a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_98f87b28-1a74-4986-8a4d-e04f25125422" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_79272619-5518-4b38-bf84-c6ad4b80162a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_98f87b28-1a74-4986-8a4d-e04f25125422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_425d2371-7807-4c2b-8150-eaf7717740d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_98f87b28-1a74-4986-8a4d-e04f25125422" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_425d2371-7807-4c2b-8150-eaf7717740d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_629f7c0b-999c-4937-90d7-28e6895e8fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_425d2371-7807-4c2b-8150-eaf7717740d9" xlink:to="loc_us-gaap_SubsequentEventMember_629f7c0b-999c-4937-90d7-28e6895e8fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dd871ae6-6ce4-44a7-b817-9c9d330dd3df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_79272619-5518-4b38-bf84-c6ad4b80162a" xlink:to="loc_us-gaap_ClassOfStockLineItems_dd871ae6-6ce4-44a7-b817-9c9d330dd3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2142bdbe-fb6f-4d86-b8bc-c2aa3a9e10a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd871ae6-6ce4-44a7-b817-9c9d330dd3df" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2142bdbe-fb6f-4d86-b8bc-c2aa3a9e10a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_c1cb7e02-5e7b-466f-b8d6-4664984e7679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dd871ae6-6ce4-44a7-b817-9c9d330dd3df" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_c1cb7e02-5e7b-466f-b8d6-4664984e7679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LIQUIDITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e755d655-3d5d-4e5f-ac40-798cfbd26589" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e755d655-3d5d-4e5f-ac40-798cfbd26589" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_467cd538-8532-41b2-bcc8-72f27df58e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_467cd538-8532-41b2-bcc8-72f27df58e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b1ee222e-f7e4-4af0-8a34-b4f7b0227754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_467cd538-8532-41b2-bcc8-72f27df58e2d" xlink:to="loc_us-gaap_RelatedPartyDomain_b1ee222e-f7e4-4af0-8a34-b4f7b0227754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_3bf923e2-9ff0-4b35-ba19-2fe244e66a90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b1ee222e-f7e4-4af0-8a34-b4f7b0227754" xlink:to="loc_us-gaap_InvestorMember_3bf923e2-9ff0-4b35-ba19-2fe244e66a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e56d2d9f-54d0-451a-9561-b1fdc7be619b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e56d2d9f-54d0-451a-9561-b1fdc7be619b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_08014082-e8c6-43e1-b4b0-265fa0ca9c46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e56d2d9f-54d0-451a-9561-b1fdc7be619b" xlink:to="loc_us-gaap_EquityComponentDomain_08014082-e8c6-43e1-b4b0-265fa0ca9c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e1c53fed-ec84-4a8a-b7d5-6dd5f099ee79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_08014082-e8c6-43e1-b4b0-265fa0ca9c46" xlink:to="loc_us-gaap_CommonStockMember_e1c53fed-ec84-4a8a-b7d5-6dd5f099ee79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_956b11cd-e0f2-45e7-baef-18c49c0b5e15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_956b11cd-e0f2-45e7-baef-18c49c0b5e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad054b6c-9319-41c0-9be2-33c639006ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_956b11cd-e0f2-45e7-baef-18c49c0b5e15" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad054b6c-9319-41c0-9be2-33c639006ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_668329e2-1ea3-40ea-b032-8ced12b2d217" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad054b6c-9319-41c0-9be2-33c639006ae5" xlink:to="loc_ck0001824293_PublicOfferingMember_668329e2-1ea3-40ea-b032-8ced12b2d217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_52f93b8e-e675-4eda-9615-da120cc6aa92" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ad054b6c-9319-41c0-9be2-33c639006ae5" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_52f93b8e-e675-4eda-9615-da120cc6aa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_fd8b97f5-3a20-441c-bb22-5abcfbf491a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_fd8b97f5-3a20-441c-bb22-5abcfbf491a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_fd8b97f5-3a20-441c-bb22-5abcfbf491a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_a5e3a5d6-3175-4e91-a487-0231b977b117" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_a5e3a5d6-3175-4e91-a487-0231b977b117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_2bbc82fd-f082-45d8-a275-9b9ea504ebf9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_2bbc82fd-f082-45d8-a275-9b9ea504ebf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_93ddd4d6-e9ab-4c99-b718-f02bd1d0dda0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_93ddd4d6-e9ab-4c99-b718-f02bd1d0dda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_75a3bdc6-3d83-431d-bac4-7641f84b4bbb" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_75a3bdc6-3d83-431d-bac4-7641f84b4bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_5c465584-5bf1-47ce-ac93-a2ba17530f02" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_5c465584-5bf1-47ce-ac93-a2ba17530f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_e5ebcbe7-047d-40ff-8fee-ca9dcbb29c9e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_e5ebcbe7-047d-40ff-8fee-ca9dcbb29c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PriorWarrantsMember_39babd5b-df36-47d7-8650-42603e39028f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PriorWarrantsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_PriorWarrantsMember_39babd5b-df36-47d7-8650-42603e39028f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember_2d162b2d-feae-48ec-939c-e464649c7165" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesD1WarrantsMember_2d162b2d-feae-48ec-939c-e464649c7165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember_b0eda515-0ac6-4a14-9709-6f3c230b8eb6" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesD2WarrantsMember_b0eda515-0ac6-4a14-9709-6f3c230b8eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember_4f5ae273-1bd2-4ac9-817d-d4b1c6cdb330" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesDWarrantsMember_4f5ae273-1bd2-4ac9-817d-d4b1c6cdb330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember_db7b1324-3739-483a-9dd6-b48c1551c063" xlink:href="ck0001824293-20241231.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_June2024PAWarrantsMember_db7b1324-3739-483a-9dd6-b48c1551c063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesBCommonWarrantsMember_25c31739-0213-410a-b081-92b6d26c70e8" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesBCommonWarrantsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_SeriesBCommonWarrantsMember_25c31739-0213-410a-b081-92b6d26c70e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_October2024PAWarrantsMember_50d37763-5e31-4f62-91b6-34167da69bc6" xlink:href="ck0001824293-20241231.xsd#ck0001824293_October2024PAWarrantsMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7b1959d9-081e-4f6f-986e-51e253bd2861" xlink:to="loc_ck0001824293_October2024PAWarrantsMember_50d37763-5e31-4f62-91b6-34167da69bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cbc3c82c-2b5f-487c-b856-8d8dc02cfae6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_srt_RangeAxis_cbc3c82c-2b5f-487c-b856-8d8dc02cfae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d976d178-c613-43e5-80d1-3f1815fa6646" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cbc3c82c-2b5f-487c-b856-8d8dc02cfae6" xlink:to="loc_srt_RangeMember_d976d178-c613-43e5-80d1-3f1815fa6646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_55c13ae6-2288-40f5-9d31-fb5986a41d01" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d976d178-c613-43e5-80d1-3f1815fa6646" xlink:to="loc_srt_WeightedAverageMember_55c13ae6-2288-40f5-9d31-fb5986a41d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_ba625286-259f-4b96-83e8-268fd6f68f5b" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fba6a1a-58ee-429d-a171-4e5b210f863d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3fba6a1a-58ee-429d-a171-4e5b210f863d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d7be121-0219-4ac3-8a92-364a92adc6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0d7be121-0219-4ac3-8a92-364a92adc6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_5c1d4224-d93c-4572-b800-21bd6e058a9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_5c1d4224-d93c-4572-b800-21bd6e058a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4ed5763d-8de1-4d18-b8f4-56b554e2e1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_CommonStockSharesIssued_4ed5763d-8de1-4d18-b8f4-56b554e2e1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_62d6abff-3415-4104-9667-292855e1aeb5" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_62d6abff-3415-4104-9667-292855e1aeb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cbc6b4fd-ad11-4dba-9ec8-6f758b85adbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_cbc6b4fd-ad11-4dba-9ec8-6f758b85adbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_42345052-24b1-4993-b25a-b5eba3561caf" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_42345052-24b1-4993-b25a-b5eba3561caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_40a79879-1381-4018-ae72-3f32bd8d7174" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_40a79879-1381-4018-ae72-3f32bd8d7174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_a4b8e1b3-2dc1-48ed-86a7-2cd134a68cb3" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_a4b8e1b3-2dc1-48ed-86a7-2cd134a68cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fdc1ecec-b823-4288-8595-92ff11937fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_fdc1ecec-b823-4288-8595-92ff11937fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_651d98ee-e20c-4033-a7dd-562b2ed7524a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_651d98ee-e20c-4033-a7dd-562b2ed7524a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6b1d59ea-5614-4c72-9328-dce5f072411e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_6b1d59ea-5614-4c72-9328-dce5f072411e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_17f1434a-9a5e-4fc8-b9cd-442f9558ae34" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_17f1434a-9a5e-4fc8-b9cd-442f9558ae34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e34a5d56-7fa3-4fc2-9e84-45d7e2e8d7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_e34a5d56-7fa3-4fc2-9e84-45d7e2e8d7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_de6a95e9-0286-4030-b8fe-27b5305b47ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_de6a95e9-0286-4030-b8fe-27b5305b47ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_9fdd7a0f-0e1b-4fd3-80eb-1beccf3feae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_9fdd7a0f-0e1b-4fd3-80eb-1beccf3feae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_2786898f-cd8e-4180-9cbe-21cb4d02904e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_2786898f-cd8e-4180-9cbe-21cb4d02904e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_d750fff5-cdb7-4fd2-a129-5e19fd8951b0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_d750fff5-cdb7-4fd2-a129-5e19fd8951b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_96194dab-d597-4222-a1ef-fffae5dfc53b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_96194dab-d597-4222-a1ef-fffae5dfc53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_94260dde-76f8-4c1b-912c-a4368de6f266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_94260dde-76f8-4c1b-912c-a4368de6f266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_76e6c9bd-46bd-4fcd-ac66-78f286b30b6c" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_76e6c9bd-46bd-4fcd-ac66-78f286b30b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_33286b95-81e1-4d42-9859-9dc2f07df715" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_33286b95-81e1-4d42-9859-9dc2f07df715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_ba7628fb-9e3c-487f-9e03-e9e2bb992b56" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_ba7628fb-9e3c-487f-9e03-e9e2bb992b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_a072f5b8-4569-4095-9877-76283c52ed76" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_a072f5b8-4569-4095-9877-76283c52ed76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_81421229-23f1-4fc9-a5e0-57a8e8ac6f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_81421229-23f1-4fc9-a5e0-57a8e8ac6f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_2d7b4dea-9012-492a-9634-8312f11d10d9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_2d7b4dea-9012-492a-9634-8312f11d10d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d4e76d3e-3d26-480b-9864-ef4ade4aad31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6b985177-d05f-47c7-ae2c-13f1a1fcc2e3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_d4e76d3e-3d26-480b-9864-ef4ade4aad31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a1b57a3b-3424-4d78-aa8a-27793e2f0a83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount_df165f06-ac54-4777-b196-d1ac96d7865e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1b57a3b-3424-4d78-aa8a-27793e2f0a83" xlink:to="loc_us-gaap_CashFDICInsuredAmount_df165f06-ac54-4777-b196-d1ac96d7865e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_9d930bcc-0ac2-44ac-ab3c-4cf0dcd47c88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a1b57a3b-3424-4d78-aa8a-27793e2f0a83" xlink:to="loc_us-gaap_CashUninsuredAmount_9d930bcc-0ac2-44ac-ab3c-4cf0dcd47c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2d3fc7d7-47b0-48ee-9352-15dc76ad5a09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_63462edc-2ca6-4d2c-9b75-ac687884799b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d3fc7d7-47b0-48ee-9352-15dc76ad5a09" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_63462edc-2ca6-4d2c-9b75-ac687884799b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c3d8c4f-6317-4923-b4a0-f9e9d04f88ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_63462edc-2ca6-4d2c-9b75-ac687884799b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c3d8c4f-6317-4923-b4a0-f9e9d04f88ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2457e3dd-8263-4222-8d62-a41ba2b28b29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6c3d8c4f-6317-4923-b4a0-f9e9d04f88ef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2457e3dd-8263-4222-8d62-a41ba2b28b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_92c6d919-601a-4ffa-a9bc-dbd8ce186717" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2457e3dd-8263-4222-8d62-a41ba2b28b29" xlink:to="loc_us-gaap_ComputerEquipmentMember_92c6d919-601a-4ffa-a9bc-dbd8ce186717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PeripheralEquipmentMember_1a048954-cfb0-41d9-abda-d6dda9065dcd" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PeripheralEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2457e3dd-8263-4222-8d62-a41ba2b28b29" xlink:to="loc_ck0001824293_PeripheralEquipmentMember_1a048954-cfb0-41d9-abda-d6dda9065dcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b8cff0e-508e-45fb-b198-eda11f742930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_63462edc-2ca6-4d2c-9b75-ac687884799b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b8cff0e-508e-45fb-b198-eda11f742930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3568001f-a409-482c-8f0d-4ef17ff46493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1b8cff0e-508e-45fb-b198-eda11f742930" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_3568001f-a409-482c-8f0d-4ef17ff46493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aafdebcb-080d-4348-83c3-174bb59d788b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_545adace-bf93-4a8d-886b-05f181863c61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aafdebcb-080d-4348-83c3-174bb59d788b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_545adace-bf93-4a8d-886b-05f181863c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5433652-08fd-412d-b956-ae061af114c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_545adace-bf93-4a8d-886b-05f181863c61" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5433652-08fd-412d-b956-ae061af114c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ff905b8-84d3-4520-9c49-72698d56477b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5433652-08fd-412d-b956-ae061af114c9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ff905b8-84d3-4520-9c49-72698d56477b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_59c56e49-82a8-4aa5-aa6c-e90c3cfd0164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ff905b8-84d3-4520-9c49-72698d56477b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_59c56e49-82a8-4aa5-aa6c-e90c3cfd0164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_16418cce-9bcc-4411-9d71-8f0251203d10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9ff905b8-84d3-4520-9c49-72698d56477b" xlink:to="loc_us-gaap_WarrantMember_16418cce-9bcc-4411-9d71-8f0251203d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_55d4635d-d2ff-4994-8a68-33db0d70b8ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_545adace-bf93-4a8d-886b-05f181863c61" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_55d4635d-d2ff-4994-8a68-33db0d70b8ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6b11f813-521a-4bc9-9529-20c05e30949c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_55d4635d-d2ff-4994-8a68-33db0d70b8ca" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6b11f813-521a-4bc9-9529-20c05e30949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#MERGERWITHVALLONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_55cf05d6-be30-45cb-a390-02559acba066" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0e6e3169-17cd-4981-97b0-284805b7da62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_55cf05d6-be30-45cb-a390-02559acba066" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0e6e3169-17cd-4981-97b0-284805b7da62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_dea6e6ff-4b10-452c-9087-5b410ea605c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0e6e3169-17cd-4981-97b0-284805b7da62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_dea6e6ff-4b10-452c-9087-5b410ea605c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4b6a7b86-c200-4ed8-a229-ed9a7128bceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dea6e6ff-4b10-452c-9087-5b410ea605c0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4b6a7b86-c200-4ed8-a229-ed9a7128bceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_ed1e55ea-59f8-4d90-be7a-67bb04dd2e55" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4b6a7b86-c200-4ed8-a229-ed9a7128bceb" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_ed1e55ea-59f8-4d90-be7a-67bb04dd2e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d9b5e821-df57-4179-8f3e-eabdd77f17ba" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0e6e3169-17cd-4981-97b0-284805b7da62" xlink:to="loc_dei_LegalEntityAxis_d9b5e821-df57-4179-8f3e-eabdd77f17ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1364b7da-6cea-41fc-9caf-e4436677d16b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d9b5e821-df57-4179-8f3e-eabdd77f17ba" xlink:to="loc_dei_EntityDomain_1364b7da-6cea-41fc-9caf-e4436677d16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsMember_c1ca93e4-32af-4a13-a747-5ef1b0303263" xlink:href="ck0001824293-20241231.xsd#ck0001824293_GRIOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1364b7da-6cea-41fc-9caf-e4436677d16b" xlink:to="loc_ck0001824293_GRIOperationsMember_c1ca93e4-32af-4a13-a747-5ef1b0303263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0e6e3169-17cd-4981-97b0-284805b7da62" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockExchangeRatio_bb97cff1-c7da-4528-9cac-c7e7e7ba66f0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CommonStockExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_ck0001824293_CommonStockExchangeRatio_bb97cff1-c7da-4528-9cac-c7e7e7ba66f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e50efa50-a5f9-43c4-897b-78805c0b3cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e50efa50-a5f9-43c4-897b-78805c0b3cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a3ea75dc-eae3-442b-8c36-4c277de9bd21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a3ea75dc-eae3-442b-8c36-4c277de9bd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage_109230bc-e885-4591-9118-acea300566f9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_ck0001824293_CommonStockOwnershipPercentage_109230bc-e885-4591-9118-acea300566f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_4c90f0c9-5472-4674-81f5-e072691af72f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_ed9526a7-0ac6-41d2-9567-8f61e68412f3" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_4c90f0c9-5472-4674-81f5-e072691af72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1186c33d-ffcc-4858-abab-8eddffe7235c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ddd26183-b4d0-44e2-8a56-5794a2e55578" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_1186c33d-ffcc-4858-abab-8eddffe7235c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ddd26183-b4d0-44e2-8a56-5794a2e55578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_3ef461ae-8fdf-4fa7-89bb-44497164479c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ddd26183-b4d0-44e2-8a56-5794a2e55578" xlink:to="loc_dei_LegalEntityAxis_3ef461ae-8fdf-4fa7-89bb-44497164479c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5c77e232-82f1-4b00-acb2-bfa7e5575588" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_3ef461ae-8fdf-4fa7-89bb-44497164479c" xlink:to="loc_dei_EntityDomain_5c77e232-82f1-4b00-acb2-bfa7e5575588" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsMember_74a077ba-4390-4362-bf1c-87fb12261972" xlink:href="ck0001824293-20241231.xsd#ck0001824293_GRIOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5c77e232-82f1-4b00-acb2-bfa7e5575588" xlink:to="loc_ck0001824293_GRIOperationsMember_74a077ba-4390-4362-bf1c-87fb12261972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ddd26183-b4d0-44e2-8a56-5794a2e55578" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c94e851f-3dbd-4913-8f80-2dd793294e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_c94e851f-3dbd-4913-8f80-2dd793294e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2436dc12-aadc-42da-87c6-ff5949c98e30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_2436dc12-aadc-42da-87c6-ff5949c98e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_b1039285-914f-4bf5-8391-3af7ae842302" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_b1039285-914f-4bf5-8391-3af7ae842302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b367ee1-6137-4f11-bcb2-caa5029e1fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7b367ee1-6137-4f11-bcb2-caa5029e1fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_5b78d1cf-7bba-4d1d-b7b7-5e9be4da904f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_5b78d1cf-7bba-4d1d-b7b7-5e9be4da904f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_c68f7eac-76eb-4112-85fb-d8468857a0bf" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f4fea9e9-682f-4637-b31c-58337a87369e" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_c68f7eac-76eb-4112-85fb-d8468857a0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_25a130fc-0791-443e-a2cf-008d69514f25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b82066a7-9af0-4816-bf71-70f07f725e08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_25a130fc-0791-443e-a2cf-008d69514f25" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b82066a7-9af0-4816-bf71-70f07f725e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29d9b44c-09fb-4cbf-a208-f3b0a37ea68c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b82066a7-9af0-4816-bf71-70f07f725e08" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29d9b44c-09fb-4cbf-a208-f3b0a37ea68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cc09061-af08-4687-bd88-bf9b13e5fcaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_29d9b44c-09fb-4cbf-a208-f3b0a37ea68c" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cc09061-af08-4687-bd88-bf9b13e5fcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_56f64f38-657f-4987-b496-67b0f1507643" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cc09061-af08-4687-bd88-bf9b13e5fcaa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_56f64f38-657f-4987-b496-67b0f1507643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2a20a591-90f7-4a1b-b94e-402c7be0c17e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cc09061-af08-4687-bd88-bf9b13e5fcaa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2a20a591-90f7-4a1b-b94e-402c7be0c17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_43ab8589-a483-4572-b6fb-ac4985a430e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7cc09061-af08-4687-bd88-bf9b13e5fcaa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_43ab8589-a483-4572-b6fb-ac4985a430e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e97bdac0-59c9-471a-abed-605140c4dc69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b82066a7-9af0-4816-bf71-70f07f725e08" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e97bdac0-59c9-471a-abed-605140c4dc69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cadb54f2-cdf9-4dce-b817-963ec7772061" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e97bdac0-59c9-471a-abed-605140c4dc69" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cadb54f2-cdf9-4dce-b817-963ec7772061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityFairValueDisclosure_1985f087-2035-4ffe-b5ee-40f1ea3ff0cb" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_cadb54f2-cdf9-4dce-b817-963ec7772061" xlink:to="loc_ck0001824293_WarrantLiabilityFairValueDisclosure_1985f087-2035-4ffe-b5ee-40f1ea3ff0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7b5f3758-8dc7-4811-b063-d80eca977374" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_60cc3e42-e067-44a0-bfb9-c3cabce8531b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7b5f3758-8dc7-4811-b063-d80eca977374" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_60cc3e42-e067-44a0-bfb9-c3cabce8531b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_40743f7c-8ed0-4835-86cd-79f339fdcc78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_60cc3e42-e067-44a0-bfb9-c3cabce8531b" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_40743f7c-8ed0-4835-86cd-79f339fdcc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8199a083-58ba-4428-a183-29d7f1caa9ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_40743f7c-8ed0-4835-86cd-79f339fdcc78" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8199a083-58ba-4428-a183-29d7f1caa9ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember_4cd3461d-a9b1-4af3-bfe3-81589dc7b004" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8199a083-58ba-4428-a183-29d7f1caa9ab" xlink:to="loc_ck0001824293_WarrantLiabilityMember_4cd3461d-a9b1-4af3-bfe3-81589dc7b004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e4a3176e-5d9e-40d4-a305-19aaaf503ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_60cc3e42-e067-44a0-bfb9-c3cabce8531b" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e4a3176e-5d9e-40d4-a305-19aaaf503ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c3bbd8d3-4a24-4446-bf70-1d1688c3818f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e4a3176e-5d9e-40d4-a305-19aaaf503ec9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c3bbd8d3-4a24-4446-bf70-1d1688c3818f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7e094f57-64eb-443d-ba9c-9208bcc9a97d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c3bbd8d3-4a24-4446-bf70-1d1688c3818f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7e094f57-64eb-443d-ba9c-9208bcc9a97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_26c65138-a73e-495c-ae9a-1fdf6160dc78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c3bbd8d3-4a24-4446-bf70-1d1688c3818f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_26c65138-a73e-495c-ae9a-1fdf6160dc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_293d18d7-0b91-4ee4-80e2-be7b6fdab4d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c3bbd8d3-4a24-4446-bf70-1d1688c3818f" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_293d18d7-0b91-4ee4-80e2-be7b6fdab4d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6d4914b5-73fc-474f-8765-7435a655396b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3c87b016-f841-41ff-881f-9a2d9d2247a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6d4914b5-73fc-474f-8765-7435a655396b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3c87b016-f841-41ff-881f-9a2d9d2247a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_76e2ee2d-867e-40be-8e82-109a51ff8121" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3c87b016-f841-41ff-881f-9a2d9d2247a4" xlink:to="loc_srt_RangeAxis_76e2ee2d-867e-40be-8e82-109a51ff8121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be47446e-4ec9-42f6-8c07-40eeb4a9c8fd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_76e2ee2d-867e-40be-8e82-109a51ff8121" xlink:to="loc_srt_RangeMember_be47446e-4ec9-42f6-8c07-40eeb4a9c8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_56816149-d8cf-4665-b4a2-1aa5c76fb9d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_be47446e-4ec9-42f6-8c07-40eeb4a9c8fd" xlink:to="loc_srt_WeightedAverageMember_56816149-d8cf-4665-b4a2-1aa5c76fb9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e4802ee2-7ba8-451f-9b7f-68c343308da3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3c87b016-f841-41ff-881f-9a2d9d2247a4" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e4802ee2-7ba8-451f-9b7f-68c343308da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e4802ee2-7ba8-451f-9b7f-68c343308da3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_eede9158-7d66-49bc-ac13-79295168a79a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_eede9158-7d66-49bc-ac13-79295168a79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_f7dd7fcc-1406-4f1c-8a21-f42a716e9c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_f7dd7fcc-1406-4f1c-8a21-f42a716e9c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_801bffc8-1896-4185-b150-adfbcba1a740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_801bffc8-1896-4185-b150-adfbcba1a740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_fac63426-0fd9-4130-9d2b-3fbdc1e35825" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaaf855c-7e46-4d2d-ab09-d65fae5bf566" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_fac63426-0fd9-4130-9d2b-3fbdc1e35825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9e380ad5-e8b2-4514-849f-c825638f54b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_3c87b016-f841-41ff-881f-9a2d9d2247a4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9e380ad5-e8b2-4514-849f-c825638f54b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_c0d268b1-c390-4456-92d3-4311e7a39060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_9e380ad5-e8b2-4514-849f-c825638f54b5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_c0d268b1-c390-4456-92d3-4311e7a39060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4dff8812-643d-4da8-a457-eeb1a0166991" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2bc372c-afb7-4cba-b34d-d38e8ad7ac23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4dff8812-643d-4da8-a457-eeb1a0166991" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2bc372c-afb7-4cba-b34d-d38e8ad7ac23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_572cc00b-6f4c-4fa9-8e30-39802653a956" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2bc372c-afb7-4cba-b34d-d38e8ad7ac23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_572cc00b-6f4c-4fa9-8e30-39802653a956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_004d9cec-f3b1-4209-9b09-928073e91ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_572cc00b-6f4c-4fa9-8e30-39802653a956" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_004d9cec-f3b1-4209-9b09-928073e91ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_60cbf7c6-8648-45a5-9f1d-c098bc1cf42b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_004d9cec-f3b1-4209-9b09-928073e91ee8" xlink:to="loc_us-gaap_ComputerEquipmentMember_60cbf7c6-8648-45a5-9f1d-c098bc1cf42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c7d0189e-b1b6-4d39-ba62-859997c4682a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_004d9cec-f3b1-4209-9b09-928073e91ee8" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c7d0189e-b1b6-4d39-ba62-859997c4682a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b83598e2-a031-44ff-841f-7937256ade25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e2bc372c-afb7-4cba-b34d-d38e8ad7ac23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b83598e2-a031-44ff-841f-7937256ade25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_298bb488-884f-4711-ab52-1a9d0f05ba8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b83598e2-a031-44ff-841f-7937256ade25" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_298bb488-884f-4711-ab52-1a9d0f05ba8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2d2b5bbf-d9dd-4080-a003-987fc60c8cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b83598e2-a031-44ff-841f-7937256ade25" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2d2b5bbf-d9dd-4080-a003-987fc60c8cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c0360152-e16b-4aea-a38a-71dfcc0d4da9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b83598e2-a031-44ff-841f-7937256ade25" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c0360152-e16b-4aea-a38a-71dfcc0d4da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#PROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3b691c7-2bd9-47db-9de5-dde62a8d06ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_48dd7593-5b73-4226-8433-4fa01a2941eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a3b691c7-2bd9-47db-9de5-dde62a8d06ad" xlink:to="loc_us-gaap_Depreciation_48dd7593-5b73-4226-8433-4fa01a2941eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f0cedb3d-1cef-4a8b-8437-9bc5fd43d532" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c7b7d1f8-b61e-4479-a84d-3e1c09453196" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f0cedb3d-1cef-4a8b-8437-9bc5fd43d532" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c7b7d1f8-b61e-4479-a84d-3e1c09453196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_b862e24e-aa92-42ba-95ae-08da83c4c5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f0cedb3d-1cef-4a8b-8437-9bc5fd43d532" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_b862e24e-aa92-42ba-95ae-08da83c4c5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_965cb8df-bede-457a-ac2d-6f481ca34613" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_b862e24e-aa92-42ba-95ae-08da83c4c5a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_965cb8df-bede-457a-ac2d-6f481ca34613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1229d34f-dd3f-4854-85ee-a07769b07192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_b862e24e-aa92-42ba-95ae-08da83c4c5a1" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1229d34f-dd3f-4854-85ee-a07769b07192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_e7f9bc9d-5cbc-4cff-ae9c-dbcd652fbce9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_b862e24e-aa92-42ba-95ae-08da83c4c5a1" xlink:to="loc_us-gaap_OperatingLeaseLiability_e7f9bc9d-5cbc-4cff-ae9c-dbcd652fbce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LEASESScheduleofFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1f5ebbd6-d32a-446f-b6c7-a08f15b63ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85c526e0-93f1-4ea5-b704-d0314c62f544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f5ebbd6-d32a-446f-b6c7-a08f15b63ac4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_85c526e0-93f1-4ea5-b704-d0314c62f544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7465b69b-c1f5-46ce-a890-0265585c30bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f5ebbd6-d32a-446f-b6c7-a08f15b63ac4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7465b69b-c1f5-46ce-a890-0265585c30bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dbddd66a-6d87-4bf4-b0a8-9f75083d0e38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f5ebbd6-d32a-446f-b6c7-a08f15b63ac4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dbddd66a-6d87-4bf4-b0a8-9f75083d0e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c3903e0-529b-4653-8e4f-65d4a3502e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f5ebbd6-d32a-446f-b6c7-a08f15b63ac4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2c3903e0-529b-4653-8e4f-65d4a3502e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8de89e10-98b2-4e5b-b702-63208871b542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f5ebbd6-d32a-446f-b6c7-a08f15b63ac4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8de89e10-98b2-4e5b-b702-63208871b542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ed4cd056-0bc8-46c9-97d1-c577a80e37d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1f5ebbd6-d32a-446f-b6c7-a08f15b63ac4" xlink:to="loc_us-gaap_OperatingLeaseLiability_ed4cd056-0bc8-46c9-97d1-c577a80e37d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LEASESNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#LEASESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LEASESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5d993504-e7cf-432b-9915-2f2d6274e3a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9047020b-837d-43fc-bf07-30478f340215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d993504-e7cf-432b-9915-2f2d6274e3a6" xlink:to="loc_us-gaap_OperatingLeaseCost_9047020b-837d-43fc-bf07-30478f340215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_cac1eaee-65ac-4bec-baf9-6e82b33ed555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5d993504-e7cf-432b-9915-2f2d6274e3a6" xlink:to="loc_us-gaap_OperatingLeasePayments_cac1eaee-65ac-4bec-baf9-6e82b33ed555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_68711643-003a-4a81-89ef-77c8c2cacb26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_a09e1246-da0f-4ef3-b347-d62083bcdd04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_68711643-003a-4a81-89ef-77c8c2cacb26" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_a09e1246-da0f-4ef3-b347-d62083bcdd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_e631aeb4-b1ee-44e0-ab10-8730f27a24d7" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_a09e1246-da0f-4ef3-b347-d62083bcdd04" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_e631aeb4-b1ee-44e0-ab10-8730f27a24d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_434626fd-e874-4635-8cdd-47454c41d2e1" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_a09e1246-da0f-4ef3-b347-d62083bcdd04" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_434626fd-e874-4635-8cdd-47454c41d2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_13f7bb91-2805-4379-a069-8d55df0ddb53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_a09e1246-da0f-4ef3-b347-d62083bcdd04" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_13f7bb91-2805-4379-a069-8d55df0ddb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_81bc1243-5adc-472c-b3d5-9fe6381a266a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_a09e1246-da0f-4ef3-b347-d62083bcdd04" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_81bc1243-5adc-472c-b3d5-9fe6381a266a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#PROMISSORYNOTESBridgeFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6b1c6460-e109-44c3-8fb9-c805e997246c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6b1c6460-e109-44c3-8fb9-c805e997246c" xlink:to="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b3cc9cbe-3029-4c55-b1a3-f2b29695c045" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b3cc9cbe-3029-4c55-b1a3-f2b29695c045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_23a39684-d895-4f8f-9a86-cbde7ff8cdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_b3cc9cbe-3029-4c55-b1a3-f2b29695c045" xlink:to="loc_us-gaap_RelatedPartyDomain_23a39684-d895-4f8f-9a86-cbde7ff8cdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_1af86d6d-91c2-4922-be41-c849b3068a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_23a39684-d895-4f8f-9a86-cbde7ff8cdcd" xlink:to="loc_us-gaap_InvestorMember_1af86d6d-91c2-4922-be41-c849b3068a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_a612b41c-6bcf-47aa-ae4f-9bc3ba08083f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:to="loc_us-gaap_DebtInstrumentAxis_a612b41c-6bcf-47aa-ae4f-9bc3ba08083f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_69c8264a-bd22-477d-8e2e-7ccb1d71f230" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_a612b41c-6bcf-47aa-ae4f-9bc3ba08083f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_69c8264a-bd22-477d-8e2e-7ccb1d71f230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_030c9716-6b77-4510-86ad-8b152139b6cd" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_69c8264a-bd22-477d-8e2e-7ccb1d71f230" xlink:to="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_030c9716-6b77-4510-86ad-8b152139b6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_e9e86bb5-2412-4abb-ac59-6a6c8e4a4569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_e9e86bb5-2412-4abb-ac59-6a6c8e4a4569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_2f544de2-40da-4741-8a6b-a005d5400e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_e9e86bb5-2412-4abb-ac59-6a6c8e4a4569" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_2f544de2-40da-4741-8a6b-a005d5400e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_95043c4a-b633-40e9-8d50-1c3faf40d3c7" xlink:href="ck0001824293-20241231.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2f544de2-40da-4741-8a6b-a005d5400e9b" xlink:to="loc_ck0001824293_BridgeWarrantsMember_95043c4a-b633-40e9-8d50-1c3faf40d3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_9b8225c8-22ad-4725-a1dd-39c6b1fc3220" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_2f544de2-40da-4741-8a6b-a005d5400e9b" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_9b8225c8-22ad-4725-a1dd-39c6b1fc3220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_614d32aa-72b7-4b9e-805e-054b9760a6f5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_b24710c3-cb62-45cd-aadc-40dcfab30e49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_b24710c3-cb62-45cd-aadc-40dcfab30e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_4b486c6b-45ad-4093-b68f-2cf3f99235e7" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_4b486c6b-45ad-4093-b68f-2cf3f99235e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings_162ccedb-a419-49ee-a88c-64815b359480" xlink:href="ck0001824293-20241231.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_ck0001824293_DebtInstrumentNumberOfClosings_162ccedb-a419-49ee-a88c-64815b359480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_087ac18d-12df-4a85-ac0e-dbe72d595a14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_087ac18d-12df-4a85-ac0e-dbe72d595a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45a8720e-5bd8-4ec6-825c-cbb21e89bafe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_45a8720e-5bd8-4ec6-825c-cbb21e89bafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7f49c7f3-ef1f-4480-959b-41eb78f8fc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7f49c7f3-ef1f-4480-959b-41eb78f8fc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_9fb9ff8f-fb32-4a5c-9b96-c07419758cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_9fb9ff8f-fb32-4a5c-9b96-c07419758cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_9ee47f27-e61a-4b38-8f7c-198a09ea07fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_9ee47f27-e61a-4b38-8f7c-198a09ea07fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_e088f1a9-82d5-4049-ad26-70b5d8205b25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_e088f1a9-82d5-4049-ad26-70b5d8205b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5319dc7d-a11e-4f0d-b5f6-2de9462105bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_5319dc7d-a11e-4f0d-b5f6-2de9462105bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_85b2fabb-5474-4327-9f15-9366b9052f52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e6e8704a-9a3e-4831-9d60-4179d7015c4c" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_85b2fabb-5474-4327-9f15-9366b9052f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_25df9bbe-cffc-40c6-a812-d6ffb7ade953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_25df9bbe-cffc-40c6-a812-d6ffb7ade953" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c374fe92-5ddd-4be6-bb87-04a4a93a0f63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c374fe92-5ddd-4be6-bb87-04a4a93a0f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7ab4581e-0a6c-43eb-8dd6-4b7d2b1bb435" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c374fe92-5ddd-4be6-bb87-04a4a93a0f63" xlink:to="loc_us-gaap_RelatedPartyDomain_7ab4581e-0a6c-43eb-8dd6-4b7d2b1bb435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_627ada3d-9885-479f-852b-20f5d633ae94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7ab4581e-0a6c-43eb-8dd6-4b7d2b1bb435" xlink:to="loc_us-gaap_InvestorMember_627ada3d-9885-479f-852b-20f5d633ae94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_53707d90-5ed7-44c9-87b9-b2f9f022f4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_53707d90-5ed7-44c9-87b9-b2f9f022f4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9c5cf851-49bd-4a25-9d95-b8eb0a1d04a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_53707d90-5ed7-44c9-87b9-b2f9f022f4ac" xlink:to="loc_us-gaap_EquityComponentDomain_9c5cf851-49bd-4a25-9d95-b8eb0a1d04a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_7f3c6d73-4367-4ca8-98c1-e0a8d13e9c50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9c5cf851-49bd-4a25-9d95-b8eb0a1d04a1" xlink:to="loc_us-gaap_CommonStockMember_7f3c6d73-4367-4ca8-98c1-e0a8d13e9c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_06f0f71a-579b-431b-b008-4b01c85efcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9c5cf851-49bd-4a25-9d95-b8eb0a1d04a1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_06f0f71a-579b-431b-b008-4b01c85efcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_3ed768b5-e3b2-4602-b728-a4f28f7d4bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_3ed768b5-e3b2-4602-b728-a4f28f7d4bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58bc84c3-d1ae-4340-899f-03f588c41525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_3ed768b5-e3b2-4602-b728-a4f28f7d4bd5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58bc84c3-d1ae-4340-899f-03f588c41525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_b469a2b2-3b12-47ca-b70e-fb1640a2627d" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58bc84c3-d1ae-4340-899f-03f588c41525" xlink:to="loc_ck0001824293_PublicOfferingMember_b469a2b2-3b12-47ca-b70e-fb1640a2627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_c987e29f-79c2-4344-ae27-82ca436645d4" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_58bc84c3-d1ae-4340-899f-03f588c41525" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_c987e29f-79c2-4344-ae27-82ca436645d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_34dacc10-d034-4f12-a784-f324454264d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_34dacc10-d034-4f12-a784-f324454264d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_34dacc10-d034-4f12-a784-f324454264d4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_7cfeb793-39ec-4688-bee0-7046b909cdcf" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_7cfeb793-39ec-4688-bee0-7046b909cdcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_be746661-58d6-4659-af4a-345a34191367" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_be746661-58d6-4659-af4a-345a34191367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_f6e3c5d6-60f0-4b0e-8a4b-a517c592eb10" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_f6e3c5d6-60f0-4b0e-8a4b-a517c592eb10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_bdd25a3b-d897-4855-a255-06fd54fbcfa9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_bdd25a3b-d897-4855-a255-06fd54fbcfa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_03fb955e-4ec1-4a06-8732-6915671575f9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_03fb955e-4ec1-4a06-8732-6915671575f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_3ca78e3d-a5ca-42a9-a0c3-d5a537dc5126" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_3ca78e3d-a5ca-42a9-a0c3-d5a537dc5126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_cf974f56-d4fb-4d44-ae8b-33229b579f77" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_cf974f56-d4fb-4d44-ae8b-33229b579f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_June2024PAWarrantsMember_c08cdf1d-aae2-43c1-8a19-6500675ab3ee" xlink:href="ck0001824293-20241231.xsd#ck0001824293_June2024PAWarrantsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_June2024PAWarrantsMember_c08cdf1d-aae2-43c1-8a19-6500675ab3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PriorWarrantsMember_982abc2e-26f6-42e5-ad15-4552733598ad" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PriorWarrantsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_PriorWarrantsMember_982abc2e-26f6-42e5-ad15-4552733598ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1WarrantsMember_3fbb2b43-7172-4900-aeba-b270dde6f998" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD1WarrantsMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesD1WarrantsMember_3fbb2b43-7172-4900-aeba-b270dde6f998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD2WarrantsMember_617576fe-f33c-44ab-b071-efff88c7a456" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD2WarrantsMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesD2WarrantsMember_617576fe-f33c-44ab-b071-efff88c7a456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesDWarrantsMember_e9ce450e-4736-47c0-be4d-4c4ac9938e68" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesDWarrantsMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_a36c4152-b398-4261-8d9e-8785a48001a5" xlink:to="loc_ck0001824293_SeriesDWarrantsMember_e9ce450e-4736-47c0-be4d-4c4ac9938e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17ff2281-2077-40a4-97fe-04406e0320e7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_srt_RangeAxis_17ff2281-2077-40a4-97fe-04406e0320e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ea58fd3d-d165-42e1-ad92-3cb15c10c644" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_17ff2281-2077-40a4-97fe-04406e0320e7" xlink:to="loc_srt_RangeMember_ea58fd3d-d165-42e1-ad92-3cb15c10c644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_bf429d62-7807-4043-b49f-08d74049644d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ea58fd3d-d165-42e1-ad92-3cb15c10c644" xlink:to="loc_srt_WeightedAverageMember_bf429d62-7807-4043-b49f-08d74049644d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09ec963b-2dc3-4c87-8331-b1f4d478c9ca" xlink:to="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_788cba92-e0a6-4ff8-850d-8117c0a8bef9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_788cba92-e0a6-4ff8-850d-8117c0a8bef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5a827193-1e35-4b37-9be1-0ad54cfd103c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5a827193-1e35-4b37-9be1-0ad54cfd103c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_1b605878-f408-4a72-a267-4770fa7b5985" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_1b605878-f408-4a72-a267-4770fa7b5985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_f1d74c25-9893-45c9-a4b8-786e2edb5645" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_f1d74c25-9893-45c9-a4b8-786e2edb5645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_11cfa2ed-cdb3-42a1-8826-363a43e78193" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_11cfa2ed-cdb3-42a1-8826-363a43e78193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5bd18047-fed9-4a16-b8f4-f4a6cdeed3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5bd18047-fed9-4a16-b8f4-f4a6cdeed3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f53866bb-99e1-40e1-ba62-0538dfe00a32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f53866bb-99e1-40e1-ba62-0538dfe00a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6b248d1e-f6ed-410a-a7a7-317177fa9d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6b248d1e-f6ed-410a-a7a7-317177fa9d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_24e55be2-556a-43fa-a300-bfb1fc524d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_24e55be2-556a-43fa-a300-bfb1fc524d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_6c89cf14-6dfa-4a5d-ac44-5768024b613f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_6c89cf14-6dfa-4a5d-ac44-5768024b613f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_9be42273-58fe-45b7-a2bc-a4e49f7fe49d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_9be42273-58fe-45b7-a2bc-a4e49f7fe49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41c15a5e-bf6e-467f-b84a-d967a7bad2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_41c15a5e-bf6e-467f-b84a-d967a7bad2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_41c86509-4cd5-4067-8933-7635bca5c059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_41c86509-4cd5-4067-8933-7635bca5c059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e8c5b1c3-6b0d-460f-b765-5748ed0de9b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_e8c5b1c3-6b0d-460f-b765-5748ed0de9b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_8233730c-4529-4251-b1d5-967ef1376271" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_8233730c-4529-4251-b1d5-967ef1376271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_8bdd7beb-2754-440c-863d-94ffaee57bf2" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_8bdd7beb-2754-440c-863d-94ffaee57bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_cdba2d01-c120-49b1-b3a3-35c356e966e0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds_cdba2d01-c120-49b1-b3a3-35c356e966e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_46cda79d-1859-4559-bddd-7e063e84e120" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds_46cda79d-1859-4559-bddd-7e063e84e120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_baf1cdbc-6680-407d-beab-6bb0512e54cb" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockReimbursementOfAccountableExpenses"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses_baf1cdbc-6680-407d-beab-6bb0512e54cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_bfb1b33f-1afd-477b-a1a8-2b1dc090e456" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses_bfb1b33f-1afd-477b-a1a8-2b1dc090e456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_cbfdb703-b03e-4e70-ac1e-2aeb5ff15538" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense_cbfdb703-b03e-4e70-ac1e-2aeb5ff15538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_609248ae-0ef9-4bcb-9048-0000d38b769e" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ClassOfWarrantOrRightOfferingCost"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_ck0001824293_ClassOfWarrantOrRightOfferingCost_609248ae-0ef9-4bcb-9048-0000d38b769e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_29010216-7a83-4100-a1e2-ce2201265f19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0fa5b94d-f1a0-489d-b75e-8aa853c6ad1b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_29010216-7a83-4100-a1e2-ce2201265f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b292f1c5-3ad0-44f6-bb26-c6ac45c1ec95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b292f1c5-3ad0-44f6-bb26-c6ac45c1ec95" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_baee52d5-70f4-474c-a9f0-d9281558678e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:to="loc_srt_RangeAxis_baee52d5-70f4-474c-a9f0-d9281558678e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_516994d7-5651-4efc-9114-be05595da765" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_baee52d5-70f4-474c-a9f0-d9281558678e" xlink:to="loc_srt_RangeMember_516994d7-5651-4efc-9114-be05595da765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_1ac862ce-08c0-4295-8d0a-d273dd346f44" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_516994d7-5651-4efc-9114-be05595da765" xlink:to="loc_srt_WeightedAverageMember_1ac862ce-08c0-4295-8d0a-d273dd346f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_07e5b269-b859-4ead-9b94-351680ef8ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_07e5b269-b859-4ead-9b94-351680ef8ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_08129385-88a3-475b-ad8e-c9a033f16c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_07e5b269-b859-4ead-9b94-351680ef8ebd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_08129385-88a3-475b-ad8e-c9a033f16c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_52d65e99-2a6e-4e60-9c5c-f1a908cb80ea" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_08129385-88a3-475b-ad8e-c9a033f16c0d" xlink:to="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_52d65e99-2a6e-4e60-9c5c-f1a908cb80ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_3fd6aa1f-bb22-4bd5-bd4f-024dcc0f7f02" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_08129385-88a3-475b-ad8e-c9a033f16c0d" xlink:to="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_3fd6aa1f-bb22-4bd5-bd4f-024dcc0f7f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember_9f500cc6-f649-4a2b-8726-e3b2aa81cde7" xlink:href="ck0001824293-20241231.xsd#ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_08129385-88a3-475b-ad8e-c9a033f16c0d" xlink:to="loc_ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember_9f500cc6-f649-4a2b-8726-e3b2aa81cde7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7c27a41e-851a-4845-b0d4-e2741a955017" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7c27a41e-851a-4845-b0d4-e2741a955017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7c27a41e-851a-4845-b0d4-e2741a955017" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_d405dfe0-0bfa-4296-b6dc-149e9cee2395" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_d405dfe0-0bfa-4296-b6dc-149e9cee2395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_b6594a7f-b2e0-4389-8a7b-1f97cfa4296e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_b6594a7f-b2e0-4389-8a7b-1f97cfa4296e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_11bfe669-dd41-4144-9d0e-851a76e6645f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_11bfe669-dd41-4144-9d0e-851a76e6645f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a4fd6ca9-f3fe-4d50-9dec-8c9a6a1fb7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7b40fd5b-6b12-4fce-b73b-bccc373ec5ac" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_a4fd6ca9-f3fe-4d50-9dec-8c9a6a1fb7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e347a376-321b-41df-9b21-bd9387adb910" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3fcc7878-8df8-473f-8fd1-86a64ed13e86" xlink:to="loc_us-gaap_ClassOfStockLineItems_e347a376-321b-41df-9b21-bd9387adb910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_772a6b16-a6b0-48fe-b55c-18d9dcef6368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e347a376-321b-41df-9b21-bd9387adb910" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_772a6b16-a6b0-48fe-b55c-18d9dcef6368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_798f06ab-5dab-4c8a-813b-263912b114d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4e7104aa-ac63-4641-a5f3-c2563211dc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_798f06ab-5dab-4c8a-813b-263912b114d8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4e7104aa-ac63-4641-a5f3-c2563211dc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_70a200dd-4cad-4777-aae9-c03fe2b97ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4e7104aa-ac63-4641-a5f3-c2563211dc3d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_70a200dd-4cad-4777-aae9-c03fe2b97ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_70a200dd-4cad-4777-aae9-c03fe2b97ce6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member_52c7fe9a-1e08-4d75-8eee-30575af722a1" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInAugust2025Member_52c7fe9a-1e08-4d75-8eee-30575af722a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_d2842271-cca6-4ade-a88e-b37e6a7e6976" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_d2842271-cca6-4ade-a88e-b37e6a7e6976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMarch2026Member_6d65c3ae-91c4-4e0c-b523-c18be05b425b" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInMarch2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInMarch2026Member_6d65c3ae-91c4-4e0c-b523-c18be05b425b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2026Member_b8c57737-3477-4181-b704-db3492e8f243" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInApril2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2026Member_b8c57737-3477-4181-b704-db3492e8f243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_49f3336b-a42a-4230-8eb7-bacd359fed7b" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_49f3336b-a42a-4230-8eb7-bacd359fed7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_ff0e7962-2860-4ed7-a933-ef493f4a48b0" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_ff0e7962-2860-4ed7-a933-ef493f4a48b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_e2b1283b-b0d4-44dd-9710-afee2955c1d9" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_e2b1283b-b0d4-44dd-9710-afee2955c1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_1ecb9857-1996-4ae7-8e28-25ae1b43a10f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_1ecb9857-1996-4ae7-8e28-25ae1b43a10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member_95296b96-cd16-4382-ac59-2e95fc8d718f" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2029Member_95296b96-cd16-4382-ac59-2e95fc8d718f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_a0aa65be-84e0-43eb-ac35-2831c46eda14" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInSeptember2029Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInSeptember2029Member_a0aa65be-84e0-43eb-ac35-2831c46eda14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_6c24bdea-6580-48ac-895c-cd30041e95f1" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInOctober2029OneMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029OneMember_6c24bdea-6580-48ac-895c-cd30041e95f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_57305734-8b5e-430b-b806-a948a37de639" xlink:href="ck0001824293-20241231.xsd#ck0001824293_WarrantsExpiringInOctober2029TwoMember"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_707feb35-6b09-43bf-8ce6-bff9f75634cc" xlink:to="loc_ck0001824293_WarrantsExpiringInOctober2029TwoMember_57305734-8b5e-430b-b806-a948a37de639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_130e5db9-0743-4e22-a171-ae363c6eb3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4e7104aa-ac63-4641-a5f3-c2563211dc3d" xlink:to="loc_us-gaap_ClassOfStockLineItems_130e5db9-0743-4e22-a171-ae363c6eb3a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_abf87f97-1200-4305-af13-14c9ae5015d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_130e5db9-0743-4e22-a171-ae363c6eb3a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_abf87f97-1200-4305-af13-14c9ae5015d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_61de5a7d-018d-4e57-aa5a-41349bdecd12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_130e5db9-0743-4e22-a171-ae363c6eb3a7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_61de5a7d-018d-4e57-aa5a-41349bdecd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4aeb30b-2ee5-41a2-beb6-6bac12f941cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f4aeb30b-2ee5-41a2-beb6-6bac12f941cf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47a68cc5-7449-49c2-8825-a1dd7f53c173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:to="loc_us-gaap_PlanNameAxis_47a68cc5-7449-49c2-8825-a1dd7f53c173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a646cc03-c654-4705-ac85-a5405b13112e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_47a68cc5-7449-49c2-8825-a1dd7f53c173" xlink:to="loc_us-gaap_PlanNameDomain_a646cc03-c654-4705-ac85-a5405b13112e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsPlanMember_3c531a12-90d4-4bf5-aa9d-c37053b9c460" xlink:href="ck0001824293-20241231.xsd#ck0001824293_GRIOperationsPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a646cc03-c654-4705-ac85-a5405b13112e" xlink:to="loc_ck0001824293_GRIOperationsPlanMember_3c531a12-90d4-4bf5-aa9d-c37053b9c460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_6dc68eb8-cc84-4070-bdf6-e611be1c6b23" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a646cc03-c654-4705-ac85-a5405b13112e" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_6dc68eb8-cc84-4070-bdf6-e611be1c6b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_af803000-b093-4751-bf88-68b469f477bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:to="loc_us-gaap_AwardTypeAxis_af803000-b093-4751-bf88-68b469f477bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee75cfc3-6d47-41b9-ae5b-fb0e63cdbf08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_af803000-b093-4751-bf88-68b469f477bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee75cfc3-6d47-41b9-ae5b-fb0e63cdbf08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f6f37f07-b7f7-4663-a493-c281dabb81ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee75cfc3-6d47-41b9-ae5b-fb0e63cdbf08" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f6f37f07-b7f7-4663-a493-c281dabb81ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4bde8413-6914-4320-9f00-a6b45f2966a8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:to="loc_srt_RangeAxis_4bde8413-6914-4320-9f00-a6b45f2966a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1dedb631-5651-4ac9-b45a-11113a3fd1bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4bde8413-6914-4320-9f00-a6b45f2966a8" xlink:to="loc_srt_RangeMember_1dedb631-5651-4ac9-b45a-11113a3fd1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1108ed24-7f62-4906-aca7-e49555e0bf29" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1dedb631-5651-4ac9-b45a-11113a3fd1bb" xlink:to="loc_srt_MaximumMember_1108ed24-7f62-4906-aca7-e49555e0bf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b14ec3e6-15ca-4b88-9c8a-cd1ecd158600" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_950975a5-4055-428a-84cb-8289091ed8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_950975a5-4055-428a-84cb-8289091ed8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a92f38a8-b4d2-46e7-a1c6-c4171ac1d94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a92f38a8-b4d2-46e7-a1c6-c4171ac1d94d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44c0fa92-7023-418b-9e11-48acd0d19666" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_44c0fa92-7023-418b-9e11-48acd0d19666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_198ac894-56fd-4b3b-961b-24f257822c68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_198ac894-56fd-4b3b-961b-24f257822c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_36287e4c-302f-4681-876b-cadf87926260" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_36287e4c-302f-4681-876b-cadf87926260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_cbf00094-1785-4616-90ea-8cf67971c717" xlink:href="ck0001824293-20241231.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_cbf00094-1785-4616-90ea-8cf67971c717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b9c90b15-7045-4d86-a075-0cc8bc65137e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b9c90b15-7045-4d86-a075-0cc8bc65137e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86493196-a0d7-43f5-b5eb-9c3d8926b477" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86493196-a0d7-43f5-b5eb-9c3d8926b477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c3649af-f719-41b4-8325-3c8fabe06b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1c3649af-f719-41b4-8325-3c8fabe06b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5681877b-fabd-43e6-8479-2758ca609662" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5681877b-fabd-43e6-8479-2758ca609662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c80166b-8b3d-4179-84b9-06ea9e488b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a3d5f988-b2ff-42ef-8ecb-092fb2bc9df1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1c80166b-8b3d-4179-84b9-06ea9e488b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43dd08cf-c3dc-4fe8-a594-290d3ef12ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3e30aa58-90f7-4204-8b49-b9c6892685f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43dd08cf-c3dc-4fe8-a594-290d3ef12ab4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3e30aa58-90f7-4204-8b49-b9c6892685f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3dfd30c0-faa9-408c-b22b-d0cb1e025366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3e30aa58-90f7-4204-8b49-b9c6892685f3" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3dfd30c0-faa9-408c-b22b-d0cb1e025366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bd060480-9ca3-48c9-b61e-502c4ee509ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3dfd30c0-faa9-408c-b22b-d0cb1e025366" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bd060480-9ca3-48c9-b61e-502c4ee509ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6096838c-874b-40a5-be20-03c08c8d2738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bd060480-9ca3-48c9-b61e-502c4ee509ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6096838c-874b-40a5-be20-03c08c8d2738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_fa31d4d8-5ec7-43c7-8158-b03e982f4ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_bd060480-9ca3-48c9-b61e-502c4ee509ad" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_fa31d4d8-5ec7-43c7-8158-b03e982f4ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_65e1ba22-231a-4577-9ccb-99eafb27a545" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3e30aa58-90f7-4204-8b49-b9c6892685f3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_65e1ba22-231a-4577-9ccb-99eafb27a545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b905b9d-9115-4d0e-9f52-c4becd930dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_65e1ba22-231a-4577-9ccb-99eafb27a545" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2b905b9d-9115-4d0e-9f52-c4becd930dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a36d81c-e992-4eaa-8049-5c54de769f54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0298a00f-41c5-4036-8bd2-cc6697fb382d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a36d81c-e992-4eaa-8049-5c54de769f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0298a00f-41c5-4036-8bd2-cc6697fb382d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ff38586f-b8a3-4aef-a3ec-b03e9830007f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0298a00f-41c5-4036-8bd2-cc6697fb382d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ff38586f-b8a3-4aef-a3ec-b03e9830007f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f991a5d0-68ed-449f-bc8e-f67833be6eae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0298a00f-41c5-4036-8bd2-cc6697fb382d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f991a5d0-68ed-449f-bc8e-f67833be6eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5177038c-1518-49fe-b618-d6613c2cdff4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0298a00f-41c5-4036-8bd2-cc6697fb382d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_5177038c-1518-49fe-b618-d6613c2cdff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1b27cd47-866a-4220-8569-d2ea04488132" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0298a00f-41c5-4036-8bd2-cc6697fb382d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1b27cd47-866a-4220-8569-d2ea04488132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db9ea906-ba85-48e8-a76b-8f69d8ce74aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0298a00f-41c5-4036-8bd2-cc6697fb382d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_db9ea906-ba85-48e8-a76b-8f69d8ce74aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cbe57353-8fe5-4159-a225-4c2f28a4db56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a36d81c-e992-4eaa-8049-5c54de769f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cbe57353-8fe5-4159-a225-4c2f28a4db56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_427b0706-2819-4d0a-8fde-fc4dc380d9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a36d81c-e992-4eaa-8049-5c54de769f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_427b0706-2819-4d0a-8fde-fc4dc380d9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f6d3d399-0662-49a9-b1ae-c58e9d981a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a36d81c-e992-4eaa-8049-5c54de769f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f6d3d399-0662-49a9-b1ae-c58e9d981a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f0c65a4e-1288-477d-97b5-4106c44d9107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f6d3d399-0662-49a9-b1ae-c58e9d981a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f0c65a4e-1288-477d-97b5-4106c44d9107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46f56e83-e266-41bf-9248-07f1dcccfb3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_f6d3d399-0662-49a9-b1ae-c58e9d981a1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46f56e83-e266-41bf-9248-07f1dcccfb3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_32b67de5-9f76-453c-9031-ab2c331c8880" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a36d81c-e992-4eaa-8049-5c54de769f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_32b67de5-9f76-453c-9031-ab2c331c8880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a0b897b1-5132-4cc1-8317-7e94368638b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a36d81c-e992-4eaa-8049-5c54de769f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_a0b897b1-5132-4cc1-8317-7e94368638b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_83195ac6-5fcc-40c6-a3e4-125df925048a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a36d81c-e992-4eaa-8049-5c54de769f54" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_83195ac6-5fcc-40c6-a3e4-125df925048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1df7cf27-fa51-4c86-a013-2afde6d5d65e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_83195ac6-5fcc-40c6-a3e4-125df925048a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1df7cf27-fa51-4c86-a013-2afde6d5d65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_074e2440-50e9-4694-a474-d9ffdb30aab5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_83195ac6-5fcc-40c6-a3e4-125df925048a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_074e2440-50e9-4694-a474-d9ffdb30aab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53b0c6c1-cff9-4c1d-8615-4c88a445abee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_83195ac6-5fcc-40c6-a3e4-125df925048a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_53b0c6c1-cff9-4c1d-8615-4c88a445abee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_618672d6-cd90-48c1-9ad9-7c380f72c626" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe0acfd1-4916-493b-81b1-7e8c52a1f9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_618672d6-cd90-48c1-9ad9-7c380f72c626" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe0acfd1-4916-493b-81b1-7e8c52a1f9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c7eb95aa-94c5-404c-917a-155a3e39629f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe0acfd1-4916-493b-81b1-7e8c52a1f9d8" xlink:to="loc_us-gaap_AwardTypeAxis_c7eb95aa-94c5-404c-917a-155a3e39629f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05c4a7c5-05b2-497a-9a09-457199877d61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c7eb95aa-94c5-404c-917a-155a3e39629f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05c4a7c5-05b2-497a-9a09-457199877d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35303a5a-f0a0-4e4c-9bab-cfec57b12138" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05c4a7c5-05b2-497a-9a09-457199877d61" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35303a5a-f0a0-4e4c-9bab-cfec57b12138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fe0acfd1-4916-493b-81b1-7e8c52a1f9d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7685865e-f6cf-4c15-a01a-41fc5fb38777" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7685865e-f6cf-4c15-a01a-41fc5fb38777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_416e6df0-872f-4ffc-93c4-430904dc006a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_416e6df0-872f-4ffc-93c4-430904dc006a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b98c1d91-0727-4411-9125-af1cf8534276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b98c1d91-0727-4411-9125-af1cf8534276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_49dbbcc1-2664-4062-9c68-2196e9745ece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_49dbbcc1-2664-4062-9c68-2196e9745ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_ea9ce262-f0e0-4f66-8771-964fe85b63b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6b6fcea-b1f4-40ce-8c47-1769c89726bd" xlink:to="loc_us-gaap_SharePrice_ea9ce262-f0e0-4f66-8771-964fe85b63b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#ASSETPURCHASEAGREEMENTDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ab4c1daf-4fb5-4237-99df-aa066c347a00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_aead575e-80f5-4113-b460-016bd55c9bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ab4c1daf-4fb5-4237-99df-aa066c347a00" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_aead575e-80f5-4113-b460-016bd55c9bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9e41de7-2452-401e-8910-225d9d119009" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_aead575e-80f5-4113-b460-016bd55c9bd7" xlink:to="loc_srt_CounterpartyNameAxis_a9e41de7-2452-401e-8910-225d9d119009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a7209c-864d-4aff-8127-5fb247479959" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a9e41de7-2452-401e-8910-225d9d119009" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a7209c-864d-4aff-8127-5fb247479959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AardvarkTherapeuticsIncMember_7a556339-6415-469a-a15b-925b41876ca6" xlink:href="ck0001824293-20241231.xsd#ck0001824293_AardvarkTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77a7209c-864d-4aff-8127-5fb247479959" xlink:to="loc_ck0001824293_AardvarkTherapeuticsIncMember_7a556339-6415-469a-a15b-925b41876ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_fe8f3bcb-c311-4cf9-b677-7d7c76b61c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_aead575e-80f5-4113-b460-016bd55c9bd7" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_fe8f3bcb-c311-4cf9-b677-7d7c76b61c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_654653db-b72d-44ea-b8ca-892d43ac8898" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_fe8f3bcb-c311-4cf9-b677-7d7c76b61c9e" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_654653db-b72d-44ea-b8ca-892d43ac8898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ed2459a4-3b8d-46bb-98ad-ff4c2313ac77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_d1033d35-e5f9-4c4e-942e-bdfcf3be0c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ed2459a4-3b8d-46bb-98ad-ff4c2313ac77" xlink:to="loc_us-gaap_LossContingenciesTable_d1033d35-e5f9-4c4e-942e-bdfcf3be0c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_d67c2966-bc90-4a46-a419-001863e6a07c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d1033d35-e5f9-4c4e-942e-bdfcf3be0c4e" xlink:to="loc_srt_TitleOfIndividualAxis_d67c2966-bc90-4a46-a419-001863e6a07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ab3b7b1-c0e8-4a72-b1f2-d41d63a9bfe7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_d67c2966-bc90-4a46-a419-001863e6a07c" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ab3b7b1-c0e8-4a72-b1f2-d41d63a9bfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_d7f64ec9-6a54-4f25-960a-56b0b5e0f19b" xlink:href="ck0001824293-20241231.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0ab3b7b1-c0e8-4a72-b1f2-d41d63a9bfe7" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_d7f64ec9-6a54-4f25-960a-56b0b5e0f19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_b4768071-e022-4f95-9f6a-f8a08f2dfe94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_d1033d35-e5f9-4c4e-942e-bdfcf3be0c4e" xlink:to="loc_us-gaap_LossContingenciesLineItems_b4768071-e022-4f95-9f6a-f8a08f2dfe94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_598bbea8-ee5a-4842-83ab-62d1bd4e81ce" xlink:href="ck0001824293-20241231.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4768071-e022-4f95-9f6a-f8a08f2dfe94" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_598bbea8-ee5a-4842-83ab-62d1bd4e81ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_cc0c708e-6e6b-4c5e-a383-e8b6c8ded699" xlink:href="ck0001824293-20241231.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_b4768071-e022-4f95-9f6a-f8a08f2dfe94" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_cc0c708e-6e6b-4c5e-a383-e8b6c8ded699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0496e165-5b45-4513-b501-08cd05093f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4440b74d-e6e1-4836-9b61-55a2053c438b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0496e165-5b45-4513-b501-08cd05093f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_4440b74d-e6e1-4836-9b61-55a2053c438b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_63ec930e-dbfb-4136-b060-d6079bdab9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0496e165-5b45-4513-b501-08cd05093f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_63ec930e-dbfb-4136-b060-d6079bdab9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_e8702192-d745-4a83-99d3-c1fb378f0641" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0496e165-5b45-4513-b501-08cd05093f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_e8702192-d745-4a83-99d3-c1fb378f0641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_9c758ff4-6d66-420e-8584-dce885592aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0496e165-5b45-4513-b501-08cd05093f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_9c758ff4-6d66-420e-8584-dce885592aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ea1b361a-d4e9-425f-bf39-06de4f010a77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0496e165-5b45-4513-b501-08cd05093f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_ea1b361a-d4e9-425f-bf39-06de4f010a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_c5c6ee6a-cb15-4d6d-8aa8-e94bca5830a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0496e165-5b45-4513-b501-08cd05093f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_c5c6ee6a-cb15-4d6d-8aa8-e94bca5830a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8af5a38a-41af-4686-af9e-d85b1971cdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0496e165-5b45-4513-b501-08cd05093f3e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8af5a38a-41af-4686-af9e-d85b1971cdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#INCOMETAXComponentsofDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1a151fa3-2dd2-4d4d-9f10-7b4234f38ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3258e095-f428-4b43-b715-5bdeccb18360" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1a151fa3-2dd2-4d4d-9f10-7b4234f38ec8" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3258e095-f428-4b43-b715-5bdeccb18360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_18b8cba8-f8ee-42ad-b577-c23610f3d659" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3258e095-f428-4b43-b715-5bdeccb18360" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_18b8cba8-f8ee-42ad-b577-c23610f3d659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_401dfb56-5da1-40d6-8146-199bdbc65ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3258e095-f428-4b43-b715-5bdeccb18360" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_401dfb56-5da1-40d6-8146-199bdbc65ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_41ebed2a-3144-4c79-a5a6-73de7bd78308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3258e095-f428-4b43-b715-5bdeccb18360" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_41ebed2a-3144-4c79-a5a6-73de7bd78308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0d9f27af-88f0-440e-bcdf-161c56a184a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3258e095-f428-4b43-b715-5bdeccb18360" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_0d9f27af-88f0-440e-bcdf-161c56a184a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f18dacb3-eedb-452d-a39f-7c7b6cba2977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3258e095-f428-4b43-b715-5bdeccb18360" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_f18dacb3-eedb-452d-a39f-7c7b6cba2977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1219d9dd-0331-455b-be0b-7ce4db2f6e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3258e095-f428-4b43-b715-5bdeccb18360" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1219d9dd-0331-455b-be0b-7ce4db2f6e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_eed8ade5-f624-45ae-957a-c6d672ca1b60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3258e095-f428-4b43-b715-5bdeccb18360" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_eed8ade5-f624-45ae-957a-c6d672ca1b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_153d0a5b-2660-485c-a6b5-e39fd636f8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_3258e095-f428-4b43-b715-5bdeccb18360" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_153d0a5b-2660-485c-a6b5-e39fd636f8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_83c8013f-57f7-4aa1-bbb4-318b2790bf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1a151fa3-2dd2-4d4d-9f10-7b4234f38ec8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_83c8013f-57f7-4aa1-bbb4-318b2790bf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9773f3d1-d61c-4503-9916-4e5263b697aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1a151fa3-2dd2-4d4d-9f10-7b4234f38ec8" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9773f3d1-d61c-4503-9916-4e5263b697aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_236d41bd-f3e3-447c-98f9-68932f811f37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1a151fa3-2dd2-4d4d-9f10-7b4234f38ec8" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_236d41bd-f3e3-447c-98f9-68932f811f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#INCOMETAXNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7ea93062-bec9-47be-ab0c-cae7bc89bac8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_58006ed3-b30b-49ec-8bf0-ddbec3b59ee3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7ea93062-bec9-47be-ab0c-cae7bc89bac8" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_58006ed3-b30b-49ec-8bf0-ddbec3b59ee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_71a344b5-577a-48fd-845d-deb5950d3214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_58006ed3-b30b-49ec-8bf0-ddbec3b59ee3" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_71a344b5-577a-48fd-845d-deb5950d3214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_aa794df1-c212-4f0c-b2c7-f214dd01ecc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_71a344b5-577a-48fd-845d-deb5950d3214" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_aa794df1-c212-4f0c-b2c7-f214dd01ecc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_d017dcce-f4ea-4c01-a79d-f12655b7cc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aa794df1-c212-4f0c-b2c7-f214dd01ecc6" xlink:to="loc_us-gaap_DomesticCountryMember_d017dcce-f4ea-4c01-a79d-f12655b7cc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StateTaxAuthorityMember_e06e5cc7-5364-4ba2-9a36-611946e08d23" xlink:href="ck0001824293-20241231.xsd#ck0001824293_StateTaxAuthorityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aa794df1-c212-4f0c-b2c7-f214dd01ecc6" xlink:to="loc_ck0001824293_StateTaxAuthorityMember_e06e5cc7-5364-4ba2-9a36-611946e08d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_LocalTaxAuthorityMember_ee8f18a9-b9f6-4aa9-a3eb-c8534519e027" xlink:href="ck0001824293-20241231.xsd#ck0001824293_LocalTaxAuthorityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_aa794df1-c212-4f0c-b2c7-f214dd01ecc6" xlink:to="loc_ck0001824293_LocalTaxAuthorityMember_ee8f18a9-b9f6-4aa9-a3eb-c8534519e027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_58006ed3-b30b-49ec-8bf0-ddbec3b59ee3" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d633b655-5333-4818-b1a9-4b02553a087e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_d633b655-5333-4818-b1a9-4b02553a087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1c07bb35-0de6-48c4-ba60-68e4660972d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1c07bb35-0de6-48c4-ba60-68e4660972d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration_fa0b7f66-26cf-4ba5-91b8-c8d31b697771" xlink:href="ck0001824293-20241231.xsd#ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration_fa0b7f66-26cf-4ba5-91b8-c8d31b697771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration_dd8b4fc0-cca0-430a-b47b-808c0da579fd" xlink:href="ck0001824293-20241231.xsd#ck0001824293_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration_dd8b4fc0-cca0-430a-b47b-808c0da579fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e0bffd91-0078-42cf-8c59-67b59dee79b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_390eb278-4023-46bc-8182-6a5b37bf7c59" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_e0bffd91-0078-42cf-8c59-67b59dee79b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="ck0001824293-20241231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_cd72ba54-92b7-4256-9a79-b4e8236d8995" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_a321b070-afc2-4eb2-b168-48b033ad7ab2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_cd72ba54-92b7-4256-9a79-b4e8236d8995" xlink:to="loc_us-gaap_SubsequentEventTable_a321b070-afc2-4eb2-b168-48b033ad7ab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_aba401a1-6233-40c1-8d2e-c87c172b4c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a321b070-afc2-4eb2-b168-48b033ad7ab2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_aba401a1-6233-40c1-8d2e-c87c172b4c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4988cd89-72eb-4856-b63f-b1ebff55d8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_aba401a1-6233-40c1-8d2e-c87c172b4c4c" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4988cd89-72eb-4856-b63f-b1ebff55d8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_cea9c2e2-2677-499b-8727-0c7a860372ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4988cd89-72eb-4856-b63f-b1ebff55d8e4" xlink:to="loc_us-gaap_SubsequentEventMember_cea9c2e2-2677-499b-8727-0c7a860372ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_3452b0d6-1429-41b0-8520-fdfbd1ff38db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_a321b070-afc2-4eb2-b168-48b033ad7ab2" xlink:to="loc_us-gaap_SubsequentEventLineItems_3452b0d6-1429-41b0-8520-fdfbd1ff38db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_77f3411c-cbb6-48b1-9eaa-47bca81037b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_3452b0d6-1429-41b0-8520-fdfbd1ff38db" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_77f3411c-cbb6-48b1-9eaa-47bca81037b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ck0001824293-20241231_g1.jpg
<TEXT>
begin 644 ck0001824293-20241231_g1.jpg
M_]C_X0#*17AI9@  34T *@    @ !@$2  ,    !  $   $:  4    !
M5@$;  4    !    7@$H  ,    !  (   (3  ,    !  $  (=I  0    !
M    9@        !(     0   $@    !  >0   '    !# R,C&1 0 '
M! $" P"@   '    !# Q,#"@ 0 #     0 !  "@ @ $     0  !Y.@ P $
M     0   <JD!@ #     0            #_X@) 24-#7U!23T9)3$4  0$
M  (P041"10(0  !M;G1R4D="(%A96B 'T  (  L $P S #MA8W-P05!03
M  !N;VYE                        ]M8  0    #3+4%$0D4
M                                                      IC<')T
M    _    #)D97-C   !,    &MW='!T   !G    !1B:W!T   !L    !1R
M5%)#   !Q     YG5%)#   !U     YB5%)#   !Y     YR6%E:   !]
M !1G6%E:   ""    !1B6%E:   "'    !1T97AT     $-O<'ER:6=H=" R
M,# P($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D    9&5S8P         1
M061O8F4@4D="("@Q.3DX*0
M
M        6%E:(        /-1  $    !%LQ865H@
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M :(   $% 0$! 0$!           ! @,$!08'" D*"Q   @$# P($ P4%! 0
M  %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*%A<8
M&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)
MRM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ 0 # 0$! 0$! 0$!
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M\-@:"P]&ZG?E3T<;?)<NG8=_Q#[?LS_]'8?\%(__ !,CQC_\IJ/^(?;]F?\
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M  BK_P#S<'U.A_T\_P# E_\ (!_Q#[?LS_\ 1V'_  4C_P#$R/&/_P IJ/\
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M_P"4U'_$/M^S/_T=A_P4C_\ $R/&/_RFH_XF4\1O^?F4_P#A%7_^;@^IT/\
MIY_X$O\ Y /^(?;]F?\ Z.P_X*1_^)D>,?\ Y34?\0^W[,__ $=A_P %(_\
MQ,CQC_\ *:C_ (F4\1O^?F4_^$5?_P";@^IT/^GG_@2_^0#_ (A]OV9_^CL/
M^"D?_B9'C'_Y34?\0^W[,_\ T=A_P4C_ /$R/&/_ ,IJ/^)E/$;_ )^93_X1
M5_\ YN#ZG0_Z>?\ @2_^0#_B'V_9G_Z.P_X*1_\ B9'C'_Y34?\ $/M^S/\
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M_B'V_9G_ .CL/^"D?_B9'C'_ .4U'_$RGB-_S\RG_P (J_\ \W!]3H?]//\
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M "FH_P"(?;]F?_H[#_@I'_XF1XQ_^4U'_$RGB-_S\RG_ ,(J_P#\W!]3H?\
M3S_P)?\ R ?\0^W[,_\ T=A_P4C_ /$R/&/_ ,IJ/^(?;]F?_H[#_@I'_P")
MD>,?_E-1_P 3*>(W_/S*?_"*O_\ -P?4Z'_3S_P)?_(!_P 0^W[,_P#T=A_P
M4C_\3(\8_P#RFH_XA]OV9_\ H[#_ (*1_P#B9'C'_P"4U'_$RGB-_P _,I_\
M(J__ ,W!]3H?]//_  )?_(!_Q#[?LS_]'8?\%(__ !,CQC_\IJ/^(?;]F?\
MZ.P_X*1_^)D>,?\ Y34?\3*>(W_/S*?_  BK_P#S<'U.A_T\_P# E_\ (!_Q
M#[?LS_\ 1V'_  4C_P#$R/&/_P IJ/\ B'V_9G_Z.P_X*1_^)D>,?_E-1_Q,
MIXC?\_,I_P#"*O\ _-P?4Z'_ $\_\"7_ ,@'_$/M^S/_ -'8?\%(_P#Q,CQC
M_P#*:C_B'V_9G_Z.P_X*1_\ B9'C'_Y34?\ $RGB-_S\RG_PBK__ #<'U.A_
MT\_\"7_R ?\ $/M^S/\ ]'8?\%(__$R/&/\ \IJ/^(?;]F?_ *.P_P""D?\
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M  BK_P#S<'U.A_T\_P# E_\ (!_Q#[?LS_\ 1V'_  4C_P#$R/&/_P IJ/\
MB'V_9G_Z.P_X*1_^)D>,?_E-1_Q,IXC?\_,I_P#"*O\ _-P?4Z'_ $\_\"C_
M /('R#^V[_P17^!WP0^ FK>/?"?[4G_!06_UBV\5^!-'AMO$O[6GC+5])^R:
M]XITO1[T?V?_ &9;J;DVERQM.1B]V_WL#Z[7_@WX_9HV@G]J_P#X*1#(YQ^V
M3XQX_#^QJ];%?2-XZIY!E5>']F*I4QN:>VE+#8AT^2C1RY4?9Q6,4HRY:L_:
MWG-2?L^10Y7S+^S\/SM^_9<J23C>^M[OE?6VR5O,?_Q#[?LS_P#1V'_!2/\
M\3(\8_\ RFH_XA]OV9_^CL/^"D?_ (F1XQ_^4U>3_P 3*>(W_/S*?_"*O_\
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MC_\ $R/&/_RFH_XF4\1O^?F4_P#A%7_^;@^IT/\ IY_X$O\ Y /^(?;]F?\
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M[S3^\O\ Y /^(?;]F?\ Z.P_X*1_^)D>,?\ Y34?\0^W[,__ $=A_P %(_\
MQ,CQC_\ *:C_ (F4\1O^?F4_^$5?_P";A?4Z'_3S_P "7_R ?\0^W[,__1V'
M_!2/_P 3(\8__*:C_B'V_9G_ .CL/^"D?_B9'C'_ .4U'_$RGB-_S\RG_P (
MJ_\ \W!]3H?]//\ P)?_ " ?\0^W[,__ $=A_P %(_\ Q,CQC_\ *:C_ (A]
MOV9_^CL/^"D?_B9'C'_Y34?\3*>(W_/S*?\ PBK_ /S<'U.A_P!//_ E_P#(
M!_Q#[?LS_P#1V'_!2/\ \3(\8_\ RFH_XA]OV9_^CL/^"D?_ (F1XQ_^4U'_
M !,IXC?\_,I_\(J__P W!]3H?]//_ E_\@'_ !#[?LS_ /1V'_!2/_Q,CQC_
M /*:C_B'V_9G_P"CL/\ @I'_ .)D>,?_ )34?\3*>(W_ #\RG_PBK_\ S<'U
M.A_T\_\  E_\@'_$/M^S/_T=A_P4C_\ $R/&/_RFH_XA]OV9_P#H[#_@I'_X
MF1XQ_P#E-1_Q,IXC?\_,I_\ "*O_ /-P?4Z'_3S_ ,"7_P @'_$/M^S/_P!'
M8?\ !2/_ ,3(\8__ "FH_P"(?;]F?_H[#_@I'_XF1XQ_^4U'_$RGB-_S\RG_
M ,(J_P#\W!]3H?\ 3S_P)?\ R ?\0^W[,_\ T=A_P4C_ /$R/&/_ ,IJ/^(?
M;]F?_H[#_@I'_P")D>,?_E-1_P 3*>(W_/S*?_"*O_\ -P?4Z'_3S_P)?_(!
M_P 0^W[,_P#T=A_P4C_\3(\8_P#RFH_XA]OV9_\ H[#_ (*1_P#B9'C'_P"4
MU'_$RGB-_P _,I_\(J__ ,W!]3H?]//_  )?_('R!\2_^"+'P.\-?M<_LS?"
M&P_:E_X*"S^&_B7X:^+VI:[<WG[6?C*?7+*7P?X>34-(_LG5O[-']EP7%T2+
MQ5MC]M '.<BOKS_B'Y_9G_Z.O_X*1\?]7D^,/I_T!OY5[&<_2+XYH8;('1>6
M)XW(E*M[3#8AJ57^ULV3=%1QD.2')&-HSYY<W-[[344E@,/N^>U]+..UEO[G
M=_D.'_!OO^S/_P!'8?\ !2/_ ,3(\8__ "FI?^(?;]F?_H[#_@I'_P")D>,?
M_E-7C_\ $RGB-_S\RG_PCQ'_ ,W#^IT/^GG_ ($O_D _XA]OV9_^CL/^"D?_
M (F1XQ_^4U'_ !#[?LS_ /1V'_!2/_Q,CQC_ /*:C_B93Q&_Y^93_P"$5?\
M^;@^IT/^GG_@2_\ D _XA]OV9_\ H[#_ (*1_P#B9'C'_P"4U'_$/M^S/_T=
MA_P4C_\ $R/&/_RFH_XF4\1O^?F4_P#A%7_^;@^IT/\ IY_X$O\ Y /^(?;]
MF?\ Z.P_X*1_^)D>,?\ Y34?\0^W[,__ $=A_P %(_\ Q,CQC_\ *:C_ (F4
M\1O^?F4_^$5?_P";@^IT/^GG_@2_^0#_ (A]OV9_^CL/^"D?_B9'C'_Y34?\
M0^W[,_\ T=A_P4C_ /$R/&/_ ,IJ/^)E/$;_ )^93_X15_\ YN#ZG0_Z>?\
M@2_^0#_B'V_9G_Z.P_X*1_\ B9'C'_Y34?\ $/M^S/\ ]'8?\%(__$R/&/\
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MFH_XF4\1O^?F4_\ A%7_ /FX/J=#_IY_X$O_ ) /^(?;]F?_ *.P_P""D?\
MXF1XQ_\ E-1_Q#[?LS_]'8?\%(__ !,CQC_\IJ/^)E/$;_GYE/\ X15__FX/
MJ=#_ *>?^!+_ .0#_B'V_9G_ .CL/^"D?_B9'C'_ .4U'_$/M^S/_P!'8?\
M!2/_ ,3(\8__ "FH_P")E/$;_GYE/_A%7_\ FX/J=#_IY_X$O_D _P"(?;]F
M?_H[#_@I'_XF1XQ_^4U'_$/M^S/_ -'8?\%(_P#Q,CQC_P#*:C_B93Q&_P"?
MF4_^$5?_ .;@^IT/^GG_ ($O_D _XA]OV9_^CL/^"D?_ (F1XQ_^4U'_ !#[
M?LS_ /1V'_!2/_Q,CQC_ /*:C_B93Q&_Y^93_P"$5?\ ^;@^IT/^GG_@2_\
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M_P""D?\ XF1XQ_\ E-1_Q#[?LS_]'8?\%(__ !,CQC_\IJ/^)E/$;_GYE/\
MX15__FX/J=#_ *>?^!+_ .0#_B'V_9G_ .CL/^"D?_B9'C'_ .4U'_$/M^S/
M_P!'8?\ !2/_ ,3(\8__ "FH_P")E/$;_GYE/_A%7_\ FX/J=#_IY_X$O_D
M_P"(?;]F?_H[#_@I'_XF1XQ_^4U'_$/M^S/_ -'8?\%(_P#Q,CQC_P#*:C_B
M93Q&_P"?F4_^$5?_ .;@^IT/^GG_ ($O_D _XA]OV9_^CL/^"D?_ (F1XQ_^
M4U'_ !#[?LS_ /1V'_!2/_Q,CQC_ /*:C_B93Q&_Y^93_P"$5?\ ^;@^IT/^
MGG_@2_\ D _XA]OV9_\ H[#_ (*1_P#B9'C'_P"4U'_$/M^S/_T=A_P4C_\
M$R/&/_RFH_XF4\1O^?F4_P#A%7_^;@^IT/\ IY_X$O\ Y /^(?;]F?\ Z.P_
MX*1_^)D>,?\ Y34?\0^W[,__ $=A_P %(_\ Q,CQC_\ *:C_ (F4\1O^?F4_
M^$5?_P";@^IT/^GG_@2_^0#_ (A]OV9_^CL/^"D?_B9'C'_Y34?\0^W[,_\
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M-%Y]E_7S ./5/R'^-''JGY#_ !HO/LOZ^8!QZI^0_P :./5/R'^-%Y]E_7S
M./5/R'^-''JGY#_&B\^R_KY@''JGY#_&CCU3\A_C1>?9?U\P#CU3\A_C1QZI
M^0_QHO/LOZ^8!QZI^0_QHX]4_(?XT7GV7]?, X]4_(?XT<>J?D/\:+S[+^OF
M <>J?D/\:./5/R'^-%Y]E_7S ./5/R'^-''JGY#_ !HO/LOZ^8!QZI^0_P :
M./5/R'^-%Y]E_7S ./5/R'^-''JGY#_&B\^R_KY@''JGY#_&CCU3\A_C1>?9
M?U\P#CU3\A_C1QZI^0_QHO/LOZ^8!QZI^0_QHX]4_(?XT7GV7]?, X]4_(?X
MT<>J?D/\:+S[+^OF <>J?D/\:./5/R'^-%Y]E_7S 3G^'!]>!S_GV_\ U>+_
M +1^/^&>OCK@<?\ "G/B=@_]R1KG;_.,>E=> Y_KV$T7^]4+>G-']>@U>^FY
MY_\ L.?\FA_LZ^G_  J?PA^7]F1U]49^]CGH /3CL/\ "NS/[?V[G<DMLRQ^
MW;ZU5=E^!,?A7DE^B%X_V/R_^O1QZI^0_P :\B\^R_KYC#CU3\A_C1QZI^0_
MQHO/LOZ^8!QZI^0_QHX]4_(?XT7GV7]?, X]4_(?XT<>J?D/\:+S[+^OF <>
MJ?D/\:./5/R'^-%Y]E_7S ./5/R'^-''JGY#_&B\^R_KY@''JGY#_&CCU3\A
M_C1>?9?U\P#CU3\A_C1QZI^0_P :+S[+^OF <>J?D/\ &CCU3\A_C1>?9?U\
MP#CU3\A_C1QZI^7_ ->B\^R_KY@?GE_P5$'_ !B5K_\ V4#X2_\ JP=!%?H8
MA 4 _0?ABOI<<XOA?A]<MF\SXAOYI4<BT_\ )OS%U\K+];"\>J?E_P#7HX]4
M_(?XU\U>?9?U\QAQZI^0_P :./5/R'^-%Y]E_7S ./5/R'^-''JGY#_&B\^R
M_KY@''JGY#_&CCU3\A_C1>?9?U\P#CU3\A_C1QZI^0_QHO/LOZ^8!QZI^0_Q
MHX]4_(?XT7GV7]?, X]4_(?XT<>J?D/\:+S[+^OF <>J?D/\:./5/R'^-%Y]
ME_7S ./5/R'^-&!_L?@/_KT+G[+^OF J\<>G?_/I7YX?MU$'QU^POZ?\-@_#
M_P#](-7KZ#AEIYO3<5MA\R_#+L7^0I7MIY?FC]#1C ^[^0_QI>/5/R'^-> W
M.[T6[_K<8<>J?D/\:./5/R'^-*\^R_KY@''JGY#_ !HX]4_(?XT7GV7]?, X
M]4_(?XT<>J?D/\:+S[+^OF <>J?D/\:./5/R'^-%Y]E_7S ./5/R'^-''JGY
M#_&B\^R_KY@''JGY#_&CCU3\A_C1>?9?U\P#CU3\A_C1QZI^0_QHO/LOZ^8!
MQZI^0_QHX]4_(?XT7GV7]?, X]4_(?XT<?['Y8_K1[_9?U\P/SO^. '_  \,
M_8A';_A"_P!HSI_V*%E7Z(XY/<''X8KZ7/W&6%X8T_AY"EHNO]L9Q^7,'3YO
M\H_Y"<?['Y?_ %Z./5/R'^-?-7GV7]?, X]4_(?XT<>J?D/\:+S[+^OF <>J
M?D/\:./5/R'^-%Y]E_7S ./5/R'^-''JGY#_ !HO/LOZ^8!QZI^0_P :./5/
MR'^-%Y]E_7S ./5/R'^-''JGY#_&B\^R_KY@''JGY#_&CCU3\A_C1>?9?U\P
M#CU3\A_C1QZI^0_QHO/LOZ^8!QZI^0_QHX_V/R_^O1[_ &7]?,!QX'3/M7YV
M:#G_ (>C^.?;]C;03CZ?%:'C\Z^BR%Q5'B%-?#P_7FO7Z_@-O,+?A_D_TN?H
MCQ_L?E_]>CCU3\A_C7SMY]E_7S ./5/R'^-''JGY#_&B\^R_KY@''JGY#_&C
MCU3\A_C1>?9?U\P#CU3\A_C1QZI^0_QHO/LOZ^8!QZI^0_QHX]4_(?XT7GV7
M]?, X]4_(?XT<>J?D/\ &B\^R_KY@''JGY#_ !HX]4_(?XT7GV7]?, X]4_(
M?XT<>J?D/\:+S[+^OF <>J?D/\:./5/R'^-%Y]E_7S ./5/R'^-''JGY#_&B
M\^R_KY@''JGY#_&CCU3\A_C1>?9?U\P#CU3\A_C1QZI^0_QHO/LOZ^8!QZI^
M0_QHX]4_(?XT7GV7]?, X]4_(?XT<>J?D/\ &B\^R_KY@''JGY#_ !HX]4_(
M?XT7GV7]?, X]4_(?XT<>J?D/\:+S[+^OF <>J?D/\:./5/R'^-%Y]E_7S .
M/5/R'^-''JGY#_&B\^R_KY@''JGY#_&CCU3\A_C1>?9?U\P#CU3\A_C1QZI^
M0_QHO/LOZ^8!QZI^0_QHX]4_(?XT7GV7]?, X]4_(?XT<>J?D/\ &B\^R_KY
M@''JGY#_ !HX]4_(?XT7GV7]?, X]4_(?XT<>J?D/\:+S[+^OF <>J?D/\:.
M/5/R'^-%Y]E_7S ./5/R'^-''JGY#_&B\^R_KY@''JGY#_&CCU3\A_C1>?9?
MU\P#CU3\A_C1QZI^0_QHO/LOZ^8!QZI^0_QHX]4_(?XT7GV7]?, X]4_(?XT
MR3'EOROW&Z#_ &3TYIQY^:.BW7Y^HUNO5'\07_!./_DT7P/_ -C_ /M$?^M(
M_%NON.OZRXL_Y*KB7_LH,Y_]6.)/,A\$?\,?R1__T?Z%O^#<;_E&CH/_ &<)
M^U!_ZNKQ57[Q5^C^+_\ R='C[_LJ\[_]3ZQCA_X-/_"%%?G!L%% !10 44 %
M% !10 44 %% !10 44 (.@^@K\\?^"G_ /R:KJ/_ &4GX3?^IUI-?1<'_P#)
M3Y%_V-,-_P"G29?#+_"_R/T-3[B_[J_R%.KYY[OU9;W?JPHI""B@ HH ** "
MB@ HH ** "B@ HH ** "B@ HH ** "B@ HH _.S3O^4J.O\ _9CUE_ZNZVK]
M$CT/TKV<\_B9?_V*,K_],0&]EZ?JQ:*\8044 %% !10 44 %% !10 44 %%
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M_*5'7_\ LQZR_P#5W6U?HD>A^A_E7LYY_$R__L497_Z8@-[+T_5BT5XP@HH
M** "B@ HH ** "B@ HH ** "B@ HH ** $Z4M !10 44 %% !10 44 %>+?M
M(?\ )O/QV_[(Y\3?_4)UNNK _P"^X/\ ["L/_P"G8#6Z]4>>?L._\F@_L[?]
MDE\(?^FR.OJRNO/_ /D=YQ_V-<=_ZEU"5LO1?D%%>4,** "B@ HH ** "B@
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M* %HH ** "B@ HH ** "B@ HH *_.S0?^4H_CG_LS;0?_5L05[N1_P '/?\
ML35O_4[!#Z/U7Y,_1.BO"$%% !10 44 %% !10 44 %% !10 44 %% !10 4
M4 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !3)/]
M6_\ N-_Z"::W7JAK=>J/X?\ _@G'_P FB^!_^Q__ &B/_6D?BW7W'7]7\6?\
ME5Q+_P!E!G/_ *L<2>9#X(_X8_DC_]/^A;_@W&_Y1HZ#_P!G"?M0?^KJ\55^
M\5?H_B__ ,G1X^_[*O.__4^L8X?^#3_PGQ)\7/\ @HM^P?\  /Q_K7PK^-7[
M77[/OPM^)7AE--EUWP)XY^*?A3PWXITB/6])L]?T@ZCH^I:M:W5J-4T/4K/5
MK+[5&#=6-W9WZY1D8Y_P]_X*7?\ !/7XJ>(],\&?#W]MO]EOQ9XKUJY-IHWA
MG1OCC\.9M>UF[[6NDZ1_PD$=[J=SC_EWL[:Z?(&%XYXX^&/'<LJH9_3X:S*>
M3XC!TLRIXBA3A7A7P^(I4:V'Q484I3K^S<&IV5._*U*2AK:O:Q4E[T5RWT>G
MYK_+73H?<Q8# 7JW3_#T_P \<8PIP!GKG'Z>F>/PKX1IJRO9SN[]4M%>WEIH
M_GLS7E^'S_X;\@!ZYSCC\/RI<\]>G7Z>O3U.,?RK--6<I7Y*<JGO6_DNKVZV
MU5O^ %OZ^ZWZ 1D#H?<\<?ACI_D4W_=X'Y9Q[>@]/_K4)SNE'X/<5]-MY2M;
MR4;+KTT%TLO^!T_R%.#@YXY_SQ[8^G'6FCMD9X./?O\ AS]/>E[C?+RI5():
M.^\>:4==+VYOQ7E9^6VC\OZVM\A^WN.OIZ_X?E2'[O)Z'OSC\O\ #VZ53Y_?
MM*VGNOE7N62Z?:OO^&F@7V\OTV]--!<+WZG_ /4.G%!'J1CW'3Z8(IZ^[:73
MM>^VM_\ (0B^G.!QTZY_E_3\:4X4>G^?_K4K/WHJ6KDGJK6TM%+H]MOO'Y+^
MNP^BK$%% "#H/H/Y5^>/_!3_ /Y-5U+_ +*3\)O_ %.M)KZ+@_\ Y*?(O^QI
MAO\ TZ3+X)?X7^1^AJ?<7_=7^0IU?//=^K+>[]6%%(044 %% !10 A.,>_ I
MG'.>P'/Y8XJ+)I7^R[Z=XW7](+V^[\#Y%_:)_;R_8T_9*NK33OVD/VF/@]\(
M=;U"U^W6/AGQ?XWT>R\77EAP#J%MX0@NKCQ-=:>#UO+72&M!@C?Z;?[/'[9W
M[*7[6MCJMY^S9^T%\*/C0NB102ZY8> _&VCZUKF@PSL1;3:]X?MKLZ[H4%V
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M* "B@ HH ** "B@",= 1QC\N>".YX_R*^&_CI_P4G_8&_9F\3W7@7XZ_M=?
M7X<^.["YL;34_!.L?$+0)/&NCS:E!;7&GMKWA+2KG4?$&@V]S:7=K>+>:MI5
MC9_8C]N9Q9_O1[O#G"W$/%F8?V7PUE>(S3&\LJGU>BE&$:<)<RJU:\^6CAX<
MT4E*K.$93<:<;SE"+F514N7L]/RV6^GEV[;>\_!3]HOX"?M)>'KGQ;^S]\9O
MA;\:_#-A=Q6.H:[\+/'?ACQYINFZA+;B==.U6Y\,:IJ0TO4_L^&-CJGV2]4
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M/G3?;D?+?E>]G\MAVM;KY?E]Z):*T$%% !10 44 %% !10 44 %% !10 44
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M(5:T:TU[S>(<*$5&G*4J48\W+5+&PJ/53@K77-I[E]))=._7M=G\_P#\6?\
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MN;34=%U2V%Y)X?\ $5I=M9:B+&^L;VSL=<TO7M TVM^TG\0OV.OAC_P;T?\
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M"/P_F:UTRY&G>(/%QM=;N!=6G]IV-EJ]U:^&Y-$T;6;I- EUS^WA?Z?I^_\
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MZF-M#+<^4?(@EN8;>Z:V@,H ,_V>ZV MA7P ?YI_^"=O_!!OP_87O[0GQ_\
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ME\$O\+_(_0U/N+_NK_(4ZOGGN_5EO=^K"BD(** "B@ HH A.0?IP/RK\:?\
M@X!^#GB7XV?\$C_VPO#'@^SN=1\0:!X3\(?%**RMA-))+H_P@^)'@_XD^+@E
MO!\UT\'@WPOX@NK6T_CO8X_I7VWACF$,K\0N",RK2C"G@^+\BK59SY5"-"GF
MU#VLI-VBE&CS2N_A:YNA%6/-3G%=8].ON_#Z7-C_ ((1?'GPC\>_^"5?[(.H
M>&M7TS4-2^&7PKT+X'^,-+L)H3>>&_%/P@M1X).E:S;(VZWU.ZT32M'\0J+I
M0]_8ZU8:SC9?J3W'_!3O_@J=\%O^"7G@+X5^*OB9X6\3?$WQ%\6_B);^"/"?
MPP^'=[H__"P;_3X=.N;_ ,0>+=-TC5KNR&J:7H5RNCZ1=6RW,9N];\4Z#8"\
MC:^%?3YIP%C>(?&/B/@S#QEA\1B^+L^A"M47M/88'#XK&XZ&,JKGA>,<%%5?
M>J)S32^.21,:T'2O+LGVZ+[NR^7R_)+]KO4)]5_X.;_^"16IW>E7^@W.I?LH
M_$/4+C0M8-@VKZ1+?>!?VL+J;2=7.G7FJ:;_ &CI>?LEY]CO;VR^V_\ (.OK
MQ=MZ.1UC]M#X\?$C_@I-^V;\+?\ @BW_ ,$__P!F;5/C)\-]:_X0G]L#]L'X
MXZC?Z19:]XGTS7M5T>:PN[#0/$O@^\S:^+]!\2:1I)_MGQ1K?B<^&+_6_P#A
M%++0M!#O^O8?(,#F.3<)U\YX@Q&2\*Y/X)T\9Q'7P5!XBKC</7\1\\PN#RRD
ME1KSIPQ>.K8>HZM*GSJ,8PUYN>',ZCH^UY4I/ZZDKZ+X%OJK6UWT^ZS^+O$V
MF?MY:#_P<(?\$M_^'A/Q-_9\\;_&74O#6MZGH7AS]G;2-0T[PYX ^'^H:7\8
MM/T_0M5O]:\-Z%X@U2XU77;7Q'="[OCK%EE;^PL+T*03]O?M7_L3_M$ZE_P4
MO_:$_:__ .",7[>G[.^F_M4:EX8\-Z-^UC^RSXH\3^#_ !'J&E3:-8:%X76U
MU#2!HGCW3M+.N3^#M'N;SP_XYT?POK/AGQ/_ &CJ&G^+[!=>L].T_P"KS/B;
M@_)<RX,GA^',RQ7AGG/@W7R+.\"Y5YXO!91B>,,6XYM5J^UJXR*I9A&AB8>Q
MKNO"G6C*DO:4HPC$:3<:UIQYUC-_A7P7Y4M%:W3EMWT;-C]@#]O_ .,$'_!3
MNR_93_X*D_L%?L^? []O7XB_"K4]1\ ?M3?#7PMX0A\1>-/!'A+PQXGU]M-U
M_P 9PZYXZN+GPQJGA?P)XD^R:OX5^(QT2QUKPN?"FH>$]/O<_P!A_,?P@_8R
M_P""B_[*WB[X]_%W_@@I^V9^RQ^UU^R+XV^,/B/Q+KWP*N?%_@#Q3#IWQ EL
M],O]0\'KX@=CX'_M+0M"U#1=*/B#P]\7OASK6MZ$?#Z^(-/)L+&^KQ_8\$\$
MYYG.4Y_4S3BWPCXZX2X5S/+\\3Q_UCAW#4\7F-'(J$O9<F+Y<%B:&.HK#4X>
MWY*5*G4HRYL3,KGE4@W'DCC87O'W5%Z)/^Z[Z:O1]&O=/TK_ ."'G[<^@?M#
M_$K]L;X&_$W]B7X2?L6_MQ?"SQ=9:Y^TQ;?"/P;H'A?3/C)J][KWB:WOO%^O
M7-HMUXEU+Q+H7B?4-7^UMXC\2>-K.\L_%=AK_A[Q=J5EX@O8K'^B\'OD;>>G
M;],]>W;Z5_/'B[P['A3CO-,FAFU;/J4J6 S#+LUQ$W4Q&,RO'X+!XO!5:L[*
M#E3P^(A32BHQE",7"$(M4X=5"?M*=^51Z62LHN^R6_1K7K]Y)17YP:A10 44
M %% !10!^=FF_P#*5'7_ /LQZR_]7=;5^B1Z'Z'^5>SGG\3+_P#L497_ .F(
M#>R]/U8M%>,(** "B@ HH ** /PZ_P"#CW_E##^V=VVV_P !^,]_^&F_@O\
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M7\ ?$;4/A'K/A#0M>T&SQ:F\UCQ)>7N6\4_$5;U0U[X@K]6_^#8'2OA_8?\
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MUHKJWPZ+3>VFUM%H?U045_$1Z9^>'_!43_DTG7O^R@_"?_U8.@5^AB]_HO\
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MLITI2TQ]K)^PM&,8_78I=7+W[+?L^9V]U6Z:'L-O^QA^W+\'/VGOVNOVG/\
M@@O^W)^S'\>/AK\5?B[J7B[X]_LY:MXM\ >,!H?Q.U;4=:\3W'@C[>+77?"*
MVVFWFO:M_8^J-XX^%7BJQT6['A._O==_L&[U ZG[./\ P4 \;?$KPC_P5_\
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M:9IGA[_A'\W5[>KX&'A,L0@%E7W]_P $G?V8/VGOA7_P6 _;!^-7[3'[1_\
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MP!UZ?@,<D?C^E?,<><4XWC7BO.^)L4N2KFN-=:G1<5%4,)1C"E@\)&R4;8;
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M::W7JAK=>J/X?_\ @G'_ ,FB^!_^Q_\ VB/_ %I'XMU]QU_5_%G_ "57$O\
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MZC9[Q>)\5?!3_@D[\'_!W_!+WPS_ ,$N_CMKW_"^_ASH_AKQIH.I^.XO"O\
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MTIT'Q-_9EI=^(_!YUK%T+33S9Z]8:YHFA^(-/_/&[_X()_M2_M$:U\,_"/\
MP47_ ."I_P 4_P!KO]F;X1>)=-\1Z/\ !&Q^&%O\-)OB!=Z1;B"PF\?^,K7Q
MUKVIW5R+07ND7FKWEIXG\;?V-K>MKH?CWP_?ZG>:@?G^$/'#"\.9+4PF8\)8
M/.<[R?'YMFW!6<XBNE/AO'9[6A+$<L'3J1JPHXF$L;3<91]I648R]G>-6F3P
MDM&I./M/XEOA=MNUNVNR?R/:?VS/^"(GC#XC?M@:3^WE^P;^UWKG[#O[1/\
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M?\(Y:>"+7[>/'W_"=:J/%'VL># 5M!X-\,_9/[0"_:[LV.^\D_:<_P"":?\
MPT7_ ,%"?V+?V[A\9_\ A$!^R%I_B:R/PL_X5X=?_P"%@_\ "0C50)E\:CQW
MH7_"(?9/[34LI\(^*!>"T4 V?)KY3_B)]:/$<>(O[(ASK@;_ %(^K_6GR^S_
M -5O]5_[1]I[&ZE[/_;OJ_+R\W[E3M^\-517(H]%B>:^G3$<]K>BW_#8_50=
M!]!2U^4&H44 %% !10 44 %>+?M(?\F\_';_ +(Y\3?_ %"=;KJP/^^X/_L*
MP_\ Z=@-;KU1YY^P[_R:#^SM_P!DE\(?^FR.OJRNO/\ _D=YQ_V-<=_ZEU"5
MLO1?D-SU '/;W_E7Y*?'/_@EY_PN?_@JE^RS_P %,!\;5\-C]F?X6WOPV/P7
M?X;G5_\ A-?MMM\:XAK ^(H\=Z;_ ,(U]F_X7"6%B/ NM;O[" ^WK_:0_L_U
MN#>*JG"68YACZ>#6-_M#A_/<A=-U?8^QAGF5XK+JF(YE&?-]7A6]HJ=DJDDH
M<T4W*)**E%Q?6WRLT_T/UHR.G\/;';'Y_P"3^7Q9_P %"/V2#^W=^QS\;?V3
M_P#A8+?"O_A;^D^'=(_X3X^%3XW_ .$<70O&OAKQ=]H'A=?$GA ZI]I_L#["
MH_X2/3OL9O/MVZ3[&+.3S.&LWGD/$.19X\*L6\@SO+<VCAG4]C'%3RW&8?%Q
MP[JJ,W2C7Y.1S4).&]G9()PYH37>+6GI;IV_X;0]%_9:^ -M^S7^RW\!/V9;
MOQ GQ!LO@M\&/A]\';OQ3=:##H,/B^'P/X/TOPG/K$_A>74]>@TF#7O[-:Z;
M1CJVMBR6\^Q'4+]4:[?\';O_ ((&_'[]G7X@?%/7/^"7O_!2;XD_L6?"?XPZ
MQ-K7B?X"7WPYT_XG^$?#^I:@#;7]]X)U6\\3:5_9']FV>++P]_Q3G_"56%A9
MV%E+XZNDL;#[#^G<$>*F!X?S;BI\0\.T.(N%^-,3[?->'ZM?DIT\;1S"MCL#
MBJ525-QG/!5*E:%I1INJG&;G#V4(/.='W:33<7%^Z]=+KE:WTNFMON/O7_@F
M5_P2-^&?_!.Z#XM^-?$'Q+\6_M-_M+_M"W7VKXX_M ?$JS$.K>*8)+JYOI]!
MT;0KC5/$MSI.A:EJ=W=:UX@.L>)/%&N>*-;87VN:W+9Z?H>G:7\*2_\ !!;]
MHK]G7Q[\4]0_X)C?\%+OB-^Q;\%_C1XAE\1>+/@'?_#'3OBIX8\+ZEJ,)@O[
M_P  :KJ7B;2UTG[+:K8Z3HNWP]:>*+31;"QL;WQW?+IVG?8OHLK\<L)_K3Q9
MF/$?".!SOA#B^GEU&7"3K1AALNAD'*L@EAZKHVJRRZA"=&5Z5%5_:<[E#V4:
M)E/#2C&DXRDI1VEUL]9;:ZZ6>NUNK:]A\)_\$"_A3X!_X)V?M/\ [%7AGXY^
M*[OXO?MAZEX7\4?'K]K?QWX6_P"$Q\7>,/&'A?QQI/C:QOY_!7_"6Z$3H5O=
M6OB#[!H]WX]O=;L[[Q9KNN:CXJUS4;LD^C?M=_\ !''_ (:H_P""87[-_P#P
M3>'[12>!'_9[TKX%:=_PN3_A4/\ PE(\7_\ "E_AWJ/@!Y_^%=GXFZ%_8/\
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MTGM2IJE'ENV^K?>RV\ELOTV'T5^?FH44 %% !10 44 %% !10 44 %% !10
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M#^SM_P!DE\(?^FR.OJRNO/\ _D=YQ_V-<=_ZEU"5LO1?D%%>4,3';M2T %%
M"8I: "DP/2@!:* "B@ HH ** "B@#\\/^"HG_)I.O?\ 90?A/_ZL'0*_0Q>_
MT7^5?18W_DE^'_\ L;<0_P#IC)!=7Z+]1]%?.C"B@!,4M !10 446 ** "B@
M HH ** &G[R_C_*OSR_;K_Y'S]A?_L\'X??^D&K5[_"__(YI_P#8%FG_ *J\
M<*7PR]%_Z5$_0X=!]!_*EKP7N_5C"BD 44 )BEH ** "B@ HH ** "B@ HH
M_.WXW_\ *0S]B'_L2_VC/_41LJ_0].GX_P!!7T6>_P"Z\-_]B%?^K?-Q0VGZ
MO\XCZ*^=&%% "8I: "DQ0 M% !10 44 %% !10 5^=F@_P#*4?QS_P!F;:#_
M .K8@KW<C_@Y[_V)JW_J=@A]'ZK\F?HG17A""B@ HH ** "B@ HH ** "B@
MHH ** "B@ HH *3 ]* #&.E+0 44 %)@>E "T4 %% !10 44 %% !10 44 %
M% !10 44 %% !10 44 %,D_U;_[C?^@FFMUZH:W7JC^'_P#X)Q_\FB^!_P#L
M?_VB/_6D?BW7W'7]7\6?\E5Q+_V4&<_^K'$GF0^"/^&/Y(__T/Z%O^#<;_E&
MCH/_ &<)^U!_ZNKQ57[Q5^C^+_\ R='C[_LJ\[_]3ZQCA_X-/_"%%?G!L%%
M!10 UL#G'/0?Y_\ K4P Y]#]0?TJ'9N#;MV6FK:V^2_X GMIH2T58PHH **
M"B@ HH ** $'0?05^>/_  4__P"35=2_[*3\)O\ U.M)KZ+@_P#Y*?(O^QIA
MO_3I,OAE_A?Y'Z&I]Q?]U?Y"G5\\]WZLM[OU844A!10 44 %% !10 44 %%
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MR@_"?_U8.@5^AB]_HO\ *OHL;_R2^0?]C;B#_P!,9*+J_1?J/HKYT844 %%
M!10 44 %% !10 44 %% #3U7\?Y5^>7[=?\ R/?["_\ V>#\/O\ T@U:O?X7
M_P"1S3_[ LT_]5>-$_AEZ+_TJ)^APZ#Z#^5+7@O=^K&%%( HH ** "B@ HH
M** "B@ HH ** /SM^-__ "D-_8A_[$O]HS_U$+*OT/3I^/\ A7T6>_[KPW_V
M(5_ZM\W%'[?K^L1]%?.C"B@ HH ** "B@ HH ** "B@ HH 2OSMT'_E*1XY_
M[,VT'_U;$%>[D?\ !SS_ +$U;_U.P0^C]5^3/T3HKPA!10 44 %% !10 44
M%% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44
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M/^K'[(?^9MMZ_1+<,?@./K7M9\^6>6V6V28"3]51C;]2G\,?G^8ZBO%)"B@
MHH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH 3_/Z"O%
M?VCSG]GGXZ^_P=^)W_J$ZY_A73@5_MF%_P"PBC_Z6E;T''=?UL>??L.?\FA_
MLZC_ *I-X0_]-L=?56WK[XZ>U=>>JV=YO'_J98]?=B:B)6R]%^0ZBO+&%% !
M10 44 %% !10 44 %% !10 44 ?G=_P5$_Y-+\0?]E ^$O\ ZL'0:_0T8P,_
M7CVPH_S[5]!CKKA?(9/7_A1XBVM]BED7Y\XNK]%^I)17SXPHH ** "B@ HH
M** "B@ HH ** $!R :_._P#;K 'CK]AC'_1X'P__ /3?J]>YPU?^UZ:BKM8;
M,ON>6XNX='_V[_Z5$_1 =!]!_*EKPP"B@ HH ** "B@ HH ** "B@ HH **
M/SM^-Y_XV%_L0'_J2?VC>/KX0M,5^B"XP,=*^CX@3AA.%-/XO#:J_P#F>SR&
MR[)+Y#^S\_T0ZBOG!!10 44 %% !10 44 %% !10 44 0=QC'?=[^AX^G0>@
MK\[] /\ QM%\<8PW_&&V@CT!Q\5XA_3^E?09#K0X@YO=Y,AKK_M[ZS@/3O82
MC4;G5C:I&FM%\.D_94W;9>[J?HAQZ'\Q_A1QZ'\Q_A7SWO\ \C':7\OY_P#R
M(<>A_,?X4<>A_,?X4>__ ",+2_E_/_Y$./0_F/\ "CCT/YC_  H]_P#D86E_
M+^?_ ,B''H?S'^%''H?S'^%'O_R,+2_E_/\ ^1#CT/YC_"CCT/YC_"CW_P"1
MA:7\OY__ "(<>A_,?X4<>A_,?X4>_P#R,+2_E_/_ .1#CT/YC_"CCT/YC_"C
MW_Y&%I?R_G_\B''H?S'^%''H?S'^%'O_ ,C"TOY?S_\ D0X]#^8_PHX]#^8_
MPH]_^1A:7\OY_P#R(<>A_,?X4<>A_,?X4>__ ",+2_E_/_Y$./0_F/\ "CCT
M/YC_  H]_P#D86E_+^?_ ,B''H?S'^%''H?S'^%'O_R,+2_E_/\ ^1#CT/YC
M_"CCT/YC_"CW_P"1A:7\OY__ "(<>A_,?X4<>A_,?X4>_P#R,+2_E_/_ .1#
MCT/YC_"CCT/YC_"CW_Y&%I?R_G_\B''H?S'^%''H?S'^%'O_ ,C"TOY?S_\
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M5PB"B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH
M*\Y^*OA6Z\=_##XB>!=/N8+.^\8^!?%WA2ROKE96M;2\\0:%J.CP3W(MLW'V
M:VN+I7N0@W[58+\W%:T*GL:V'J?RXBD^FT7S/\%IT_ <=UZHYG]GWX<:E\(/
M@A\+OAAJ]]9ZIJO@3P;H?AF_U'31<?V?>76F6WV:::V6X$-U]G8IN N0&[%<
M\'VRM,?7^MXS%8NSC[?%XFI9VO:K7YM;;/YOR\Y6B2[:?<%%<PPHH ** "B@
M HH ** "B@ HH ** "B@#Y9_:\^!NN_M$_!?4?AGX=UC2]"U2\\3^#-=2_UC
M[;_9X@\,^)],UJYB8Z?!<7(GN+>T:.U"H?G9<X4$CZB !Q[ ?CD>E>CB,<JF
M69?@+.V&Q>.JIVT?UVE@]/E]32>B7PI=DNOW$E%><,** "B@ HH ** "B@ H
MH ** "B@ KY9_:(^!>O?&3Q#^SSK&C:UI6E0_!OXX>&_BEK$6I_;_-U72-#M
MKRWN-.T[[+;RC^T+@78""]*6F =SY(-=^58Z.6XVGB)1<O<Q</=2O^^P>(HW
MUM91YTWJM%IK9!T?R_"2/J4< #TI:X "B@ HH ** "B@ HH ** "B@ HH **
M /ECX@_ S7O%W[3G[/WQRLM7TRVT#X0>'_B?I&KZ-<&\_M;4I?'6@)I-A-IQ
MAM_LH%G.F^]^UW2GRSF)2XKZDX88''"_AW KTLQQRQE+**:3_P"$_+O[/UMT
MQ>,QEU:^G^TV];]@Z>E_T7Z#Z*\T HH ** "B@ HH ** "B@ HH ** *W0'Y
MC@>P ZCT_#I^5?A/^WU^V;X'_P""<G[9'A#X[_$3PSXK\=:7\:?@'J_PTT/0
M/!*:.-0TFY\!^-M"\0ZMJFL3:]JVCVZVUT/$-A;6%O8->$.EX][]DC.7^NX.
MP3S;,YY53DZ;S/ XB@II<W+K1JW:;C?^&E:_^:_1_"CPYS/Q8X[R/@7**T<+
MB,V_M%J<HJ:M@LMQ.,^'GIW7[GI*.BWT/G__ (B:/V</^C>_CC_WWX"_^:^C
M_B)H_9P_Z-[^./\ WWX"_P#FOK[K_B#6:=,7'_P"/_R9_9__ !3MXY_Z*C"_
M^&J7_P W!_Q$T?LX?]&]_''_ +[\!?\ S7T?\1-'[.'_ $;W\<?^^_ 7_P U
M]'_$&LU_Z"X_^ 1_^3#_ (IV\<_]%1A?_#5+_P";@_XB:/V</^C>_CC_ -]^
M O\ YKZ/^(FC]G#_ *-[^./_ 'WX"_\ FOH_X@UFO_07'_P"/_R8?\4[>.?^
MBHPO_AJE_P#-P?\ $31^SA_T;W\<?^^_ 7_S7T?\1-'[.'_1O?QQ_P"^_ 7_
M ,U]'_$&LU_Z"X_^ 1_^3#_BG;QS_P!%1A?_  U2_P#FX/\ B)H_9P_Z-[^.
M/_??@+_YKZ/^(FC]G#_HWOXX_P#??@+_ .:^C_B#6:_]!<?_  "/_P F'_%.
MWCG_ **C"_\ AJE_\W!_Q$T?LX?]&]_''_OOP%_\U]'_ !$T?LX?]&]_''_O
MOP%_\U]'_$&LU_Z"X_\ @$?_ ),/^*=O'/\ T5&%_P##5+_YN#_B)H_9P_Z-
M[^./_??@+_YKZ/\ B)H_9P_Z-[^./_??@+_YKZ/^(-9K_P!!<?\ P"/_ ,F'
M_%.WCG_HJ,+_ .&J7_S<'_$31^SA_P!&]_''_OOP%_\ -?1_Q$T?LX?]&]_'
M'_OOP%_\U]'_ !!K-?\ H+C_ . 1_P#DP_XIV\<_]%1A?_#5+_YN#_B)H_9P
M_P"C>_CC_P!]^ O_ )KZ/^(FC]G#_HWOXX_]]^ O_FOH_P"(-9K_ -!<?_ (
M_P#R8?\ %.WCG_HJ,+_X:I?_ #<'_$31^SA_T;W\<?\ OOP%_P#-?1_Q$T?L
MX?\ 1O?QQ_[[\!?_ #7T?\0:S7_H+C_X!'_Y,/\ BG;QS_T5&%_\-4O_ )N#
M_B)H_9P_Z-[^./\ WWX"_P#FOH_XB:/V</\ HWOXX_\ ??@+_P":^C_B#6:_
M]!<?_ (__)A_Q3MXY_Z*C"_^&J7_ ,W!_P 1-'[.'_1O?QQ_[[\!?_-?1_Q$
MT?LX?]&]_''_ +[\!?\ S7T?\0:S7_H+C_X!'_Y,/^*=O'/_ $5&%_\ #5+_
M .;@_P"(FC]G#_HWOXX_]]^ O_FOH_XB:/V</^C>_CC_ -]^ O\ YKZ/^(-9
MK_T%Q_\  (__ "8?\4[>.?\ HJ,+_P"&J7_S<'_$31^SA_T;W\<?^^_ 7_S7
MT?\ $31^SA_T;W\<?^^_ 7_S7T?\0:S7_H+C_P" 1_\ DP_XIV\<_P#1487_
M ,-4O_FX/^(FC]G#_HWOXX_]]^ O_FOH_P"(FC]G#_HWOXX_]]^ O_FOH_X@
MUFO_ $%Q_P# (_\ R8?\4[>.?^BHPO\ X:I?_-P?\1-'[.'_ $;W\<?^^_ 7
M_P U]'_$31^SA_T;W\<?^^_ 7_S7T?\ $&LU_P"@N/\ X!'_ .3#_BG;QS_T
M5&%_\-4O_FX/^(FC]G#_ *-[^./_ 'WX"_\ FOH_XB:/V</^C>_CC_WWX"_^
M:^C_ (@UFO\ T%Q_\ C_ /)A_P 4[>.?^BHPO_AJE_\ -P?\1-'[.'_1O?QQ
M_P"^_ 7_ ,U]'_$31^SA_P!&]_''_OOP%_\ -?1_Q!K-?^@N/_@$?_DP_P"*
M=O'/_1487_PU2_\ FX/^(FC]G#_HWOXX_P#??@+_ .:^C_B)H_9P_P"C>_CC
M_P!]^ O_ )KZ/^(-9K_T%Q_\ C_\F'_%.WCG_HJ,+_X:I?\ S<'_ !$T?LX?
M]&]_''_OOP%_\U]'_$31^SA_T;W\<?\ OOP%_P#-?1_Q!K-?^@N/_@$?_DP_
MXIV\<_\ 1487_P -4O\ YN#_ (B:/V</^C>_CC_WWX"_^:^C_B)H_9P_Z-[^
M./\ WWX"_P#FOH_X@UFO_07'_P  C_\ )A_Q3MXY_P"BHPO_ (:I?_-P?\1-
M'[.'_1O?QQ_[[\!?_-?1_P 1-'[.'_1O?QQ_[[\!?_-?1_Q!K-?^@N/_ (!'
M_P"3#_BG;QS_ -%1A?\ PU2_^;@_XB:/V</^C>_CC_WWX"_^:^C_ (B:/V</
M^C>_CC_WWX"_^:^C_B#6:_\ 07'_ , C_P#)A_Q3MXY_Z*C"_P#AJE_\W!_Q
M$T?LX?\ 1O?QQ_[[\!?_ #7T?\1-'[.'_1O?QQ_[[\!?_-?1_P 0:S7_ *"X
M_P#@$?\ Y,/^*=O'/_1487_PU2_^;@_XB:/V</\ HWOXX_\ ??@+_P":^C_B
M)H_9P_Z-[^./_??@+_YKZ/\ B#6:_P#07'_P"/\ \F'_ !3MXY_Z*C"_^&J7
M_P W!_Q$T?LX?]&]_''_ +[\!?\ S7T?\1-'[.'_ $;W\<?^^_ 7_P U]'_$
M&LU_Z"X_^ 1_^3#_ (IV\<_]%1A?_#5+_P";@_XB:/V</^C>_CC_ -]^ O\
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M% !10 44 %% !10 44 %% !10 44 %% !10 T_>7\?Y5_(1_P<^?\CG^Q_\
M]B]\:O\ TZ_"JOT;PK_Y+3*?\.*_]1JY_6?T(_\ E(_@7_KQQ'_ZSN;'\K%%
M?UT?[^A10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 45K0_C4?^OM/_P!*1RX[
M_<L9_P!@N(_]-2/WL_X)/_\ )@OP-_Z_OC%_ZO;XG5^BE?F7&_\ R6G%_P#V
M5&?_ /JUQ9_RT9K_ ,C/,?\ L/QG_J14/__5_H6_X-QO^4:.@_\ 9PG[4'_J
MZO%5?O%7Z/XO_P#)T>/O^RKSO_U/K&.'_@T_\(45^<&P44 %% !10 44 %%
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M5VM\2\NA)^#B_P#!S3_P1RS@_M)^)U[<_ +X\XX^GPYX_3^5?HW^QY_P4/\
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MMBDYKE3BO:?O(1G;W;7E%RE\G*]EMJM+6"W?U]?\K]/RV$';N.N<8' X '^
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MT_94,'A<EQN83I4\10IRE"$%"3J>SEV-R;T<;M]5HE&,)<WJV[:Q>GH8>O\
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MIE/^'%?^HU<_K/Z$?_*1_ O_ %XXC_\ 6=S8_E8HK^NC_?T** "B@ HH **
M"B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH **
M"B@ HH ** "B@ HH ** "BM:'\:C_P!?:?\ Z4CEQW^Y8S_L%Q'_ *:D?O9_
MP2?_ .3!?@;_ -?WQB_]7M\3J_12OS+C?_DM.+_^RHS_ /\ 5KBS_EHS7_D9
MYC_V'XS_ -2*A__7_H6_X-QO^4:.@_\ 9PG[4'_JZO%5?O%7Z/XO_P#)T>/O
M^RKSO_U/K&.'_@T_\(45^<&P44 %% !10 44 %% !10 44 %% !10 44 %%
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M4I0P]*?LH.,G%)N27525H+3D?\JBHZ7T5HVZ6UMK]Q^ ?_!3_P"#GQ;\??\
M!4G_ ((=^/\ P+\+?B+XU\"?"GXI?M.7_P 4_&GA3P3XG\1^$OAEINNZ#\%K
M?0;[Q_XET;3+O0O!]KK5SIFK)I%WXBN['[=_9]_]@_X\;ZOW[ ''; .?H?\
M#_"N;BS,L)B^%?#;+\/5IU*V4<,9QA,;3A.,IT*V(XPXDQM.%91DY4ZD\)BJ
M%51GRR]G.$DN6410BXU:KZ2Y;::?"HO3R:?2U[KH?@%^UY\'/B]XE_X+W_\
M!)_XP>'/A;\0]=^$WPY^$/[5FF?$'XIZ+X(\3ZE\.O NH>(O@W\5M-\/V'C#
MQK8Z7<>&/#-WK^HZC:6.CVNM:M9W5_?7EA8V"O<WX4K_ ,$5O@W\7OA9\>_^
M"R6L_$WX7_$7X=:/\4/^"DGQJ\<?#;4_'7@CQ/X0TWX@^#=4\:^-[C3O&'@B
M^\0Z7IUMXP\,:G:SVMY8^)/#K7NAWEE?6'V*]?M]WF7$F1U> *>6T\70>,CX
M9\-9/[)58>T_M#">)F<9Q7H<JES>UAEU>EB)P:YXTI1J-*+3'ROVG-ROEO\
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MQQPDZK4*,>(LAG5F]HPAF^'E-_*&HJB3IR77EEI\G;_AC^>GXO\ PF^*$/\
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M'6].O]/^VV-CJ%Z/O.#:>>4.&L%_8%3*<!P;G/#WB9+BS&WR^>/S3BRM#B[
M9=E2A6E]<HRE2_LBK1JX:-I?5WAY3A3C&G4PQ*G*LTTW)-*-]HP]V7,M+6^)
M6VUO;J?T._L1PJ?^#C#_ (++3&,;D^#7['D<4A_UGDS_  0^$'8\[<VWUQ^5
M>)_\'!=Q\0?V%/CE^R7_ ,%>O@9I'VOQ9\.-%^)?[+/Q:L_^7/6/#?Q+\%>,
M9_A!?Z\%"JND>%?&.H^*[RYO+I;O=K6H>$['&[['C\IX=G@<=XN\$9)CY1K9
M9Q-X7\)\)9@H59V]GFWASA,+3C^Z?NSH8]X=M-6IRIWDHN'-#HJQ=/#67Q*3
M=]/L3O\ H[;=C]3/^")O[)5Y^QW_ ,$YO@+X%\46US!\4_B)H\OQX^,]U? C
M6[OXG?%X6WB?4;?Q"TA)N=;\,:"_AWP+>7A_X^O^$563 '3]9@/F;_\ 5UK\
M"X_S7^W>->+,W7P9CGV;5Z5O=Y:+QM544TKI25'DB[/IH=%)*-*,;;12O>_1
M7^5]NVP^BODB@HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "
MB@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "
MB@ HH ** "B@ HH ** "B@ HH ** "B@ HH :?O+^/\ *OY"/^#GS_D<_P!C
M_P#[%[XU?^G7X55^C>%?_):93_AQ7_J-7/ZS^A'_ ,I'\"_]>.(__6=S8_E8
MHK^NC_?T** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH **
M "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "BM:'\:C_U]I_\ I2.7
M'?[EC/\ L%Q'_IJ1^]G_  2?_P"3!?@;_P!?WQB_]7M\3J_12OS+C?\ Y+3B
M_P#[*C/_ /U:XL_Y:,U_Y&>8_P#8?C/_ %(J'__0_H6_X-QO^4:.@_\ 9PG[
M4'_JZO%5?O%7Z/XO_P#)T>/O^RKSO_U/K&.'_@T_\(45^<&P44 %% !10 44
M %% !10 44 %% !10 G%+0 44 18_O=_T"\_3L*XCXBZ#XC\5?#_ ,<>&/!O
MBVZ^'_BWQ'X0\1Z%X7\=6.G6VKWG@KQ%J^CW>G:/XNM=)U PV6J7/AG4KBUU
MBUL;MUM+UK$6<NR-VJL)4I4*]#VL/;4XXB-6=)NRG2]LFX-J,DE*'N[.VK0]
M+K^73]+GY<?\$\_^"8'BS]E+XP?&3]J[]I?]IWQ+^V9^U_\ &C1-'\":G\8_
M$?@RQ\ Z?X0^%F@RVEU!X \'^%+#7->M--M-4U/3M(U/6KFTNK"QO'T/1/L&
MAZ=+'K=[KWKO[7/_  3^'[57[6G_  3^_:D;XL'P,W["7C7XL>+T\$#P,/$@
M^*)^)^G_  ^L6L#XE'C#0!X-_L3_ (04/]J/A[Q7]O;40/L=B+'=??JF9^)5
M+$<=UN+,%D-/ 9?1R7&\,9/D<<3+V.!RS$<*8KA;"1CB8TG=T*6*EBU#D49U
M%[&\8OVAE[&/L*B[ZW\[J2^]KILM;:6?Z08P"%Q@8SQ_G_\ 50$!SR&7C@K_
M (]/PK\H]WF52*?/9T[IRV3OUT^R[/JNK5C5.*BH);:_U;3Y=!V BX&!].,?
M0?I_6DQWXR>GM^((%1R\S?/[R:B^6[U<'S-]UJUUZ"V7W_=8' XX'&>W3Z?7
MVX^E(0.>>?3'^>W_ -:J;E9*5VI>Y!<K=DUUMV;MTM9!M=]EW[=O^ .^7Z\X
MQC!XQ@#TQQ0 %Z=L>P'KCW-)I_S6@FFU:RY(IQ4=?[[O\DK:#^73]?ZT&\=2
M/O8Y''3B@8'ITYYZ<^WT'3IFE9M^T4K<\$ET3FN5P_#FT%>]N^EEVT2_!60;
M=WIC_P"MCH?\^G%."X.,#'T&.GI]>PZ5:<VE[W(TM;6:ERWC%>7-=2TU5K/R
M>GW+339_U?4084G/^>.V,_E2X0%NG;MZ8'6H5X1Y)S;YVX)[.7->3]+7:79)
M+JD+IMIVZ=/U H.P ^@'^128&1\HW+]!UZ]./3T_&JDYK2/,_=;D[[]$H]GK
M==K*WDU]W?TVVL*.1\P!7UXQ^7_UN*3CT&1Z]![\8 ].!FESVY;+W%&4G.]E
M!*UM/.[[)6%;\-M/Z\D!^4CZ?XTT+P>F/_KCT_\ K?2FW*%I)^Y%7FK7=HZI
M^7;^M"VL7V_JPYL'C^[QD]?T%. &>,8'7CU'%"FFW!2]Z.Z[<R3\E;5?=8>J
M2[=/\AN,Y'IV&.!Z>_H!2C W \#T[#\NE/F\^RBO--N4ON_%>8DEK\M/3\-A
M$4#@8X[*,#T]!3L;1U[]<?Y]*F//ROGE><KN_;9+[M 'T58!10 GM49"E=IP
MV3T8'';BI<FK*.D]>7M>*OKY )\H!&U=O3&."#VQTQQTQCM67IVC:3I23)I6
MEZ?ID=S<37LZV-E;VB2W4Q0S3SK $$UQ-_%/@LV!NZ8;2GBJ].G5I4JU2-"K
M["KB8*<XQK)*4H7BG9RAJXWORN3:2W!I/3\OE?Y-[][&J-OID]LC^77_ #^%
M9=YI.EZE);2WVF6%_+I]S%>V4EY9V]U):74/W;BQ:9<VMR.-MS;[6Y([T4*^
M(I5(5*$JE&\>;VL:LHSI\_->*::E:UXM1:7(W'X=!W3U\[>B3Z?/RW5S\[O^
M"M_[(/Q'_;S_ ."?/Q\_90^$6L^"O#'Q"^*;_"D>'M7^(FHZYI'@RT_X0CXV
M?#KXC:N-8U'PQX:\7ZY:_:M!\'ZK:61LO#FH;]0NK**[%G:&[O;/[&^#OPY7
MX>_#;X8>&M8L- N/%?@OX9^"O VK:[IMN)3=3>%_#^FZ7/%9:C<6EKJ5QI;7
M=M=3VJ7*VC!6#M9*Y;9]=/B5_P"H^#X8HRKPQ.&XESW.9U5+DHU\-FF5Y%ET
M<.^6K&<N2KE'/-3IJFXU824IR3BIY8RJ:ZO\=&W?\?ST/4+[3[#5+.6QU*QM
M-2LKB(Q7-C?VT-W:SQL!F*>WG5K>8<<AE(/'M3[6RL[.WBM+.T@M;2VCCBMX
M+:%8X8(HL>7'##$H"JN.BC';&,X^4CBINDZ*KS]C3JN4J'/-4U645#G5/X%-
MQ2CS15^7W2DK;-+3TO\ EU]+!/86=X]N]S:VUQ-9R;[>66&&:2UFQ_KH&=3Y
M,O\ M+TP!5T+P> #QZ_X^W;TK.524XPH3E4=*BG3H1=2;@J<USN,8WTN^:3[
MR?-NTQ;6?W>5OZ_)6T&X]$ _#^?X>N?H*"BX4%00,_+CC\N@Q4\W*H-S=VU=
M:KE<KI*WK+E7I?II7:S??M;3_(R]/T72-%@>UT?2['2X))9KE[?3;.VLX6FE
M.9I3#;K !//_ !/C)(Y-:VT @< ?P@>GY5I7K5,17>)KU)UL3)/VE>I4E.<N
M=I3O.3DV[T[WDV]M5<F,>3;^OETWT_ 0!0, ##'@#Y0!GCM_GM2GH., #_(Q
M_G\*Q<I/X7^\4U&2>O*]'UWLG^ [;=[^G7_,R;C2=+N+RSO[G3;*XO\ 3_/%
MC?36EO+=V/VH>3<&RN3']HM#. !/Y#+Y@&'X K4,:]-H([?*.OO_ "%:U*V)
MK<G-7J2I4J+HX:,JDI1I1E.I5:IQ;:IQ4ZLI.$4DZDIS?O,-$EI\]M%T_P"#
MTVV&[1UQT'!_''%+C)]\<'\AZ?G]*2F^5/7W933_ ,$>=KTYN5?)V"RMOM4Y
MOZ]10!QQD]N "/T(_P _EFWNE:7J3VDE]IEA?R:?<QWME)>6<%U):740XN+(
MRJ3:W(XV7%N0>2,U5"OB*=15:$ZE!V]RK"K*$XJI"2DO<:E%:N,EMR-QV'NT
M]?\ ))]'VOKMI:YI;5(QM^H[#N!C  'IQQQ1M&"I"XXX.,'TQVQ]/ITK+GGI
M&#O)-6N_LK[7_;^B]?1BVOKU3_I?=YZ?=0O-.L-3LI[#4["TU&QN(S%/8W\%
MO=VDT;=8IK>96MY5X!(93VJ2WL;.QMH+:TM(+6UM8TCM[>VA2*&"*/ BBABB
M4!54#[H4#MC'%;1Q.+EAU1G6G1IN?M7A?:<U.G7G'V?M4O@<VE%.5N;E7*W9
M)#NG*]_S7_!M?_@%L?+ST/(/Y<?X5^!'[8W_  3[_;S_ &^_VNO!O@[]H#XH
M? #2_P#@EI\*_C/X%^.&C_#+P=IWBC_A>GQ8O?"'AZT:R\!?$\:CH9\/_P#"
M/GQ5<^)+6^_L_P 16=FWAC6K*^;3[_Q!8V/]A?;>'?$&5<+YQC<]S*A6Q6-P
M&78NKPS[*4XJCGS5*G@,15<9QC[+#2G5KRC54Z;5)+DE/V<7%2/.FK]+7?5=
MEH[7T73[KL_?A0HVJ.@QQZ!1@?G4F>2/3%?!VLK7O[W-_P"!3O\ AM\ABT50
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
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MGQ%^V?>:QKVA7_C[X,?#(ZEX7N6M-5\0ZEJ>K>&_ =CHRZ+?Z?H=WH5C]O\
MMMBMZ/U7(<BP%'AS(\;C<IEF^,S[->)'0PU.?LZL<NX;X>M&K"I4G3@H1S/,
M)8VLE*\H90H)S;]F1)_Q=;*R?WOR_P -NGQ=#\A?VY?^"T'[4/["?_!;OQAX
M#\4^(/$/C+]@7P%X?^"T7Q=^'>G>"M!OHOAOX<^*/@SP;;ZA\3;#Q'IFA'Q2
M-1T/QEK-AJUM8ZOK#:?KBWE]X0L5LKW7=/O;#]K/^"QG[5'Q!^!O_!*'X_\
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M$.HVFC^']:U:QUC4K2ZMK+7M7U&RTK1W=,:A?WMG8V&^[D1:I?!?]N3]C_\
M:*\"^-?B3\#OVCOA#\3?!?PTTR[UCXB:[X7\8Z1>?\(-I-M8W>K3ZAXPL9KB
M'4O"^F?V;IUY?+>:Q:6-K=65A>R6KLEE(4_.?]0N,XY1'/GE&*63RG@)K'<L
M/8NEF-2B\%/XN=T:].7LO;QA[&G5:C4E"?NFG/'VG+IZ7OL[-?Y+RTNC\S/^
M"5/_  5U\/?MT?'3]L_X6^,OBK\%'U?P3^TIX]\'_LL> _!&J6L.L>.OV??
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M?",UT-.LM=^(?BK1_#5KJ6H[&G&DZ/%J-Y;W6MZHUNIN4TG2;>\U!K5&9;3
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MO!_A;Q2-+\._!R6PC\1^']*UX:<+R]^*/VG["=5M;K[/]H%K;&X^S'&\*#C
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MCH/_ &<)^U!_ZNKQ57[Q5^C^+_\ R='C[_LJ\[_]3ZQCA_X-/_"%%?G!L%%
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MIX:>)&/EA^"^(\!F^+P\5.KA56IT*U*FW925&<U.I%M63C%JZT=S3^''Q/\
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MQ/L)OAUX%T_S8?#_ (/B\3:I\0H;FP\/Z>/^/6UM],T#PWHX"97[#H=A8_\
M,/%?483/<RS+BCB+(ZF+G6RO+L%X$U,LP<K/#X*O#B#@&E[7#TFK4IUGFN-^
ML2BHRK\Z59R5.CR0THT79*_-6UMK9JIOW^%6Z+IU1]/?'+]CC]HOXU_LJ_\
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M&,O?E=4;ZZWZ9NU:DEVGZ:<BO;\5=:?E_2/17Y8:A10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %)0 M% !24 +10 44 %% !10 44 %% !1
M0 44 %% !10 44 -/WE_'^5?R$?\'/G_ ".?['__ &+WQJ_].OPJK]&\*_\
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MX?\ C]\1M9>VV*AD_LKX-?""^\M<C ,_D9'N178_\$-OV\_VC_VT_$'[6/\
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MPVWOM:N]E]F33M&[T::>OGL?-'[5_P"PE^R7_P $U?\ @E#\-?V/OVV?B/\
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MJO9W]E4M'+^\YNBB]+=[?_(O;;KN?M/17YL:!10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
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MZ:E@I8B7-3GRV_=2?>_$3]N#_@C=_P %*/!7PG\0?M@ZCK7PO^)/PZANKO\
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M^SK\!?\ @IS\?_VB_BGX]N/"WP?\='X\MX7\4KX1\::XU^OC?XIZ3XI\-_\
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MPVFH0:].QBO-8UO0?#.ML8[+Q#K.KZ#9VBQ?'1X+XOP&#X:KX'#*684<-FF
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M3O"'QL\-N?AY_P (MXS_ +366X^(VAZ9H%S;CQ%_PBV+6UN1JV,?8O\ 1!>
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M]I_^E(Y<=_N6,_[!<1_Z:D?O9_P2?_Y,%^!O_7]\8O\ U>WQ.K]%*_,N-_\
MDM.+_P#LJ,__ /5KBS_EHS7_ )&>8_\ 8?C/_4BH?__4_H6_X-QO^4:.@_\
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M<I.]G96UTY.=W2\U;[D@Y7;9_P!6Z'SE^T?^R]\&OVL?"WA/P)\=O#MYXO\
M!/A+XE^"OBQ;^$QK^LZ3H.N^*?A[?SZOX5MO&NFZ1>V=MXQ\+VNJF/5KSPAX
MB2_\+ZE?V.G-?Z;>_8HQ7T8N!P,   #H.G^?I7H5<SQ.(P. RR3?U3 RQ6*P
MT.6UJN.^KT\3-]Y2C@\/'9)1A%*Z5RFG9>ZUMKWLM+>5NVFH_(]1^8HR/4?F
M*X[/L_N)L^S^X,CU'YBC(]1^8HL^S^X+/L_N#(]1^8HR/4?F*+/L_N"S[/[@
MR/4?F*,CU'YBBS[/[@L^S^X,CU'YBC(]1^8HL^S^X+/L_N#(]1^8HR/4?F*+
M/L_N"S[/[@R/4?F*,CU'YBBS[/[@L^S^X,CU'YBC(]1^8HL^S^X+/L_N#(]1
M^8HR/4?F*+/L_N"S[/[@R/4?F*,CU'YBBS[/[@L^S^X,CU'YBC(]1^8HL^S^
MX+/L_N#(]1^8HR/4?F*+/L_N"S[/[@R/4?F*,CU'YBBS[/[@L^S^X,CU'YBC
M(]1^8HL^S^X+/L_N#(]1^8HR/4?F*+/L_N"S[/[@R/4?F*,CU'YBBS[/[@L^
MS^X,CU'YBC(]1^8HL^S^X+/L_N#(]1^8HR/4?F*+/L_N"S[/[@R/4?F*,CU'
MYBBS[/[@L^S^X,CU'YBC(]1^8HL^S^X+/L_N#(]1^8HR/4?F*+/L_N"S[/[@
MR/4?F*,CU'YBBS[/[@L^S^X,CU'YBC(]1^8HL^S^X+/L_N#(]1^8HR/4?F*+
M/L_N"S[/[@R/4?F*,CU'YBBS[/[@L^S^X,CU'YBC(]1^8HL^S^X+/L_N#(]1
M^8HR/4?F*+/L_N"S[/[@R/4?F*,CU'YBBS[/[@L^S^X,CU'YBC(]1^8HL^S^
MX+/L_N#(]1^8HR/4?F*+/L_N"S[/[@R/4?F*,CU'YBBS[/[@L^S^X,CU'YBC
M(]1^8HL^S^X+/L_N#(Z9'MR*,CVI6MTL*UNG]?U8P/$FO:;X8T#7?$NN7<5A
MHGAW1]1US5KZ7'EVFG:38SW]_<S?W4M;6!YV/8*<=*_BW_X(Y_LW?\%3?CO\
M#/B]^VG^R_\ MM_#']E_PG^VI^TQ\;/C)KGA;Q=^SCX6^,?B+5M6_P"$XUS0
M-1U__A)_$$B8M$UVT\06MII%J/[/%[9W=\"#J-Z#^\>%F.X3R3@;Q"S+C+)*
MN?93CL5PCD$<'A\9/ XBIB*D\WS>5J]*OAZL81J97A:LXQJ6GR1YHRBFESUK
M^UHJ+MJWJKQZ1?1]W;30_5'P=_P3_P!8_8*O/VI?^"KG[8_[5_BO]N#]K;X;
M?LT?%&]\-^/O%G@30/AGX$^&7@[PAX1UKQ1<:!\.OACX?U/7M*T&[U,6LFCM
M=Z->:/826>LZ\++PQI^H>*_$%YJ7YA?L=_L,?LO?LM?\&^WQP_;4^-OP6^'/
MQ,_:&^.O[,/Q;^+NH?$#XI>$])\7:O82_$?3->TSX%^'O"=_KUIJ5SX8T[5$
MUOP-J^KW'APV=[K?BC6;S4KZ^OOL6A_V?]QEO'N*SO)\4^'\/_JWAL_XZ\,N
M"LFP.&Q$JCR_A[)(9[BXX:EBE"G5K7QV.A4QDX*-2I#%2I59U(-^TRE14:B;
MLU:3=TMW9/2_;2/II;0R+_0O"6L?LH_\$8/^";#?LK?$']M_]I71?V??"/[;
M9^ &H_&_2?@G\!-!\+>)YY]<LM9_:%O_ !!H7BBU\8:5H-[J?B3PAHO@;[#9
MV#6 UW1/MFS7-.T/4>I^$'A3XE:M_P ' W[%GA;QQ^RO^R+^R!XK_9V_9N^-
M_P 8?B5X=_9%U^#69KSX?^,/ 7B7X:^$-&^+VLZ5X+\ Z(VJ:!JFJZ/<Z-HU
MKH]_]B\,^*/MWV_[%?Z&;+ZZ#P$L%QAB:^?XCZQC.'/%[BG)N"Z.6U:>7?V3
MQ+B<XR_!X_-<<HRPV)JK%+#K#Q<Z56C+V&'HQ<)3G64HN-2E'E6CIQ<KKF32
MCI#9I6WT:>K?EH_'#P)XK^''QY_:]_X*L? 'X!?LL?\ !8'_ ()Z?M8:9IFK
M_&"QU1O#^K_&?X.:%\'/#]WX,\>6_P .=7\7:;KFDZOX#TTZ5=W>K6'A[2=:
MO[ZTT30=.O-"T*Q\)?\ "77_ ,J_M%Z%X%\:_!S_ ((I?L,?\$_?"WC?XJ_L
M>_M1>+/B]^U*GP-_:(^+S_#X?%+4?AY?VGBRX_9Z\:?$6PTN]M-"T+PQKD7Q
M%L]:\.V2Z[8WWBK6-.O=$U#4+Y-"UU>WANKA\9B.&\?CLVK9;E>60>"XMR+$
MX%XS$<+<7^'WAUFL,HQN5TXJM3K8?,(T:^:.AAJ%:&*Q6#A%J56K5HPRJ^ZN
M6R;^S):*4923?-L^972U::B^R3/LW6_A'^T?XC_X*;?\$R5N/V2OV%OV OBW
M\&?&NK^(_P#A&/@C^U%\.Y_B7\5_V;+K2QI'Q&\,6GPJ\-> ? 6M^)M T'PK
MH/BUM)*M>V%C9_\ "665E9"R.O5_80Q1(]SD  #)Z=!^(_SQVK^>?%ZMD]1<
M#4<GSC&\0RI\,UW/.,RPN*PN-Q].OQ!G5?"^U^NT:-:<:,)3H49N,H^QI0Y&
MXV.^C%Q6JC%MQ:C#ELO=BE91=D]+V^\_FM^/?[7_ .T5_P %:/B/\2?V&_\
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MW_SN:/\ B&O!W_0!^8?\2<?1W_Z(6G_X65@_X?-_\%,^G_#5'B;'_8C?"?\
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M_H _,/\ B3CZ._\ T0M/_P +*P?\/F_^"F?_ $=1XF_\(;X3?_.YH_X?-_\
M!3/_ *.G\2_^$-\)O_G<T?\ $->#O^@#\P_XDX^CQ_T0M/\ \+*W^8?\/F_^
M"F?_ $=/XF_\(;X3?_.YH_X?-_\ !3/_ *.G\3?^$-\)O_G<T?\ $->#O^@#
M\P_XDX^CO_T0M/\ \+*P?\/F_P#@IG_T=/XEXZ?\4-\)O_G<T?\ #YO_ (*9
M_P#1U'B;_P (;X3_ /SN:/\ B&O!W_0!^8?\2<?1W_Z(6G_X65@_X?-_\%,_
M^CI_$O\ X0WPF_\ G<T?\/F_^"F?_1U'B;_PAOA/_P#.YH_XAKP=_P! 'YA_
MQ)Q]'?\ Z(6G_P"%E8/^'S?_  4S_P"CI_$W_A#?";_YW-'_  ^;_P""F8Z?
MM3^)1_W(WPF_^=S1_P 0UX._Z /S#_B3CZ/'_1"T_P#PLK=/F'_#YO\ X*9_
M]'4>)O\ PAOA/_\ .YH_X?-_\%,_^CJ/$W_A#?"?_P"=S1_Q#7@[_H _,/\
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MAH?^%E?_ ##_ (?-_P#!3/\ Z.G\2_\ A#?";_YW-'_#YO\ X*9_]'4>)O\
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MW-'_ !#7@[_H _,/^)./H[_]$+3_ /"RL'_#YO\ X*9_]'4>)O\ PAOA-_\
M.YH_X?-_\%,_^CI_$W_A#?";_P"=S1_Q#7@[_H _,/\ B3CZ._\ T0M/_P +
M*P?\/F_^"F?_ $=1XF_\(;X3?_.YH_X?-_\ !3/_ *.H\3?^$-\)_P#YW-'_
M !#7@[_H _,/^)-_H[_]$+3_ /"RL'_#YO\ X*9_]'3^)?\ PAOA-_\ .YH_
MX?-_\%,_^CI_$O'_ %(WPF_^=S1_Q#7@[_H _,/^)./H\?\ 1"P_\+*_^8?\
M/F_^"F?_ $=1XF_\(;X3_P#SN:/^'S?_  4S_P"CJ/$W_A#?"?\ ^=S1_P 0
MUX._Z /S#_B3?Z.__1"T_P#PLK!_P^;_ ."F?_1U'B;_ ,(;X3__ #N:/^'S
M?_!3/_HZCQ-_X0WPG_\ G<T?\0UX._Z /S#_ (DW^CO_ -$+3_\ "RL'_#YO
M_@IG_P!'4>)O_"&^$_\ \[FC_A\W_P %,_\ HZCQ-_X0WPG_ /G<T?\ $->#
MO^@#\P_XDW^CO_T0M/\ \+*P?\/F_P#@IG_T=1XF_P#"&^$__P [FC_A\W_P
M4S_Z.H\3?^$-\)__ )W-'_$->#O^@#\P_P")-_H[_P#1"T__  LK!_P^;_X*
M9_\ 1U'B;_PAOA/_ /.YH_X?-_\ !3/_ *.H\3?^$-\)_P#YW-'_ !#7@[_H
M _,/^)-_H[_]$+3_ /"RL'_#YO\ X*9_]'4>)O\ PAOA/_\ .YH_X?-_\%,_
M^CJ/$W_A#?"?_P"=S1_Q#7@[_H _,/\ B3?Z._\ T0M/_P +*P?\/F_^"F?_
M $=1XF_\(;X3_P#SN:/^'S?_  4S_P"CJ/$W_A#?"?\ ^=S1_P 0UX._Z /S
M#_B3?Z.__1"T_P#PLK!_P^;_ ."F?_1U'B;_ ,(;X3__ #N:/^'S?_!3/_HZ
MCQ-_X0WPG_\ G<T?\0UX._Z /S#_ (DW^CO_ -$+3_\ "RL'_#YO_@IG_P!'
M4>)O_"&^$_\ \[FC_A\W_P %,_\ HZCQ-_X0WPG_ /G<T?\ $->#O^@#\P_X
MDW^CO_T0M/\ \+*P?\/F_P#@IG_T=1XF_P#"&^$__P [FC_A\W_P4S_Z.H\3
M?^$-\)__ )W-'_$->#O^@#\P_P")-_H[_P#1"T__  LK!_P^;_X*9_\ 1U'B
M;_PAOA/_ /.YH_X?-_\ !3/_ *.H\3?^$-\)_P#YW-'_ !#7@[_H _,/^)-_
MH[_]$+3_ /"RL'_#YO\ X*9_]'4>)O\ PAOA/_\ .YH_X?-_\%,_^CJ/$W_A
M#?"?_P"=S1_Q#7@[_H _,/\ B3?Z._\ T0M/_P +*P?\/F_^"F?_ $=1XF_\
M(;X3_P#SN:/^'S?_  4S_P"CJ/$W_A#?"?\ ^=S1_P 0UX._Z /S#_B3?Z._
M_1"T_P#PLK!_P^;_ ."F?_1U'B;_ ,(;X3__ #N:/^'S?_!3/_HZCQ-_X0WP
MG_\ G<T?\0UX._Z /S#_ (DW^CO_ -$+3_\ "RL'_#YO_@IG_P!'4>)O_"&^
M$_\ \[FC_A\W_P %,_\ HZCQ-_X0WPG_ /G<T?\ $->#O^@#\P_XDW^CO_T0
MM/\ \+*P?\/F_P#@IG_T=1XF_P#"&^$__P [FC_A\W_P4S_Z.H\3?^$-\)__
M )W-'_$->#O^@#\P_P")-_H[_P#1"T__  LK!_P^;_X*9_\ 1U'B;_PAOA/_
M /.YH_X?-_\ !3/_ *.H\3?^$-\)_P#YW-'_ !#7@[_H _,/^)-_H[_]$+3_
M /"RL'_#YO\ X*9_]'4>)O\ PAOA/_\ .YH_X?-_\%,_^CJ/$W_A#?"?_P"=
MS1_Q#7@[_H _,/\ B3?Z._\ T0M/_P +*P?\/F_^"F?_ $=1XF_\(;X3_P#S
MN:/^'S?_  4S_P"CJ/$W_A#?"?\ ^=S1_P 0UX._Z /S#_B3?Z.__1"T_P#P
MLK!_P^;_ ."F?_1U'B;_ ,(;X3__ #N:/^'S?_!3/_HZCQ-_X0WPG_\ G<T?
M\0UX._Z /S#_ (DW^CO_ -$+3_\ "RL'_#YO_@IG_P!'4>)O_"&^$_\ \[FC
M_A\W_P %,_\ HZCQ-_X0WPG_ /G<T?\ $->#O^@#\P_XDW^CO_T0M/\ \+*P
M?\/F_P#@IG_T=1XF_P#"&^$__P [FC_A\W_P4S_Z.H\3?^$-\)__ )W-'_$-
M>#O^@#\P_P")-_H[_P#1"T__  LK!_P^;_X*9_\ 1U'B;_PAOA/_ /.YH_X?
M-_\ !3/_ *.H\3?^$-\)_P#YW-'_ !#7@[_H _,/^)-_H[_]$+3_ /"RL'_#
MYO\ X*9_]'4>)O\ PAOA/_\ .YH_X?-_\%,_^CJ/$W_A#?"?_P"=S1_Q#7@[
M_H _,/\ B3?Z._\ T0M/_P +*P?\/F_^"F?_ $=1XF_\(;X3_P#SN:/^'S?_
M  4S_P"CJ/$W_A#?"?\ ^=S1_P 0UX._Z /S#_B3?Z.__1"T_P#PLK!_P^;_
M ."F?_1U'B;_ ,(;X3__ #N:/^'S?_!3/_HZCQ-_X0WPG_\ G<T?\0UX._Z
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M]'4>)O\ PAOA/_\ .YH_X?-_\%,_^CJ/$W_A#?"?_P"=S1_Q#7@[_H _,/\
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M_P#07A__  ;3_P#D@_M?)_\ H<Y;_P"%>%_^6AQZ'\Q_A1QZ'\Q_A1]:P?\
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M_P"ASEO_ (5X7_Y:''H?S'^%''H?S'^%'UK!_P#07A__  ;3_P#D@_M?)_\
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M_P &T_\ Y(/[7R?_ *'.6_\ A7A?_EH<>A_,?X4<>A_,?X4?6L'_ -!>'_\
M!M/_ .2#^U\G_P"ASEO_ (5X7_Y:''H?S'^%''H?S'^%'UK!_P#07A__  ;3
M_P#D@_M?)_\ H<Y;_P"%>%_^6AQZ'\Q_A1QZ'\Q_A1]:P?\ T%X?_P &T_\
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M_P"%>%_^6AQZ'\Q_A1QZ'\Q_A1]:P?\ T%X?_P &T_\ Y(/[7R?_ *'.6_\
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M_P#07A__  ;3_P#D@_M?)_\ H<Y;_P"%>%_^6AQZ'\Q_A1QZ'\Q_A1]:P?\
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M_P"ASEO_ (5X7_Y:''H?S'^%''H?S'^%'UK!_P#07A__  ;3_P#D@_M?)_\
MH<Y;_P"%>%_^6AQZ'\Q_A1QZ'\__ *U'UK!_]!>'_P#!M/\ ^2#^U\HZ9SEO
MI];PO_RT]_\ V4/^3IOV:_\ LOGP9_\ 5D>%^E?ZBULP^SVY](HN>>\8SQCC
MT K^>/&^M3Q&-R1TE32CA<3%^SG&:UJ4[<W*W9Z'^0O[23%8?$\6^'%2C5P]
M7ER+.%5^KXBEB(PMB\&TFZ4I*+MM%V[K2Q9]*_&+]H[_ (+B?LC_ +-G[1WQ
M._9:UKP%^T[\3?BA\((O"$OQ A^!_P $=1^)NB:$WC7PQI/C#1H)]1T;689T
MG?2M;LOM*W%FH6]^WV:[FLKTQ_GW _ ><\?9CC,NR7ZK"K@,MJYIBZF,K2PV
M'CAZ=;#X2SJJE5M.57%4U3@XQY[.TO=/\SZM2-*/-*]MM$F]M-&T?0W[$?\
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MZCX[\9^$?#%M<ZR5L;+_ (0;PH?^)WXKUZ_'A_7/"K>V_P#!L1\2/B+\5/\
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M/_#IC_\ YI#_ (4M\)/^B9^ ?_"/\/\ _P @4?\ "EOA)_T3/P#_ .$?X?\
M_D"C^T\?_P!!5?\ \&S_ /D@_P!=.+_^BFSS_P .F/\ _FD/^%+?"3_HF?@'
M_P (_P /_P#R!1_PI;X2?]$S\ _^$?X?_P#D"C^T\?\ ]!5?_P &S_\ D@_U
MTXO_ .BFSS_PZ8__ .:0_P"%+?"3_HF?@'_PC_#_ /\ (%'_  I;X2?]$S\
M_P#A'^'_ /Y H_M/'_\ 057_ /!L_P#Y(/\ 73B__HIL\_\ #IC_ /YI#_A2
MWPD_Z)GX!_\ "/\ #_\ \@4?\*6^$G_1,_ /_A'^'_\ Y H_M/'_ /057_\
M!L__ )(/]=.+_P#HIL\_\.F/_P#FD/\ A2WPD_Z)GX!_\(_P_P#_ "!1_P *
M6^$G_1,_ /\ X1_A_P#^0*/[3Q__ $%5_P#P;/\ ^2#_ %TXO_Z*;//_  Z8
M_P#^:0_X4M\)/^B9^ ?_  C_  __ /(%'_"EOA)_T3/P#_X1_A__ .0*/[3Q
M_P#T%5__  ;/_P"2#_73B_\ Z*;//_#IC_\ YI#_ (4M\)/^B9^ ?_"/\/\
M_P @4?\ "EOA)_T3/P#_ .$?X?\ _D"C^T\?_P!!5?\ \&S_ /D@_P!=.+_^
MBFSS_P .F/\ _FD/^%+?"3_HF?@'_P (_P /_P#R!1_PI;X2?]$S\ _^$?X?
M_P#D"C^T\?\ ]!5?_P &S_\ D@_UTXO_ .BFSS_PZ8__ .:0_P"%+?"3_HF?
M@'_PC_#_ /\ (%'_  I;X2?]$S\ _P#A'^'_ /Y H_M/'_\ 057_ /!L_P#Y
M(/\ 73B__HIL\_\ #IC_ /YI#_A2WPD_Z)GX!_\ "/\ #_\ \@4?\*6^$G_1
M,_ /_A'^'_\ Y H_M/'_ /057_\ !L__ )(/]=.+_P#HIL\_\.F/_P#FD/\
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MC_#_ /\ (%'_  I;X2?]$S\ _P#A'^'_ /Y H_M/'_\ 057_ /!L_P#Y(/\
M73B__HIL\_\ #IC_ /YI#_A2WPD_Z)GX!_\ "/\ #_\ \@4?\*6^$G_1,_ /
M_A'^'_\ Y H_M/'_ /057_\ !L__ )(/]=.+_P#HIL\_\.F/_P#FD/\ A2WP
MD_Z)GX!_\(_P_P#_ "!1_P *6^$G_1,_ /\ X1_A_P#^0*/[3Q__ $%5_P#P
M;/\ ^2#_ %TXO_Z*;//_  Z8_P#^:0_X4M\)/^B9^ ?_  C_  __ /(%'_"E
MOA)_T3/P#_X1_A__ .0*/[3Q_P#T%5__  ;/_P"2#_73B_\ Z*;//_#IC_\
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M  ;/_P"2#_73B_\ Z*;//_#IC_\ YI#_ (4M\)/^B9^ ?_"/\/\ _P @4?\
M"EOA)_T3/P#_ .$?X?\ _D"C^T\?_P!!5?\ \&S_ /D@_P!=.+_^BFSS_P .
MF/\ _FD/^%+?"3_HF?@'_P (_P /_P#R!1_PI;X2?]$S\ _^$?X?_P#D"C^T
M\?\ ]!5?_P &S_\ D@_UTXO_ .BFSS_PZ8__ .:0_P"%+?"3_HF?@'_PC_#_
M /\ (%'_  I;X2?]$S\ _P#A'^'_ /Y H_M/'_\ 057_ /!L_P#Y(/\ 73B_
M_HIL\_\ #IC_ /YI#_A2WPD_Z)GX!_\ "/\ #_\ \@4?\*6^$G_1,_ /_A'^
M'_\ Y H_M/'_ /057_\ !L__ )(/]=.+_P#HIL\_\.F/_P#FD/\ A2WPD_Z)
MGX!_\(_P_P#_ "!1_P *6^$G_1,_ /\ X1_A_P#^0*/[3Q__ $%5_P#P;/\
M^2#_ %TXO_Z*;//_  Z8_P#^:0_X4M\)/^B9^ ?_  C_  __ /(%'_"EOA)_
MT3/P#_X1_A__ .0*/[3Q_P#T%5__  ;/_P"2#_73B_\ Z*;//_#IC_\ YI#_
M (4M\)/^B9^ ?_"/\/\ _P @4?\ "EOA)_T3/P#_ .$?X?\ _D"C^T\?_P!!
M5?\ \&S_ /D@_P!=.+_^BFSS_P .F/\ _FD/^%+?"3_HF?@'_P (_P /_P#R
M!1_PI;X2?]$S\ _^$?X?_P#D"C^T\?\ ]!5?_P &S_\ D@_UTXO_ .BFSS_P
MZ8__ .:0_P"%+?"3_HF?@'_PC_#_ /\ (%'_  I;X2?]$S\ _P#A'^'_ /Y
MH_M/'_\ 057_ /!L_P#Y(/\ 73B__HIL\_\ #IC_ /YI#_A2WPD_Z)GX!_\
M"/\ #_\ \@4?\*6^$G_1,_ /_A'^'_\ Y H_M/'_ /057_\ !L__ )(/]=.+
M_P#HIL\_\.F/_P#FD/\ A2WPD_Z)GX!_\(_P_P#_ "!1_P *6^$G_1,_ /\
MX1_A_P#^0*/[3Q__ $%5_P#P;/\ ^2#_ %TXO_Z*;//_  Z8_P#^:0_X4M\)
M/^B9^ ?_  C_  __ /(%'_"EOA)_T3/P#_X1_A__ .0*/[3Q_P#T%5__  ;/
M_P"2#_73B_\ Z*;//_#IC_\ YI#_ (4M\)/^B9^ ?_"/\/\ _P @4?\ "EOA
M)_T3/P#_ .$?X?\ _D"C^T\?_P!!5?\ \&S_ /D@_P!=.+_^BFSS_P .F/\
M_FD/^%+?"3_HF?@'_P (_P /_P#R!1_PI;X2?]$S\ _^$?X?_P#D"C^T\?\
M]!5?_P &S_\ D@_UTXO_ .BFSS_PZ8__ .:0_P"%+?"3_HF?@'_PC_#_ /\
M(%'_  I;X2?]$S\ _P#A'^'_ /Y H_M/'_\ 057_ /!L_P#Y(/\ 73B__HIL
M\_\ #IC_ /YI#_A2WPD_Z)GX!_\ "/\ #_\ \@4?\*6^$G_1,_ /_A'^'_\
MY H_M/'_ /057_\ !L__ )(/]=.+_P#HIL\_\.F/_P#FD/\ A2WPD_Z)GX!_
M\(_P_P#_ "!1_P *6^$G_1,_ /\ X1_A_P#^0*/[3Q__ $%5_P#P;/\ ^2#_
M %TXO_Z*;//_  Z8_P#^:0_X4M\)/^B9^ ?_  C_  __ /(%'_"EOA)_T3/P
M#_X1_A__ .0*/[3Q_P#T%5__  ;/_P"2#_73B_\ Z*;//_#IC_\ YI#_ (4M
M\)/^B9^ ?_"/\/\ _P @4?\ "EOA)_T3/P#_ .$?X?\ _D"C^T\?_P!!5?\
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M9Z$+ 7]IH=@_A:]U_P X^"/_  5#_P""B'C?]AG]A7P7X.\6:'XQ_P""@/\
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MOK8:%H>F:#XF_MRUO-)\(^&OL+>.=<T0>'_#^GV5CHA*?I#^VU^V_P#M8?\
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MU/XR?#ZT\6PZ<VLWOQF\$7UW]HU5]*TS2=)L[[6/$=YX:T);P-]B^(VH:?\
M8= T+\S\+8</<24.+> LUS*/#CXRGE.*X>S*<*E7#PS_ "7$XZ66Y3B'!1:I
M9C3S3$895I3@HU*=*RE4E2I3TJMJ:?1-W_F2MTUMI9:+H^VIZ7^U5=_LI:#_
M ,$G_P!O_P#X*4_\$UOC?KGP@C_:[72OB/\ %WQ7HME#KP\4^,9=8UOX<ZM\
M,)O 'CC.E?"7Q+XS\8_$R\TCQUJ_AS2;#Q7]NOO[=L;W4&&A7R^-?"*S_;&_
MX)X_ ?\ X(D?L1?#K]IWQ#/XP_;*_:%^'7C?Q/X;'PR^%VG#X3?L[Z/X'T'X
MC?M'?!/0?/T#7;K7;8>)?B3JOB&[\=ZQ_P 57>7MD187^A:>+NR/ZMEU.CC^
M'<?PSQKP]3Q&?3XQXAH9MF/UJI!TY>%/ 'M\/!4X1E&K&>&<L'4K>T2G3Q-3
M$1<ISARY)052[EHE%=+/ZU-J^EFN6UUYI*ZV/UD_;P_:D^._AC_@H_\ \$JO
MV./@)\09_!UI\;_&'QA^)_[15O:Z#X7UJ76_@[\(/"^F^)[?PMJ$_B#0M5N=
M TOQB=.\7Z-_:VC/HNM+?6=FNG:BMWPOQQ\+OBK_ ,%&O^"NGQ2_:9^*?[*_
M[8W_  PI^R%^SY\4O$OP/^ -SX<^#7@?XL>)/CY\0? OV3_A(_B/X]?QUPO@
M+[5/9_V-HVDLMA?:?K"Z=?6*Z[X?UF]O_B<BX>X/R'AK)>,.)<G6=4<'PM0Q
MV+RB.)JX59GF/$'&.>Y5E?/7A"2HQP^2Y-C*S22CST(-.[@Y54G[6K[&+Y=;
M7VT4$WIH]&XKT=ME8_(CX!_'C]N;P]^P#_P63_X*T:-XUTOP-^UWJ/[4O[/O
MPY\4>(?"7AOP_K'A_4- _9VN/ ?P^\=Z/H&G>,=+\4:7;>%[K2OBK(+N]LS_
M ,RI_H%]8_80:_H(_P""A?[;GQK\9_$#]B?]A_\ 8#\>_P#"%_M)_ME7/A;X
MO^+/BI::!X>\7R_ /]DG28%\0^,/B/-H_BC3-=\+?VMXIM[>[T;PA_;-E>V6
MHOHVN:#9&QUW6O#U^OW?'W#7"V;<:T\72P<H9/P[FW$>59S0<Y_\DWP!P!P7
M6P6#51RC)*4Z.,PD9WE4E6Q;J2C._O94I/V%&+^)V_\ )IRBK[K:ST6RMH?N
M?86TUI:6EM->7-_);VL%O+?7OD?;+N2&WCA-S<"WMK:U%U<LAN;G[+9VEJ')
M\NSC4X&G7\>RLY-I))MV2V2OLM]%TU>AVA12 ** &G[R_C_*OY"/^#GS_D<_
MV/\ _L7OC5_Z=?A57Z-X5_\ ):Y3_AQ7_J-7/ZS^A'_RD?P)_P!>.(O_ %G<
MV/Y6*48],_C_ (?X5_7L:D>7GE3Y\3;1=+;?X?U_,_Z (U*4XZ4/:TTU3MS<
MO[F:TL_Z[!G&0.AP#_GMST_6E]NG^?\ /Y=>U#]K%4G&"]H]Y)JVW;9Z?\#L
M$959M.C!3HPG[DG[O)&I&K-TVGO:K5AKY=-DVBH(% XSZ?Y_SZ"CC_/TK11_
MBOL_\O\ +^NFEUS3B_L1P]2]ME!V;[+S#C ]?3_/^%+CIG@'[O8?AUQ_(4Y3
MA;W8/3F]NK[^SOM;T^ST);4?X#]NZ?L*LIOW$DVX5++K?VGHK#:*R)"B@ HH
M!:6\A?\ /T]O2E[?J./\\<?X]*T?+ROEUE4Y;^7/:W;;T*E4IIQJUIMT*+Q%
M6HE!^ZTG."25G+2'33T!1DXX'^?Z?YXI#WY[_P N]*TKQ4-J>[]>@W*C#_:I
MSE&E5G6H>R4>9JG+#JI-JW;3TZ"45&[]2%W7R_04$@$#OP>G2C_]7^':BI*4
M>2G35^1J[T\E^13=2_M,1']S3@W22^U5JXCG2T[1TMVT8?\ ZORQ_GVH_+Z=
M/;M532IMQJPO+#K2:=_P2_/4I.FHNM47+-OVE:AOJ]*:BU_+Y!GK[TO;&/Y>
MA[>W/Z>U5'G:=5TG&7NJK*]M)[67_P BAQYKRIWYJ<,-4ITI6Y7"5:W-HNWG
MMWT%&0<#]/\ ]1Z>])TSD>WT_P ]NE3.]-QY-5#?_)^5O^ *SES^V?-A<+*K
M0A%>ZZM3ZO[.;NM=)?<')QZ+TX';G'^?PI/;C^7X9Z=J4)RJ+GC3<,54^:5N
MRV]5MV"FVHRK5_WE62A1J4^7D]FG-T:=K?%:GR/3H]0SU]>.P_R/PHQT_3_Z
MW%5*].'M:M-O$U/;+1Z)O2>VBM\O\HC*:@W3?M:LJ\K1LH^RG*ZM?9\O+/\
M\"7D&>,8],'T'\OTH_S_ )_S^5-NR=%4W"I4M3;YM$OR5]>QJHTVO9SI<L?9
M0I^U4N9RJ1BIP7+NN7G;?^!>0=O\_P"?T_I1GC'8=A1%1E[:,H>S:?K:UK?I
MVM\A7J).5.2HR:]C.6DE)=--D_3[A**S,@HH ** "B@ HH ** "B@ HH **
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M@\9:AX2L]0TF\O;>W_M@>&+_ ,0>&[6>VN+FTM[07:Z7=6HO%$:WI&P5D_\
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M=V= 7^SKN^O6L[-_F[]H[_@F5^TW\*M+_P""-OC'P-^RAX3_ &[OAO\ L+?
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MG6K/3[&!&%Y>VGWO%>>RR'AW%YA3@ZE6]-4TK_%5DHP2T=M6M.NRZ']=^/\
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MG6"V-\->.HV$9/XB9O3R3B*MF=)_VAEM.A.BO<YG'-6_8N*[)V77EO\ (X>
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M %_?&+_U>WQ.K]%*_,N-_P#DM.+_ /LJ,_\ _5KBS_EHS7_D9YC_ -A^,_\
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M3P'EF*C4XEXLPL\JFJ%11G@,G7[O'XN3A*\)U?\ =Z4+J2TFFXIG]#P4* H
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M'*Z<>=/%5%&/M](/1_$Y2G=ZI-]7^E?2&X&SG@7$91A^(_$R5;$\)<$\,4^
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M?$V"PV<\*O!9=GZKU[+#P> HO%X#%Q<KQ7)AI0Y9K1J6^Y_6E_P3>_9:T?\
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MK:-J=O+8ZEI&KZ;?17%GJ6FZE9W%U:7=I=VCVE]:,]I>(8RRMP_PH^"_P?\
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M'\&Z5\(/^"S?_!,'P+\(=-^)^G>#OBKX#TCX?_V\9#;ZOJG@'XH>!--F\/\
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M'8K-J]//LK_MF^"Q> =+VM7+ZF)]E3OB)QC"-*E'FC!K]6?V2O\ @E[\%_\
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M2I1BG+6UW=A15G8%% !10 44 %% !10 44 %% !10 44 %%:T/XU'_K[3_\
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M ,G1X^_[*O.__4^L8X?^#3_PA17YP;!10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
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M.R;4HOFY_<O%VBTU%.]K:KWK/5)M*]A)Z?TK>5OP\B2BM "B@ HH ** "B@
MHH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@
MHH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@
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MCH/_ &<)^U!_ZNKQ57[Q5^C^+_\ R='C[_LJ\[_]3ZQCA_X-/_"%%?G!L%%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10!7E/[MB3_  L<8Z
MU_"IX%^*?Q<^#?\ P;D_M$>//@7\0_&/PM^)VF_\%!?$-AX=\9^!/$>H>%]<
MLI=8_:D\#:?/;#5](N;6X&EZK:W1L]:L[K-GJ%A>7UAJ5A>:?>7=@W[SX,8+
M"YE0Q.7X^C3KY7BO$+PPPN8T*L5*%6A4J\4P=*4)+WHR@Y)K:ROJ[)\]=RCR
MN+M:,]O^W#]&?C/\!_CG_P $T?VLO^"9/Q$\(?MW_MB?'R\_:@_:HT;]G']I
MGPK^T%\6+GQQ\-?'\/Q%T2]NQXF\+_#G[-9Z#X ;PO<6FJ#PY8Z.+DZ'9?V%
M8V5[LLM;.O?GG^W_ 'WC[XY?\$__ /@O=J?Q%^-/QNURQ_9M_P""EFFV_P ,
MO"TOQ7\83^#+/PM+XZ^$?A"V^'&K>&[_ %2YTRY^'.AGQ5>^)/#G@6U^Q:'H
MGC>RT+Q98Z?_ &AH=A7Z3P;C<IS#/.#.+\/P[E&"QL9<+*IAZ.%@\-AH4?%3
M#9%@ZM&$T[8NCDL\/@UB8VG[6E"HE&$(TH35YO922E4WDF^;5VHN33MO%R=[
M6V?JS]>M1LO'7[,O_!1S_@BO^S%X1^/G[0_BKX5ZW\&/VZ=8\=67Q2^,_C?Q
MUJ7Q,U*'P#'XT\/W/Q/O]2U,6WCP^!-2URZM/ ?_  DEG?#P3H=EI^GZ ;);
M &OQ1^/7QFT/QK\,_P!JOXKZ'_P4%_X*O?M<_M:> ]0^,7CCPU\5/V"](^-/
MA3]@_P"!4_@NRU/5O#_A^>&8Z'\-M-^%'AFTTNS_ .%B^+-(\2:@VHZ*;Z_T
M+4=</^G:\N&<H6)QV7YSA^&.'9+,,DRO'9QF692I8/*\OP.:\>\:Y=F5"E37
M-..-S7!8:&!P<O9U/88; SA.?)*-*JJE5Z7E5]ZZ2A[TG:,7'?2T7K+6[<KI
M=5^DGPA^+OC7X]_MU_\ !N3\9OB3J1UKX@_$K]@C]I+Q9XVUDV]O9C6_%>L_
M #PA<Z]K"V]LEG:VUQJ.J&[O;JUL[2SL5-[BPM%L5PGZV?\ !:[_ )12?MWY
MZC]GOQE^6RUQ[=Z^'XBPF$RSQ)\(,OINV'R_$X#+J:26E+">*W%U**]R*C=4
MXK1>ZK::6;KF;P]:?5\WI9TX_DW;_@W/SM_8M\6?\%Y(OV7/V4+?P#\(_P#@
MFA=_"*W^ WP.@\'ZIXH\?_M!P^.+OX=K\//"ZZ!?^(+'3]/_ ++MO%,OAK[+
M/JEI9L;%=;8K:9L^1U'Q:TKXL?\ !1?_ (*P_M#_ +&^O_M%_'O]G_\ 9;_8
MF^"/P;\3ZIX*_9T^(&I?!_Q?\:/BG\<=(;Q/#K'B[Q_H!_X2#4O!GA?0)_['
M'AFS9=._MRQL+[<ET+[[9K4P?A[@>)>*,_X6Q&+SZ?#>0<19V\'G5#EH8?-*
MN=Y3E.62]FL/A_K%.A+-J^)NGS>TP=*<*M.SFW'F^THPN[7@W=IQ=U=R:3M&
MUM%9ZK8^$/BC^W?^UE_P32^&_P#P6$_94L_COXU_:#U_]DNQ_9:UC]D/XU_'
M&['CKXE^$=!_:XUCPSX>O]"^)_B^XM!:^*-4^&#>)O[8\'ZOXQ^W?;KVS']H
M6!\*7>F^$]._4;P'_P $N/VD_P!GKXG?LR_&CX1_\%(?VG?'7BS1/%^A6W[7
M'A?]J'XK>)_BI\+OC_X*OM./_";P>"? VH%K+P%XP$\ M/AVUF;M/"]A]C_T
MUKK1+[_A(/0XJCD/"F48/-J7#F7UJ'B5AYRJX>G0BZN547P'PAFSIY=)-/#\
MO$7$CQZ@H\OL\%0I0]ARTZL51YZC=Y27+))ZZ-WDO>76\%JUKJ]S!_X)8?&/
MXI>-?V0/^"E'BCX@?%#Q_P"+]=\ _MO?MZ>&/"7B+QAXUU_Q)K'@KPMX0M=-
ME\+^'_#^KZOJMU=Z#H'A3<3X=T?2+JQT_0PW^@65ASC\G+OQ[^WA\3?^"57_
M  2+^*8U_P#;P^-?[.]]'\;M3_;TO_V0?B!K^H_MG>-K6'Q-KEA\(+^V\4W^
MJW'CW7_!VF7=MXC_ .$PLQK/V*]T2SL+'7+ZR_XD5[8:Y9DG#.!XFXBJX_#Y
M=AL-A./\)E655<70A]1P>*Q'"/&%7*(XCE=/EP$<ZI937KTXU:<%&A%R<$G*
M,NH^2UY2O%:1?O-WCS6Z-\CDK\NES]'_ /@D)XY^&WQ\\+?MN?!GX-_\%#OV
MI_BSX/U72M&TGPK\'OVF-'\7:-^V5^Q1<>*O".O^&_$-_P#\+7\8ZK<ZQXQM
M[G7Y4O?"!TBP.A_#F^\,Z=8"_DUV]U*_UO\ <W]G3X/7OP#^"?P^^#NJ?%/X
ME?&N^\":*='N?BG\8O$=QXJ^)OC647]U>G5O%_B&X5;C5-4_TK[(+IO^7.TM
M%Y"U^6>)BJY+GV<Y%F60X'*<S^N9-F.(J8*<*F'4EDR6(E@'&FKX'-:];^TX
M+G4J<N2G5IJ::AO1G>BK-M7=N;>UUR\UOM+;;KIH>Y45^7F@44 %% !10 44
M %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44
M %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44
M %% !10 44 %% !10 44 %% #3]Y?Q_E7\A'_!SY_P CG^Q__P!B]\:O_3K\
M*J_1O"O_ )+3*?\ #BO_ %&KG]9_0C_Y2/X%_P"O'$?_ *SN;'\K%%?UT?[^
MA10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 45K0_C4?\ K[3_ /2D<N._W+&?
M]@N(_P#34C][/^"3_P#R8+\#?^O[XQ?^KV^)U?HI7YEQO_R6G%__ &5&?_\
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M1WQW\"?V/_VQ_BAX[^+'QF^ FF_ GP1XO\=:?KWQ7VP?%32OAE\;==U[^T?
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M2C5E3G3;B_9U*<I4ZD+Q;3Y9Q<;IN+M[K:1;5G;II;T:T'T5F(** "B@ HH
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M!?\ A50_^3"BCV]#_G]2_P#!D/\ ,/[2R[_H/P7_ (54/_DPHH]O0_Y_4O\
MP9#_ ##^TLN_Z#\%_P"%5#_Y,**/;T/^?U+_ ,&0_P P_M++O^@_!?\ A50_
M^3"BCV]#_G]2_P#!D/\ ,/[2R[_H/P7_ (54/_DPHH]O0_Y_4O\ P9#_ ##^
MTLN_Z#\%_P"%5#_Y,**/;T/^?U+_ ,&0_P P_M++O^@_!?\ A50_^3"BCV]#
M_G]2_P#!D/\ ,/[2R[_H/P7_ (54/_DPHH]O0_Y_4O\ P9#_ ##^TLN_Z#\%
M_P"%5#_Y,**/;T/^?U+_ ,&0_P P_M++O^@_!?\ A50_^3"BCV]#_G]2_P#!
MD/\ ,/[2R[_H/P7_ (54/_DPHH]O0_Y_4O\ P9#_ ##^TLN_Z#\%_P"%5#_Y
M,**/;T/^?U+_ ,&0_P P_M++O^@_!?\ A50_^3"BCV]#_G]2_P#!D/\ ,/[2
MR[_H/P7_ (54/_DPHH]O0_Y_4O\ P9#_ ##^TLN_Z#\%_P"%5#_Y,**/;T/^
M?U+_ ,&0_P P_M++O^@_!?\ A50_^3"BCV]#_G]2_P#!D/\ ,/[2R[_H/P7_
M (54/_DPHH]O0_Y_4O\ P9#_ ##^TLN_Z#\%_P"%5#_Y,**/;T/^?U+_ ,&0
M_P P_M++O^@_!?\ A50_^3"BCV]#_G]2_P#!D/\ ,/[2R[_H/P7_ (54/_DP
MHH]O0_Y_4O\ P9#_ ##^TLN_Z#\%_P"%5#_Y,**/;T/^?U+_ ,&0_P P_M++
MO^@_!?\ A50_^3"BCV]#_G]2_P#!D/\ ,/[2R[_H/P7_ (54/_DPHH]O0_Y_
M4O\ P9#_ ##^TLN_Z#\%_P"%5#_Y,**/;T/^?U+_ ,&0_P P_M++O^@_!?\
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MT5F(** "B@ HH B SQGZ''7U_EW_  Q7\>__  6U;X?_  @_X*O?L??M,_\
M!0?X*>+OCA_P32T#X'ZEX%TI-.\.77C'X?> _C[J7B'QA?7&I>/O!INAINO2
MW=HOA"ZNM'U3:/%>AV-E_9>B>*;[P)>Z'>_L7@/SUN-L3A<!5HX+/<UX7XIR
M_AS%8FI2ITJ6?8G)<91RN=2=:,X*[4E3]R3C4E"2C)QL9UXJ4;=$XZ+MS)N/
MZ>?0[/7?@'_P1^_X*0>-/V<_B%_P29_:'_9:_9'_ &OO@K\5?#7Q(\+7WPM^
M&P^$OC#Q5X/\.6UU/XB\(:U\ H9/@IKWB>*XF&D&^UF'2;PVNBV.H:!>7O\
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M."TY^=98GK?2IHM$FI591533X>5?^2QMI;^];I9+U/C#]J__ (+"_M ?"/\
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MOP(^,NG?&77OA5J_C6!9](_X6+X)T:TU"\NK73;>.\U?Q+J%F^C6-EHEE?\
M]A_V_KEBN@7W]% &>G0X(X]OZ _RKY_Q%X1X>X:J95BN%N('Q#D^:4<=1CBJ
MN%>#K8?,<IQOU7%X>="<*550:J8>M1E.E!3IU5R2J17.W2G[15$THM65O6UO
M33=)]]B:BOS<U"B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH
M** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH
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M>./_  _X[_(/^'L7C;_HS'_@GE_XC.O_ ,V5'_#V+QM_T9C_ ,$\O_$9U_\
MFRH_U#I_\_:__A1B?_EP?\2?T/\ HY/''_A_QW^0?\/8O&W_ $9C_P $\O\
MQ&=?_FRH_P"'L7C;_HS'_@GE_P"(SK_\V5'^H=/_ )^U_P#PHQ/_ ,N#_B3^
MA_T<GCC_ ,/^._R#_A[%XV_Z,Q_X)Y?^(SK_ /-E1_P]B\;?]&8_\$\O_$9U
M_P#FRH_U#I_\_:__ (48G_Y<'_$G]#_HY/''_A_QW^0?\/8O&W_1F/\ P3R_
M\1G7_P";*C_A[%XV_P"C,?\ @GE_XC.O_P V5'^H=/\ Y^U__"C$_P#RX/\
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M_7+RPT.RO]1L>N^//QH^&/\ P4+_ ."YG_!-#P[^R'XVTKXO^&?V)/"_Q_\
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M_:M_;4_X)$?\$OOVY_VJ[KXIZ3H?P0_;'NT^-?Q?^#-G8^#/BA_PJ(^*-/\
M#WAK]HWPTNG:9_9?A;QSI5SX8U3PYX:\0V>DC0SXUO\ 0]<2PVZU8[?V'"?6
MZF><,9CQQDF PW&.1<5X'A3+>*'*C3PO&F!XAX6XAHY=.MA:3?-1PU6IE3KR
M]O5A"I7JPC5H..)HTN?GA&G547)J7O<BO>'+*/-;I=V=M-DMU9G=?MP> _\
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MU_J+W5]>,]ZS73EN<^.'[,/[.?[3NCV/A_\ :'^!7PE^-VD:1-<W.C67Q1\
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MC04ERT83E3I*$79"CTBHK_MU*WIM:_7N[7N>"_$C_@GK^PC\8?B#)\5_BO\
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M7'XO\<ZT;<:SXP\4)X9TS3!K_BC5OLUL=5\1:N+W6;_8GVR\<1KCS6;]C?\
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M,V/Y6**_KH_W]"B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH
M** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HK6A_&H_]?:?_
M *4CEQW^Y8S_ +!<1_Z:D?O9_P $G_\ DP7X&_\ 7]\8O_5[?$ZOT4K\RXW_
M .2TXO\ ^RHS_P#]6N+/^6G-&_[3S'5_[_B__4BH?__4_H6_X-QO^4:.@_\
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M?^"HW_!4;XR_L*_&C]D3X!_ 7]DVT_:I^)O[7$OQ)T[PGX<F^+5O\*[R'5O
M4W@OR=.L;C4/"NNZ1=?VG:^*+NZ-UJNKZ+'8_P!G!2S&[^7[SPQX0PG''&&$
MR#,\V62Y74P6:8_%YI[)5OJE+*,LQ^:5IJE]I>SPB3WM&]E?6.5>I[*DY*[=
M[67GHOUV/!?^'D/_  7"_P"D$DO_ (FU\)O_ )0U^Z_P:\3>//&7PC^%WC#X
MJ?#\_"GXE^*/A_X/\0>/_AB==L?%/_"NO&NKZ#IE_P"*/!/_  DFG#[%K_\
MPC&MW%YHO]M6*BSU#[#]LC 61*]SQ(X2\/\ ARCE_P#J1QU_K?/$N:QJ6!^K
M/!<L&XVLGSW=X^>ZT6DX>JYIMIQMM=-?*_\ 5N^QZB"I& 0?Q&>/I1G;]XC
M_#H/P%?DZCM&SZ*S3]-OD;GPA^S5^WE\//VGOVCOVSOV=? OA;Q5IFI?L4^*
MOAWX&\=^)O$/]G0:;XK\6>.H/'-S>P^%K"RN[N[_ +"\.CP>+;^UM5^PW6L7
ME_($TRUL]/COM1\Y_P""8O\ P4!O?^"AOPV_:!^(&I_#"P^$[_!+]K'XI_LT
MPZ;9>,)O&47B2T^'6A^!=7A\737T_A_PPVF7.K'QB;9]%^QW@L/L *ZC=_;
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MA>WU[Q;X@L[C3=1U?4M,US2+RYT_5=7\%6(76-.M-.UW6M1_M#3M.Q/V;O\
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MKXDU!M9\1ZE%HFG6VGQ:AKNKW \[4];NUM%NM4U!@6O;XR79VER*_"O%+/\
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M^-_BM_P3X_X(:?L;2_LF_%_XL_\ #0__  4N\<?L]?!_P[KOQ+\=:EXO\-_
MF\\;Z)XD.K7WP9T^ZTO['\.]*/\ 9MMH]I96-G?7EB-;&N6/^GZ#97MC]AF>
M5X.EF>;>',<HPG]AXCQMR7%9A@DE%K RX6CQ1F& IU8N,(P4\%6H0=*G>6&J
M5*=YSG&4,(S_ ':Q-WS?4Y>BDI<L7M>Z_K:Q])_MP?\ !-3XU_\ !,S]D_7_
M -O']E+_ (*$?MG>)?VD?V<K3PW\0OB>OQL^+FH_$#X6?'O25U?3=)\=6'B?
MX=ZC";2WM5M-4N]7T6SU?5/$C"RL!HMW?MK;6'B[3O(_^"K?[8/C'XH>*O\
M@F1\:_VA?%/[6OP4_P""4_Q__9:\*?%OXK:S^R%K.K:1K$/QQ^)GA^?7['P5
M\2/$^E+:7=SX6T/2]4\$-96=X+R^U"U_X2V^\)Z$-;T^^O\ 3_E>%L9@?$3'
M<'\6QR+)<KXHI9CQYPYED:TE2RC%9I@^'<-FO!<<72DYJV6XG%RIRE%\]6-'
MVJIQE&C"GLTJ?MZ+<^5<C>MYI.7+.VB2NEUTZ7:W^Z?^"+LW@!_C#\?KS]DC
M_@J)K/[97[%NH_#C2-5\,?L]_'#Q1XN\2_M+_ SQX+C3K6;7+@^.-#\,^(=!
M^'5P+7Q%I-E9VWAK3;*^-[H0O/M^N:$^NZ]ZO_P;5_$CXC?%?_@EEX&\7?%'
MQ]XS^)'BN?XK?&6RN/$_COQ3KOC#Q'/:67BAX+&UFUGQ!>:EJBVULH_T:S:[
M*V2' ZFO@^/LOJ2RCQ$Q6;\-4^'\_P )GOAE1S##494I8=9CB<FXHGF6+P;H
M5:U)X7-,1A:.,I\E6=MJK=7VB-:"I\U"SNO]JM=ZV4HI7V^'9Z6Z)61^'O@'
M]H#]OS5_^"#/[0?COX*_$G]H#QCXTL_^"C/C_P ,_%WX@^$_$GBCQA\<O!/[
M,5EIFAW'BZ;X<:M<:E=>)]+_ ++US_A'+2X_L>^L3HGA;6_$&H+>V-@NH:@/
M9/V ?%'[(7C3]JO]EKQ7_P $TO\ @K?^T+X9\12^,H;;]HO]D3]O+QWXX\07
M7QN\(7?]GSZQH/@?1];T32O!&J?%K5+2T\19N_#6O^*A87S6.N:$=$70=0L=
M=_5LSR%X')_$2MPYPSEV>Y-A^(..L#QKA>>C_;&!P<<HR]\-XS TZM:D_999
MC?;XRK"G&I5]V+PU+GG.HL>6E^X]YQERP<-6HMZJ2E:^ZLETZ-VM?^V!_P!,
M9'X8S^E?S6?\$>;VX^//_!3G_@MS^U/XL3[?K^@?M%:#^R?X U.63SAH_P /
M_@I?>,?#.H:/I6"/LEGKUOX0\":O?6@X-]9B[(%\]_7\S\$KV'"'BKCXQ3FN
M&LDRR,[*\(YCQ?DDJZ3Z<]#!U(Z>FYTS^.EK9<S_ /278E_:V_X)[_\ !03X
M0?MW_%G_ (**?\$FOBO\&=0\=?&WPQX<\._M)_LT?'#/_",>*]2\(:-H>D>'
M[[P]?6H$%O<:C9:#:7=S:WOB#X=ZSHVL_P!N7]EXOU'1/%NH:#8>/^#?^"F7
MC'5?VN_V3OV?O^"UO_!+O0/@3\9;WXDZ?:_LH?M'V/\ 8WQ)^%ND?&77=8T7
M3])N/"%]/<>*;7PK>7?B#3/"5FWB'P?\3_'&H:)J-[X4O_$%AH.AYUVQ_8<!
MAN%O$O(<'C,KSO$\,>+O"_!O]EO**N'Q%;#\68+)LD>&C4H3E#V&&K8CA^$Z
M?LJ*4_XE2>'JP]G6>$INFUL\&].963B[[/9VYOEIHXNYZ+^S%_RM%_\ !1C'
M_1C?PH_]-_[+E?TS/_JG/).TXZ^G^?H?K7Y'XJ12S7A&,E:4O#/PX=UM:7"F
M6W?;KMT.K#QBE-?]1%1;O1<_^7HON/X1/^"*?QI_X*Q_#KX,?M3Z'^PA^QO\
M$?VA?A-<_MR_&[5/$?C3XC_&32/A_KFF_$67PE\*;?5O#-OH]_XNT.YN]-M_
M#-KX1U>TU4VK*U[K-]IYNR+#G^F;]AGXS_\ !5_XB_$[Q%HG[>/['/P5_9Z^
M%EGX%N]3\,^,?AQ\7]&^(&M:KX^AU_0+6R\-7VBV'B_Q)<6FF7&@W7B'53J@
MM$1+O1[&T-XQO51OU;QMR/PBI9SQEC,MXSS2MQ?]=I3CD<\JQ*P2Q;I4_KN'
M^O2P,:35.5W2J+$N-H\KE._,<V$6+E0HJ<*<=.CCS\J32TYM+Z?9\K'P1^W9
M=S_L]?\ !?\ _P""4/QK\.I_9R_M4?"SXY?LL_$L6TWV.'Q3H'A0?\)#X?M[
M[R!_I-QHGC'XB>$=6S= _;O[%T33\G[!8FQ_I0&,J!Z9_,?TQ7Y/XA4X5<A\
M*,T4N>KB^ ZN%JRW;EE7%G$V603E\5Z>%H8?#Q3TITJ%.G&T8I+:DWS5>EG'
M3UBK_P"?WLDHK\P-0HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH
M** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH
M** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH :?O+^/\ *OY"/^#GS_D<
M_P!C_P#[%[XU?^G7X55^C>%?_):93_AQ7_J-7/ZS^A'_ ,I'\"_]>.(__6=S
M8_E8HK^NC_?T** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ H
MH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "BM:'\:C_U]I_\
MI2.7'?[EC/\ L%Q'_IJ1^]G_  2?_P"3!?@;_P!?WQB_]7M\3J_12OS+C?\
MY+3B_P#[*C/_ /U:XL_Y:,U_Y&>8_P#8?C/_ %(J'__6_H6_X-QO^4:.@_\
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MO4G*E35&IA<9.A%)\GM?:RJ44X1;"C2M[*\4[/%Z*]M<0FK>36WD?D'\'?\
M@AG^T-^Q]_P7-^"7QW^ WA&;7O\ @G?X>\6_%;XIZ3<CX@^$;2R^ NI?%+X0
M>._"NO> ;?P#K_B:T\8:CY'B@^&K/2-8\(>&];6[\%-X2T_7=0:]T'6]1LOU
M+_8:_8\_:)^#W_!6K_@JG^TS\1OARWA[X(?M'Q?!+_A2_C?_ (2WP/JP\:?\
M(GX>-GXA \-:!XGU/Q=H/]F70,9_X2WP[H?VP-FP-XOS#Z3CWQBX9XQRO$8E
MX^K2SG,?!?(>&<PIO!5XQK<6X7C3"YOF%/VD:4*/L:^%HRQ2KI1P\I3]C=5F
MJ:B&&Y?18MU%:WPO#<MK7TMM;?Y79\\?MZ_\$]OVN/@9_P %"?A/_P %1_\
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M]'OPWUGQ9XC^'?@37_'WA!OAYXY\0>$?#6L>,? !UC3O$A\$^*=1T>TO]?\
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MK-?=K;YI(\]^(_[&_P#P4U_X)S?MQ_M)?M=?\$T/ /P\_:Q^!O[:/B1_B/\
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M,'5LM4ZC4O>32V@K3J^L?PC;\&FK>1)17YL:A10 44 %% !10 44 %% !10
M44 %% !10 44 )2T %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M#3]Y?Q_E7\A'_!SY_P CG^Q__P!B]\:O_3K\*J_1O"O_ )+3*?\ #BO_ %&K
MG]9_0C_Y2/X%_P"O'$?_ *SN;'\K%%?UT?[^A10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
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M;#\U2RT:O[-JR>_35']'?2X^BKQGXP>(V6\5\(SRUX6/#&#R_'?6ZM;#OVV
MQN-G2FE0PF(4[X>M2@W)IVA%6T'_ /$2W^Q=_P!$>_:?_P#"2^%7_P ^FC_B
M);_8M_Z(]^T__P"$E\*O_GTU\#_Q!O/OYJ7_ ($__D3^6?\ B0/QL_ZD?_A;
MB?\ YV!_Q$M_L6_]$>_:?_\ "2^%7_SZ:/\ B);_ &+?^B/?M/\ _A)?"K_Y
M]-'_ !!K/OYJ7_@3_P#D0_XD#\;/^I'_ .%N)_\ G8)_Q$M?L7<?\6@_:?\
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MCW[3_P#X27PJ_P#GTT?\1+?[%O\ T1[]I_\ \)+X5?\ SZ:/^(-9]_-2_P#
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M_P"$E\*O_GTT?\1+?[%O_1'OVG__  DOA5_\^FC_ (@UGW\U+_P)_P#R(?\
M$@?C9_U(_P#PMQ/_ ,[ _P"(EO\ 8M_Z(]^T_P#^$E\*O_GTT?\ $2W^Q;_T
M1[]I_P#\)+X5?_/IH_X@UGW\U+_P)_\ R(?\2!^-G_4C_P#"W$__ #L#_B);
M_8M_Z(]^T_\ ^$E\*O\ Y]-'_$2W^Q;_ -$>_:?_ /"2^%7_ ,^FC_B#6??S
M4O\ P)__ "(?\2!^-G_4C_\ "W$__.P/^(EO]BW_ *(]^T__ .$E\*O_ )]-
M'_$2W^Q;_P!$>_:?_P#"2^%7_P ^FC_B#6??S4O_  )__(A_Q('XV?\ 4C_\
M+<3_ /.P/^(EO]BW_HCW[3__ (27PJ_^?31_Q$M_L6_]$>_:?_\ "2^%7_SZ
M:/\ B#6??S4O_ G_ /(A_P 2!^-G_4C_ /"W$_\ SL#_ (B6OV+N?^+0?M/]
ML?\ %(_"GVST^-5)_P 1+7[%V?\ DC_[3^/^Q1^%/_SZ:3\(L\:Y)3I?#9*[
MWM327POWKS2CYWU5@7T!/&O_ *D?E;&XC_YV["_\1+?[%O\ T1[]I_\ \)+X
M5?\ SZ:/^(EO]BW_ *(]^T__ .$E\*O_ )]-/_B#6??S4O\ P)__ "(?\2!^
M-G_4C_\ "W$__.P/^(EO]BW_ *(]^T__ .$E\*O_ )]-'_$2W^Q;_P!$>_:?
M_P#"2^%7_P ^FC_B#6??S4O_  )__(A_Q('XV?\ 4C_\+<3_ /.P/^(EO]BW
M_HCW[3__ (27PJ_^?31_Q$M_L7?]$>_:?_\ "2^%7_SZ:/\ B#6??S4O_ G_
M /(A_P 2!^-G_4C_ /"W$_\ SL$_XB6OV+L#'P?_ &GQZ_\ %(_"K_Y]5._X
MB6?V+>/^+/?M/^__ !2/PISTX_YK5_D=*7_$(<^BHI3I>\YVL_Y:G+K[NEYM
MN/D^@G] 3QK5O^1)O;_?<3;R_P"9:)_Q$M_L6_\ 1'OVG_\ PDOA5_\ /IH_
MXB6_V+?^B/?M/_\ A)?"K_Y]-/\ X@UGW\U+_P "?_R(_P#B0/QL_P"I'_X6
MXG_YV!_Q$M_L6_\ 1'OVG_\ PDOA5_\ /IH_XB6_V+?^B/?M/_\ A)?"K_Y]
M-'_$&L^_FI?^!/\ ^1#_ (D#\;/^I'_X6XG_ .=@?\1+?[%O_1'OVG__  DO
MA5_\^FC_ (B6_P!BW_HCW[3_ /X27PJ_^?31_P 0:S[^:E_X$_\ Y$/^) _&
MS_J1_P#A;B?_ )V!_P 1+?[%O_1'OVG_ /PDOA5_\^FC_B);_8M_Z(]^T_\
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MZ:/^(EO]BW_HCW[3_P#X27PJ_P#GTT?\0:S[^:E_X$__ )$/^) _&S_J1_\
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MX[_<L9_V"XC_ --2/WL_X)/_ /)@OP-_Z_OC%_ZO;XG5^BE?F7&__):<7_\
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M7PG@*.25,H61YEF6)DI5?:QDL3%*F^EY12E>\=+Z.QZQ17Y@?QJ%(>!^% $
M.>W8<>@Q_D]*_BP_X.5DL4_:4^!9A:?[:WPMUO[7NXAV?\))&8/)^MOO^UC^
MYLXK],\)Y-<84(+:.$Q+EILK*UO5\KUTZ]$?V+]!)2G](KAB"TC++^()5?\
MKW3P-?RZS5)6?30_FX.,]2?T].._Z_\ UJ3_ /5]/\__ *J_K9RHT_83JR]I
M+ZSSZ)JT;=H]'HM>A_O@OJUW]7:E"<?8*ZLEK[-[]G4MI;8,XXX_(?X49^GY
M#_"F^6^D5_X$C.U+_G\__!;_ ,@S]/R'^%&?I^0_PHT_E7_@:#]U_P _G_X+
M?^09^GY#_"C/T_(?X4K1_E7_ ($@_=_\_P!_^ /_ "#/T_(?X49^GY#_  IZ
M?RK_ ,#0?NO^?S_\%O\ R#/T_(?X49^GY#_"C3^5?^!H/W7_ #^?_@M_Y!GZ
M?D/\*,_3\A_A1I_*O_ T'[K_ )_/_P %O_(,_3\A_A1GZ?D/\*5H_P D=-O>
M6@?NO^?[_P#!;_R#/T_(?X49^GY#_"GI_*O_  -!^Z_Y_/\ \%O_ "#/T_(?
MX49^GY#_  H]W^5?^!(/W7_/]_\ @M_Y!GZ?D/\ "C/T_(?X4K1_DC_X$@_=
M?\_W_P""W_D&?I^0_P *,_3\A_A3T_E7_@:#]U_S^?\ X+?^09^GY#_"C/T_
M(?X4:?RK_P #0?NO^?S_ /!;_P @S]/R'^%&?I^0_P *-/Y5_P"!H/W7_/Y_
M^"W_ )!GZ?D/\*,_3\A_A1I_*O\ P-!^Z_Y_/_P6_P#(,_3\A_A1GZ?D/\*-
M/Y5_X&@_=?\ /Y_^"W_D&?I^0_PHS]/R'^%&G\J_\#0?NO\ G\__  6_\@S]
M/R'^%&?I^0_PHT_E7_@:#]U_S^?_ (+?^09^GY#_  HS]/R'^%&G\J_\#0?N
MO^?S_P#!;_R#/T_(?X49^GY#_"C3^5?^!H/W7_/Y_P#@M_Y!GZ?D/\*,_3\A
M_A1I_*M/[X?NO^?[_P#!;_R#/T_(?X49^GY#_"C3^5?^!H/W7_/Y_P#@M_Y!
MGZ?D/\*,_3\A_A1I_*O_  -!^Z_Y_/\ \%O_ "#/T_(?X49^GY#_  HT_E7_
M (&@_=?\_G_X+?\ D&?I^0_PHS]/R'^%&G\J_P# T'[K_G\__!;_ ,@S]/R'
M^%&?I^0_PHT_E7_@:#]U_P _G_X+?^09^GY#_"C/T_(?X4:?RK_P-!^Z_P"?
MS_\ !;_R#/T_(?X49^GY#_"C3^5?^!H/W7_/Y_\ @M_Y!GZ?D/\ "C/T_(?X
M4:?RK_P-!^Z_Y_/_ ,%O_(,_3\A_A1GZ?D/\*5H_RK_P)?UT0?NO^?[_ /!;
M_P @S]/R'^%&?I^0_P *>G\J_P# T'[K_G\__!;_ ,@S]/R'^%&?I^0_PHT_
ME7_@:#]U_P _G_X+?^09^GY#_"C/T_(?X4:?RK_P-!^Z_P"?S_\ !;_R#/T_
M(?X49^GY#_"E:/\ *O\ P)!^Z_Y_O_P6_P#(,_3\A_A1GZ?D/\*>G\J_\#0?
MNO\ G\__  6_\@S]/R'^%&?I^0_PHT_E7_@:#]U_S^?_ (+?^09^GY#_  HS
M]/R'^%&G\J_\#0?NO^?S_P#!;_R#/T_(?X49^GY#_"C3^5?^!H/W7_/Y_P#@
MM_Y!GZ?D/\*,_3\A_A1I_*O_  -!^Z_Y_/\ \%O_ "#/T_(?X49^GY#_  HT
M_E7_ (&@_=?\_G_X+?\ D&?I^0_PHS]/R'^%&G\J_P# T'[K_G\__!;_ ,@S
M]/R'^%&?I^0_PHT_E7_@:#]U_P _G_X+?^09^GY#_"C/T_(?X4:?RK_P-!^Z
M_P"?S_\ !;_R#/T_(?X49^GY#_"C3^5?^!H/W7_/Y_\ @M_Y!GZ?D/\ "C/T
M_(?X4:?RK_P-!^Z_Y_/_ ,%O_(,_3\A_A1GZ?D/\*-/Y5_X$"]E=?OGT_P"7
M;_R/T>_X)$C_ (V0?LI]O^*^O_\ U"_%7_UN!7^CRH"J,=L*,^BC:?\ /^%?
MS)XV+ES_ "RFTER93&+:[_6Z_;^[^"1_B]^TBC3CXM<'^SBHJIP1"I*SYK/^
MWLZ@E]UK(L45^+G^=X44 %% !10 44 %% !10 44 %% !10 44 %% !10 44
M %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 T_
M>7\?Y5_(1_P<]_\ (Y_L?_\ 8O?&K_TZ_"JOT;PK_P"2URG_  XK_P!1JY_6
MGT(E?Z1_ B_Z<\1+_P UW-C^5H\<?Y_*OW'_ ."*W[ WP#_;IUS]H>P^.MEX
MEO8/AIHWPVU#PR/#OB6[\/>5-XHO/'D.K"]%G')]IY\/V7V7<V N< &OZ3XU
MS6KD?#F88S#V<J?U51[)O$4+7U6E[7U6E[6/]B_I)\:\0>&O@YQ9Q?PS6I4<
MTR.>6QHRK0]I#_:,XRS 2O%3IR?NR=DI1UMT3OZ[_P $\_\ @FG^S3^TK^V7
M^WQ\#_B/IWBY_!/[/7Q$\0^&_AW#I/BN_P!+O+?2=-^)GC[PI8KJ5X(I9-2N
M4T?0K'%Y(^?M"M>$>8RD?$?_  5=_P""?ES^P3^T!#H?A=-4O?@?\2;";Q%\
M*]?U2<W=S;?V>+6V\3>#=3O3! \^L>'=3GM;Q+IV;[9HFN:+=,\FH1Z@]E\G
MD_&6-J\8O(L4XPA7RS!XG#]+XBIA,/B>1=]%-I66D7JV['\_^'OTC>(LQ^D'
M0\,L]EAWE6?>'F18[*N5>SG3SS&<.99Q+C?BJ24J=:/]H<D>6\.2,;RNVOLG
M]JW_ ()O_LV?"/\ X)0_!;]K[P?IWB^'XP>._ O[/&O:[/?>*[^_T"74?B5X
M<T*_\2F/0G0V=O;F?4KQK79,BV3$%3M&#]J_LY?\$DO^"<6H?L,_!O\ :G_:
M+U7Q5X1@\2?#'P5XQ^(/B_5/B==>'/#&G:CXJAL;0;BUM#9:=:7.IZK;Z5:6
MJ[%_?V<0_>[<^!C>-N(:.1*O@I?[1B.*<9ED8I1;MRR<+7V;\NS2B?D/$?TF
M?&&?AGE>=9-7PL^)LQ\9LY\/\$HX;W:F"PF#4\MPL(SQ$$JKQ%2G3=:I/E;T
MLEJNGT'_ ((Q_P#!*S]J?PWXEA_91_:/U:\\3Z+: _;O!/Q3\*_$>/P]>7$9
M_LZ;Q)X9GLKC5VTZZ8#Y/[3T1KU ?L5^GWE_EH_:7_9[\>?LJ_'#Q_\  CXE
M6L:>*/ FK_8/MMK%-]@\0:3>6_V_0/$VE><SS?V=K6B7-IJL #->6+7C:=>G
M[?87UF/=X"XMS#,L?C\KSV/LL90P="MAXV^.-.5&SBEJ_<@G)Z:RMI:R_9OH
MK_2 XXXVXHXG\,O%7+OJ?%F1T*.;X&7LW0E/ QE#"8S#2H2G4Y[3Q.#G3Q-&
MI.G4IU_=5/V2G5\([?Y^G^?Y=Z<JEONC?SQCVZ^G\J_5IU,-'V3ARX:%;XZL
MYKEIW\I-+YG]S8C$0P\5/&8FAAJ--SIU,17JT\/3J.:52"O4<4N9;6>@GY<#
M^OM_D"AL \=,<?Y/Z45*GLX0]KBZ:H*4I4*7N>]5A:\U/JK37=$5,?E="G2J
MU<9A,//V>(KT.?$T5"M0<JM/VE.3GRU5225^5RTM)VT%*E?O?+WYXQ[=/\]J
M0_YXZ?\ U_R]J'6P<Z:Q$:E-<D_J].O[2/*Z/3JHZ?>*&/R_ZI#&O$X.>%]I
M*+Q$<71^KTX2?LI2=53Y+MZ*+E<<RF(NI0(Z \#MZ#/.>W';I7]#_P "_P#@
MFE^S7X^_X(_^,?VU-?L/&$WQJT?X>?'+Q+974'BR]L_#46H_#_Q5XTT/00NA
MB$)]G6U\/V0O4^T?Z5>-=L3\U?'\8YYC,GP^7?4,1"V-SK+J-2O#EE&2Q-2M
M"JNRLGWLG8_G+Z1GBAFG 7#WA]G/!V8X)T\[\3N%>%\VK*4,32J9?F,<;5Q5
M&+IU$HSDJ"O*[5/526UOYW\-U_O\<#\<?3/IT'Y5^]__  16_P""=O[._P"W
M/H?[0^I?'6Q\57TWPTO_ (>V_AF+P[XGN_#T<:^)-/\ &<VI+>BSBE^TJ6T>
MV,!)^50HXR35<9YYB<EX9QV;8+$0GB*,J>#E4ARRBO;8O"J6D;JZBW;;30ZO
MI(^)^9< ^"W$7'?"&,P=;-LKQ/#^%HXF+CBJ,)8W.\ORK%3G3HUHJ_L,75M'
MGC9U(O51://O^"?G[-O_  3G^(7BO]J#1/VSOBEIGPX_X5]XZL?#_P )[77O
MBSI7P]DU73(M1\9V^LR_Z;/%_;ES"NG:!]KNL$V9NAAD%YAOQU\;6>C:;XR\
M6:?X;N8KSP]8>*->M-!NHYA>07>CV>KW5OH\_P!HX^TBZM/L?^EG_C][49/F
M&;2SC.88ITH96L%@GE;]I2_Y>0@W*:4G*#<I-?O%"]M+[F/AEQWQQG7B;XDY
M7Q7.EA>$<HRS@C$<+XB<:=*"^O9(JV;.=7VC4G'$RC#6-*TFHOG;N<WM<_=_
MY9G_ !^F._<<#VIE?74JKG[L94Z_LXM/EG&U&/>33Z?WC^AX9EA:[KT,)F6%
MJ2P\E[;V-6C5ER4]4G&$IN"?=I(D*G;NQQ_7ID=L9XZ>P[80@#&&!]>W;I]/
MI]*R6*P<6W#&0KUUBO8*$7':W,K)-]%^HJ69957G4C1S/!SC2J4XPPU/$T9U
M*E>FHU*]**C-SDU*;G))>XG9V25DXSV/Z?\ ZO3TIRAG+LJ [,>;^>/_ *_X
M?EI4KTL))PQ;A[.IHJKG&*6)=G;?IM;8TQ&/P.#]G.OBL/06*Q<5A\1BJU/#
M1E"6L815:45[NS&?Y_SVY_SQ1QT[?3V_I45*KIJ+GBZ:H23Q4)7A;]WIH[ZI
M?U8)YAE"I\N)QN$53%UN6DYXFC3A4I59ZNE)S49QHKXIPNK;NPYE9&VGY&[=
MORX__50J%FVK\V.X'7^7^1Q3]NXQE)8NG[&I+#..)]SDYJ?M^9+IIS1OK^EH
M^OY0Z'M*F-PBPM*O3HK%?6:/U=NC7YX2]OSJEK4I\MN?K;8_H@_X)(?\$T?V
M:?VQ_P!F'XU?%KXS67C"\\5^!_B)K_A?0SX?\67NAZ?%I^E?#_PKXDMO.LK6
M*=9K@ZAKUY]HW3MNMM@X%?SN_P"?_P!5?'\/9WF689[Q1@O:JOA\!C,$J$HJ
M&O-3JS=K:6N_N5G=JY_.W@YXF9_QKXH^.?#>98BA7R[@C.,BR[ASZO%6I86O
M0QE6M5J5(SG"JZE2E1FG%023<4K*Y_1A_P $8?\ @FA^S#^W#\&?BSXV^.UC
MXQN=<\&_$W_A&-)D\-^*KSP_:#1CX2\.:L#-!:1R)<7 N[Z\S=$[C@;>AK[E
M\ _\$OO^"(OQP\3O\./A/\?I?$7CR=;Q;/P_X2_: T74?$<GV+ OWTW2+FUO
MFU!+;K>O;V5VD:YWE0,U^<<1<9\787/\]PF5RE+"Y4\-+$-0A>,/JL9-NZZ>
M_HKWTTOO_&_B]](WZ0>1^*7B=E7!E&C7X>X!KX*6-4,(Z\L%EV,P5'&QGB%'
M%0G.$I*NY2I4_P!W2@W*R3D?E!^T#_P2LTW]EW_@HE^S5^SAXH\0:MXZ^ _[
M0?CSPC;>&O$CRPZ+XGN?#]YXIMM$\6>&]6GT^"&"#Q!H?VJPSJVD6L5G?6&M
M6=ZMI8W@N[:RYW_@LQ^Q#\$OV(?C'\(O WP/L?$5IH_C'X>7GB36(_$/B"Z\
M07,NJ1>(;W3+46\]W$GV>W6VB(-JK[&P %7!KZO*^-ZV9YMPM2=18;!9ODF)
MQ&/E+ELJV%6)IV<KJSYXV]U'[CP/])'.>,_$3P1PE\+E_#''_A_FO$'$.&K2
M2>&S/*:V88/$QIXJ=6$/8TZ^62Y>:FIS@UI"3<8_C7_G_/\ GZ<4]59AM5 ^
M?8]NV?Z?G@=?TSZSA:-)5ISA.C6;I2K.:BG[-6TU2^[6VA_<$\QRRG1>*GC\
M+]5A)O#UIUZ-*@W4_B*%64U3J<G[WEY9._/I\*&?H?IBGA"<;%W[!UQC_P"L
M,>W'KCL/%8:%"&(J2A2HZ^PJNI&T^3XK7=GTZO\ (*V:Y70H0QN(S'!PP_\
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M]'1?$+_PB/#?_P L*/\ B--?_H31_P#"E_\ R ?\5'>*_P#HA<'_ .'NI_\
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M^B%P?_A[J?\ SN#_ (ABOA7_ -'1?$+_ ,(CPW_\L*/^(8KX5_\ 1T7Q"_\
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MT?\ PI?_ ,@'_%1WBO\ Z(7!_P#A[J?_ #N#_B&*^%?_ $=%\0O_  B/#?\
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M?_H31_\ "E__ " ?\5'>*_\ HA<'_P"'NI_\[@_XABOA7_T=%\0O_"(\-_\
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M*^%?_1T7Q"_\(CPW_P#+"C_B&*^%?_1T7Q"_\(CPW_\ +"C_ (C37_Z$T?\
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MH ** "B@!I^\OX_RK^0C_@Y\_P"1S_8__P"Q>^-7_IU^%5?HWA7_ ,EKE/\
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M!S'9C*E=<F7XOA7)\-6]I**;C"M[V!E>+3^M6>MHS^)?^"EOA3Q)X"_X(5_
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M[_<L9_V"XC_TU(_>S_@D_P#\F"_ W_K^^,7_ *O;XG5^BE?F7&__ "6G%_\
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ME%1A2IHEU:DL+753W9PTNK*[NDMK=.RUM>][G"G]@'_@YO:(%?\ @K9\"@2
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MPO?VZ_;E_P""M_PT_99_X)D>%?\ @H1X1T9?$\WQO\$?#.^_9V\"^(Y_L/\
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M4 -/WE_'^5?R$?\ !SW_ ,CG^Q__ -B]\:O_ $Z_"JOT;PK_ .2URG_#BO\
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M_P"#;KQ9"\L7F#X1_M.'RO,42*#\7?B@0-F=QX^8<=#GH*^G/^"=WV/XK_\
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MNC 2?C,^;"X7(L1F&%KXS*J6=9TZF&C&<%.I/D4+I6N[IM7TNK:)G^<E:?\
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MKC[ON[)ZZNW7LEV7]R\%O!:VD%I;PQP6L%M'%#;Q1B*****/$444/ 3:%"
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M!2USGFA10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
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M_BHX-\]FFZ=5I2C=)-^ZX''?WQ2U^0'\%!10 44 %% !10 44 %% !10 44
M%% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44
M%% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44
M%% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44
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M_P )^'/C)J$'P0O?!O@;1K/1-$F^)&IWXO\ P%)!!IR16IU+QK8ZCK6D/*4
M">&M.7=@BO3O^"N'[-7[('[$/[$GP2^#?AGX4_"R'X^_$B?P3X1?XO3^%K)?
M&T>D> (-$U7XD?$BXU6RTZXUPSZO?C2='UC['"[FV\;7=K96;J5LF^RR[BC.
M,VH<$991J-8F<LU68MTX>^L!S.S7+[ON1MS1Y>5M;,_H+@SQDXYX[R[Z+'"N
M7Y[BY<0YAQ!Q74XR4)48UL?@>$<<Z]*EC^6#E2CB\#"<>1*FJBNZCORL]/\
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M]IXR>,S"->BH\E12P4L32HU9+VF'5"*I1BI5)5?./V(/V&_V*/V3O^"?MO\
MM^?MJ^ M*^+>I^*/!^D^/;?1M?T6'QCI.B^&O%^IV=I\/?"GA/P;JXMM#U?Q
M+XL_M;19KG5O$*[K/4M;:Q_M2PT&SN[ZYYC]HBY_X(N_MD?L:^+/B?\ #"+X
M0_LG?&[2=,\4W'@GP[+:^"_A5\04\6^'[0WEOHOB;X?>![_4K7Q3X6\6;+."
MWUFUT[7C8Q:@;W2[NQUZSN[)/<AF?&69Y[C>(,M]I_9-#//[,G3CR*'LHM>T
M3C)W3M&T6DM^5->]$^_7&WCWQCXL9GXJ\&5L?F7!W#OBDN"*.186H_JN(R7
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M-EK:W?V6+GRV0.V[]YS#*L'Q#DE'"8_6.,C3JS;;23I\M17::M9QOT73R/\
M6#C#@SASQ;\-L/P]Q51EB,FS? 9+C\72CB:V%]C4BL)CZ.(>(H5*=1JAB(<S
MBIQ4E[L_<NG_ $:_\$+_ -E;XM_ CPQ\;/VWOVDO$&H>!='^,W@YM3MM)\8W
M@TZZO_#UC?7GC77?B[X\&H,B::;MS=W6@M>NMW'HM]KFKWQ%KJ5BT_NG_!&'
MQ[X4^.OQ4_X*4?M*>%K0167Q3_: L+?0IYK0V=]-X.\.:7KDOA"YO+=OGM+J
M[TW7#?75J<E;F\?<:_GO/\13Q4N.,;EU)0P+EE.6KD=H76+I<UGI%_[I-2MT
MG:^I_D;XMX_ \2XWZ37%W">'A0X/P?\ J!P1AZU!*-'%5L+G^41G.CRI4W3G
M/A[$U;Q=I0JTVKJII\(_\$#OBIXN\6?MV?MOKK6K7EZGQ+TG7OB%XBCN))I!
M>^(=/^*MS!;7<OG@;9[2V\7:G:D+@ 773:!CX4^/'[:/QU_X)V_\%#?VY[7]
MF_4/"6BV?Q&^+W]J^*K+Q!X8T_Q!!?2,U_XH@BAEDDM+^P@75/&_B'[1;Z9=
MVCW#'-R1]CM37VV#R;!9AQAQ'DN+IJA@L5D64S]E!\L$\/\ 5?8.T7%>MK:.
M5^I_1O#GAOPIQ=](;Q6\/<UP_L>&,Z\(^ Z^,R_"5:F!@Z^5X?AJMA&ZF%G1
ME%4:N'A*6MJD'*G-.$YPE^G?_!#7]E[X]O\ $WXO_P#!2+X]:E=^$-'^,GAO
MQ:=&L-88Z?>>/E\9^+=,\;>(_B#J-O>NO]E>"X+K0E7P>MS\VMV]])K=DMCH
M5KIE[XAXW]A+XR_"']HK_@MM^U=^U!;>)?"^E^![3P;>:%\-[O6]5TG0V\2:
MCIUO\/OAC9>(= @O+FVN-1BUGP]X5\0ZH'"/>+I^N:<EVEH2D9\'&R^M9EQK
M6RO#6PN R./#\O8I\LZUXQ<XJ*Y92C[&>RO%:7L?EO$WL^(N,/I.9WX?99*>
M0\+>%>7^&%*66X9RI8W$U<7DN65_94J,6\15IT<KQM/GI1=J=&,G>,XR?V1\
M8_V-/^":_P#P4*_:.^.%MX>_:@\4:I^TU>_9K_Q/I_P\^*5G=)X47PGH&A>"
MH[72/##Z3=>&KW1]$_LW1[3Q';6YOKVRU2]9=0U;3K_4HP?Y"_VP/V;O'/[)
M?[1/Q(^ WQ!U&/7=;\%:G$+'Q-&+B&+Q9X=U2PMM4\->)8;>>XN?LIU'1;BT
MN+S2?M5ZNC:A]OT,:A?BQW'Z?PQS?,*5>7#F:8".'Q-/*XXS+ZUH1G4P;W3L
MDWJG:_IN?M'T+O$/B>CG]7P>XXX<P^39GEW".49QD%>.&AAL95R'#1P^#]AB
M>7G<W66(P=1SG.$^>$X5*,90E;YDHK]@/]'?P"B@ HH ** "BM:'\:C_ -?:
M?_I2.7'?[EC/^P7$?^FI'[V?\$G_ /DP7X&_]?WQB_\ 5[?$ZOT4K\RXW_Y+
M3B__ +*C/_\ U:XL_P"6C-?^1GF/_8?C/_4BH?_7_H6_X-QO^4:.@_\ 9PG[
M4'_JZO%5?O%7Z/XO_P#)T>/O^RKSO_U/K&.'_@T_\(F*6OS@V"B@ HH ** "
MB@ I,4 +10 44 %% !28H 6B@ HH ** "B@ HH ** "B@ HH ** "B@ HH *
M* "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH *
M* "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH *
M* "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH *
M* "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@!I^\OX_RK^0C_@Y
M\_Y'/]C_ /[%[XU?^G7X55^C>%?_ "6N4_X<5_ZC5S^L_H1?\I'\"?\ 7GB+
M_P!9W-C^5G_//\A_GL*_JD_X-A4+^*/VR$!QNT#X(J2!GK>_%D<#N1GV_E7]
M!^)7*^",YJRT:6&LMEIBJ#M9=_+U/]5_IIR<_HV>(4Y4W3^KU,C7L[\W-_QD
M&6;O]'Z>9[UX6_X(L_%OPY_P5/D_:AD\>>#;GX Q?&S7/VA+>Y74;V+QY_;N
MKZOJ/BZ/P?-H7]F-8HMIXPO!:76I?VU]DOO#-FEX0-9_XE"[?QO^.W@_XK?\
M' ?[&O@#PCK=KK4/P2\*?$;PMXKO+)H9;*Q\:ZY\+OBCK6JZ#]IBR)Y]/T63
MP_#J)1F2QU5[K1+O9?6-]%'^2PS&CQ5C%C*.&G166\"9E#%WYDGB9862Y%&R
MZ\MEMH[=+_Y^4.-H^,^>+-<LRRO0H>''T7N-,!G$YPJ0C''T^'<TPLZ4/=Y9
M?O<925&[4:L54G%+V?O?E5_P<4S&7]OW25:19([;X ?#^"/:0<1?\)9\1YB,
M@X_X^;@?R':OVV\?_#CP_P#\%@/^"4?PN\._!?QSX<TOXBZ!IOPYU:'3=7O)
MDTG1/B?X"T >'_$W@?QB+*RGU32;::VU35EL;I=)W7=I=:)KL5A-HU\HE]3,
MJF,R_A;PYSZG1<J.2NG[56:48RY/>DK>26V[1][QC/%<(>"'T/\ Q.675,3E
M7 ^9X+%9NJ<9.<,-F+HU^;E4;1UR[$QA)N-ZM6C3O[Z<7?\ !/?]F2V_X(Y_
MLI?'_P"*7[5?Q \)1ZMXDO8O$WB.V\)ZG-=Z38Z3X3T>_L?"7A?0Y=7M=$O?
M$OC/Q%>ZAJ:06=O:1?;[Z_T;2K-'>SFNYO'O^"*'QM^'O[5G[*'[2O[+WB[Q
M%:^'_'_B7Q9\8]8UK0K6>QM]7N/ OQR@>XO?$>A0R@>>NBZ[XAUC1KD?8Y/[
M'9-#&HHHUFP$O@8YXG.\+Q;Q3@L-/ZHLVRFO3IN]YPP2DG.-TI.T9<]K*ROV
ML?E/%]3-/$S(O'CQWRG*JT<G?'WAYC<#1<:D'6P?#U#'Y?B,0H<G,[0Q.6UZ
MMU[BKUEI*E.!Z)_P2@_X)(>,_P!@KX_?$3XH?%GXK> _%FOZYX,USX??#G1/
M!$^J,M_X5O/$?AS7M:\2Z_#KFFZ1<6FMQGP_X;M3I6D_VQ8V O+P76N7Y;3R
MKOV-L_\ #\#_ (*5;)%BSX ^'8#,0!C^P_AQ@9; Y_/BN?'9RN(<9Q9F$,-.
MCAZG#6$Y*4D^:\<QP#EMK\<9_)=M#FXH\2H^+^>^/7&]++,1E>%QG@_D-&A@
MJRYZM2.7\0\*8.I/FBG[KQ5+$-<LII*"7NN\(_S&_MF6WAGQ)_P4^^.6E_$+
M41I?@S5?VM=4T;QEK#S^2NG>$9OB#'I&LWZW0&+4:9H7VR[!YXY'%?VC_M2>
M _VO_ ?P@^#GPX_X)C^'_@-X \/PR/I'B34?$EKI]I8^!O#$=EI?_".WWA+2
M&M+G1;^W=SJL^ORW&EZSJB_9[$6.F7SWU[>0_3<:UJ%*AP'A\?"K+)?JBJ8F
MG2]I#]]]6I*,9NG[RZI1[-VVT_7_ *26/RJAD/T5LLXMECX\ U.#:F,SBC@_
MK,57Q6%R3*J>!H26%C[:,HOEA%Q:<88VJTX^SYCX>_X. O#?BV;_ ()S?#YM
M3U63QCJ7@WXN?"N\\:^)K.PM=.BOY3X2\8^&+WQ%=Z=IH^RZ7;:OXDUNQ"6U
MH?LEI>:A96-G_!7D?_!<:Y5O^"6'[+,43*2GQ#^!Z,%89'_%F/'PY7VQCD>W
M>O$X<]A-<%1="<88?B;-)RNIIJ%2.&45\DGZ.Z1^7^#UJN&^C@\/1G2H4/'+
MC""I2C*3H^VP_#,H0;E[TO<:]YVV^ZWK$BC_ (-L(,2+O'PCT#C<H;'_  O#
M3>W;\N_H*I_\$@)$7_@CC^T^A91F\_:.V@L 3_Q:O1QC'?IV[^N*ZL1&#R+B
M"$8/FGXB)Q7*]**?3RN[^6G1'T.>4(/PF\5W[.2Q%/Z8M14ERRNZ+4KK;I)=
M=.A_'/@>H^G_ .K.*_LN_P"#>BUA\7_L#?M+> +'4;*WUW5OC5\0+*.&YFXM
MX_$GP<^%^F:9?7B0'[3;P7%U9WX(7Y\VMV5R545^D>)_-#A&4Z<>:-'-,JKR
MM_+2BE+3\K:Z:G]D?3HHU<-X%8#%PISQ4,MXKX3S7'*E%MTZ4*DZ:;Y5I><Z
M=./]Z<5UUM?\$9?#6H?L)?&K]H+]@+]H'Q#X*T_XO^+=.\#?&#P*WAW7+F]T
M?Q;87NB:GI/B'2=,O]7TO0IY]8T&WTO2KLZ5!;7#7=FVLWED;NTT34KT>;?L
MV_\ !";XM?!K_@H!H'QN\1_$3P+<_L__  Y^)FI_$WPA-IM_JLGQ"U\6UY>Z
MMX2T/5]/FT2UTC39[34[FS'B.\35[^WOK.QNEL8XSJ0_L_\ .,9Q)2RG,^*<
M2L/*5/BG(<&\!)*=G/\ LZ%'E^'XG*;E9I6C9O5I'\=YYXT8?@3C+QQSG&Y3
MBL1@?'OPNX>S#A&JZ4X)RQO#<,MH1F^6T8TI8S,(5.5SC&>"Y'><U%?G)_P7
M[_:5\"_';]K_ $7P9\.]7L/$>B? GP0?!NMZSI<T-WI[^.]7UJ]U+Q+IUI?0
M-=6VHP:);Q>'=,O@ISI^M6NN:>X$MBP'B?\ P1/^'7P>^)_[?WPVT#XSV.A:
MQI%AX?\ %_B#PCX<\3107.D:_P"/-#LX[[1+*>POP;74;G2[(ZQXBM;>[^U&
M*[T2RF%HK1;J_1,'AL3E'A?.,%+ZW+))U$HQ?.J\E*2BDNJO:W2VRV/["X>R
MKB?@/Z$D\%0HUJ'$&$\+,ZS:+BW'$81YEA,SS*$8PY6XXK#JK'W$KJK3Y8OE
MLW_8%XUTW_@H1JO[:W@NS\&:S\(/AY^PSX=31M3UW5[2UL-5^)/C,0:-G5/"
M-U8ZM:7QTAK_ ,2*FGV=WH8T>WL/"['4AKU[K@&AK\+_ +7OQ=T3]GC_ (+8
M?L;_ !#\>7D'A_X>_$?]G[7_ (/'Q7>KLTF#Q#J?BOQ<ULLU[+FT@BBUO5_!
M%CJ5R-BZ1::ZE[J+IIY,@_$LGI8?%XR-#!TJDZE?A3-J>,E+VC<\REAJG[M<
MT=U)IV7NZJW4_P S/#_*LBXBS["9'PE0QE7-,?X,<<T,_K5_K<GF'%4N',YQ
M=?"TH54VH4I0PU./U=>SJ_%%2FY2EY#_ ,%)_P#@C'\6OVOOVUM,^/'P_P#'
MG@K2_A?\1;+P/9_%1]<U6^M_$G@^+PK9V^B:A>^&--@TV[LM:_M'PW864^DV
MLNH6 _MW[8+YK*R=;XZ__!R>UL?V3OV?5M9HKB&/XYZ=% \4RRQR(GPU\?K'
MEE+><"54J,D'C'K7TV29_',\W\/,+4P]2V10E@:R<)V;Y+0UMUM)VZ):Z'[/
MX<^*5/Q$X^^B3PK2P=?"5?#K"9AP]F5>=*?LW7KX&."I23<+2<L%E%+$\L6X
MKVO+?GIU+?7G_!)GXP> OVW?V$_@D_Q2L+#Q;XZ_9L\6:5X9U-M98RW>G>-/
MA1!:GP%XS2220W-SJ=QX0U#1M0?4YU'VK69=8(4A<U_-M_P5A_:.\)_M5_\
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M@M8_:$^/?B#P%'\*-<^./Q@UKX7PVNG6*?#76/B7XRU+P!#9Z/>6MYI&G_\
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MVC2]G:&)4JLI*M!1GJVI:MO*^&7QE^+OP5UF7Q#\(?B=X\^%^M75O!;WVH^
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M._W+&?\ 8+B/_34C][/^"3__ "8+\#?^O[XQ?^KV^)U?HI7YEQO_ ,EIQ?\
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M+3*?\.*_]1JY_6?T(_\ E(_@7_KQQ'_ZSN;'\K%%?UT?[^A10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 45K0_C4?^OM/_P!*1RX[_<L9_P!@N(_]-2/WL_X)
M/_\ )@OP-_Z_OC%_ZO;XG5^BE?F7&_\ R6G%_P#V5&?_ /JUQ9_RT9K_ ,C/
M,?\ L/QG_J14/__3_H6_X-QO^4:.@_\ 9PG[4'_JZO%5?O%7Z/XO_P#)T>/O
M^RKSO_U/K&.'_@T_\(45^<&P44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
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M_@D__P F"_ W_K^^,7_J]OB=7Z*5^9<;_P#):<7_ /949_\ ^K7%G_+1FO\
MR,\Q_P"P_&?^I%0__]7^A;_@W&_Y1HZ#_P!G"?M0?^KJ\55^\5?H_B__ ,G1
MX^_[*O.__4^L8X?^#3_PA17YP;!10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10
M44 %% !10 44 %% !10 T_>7\?Y5_(1_P<^?\CG^Q_\ ]B]\:O\ TZ_"JOT;
MPK_Y+3*?\.*_]1JY_6?T(_\ E(_@7_KQQ'_ZSN;'\K%%?UT?[^A10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 45K0_C4?^OM/_P!*1RX[_<L9_P!@N(_]-2/W
ML_X)/_\ )@OP-_Z_OC%_ZO;XG5^BE?F7&_\ R6G%_P#V5&?_ /JUQ9_RT9K_
M ,C/,?\ L/QG_J14/__6_H6_X-QO^4:&@^G_  T)^T__ .KJ\55^\5?H_B__
M ,G1X^_[*O.__4^L8X?^#3_PA17YP;!10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %% !10 44 %%
M!10 44 %% !10 44 %% !10 T_>7\?Y5_(1_P<]_\CG^Q_\ ]B]\:1_Y5?A7
M7Z-X5_\ ):93_AQ7_J-7/ZS^A'_RD?P+_P!>.(__ %G<V/Y6**_KH_W]"B@
MHH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@ HH ** "B@
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M1;_Z/ N/_$=_VH__ )RE'_$N7C!_T2]'_P 2#AS_ .>P?7L+_P _'_X+J_\
MR ?\1*'_  1;_P"CP+C_ ,1W_:C_ /G*4?\ $2A_P1;_ .CP+C_Q'?\ :C_^
M<I1_Q+EXP?\ 1+T?_$@X<_\ GL'U["_\_'_X+J__ " ?\1*'_!%O_H\"X_\
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M<I1_Q$H?\$6_^CP+C_Q'?]J/_P"<I1_Q+EXP?]$O1_\ $@X<_P#GL'U["_\
M/Q_^"ZO_ ,@'_$2A_P $6_\ H\"X_P#$=_VH_P#YRE'_ !$H?\$6_P#H\"X_
M\1W_ &H__G*4?\2Y>,'_ $2]'_Q(.'/_ )[!]>PO_/Q_^"ZO_P @'_$2A_P1
M;_Z/ N/_ !'?]J/_ .<I1_Q$H?\ !%O_ */ N/\ Q'?]J/\ ^<I1_P 2Y>,'
M_1+T?_$@X<_^>P?7L+_S\?\ X+J__(!_Q$H?\$6_^CP+C_Q'?]J/_P"<I1_Q
M$H?\$6_^CP+C_P 1W_:C_P#G*4?\2Y>,'_1+T?\ Q(.'/_GL'U["_P#/Q_\
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M\1W_ &H__G*4?\1*'_!%O_H\"X_\1W_:C_\ G*4?\2Y>,'_1+T?_ !(.'/\
MY[!]>PO_ #\?_@NK_P#(!_Q$H?\ !%O_ */ N/\ Q'?]J/\ ^<I1_P 1*'_!
M%O\ Z/ N/_$=_P!J/_YRE'_$N7C!_P!$O1_\2#AS_P">P?7L+_S\?_@NK_\
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M ."ZO_R ?\1*'_!%O_H\"X_\1W_:C_\ G*4?\1*'_!%O_H\"X_\ $=_VH_\
MYRE'_$N7C!_T2]'_ ,2#AS_Y[!]>PO\ S\?_ (+J_P#R ?\ $2A_P1;_ .CP
M+C_Q'?\ :C_^<I1_Q$H?\$6_^CP+C_Q'?]J/_P"<I1_Q+EXP?]$O1_\ $@X<
M_P#GL'U["_\ /Q_^"ZO_ ,@'_$2A_P $6_\ H\"X_P#$=_VH_P#YRE'_ !$H
M?\$6_P#H\"X_\1W_ &H__G*4?\2Y>,'_ $2]'_Q(.'/_ )[!]>PO_/Q_^"ZO
M_P @'_$2A_P1;_Z/ N/_ !'?]J/_ .<I1_Q$H?\ !%O_ */ N/\ Q'?]J/\
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M+T?_ !(.'/\ Y[!]>PO_ #\?_@NK_P#(!_Q$H?\ !%O_ */ N/\ Q'?]J/\
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M>PO_ #\?_@NK_P#(!_Q$H?\ !%O_ */ N/\ Q'?]J/\ ^<I1_P 1*'_!%O\
MZ/ N/_$=_P!J/_YRE'_$N7C!_P!$O1_\2#AS_P">P?7L+_S\?_@NK_\ (!_Q
M$H?\$6_^CP+C_P 1W_:C_P#G*4?\1*'_  1;_P"CP+C_ ,1W_:C_ /G*4?\
M$N7C!_T2]'_Q(.'/_GL'U["_\_'_ ."ZO_R ?\1*'_!%O_H\"X_\1W_:C_\
MG*4?\1*'_!%O_H\"X_\ $=_VH_\ YRE'_$N7C!_T2]'_ ,2#AS_Y[!]>PO\
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M_P#G*4?\2Y>,'_1+T?\ Q(.'/_GL'U["_P#/Q_\ @NK_ /(!_P 1*'_!%O\
MZ/ N/_$=_P!J/_YRE'_$2A_P1;_Z/ N/_$=_VH__ )RE'_$N7C!_T2]'_P 2
M#AS_ .>P?7L+_P _'_X+J_\ R ?\1*'_  1;_P"CP+C_ ,1W_:C_ /G*4?\
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MX_\ $=_VH_\ YRE'_$N7C!_T2]'_ ,2#AS_Y[!]>PO\ S\?_ (+J_P#R ?\
M$2A_P1;_ .CP+C_Q'?\ :C_^<I1_Q$H?\$6_^CP+C_Q'?]J/_P"<I1_Q+EXP
M?]$O1_\ $@X<_P#GL'U["_\ /Q_^"ZO_ ,@'_$2A_P $6_\ H\"X_P#$=_VH
M_P#YRE'_ !$H?\$6_P#H\"X_\1W_ &H__G*4?\2Y>,'_ $2]'_Q(.'/_ )[!
M]>PO_/Q_^"ZO_P @'_$2A_P1;_Z/ N/_ !'?]J/_ .<I1_Q$H?\ !%O_ */
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M_P#E@?\ $\WT;?\ HMZO_AHS#_Y4'_"^/A-_T-,?_@J\1_\ REH_X7Q\)O\
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MPF_Z&F/_ ,%7B/\ ^4M'_$-N(_\ J7_^'#"__+ _XGF^C;_T6]7_ ,-&8?\
MRH/^%\?";_H:8_\ P5>(_P#Y2T?\+X^$W_0TQ_\ @J\1_P#REH_XAMQ'_P!2
M_P#\.&%_^6!_Q/-]&W_HMZO_ (:,P_\ E0?\+X^$W_0TQ_\ @J\1_P#REH_X
M7Q\)O^AIC_\ !5XC_P#E+1_Q#;B/_J7_ /APPO\ \L#_ (GF^C;_ -%O5_\
M#1F'_P J#_A?'PF_Z&F/_P %7B/_ .4M'_"^/A-_T-,?_@J\1_\ REH_XAMQ
M'_U+_P#PX87_ .6!_P 3S?1M_P"BWJ_^&C,/_E0?\+X^$W_0TQ_^"KQ'_P#*
M6C_A?'PF_P"AIC_\%7B/_P"4M'_$-N(_^I?_ .'#"_\ RP/^)YOHV_\ 1;U?
M_#1F'_RH/^%\?";_ *&F/_P5>(__ )2T?\+X^$W_ $-,?_@J\1__ "EH_P"(
M;<1_]2__ ,.&%_\ E@?\3S?1M_Z+>K_X:,P_^5!_POCX3?\ 0TQ_^"KQ'_\
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M#_B>;Z-O_1;U?_#1F'_RH/\ A?'PF_Z&F/\ \%7B/_Y2T?\ "^/A-_T-,?\
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M5DN+?^S-;E\I+WXT?$6_M5\R&T:)O]$N8#E#BOOW_AHGX-_]#0?_  4>(/\
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M_P ^%E_X"P?_ !NCZWBO^@G$?^#JG_R0!_9NG?\ /A9?^ L'_P ;H_LW3O\
MGPLO_ 6#_P"-T?6\5_T$XC_P=4_^2 /[-T[_ )\++_P%@_\ C=']FZ=_SX67
M_@+!_P#&Z/K>*_Z"<1_X.J?_ "0!_9NG?\^%E_X"P?\ QNC^S=._Y\++_P !
M8/\ XW1];Q7_ $$XC_P=4_\ D@#^S=._Y\++_P !8/\ XW1_9NG?\^%E_P"
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M ?V;IW_/A9?^ L'_ ,;H_LW3O^?"R_\  6#_ .-T?6\5_P!!.(_\'5/_ )(
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M_P#) ']FZ=_SX67_ ("P?_&Z/[-T[_GPLO\ P%@_^-T?6\5_T$XC_P '5/\
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M%@_^-T?6\5_T$XC_ ,'5/_D@#^S=._Y\++_P%@_^-T?V;IW_ #X67_@+!_\
M&Z/K>*_Z"<1_X.J?_) ']FZ=_P ^%E_X"P?_ !NC^S=._P"?"R_\!8/_ (W1
M];Q7_03B/_!U3_Y( _LW3O\ GPLO_ 6#_P"-T?V;IW_/A9?^ L'_ ,;H^MXK
M_H)Q'_@ZI_\ ) ']FZ=_SX67_@+!_P#&Z/[-T[_GPLO_  %@_P#C='UO%?\
M03B/_!U3_P"2 /[-T[_GPLO_  %@_P#C=']FZ=_SX67_ ("P?_&Z/K>*_P"@
MG$?^#JG_ ,D ?V;IW_/A9?\ @+!_\;H_LW3O^?"R_P# 6#_XW1];Q7_03B/_
M  =4_P#D@#^S=._Y\++_ ,!8/_C=']FZ=_SX67_@+!_\;H^MXK_H)Q'_ (.J
M?_) ']FZ=_SX67_@+!_\;H_LW3O^?"R_\!8/_C='UO%?]!.(_P#!U3_Y( _L
MW3O^?"R_\!8/_C=']FZ=_P ^%E_X"P?_ !NCZWBO^@G$?^#JG_R0!_9NG?\
M/A9?^ L'_P ;H_LW3O\ GPLO_ 6#_P"-T?6\5_T$XC_P=4_^2 /[-T[_ )\+
M+_P%@_\ C=']FZ=_SX67_@+!_P#&Z/K>*_Z"<1_X.J?_ "0!_9NG?\^%E_X"
MP?\ QNC^S=._Y\++_P !8/\ XW1];Q7_ $$XC_P=4_\ D@#^S=._Y\++_P !
M8/\ XW1_9NG?\^%E_P" L'_QNCZWBO\ H)Q'_@ZI_P#) ']FZ=_SX67_ ("P
M?_&Z/[-T[_GPLO\ P%@_^-T?6\5_T$XC_P '5/\ Y( _LW3O^?"R_P# 6#_X
MW1_9NG?\^%E_X"P?_&Z/K>*_Z"<1_P"#JG_R0!_9NG?\^%E_X"P?_&Z/[-T[
M_GPLO_ 6#_XW1];Q7_03B/\ P=4_^2 /[-T[_GPLO_ 6#_XW1_9NG?\ /A9?
M^ L'_P ;H^MXK_H)Q'_@ZI_\D ?V;IW_ #X67_@+!_\ &Z/[-T[_ )\++_P%
M@_\ C='UO%?]!.(_\'5/_D@#^S=._P"?"R_\!8/_ (W1_9NG?\^%E_X"P?\
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M_P ^%E_X"P?_ !NCZWBO^@G$?^#JG_R0!_9NG?\ /A9?^ L'_P ;H_LW3O\
MGPLO_ 6#_P"-T?6\5_T$XC_P=4_^2 /[-T[_ )\++_P%@_\ C=']FZ=_SX67
M_@+!_P#&Z/K>*_Z"<1_X.J?_ "0!_9NG?\^%E_X"P?\ QNC^S=._Y\++_P !
M8/\ XW1];Q7_ $$XC_P=4_\ D@#^S=._Y\++_P !8/\ XW1_9NG?\^%E_P"
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M\?\ E]4_F7]XX=J.*MI?EOY^]5)_[,TW_H'V/_@);_\ QNC^S--_Z!]C_P"
MEO\ _&ZX'C,9=_[5B=W_ ,OZO_R1%EV7W(/[,TW_ *!]C_X"6_\ \;H_LS3?
M^@?8_P#@);__ !NE]<QG_05B?_!]7_Y(++LON0?V9IO_ $#['_P$M_\ XW1_
M9FF_] ^Q_P# 2W_^-T?7,9_T%8G_ ,'U?_D@LNR^Y!_9FF_] ^Q_\!+?_P"-
MT?V9IO\ T#['_P !+?\ ^-T?7,9_T%8G_P 'U?\ Y(++LON0?V9IO_0/L?\
MP$M__C=']F:;_P! ^Q_\!+?_ .-T?7,9_P!!6)_\'U?_ )(++LON0?V9IO\
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M_P !+?\ ^-T?V9IO_0/L?_ 2W_\ C='US&?]!6)_\'U?_D@LNR^Y!_9FF_\
M0/L?_ 2W_P#C=']F:;_T#['_ ,!+?_XW1]<QG_05B?\ P?5_^2"R[+[D']F:
M;_T#['_P$M__ (W1_9FF_P#0/L?_  $M_P#XW1]<QG_05B?_  ?5_P#D@LNR
M^Y!_9FF_] ^Q_P# 2W_^-T?V9IO_ $#['_P$M_\ XW1]<QG_ $%8G_P?5_\
MD@LNR^Y!_9FF_P#0/L?_  $M_P#XW1_9FF_] ^Q_\!+?_P"-T?7,9_T%8G_P
M?5_^2"R[+[D']F:;_P! ^Q_\!+?_ .-T?V9IO_0/L?\ P$M__C='US&?]!6)
M_P#!]7_Y(++LON0?V9IO_0/L?_ 2W_\ C=']F:;_ - ^Q_\  2W_ /C='US&
M?]!6)_\ !]7_ .2"R[+[D']F:;_T#['_ ,!+?_XW1_9FF_\ 0/L?_ 2W_P#C
M='US&?\ 05B?_!]7_P"2"R[+[D']F:;_ - ^Q_\  2W_ /C=']F:;_T#['_P
M$M__ (W1]<QG_05B?_!]7_Y(++LON0?V9IO_ $#['_P$M_\ XW1_9FF_] ^Q
M_P# 2W_^-T?7,9_T%8G_ ,'U?_D@LNR^Y!_9FF_] ^Q_\!+?_P"-T?V9IO\
MT#['_P !+?\ ^-T?7,9_T%8G_P 'U?\ Y(++LON0?V9IO_0/L?\ P$M__C='
M]F:;_P! ^Q_\!+?_ .-T?7,9_P!!6)_\'U?_ )(++LON0?V9IO\ T#['_P !
M+?\ ^-THTO3<C_B76/4?\NEO_P#&Z:QF,NO]JQ.Z_P"7]7_Y(++LON'1:/I,
M<:HFEZ<B+PJI96RJHST"B( ?@*D_LK2_^@;8?^ =O_\ &ZTG7K2G*4JU64I2
/;DW4FVVW=MMN[;>[&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ck0001824293-20241231_g10.jpg
<TEXT>
begin 644 ck0001824293-20241231_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $, G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **\ST#XZ:9??\+-76K.3P_)X!NY(]16XE#[[06ZW$5VI 'R21DD
M#J"C#M4'@7]HGPIXFL_"=KK6I:=X5\7>(K&"^A\+7VH1M>QK,N^)&''SLI!V
MXSG(&<5M[&IKI_6XKGJ=%>0_#7]IWP9\1KB\TJ/5-.T[Q5;W>H6H\/3ZA&;I
MQ:S21E]O;<(]^,9"G)XYK5M?V@/!ECX?\*7WB;Q'H?AF^\16\<]I97&K0R!]
M^!\D@(5UR0-X^4DBAT:D79QU"Z/2:*\FT/\ :5\'R>$KWQ!XGU*R\&V4&O:A
MH,?]JWB+Y\EI<R0,R=,[O++8'0'GUKU'3]0M=6L;>]LKF&\L[B-98;BWD#QR
MHPRK*PX(((((ZU,J<H?$AEBBBN>^(7CS1_A?X(UKQ9K\[6VCZ1;/=7+HA=]J
MC[JJ/O,QPH'<D"H2<G9;@=#17BWAGXX^-KC7/#\7BKX1:OX8T37IA;VNHPZA
M%?RVLC(7C%[!$N;<, 06#.JL0&(SFN(C_;%\10> 9_B)?_"J:V^'%M=317&L
MPZ_;R7,<,=TUL\WV4HI;#H3L#;B.F3Q72L-5;LDOO7^>_D*Z/J"BN)\ _$Z'
MQYXF\=Z/%826;>%=5CTMYGD#"Y+VL%P'4 ?*,3A<'/W<UP5Y^U%%:^-KBT'A
M2^E\$VOB&/PI<^+%N8PD6IN579]G/SF$2.D1ES@.3P0":S5&I)M)!<]SHKPK
MPE^U!+XN\0.;7P+JTG@^1;QK77[6>*XED6W$F99+-#YL44IB=8G.=YV#"[Q4
MG@[]I>XOM>CTWQKX(U'P"+W0I_$FGR7=S'=/)90;/.\Z*(;X9D$L9,9#=2 2
M1BK>'JJ^GXH+H]QHKS?X%_&JT^.GAO6-:LM&U#0[>PUBXTI8-5C,5Q((@A$K
M1D!H]P<'8W('7GBO2*QE&4).,MT,****@ HHHH **** "BBB@ HHHH ****
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MF*(NQ.1O3$F>P.#S4O\ PI/PK_SSU;_P>WW_ ,>H_P"%)^%?^>>K?^#V^_\
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MX5@TF7X4ZW</'/<R^9'JUEC$D\DH'+]@X'X5K]6K_P C^YGO?ZM9W_T!5?\
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MY\?/!^O^#/A3X.\+_"S6+^ZLM!\;6OAQ;:_U*5;)W^SJ&(>$ I< S@;7\K8
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M^"G/_)0_@]_UY:Y_.QKLPB:Q$$^Y]=PC_P C[!_XT?)-%%%?;']KGIW[)O\
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M()/)SM(YR,$ 5-?>!?\ A)])MO&MA!J$$^DM';:7I\E@\$!5A'OD:#&Y3DD
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MX XK/TV2UTW??P;[BYND1;DL<89<X_4D>^!6/-KR6,5ZA<P7$Z21J;G"?/\
MPY]N>M7*6G,WL)16UMSLM+^(GCXW]W!=>(H)%+J8F2WCQMVC<%^7G!W=:UO^
M%H>*)+R2R;5ECN(8O,8B%/W@;.TC*]L<^_UKQ*QGUM=,GO+?Y;E)%O9)I$2V
M:.)A]W:"RE2",,#SU(KCO'G@/Q=K_AVX\0:)XKO9YY+KR]0::,(5@#%28"I#
M8C#8(XWX)[5E*O*,.>,6_P"OZVN:QHQE+E<DCZ&3XU:_]JMISX@)LMNZ5A%$
M(U0 MO8[<@8'6HM0^,?C74KV-O"^IPZG;V\D;W?GHB)Y; Y"'9ECC##L?6N
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MNFZ9!M,]W.EN$C!8*"3O]2!^-?<44@FC1P,!@&&?>OR,_:B_Y('XN_ZY0?\
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M-&N2N!U &<CD8/M6?XVFT[6O$.@Z?Y$,]Q/(0+J5.(P#]T9Y+8W$#IZUS/\
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M97$C;[::$- T;@*RD9!/'<=.*Y[5M6N%^SZOHVU&LU>2&UNXFABF?:5,9?\
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MOX9LDL(8823-++%N1B ^1D#J2HR>Q->L?LZQRKXAU-G?[0C6N5G"A5P7!"@
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MFK)]H6;_ $>:)68;HS&Q1LY*2+D9Y/L7C;X9>"M=U_3?&&M^&M'U'Q+HB_\
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M"P7R\X!(&?<5V'AWQ-IWBS31?Z7,UQ:EV0.\+Q'(Z_*X!_2@#4HHHH ****
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M>,_7GH.,5)J4<NI?;+Z*T\BQW*6!P-K 8R0.IYY[<\UA&,.1^S>JZ6=UUO\
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M)CF1<8SWKQU_C#XI^)FE_!Y]6T3^T;$^/X(QXOT_RX+"Z$1G5"D#2&4;AQD
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MIRBI\QZ9[9I=#N-4\5?#-+3Q*]G:^&K;RQ?ZE&Y\VXB5@Y.S&(BK[2QRV<$
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MK_D=X+_K[3_]*1\;T445]T?W">H?LD_\G>?"C_KKJO\ Z;+BOUFK\F?V2?\
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M5[I^D6\$T>X%6VNB!AD$@X/(-=E58BI&K/GBK7_/[V""BO%OC9XT\4:!\0O
M6E^&[O4H1?SN]Y''I!N;#R4P6\^8(S*[?<C12N2Q8G"X/C/A7XL?'*34?!MK
M)#J6K&2_:&XNI-'\BUU;][")02T"/:Q1Q/,064,7C;EP #SC/8?A#T^./_8V
M7O\ Z0VM?DM\._\ D0?#W_7C%_Z#7ZK_ +/MUJMYH?QGGUNPM]+U1_%=\9[.
MUN?M,<9^Q6V )-J[N,'[HZU^5'P[_P"1!\/?]>,7_H->[E/\27H?N/A3_O\
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M@_D%_+\Q?/C3<-QQQFO6:^#/V226_;$U8DY_XH$?^G$5]YUS2CRRL,****@
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M_%5A\(=4T74;75M-N/'6G&*\LIEEBD 2<'#*2#R"/PKY>_X*8_\ );?A7_V
M]6_]&VM>J^(O@.?A=_PJ6\U#6;B]UF3X@6\TT&GRRV^EAIA.QV6I8KD ##')
MSFO*O^"F/_);OA7_ -@/5O\ T;:UTX/_ 'B'J?7\(?\ (_P?^-'R[1117VY_
M:Q[-^P__ ,G@>%O^P!JW\[:OU0K\K_V'_P#D\#PM_P!@#5OYVU?JA7QN8?[S
M/Y?DC^/./_\ DI,5_P!N?^FXGSMX@_;E^$5O>ZUHKZIXCDGL[FXTRYGTOPYJ
M,JQS1NT4@26. J2K*1N4GD5XYXD_:2^&:W6@?V1XV^+9@&HK_:.ZPUC_ (]?
M*DS]Z#^_Y7W>?UKR?P:S"X\:8)'_ !6.O=_^HC-71^8W]X_G6$:*:3N?GESW
M+PC^V)\'O"+W+1^(/B)JOGA01J^@:Q=!,9^YNM_ESGG'M7OGPG^+WACXV^$A
MXD\)7LU]I7VF:S9KBUEMI(YHFVR(T<JJRD'U%?"*R-N'S'\Z]^_X)W?\D5\3
M?]CKKG_I4:BI3Y$!]1T445@,**** "BBB@ KYE^+4OANW_; \$2?$5K!/"Q\
M+7B^'VULJ+$:M]H3SL;_ )/.-OMV[N=N_;SFOIJLOQ%X7T;QAIK:=KVD6.MZ
M>S!VM-1MDN(BPZ$HX(R/I6U&HJ<KOT$?&GB33O GBKQO\/=,^$.I3^&-.E^)
M-\MWK&C(C6QN_P"Q+DW)L-X>( J-C,B[1(7."V34OAGXJ>*O$WB/2_ GBCXJ
MW/A'2].E\1PGQ4@M+:ZU::PU!;>")Y)(S$K)"WF2!5!?KP :^QK/PKHNG6NF
MVUII%A:VVF$FQAAMD1+0E2I,0 PGRLP^7'#$=ZJZMX!\,:]8FRU/PWI.HV9N
M&O#;W=C%+'Y[$EI=K*1O))RW4Y-=GUJ+LG&]N]F^O^8K'P?X7^*?B#Q1J7_"
M6ZH]LVNZI8^ [>XN6LT"7<3>([R 7"Q."$\Z("1<#Y?,!7&!7=:#\2OB-I<7
MA;QQ)XUU#Q -8\;:[X;_ .$7EMK=;1K6W;4OLZ(5C$GG!K./Y]QR&(([U]@S
M>&-&N)3++I-C)*1""[VR$XA;?",X_@8EE_NDY&*='X;TF*.WC32[)([>X:[A
M5;= (IF+%I5&.')=R6')W-ZFG+%PE?W/^&M:P6/B/]G_ /:#^*&M:YX7OI+L
M>-IO$6@7.IW?AR37-,,KW""-D^QQQ*K6J(S-&Z7#'J,G>IKLAXB\,ZQ^U5<:
MA\5M$T/PE<3?#ZUQI7BJ[LI_)(U.['$A8QME<$[3P#S7U#H_@GP[X=U2^U+2
MM!TS3-1OSNN[RSLXXIK@YSF1U4%^23R35?Q'\.O"GC"\AN]>\,:-K=W"NR*?
M4M/BN)$7).%9U) R2<#UI2Q-.4FU"R:Z;_Y!9GPAHOQ+\0>$_#^A^'_ ]W=:
M1\-O$GC/Q$=#O=/OK6P8Z= L;P06EQ=JT443S-<N@VY9(\)@5E^(-?\ $7C+
M38?'NO>)8M2\0:/\,?%=S:R6WV.\L9S;72PQRD&(HQ==GF%,*S1C;A20?T/U
MKPCH7B31ETC5M%T_5-)7;BPO;6.: ;?NXC8%>.W'%(WA'0FM4MCHNG&W2T:P
M6$VD>Q;9L;H0,8$9P,IT.!Q6JQL%JH:_GN+E/E8_%34+SQ9XCO-7^+8\"S>'
M-9TS2=-\+&R@GBU"WFMK9LR0;?.F:X:9PCQL!&$S@[6KR/\ X7]\0O\ A&?#
MME9:^OAJTT[P%;:_;W-O?:9I<%Q=22W"O+,MQ&1-!%Y4:M%"%/SG/++7Z!7'
M@KP]=ZY9ZU/H.F3:Q9)Y5KJ$EG&UQ F"-J2%=RCD\ ]S5?4OAUX4UBUTZVO_
M  QHU];Z:=UE#<Z?%(EJ>#F(%2$Z#[N.E1'%4H[PO]W]?>%F?'GB#XK?$RZT
M7XB>/3XZFTEO",OA^2W\.V,$#Z?*US:V<ETDK/&97C<SOL^92N0>M>O?L@VD
M=C>?&6W.OW6K74?CW4A+;7<T;M;C*E6VJH*[P>_!"C&.:]VN/#>DWD=\D^EV
M4Z7S*]VLENC"X90 IDR/F("KC.<8'I2V/A_2]+U"_O[+3;.TOM096O+J"!$E
MN2HPID8#+D D#.<9K*>(C*FX*-OZ7_!^\=C\^8[KX8C]B?Q%#*WA]_B2=1U@
M:)%9& ZU_:O]J7'V(Q!/WWF>9Y9'^SU^6NG\6?&;QUI.MR>'+2\.G0ZIXYU3
M3]0U#2[BRTV8&WTVUE2W2YN$,2N\CR,6<%V6,JIK[*TWX9>#M'UIM8L/">AV
M.K,S.;^VTV&.<L>I\P*&R<G/-6]4\$^'=<T^[L-2T#2]0L;R;[3<VMU9QRQ3
M2\?O'5E(9N!\QYX%;?7*;DVXWNV]?/\ R%RL^//@AXHUKQS\>/A/KWBGQBL^
MHOX<\16,!L;VV>VU-8-1MXT!9$"R2%"#)Y)VEH RX7.?MVL=?!^@J=)(T330
M=(S_ &=BTC_T+*[3Y/'[OY>/EQQQ6Q7'7JJJTTK6_P VRDK!1117,,**** "
MBBB@ HHKR7XK?M"6?PK\=>'?#USH]Q?0ZBL<EU>Q2@&UCDN$MXRL>"TI,CC*
MK@@ GGI0!E_"'I\<?^QLO?\ TAM:_);X=_\ (@^'O^O&+_T&OTI^&OQU\*:'
M_P +8^W)K]O_ &QXCNKVPW>&]1/GPM:6Z*ZX@Z%D<<XZ5^;G@W2/$.D>$=&L
M;OP5XQCNK>UCBE3_ (1F^.U@.1D18->SEE2%.<G-I:=3]B\-<?A,!C<1/%U8
MTTX))RDHWU\VC;K.\2_\BUK'_7C/_P"BVJ9KR^74$T]O#'BL7\D33I:GPY?>
M:T8(4N%\K)4$@$],D5'KEAKMYH>I6\/@SQBTTUK+$B_\(Q?C+,A '^J]37OR
MQ%'E?OK[T?O5?B+)G1FEC*6S^W'MZG[$? '_ )(3\./^Q;TW_P!)8Z^9/VTO
M^3BOAQ_V*^L?^E5A7I_P=_:*\%>&_A'X(TC4I-=M=1T_0[&UN8&\-ZB3'*EN
MBNIQ!C(8$<>E> ?M7?%+2?&'QG\#Z[H>F>)]6TNQT'4K*YGM/#&HMY4TL]H\
M:D>1GE8I#G&/E]Z^*IZ25S^(5L8E%<G)\2+.*-G?P]XR1%!9F;PEJ0  Y))\
MBH[+XI:;J5G!=V>B>+KNTG020W$'A347CD0C(96$."".XKT.>/<#U_\ 9'_Y
M/$U;_L01_P"G$5]Z5^</[,OQ(T_PO^TKJ?BC6-(\4Z7H3^$/[,2[NO#&HH&N
M?MHD\L#R,_<YSC%?H%X.\9:7X\T./5]'>XDL9'9%:ZM)K5\J<']W*JL.>^.:
MX*CO)M%&Y11168!1110 4444 %%%1W%Q':V\L\SB.*-2[L>@4#)/Y4 >/?M:
M?\D@3_L8-#_].EM7SM_P5$_X^O@U_P!A/4O_ $CKO/CC^T;X%^(WP.-W;:JN
MCLOB+1"MIK;):3R1_;K.=9D1FRT;1.L@8=%/.,$5Y!_P4D^)'A+Q7??"*/1?
M%.BZN]OJ.HM,MCJ$,WE@VF 6VL< GCFNG#?QX>J_,^CX;=L[P3?_ #]A_P"E
M(^6J*J_VOI__ $$+/_P(3_&C^UK <&_M!_V\)_C7W-T?V][2'\R/6OV2?^3O
M/A1_UUU7_P!-EQ7ZS5^0?[+_ (NT+0?VJOA=J&I:WIMA80S:GYMU<W<<<:;M
M.G5=S%L#)( SW-?J%_POCX:_]%!\+_\ @YM__BZ^0S+_ 'A_+\C^2?$62EQ#
M5:?V8?\ I*/SW\)_\A'QU_V.>O?^G":M^O-_#WQ5\$V.J>-DN?&&@V[R>+]<
MF19M2A4M&]]*R.,MRK*00>X-;0^,'@(YQXW\.G'7_B:P?_%5,&N5'YD==7O_
M .P#_P BE\4O^QYNO_2&QKY1_P"%Q> ?^AX\.?\ @U@_^*KZ _8-^+_@33_"
MOQ'2Y\:>'[=KOQM<2VZRZI IF1K.R563+?,"P(!'<$5E6?NH$?:5%%%<9044
M44 %%%% !1169XH\1V/@_P -ZKKVJ2F#3=,M9;RYD R5CC0NQ [G /% 'E_[
M1W^O^%'_ &/>F_\ HN>OD[_@IC_R6SX5_P#8#U;_ -&VM>V_%KX^>"_&6F?"
MN_.KP:%/#X\LQ<Z;K<T5M=VWE"=7,B%CA02/F!*_,.:^;O\ @H_\2O".L_&+
MX8W6G^*=%OK:'1=426:VU"*1(V:6VVJS*Q )VM@'K@UUX1I5X-]SZSA.<:>>
MX24W9*:U9X#16'_PGGAG_H8M*_\  V/_ .*H_P"$[\-?]##I7_@;'_\ %5]I
M[2'\R^\_LOZ_@_\ G]'_ ,"7^9]!?L/_ /)X'A;_ + &K?SMJ_5"OR/_ &*O
MB%X5T_\ :Q\-WUUXFT>VLH]"U1'N)KZ)(U9C;[5+%L G!P.^#7Z<CXX?#D\#
MQ_X7S_V&+?\ ^+KY#'M2Q,FO+\D?R-QY4A5XBQ,Z;33Y-5JO@B?GCX-_X^?&
MG_8XZ]_Z<9JZ*O-?#/Q4\%:?>^,8[KQAH-M(_BW7)E6;4H4+(]_,R. 6^ZRD
M$'N"#6X/C!X";./&_ATXZ_\ $U@_^*JH-<J/S\Z]?O"O?_\ @G;_ ,D5\2_]
MCKKG_I4:^41\8O .1_Q7'AS_ ,&L'_Q5?0?_  3_ /BUX'T?X,^(([_QEX?L
MI)O&&LSQK<:I!&7C>Y)1P"PRK @@]"#6%9Z($?9U%-CD2:-9(V5XV 964Y!!
MZ$&G5R%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %8>M>!_#_B+7-(UG5-&L[_ %72':2PO+B$-);,
MW4HQZ=!^(!K<HH **** ,Y_#^G2>((M<:TC.K16KV27>/G6%W5V3Z%D0_P#
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FX5[X5X'_  C.CX_Z\(O_ (FN@HH 15$:A5 55&  , "EHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ck0001824293-20241231_g11.jpg
<TEXT>
begin 644 ck0001824293-20241231_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $2 G # 2(  A$! Q$!_\0
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M37=-UB6R?RKI-/NXYV@?GY7"$[3P>#Z5LT--:, HHHI %%%% !1110 4444
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M^+_BC\1O&OC_ , S^$=2\80>*[WPC\9]%TC1?&OV.+$^]793)''B-WA8C.,
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MU>XTZ)[D,OW6WE<EAQ@GD8&*[RN#$5:=2,%"-FEJ4DT%%%%<904444 %%%%
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MQM[+2K2!;6WLH(PD,4*J%6-5' 4*  .F*ZI8BDYQJ<MVDE9^22_05GL?GO\
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M5M5TKQ58W-DFH6^ER$EDDCNIW5((7C8!T9V=0NX#.1BN!0G)<R6@ST"BBBH
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MUS/<2>$].>>>>"YFD9"6EDA&(BYS\V!V/!ZG)J&8G_AH2S';_A%I_P#TKBH
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M]> ? O\ ;X\(?$'QY?\ AO6?$%G&9QI-OH3PZ==(]]<S6RFZ5B4VC;.2@SM
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MJ^5/VPOVB?B5\-?C1I7A;P9K>G:/ILGAY-4F-WI:W;O*US+%@$NN!M05Y/\
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M)!;[<_+CS/FSCK6S10 4444 %%%% !1110 4444 %>5_M4?\FY_$/_L#S_\
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M7-_Q\'_?_K7Q6 ^%G](^%_\ !Q?K#\I'VM^QG_R8[:?]<]=_]+KNOEGX4_\
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M;P_Y.?TG_L38O_2Z>O'?"'_)5_A;_P!CEI/_ */%>S2_W5^C/Z+R7_DAZO\
M@J_G(^NOV\/^1D^#/_87U'_TWS5\R_&+_DD?C;_L"WG_ *):OIK]O#_D9/@S
M_P!A?4?_ $WS5\R_&+_DD?C;_L"WG_HEJXJ7P,_G/J??/Q9\?:W\-_@UI6J>
M'(=/FUFXN=*TRW_M19&MT-S<0P%W$9#$*)"< ]JQU\/_ !_75I=0&N_#CS)(
M$@*?V3?[<*S,#_Q\=?F-1?M$_P#)$/"O_8?\-_\ IQM:]VKC&>?? 'X@ZG\5
M/@_X;\4ZS;VEKJFH0R&XBL=P@#I*\9V;B6P=F>3GFO0:\9_8Z_Y-N\&?]<[G
M_P!*IJ]FH **** "BBB@ K\LOC)X;T;4/VH/$UA/H'AS5/#]SXXL;K4/B+?^
M&[J=M*O,6^W2))@ODE'94C+$X G.X;L5^H>J74]CIEY<6MH^H7,,+R16D;JC
M3N%)"!F(4%C@9) YYKX!\9:;\.?%WC;7+W4!^T)X>U_5M5AUFZ\'Z;I-Q]F:
M]B\ORW5$A>!\&*,AO,*G:I)X&/6R^7+*3\NG]?\  (D?97P&\-W'A'X1>&M)
MNKA;FXMX&WO&I5!ND9MJ@_PJ&VCV45WU<?\ "&QN--^&^A6]W:ZK97"PEG@U
MR6.2]3<[-^^:-F7=@] 3C."20:["O)LUH]SKQ$U4K3G'9MO\0HHHH.<*\W\%
M_P#):_B3_P!>^D_^BYJ]'KSCP7_R6OXD_P#7OI/_ *+FH _%KXM6=O)\9_B6
MSP1,W_"5ZM\S("?^/N2OIW_@E3!%#^T5XQ$<:1Y\*+G8H'_+XGI7S1\5_P#D
MLOQ*_P"QKU;_ -*Y*^FO^"5O_)Q7C#_L5%_]+$K]+S!+^PH/^[#]#SJ?\;[S
M9_:V_P"3M?&__8*TG_T":N6^#_\ R<7\'?\ L8S_ .D5S74_M;?\G:^-_P#L
M%:3_ .@35RWP?_Y.+^#O_8QG_P!(KFOCH_[K\C^G<)_R0C_P3_\ 2Y'Z*?&3
MX\^!/@Q'IEKXUU6YT]M:$RVD5G975S+*(POF$"W1F7 =>>.M>-^%_P!M3X)^
M&Y-4N[SQ-KT*&ZD$4M_I.KO$D!V[3F2(JHSW.,5D?MQ,5^*WPA()!^R:WT_W
M+6OF[XU2.WPE\5@NQ'V%N_\ M+7F1IJ4>8_G(_5&:XBM8S)-(D48ZL[  ?B:
MY^'XE^$+B^%E%XJT26\+;1;IJ,)D)R1C:&SG(/Y5YE^UUI-EX@\ ^%=+U.UB
MO]-O?&>@V]S:3KNCFC:_B#(P[J1P16Q_PR7\%]V?^%7>%<_]@J'_ .)K 9ZM
M'*DT:O&ZR(PR&4Y!_&GUXC^Q2@C_ &6?AY&HPB6#(J^BB:0 ?@ *]NH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#DOBUJ
MT>A_#/Q/?S)JSQ06$S-_83%;U1M(+0L/NN.H;MC/:OD/]G3P!9?%+QEJ'BWP
MT^FZK;Z3JT,[ZCXX\)V%[>W>YRS21:A;I#(EP A8[PY4O&23NP/LKQ_8ZIJ?
M@7Q%9Z'JD>AZU<:=<16.IRC*6D[1L(Y2/16(;\*^%_A=\%_B?8^/O!DL-A<>
M$M3L-2MIM8\57/Q3GUJ'584;_2(AI[+@F<9 #8V;L]17JX5KV4U>S^7Y/]+O
MR(>Y^@]%%%>46>.>-/AKX\U+XQKXHT3Q)'::(-&:P6QDNYDVS-YBEO*"F,@%
MTEWGYMT*KP&)&7X3_9[U^^^$-OX0\9>-M727SIGG&C7BS*\;2*Z(9KF%Y&VE
M=V?EQO(Y %>[US'Q*^)?AOX0^#;_ ,5^+M371] L=GVB\>-Y!'O=47Y44L<L
MRC@=Z<8N3LEJ!Y7\7/V/]$^.FDZ?IGC3QMXPU:RT^[^W6T:W%G#LFV,F[*6P
M)^5V&#QS7C&F_P#!*WX<WM]XBM]7U7Q6-+:X6/3O*U2'<]N;>/?YG[CKYIF'
M^Z%KZO;XQ>#5\0>#]$778)=2\7VTMYH4<2NZWT,4:R.Z. 5 ",IY(SGC-=G7
M5#$8G#QY(3E%/HFU?I_P"7&,G=H\4\4?LN6/C/X=R>!M7\>>,+KPQ);PVC68
MFLD)CB*&,;Q:AN"B\YYQS7F'_#OOP_\ \)EM_P"$F\5_\(Y]@W>9_:%OYWVO
MS.F/L_W=GZU]=5C>$_&.B>/-%35_#NJ6NLZ5)+)"EY9R"2)VC=HW"L.#AE89
M'&0:PC*<5>+LCTL+F.,P*:PM:4+[\LFK^MF>7>"_V7[+X>^!4\'Z#X]\86?A
MY!<!;4SV4A FD>27YVM2W+2.>O&>*\]D_81T?0?^$6TW0/%?BQ-%M9?L]ZLM
M];%H[58)!'L)M\D^8(AWX)KZLHJ%)K9G!)N3<I:MGB/@']E?3_AC-K,OASQW
MXPL9-8GCN;UFGLY?-D2,1J?FM3C"J!QZ5!=?L_Z[X*\*:O#X%^('BF+4[[4G
MU)DNIK%D>:>X$ERY+6O&0TA ' .,5Z:WQ,\-+\2E\ '5$_X2YM+_ +9&F^6^
M[['YOE>;NV[<;^,9S[51\5_&;P=X(\0W.AZWK L=3MM%N/$,L+6\K!+" D2S
M%E4K\N#\N=Q[ U?)-O9B.;?]GTR>,H?%)^(?C ZY#82:8ESYEC@6[R)(R;?L
MNWED4YQGBO1?#>BSZ!I@M+G6+_79-Y;[7J7E>;@_P_NHT7 _W<TGA/Q5I7CK
MPOI7B+0[M;_1M5M8[RSNE5E$L+J&1@& (R"#@@&M:H::=F 4444@"BBB@ KR
M[X\_"+4OBYI_ARVTW7/[$;3-4COI'*NVY0K#*[67$BDAE)R 1R*]1HH ^6_$
M?[)/BKQ-\0+SQ--XVAM3=ZI;7\EK!%/M&P<L/WO^LB.5B.,!2=P)KUG5/@BF
MI>,)O$@\:^++/4)(I+=5MKR%8HH7D$AC13"<*"HQG)P.M>EUYMH/[1OPY\3>
M+/&'AG3O$]O/KGA".2;6[1HI4-FD9(D8EE 8*1R5)JXQE*[BKV H^*?A#X@;
MPSJPT/XB^+AK1M)18F>\MA'Y^P^7N_T?INQGVJ_;_"+4/L\7G?$3QEYNT;\7
MEOC=CG_EAZUI?"/XT>#?CMX7D\1^!M:37M&CN7LVNHX9(@)5569<2*IX#KVQ
MS7;4I1<7RR5F!\_>-OV+/"7Q%\21:_XA\3>+]1U>*T%@ERVI1H1 '9PF%B ^
M\S'.,\UQ_@/]@+PS8Z=X?U'7=<\3)XGTVZ2_66UU53'%<1R%HG7]U@X&WJ,5
M]8T4^>27*GH>A#,,93HO#0K25-W]U2?+KOI>VO4\2\;?LIZ+\1KC2)_$/C#Q
MAJ,NDS23V3-J$2>2[QF-R-L(SE&(YSUK@[7]A#0-<M/$^F^)O$/BBXTN\N9(
M+2&/54^>Q:&,%7Q$/F+F7\"*^J:QO%7C+0_ VF1ZCX@U6UTBRDN(K6.:ZD"!
MYI&"1QKZLS$  <FE'FVB>>>=^(/V<;/Q1H]MI6I^./&5S86\]O<Q1&_A7;)!
M(LD+9$(/RNBGWQSFDA^#OB3_ (2Z\:3XC>+O^$?^PPB "^MO,^T^9+YN1]G^
M[L\G'OFO7J*D#RKP/^S]:?#O2=,TK1?&?BV'2=/?=#8R7L+QD%R[*V8=Q!).
M>>]>JT44 %%%% !1110!SGQ(\17/A'X=^*-=LTCEO-+TJZO84F!*,\<+.H;!
M!QE1FOG/X'_M^>"/B)XBCT77O%/A?3+B31M%N+>2*_"FZU&ZC<W-JBL>L4@1
M=N2?G -?46M7,5GH]_<3VLE[!%;R226L,7FO,H4DHJ?Q$C@+WSBOBWXG?&C2
M_%'A_2[#P+\&O&_A/7IM<TK;J]]X*%E#! +Z$S[YB#L!B$@_'%>AAJ<:L7&4
M;^=]B6?;]%%%>>4%<U\2O"EQXZ^'_B'P]:WS:9<ZG8RVL=VH)\IG4@$X(./7
M!!QFNEHH ^=?#?[,_B+2_$/PTOKKQ5;M:>$8Y8S#;PS*75\MLCS(0JY8Q_-G
M]VB#KFNTM?V?;>RUC4-4@\=>-([Z_6-;B4:G'\XC#!!CRL# 8]/6O5J* /CO
MX@?\$U/AUK4.IZEIDWB";Q'J&H)>7%Q=:RX$IDN%>Y<_+C<R&7&!U(Z5W'PY
M_83^'_PCURZUGPAK'BO0M3NK;[)-<0:N69X=X?80Z$8W 'IFOHRBNB6(KRA[
M.4VX]KNWW$\L;WL?.GC#]A_P9XPUK4O$&HZYXKOO$-W;I"]Y+J^TN(U81 @(
M!@;CV[UE>!?V#O".AP^%M8OM9\31>+=+CBN3=6^KDK%>>24D= 4QCYY ,C&&
MZ5]045ESRMRWT/1688R-'ZLJTO9_R\SY?NO8\0\7?LF^'?'FI:7?Z_XJ\8:E
M>:6LR6<LFJA3")0HD VQ@?,$7KZ5Q&G_ +"/AO7-(US3O%>M>)KRTNKV=(88
M]8.UK,L#$K80?-@<_P Z^IJ*GF:T3. \C\0_LY6/BNWM(-6\;>,[V*TO(+^!
M6U1!LN(9!)%(,1#E74$=N.:CM?@OK_\ PEFI-/\ $3Q@= -G;BT5=3B\P7&^
M;SRW[G[NWR,<]FKV"BD!Y/X(_9WT[X=Z3I6DZ'XO\76ND::1]GT]M21X@H;<
M4.8\E22<\]Z]8HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?C_ /\ !\W_ ,11_P *"3_HH?C_ /\ !\W_ ,10!ZI17E?_  H)/^BA^/\
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M5?VF_!_AS7OB!K'B30]3L-2DN++48[<*6BB1D8&.)2""Q[U^B5?E_P#LJ_\
M)X7PY_[!NL_^B8Z_4"LL3%1JM16AXG&&$H8'.JV'PT%&"Y;);:Q3_,\]\ _\
ME+^)_P#V$++_ -((*]"KQ?X.W?C&?XO_ !437=&M=/TL7MN8+N$N3<D01I&4
MSQM\I%+>C-CM7M%367+*WDOR1XN;4W1Q*BVG[E/9W7\./5!1116!XP4444 %
M%%% !7&_%?Q=J_@?PG'JNCZ9#JLXU"RMIH9G==D$US'%)(H52695<D+P..2
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M^2'C?_DL/Q7_ .QRU/\ ]&"N_!?Q?D?J?AQ_R.I?]>Y?G$]:_87_ .3IKO\
M[$VY_P#2VWK]"=5NKNTM#)968OIMP'E&41<=SDBOSV_87_Y.FN_^Q-N?_2VW
MKTOX_?'SXH:#\>?$'A+PGX@TC1-'TO2]/N@MYHWVR222?S]Q+>:F /*&!CO4
M8A.5=I?UH>)QM_R4&)_[=_\ 2(GUAX2UVZ\2:+;ZC<:<=-2YB2:*-IUE)1E#
M#.W@'FM2[MQ>6LL#/)&)%*EX7*./<,.0:^%OA3\>_BQI/Q.^&7A?6/$VBZQX
M>U74O['FMX="^RRK&MG/(K"03-SF!1]WG)KVWXU>"=*^)7[0_P -_#OB 7UQ
MHK:%K-VUG:ZC<VBO*DEDJ.QAD0L0'<#)_B-<LHN+LSX<]8\#:7):C4)I;W4+
MIA=SP(+RY>10BR$+@'V'7K755\E?M%?LV^ ?AG\&O$'B3PS8:KI.MZ?):SVU
MU'X@U%BCFZB!;:TY4Y!.<@YS7UK4@%%%% !1110 4444 %>;?LZ?\D;\/_\
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M09'!^8O6A\(_"^C^$?B9\3K'0]+L](LO/TY_L]C L,>XVHR=J@#- 'K-%%%
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M^W=9'["__)TUW_V)MS_Z6V]:_P"T!_R=CX\_[ >B_P#MW3J_[R_ZZ'A\;_\
M)08G_MW_ -(B<]X1_P"2\?!C_L:&_P#3=>U]=>,/^3KOAK_V+6N?^CK"OD7P
MC_R7CX,?]C0W_INO:^NO&'_)UWPU_P"Q:US_ -'6%<U;XSX=#?VQ?^3</&'T
MM/\ TKAKV>O&/VQ?^3</&'TM/_2N&O9ZP&%%%% !1110 5Y=\>;WXC66G>'3
M\.H//NI-4C2__=Q/B#:V-_F$8CW;=[+\X'W:]1HH \RTZX^(UWXB\830&UCT
MV>'3YM!@UBV$<=N2L@NHI/*8N[ JAR3C+ #@&O%_'7VC_AV[XV^U^5]J_P"$
M6U7S?(SY>_=-NVYYQG.,\U]:U\H?$3_E'1X\_P"Q9U?_ -"GIK<#\GH_]6G^
MZ/Y5^JO_  2W_P"36_\ N8M5_P#2@U^54?\ JT_W1_*OU5_X);_\FM_]S%JO
M_I0:_2>*?]VI_P"+]&>=A?B9\-^ _P#D4;#_ 'IO_1\E?77_  3D_P"1^^,/
M_7OH?_H-Y7R+X#_Y%&P_WIO_ $?)7UU_P3D_Y'[XP_\ 7OH?_H-Y7QV)_P!W
M7R/Z<XO_ .24P_\ W"_]).#\3?\ );/C!_V-+_\ I);5TO[/?_)U_@G_ + .
ML?\ H5K7->)O^2V?&#_L:7_])+:NE_9[_P"3K_!/_8!UC_T*UKBE_"/YRZGT
MMHW_ ">!XJ_[$G2__2V]I?VFO^0;\./^Q\T/_P!*:31O^3P/%7_8DZ7_ .EM
M[2_M-?\ (-^''_8^:'_Z4UQE'LM%%% !1110 4444 %%%% !15/6+&34])O+
M2&[GL)9X6C6ZM2HEB)! 9"P(##J,@_2OE*\^$/[02Q6*1>+IIXH-!L;:Z4:X
M\;W4L8B%S$K>7\DTC)*WVKKAPN!V /KFO,?C5_R&/A=_V-\'_I'=UX-=_!O]
MI,V%]&_C@W=P8+9&>'67M_M)$4:_NR(OW!BD61G8<S!L''2O4OB7I/BFS\4?
M"235/$%E?6">([2*6TCTXI*UP+"Y#R>=YF,%@S;?+'! SQ0![K1110 5^+?P
M[_Y$^T_Z[77_ *4RU^TE?BW\._\ D3[3_KM=?^E,M>C@?C?H?L'AG_R,Z_\
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M/)7&_'C_ )*)\"_^QPD_]-5_79?&C_DCOCO_ + -_P#^D\E<90WX)?\ )&?
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M2>&XHT#1ROJ$-SYK9Y7$9R,#G)KJJ "BBB@ HHHH **** "BBB@ KS'XU?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&&)&D60HID4%0V.0#C(S^ _*GT44 ,DA27;O17VMN7<,X/J/>GT44 ,DC2:-
MHY$61&&&5AD$>A%/HHH *9%"D$:QQHL:+P%48 _"GT4 %%%% !1110 4444
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M=:A(LMU*HYF=46-2WN$55^@%7:* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ck0001824293-20241231_g12.jpg
<TEXT>
begin 644 ck0001824293-20241231_g12.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0! 17AI9@  34T *@    @  8=I  0
M   !    &@       J "  0    !   &0* #  0    !   $*     #_X@)
M24-#7U!23T9)3$4  0$   (P041"10(0  !M;G1R4D="(%A96B 'T  (  L
M$P S #MA8W-P05!03     !N;VYE                        ]M8  0
M  #3+4%$0D4
M              IC<')T    _    #)D97-C   !,    &MW='!T   !G
M !1B:W!T   !L    !1R5%)#   !Q     YG5%)#   !U     YB5%)#   !
MY     YR6%E:   !]    !1G6%E:   ""    !1B6%E:   "'    !1T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D
M    9&5S8P         1061O8F4@4D="("@Q.3DX*0
M
M                            6%E:(        /-1  $    !%LQ865H@
M                     &-U<G8          0(S  !C=7)V          $"
M,P  8W5R=@         ! C,  %A96B        "<&   3Z4   3\6%E:(
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M-RE1C(_8,3F']H2QBPF)FJDHS<J-575EK)1DG9.-O=NDU8YDK6NOF</^S/\
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M] \.V%Q?2#."XA0L$7_:<@*OJ2!7@G[;OP:_X7C^S=XL\*V<'GZQIT/]JZ8
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M+XI^ 6TGX3?L>_#?Q+KFD>+[4>*+VR>^T:Z^WZ?<VLVI0 )',54/L1_*8;<
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M+AW"QH4ZN(YIQI4IRY>9ZM5G!+^['6[Y;?B5SN^G?]#WWX(_MP^'_B;\2_\
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MW1/+?( ^8AV1E7E@O2OM+X'_ !Q^'_[0G@&U^(GPYNWN-/F=H9HID\NXM;A
M"\$R9(#J&!X)4@@J2"#7YJ_LU:%^W]#\!O __"H=7^'D/A"3389;!)TN_M"I
M)EW$_EPE?/$A;S<$_O-W)KU3_@GO\,?$_P -O%'Q@/B+Q=X3\0S:UJ=O<W-C
MX7OS<KIEZ);KSXY8#&AMU8MM13DXC(_AKBXEX>RRGAL0\/RQG2:2M.4G)<W*
M^=-)1?72RW5ATYRNKGZ:T445^4'0%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7Y1_MC_$OXG_%WX_\ A?\
M8E^#.N/X;_M: 7GB/4X&(ECMV1IC%E2K!4@3S&567S3(B$A=V?U<K\@-*N+3
MP+_P5SU^7Q:1"OC7084T>6;"JTALK9!M)P.6M)HE]6^7J:^ZX"I0]OB,0XJ4
MJ5*<XIJZYE9)VZVNY?(QK/1+N>JV7_!*?]EB'P]_95_%K%YJ3( ^I-?LDYDQ
MRZQJODC)YP8V_&MC]C3P+^T3\$/'WC7X&_$ WWB/X:Z,D4OAO7KIH]JK\I^S
MH&<RX9).5 *1O$P& PS] ?M&^%/VF/%6FZ)%^S9XUT[P9>V\TS:C)J-M'<+/
M$RJ(E026US@JP8G 7KU-?%'P*^*7[7'AO]M&#]G?X]^/K/Q59C1IM0D6QL;2
M"%BT6^+$B6EO+E3U'3ZU[>%QN99EEV(=?%0JKE<G";DYQY7\4?=LGTLI6:>J
M):C&2LCYO_9'_9.^#G[2?Q ^.%_\4K.[NI="\2R1VIMKI[<!9Y[EGW!.O*#'
MI7H7[6_["7P:_9Z^#VJ?'#X/Z]JWA#Q)X6DMI;9OM[,L[RSI%Y:-@2I+\VY&
M1^QR,<CRK]E?]GKQY\;OB%\;KOP;\7->^&::3XDE26/1I9HUNVEGN2K2^5<0
M9*;2%SG[QY%<E\0O@Y?_  L_:3\,?#_]N?QKXB\;_#K5W\S2=9DU.X^RE\A3
M]I2X,SQJI8+.L<BLBLKARIY_2ZN)KRSB4:>8.T%&3HI2;<5"+<4G:+;71.^N
MVAA9<OP_,^J?VK_'GB'XG?\ !,7POX\\6#_B<:Q_8TMT^T+YLJR%#+M' \W;
MOP  -W  K]1?@O\ \D=\"?\ 8!TO_P!)8Z^(/^"FNF:5HG[&%QHVA6\=IIMA
M?:1!;0P@+%'#$^V-$ X"JH  ':MGQ/\ M ?'+X1^!?ACHOPL^#5_\2;"\\*Z
M7<3WEI++&D$WDJGDD1V\HSM4-R1UZ5^8XG!2S#*J,<)%1YJU5I-J*2M!VNVE
MHCH3M+7LCT_]NSXUZU\!_P!G#7_%OA:?[+K^H20Z7I\XQF&:[)W2KD$;DB61
MD_V@#7QY#_P32\*-\"$\:+KNL)\9FT[^V/[9^VR;O[3,7G^25SG9O_=^9GS,
M_/N_AKS+]MWXH?%[XT?L@3ZU\3/AG>?#:XT3Q=INRWNI))#<6[VETIE'F10D
M 2.J]#SWK]L(=>TK_A$D\3^8O]F_81>;\C;Y'E>9NSTQMYJY8C&9)EM!8:7+
M4G4GSN+3ORJ'+%M73C[STO;45E.3N?C]J?[</Q%U#]@'P_XOT2\=OB9KVK#P
MA]L0+YOVI 9&ND  'F/;[!G VRR;@.!5G7/^"??P*M/!<GA^V^(_F?M >3]K
M@OI];2.XFU=1N"" MY@B:7Y0^#*N0VXG@_FY<:3KNF?L+>#?$UM</9+_ ,+(
MU!X)PQ0QNVG6RQR*XY&U[=SD<@@^E?KA\2?^";'[/FF? G6YM/CN_P#A-]+T
MVXU#_A)9;V=[BXOH(VF:6:-I##Y<CK\P" A3D-NRQ^^S6&$RF48X>NZ/M*U3
MX(J5[222E=KW(W^%7O=Z&,;RW5]#LOC#I'[:<7['7AWP'X=B.J?%6]EBT[6M
M1TV[19(K!#+FY2>0PMYTB+"LC("V6<CG#5X_\5?^";WP0^&?P)UWQQH6N:KI
MOCGPCIEQJZ^(6O71I;RTB,Q+1C"HLCKA=F)%R#N8@[OI']A?XUWWB_\ 9"T3
MX@?%/5E1O#RWEK>ZG>/M#6]@Y"32R.>2(MH=R<LRDG))KY1\:>-_BA_P4E\6
MS_"_X2"X\+_ O1[I!K.O2HT<NJ/$P81QHV,]FCA/3Y9)L'9&/D\JK9EA\75P
M\91HTJ-24JLXJR>OP_WM%:$%WU74TDHM7W;/HOX'_M-^.(OV#-'^/?BG1+SQ
MEXEL8C9+:VH/VG5)EU'^SK=QM5V+,2AE8*Q)#L%)P*^*/AWK7[17B7_@HQ\(
M?$W[1MHFC:GK6FZG>:;H\3833;![&_C2,QY8I(S1LS[F+G(WX("+^W/@7P3X
M;^&_@_2/ G@^T6QT;0[:.UMH5_A2,8RQ_B9CEF8\LQ)/)-?F]\8_^4J?P-_[
M%F__ /1&K5P\-YQAJE;,(X?#J//"O)/K&/*VHI;+S:WVV0YQ=HW?8_4RBBBO
MR8Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^(/
M^"C_ /R9?\1O]W2__3I:5\%?L!?%OQ7^SCXQ\/?L^_%V7R_"WQ/TW3]?\+WK
M$^3'<:G DHA5FZ+*Q,3+_#.HP,2%C]Z_\%'_ /DR_P"(W^[I?_ITM*\@\:_L
MR6_[2?[!_P *[/1E6#QKX;\*:-?:%=9V-YZV$)>W+\82<*!G("N$<\+@_L7#
M&-PT<@6$QO\ "JUI1<NL'R0<9KT>_E<YJB?/==#'_;F_Y.V_91_[&"3_ -++
M"O</#GB3X+2_MZ^*O#.G^$;J#XE0^'(Y;S76NY&MIK(K:8A6V,A16 :/Y@@/
MRGGGG\L(/VC]2^/OQA_98TSQI'+!X[\#>)3I>N),A1Y)!=V0BG8$</((V$B\
M$2(_ 4K7W1X,_P"4L?CS_L38?_0+"O2S'(:F&P<,+B+J5/#U=FTG^^TVWBT[
MV>CT=B8SN[KNOR-+2_\ @IGX=\7P76F?#7X7>)O&'BJTN;F.72M.A\\Q6]OL
M"W$LL22;4D9F50$8@J=V,KN]1^%7[=/AGXN^"?&FJ^&?!6MGQGX%5&O?"OE!
MM2EW2>4?( &7V-D."JLA&&494GPK_@D]I-A#\/OB=KL<*B]N_%<UM))@;FBM
MX(WC4GKA6F<@>Y]:N?!6VALO^"J'QSM[51'&_ANTE*CH7DBTIV/U+,3^->;F
MN293#$8W"4<.TZ$5-2YV^:SA>+71/FLFM5:]RHSE9-O<\P_X)8_%GQ+/#XG\
M"W?@_6;RVU_Q#J&IW/B%D9[&UG^RPDVUS*PXG.P<$Y^<5]&:]_P4*TS4O%FL
M>&?@1\,?$7Q8@\/2>5?ZAI$+?9$8$AA$RQRM)T.TD*'P2FY<,?FW]B"YU6S_
M &)/VB+O0B1J4%_XE>VVDAA,NDQ%"".<[@,>]<?^PSHO[:I_9_TZ[_9]U/P+
M:^&;F]O7=-36Z.H"Z64I)]I,43+NVJFSDGR]GTKV\^R7 U\;C<;7A%<DHP2E
M.48MM-N3:N[V5DE9=2(3:22/U$^ /[5'PO\ V@_!NK>*_#LTVCS^&R5UFPU)
M1!<:<RAF)FY*^60C$.#CY2#M8$#Y>/\ P4HTO6[S5M7^&WPD\5>,O V@R.E[
MX@LK<^2BQC+NL>PC:%^?]Y)&P7!95KX^\0_#CXR^!]4_:4\>^-/%_@O4?%&O
M^#;N#6=#\-WTC7D!D:T$ES)9/$C(OD;VD<G[TN3]ZOTU_8'@T"']D3X;CP\(
M_(DL)'F,>.;IIY/M&['\7F[@<\\8KYW-LARK 49XY0]K"4HQC'F:4;PYI>\D
MG+M%VM;5IEQG*3ML?)?_  39\9^'M?\ &'[2OQ#L[GRM"U+Q$-5CGF'E[;2:
M6^G5W#?=Q&<G/2O2#_P44O/%B:AJWP0^"GBSX@^'--F>)]5MX&@MW,8RQC"Q
M3,2!SM.UP""RKG%>!?L@ZW\+OAW9_MA:OK-I%>^ -&UBX5K2-%>*XTY9+]$M
MT4D*PD0B-02 <C.!77_!#QS^VM\3/AYILO[-OP^\&_"KX:W#3G23?O--*L33
M.9)%"%MP,A8Y-NH8\CY<&O:SW*,+4Q^*Q5:DG%>R2=2?)%?NXNVGO2E:VBT2
MNWT)A)V21]8_#S]MCX;_ !+^ OB_XX^'M.O4_P"$&@GDU32)]B7D4D$?F[00
M2A60 ['R,X((!!%>$I_P4QTWQ%H*^)/A=\(?%7C/3K&".;5[JTMV%KISLN^2
M)IECD#-&O+$A5QDABHS7QI^SP-53X(_MMPZ[?P:IJ2)/]JN[90EO<3XU$231
M*H4*DC LH   (&!7Z=_\$]M(L-)_8]^':6,*Q_:[:ZN9B  9)9;N8LS$=3T&
M3V '0"O-S[(,JRR->K*BZG+4C&*YFE:5-3>JLW;9;/OV*A.4K:G*>+OVE?@-
M\=_V-/%OQ:U71;S7_!UNB6VL:*93:7B3I/ ?(,D4@P07CD#*^&4CU('R-^W%
MKO@P_LD_L[^(_"6G2:'X674](N;.SE=IY+6R6Q=TC9R69V1."2221U->,_#>
MWALOV&OVJK"U7R[>V\2!(T'156YMU 'X "N^_:GATJX_8:_9<@UQ@FFR7&@K
M=,QP! =/82$GL-N:^CRK(J&"Q]*%%RY57DDKMZ.DI;;7UM>UVB)3;7R_4^I9
MO^"E>DZ8EGXO\1_"/Q9I/PWU*=8K7Q--;8@D5VPLOE[0NQA\PVRLS $*"1BO
MT@\/Z]H_BG0M/\3>'KM+_2]6MXKJUN(SE)8)E#QNN>S*0:\+_:GT_P *I^RU
M\2]/UF*"+2(/#.H")"%6-'BMV-J(QP RRB/RP/X@N.U>7_\ !.>359/V-OAX
MVK$EQ'J BW9W>0NH7 BS_P !QC_9Q7YAFF#P5?+/[0PM)TW&IR-<SDFG%R3U
MZJVMM-5HC>+:E9GVW1117Q!J%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__1_?RBBB@
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M";H1GY?*[_>KZSHKS)\1XV5:IB'4]^<>63LM8V2MMIHEJK/S*Y%:Q^6WA/\
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M8W;TZYQQ@ZOQ<_8=L_BW\!/AE\";_P 8/86OP]-D);U+ .]]':6QMF58S.!
M7!+ EI-O3#5]Z45U+C/,_:*M[7WE+GO:/Q<JC?;^5)6VZ[B]E'8_+B__ ."?
M7Q3\4:;8_#/Q[\?=8UKX6:;)$8]'^QI'=200G]W!)<^:VX1@+M9D=00"L:D#
M'Z5>&/#6A^#/#FF>$O#5HECI.C6T5I:P)]V.&%0B*,\G '4\GJ>:W:*X\VXC
MQF.C&&(DG%7:248J[W;44DV^K>HXP2V"BBBO#+"BBB@ HHHH **** "BBB@
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MIVIQ01B_5 BQD.D8C<+QT(Z9)Z'%3:OX,2WUS4H8]6U8BX\NYF>"8EDD.?F
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M]Q$H8"/*.5.?0$?-]".M=)^V[JR>&M;\*>(+R]"6D27"/:,QVS_-&WS*05(
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MIF=?OR@ANOS!N#7@7[1/Q3\'?L^?\*L\1^.](OO%/CN^N;J6UM(Y\78;;N9
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M/B:W\+:QX>N]#NKV.66W-RZ$2K"0&V[?3/Y#->"_ 34O!/AU)_##R26GB^]
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M>JJG+TV/<-!\=>.M/@D^,/C:_M]3\+>&TETV&>T.^0RQMY$MPR=#YLF#PV<
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M'PX\0?"WQ#IMI9-#XF\2W+^>^EV[NS"T5AY;R*_WR[[ESV _&B=6,FHJ2O\
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M<R+$@ZLQP/S-<1=_%#P-:0S3RZK"4M_O;6SU..*(TY/9&T:<I;(]"4\>E*2
M.3@#N:^7O%?[3_A72M/EE\.VTFKW"_=51@<''/>O!/%'Q1^)WQ*6&]MI!X>T
M#:ZLZOM=I,XP!U/O7?2RVI+66B.RGE\W\6A]F^//B_X+\ :=-=:C>+=7,:G9
M;0$22NW88'3\:^([R[\>?'#Q%I^K^(;$1>0Y6TLHSE(4E/\ K)&^@Y-9>D>'
M[6VO8+B*U.HL@+75U+NVG;T![Y8\"O5-#^(EOH=P^K^'[./59[U@&L+9"["/
MIM#=L9W'VKTJ>'5%7AJ^YVQI1HIN.K/2(7T#X;WUYI_A_3TO?$<T "1Q LS%
M%&"3R0N2*T/A5I?C6P\070\37L2WLDC-,A^1FM\!T8+W)+$$GTJM\--=\*:#
M?ZEXQ\;W<6E>(/$EV8X8+G*/'"N%CBCW#G( SBOH5K#1-8NX=4\M)I[;<JR#
MA@&'*GV^M<&(K6O%KYGFSJ/JBK<W<-_;7=C>Q*8CNV&0?NY IR.3WKYB\:^.
MM.UF?2?$'@C0I;R[>;9-?LAV0>0V"I'0X/<]!7U^\$$J>5)&'3^Z1D5\JV6B
MZI>>*O$?A#P_<"W@N;T32E6Q!]G8$NBKW;=@,!6>$Y=6^@8=J]V=MKOQ-UC3
MIIM*M887NY;=9+>Z3/V83#DQ2NW XYK2^%WA[7=%U/5]4\77$,NJ^(]MTZ1G
M(10-NT#I@#'UKN])\(:7IWAI/#M^$NX54AS(HP2>_/Z5Y?9VWBCP]XIOM:TS
MR]:TNPM([5I)9-D@"$MM7L2,XS0G&47&'_#D.4;-([;XE>,K'P38Z?J5SN.V
MX!D6-=[B  ^8VT<X'%=EH6NZ9XBTV#5]'G%Q:7 RCKW'OZ&O';3PV\7BK5O$
M_P 0#YFG:D(GM0[[H[1%'S1/V )Y]*YK0M%UW2O$FH7/P_UB"W\.W<\DD:7#
M;DEN7PQ2$#^#J./PJ'0BXV3U7W,48QDK'TO?6PO;*XLI"0EQ&T;8.#M<8./?
M!KR;1?$/@[1=7N_AQK"0Z;+&ZBU6?:IO(P P=3W(/!^E>,?%_P")7QN\#7>E
M7\FDP+HZ3HT\EJWF,5"D,K9]21@"LW09=?\ BRY\?ZGX/M[]K60B/[1,J/Y6
M I11U0@\C-;TL(U"\GH^W<TA0?+=O0^F[CXE>'M/M]9>[F#7&C2%)+:/F7G&
MS [[@<BN2U?X]>#O#^B_V@D=S=R&-G2':!(S#G;SWKY!\7V^E:3\4;2R$QTN
M]O5^>-9C*&BE&"I)X+)G@]J]4OOV<KQ_%VB:UX9F6;2TB F:=BS!B/O@$X'X
M=:W^I486YV;O#P23;.P\$?M-W?CSQ$_A[1O"]P98XC))EPKID?+\K=L\$U[S
MJVOOX+\)6^I:U()9T,:.&8*7=SR%)ZFO&?!O@#PY\/?BAJNL37Q6YN;=742#
M'F@C+;3Z*16=XFU[2?%WQ'L_#NN02R:=<V\=P(YN8XW()0\<+E1NSUK&="FY
M^XO=2N95*<7)<NQZ+?\ AG1_C6ECJ6OPN-&L'+0VS?*99>CF3U7' %>J77AW
M1[U-.BGM@4TJ19;91P(W12H(_ XKRKX47&I1:IXCT:"=+GP_IMP([)^?,RPR
MX)[J"< U[:#S@&N/$RDI<M]%L<]6R=EL9/B2Y\06NB3S^&+.*^U$ ".&9_+1
MLGG+5YAH/@#Q<\&G1:]J2VUM:S_:S;Q9=UE(.4$A_@R3@?A7M&W>C*_ ((XZ
M\UXSXM^(T/PPMKL:H7O@\;O8JH+RSR=DX[9(&>U%"4FN6*U%!OH5=4^$6CZ1
MI8GT_5;K3[?3[I]2D:%0TK,>6 [XQGBN2\8:YK?C'P[;P_"*\EU+6+2[@DE6
M5\Q+$IW'S.G) Z5['X1\9G4='M!XLCCTC69HP\MI(P&,_P!W/WACTKS-?'G@
M#0/C-#HFC1QI=:O:D74D Q$C1<H),#&X@G'MUK>G4E*[DKM?<:*4F[,[;X'>
M--9^(?Q!DO;_ $D:3_8-M+:3B3_62S.RGY./N #]:^T*\:\)VI'B:&[L@B12
MQ2F8J!ER=NTY_.O9:QJ23=UL<&)FG+16/._BSI=OK7PW\0Z5=WAT^&YM71[A
M3M,2\98'MCUKYA^('A[0=/\ "NI^(K&)SJ@MHTM9X3F7S@/+@V$=<L_/8]Z]
MZ_:*7=\#/&XWM'_Q*[CYDY8';V]Z_-_5OCY=ZEH_@ZU\"6=P-,T"YMQJCW*8
M:2*(!%([8SEB?85U86A.6L3KP%*4EH?#7A[0_%6@>/OVO?#MN8HQ:^&&%]))
MEY JPYVH1P6;)!)KTCP%\'=!U/\ X)Y7WB&^TBP<OX;N-02[DA3S3-%++_RT
M/S*Z[<J<\]*^I-+^#O@G7/BE\<M1MM:N%LOBWHJPSW3(JQ1$*4E$&<%_+5E)
M)XR<5\<I^S39OI ^&.G?%36]3T*U$[?\(_,C6\<EG:YE!=A@(DG.TG@DUG2I
MU))QMK9?J:04N=M+O^-CUCX'^ _BG^T?^S)\&[ZWUVVL+7PO=/#?K<*99+NR
MM9L*NX<JP0 #/H#7OWQ4^+^K?#[X1>-H;J6WN]'\+:8EJ;E-QGFDN!Y$,2*W
M7YF0M)T /J*Y'PE\"+NXLO 'A70_&<WARST>[-Y+I^G';EHE$D<,HX)61!AB
M1R1GO7US\4?#U@GPZU75;JUM[F_TFUDN%+1+L<P_/L92,%2!@ ].#6E:3NX7
MZZ"IIP:BWT1^._P*\2_"OPO^V7\+-<M?%T7B+5-9T6[77-3^<B;7=0\U%B&1
MT&Y(T[8 KGO#U\;[]F7X\:CXKT&SU"\U[6M9E?4)!OO8;JU:(H,D95$9ACGN
M:]M\8>%K./XK> ?C"="NM*\365C9?V=I,%M&D5RYE=RTNU>&8, .]=!\<_V0
M%\$:%K7B=O&E]I?AKQC<FYUO1K>,&)[VX82N$?\ @C9E /T IO"N-H26]TOO
MN..%E":;UO\ CI:YS7@?5/$.E>-/A+^T+XQ\'7GQ&\-ZMX L]%5+6(7<MEJ,
M)",6B;./- ^\1_&>>*C_ &1OB-X3M?#GQ5\ ^*-&DL[U_$NJ76C:<%#+I[F%
MBR!ONKY38![9KJM#\#Z3=6/A:X\#>-]=^''BG1E;2+@0PO):+;R\J70_*H /
M#XSCZ5Z#9?LI_#_X12?V#<>)GEGU;S&%_(VZYN[^Y!=U95S@N%)ST(K3#X?D
MK2Y]+7M]]RZ>$Y*B4GHO\K'UQ^R9;7D/P3T>340PN;B6=Y PP0P;9VXZ+FOI
M4+E@/<8KYW_9GMFLOAF+3[2;@0ZC>JN3D1JLF-@]NX]C7T(LH5U'\74?A7GX
MO^-+U(K-\[/S>\*^.M>^&WQ \;ZW;20:M;K<K:RFX81-/<7-PPAV..-J8;(/
M3-?;?@T>- ;GQ3X[U&&&VN8EDCLH #%;(!DDR?Q$CFOACQU\#+G1_BCJ"0EK
MW1]<O019YSL-RDLJ2*">6#HVW_: ]:[7PE\;/$OB+0[OPUKC6\-C96QM[N*Z
M1K:[CMD(@^T*O((63 ([]J]C%T5-*<;=+G;-*27*?6/PFUW5?$^A:AKVIS"<
M7&IWBVV!A5MHI-D8'X UXS'\0?%FF?$+Q%HMGKJZDMAJ<<4>GW$>QXK>6/)9
MF'+*9.$8<8'-=1+X-TSX>^"H/%GA/69HI+00O)/)(3;2QRR!)&:(\ #>6 '<
M"O*K:_O_  MXI\7?$+3_  C_ &JFE[(1J%W<8DGC#8DCB!'+O(0R=@#BN2E2
MBW)K5$12YKH]3@^'&F_%S5K_ ,1^-%:,:?>>5;VL#LIM[F%$29RW=CC:"/X?
MK7KW@F Z?%J.AOKAUQM/N2 TF#+ C@,D,C#[Q4=#UQ7S)!XJ^*EX=:.@::(-
M$LYY+V[,3 73-/(SRQY.0&C3;P/2L[PYX\F\-_#[3_#OPUBC_P"$P\3-<W3S
MWK>8D;0;FD>=NY"+A1]#55</4DK?=Y>HY46U^A]>^+V\31^';QO!Z1/JVT^2
M)CA,XZ_7TK\WOB1X%^)/AJYM;OQ+/-?+J^H027+":1(E:95\R$@'[N[.-O'%
M?0WA7]I6'Q+X=\*W&CVT^LZG)*J:HL$+;/+2(?:94/3$<C 8[X-9]Y%XI^-_
MCF\U.R;RM"T!7?3XC]V60 (2QZ!Y S ?W<5>$4J7QI)%X>]-W>Q[#X&^&WPV
MO/#ER]C9Q:A#J4SF:1EY#*-A1?0 <>_6O,/B5\'_ (F?\(]X>\+^ ;^";1](
MN B6K+Y6VV7&S>?XBN#DUN^"GU+QAKTVGZ7/>>%-&\-D0"U<!9)I83^^<MT(
MW':23SBOIJ&[MKAVBMIDE,84L%8$@-RI./7M7/+$3ISWOUU,I57"?-%GPG\7
M?@)=V?AL^*KC63+XA^W0!/*'EQ/#))\T6T<D*I.!^-8WPL^)'@WP/K%SK6NN
MWGW:&UL0D1EQ# ,W%PV!\J(PVL>H%?9/Q'\+>'?$.G6>I>*[N2ST[09C>R%&
M**=J[?G(YP,YXKQKQ1H&B^-K/_A&O@_/IH:+2+I4E51+'&M[-$70E>094#XY
MSG-=5+&>UAR3_P"&*CBY.+B_^&+W[/\ \3K#QK%K'AO9'$-.FE=0?^7F&YF=
MEEP>NX<$5YMXV^&^E3>+M0\-Z/=F/Q%HFF7&H:>(6.\VS,?*C?\ VHV)V_[.
M*G^$.B>$=,^,>KV.IZ6=)U"&&W%K"21&DPS))&K#[Q4D8[8X'2O6OC)X.\>W
M&L:/X^^%T=N=9TE)(YTDPKW$,F,J3W &<#UI*:A7:B[)ZZ[#YE":<79'S=X(
M\9MKGP^UC0[C57N/$-S%+:WL90']ZL6T2,!S\H!R/4>]>'07GB/0-2T.RLH9
MM3M_$=D;'RBX >1P R!3R-K#OW-=WI^B:1K^K:WJ5MK$>AZ[!+&LC!A%),9U
MVLKKP,^82OOP:P/&7A'Q%H-UX6339K9-;M]\,%L)!)<2!Y2SLYSA<;1M[Y)]
M*]>'+%M)[ZGKRFI23[GTC\);*X^"XOO%/CNQ,FFZFJN-38K)]A2+<#&Y_A0X
M&,?Q?6N/_:/^*'ASQCX4FU+P[ ]H+:>*&2]?Y)'9H/.\OR\]0A&&/0GBNC\8
M? WXLZ['H7A'3]2@A\)R0_9;N/<TKC?ES+*&/)&2%]#BOD#XO&X\3>,K[PWX
M0MFN&OM7G@C@ S^]B*P;E[''E@?C7-@X0G5]M>_<X:4%4JW;/K/]AKP>Q\,W
M?C6_TR&/SYREK,ZDRG:,,4)Z+DD9'6OKSXJ?$?3OA5X*N_&6I0FY2W>.-(5(
M#2/*P4*,_G4_PQ\.-X0^'GA_PW)$()K&RACE08XEV@R=."=Q/-:WBG0/#?B+
M23;>*["/4;&U(N/+E7> \8)# >H&<5XE:NJE=SFKJYQ8NNYU7)GSC?>+=4_:
M ^&OB2\T6"Z\,V.F2![2^,A1I_)CWNR;>J@_+Z&OAWX%>*K/PM\8M'GUF>%[
M>\GQ=7.[AR4=5//^T1G\:]T\:_M0:+X>T63X=?!;PT9M)T^-X-Y;RT526WHB
M]<<DY-?'WPWT/6?$/B./2['26U-,F1VCC,ODI@Y''&\DX'-?087#\M&<9KE3
MV/:PE/DISYU9=#]6=7\!?#GXG>/;BRA"7ECI5I$+M;:8JD-UY@>$*$. S(#O
M]L4WP)J_@F#XVZSX7\*SO9)%:*&M"Q$$UU&V'>)3W50 V._XUYIH.D#X1>,-
M%\">$EGL+CQ9I]M)=RS_ +PQR(T@>1STWKE5 S7&?$&]\,ZCXM3PIX'N9K/Q
MCX9O;>%]5:,^6B*C>:WF+G+2/)\P[DUYJHN5X\SM;3R\V>73BI2Y4]#U?XK:
MMI_C^TN$\)>#[S4-8LX[B1-21?(\O[(V"J2CEFD(*@?6ODZ[^-WB7X@>*/AY
MH'BJQ6UU&QU:)3,T)68KYY7RRQZ8X4XZD$U[ZGQP^)GPZO;WP%KNFV3WVGSO
M,U[$',$R2?O&RJ_=<[L_6LGQ#X^?1?B/X7\:^*O!UJ$\036UJ(#_ *U9DNMB
M72KU4E7! ..A)Y-=6&BX*SATTU_K02BX6OJGL?JQ1117SQ\V%%%% !1110 4
M444 %%%% #6574HX#*PP0>A!KXH\!?LC:SX1U3P-H>J^.1JWP\^%^H7&I^&]
M&&FK!=Q3R1SQ6ZWE]Y[B=+6.XD$6V")F)!=FV\_;-% !7A?[,W_)!O!?_7B/
M_0VKW2O"_P!F;_D@W@O_ *\1_P"AM0![I1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% '__4_?RBBB@ HKY-_;%^/_B_
M]G+X::9XW\&:':>(KZ^U>VTS['<RM&\GVE)"H@2/YY92ZJ B@G;N..*^9O$/
M[3W_  4!\+>#I_'>M_L^6,6E6L!N9MFHK-<10JNXN]M',TXP.6&S*@'<!BOJ
M,MX0Q>*HPKTW!1DVES3C%MKHDVF]S.51)V/U+HK\SO@S^W=X]\0Z]X%LOC5\
M-1X5\/?$QH[?0-?T^]2_L9[R9ML5O*$W>4[ME=K.)$88:,#<R_IC7GYSD6)P
M%14\2DF]FFI)V=GJFUHU9K==2HS3V"OEKXJ:MIVF^*+EKRX6/Y$XZM]T=%&3
M7U+7Y]_&#QU#X;^,&MV^LZ<#IODVP6[109%D,>2I7.64 9R.1TKRZ=-RT1TX
M>-Y&#J7Q!U&[U5_#_A32Y)KE$#O<7:M%;HK="!]YOPQBOG3Q7:3:G=RZQXQU
M\ZU=V$Y\W3XC)#:@C($$*#.9<<\]1S7M%S#/\0Y[71M1CETFY^RRSQWD/R2>
M0[[4V<G;N !(-9W@OP?IG@GX@R:'K>I2ZU>7=H;NPDNB&==KE)ATQN&5P>N.
M*[*4HP5^O]=3T8U%'2)S5AXLT7Q3IDOA[5GA?1+NR**P!BFAD;_E@5<#&U<8
M/M7+?#'XBWGA+2K_ ,&Z+;C5H[*8BV=2WW9"2"Q;JN.00,8KZL\2Z/HMSI-Q
M->:5#J'V;$XB95&Z2/E><=:X/PU'X5TJ\U#Q'+';Q7KDP0N&5@0,DQ1 #.%;
M(Z5:KPE%^[==BXUKJS5SA[#XH>+-0NY&TZ>.[$$0\]8X?-@2X.2(C(-N/EQ\
MPSSQCBM#_AH)+*6SL=2\/74EY?'9;B!D99G5MK*O)(9>I![5Z+X9^']CIFLC
MQ.MW++<SQX,0(2 ;@/\ EF."?<\UBG27\7:II6L>&;2WTZST^^:6>6:$>=*\
M;-&ZQ\XPW]ZLG*BW\.GW&;G'L:6H^*O'UV(H?#GAOR7F; DO9 JHN,EF"9Q@
M\8[UX[X[OOB%I'BC0;_Q8T&I6EC<?:%MM/?9<A&^5L1$$RK@$XZ\&OI[4M8%
MG/#96D)O+J5A^Z1@"J=W8GH!^O:N+\$W=OXC\0ZWXC:QEL'C9+-H[F,"17AS
ME@W(VG/;@]:RHU%&\N70A2:U1Y-<:WX1NO$%_JVK:JMGX<OG6XB+JL3/=! Y
M0EQO# $X'KFKFM:=X6T[POI4M]J+ZQK<LZWMLHN&'FM;$/M./X8TX /I7@GA
M;PS!\3?B8-*U*]QH\=S>R7,(4F*=H9?D96)PK.",XYXXKZK^(?@OPMIJP^.X
M;9[BYTB,)#:1D-'*)"(R-F<9P>2*[JMH2C%M_P!?YFTG9I,FN_"WBSQYX:FU
M'4I;?3K[4+5D@&QC]E+9VR [OO8KMO ^IR1V-YH]U';Q)HFR%YX'_=2-L#.Q
MR!@\Y/)Z]:\XUD^-+?Q#965UJB0>%;Z>,DG",L+1DLAD)W9,F H'05O>)/ &
MDP:3+X6TN<:?I/B2X(O06.3E,L8V)X+[0#^=<=2*:49/3IY&4U?<J^+(/"/B
M62YMX;JVU=[T1WOV488S0P,$Q%*,X.[CCN<'K6%XOUJ/2M?\,:?X6@?2]1TR
M\2&:T),5J]M,A.'<#:W/W!UW&K2^"=*M=;\KP5IJQP:-"NG/(<*$4D22&,\Y
M(X)/<UM^%-#N->UJ>Y\2Q/?1V;QRP7C )%<,N=F(_6/ YZ'KUJTXQ5V].P65
MKW*_Q+UWQ1?Z*=&L(/[*_M5X[2"1OGGDN'.<1H#PBXRS'J/U\3U_0=?L]:M=
M8\3VJ7.M&1?W/G&$ B00K*"N/W:J5; YR37UWXFTBSUV'^SC-]DOVBD-I<+_
M *R%B &=,]P*\.\,>#]!\8:AJGA[Q1J?_"0WOA\I#!>[P+A0V)&P0?[P /O5
MX:NHPOT+I3LKH]0\$_"_PSX1M+61K>.]U2 NQO'7,A9V9C@GG +$#VKS#X\:
M]H<*M=ZA:?:I/#L;2F-E9/,><!4VR8P IY)KZ75-BA1D[0!S[5Y[\2K[0DT9
M-"U>WENSK,BPK##'YDCJA#N2.,* .3GO7)AZO[WFEJ9PE[UV<-X(\8Z=XI\(
M2>$=6M)=()LS%YS<12@+\QB?C=CC)]ZIZ?8>/?$GP\U*T>:QO+=TDCM;6WW1
M.R1?<5I0V06(Y_*KWC[Q%X-N[>TT;4;1XQ:?O8"%*NK(F0OE@;B#CD#ZUW7P
MWT1-(T1KT6G]F_VB1.UMNW"(D<\GNW4_6MZE3ECSI==F:SVN<7X<\,_Z#'IV
MA7WV*[CA$5Y;WBM*X\Q<O@$\CGCJ!Q5B?PW<^%_%D5[?W=Q=^$[;3@OV38&A
MBFC/S2L!VVC/>KFHVMMKGB4ZIX!OTDU 3&*]E1A+'!E%!.,XW[5 Q[YK@=2\
M3>+(KSQ!X=UJX_M2UTZ1S L<9+2Q%.%E,8Y(.<KC@4XIM[_+J2DV]3E['XHV
M&K:CK&JZ'9W%EH5D4GBM2@\K5)"P"B-L;59B 57/UJ;QCK.N^+M4_P"$B79'
MIVAH;B2P9REZI"#,:[.I^\?0D5Z=X?\ A_X03P)!X?TRZ1;AE69&:0XBG4YW
M(A(P%;H.U8K> -(T_P 1:)KFFW:7VMVQ?^T9O, ADMPK -,!D95B"!U/.:VC
M5IJ3<5L5&21RNI?$FPU[PU'XPT&]DM]&TM#:QZ9?(R)=,/\ EK*0"RX(^7/'
MKUKZD\.:F=9\/Z=JO'^F6\4WR],NH/%?,FG^+M)M/'-Q\.=7DNM-@UM3]A\Z
M*(VUPK9W,AQD;SG"FOI+PKX;L/"&@67AS3&=[6Q39&96+-CZ_P O:N3&**22
M5O\ (BI'1:;G2?2O*O&/PJ\+^()+_7(-*AEUFZB\MRS-&LZY!VR%>><=:]4[
M9ZUB>)-?L?"OA^_\2ZCN^S:=$TT@49;:O85RT)S4ER;F2O?0\:^&I\8ZWX1N
MK&*>'1+JR,MHD:J)O( ^Z$<_-A1@#=W'I659:?=/>6^NW]DNMV^GVCV\J13^
M;=23QLP+[6XPX]#7%_#;7/%GB!/$/QKTORX%UF3;%ICOE3:08'F[00?,QDGU
MKR'4?$?B/Q ]OXJU47VB7\)DMFCTY-B?9W8E7V#)("C[_?M7M0P[E*78[%2D
MY-'WEX#N='NO#L,V@6B:;:L[%K=<;HVS\ROCHX/6H==T[4H]=C\6320FUTJ!
MQ%$7,9.[[S,_3Z#%>&>%]8TZ_P#A/J>B^%%O;J>\E>U241NDQ:0J#(['!&,\
MG)..E:7POFE\6Z/)HFOW%Y-::/)Y<KW"M'&)86P1O;[P!'J17$Z#CS2OI>QC
M*G9LUM-?Q/XIU_4?&_A!?[+O[BW2W:*Z7,3)&Q96(!/[P@\'L.HKTCP_9^$K
MK0T\5264;W,"2[YI@OF;QD/EAUR<@&N%T[P]?_9=:USPCKFS1GF8);'#QM'"
MH67#]06*GFF_$?0M ETBPMK6\.EV6HW-O)/';@.=T8+K\O;< 0>QJI:RY4[?
M\-L*79#KGX>^#8-&TI-"M+:"]URZ5VN1A) ""S%2I!RN !Z5[5JOB+3/#\NF
MZ5<.9;S49!#;Q Y=R!EF/H%49)KYMM/AS$M]=>*YYYAI^CO$VDQ2.P,3QD&4
MX3H' QCGOGK6MXOTJYUK2+'XBZ3>>9JL:336Z-Q(-R;46,<[=@.2".< &G4I
MJ4DG*XI)=3[1^&FB6EKK.L:W%N%Q?K L@)R/W88 @?C7LM>"? RR2VTN>=-2
MEU%ITB9WE</\^T[C[9[BO>ZXI'GUU:5CX]_:,\$_%3Q)XMT'4_AUJ$FG1VEI
M=).T<@C,C.T>U"Q!(!P>E>8_LX>))_ ^BZ[X;^*]]!I&NG49;@K>.$NKA6P#
M,S' <';A2.U?<_B#_6PXZX;^E?GE^TMX.\3:IX^TC59KR&W\/O#OE+*J-)]C
M.\6_F8+*TC-UY& ?I7IX6HJL?8RLO/J>M@Y\T/9R(OBQ\6E\>A_#&B7[:5X;
M\Q[JXU.>,$D6XXCA!_A+8;GG /8UYCJ+Z3X5TJUUWPTOV+Q!/;175K=R/(D]
MW<271>=6 S$ \1SP1RG/RUR'AS1K'6=+@N-:CAM[!=1%Q;6:MM@ME#['99 J
ML9#A>3D#H!7H/CC0O"VY?%O]JOJ5E $%F\UR9'%S$V);98WS''&=ZXDY;.02
M!7JPIQ@E!;'I>S4>71E"Z^(?C[QKX;U*/Q/%=SV5U>B"*\15-D/NK@@G;O!+
M9P,8'K7AWQ$6_P#!%EX9N]2F35$,L_DQ6W[J22U;+E6;J45N%P,'OZ5]*^(O
M$/@2Y\!1^ +.[M_[!\)QR7NH6J0NLKWR_OE0C./E9B3@G)&*\Q\7:IH_F:%X
MDUC1GO4@Q%IL%RX;RH6CW2-+/Z+E2 >G09Y-;X9VT4;(WI6D]4=G^R_\%O"7
MQ0T_6?&?B5KFYMVGDM)+"< )$YP_R/@$X&.>HZ5]SP_!SX>6/@RZ\#6.BP?V
M9=!R\<H+%W;G+.?FSD]<\5\/_LP?$J7PEI^LRI! NCZUJDU[)([-%'!;PC;=
M7(8C!5#M '&<&OLCQ9\=? W@F"]G\03O$;&**8*BY,R3!3&Z=L-N&,GZUY>8
M.O[:T;VZ'+C:=3VMEMT/S=^(?@CQY\#M0TF;58+2[NM1N99K>&V^6W6WMU5'
M\SH=IC)!!^N<UMGXIV<F@7^G_98K6.3:\0@8(09_FR"X8+E.@)P6!]ZXGXR^
M+M0^)/CW7O&TMWY%B8?^)1#-,% M(X<$?[#NYRR=23Z\5D>"XOB?;^%+GQ+X
M!A1-.MK!I-0A*&=-L1W,K%\C=)N##\N*]N,&X*4]_N.]TY3@I/1]3W(>(]2M
M_!Y&@NL5EJ<D$%M^Z23"S;0R.7R8P_53V/>O8K^[?PCX+34OAWK5GIUQI"V^
MFW]OJOE_;]-MXI=\D,9'WE<@@ @@@Y!KYD^&7PX^(OQ*L]5U#0=$N;:Q5X7\
MAIPEN\KPX(".3E1P=N<*<=*Q/%GAG7]%\<PVNLZ7)9ZJK-)) ^T"Y$F (W=F
MP0<$ J3G(P=U8.C"4K<RT,9TXRTOMT/J'0KWX>>(OAV=:^*6M0:/>:SJ)CT]
MS"JR(T0^<!47/EL6SD\#CD&O'I_&6H> ?$A\'6,6G:O/8J)H;BW9[J*Z5CO"
M;F);)X&,Y!]C5_4_A-KMN+:U@\-_:->U"!3;6;RED:!@ Z$ $@#@AF[US7B'
MP9IGA&:\\-Z_;7VB75H+9A#&$?\ =&-UP7X7#L1EDY[8&*=*$;OWKWZ=BJ5)
M<SU^1]17'QJ^&_B>PM9?#UU>^$]>TN>-&6S1/+D:9M@BD9OD*,YZL.#GO7.Z
M_P#$K7X/C'X>UAH(GUVPTN7[4PMB(FM@@?:T@+$C<3M8''/R]:^6=&TRWT+1
M?$8T.U(>V\B&RMYCB0Q-(C%I%D&"X.64G.<YSTKZQ\'? +Q)XQEN-:NX(/#=
MLOD);3"$_:+F+*.WFC=\R!040$*,8XKFJ4:-.[EMK^)BX4Z;O+8V?AK>I\?=
M<\4Z5XRU'?'"XN+>!) C"*X)5H&3A]B!!@'H6]:UOB)\&_#=GXB\(^$[+4QH
ME@^J2ZL+B[G$GVN[10HMF5_O;5.4!/3(%>9>*_"/Q \&^.=1\0^&?!T]E'#-
M(UC>6B+//<2++E]\:D_NI0<E6P-O3D57^RZ;K7B*XC^/D4]Y/-&L@26)K>:S
ME1/-FDL\D^;&<C*K\RC& >0,G&TN:,O=ML9S@F[TY:=BG\9?@GXR\ R3>/'U
M+^U[*(74LEX8@_V%;AR=K(Q/[M0V%/.W KR^%]1@DM+&VFB5;JW>1_-4O#(?
MEDC=T)'SGG! Z&NQ^(WQXNM'O/$7PI\%V%WK/@WQ180);-=^8DVG?:1B9XRX
M)\I1\R!CA2,<#BN1^(GAW[*=*L=7O5O;O3X8+>&2W9-\BP0L(X)3#A=VS/0\
M\=<5WX?VEDJO]+IIT.K"2FXVJ?\ !/9? 7P]^&'C+6TTF9[O2];UG3UU*T+2
MAK228.RK-"O&3&5(*\\$UG6=WX2L/$M[\/O'OV9;3PEJOVF]G9@LO[D?)Y$8
MP4CDRH;KG'6O-])EO/&_@/X;IJMTLUYINI7]M'&PDMQ'<"5I(&E>+YHED4^7
MTP,YKKOB?IOPMU/2==FL;"\\*>*;>>.VU737/GB0VK^8\ZR$G>!Y@;=D;EQD
M<5CROGY9-V?X:V,97<[2Z_U<Z2#2/V9?%NK2?$?5M3DTW1+VT+#2 [0*DC,4
M?Y4)W%Q@G#=2?7%>_P#@WQ[HGPF\(^&/#RV*OX5NQ<I875G<_;6A5"T@688W
M,3D#*YYX-?!MY\'M;L?"EKXA@%I=[[(W6GXF7;JB,Q,L,<.=JM"-K'^]_#R*
MMW'@[Q5XU\$Z+K?A)X=;TR#,D]O93;9X"QR[202[& R, H<X'-35PD)I*4[K
M;^O,F>&I2^UH>R^,/BQX7\:>/+;_ (0WQ!;:4MGJ-OJ4DFHH(5$EI&RS&#.)
M%DD'!1^&*XZYJAHFE1Z9J.E:YKCKHUQX>U&T&I(KM(LDMZK2;@/EWS,&1Y I
M^4DGI7FS2^$XK&\UJ]N=+\02ZM:I$RWEH1>64H?<5EB 'S/&"HD8G)[YZU/#
M'B[PSIVKZ_;^.=&^PZG;117NCW,DYDDT^ZB" !@Y(='55(DP1M&TG&,:>PM&
MT>@*ARKW3Z(^*?Q%\>V>JZE=O+;'PIJD-M"+R6)[:Z1N=DJ1L#DQEN6QQ@$=
M,UG>'?@SX>^,WAI=8U/QH=0UFSNIHY+FY*9NX%.$5E;:ZH"<#OQGC->L>,OC
M1X'U./0[_6]=TO4O#EC=)>7 TT_:+EI(49X \+ D1%ARR_Q;5X!)KYD^+/Q'
MMOB'96GQ*7PI)X:LK*=A;7%P 5U.R)"L&C&,R)U 7('][ -<N'51I**Y7W.:
MA&;:25C5\1_LF>)K+4-0M-*LYY8Y622T:+YXT1!\RE]P8$G( "\BO(]7^$/B
M?0!!;WLR:(\T^VWC<2J"T'3(EPSG_:4'FOMO3O@_XIGA\)ZEHGBV\_L)E269
MOM,JRQK*F>BL58\X&> :])T;PI\-?"D&N7>O:[;R.6:-;FYO_/GM(E&X!7E9
MF1]V7(!Z]!369RCI>_R-GF-2&[O\C\NK'P=\0M1BTZ7['J6H0Z:UTUK)+%,T
M"M*QW#=(N<$ \'@=:R;K2++58Y;QXXX9ED627R,K(DL? 7<,8VGMCI7ZH?"_
MQ+\8_$GP[MO$[Q:7J#7ZW!M%G+V[/ KLMO+(T8=3YB ,0%'7K7RAX]\-^$O"
M7PS^W26\2?$*UGE@U*RDD,D<\TC%YG3C!3!_=D8P" 1QBNS#X_FER<O6VAW8
M;-[OEG';L=?^SIXIT'0O%]O'KOC8++>VPB2SOXQ'+(SG<JK/PK 'A>Y(Q7Z,
M*=X!!]Z_ 6]M]%GTJQ\56%W%J5Q9I%<F%TE\N*19 XBXP#M^ZVW@'IUK]N/A
MOX[L?B+X5TSQ=H<1&EZA;K(C,=KB0,5="G. ,=<FO&SG#<LE-;,\S-\/M574
MF^(_A/0OB'X6U3P3J0BEN+BV:2)6(\R*09\J8#J,..OU%?CDO@7QQ!//I=]I
MFI/JFF7 %I'+ _DM/;+@JIQS&L>6SGN,5^W<TFF6MY#/<-%#<W7[B-G*J\F,
ML$4GD]S@5\,?M5?&(^$_$VEZ%IOAF2^N=+EBO7OIC(($\U2A"!"-YV\$'H>W
M%7DN)G?V25^OH<N65I1ERKU/*--^&NB>.?AR?C+J.H1P:M&4$=KIRK]FC@M7
M6-HY3U:3!+'G)/ S7TKX4U#PGJ_Q+M] \+QP:7!X>U&T;F4&2\*VDZ'"#D,%
M=6(;GKGFOC+PQI]S\/-=T:V\06Z:4D=]%>7^FL)+FW2RW!HV8H=J2@L)"#VQ
MGD&OH[X/7MHWQ&T3Q+XAU_\ X2+7/%%[>M$8XT,,%LJX@QM*^6^Q2",,3G)P
M#7=BHRLVW?M_7HCMQ47)/5M:_P##'Z'5\>?M7^$[SQ,_A&2U@$ZV-S-(X/3:
M0HK[#KQCXQ:AI^GV5A+?2K%\S[2QQT S7S5&HXRYD>!A)N-1-'@'A/0X-)M4
M41_O57:7VA21G.,#C\:W)5999+DAY=^U?+'08/WA^?-9T?BS0)&55NXP6&1E
M@.*YWQ;K+#29-3TF[41P*=P0@E\CH,=".:.64I:H]%4Y2E=H\I^.K0:=8IK5
MY=FU>T"_)'U<$G'YU\NQ^(&U#5;K6K$B*0HH,KD;B .IQW':MSQUX[>;18_#
M.O">]@GF 215R\:DY!9CUKPS7);:^U>33='21([Q C3QG&,'(&T=>1S7TN"H
M.,+/<^APM#DA:1ZGI/CZ\T=K>6UO5O\ 5K8R,TADP63^ZH'<9KUZ3]J;4+*U
M6^:S0P0J-Z;BTG YXZ]Z\*\$>'/#$A>ZU&R29D&9/+RH=P<LISR#QD5O>(?"
MEA=SS7^B>';E+<D,&4DNR[<GCN.U%6A2E+WD%2E3;]Z)]C_#?X^>&_'\LUF5
M^Q7,$22LLAP2&&>!ZCTKT^[\<>';.UAO);D"*=<H>A..V#7Y3'P?J=O,VIV,
MD]I<QSQ2A9OW;%>WS>V<8-=!K?\ PE6HVT*7]Y)+%#*J!(SES&_5O;'6N*64
M0<KQE9''+*X-W6B/LKQM^T;I_AP/%9"*6=QB-,EF![9Q7B.H_M!_$J^MY[#2
M$^SW\C(3.8R8@#SCGIQQ7-:/X#U'5&A@TVSWLT32>;,A9MB^A]6/ KVO3/AA
MX>$*Z?K-\%O-1MPSI-E/)*8+;5_O+_6G[+#TUJKL;A0I^[:[/&_%/Q'\=^-]
M&BMM0NS;R^9M$07;YK+P1@=CZUDZ-\/=>\10W!MK.2>VAA@E8R$HGGEONJ!C
M..IKVF_T'P)I&I2)I=^))K50LY#AG5Y2%C3/10QY(ZX&*F\ :9XJ\7R&U\3>
M)_[.MV68B&,I$[$[E&!P"-H!!'2M7748W@K(FIB[?PU9'+6'PKM+#19M;UBY
M:UN7VS1Q16[;I!T"Y&02?0>U6_%7AU?#NJ>';VV\-W,MI.8XE%P=N&D)9V*J
M>"?<8%?6O@?Q#X?'A+2;>2]3,,:0XG8;]Z'8,^Y(X]:S/BKX=TM]-D\=2L\=
MYH4:R%E+$/!&^]X]HXRPS@UP+'R<[21Q/'3<O>/.)?AWXPUJ2+546*'3M0EM
MU:VC'E2Q6RMER_8L1G\*]HL_#?A7PYKVE6.BZ?!9,L5PZ>6H5B3L!/J:POAM
M\7= ^(T?^@03V,C+OBCN$*&1!U*Y[CN*T/%OAK3_ !'XKT:+45FB2"WN"DT,
MIC)9BH,>1STYKDJ59N7+/2QR3;YK2/-?CC+X5U3Q)X1M+FU&H:KH]\+S 3>D
M,04DF3'3) Q^=>H>&=.U74O$4GCF>=K2TO;9(H]/7#)A3D3,1_$?Y5QLGA_0
M_ /B@/"3;1ZX?)CNKC,J[Y%"F$L>1G&5)^E=#\+[/6=,BU#3]9U<WZQRL+6$
MH$,-NI*IC^]G'6G5?[M<KV!M<NAZM/&9X9;=6*&1&4,.H+#&1]*^3M)37AXA
ML;30[F/4+:UG>(( 8]DZJ3,LDO=G(S7UDS.B.\8W.H)4>I X'XU\L^!/"UQ#
M!J$OQ M#X?BAE?4)9(I#&LDCLS!B^?O(#T%3A':,F.B[)GL&K:;JMSI,^H>*
M[A%ECR;>UMRWEB0_<#'J[9_"H[[Q[X6T+P<NL:U']AM052>!@%:,Y&XE?0=3
M[5SR^&?%_B.WTC7[35B(;6Z%S':R=)[?!5?,;KN*G(QQ69X>A\*_$Z'7-&\;
M:5+%+]N;$%V-@=4"A3"1]Y,  T*,;7;NEO8E17J:MG\1O#OQ?T/6_#_@)_MY
M:W:"6693'"@G0A3SRW'I7#6NB:GX8G\"> YM0M7U#2;AG\J7.)X=F/W>.ZCG
MFO0=3\/>&-*\2Z)'X<N1I#6^;*:VM/W8DB*Y0/@8RAZ=^:X;XB?!/66U&Z\:
M> M5GBU58G*P2/NS)@\QN?NG' [5M2E"_(G9/:_W&E.2OV3.I\9V=AX[\;WO
MA&]U,6D>DZ?'*L;*!MN)V)$V3P=JC ],U\[^)-0AD\3ZPWAK47AT^"6*P,D3
M8C>XMX\-(RKP<D')Z5T&A?L]>//&<5KXC\?>)[FTU!X1%+$ "[*.SD8^E<YX
ML^%TOPKCM]/M91?1ZC/OCWJ2BJO,A?GC([FNS#J"?(IW?;\SLP_)%V3N<G<Z
MY!XCTS0M#\1:09]8L;J6:.^V["L70%NY4]!7K_P*^,UO8:K-X$\7WIBEN9V6
MS\[(=3G 1O8_PG\*\XNK&XNY8[C3=LL]V4A9L92*+C!B/\0)/YUU.H:?X#U_
MQ%8)Y?V34+3;$3*I225V(\MEDZ8##./6M<1&$H.,E_P#2I9QY6MS[2U_PIH?
MB98SJT):2%6$<JG:Z!NN&%>5+X%U#4-,$S:S'>Q:2DRPI'$OF.8QM0.XY8@#
MC-><MKWQ,USQ-%X#MHUU&'25WW,A<Q^<"1A688Y4?@:Z73M#UW2+/5G@U9]-
M_MF[,<CQ,C0VK#"G8.Q/3^=>;&G*FK.1P*+BMR[I'BSQIK[VOAWPOID.@R+)
M$;RZGP',.W+&*+J6/3)Z5VW@W5O*U379O$.KN\]K<&V G81Q;$ *M&OOGDBL
M;PUX/M/"D M_$TCZQ+(S)'J;'#['Z*V/NXZ9K&\1_!X:Q;+%X0U<06<D@9TE
M/GA6!R61\D_A4R]G)N.R[B;BY:['6>.-6NY+_3X_#OBI+!KIPKIM22-8EY=R
M?X3Z5R>K>&='TW4KRR$]UJDFJ62K#.I5Q"X?>VUC\J;C@X[UW?A/P<GA#0;^
M+Q%=VUZT[R2M.T*QJBN,8.>PK*N=#U70_"LT<.J69T>"-BSM&6DP1\K!@>6#
M$8%%.HDU%/\ X)*[7.<T/QQHC^(X8/':I+J-G;M]CS"=X485^,8R>/:G>#_'
M^C:KXJU2ZU_1CI\+[H[>9K4!/*4D'>X'WCW]J^<=*U;Q#HD=W/KTCZGXLU%C
M!:AQN:WM0?D*H.CR'G':NGT"X\<_!SQ+;GQ<LNHV>NJ7DB;YDP0"0,\;ESSZ
MUV3PB2:6_P#5['H1P2DK[-['T[^SEJWB#6O'WB41:FEYX9TQWMK-1)O8N&RW
M_ 0,8K[9KY)^ ;>"M6UFX\0>!+5;:QG643!5,?[_ '#<"O2OK:O-KM.3LK'A
M8N+4K/<\P^-.DZIKOPI\4:/HI O[NRDCA+8P'/3.>*^,O"WA*76/ANO@K3A!
MINK>'KQ;*_*J")!%\S<GDK(CY'Y5]K?%RPU#5/AKXAT[2@QN[BU9(]K;3N)'
M0]J\8\/>&M&\.BX.F1;)KQE>X?<6+NJ[<DGT'%7&MRP^9KA*EHL\Y\4Z5!/\
M2_#&F3Z$]YI$ME<0^=&-L5HX8.-V,<,%QCZ5Y!\6?$>A^&?B+J;7&CO-J]]:
MVD$))"Q7.FQYENDSVY7!/4]*^R=QZ UXS\;?A?I/Q&\(W3/;YUG38GFL)4.V
M02HI(3/]UCP158?$+F2EML==.<7)*1\OV'CK6-+U:^^.$,MK>P6\"0M:H,22
M"4@!%]2L2$@]L'UKK/%G[03^,_$\?@;PSITEQIC1VTEQE=WVKS<,80PX"C.U
MO4Y[5P_P;^(_P_BU2*#QY9PZ5'IVBVD=M%/'\LDI:3S&'9G/*DGOQ72:3X.U
M;PE!!\>?#=A)#I;27FH7&D3%4D2RV$P8)^Z>"Q7Z5Z=14^>\HZK;L=M25.]V
MM3Z;\/Z)]OT#3_%OBS2!'KUE"S^4Y#-'L)95&.,@=/2NL_M3PYXF\'Q:[JL*
M2:/>0)<E;A,@(?F!93W%?/VK_&#QCXR^'8\6> ](-G:S91GNSM<LY$:1HI^]
MO9QR.U>W:;=:!X,\&VMCK-_$ZZ/9Q6]QN96.8T&5V>I].]>55I2LG+>_W'%*
M-[/J>4Z3>V^M>/O.\%VS7>C>(%E_M:.]3RUC4)Y<<L"MACNVXQTQS2_%/PM\
M-/AEX OO$US9,TL$UOY4QD8S?:"PCCPYSM&"0>V.*\M\1WWQ.\0^/;'7-#N;
M/3-2MA#-HUA*A1;JSN ^[S''WF11PO0$^M6-8\876M^&O&VL?&*S6'1OL-M:
MVMN4**]VH,K?*>Z. 2>PKNC2ES1E?32Z-W2=TST#]G7Q7INH7VNZ);GR&E$-
MTL+$?-+@K,\8'_+-OD(KZI4<>AK\[?@O)X=T_P =_#VZAN8EO(-/ETR]CBY)
MO"G[L$]2F#@>A%?HAFN+,(<M2_<QQ,;2N?)'[2?^C^(/#4ME*8]2EDMY[4;P
MJ?:+.X41,^?X1YS YXYKV6[O/A]X6O;>\\=RZ;!XCU&UCAFD**OFQARP !_@
M#Y.3]:XK]I?1?#^K_#.^U?6(1(=#DAE9L[9/*9UWHK=MV1^(%>'_  7TW2_$
M/B66_P#&+P7D'B>SCGTZ.>47$EI;QGY8"6SM;))QU_*NF$%.C&5]MS6E3YH7
M?0^K/&=EX=^)G@NY\)Z-K5O"FJQ[(3"RG('/"^G'I5UO"V@>//!*^&/$=K(8
M8&$$HW&)C-;87S 5QG)&0:QK3X/^'=.U32-6TL^0^E7S7:[1@F-HFC,((_AR
M0<>U>O@8  Z"N&I444E%^9C*:5N5GS1\;] \9^'?A5#X0^#5D_F7<IM[AD^:
M3RI5(9F)Y)<G#-U%;>F_ VST7X86GA;0)8[+Q#;6L:C4'7S2;C:%DW9Y*N 5
M/M7OJG'L33\9H^MR45%>OJ-UY6M<\ITVP\#?!/P9IUM<-#IT5G EG&R)@S3-
MSA%'+/(W..YKB?#^J_$_0O!&K^*=-\.0,LCSZC!8%_+GD1U4A0HX5S@L<]R1
M7F'[4GBJ2QU^QTF:]B2RCL/M"@<S6E^)PT5P.X^0$#\:O^"O$WQD^*/P?M[S
M2[R!)Y_-A,WEDR3QQNR+DYX+*.2/6N^.'?(IRZO6YT1HMPYWU)](\,_$WQSX
M&37[*_B^P^,[5YY[*#]P]I+.0^Y7/).X?./7.*[C]G#P3?>#],URTU29[N]@
MN5L?/\TRQO%:@[%7/0H78-[UPVC>(?CEJ/P^-UX0?2-/&D3W-K=F4EO+:%R6
MVCIA00 .IKL?#/PNET_PM<>*(M?U&WEUJ,ZE?0R2"-3=.-SLI/\ JLXQZ=Z5
M>[BX2:5V*I)V<6]#Z5E@BFC>"X02Q."K(XW*P/4$'M6-H/A;PUX7BFA\-Z;!
MIJ7#;Y! @3<WOCZFOF;]F_XH7_B'4/%7A/Q#>F;^RKYH].EF.'N+;)P<G&X\
M9]P<U]:GJ 3TKSJ].=.3@SEJTW%V9\X:[\-(_%GQC;Q3IOB1+<Z8;.2ZL8U#
M2*\0;:2>VX'%>A_$S6?$]AIL6D>&M)N+]]722U-Q;.$>T=UPLG/89SGMBMS4
M? ^A7EY+JEO$UE?321R23P$H\AC((#D=1QCGM7+>.?B:WA'6] \,Z7ILFMZC
MKLCQI%"P!01+N=F/0#'-;JHYN-M;(TC-RLM['QK??#'Q1XRTBW\7:[IXNKK3
M9K>SN81A;N6.UD!,[*G5W/)SUVUX5\4/":IX@MM0N(;RPGO[O>"J,KLSCY0I
M/\6X$#'K7Z!>-O'>I^$_$T?B:V\-3*LEK+;1%P8UFOG^94E9<C;A3M;'4XKF
M_%_Q-\(ZG\1OAS'J[K<6R1S7%Y"B":*TNV7$+3,N2I5PVS/U->Q1QM1:N-]&
M=M#%N-O=3/G;X=_&/XQ^$8#HOA[0;_7;2_B9;:2\5W,5QN*F1WQT[[?:OI/X
M ? .Z\(WX\?>-7CN]<N4D,2[<"V\Z0R,0#QO^;D]:]&\<?&CPEX4T/4D\/7,
M%[K<<92TLH@=\ERYVHI51G 8Y;T%?.7Q1\1?M!_"WX7-=ZQK4-YJ&K7?EFYM
MX]QMXW&XE?\ T$"N?FG5]VFE'F^]C]HY[*S9]S:;XDT+59I;>POHI987*.@8
M;E(_V>M<U\6/$][X/^&_B+Q'IT+SW=G9RF%8TWGS&&U6V^BDY/M7Y$07M]/H
M-SXOBUNZL=:LIX-S*Y$K&<9WLHX.&KH_!_C?]HGXMR2Z5X5U*YU*2>S9)9-X
M$2 _(0V1M!Q^-4LGY)*;:LC6ME2B_BV/,/ ]GX@EUNWN])M8[[6[1EN$@E_U
M4TTC*I4XX(7/0]>O2OTW\*?$+4_"VG:GX.C\(RVWC);=KB"WMX8PDGF K$[N
MF %W@Y)Z"ODSX'>!-/\ AI\4;'2/BK=&SO+C3FO4BD;K=+)@*''^RI('<5]9
M^%+K3OC;XDO?&[ZI'I^FP-+H\=O$QBNYH89=YWL<$+(2#@=@,=ZWS.K&4G=:
M+J&8R4_AV+/AK5O$WB^]O?AYXSU*%]8AB8:D$BC5[2)E!1HY0<_,W0]CGTK,
M\0> O"_PL\,^5X&_M/6+NYU(:A<SVK"YN(X,@29/((X4 'GJ:P?%6A>%]1U/
M5;/2HVT2RLR=.EO!#*\LDB$Y\V9"6(+' ![<UL>$?%T7P4\&3>+]<TVZN=*U
M.*W>9[0!T2[YB(52<HCX4 'G)KD]Y6<?N.*45;F3L^Q4N]'\6?&N&\TOP;?Q
MZ9H5A:P-YEQ&KW=Q=R LZ2G^$J-H]OPJ+PI\-KAO%%K\-O&.M+)>Z6;#67NF
MC_?7$RR!FC$C<%%VC<%ZY%>DZ;X;\7:2NN?%C2();.>_MVNH_#L.W9+*L8$9
M=O[[<LP'<UQ7A/QE<:_\8M"U_P 56L>J:R^D+%%::?N9+#[1.OF^=NX+8 )/
M;! JO:SL_9_"MNY+JO9?TS]&J***\<^?"BBB@ HHHH **** "BBB@ HHHH *
M\+_9F_Y(-X+_ .O$?^AM7NE>%_LS?\D&\%_]>(_]#:@#W2BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *RM>.KC0]1/A\1G5!;3?9!+_ *O[1L/E
M;_\ 9WXS[5JT4 ?R^?L4ZA^V_+^VWI<7B:3Q0]P=0D'BM-4-S]D6RPWG>>LG
M[E<?\L,8&_8(^,5_4'110 4444 %%%% '__5_?RBBB@#XZ_;+^$WQ$^(GA3P
MCXO^$L5O>^+?AMK]KXBLK"Z;;%??9 VZ#)( =CM*DE>A&X$@CPK6/VT?VBO$
M.DS^#_"/[-7BFT\9WL)@1]0B==+MYI5VB5[AX41XU//S&-6Q@L.:]G_;;^*7
MQ2\ >#/!WA;X.746E>*/B)XEL?#MOJ5PBO%9?:]WS_.KJ&8@ $JQ"[BHW $>
M8P_LD?M?O&KW/[5FIQRD994T.-E!]B;M<C\!7ZAD?U98"C+,G3Y4Y>SYO:WW
MUNJ::<;]'9[ZV,)WN^4\>C_9R^-NF>$_V?/V5;70&GT?P;J=IXO\0^)A+_HM
MK.MY=S/86Y8*6D02D H<G*' 4L:_8*O,_A!X.\8^ ? &G>%O'WB^;QUK=HTY
MFU>>W%K)<"25G0&(/(!Y:,$'S'(7/'2O3*^3XDSR>,J<LFFHN3O%-<SE)MRU
MU5^BLK*VAI"%@K\_OCGX.\.Z[\8K:XU^2Y7][#)#&% MI9(X@0&;KGCIWK]
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MN?'%O+#<Z9K%O#!?+$BL(RT:$*7/*E^P(JM^R#\/?!1U^3Q;>ZM:WVJ10O\
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M.:9D>?$@&YY&' +#MVKR#3?^%@:#X?N?#^JO_94D=V4T^XR'1TN0=J;O]C.
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MCC[RGUK]0;C0]:\!_#NVL/AOH=H-5AC@1X441J20!*V1U.>>>M?G7??#K4/
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M7FA0?:^M36^U[:'+/??7YGZF?LZ7NM:C\(]&N_$/C^R^)U\[W6_7]/2%+:Z
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MT=LIX G,JE&SVP1DFN?M=$\0Z5X=FTWQ/IT>J6[*]P\EF2TRS."6 C8 O@G
M8')]*RP]5*FO/^FSEIR2C=GG.G:1\2K1I?'GADKJL=U)/;K;SL/-^QL_R2I(
M>I"C[OK7HM]JUKXF\)'PCX N!!>73I!.SQEFMXR<S.V1@L,8Y[FN;T76]?\
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MV^';')(RN))(0XP3C!7O@D]Z]9_99UCPA\,? ^C:7KVJD:CXVO9A;L[(\2M
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MWHOSX9NH)'/->O7_ (1T'6/ .EZ[9W,C:JUA9W#SPDSS>>)##+'<#K\S[<,
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MOWRK,YYB7.0=P4X';%>L?L[:1XPT;5]13QGX>:-M9ABO!?/AA@%L1-G)#!6
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MNT#!<;2A/4$5&*@\/%12T>_^0JD)4HW74TM$GO-=\/0R>(],%E-=Q8GM)")
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M#)K[OKXI^,MAX93QAK6H73*][)% I^8-(CA0(_+4]&)(QCO7+2DU)-,Z,/\
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M3BTN32IK5!( ,E'V':6#9)P3TW=JV;WQ?I.E:[#HTFP"X&9)5(VQ2,P5$?\
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M::JW3Y]S&-6=U-*S/DS0O%&BZSI/FZ0YL[B!8GNWD,EPI6X(.TP!26') &<
MGBNOO[W2=&\1VVOV%[>V-]<6'[RVL5$'[B1A$72*9@,A@&4;E?9GGM7?_M,>
M ]4\(ZEX7U+P=H-E9>%;5!;R_98E299"2?+E;:V4('[O R&SSG%>0:CX$\:^
M(M0T:UT8/;P?;FL8;EFQ/'), 1AB-[&-%)8D$#DCFO2ISA.*J)V3.V%7VJOL
MCT?4O$7Q1\7+IWA/4-6N-5U#7,0W&F(BR-';$Y+W2QJ+>W) 7Y&8MSC))-=?
M\"['0+[XW2V/C%X7\0>&K:$6(69XTB(5X$BAA7;&0L2G.-W)/2O3?#O_  D/
MPFU8_"+P7IP\1W#P&^.HS*J?9WN)&P+HK@OR"5.02.O'-87P>?4M4^,UYIOB
M.&RT[6M#A:62"PB,<$R2.5>8@[L2;L+G=R!QWK@G5_=R2T5M+?G\]CEG-.$D
MK6L]3[HKR;XJ?\>MAW^=OY"O6:\F^*N#:V _VV_D*^?EL?/T?B1^3'[0WA:#
M0O& U+3YHXI-4&XQLNX+N^4D^F<5U_P'U"Y&J7VBZC/LTI;5BL&<JSCDMZCB
MLC]J"YBFU"VN)4\R"V98Y<#^$'<"2.3@\XK!^#NL6]]KDB/N@_T.28@K]]4Y
MP#WR*]^2<L,FSZYQYL-[VY]#ZG9_V;#>26>S3+%3'<S;"=\C.I+9]R<<5E>%
MO'<RI>W6B:;/)%%@2HJ;F=P/OA>" >F:\%^+OCW2[K3H]>TRYN?[0UJ&-/LI
M+*L6]2$<(?0<UVGPY\12Z'=:99:C*8QJ2K;3R2'&QT^:.3GI&R\9['BN=X?]
MW>6IYSA:-V]SZ"DOS?>%M;\4F1;-[J CU,0C7: 2.^>OI7QU;W%_JLFE:#9L
M+6VU"X3[0Z\RS>9\K%CU(!Y K[0\.+I<V@:D8X"(+^6=Y4(QEB2'/L"1GTKY
M+\&_:==^).F*D"QQP7.8(HAPD,;%LD_[O)]ZC"2Y5)]CKP$TH3;Z'V:?"5CI
M'@:7PKH<8CBAMF$7J9%&X$GU+#DU\]>'-3L%\6"/7(Q>+I4GVB-Y"#B"[ ZD
M_P#/-C^1KZZ_B&:^(O'XL?#WC?7[:>W%QIQL9;=%']]H_-5#ZD' %<^#;ES)
MGGX:5W)=3T6 ?"SQ%XYU&V@E2U22.2$@$P>7<GJZG(^_QMQQBE\+_"'2(O!S
MHICUV]FN6%P;J0LN(G.TJI.-RD DGKS5[2-5\*:G-H;6>CBVM-/,*W-[+!B!
MP\0"J'/7Y\#/;%2R:#X/?XM7>KO?&YL-0L5+VT,S-%'/&^&8I&>-PQ^M:2G+
M9-_\,4Y-JQKZEJ(^(-AI=AX2M(K81WNR6YD50(_(!64*O4D'@=C75^'?#/B[
MPJ9M%L+B"YT^YEDN'O)!LG1I22RB-?E..QKG?B!J.BSZ);Z9X0BAN=5ENX8(
M1 VQH7SNW-CD?*._6NUCTWQ\[PWCZM;PL@ >V\G=&W'.7ZYKFG*\4E^)$F^6
MQRGB;0/#^D7>G7%T9=3GM [W9E/G2M"0=K'.%&&Z>V:ZJ3P9H7B/Q%H'Q :-
MX+W2X'2%5(P4E'1L=<=JXJ72_%WC.Z\6^'->T^VMK">.&T:99&_T@%<ML(^9
M, C\:[?P-X<UGPY;?9-0ND%I!%'!;6L9+)#'%QDNW+,W<U,W:.CU_0ARLM]2
MFFGZ;XT\6ZG<7L[SVVB;+5(4D*QF1E#R%PI^8\XYJI:16^N^+=3LM0SIB:!(
ML=KY+B)IDD168D]U'0#I5GP3X>\/^$/$&N:-HJN#>&*^E:1RY9Y,J3D_2L3Q
MROB3QIH.HZ1X4TN.#5;>[6&.ZN' $7EMS(0/FY7H.X--?%9/334F]B_<7NB^
M!?%D=SKUYY]OK82&TFG/F/"Z]8P<?=.<@UU'BSQ-?Q:/>6W@EH[[75C#6\>-
M\98] Y'"@CUKR_P+)HD7B_4-(UVU\F]T1(;-/-W2Q2RR+YC21%@1\Q/Y5W=S
M;6!\;V2>&%,5U"2VHF$XB\EA\JR#H7SC;W J9P2EKT*E'6QZ!H,NJS:/92:[
M&L.HO$AG1#E5DQ\P!] :^0_C#8CPUXS36]5O'A&I3@I, =@CQCRW(Z+G K[.
M!P>.M>8?&#PU_P )/X0DCB@%Q<6#_:8TQN)9%/&.I![CO1@:RC/79AAZG+*_
M<PO@AK?AB;1+G3M)N;<71NI7:.-AN92>& ZD <9KU^VTF"TU.ZU*&5P;P+OC
MS\FY?XP/4CK7E'PF\(> K#3K?6M#M8_[61-MU+C;*DK*-Z,IY7V%>U"L<347
M/+E,ZS7,['G?C_QII/AK^S]+O[MK*34YXT64#"A-WS#?T!/2MUSX2TVT59FM
MO+"\%BK.X^OWF)JWXBL]/N](N5U.TAO88D+^7/@(=O/WC]WZUXROB73]=UQ?
M"_A'0HUU'27@N+GS"%"QD97RF_BR#U'%7""DE;IN*$5)6.AM?&_A?X?Z?]AU
M".:TM7F=[?$;-O20EUSGD$^_TK77QGK]M*+J_P!&GDAO8D-G!;+YCLQY/F-T
M3MUK).N1_$'4KOP_:VJE8(PEW'=18\@DD;HVZL2.F.!7:ZWJTOA/3+**RM_M
M&]EMU9W"I&<?*SD]N,5I)=.75@UIMJ>+^*OBCI_A/P%/;:C(UCJ\UTT$\"J)
M&@,CY?IP5"MP:]'U*#_A,="L='TB,7=G'Y,C7DIY0QD$>7GJ_'TK9\,^&;2'
M3F36]/@GN9)'>21PLQEWMNW9(. <\#M7)^8OP<T9XU0W^DRW,LD:[\31F5BY
M0!N&52>/04W)/2"UN5S+9;GD'C71?#HNH_&]]K'V77--9$EM[H_O'/FX.R,?
MW@<9'6OHS4/"FA7\5OK21);7-K%YD<B@!1QG+K_%CWZ5P_@FWT;XF:J_Q)U.
MPB,EOFUM$==QC1#R6R,$DG(]*]CO[&#4;"XTZ?(BN8VC;:<':PP<'M55J^JC
MVW_R*J3:LNIXK\-+"\O/$>J^-IT^T2ZI&BM,R>6%\K("19['J3TS72QQZK\1
M-,+W3+IFGR*ZA(V$DX<$KDMT4CVKD]9U^/PQK]G\.I]6%EI?V;SGN9"/.V A
M1 N.[>O7'2LW1->\$^'O&&M7NAZBXTBVL5FOK<!O+@D8X4D-R&8']:<HN[DM
M^GH4U?5&;KGA[QOJ=M/X,\$ZL;C1+<%+N24!II3D^;%N/7/8_A74^)+SP?IG
M@F:_TVU!U/3+=91% O\ I:^3C*L!R..QZUU6CI)X:BN/$*68%IK#QRF*-R61
MY,*N W'S<$^]:WAO0A'XAU[Q-=Z<MI/J;QHI)!=XHT !;TYSQ3=;J]E^/>XN
M9GBFFZROQ!^*?AF>U;RK72;+[5\_RNQF4$+CU&>:^JWDCA1I)6"(N2S$X  [
MDU\D?%;PI!_PFMG<^#9YK#65 =/*7%NS-D;&<<+TZ>]<WJVE_'KQKI5Q!)<V
M=W:.OE^7'<JF]@=K!L=.E:U,,I\KO96.J5.-2,6G8^W?AOXXT/6_&)T?1IUN
M]L,C/(A!0;2!@'O7T;7P!^S!\,=<\+>.KC4]9O(5:WL_*-I&0Q1I"&))';BO
MO^N>O",9<L7<\G'4XQG:+N>1_'K3)-9^#?B_2X8/M3W.G3*(L9W\=,5\T?!?
MPYH&B^!M,U#1E1YM2@2>:5<$EF'W<]@O3'M7U]\1FB3P-K1GG-M&;9PTJG!0
M'@D&OS[LM17P5JEAJ/@^T,?@C2C]CN979BTLUU(@WJA^\H) 5AU)-5&[IN*-
ML)K!JY]/22Q1*S2R!%4;B6.  .Y]JX"X^*WP^MVEC36H+F2 ;I%A;S"B@X+'
M;V'<UX=\:+?5-8\1VMEX?U,6>NWDJ:7#;3;A%+!/\SR+T5F1<L1["N=^+'PF
MT[X?_"74$\+N1>(S/(\48%Q<PR+LF1F'088MZ# %.CA8.RE+5G7"E&Z39]#_
M ! USQC9SZ#9^ $M;F]U!Y)&BNGV1R6\2!F(8<Y&X$5\W?$?QI\18OB)<:.\
MT$<_AE+?5[: )OCG)C960$\CJ>?6K/@WXGW-P-(T:+3KS4M4\)9A@5HS'/=1
MO&!("S?+M6/H0?F*BM;Q!H?B'XU:DNMZ9H5UX3ACM+N"6\G"BXN5QMB4(.1R
M#MSTKIHT_9RM)+KJ:T(I2M+8]Q^'/CR\\;V<&H?V7-;V-U;"Y2XD(QYA<H\.
M.H*D'ZC!KU->@.:^4?"_QC?2O NCZ'I6DDZSI]DGFP7A-HC^2"KK$6&7E)7@
M#J3FO>_A]XQB\?>$K#Q3%92V O <P3##H5.#7#B*+BW)*R.:M3:=TCS/3O!7
MQDL+G5H$\06MQ9WDN83<JTC(N<@@=B!VZ$U8C^$GAW3_ !!)XY^(VJQ:C,J6
M\<#3@0Q6YB+G:A)SABQR#UKWE3Z5XU\9?^%::Q8Z9X1^(UP8A?3?:;1%W;I)
M;?G V]3ST[U5.M*4K;+R*IU6Y)'SO\7/'FE:AKVIP:3K,D^G"YLFB5@!';W=
MK\[M QZ@IA2HXR<U:\)ZAX-\(_#B_B\563+XCDM_*BNY%#22I(7>U53DD1PJ
M0,G&<513X;:K=VE[I>H>'+?2+"V@%W+J]PS22&W21IDD"<@.N!E<?6M[]G73
MDU33/&/AS5M(.L3)J<J3W]T=T-Q&5'E;">F$(X' S7J2<(TU;9'9*,5\+T1\
M\:7XJ\07'B6V6WOO)O3#*K,(OW;EX@LPSTV,-K#/?Z5]A?"WQP_AJ[LO#-[>
MF\T&Y1(K>20J6LI@N3&[@_,CD_)GITZ5\D^)]%OM!\>>)/#M]9Q0B..W\B"*
M3:1"K9+#T0+^)Q6YX3O]$@\!7'AK4WD7PXDD]PKHN!* N83-(/G"HZ]1VR.E
M=6*H1J1T-JU-2C<_3\'//8_RKYL_:"^'_A'4]"NO%U]9--J9$-N40L!= ."B
M2;<].<$],\\5G_##QIXTTZ6V'B6>'4/"MZEO':W@)\R">4*HC+'[\9;(W=1D
M9KZ<<J 0ZAU )VD9Y'M7@Q<J-1.__!/,<7"6A^5%]I<6B:KX8DU[3(X-%GU"
MU6Z,CC88Y"-V3_#Y2*%8=\8Z5H?$GQ1X U#Q5::_\+6CL4N&,;1&,)!( XC:
M13V[[?\ :K[$^(OP17Q_=Z7<V=Y'8Z>P=]2@EBS]H)7"-M'"LN3GUJS\-/V=
M?A_X&TJV6[M8=;OXF9A=2(-NTL60)'RHP,<]SS7K/,J:BIMN_;_,[%BHKWNI
M\4ZA)XTTNRU+7X5MY[&XF2S)G4EXI&10RA?X@<G##C-=O\#O@GK/B'76M]>G
M0Z-H=RT\15=Q+/D;-YZ\'\,5V7[0-SX4T7Q,VG^%;2*\U'[/NU6V0DB*W#&0
M,"#B.0GH?H*XWX:_%34Y3=>#+O6WTUC;I(J6R@PAV4AQOZ[F)4CG@C%=$JE2
M5+FAI<Z%4E./-'<]#^*7PJ3P]X5UO6-.2.:U@N)=1FLHL(UQ#$V6263.<%3D
M8')X[UWW[./BFW@^'6LZW-I8T?0VNY;NU1I-SF.0#*9/4@C []J^7?"7@KQA
M:R2:O9SRZ]:_;95B-S-YBR0[ QB^8X=BR'CT%?8WA?P5IOC;P[X-\5V3I:P[
MH+F_LH!BUFDCW'E.BLCX^M<F,LH*,W?7<59-4N6;O<Y[P1\<="\*-;>!O&,U
MR+N2ZN/LEU.NQ7M78R0F0M@J0&\OGNOO7QK\=+W0=3^)&M?\(<Z&!KA97D+F
M6![BX4"21".,DG!YX P.M?37[9&@V>L:+97BZ9*+W30]P-0"@0(B88QNWJ2/
ME![\5\5:5-8II!U;PM%/?VEM#&\ELZX\O<VYG0CJB[AG/-=>748)>UCI<SPM
M*+?,]!GA+1KWXC>+-+T70+P27=W<1DKY7[NV",&&Z,]5&!DGJ,U^P]OX:DT3
MP[+IWA$0:??.BE6,>8?-  )*#^'V'2OGW]F;X.:7X4T@?$74K!;;7]?BWA,[
ME@MF.Y%7T9@<L?PKZ&\8^-?#O@'0Y?$?B>Z%K91$+G&69V.%11W)/2O+S'%>
MUJ*,.AS8N=Y<L3S+Q+\1_&/A*?7-).@3:IJ!YT=H%W1S9CW,9/[JQOUSU%>(
M? _XOZ5IZ>*_$?CZ,P>*M6O;<3PQ+F68B,*BI&,[57IC\:^C]#^+_@S57O&O
MGDT;4-/M?M-U#=H8Y(8">#GH<\$;<]17Q?=^-;+P5XLO=;^&.@6U^CREI[V[
MQ)-,5R=ZD_<W9QC&16F&HJ<90<-=/Z_X8NA&]URGNFBZIH7B[QG#\7O&&H)H
M=IH<QMK.PD.V4R3J0DDW?>PSM7'0"NL_:*TR?Q7\/XQX7U2"'5]/E74K9?-"
MF9(E8.%P<G*L>.YXKR7P[XN\._$CXLZ7J_BG3K/['!:PRVK(VV$7@W-O?/#R
M(<H >GXUM?$NP^%GASP"WBKP?:)JO]IWUM;&5)'E:%26?]WSE,=0.*:@U6C>
M]^W04HVE$\IU?S?#UAH7B6ZT>-XO$,%O=7FF2L&1[E!Y>]2HW#"A69?4UN^
M_%]Q'J=]J/@K7(]&AMP9AIMZ2UK> (68Q'^#&#T[UYC:?$G6!X;@TS5-!AUN
M32Y7B%X)=N]6^92K#D' &X#H<5U6A:TGBCPA/X,\,>&8)-3U@/%93Q(%,",W
MS#<> 5/4]Z]"I2]VTU_7]?,]&5[-/5'<W/Q<\,^+]&U;5?'>AW,U]=[K+3Q$
M#Y(RH95B;.0Y)W,Q'3BO!/@?XXTSX:>*!K?C:UDU9Y\VT<J ,(#NW;PN=H(R
M=S=<8JCJ7A3Q?X!\36?AWQG(<"-QYA;,<WEQLJ2 <#.>,BO9/@U^SG8>+[/3
MO&-W?+)I[/+&\8SO*HNT!<?+\K?RIU(TH4FI/W7_ %H=->A3I4^>+]V2_I'M
M_P"T1\2H-.\/:)HVAR"\;7Y%F?R7^86BC=O..=K'O[5\9^*&O8+QK;3[&;3E
MALA.)L!A,5P20W09(YSVK[:\)?LS>%M#U#4+C7+A]9B,(M=/,Q/F6D!W94'\
M>.W%?$WQ"\*>/O"FJW/A+Q-JGR.LJ0 Q^8DEL@#A^.<$+C'8YK/+94TN2#V_
M$\["N'P0W)[+6YKW2W%Q:Z?$\?VA0+J/>[&15S(IZ*$5N,]Z]Z^#=UJW@&^T
MBPO[&:^M-4CM;3S;FYR"C3%PRQDYZMP?3BO(_%'A/3/#NB:=\1#:3D3P1I&\
MRG[(T>0K*P]=G(-226$4'BKPEKUCJ]S//J%]IBQ).2RK;F4'R0!]TKGKW%=-
M91J1=MCKKI2OU[G[;T445\H?$A1110 4444 %%%% 'Y]?M)VGC7P1^T#X>^-
M^E_#C4?B99V/A34=(T>#3;:*\DTKQ!+<QS0W,D<C+Y44\:^6]PF6C"D$8;GR
MWP'\&=?\(:C^SE\$]-\*7G_"4> ;P^+?%OBC[+BRB>]M+M;RT%^1BXFNKF<(
M40L?+C#, H!7]+O&MQXRM?"VHW/P^L[+4/$,48:SM]0F>WM97##*22QI(R97
M(#!&PV,C&:^0(_V\OASX*\5P?#G]I#2KCX2>*YEW)'>SPZCILHZ[H[ZR9PJ8
M.=UQ'#@=<4 ?=%9,N@Z%/K=OXEGTZVDU>S@EM8+UH4-S%;SLCRQ)*1O5)&C1
MG4$!BJD@D#%G3=2T[6=/MM7T>ZBOK&]C2:"X@=98I8I!N1T=2596!!!!((Y%
M7: "O"_V9O\ D@W@O_KQ'_H;5[I7A?[,W_)!O!?_ %XC_P!#:@#W2BBB@ HH
MHH **** "OQW_P""K/[(?C;XYZ9X<^+7@C4[99/",#65W87;M&KQ7<Z!)8&"
MLN\.V'#8RN"#E<']B*\+_:5_Y(IXB^ME_P"ED- 'G_[$O[/&M_LP?L^Z-\+/
M$NJ1ZMJ\4]S>W<EN6-M'-=/N,4!<*Q1 !R5&YMS8&<#ZTHHH **** "BO/?B
MG\4_ GP6\"ZG\2/B3JB:/H&DJK3SLK.2SL$1$1 6=W8A55022?3->8?L[?M8
M?!/]J/3=3O\ X2:O)=S:*Z+>VEU"UM=0"7/EN4;@H^TX921D$'!XH ^D:***
M "N$\:?$GPA\/C9CQ5<7$'V[?Y7D65U>9\O;NS]FBEV_>&-V,]LX-=W65KUI
MJ&H:'J-AI-U]AOKFVFCM[C&[R970JDF.^UB#CVH \&M/VM?@#J&K7>@V'B26
MYU.P :XM8M,U%YX0W ,D:VQ90>V0*]H\)^+]!\;Z2-<\.2RS69=HPTUM/:MN
M3K^[N$C?'/7;@]C7\UG[%_[''[5G@G]MK2[SQ)IT^B'P5>+J&NZD]TDD=Q9W
M7G* CARTXO=CJ.">K.%(-?T\T %%%% !1110!__0_?RBBB@#\\/^"BEM'K_A
M#X7> =>U.31_"'B_QOI>FZY<QRB'_1'65@CN?E"DKORWRJR*Q'%?'FB?L+_L
M\:S^TU\6O@!J5M<Z7;P:'I>L>&;I+R4SVD;1"*[<B1BDZ_:&5B'!P!@%1S7U
ME^T_^U;^R'X@T6T^$/CRZL_&%AK6N0:3K%JL\MK+HZH[>9?.P0.IMI$ 8(5;
MG&<9!\1^+UC_ ,$T_BCX:\+:=JOQ/.ES^"-(BT:SO-+NV2]FTZW3:MO,7MY5
MER-W\ ;+-V.*_<.&,1F&%P-/#\E:DI*6L(-J[E&2G9-.^G(TUK%Z-JZ.6HHM
MWT/K+_@G=JVF:I^R9X/@TRQ@L1I;WUC+]F+F&>6WNI%:X4N229_]8QZ;F;
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M<9 V,-Y)'!8CK5'3CX[O]'N/&WB-X;013(;=;:XD#WD$+D*'50JGS024&3U
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M&!R&)/ X!'6L/9J=Y2=G_6QS63>IZA\3[O2M:DT_P<;G=<K-'=W"1X9H8$.
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MG$T,\H+0[</F ;E*L5P0002,=Z\6^$UW\3EL[?Q+K%L]WK-U962W:7;LLUQ
M8MR3>4.$*R%U/ ]^HKZF^,%[]GL8H+:[TR&\E4F./5<"!PK*6Y^]G'3'Y5X9
M\8->O8]*$-O+%9&XM6>RUB"X$;)<1\RPAFCD0*R\\D!AD<$ CMH2]U02W/4P
M<FHI6W/2?#_BZ5O#=EKGC&2TTAK^8QPCS=B-N8B-<R8P[ <KS[&OEKXV?#[X
MA0>,+775\5W5SHVN"_LY8X[95EMHI(O,2,/&.555?:6'7 )R0:^=O#_@BR3_
M (2GPSXI@UKQ!I>A::E[#!*&)11YS&6159@=KMPH+$J 1TK]//!=FUAX,T*Q
MED:X*6%N"[R&;?F,<[V&6'/!/:M:D%AI*47?Y'8VJ,N9'Y3?LUZ[X:T3XI6F
M@>*3+,-2>98+Q6V*PNO]678'(+-\I*XQD FOV&.=WO7Y0?&SPO9?!'XG77B/
MPYI$5Y9O)!=)YIRD .YMNP[0W[UE((Z*,#G-?</P5^-UO\68Y5N+6*PNHX4=
M8Q+O>4J )FV_PH&(VY))YK7-J;FHUX[6.C'TI5(JK%:'T "1TXKGM8\*Z%K$
M%T9M/@:YN(W0R%0&;<,89@,X]:V84F1I#++Y@9LJ-H78N/N^_.3DU9S7A1J.
M+]T\?F<7='YC_'?]FWQ/INK:9=^"-.:[L;E9!/\ 8U.89D^='(Z[2!@YX/3O
M7@^E:M<:S)IAT"1)=>\.QQRVX27BXV2;F@(8;AD!E5<8R0,<"OVUC8J5/6OC
M;5OV*_ -Y#J]_IFL7]KKVH7$MS#=YC(@\Q]_E+&% VYQ\V<_RKZ'"9NG'EJ_
MUZGL4<RC./+6$TO2=?\ #?ART\5?"62";PC>-#=&&TB:2^BG*!)VNI96+R$O
ME3\J[-OS# S7 WGQ0\4^/+O6/A]X!G@\#>#]$,J&[B1I&N%VLQ5W4'R][A@V
MWYCSDU\XZSXJ\=>#KM=!\6:3+X>UJU9;674?/:&:=)6P>(F ESU7=NSD<XZ>
MV>#?!-SXH\&7NL^$]<?4)+-(Q=V>IW(@C;;^\^:-D&8@O*JS<_,K5TK#J'O5
M/O\ U]354%35YZ]CSO1(O!LFH>$[>RFFU;4I[Y;9'F$DEU)%*%:!=H!,8W+D
M,^-BY!]^_O/!_P 2O'GB;Q5-X7>37YO#1FLD74!$DZR22@L\$;XCCD!7/RXW
M*JXY/.-\*=8U+P'JMI>^,O#^[PG'>W<W]KVH+R7,\QWM+@,6V1;<%8P0%4XZ
M<^T>(/BS9>(?B)J?B'X0R0W]QI=G$EU;F?R8=6#EF0_=^22!E&&;&Y25SBJJ
MU)*?N*_GTW*JUG)^ZKZ'LWPV\<>%_#GPFMXO&%Q'I,6C2MI=S%=A8MC[MH79
MDAE8-D$9!7GUKHO'FK_#OX:?#BZMM006.B7EK-!"+:$RK^\B.-JKG.1C'KVK
MS#Q%HWP;^*'@#3O">NFSU;5_L/\ :CRQJLDEM+$"\LLS8RB/*K1G=@,?EZXK
M4\$?$;P?\8%T[08I&MHGL+B!K.)$-O%- 43>&925=/\ EECY>O4@@>,J>O.D
M[7U_0\OENW)K3J>,_!_X;W'B'P]>>'=<T:TT&ZO=.@DT:\DBDA>Y>"4L':W+
MB0"(% 5R"<YS@U]0^)=/GL;CPC!9)#?^)S>V_P!IFC!51$D;)>7!0,=GRN=I
M/.2!S6;\6M)TC6_A_+J&IS*^I:#*L4=\2?M $<B"X5&APR-+&IR%QVR*\AU.
MPN_@-JVF>-8X8=035=:2R1=.B*O=Z7>Q!F:1 69Y;=T#[R3D$\\\:N;JZK?7
M3Y=QRFYN[/1O&'A?3M*\-Z=X;\8^,&GF2_>]>-X1<37-I(Q7R@CDLH X$F<#
MFO&OAC^SZ/%GA*"[L[^?2="U%+J2URS-<K)YK19=]RGRW0?*HSUZ]*\[^+NN
M#XI^,O$+WUG';:3=QII=K<";R[@P6[,S2YWJP4R$JZ;>&(!SR:ZVX^)NI:9^
MSY+X#TK5PWB70+>VFLKJTDRUS;PR"1F1PNP-&H*OGV/.:Z_9U84XJ+U;U\KF
MOL9J%^K/8/A3X9\$>#+?5/!OC:X8:EX?M98KX3\6MQ;.@;SH=V6*A/?(.>_-
M:OPCTKX5^-_A;>_#WPY%',NFO(5DE@=)&\UW:VO!O^9MP .[/)!!]*YG7OAS
MX)U'PI#\;-1:[UR[O(+6YN8=4D\X36DRJAMAY:*4X8$;5ZCD')K?\,>)?"VM
M^/=1\26NH1Z#IJZ(FG0*&,,BS1.?,2560;FA.-A5B-K9'6N6I[Z<HMW_  N8
M3][76_\ D-^,GA:S\':+-J-K;;=%U+2)=(U2*RM,R7#,04;]T#Y9.7VOM(!Q
MGBN4-IXRNO#VH_ /0/%EI??:])>;2FU"WDEOYM/>-'5C("(BT;-Y:D^WI79R
M?&?53\-;*[TC6(7U6QU:UTG4]1N;+$&QWVRW*0"7_5D%<'?QG)K*\%^&H_V<
M_%E_?>+=2GUCP]K2Q1Q:W>(BFQF=F?[*NS)$$A("#LV!WS3@Y*%I+WELN]NO
M];@FTO>W.;\>?#Z\LO@WI7B=-:U'S-#:PO(=,9H7GB-M,K75O#,@#,2%8;23
MC;7I?PZ^(5WK7CKQSJFD^'KZ/2[JTM]3MGFC2 SM%"(RH1CYNYRI&2NWY?7B
MOG77M6T_XPW>J7'P_P!0UAKOPY?7^K6QMHW O+0%#_H23+L64RLR,5&<*<@[
ML5[7HEL_C/Q?<-_8]KX*\?:7;6MQ9++?R322V$H$DLDMK;,BKF0E2&7DY)'0
MUI5C[C4M_P M>WZBGJM7JSE=8^"7PGU+X0WOCA[*/2I-13[2RI=/);1K=7"R
M/'ABJG=GD$9!Z8J7XE>)?@%X6/A[4=(M+34;?P#+,MU:VHW/913($67:/O9D
M95SSG<37;1^!?%/A76(M>\8WL-]X"\.RW%W;Z<RF1[<3 AF?[WG+"2S)N)(4
M],BOF/Q1JOPJT^XN5TK3K8:]XLFNK:\T^:%C!&)6V0([H=J^6I1\8.<Y!Z"M
M<.G4?O2;7EMK_P  VHPYGOZ?Y#_#OAQ]=^,_AGXO^$TMHO"GBTK9W:QIYQM[
MH@^7%*'0?ZW;D[>!G&1WP/CMX+\/^"/B[HNL^%+Y=*T36(9)=-73]D2V]_&P
M$A=<#<6< C\NU=+\(O'%SJ,6@_LMWEC/9WMAJ0DGU*+Y9(C;O]J!B&/D<?*
M2,!36S^TUX&\9Z3X^\*>.-9NO^$DB$TECIUO;VNUX53]YNF"YWR/R2ZA?3&*
MZH5)1K\LWT?S70Z8<T*\8O;7[CSWQMI_Q0UG7X/B7\0-=L_ ^H1Z:(EAG1IY
M)+;&T2R"%7\LON(P^,9XKP6'1;2PDN_[&B!DG@G2XN(7$8F+<D/O&<D X !P
M2<U^@NOVGQ*\)^-?#NH_#^V/C7P_XV=WOK.YB BC<?.6EN&#"-(T^X",EEQZ
M8\C^)/P=\":-XF3POX@\=RZ#KK1F[C<6N^TN'NWD 4*"7C*KA<AOFZCK6^%Q
M<=(O;R\OQT8Z5>-^7\%^)K_!#XR)]GL+:/PS8/XGOF)#P^9:QQV4"B1WN;A]
MY=SAI $4@;2IP2,]1JOA7XN>*OB?::M\,4TSPE_:UDNHWNH6\C2BXMW<"%0"
MBDER"3E1C/(XKYV\">$_APWC/3IM0\;ZEI3:/<HUI.MJ"S&U8AMSJ'*(^&!5
M@3COZ_1GPJ^)L<'C;7]$^'-Z?B'-;:=9VD%U).8VWK)+)EP5)\E#+@L,G@#D
MUS8BER2E*FOOO^NAG7IRA-N*^\[OXR^&?B3I?@32?$UQXAN+V+0Y[>:^TU(8
MSYT6"KJ2JEI6WE<<C YKX[T[QU\0];U_3]#T.VGOM3U>^M;_ $PS1*MO;W4+
M%VCD?KN53B3KG':OI&]O_C%J^O2VMK?Z=J1\,W-S>7]GI^ZVB$R1%I89)IF;
M<=QQG 'MWKOI_ACHEI\,M%\?_#V?[7KGARU-_:SI-NBNL;Y958+^[=CN8*Q4
MG(&<CBL:=54XJ$[-O^E<PIU/9Q]_K^IRGCVY\9?#H>(_BQKEQ9_\) 8[='@T
MB\9]LZP&&!);:4#>/G9@"0-P!Z5N?"O7_#/BGQ?X6N?"6J:SK.KQ /K EE,=
MO;#RG,GG* JR,9I ,9;!Z=*\K\0?"K5_%?A33?%&K1V^DZGXWN[">X0(U]<:
MLXC)"7CCRH(XQ'R%5<\'EFP#]!_LU:IX8U&[UZ/0!9P+IDL5A%#:#8HCC#.[
M!,*PW2,V21U'4XK+$-1I.2U:T_3_ (8YZD4Z;[H^O*^=?VDM?N?#7@EM7LHO
M/N(%<QID#<V!QDU]%5\T_M-Z)<:[X.BL[49D!D8<^BUXU-+F5SR\(DZD;GX]
M^+?$.JZ];3W%_&S_ &EP-AY"ENI8^@Z5Z%\,;Y=,\46=G%;M.M_']C@"_<0*
MN]I/IQBO(WAO8-1GTG46,$TJD(A.0R \GGH?2O:O /AQ[7[/=VLCP)8F99)M
MX9O+DC.5P>4/&5:OI,3RJG8^UQ37LW832-0TK4?%NH)KVAR:HLMO>[-ZD_9U
MM,JFP#H<\8Z]Z[[56N[OPKX6\46FDPZO86UFUKJ<>.40*1QWX(KG_ 5_I/EZ
MGK.O:C]AL+-9[E;-W!N9'5B-Z2#G! Y ZYKM_A+XMTWQ7_:/PYN=/6UTV\MC
M-;RJ[9GBF^_AL ,RGKCI7#6DT^:VVYXE2:WL<WJOC;4Q\/;?3M.F$"VTWV.X
MEB<.VU5X!*^O2O5?@EIG@I;$Z[IK :G,HB=9#\Z#^[@^I&<BO'? .D:;\._%
M-UX4UN)DT^6ZF2&69<Q3R+RD9SU;9DY%5_BK;3^%O%,.L:!;26%A=H)3)%P+
M>9,X<#I@C/L#45*:E^ZCI?4Z8Q4X^R6C_K<^RO$7BW0?"UL;C5[I(7(^2,MA
MW)Z #W-?#-_XTMM9\;&ZU!EA6?6(9G5L84':B#=W! P:XKQ-XL7Q)<QWFMZB
M;B3R JR2$ J(B&7:PX)8G.>W-<O")O$&K0 K'';JPABW#=YDR $DXXV\C!K;
M"X%03;W'1H0HIN3]X^[;OQ'X/F\/:?\ #MIW^S^(&E2WF"GRD@#DAA)]T'C"
M^]>:#P[)X(^(UYH'@70I?$EE>::&U"X6YV2(P;Y5WC@'V')KT?XCV"VO@K2[
M.Y6WLKHFUMK) ,H9V928MHZ@[>#VS5?2?$7BKP/KEW#?>%0\%Y-$\TEEDE0R
MX!YX(4#FN&FWRWCK?I^IPQ;MH6/"'PZT[75A^)ZF33_$5RH<(CDPQ^5\JQNA
MX8@?*2>>M>I:)XBU+Q)IYU+06M+FWD)16WL"CI\K*X]0V:\>O]?\6V&CZOKG
MA]Y;'19KVX.\Q*TD"$C,@!Z(>2,]Z\XU+7D\":W)I?A431JEI)?;;:03-/+C
MS#)(O\&_/.>,U+P\JCU=Q*%]V;VL^+/&O@'08=;L-4_M37'U"0:K:S1G;L9L
M+M4<KC& W3')KUH?&G0].\,)X@\30M;>=M6)(E:03.ZDA4..O;FN4^'7B/PK
M<:7?>(=76=-;UIC)=17,1)R%X1 1@*1COWK UGP;\1/%6CZ+#I0MX]#U6\6X
MN(4 #VD*_-&0QSSGKBJE&G)^^K6_$;4=$RMX+TSX@>(&DU6VL;KP]?W<ZL]U
M+-E$L22P0*W4\_AFO=?AWH/BC0KG7?\ A)I5NVNKGS8+@-EI8]H ##L1C%?*
M>J> ?VAK[Q-J7AR/6OM=C%&C!A(8U\MCP!WR0,5Z]<?%*3_A$;OP1!;7,7B^
MWC-F;>)2SQG&%FS_ '3ZT\33<M(V:=OD75IW^%[GH/CGPYH=KJ5CXOU'5[C2
MU^UPB:-9,17!8>6J%?7D=/2O0]._L33[W^S-,B19+E#<.8^0>< NWJ>U?+WP
MPM_#$'@M[;XO7[75_:W[3-'J+-MBDW9C,:GG !KV?4-'7PYK\'B?PF!OUY5M
M)(68M 65&>&0#^$#!!QUS7'5A]AO5=>AS2@_A+WCNQU"[U71)+34Y]+CWR1O
M)$-R[F V;@>.M41>P>!]8M]4UK7?MEGK!6U9I&&(YH@2"N.S<@^]>9W^K_$7
M69X_#7Q"TQEBNV5XK:R8(91"0S$RCH .>/I7@.J&VNO%MQK6NW/V?0=,G5-/
MLD9I=CN_SEE&>:ZZ&$;CRR>GD=-.BW&USZ4T+Q'/J_Q:U#5_#%O<6FFQQ!-3
MCF01QW#H2@GC_O%0!DCM7TG'+',@EA8.C<J0<@@^E>3:3X:O=5\"V8\07/V&
M:W!FAEA^5HX,9VR$_>ROWJP? 4NN0P)X6T..6STL^?-;:C=$2M.N[C8AZ 9S
MSVZ5RU8J6L>FARS@K:=#W.=;>1#;W.UEE!!1\88'M@]:\<\9:GX>O=7AT#09
M[<:U&A,AC<1.D1!VJTB],[3A:Y#Q;\.+O1]3N?%^NZU/K%K=+% T<KM$83NS
MNC*$  GC\<5)XN/PYL=0T_Q/<)]AAMT5+H;=OFHG^KW,/O8)/-71I*ZL[E4Z
M>JL7M)\/3:9HK^)O^$@,.O7=LD%R1@IAFP-D9Z/SPW>OGSQ3=:]X;\27_A[5
MO$,E]!:$I:Q.<XW+N'F9Y9CG''X5[WH;:_KWA?7;OPQ-%=7LTLLD4=T@)AB<
M;H%C8?W1@@'OQ6%\0/$]QH6@Z-XBN=$2Y\2V\7G7 F@4D*!@!NP9CT[UUT9R
MYVGJS>E/EG=JY[-\'M:N]?\ AOHFIWEI)93O"%>*4$,I4X_BYP<<>U7O'VJ:
M%9Z='9Z_9I>+<L1$)<+$)5Y7<Y("GT]:G\$ZUXBUK2K6]U[2SICW%M%+Y7'R
M.WWE./3K^-6O''@K1?B#X:N/#&NJQM;C#;D.'1EZ,I]17F1:52\M-3CF_>N>
M1_!^V^)3:=>->ZM:2Z<EVWDJT?[Q8@?F3(XQZ&OH=)H) QCD5@O7# XQUZ5X
M5:?#"'PSH^HZ;K6M75SX;6-1%"A\N2/H&8NF":\.7P[>Z/?:WKG@#4+R32[2
M\%N=I:154JN]LMD-M)(/Y5U2I1JMR3M\C?V<9O<^FOB!XM\ ^$8K+6?$\$-S
M/-*J0'RUDDR>C X. .QKS2TT*RO?$=_\0KN>&31/%;6OFV: ,_[@;8]X_BR<
M%A["NUTKX6V>KZ8/^$TN/[568*R@#RQTXR%XX[8KQGQ5;:;\ ?&>D:E!!)?:
M9JDGE6Z',DL;R$*R+VQG!!/2KHQBTX0=W^84U&_+?4^K?$YLXO#5]/=I^XM8
M3, HY'E?,N/H0*H^"_%VB^/?#D&MZ1+YL$RE'4\,K#AE8=0:X7Q'<?$>;3=2
MFN8+6+2;J$(JHQ,T/F8!=STP!UK%TC0?#OP\DTV#P=>>=?7DB_:5WAH9(W.7
MD8_=7'\-<ZHQY-]?ZN2J:Y6GN:'Q$^%_B'4=)>+X:ZM_8MP[;Y(I"7CE8<YR
M<D&L+3=!\%_#SP9-JGCRY%EJ;(1,^\I^\[>6@.#SS_.OH/4=1M-+TVXU6\?;
M;VL;2NPY^51DX'<^E>+?$S1]#^)_A5!)$MK>6H%U$+M-K>5C+8SQR*VP]9RM
M&>W<4*C:Y'L=+^RQX*UNQU*?QOK^M'4+O68BXB7&Q(N/+!_VMN,U]S5\Z?!+
MP_HGANWMK+0(]EL\&_(8L&)QSD^M?1=8U:KG)MG#C/C9Y=\;+Z\TSX3>*K_3
MF*W4-A*T1 !(?''!XZU\1^++KQWK$7@_PO9:.-/EG>.Z:1V62V$ML X615P=
MH;YL#VK[[^(6H:9I7@G6=2UDJMC;6SO,6&X!!UR.]? >LZ_I_P 6]8\+MX#U
MM[5--,^H"X5?W1F"A((I,]=Y8Y3KM%:T/0ZL#\+=C8UV'Q)X_ACT*ZL+?3/$
M?A^>"\6\$@=8)<,4DB&-Q63#*0>Q.:\F^+'B'XN-;6>G:YI8TO3]5Q;7<UN3
M<(1G&!@?NE?JQ->PC5?$.GZ[9^,/$VE?V:A TB[*/O5UD<&.< =%$GRC/0-4
M_P 4/$GB6*VOO#7AJT1VO+0QK.[A<2SA@H3L2 #SZUI2E[R5DT==*][(]+\/
M7&B:AIUMJ&DB&1400B2, D&,;2N[VQBMJ:YAM8);JYD$44*,[LQP%51DD^P
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MM+Y7F7:M^[1,$,Q4 G@]2*YWQ3H7AOQ'X?T_POJ;DZI+>([AR6E6?/[QV/\
M#Q]T\ C %=WXSM;"X\.GPT"#<WH2"W4,!*IR/WB]&&P#<2/2HER\RE'2_P"!
M#LU=;GK/P:\.)I'BSQ)J$3SF*ZBM%1))FDC C#YVJQ.TDGGUKZ.KQ'X/Z1!I
MG]H,CO-+((@SRL78A00!D\X%>W5SN5SSJR]X^=OC5/\ "BRU?1+_ .(L%L]Q
M")3:RW4;21QY*Y.<%03P.17R]X@O?"7Q$\6V'AGX?0Z=>^'K,FYU.Q"[(=3,
M2;XHH% 6-9"&)5_XQD=LCN_VP?AYXJ\9ZGH5[I%V\.GVMK>1RQ[R8FEEV"/?
M"/O]\$D 'WQ7S=X;M;"U^$MG=_$7PU$\FF3O9VE[;R,L<,D$A1"_E,A (R<D
M_*<^N*]G"T5R*:E=_D?0X+#)T8RB]3UR^^(OP]^%WQ#\.:C>2ZD-(\3P/:[+
MJ1Y(M*F)RD3V^#)'NPRLIR%QD< XZ9_"'Q,\,V>K7/PF\10ZSX9U!/M-I \B
MR7%M.LH+):RX:)H2@*^6<#LI4\U\K^ _'$3?$NV\'?$.T@U6PUB\(N&D10UM
M<AV>"1+R,JSCY00K= >N:^F_C7J^D^ =(C\2^%=._M'2[Z_BC\06]E,PB%NP
M&962(XBD'!#KM+$ -G-.O2<9J'?OM_PXZM*2ERG*^+[K1OCGX.UO3=?TR*'Q
M=HEP42U4M#=Q6+D;I'@<[VC53EL!@< C!KYN^"FI0_ +XYQZ7XDOO/T[5K=M
MEX6 MFMIL8E!QD,"J[Q^/2OK#XK^,_AGK]YIMS8Z5>:MXFLK6>6UNK-&1[%6
MCQMN75@Y!SD1KN)QQC.:\-UKX9VWCWX61/XBC0WUM!;W.F:E;*RRB*4J&WQM
MU!<$$,.FT\5MAYKV;A)6B^G;T.C#5%9PELS](--U.PU>RAU32KB.\L;E=\4T
M3!XW7U5AP16AG%?FS^SG\?M>\,^)+/X4^/IQ<:7<LD&FW07)C>0!HU('*QX(
M!##*DCM7Z3%=I([UX.+PDJ4^5[=#S<3A_9RMT'@X7 &:=TIF3T[4$XKD.9(\
M<^,WP0\+?&C1%L-9_P!&OH 3!=*H8@G'RN.-RY [@C'!K\\O&GPY\?? 2]<:
MS-)J>FWG[H:E&)&4PLI#(X&2P X*MSCHU?KD".U<SXN\):?XVT=] UB1_L,I
MS+&F!Y@'0$]1@\\8.17JX',90]R6L3TL)C94WRRUB?F=I?B3P=J:Z%XIO[B>
MYN_#\ L[2+[7*]HZHK!#L.3N 9EP<' PV:;93>"/['N&\.V1T_4;?:LD+W2^
M=J*29.]G?AADDCD\C'7BL?XZ? ^_^%7B#[?X;MW;3;Y46.X;/EF7.6,@P5#C
M'!/7MS6/H=MIOC&UGTZ+8TD$3;I,8>!-PPP7/3)R1Z<U]'&,7!3B[H^@IT*;
MCST]$?1GPC^%=AX@;28K_6GO-)U^&[:]T]8S"JQ0&-Q$YW$LS-)N+9VE3T!Z
M<;\9[B^^#5MKVG>!;A-/MM)N!+-&C0I=?9KMDD@*JZEY%!+QE\@ 9S\W-<5X
M;\4_$+PAK;^(K:XGMM.N]3LA 9T\XI L)W)@[?+7:!O]01QG!K]"_#7AKPMX
M[TF3Q%XANK#Q?_:<\%Y%+%$HBACC0>3$N&9BJ$L?F.3DY':N#$572J<\]4>'
M5DX2YI.Z/D2ZOM>U_P "0^(;'Q%:JVI7]K?ZW8VS-$;3[1 HL-J$L8W:0;FP
M</\ Q9QSWG@ZVTSXDZG/\)?$/B'4FU?09;?5[&Y("RHB1I]HMW<8SF0EA@#*
M'C.*^A?BGH/A^P\*ZIXF2"QT^ZA:*ZDEEMD<73VZ-'%$Z_*78AML8SD$C%?(
MM[JNL^!/ ?BWX[:S#)H_B2ZNVTW1%6VDC1HI (H?W1&X;4S\S'&><D8K&E4]
MI#W='?3U_K\"85(N#MHSKO!WP6T7Q_<^(?$GQ)M;BX>RUFX,-NLC A@ZON5E
M DV-GE=W%8@\!^*-,\9:_9Z+H9MK&*XBO;9%N@))K1)F:=(R5=/WQ1!Y1"\$
M@MWJ_P""/VD?B-=Z7!I>L>%+"UU#5([)[2X>Y.'^VR>2EQ<(ORD-M+?(V2>V
M,D=)XACU?2?&>B6LGQ GOK_Q9<P6$SV-O;_9[6V7+?NVP=KM(VT/SD$\9 I5
M'6YI<^WW_D3-U&]3O?%NJ^+=9M_!@N]%AL/!&IRPGQ!!>G;<6ZR$+# RQY4*
M)"N\@XX Z5ZOKGPV\(:QXMT34+QO(O-(B/V:! H#1AP7!W E@3@'T'<9KB/&
M/A;P[X,\.3:)<:HT7AS7)1!J$%[.TLBI,P#S6SR-N4@XW#D#.Y=I'/S-+:Z]
M>>-8-<^$V3-;7HL$T\W$MPT%W!(JW/FROO("QGS&+':R,,9)&.6A3<E>+M:_
M]/S,:,&]4[;GK4VM>"(M'\7W_BC1K?4M$U34;^TA%E8RVH4VR;EAG5]OF.Y4
M[9%^5F&!SUXKQ/X[^*6D_"W0]/\ &T%BB>3:7EE,Y(GU![1UE6V:+)"3*NPL
M"?G&=I!R*^A?%%S?^/[_ $SX>:SX;OM.TV[N?M%U<RR11I)%8_.8T*.7R\FS
MH/N9R17C/QJ\'^,8+_2M/U?6GUCP]]LBETRU*(C)-%SY4S8+2X RI&"<8Z]>
MJA*+DE+??77[NQ5)KF29S.G?&@V.I>&H-/\  H\-7_ARY$FIP6FWR-FI@&:.
M)% +9!\UB>C(!WKZWUWQ_P#"+PSK5GKNL:EIUKJ>IVX2.\VJTK6V[ W2J"5C
MW<#<0,Y]*^*OA5=>)/BOXV_M#6] >.TF,T1GDDEC@A-N6B(\D%0SMGC/W0,G
M).:^G/$?[/\ X:N+%6T* SWR+Y6V>3]VT9)) ^4X()RO89.!DYJ,92I1FHRT
M] Q-*$6DST'6_&?@#7](UC3H-9M+N2VM9C(BOO*;HCRRCDC#9[U^9>HP>']1
MO?#EK\0I6EDTZ2QM/M=C*7#6:/OC$I3!279TVY.Q?F)P,6[C1+_Q-<7%YXFN
MY+>WL[MK>6V:7R=1:2U8QMYF3AXU9"HZ\<XKV-=:\+>#_#,GB7QA>JVD+"5:
M-EBDM[=N2%#(-XD=6VX]/NXZUVT*"H)QBV[G;1HQIQNF=#XT\$_##1_'JZ!X
M3CN=-?Q9HU[YFI:29+R[AD4Q-#*A4R2(S $$\;NU17GQ)\3:AXE\.6/C?PYJ
MUE;Z-X?OREU<1-;W&I75Q!]G8Q0HQ9"0"P!(<9Z"OGGX-^,IU^(]KJ/PIT9I
M[2W1KUFCE"QS6JHT;Q^2WS-*68!277CIG;7:_&G7-?\ B*-5UGQ"9M'6PN(5
MM;+:T'V>3:O[[S\%KA@,;@G X4<Y-+V'[SEEJK;WUN8>S3DE)Z6/5O WQ*F^
M%-U8^$;"TN)M'O-$^T6T,[O+)9WT3%?*N-_S*S<&0=NOK7CEC:W?Q<\0:_XE
M\5>,K;PWXVL3#;64#%38.1'GR)F<X)+8QN (&#S6-H^NQR:;JGBV]T6ZU?5=
M+CVFXG$JW-U+(57S8BQ.(R^X,&7(QQDUZ-X,\&ZU86E^?B7+9&[O_/O5\/VM
MLOF3C9A2UQ)]YU4@D/RW"C&2:VM&%Y+=_C\OS-YVC>2W[G!^!?V9/BYKUE=_
M$.YO=.@D6:\ TZ!7:</#NB;RIE^5O,8-P?EYK3^'7[/?Q!\%PZS\2;O3M8TO
M6=&Q#:6>E3C[7J#'Y<NQ!0Q%CO/RD=O8?5WPZ^)L/A*]C\'^-M4:9+J3;ITX
M0M$D8&$BD=5PLK ;BN6"]-QKT+Q]\<_ ?@. Q7%X+W4Y5?[/:P R&20 D*6'
MRKSUR>.]<E3'8ES=/EO?\CEJ8JLWR[W/@67PWKOPX\22C4M7N=%TOQ#=S'4M
M8NEGN;A+@IN+S ;8W7(\O"E@Q[  5]%?"OQ'\1KOX<1ZKX4OK"^T_1A?PW&G
MQVN^2Y0Y>*:%$D4J2#D1' (.#@]6GXU^-$EL_&_B[1])GL6L@UKI\%T7O(Y9
MN7$B$,-PPJ^G)(KPVP^(NLCQYK'CCP_IZ>%KNWNK17TW3Q]I%Y#/;IEI54>6
M#&,]" QX]"=YJ=1>\E^8YTYS]V2L>C?"3Q)\7_$-Y=?";PKXJ@OM/TP1SIK-
MSI[1S00C[T**24<,WRJ?O*N>>E=7X0^&4?PV^//AS4$\00VLNLQM#<Q0$E=2
MNDC9IT1"S&-$;Y]IZ>HJU\#/ GQ"T/QK<ZPFE#1-%N;*>XC/F;TN+FZD,BJR
M$L5VYW<$8SC%6_@;<:9XD^+FL7MYX8A\)2Z'/=>1$+^*>2ZO[X@WTCQ*[D,3
M&I4@C"G!'ISUYV<^6W+;I;K_ %V^XYZVC:CM;4^[*\>^+Z&33K.-3@LS@?D*
M]AKR/XL?\>MA_OO_ "%>#)Z'BT7[R/Q0^)L][:_$"X&MV0>6&<+"<[0JEN /
M48Z>M>J> 9].O9]7TZ\EWVUQ"(YXSPP&0VX8YP!Q[5P/[1-U<:YXZOE.Z/[!
ML2/:.<]<\=<5:^'LEYJ-]%'I<(FU"55CVAMGF;L EL]."37TTU>BKGVD[NE[
MW8?XLL]/L=$B\1QWD6JHCO:S6;$ 1B"0;0Y7YAC !(ZYKM_#FJ:MX3T)]>\,
M1KJ=MJ-];O86X^8VK7 Q.K=P%SQV-9+?#6\M/'QT_5H3/ \GE2M'P3%*GRB0
M#ABIP1W:N9C^(L_@+7DTKPZ8)WBF\F53$461@^QMZG^(]B.!637/&T=3S8KF
M1ZNMW<W-]HUC\1[)[C1Q.M[;NS%)+64\,9'[@$@C/8U:_M#3/!WCRW-[>IXE
MTF[612WF@Q0QD?>D5LJ6QA>.M.U+QYX0^(4+Z1KUC-';E'O+J-7*LRPJ6\LD
M=LJ !W[UR5AI>ESR*WA/33I]O?:7;W<T-U^],(Y*2<\'/1OQKF@NDM".36S5
MCYKU/PY=:]XDU)[1A8Z/I\MQ)$K+_HJP9#.,CG)STKZA^!OP_MF\$ZAXZU&\
M66P2TO(VTT@-%')&"2^[J,X! ]*\W\!^"M7N-?$L-L;[2[^&:-I5D+6\KRY
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MO?VQ/H\NV 2.!LD*Y*JGHJG K)OOC3\-HO"%W';WPU>:QMC']GBB):215VC
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MEZ%XHUC3UNH;>7;>BTR)H+:?<,RJO#B(%<D#.02.M>@_$KQ_8:V-$\*Z2EU
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MV-D<]RD9@B8Y&0\@V\;L9&>S_:5_Y(IXB^ME_P"ED-?RT?&GX(>(?B;^TO\
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M+-7\0GP1K%[-8:9;01W 6VA BG0':\+,?FC'3Y03D9[5[^;&RDM5T][>-K4
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M*5[3?1Z?\ QI4VW:1[)9W/Q'^(WB#1OB7X.?3XO#]BVU(GO/M"WD>62=H7B
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MO/%<51QAS1I+1^O],\VM:+DXK='U'7D'Q:(%II_^^_\ (5Z_7D'Q;_X]-/\
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M- TA)P^CW+Z>USF5H[=@$?GEMO3ZD5Y7X'\!SMK7C2\A\0WB7-Y?-$98Y0[
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M$J%BCB0%8T<_>!:7MG^&LW]I=/[.U?1+#2+V)HM1V6]Q8D@!5MBNQV/WB5W
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M.\OO&,4>@WFFN%G1I \;1N2(Y(V'4/CIU!X-<S<W&,K;:&#G)I>1M>"?'?\
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MRH.1C/?%?07P;^!7BWX2>.]+N]0U:&]TK4K]WC: --(SF)VS*[*N-X)W,.I
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M!)(\YQ(9 >K97=G'>K?B3Q_H/@>.:\M--;5=%U=/M%R;0AWC>7@[D'S$R#D
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M_CH?ICXCWNM_"PO'X-T6VN-,\0O;1*9=_E6UW&1&J,%(^1U V\@ @CN*]0\
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M ME5('F9MX:3YG)+?>&?6MJ^(NE*^JV)JU;N^QTWAG0M&T[4XK*YTF--5MH
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MGRV<8#8[XKX#\&6.N_!NU&CWVDG7+_6YG=9[5QOF:*/.&4\(H .,<#-?H/\
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M?^13OO\ ME_Z-2MRY_Y*[\;/^RB>*/\ TM:L/Q[_ ,BG??\ ;+_T:E?=8/\
MW5>A_;7"?_)-4O\ KT_R9V%?0G[ G_)[^J_]D[N__3O9U\]U]"?L"?\ )[^J
M_P#9.[O_ -.]G66=_P"[OU1Y?C/_ ,B*?^*/YG[L445\C_'?]M#X5?L^>.K'
MX=>+]+U[5=:U#35U5(]&TXWP6U:9X-S[74CYT(/&.1SS7Q1_')M_M>_LXVO[
M4_P0U3X42:J=$NYIH+RRN]GF1QW-LQ*"5 061@65L'(SN&2,'X]_X)@_L<3?
ML_>']?\ B?KVNQZKK/BKS-.2"V1D@MK?3[J6-R6?!=Y9(\_= 50!R2<>C_\
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M;WDFE:M;02/;WCA(UD0L=CQE6(VMT!ZU->^#M?M[B#3M.U^_N?MTC&Z:<+)
MMJ1\R*,#8Y_A//>L/Q(ND^)OB!IG@Z+ROL6AIMO(9PH2?S0&BC"D9;;C<".
M:\FG9RYF[_\  _JQYC5V8_PWU_Q=96\V(AJ%V8HY9].:X+2($0*TD$CD[][#
M)7CD]:['P)XNU35]9U66733;-J,K^6ZN)(D,,:JF_&&!?OQ@$$5T7BWX?+XB
M:UN=%U!M"U"QAFA@N+=!O42@ =>, @'D5Y5:R^&+WP;JOAW1S)_PE%N)=/\
M.M6)N6N(B&,H?C"E_F)./2NB+C43E%;_ (#T=V?8'P(T_7M.O=;'B"ZM[RXN
M3%+YD2,C+N+X0Y)R%  !X^E?2-?*7[-^H7C7.K:'J+W-Y>Z?;V8N;FX"Y,SJ
MY,?R#;E1@G'K7U;6%1.^IYM=>^SX2_;2L_%]QHL*6>V3PW>VLMI?1+&99F:2
M2-@5VJ?+ C23,A.T' (YK-\-?'#X1>%]"BTNQCN],L+%(5AS:2$3)*BE)=Z+
MM._(R<]:]5_:GU[08?!EWX/N]6%CJ_B*UEMK&!9"DUP[%5*(!R00<$>AKPOX
M5^.]9T>\\+_"KQA8+;QS03VEND=HS0R+#A[:0R@^6J^6"I&"2PSQ7:EST/>6
MU_+H>OAU>BKK8W_@3?:!XN_X6!KWAV:XT^YU;59DE1D*"-<$07"12 <R(V22
M.2,<XKFO@CJ&B^'[;Q@^HE[GQ!X5ENA+ !AA:!B(@I( )<(/<<"N>L?B)J?B
M[XXZXWPRO+.SN?+70[^VU!60M);>:\=RBJ,DI\R[6QD$<X-<[+H'C32/$GB;
MP1XAU*#5)[N[MM0F,;/;&>.>,K$X3=D_O(B&3.#P*U='XDW:]M#I4&VTV6]0
MUOQ+X^U2XN->D@M]+N0D2AKA4N0N0)HX$/0Y*[6&>,]\5)\/X]0G_:,\+ZC/
MY7D)IFHB(1 C;$?D4'KD K@'/0<=Z[B?P39+XBN].U_1K+5+@&VO[.58Q%-'
M(8U222-NJLVW.T,VWIR*P_"-E+X<_:$T[3+6*XEMX?"]RL4LV'D8Q2_*2%P6
M)'<!2V>1DYJG5BXS2[,VY_=:MT);.TENOC%\3-%",3<WVGW/W=P\O[.%?@Y!
M!'!!'-=AXJ\/V:+X:TK[&R0^*)3830A>+>3RB4D8X^X?+56&,$GTJK)=Z%9?
M'+5;2\N!&OBS3-/E12&5I+N"1HFC"YW L@Y';K75_$[Q=H0TVWFT:X^T:AHM
MRK"WB4LX*_+@#T#8!(Z5SN4N>-ET7Y&?M7>*1\:?LX1^+/!7[0NO^%M&L6U*
M*VEFL+W$GE06T$4BA) O()ZD>O05^I,<DC&421^6JN0ASG<O&&XZ9]*_-+XI
M>-;KX*_'?4?&NBMY^G^)4L[FYAE(5#*B '#@< X_!LYK[N^&7Q%TGXI>%8O%
M6CQ26T,CO$T4N-X>/&[H3D<\'O3S2G*7+6MHT:9A"4E&K;2QZ,"#R*HZMJUE
MH>EWFM:C*L-K91-+([MM4!!GD^_2EO;ZSTRQGU'4)5M[6VC:261CA4C49+$]
M@!7YM_M(_'9M;UBY\/\ ARZ:;PZUO%%*8SO2Z.\2ET7/0=,]ZY<#@Y5IV6QR
MX/"2JRLMCR/3E\3_ +2?Q=77-<</ID][Y3P*Q CMXP NP^BG ]2V3[5]C>(K
M"30/%)\&?"#3;C5M3TD02ZM=O<1H+2(JQMHF>4X  W-@#ZGFOD?X&01+K,_]
MJ:N=*T^*1[R-BO(DN/\ 4AU'S,5(X0$;L=>:^AM.T/09/%3WNHWMWJJ>-I6N
MKFW):SW+9ITNHP1L1 ?E#@9!'7K7O8S27*MDMK'IXQM-16B1VNM?$[Q?XZ^
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MFU6S,FIW_,D-[J+?,PP#\H(XP,8&17[&>#98)_".BS6EJMC#+9P,L"+M6,%
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M0OJ3'9*JIYB%74AMBGJ"HQ7V5\9/^20^./\ L!:G_P"DLE 'D_[$_P#R:/\
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M?\6H?#&L>)([VUO=.::.W>$0.D@?IZ$X/3K7O&0*\Z2E2:L8:Q/B^+5K*_\
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M3E)QA'Y=_P"NQ=2<6_=5D:]AXKT;PCJ"V_B>XN;;4-<E"BW:,F#SFZK&P^4
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M)>IX7U7QI+=:/HMZ+9+BWMU@P9"L,K*90><M_$%)['VKZ.^(4=U<>)_"^H>
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MWNB//!?$ BY^P<['AXPKAV"L3]:]'%1=2C%W\WZ,[JT93HJ1]8^+O%-GX/\
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MT3;.1J!96^;=MV[BH)"G!Q](HBQJ$0!548 '  '84Z@ HHHH __7_?RBBB@
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MYXCO( 6:,?O-J]!&@Y '\ZXZ\UF[U%]#;7=6#&"=4>UB5D-UN)!=D!RPVX(
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M $C(+,0.,8!.:T=!UFP\8?$34W\<:_>>&I?#%I;1V*)/L_TYE<2ETQB7:4&
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M+ASF:$6)BFA,+ [D"9VXQC:<=A57P7=6OQ,^.?PQD^)FEQZK96'@VSU22UF
MD2[N+B0+)-,"1NW*VXY/&*^D? _[#_[0\7A#7_ 6G>([#PSX$\>XOM;CN;=G
MU"U$K R0P$=?,5!G/0<'!SGJ_P!J']FBY^&GB_P-XZ^#6LVUCK.@Z5%HS6NI
M)YL,FFQ((HV,:\G:=Q?W(-.ARN?):ZTT]$TW^)2@^?EMK^>J8S]B#QOXO\.7
MWQ.^#WPJ"2:=I?C2Y-C;RAI$M]/FW!ECD^XNPJK?,>>>M???PU^*?C3Q'\3-
M#^&^LV-I>76D6\USJUSN#M!=1R21;8B..A '?!-?*/[%_P -= ^"_P -=9\<
M>(Y)->\4RZC>:BLMO'-L>69"B,$  *L%."1QDUWO[-.O:IXK^+MOXMU>^CMO
M[6/F1PZ>@EBG^63<EPZX:)U8$MO'S' '2NE4%[.6GPI*_GU]2_9**DI+O_P#
M]3J\2^-=U;6.EV5W>2K#!$SL[N<*H ')->VUX-\>;"WU+0[6SNX5N8)"^^)A
MD.,#C\:\A^9X]#XU<_'OXNZGIOQ3\?K):%9K:P.R)F!VF%<%VYXSGI7JO@*3
M0-(26^OK5Y=26$W%M)R(=C$1!5<<%CP,>IK3MOA;X6:WUK4KJ/\ LX:D\T2V
MLDFR.-8C@9?J!QDXIL;WC_#O3H] C@CDAGMHH55O,B18Y=OG#U!&&P?K7KU*
MRE!0CL?25:Z<%""T#4/#&L7"W^I^++>&QDM(TN(9H6V^7+<,%'G=MJ  D5N>
M"]6T#POXS%A%OOI]1A@\NZ^8K<3N[&=XUZ*HS4/B87=I?:]X4<27\%U:1QR2
MS/N GN.?,<=-JCD#M5;X7VVG'Q#<V>H6]S?I?0F.*Y8!8;=83M\L=T8]0>XQ
M7/*5X.YSM7C=E"Y\$Z?<77BJZL62+Q+/J@6V4-N/[B3S59@WW0P)R1ZU])>$
M?$UMXBL!N94O[7$=U &#-'(.HX['L:\:F\'7O@+Q8^O*5U2PNTDEG:X;]\S(
M1L ]64' /<8%<QX3DT_P;XSU7QRL/E6WB("*!'8QI'-PZPG/!9E.<^HQ652*
MJ1T=^W^1,TG'0^N.*>#Z5XE)\68(]9EO)(9(?#-O$T9NFB;$EV"<HK=-N!PW
M0FNE\!_$K2?'C3IIT$D1@P23\RD'_:'&?:N"=":7,T<_([7L1?%+P)<>.=)L
MO[-F6'4M)N%N;8R?ZMF7JCX_A.!5.R\ Z_J&C#1O$'B&>>UN$;[2@4;V9P5=
M0Q_@P>!7K'!XS7'>,=-;45TYC<O;00W&)2C%25D4J.?9L5<*\E:-]"HS>QX/
MX3T*R\%Z9#I/A"QN+J2SOIH);AQE'"LWSQ,>K(> .XR*]P\ >-D\4Z'#=ZF8
M[2_WO&T18*[;&*[MAY&['2MW4;73M.\-W4&P);6T+R8'!!0;MV?7/.?6OA5K
M2^L_&GB?Q@D#2SZ?;QZ@+<R8G78/ED1>F"6)(Z=:ZXQ5=.^C-(1YT[GZ&B1&
M=D5@63J >1GU%9.K^(=)T.6RAU>40#4)#%$S<)O W88G@9 XS7DWPK\76-XK
MPZ[#-IWB+4-LLRW/!FR.&C[8QQCBO7=7T;1=?MUT[6[:.\AW"18Y.?F7H0/:
MO/G24)VD92IV=F?-GQ%^''A_Q+\16UC19A=ZAJ%JB7EFLBQQS0\KN1^<N,9Q
M7I5IX:L_#MCIO@V;Q!+':^6=D4SC>&4YC7=UVCN.^*I_$7P[%X?%AXO\.0QI
M/IDJ 6@&WS\\80CD-@_0U@V%SH^A^-M=\1?$*U-G_;Z6SV_G9FBABC0*5) .
MPE\FN_GE*"=[K\3H3?*NQR>C^.KZ37==N-2\-_;9=/O5A@M;4Y$L:J%>55^Z
M22,X(]:\7^,OBN[?XA65KX)M+K1;BS19Q!-'Y0DFZEU[+CH?7%?9-BOA/P]X
MITH^%].\\Z^DFZ6 [DB1/F\QL] 2<&N>\5^%M*\87<OBKQ[H4ME_PBDLQC,3
M!_MMNHW G;R5XSM]:VHXJ,9\SCT_K0KVD;^1F?V/XTU)O"/C_P 00C5?L<)F
MN;6VB59UD=?E8$\MCH1GWK7T+XO:;XL\7+9Z#=O!#:H3=6UW%Y7RJ2"R.3]X
M'M7GF@_&#4M6ETGPYHO_ !+SK4ACMUE*XAL^<2(Y.3( !\AZ9KU;3?A5X9T#
MQ/9ZI-.;IA;R1E;D@[F)'S#IU.<UG5BE=55KT%)*_O&W\1?&6H^&]%TVY\-1
M1WM_JE[#;0(W*,KY+G([!03FFS?$W3]"LGO/&5I/I*I(8E?RVD25EZE=H)P>
MV>M86G^"_#VH^)[BQM))XX-!D2XMECD.R-[B/E5] .N/>EU2Y\8C7)O!5U#]
MNL#;&[BOL RR;6P82O0,.@/>N>%.GI'_ (#,DHVL>9Z;XS\$:Y\1X+7P=8W2
M7EA.TDL<DAAM)?.&XG8?ER,Y7W->P:MXS\)>(M#U?1=6N$TZZ@1UDCG!;R9$
MY1\@%2 P!R#7/?#V/0;K2)M"\264=AJDAED,<B>7.( WR,S=V48Y!X-;?@SQ
M/HVJ6E]I5]ICV\-I,]HL\T.([I.S@D?Q#KFJKN-[V>A-2*V1AWNN>/I? 6GZ
MI<:9#KMI=0H]V+&1H9XT !$D.?O'OBK'A[Q;:79TWQ?JM_\ 97<+:/#>Q>3*
MD;YVG/7)8=3Q7HVI>)/#W@RPM[>?=Y041Q10(9#CH!A>W:O)?#0U'6/B/J=Q
MXSTX6EA/$#I\=VH;S4SD'/W05[+UI0DG"3DK?J.$4[MG1_%/P/X4ODD\=ZX)
MMEA"OG^3\Q,29VLN.A0MG(["K/@+Q/IWB_PJGAC4G;S[FV:)6=LFXA88613[
MC!/<58^(VGZQXNTZ7PEX9O5MT>*5;TE-R["ORIGLQ([=JY#X=>&?!_BSX>V6
ME:'=RVM[I3+#+=0';<QS1C:PW'L1Q]*$U[)<^Z_ <?@LS@H8/BEK46I?#3PV
MUC<1:!,MO<2NOEJN1O3&.I''/K7 -H/Q7T7Q38^#?#%O&FJVR^>]R9/-!D )
M9I2>H8' !]:[SXE--\$)G@\%ZE(+G7X0[B:3S91/$W,S9Y;*\8]JW_A[\/-1
MU&YTWXA>&]4E@OI[5_MD]T&,L]RQR0R'Y3%CH!TKT?;<L.=VL]O4Z%-M<UM#
MPO\ ::^)W[1/PKTKPS\4?+73[3P])&=4MX9@+/4(I#CRRC<B3KP.WTKKO@9I
MGB_XZ? 77?&7Q3U6?Q%;^/YO-M]+M9@BV%H)?ECC8<JX_B[XXKVKQ]^SQ#\6
M;[PK<?$;Q!/J%CX;NC>/IR(JVMW-G*^:#R57H!Z?6MOX*_ C2?@=/X@M?#&K
M7,VBZW=M>0Z=*!Y-D[DEA"1SM/I[5XKJQUT_K_@GFU%[Z:V/CC]C7PMI/PS^
M)/[0?ACPP)(K71KE([597WR9CCE*@L>2<U\FZEIMK)^P!J?BX6:W&KWGB:ZF
MNKW:#.DJ7#!&,A&X<>]?H)H?PDM?"'Q\\9>.K-[Z]L]7ODN'@8>7#)J!0E4W
M=XU#'K7FWB+]@W4+KPYJ\'_"=7>F:!>W,FL3:!&H:Q%SDR;<]=O:NF"Y7%RW
M:0YT7:ZVNW]YX]\#IK/5/C)\1=<\=6L>L)'H6F6;+>@S21P7%L<M&"#CIS7T
MK_P3]\92VO[/OV;5+:9-(TF_U 17C<Q+"LS$*!UPH_ 5YYX^^ 7B;QCXWT?Q
M7X.U"]\#W/B.PBTK4+NU 6&:")-OSJWW24&%-?<G@CP7X(^ /PRTCP!80S7.
MEP9M_P#5F:2=Y<M([J.NXDDT3222:U?^82I.+2?<]A^$7Q4\#^*O&W]@>'-1
M&H7!MI)2T0S&%5@#\WKDU]75\(?LU?#WP-I_CW5O%GAU98IHC<6T<3 QI%$[
M*V!&?4\Y-?=]$XP3M#\3FQ:2EH<'\41?GX=^(?[*G-M>"RF,4@7=M<+D';WY
M[5^>&EVT=UX8T3XH:SLN?$5S?6;B54P+<SLEO)$,]$"DDYZ'FOT8^(FJ6NB>
M!];U:^#&"UMG=P@W,0.P'<U^:'@KQ-I^M:7XUTF_@8>&;R:];3Y3U A0">-^
MZ.LG*CJ>U:TD^5M'7@%[C.Y^(.K2^(]6T70_#'+VFIQ^9J (,-O*$8B,,#R[
M XQTS7<Z/X?/@R+4]6N=7N;\2J9&2[E'E*_7Y2>%!/'H*\QV6_A7X'V\\VC2
M:?>/'#,MM;J99?MFX-$S8Y)9E!8^]>5_$'Q1X^\?^ [V\\1:9-X9TAF2Q2T8
M?O[N[N'$<><=(R6S[4*ES6BG:-[':HMI+H>Y:7X2UBYU(_$G1;];/4_$-I'#
M?B;,D<42,6C\H9P&B!*\\'.:\$?Q3J_QWOW^'/B+5+72O#VE3LE[,& N-2-L
M"2R#[JKD;L#TK \&_#/XK6]EJ/@J'7)M)NM,L@(M[M)"978AE&>H8 '/:O'[
M#P'+9^*KSPKJE]':>)&N//9'.(%$B'<L97E23R2>,<5Z-'#0O*\KOIY>9U+#
M)7=]4?3#_'/P[\,+BS\)^$+9]9T.QBQ+(Y(G9@2&9"1\^.,]^:D\1_M#>)[X
M:?J?A6SCL-.NFC2$W'SF>5FPZL!RJH <GM7B]U\)O%R>%8?%GB/6U6/7#!#8
MVYC_ 'J!R&+J1]WY<DGL/K7HWC*S^&5K=74/@S7%T<:+ L,TY'G1J_E9 MD.
M0SR;L2'M]:/8T>965WW(G&"=WJ?5'P^^(^G^-+8V\RBSU:#/G6Q]%/WD)ZJ:
M]*[XK\K]"\?WOA*?3=;C,]U=:%<227,;##SQ[1&B,W9"3D^G%>XWWQ ^-OBW
MPK?^,$N(?"_AY7B=9(HC-=*H;8P1?X@6YSBN+$99:5T[)F-3".]UL?;LDB0H
MTTC;4C!9B>@ Y)KY7^*?CKQ1XLU2P\/_  QU.W_LE9[%-0N,LJR"^<K&B3+G
MCH& YR:YGP)\>WTOPO=6OQ#U&#4]5EMQ);60_=W,C8*S13$_(C9/RC^[UKA_
M#FIZ!J?@Z/2?AWH%U+JOAW4%N9981PH%ZYB5T!P[!<?EFG0P;IR<I+_(FGAW
MN>^ZWX^\8_#;58?!^K6RZO'J;PPZ==2.$7$Q",)#U.QB0.Y&*BT;PM\6/ACY
M<5A?1Z_H>G6*DQS-MD5DD=G1>YPA&TGKC%>NVVA6GBV/1O$7B_2$@U.P9I88
MG(<PDM\I/;=@ ^QKPKQCXU\53:YK6DV4ZZ?+-=&UN+B&3S!8PVD32)),C=%E
M!!8J/:LJ<N:\8I>8+R1W&G^%[OQY\4T^(6N+-'HV@V]LVB)OV?O9X]UP94'4
M@D<GZ5[_ -?I7#^!=*M],T3[1!>_;AJTAOFD5MT6^=5W>5Z1DC*CMFO*M2\2
MVT'[0>FZ1<:K<VTDL(ACM""MO*I@D<D=F;?CITKEG#VC:6T5^1')S-KL;7[0
M7B"'0/!%I+>M-]@N]2M;6[2W(\V2WE+*Z+GZ@UA7WP"M],\,7&B>"]6NH[":
M:*\.GSR9AGD1U<AY/O!64;2.GK7EO[3%AJ^K?$#0=(N(5GTR\T^6*TCDF\N-
MKW?NW/V!P H/;)KIH_#'[0-IX1M=!M9UC@;=',%E6286TBC*I(>=PY"GW%=U
M./+2A:=KZ^IUTZ7N))V/&?&'B*7P"NI>(M NPFN7.LW-U)9J!]ELH@OD$(V/
MF*E0QQU!]Z_0Z*.;4M"CBGF*37=JH:6/@AW09=?0YY%?GOXC\$7EQK4'PZNX
M;B6\U&U/V9KJ,0ME!T7^&0[,!@#G*YK[S\&3ZU/X1TB7Q':"PU,6T:W$.<A'
M0;3S[XS2S&W+#EWU%B7%I6=SSCX?_"WQ%X:\5W7B3Q9KJ>))?LRV]O<2PA;A
M%R<@L.V#CCK7,?%6X\5Z+XNMM2TVRCL=%CMGD^WP[4?[5&#)_I!QDH0NU0>K
M'FO<?#7BK2/%UM<WVB2-+;6UQ);&0J55WCP&*^H!XS7 ?'V:)/A)XBL_,"SW
ML AA'5FD=@, ?3K7/0K2=9<^[T,Z<GS*Y\[Q^ ;GXZ^'].U^RLAHNAZ \@@M
MHR?.O[A2'=V<?PK+D#U.:YZVTS4M8\->-_#_ (C\+R7?_".^6VEZ@B!_L\S<
MW#+(IY"'#E>>01UKZF^%6N^&/#7PMT*REU"!6TNQMEN0ARR2R8'*]<LYP..:
M\M\2:WK=E978^"D4FIZ->W'VG58=AC^R)D-/Y189WR#ED(]Z[J>)FY.%K)/3
M^O,U=27-R;:GTQX*N[*[\,::++55UL0P1HUV""96"C+$#H3Z=J\\;XAGPGKV
MMZA\1-1CL+39&+*PC!>2*%6DS,^.ID !XZ=*B\0WGA;1/ NI>#/ EVNFZI)8
ML]K':J6FC>5"Z.0O<^I]:X;X<Z!H_P 2-*-UK.M27^JV#^48IR&FCCC^X)8R
M RG).>QK@I48V<I[/[SF4(N3<GH>C>-(O"?Q)TQK"#5+9VLA;WZQ2E6CW%#)
M"LZDY"G(;&:V_AMXAC\5>'7%]9V-FESN2*&TD5DGB50DCA1@A2V<<=",UXU=
M? 3P=X7\'^*]8\7:C.\VI0R^9+"Q46Z@>7#Y*C^(#"KGUQ7CWP>\ 3:WX>O]
M52\N/"EYX-:32TP^9V=MKM),3QM;('T'M71&A3G3TEHGH7&G%IQ4C[XN[O1+
M6PAT_P R-8F(BACBPQRF,!0.ZX_"OF#Q#IGQ/^-5[J7@S48QI.@VUP)EG=2I
M/DOF+!'WB2,D=!7SU\'_ !>_@?QI/JVLVMQ?S)!\R1!_)4S#*O$'SN9SU*^H
MK]-=&O);_2K2^N+<VLEQ&LC1-U0L,[3]*BJGAGIK?J:RBJ2O:]^I\[^*?"GQ
MRN?"<GP[TF73?[/O;<VKWT8,<J1OE7'E],D=QZU!\4?@IX6M/@IJ?ACPQJ2>
M#-5DL4@MM3BD,2K<Q*'42$DC8[)AL]C7U'R*\"_:>\*Z=XX^"VO>$-3U=]$B
MU,11F>(!I.'!VJ#TW="1SC-<OMYU+06GH<T9N3M;<_/W]F#QY\2?VT_%3V7C
MWQ%)IOASP!I=K9WUE92J)-4U+<ZF[8XR$.WDC@\#O4]W\!_#'P-_X* ?!B+P
MC/<R:?K\.J7)CN9FF,<J0RA]N[@*V[.!5KPY\(#^S_\ 'OX;:WX"U,>3?:9!
MI;QVL1\N^@4E6^TJ/XOXM_8@&ON?XL?#+PF_Q)\(_M%^(;Z[BF^'$%TD5M;Q
M^8LRW8*L7'WN,]JZ*D90E&%]'?\ &^OWG-.C-4W&77_@'PXND6/C'X__ +7E
MSXEM8[^\TW2M/LK/SU5S!:O'\QCW9V@A5)(_K7YO>&KNXUWPM\$O#>HZD]Y;
M1:IK2I!+\\<*P.I@0 ]026('O7Z0?$OX"^.OB!K6N_'Q=8O?!6D^*@MOJWV-
ME\R?1LIY3RH>,HO7OM%>'_$7X)_"V:QM/#_PUGOK&S\.3PP:)J"#YKF\5-TD
MP)X_>G)].!7H8"@TDDOAM\[,WCA)N37J_P M#<_8]^&^@>,?VH/'6@RR2'18
M-#L[NXABPB27)**-P X*[CT[U]#>)?"[^#OC[ID,EQ+?6/\ :EM&D[DR#B96
M$9;LZ!@"/I7E7P"\':E\&+#6/&WA[7;BZU74&MUURYF9!+)""<+$A_YYDD\=
MP*^D(_$J3>)M%\+?;O[6T^XU>UU*W:6,&\69W5I SKQM.<_I7=2C.,G?9W^7
M4]&E"K!RD]$[Z=C]B****^</D0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#__T/W\HHHH **** "BBB@ KY0^)/[*?A[XD>-M1\;WFK3VEWJ$<,1$:*=B
MP[00"><,%P?K7U?7F\7Q:\!S>(;_ ,+1:@S:EIC%+B,02[8V!Q@OLV_D:N%5
MP>C-:52<6W \RM/V:/"\5C!97UVU\+8,J&:-6(5NHYXKD;_]DBPNBUC:^*+J
MQT@L[BT@BC0;G4J<L,$CDX%=SJ_[5GP.T+6+C0-5UV6WOK5_+D1K&[^4DXSN
M$6-O^UG'?->J6_Q$\'W<*7-M?B6*0 JRHY4@^A JE5E%VZENK4>K/'Y?V:]"
M!TO[#JDUJ-+DW*$5?G4H596SV/!SZBHO$W[,/A3Q6^GMJ]W)*-.F,\8**?G*
ME?ZY^H%>T2_$#PI#$\TMX51 68^7)P ,G^&O-YOVF?@["'8ZO.ZQ@EC'8W;C
M X/*Q$&H4VG?J"JU-SRWQ!^QIX4UF^^T6FLW.G0R',\4*@><0H4%CG.1BO0;
MG]GNRN?#TNA/K,H:2/8)1&H(QC!QT/3GUJ30/VJO@;XFU2/1M'U]Y;R4A5C>
MSNH^3ZEX@!7K/_"=^%\X^UG_ +]O_A52K2EH^@YU:GVCR+4OV>=,U"]TJ^_M
M-DDTMV<9A1MQ9-O?[N.Q%<;XV_9(TCQM-%=W/B6^M+F C9)#A=J;@Q4#ISC]
M:^D!XZ\,$9%V?^_;_P#Q-!\=>&!_R]G_ +]O_P#$TXSE%JQ"Q$ULSP^[_9DT
M1A:2:7J\^G7-JNSS844,XX^_Z].]<G>_L;^%]7UO2]7US6[J^33%=O*=5 EN
M'.6E<CDGL!V%>K7O[27P<TVTEOK[73#;0N8WD:VN @8'&,^7CK4&D?M,_!S7
MHH9M'U>:[CN+G[&C1V-T0TV,[<^5Z<YZ>]*.(:U3-/:U4[E6P_9W\+:4(8])
MD%G#$&!CBB158-SR!UP>:9-^SOH4\T\O]J74*SJHV1-Y:J1GY@%/4D\FNU\3
M_&;X?^#].&JZ[>SQVN<%XK2XGP>O(BC8@>YK<L?B+X1U&Q@U&TO&:"X170F*
M12589'RE01^(J+LS=6=M3SRQ^!6GZ;I":39:K.OE1^6DC ,P/]XYZG/-17'P
M-DFTVWM(O$$T-Q&R&2<1)F0*<L,=!NKU'_A.?#)_Y>C_ -^W_P#B:=_PF_AK
M&?M1_P"_;_\ Q-.W6PO:R[GB]]^SCI=]>2ZB=8GANFGCE26-%5T5$V%,]U89
MS7&:G^R1!K5K'9ZMXNOKF**9I0"J\YSQG\<''6O98/CQ\-KG6?[ CO+H7OFF
M+8UA=J-RC).XQ!=O^UG'O78S>/?"\$+SR73;8U+';%(QPHR< +DGV%:0K26Q
M:K5$><:+\!]"T'3(-+T^[>.*!0.$4;CW8^I/4FN=\0_LTZ/XEG>74=9N2A!5
M$4!0@(YQCN3SFO3O#7Q?^'_B[3_[3T'46G@WM&=T$L;!UX(*N@8$>XKH?^$V
M\-_\_1_[]O\ X5G";OS1!UZB>IY%I'[.?A32-+@TJ*4RQP;2&>-68LO1B3WS
M6=K_ .S7H^KZ=JEI8:K+ID^IVYMVGAB3<JDY)'8DCCGI7J'B3XM^ ?"6F-K&
MOZD;6T5E0OY,KX+<#A5)K4L?B'X1U&SAO[*]\VWN$62-Q&^&5AD'[M/G=_,3
MKU-[GG/A[X%VVB:-9Z3/K5Q?/:1K'YTJC>X7@%O>L[PW^SUI_AT3@:S/<"X.
MY]R*,R%F9GX]00/PKV$>-O#9_P"7H_\ ?M_\*X1OC_\ "I/&:_#Y]7=-==6=
M8#;3@$*NXD2&/8>/>DV]=!>VFQQ^#VGDY^W29]=HXK.UCX%:)K>G2Z7?W;20
M3\.K1JP*]Q@^M>E?\)MX;_Y^C_W[?_"N*\9?'?X8> 88+CQ1JDELEP<)LM;B
M8GZB*-B/QJ=M0C5FWH<#_P ,SZ5"DECINO7EAICHJ+;0814P,':>H!]!Q5'1
M/V8V\/V4\&G>+KXSS+"@DE59%181CY4/ +?Q'O7J/A?XY?#7QDI;P]J4EPNW
M?EK6XC!7.,@O&M=)J'Q$\):987&I7EVRV]JC22%89&(51DG:JDG\!6BK-H;J
MU-F>,>%/V9](\/)J$E_JTFJ7>IRM)--)$BDACG: .@!Z59G_ &;M&ANC>>'M
M4ET>61!'(88U^<!BV3G^+D\]:];TKXD>#M:T^WU33KTRVUTBR1MY4BY5AD<%
M01]",U=F\<>&8(9+B6[(CB4NQ\MS@*,G^&E[1WOW#V\]KGBUQ^S?IC0WEO9Z
MW<VZ:@%\_P"4,79>K9/0GO47_#,^A13K?V6JW%O?-M\^=1\\X4$ 2<\CGCTK
MO_#'QS^&OC!WC\/ZE+<% 2VZUN(P,'')>-1GVKKY?''AJ&)YI+HA(U+,?+?@
M 9)^[351]!NM46C/%];_ &;-#UNQBM9-3EMY(BF)(45&VJ06'&#ENF>HI\_[
M,O@N6]TV^262*33F+948\T,.DG/S<\Y/?FNLC_:"^$DUO]JBUU7C)9<B&4G*
M]>-F:'_:#^#T<D43>)("TWW<!R!D9&XA<+GWJ/;VTN5%U>ESEC^SOITD#V5S
MK$\EF[R2&$HNPL^2,^H'ITI;/]FWPGIMY;ZIIL[V]]"?GF51F1=NW:PZ8]/3
MM7:'XY?"X;,:VC>9((EVQR'+D9'1>GOTK1M_BWX"N)I+?^T3#)&0N)H98=Q;
MIMWH-WX9I*LMDR74J['FGB[]G.S\96\EEJ/B&\BM750(X<1@,IR6R.23Q2R_
MLY:?=[/[0UZ[F\@J(EX"(H&-NWH?7)YKVH>-/#C#<MT2#_L/_A7G]W^T)\)[
M'Q3_ ,(9<ZPZZQE1Y M;@_>&1\PC*]/>M%4<59$QJSZ'0_#[X<67@&*Y%M=/
M=RW>TR2. "=N<=/3/%>D5E:9K6FZOO\ [/E,GEXW?*5QGIU K5J&[NYG)MN[
M/!OBC\!=!^*GB_P[XIUVZ<1^'_,Q:[ T4Q<JP+Y_NE017H$G@J(M&8KIHU0Y
M8;0=PQC'MSS7<T9%5*HVDGT-/;SLE?8\%\4_ /PWXI\0Z'X@N9WA?29S)+&B
MC;=QA6"QR^JJS;_K3=4_9\\)ZMK<>H7$C1V A\N6PA4103R*^Y))0F"Q49 '
MH:]\R*,BFJLDDA_69]SPR/X)66D:E;7?@_43H5I$B1RVD,*F&54/&0>A XR*
MMWOP:TW6-6&I:_>R:A#'"D4=NPVQ*RL2SD#J7X!SV%>SY'K3?,C_ +P_.E[1
MC^LU-[GBWC?X)Z'XYTVWTB_N&@M8IO-D2-% E!4J5..0.<Y'/%<AX6_9>\%^
M'K5K"^E.KVR2B6$7"*7C(XQOZL/K7TQYD8.-P_.EWH.K#\ZN->:CRIZ%+&U4
MK*1XCX<_9^^'7A/7;[Q)H5@(+_4!MDD)+87KM4-D*/859\;_  8T7QK96T4M
MPUG>V-S#=6]U&J^;$\3;OE/7##(([@U[+YB?WA^=+N'K4*;OS=2/K%2][GRS
MXD_9G7QHETGBWQ3=Z@)DE2)2B(D(DZ%5'&0.,FL"Y_8W\&M96^FZ9J$NGVL-
MK]E:.)%VN,8+'_>SR.]?8?F1_P!X?G2[T/\ $/SK=8RHMF;+'UDK*1\)W7[#
M^G:EI-KHVK^,]0N[>QC$=NK(@$9!)! '4C/&?05V^M_LH:;JNBZ/HT7B:^A7
M24B"R-B1S)$.)!NX4YP>/2OK7<OJ*-Z?WA^=-XZJ[79/UZK_ #'R /V.O!4L
MMA/JFI7.HR6ELT$DEQAY9V:?S]\CGDX8D*O09K>\+_LYW_A.&YAT_P 73L+A
M9D#-;1%T$K[^&Z\<X^M?4(=3T(HWH> P_.I>+J-6;#Z[5M:YXMHWP6TGPWIE
M[HGAV]DT^ROIDF98P-P;:%E(8\YEQDGL36I:_"RSLO#FI^'+>^D$.H&YVLP#
MM&MSG(Y^]MR<9KU4N@ZL/SI/,C_O#\ZQ]H]S/ZQ/N>=0_#X6UEI^GV^HRI;V
M5N;=EP/WHV!%8GJ"O6N7^'_P.T'P)HL^E&<ZG)<RL\D\Z*SLIX53G.0HX%>W
M;E_O"C>G3</SHYW:P_K53N>1>//@]HOQ T6#0=4NIX;2*YBN&6%MAD$6?W9(
M_A8'!QVKRGQ-^RIIWB374OI/$=U!I5I L%EIZQJ8;94C"#:3R>1DYZU]:;E]
M12;T_O#\ZNEB)P5HL<,94CLSX1TO]A#P99F2>^U^]OKJ:[ANGDD"[6,+!MI7
MH00,?0FMZ^_8M\'7OG.=5FCFN;A;B218UW;ER %_N\8''I7V@&4\ @TN1ZUO
M+,*SUYC3^T:VW,?*-S^R7X+:6R-E>S6\.GR7,D,1 =1]HV,1SUVL@(/X=*U[
M3]FK0K9;=SJ#/<6%E+:6DIA0&-IQB25AT=R.F>G:OI8,IZ$&C>G]X5D\74[D
M/&57NSYK\)_LX:9X(U[1]4\,ZS/9V>FVQMY[0*I2[9NLDA/.XX7GV%)\6_V9
M?"WQ;O-/O]3OI[*>TPLCP_>FB4[EC;T ))_&OI;(HR*F->:DIIZB6+J7O<^1
M[+]E.VTF&.UT/Q3>6$"0M&RQ(HW.6W>9G^\ =OTK*L?V/K+1M6M_$6B>+;ZT
MU6 Y:X*)(9,@*=P;@_*,>W6OLS<OJ*"Z#JP_.M5C:FJON:2S"LU9R/%="^#K
M:;K=_K>J:]<ZF]YM"1R*JQPJN3A0OJ3R?I6G?_"?3;V=;K[4RSQ@[9-H+JS?
M>(/49[BO5]Z?WA^=+N7L16#JN]S+ZU474\#U_P" FD>(M-OM,O\ 5;IX+^VD
MM60D%%20@DA>FX$<&L+X;?LP^%/AY;JPU"ZU;48HA!#=73;FAC48"QKT7\*^
MF-Z#JP_.E#*>A!J_K,^7EOH4L952LF<G_P (LC06T$ES(_V=LEF.6<#LQ^M>
M-?%#]G73_B98SQ3ZU/I]Y<3!VN8T5G$(4KY(ST3H?J,U](;E_O"ER*SI5'!\
MT=R(XB:=TSQ:\^$5R?LXT3Q#<Z4EC8+96J0HI2)L!6E*G[Q('0]*Y_PG^SUI
M7A7QZ_CZTU)Q<R3/(\,420PNKKC:57J0Q+9]37T264=3B@,IZ$&K5>25D#Q,
MWNQ:\_\ 'OA6^\46]K%8R)&8&9CO[Y%>@4TLJ_>('UK$RC)IW1\+^+/V8?%W
MB2XFM#>6@TZ4F5@=V]I&R"/9>1]:D'[,_C'2/ ]QX8\.75E!<&,I!*0WR'C#
M8]0>E?<F],9W#'UI/,3^\/SK7VKT1O\ 6YVM<^*O"_[-/BW0/#EQ9RZO%=ZO
MJ3&2ZNIQYOSE=N5![+@8'2L[0?V:OB+IMGK4>H:Y;75S<R*UK)M*C"'(+@?E
M@=J^YPZ'D,/SH#*1D$&CVKUN@^MS/E"7X(>+K^5#J5S:O&+-HR!D_OVZMSVX
M&*\T_P"&4_&5Q\.+GP/J^I6E_<>8TUO<R Y1RVY21_LYQ]*^^BZ X+ ?C0'4
M\!A2C4ML@6+FCX8OOV<OB=*E]I%EJUC%HDFGQ6\%J8R0MP/]8YSV/:N5\ ?L
MA_$;PW/#?WGBM;.2.99)8+1?W%PJC!#@],^U?H@9$'5A^=+N4]"*T^LOE<4E
MJ5]=J6L?/G_"I=<'2YA_6L&;X(^(-7AO]/UVXMY+.:0>2(RRLJ#!!)_O!N:^
MH=ZYQD9IV17.DEK8S^LR/E1?@;XI;PG/H5WJ$-S<RP21>9)D[MV0N[\.M8?B
MC]G/6M7T);*Q-DM_*MM;SSL"&:UC<-)'N'.#C@5]B>9'G&X9^M*&4\ @U2E;
MH/ZS,^%(_P!FCQUI/C6X\2:/=6,T,BJJ_:=[N"7RY'IA>%Q7:>*?@AX\OKG1
M=1T6_MEN--ED>57+*LJLF IQVW8-?7&10&4]#FJE4NTVAO%3>Y\@>,_@C\0=
M=\.V,FDW-E;Z[8W$5RF\L8-R@JX/<C!.*XX? #X[7NFZ?;:GXFL?M%E(TDT@
MBW"Z&<K&ZG@*.G%?>.12%E'4@4XU;*R2".+FCXLM_P!GCQ;IGB+3/%.E"PAO
M9D,.I@,XC,9YS"G0'-=+XW^"_P 0=1TUY/!^KV]EJ*HT:B92\+J_7<OJ.QKZ
MNR*7(I>T]Y2MJA/$SO<^!+7]CB"V\,:;8WD%GJFJVA5GGG9U(<G+.C*05.>E
M7[']D749&2_U/7[D7D>3%B=G6$@Y7;NZX]Z^[,BC(J_K,C3Z]4[GYX>'?V:O
MCEH+SBW\064:SQ21LWS,V<DQOD_Q GD^E>B/^S]\0X([;5+#Q(IUA8O+E:<>
M9"1C)"KV^:OLO(II91U(HG7<G=I$RQDV?&A_9[\::UXA&M^(;ZVC:. 0QFW+
M9'RG.0>H+'.*]&B^$>M1VT=C-/!/$(]CLPP6(&,D#CFOH3S$_O#\Z7>G]X?G
M64VGT$\5-G@-O\(KZW011R0A%X'!/'XUP/Q!_9OU[QV=,4>('TR+3YUF=(>D
MNT]">H_"OKS>A. P_.@N@."P'XTH6B^9(7UF=[GSIIWP7U#2-,;3K"YCR5;+
MODLSM_$Q[FO&+K]ESQMX?MUL/A]J5M9VUU&?MF]F5I)B3F12.A(-?>>1ZTF]
M#T8?G5TZG+>R&L5/<_/'0/V3O'6GRWFJ>(;JR\0ZI%;@6,]X\C;903\KC^YC
M\:^DM)^&/B&+3;5+Y[:&X6-1(D.?+5\<A?;/2O?"Z#JP'XT!T/1A^=%:I[36
M2"6*F^IXK_PK;5O^?B+]:!\-]7_Y[Q?K7M/F1C^(?G2[T/1A^=8>SCV)]O(^
M4_'_ ,(OB-J]M%9>&+FQCB?)E>;<)$D4@HZ$>G<'K6#JGP;^,^L:?9:;<ZMI
M\*1.C7#HK9F"8.".P)'([U]E[E'4BC<IZ$5T1J))+E6A2Q,D?-TWPI\6ZOI"
MZ9JLEI"LC%9A%N(,0& %ST)_2H+3X%ZGIFL6>I6.JN8+:-H_L\KET ;'*D\@
M\5]+EE'4@4H(/(.:SOI9(E8B1YAX7\ G0]??7I?+,\D1C9DR"W3&>QQBO4*,
MBBDD92FV[LPO$^@VGBGP_?\ AV_&ZVU")H9!_LMUKY9U#]E"U>TAT;1M9^P:
M3!J$.H+ (LMOCYD!;.2)#RV:^PB0!DG%)O3^\*N%1K8NG6E#X6>2M\+48_->
MY_X *X;XC?L]IX^\/QZ)_;4EB\5U;W23(N2&MY X&/0]*^DC)&!DL /K2)-#
M(,HZL/8YJ(Z.Z*6(FNI\[:_\!KG7+B&Y7Q!-926R[HF@4*1/@@._]Y0#C:>*
M\O/[&NEQW<VJ0:T7U#5+6:'4KB:,.]Q-*% F3_GFR8.T#UK[;WI_>%&]/[PK
M6-64=AK%5.Y\=>.?V4IO&>F>&M''B>6RM/#T:J52,9G*HJ#<>H&%[5P=A^PC
MI5IHT^DR>))93)<BY1_+ *D,&V^XXK] =Z?WA1N3^\*TABJD59,N..JK9GY[
MW_[!]E<64\%GXHDAGF#+YIA#$*TWFD$'KQ\OTKTO3_V;?%ND^$Y/"6G>+U2
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__1_?RBBB@
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M<XO8*L+2/!OV6=9MM0\*7ML !/!-@G.2ZXX;UZU[[XXU$Z3X/UC4ADF"UE8
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MK>7Q@GO@UZCH^AZ9HD#6^FVZPK*=[[0,LWJ<5K[>>*]6G2]VTCQ:E;WFXZ'
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M>+K +%<!; 6<Y#F-$^8J=N!P3QWKJ/@;XGB\2_#K2;YEM[:8H4>*# 0,IP<
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MB1/LC2Q3Q1\,N6W-N]QCG]*Q-(N[/X@6VC7AN+JZ%C"D'V<C9:2F-N)6C/\
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MR+O5=1BV06ZC<1*W$9;TYY_"LOP/\!/ GAO1K:#5].CU>^5<R27?[X*[#+!
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MB^ IO"MY#K&F>('F6%=.OX,K#(S.R@J2^W:&#%BNT[@*_,75?C]\=?%>G3>
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MR\4>'8/$%G"6NK?4)(L^46P-RD<C@9^M?ISQZUQ>M^ ]%U[4IM6O&D6XFA6
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M>T:?B2-)B8V&<D$-G@XY%3)/H:4^2WO')^$+>XO+2[\?Z1>0"\UB;[4UH@W
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M8P+?"184"C 3,8&,]@"?4UY[9Z9>^*/$ITB6ZCM+:ZD1EN;><!B7/_+2/C(
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M.-U+/G:U.B^#_C7P!JOAJQT+P?.(UM(0J0RX25@"<N1W)/)[^M>S9R>#C->
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MPP(0JI&N N>^!^IK9L\_;+?_ *Z)_.NB*:6ISR:;T/;J***P)"BBB@ HHHH
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MY?ZW/;)/<RR2@0)$#L1F8C[P Q]!7V)XD\41Z#;P+9P?:[FY'[J-3C('?/\
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M:/X3-TDNGO,%7S,176WH41<DYQQ[5W?[/_PY&KZ;-K?C/3Y8+RTN0+4G,9V
M?Q# W<\<YK&K4YI*,3:E3]G#GDST3X>^!]%T3QUJ-AJL]QK&KZ2J2VMY<W#S
M.EO," F&.%( Y&/>O2?$?PN\%>*+Z35M2L2FH2A5>XAD:*1U3H&VD!L>]><Z
MYJVL?"CQCJ/BK5[;[=X4U<!I+BWBDFNK61% "LJY^0]L#BNBU'XPZ/=^'+#7
M/ 1@UZ7491'! TOD,^/O#E2P8?W<=:V@DDU(Y9\\I)Q9R/A& >'?VC-,\/\
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M_3K7I2M6T9I[,SE!K<=]*.!29P:PO%'B"Q\+Z%>:[J#!8;1"V">6;HJCW8X
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M&+X>^(AFPU:/E5=?,^3<K<@C/6OSIE\0>++^;4O"GB[4)Y+4GFVD)"*T!VH
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M=S2V*3O:W-O=1B&ZM;A%5C%,@9U!VLK JS*0>&/./=J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#__U?W\HHI&4,I4]#Q0!\7_ +:_PS^(/QA^&&@Z
M?\'I-+3Q%HWB"SU2UO[ZZ:W-A+9I(R3VTB$J9@Q5=KJR[68[=P4CQ>P\1?\
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M)*-]S3EC*FYI:GW)9VT%G;1VEJ@CAA4(BCH%7@"K.T=JKP*T4*1;MVP $^I
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MQF2<YVEL]LBOT-01A L>-H QCICMCVKOP5-)M]3S,?4>D;$G>I[1%>[@4_\
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MN=9G$A@0D0H6<_O"$&%V@G=GGI[5^COC"#5]#^'>H6O@V/9?VEF4MA&,E2
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MSZ;&:HQ3Y9;GQ5\-_#7B7XB>)9]&LB^HQ/.D]P\@S!;KOW"63/&3C 49)/;
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M!X-<7^S'JD.M_#G5-6@AGMX[OQ5XME6.ZA>WG0/KMZP$D4@5T89Y5@"#P>:
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M)KE'!(9&B^;((Y!QQ7@W[,GB&\U*U\0:WJIFF$4<(BDD!9S#&&^7)Y.#7O\
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M/1++6]6UN^TC4]-='0H7O)&'DLH8-M1OXP.1T^M*51I2TM^O^1/+>SN9.O\
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M2?%/A_Q?X>\!^!;**77==MRT=Q<',,";V!8H.21C/I]:^VJ^-_VD/A=)XO\
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M55_MIKZU1@&P3#Y@Y/T[4Z]"*C=(5#$2;<6?<=%%%;' %%%% !1110 4444
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MX)[".$O8:E;QLXW@<(_8'/K^M>T?!_X<Z7IU@GC35K19-;U8&9F;GRXY.54
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M//\ QWXVF\(0VRVNG-J%Q=;R%#B-%6, DEB#SR !WKQ";XF7GBQG@U()9P1
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M\)0Z=)XOFU_5-:\0WNGZ_8ZD-$\+"TFT[3?#TJVES)YK$+!*0L92-OF+!N
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M4?A1I/[/7CN_^.%L][X(CTYQJ,$(_?2J[*L20G*XF:8H(FW##[22 ,U^2/\
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M]G6$?O$C1A@D'/RD=<\8KZ%\">";?PE:NV\S75RJ^8[=1M[9ZXIG@OX<^'O
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MP7OQ][H?;6K>,)-2U&]\+Z!I1UA$@<7$XD"P([ @1D\Y)[XZ5Y=K'PUTC0_
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M&*^Y_ 7Q"T3QYI%M?Z?(([B6,.\#$"1>V<=UST-%*NG+4K$4902ML?$WPO\
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M[1/&OAW6_LT^EZE"CR2QA!,?+8Y8<;&PW(Z5<JJV8O9/=(^HZ***S,0HHHH
M**** "BBB@#YS_:N^'?BCXI_ W6_!_A"SCU6_DN-.NVTR:?[-%JEO8WL-S<6
M#S'A%NHHVBR?E^;#?*37RWX-\*:K\0OC;\-_$_@GX 3?!B'P/=7-QK.LW46F
MV3W-K)93VPTN".PD=KF.262.3<^U(_+R &(!^A_VU5\3-^S;XI_X12+5KJY\
MW3!<6NAQS2:G=V+:A;K>VUM]G!D5Y;<R)O PH)+%5RP_/C0M>^#'PF^+_P .
M_&G[._P>^(O@FRBFNU\4[/#FMFUN].>SE6*":U;S1-<"Z,+I(!\NUF9V^44
M?MA7Y,P_'?X _'+XW:/\-;'Q1H'@KP%X"\6QW5IIL<D-OJ'B?Q1#<EXGC@CP
M(K1;Q_,WD&2ZFYX7);]2/"WB&U\6>'--\365M=6<&IP)<)#?6\EI=1K(,A9H
M)0KQN.ZL 0>M;U 'EOBGP;\0]9UB2_\ #OQ N?#]DZJ%M(M.LKA5(&&/F3QL
MYW'GD\=JXO\ 9CM+^Q^'.J6>J7S:G=P^*O%J2W+QI$TSKKMZ&<I& BECSA0
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M>:I<)<2P6S.':&'RXXE5&95))4N=HRV* /6)O^3E[/\ [%&Y_P#3A#7X[?\
M!7[XI?M*^!?B1X.T_P $:WK/AKP)/IRRPW.DSSVB7&J^?*)4FF@*LSI&(BD;
M' !+*,DX[+4?^"I_@*T_;-&FGPI<-X4LQ+X3?5/M(\XLUZA:]%OY?^J#I@)O
MWE/GX;]W7[ED ]: /B#_ ()U:EXOUG]DKPKJWC]IW\1WE[KDVH/=*5N'N7U6
MZ:1IE8 B0L27!&<YSSQ7V_7A?[/?_(F:[_V-WC#_ -/]]7NE !1110!__]+]
M_*"0!DT4UE#J4/1AC\Z /B7XA_\ !0;]FWP3?_\ "/\ A_6+CQ]X@=BD6G>&
MH#J,DC]@LRE8#SU"R,P_NU\4?$;X&_&_]L74$U?1O@3X?^#=O)(LJZ_K$LL&
MNL5.=_E6?E/O_P!F>%AZ.,9J]X7_ &%/V2M*^*]U\'_!/QH\4VOCE+=Y;FQT
MZ\@26.*':S":6&T"*1O4[&<-SG'6O)?B%X=_8Q^&?CR?X>>(OVAOB/+J5A.;
M:^DM+LW%O9S*<,DLB6WS%#PPC#E2"IPP('[[DF P&%J+^QW4=7EYN:5.I)V?
M51BXQL^E^9,XYMOXMC]GO@)\-_$OPD^%.A^ /%WBNY\:ZII:RB75+O?YLHDE
M:14_>22MMB5A&N7/RJ.!T'L->0_ CP)H7PW^%>A^%_#'B2]\7:4B27-MJFH7
M*W<]S%=R-<*QF155UP^$('W<5Z]7XCFM5SQ56;ES7D];<M]=^7I?MTV.N.P5
M\>?%/P;X<\:ZE?Z;XBM%N8DN6=#DJR,#U5A@C\Z^PZ^&_B)\2M)L/'&J>&=#
MB;6M<CED=[6#_EDHSS)(1M7D8 )SFN%-+<UI)MZ'S'^T!X,L_#ND>&[RP2_N
M-,AOT2\C266<+%C@["3@9[U])^$_$WA'5O#L5UX=NHY+"TC"%?NM%Y8Z,K8*
MD8[BOGW4M"^*GQ?\._V[KS0Z';6:37%E96;LTDLR_<\YB<$#':OF/0M(,#W3
M?$'4Y=->60+';@,)GE+<YZ )SU.?:LZNEI([81YH\K>J/TBB\9Z?%H;>(=3C
M>VLE9OG"F4;%/#G:"<&OF+X^:YX>\=:#X;E\+ZLKPW$\[F%)3"TRHN#E3AN"
M"!]:^MM&TZQM= M-.MD5[1($15ZJ5VX_'-?%>H?"OP]H'QOT/3O#S"9'O&FD
M@<>8+=0@=@?]DYP,T^9\M[F5.W,?37PBTKP+HG@>T/@J!;33YCO?>?WAF/#^
M8QY+9XY->I[E0%\X'4D] *^)S\ _B!IGBO6&L;F.Y\.7;N\$,D[J(\\J1&O5
MD[=*DU7XNWB^ H++PQ>?;IK.UN/[05V+S*\3^6L9/49Y.>XK/FE%ZZC]A&6L
M6;OQ4\8>*?B)<W'@GX?VFFZKHGE@W=S<RXPR-R5)*@!3W]:X/POXU^)VAF\3
M4HK:/P_ID1@DN+=5F *C"Y"\MGMG\Z\B\,6&N?$[1-2U:WT>;3]/TFV"7 M@
MT9E;=N)4XRS8^\/2OO#X*+X+U3X<V%UX7AWV5VFV42K\S21_*X<'/((K9J,G
MRM:A)N"TV/G;P3\3SJ.JW>E:$QMM=UA?W$WEC:S1J2L>WH-V.3ZU%X2_:%\?
MZGKNG^$M6,-I>3,T3S.JG$BDC! '5CQ7U!H?P=\"Z#XLG\9V5F3J4I9D+L2D
M6[KY:]%]*Q_B-\*?".JI)XOCTQ1K-BOF+)$-KOM]<8RP'(/6LEA^6+'*O%R.
M9U#1?^$T\7Z5I?CPIM>)Y((C@><86!8I],CGTS7N]RFA^&=(EOF@CM[33H6?
MY5 VH@SQ7Y_>%M'\>Z'XJTKXE7IFU;PY;2.D,LLN^2%68JPV$Y&!Q[U]0^,O
M&$'BKP;KNG6\3)9W5K)&)1UVD?>/H,\4HSC&RDPJTFW[IE>#?VB-.\0Z3=ZO
MJ-F+8+=I:V]M$2\\ID!*\'@D@'@5S/BF7PGXI\5RW_Q!CU/1[.Y$*V1>W:,1
M&'JQF7=MR3T./QKDOV?/A?9ZAKEIXVD=WL]+1D@C883S\;=P]2%[^IK[BFM;
M>[B:"ZC6:-AAE<!@0?8TTN:^NA,JBA+1'R1+:W/A2ZM]4\">/7U.SBN8XY;&
M9UD+*QQM0GAAR<X''K7LOQ-^+.B_#S2I$9Q<ZS)#YD%HN2Q4\!VQT4'\ZY?X
MM>!UO#H$>@VD=LK72P.T<8&P-R#@#IG-5=%^"#W&IZ[J'C2\;46U%1' Q;YD
M7KT[;3P .,5"YE(TO"44VR:W\-?#M_APJ:\\-[=7\!=II1NG:XD&_P"4#+##
M'C JS\/_ (HZ/8+8^"/$LLEOJ:'R()) S).H^Z=Y[XXYKYL\9GQOX'\96WAG
M3=,0_:\I!<R*2T@4' 0YP..@%=UX4TWQUX_@M](FTV"SMXS*9=0QN>,\A%5@
M<D^N/7DUDW-25U8U<(N+=[GJ/QHN_$GB.WM/"O@9DN#=)(\\B.&4%2%521QU
MS7@EK\(/C*\&C66JZ9!<0:=,TS;ID(D9SR6'3I@8]J]&^&OPS\0N9;2+6M^D
MV&HL6GC^62X:!NQ'8'CJ>E?7H&%"YSBNBF[N[1A4GRKE3,W1[&+3=,MK*&%+
M81(H*1@!0<<X ]ZT^*9WYICR)$A>1PJ+R23@?B36\=$<C=S@OB?=WMGX,O)M
M,U&/3KW $$DAPK..0O;KC]*^3=3^+_A&_P# $?A^^L)-3\2,A@E9URY<G#.K
M ]">@KW_ ,67WASQSXYTOX?R>3?1V:->7";MPVXVC&#@]>>M=+??!CX<:C>V
M=\VD1036,JRQF(;,[1@*P'WE]C7/;FEIL=D)J$;2W/C2/PI/X/O8M<\.64HF
MU/38X 9P(HXYG8;F5CQQC!)^M9=CI'CK5?$%EX>TB*.[\IF::2$!PC,>?F]!
MV.:^YK_X7>']375QK-S<7%OJF-\;2[8XD3HJ*. !]*\$_9INS;^(_%_A^TM%
M.FV%R%M[I<G>I!PI;H< 9&/6B4'+66HXU4DW$Y;Q3I?Q:TO7++3-=LY=>TH6
MX 64&>U4J/O2#IN&,\US>I>.-5\&KI&IZ!:C[;)/(+C[&IVI'D;$\I1]T_2O
MT.;T/*XY%?//Q>M-&\!6D/Q TG3O]/%S'$YB VE7[LO3J,9]Z<Z3:21%+$*_
MO'KO@WQ58^+]!M=9M.#,@+QGAD?H5(.#US75@8 ':O,= N=*DT@^)-':*&XO
M8EG:'< JDKN92.,9/K6[X/\ &ND>,[*2?3I )[5O+N(3]Z*3T(]#V-%.:M9F
M%2GJVD=DM>,?'?6XM/\  [Z2%$ESK,T5O%&3R0&#NV/8#]:]@EGB@C,D\BQ(
MO)9B% 'U->(^+?"]A\6-:A-E>/#:Z:C0O<1,-P+X8B//0GN<=*=1JUAT$N;F
M>Q\M>"KWPWXKC'ANTL#'JFJ7\:2F$-YK6T;_ #^9@?*HQU)P<U]D^+OAMI^L
M0B]TF**WOH(3$&"C+(%Q@$<@XX!K9\&_#KPCX%BDC\.V"P2S<RS-\\LA]6<Y
M)KO,THT474Q%VFC\_P#7[[1]+\'SZ&\NJ6VL).R1.%D&T.>%V@@;>N3U%>@_
MLXZ2OAF_N[751+?ZOJ2E_MC.SX@3&U/FY R?QKZLU#1=*U1"E_:QRY&,E1G\
MZKZ5X=TS1Y&ELHPK, N?0#M5QA**Y5L.=:,E?J>V_#C_ )??JG]:]1KRWX<$
M9O1W^3^M>I5;.5GYY?MR>'/$NMOX=N=.AC72[19S<W)&7C9BFP#O@D<]O6OG
M31]$\=Z'X"D\9ZZMC9VH19X9)&9Y)9HW_=;8R!MW%0V2W3L:_4CXA);.T O%
M5H?+?>' *[1CJ#QBOS/^(?QN\%>,?'>F:.+:6?0-'N?*G>3]W&TF1ET0GYE4
M#J0!Z5Q5X)7FSV,)5<HJ'1'TW\'_  AJFDZ=/XL\4WC7_B'Q$L4UU*PQL0#*
M1JO0 9S@8YKC_B3KVMW_ ,3M+^'^GZT^GV,]H+B[$8&2%8_)N(_C KKG^)5[
MJ&K:;!X2@75;*ZF"NT:G:D/=BW0'O@]JXGXY37FG^*/#.J: EN-2B$OF>:!^
M]C."J$CGJ#BAR7LVHNXH1DZEY'E5MX#\!>(_C#_PBFLW,KP;VF%K-]R=XQOV
MA<[<?-D-C/!%=>O[-.GR>)+NYTGQ D0DE+L+95CDMDY 50ASGMG('M7DJ>)]
M7\4?$C0O'FK6T>G3:&X7RH"=KC)#!R2-N03SD\5Z?X6\=_#^\\9:EH>FW)L]
M0\0I);O-%'L=,CY27 P>>YY_.L:JA3?)(W_>2CSHX?5/AYXLU34]0^&>D:H_
MB&ST199[*2=MJQ,5W")W3+'#8'UK4^!^@?%/2/&NF76N:++!;CS([LS(P"[U
M^^I.0,'I@].,5R5AI'Q.^ 7BK4=<GT]KM]4A2TCN3*UQ$R>9N:3!(P_^\.]?
M4.D?&>XN+VXTW6$M]/:T@:1Y)F* [,98YX4'/&,@TJ6&3NVM5^05J[MRK5&!
M^TOKWBF#0]-\/>%-1CL1J-P$OVX9_LI'*X[!OPS7;?#WX)^"/!L1UJPL@NK7
MMMY4DS.T@42+A@@/ !'6OE?QGY?CR]U[7+&],QAC2=G8E%:,$8,*D\ X(RP!
M KW7X8?'3PLWA.VLO$$S6M_8Q8DW9=2H.$8,.N1V^M6L5!S]XSEAIJ"43S[X
M3_#CPOXI\6:SHGBK38[L^$)1$J2+A9&E8LKX'&W(Q@]2/2OK'0/A[X-\,ZK<
M:UH6EQ6=Y<KL=TS]WKA0<A0<#./2OF'X,?$_PQH6I^(H/$ GCU'5KXW!NC$3
M%*CY"*""<;>>H[U]!_%3XCV_PV\$7/BU;<7\B[1! &QYC/T/&3M Y.!6V&C'
ME,<5SNIRHZ7QKXLLO!'AB^\2WJ^8EH@*Q@A3([':J GU)_*OB>\_:A^(JZK#
M#9V5C)'=$A(%C9W#9XVG>"Q[<BO,O'OQ%\3?'2UTM-1"Z0D"3-]C5F"$GCS6
M[D@?=SVS7O\ \ /@GH]O+IWBO57^WW-C&)(W (C$K$\!3UVCD9Z&IJ<T]8[;
M&D80IQ][61O>&?AY\2/B4/\ A+?B?J[V<$DLGE:4ML$"0H?D.2>"W4Y&>*^4
M[K11>>.[O1=)!(M \EW,^!L1CCAFZ.>,_6OUB8+@[CQWK\Q/'MOIOP^\67<.
MFS'4;'5KQI[B</YI4[L(C29R=HYQWS7+C,-[J?4Z,#B6VS;N[2+Q)8Z9X-\/
M1/97FJND<D]VI^55)  QG/ W;CZBON!/A]ITGA&Q\/32-++8VZ0B<?*[%%P<
M^Q]*^88?BCK-I>31V6GV?V%MS69+AIY&D!VN <;=K?PG/6O&](L?B9XS\1QE
M-4O+K4)G&]_-9MH;KN5"%15'3.!Q4X:K%+E*KTI2?-LB[X[\*6'A_P 3/86%
MBK75TGG,YR\K%1@\GM[=JX9KM/#HM//MHY#J"&3=(6_=RIC"G'^<5Z+;?#;X
MR^%_%-_K)L[B:'3'WI._[WSX\X&T9).<].>!6$^LSZQX@OO#OBVR%M-(/.A9
M(P!O9#B-^,JN1G'4?C6%2+O>2_X)UPFK63NK'*6,MQJNK3-;J+:&TE6;,+OE
MG90=R8Z8;KCTKZ#OO%WB[Q]+IWA3Q!Y%S',%D$+(%5BBD!I,Y)?K@=,UY=X9
M\#Z_?Z?%?>:L@N8Y(G Q'Y"Y*AEZ?,1W]A4H\"^-;K2[G69KR.9=*9O("Y2Z
M>*+Y849C@'N2<\YKIE%RC9?F<O/%2N=!K^D^(--U6V?39HXK736)NX\C?L09
M78OH!U Y]>*^BO#OP\T-=,_X377+A+F\O;>-($MV(C$8'RIN!RQ/\5?&%SKG
MB3Q%92ZC?2(U[8Q*S(BE7:-F&[=M^\QX!([5LW7C34_#'A^"UTJ-](MD^<QY
M,DJ2,!(8U5N26)S[#KBJE34%$CWIW29ZOI?B"^@O-9T[6)[2"]CWA88 ?+@0
MC&'/0L%Q@9SQ6'^S;X3T'XC^(M4U?4(\Z;X6N%CMK099)+C<29I2?O8QE4^Z
M.O:O)?!?B&*XN4>P,T]Y>^:9+6X79\Q1F=D_O'J<D<=JW?@A\=M&^%OA6]\/
M:)ITFIW^H:C-,"5(D&[ VNH&YB,'%/:=W^ IQ;ARQ/HKXUZ';7/QR\#W\MUY
M7G6QC*QMMD'E3AU#?[#EL>^,5]@"WB)WF)2X&TL5&<>F>N*_-S0K/Q3\6/BS
M9:KXWLW2YM[F"2%8V,:01P,'"$=VQ\Q';O7Z4Y(.ZM\/44VY(XL53<+19CZS
MJ]EX>TN74KLB."#&>P KYD^(^L^/-6AN=;\&:[%$FG2AX(8I!B6,@8\S&3CG
MG/M7H7[00A7X<7M[/?K8BR*RX<D++_TS.,]3C%?&_AO4-"GLHYHF>&62$J6#
M'89'!/S#@$$9(QGCCK6=>K*,DDM#;#48RA=GV3\(_B=J'CM[S3M:MXK6]LXX
MG(@8NC!OE;D_[0KVT'!-?.7[..D:+8^&-1N+1%_M W3174@.20OS1CV4AL@5
MZK\1=8U30?"EUJVD.$E@*%FPI81DX;8&X+>F:VI5+QYF<M:FE/E1W$C*B%F(
M4+W/ _.OSI^)OV:\^(7B?3;V"ZNKS4;D&R1(3)]JB$:JJH<?=5LY/&#S[U[O
MX!^)&I>.I(-)URX5 H>.X0;=TBD_(QV?=9>!Q@'T.:K?%G6;[X>W>A2!&BLI
M7F0SP$[XU) Y8\L=G)YY/3I43;FO=-:+Y&[G?/\ "6Q\5>#_  KI7BFZF:[T
M.&+<ZL/,+! "C-[=#ZU4\3_"5KK5?#PT>=++PQHS23W5J&8-(_)+<?>+#@EC
MP/7I7C/A/]H+P3H/B2ST#PY'YNC2E(YKN8OY\A/WI#N) PQ^Z><9]J^T;FYM
MFTV:Y,X6W:)F\Q<$!"I^8'H1BM81WBUJ1>46FCXH\.>#+WQ5\5Q/X<MVTK0;
M2W:5;]&#O,SX&TG&"/\ 9[5Z1'\&M#\-?$WPGK4E[/+*^J6\L<2;8T+I(IW2
M=2QR?6OG6RO]<\,O<VOA/75C@65K\DR.R8W_ #]!G '&.*^C_@YJNM?&?Q?;
M^-KYUM=+\/W<<$!BW'[1,A5WV!N @. QZGD<4G/G]Y+;J:RBX)IL_0&OC#XY
M^ 5\6?&[PKJ][=8L]&TXS?9@H)DE$S[6)]!GIZU]GU\1_M-?$V+X:^+K743I
M$FI2MI7[LHVWDSL,$XP!W/>KKM*.IQX.,G.T=SC?BU\+H/&TUGKLFNMH TR-
MA),D:LQCSNQO8C;7RJ]W\.(- UV*\2YN=3MR4M3-$&%P3]V7!Q\O^]S5SQA\
M9?%?Q3TB/PDMC%ID=W)'+(T$N7\M#G&6('UXK@[WP3;2/>2VBSSA2JJ\AR2<
M9W@ YP3P":\[$8FG)IQ/;H8:<8\DV>[? 7XOZ;H>DV_@_P 3PQV&"6BN(DPC
MEV^ZZJ.O^U7VK#*L\2R+]U@"/<5^4_AC3[BXNYKF2UDLKBU3!CE0JTA!Z'N!
MQ^-?;GAKXV>#M*\+0MXPU&/3;NTC59$?(WGH!&!DL3Z"ML-B+-J3T.3&877W
M%J6/V@=7T&#P:= U19Y;K4F_T86^S>KQ\[F+$#:.A]:J?L^^#;70_#"ZK>V*
M1ZG=$_O2@$OE=AWP#[=:^-_B5\0M5\3>-KCQOHQCV1@16@D <I$G?:>-S=2#
MT]*].\(?$35O!V@/KD%V^N^(M?N5M[>S>=)" %R9& Y  X Z>U5.O>>FR']5
M:IV6[/L6Z^(WA^V\:0> P9)=2E0.P1<K&",KN/N!VKNV8*I<]N:^)?@U=ZY<
M_%J\U7Q9+YFH:M"S[, ^64Z*<?= ' 'XU]JW,CQV\TL:[WC1F"] 2 <#\:[*
M-3FNTSS\1146HGF7@#XLZ!\0[_5;'2HI(3I<[0@RE1YVS@LJ]< USO[15UIM
MO\,KQ-0MUG>:6)(-W1)2>&SVQZGCFLGX'>&?#]NM[XI29;G6-8GFNI1&-L=N
M7;!C51P.G/J:]<\=^%XO&'A>[T>55:0XEAW@,OFQG<@93P03P15+WD[%6C"H
MCX!MH?C#82Z/J6HZ!/>IHR#[-/%*&D6#.['RGD>GMQ7L@^+?BOQ]!/X6U;1)
M=)CO%" E2P89QAB 00Q[#FOH;X8^-M+\8Z$!:*D-YIS&UN[=5"F&:/AEV]AZ
M5Z1A1VKC6%OU.BIC+.TH['PUXX^ WQ/U6P@UV[\0R7!T@H\-E "_[J,@XC3"
MC=QTKZ>\#?$CPMXK@BT^TNO)U.%0DUI<)Y-PK*.<HV#^5>EJ>#7Q]^T)X5BF
M\1:1=>&I8+35-2D$<AW[#YN<)(V.G]:WY+62>Q@JBJ.TT?8G\)P,D#_/-?$>
MK?"3XKS_ !,UOQ5X-C'A.RU1HT+6[(TC;3\TC9.,GK@5]$_#3PMXO\+636GB
M/7CKD)1?++#YD;^(9YXSTY->D7VH6VF6,^H7[^7!;H7D;KA5ZFJ^*-GH*G-T
MY>[J?)?@;P;IEI\2=5TKXMJ==\0W?-A<7L?F13VR 9,9.4!'=1TKZP@T;2K?
M3VTB"SBBLI%9&A1 L>UA@C:!C!KX]U#XI6GB/XIV_C+2;6[U#PWH4"Q>>D+^
M6&F/SR-D# 7U]*^LXO%7AV2"2XCU&$Q11><[[QM$>,[MW3%9TYJ]F:XF$M/Z
ML'AKPEX=\'V#:;X9L8]/MF<N4C& 6;J?6K^L:C9:3I-UJ6H.L=O;Q.[ER%&
M.A)]>E)HU];ZII\6H6MW'>P3C<DL0PK*3QCD]J\U^,'@#5_B3I%EX9M+E;73
M9)Q)>MN(<HO0* .>?6M]#EBKRLV?$_@_X3BZ\GXG_88-5L9[JX9+"ZN&@C@D
MW[H^2!Y@X/RYQ7Z(^$=3N]6\.V.H7UC_ &=--$I,&<[/0?2OGSXQZ_X+^%7P
MZL_"D8:6YM?*-I F"Q9/XG[XQG\:ZKX._&SPOX_TVUTIYC9:W'$NZWN!L:3
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M(4WP]\8W]YJ6K?\ "=^&E\Z*X>S)%PNMPSAB9&AA3$T3@CH=[;J /UHHHHH
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M&P@U+Q1/-!;W$GDH8;6XNR7VEL%;>.1@, \D >^:\Z_:)_Y$#2O^QO\ !/\
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M[9K!I2GM:QUKX+=SWWQ=^T;/XGEE\%R>#98K>[7"RS2$AFQT"[%'ZYK"\)>
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MR\O%@N+CA!D97.<$YX R,#-9*$8:FTIRF8WQ!\80>!?"UYX@:+[5/ F(+?<
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M3E%;/J2VOQ?NX_&.G^,/$9BUNVM@D=K &\F:WC;"F5A@D\Y.><U]K>(?BWX
MT"Q@DU36+>*6_BW0P[\R.&7=R!T&#WQ7P%-X&L%\-7&KZA$]IJE@3%;)+*J"
M1VVD * 6XP>-V*^C-8^"WPWUCX<KJ&KQIH_B&2U2[,TUWN:*0 ,W#,%*$9[8
MYK:A)]]+'+B:<;W/"_#'PK'CCQYJ47A_Q!'IUM<L'A@C@::+8N2S-\R8QDX.
M3R<&NRO/%/Q,\!PR?"35])#:$WG0Q7178[C<7+JWW2"3GCD9J?X=>-O"/@3Q
M!::]_8M\FG7$2VOV\JI'SE1YGEYW;._ S@]*[/\ :-^/?A[P[')X0TS1;3Q-
MJ$$8ED-W(1;VS]54[/F+E><!@!QFE&::?=;#E&?.E:YQO@W4/$NG^'I(=3M7
MM[;S'93#F5U3@KA2.OIC->^^"/BG9G2X&OHW@$H8E)CMDRO!(S@<^E=IH^J:
M'XI^'&D>*9[2.&.]LK>Y4*H'EET!VJ>N%/'TKS2'PUIWC&YO-.LKF&281$^5
M*F0K<<EA\X_^O5\UMMV<_P ;=]C%^-GC?3/&/A=-"T2VN'NQ/'-'*Y2.%2H(
M.[YCN&">W!Y[5S6B:>UU8+<V&H16FN2(DERR@2I'MC ?[V!SCKZUX[XTTO7O
MA]XD2/6HY-.MX7_=[SYT$Q<<!'ZC..,]*E_M;Q!?>(;6R54FB*();=<X$+8P
M6;Y3G(SZ>M3*A*;3ZG0I*,;(=X@O=>USQ#%$E_*MII2".)S&,R(%S(R*.NYN
M^!7O/@K^U=2^';Z<&2"XE+!)9E^9HQ_$H(&,GT&*G\-_"2"Y\476J65_<R3R
M!1-=2'**P &U%XZXY]J\[U+XGW%_XVUKX>6NDIHR:+',G]HRO()&$3!2Q7;C
MYB=P"G@'G-5.7NV4=#-*\MRCXE\ 6NF)!J^J[)8%:3"HQ\Q68;21@@X'7/K7
MET%IJ/AV6;3Y9XXK36+<*KJS91(CN '.23U<_A6[X:\.>)/BGKUSI;ZC%=QV
MR,$N8VPQRW\2'GJ<]!CZ5V</PYTVW\7Z=X:N]2-_=%6MT%NH\J-U.Z4EB=V<
M=?RI<TH/G>OEV+T:Y3T+X3>,8-"TFZL="TIKV\@#2S7#$G<NT' P.,#J*G^(
M/B]_BYX=;PAIAETZ\9T=8EDV&Z95W[8VZGY23CUKU[3[OP#\(_!-SXDO<6%I
MN_?R$%I)92=H"KZL>@'%<7\-H'^*'B^3XI:I:-:V>DO)!H\3(%RDJ@M+D=QR
MN"#SDYI>RDK=F<_M(ZR70X?2O&'QUT :$RZ2\_ABP"PW4ESM-W*A."W))+*.
MF*[IOCC96%U>Z!\4-/;0X[T,+.6)9)!);2 K\^5&UP#DXR*[SXO> Y?'&AVB
M6%^^G7VESBZ@E!Q$&09/G#(^7 Z]NM>7?#^]T?QYJ;Z5\09K;7;VTFD_LX >
M8OE(IW-N7"L&Z9YSBE-.+23+A*,DY21P-BVB?"L0KHKR^,K+Q89[))H"0D$.
M,L)#DDNQ..V!VJ'X4_"?2O&&J:EJ&KZQNLHVV?V5!*VZ)E./W@XP   ,"K7Q
M'\#:-H^I6\/P]\0+%'!/)]ITP2%A%*^!N5AG85Z$'G%51HGC'X>^3XEDQ97S
MM&KS\M$8WPIWN5VY<=R,CM43T2NUYI&D7>]GKW/KN'P3X6@M-/LUT^/R-+D\
MZW3&0LF,;C_>/US7F/C+QE\,];T6ZT];L33:@TMD@C4C;,J[B&R !C'^%6_$
MGQF\*Z?X:U/^R->T^X\06, Q;-+C=,0/E X))YZ?CBO,O@OX)O/&^AOXC\5>
M6EC//+);6\$:I^\S@R[@/0;1^M=#=U[IS1CR^_(\>^%OPRTCQ'XWM[+4M2>(
M6Y-RGE+AI_+8';D_<P,$^W3FNK\:^&KGPAXSN[.&Q6ZFN(#*;I02[H6^56P
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M[$=^E7+DJ>[N31YZ?O'+?"O3'\%Q/!/<#[=<R^7&H.YVP-W/3@CI7VY*R3Z
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M(KY>\?>#WL/'-]XFL3Y=W>VS&!\\%BH1U(/!XZ4Z^D;WL9T$F]3Z%T#7]/\
M$6GIJ&G2AT/#J#DHPZJ?<5L_2OSDT+Q-XL^'VMH(6F6>[8^:C M"TH/W3VY
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MC#J&E2ZA*=,UFYN;^/2(I;*=)+Z+?'&UFT;!;=4N7D^24HJ^8V\@'ZVT444
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MEAL?KQ_P20L;/3K#XIVEA"EO"D^CX1 %49CN<\"OV,K\??\ @D[_ *CXJ_\
M7?1O_1=S7[!5^2<3P4<PK1BK*YZ6'^!'X ?M$_\ )QWQ/_["\/\ Z;[2O(J]
M=_:)_P"3COB?_P!A>'_TWVE>15]%EW\"'H?WCX??\B3"?X$%>Y?LK_\ )TGP
MR_Z^M4_],][7AM>Y?LK_ /)TGPR_Z^M4_P#3/>TLS_W>?H9>(_\ R(\5_A_5
M'[U5^;_[:_\ R5?X;?\ 8$\1_P#I3I-?I!7YO_MK_P#)5_AM_P!@3Q'_ .E.
MDU\/0^-'\,2V/EN\L[34+2:POX4N+:X1HY8I%#(Z.,,K*>""#@@]:X3P5\*/
MAU\.KBZO/!>A0:7/>C$LB;F=ESG:&<L57/.U2!TXX%>AT5ZMEN87. ^+'_)+
M/&7_ &!M1_\ 2:2OW[K\!/BQ_P DL\9?]@;4?_2:2OW[KAQFZ-:9X7^T3_R(
M&E?]C?X)_P#4FTVO=*\+_:)_Y$#2O^QO\$_^I-IM>Z5Q%GYR77_!+K]F2\^.
MS?'.6/4_.?4/[6?11/'_ &4UZ9/-+E/*\WRS)\YB\W9GC&SY*_1NBB@#PO\
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MW<1;<&#H0.0V0>W_ -:KA974MR9S;:['A_B#]I/PN^F._P /W36=0B7S9H9
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MRKN_U@QG<HZ8X^M?5FB?&6:WCATOQ)I[W6IHVRY?3P)($Y WDD\*<UY%XO\
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M=G&6I\O_  D_9@LO#>B75O\ $R:/Q)>7## R_DQH.@ ."3[FOH.[^&_@J_\
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MB?X_^)_#.K^&Y-;\,0)JUG<6AD#7I*">-HRP'E<XW9Q7W5Y_[3/_ #X^$/\
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M\3? KXX07UK;6%W::GIEEN$;B.-)=A_O9 9CP!C--?Q%XL:Q;P[XU\,:="I
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M;QW\%?!7Q+_9"NM'GO=8UW4;J"SCBMVDDG^TLH#QLO!#JH//3\\?K?\ !_\
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M@>GZ'TKZ9^#GC*S\,>$[J^U_4WGN%E2"WM&P)&+ ;.!U+$X)Q7DN@:A9>'M
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M@'>PWUSXC\,7;RW$S?<!VRIN/)0Y KIKTY-*44<V"Q$%>,WZ' ^*?"=I\/\
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MMK_0;^VOKB]D5Y&E0!8QUW\C+'/45]$_#SX<OX4:\U/7;M-4UB^<-)<>7@*
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M7E=RBI(PSD  EACDG@5Z-<?$.]AM6F%FC,@R1D_C0XM/4=G8]46&%#E44'V
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M.1\=_#/]DOP6?BK^TE^SCI7B'5=,TJ#3_"ES#JLEPKWL=TD9OA-))M4,!/\
M,P 7Y> 5."/TF_:;\"?!OXA_"'5=!^.FHPZ+X91XY_[1EN([5[*YC.(IH9I,
MJLH)*@8.X,5P0Q!_'&#X8?L_G7M;N=8_;1NKO3/$L5M:ZO&D<J7M_:VB^7%!
M-=M/('58_E&Z-EQU4CBOV;@G$J66RHTIRIR6[5.4TY*<)QE>*>L5%I1E9:WZ
MLY:J]Z[/U,_8.^(_B[XH_LR>%_$?CF[;4M7MWO+"2]8EC=I9W#PQS%CRY**
MSGEF!)Y)K["KQO\ 9_B^$EI\(?#FF_ RZ@O/!5A"]M836[%TD\J1EF9F(!9V
ME#F1B.7)/>O9*_,.(*L*F.KSIPY(N4FHM6:5WI;I;MT.B"T05\K^(-"O;3XC
MZ_K=S<*T-YY*PPH-JJJQJ"SYZN3W],"OJBOFWQW?VLOB'4(/-$;*RPY/.'*
M]!['->5%FL#\B?&7Q#FG_P""BG@_5=&M;Z^L(M!F0V\8VF<1+<!I(T8@.N1E
M?7'%>#?LQ?LZ>'_VDK3XE^)O$>M:W9ZKI6NRVUD;.[,?EK+\V3&P.2I.<9'
MQ7V%J7P"^)FC_MF^&/BSIT2S^#M'TI[,73/'OA+)+B/RRV]N7^]CO7BWP9\
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MA\F-(8;4<+'$NW!R?3C'X5YGXC?Q%9_$"YN-!26:5K"$JK.?LFW>WF%D[R\
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MRL#HA($F6Y^Z.2:BZ:OYC>MRII/A"3PSK<^N7^I-K6HQS2/$9WQ+':W!&8U
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M6R1*XVA R^9^[![_ #?/[\=J]F-_9I,;>695< $ACC&>G/3\*\4^$GPR\/\
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M4[AN &1QVIR36VQQU**Y;Q>A]LT445S'GA1110 4444 %%%% !1110 4444
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MI@ QB.'B? /&Y",@\@Y%<]XW\4WUUX9NG\-Z*=:MVA8WB32-:F.$KDXW*29
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MJ<,QXXZ]AXE?0?B_\1EMO%]ZL=M8RVEOIFE)/ND>&659/MLR*5YD\M@B_-M
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M0L9Y69I+9B-PWG<S$ 9 /!-.UCP1\)M9TNX\0^,+.VOK>8Q>9)<8^62'Y45
M/NN#P O)/ K(M/BM+K.C:C:>$M(E74[-8TMXI2/*<R#*H)!G# >HQZ<&N-O?
M"/B7P/INE:UXBO9/$,LFH12W-O*RKI]KYK@-+M5=S-%_#D^]1#F2W(I\[7Q:
MGB-Q\+KNRMM9\3>#[O[';L]O<^'K=XPI=5!?SDP1(">5 &&ZY':OIKPS\+]*
M\1:4OB_Q';^;XCO)VU""5V?_ $9I &CAR#EDC/8^X]JYTS>'/BYIVL:'H6HK
M?Z59M):"VMB([M(]P:.>"<'A=R_*0.E=SX:\0IX$\,0:!?:#J<*:6XMD?9]H
M:X!8 S%U/<L68G'0FM*DG;4Z\7B:C7]XS?'6G:9\5-(?X<Z]9N+R:4P7> X6
M$* YD1L .C#&!GV->X:780:5IUMIML28K6-8U)ZX48%68GBF59XB'5QD,,8(
M^M2]*YY2NK'D5)WT,N36M*BU.+19+N-;^=2T<).'8#DD#OQ7E^M>.I-5\56/
MA;1](34+4![BXN;EU2+9&&4^6"&)(88+8&/H:S/%/@+Q+XM\?#6PMGI^GZ;;
MRP071#M?&26/;OB(.R-5).202>G2N9\$?"VZTO0_$GA'3M7>UNGE>"2YGQ/=
M10S*K#8<X(9<[2>><8X%:^SBE<Z*5&%N:3.Z\&>#KV'QYK'CP7'D:;J-O;Q6
MUI#/YL1*H!(YQ\N 0 @7W)Y->GZWK%AX?TF[UK5',=K9H9'8#)P..!67X/\
M"FG>"]"@\/Z6\LEO 6*F5B[9<Y//IGH*W-1L;;5+&?3;V,2VUU&T4BDXW(X(
M(_*LIRYGJ<]5IRT>AP>I^.XY]9@\+>$7M=0UIXC<R0S.ZQQP8XW.BL%=B5PI
M.<9/:O/?!UG8:]\1[[6];TN/1M<TL1B2,84S?:4SD#=\ZA@?F*C+#-3Z9X]\
M#>"M7\1Z6UP9(=&9?M$BQ,TD'W$6$D+E_O#![#VYKK[^\N?%*7D&DZ!<6\EY
M$+=-2F5(BH;(W !A+A025/\ >/2K>B:L=6L%HM.YD?$GQEHVFZG;Z-J[6=Q9
M3_N)8\>?<>>09=AB4$KB-"P+8R<"L;Q%_9G_  @<,_A. PQR*UVT]W$K;8R0
M[QR;P=JRCY"!P,CIBM+5_A5IEA9Z7:>']-BN7L8I0]U<-F42^5L6=R06D=AD
M$D@X/6OG\>*/$>C:;'X&U.^CM-;$B0K<-%*]G,CE=L9XP<Y ;!P"1DYS50C>
MW*;X:ESI<NZ.\UOP5X*\4^'X?B;:70T>WT;3/*BMK9!/%##*XD<-%&&)9L#;
M@96I?$7B?4_#/PO,4-SJ&J:W:J/.N8 4VD,NQ65L?+*K!0ZJ1G)QQBIOAKI-
MQ\(K?Q(FM22.^M3":VTXGS6:<JS2%.P60G@9P,=J]U\"V^J)X9MXM>$1NE+#
M;&"0B!ODC.XG[GW<^V:<II274JO-1;ZQ3/&OA3X6^'GQ-\.Z-X\U/PM_9FM6
MT+6\L$Y/F0ONW$L.,Y/S*2,X.:Y_XF_#F>\\133>%O$]WIUW;V]OYXM[E([B
M,.[9FD8KGYAW)Y^F0>NUKPA)K/Q&U&]3Q/>^'II7@V+8S>3YB0HI;S(W#+)V
M&X 8%8MC82Z_\3/$'A0:XEQ#J%FLMT"\<[RVQ7RH\1[!Y9&"#G<'R2*OFLVT
MR(SO+G3Z;&7IWQ5UW1?.\,>)KF[O;G0YI;*"XM8//EOI0<)YCK\L3[2,LQ52
M"#GK6SX6U2XTOXC66MZGJ4CZ5/'<:;Y,X82V]_/)]I*O@>7L6-<;P3R2"U=Q
MXBNI/!6@3Z/X:N$O[ZY_T>QM$@0%I]N(U>1<#"A0"2<X%>3:'!X(\(1ZIX/^
M+-Y#%K5VS7=]<22.UI.]^,2F-1D1YVX*X XR.M-<MM%_7<KFC*[2/3=>TKPO
MXQ\;6U_J6A3W%GJ%E-9/?QNGV>:*)L^1,,[L%BV,#J.M6?AOX]U7PU\3+;X2
MZMX?N?L8P^EZC$ 8&M2/N29QM:+(7Y<]N.];WPZL_"7B3X;Z=I5G?6_B'2K<
ME(KFW8E7:)R0^<DAP>3SD&NQ\,_#?PY:>+-,UYFNKF^LRRQR7%Q)*<')QACC
M@GBLO:1MRR.6\%S0EM8^BZ***YCRPHHHH **** "BBB@ HHHH *:'0N8PP+J
M 2N>0#G!Q[X/Y4ZOQ"^$ZZY:?%/X<?'*[T6&R\+>+?B)KEO;>,D<-XAUJ+5&
MO;>RL-1M=VV.R\P;(R'DVB*(K#"6+4 ?M[17DWB/Q#\9[+6KFU\+>"M)U72T
M*^3<W.O26<L@*@MNA73Y@F&R!^\;(&>,X&M\*O'%U\1_ UCXNOM-&D7-S+=P
M2VJS_:5CDL[F6V?;+LCW@M$6!V+P>E 'H=%%% !3))(XHVEE8(B EF8X  ZD
MDT^O)?CG\*;;XW?"S7/AA=ZE-H\6M+"IN[=(WFA\F9)@T?F*RJ^4^5\91L.O
MS** .YC\7>%)M/TG5HM:LGL=>:)=.N%N8S%>M.ADB%NX;;*9$!= A.Y02..:
MOP:SH]UJ=WHMK?03:AIZQ/<VR2JTT"3[O*:2,'<@DV-L+ ;MIQG!K\D9/^"4
M\%QX!\!^$YOB->1W7AJ427LL=K;A9_-@5)EW&+?-&DB!88YB0("8V)X-=V/^
M":.DS_$?QYXRN_']_':>,8V2.&*UM-UH9YWFF>%6BV0RIE/)EC&X.9';E@
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MJ^JZA;Z7HFC[ [7FI7(;RD&5?;A0Q)"DG[HY85\7WNI_\%"/#^EMXYU;X,^
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M*1FC^;;DYP2"0,@YKY9\;^)_%'B./Q#I$6G6.GZ48K:Q^TPR>;>R/&LRQ!X
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M&SUFW%WK\$%TEA,L]LCQ[@C(>#SU8]CCCTK86WN=2FMYKV!(K>#$B)G<Q?&
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ML:<9:E)]#EM+\9>(?^$DL]-U+PW-%!J\EQB[5T9(%A)$:RCD[F )XX!XK?\
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M:T[C=N;C'!.*XWQ#HFCZMH6D:C;Z@)=6MI$U(:9;2JT[P$J&9@=S*%@ "H
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MPP]I'KGB)&U#5KFW"^:\A<P9&,0N0&&!T/6NDT4_$F/4;>U\17&G2F> F=(
MZB,@G!C!R6]#G'K756%E=^'X887O)+ZVW!#Y@4.F> 05 R/8\U3DXW28T;L-
MK<IIXM#<8F5-@F"C/' .#D9_K7BVA?"RVG\7>)]0\4W#ZF+EXQ _F21.JE0S
MG:C +\W&5 S@'%>E^)KKQ% ]A'X>$&9I=LC7&=@'!QQSR,XQWQ5R!-6DU6>:
M1HH(TC1 @&\L>3NW<<=L8H4FD%CSV[\(2Z+XHM+[P_;27)3R0J/=.VR) 5<X
MD+ =>O5JAM?#'B'1OB&GQ U#4(P-9B6RGTU7S&DBG*/"Q +-@?,"/>O0=0$N
MF2V^I2S[YYCY!.#L^?E1M!Z#!JMJFD*NLZ=XGOYI;C["LB>2J;HT,F/W@0 G
M<,8R,\&G[6^XTSJYKH0W%O#Y9_TABNX?=4CD9^O:O-TUO3+J[;5S]KAU:W>6
MTBC9)5CE*D9PF-C#C[WIT-;>M^,-!LKK3+"XO$MYM0F C,H*#(!8 [L8SC%-
M\%7NGIH;0C4(KF6":<RLL@?:Q<D\YS@5*5EJ%B[?>*)(;.&/3K*6\U&Y7$48
MC94#@<^8^,(H]3^%/UEKG4["SL TUO-/,OG+;L-P6,%G4MV4G )'/-;MI?VU
MX"]K*) .N,Y_(US6GV>H6GC;5+FY?SK6]@BD@^;B'9\KH%]R-V>^:47U["\C
M:\/33MH\1OB1*@8.&QE,$_*3[#O6!I$5YK$5Q)8:TLVDG=% 8HT8D\@DR<Y
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ML-0\C2-'@B;SKF81W#RK"K+'&YP2I+#D9(Z"O2O"?C?PGX0\)0:;KTJ:;=Z
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M)E-OJ#2;;FX2905520!;ML+8D)Y8!1C=6MX;\3^)_&C2V_@C494>)84GM[J
M!;:..7)7S3N#MMR&.">.#7::I)IG@C3K7X:22PC3Y;*2<3W:2W+$^:SR80 C
M@D>6N<YX P!472>VQ#T]3D?"#^.)?#Z>(/AE%*L>K?OF.M1G?A%"1(5# CN2
MRG!&.^:] \._#:UL[D^./B#=IJ&O9::6X'[F"%2,;% (RJ*=H+'I7;^'IK,:
M0^B:6);0:5$D"M<J<J GR.=Q^88YR37%6?CZ_P!=\"&^70&U>]FFNK.6QB=5
M$JV\IAD96?Y<,/F4'KGKCFH<F]#.=23?NJWF9&K6WCN\UZ73_">J+/9&3[3
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M+_\ @GYX0\5>"OV4_!^D^+;::PN9S>7D%I<9\VWM+NYDF@1L\@E&#X(!&[!
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MW $>[+GN2S'WP*;C978['HX.>:CDD6-6D?.U02<#)X]JS;K5]/TYT2[E$(?
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MY9N'B&'(5 /GP?NC)KXK\9?"_P =:?XD2W\16=Q)JU[;+=-#(0^V)C@'<3D
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MKX.\DCDOL=8XH^1\Q #'C)R>*]I\/ZCJ/B2P8Z]HCZ=&ZI^ZG97WDC+?*,X
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M"MM"E &5N.I!Y%<AI \I^(^JZQX<T2#5O#MM:O<13)$#<2"-564[,*. S$D
M+D9->;V/AGQ]K_B:SUGQS/\ V3:I!"0+5P@GFE4I+!.BDJ0!@*=QZD"O4=;T
MYM5TNWU&XN)!+;.)(U4 QB3[BET;.<9]>M<AXVTS7=;M-)LGN9DU-+R&[2&!
M5"@6[ _.3E0.IPQ.<\5<9-))&S=SL/$)US19;/\ X0;3;6Y*$_:;5F\C?"
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MKGHX:K&2DUL.*4NISWA;2M1BOQ+9^,8_B5::I%.B6R,(2IEW(QE1 5*)C"\
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MD]S$89(9/,C#6Y1AD$#!.#@UYQ\.;W4?%-O;6GA"4:19:5/"99!;*/,CB?\
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MS)#9I_KI#G*Y;[B9')/M47C3X7PKHL^LZ)K,]I>:582166](Y(H$","J#:"
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M_JV.<C<01G'KP<5X_%K=AJ?C[1]*U&VE0V\4A=-LX8AE5W8+M"^4Q9E.[YB
MN:?\/-1\2>"!:ZKXIT.#3?/O9KF]N(G(6" !P-ROD^6"20H.5R,5UNH&[UGQ
MFWB?PC;WNK76HS_9+B..Y"0VR6F75OW@QM;?M91W !&:TB^6Z122A)KH>O\
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MBO6-)U>RUFRCOK-F"LH8I(ICECR,X=&Y4_45%;V265RD=I ([=(@BX. N#G
M'XUS]QX4M?$AU&;7BQ%RSQ1B)FB:*+;Y>"RD;F/)R>F<5+LW8"Q>6G@K5=1-
MU=V=I>W-N@5YFC1Q&K_, S],' .*^:_C1^SOI_CG4+?6?"<CVE_>N6-RDP:.
M(1@#:L1^\AZG:<J>W->P>%M>L/!UE8>'M9LIK<7=U)96]P8HQ'.(1\CL(AA
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MO; X4J_<$'[WKG''-8^MZCX5\(Z%<^(]:O;B:.Z=)'2=S*41\(J1H <*2PX
MZGGFLZ#P_'XZT<ZOHE_>:-;RSSRK(DK(\HDC$>X*20$P/E! QU &:II,Z9>^
MKO8@\3Z0T=U;Z=9:M$FE(Y>>+):YG_=,IW3,<!S(001S@8KK]"_L!O"M_;79
M232+<-:R*[*5.4 8MR<%MW.[GO7@-O,MQ=WO@'P9?2:EXP\/N4MAJS%H[BWE
M*-<2I)@AF13Q@?*0,<$UZ=X*\&M8>&&CULS6TETKR3QXV*T_S,S,O3.?\FG-
MJQ4URK5['SWIFF^(-;TB\U0SRW=KI4DC:?;O/(YN45V'FLI(9@@Q$,KCDGD
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M?YQG&Z-LJ-RKR<C![ 5E+8^,_%6CVNOV.HZ>^HV\=VD$HMCL$NTQA>78LA8
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MX$V#7$NOR3Q!]8U&?2WL?)MK="98UWSR2SM( K$;1GN ??U%%% !7A?[-_\
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M<:@QE?E8%_4E@,UO%*VK.RG27VI:'TS>W5OK?AZXN=+\O5;6_MV$/EN&282
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M:,<21.0#MD0\J>>]4I-:HNDI1]]$\?A[0DO(M0.GV[WL,0A6<Q+O" YV@XR
M2<XI\/A[0H+PZE!I\$=T6+F58U#;R,;LXZXXS6ITH9U098A1[\5E&;V%S/N.
M)(X%?,OQE_L#3=6M[I=7MM#NIMGFS.BN\0F)7(SG:9&4?7'XU],#D9ZU\O\
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M.E9WC'_DX3XY?]CIJ/\ Z#'7%?$'_D1M?_Z\9_\ T U]5A<LHRPZG*.MO/\
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MEA&0KGC Z@'K@#I7-W>C^+[_ ,6:?K=OK<=MH<%NX:Q6W#-+,^"':0GHHX
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M.!CG&:R]%^)'AC4+*VM+ M \B^5#YL?E6[,,* DI_=L,]-I.>U2I=1V_BO\
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MIUF^GVUNOE39\W(!,K-PS2'^(GN3UKS'6-<\83/:SVNFHLL21SK#(Y61Y78
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M5Z']J<&?\DQ2_P"O<OU.PKVO]BK_ )/?T3_L4M6_]'P5XI7M?[%7_)[^B?\
M8I:M_P"CX*G.O]W?R_,Y_&+_ )$-;UC_ .E(_?&BBBOB#^,PHHHH **** "B
MBB@#PO1/^3F/&?\ V*'AG_TX:W7NE>%Z)_R<QXS_ .Q0\,_^G#6Z^'?VT/\
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M&YVBF;<0QSRCX# ] !TX%<9X1%Q;^(UE\7!=1"Q^3!-/ /M<1F?)1V4X*#
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M_A;2+#PW_P (TMNL5J\>QD3H!UX)].QKEO%FC:[8Q^&]-\"6D=O#]LCBNWX
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M;MM/FU2:TP\=M"0'D< X&6( &>I[=:^)?B/\0YM=\*^(-7UC29T\+Z+&L8M
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MN=5"FHJYZQ\(M$UR_P!2DTS4M*&H:9"IM&@NQ'=&8+(=LC2; &R!GH,?I7Z
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M\N+)=3B\ZU;RYADXC?KM9L8#>Q-8GC!=%\6^'CIDEZ8K:>:,-./D"A'#'#L
M!G&/Y5K!I.S+Z'FWP\\&1_8)]1\*7RWD7VL &[#L)(R?WV2V"21]T@8K7TCP
M:]XMRFA@?V7'<31".Y78I D+%UPN6.> <XQ75Z]-9>!M'2'05(END\J&!6!)
MXP)%#<?+^5=QI;6D-C:V<$JMLA1N2 2"/O'\:)5)6N@L1:%+9K;_ -G1#9-:
M_+*NTC!^IZ@]JT3:VS7:7[1@SQH8U?OM)R1],U0BU[2+C4?[+M[@37&TL?+!
M90%ZY<#;GGIFM8_6L&RR""U@MWEEA0*\[;W/=C4X(QD].N:H:K=366G374,?
MF-&N2/0=S@=<#G%<W:3QZ@Z:/(1):*A8B$?*XP.I';GIU]:<4[";L=P,;>>0
M:I:G9?VG9_8V*A&=&8,NX$*0<=1W'6IK:W@M88[:W01Q( %4= *KZ7<7DT,@
MU 1I-'(R'RR=I&?EZ\YQUJO,ELU=D>Y20"RC /?%8&N:''=7$&N07!L=0L(W
M6*?J@5\%ED0\,IP/?T-:KW3I>0V^P%)0QW9Y#+CC']:\H^)"ZOHME;PZ#IQN
M+2_EV3/%.ZW:3LP:/R@?EP2#NSP!3B[LAFO8Z'Y\T^I07<NGZU$RRSR"-6\V
M/[WEX<$F,]L<CUK<\&-K\]G<7NNM'NNI2\21C:%CZ#KSSUK#L/"FMWES#K_B
M;498Y(K=5%I$PV1$<N&D&#)NQWX':MRR\57 TBYUC4M)N+"*V1Y%4[9"ZIGD
M*I)&<< BG+70IZ'$^*_%&M6-YK%YX7E%WJ%O&+>WLY)!Y1E7DR; <X[$^HKG
M? ^@^-/#>F016LBRZSJ<AO)VE=S99<[I$51@KC/%=EX(L_#=UX=F\7:+$EU>
MZFKR2S291]S,6,19OF15)(QT%7=(O[R76&L+"S>YM].P?/9OD(D&?+C?^(J>
M]4Y:-(5C"\3ZKKVKZ3KNCKHCIJ?DA84!WI,0?OJ6! 3J#D9/2OD;P$;VS^-W
MAZ2:W71IK8O:S6P VH[)G8 ?TXK]&8[R*2)[B,%C'D%<?,"/X<?6OCOQ%IMC
MX,^/NB^(?$VI&WTR]MY;H+,I98YP-I&Y0?P!SBM\/43A*-NA5-VD?:@QCWIW
M0U5M+J"]MHKRT<213*&1AD @]#SS5D=#7GCEJ/X(^E&5SC-"].>]1B&(2F<*
M!(P +=R!TKH@Q0/1/AY_R%9O^N7]:]DKQOX>#&K3?]<C_.O9*5S"M\1POQ-E
ME@^'^OS0??2SE(&TODA>FU02<].!FOSPLKR;P;:2Z5X4NXM,O=7M_-GBU2.9
MI;:0J618W& ^265 3DM[YK]+O$C*F@W[N< 0ODGMQ7P#XJT3Q5X^O+>_T>WO
M=$GM[:X%M=+>HL#;W&S=#M?=(P7(9AA W<UI"5CIP<TKWV)?^$4OM=\+17/@
M::/3-1-NUO+([NDUO-)AV("90.I.<%3UQ6_\,?$7C._DET?Q18F6&Q1D35!+
M&R7$L+^6R%5PP?C<3M %<C<^%_$VL>'K_P 4>#_%%YI=]<Q#="41C%<VH,<R
MG*@,Q(P3MYP,8KC_ !CX;^)=C\*]-\3>"O$6H:#>>&[>2YDLWA$TNH3R$!_/
M3/5CDJ <#.<"M+)Z7.]\M16YD?7A#$]:=['O7B>AZ)\3M;\$6MYJWB233/$%
MS:$X6*(Q1R2#AG51R0,'@\'H36UX?UKQ78KJ<_BR6"2QT.%DEDB7$\DD>&#L
M@R%W1X( )Y-<\Z23.5T]':6J.TU;1;B]BE;2+Q],NY/+ EC ;&QPQ!4@@[@-
MI]J\6O? 7]KVNF>*XYVENM-NYKRX>X<W(\Y 5\VV>4YA56!.$P"H(Z5W+:SJ
M'B35)--LXKO2[RSCF9XRX5)/+*&,\9.R0G;NP#C<,\5Y=<>+/B/I%[%\*?!O
MAV'5=2CT^.ZN9;V80V=I'=22 Q[T!>5@.@ SCK3IHN"L[&=X3\4>"M+LO$^G
M?#6]GGNKU$EEU'86$MU(GEB022\-(I&6!Z9%>>_"[P3XR\2>(-*TWXA>%Y/+
M\-O+Y>H/=G.R;+<>6PW[F^8!ER"2<XKZ;\$?"?PMX,%K>VUFBW\%L(=JLS01
MECND:-&_B<]6/)P*]57 4D#![UJZO8U>)C"_)U/SM\=_"^X^&)U&^U8:EKF@
M32K/+O\ *:*1VFCCB9G0*\3Y;)P""%))!-<3XP^,-[\-]6U#3I=,.IV.DSQ6
MUK.\O[IL,#+,$0\':Q52",$#-?IY>6UIJ5I-8ZA"EQ;W"E)(W&Y64]00?6OD
M3]I+X7_#S1/@KJ\^E:3]DG6:$K+ "SJ9'56!9MQ"$#!P/I6]*NGHST,!BXU*
MBIUHWOH<!XB\4_%R6PNM:T[PK/J%O?V2)I,EFIEGMX+E2SPLP(4,&X9U&6[&
MO1?A[^RQH&IVVD>+_B_$^JZ[%F9+)G;[+;HZ "%TS\Y7J020&SU%3?LN:UJ7
M@KX=ZOH/C]X](L_#LB20-/<!\6LPRL@SRL;'!4=LD5]9Z1K&E:_8QZGHMU'?
M6LFX++$=R$H<,,^Q&#65>JTN5&6*QLZ;E3I)1\T2V-A8:59PZ=I=O':V\"A4
MCB4(B@#   XKYQ\6_';5/#WC76-%;2X+;0M :-;O4[N0QQ9DB\P!><EN"-JA
MB?SKZ98%3D#I7QQ\>K!K7Q5IWV&]E6REN([Z]T^*W\Y[F1?E63<V0 !WZ ]>
MM94+.6IYN%I\\[,]N^$WQ(N?B'I5U-J6G?V5J-@RK-$'#HRR9,<B?Q ,HSAA
MD5TMWXFN)?%C>%-.,8GM[,7<@D^\ZM(8QL]=I'S?45\]>(]1UCPI)JWCOX=Z
M5/J.IZOI7D+<_+#:I*L[D-]E;DN"P);H16=KGAGXCV/@@^)?$LBZSK%YIJ0M
M!O6VN(YI9%$R"<8 AD3:V H8,,CKBJE05S>6'5^:^A=^(OB+XA6GBZ34[[4Y
MM*\.^'-0AN9;9H-D%[&(]R0QW!X;+#Y]W /8]*Z[6/B<WBV319_!#_9=1M$D
MFN;@LK6MJSA5>"4/L,V 0S;/NJ,YSBNM\3_#:;Q;X7DM[P1RZC#8?9K&UO':
MXLHW7:RO*HVF1R4 +DYP?<UYSI/A?XCZOHUGJ]U/8Z[?&^9[A8[>.SDTYA&(
MIH(T;>I^90S'(;\^*C)&L)PT;6QDZ/K7A_QMIEU?>*]"-QXLBU&6W-A8JQ03
MJ-J>:C/'NC?89B7^50>#GFO4],N_#.@FP\/^,/"]MI4[1,UKY$)GM_+12[J9
MBN$8'.5)YR,$UROAW26\'^)[;7/&.D1Z3I^F65RUK<F4W%S+<(Q+O*X/S%HG
M;8G+?>KT7Q--I'Q&M/["T*2*[EMW,C3M&TD-O*L9VAR"N6^?E0W'<4JC;=D1
M6:3LMGU//O\ A'O#6H73:;XNMM-M8=68065D"GGVB_.(FQTW9Z#'RMBM75_!
M?Q=\2>'I/#6J:KIZ?9 JVFHVPD2^^1"AD+-D*[YPQ7W]:\)U*V\4:>]]X)UV
MYT^+5K:^;5;:Z"R1>4V4=F1OO$?>(///RFOH+P7X@\4^,O!NF/I>MV>H2S-(
MES?VZE"%C#(=HS\LA<8W8Q@$XHG>-FF:SA*FE--?UU.7*:3X[^&.K>%+;3[N
MV\4VUM_9\\<L<D=QYUH54NLHRI#'D.&YSFM_2[#4O 7A&/4+'4+NZU258+2[
M=HVN94,(!;*-\V54D C/J,UW-CXPTC0=??P1+;NVIPP6]S)]G!E!6X9D5W8X
M.<H2>O&#5#7? OB#3I;[Q3X0U.XO]>$LD]M:WTY%CYDI"L&51G:L?"CH,9')
MJ'._NO0YE6OI+;<\A^(MUX?\6>$;[4O&&AZ[)]G1I1-% UC^X@D^^P5RW,;?
M-E<LH( ' K;\&_$GX;R^$]*E\%1FR2X#0VUO#9O>S($7DN$'RK@CDG!!_+O=
M/\.>+/%ECJ=]X[$?G,\XL+#A($C:$Q;9VC)9U9F)P3P,$ &OF7X4V4?@74+#
MP_X,N(+C7GDO4U*SL9=EM)<+\W[N6=3N$:_<!(S\P!Q6D'%QLSLI3A*$HO=/
M3L>I:OHT'C;PQHK^(IH=?OI@5TNS<FWB6XF.7>21,_*D2E.">"1U->NVEZJ:
M!J.A:YX?BLKFSC*I:Q$307(D7"^2[!<@_=;<!@]3CFO,="NO&6E>$H?"7C/P
MY%=7<<S212(\61"TH=Y=F[=N0.3F,' &3@G%>C>+]%M_%GPQ%OM*SBWB,$S+
MN>)U(Q(,XS@#(SU[UG-6T9Q344]3C-$^._AN_LM2\(Z%8W-GKNBV[1Q6[+&Z
MYB7:&C96*NJ'!('..Q'-<1\-O!6O:UX;O-,N]:<:1XO!U6-I+,+(+H2*;A7#
M= 67Y0!RA)Z\UU7B71]/F^'D]['/"TFFVX+SJ1#.DD84[GD&XC!XD]%R!FO1
M-=\3Z;X:\.:=+XC5]66\VQVCZ=$S&:64<(H3A00>&) P#WJFVE[B-96A\!XS
M\'9_'E];ZOI.FJ]UX?AG*P2%$LQOWD$+]YBHV_-@X8'CG-6=#\+_ +1.@?$&
M/1)%TN?P1=;A<31 1,D+.6VJH&_> =@&2N,UN6TGQ5\+7^E:;J:V&F:-J^L+
M;PK;.TMRD+*&C7E #G:WF9SUXXKT7Q;\:O /@C45TC7[J9;UE9BD-N\NT*RJ
M2Q4$ _,#C.2,D4YN2;LO,*U>;=TMS1;PE>V>H?;X&BNX))1OMW41K%;!-FR'
M P/[QW'N>U>7QZ_;>&_B0MM%>7-_I5Y<QVEQ)=M)Y$$Z0[D$;OE#YF[ VX4E
M<9W5[!XZMKF^\-ZA86^M)HDFIV[6L$[[?EFE&%V[NI(R,<^O:O*])\4QZ_X+
MAT+6?##2I#,NGYQF))[88,C A6"H5W!E^\.A%%-W2;,*,6]7Z'H_C;2]%TZV
MF\?FQMIK[2XQ+YTY8 1Q L,,H8KR>2!TK8\%>'H?$&KZ-XMO-2ENY))8[R)!
M)NMHQL.U(@H ( 8_,1D]37@4WQ$T32?AE-H<^JO:3:A='3+:YB_>R'[0V'EB
M60$>7$6.,Y"J :]5^%]MK?@.;PMX7@O6\0:7=W 6+4IB"5@$>55MO!=R,J>A
MYIR@[%5*/+%K[C[+HHHK \<**** "BBB@ HHHH ^>?VK+'X@:E\ _%5G\,X[
MZ;6W2U)BTN7R=1EL5NHFOX[.0$%;A[03+$1SO("\XKYM\*>/K;XC_M!?#2X^
M".D>,=.L_#UC/IWBE];M=3T[35T>"TG%G!/%?[%GOA>.ACE0-)@2;V9>GT?^
MU=X/\9^/?@-XC\*^!+6;4-2O'L&ELK>Z^Q3WUC#>P2WUI'<%D$;W%JDL08L!
M\V"0#D? _P *_AWXB\.?M.?#[QIXXTE?"?C_ ,;:SK^KW9NM7MY+B+PXEA-9
MZ;X>6W6X9KIXTBAN7*(R1;"Q;<,  _8&BBB@ KPO]F__ ))-9?\ 82US_P!.
MUW7NE>%_LW_\DFLO^PEKG_IVNZ /=**** "BBB@ HHHH _FH\8_\G"?'+_L=
M-1_]!CKBOB#_ ,B-K_\ UXS_ /H!KM?&/_)PGQR_['34?_08Z^?/C[\2K7P5
MX<_L(6IN[S7H9HE^;8L<8 5G)P<GYA@=^>1W^UPM6,,&I2>EC^Q^',QHX3A.
MG7Q$K15-J_JVE][9[]7M?[%7_)[^B?\ 8I:M_P"CX*^4_AE\0+3XD^%T\0VU
MNUHZRM!-"6W;)4 ) ; R"&!!P.M?5G[%7_)[^B?]BEJW_H^"EFU13PKE'9V,
M?%/'4L5PU/$4)7A+D:?ES(_?&BBBOBS^/@HHHH **** /D3]NVT^,E]^RUXV
MMO@1]K/BMX8=JZ>6%\]H)D^U+;;/F\PP[L!?G(R$^<K7YN?\$>-%_:1TO7_'
M$GCZWUFS\ /:((8]76>-&U;SEPULMQ@\1>8)B@QGR]W(6OW/U'5-,T>U:^U>
M[AL;92 99Y%B0$\ %F('/:N=_P"%B?#_ /Z&?2__  -@_P#BZ //-$_Y.8\9
M_P#8H>&?_3AK=>._M(?L"?L_?M1^+=.\=?$2WU"SUNPB2WDN-+N5MS=V\;%D
MCN \<H8+N(#*%?!QNP% [;1O'G@9?VD?&%TWB+3A"_A/PVBN;N':62_UDLH.
M_!(# D=LCUKV_P#X6)\/_P#H9]+_ / V#_XN@"YX-\(>&_A_X4TGP1X/L4TW
M1-#MHK.SMH\E8H85"JN6)).!RQ)).2222:Z6JME?66I6L=]IUQ'=6TPRDL3A
MT8=,JRD@_A5J@ HHHH __]+]_**** /G3]ISX^6/[/GP]M_$1T*;Q3K&O:A;
MZ-I.D0':]]?78;9$6"N0NU6Z(Q)PH&6%?"'Q,\>V/ACXP:'\/_@!^S9X7UWX
MEVFAV_B37EDL;.&73=RH[01RH(_WZ%E^?<22Z!58GC["_:^^$/C[XE^%O"GB
M?X4RV8\8?#O7K7Q#I\&H-MM+HVP8/#(V1MW9!!)7IC<N=P^2/#7A3]H;X,Z1
M\4?VEO%\?AM?C/\ %&YL;/2-+N=2MX;.VM$9(RJ3RSI'(40HP02GY8E^9BVV
MOU3A.E@HX2-1.+JNZY7.4>:3:44TFO<C'FDY=]&SGJ7N?H3^S[\9M'_: ^$7
MA_XKZ+:O81ZS$XEM9&#-;W$$C0S1[AC<%D0[6P-RX; S@>S5\V?LD?!;4O@%
M\!_#_P .]=O8]1UB(W%W?SPL6B:YO)6F8(Q +*H8*&(&[&[ SBOI.OS_ #N&
M'CC*T<([TU*7+_AOI^!M&]E<*^./BWX4DU#XC6WB"TO;FWDM'$<L414I)%(@
MSG<#M((!RN#VK['KYQ\=$?\ "4WF>/N?^@BO-B[:FL'J?,?BW3?%GA>S>^M=
M;%WI,CW!N;6:,1N8WC.Q(I8EW!@1U/WL\G.*ZG0M.\6VFE-);7,+P2V\7V6R
MN%;_ $?Y "CS#YG^I&:]!=58?, P]Q65=:UI>G7]CI=[=)#=:D76VC8@-*8Q
MN8+ZX'-2YMJR.M,\JN]%\<V,N@Z<;G&AZ9$9KJ&R5I;BZD3(2',A^X,ACDY)
M %37UMJ<U_>^(;"XENK-E73HK0H5DB8EA,ZN"OSL2 #T7!P:Z76M;UNP\5QQ
M--;V7AN"R>6[N9#B5;C?A$4DXP5R34WAO[;J.J2:I"ZR:"($%DS B621B6ED
M8$?=Z!>/4U7.]R9:HG\#:9JVGZ3OUQ#%>3''EF4S&.)/EC5G/WFQRQ]2:[,L
M.0>U,W R;A2,<DUS.5]3,GS^5?-'CKPQJ?A#6]4\9Z7JYC^VS"[2&<!XS*%V
M"($GY 7P<_A7T(VH0;9C'.FZ %I!D$I@9Y';BO!-(O9/B!9ZUX@UVPED@U*=
M+>PB!5E^RQ' = I/WB26)P<\=JZJ5UJ]B^5GI%U?0W>M:=*C7<5R\>V[GAS]
MEC6,;C&Y/RAF8C!49XP378ZZX_LF8QF)R^U469ML4K,<*C$=F/!Q7(:3?S6V
MIQ^!-/T=[2S@M$D^T/@Q; =K1X'5C7 ?$D^"/ -B]S=6<DUS<W<#:;:H)947
M4)-RHZQID#!RQR.Q/6CEN[$6NR&PT:QD^*D::OX;_L&;P]8*VFW<$C/;.URQ
M69(D7"K@@<%03DUU)_X3GP=8:Y!#$_B34]6N7GL8X8XX(X(Y<*5DY'"<L6Y+
M&D\;6NMZ[X&@T_2K]+'6=8N+95NVCW")HFW[PO']S !.#GFM^T&N>$='C?7K
MD:WJ#K%$]X3';$EFPQ*G"JJYW8'6ART7F6U9"VVLC0_!EHD%SMDAMPLDNHL(
MRKD859#D#>S< 4VX?2)M$C\2:[H44%PUH+B:';')+(T8!2-2/OLI&5'Y5!XP
MTB+Q#<Z9X3B6"X@)$]ZCNI/D @KN0@[@Y!()[C@UU'B"Q:[T.>RTR"&:(1;(
MLD8C(X#KD$?N^& [XQ47>SW(*]\VHZK#INK:>AMDT]TN'^T0J'DC9<.BY.4(
M!R3[8K2MDAU74Y-12:22T18UCB;_ %1<9)<+US@@9[U02S\7'PG%I]S<PSZL
M8DCDG0;0Y& [A6! W#/';-86HV'BG6?%^BW'AW53I&CZ5YG]IVWEJQNG(Q''
MGD!1R21[4[7T&KG6^'= 7P]'>6T-PTL%Q<RW$<94 0B4[BBXZ@-DC-='7+^+
M1XH.E2-X3N8;6\"/M:XB\V,-C*LRY!(!Z@<XHL]7FTCPK#K'C:\M8)8(%DNY
MXLI;!L<E-Q)P>P/-92BWK<;C8Z?CI7">)/!DGB/6;+49M0:.WLD.R H&592"
MOFKG^/#<'M@$5VT%Q#<0QW$+AHYE#(>FY2,@C/M38;JWGEFAA<,\! <>A(R/
MT-0M!'EOB#X+>"O$'A>+PNL<VGK;S+<QW=K*8KH7"@CS#*.68Y.<YSWKP_5/
MV;OB+HUI<Q> /B)>HL^W]U>-NPQ;YVW+QDCN%%?8Y90<=Z4,#S6T*TMD6JK2
M/S"^).A:'\.OC9X:LM4BNET.UT];:[G.56[D +R\M\LBDGYE.1SBOKNZ;P9X
MD\'Z'X4\-:O%8:-K$D2P!RS$_9V$K11Y. 2%Q@G&.@Z5R'[4KZ_J'A1(= T^
MTU**W=C/'<!#(5('[V [@WR<AL<\5\"^$_&'_"%7MYX=U=O[3TH3P3P1R(TL
M4,P<-N4H01CGN.WI7J\GM(J3W1Z,</[6DIVU1^G/CW3O WB*^T6<17+:OI(G
MEL9XK>1HXSY94EV("'J-N3R>AZU\7?%;Q#8+?VUG<Z;:J^L,UM+;O)YDYN(U
MPT@"DC,C 8ZGKWK[O?QAHVM>';"YT^\,-N$%Q*L<9.^*-=VP9!/+8^[DUX?\
M/]"/C+QN=7FL[> Z==RRR^=B:9&SN0+E0N"I &.5K'#/D3E+H<.':C4O+H>D
M^#/@OX6;P;807]C+!)-:B-XYF65X@X);8Y!*DYZCMZ5\!_$'PQ8^'/BIJ5S\
M.I+J<6\\-C^ZR\<3,0#YDO0X'&WDU^NE[+=):3&Q427.T^6&.%W8XR?0&OS2
MO=.A\._$6^T/6OLMMJ4UZDP8ADEDN')(; RC!_PZBJP=:4N9L[L+7DW)O7R/
MKCPOXPT[PWJ6G>%;L>9K%[IS70.S:JI$VT[CUYR,#O7;Z)X:76$L=8\7V\3W
M5DYFMXH@1%#NY&0.'(!X.,>@K'U>Z>?0;C4[...>ZCAC$L;@AUB)'F;'4%B0
M.0 ,9ZUHG5=;M)M*@L[87UCJ 8/,'VM  @*#8 0P/())R#CK7-.-W='DM[G9
MZ'KOAV^MHAH<J&W8-L"1LBX#$'@@8&0:YKXA:=92Z+)>75H;BXA=$MVC.&#3
M,(^/3@\XZBM&PN[:6PNK&YMWL[:-)#+*^U4C"@%MQSP"#G/UKG= LM0\9W%I
MKE]-LT"RD$NGPIUG*@A9I#W7G*+]#65^5\RZ":N>07'PZ_LRSTIM*L_/;2IO
M.AD!*-9.) KA2#\^.3A@<^U>>Z_\7O%'PSU&9]01M6@OXC':*"IFO26)8F)2
M$0KG!(7)&*]X\7ZS+I>GZO>7UPEM8VEU-YDC2%?ER-PV@<\<#OFOGSX/?#VX
M^,GC2V^,^H(^G:;I5R4L[:50T<L2="J]%/<GGFO0BX\O/-'1@:=W*4OA7]6.
M+;Q1^T;\1K)[?P?X-DTO3WAD,+,1!Y8 VG: $4MV (/TK[.^"/PMMO!'PYT[
M1_$%K'<:M/&LM^\BJY>8G?@G'.T]*]Q4!1A % ]*<O-<=3%RDN6*LC6KB(VM
M"-CT?X86=I86MU;6,*6\*L"$C4*H)R3P*]5KS/X=CY+P_P"TO\J],K&QP57>
M1X1^TAXBF\,?";5=0M)'BNIGAMH'C0NZ27+B(,H'<!B0>W6ORXN/"$=Q=66A
MPVZ07,TL%S-SYDB0VI.P,2?FD."V,@ X]:_5+X^RK!X#\^0?)%=P,Q] "><=
MSFORZ\326%M=217NIRZ*^IS%O,<#]Z$^5$4D@;3CG)&:^GR.5J4K&4:7-+4G
MOHDUO7K+5[NPO+FWX@^S2!T6W0CA@!MSC )R.#GJ*^P?@_X!BT*PGGU'3S!(
MLK"W9P%<PN-V" 6X!/&3S5_X;?#7P_I-M9^)/LO^G26ZQLYE:177KR"2OTXX
MZ5[8 N!CIVKS<=CV_<@="(T@BC&$15 ]!2.Z <GFIF.%)KEKZZD63"#BO+N"
M=S'USX;>#?$5\=8N;(1:BRA?M,),<AP>,E>I'J:^=?&G[/\ >>&]8/C3P/))
M<B /+/;M(WG2,1R0W1L\<'@8XKZ<MKR]<PFVC#AY%#[R5VH>I& <D>E=9_LM
MSFNRACITWO==BI>9^<_A7Q?X@N+66VL;I+#455O($SLULYDP[0L00089 I&#
MGDKR"17T+='4_BY\*_$>A>/=-2#4M, RMG.4%R8HUE+*P^:.-V#1D'J :XKX
MX?LV#Q)+-XH\*7DT)B29GTY3MB=Y<;I%8<J0!G'J/>O/?AW\3=;\&7%QIRP/
MK^Y6,=S'@>9:KC+$9PS)QN!/S#G.:]EPC5AST=T8RBDO(\"\5Z7IT'PWL=9_
MMB'2)--:Z>9;F-)UFEB+-AW'195V[%R< *5Y%>KV4UE>^!K#6=.C4RZM'%?R
MK#,3;,C_ "><OF'>7"@QL.@88 KBO$WPQU#XA:WJL&CZI8^'-=FE,,^C(,V.
MI,JF:.ZMU;(1Y$7/EM@ @X.#2Z+=6FL:/X6^$_A?3/[ UG1]23SEU#'DW(1#
M,4RP;9EU8"-0#SD=*ZXUVFG)Z(Z9PC4HWCNCOO$=E:^,M/T'Q3X.M4,EF\FR
M0-B>)'4(Y1"0)!V(/ !S7+VDHL?$E_-)I\-]<7XD2SN0X^9'*AHC%T #KE7]
M,CJ*]*6>UU.V36O"^FA[6QN[B;"QO"T<=M&T3+%&X5BC,  <8:N;\3Z3I4E\
MGC+1XH8Q8(LR(RD_?&Y,C/0#(7@#.>:Z(U%UV..E5=^1GU-\ ]0TNV\.6^CK
M(J7,6XR*SY*R2'+ $X)&3QQ7T=QZ9K\Z_A[>V%AJ:^+-9U"&UM8FA8/(VPF>
M0DB';ST &#W%?<?AOQ-=^(+J5$L2+%((98KQ94DCF:3[R +R-O7)]:^8S'#\
MM1M;&_0[/D TVD2194#QL&4]P013NU>7(:0NZFDYHHK.[&*#B@X8%2.#Q^=)
M1G%"DQ"J@7I],=J<20,TT-SUJO+:PRW4-XV[S8 P7#$##XSE0<'IQD<=JT3N
MB;%H'-!.*1::6!_"DWI<JVI(K=ZS-:UG3M!TRXUC5I5M;2U0O)(>@QV'<D]A
MW-8GB?QUX0\%);MXJU>VTPWA9;=9Y C3,@R5C!Y8@=A7Y[_%SXD>)OBY+)I6
M@1WUO9RRJ+3RF"Q"(\&249R'<< 'E<Y'K7JY;@)5Y7>B,ZCLKD'Q8^*D'B:.
M]\8WL$?VLQFVTRS<B0PQGLP'1F(+.>!T7M7FNCZK#XOF&LR1"[NK"X0W4TC8
M6V X9@,8PBD$#C/X5JP_#28QA=+M4O-+T2,0RNC!Y9G5#).X)(Y#'8H9ASGK
M7#6D[Z/H^J:!=:;)I,6H7<D-Q,HS)\Y&%!Z' /(ZYX%??X'#P:Y*)YE7$.$'
MS!>:G'H^HZA/K@\V5=H*+UVQL0K#M_"#QZUNWVI7=[JR>*;2'S3*LEJR2G=
M< $'8H##!Z,K>H(Q7)!YO%]K?Q>(XTN/[,C9;>]B+)D\Y,@ZGIT/-:FA>*PB
MS>";E0T-M)'<F=BP/W%C>)>,<$;O?-=.,P<HQ][<UPV+C.7NGUC\-?%OB+3_
M (?7!\"6PGDTV^19K<1;Y(XR 90"<E@6YSU KZ^LDU;4;2TF"-&LX21PW#1@
MC)7'UK\YOA=XPUWX<7G]D0Z:ZR7\D;68)<K=LV0S1\8^7(W \]#7Z2^"[Z^O
MK"26_548ME0HP0,<@^XKX#-Z?+)V6A[,ZBE%:?,[6- NTY[=JF(R,5"A%2@Y
MKP8ON8/N(J!1@=*W_#W_ !_/_N'^8K#K<\/?\?[_ .X?YBK(D]#M*\^^)O\
MR*TG_75/ZUZ#7GWQ,_Y%:3_KJG]::)ANCYI,<<C(SJ&*9P2,X-8EQH8C\Z71
M9&L99\;]A&W('WL$$ ^XK>SGGI2\#BFW;<Z[7/"M=^#%GXDNEUOQ/(VKZC;2
M12C<[*DBP<HFW.T?ER>M;>CZIX%\1W[6\4,6GW5LS,]N<QL)%ZM)MVKP/4UZ
MWGM69J6A:5K,3VVH6R2K)P20,\^]4ZEUJ)H\N32?#USXILO^$!OX;*\YGU![
M5MX> @A0%.4!=N=V.U=SK&B6LUQ8S:C<SW:QN8S [?)(91C+*, E0./J:Y+0
M]9M]*OYXM2DM[.VTQ1;AV #%2V$!.,GL!5SQGXA%E/I>I:8\E^MA<G[5!:(L
M[&-T(RW/R[>#Z^U#@[B33.^BT72K:Q.F6]LD-JW6)!M7KGH/7O6-#H&E:#J4
MFL:5IEO"'A6*1HE$;A0Q8G &".<GO6?+->G48]80M=3^4?)MT^5%C?D;VY^8
MD=<5NPW5[JUK"# ;$R*#.DA#21Y_@&#C/J>F*S;L,W-T4H RKY&<9!X^E):V
M\%JGE0($3DX4>M8ESX>T!HIFDMHX=RY>11L8 #KN'-;T041+M.5 &*;:ZE'
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M<T>[)\M4Y*XY]<5I!MJQ6QZWX7GTA-)M-,TFXAN8[>()YELF(24&#M(RHY[
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M%$7C$3894DZ95B<CT/I7BNMZ+HE[J<^O^--3DTSQE#"9;;RYQ':/+;*QA.
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MDD=DZ<E/E24D=SH&B^,V\"6OB"]O+Q;RUAAN8[*?8KK+!$$(;!88D;+L,YY
MSD5B^.+71OB[HNCVVE:3-+JFNQPQRWI)M18Q0R"619E9E=]CC_4CDY&3CFO9
MM!\?>%?$.KRZ'X=N#?+:0B1IT7_1U'14#G[S8YP.F.:P/B3K\%MX?N;31'MG
MU!FB.]V!%OO*D2NJ_-@KW%8ZIZGGQ<^>S6O<S]1N]3US1W\+ZS)-X<ETQF-Y
M<VC["]O$66.2%\95),;V/50"N<UQ4'A[QS:>$]3A?5;7Q-H-]Y<J7]YOCNQ:
M,BF1E*Y#9Y*-D$5S_P 6/ FK_$&TLM<O_$K:?+%-'I]E#&$C@DDN63F1Q@MD
MJ2,'@< 9KWC7[/5],\+Z1H&BF"6\ M[=K<@*DT*;5F*YSM"+ENA[ YS372Q4
MU;J>0>&-1^(26VC7_@_4EDT1(VEGTZX"WDC0AOE-O<$AW4@,0221]TBO4/A1
M-H]I8:CI=M'-97\M]<WEQ;W3'S"UP^_S$R2=C#'7!'IC%>=>)_",/@Z[T*'X
M?:PL%[HNJ?:?[/N)PD8M[\E)!ANB%FR%Z ],&NAU?2-5\;Z?INL^$W'A[6X+
MB6:\><+)>1( ?DB/S*49U&#R"G ZTII,B=GH=1XCT31(/&.C^+_$XCD%DEPJ
MW$[,(+;.WRP$)V+(V3\Y!R,C(S7?:0FD)8M<:2J0VERS3E@-JL7.6?M][U[U
MY#X-\0WLGB#Q+J/C34K+^SA#9W-EYD8@>&!XV#F1GP#D@_2K?BKP?HVA>"]0
MO=,N[B'2[8B^$/GEK>,>8LKNH;.5 RP3[IZ8YK%Q^R9RCHHR)+.TT;QOK-]%
MXCCM;J>S=C;6K(&*VV_$<I9A_$RG@'%=#96-EX:\9P:5IT<-O!J=D2L$<6S8
M;5R2P(&W#>9C:<$8SWI-=U?PQK_@1-11EGTO6UMX5DA#!]MPZJK+M 8%201Z
M8SQBM#_A#](TC3H/LL]U"VEQ-B3[1(SR*BG_ %C,26'?GOR*N[M84GWT,F#2
M+VQUC7;6QC>&_P!4G287WRR,EL0$V@M_=P0J]NU<GX03XB>#?%<.C>-=2;6M
M'NV^RV%X\@\UY64N!(@ );"GG& *Q?"WQ)\+>#W6UU/59]1_X2%KC4+>2:4W
M-VT9*E(UB505C5#\N<=, $FH_&WQ#T7Q/<1?\(]J-SIUUX7;[>TQLY'XFB:/
M.QE!RBL2<9QZ4<LMBDY)6L?1.K:I::)I5YK%\XBM[&)YI'.2 J#))QSCUKY$
MT"_&@:#8RZIH$6EWT^H7!53$3:)#)*\J3.S?,OEH 0<@#=QP<5[/X!\3ZOJD
M=W8^+E2;3KOFPOMRM#=VT@!&6!*Y(..<5Q>I_#VSU/Q=JWAZYSI5IJEJ5AG8
MJXO;D!'1T5FX,"KC:N >21BKI-).++PKY;W12\#>)K;XA>,YI_%<-C=7"--)
MI-Y:LT;)"$6)HG\P*[>9NSC'!R,< UT7A7Q_-XN\8R> =*U"&VC\-VK0ZG"D
M7F%KILJD:.0%\I45N1@DCL*67X(^&]$T*,RWAFEL)TOUNIU4/]K0YWG!5=I)
M.5(QS[5AZC>ZYX,\0>$Y]/M&M=-DU)=/U69(=T,D,\>;>97 )P9"$SG ).15
M:.]OD:-4IM\AK?%[P3-KFGV'AV\G6WTC4]1MK;;:PN&9F)^:<J<\!>#P,_>S
MVYOXCV,?P,L_#GB/PA:S7L:W45I):R2LT+O)\@*(3M25P2JMT'I7T3XT>>W\
M+:DUO:27L_E%4BA8+*SO\H*,W 89R/I7AFF:GH_C?3-"\->(I;TVTNV6XM[]
M\3K+:/MB+N$!+^8FX[6''7@U$9W:OMJ%&4Y13:T3.TUWQ-X*^(D;>"U\Z35U
M;[1;08DA9985WI)YL9!1.2,[AGD"O-M8@T[PGXO\&6?B.Z>*^7$EU$LGE6ET
M&1@RJF3N\M@&(.3TYZUU_B:7P3\"=5U#XAZA%>W/]N;%N751)'!' %0-DX"C
MD<=6["NFT/2_!?Q:&E?$W9+=6LD?^AI)E%V([#<4]6.3[C%.,HQ6NQ:<5:23
MY?U/!?'>J>/-4\"7/BG1+H:WISV2ZE8^<L<48E>1XP('X998MR.@;@\J<FOH
M/P?KFMQ^%K#P]XI@D_X2L:=$UT$ ='E8;-^]>,L1D\5YGXNUSQ'X0U?3/AYJ
M%F+^PN_M5U:26]L#;MY?_'M;70/^K&\@EUZD#@9KT;X<P6WA;1G_ .$JLK70
M=>O!]IO<3>9&^.!LE?DJ@^4+_#]*=2ZBB*U5NG:QP'B2'P?XI^&6K^'X=%_L
M2]TN4I]CN\0.DS.N9"8F+&)RP8LI^;%?3_@G2_L4>B:;=[9GLDA7<%VC?&F-
MP':O--$\">$KKQ3JGQ#M5:[NM81(C))(9(S%&  $4Y 4D9''7)KT;P3K#ZEX
MEO+!H3%_9ETL()(.]6C#@@#H.<<XI3=]NASU9WCRQ?F>]4445F>6%%%% !11
M10 4444 ?"?[6EM^U;<>(-*'PK:^/PR^QC^VT\*R6<7BTW'F/O\ LSZB/)$7
ME;-GDD3[]W;%> _L%_\ #..F_$'QOI]Y;R6/Q8N/$%Z^FIXQC=/%[Z2;6+9\
M][^^8\3&01,> Q;Y0#7ZU5CWWAWP_J>IZ?K6I:9:W>H:2SO97,T*236SR(8W
M:&1@6C+(S*2I&5)!X- &Q7YOW&D^+- _:$\'>$/ _P 0M=\9>/\ ^VYM6\:L
M;NX&@Z?X9G%P\5I-IS2S6MK(=\4=FJ 3MM:5FV5^D%?'_P +?V0+/X1:Y)K'
MACXJ>,YHKS5)-8U"TNI])>'4KJ9]\INW334GD#_=.)0P7"JR@# ![/XC^+"^
M'-:N=%/@_P 2:G]F*C[18Z:9[:3<H;Y) XW8S@\<$$5RW[+E]_:?P6TO4/L\
MUK]HU#6W\JX3RY4SJMWPZ\X([BOH*O"_V;_^2367_82US_T[7= 'NE%%% !1
M110 4444 ?S3^,O^3A/CE_V.FH_^@QUX'\2?AGH7B73[>X^('B=H+>S8^5/*
M+:VV&3&5W[5!W8'!]*]]\8_\G"?'+_L=-1_]!CKYC_:+^'/B[QS::1=>%X_M
M@T\RB6VWJA/F;<.NXA3C:0><\\=Z^QI+_8T^7FTV^9_6V74[\(4I?5W6:C\%
MWK[W5+>V_?32QUN@:%H?PL\(?VG8>(G_ .$<L@;E]D<$BS!B.?,52S%SA1@^
M@&!7T=_P3F^)V@_$K]M+3K[1H9[9;7PQJL)6X"*S$RP,"NUF!XS[\5\K_#SX
M3:A#\(+KP#XV<QOJ<DDI2-PYM@Q1D4$94E73>0,C)(KZ0_X)J?">'X9_MH:=
M9R7_ /:CW'AK5;A',7E>61)#&,#>^3@G)SWZ5QYG[54(VC:-E?R9\EXC?VE'
M)J*I4/9X9QBYQ;NXROI'5W2VLDN][']*%?D]_P %,_VVOBI^RN?!OA;X46=K
M!?\ B:.ZNIM2O8/M"1QVS(@BA0D(7)?+EL[5VX&6R/UAKY'_ &OM<_9#T;P7
MIB_M>?V6^BS7+?V?'?037-P9U WM;):J]P, @2,@P 0'/(KYH_G8^&;3]I3]
MJ[]K']@KQ#KOPV\#W-MXQN4DL)=5TBZB@\X6LT;736=N\GV@226Y9 (RQWEA
M'S@#YQ_X)1V/[5_@GQ1XPUEO"&MZMX%GMY;6:TO9UL(O[8AN54O"+YD!DB"3
M1S^6"0Q"R?,% _3;XT?%K2/AK^PEKGQ/_8UAT^XTO2M.C.BMI<"O:VL#W*17
M,ZP;<;[=6ED=9%RKJ3*#AA7P7_P2%_:*^/'Q*\=^-/AYXVOIO$'A.VL[G6C=
MSQKNM-4O;X2R+YJJ,_:VFGE*,3\R$H -V0#]H]*^+/P\U'Q)#X!F\2Z3;^-3
M LL^@?VC:RZE 2@=U:!)"YV#JP7&.1Q7H]?S0^$O^";7[7FE_MAV/B>]C"Z)
M8>)4UJ3Q7]MA(EMTNOM!E$8D^T&>09'EE/OGD[/GK^EZ@#X)_P""CNG6.K_L
M\66DZG"MQ9WOBKPW!-$_*R12:A$KJ?8@D&N]_P"&"_V.O^B3:'_WX/\ \57D
MO_!4'Q1#X-_9?'B22+[0VG>)-!N4AW;?-:VNUGV;L';D1GG!QZ=JP_V#_P#@
MH7%^V!K_ (A\#Z]X67PSX@T6U&HQ?9[AKBWN+3S%B?EU5D>-Y$&.0P;(QC%
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M<1-PY6YRTNG;5Z76CMY:=CHA\*"ODCXF>()8/B5'H%I )#<KYDTK%PL:JHP
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M>:^LY[2'=!#&W$GFJ<J7/)R<#.".:]'\-V$VC:"OA.)TFDTV(6[2G">9E?\
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MTO=FC-^-/]J^//$,'PV\(;VN-5NV>:Z124M8&;+R$CN=N!GM]:^O? O@W3?
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M/OFM6U'45KLR+CPOX=CBDU+70;R18U#373F0IM.1LW<*=W(Q@YJKI5QXSOQ
MEY"-/%J268A91=I_#@]8SCD]\UT^I:79:HL27ZF2.&190NXA2R\KN X.#R :
M-6U./2-.N-1E!9(5S@ G))P!QVS62;!I&?IU_>ZB9]0M4B41R/"\8/S,T;8.
M6QU%4;SQ'%;>)K/2[8PB:]BD:2*5BDS-'@#8,8) Z\XZ5R.@6/Q(T:]U6X62
MWU#3-1\R[@#2$2PS/\VQ5"#<A[ G(/>N=DF\/ZCXMTG7+1O.OK!\7T<X9+B#
MSAD':X!VY';CTK3DU9-CV"QOX[&::S>!H+=,.J!<LNXY(XX(STQ5#2_#5O<:
MI>Z_J\,5S-<.X@9X%26&%N-F[J>F:[3(^]Q6#_PE&C+,T$LS0G^$RHR(QSCY
M68 =>*SBWL@2. G\%V'@3Q!?^.?"MH&NM6B2VG@"C#R+GRF7;@]3\_7BN@BL
MO$NN:%'H6OO"ET4C:ZE"!HIAG+(J'E0>AS^%<SX=UIIM=U&Y\:R)9S:/&LD:
MR2G;$DPR6P< ]@#U[5Z%&^KR&XUBR6.99D'E0/F,D*.,OS@L?:M)MC*^E6]E
M-=/I5QHB6D>E,K0N%7RF8@_-'CD8'K6[KD2SZ'J,+SM;!K>4&56VL@VGY@1T
M(]:L64MS+9PO?1""X=09(PVX*W<!N,X]:=<)'/#-:-M<R1L"A(Y# CD>AK)-
M7';0\ ^'MSI6_2[OPOX4N(;4B5S=84(58[6<')+-)@'U]:]GU76'2!'DLKA4
M66-E<+N!&<'<!DKC/<56\,27^FV]OH.J6B6\D:-Y1@;=$8T. "< @XQQC'I5
MM]2CU*_72N8FB?=(K$%B!ROW2<9/KCITJIRN]1-&!\0=#\*>._"TNFZS?-;I
M%F>*:!\2Q2("0PQW]CUKG_@5XQN/$/AJ?2-2N1=W^AS-:O+_ !2QK_JY"/5E
MQ7KTGV, VLQC4S*?D) +#'/'4U\E^'+GP[\(/BY_8UI.T&E>*XA*(Y'9UBF#
M%5^9N0K8P,_2M8KFIM=5J..]NY]C;AP!2X/UJ(-N (Y!Y!I<\5A&5BK'H7P\
M_P"0O+_UR/\ ,5[+7C'P[_Y"\W&/W1_F*]GJX['+6W./^(&L0>'_  3K6N7,
M;S16-K)*Z1 %V5!DA02!GZD5\7:_\2H91I^FZ39/+]O6*2X%Q$5:*"0 @A'&
MV3J V&^7KS7W!XLEMX/#6I379"PQP.SEN0% YR*_-FZ^*?AK6O'6@V^LZ=+>
MZ#$TY@U%H6\NWO%&Z-2JKDYC#?-T& *U@KG9@8IW;5['M6AZ/HG@/1VU#5]2
M>ZE0,KZA>D&<I(^Y8@P )4'A5 [#%:>G^-O">L:'+XBTG5;>[L8D:0NKA2H3
M.596PRMQC! .:YGQ->6GB+5/#%OI:Q:G"-0$EPFTL(8A#(RS$Y&TJV I(Y)]
M:X#XQ_"?P!J\)\076DQW&M3LEM:0[FCAFNIGPDDR1E3($R7;J0H)H5GN:046
MU=[G-?#[XK^.O%5X+G5$M8M#UA&CM!,666.\\TJ83)'P8U7') ))P*][CT'P
MAIMK#8Z\+6ZN8R)'>YVR2;R2P;YR6 !X7]*R?#D?PY\'>$_^$/CO;**STJ&-
M;I7D7"M<$C>Y<_\ +5\X)/6N"U#QAX9\&W=U/X/T:;5+J>,1R77E27,5TEG_
M  "XCWL7C#;55@,]N!56OL:U:?-)\JLCDKC5_P#A#_%%OKFFV=WHL.OWTLL<
M4L:6EL-L8C=7R61VF$8>)#M;.6R.E>V>'AJFFSZAJU_KMG<2^*;A9M.@DA^R
MC"0*BIRV]V(7<Q/(Z#%>;^,KC4?B-I=SX6U6U9+.W2.:]N%LR39@H91+")#O
M9L95<)GOBLSQ%;_#GQQXV\+^ =5MM1M/+TJZCL9KB*2$-CRRDEO<DY\]/+SW
M)4].M-IOY%JBG;G/0O%GBFYED7PCJ5G!IVOWMG=269:<M&[;?+P&C7>JNS*,
M, 3T&2*YSX+_  K\2>'=!M+3X@W!NTLXW2*S=_,B4L<99<?,548#'!(/-7_#
MGPTCUK6_#_CJ]\9WFOV^EQ!;%"L<2SI&S;6N,*&E=2Q&["GCD9KW\YSSUJ'4
M5K(PE5<8\J>AYGI7P8^%^@>)++Q7H&@P:9J6G>9Y+VVZ)1YJE7RBG:<@D<BN
M4GU""R^-%W=:5I=_]K-K##>,0XLIXSP) P!!EB7[H[@GD&O=OPIX!SSP>OX?
MX5G[1ZHSA4UO<^6?CY\3?"D<EC\.6DN3J=R\=R=E@;N,0J?F0HVW+2#(7!R#
MS7J?@WX7^%M*EO==N-/6>ZU1]V+@*PCAX\M0F-JL%Z]3ZFN3^+7BB/2/$NEW
M%U8RPV6C[9KJ\?RXHI_/RD5NLS98G=\Q '7 S7I?PWUFW\0^#K+7+<;(;XRS
M(/-:?$;.=OSMR1CMT'0<5K)M021T3=J47'3OJ<5=_!F.Y\1KK4.L3V$ U#[8
MT%L!$LD6W'V=@."F>O&2#4^E_ 7P-I7C"Z\7P_:YY;Y7$MO-,TD)+]U#<@#L
MH.!Z5[,6&[&1DC.,\X]:X;XHW-Q9_#?Q'>VMT]E-;6<DB31R")D=,,#O8$ >
MN1R.*SYY-V(C7J3FDV>4VGP_\>OXUO[*Q\4P7_@]M0BO)+&8I<W%L%VNJKO5
MBH9E*A<@!<D<UZ)>_#/P_:V\^H1ZE?P7, E>VE^VNA@:0/Q&6. /G( ((Z<<
M"OF7X,2^&?%WC'3!8J7U,Z&\EQ>6<,]M%!<AHVC>5'/ER%@?D//(.  :V_B%
MX1^+":IH:^-;BX\<:2LL3K_9RII_D7,3EE\V,;M_F9 W'@8/ SFMM>>SE8ZI
M0DI^S;2/7/!/PZ\-7G@6UE2X_MZXO[E-3GGOY?MIDG(&%:3C(08"X '&0.:J
M7]IJ7Q \1Z]X?TI$\/W.@7=E&^HVTNZ5PB"8 ( /DPQ3!)'!]*[OPGHNM:-)
MJ>H1VHLVU.2*86LLPD2W6*(1B*,1JH&=N2<\D_2O"O!/B>/X5:OXAG\<N\/A
M[7+HWMA<K'+((Y9V8&.0C<4\PGY,@#().*B*;3=[OH<T4VVUK8[/Q)H7PZ\#
M:-J^J>)+BYUJX2WEC,.HRN\=S+,,B/D!,N<*.<"NON+6_O\ X7R>&H;">P^T
MVZV,9DE3S(EFPJLK+N \L'"D\_*.*KR?$OX7>-/#3Q/>Q:C9W\_]G^2R;BUT
M06\O##&Y<9STX!KPK2;#QCI]O+J%WJ*WEAX?N[2.U@CN]DRF+DF\8\.7CP2G
M/7IQD*TFKLJ*E+26Z/I6W^'>DF6#^V'.II9D- TW$F_: 2Y7 ;IGH.237$3_
M !-\!> ]9UG3[R\EGNA="!88T:657\M7,*?[*;L]>,G-8LWQGTGQC!-IND32
M6\23FVO+R$;X(4.5D5FR"&&,!AT)!KROQ=XZ\.:.;.Y\ WZW>DZ7;8F6*V26
M]'FEX?M)N+C)/S(JG@D]P<UK&FWN$*4G)QDCV+X:#PYK_B>?Q;!HYMM5NX0L
MLT\065HXF8;=W/0CH"!R,5[S<:9IM^"M[:Q3@\'<H/6OE;X(ZWXCT^36K?7G
MAN+A9Q)YIF:9_G'RHP5(XHV*A3M4G'<#O[[9^*=2O[>(IIR0,P?S9I)U^SPE
M3A1NX+%O0 8/4UA4C:35]#.M%J5D8OB/11X?M;#1= 1#I5_*MF^F."L ADR9
M7C=06C=1DKR%)XX.*\E^'/@_4?%_B">ZUVZ>?3=#^U6=D[7IDO[5796ARR ;
M7V@_,26VX&>377^+C?'QAI L+9]5F\Y[:\O0[K#IRW$9*L$7*D!1@YY&1SDU
MTOA[3K7X7:9$[7!O=.G6-)VMH=X69<('7!9RIS\VYFQCK52ERQY>HHMJ.F[+
M'C/1[CQ6D?@B_L)YH4>*>*^;'DDHK?-(58,74D8&/F/-<?\ $#6-6OO#VH?#
MC6=("SW-O'!9W]U/Y-M/<'_5.C1@LLB,N['4'G->PZ9XV\):UJ\V@Z5J]M=Z
MC:KND@C<,ZJ#@G'?!&#CH:\J^,NAZ)KO]F:!KNHSVK:M<?Z-)N"Q1O" 0@)^
M4,Q/'\3=**$KM*VPZ'O249DO@?PGXCTG7-$@\0:V=;2VTU3*Y=R1>)]Z1@25
M(<-P3SE0:W?C%9>)+SPK W@1;9M::\A\I9O]7,,G<K,OS 8Y..H&.AKRKX->
M'M4T#0-:\(:]?QV&I:E<7$:V=]AR\,*F/[1$ 0623[VW=P*]@\ > 9/#FV^U
M>19[Z)/*0QC9#M"A=XB!(5F QQT%)U+2O<TQ%E4=G>QR?ASX7>)/$'P\F\*?
M&&ZCU.Z8)Y30.X\LIA@=QZX?H,'Y1CFK'AC3?B]I>G6NA:Y>:1 C31(L=C',
MK"V5SYS"1V.&9<8 4!3P.*]9\4:Q<:!X<U/6[2T:_FL;>29+=#AI609" GIF
MO.M*\=77C?PY::EI7AJYFDD57=9@8%C#$JQBD;DLO7 '([\U,7=:[$1G.2?8
M].C\.:.D;12PFX1C_P MF,N/FW#!8G'/-<CXC%KJGQ#\/Z5/9O?_ &&&>[D!
MV^3!O'EQR.#]YB=RJ >.N.]>$>,/%/Q>T>"?3_!FN0ZDT-W9Z>WVRWVR(9X
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M80OL9\S/B'3OBO\ M<^&/VHK/QYX@\0ZU'XHEUNWBN+N4R_89H[BX6(1[/\
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MER>N<UFM!CC\PI!Z>M+G'44IX/'2B0"C</QK!NM#D6_.L:1<-;7; !T8EH9
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M<'/6M[XG> O$<E[X5TNZO;6>UU'4H[F20H+21X6!C\HE6^=T1NH&XGOVK?\
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M\;Q^!_!>F7IM(]3EFU"(1V3,5-PRY("XZ[3@D=*]XT/5#K-E'OLGMD>"-R&
M"Y<?,@ YRO?]*^2O$?BCP+\>[VPTKQ)I4NG'P;J2WMQ!=X*W%N595\AH\[R^
M%8*.P(/(KVV/XLZ;?K%:>"M/:_GFDBBQ*?L\<3/G<LA()5D&/E(!.1CN:Z*E
M-J*5CNJ491I)<NO]6':AJ?@*V\5&7Q8;32'T'+6HF<QAE^7]\<XCZC"<DU%\
M5O%VBW7PZNM9T*XCU6:.**ZM[6$QR-=*Y^52ASE'&0<<@9(Z5J^(=2M=4MQX
M0\5Z&EYJ6H1RM;0!0\$QA4."LC\*R\''4'D<5N7^AZ=IOA@O;:0E_<:=!YD4
M,857::-.-C<88GH<THI73,8K9LM>%KSPMXM\,6&H:0D$]C/!$R>6ORIN&2JG
M'!4Y! Y!%6M#\"'_ (6%HGB0:G+*FG>8B03*L@!EX+!S\P.!M'M7R'X+\1RQ
M:SXBO;".^T2^6^C6'3K2 HM[.T>_$PEW(HE.067! &2>:^C=+\4^.(O&_@'3
M]3LIK.34KF5;]+=1+:H%0LNY]I;G&,Y ]CQ3=)WW#$X:4=>Y]HT445)Y 444
M4 %%%% !1110 4444 %%%<#8_%7X8ZIXUNOAMIOB[2;OQ99(9)](BOH'OXE7
M[Q>W5S(NW@G*\ @GJ* .^KPO]F__ ))-9?\ 82US_P!.UW7NE>%_LW_\DFLO
M^PEKG_IVNZ /=**** "BBB@ HHHH _FH\8_\G"?'+_L=-1_]!CKSWQ[\-O"_
MQ'L[>T\1Q/NM69H986V2)NQN )!&&P,@@]!7H7C'_DX3XY?]CIJ/_H,=15]U
ME].,L-&,E=6/[:X#P-'$\.X:AB(*4''5/5/5G->$O"6A^"=$BT#P_"8;6(EO
MF.YW=OO,S'J3_P#6& !7TA^Q5_R>_HG_ &*6K?\ H^"O%*]K_8J_Y/?T3_L4
MM6_]'P5EG$5'#-+;0\OQ:PU.CP[4I4HI13@DELES(_?&OR _;<_Y/!^'/_8H
M:I_Z61U^O]?D!^VY_P G@_#G_L4-4_\ 2R.OCZ'QH_CA['Y(>*/VR?&.E_%N
M]T:+1+.30-/U![%[=XF-W(D4AC9_,W<2'!*C;@< @]:]2_:E_:"\2?"'7M)\
M+>#].M/.N[;[9-<W,/F+M,C1K&B@J,Y0EB<\$8Q7TI=_!OX7WWB]?'MWX<M9
M==1Q*+DJ>9%Z2%,["XP"&*[L\YS6AXX^&/@+XD0VT/C?1H=5%F2T+/N1TW8R
M%="K8.!D9P<#(KOY)V>IGS(^?W^(5S\4O@IX&\:7MFMC<WGB/1DEC3/E[X=2
M2)FCSD[6*Y )..F3C)_IXK^<SXM:3IFA>#?"NCZ-:QV5C9^(M CAAB4(B(M]
M%@ "OZ,ZY,4O>5^Q<=CX6_X*%_\ )"=(_P"QO\,?^G*&ONFOA;_@H7_R0G2/
M^QO\,?\ IRAKZS\::_XNT&&U?PGX6D\3O,S"5$O(+3R0 -I)G(#;N>!TQS7,
M4>8Z%I6EQ_M3>--32SA6\;PAX;S.(U$IW7^L*V7QGD(@//(5?05[5XD_Y%W5
M/^O6?_T6:^8;#4/CA:?%C7?B$_PND:UU;1-)TM(1K-CYBR:?<W\[N3NQM87B
M@8YRISVKW.SUGQ+KG@K6+OQ3X??PW=K%<(ML]S#=%HQ%D2;X25&22,'GC/<4
M ?.O_!/'_DR[X5?]@Q__ $IEK[/KXP_X)X_\F7?"K_L&/_Z4RU]GT %%%% '
M_]7]_***:Z[T9<XR"* /G#XX?M!_LS?#O2KO0OC3XDT=XW4B;29U34)Y!V#6
M2+*^#TRR8]Z_)76O"\'Q=\0#Q+^P+\(/%W@2_G=3_P )-#J)\/:3(H/.+:0R
M12QX_@BDC..J'.#Z;X1_X).^._ NL#Q!X8^,-I;:BIREQ)X=CN)$;.=R&>X?
M8W^TN#[U]##]E#]LX<#]J6]_\$L?_P D5^VY96R?+(_[#CE.3WY_:J#]:<8:
M_P#;TFO(Y9*4MU^1]C_ 31/B[X=^%.AZ1\=-:MO$'C2!9?MMY:@")P96,*Y$
M4(+)$55FV#+ G)^\?8:\P^#GA#QOX%^'VG>&/B+XM?QQK]JTYGU:2 6S3B25
MWC!C#.!L1@G7G&:]/K\@S.HI8FI)--.3UBK1WZ*RLNRLK(Z8[!7R'\9?A]JO
MB77Y%@TR;4;.\N[5Y0&*JJQ;6WC'7:4 QWS7UY7.7OBO0]/O)+"[G,<T6,@J
MV/F&1@XQ7#<TA)IZ'SD/"_B$ ?\ $OFQ_N5SLWP_U_4+34+#6[.;4+6X<E(W
MBVJB#D)\N"P&.O>OJC_A,_#G0W/_ (ZW^%(WC7PVO+76WIU4CK^%*R-/:R/E
M[PQX=\2-HEJ7TBYAPFT+)'L?"G RO;Z5T2^&?$ R?[/FR?\ 9KZ _P"$S\._
M\_/_ (XW^%59_'_A6W.)KO;GG[C?X4I);L:JR['S]J.DZYI=E-J$VE7<RP+N
MV0Q%Y&/HJCO7%Z-X7^(>LA=9\2Z-+9RO(QM;3&_[-"> TA'!E(Z^G0=Z^L;+
MXA^%-0$AMKEF6-MI)C< D>F1S^%7O^$S\.?\_/\ XZ?\*I)= =22W1\PV_A/
MQ+&USJL^E3.\880QA,MM3O[L_P#+BO+?#_@7XV^+-/GG\21II&G72JUO9);N
MTH4E6VS%V!!5A_">0<=*^ZKCQWX8M;>2YFN2(XAN;",2!ZX J5/&OAN1%E2Z
MRKC(.T\@_A5*6E@]I+L?*=MX)\>ZM:PP>(;,*8RRR&W22,L < J2Q*[AU'ZU
M?/@34KBT,!TJ:V^RS%K=@FYD8' <>N>3WX-?3W_":>',_P#'S_XZ?\*7_A,O
M#W_/Q_XZ?\*38O;,^05\+:WX)OGE>PU348]:G7(CB,ZQ3-P6"C_5QD8)QP#V
MJ1O /BW7-;G&L17GV6PE2>U2.+RE#.A4@N"?, !Z$#!-?7?_  F'AX_\O'_C
MI_PJI<>/_"EJZQSW>UG!(&QLG'X4E9:C523V1\I:=X-^(VDZAJ,-M9SWUK<S
M(T4EP^##'L"LJ )D[2,\]?6M9O!NO:7J<NK2V=[=K.C,4V[PCQJ,;%&/O $?
M6OI=O'WA9'C0W1S*<*=C8)(SC.*N?\)?X?\ ^?C_ ,=/^%-2!U)=CX3U'1/$
MOBGQ%IEUHWA;4=,U739IV^U7-H/*"%%RK$MAA*. 1RI&?KZ[I'@_Q?9QW!U"
M*6Z::1I5'EA=@;G8".H'8GGUKZ)N/&WAJUB,T]UM4?[+?X4L7C;PW-PESDC!
MQL8=?PHE),7M)=CYE;PMXL25;Z^T>XF56\Q880,*XX!;<1DXY^O:MFU\'ZC%
M/+J,6BO!<W04RN(E$CX& '8=<?6OH?\ X2_0,?\ 'Q_XZ?\ "C_A+M '_+Q_
MXZ:GE0>UD?$&C> /%GA[X@ZKXOO]/GNX_%'DPA8[7Y[,P*5"LPY*-C)8XYKT
MS6?#_CJ..&71M+,S(Q:6.0;2Z!20JGD EL#FOH]_&?AV/ :X.3V",>GX41>,
MO#TPW)<$CUV-_A1HP]K+L?)E]X;UAX;6WDT6\CO-8F!,L<!_T9T&_+MR !@*
M.Q-<]X@\(^*M'2^M8;"^O+[4HI8OM<4!,W[TXC 9 H"Q$GJ1@5]L?\);H!_Y
M>/\ QT_X4'Q;H'>X_P#'3_A320.I(_'_ %[X(?$WQE\1-*\)S>%KJ'P]:R02
M7UWY;*C&W)VX+$9R .F<$]^M?H+#X6UR&%(H].E"QJ% "]AQ7O?_  EN@?\
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M_P "6D?FW&K1HO'.&/7\*4*B5DB%B*KT2/C?Q1^SK\5+CQ!9^*UOHM:-@?\
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M([[3[R:Y4;1NWR17<2'YLD80<8'7D^9> OA_^T;X"\,Q>&;'Q%X4N(8KB\N
M\FE7^XF\N9;E@<7P'!E(''0=^M?4U% 'S;XITW]K"3PSJ\?AW7?"0U5K.X%H
M5TR]0_:#&WE8:2]9%._'+*0.X(XK^1_Q3\,/VKIO$^IMXL\+^,+G7#=.+R2>
MTOYI7N#DL6DVMO)Y(8$Y'()%?VY44 ?PR2_#OX_P7%K:3>&?$\<]V,V\;65Z
M'E"\_NU*98#VJV?A;^T:-^[PCXK& ^[_ $"_Z*?GS\G0'[WOUK^V/6?!VG:W
MXI\/>++F:5+KPV;LP(A41O\ :XO*?S 5).!RN".>N:ZV@#\H_P#@G?X=_;/T
MG]G&RM/&5[9:9#]NG;2[;Q197MQJ4>GE8]@.VY@9(O,\PQ(Z[@O(.PH!]T?8
M/VF/^@YX0_\ !5J'_P GU[I10!^2NJ?\$\/BCJOC;Q?XYF\?Z,EUXQU6?5KB
M)=*N/+BEG"ADCS=$[1MXR2?>N&^)?[$/Q-^'?@/6_&[^-='O5T:V:X,(TVX0
MOMQQN^U''7TK]HZY+QYX.T[X@^#]6\%:M-+!9ZQ UO+) 5$JJW=2P89X[@UV
M4\PK0BHQEH?78#CW-\+1CAZ&(<81T2TT_ _,'_AW=\4/^A_T?_P5W'_R575_
M"C]AOXN_"3XN6GQ@T7QSH=YJ-GIESIBV]QI5UY!CN71V<[+M6W H,<XK]0**
M57'5IQY9RNC/-.-\UQM%X?%5W*#W3MTU['A?V#]IC_H.>$/_  5:A_\ )]?,
M7Q:_9,^-?Q>^)^A?%/6O&7AZRO\ 0=,N-+B@M]*N_)>*XE65G;?>,VX%<#!Q
MCM7Z(T5RIM.Z/E3\U?\ AC+XQ_\ 0[:#_P""JZ_^3*X;X=?LR_&'Q]X:;Q"O
MBS0;0+J&J6/EG3+IO^0;?SV1;/VL??\ )W8[9Q7ZQUR7@CP=IW@30F\/Z5-+
M/ U[J%]NF*E_,U*\FO91\H4;5>9@O&=H&23DG7ZQ/N+E1^;'B[]@;XK^,+*Q
ML;WQYHD"6-_9Z@ICTJYRTEE,LR*<W9^5BH![XZ5]P?8/VF/^@YX0_P#!5J'_
M ,GU[I16<IN3NQI'YA_MZ?"K]JKXF_LU>(-%TF?1=<NK">SU%;+1+"\AU&;[
M),KG[.TEU*"Z#YPH7<VW:GS$ _%__!*KPA^V9HM_XR=5FT#P?)#&!'XJL[U[
M>34/,^]:0F6!PX3>)74[3\H8%MN/Z#**D#Y1T_Q)^TQ??$S7OAY_:?A%?[$T
MC2-4\_\ LO4/G_M2XU"#9C[?QL^PYSWW^U?B[_P4Z\$?MIZW\9M!FOK74?$/
MA\V<":2?"UI>_8([K<WFJ84>=DNBV#N9LLFW;PI _HCL_!VG6/CO6/B!%-*U
M_K6FZ;I<L9*^2L.F37L\3(,;M[-?2!\L1A5P 02>MH ^!OV4/AA^U'\+?V=?
M ?@2^O\ PWIL^F:<N^TOM/NYKJW,[M-Y,TD-Y'&SQ[]K;5 R._4_1$5C^TH)
M$,VM^$C'D;@NEWX..^";X\U[C10 4444 ?_6_?RBBB@ HHHH **** "OGSQX
M,^)KCD\*G'OMKZ#KYN^(VE7$WBN:\LKIH)=B!E;YHW&WC*]C[C%%KFU&U]3C
M[S7-,T:T^V:S?065N'">9<2K$FYN@W.0,GL*P_$'C'PEINH6NGZOKEA8L!YQ
MCN;J*)B"/D;:[ XSR/6OAK_@HY+<Q_ 2SBG!AE77-/)*GY7!+C@]:\U\5?#C
MP=\4?V_;#PEX\T]=6TAO!MO<?9Y&8+YD<:;6^4@\9-3"\M//]+EU/=_KSL?J
MCIFK6>K6POM)O;;4;;G][;2K*N1VRA(_6I;9?M;BXF82*H^48P,Y_6OS6\!>
M&;']G?\ ;C_X57\.WEA\)>,_#[ZA)IK2-)%;W,.[:R;B2!\A_!L5]D?!CQ#\
M5]1T.Z/Q?T.UT'46OI4M(;63>'M  5D)+-AB<Y&:;2:37]:V&KZH]OGGMK.%
M[FZE2"&,99W8(BCW8\"H[B[M+2U>^NYXX+>-=S2R.%C5?4L3@#WK\Q_^"B]E
MXW?X5ZKXITOQS<V7A^*:RMY-"CA")*S/AG:889AD9VYQFMK]JS5(O%4WP"^$
MDU\1H'B[4X1JJ12E//AMXXR(G*G."2<BG%W6G>Q,KIZ]KGZ,:;JVD:W:B\TB
M]@U"U;(\RWD69#ZC<A(J.&[T^SNSI9N$$NT.L18%MAX!V]<9XSTK\V_AMH8^
M%/[7/Q%^#7PID.C^']9\-P:E;0JQEAL;O")YT:/D<%R=O0\"LSX):5XV\,_M
MP^.='\<^*KGQ9=6GAZUD>\N4$>V*5XGVK$ORJ%W8&*:LVK=4_P !/1._];?Y
MGZA333R/Y-CL+#[S-DJ!Z#'4U5=]4%[!:!D4$>9(VWAD'!4<\'..:U(!$J+Y
M&"A ((Z$4EU;FYCV))Y4BG*N.<$5&NY7,B?*H-S' '))["L'2D&I;M8ND!,C
M'R ?X(P<*?J>IJ"\L-?N&^S"ZB:WE4K(Q4[@/]D#N171P1)#&D48PB */H*I
MMLKX8Z$=U L\#Q'N.,=01T(^E%K-YL2EOO#Y6]B*M<=1WK#X&H2K-,T"N<H@
MX#XQELTF2M="U>75G]KMK<RJ9>6$8Y8CIDCTS3&OKD7+!;*0Y  ? "\=CSTK
M1BM[>,[XXPK'J<<_G5GVH:'SK:QGHVIA<R1H3GLQZ5+]M@*98[6'5<9((]JM
MX[BJ-]:12Q22[0LBC<&'7*\TGL2FF]AMD\NZX29<,DAQ[JW(Q56R01ZK>HC'
M8BQ*!DD#@GI^-3)9I<JLUVQD9P.AP,?2K$&GV]M/-<0@AYMN[))^Z,#K2BF7
MS)7+H['I3R..#35X&33N_-68B>XHSSUIN<G%,=UC4NYQ@=: 1GW<"7EY"BG_
M %#!W&>.,E1CZG-:X&!UK'2[@MYKB67<I8*V.N5P ,4U==L6;RV617'K&W>I
M35S7E;V-O*CENE<]'>7L9EFC'GK.X\M3P$ '//\ *JUUJ-QJ<ATW2HV3<<2S
M.-NP=2%'<_I7065K%96XMX\LH_O')/UHO?1%<O*M=RQ&P=0YXXS66FJX7[1<
M1F*!C\C]<_7T]JDFBNH@8HBHMY#\S,3N7<>0*T0B;?+*@J,#!Z4._0S5C-LK
MV&^O;B2')6-53D8YR3UK44 'C\*H.J0SM#:%(Y&7=L_'EL#ZU#<::U[#)'=3
M,P8?+M^4*>W3K23?7<&C8![&@GG!YK*T][.W0:?!\C0_+M))(_/K]:U2,G)J
MR6AW'K59[19+@72N4E1-H[KCD]/QJ6169&5#M8@@'K@]C6=:+J-I:JE\PD*'
M:7'4CU-3-CCM<]3\ M,3>+,H!&SD=#UKTBO,_A^[M)?;CE1LQ^M>F4TS*:U/
MGCXT75RNJZ59V\!?S4D+/D *H*YY]Q7E<C+;+@?O)3G[HSA<]37KGQE\L7VF
MEFVDI*,^GW:^-OV@[^[TC]G3XE7^BR207,6BWDL=PI*2H5CR"I'(.>E95=+L
M]:A;V:T/<IH)L+%-^Y5EZ]*TTN+.V$GFKYB[?E(YS[5^(/B7Q#K'C7X>?LK>
M%)?$VHVS^))9;;59K>X=+AUFFC7<6S\Q SC/2O;_ !'H?B+]D3XQ_#/4] \7
MZGXA\'^-M4.B:C8ZE,9BC2% LJ$YY&_(]U]Z<J33Y?.QA.H[7MT3^\_4-$^U
M2#! 1B3M'0GKBI_.)9L<XXX'?UKR+PC\3;WQ+\3_ !9X&?PQ>Z59^%@C0:E,
M/]'OMY"MY7T!YKRSX_\ PS^*'Q4\7>%=%T+7I?#OP_M!-/K\UI/]GNG.T^2B
MM_=R.3GC.:XI1NU?J.ZU?8^H9Y8(',ETP09ZG@$?6I?*!A9G7<I)(8=.>G/2
MOQ>N?B_XY^'GPD^.6E>'/$%SXC\.>'-7LM+\.ZQ<N97WW;M'.J2'[XC R#V.
M#7OF@Z7K_P"S#\</@]H(\5ZGKV@?$BSN+76+;4)C,@NHHED$T.<[?F88 [?6
MME25K7W_ ,KE3JJ,5;?]+V/TXL]*M;NS ^4RM]\@8(] OT%>>:QH4^FS2+;2
MO+?RY2"8D9R02N?3O7XV:)\9-*^)!UCXH>.?B+XD\*Z[+KCQ:?)IT4CZ3I5I
M&ZB%+C'R$N,YS]3UK]C=9_MC5=,TNXTJY%W(D<,TD\0'[]B!\RYXV,#N^AJT
ME97T9T9?7?M>6^GF=E#/+IWAN#3;RX\VYBB'VA^H+XR0#[GBO(/$?AW3=773
MM?2XE6ZF=(!!$^59D;=\Q]@34_BC6O%30C1;&U6.\E7#N1]P./O?45I>#X+B
MTM-(T"V07LRHTJR,<8ZDN3[]JI)IIVW/=P^'EAX>WNKM].VIV-J;2[B6!9EE
M\H&-QZ-T8$^W05Y_<^'1<>(KN;5KEXK*)Q]G1#M5T."2>_4UZGIO@>2+5_[3
MU"X4("'\F'(1I.,EL_05:\1^#WUZSE$4JVUU&[/"X&<'^$'VJJ5-IM,X:&/A
M"HTI:/KV.2U6V6;0-0MX%9H9T4*Z\EX\\KZYXQ77V=Q;74%K?2/LMYE!Y&W;
MN&>1^E.\)Z<MSX?A&H;OM(RDRYQLD0D,!^(S4MYI_P!CC6&XYA)(20>O;</P
MK.5&70Y*M9-NGV;&B*/[6EZ!'((^5SS\I'7VQBLY8HGNY+J%6A#X3:IP&*L6
M!)_$BL72@T]G-8S[8;N!WBFQQG)R& ]P>*Z!)[.'3##$P8JY0XY^8>GXTG)V
M=@E3<$U?_AC,2WA42D9!NG+'=V((X_0U'-HEIJ=U&D[;C&F]<#H1P3^-7&L;
MJY @@!&U3[E@16:G]HZ$;E94PVW=NSD@9X'XUI%MNYTPN[R3U-N.[M;-W!9!
ML?E0?X?X<TS5[07K102@ %\N?[R\]#[\8JG::.;F9)6(\FXAW29_B&?Y@C-=
M##!#,TDDQ*16J_,W8!>GX8K"^MD<L[0E>+U*C:=96URS0##JJQHO\6?;VJSI
MMDESYS*P(C.,+T/J<TW5<2K:MIQWR<;AG!\L]2#Z\U6,D>C1X=PJKDG!R<#V
M'M6J1%G*/F:4L%K+)%+#M.P\AO[N,4^T: XNV4#>S;%Z@')'7T-8-A<QZI#+
M=PP%XY.(.< +GTK?2TBLX&>=_DP J^AZXJ7IHC.I#E]WJ0SVTFQKR4*KGAAC
M(0?_ %Z?A1%%) 2O.YF[X'].U/@L#=,P+ *0K$C.#]:K:A*^F:@!:('4I]TG
MC!]/J>U*3%'WO=1+=*MJC.Z[G=AEATP>F*B'V9H$6:<0L7./7=V-<X=5O'N6
MBN8SO3  '3).<@>E)")KQW:8 %, (.,X]<_K24.IU+#-+WCI?*X!B)+-@E^N
M%SU %5 VV[E2)O.DX'3CGLM0W3-$D$$+M$"P!(_B]O7!Q4L*^5="!0&.2X4<
M8VXXS]:CT,HQTNB_%"(P&,7F"(_.">_M3TG"PQ!D589?N <D'DG/O5,S26;-
M"&W,^6^;CW(JL9GBBV*HD.2>O )XS4J[T8HT^;<DDMA(R31R$H"<#J2W_P!:
MF-*S2QK.V1SAR=N#C(P?7%4DGN;I?L9E$?EMNRHYR1C_ /72[H8+9+2[<73Q
MOP[=ASS@5>J6YT*G;<LZA>V?V&>VL'67[2H0E>?+W]<FO7/AW-"=:M[>)QF.
MW<%<]?N\UY0+**Q@DNK9 RLV75!R2<#I["O2/AH-GB?8(/*S"YY&&YVUM%O2
MYS8E+V>A]"UX3\5R!J]EG_G@?_0C7NU?.GQDGU*+7[#[/ )+?[,2S;N0V\\8
MKHN>135V>/:[?/IJ?VBUU#:6L"%IY)V"QHN>I)X%<GJ?C_PKI-I8Z[?ZY9V=
MM? O#YDZ+'<+T+(Q//X5Y3^UM-<_\,Y^/)4((.FD,/0%TK\ZO$.AZ)XNTC]D
MOPQXBMOMFF7UL8KF%R0LB%02#BLM)MJ]M4=$I<MC]@M-^(7A'6A_Q(=2AU1P
M0"MK(LI!/KM)Q79AC@'IFORV^*WPY\*?LT?M _"3Q)\(K=M'M?%%\^FZA81.
MS0S1L5&_:3U&[]*^\/!VK_%F\\>^*-/\9:+:V/A>U=1H]U%)NFN%).XR+_#Q
MBM8*ZO?^D9N72QZ/JVN:-H-K]MUR_@T^WSCS+B18USZ98BI+/4],O[)=3L+N
M&YM'!831NK1E1U.X'&*^:/C]\%M \=:WIWQ&\;B\U_P_X4M)2?#MNA9;R9S]
M_ ()89&![5^:]AXKU'PY^RK\1+;PQJ$VDP:OXMBL(]*9V%SI5G,QS"V>5W!>
MU$7=-=?^"#Z'[8Z9XI\,ZRLS:-JMK?"V.V7R)DDV'T;:3BH;KQGX4CO)-&;6
M+/\ M H<6WGIYQR,8VYS7YM:Y\,?#'P;_:(^$.B?#B.31K/QGIMQ::E'$[,L
M[I&665U).6#8.:\D_:)^"/A3X):=H6DC^T+SQ3JNL6]W+XQG#I#:I),<QR."
M>@Q@4II[+O;\;!=6OUW^5C]?K*XU "&TLT4(."S\X'X5N1)=R;[6]4$%>)%^
MZ?P[&F:,D*:79F"19E:&,^8O1\J/F'UZU-J%VEI:/_>?Y5 Y)+5FJ;BG=E<U
MR#[?;- T*,)712/KCBL];>[F7S539N Q@]_>G:?;BW:-KE=K-D8^M=&I"KCM
M2A[RU-.?EV.6BL=0L;Q)[I_.ASU Y5F_I6\^H6L.[+@A?3FLS6=9.GM':01F
M>XN/E5%ZCW/M6:FB:I @O4F'VC[QA'*8],^HIJ\=(FG+S6E/0T](NS<W%S?7
M2>29FVQ*W7RUX'YGFNCZG-<SI]O+>6YDO\Q7G.0.BXZ8J#1?$MK=23VEU($D
MMVVAB<!QZBJ@R9T6[N/0ZQT1G#L@)7H3U%2%N,4Q2'&Y#N4]"*>!V-6<[\Q<
M''%(G7)HQ[T#B@5SD+."6P\57"22>:MU&9$S_"-WW0/:NPX(]JX[6-/U/^W+
M;6-/.X0Q&-T/0@MD_B:T)-?CC4K]FE:521L"]Q_2IC!)LZITG))Q[%2\ELXQ
M<6+Y5D?Y%' .[I706LD,44=L) \BJ.">>*\XDNM7U?4C<0V#&/*AC_=Q]>M=
M') +B]MGBB:%23O)]1QM_&N1MJ3T+JT.6R9T,VIV43>7YH9\@;1UR:J2Z<=2
MD6YEG:%ER (CQCMDU>.FV+.)3",CMVS52&U6&_F2R<1(0I8=?F]*U:;?O+0Y
MDRU+');6^;=^4.3N&<@TZ.(WUKLO/F5^H7BLR:[NH;B:!V#A2!C'4$<9JUI$
M\;V[QA]QB9L^W.?Y4HU8N5@:T)K&&.Q!TY2<1\KGDE3[U#K3*;,H"&DC=)0O
M?"L,FK29NKM)TXBC4KD]6)_H*Y[4;;4GNHKP18N%5XAM.1L)#9_I5MJ*95-)
MO4["-PZA@<Y&::SB(&1N H)KF["#5A:;[>8*%+$*XR3^-1EBQB:ZG9II>-HX
M&#Z"I]O=;$^SU-VU\AT3,8(<EL8!Q5TI'&K84!<$X[5%;+MB1,8P.*=>K)):
M3QP\2,C!?J1Q6L8Z7)>]C'U'4(19&QM1YD]PA"H.<#'?TK8L'5[2$ITVBLJU
MBTNTL8[R15Y R_4EN]9[7&I6C/-IP5K:,AY(VZ!&ZE3^M8*IRN\C2R::1[=\
M/"/[<?'_ #R;^8KW"OGOX8ZI;7?B$1PY)>!FR00, CO7T)73&2:NCEFM3E_&
MO_(J:G_UQ:OE#_9'.*^K_&O_ "*FJ?\ 7%J^1[DW MG-H%,V#L#D[=W;..U,
MJ"(S>V!,T1N8MT S*/,7*#_;&?E_'%<U:SZ:^HO%INHVTLN L?[Y)&QW  ;)
MK\JWUN]L_B5^US;Z@TCW$FC;5$1.R-_())&3\HJG\.?V:OASXF_9'M?BA;2W
MVE^-4TJ[U"+4$NY5'VBU9V7Y-VW:0@!XK.HU:\O+\3HBI)V76Y^L-SJ=U:O'
M!;6$EQ=A]LB@[5"_W@3D8KK(7DDA62=/*=ADKUP?3-?$WPB^-GQ=\5? ?X6^
M+]!\,_\ "5:AK4OV+6)GE$1@AMY#$UR>1N)"Y([FOK7QMXPT+X?^%=5\9^(Y
MQ;Z9I$#SROW(7H .[,< #N35N')>Y'M5-))'1O<6ZR^094$I&0FX;R/4+U_2
MLC4<03P7&[9E@ 2<=>V#7Y6_#YO%\W[:G@'QKXXU!EU'QOI-_J;V/FYBL;=H
MY4M+;;G&Y(E4MW+$UVO[1R?%K2OVA?A*NO>+%O\ PUJ_B=/L.F00"W$ 1EQY
MKJ<RG#8R?>B4=$*$[-VZ'Z,:AKITYXYWC\RT(P[*0&0CN0>U;]M<PW4*S0.'
MC<9!6OS:_;[T;XMZ-\,-1\3:7XO2T\+1RV5O-ID5N$GD>64(Q-P#NVY(.WVK
M[;\)7C:;H>FR'<(FLX&=2<G*Q*2P^O6LE4?+=]S:4$](H]2+(JEG^4*,D]L4
MJ.DJ*\9#JP!!'0@^E5-]I?6)9SFWN$P3T^5QC\*X?0(M4\&V\?AZ[CDO[.'B
MUG!R_E_W&'JHK5R5KBC24HMWU70]&_G5'5;$:GIMQ8@A#,IVL1G##E3^!KE]
M2\3WT,T*Z;8LR>8HE,P*':3CY,9Y'O747.HVEK;R7,CAA&"2!UX[4)H(TIQ:
M9X+H<UQ#=W=GJ$821S(C@G^)2%;D]NXI^NVD.LRM83JHCO'ACWL.$V'@GW.!
M5^"Q;7-4?6I1L:X+ KG &1P#[]!6M+I:W(MPOR[\.1UY3D9KGF[2NCZJ>(4:
MBDM[?B>M6EO'9VL-I'C9$BH/3"C%7?E]*YK2KN75+69[DB-(GQD<8V]<_P!*
MUK:^M+IWBMVWF/KP0!^=;0FF?)U(N[;*>O3:I#8K)I./,$B[_EW8C/WB!ZBN
M4_X1^[EN6UFU9C=*WSENDB$<\#TKT7&>#T/'YURD]I<:MHMQ96L\EM<VS,()
M4)4ATSL)[$=B.E95::<EJ;X>JUHG8JR>'H+F&+5HI,7"(Q(Q\K*>2OZ<UR6J
M&"017#*42U 1/0L22<X]N!4_AS4[_6M%6_(D@F'RWD"GB.93B15]B1D#T-94
M^FS:F;F2W<));R 0@GY6*GD,/4L!6,5:5CU</"49N-1[$HOM&%\TER%M8BP2
M<#@L%'#<]L<5T%M:VVG+,MFP93(0_<Y.&5NN!G-8@M-/UJVM6NX<,SNTR9^8
M.5VD'_9!Y]Z<L?\ 9=ZEI;7.Z-AM^;I(I[9]0<;314LT:UDI*R;OV]#JYS;_
M -FRB3<9B#N9#@@#)7'KG\*YV[A6:$VTH#[,*''\+DAAC^5;-S,FGI)&D8FE
MEVY).!M[G_@-8]_J,<5KO:U:\^9',<?4*IZY'H<5$&]#BPZDFFC,M(KBPMHK
M."19+>4E=C<G<#746=K<3_9@T(Y.4##.-G'X9ING:#(\;:DMN4._S!'WSG)Z
M]175VVJ6,K06]NN"23_N[>#6\K2]V1>*Q"?NQ5V9LL!TZ999E,9P5WJ<@ANS
M4^>U6^L8[>7#;G #)R=H/!'I6SK-DM_8F!SM"LK9]AUKE["T?[8L37!B\Z-I
M%8'^(D#']:E0Y7H<5)W7,='H,\KV\EK<G=):N8RQZL!T)_"M_=TKEX;J*PNS
M]J8.+@(OF*/E\P<$$=>:Z?TP:Z*3NK,Y*RZ]P/6N*U*SM_[8-FQ$0O<.A R6
M91\R^V:[3H>>E<UXD5$CM+HY#)*JY'4*>3C\J5:*<65AW9V&!XVMFTV1C&%Y
M#-@Y.#\H[\563R--OQJ*OYB*@2;9R< <$CCIUINE/:ZC=O#/(SM V4)&TGL?
MKS76Q65I%A5B4_49)KEA1YM32HN71DD-Q;3@/#(KA@",$'(K.UJ5ML-O"Q#.
M3D#NM27>C:==D;X_*=<[7C^5ES[BLF#2;B+4XXKU_M$8)96/4C&.:Z:E]B*:
MCO<^WK(8LX!Z1K_*K-06H MH0.@1?Y5/6R.-A1110(**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#__7_?RBBB@ HHHH **** "O"/'&!XCG/7Y4_E7N]>#>.#CQ
M'<#_ &4_E519<$?&O[6?P1UWX_?"^#P/X<O;>PNX=2MKWS;D,4V0;MR_*"<G
M->.?$G]G+X[7'[0%M\<?A#XBTG2[JWT2#22E_$\I(10)#M (Y(X[U]_$YIDL
M9FB>-7,;." Z]5)[C/<4DK.Z_K2WY&CU_KYGQU\$_P!G3QKX:^)VL_'?XU>*
M(?$_C74+3[#;FVB\FULK;C*HI[G '0<9[FO6OA;I'Q2\/>'[R+XSZW:>(-2:
M_DFM9+6+RU2T*@1QD #+ YYKT_3DNI)%BN!)- F6\R0CYBIP,@ #WK:6VABW
M-!&J,<XX[FIYKK0=DM3YB_:>^#>L?'?X0:E\.O#5Q!I][>W=M,DURK;%6%]Q
M!V\YQ7._'W]GO7O'N@>#)_!&H6NE^,? EU#?Z=/.F8)7B55DCDP,[6VBOKJ$
M'[9,K-DJJG\QC-)J,*R1).8_,-N=VWU'1OTYJ.2RLO4N4M;,^/\ X%?!;XEZ
M9\4O$_QR^,M]8WWBC7[>"P6'3%86EI:P ':A;EF8JN<#CZUT7A_X0:]IO[4O
MBKXX0W4-UI>OZ/;Z;'; ,)8GA\O+R%@%V_(< <FOJB"2*6)7M\;#TP,"F7/R
MR).9"@P0P[,!_6M&W9-&76S$TM88;1;>&3S/*R&QV.<D8K0X-9.DP^6)Y@FQ
M9I"P]3P!G\:UAUHAL*IN.Z#I3^WM48'((IW)/'2J9.IGW,-_)=$QR;+98QA1
MU9\G.3],8J%A)J;)')!Y?DN"2W7 YP/K6P#@?3MZU!9K,+</<#9+(2S*#G!/
M;\*SDC92T+@Z<THR>15"Z>613:VL@CF8</@'9[X/6KZY"\G/OZU5R+=2I<7D
MELQ!MI)(PNXN@#<YZ8SFHK>\MM6M)#;2<,"A[,I/&".H-:0.3QVJL]I;RS"Z
M"[)@?OKP3[''4?6DT--"VJE;>-&38R#:5],59X]:RFU!A*T(:,'=@%FZGTX]
M:KWTLT,T,AG"N<@QAA@ ]\=34NI97+46S<&,51GNKB&ZBC\G=;RY!E!^Z_8%
M??UJI$);"1YS(\EH5!+,=Q#=SST'M4MX;J[BC-F/W:,LA.>7VG. /I5<]T*V
MNIJX%8U^CS75O&8S(L9\T8.,L,@9]JU894FB$J @,.AX/XU6AE>6YFW#A, >
MWM2O<459D!MKV56>1D#G&!C( !SC-6O/W%8)8]DO4 \C\#5K)-4;V-<QW@.V
M2$X^H/4?6DXVU0U*[&7\21P^?;N(9E;(8_=+?W6'H>E2"YO]F_[*">. XY]>
MHK-_LYHI4NKE0T&[<RDDX8]&/;BMXR*N,\9J(-WUT!E*>\C(2*XB=&=QA2,\
M^N1D57OI-2M(C)'(B0QGEG7<V.Q_/BK>I(9K"15/)Q@C^$YSFI!>6L\!'^MC
M=?F&TXP>N1VIM=V-::V,31(IEO[R2=C-(0H+MU'&=OL*Z5B(U9G("CJ2>!6,
M+O3;6">YMAG&,@9!;TQG&:L&5=0CCC"LJOAG#KCY>P/:E2=ERA/5W.=U#^T1
MJAUG2-KL46)H9@5$BCG(;J"/RJ\=0\51LCR:;;^4Q )$QRH/X5T$UK%,\<C9
M#1D=#P0/459RH^]C'H>E-)HT=96M:Y'YPVC:,L>WI089)%PTQ7/H!4$;?Z?.
M0O0*,^I[U>)SCTJUJ<[T.W^'4,MNMW!(YD VD,0!Z\5Z=7GG@5U)NESR-F1^
M=>ATTK&<MSYQ^.LZP3Z:TJKY963<6.,#*U\L_';PYKWC+X)>,_!WA#%[J6N:
M1<VT$>0!*TJ$*,]!D\5]?_%^33EN+!+ZW6Y+))M4C.3E>WI7B*0NMN(H0$D^
M5AL(" 9X 'H#7+7=EH>K0J+V:TU/RU\1?LZ?':Q\!?L]R^%/"L>IZ]\-6DGU
M*U:58QYBR(\:%^X(7J.E>DGX:?';X^?%WP;XN^,NAV/@WPQ\/KDWL=A#<>?-
M=WBD%<GL 5'X ^M?H=_;EW"LD:(&8 DR>I]<5EV\+7X:<C>$&[GY<LO4^]6Z
M^J=M=60J#ZO31'FW@_Q#\6[_ .(GBG1_%>AV]EX1M%C_ +'U!)"9;HL1Y@=/
MX< FOG+]M;2OCUXNB\.>$/A38O=>&+AR^M"*X%M+=G> EMO^\%*@DX]?:OKN
M/6KAGFGE59(XP'B9.^>,'W[5G3-<ZS<QZA=R*@C(9$X^\#P<U'LG=-]#OA@&
M[N3T/B_4O@U\5_BQ\ _$WP-U?X?V'PX%M;VMSH$<$XDBGN+63>ZR'L2 !N/)
M+>U:7A7X??'GXT?&/X<>,/BSX07P?HOPNLYP_F3"4W]]+$(MT8'1,J&_.OOJ
M+5-)U+38I)M2BDFM5+%P< ,.&&?KQ5NRG;5;2X$[/+'!@+L;[W?J.HZ5HI:W
M:_X>UCS)T)):]#\DE^"_[1'A7X2^,?V5?#O@:VU31_$VJS3P>(3*JI#:3RHY
M,B'G>@3 ]*_1'3[;QCX/\-:+X3TJ(_8=#L+2S%R$W23>1$L><G@?=R37N5Q8
MV<D4,BO]CG105)/;T/K7.76IW]T%L<!XPW+*.".E"FXK5?UL=.!DHSYN6_J8
MD<D7V&+[;)YDMQA7DP 27Y/_ 'S4OPAM;LZ5<:CJ !:1A' X'!@3I_X]G/TK
M6EL;;5;>.S@C5I'7:&[#D@L/H*[#3X;?2H+?2+9,);J$  Z #J?K54?AU-:^
M,7L90ZM_D7[B[M[9#YC -C('<]A5*WU.*.)O[086SKDMN.% /H:Y_5+^&SU6
M]G9MC+ D:$C(\U^% _$BN5'AZ0V+65S=M,"QF9Y#N^8@%E!/8\\54JEG8YJ.
M&BU[SM<[/1?$&AS7M_;0W"I(TY<*YVDC:!N&>H)!K9U.XTZXLWMI9%82X4 $
M$[L\?E7EIT&RBA2YU) ^,[.0"JGCCUSBH[XW?ARY@BT*U6Z6>95F=CGRXF!^
M<9]\# [U+K*S.JIA:=^:+?\ 7F:_B+1X;F[COK9GMI8RI9E^[(J\8]\UHVT5
MO9P1)_K3AB<C&2S9_F:S@+@3B6_NO+B)4",D* %SG ]>]6='NTU&5].@=IG4
M%E9EP"!T&?Y5DY76AK4<O9I;HUK1YYF9BXA#<A3RV.X!["LR>/\ LP31S2_:
MA=,<2'DC.>/H*T%DBEY"ABJ$[N@) Z"J-W;2C%J(<1E$D,Q&5'F-@*/<#^=)
M-W,8-<VI7@OF9?((!2+Y P_B&>2*;)>37-K<R6Z[H8P5=E/#%AD#Z"MK33X;
MN]^E:9-]IE@7#! 2HX(QNZ51$$ +V,8!+A@0IVA2>,<>F,4H4];LN#C=MHLZ
M)8&_\R#SLPQ,N7'+$*.@/;/>NRET;39HO):$=,!NX]P:P/"=L;".XL)!M96W
M GJP/<UV7/-=4$K'#BZK53W6><:9)!I>J2>'+HB)[1?-CD)P)(F[_4'K3EOH
M7E,^#*%9A$K?= Y&[WSFJWCC15NM5L=6@&Z:&-H77/WD+;E/USFM32;8R72Q
MNG* AP1TP1@5G4DKV.N?(XJ?5K7U+%M*WDA;:8;2C,0>N1Q^54)(;B9A,V,+
MP3W![8K7U+3X%22X@B/RDJ^.,#&?QK&M[EYVCA:<&50S;3P2<YQCO@5C*^R,
MJ>UXE^R2VTZV-S> ><=Q&>3D_P -95]%<R$2)#AVZ;>/F((R?I6E^[EN&N;U
MP6!*1H3C@]Q[=:LVD=MJ,K[[C:%)(7W/?\*MIC4FM68&J0:O<0P2V$:(T97+
M,<X/0D?G^E7+(Q0)EER7&"W4[AV!]ZT'BGM'GM ?-'#@CHH]35,_95VQQ@YM
MLO*W8+@@'\343L]$6ZG,E$CF=+Q$:5<,/E4GH,>IJOY$Z(+I",YV+CD'C/ I
M;S2M5D\BZTXJ\!3YH7^4\G(8'U%<QJ>O3:<DL)C+W5NZEU4$H%;DDGIT_6B,
M&=%"DYV4-3H@UO;&.56$C%LMZG(Y%&H1K)=P_9K5TCE&[S /E4@@8/U'-6_"
MLMKJFH7%PZ QA1Y61V/)/UKT60QI"P(&T#I6JII[F->O[.=K:GGUC%)I;^4I
M+@E@&/4MGWKU#X=O_P 5(1-\TK0MSGTQFO.=MI?& 21O&5SY<J\_.,C)'IVK
ML?AE-<GQ8898]JK#*#[$$?SJ8QLU8YJWO1;/HRO _B]N.I6809)@(_#<:]\K
MYS^,L6HW&OZ=! 5BM#;DR/GYR=Y^4>GUKIN>936I\G_&KP/J7Q.^%?B#P!H\
MRVEUJ]JT/FR@E%;<#EL=N.U?'WC']E'XH77AGX11>$M?L++6/AM;%/M$\;O#
M)(0 &4#MP>M?I9&D<2")!A ,8KG+RVU(W"Z?!\UI*"68_P  _NCZUA[-K5,Z
MHVEHSX]\#_LZ?$_Q3\3M#^*_Q\\6VGB)_"RL-,LK"$Q0)*W_ "T;/4U]'^#M
M%^*]AX]\4:EXOUVVU#PQ>NITBTBCVRVR@G(D;^+(Q7I]I;)9VZ6\0 "CMQ4^
M<=*WBW9&,TKNQ\R?&SX=?&C4_&6A?$;X*^(XK&_TJ%[>XTR^9C972-DABHX#
MC/7Z5\]2_LEZM=_#;Q[:_$W7X'\:_$"_BU-I;-"+>VG@8F/:O4@;CN/O7Z19
MYJI=V<5RKDHOFE2H8C) /I1;2R"FX\R<CX2\ _!'XN^)?B#H?Q/^..N6%W#X
M/T^6PTV'2P0S-*I1II&/1L'\ZX'Q7^SC^TMXE\'S_"#6/&%AJG@/4;];D7ER
MK/J?DE]XB&>X]?Z5^B<]E9Z3:YA4JDV%D0'[Y/<>]6X)?/O[=?)>*&*,[ XQ
MENG'T%8J<KV?]:W*Y5T+/A_2TT30]/T6+_5V$$<"Y.3B-0HR?PK7(&<D=.13
M0>.:I:E+-%:^9"X0ATR6_NEAFNB3>[,8J[T);ZU-[" K;)4.4;W]#[50&L"U
M;[/J,#QS!2WRC<K =P:V1SR*7:K#8P!R"*AJ^J+C/HS TJPD:_N-:N$ -RJ"
M-<Y*J!_6ND^??[8Z=\UB:'*[0S)(<F*1EQZ8-;8QU!HBS2K)WU,'7[I].2*\
M1,AB4)Z %AP345CH<$NGF*=5*3?,<#YAGWK2UEX$TV1[D;E&W:.N6S\OZUG6
MTFMG3E\B)'F7A@QVX(/3\JRG;F-8S?)[N@ZQ\+P:??QWMM=SB*-67R2V4);N
M1[=JZ<=A4"2OY8\U/+*C)YS]:B:^MUB$JOOWC*A>2?I6ETD8SE*3U+AXR:,X
MK&T^VU1+R:ZO)\P2@;(2!F,_7WK<X[4T[DM)#%ZTG)SNZ?2G#^M*<GBF3<C:
M-64H!A3Z<5S5YJL273Z4^Z.4KN1C]>N?>NIYZ5@>(-)?5+!UMCMNXOFA;W'\
M)]CTJ)PNC:C9RM(LFZN!;>9 HF**<[3T(INC!)+1;L'>\V2S>IKG_#FHKYA@
MV>7YC$E?1NXK:\/1)%;7 B;="9Y2GL"QXK*E.^II4A9-%75[6>?5[-(I D5P
M&\P=SY?/!]\XK4NXH[6+SHUVXVJV.Z$X.:AN9?\ B>64.W(,,K9]#D5LLJ2*
M4<95A@@^E5R139$GL*BJ "OX>F*?]T CBLNV=8)6L'8AQ\R \_(?0]\5J  #
M'7WK2+T,I(![#\JY36+E=,O].<IN4[@2!V]/PKJP<'%8?B+3+C4[*-;)U2XB
M<,A;I[C\JFJI->Z70DN;4OM?PF$O;'S6QD*.M5K?46O[<O9(5?.,OT'O5=-#
MD0LZW;1^8 &"#'Y&MFVM8;6,1PK@#\S64>=KWAOE2,J&PGM+ Z>VV?<<@_=P
M34\&C1QNLDDSOP 4SA#CV]*BOK/4C?0WVG3Y52!+"_W67'4>A'6MY2>,U<:2
M%*5EH=[\.@HUQ@H  B;&/J*]RKPOX='_ (GK?]<F_F*]TK5(YY'+^-?^14U/
M_K@U?)O0 ]J^LO&O'A35/^N#5\ER O&54E20<'TIE0/SZU7]G?QTGC3X]:Z+
MBS,'Q1L1;:9B4ET=8]G[X;?E&3VS7!Z!\!OVQ(_A!:? DZAX<TGP[';O9/?1
M>9)>BWE9FD R,9(8CC''>OT<\.:"FD:<MK<$W$W*EW.3C)Q@GZ\^]3*FI7I*
M6EP+6&!V56QO,A!YW>P]*R=UH]O\CHJ*-]'W/#(_AS\1_A?X#\ ?#WX&7-BE
MAH,L<.J2:@/FFM>LKQ@ XD=BQ[=:]4^*?@GPI\1O ^I>#O&-JU[I&H;!)"LC
M1,Y1U=/F4@CY@"<5L2>(H;"RN)+LBZFLFVS" 9QWS@X[=16M:?9KZ9K\J&7:
MH3<.@(SG!Z9S52J\R\R(TW'5GYTV?[$OA70_C]X.\<^&X!:>$='@:6YBFOIW
MN#?1LS0E2Q)V [,C(!YR*]W^._PG\0_$OXH?"OQ)H4]LEOX,U8:C>^<Y5GB)
M4_N\ @L-IXXKZ7&FV\FIR3R#]W$%VQCA<GJ3ZXK2:UM#@&!#CI\H[U,%/2_0
M)<JVZGSK^U7\*/$OQL^#.I> ?"<D$6IW-U:3*;EBD>VWF$C9(!.2!QQ7?6#7
M&FZ-;VDX5I+:&*&0KCC]V <9]U_2O06TR+S&FM97MY6&,@Y  _V3Q7+ZKIKV
MTX6?+0SJ 2G 9AUW>A-*HVEL=&%E'F5S T;4-;FU6PT_3[@/:'!E1@&S&.ON
M"*]6GBOY;J!XF"119)'7=GK[UY_X9CN--DF6U6.5KEF$:GJFTYY/<$<UVD6H
MWZN(;ZQ93S\T?S(?QJ(6?4UQTDY^ZBUJUM<7=HT=N 9 P/S'&1WP?6N*OH+T
MN(V0QE1D@CD@?SKL[G5X+9<R(Z^@(VY/H,US][J'GNTSQA1A3R<D*1T]QZTJ
M\DEIN9X:<HO8Y9;;>@\O*+GL!]Y>O%7H)!;WEM;IN=Q&5#$<$?7U[5:MIHID
M5;4;5 (;OG=D\9I\EI#-=LD+[T11D '@MSQQZUE&]KGH>T;W(-.GG19MWSP.
MP#+T;?R>/6MF36;+3;:2ZM8R\NTX3/5AV;T-9=VMNB&YMOGN(3N8+]Y&Z\>H
M/6L"UDCUG3GVYAE$F'. KD]L$\5,92^(E4E-<[V.KAU7Q!=QR7%Q/;V:;<A$
M&Z0D=1\QXKK-.DCBT^ .WS; S$]<MR3^=<=I]B;>S5-8CRY!Q,IVL?8C^][]
MZ\SUC4+^::2V2Z:2QB?RD*G)Y]>U=,.9LTI8'VTW&#LD;/B?6DTB_N;'0E</
MJS,#Y9X$@ RW'L?SKH_#E@T=G:PA=TB$+(2<D.V2Q_$UQFF:=IMUJ1N+8*DM
MON"R.VYG?'.%'''05V]KJL5K=6]MY?[^,[G*C'#=O>B=K\IV8Q<L/906MM61
M:M!-IVN6VG1#BXCS$P.,A>&!_ _G5*]TN>=H8E(>(*\AQUV'(./<=1Z5I>)K
M>.9X]7:1S/O6-$)'RIG+C:/;DFJLVJ0175O!(I2!P%A9?O!B,LH]?IZ5D^\3
M"#ERQE'5D[ZM9Q6\&GF R-_%.QPJ8X .>N36YIFAQW-A(MI(+>5'/EF/*X/H
M?4$UR>J:8(;9A-^^21@5#?=7VR!TJUX>U2]M[:YTVX#JTP=H)B 0H4#(S^/%
M)+J95:/N<U/Y^9Z'I5Y*UH3>L \3%6;( P.Y^M84DD-Q>K<6T31(S9#,N 2>
MN/8FN72:[\H03@_9Y)%3&1ESCJH]?K7IMJ(-0TWR5&R-@47GE<< @TFW+W3@
MJ4W3=^YF7$M[>22V<3*$VYW#G(QS4FIV< M;6:W(26,I&A_O*WRX/\ZQ+431
M1PS/@NQ,".AP6"\$,._U[8J]/H]U]BVW%R'P"57!_ 9)ZTXIO<GDLUJ"I;2"
M31Y8F:YD!(?L/3YNU46UK7+%GC$$4\4.1EWV,,#(4XX)/8]ZH6^I,K"\NXW3
MRF".&5E8 <!AQR #71:W<6LVF+>V2)/L*N649^5>N1U/':M(IFWL^65I*Z-;
M2]6MM6M$NHOE9OO(>JGTK4:.*7 D0,!R >>:XJ[TNRG@;7M&NMBR19 4_(^>
M=PZ8-&B^)+@@Q:K$ZJI"B8C@D\<_XU2JM:,PGA]Y1Z&WJF@V^HR+/ YMKA/N
MLG _$"L[2=:>TF;1+Y7EN;=E7<.=RMT.?;O77+UR37(:K:)I>IVE[;(,2AHP
M2?\ EIU')Z ]*4E;8FDU+W)':'I]::?+\Q&<#=R%/\Q6;_:]@B1--,B-* 0A
M(W9/;%8FHFWN;FWU"ZDV11GY$!(..['\<?A6DJED81IN^I]Q6W_'M%_N+_*I
MZKVF/LD..FQ?Y58K4YF%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]#]
M_**** "BBB@ HHHH *\$\<_\C)<?[J?^@U[W7@?CK_D8Y_\ =3_T$546NI4-
MSDQQ0V<''7!Q5*[O[6R -PX4OPB_Q,?11U)J!IK^Y1H[>W,.006EXQGH1@G-
M2S7E?4O6;?Z+$<]4!X]:+JY2TB,\F2!@8'4D] *CLH[F*V6&Z*[T&,IG! Z'
MGI5O /+#..E-!U.?#F"3^V0&*M\MP#S\@^ZP'8+_ "KH'F5(3.#E=I;@]1CC
M!J@P077D(OR2@AP.F&S67)+-:V*:<V591MWXR-HZ8_3-9WMN:<MR_8I?6D,5
MO)&)58#Y@0"HQSN]>:LW2XC$DW3<JX'09;'-6;>(V]O' TC3%% +MU;W-2G:
MX9&Y5A@BM(PT,W+4I2ZIIMFB+-<HN6$8)(QN]*TE.0&'?\JJK:6BPBV,2F/^
MZ0#^>>M64"*N%&%7@#Z4UH*3B]B3I61K-W-;VAM[)BMW<@I#@ D'NV#Q\ON.
MM:H]36)9:;+!J,ES=SFYE8%E)& BG@*H["E)E4TKW8NG:;>*D7]J3/.R)@EF
MP2WKA<"KD\-SA@USY<1(5 F0W/J3GMZ5I[JKS;7DAA_B#;^.P'_ZZBR2#GNQ
MKVL<42F%<-'QGOCOSZTZ&^MY2J+*'<\''.,>M332B.)E)PQ&!ZU _E1VXCA
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M^AZL,;.4>962]"Y+8Z<MK96=K8BX<N%,:C 0C.6/<]*Z"R&IV.R&VB%KN)+
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MC+O1(YE5+6=2K$$'/S+C/>JFI^(G6W,.-B%0#GJ01USZ5MWMI9V=@L5NH,[
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MZ7'W4]O<]*3Y4]#S,RY?:\M/X49/AR0:A<2S3.LAM<JH4<*7.XX'KS7;&-'
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MK51_X<^][,8LX!C'[M?Y59JM9D&S@(Z&-?Y59KK1\^]PHHHH$%%%% !1110
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M9%B4G>"5Z]TWG'S=>:PK>4S0FWN)%5H =PZ]^1@^]:,_B>.W,EG(RQ[<IAR
M N.N>.HZ5SI*^IZM6$F[+<Z.Q:V2%XKLQM,ARQ. "?;MBL6_:!)6N(D*Q3!P
M&ZY(P" #SWJG;WKSG[3PV5#)N'!4=#SU_"F&U::22ZG9BQW;!T+/CD8],=*Q
MG9JQC"E9ZLE@CO+-/MDEL9[=CLVYR02."/H:L1FUBB\R[Y#KE@1M*XXY!YKM
M+/8+6((,+M& :YOQ'9^44U>,-)L:-)$0$DKOZ@#KU&1^-:JD[)D1KJ3LS/NA
M_:EI'91*;E4^<[<G#*!M''3UQ7*QZ==6&H2:DDTDER3\ZE"A)QC SQCVKVB-
M(XDV0J$7T P/TJ*ZL;34 JW*;F3[K=&'XU3I2MHQT<?*#Y5L>6V%Q:K>F[<*
M5C7;_M(,Y8XJU>7U[<6TG]G1KL0LPWD$F+G\B<<>E5]9TG4--U5!9JUP&7:3
M@ NC=O<@\55T^UOL)';K+-:;&VR-N,87NASTYJ+WW/5M"250M6^L0:SI5E:P
MHS#<6=L;<(H(Y]>:L1E;$6]I ?FQT _@SR:SM,2VBN'MDC!0=$/3)_ICI[UJ
M:%I=SJVIW5XYVPQ%8\G@DQ\A?IGDT73T0ZJA%.VV_P!Y<N)?M4UJ\S#:?FV]
MMK?*,_0X-8.KVTEW:Q>6H\VYE1?+SL"X<'=D\=JV$CNKDE;B(Q,^XH'7#+M^
M4X'\C^-:$NG/?6PG219TCVG(Y+%#E@?H10OB.>%51DF,\16ZP:9FTF&4*LG?
M[I&1GI^%,T*6$ZH]OY@CCF16V@8W.O52?QSBNICBM;F(VRJDBXY3KC=7G6O6
MHL9I%TUP5BPS+TVD=,=2<'M4U=+,YX34X\C/6UB1$"(-H P!2J"!]*S-$U*/
M5M.MKQ2N9%!(!S@]Q4T.H)+=SV>Q@\ W<CAATXKJ4DEJ>=*+3<67R<+GI7ED
M>LS^($DDNRL'ER.L.P_(X1L9#_Q>O85T^JS.X+3+)&&C(>+. 5/!YS@\5ST\
M4&FV$&U-T"#Y40!@0>0!CI^%<TZUW9'=A8+MJSHO#\5OI&FYE<A&W.2YR0<\
M@>WI5_2E>^VZK,61V+!5!^78. "._P#C7+:9!8ZM%;/<O+Y4:JP*MM /<>_N
M#75:&ZBVDML8-O(Z?AG(_,5:>I.)6K?4J7-G:6$\TE\@DLKZ4$Y'W)2,<GT/
MZ5C:G:-H9E>WW26-U"R#/S[)!RG/7!_G78:A)_HDRK$LY &Y&.!M/O[5P:PS
M-=)8;7$<@#$;N/P!I59*]AX>;>YRD6KRVK?:[96\YA\P//UQZ5U>G_;;QK9)
MK:-53YMTN6)Y^]Q@C/89I)K)(8S) 4, ) RHW;O_ *U;*V\2-I]]Y[;SS(F?
ME*$<9'L:EU-+)';B<1!Q7+&Q]UV@Q:PCT1>GTJQ5>U(-K"1W1?Y58KM1\ZPH
MHHH$%%%% !1110 4444 0W$7VB"2 .T7F*5WH<,N1C*GL1VK\??%O@;3/A;\
M.?VO/"'A66^DTZVO/#K7UQ<W4]W>36MU864FJSSW#LTCM)#).\A)Q@D !>!^
MQ%82>%_#,=QJ]W'I%FL^O[?[2D%O&'O=D0A7[0VW,NV(",;\X0!1QQ0!\@?#
M6P\(6'[7'C&V^$$>G6FAR>!=#:_&EQQ_81?F\O!8LZ6Y6,R?9<XY#&+9@[=I
MKN_'.K?M$_#S04\5:AXK\*ZK:PWVFV\UM%X:OK622.]O8;5]DS:W,$91*6!,
M;#(Y%>W>"/AS\/OAIILNC_#KPSIGA>PGD,TD&EV<-G$\AZNR0J@+=LD=..E<
M#^T7_P DJN?^PIH/_IWM* /<:*** "BBB@ K$D\2^'(K'4M3EU6T2ST8R+?3
M&>,16AA022"=]V(RB$,VXC .3Q6I=0"YMI;8L5$J,F1C(W#&>>*_)*+_ ();
MRVWPZ^('@R+XF7\ESXKE\VSEDACVP^5 Z1(2%W11R/(5FCCX, $:GDF@#]<D
M=)$62-@RL 00<@@]"*=7EGP4^&,7P:^&&A_#2'5)]:31$E07ET%$\_FS/*6E
M* !G^?YGP"YRQ&2:]3H **** "J.G:IIFL6OV[2+N&^MM\D7FP2+*GF0NT4B
M[E)&Y'5D8=0P(.""*P_'7A=/&_@K7_!LEP;1-=L+JQ,P19?+%S$T>_8_ROMW
M9VG@]#7S9^R#^RPW[+7A?7="F\47?BF;7+Z6Z:6[VLT2":9HE$F%9BT<BM(#
MQYQD9>'P #Z]HHHH **** "BBB@ HHHH **** "BBB@#_]+]_**** /"OVDA
M\$/^%.Z\W[0PMCX*5%^TFX#,RR$[8C!Y8,OG[C^[,?SYZ<9K\5?"V@?L)>(/
M#WBWQ3>W7Q.N/!?@,Z2USI6HW5N+5X]3G\J%H88B)3$N Y)=&V<KN.!7Z._\
M%#-*NU\ ^ ?'UWH\OB/PMX$\7:;K.OZ=$@E,NG1"1))&C/#JF[:5/RX<EL*"
M1\F^&/VROV9]&_:!^/WQ.UO5UU;POXLTCP_#I]I]CF9]2:WLC%/;"&2,!2&.
MQO,VH/7'-?M? ^'Q$,LE5POM)MZVA*R34X1Y;6=IRC)OFTLDK)V9RU6N:S/U
MU^%E]\/=3^'7AZ^^$_V7_A$)K.,Z8+)/+@6WQA55, J1R&4@,&R&&[-=_7Q9
M_P $^O!?B7P+^RIX2TOQ3:2Z;<WCWM_%9S9WVUM>7,DL"'/(W(P?!Y&[! .1
M7VG7Y5GV%A0QM>C"?,HRDD^]F]?F=$'=)A7SM\1A&GB&>9W$:HJ%CCJ-O2OH
MFOG3XB117OB.ZM&)*!8]^."/E! _&O)9K3>IR$,<,XANV7+INVL>H#]?SJ_E
M?2HT6.-!&B@*HP![4RXD\J+IS(=H^II7TU*EJPN[:*]MY+6;[DG!P<?J*ABT
M]_*\N:;)!)!48Q[5FQ6ESID:KIT9*$_ZL_=]_H35J'68W.)+>>/'!)C+*/Q7
M-*Z>YK9]#1M9#F2%FS)$QW< 'GH<#U%6QU-<^)6>YEO81Y0E"IEAG(7.#^M6
M(Q=R956+-W;@8/T]*2ET$X#M3 FDL[89WO+N#+U55&6/T/2K36MQYP\J11 3
ME@1EOH#Z55M[H/Y8EVL=A+/P&!SCI[_6M<8P#VZBJT>I+NM"CJ @%HX*J74;
MD'0[ATQ4AO8(POF$J6 *D@@'/8>_M56[M1+J-I,W(4-S[CD<?C6L"N<&DMV)
MO17,Q)85E::&)V65<,-I 4CKD'%%Q9PND?GIN4X&/I5^ZW,JJK%2QQQU(QGG
M/:H8S<2G-L55 <98$CZKCK2DM2TR>.#3YU$BP1,I &=O85F7]G;+&8[>1H6D
M !"L6!']XCV]NM(T#+=-&[&=68,"3M )ZC XXK<6.).40 GJ<<TDDT-NVI
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M;D8Z@UZ=5IZ'/-*^AX3\8!*T]D+4*;D12E W0X*Y!_"O%([=XY/-N5$;.P(
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M7&ZSX<U:]NI;NVOR\;;2MO(/D4@8X/O78J01[TI<(!N8+GCDT6[FU&JX.Z.
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M>E>>V;O_ &H;?!8@M&V\$_*WW>/IWJ9T[.Z%1J2E%J70UKS5!/O2ZMO*:/\
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M]U[XI>(?'6C:IXGD\6:'X=L](O+?4M0TM="U%9K^.:2YA>QVQN;>,)&8IS&
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M0 4444 ?_]3]_*" 1@\@T44 >$_\,M_LS_\ 1)O"?_@CL?\ XS1_PRW^S/\
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M+<'RS*61065^/3H,=QBL>IHMR21IHS%Y&%60'*+SGG[WXU7EL52,PR2OYK,
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MOVB_^257/_84T'_T[VE>XUX=^T7_ ,DJN?\ L*:#_P"G>TH ]QHHHH ****
M"BBB@ K.UC5;+0=(OM<U-_+L].@EN9G )VQPJ7<X')P >*T:CFABN(GM[A%E
MBE4JZ, RLK#!!!X((ZB@#\?OV<O^"LVA_';X_P!A\(;_ ,"2:!I7B.>2VTF_
M^V">82JK-&+F$1JJ^:%Q\CML8@'<,N/V%KXE^$O_  3W_9A^"GQ6?XP^!?#\
M\.MQM*UG%/=/-:V#3 JYMHFY!VL5!=GV@_+BOMJ@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH __U?W\HHHH ^2?VN_@]\0?B?X8\)>(_A*]H?&?P]U^
MT\0:=;WY*VMVUL&#0.1C;NR"#D=,;ESN'S3\/OA'^UI\/]-^+?[1UUH&E:I\
M;/B'/96]AI"W"-:V%C&ZQ',S2JC;$VG9YI&V%<LQ8K7V]\>/@=IOQ[\*V7A3
M5/$NM^%HK&]6]%QH5TMI<.RQR1^6[M'(#&1(21CJ <\5\6^*_P#@FU"=!O6\
M&_&KQQ9ZLD3M ^HZH)[;S N5\Q8HX6"YZD-D#FOTOAS.L/'!QPN(KQBKZITY
M2]WF4N5R4E[K:3:2OYF$XN]TCZN_9+^"FJ?L_P#P*T#X<>(+R._UJ!KBZU":
M(EHFNKN5I7",P!8(&"[B 6QG SBOI*OBW_@GSXDA\4_LH^#]0%Q>W=U$U[!=
MRZA<F\F>YCNI!(PF(7=&Q^9!SL4A-S;=Q^TJ^0XFC6CF.(5=WGSRN[6N[N[M
MT-*=N56"OG/XAG54\3736JPRQ[$PK%E?.W\J^C*\#\=$_P#"27 ''RI_*O#-
M8/4\UMY+J^"_:D^S_P!Y,\DCC([XK5V1E?+(^4=,57O=J0/.<;H@6!/ X[?C
M4%M?PS(C01NRL.,(?Y]*G9G0[M7&O:F.>!2P:(LQ.Y02<C[N1_.GWNGM,D3Q
M2X$'(C/*M]?6H[R>]?R;>WMG#RN,LV-J*IR6;!//8"M@*<>]'*@>EF8R+LU2
M&9^3<1NH8<#"8(&/Q-6=3BPJWJKEX?O8.-T9^\..>.H^E-ELI(BLUH=WEOO\
MMN>",,%-:,$J3KO0<-U!ZCV(J4N@Y/J4M/MH;53Y2!//._@Y!)ZUJ UC21"V
M;:\YCB!^0D949/W<TND2WDS7 N'$D2/MC<*5)QUZ]1GO2C/H3)7U-OZT#(Y[
MT&E%:F8N3G%5;SRFVH?]:OW?4#OGV-62512S=!52WA6.%FD<22R$LQ^O. .P
M Z5,NQ<!T:N9!N<JIZGH<_RI/[.M[F[$]TBS_9_N%E!PQZD>GI56YDOGBV6<
M;DYYX !'X]:N65Q'YLL1)CV'!5\*<^OT-91GK9FEVM4:@Y&#QBG=13 P(R"*
M<,G@GBMSG9')=6T$L44SJLDY(C!/WB!D@>^.:+VZAL+26\G)$<2[C@9_E45W
M:17<:^8H+Q,'C)'*N.A'X&F-,SQ&*\C 5Q@\]<U,F:12+L+^?"K,,;QG:>>O
M:HEL+=,-#F*1>C9R<>G.>/:DM5>*,(>5[#T'UIMX;I$9X& 0*=W!+?A^%*^E
MQK?0=9M=%7:>5906^3:NWCWY.:L32^7&T@5I=@SM098^P&15.TN[*6!3;2 K
MC@=_IBIH;B2622-X_+*$;><Y!'6J3T):NR+^T8W^4*P8#)##&WV/I4<\>[%Y
M*V?*ZK_#M[T^_!9H@OWF)_'':JU\]Z;=H[2,3^;@#)VD$\<^P[UG)=QQ78MP
MYG7;;N!;G(RIR??%2"6*"[^SEL%TW@$\G!P:BTVRCTZSCM(^B=3ZLW)/XG-)
MJ&F6FIQK%=(?DR5=&*.N?1EYJN70+KFL]BI_Q,;*W>5 L\;.6 _B56/3WZUH
M+%#L>2X ;S!ESVQBN>O+J[T7;:7$HN+>X#!))!@KCJK$=3Z5?3S[ZRCN/+*;
MEP\9)X /4<=ZPOK8N42]9W#,-C#"]5)YX[5=SFLORX85C:W 5G<+D>A&3_*I
M)VGMEWJ0Z#@[LDC'TZUJFT9N-V0ZCM,J28+HJXD11EL9RIX_&I)%DOEAD53
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MRLC $GMM-06MB"F(@2I& 2/UK&U5;RUNQ-<<*^ #UR0#QFNCAFFNK2SNK9N
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MN=/C'FQ,#M8?*=Q!(Y^[G&>.]',KZGI8:K2]IR35T^IR^GV?BC73*\+?NV)
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M?)<K$J_O/,+97<>#@C^C&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO&*CCL3'=FX,QD7LK 97/;(ZCZUG.#>B+4[%&0CS+>[E^3RL\CH0W'-;RON
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ME[ODH"<*K>_7KWJ 7]Y=J=,O(?+E<JK@'!4=V'J*Z?ZU0OM,BOWMY7=HVMI
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MD'_"J.DW*6L$<-T&AVYVEAA2&.>OK7.FE(NS:+UU'K4<9DM9T?:,D%<'CM7
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MQUIZ10*/0F>5#J,2E0'"MD]\9XQ6L#S@5P<^F:X]VDPP!V*MR.<\YKIX+[R
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MIXGO85#R2*T8PIP?F R?P-:0$RW]I!<MYN<_4<=ZY[4O$.I1NKPZ?Y4RG+2
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M^U2+'&I;HJ$@$D=\9SBLZLM+FN!JN$[IV(M&U;38;74-!O&"S1*9,!L^:C#
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M2WMXRS8WL7=W=RSN[L2S,Q)).2:[VBB@ HHHH __T?W\HHHH **** "BBB@
MKP'QY)*GB.X.S<@5,;>6^[Z5[]7A'CAO^*BG[X5/_0:"X;G"1B.\G\WEEB!&
M#P-Q]O:FW_E"(0[,ER%  Z9-5;Z>2-&N+)LNPR1V..]6+2VFN+?S;\_/*,[1
MP%';'O6;DKV1T6MJ7K>WAM8$MK= D<8PH'0587BJD4S1DQ7!&]<X/]X>H]_6
MF1,XGDG?/ER;54'MCV]\UI<BURZ6SG-9VH2));O"K'+#DCD@4L\1-RIWE0X
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MM2'XY(+G(IU-CQ<*USZGGVFW/VVQ@O.GFHKX_P!X9J\.M1011V\2P0C:B *
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M'2A5:E!=%^!V^/2EI,COTH]A70>.(..O6E.:3KQ3=QZ4[ )(B2Q-#* R."K
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M (+'^"?B#X_/@K3_ (2^([K[?(8M*73)K:]O[QQDA7M&,"QDJ"<+-+R,<]:
M/A']O/\ 9@U/7?VZ)]._X6%X>MF^)-U!<1/J6HK!-I8,4<:QW49RR#Y<6X&?
M,7:!@U_3CH>G2:/HNGZ1-<R7LEC;Q0-/+S),8D"F1_\ :;&3[FOY0/VL/@5\
M:?C)^T[K'C[P_P##'QM8Z=XZN5NHK?4])4:A'Y,4:W*11QSNDJQ*,I^\3Y2%
M.W&X_KA\0/\ @IWX._9]T/1/#7C?X3>.]+U)K6..T77+:SLGNHK<+&\I<7,K
M$^IV$%N] 'ZQT5\\?LQ_M)>#/VJ/AF/BAX&L;W3;%;R:PD@U!8EG2>!49O\
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MOTS^$FOW/Q'^%7A/X@VVVWGU_3+:ZFC'">;(@+D>G.:KD?+]WXEPE'F^_P#
M^L?ARD<:W:1J% V=/QKT^O'/A2=407UOJ4:@Q^7M=3D,,'MV(KV.G#8YZR]X
M^?OC%<M;ZKIAC^]Y<A]\!EKB[36[*5/WKB)QU#'&*[OXK65K<>(]%EE.R1$E
MVM^*G;^->:7EMI&HS7"QC-Q%RZ@<DYK&4K.Z.V/*X13)M6EMK^UV1R@[&)^7
MO@=*S1;3+:?O#L* . 3UXSCZT-%%8%&E3A7 ( _ASS6OJ]U:MILDL9#\ @K[
MD#-0GSN[-(Z:+8S4@B93'+T< D@X'/?\*=;ZI;Z'I:2WSLX:1^$&X@9XQ[ 5
MT_V:U2/YE&Q1SGTKAM12*YOI+.R'R(R'_9Y ) I1ARZW%22F[/8ZFWN+'5HC
M?6($C $+D8R>QQ7,ZS!<V,MC<2N"7E&<<89<MS[$"H8+:;2YPT3F))!D#TSU
M'X5;N)H=0DB@FF+B$[SD<9((&:K1LUA149Z:HU)-22[#1 ;%=>&SP3Z?C687
MN?WMU8;5X$1]"G7./7MFL9+VQ>=+#39?,<AN ?E0YQDD]AT IAT;6(I(ELKN
M6*27+%6564JIP>O2IY7U-8X=1TD[>ITEM#+<W+LTIVF,KCL&Z_TIIAB$4<;8
M8'&2?[W4T^WEA2!9Y)MID(#8'!9#@XK-E0M&)$9@$8D;>^XY/Z4G$A1NRZ+:
MWM8VAA421.Q <#D,QYS]"2*KZC;BZMWBC^8R 8'L#@_G69X2GO;>*\M9'+VK
M3,\&X9;#$DH?7GFJJ:]?'?;M;&-8F*E3]_ K34ZO8SYFEK8UDN9X[F.*!%5
MNT@<*N!V_.IXKN-Y9)ED_P!6 ![M]*KV\MS*8)C;[8Y22S$C( '&1VS6FUDL
M$:S1X\\+D'''K2Y6]R:B77<?*&62&&?')W +R<#J/K4EI,;AX(R%B%L0^\C)
M*Y(_6J$5S>"-2J (S9+9W$9'(JL9-LSH,@,HPH/WB!C::(Z:&:I-Z,FN+RST
M_P"_)^Y+?*N=SLS'VIL]];6AN9V5E22,@(O)4,.OMTJ@UHLLT5TL:K( _P W
M8$\'\!C%9^J.GERW3%Q)(-C;.G Z5:C?8ZZ5",M%J:IN%NHRL;B-"J.%Z>Q&
M?7CFGVER4DDD?!(&5QU!.>:YS2M1CGME>YC(,:#KT!SZG]:Z"U(MW\Z(AY'!
MR0.!GZUE*5MT54AR7311>ZEOLVN\KD,K-V"K67IFH#3;J^L3*8_LQ1@,<E6&
M>/;-=//%;Q2K+@2;2&(4\,6["FWFG1W"B\>+9*V0'_B '8TTU8<*L4N5K1_F
M<OKVLVVG+;!B2D[,'!X)4XS@^M;FESB:)9[)ML4@'+# !7GCW-86M>&UUN*'
M4)276 AMI&[:#Z#WQBNHT6XTR;2G1YEC4$&/TRG! 'KZBB5K)&E?V?L5R:OJ
M:,5UJ4#L;B1#&#@JI^^>.GI6^NMJL'S##KV/:N416DN&FD&]6/RCI@=,D46J
M+?2-YC! =R[/IQN)J.4\Z=!2U9>NM8U=U55*J6W#"\?*/0^M<I-"XF$\A,D@
MY" \$]/YUOM9P[RXD_X]CE%)ZDU ^DMJMG,(F,#N^.#SQC/Y41WU-Z+A!WL.
MTC197B%[> 9)^8 \#/8?G786D)74;B-XU5(E0QX_B!!R?Y"J]HJO:)$_[O9Q
MGJ/EX!^AKPGXT_';P]\)=;\,Z!X@2XM!XFN1:6VHJN;6*9C@)*_\.[.>>*V3
MV.*K*52339[AXMOK:TTLQ2$>=<$)&#UR>2?P%>5O9K-/;V$B$0D@,<=<X^4>
MA/\ 6OEG5?CEK7Q"\"^/]<^#>FWGBGQ#X5N186TDD>;>>Z:38WD<X=8ER[8Z
M\>M>7)XY^-WP<^+GP^\*?$/Q7%XNM_&UG<W%[;K"(I=.EMH?.<IC^!2,9/7!
MJG;^OO.^E4IT8\B=^[Z+H?J-'%%'$UNOR"5?+4ISL*C@$U,\018=[E7"C<XX
MR5]:_&\?&S]H1O@PW[6\?B6)?#G]K^4WAT0_+_9QN?L^XR]=Y;/->U:WX_\
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M$*K(VZ3: S#@%L=?SJK;SNL02X;?+SG:.H]<5V#^!?$XB98Y$+CH<@9-.M/
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MZN/!FKW7%QI4CD=RO/YU5E\ ZK(@":=/&R'<C '(([U2I-= 55;/8K\8Y%9
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MOA?7I%Q]@E##H0O(-:PIM(BI43E=;&1R1UHR< 5LKX=U\@HUC+D<$[>#3O\
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M[LXGXCE1X'UDMR/L[5\CZ8Z,G(PX]NU?7/Q&L=5U/P1K%AH<"W-]/;LL,;'
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ME((T88*J ?P%35V(X&%%%% !1110 4444 %%%% !1110 5X=^T7_ ,DJN?\
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M?^DD=<S^TS\6M2^!7P(\8?%O1["'4[SPU:+<1VT[,L4I,J1X8K\P&&SQ6Y\
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M7LD=T45B 6"B4#.!FOTCH **** /_]3]_**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSQ7H5=<LZKM-.WW'U>)\8LZJTY4IN-I)I^[T>A\;?#GXL?%'PI\.?"OAJ_\
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MZG"L<"DL5D&X2X"C&^OZ4:*R&?+UQ^TEKMIJ^EZ#<_!CQK'J&M6]W=6L+'0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXT>%/@_JNA7+GQGI6IWFF:@'40W.H:<%D.G(IY\UXBSAF(&=BJ&+';^/EO\
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M2^.FM_!C3_".F^$-!@U_Q/X[UF/0]+BOKO[!8)<2122YN+G8^W(C*QH%W.Y
M'>OR[\8Z/XP^/WQ:USQGX:\#S3^)=,N=.7XG_"/5=0CMO[3%A!-;Z?J%E>G9
M%<PK'*"O*H[)&2K KN^@?%_Q2U#]N3X?:3\#-/\ AZEKXC&KQV_CFUU6Z^RW
M/@]K$B0W5MM(GDEF^864R(T9.1*"I9#]"?!']E_X@^ _BPGQ9^*_Q'/C[5=)
MT%O#.F3#3DL+E]/>X6YWZA*LDANIE9%56.!]YSEV) !Q/[+_ .R/I^D>%_"/
MB;XV>&@GB#P3JFLW/A/3;R\&I/X>TO4)D>ULY)U)CN);81YC?+",M\A# $?H
M3110 5P.O?%+X?>%_&WA[X<^(M<M]/\ $?BQ+A]*LYB5>[%IM,HC;&W< XPI
M(9N=H.#C?\4^*O#?@CP]?^+?&&IV^C:-I<1FNKNZD6*&&,=V9L <X [DD <D
M5^._[47QH^!O[0_Q!\*:+XN^(?\ 97P0?39KC3O$VB)$9;'QK;3,8X[JYDAD
MGL_+M<21(!$92>6*C  +'[5_[3&N^-)/$_PP^(WA&ZTGX/3RW]C?:EILMVGB
M338]+OXK)==EA55@;3GO6\N. EGF6-W_ (2H^F_V>_@SJ_Q!M? _Q0^--E"/
M&?PY;[)H7BK0;K[/'XGT&2V'V>6ZA0!Q#(L@+028Q(K$81V1N#_9E^"&N_'[
M1/"?Q]_:/2\?Q+IT5I;6EQ9W\UK9>)]*T^;[9I=[JFF[5&^.9C*B,0&8!V7:
M5%?I^ %  & .U   %  & .U+110 4444 %%%% '_U_W\HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
9BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ck0001824293-20241231_g13.jpg
<TEXT>
begin 644 ck0001824293-20241231_g13.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0! 17AI9@  34T *@    @  8=I  0
M   !    &@       J "  0    !   &W* #  0    !   "L0    #_X@)
M24-#7U!23T9)3$4  0$   (P041"10(0  !M;G1R4D="(%A96B 'T  (  L
M$P S #MA8W-P05!03     !N;VYE                        ]M8  0
M  #3+4%$0D4
M              IC<')T    _    #)D97-C   !,    &MW='!T   !G
M !1B:W!T   !L    !1R5%)#   !Q     YG5%)#   !U     YB5%)#   !
MY     YR6%E:   !]    !1G6%E:   ""    !1B6%E:   "'    !1T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D
M    9&5S8P         1061O8F4@4D="("@Q.3DX*0
M
M                            6%E:(        /-1  $    !%LQ865H@
M                     &-U<G8          0(S  !C=7)V          $"
M,P  8W5R=@         ! C,  %A96B        "<&   3Z4   3\6%E:(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6&SE<^'[JY.(TN75@3Z$@#!_"OO:*6*>))H7$D<@#*RG((/(((Z@T 24444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+Q"_BSP1H'B>08?5;&WN6 X :6,,?U-=;7G'P?TBYT#X5>$=%O 1/9:59Q2
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MY:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?FI_P %"_V5#\;/"5KXRT*Y@T_4/#Y:
M:=Y209%("(1VRN3G)Z5^9G[/7[!'C9O%NG?$#QMJ,2:%ITRS&:8%(W"G)"MT
M/%?87_!33]I#QYX7O-*^%'@"ZEL6U"3RKGRB<S[X]X4@=A@8]_PKP3X^_M ?
M$3X<_LN>$O#=Y?2O<:M&\+J>)!\J@9[C&>G2@"'XM_ _1OCE\=8_#_AWQ58'
M2X;HQI$91C;UQFOW9^$WP_LOA9\.M"\ 6!5H=&MQ""HP"<DG&><9-?R;6'P]
M^*OPET3P_P#'"RO+@'5U^U;@I&W!V_>_"OZ<_P!D+XKWOQC^ GACQEJ\YN-4
MGMP+EF.69NH8_4=_8T ?35%%% !1110 4444 %%%% !7"?$KQ]H_PR\%ZIXS
MUMAY&G0M((]P#2N!PBYZD^W:N[K\CO\ @HOXJ^(__"2^$-$T+PS?:QX?LIVD
MO(X(G=+A'3Y@2JG@<#Z@T ?-GQ'\$^*/CCX:\??&_P 8V\K:'/:/-IWF(5"2
M)P0#WXK[+_X)@8'P80 8 A@_]FKY$^*7[8.M_P#"@+_X7V?PHU'0]/%HT7FM
M!,J(#W.5 [Y.:Z[_ ()D?'35(M$M_ 3>%KN:WN/)B-VJ-L Y^8G:1CGGGM0!
M^N.N_'+X0>&=3FT;7O%^FV5];G;)#)<('0CLPSP?:N@\)?$?P'X\,R^#=>L]
M8:W :06TRR% > 2 <@5\F_&?]A3]GWQ_-KGCC4O#T(UF>)YFDQE2ZY8G!Z9'
M'&![5\I_\$XO">E>"_CC\3- T:(06MM91JJ+T'[\#^E '[)T444 %%%5KR\M
M]/M)KZ[<106Z-([,<!549))]A0!9HKXAUG]N_P"$6CZG<:;(ZN8&(W>>JY'8
MXP<5F?\ #P+X/^J_^!*?_$T ?>-%?!W_  \"^#_JO_@2G_Q-(?\ @H%\(!W7
M_P "4_\ B: /O*BO'/A!\;?"'QFTZXO_  Q*I-J5WH'#X#9P<C'I7L= !111
M0 45CZKXB\/Z$%.N:G:Z<'^[]HF2'/;C>1FKUG?66HP+=:?<1W,+]'B<.I^A
M4D4 6J*** "BBB@ HHHH **** "BBB@ HJM;7EI>H9+.=)U4X)C8, ?3BK-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X ?\%,;#4_!
M/QT\(_$.^LWFTQ;Q)@W&U@D!0X/UXQ^G2OA?XE?&.3]I#QEX7\):=:MY$=V
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MLWP;_:F^(/P)TNY=_#D]LUY;0N2WER;(9X>23RL,K(QZMM4GH* .C_X)Q?\
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M.P Q0!^6O[/_ (]TG]E+XF>-/A!\6"VD:=?W2W-A?F-V@95W!&)4$[)8RN&
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M@$>IY/7TH ^T**** "BBB@ HHHH **** "BBB@ HHHH PO%'_(M:K_UZS?\
MH!K\L_V$_P#DXWXI_P#7FG_I0*_4SQ1_R+6J_P#7K-_Z :_+/]A/_DXWXI_]
M>:?^E H _6FBBB@ KS[XL?\ ),?%7_8-NO\ T6U>@UG:OI=GK>EW>CZBGFVM
M[$\,J^J.-I'Y&@#^&7XOH[?$#52!G]Y7FGDR_P!P_E7]7NO?\$P/@YKFK3ZK
M,R;YSDYAS_[-63_PZJ^"_P#>C_[\?_94 ?RL>3+_ '#^5-,4@Y*D?A7]5/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAP_\$Y_"1Y\VV_\ (G^%'_#N?PE_SUMO_'_\* /N,_&OX0CD^,M)'_;Y%_\
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MO^OR'_T"OO#XD_\ (@>(?^O&X_\ 0#7P?^P#_P A#XA?]?D/_H% 'Z34444
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M\>[;%4$2C[A/.\;>=PQ^B'Q0U74-"^&GBW6])F-O?:?I%_<02@ F.6*W=T8
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MM^U?\</$OP3\*Z-<^%+:"6_UV]^R":X!=8%"[BRH,!F],G [@]* /JJBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_T/W\KX _:R3]
MECP/!-XE^)>BVM_K]R-Z1"39(PR,L5)V\X_N\]?K]^N2$8KU .*_F@_:(\*^
M-OVB/VSA\+]>O#8QS3W20-,6""..1 .%)R,'% $.K?M@?L>Z;>O:I\*GGVMM
MW)(,?6OO3]FW7_V)?BO/;)#X:M-+U>=LPI/-UXR!\I4<_2K^@_\ !)WX/0:-
M'#KUPL^H; '>-"5W8Y.6(.,^PK\O_P!I3]G;6_V2_BQI[>"]1%P^5EACM]Q;
M#C(&UB.?\^] ']3EI;6UG:0VEFBQV\"*D:K]U4484#V JQ7GWPGU#4-6^&'A
M34]5#"\N=+M))=WWM[1*23[FO0: "BBB@ HHHH **** "BBB@ K\K_\ @I[X
MUU6V\ 6?P\T^Z^SPZRK23#C+;6 7/Z^WZ5^J%?C-_P %3=!U?4[_ ,-7%@_D
MH+=E\PC*@ASG/X&@#Z[_ &=O&7P&^$_PET'1I_%FF6UY=VD,ET'F"L9&0$@C
MU&<&O7OAC\*?@#9:Q/\ $/X8Z;8O>74CL]W:R-(-[_>P"Q S]*^3OA/^P!\'
M_$'PZT/5OB$D^IZE>V<$X:"9HD3S$# 8(///T^M>&?L\>*_&7P._:;NOV?=-
MN1>Z5J<MVT,3_,%%O]T;F((XYSGGTH _8KQ'_P B]JG_ %ZS?^@&OR@_X)EX
M_P"$O^*F/^?Z3_T<U=?\:_%O[8=IK'B"TT97CT0,P399JR"$KVD&3T[Y/->5
M?\$GI=2EU'XD2:J<W+7),G&/F\TYXYH _9^BBB@ K\FOV,>?CGXU)_Y_KS_T
M.OUEK\COV.]1L;'XY^,OMEPD&^_O -[!027X'- 'ZXT50_M73/\ G\A_[^+_
M (T?VKIG_/Y#_P!_%_QH M3?ZF3_ '3_ "K\B_V&_P#DN/Q*_P"PU/\ ^@FO
MUEFU72_)?_3(?NG_ ):+Z?6OR7_88D27XW?$AXSN5M9F(/\ P$T ?KY6=J^J
M66AZ3>ZWJ3^5::?!)<3/_=CB4NY_  UHUP?Q3T6^\2?#+Q=X>TQ2UYJFD7]K
M"!U,LUNZ(/Q)% 'Y[?#U?VA/VNM0UGQW;>/;SX>^%+*Z:WL(-/\ ,!9E 8*1
M%)"9-JE2[NYRQ(50.%X+2K#XI:)^VIX#\-?%C4QK>I:,GV>TU +M-W8LES+%
M(W )8-(Z-GD%2,MC<?H[_@GWXKT:^^$5WX.CF5-7T74)WGMR0)/*GVLDFWKM
MSE<]BN#VKA?B3XIT3Q%^WUX L='G2YDT.V6RNG0A@MQMNI3'D<919%SZ,2#R
M#0!RGQ3^'VA_%/\ ;BOO GB$'[)JFCE-Z_?BD6P+1RK_ +2. P['&#P378?L
ME?$37_A5XYU3]EGXH/Y5S93R'2)G/R,3^\,2$_P3*?-BZ<EEZD 6Y_\ E(U;
M_P#8,/\ Z;VKT#]LSX'7GC?PW;_%/P0KP^+_  >!.K09$T]K$WF%5(Y\R%OW
MD>.?O 9)& #S_2/^4C>M_P#8,3_TWP5YC\6/B3HGPD_;DU'Q[X@CDFM=-TY<
M11#+RRR:=LC0=AN=@"3P!S6+^S)\1[_XL?M=P>.M6A6&_OM',=P%^ZTUM9QP
M.ZCL'*;@.V<=LUV_C#P?X=\<_P#!0F/0/%5FNH:<;:&=X)/]6[V^GB5 X_B7
M<H)4\'H<C((!YO\ "35=._:E_:,%]\>KMHC!!Y^D:(RE+651B18 6(.WRSYA
M&,S#))QP?V3AABMXD@@18XHU"JJ@!54#   X  Z"O@O]LSX%WVM:;:_&SX<H
MUIXJ\)*DLWV8;9)K6W.]9%Q_RTM\;AW*9'.U17MG[-'QXT[XZ^ H]3F9(?$.
MF!(-4MEXQ+CY9D'_ #SE )'H0R\[<D M?M5?\F\^.?\ KP_]J)7-?L4_\FR^
M#?\ N(_^G"XKI?VJO^3>?'/_ %X?^U$KFOV*?^39?!O_ '$?_3A<4 ?4]?/O
M[2?C7XF>"OATUQ\)-$NM8\17TZ01M;6K79M8R"SS&-0P)& JY!&6R00"*^@J
M^)OVU_C-XS^%WACP]H?@6Z&F:CXIN)HFOB!F"* 1[@K-E49C(/FZA0Q&#R #
MB[O]FK]I.X\-CQ)>_&[5(?$B0>>;)9)HK)9<;C$9$G5<9X+^5C_9Q7>_LE?'
MC6_B!\&]:\2_$>Y$USX2EF2XO-JJTMM%")@[A<#>HW D 9P">2:\TUS]D?PS
MH_A6Y\:?'SXHZWKMI80?:+IC<[(&(&=BF8S.^YL*N,,Q(P 3BN!_8PT2[\5?
MLY_%KPMIH+7FJ)=6T*@X)DGL3&@Y]6.* -7X?1_M#?M=7VK^/+?QY>?#WPG:
M7+V]A;Z?Y@9F0!MI$4D)DV@@O([G+$A5 X7+TSQA^T3X%_::\$_![XA>+)]2
ML([A3'-&2B:C9S[RCS#^,JRE3NR001N8 &O8OV ?&>AW7PIN? +SI;Z[H=]<
MM-:N0LQBE(82!#R0&RAXX(P<9&?-?BGXX\/>+_VY_AW8^'KF.]70/)L[F6)@
MZ_:"\TC1AE)!V!E!]&W \@T =A\2_B5\7_C/\=+SX"_!C6&\+Z9H"%M5U1 1
M+NC($A5U^8!6941%*EFR2VWIR?Q#LOVCOV3$T[X@Q>/;GXA^%S.D%_;:D)"R
M>:>/]9),RJQ&%D5QM8@%2#@WO@/JEEX"_;*^*?A3Q1(+.\\37%Q-8-/\OF^;
M<?:8XU)ZEXY,J!UVXZX%>M?MX^,-"T3X#ZAX8O9T_M+Q%<6L5K#D&0B"=)Y)
M O4*JQ[2W3+ =Z ,7]L'XM:]I_[/_A/XA_#36+K1_P"WM1L9(YH',4K6US97
M$P1L=.0I(]17(+\)/VK_ (G>$T^*%Q\4;C0=8U&'[=9:'9>;!:I'(F^*)WCE
M4*Q4@89),?Q,3DUP7[2^C7_A_P#8E^%NDZHC1W<%YIAD1_O(7L;I]A]"N<8[
M8K]/?"ZJGAK24085;2  #H (UH ^'O@I\=O&OQ&_9:^(&O:[>,OB7PII^IQ)
M?1@1R.8[)I8)CMP!(K9!( ^Z#U)K3^#7Q@\8Z?\ L>:C\5=;N9?$&N:8FH2(
M]TS2,[1RE(]YX)1,@GG[H/(KP+]ES_DV/X[?]>NI_P#IODKV/]FCQ7X8\$_L
M9OXD\:64FHZ%;2WR7EO%"L[20SW/E,IC8A64[_FR<;<D\4 ><?"GP+\;_CSX
M,7XD6/QWN[37+AI6_LRV=Q#;LKE0D\<4T:QEL X$) !!&[->I^&M,_:1\=_
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M110 4444 %%%% !1110!A>*/^1:U7_KUF_\ 0#7Y9_L)_P#)QOQ3_P"O-/\
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M)!^^J_-?]K=YOAO^T3\+_CAJ,#R:%:B*QN9$4MY9@FDD?_@1BF9E'\6PXZ4
M8_Q3_8W_ .%5?"W7?&'PQ\6ZL=5L=/N&U2*>1/L]_:-$RW8V(JE?W19@&,G
MQ][##T?]F#_DRS4O^O37?_:M>F?'_P"/?POTSX'^(;W3O$5CJ<^OZ;<6=A#;
M3I-)-)=Q&-6V*20J;MS[@, 8/) /F?[,'_)EFI?]>FN_^U: /DGX=_ B?XH?
MLK2^,O"<;+XP\*ZQ>3VK19$MQ;I'"[P@KSO4C?%WW94??S7V-\/?CO!\;OV6
M_&TFIR*/$VB:#J-OJ4? +G[)+Y=P /X90"3TPX88QC+O^">__)![G_L-7?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!7.T%\@X)8U];444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <3\2?\
MD0/$/_7C<?\ H!KX._8!_P"0A\0O^OR'_P! K]"O$^D-K_AW4M%1_+:^MY(0
MQ&<%U(S7S-^R]\$=;^$3^*;G69MYUFZ1XUQC"H@&?Q/\J /K:BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** /P__ ."L'BM=,U+PV;&PEFU&Q)\F1 ?E<HS9X'HV*^3OA5_P46^,
M'@C0+?1M42]NDMHPBKM<J,#&!QVK^@/XJ?#OX(_$&_TRP^*.GV=]>%BMHL[L
MCDXR0"I&>.QKCO\ AC/]FD\_\(/:8/\ M2__ != '\V7QQ_:P^*OQKU^"77H
M[N?3(#\L3!CA"=V!GW/2OI+X8_\ !0[QA\,?!6G>"M%TR[6TTY-D:E&(4=<#
MCI7[->)OV7?V2?!^ER:OXD\*V%C:1 Y>224#Z#YZD\,?LK_LI>+] L?$N@^#
MK.YL-0C$L,@>0@J?^!]>,'Z4 =?^S)\7M1^,OP\C\3:K;F"?*@Y&TD,,\C%?
M1M<QX3\&>%_ NDIH?A/3HM-LH^D<0P./4G)/XFNGH **** "BBB@ HHHH **
M** "BBB@#"\4?\BUJO\ UZS?^@&ORS_83_Y.-^*?_7FG_I0*_4SQ1_R+6J_]
M>LW_ * :_+/]A/\ Y.-^*?\ UYI_Z4"@#]::*** "L'Q18SZGX;U33K8;I;F
MVEC0>K,A Z^];U% 'X&Z):_M!?!'XE>*+GP_IFH0IJ$@Y2)QE1T[5Z9_PO\
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M[74J-/+.6F950MF5F(^5%&!@<=*]&HHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#_]+]_#TK\ /VT&_:$^"7QQ/Q.\"PWD>G^;/)YL2$
MQE78' ;< >#T/OFOW_K\'O\ @HM^TKXRU;Q._P '/!%K-)M9XP$B#%F4A&.?
M3/OTH -&_P""OL-I\.;FPUO0)6\4VL8B^T%E4>9C!8Q8.3^./K7R?X2F_:A_
M;!^)T&L7D-[-IL\W$IC;RXT'3<RG:!VZ?X5YSI?_  3E^/'BSPA=?$62UE0R
M+YYB,#;W##)*COBO:/V2_P!J_P =_LS^)D\"^/-.G>U:9HWB,83<F>"#CB@#
M^DOP;H]QX>\(Z+H-VXDGTZRM[>1EZ%XHPI(SVR.*Z2L?P]K-MXCT'3O$%FK)
M!J5O%<QAAA@LJ!P"/4 \UL4 %%%% !1110 4444 %%%% !5:\O+33[62]OYD
MM[>$;GDD8*BCU)/ JS7Q]^W;XT7P/^S-XKU02&.29(HD(.""7#']%- 'I]S^
MTQ\ [.>2VN?'6EI+$2K+YV<$?05VO@_XH_#OQ_O_ .$+\0V>L-&2&6WE#,,?
M[/7'OBOR-_9X^!7[''B7P5'K_P 4-5T\ZOJ"I,5FU 0%=XW,,,PY!-?I/\$O
M@7\#/AO"^M?".VA:*YR//BN/M"].0&!(H ^B, ]:3:!VI:* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]7,2Y//O764 %%%% !1110 4444 %%%% !1110 4444 8WB/_D7M3_Z]9O\
MT U^3_\ P3+_ .1O^*G_ %_2?^CFK]8/$?\ R+VI_P#7K-_Z :_)_P#X)E_\
MC?\ %3_K^D_]'-0!^O-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5^<W[??7P)Z?:;K_P! 2OT9K\Y_V^NO@7_K
MYNO_ $!: /MOX7?\D[\._P#7E!_Z *[VN#^%W_)._#O_ %Y0?^@"N\H _)?]
MH[_D^/X2_P#80B_] K]:*_)C]H[_ )/B^$O_ &$(O_0*_6>@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H
M7VJ:;IH4ZA=1VP?IYC!<X],U?K\DO^"B'AK]H76]?TB7X5V]Q-9)&!F*%I5'
M'S9VD8.?7G\,4 ?J=_PE7AK_ *"EM_W]7_&C_A*O#7_04MO^_J_XU_)?X]U_
M]J/X>>2GB.Y>UGN"5CBEA969@"< ;O:MKP;:_MG>,K47FG6%V8F&Y6%L[ CU
M&'H _JV_X2KPUU_M2V_[^K_C6W#-%<1)/ XDCD *LIR"#W!K^/OQ)XQ_:N\(
MZ\FB>(XY[#S&VI+- R!O7 W5_3U^R/<:Y=_LY>!KCQ)-]HU%[']Z^,9(=A[T
M ?1U%%% !1110 4444 %%%% !1110 4444 87BC_ )%K5?\ KUF_] -?EG^P
MG_R<;\4_^O-/_2@5^IGBC_D6M5_Z]9O_ $ U^6?["?\ R<;\4_\ KS3_ -*!
M0!^M-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %?G/^WUU\"_\ 7S=?^@+7Z,5^<_[?77P+_P!?-U_Z M '
MVY\+O^2=^'?^O*#_ - %=Y7!_"[_ ))WX=_Z\H/_ $ 5WE 'Y,?M'?\ )\7P
ME_["$7_H%?K/7Y,?M'?\GQ?"7_L(1?\ H%?K/0 4444 %%%% !1110 4444
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M:*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *_.?]OKKX%_Z^;K_ - 6OT8K\Y_V^NO@7_KYNO\ T!: /MSX7?\
M)._#O_7E!_Z *[RN#^%W_)._#O\ UY0?^@"N\H _)C]H[_D^+X2_]A"+_P!
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MQ1_R+6J_]>LW_H!K\L_V$_\ DXWXI_\ 7FG_ *4"@#]::*** "BBB@ HHHH
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MO6;_ - -?EG^PG_R<;\4_P#KS3_TH% 'ZTT444 %%%% !1110 4444 %%%%
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M\\W_  T[^UW_ -!/4O\ OAO\*/\ AIW]KO\ Z">I?]\-_A1_K?1_Y]S^X/\
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M_$N.:?\ 090_\&?_ &I_0S17\\W_  T[^UW_ -!/4O\ OAO\*/\ AIW]KO\
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M^Y_<'_$N.:?]!E#_ ,&?_:G]#-%?SS?\-._M=_\ 03U+_OAO\*/^&G?VN_\
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MUP]G(WB&:WSE;:1=K;?1AN/Z5^;6J_\ !2;XR_%/QDD?PQ@N-/TVXDVK&$+
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MJ*)O@3KTK+EU0 'N 3_]:N/,*4?85-.C_(^BX0Q]9YKA4Y/^)#K_ 'D?%?\
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MG%^24?\ "EKC_GSB_)*^H**/9Q[!]?K?SO[SY?\ ^%+7'_/G%^24?\*6N/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_7K-_Z :_+3]A/_ ).-^*?_ %YI_P"E K]3/%'_ "+6J_\ 7K-_Z :_+/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7_D[L_\ 7XG_ *!7[Y^"_P#D4])_Z]X_Y5\IP]_'Q/\ C9_0_C;_ ,BW)?\
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MJL_%+X[> /A!-9VWC"Y:*6^5GC5 N=JG&3N(ZGTKW<+_  H^B/ROB#_?Z_\
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MV&K\>?VM?^3FO"__ %^6O\Q7[#4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-?[C?0TZFO]
MQOH:!H_GG^,O_)W9_P"OQ/\ T"OWS\%_\BGI/_7O'_*OP,^,O_)W9_Z_$_\
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M"@7_ #RU?_P$>C_A>O\ P4"_YY:O_P" CU_1!Y47]Q?RH\J+^XOY4 ?SO_\
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MQO\ \$_^OCS_ *^H/_9Z /T=50JA5& . *6BB@ HHHH **** "BBB@ HHHH
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MY3A[^/B?\;/Z'\;?^1;DO_7B/ZG3T45"UQ;J2K2*".Q85]6?SN345!]JMO\
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MXJ?]?TG_ *.:OU@\1_\ (O:G_P!>LW_H!K\G?^"91!\7_%3G_E^D_P#1S>E
M'Z]T444 %%%% !1110 4444 %%%% !1110 4444 %?B7_P %+/\ D>=&_P!T
M?R-?MI7XE_\ !2S_ )'G1O\ ='\C7S?%G^Y2^1^U_1]_Y*>AZ2_(_4?]G/\
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MF/R-:72]$BDW7EI<#$EPJD9" \Y(K]NJ "BBB@ HHHH **** "BBB@ HHHH
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M-_\ !41_AA\/-'\$+:2R)I<(C!^0_4Y*DU^*F3G-&37OGX\?UY_L7?MO:?\
MM/OJNDSZ?)9W6G. DK8Q("H;!  P1G.>GX]<_P#;ZZ^!?^OFZ_\ 0%K\Y_\
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M 'TO_P 57RO^T9^PI^S?X.^"'C+Q3X?\/R6VI:;8230R?:';:^0,X^AKR?\
M8G_8O^ GQ.^#5AXJ\9:-)>7\N 6$[H,;0>U 'ZO^ /BIX"^*%G+>^!]8AU1+
M<@2B-@6C)Z;@/7%>A5XM\(_V?OA=\#H[V+X<Z8=/%_M\W=(TF=G3[W3K7M-
M!7D'[0'_ "1+QQ_V"+S_ -%-7K]>0?M ?\D2\<?]@B\_]%-0!\=?\$S/^2(C
M_MG_ .SU^DE?FY_P3,_Y(B/K'_[/7Z1T %%%% 'CW[07_)$O&O\ V"[C_P!!
MKX\_X)X_\B=)_P!>W_LXK[#_ &@O^2)>-?\ L%W'_H-?'G_!/'_D3G_Z]O\
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M,WP@M/$_[<*Z!\7B;?P]J-Q=/YL^50*SKM/.>H)Q_DT >$']J;]GCH?!)/\
MWU_A77^!?VF?@%?^)+2WM/!?ERLXVL<]?RK]>M._X)U_L2W-C!-!I<5RK(")
M!=QX;CKT[UTFA_\ !/?]CK2=2AO=,T2-KB,_(!=*<G_@(!_6@#[2\"W=M?>"
MM O;./RH)["U=$_NJT2D#\*ZJJ6FZ=9Z1IUKI6G1B&ULXDAB09(6.,!5'//
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M_4SQ1_R+6J_]>LW_ * :_+/]A/\ Y.-^*?\ UYI_Z4"@#]::*** /G?]K/\
MY-O^(/\ V"Y/_0EKQ3_@G3_R;MI@]&'_ *"*]K_:T_Y-N^(/_8+E_FM>*?\
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M344 4/[)TO\ Y\X?^_:_X5+#8V-N_F6]O'$W3*H ?S%6J* ,;Q'_ ,B]J?\
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M0CC#< CD#-?-\6?[E+Y'[7]'W_DIZ'I+\B;]I49_9:MO^P3%_P"@BOYQIO\
M6M]:_HZ_:5_Y-:MO^P3%_P"@"OYQIO\ 6O\ 6O=PO\*/HC\OXC_W_$?XG^;(
MJ^J/V-_^2^^%O^OE:^5Z^J/V./\ DOGA?_KY6MSQ#^S[0/\ D!:=_P!>T/\
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MMX/\1Q6_AJS_ 'D4:6ZDA HX)Z]3WZGI7Z?U\T?MB@']F?Q]D9_T ?\ HU*
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M4 ?FO_P5+_Y*QK/_ %]-_P"AFOR4K]:_^"I?_)6-:_Z^F_\ 0S7Y*4 %%%%
M"CK7W#_P3_\ ^3C/!W_84MOYU\/#K7W#_P $_P#_ ).,\'?]A2V_G0!_8R.@
MKR']H#_DB7CC_L$7G_HIJ]>'05Y#^T!_R1+QQ_V"+S_T4U 'QW_P3,_Y(B/K
M'_[/7Z1U^;G_  3,_P"2(CZQ_P#L]?I'0 4444 >/?M!?\D2\:_]@NX_]!KX
M\_X)X_\ (G/_ ->W_M05]A_M!?\ )$O&O_8+N/\ T&OCS_@GC_R)S_\ 7M_[
M4% 'Z25_/Q_P60_U^C?]=5_] %?T#U_/Q_P60_U^C?\ 75?_ $ 4 ?@51110
M 4444 >T_L[_ /):O"'_ %_P_P#H5?W)CI7\-G[._P#R6KPA_P!?\/\ Z%7]
MR8Z4 %%%% &;>ZQI.G,$O[R*W8\@2.%./Q-4?^$L\,?]!6V_[^K_ (U\;?M"
M?LR_%#XL>+)-=\+>*K33+1U0+#.DNY=JX/W,CMG^E?F7^TA\%_CM\"]:\%:;
M<>*+2]7Q7?FS1XE<!2JY.=Q![T ?O\OBKPTY"KJEL2>G[U?\:W(Y(Y466)@Z
M. 0P.00>X-?D;X=_8A^/-S;66JR^-]/02*DFQDF+8(!YP"*_3_X<^'-6\(^"
M=(\.:Y>KJ-]80+'+.@*JQ'H#S@=/>@#MJ*** /DK]K/]JW0OV5_"EEXBU?2Y
M-4?4)?*C1&"A3@\GUZ=.*_,J3_@LWHYD8KX=N%!)P!LP/89YKT/_ (+,'_BV
M'AG_ *^Q_)J_FK/6@#]^M<_X+%Z7JFCWFG1Z%<(;J)X\_N^C#!_0U\J? W_@
MH'I_PE^(FN^-3IL\R:OUC!7/?UX[U^5]% ']!_\ P^:TC_H7[C\HZ[/P!_P6
M!T#Q'XJT_P /W/AB>5;^58\[E0KG/((_J#7\WM>J?!49^)F@^UTE ']R.@ZS
M:^(='M-:LPRPWD:R*&X8!AGG%:]>>_"GGX=Z 3_SZ1?^@BO0J "BBB@ HHHH
M *:_W&^AIU-?[C?0T#1_//\ &7_D[L_]?B?^@5[#_P %8?\ DW/X>_\ 763_
M - CKQ[XR_\ )W9_Z_$_] KV'_@K#_R;G\/?^NLG_H$=?)\/_P ?$_XV?T/X
MV_\ (MR7_KQ']3^;YNM-IS=:;7UK/YW"BBBD!+!_KD_WA7]@?_!-?_DT_P -
M?]=9OY+7\?D'^N3_ 'A7]@?_  37_P"33_#7_76;^2T ?>E%%% !1110 444
M4 %%%% 'S%^U[_R0_7O^N+_^@FOXN_$?_(;O?^NTG_H1K^T3]KW_ )(?KW_7
M%_\ T$U_%WXC_P"0W>_]=I/_ $(T 8E%%% !1110!_8/_P $T?\ DSOP+_UP
MD_\ 1C5]ZU\%?\$T?^3._ O_ %PD_P#1C5]ZT %%%% !1110 4444 %>)_M"
M_P#)*M9_ZY-_Z":]LKQ/]H7_ ))5K/\ UR;_ -!-95_@EZ'IY+_OE'_$OS/Q
MT_8%_P"2T7'_ %QG_E7[V6W^I7Z5^"?[ O\ R6BX_P"N,_\ *OWLMO\ 4K]*
M^>X0_P!QA\_S/V+Z1O\ R5-;_##\C__3_?ROGG]H']I3X??L[Z"NK>+YS)<R
MC,5K$5,K+S\VTD?+D5]".VU&8=@37\W7QMMKW]IK]N&'X:^-K]8-,BDNH$,Q
MQ&D<+IA<=._'3GOWH ^UOA?_ ,%2?!_Q4^*VG>"M(TR:&VN6*,&CZC.,AB>O
M(K[5\,?M9?"CQ/XOB\%PW;6E_.Y1?.**I8=OO'K7Y._$_P#9N^&O[/'[4_PN
MT3X>6GD)J%L7N')'[QP?O# & ?\ "O$?VXOAO%\"OBQIOBCPIJL;S&..X98R
M<EG&2,9- ']-8((!'(-+7FWP;U*?6/A-X/U2Z.9KG2;-W)[DPKFO2: "BBB@
M HHHH **** "BBB@ HHKCOB!XRM/A_X/U/QA>V[W4.FQAS%'PSDL% !/3DB@
M#=U?6]'\/V;:CKE]#I]JGWI9Y%C0?5F(%7;6ZMKVVBO+.59X)E#I(A#*RL,@
M@C@@CI7\Z/[;GQ-^-OQ5\+ZEXANY9] \.6Z.R64J%-\1Z;2, \=Z_:C]DV:6
M7X ^$1*Q;9:1J,^FT'^9- 'NGB/_ )%[4_\ KUF_] -?D_\ \$R_^1O^*G_7
M])_Z.:OU@\1_\B]J?_7K-_Z :_)__@F7_P C?\5/^OZ3_P!'-0!^O-%>*?%_
MXX^'/@]! ^L6\EW+<*75(V"_*#C))S_*OFFV_P""A/PUN[DVL.DSM(K;6 G0
MD'./[M 'Z T5R_@_Q9IWC70H-?TM72"?H' # X![9]:ZB@ HHHH *"<#-%(W
MW3]* /Q"_:I_X*.^(_A;\2M0\(:'-):P:?<20D+$ISY?&<XSUK\Z/C1^WQXJ
M^+4$<6J7DTHC3:JLN% KA/\ @H#_ ,E\\3?]A&Y_]"KX4- '[!>$_P#@J/XZ
M\,^'-/T&+49VCT^%(4S&#P@P!DC. *_9+]A7]IK4/VE_!&N:SJ>7FT>YBBWE
M0I994)Z#'3;7\=8ZU_2Y_P $8O\ DEOCG_K_ +/_ -%R4 ?L_7QM^VSX3\.W
MWP+\1ZO<6$37JH")M@W]#_%UKZG\0>+O#'A6))O$>IV^G)(<*9W"9QZ9KXX_
M:]^+/PUU;X#>(K#3/$MC<W,B +&DJLS<'H* ,O\ 81\!^%4^%$&O-81R7KN$
M\QER0%0'C/\ O&OD3_@I-#%!XUT6*!0BJJ@*.@X)X':OJC]BGXL?#71/@W;:
M?JWB2RM+A9=Q224*V-B\X_"OC?\ X*%>+_#'BWQEI-UX9U.#4HD4!F@<.!P?
M2OF^+/\ <I?(_:_H^_\ )3T/27Y&U^TK_P FM6W_ &"8O_0!7\XTW^M?ZU_1
MS^TK_P FMVW_ &"8O_0!7\XTW^M?ZU[N%_A1]$?EW$?^_P"(_P 3_-D5?5'[
M''_)?/"__7RM?*]?5'[''_)?/"__ %\K6YXI_9]H'_("TW_KVA_] %:U9.@?
M\@+3?^O:'_T 5K4 %%%% !1110!^2W[>2K_PO3X;G YB/_H4E?J+X- 'A'1
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M\T;3M"L5QAN.V2:_+#XR?\%2+_XH?#?6O LMF8H]6B\MB%0< @\X /) /X4
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MJ-FN@_:ILNLH\O:,E1NK]=_#_P 3?@?HEK%H_A[Q#IEM#GY8XYEY)]>Y/UH
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M110 4444 %%%% !1110 4444 %%%% $%S<V]E;R7=W*L,$*EG=R%55'4DG@
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M?_)QOQ3_ .O-/_2@5^IGBC_D6M5_Z]9O_0#7Y9_L)_\ )QOQ3_Z\T_\ 2@4
M?FO_ ,%2_P#DK&M?]?3?^AFOR4K]:_\ @J7_ ,E8UK_KZ;_T,U^2E !1110
MHZU]P_\ !/\ _P"3C/!W_84MOYU\/#K7W#_P3_\ ^3C/!W_84MOYT ?V,CH*
M\A_: _Y(EXX_[!%Y_P"BFKUX=!7D/[0'_)$O''_8(O/_ $4U 'QW_P $S/\
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MFOS]_;6_:=\.?$[Q'\+YM'T^2&/P_J[W$A:0/N#(!V P.* /W1\.?\@#3O\
MKWC_ /016U7Y_P"@?MU> ;?1K.VGTR7?#$B'$Z\[1C/W:UV_;Q^'2*6;390!
M_P!-U_\ B: /NFBO'OA)\;/!WQCT^:\\,2$26P4RQLRL5W>A'4?A7L- 'XK_
M /!9G_DF/AG_ *^Q_P"S5_-8>M?TI_\ !9G_ ))CX9_Z^Q_[-7\UAZT )111
M0 5ZM\%/^2EZ#_U\I7E->K?!3_DI>@_]?*4 ?VR_"K_DGF@_]>D7_H(KT&O/
MOA5_R3S0?^O2+_T$5Z#0 4444 %%%% !37^XWT-.IK_<;Z&@:/YY_C+_ ,G=
MG_K\3_T"O8?^"L/_ ";G\/?^NLG_ *!'7CWQE_Y.[/\ U^)_Z!7L/_!6'_DW
M/X>_]=9/_0(Z^3X?_CXG_&S^A_&W_D6Y+_UXC^I_-\W6FTYNM-KZUG\[A111
M2 E@_P!<G^\*_L#_ .":_P#R:?X:_P"NLW\EK^/R#_7)_O"O[ _^":__ ":?
MX:_ZZS?R6@#[THHHH **** "BBB@ HHHH ^8OVO?^2'Z]_UQ?_T$U_%WXC_Y
M#=[_ -=I/_0C7]HG[7O_ "0_7O\ KB__ *":_B[\1_\ (;O?^NTG_H1H Q**
M** "BBB@#^P?_@FC_P F=^!?^N$G_HQJ^]:^"O\ @FC_ ,F=^!?^N$G_ *,:
MOO6@ HHHH **** "BBB@ KQ/]H7_ ))5K/\ UR;_ -!->V5XG^T+_P DJUG_
M *Y-_P"@FLJ_P2]#T\E_WRC_ (E^9^.G[ O_ "6BX_ZXS_RK][+;_4K]*_!/
M]@7_ )+1<?\ 7&?^5?O9;?ZE?I7SW"'^XP^?YG[%](W_ )*FM_AA^1__U/W[
M(!!![U^#'[?G[,7Q)\#_ !(A^/GP;BDG+>9)*L<9D9996#.#@C XXK]Z*_+_
M .-G_!0;P[\'?BI-X"\8:0]WIA>2,A4SD(=N22/QQ0!^)OB_X\?M'>+O&OAK
MQ?XETVZFU+PM#Y$3& *5 ]?FR3]:]1^&WPC_ &C/VNOB5IDWQ"LYX; .(_-E
MA*1QQ#@%BN>*_;3X9^//V1_C+ =8L/[-L;R5@Q@NWABD)89X#'GZ#FOMG2-/
MTC3K"&VT6&*&U0?((@ N#SQB@#/\'>'H_"?A/1_#$+;TTFT@M0P_B\E N?QQ
M72444 %%%% !1110 4444 %%%% !67K6C:9XATNXT768%N;.[79)&W1AG/;W
MK4HH _)3_@J18V>G_":.VLH4ABCLY%544 !5P /P%?;/[)/_ "0+PI_UZQ_^
M@+7QA_P54./A8.W^BS<GIU%?9_[)7/P"\*@_\^L?_H(H Y#XH_M=_"[PDVN>
M%KEIIKZU66W? 54WE2#R3GC/I7YP?L)_&OPY\,=$^+OQ,UJ*2;3X+EY0L97)
MS*Q R3@#WY^E?IM\1_V3_@GXJ76_$^J:&&U*YCEG>13C,@4G.,=^]?A1X9TF
MSTG]G#X^V%DNR*WFE1!Z 2L* /LWXB?\%(?V9/B*BV_B_P &WEZT"LD;BY"$
M ^A &1FOSS^&/QX_9\T'XE:QKOB7P]>WNCSW;R6]NMR%98_X06VX/Y#/;V_,
M7<<=:-S'J30!_5#\)_\ @I?\"M3U73? ?A_PY=Z9:R'8A$J2;?<@X)_$U^IU
MA>V^I65OJ%HV^"YC66-L8RKC(.#[&OX?/V>R?^%I:3S_ !_U%?V@:1J<NC?"
M+3M5M\>9:Z1!(N>1E8010 WXQ?$.Z^%W@'4/&-EHMSK\]H $M;5=SL3G!/HH
MQS^5?F/?_P#!476].UFV\/WGPTU&#4;S_4P/&0\F/09KRSP=XY_;>^//B/Q@
M_@'Q.\6EZ1?&W\H[BJAAE1P>!Q6!X@_9)_;7U_Q[I'CW4M8$VK:1G[/+Y;?)
MGKSF@#]:_P!G+XZZK\<?#]WJVK^%+WPQ-:/MVW2[1("3]WOQ7T<WW3]*_"CX
ME?\ #?\ \&_!&H>-M7\5LNGZ<N^4+O7(Z=0:_5W]FSQYK/Q'^#FA>)O$#^9J
M,T"K-)_?8*#D^_.#^= '\M7_  4!_P"2^>)O^PC<_P#H5?"AK[J_X* '/Q\\
M3?\ 81N?_0J^%30 #K7]+G_!&+_DEOCG_K_L_P#T7)7\T8ZU_2Y_P1B_Y);X
MY_Z_[/\ ]%R4 :O[?::SXJ^/OPZ^'<-Z\%AJCE'521]Y.>F*[*__ .":^FZK
MI'V.;5T$DBC=NFF9<GVVUA?MA?\ )X?PE_Z[C_T"OUS3[B_04 ?E/I?_  31
MTG2K$VT.KIN"_P ,LRC...-M?E'\2/!<O@3QQJ_AR6X,ZVEQY0)9F&!Z9K^K
M8]*_F-_:4Y^,'B$'_G]:OF^+/]REZH_;?H^?\E-1])?D?6G[2O\ R:U;?]@F
M+_T 5_.--_K7^M?T<_M*_P#)K5M_V"8O_0!7\XTW^M?ZU[N%_A1]$?EO$?\
MO^(_Q/\ -D5?5'[''_)?/"__ %\K7RO7U1^QQ_R7SPO_ -?*UN>(?V?:!_R
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MUAZT )1110 5ZM\%/^2EZ#_U\I7E->K?!3_DI>@_]?*4 ?VR_"K_ ))YH/\
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M''4_^NIH XJK-K_KT^M5JLVO^O3ZT ?VY_LM?\D"\%_]@ZW_ /1:U] 5\_\
M[+7_ "0+P7_V#K?_ -%K7K_BS6KCP[X<O];M+1KZ:SB+K GWG(["@#H:^6?V
MR<?\*%U[/HO\Z^#O'W[?WQ:\%Z_%I6H^%[RU:^8^0C0(,X[+N&3BCQ?^T+\2
M/BQ\'_$D'BS0[NQM?LX=&EB5%)W@=0!VKCS#^!4]'^1])P<KYMA%_P!/(?\
MI2-/_@F1_P ?7B#VQ_)J^(/^"M7_ "/=I_UTE_\ 0FK[?_X)D?\ 'UX@_P"
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MTXK\,?BA\6?VW?AC\0?#?@#5?'+M=^)+C[/&0N-AP3DY[<5[Q_PUK^T?X_\
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MO$W_ %[?^SI0!^KE%%% !7-^,?\ D5M4_P"N#_RKI*YOQC_R*VJ?]<'_ )4
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M[6_"D-\DBR*+I7/EJ(\ X([;CGK0!\UV_P#P5-\<VL"6\.GW"I&,#_1CT'_
M:Z?PS_P4_P#'FMZQ!I_V"<>:V#NMR!_*OTIM/V5/V2+ZUBO+;PYISQ3*&4^<
MW(/_  .O@K]JN;]F7]G3QCIMOHGAJWD<PJ\BP2;@K,3CG)/3!H _9SPMJSZ_
MX9TG7)$\MM0M(+@KZ&5 Q'ZUO5Q?PWU6SUSX?>&]7T]/*MKS3K62-/[JM$I
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MW_)._#O_ %Y0?^@"N\H _)C]H[_D^+X2_P#80B_] K[&_;1_Y-@^('_8.?\
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MQ_Z#7QY_P3Q_Y$Y_^O;_ -J"OL/]H+_DB7C7_L%W'_H-?'G_  3Q_P"1.?\
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M/^NTO_HUJ_I2\1_\B_J?_7K-_P"@&OYK;#_DWS]H3_KM+_Z-:@#\;S24II*
M/;?V>_\ DJ6D_P"_7]EC_P#)"X/^P)%_Z(%?QI_L]_\ )4M)_P!^O[+'_P"2
M%P?]@2+_ -$"@#XK_P"";_\ J?BG_P!AN/\ ]%M7Z;U^9'_!-_\ U/Q3_P"P
MW'_Z+:OTWH ^1?VZ_P#DUOQQ_P!>R_\ H0J?]BS_ )-^T+_=_P#9$J#]NO\
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M-_M!?\EB\4?]?DO_ *$: /&*>G7\13*>G7\10!_2O_P1N_Y$+QO_ -?-I_Z
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M1?\ !,G_ (^O$'_ ?_9J^'_^"M7_ "/=I_UTE_\ 0FK[@_X)D?\ 'UX@_P"
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M.JF_@S_Z'79:1KNB:_;?;="U"WU&W_YZ6\J2I^:$B@"OXH_Y%K5?^O6;_P!
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ME\9?^3NS_P!?B?\ H%>P_P#!6'_DW/X>_P#763_T".O'OC+_ ,G=G_K\C_\
M0*]A_P""L/\ R;G\/?\ KK)_Z!'7R7#W\?$_XF?T/XW?\BW)?^O$?U/YOFZT
MVG-UIM?6L_G<****0$L'^N3_ 'A7]@?_  37_P"33_#7_76;^2U_'Y!_KD_W
MA7]@?_!-?_DT_P -?]=9OY+0!]Z5^?WQA_X* ^#?A/\ $74/ALGA34->U#33
MMD-O(B_-T. 5;C/O^5?H#7XD:;X>TKQ+_P %$?%MAK$ N(&O "K8(P3Z'UH
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M_MU^%_BMH'PPN_&L1O==)$9%MC!'J/\ ZU 'ZE_MU_\ )K?CC_KV7_T(5/\
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M%_"'C..UT^V7:D1@9@!ZX/&?I0!^3O\ P4$_Y.A\:?\ 7XW]:^):_:/XB_\
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M\>ZUN_LK1;BZV==B@_UK7_X4E\5_^A8N_P#OD?XT :W[._\ R6KPA_U_Q?\
MH5?W)CI7\27PT^'_ ,3_  1XXT;Q3<^%;Z6+3+A)V15&3M/;FOZ"['_@IS<1
MVD4=_P#"?6I9U4!W66-0Q'?&#C\Z /TG^*/_ "3?Q1_V#+O_ -%-7YO?\$\_
M^1K\3_\ 7M_[.E<QXY_X*17?B3PAJ_A[3?A1K,%QJ-M) LCRQLJ^8-I)&!G@
MG'-?*?[,?[5'B;X':_J6J:M\.M4U""_B*%8]B-U!')SW% ']%]%?E/\ \//%
M_P"B1:W@=_/C_P#B:YO7/^"K^E:)+:0WOPRU2S>ZD"*)I4)?@DJN ,,>QY%
M'Z^5S?C'_D5M4_ZX/_*OS(C_ ."H,,JAX_A'KC ]Q-%C_P!!K$\3_P#!2JXU
MGP_?:78?"?6H9[J(HKO+&RJ3W(P,_G0!TW["?_)6O'/_ %ZK_P"CA7ZH5_.W
M^SE^U;XA^#7C?7_$VK_#G5K^#6(1$J1LB%2'#9))/IBOLS_AYZG_ $2+7/\
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MM)+MHXVF,D912W!.,9P/K7V#^T _F_"75Y-I7="3@]1E3^M95_@EZ,]/)?\
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MQR.F #7[8? 7X:O\'_A%X9^&\DB2OH=J(&:/.TG<6XSCUQ0!Z]1110 4444
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M6_\ WS_]>NS*J2"0"12T <9_PKOP1_T!K?\ [Y_^O1_PKOP1_P! :W_[Y_\
MKUV=% '&?\*[\$?] :W_ .^?_KT?\*[\$?\ 0&M_^^?_ *]=G10!Q?\ PKKP
M1_T!K?\ [Y_^O7GWQ5^%WA>_^'>O6FDZ'%)>/:N(5C3+E^, "O=:* /S)_8@
M^"DFDV^M77C7PW+:Y1$B%U%L#98YQGKC';U]Q7Z!_P#"N_!'_0&M_P#OG_Z]
M=D !T&*6@#C/^%=^"/\ H#6__?/_ ->C_A7?@C_H#6__ 'S_ /7KLZ* .,_X
M5WX(_P"@-;_]\_\ UZ/^%=^"/^@-;_\ ?/\ ]>NSHH XO_A77@?.?[&M^/\
M9_\ KU^<'[>/P9.I^)?A'<^"O#<ERBZVRW9M8BX5-@V[O3/./6OU3I"JMC<
M<<C- 'F^A?##P99:19VT^CP-*D2!R5Y+;1D]JUO^%=^"/^@-;_\ ?/\ ]>NS
MHH XS_A7?@C_ * UO_WS_P#7H_X5WX(_Z UO_P!\_P#UZ[.B@#C/^%=^"/\
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M/VC[?1M!U%#H7BR^=Y%#;PD;Y.&]Q_.OZ"XI8IXDG@<21R ,K*<@@\@@^AH
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MVD>*8T,8U*W27:>,$\'U[B@#K:*** "OEG]LG_D@NO\ ^ZO\Z^IJ^6?VR?\
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M\8X(XH _5BJ=YI]CJ,:Q7\"7"(P=0ZA@&'0C/>OB']CC]KFQ^/'A>'2/%/\
MH7BNPC07"R[4,S-GD(O0@8!]:^ZJ $5510JC '  [5^"7P[\1^'_  9^V/\
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M><$!3WYK] /AG\3= ^*>@C7_  ^LBP<9WXZG/0CKTKT4*H)8 9/4T +1110
M4444 %%%% !1110 51U'4;#3+5[O4KF.U@4<O*X11^)(%<3\4/B;X:^$_A*\
M\6>)9@D5NC&./(#3.!D(N>YK\6[[XA?M"?MK>)+VS\+:A)H'AJ%C) CQXC"'
MG&5ZG QDT/:XT<'\6+ZRU+]K07=A.EQ ]W&5=#E3\AZ$5^_O@K_D4])_Z]X_
MY5_-:G@K6OAG\<=/\,>(KL:A?6-RGF2IT)VD\9K]^?$?Q)N/A[\#(_&MCIDV
MI36UD"D40!PP4X9LG[H(KY/AW^/B?\3/Z)\;U_PFY+_V#P_4?\9?AE\%OB1
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MX4 2\Y-=+\;/VC_&GQ*U&#X)_!@32EC';2SVP9HY(FX(+)QC;[U)^U5\-/\
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MJW\)6-JHTNV@6W6)N1Y:KMP?7BN0T/X,_#;P[K9\0Z3HL,-\22'QG!;@X!H
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M;^T/HVN?M>?"V7Q#\(KR2UATQ614?.^5L;BR",\C!'?-?C1\-M(^.]MXNN/
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M/0?0"N]H **** "OY\?V^[;Q!\3/VA='T#P([0W]M=M&'&2-P4CHN#C/;/\
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M3<0EA]Y<8W#^\,?T-?!5GJ/Q5_8#^)<,&JEM3\#:M-^\CC!*>0N>=[$X(QU
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M8.BAY@-LH?."I'TYKVFO/?AI\,O"OPI\-0>&/"EL+>WB4!CR6<CN<Y]:]"H
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M\+>&[<6UA8H$C3J<>Y[UU% 'RE^RI\%/'GP/\+7GAKQ9K4.I63F(V<,0?,
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M.<XQ7Z^T >#_  !^ WAGX"^#(?#&AYGF'^MG8DD\#A<]!_/O7O%%% !1110
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M[<V=U:YFNHX<;O-9N2JCG&/RH _86]LK/4K26QOX5N+>=2KHX#*P/J#7X_\
M[1W[,WC+X'>*(OCE\#&=8+&0W%S!&"9 PS@;5QD9QSC'8]L^W?L/_M9_\+4T
MI?ASXW=H?$VDJL(,RE7E*J"5YZX'0_\ UJ_1L@,,,,@T >6?!?QMJ?Q ^'.C
M>)=:L)M/O[B!?/CF1D)<<%EW 9#=?TKU2D  &!P*6@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "OEG]LG_D@NO_[J_P Z^IJ^6?VR?^2"Z_\
M[J_SKDQ_\"IZ/\CZ/A#_ )&V$_Z^0_\ 2D?$7_!,G_CZ\0?\!_\ 9J_8.OQ\
M_P""9/\ Q]>(/^ _^S5^P=>7PQ_N-,^]\>O^2KQO^)?D@HHHKWS\?"BBB@ H
MHHH **** "BBB@#DO''@CP[\0_#5[X3\46JW5A?QF-P0-PSW4D'!!K\9[']G
MWXQ_LM_'W39_ R2:CX:U:\\R,0(\@\OG"L%/!&.1BOW%I" >HSB@#-TR*.6W
MAU&2V6"ZN8T:7Y K[BHR&[\=.:TZ** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K@_
MBAX=N/%OP[\1^&K,;I]2L;B",>KNA '/O7>44 ?AU^Q=\8=/_9Y^(OB/X1?$
MR*73@\R6\,\B[45D ZAL'&2<]QZ>G[>VEW:W]M'>64R7$$PW))&P=&![AAD$
M5\/_ +6/['/A_P"/$<?B31H([;Q):Y82\ R$#Y3D\9]Z_-S3_B%^V/\ L]W)
M\ O)?WME9_NX$6)I50'GC&10!^EO[?>O>'M,^ >K:=JSK]KOE9;5,_,SA3R/
MSKC_ /@F[H/B#2?@/IUUJ\4D5O=11^2'R =I;) /Y9KYE^&GP9^.G[4_B?3]
M>^-UW</X:TR82B*Y&TC/!"*W<_2OV-\.>'='\):'9^'/#]LMII]A&(H8D& J
MB@#;HHHH **** "BBB@ HHHH *\]\=_%3P%\-[)[SQ=K%O8E5++"TB^<_P#N
MIG/]*U/'OBB#P5X,UKQ9<%0FE6DUQ\WW244D _4\5^*_PB^$6L_MM?$76?'O
MQ&N6NO#GG)-&I.,1M_"H_#C P* /NMOVC/V;OVC+R/X8ZM)*_P!JD"Q>840&
M3!P 0S<GIT/6JOBK_@G5^SUXAL)(K*SN+*Z;)242*R@^ZA1D?C72^&_V!OV;
MO"?B33?%&B^'A#>:9)YL?.5+@<$_2OKG4M7T3PY9+/JMW#I]JN$5I6"(,#@#
M.* /YO/VP/V,5^!9T.]TJZ687,BE71F.T[R.2P7''/\ 6O0? '[*G[6VH>!;
M#Q_X"\0P&POHO-CCWEW*@[>%#Y/(]*^]O^"B>GVFO?""R\2Z>R7,5L3*DJ$,
MI7&X$$=J]<_8(\40^*OV6?!5RAR]O;&)_KN+_P F% 'PQ\&XOV^])\:Z;H&M
MW\G]FO<(LQE@E\L+WR23@8ZGI7[26*7<=G"E_(LMPJ@2.B[59NY ).!^-6<"
MEH **** "BBB@ HHHH ***^2OVL?VC8/@-X6M8M.Q+KVLLT=J@&]DVC.[:/7
MH/H: /J'4-<T722BZKJ%O9F3[HFE2/=]-Q&:_.#]H#]DWXV?%3QA?^+_  1X
MOL8+2[D\R%':7(7' ROR_K7RII7P0_:\_:5L)/B!J.NRP1/D6R7#B,@@Y "N
M0<?I7Z8?LK?#?XN_#GPFFF_$[6?[0_=XCA)RT;9SG(R!QGB@#\GO'?P _;:\
M Z-K%C=:NEYI4D#).8DD=#$1_>#$=*^;?V=/CG\7_@;XIUC3- MKB^EBC GA
M@C9CM+@\CW(K^I/4[7[=IUU9XW>?$Z8/^T,5^&OP,AC\%_MV>+O#EY$$CO?L
MT)5P,-F0\>A[T =KX8_X*>>(]%GV^.? ^I20=,K R'/U.?Y5^A7[/O[1/AW]
MHO2KC4=/\/WFF"VVG_2XAL8/G&UB/;GBO4/$OPA^''BZ$0ZYH5O,H.<J@0\^
MZX-=-X6\)^'O!6CPZ!X9LH["QMQA(XQ@?CZF@#H(XHXEV1($4=@,"GT44 %%
M%% !1110 4444 %5KV[AL+26\N#B.%2[8]!7G?Q2^+'A'X1^')O$/BJZ6)55
MC'%GYY649VJ*_*76?^"G<U_KLUF/#MS'H-P=@)MG(\O')+D?G0!R_P =OCEX
MI_:O^,</P-\ 3G3-*L[B..83$KYBRDH2<'&<C\J_1;X5_L@?"?X<^"1H.K:=
M#?SO&WVB>3! R.<%@" /4U^6OC?P?!:26/[2OP 86SO+YUW# 09@D(SRHPW5
MC75^,/\ @H7XM^)_@.Q^&_A:UEL/$VK2&TNY!$RL8W&WH>F<G/K0!Q'@_0+/
MPY^VEKNB_"4&73K:^"1^2WF)L5QW7 (]Z[G_ (*0?!5_#GQ2\*_&!%66SU.]
M070B7;@0IAMP&>#D'GJ37W?^QY^RM:?!71X_%WB2/?XNU*'%Q)D$@/CKCN??
MI7T%\=?A!I'QI\!7GA+4E59F5FMY& .R0C'?L?\ "@#(_9EUSP[X@^#6A7WA
ME52U56C8* ,2*><X[\BO>GY0_2OG[]FCX-7/P,^&D'@BZNOM+QS22_*?D4.>
M,>Y[_A7T"_W&^AH&C^>?XS?\G=G_ *^X_P#T"OWS\%_\BGI/_7O'_*OP,^,O
M_)W9_P"OQ/\ T"OWS\%_\BGI/_7O'_*OE.'?X^)_Q,_H?QM_Y%N2_P#7B/ZG
M3T445]6?SN%%%% !1110 5FZSI-EKVDWFBZBF^UOHGAE4<920;6'Y&M*B@#\
M$_CK\$_B5^QM\3T^*OPKDDD\+:C-@QPAG>-%!9ED"_4=L'^7ZB?LP?M->%OV
M@/"D4UO*+;7+9 +BV<@.<<%@N<]1S_G'T?X@T#2O%&C7>@:Y;K=6-ZACEC89
M#*:_"S]H;X#^-/V0/B7#\8?A"LD/AV[G4O'#\Q14.Y@P7D<GC/7\Z /WFN+B
MWM()+JZD6&&%2[NY"JJ@9))/  %?/GA3]I#X>^/OB)J'PX\.Q3ZE/IV-UU'&
MLELV>"0X)^4>N*_,#6_VR/B5^TOI-I\//AS#<6MUJ4BP7)CB9=\3_*X)'4$'
MD5^EG[-/[.'AOX#>%(88K=)/$%U&/MER,$DGDJ".P/7U/X4 ?2T5O!#_ *F-
M8_\ = '\JFHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O$_VA?\
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M*%1%"J!CL!P*N5[M*'+%1['Y5F.*]OB*E9*W-)O[W<****T.(**** "BBB@
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M\>O^2LQOJO\ TE!1117OGX^%%%% !1110 4444 %%%% !1110 4444 %%%%
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M_D4])_Z]X_Y5\IP]_'Q/^-G]#^-O_(MR7_KQ']3IZ***^K/YW"BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,/\ A=/PJ_Z&BP_[_+1_PNGX5?\ 0T6'_?Y:/:1[A]1K_P#/M_<ST^BO,/\
MA=/PJ_Z&BP_[_+1_PNGX4_\ 0TV'_?Y:/:1[A]1K_P#/M_<ST^BO,/\ A=/P
MI_Z&FP_[_+2_\+H^%/\ T-5A_P!_A1[2/</J-?\ Y]O[F>G45YE_PNCX4_\
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MTQC.#@\%@>HIJ:>S(GA:L=90:^3.QHKFO^$T\'?]!VP_\"HO_BJ/^$T\'?\
M0=L/_ J+_P"*I\R,O92['2T5S)\:^#0,G7K# _Z>HO\ XJN6_P"%T_"K_H:+
M#_O\M)S2ZFD,+5E\,6_D>GT5YA_PNGX5?]#18?\ ?Y:/^%T_"K_H:+#_ +_+
M2]I'N:?4:_\ S[?W,]/HKS#_ (73\*O^AHL/^_RT?\+I^%7_ $-%A_W^6CVD
M>X?4:_\ S[?W,]/HKS#_ (73\*O^AHL/^_RT?\+I^%7_ $-%A_W^6CVD>X?4
M:_\ S[?W,]/HKS#_ (73\*?^AIL/^_RT?\+I^%/_ $--A_W^6CVD>X?4:_\
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MU]-UK_.2OUJK\@_^"8NJVMC:^+K:8-ON9+<+@9'RALYY]Z_7I6##(KSN&%;
MTO0^O\=)-\5XZ_\ -^B'4445[Q^2A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %0W%O!=PO;W*"2.0%65AD$'K4U% 'RYKW[&?[.?B34SJ^K>$89;EF+%@[
MKR?8$"O8_ /PN\"_#&RDT_P3I<>FPRXW!<DG;T&3DX%>@44 %%%% !1110 4
M444 %%%% !1110 4R2..:-HI5#HX((/((/8T^B@#\Y?VA_\ @G]X*^)NHR^*
M_ T%OI.N2CYV8LH9A]W;C('4^E?.?@O_ ()J>.;W4;>#XF:M;76E6[*=@D+L
M5!YP%'UZU^TU% '"_#GX=>%OA;X3LO!WA&T6TL+)<* .6/=C[G_ZU=U110 4
M444 %%%% !1110 4444 %%%% ',>,/".A^.O#M[X8\16RW5C?1M&ZL,\,,9'
MN*_$37_"/CW]@WXOS:_X3AE/A'5YA&@AC+J8?O$-D8XQS[U^\5<OXP\&^'/'
M>AW'AWQ19I>V5RI5E8<C/=3U!]Q0!@?"GXF^'_B[X)L/&_AMC]EO 04;&Y''
M56 )^OTKT>O-/A;\)?!7P=\/?\(UX(L_LMH6+L6.YF/;)]NV*]+H **** "F
MO]QOH:=37^XWT- T?SS_ !E_Y.[/_7XG_H%?OGX+_P"13TG_ *]X_P"5?@-\
M;IX;/]K22ZNI!'%'=(69N !MZFOVN\(?&/X6V_AC2X)_$]BDB6Z!E,HR#CI7
MR.05(QQ&)4G;WF?TCXRX&O5RS)72@Y+V$=DWW['N5%>9#XS_  J/_,TV/_?T
M4?\ "YOA5_T-%C_W]%?4?6:?\R^\_G_^QL7_ ,^9?^ L]-HKS+_A<WPJ_P"A
MHL?^_HH_X7-\*O\ H:+'_OZ*/K-/^9?>']C8O_GS+_P%GIM%>9?\+F^%7_0T
M6/\ W]%'_"YOA5_T-%C_ -_11]9I_P R^\/[&Q?_ #YE_P" L]-HKS+_ (7-
M\*O^AHL?^_HH_P"%S?"K_H:+'_OZ*/K-/^9?>']C8O\ Y\R_\!9Z;17F7_"Y
MOA5_T-%C_P!_11_PN;X5?]#18_\ ?T4?6:?\R^\/[&Q?_/F7_@+/3:*\R_X7
M-\*O^AHL?^_HH_X7-\*O^AHL?^_HH^LT_P"9?>']C8O_ )\R_P# 6>FT5YE_
MPN;X5?\ 0T6/_?T4?\+F^%7_ $-%C_W]%'UFG_,OO#^QL7_SYE_X"STVBO,O
M^%S?"K_H:+'_ +^BC_A<WPJ_Z&BQ_P"_HH^LT_YE]X?V-B_^?,O_  %GIM%>
M9?\ "YOA5_T-%C_W]%'_  N;X5?]#18_]_11]9I_S+[P_L;%_P#/F7_@+/3:
M*\R_X7-\*O\ H:+'_OZ*/^%S?"K_ *&BQ_[^BCZS3_F7WA_8V+_Y\R_\!9Z;
M17F7_"YOA7_T-%C_ -_11_PN;X5?]#18_P#?T4?6:?\ ,OO#^QL7_P ^9?\
M@+/3:*\R_P"%S?"K_H:+'_OZ*/\ A<WPJ_Z&BQ_[^BCZS3_F7WA_8V+_ .?,
MO_ 6>FT5YE_PN;X5?]#18_\ ?T4?\+F^%7_0T6/_ ']%'UFG_,OO#^QL7_SY
ME_X"STVBO,O^%S?"K_H:+'_OZ*/^%S?"K_H:+'_OZ*/K-/\ F7WA_8V+_P"?
M,O\ P%GIM>)_M"_\DJUG_KDW_H)K?_X7-\*O^AHL?^_HKQ[XZ_%CX:ZK\,]7
MLM.\1V=Q</&=J+*"3P:RK8BFX2]Y;=STLFR?%_6Z+]C+XE]E]S\MOV!?^2T7
M'_7&?^5?O9;?ZE?I7X)?L!\_&>X8'(,$_P#*OWMMO]2OTKP^$/\ <8^K_,_4
M?I&?\E36_P ,?R/_T?W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (+@9B(K\PO
MVR/@)KWQ4U2QU+294C^R(5._KW_QK]0R,C%<CK/AR'4L[U!S[5S8O"PKTW2J
M+1GM</<08G*\9#'8.5JD-GN?@9%^Q_\ $[;A=61!Z!V _+-2_P##'_Q1_P"@
MRG_?;?XU^X1^'UMG.P?E2GX?VY_@'Y5X:X4PG9_>S]7_ .)@^(OYX?\ @$?\
MC\//^&/_ (H?]!E/^^V_QH_X8_\ BA_T&4_[[;_&OW"_X5];_P!P?E1_PKZW
M_N#\J?\ JKA.S^]A_P 3!\1?SP_\ C_D?A[_ ,,?_%#_ *#*?]]M_C1_PQ_\
M4/\ H,I_WVW^-?N%_P *^M_[@_*C_A7UO_<'Y4?ZJX3L_O8?\3!\1?SP_P#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJO)%,X91+M!&.!R/QH
ML45D?V9-_P _DO\ WT?\:O6L#6Z%&E:4DYRQR?I0!9HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBLZ>QDFE:1;F2,'^%2<"@#1I",@BHX8S%$L;.7*_Q'
MJ:EH _*;XX_L#?$/XG_$#4/&>AZ]I5DEXP95F>X#C@?W(6'ZUXMJ?_!.+X\:
M=;K+9^)K'47+!?+M[B8,HP3N/G)&N.,<'/(XQG'[A45\]7X7PE2<JDD[MW>I
M^QY7X[<0X3#4L)2J1Y*:25XIZ(_!\?\ !/S]HS'-ZO\ X%+_ /'*7_AWW^T7
M_P _J_\ @4O_ ,<K]WZ*R?"6#[/[ST5](CB/^:'_ ( C\(/^'??[1?\ S^K_
M .!2_P#QRC_AWW^T7_S^K_X%+_\ '*_=^BC_ %2P?9_>/_B8GB3^:'_@"/P@
M_P"'??[1?_/ZO_@4O_QRC_AWW^T7_P _J_\ @4O_ ,<K]WZ*/]4L'V?WA_Q,
M3Q)_-#_P!'X+W/[ W[0MIY7G7I/G.L:[)R^&;IG:QP/4G '<U9_X=]_M%_\
M/ZO_ (%+_P#'*_=^BE_JE@^S^\/^)B>(_P":'_@"/P@_X=]_M%_\_J_^!2__
M !RC_AWW^T7_ ,_J_P#@4O\ \<K]WZ*?^J6#[/[P_P")B>)/YH?^ (_"#_AW
MW^T7_P _J_\ @4O_ ,<I/^'??[1?_/ZO_@4O_P <K]X**/\ 5+!]G]XO^)B>
M)/YH?^ (_!N/]@']HB1I%2]&8FVG-P%YP#P2_(P>HXSQU!J7_AWW^T7_ ,_J
M_P#@4O\ \<K]WZ*7^J6#[/[P_P")B>(_YH?^ (_"#_AWW^T7_P _J_\ @4O_
M ,<H_P"'??[1?_/ZO_@4O_QROW?HI_ZI8/L_O'_Q,3Q)_-#_ , 1^$'_  [[
M_:+_ .?U?_ I?_CE'_#OO]HO_G]7_P "E_\ CE?N_11_JE@^S^\/^)B>)/YH
M?^ (_"#_ (=]_M%_\_J_^!2__'*/^'??[1?_ #^K_P"!2_\ QROW?HH_U2P?
M9_>'_$Q/$G\T/_ $?A!_P[[_ &BO^?U?_ I?_BZI7W[!7[06G0BXN;QMA('[
MN8S-_P!\QLS?CC%?O912_P!4<'V?WB7TB.(_YH?^ (_!.Q_8+_:"U&$SVUXP
M4':?,E,1S@'[LC*<<]<8J[_P[[_:+_Y_5_\  I?_ (Y7[OT4?ZI8/L_O'_Q,
M3Q'_ #0_\ 1^$'_#OO\ :+_Y_5_\"E_^.4?\.^_VB_\ G]7_ ,"E_P#CE?N_
M13_U2P?9_>'_ !,3Q)_-#_P!'X0?\.^_VB_^?U?_  *7_P".4?\ #OO]HO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>ck0001824293-20241231_g14.jpg
<TEXT>
begin 644 ck0001824293-20241231_g14.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0! 17AI9@  34T *@    @  8=I  0
M   !    &@       J "  0    !   $$Z #  0    !   "@P    #_X@)
M24-#7U!23T9)3$4  0$   (P041"10(0  !M;G1R4D="(%A96B 'T  (  L
M$P S #MA8W-P05!03     !N;VYE                        ]M8  0
M  #3+4%$0D4
M              IC<')T    _    #)D97-C   !,    &MW='!T   !G
M !1B:W!T   !L    !1R5%)#   !Q     YG5%)#   !U     YB5%)#   !
MY     YR6%E:   !]    !1G6%E:   ""    !1B6%E:   "'    !1T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D
M    9&5S8P         1061O8F4@4D="("@Q.3DX*0
M
M                            6%E:(        /-1  $    !%LQ865H@
M                     &-U<G8          0(S  !C=7)V          $"
M,P  8W5R=@         ! C,  %A96B        "<&   3Z4   3\6%E:(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#_]#]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKX1_;(_:L\2?!:[\-?";X/Z0GB'XH^.G$>G6T@W16T3OY2SNN5#%G!5 6"#:
MSN=J[6^[J_(#7C%/_P %?/#ZZ\3B#06_LP'D%O[-N">OUF(QW]Z^QX*R^C6Q
M-6KB(\T:5.=3EZ2<5HGY7=WY(RJR:6AV#?LZ?\%&+C2F\53?M!6L7B<H91IB
M6:?V>'//E^8(@GMG[.1^'->O?L4_M2^*_C=%XI^&?Q>TV/1OB5X G^SZG%$
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M/#*G%*]&FW96NW'5OS?5ETGOZA1117R!H%%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!__T?W\HHHH **** "BBB@
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MK6T)5&VS)****_-S<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAU+7YD5+*))7YD?LQD49%?DAXX^-OQ<\,:WI^G6'B:\N8I&4R$^62 <E@2$
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGZ'<6L+031O)),B,5,L,6 P "Y+ ,#D?CVC:.GCK7+G5=2D>U,9 5'._:H4
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M1VENR_-:W-A&ES)M]&B:-$)/KDD=.];<ZC[S,E6:;;9J+KUI;:K_ &*9 ET
M2J@[7 8;<Y[ 8SBM7P_HGB'5M173KITN;",3K>2R$?,CN-F23@C9NK9T[X1:
MQKNG6^K^+;V+3+D*CF<0A97C#9PPPFWOT)I^O?$3PKI:7.@>& LZVQ^SW5P7
M"!D8$;LJ6.1@XZ?6N6=2[N<];,(5?W:W.>N[BU,UQX.T,J+725$D+AU<[&8%
MG"+@D!Y"N17<Z#)8_P!I)IEZEL\]U$-A0J)Y8806 VY+;5R3R.,FO$KTV2:[
M=:=IEG(E[';J\<\<CE9XRZDQALY*Y.3QU7I7J+Z?:65YIOB[Q!%]EN%11&4<
MH8U?@!<;=ZG.#GM58FD_9J5RI49JFJ?8]8N9- TZ(H\:JLB[0KD9)/;I7GMU
MXCT[4+G^R-)O/](0?/$F0_'.%]3Z@=JY/XAZS<?8--UBQ%S<P/.0AM8EE8%<
MCY@2!CCU-?/=GK/B34/%Z7-NAM[W[K9'E*!S\Q*#[QZ8Q^->92I2;NV>I@<F
ME*/-)Z'TY9:MIKZX^C0:U&VHHAQ"IW%7["1P<1MG^]C!SQQ4&M:K/J-POAH1
M-'=CGSPI>,'KG>/EQVZ]?RK)T_PCHMCKD'B35]30W$Z;GC2-(LMC)9G4J6.3
MW%3>(;RSU;4K+2O#:2QK<-S<QDL JAB=V#]W(ZYZX%=L=#@Q,N6?(B'1HO#_
M ,.X-5NKF1M7OFS++!(<G;)E2P.#SP?RK/DU?P>0+Q;"6PCU79(S3@M'$J#!
M.=B@#YL]:9XIN[/QAIU[8:< VJ::(H)&55CDE6-R6!"<DD9Z^M=EI^I^'A81
M^'=7TS;<P6 ($B!E<;5^7+<[N1D8ZYK94[ZW)BT]&SE$U"5-+-Y</%82">2%
MFBF2>%4\K<LFV,\98X SG=CU KAM#U)=8UD_8]1E\S3H0B+-EC=76,1Y0X(,
MC#Y5//..:]*T[PUX3CM;F&XM97AC;S[?3DE<W$AX4 _.&8;LMR3P/:MN#PKI
M_AK3M8\1:OI,&CR7D$<MO(LC2/%<[69 PD"A9%8C &>:\NHDIZG<\SC&/)!7
M9E^%/#=_J&LV/B"X6"VN8 XOXP5WL=WRJQSU*@$9' XJUX@UGPU>!VO8#J"Z
M/)O9(U\QL@CK@-_=K!U:XN=(TJ]F$ACM+F%3YT+LUU+,0#ND0X" <@;7.1@X
MR>.@\,:)J%E:P:A:V*0C4$!G,P+%@PZX92,\FNZ\.7<X5#WN>1TN@-X3\96F
MZPB^RO>)M8%"LD8;@!<@$$]^*U-)^'7A#2%6^L+:)IX3EE>,"15/!.<#^5>7
M:K)J.@:I%IVFR^0UW(SK*L:KLY!''H-U=))XIO)I]0TJ\:XMI;.-?/N_+58I
M%)4A%;(RW(XP..]<U;#2:NI.QGB(-ZQ>YZQJ/B/P9IVHVJQ.%6[+"((?-#R2
M<+YFP<8)&,XKB_B3I*W^B2WVG,;:Z49,NPMC QD8Q\OKSUKPZUN D-_=:%<H
MLEY<JT,<S>;-$$?/"ONV\'L>WM7N/P]\<W_B;29M#UF&..2W?RI,HCE@><$%
M1PW7-2J$J:YKG)+"U(+GO<\<75[&UT5-0MK.;4)KBY87LL:,I=F506;Y3D'@
M#WK:?P3H/C/3+B&WM19+:J'C?Y5D3(.>2!]T^U;%YH&KVNL:I#H=VOD2MNMX
MC FS)P,$8(XZYYK%M;OQ// ^@3S?8KRUD*3W"PHL4JL3N .!Q^%>C%OE.R"<
MHV(/#7@KQ+:W:>)]+NU,"QLD;I<(JLP.TY7=GL:\WN+_ ,=O/?7>I7-E%:6$
MXD:T6SD5+M"W1IC(8]QQ@9')/ KW74->\2Z2+#3_  ;;6\L#ALC8KKO^8MUC
M;&0/SKKO#5II/BOP\I\3Z;'9W<H3$9&T.#]T%0% .<\@$CJ.:NGB>7<P<ZE-
MVDM#YQN==N?M_P#:%JUX8M7T^54M(=\:)-'Y:+&C[2HSS@XKU'2[^^UVZ:WB
MLY+0Q!9))3G,N3@J6P,XQFL[Q!H&E>$_B1I-EJ(E>QFDC:.-<B) =A*AMP/?
MK77:.3H7B!/"M]>I>7K[COC50F%!;#8Q@X'3'I656LI7L;SQ,.6\=SL4TR%+
M%H2$>/YG)D95.3Z$UR4/VJ/4+JZC97ALUVA-X#[& ^4MG^\V1QT_.NFU])KN
M".UL@!-*Z1HI)&68XP,=2?2O/-9UGS;ZW\&V=P!<M&?M5PD:;&8,3C</FW ;
M5(XZ5P4+J5R*<W/23/.?!&D68N-;T;[<+V>ZFW7,<7 BP<JF[D-A@>17W'\#
MH1;SQ6Z\"(*HS_L\5\\:-#X>\-7$BQVBF;DRRHH_A'.YNI/7K7T;\%IH[B_\
M^+[DC;E^AY%<N<59245(\S.'+EBFC[MM/]0OTJS5:T_U"_2K->$>"%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!_]7]_**** "BBB@ HHHH *\/_:12-_@=
MXQ26XDM$-BV98N73YEY7@\_@:]PKQWX_2PP_!WQ5+<1F6-;-MR@9)&X=JVP_
M\2/JC?"_Q8W[H_#N."Q2*U\1:;.->OHK;R1/-E'(!8\AMF/O=2!7HUGI.JV"
M:-?7][Y,GB"W!4F1'V<)D+MS]W=BO.-/M=(TC3M236)DTHW#_9XX;MQ#--T.
M(XWP2PSD@=!STKJDO]*\41^'-&T>VEC/AN*6,W$L96-3N0 ASP1\F2<U][=M
M'VTW%-I'I7A;Q+%I-M>7'BG5Y-3#@QQJP^XV1C'R^F:QECD3PSX@F@0J'@BA
MC\KERDF]0<<\G/S?TK'L8=/M=06SUF\74[VYD+10BU$*+A.,G<PSQZ<YIOAK
MQ9JVEW]_X@\3:-/I6DVDBJ 5;8Q)(C4@JH/S$ _6N.,.5W/&<G&Z/)M5BOM>
MBLM1T6>]L[W2@;9 RDQ[>DORJNXY=!WKN?!>A^+?"R:Q$8X[6:]LVMK6W1E4
MM(,L9_F8_>!VXZC&3Q75^+8+V]BEUS0M36RL+]/-M7B/DE+AL$@A6' ^<'IS
M5'3/$=EXG,_CQSB\LHI(H$+>;%&2A&<< L-Q)]J[%-RBPIJ+]3*\$^&-<U/1
M9-3UO?IFK^%K>(J]Y)'+ 974F23;$=S?-&"I!P.^>*K)K^LC4M,T\VWVF]FM
MWFPCHS!Q(R@%U.PY7GCH#@\YJA:^)]0\,:7:MK<H\76WBQ)TRG[G[)+@!D&/
M,WQDR8V_*%"XYSQI>'- LH] $6A6]UH\S.3$]P[>=&F<L$=@K#+9Z=C34Y*%
MF;TH-NU[&YK7AH)J&A--IZ6W]JW4MU?M*X+!D"/& 5;'W@<9S7*_%3XI>(XX
M_P"SK4MX4;3V*^9< W D4#]T08,ATD3YRJY8< X8$5V\UEJWCAKC[+&^H_V8
M6"!92H>./YE=B V3P<^M+]@@^(7A?4/#VI:0)KRRB<PLXPUN8P4)B)7+')!(
M&.:X:&(Y)WDQ8W!*&LG=G*?#_P +>(_!\-G:6=W%J=KKD\POW1'6+88&((#$
M$%613SD5AQR>(/"'Q'32-'DCN-!5(9;N4,K^9&O+_,AP3&,]!W[UWG@"P\86
M?@BWUS3;X:AIL%K-&;8/YIE1F=7DWY.6 )7&.@ZU\^:->>*5:_\ L>EH/#M^
M;BVM7,GV8V[\J0TNTY)R-PXSCFO052,KZ[G%"49)KH?0_A?3+*RTR[UC28&2
MZ\23/J!6<$ ?96:U5.W#@!^M>B0^,M=\&_#%8[62R'BBX7S$M(W&"NU.!\Y]
M&_BKA_!6IZO!X >/Q%(NI:CYX33BG[Q9D56!2+KN"D8;;_$#D9KRKPE!X6\3
M:IIVM74AAU..V\F":1MHD$:LS!(S]]B&.2#QD>E<DL-&^KN;86C[6HJ21)?Z
MUK0U2QU6QTQ?[?UJ:&74L$;(D0?-@[NIW<<GI7T'X/\ "NG:]HOEZC=LH16+
M+&RJ_P![@#<#QD].N>>E9WA?PA97T]QN5ENKM&\D,>2$.&;!^]@D?[N<=ZJ^
M%O"5YKM]J'A2VU%[*\TK-P9CD%E^4;2=PX^;IFLJB]ZT=$>]5@X1]E#2QYK<
M>&H;?Q)<6.DE[C8K1W$<REFVKN +,H"YZ\],\GBM'PYK%S [6'BCPQ$EM$2\
M21*P+;#M!W%F !!R<XYKJ?#US/H&MZMX@NKEKMI6>UFA"DQ.#N7>6R0,;R2<
M=NM>EK,?%&A+<6H1(1E&@*@OM!.3YO7&1PN/Y4GB5!JRN92J;02^9\MK+JEZ
MEMK5OML6M)LM;2CS#\N#\K(=H_.KVL^*M4TZY?7Y'AU!KB=9MDH)2%7RX!*E
M>0.#SVKJ?$^G6>BQWFGJC,IV,B6K>9("7 .0O/('-<F/"TNH'2X98)[:R6[6
M2\@EC.ZXB+YV-&<85ES\QS@'H<UZ5)QG!]&5BZ:4.=O4_0;7-4T@^$UUNXNX
M6L7@4*_6)2?EVJH^8G=]>]?GYH]_H%OKTNFV<BKJ"7)@N@\$ODDQGE4.T +R
M<Y8\5GW]MXCTC0[N'^W8?L]C*&M+(W@O+;YR!EHR0L;#<V!C/3UK.USX@WUA
M"_@V'18Y=8G4*TZN!(S2?*\IPA/S8RW/ ')K/ 8&I%:RN?'X>$5)OJ;>K^'M
M3^'VK1WRV<DK:[=YA:PY$4#!F=FSNQDE<5H>(/"/AA/%D%CJFEVMLKPRN)8\
MR2O.B.S<HS!?E Y8 5K_  W\83:U)IG@W4TOFO86*$VC22*0I((>=>@'&%/3
MIVJGXP^)WAG3=13P5X+L[==2M[A8&NKZ!6=@&!.Z=QG#C*=><X[XJZM:I&:C
M%'=54FMCE/ 6C6C3ZN]_"-2LYXP]NLTB%X8HPQ9,@@#(('/I7T#INEZ3XFT9
M[OP5K4ME):G=]A+*!Q\IPVT#^+/6O)M:\6^!4UFW\/>-=!@T:]FE-M)_8\JV
M\;+=L%227RD49;!* ^^#7J&I_""VM-%C_P"%>:D]G))CR+K<71USE@ZA@"<@
MC)/:LL=4E.W,K6.=3Y=T<SX5B2'6;K3M#MWO]<L5?S#,Z[4D<,K GY0>G&#7
MIUI\-]/T^5?$$%T='U"[56O2G3S, _*<$>O<TFJ> ;'1]';7;368;#4+LB:]
MN/EMUED4AF7=N&W//.3UKPW7KW7-4DTK2=<\4M96T=YYSW%O,9XIDW'RH,AU
M&YHVZ9.[:3BN>5+VCO"5D"BI:W/H36]'\(:CI3Z?XAU-7:X/V=W0@.CC]X#T
M/;':HM*?P!8""STZ\%R^GQPVK/(0=RH-H)PH]*^??%'PO\;3:LP\/.E[9ZJP
MD$OVG>B2JN"3*,A!M3&/4^];DO@*S\->'K>QN;F--0G=7OI(G#E%_BY!^;&3
MCUJ/JVO(G<SA%2T1^K'[.&D:-I'A.Z.CHJ+=S&1V7HQR1G^E>XZZI_L:]5@,
M-$_'X=#7RY^QS?W=[\-II)W\RVCF=(&*;245V!/?/(KZIUK;_9ER7SM\MLX]
M,5\I5BXU[,YK6F?B]XML[30/'>IZQ-IMM>V?VBYFFM9$<K))')\A&",$ MU]
M:T[G6O@E?>']EKX7CM;N9A+) J.?-;..<9Z  ]>U9'C2QTN;7]2M+_5KN.WE
MU/4+B:83NIBBAN&&P'/<-PN1T]JX;PQX)AA\57.M6FKS;+E3Y$<]TTRQ$ ?,
M=QZ$ C&!@G-?7TU:"/?E1C4Y3M9VT/3;8ZA?6L$4=PSN (Y&*V9QMB;&<':2
M/QKM?"'B;P1I&L72Z/9M92SPJ[-Y;>65 48^[WX[UY]=VVH2V5RNP/@$LF=Z
M,>P)Z&N6OM4N[J0:7XB7^Q([62+%S;W67DS'D0R1@*?+(.3EB,J./365/GB=
MV*P=)11Z?XH^(\VH71@M 197*%A!"=^=F6R2N0.G?TK@K?4])_LN7Q;/O@2?
M$?EX^5W&1SQ['OWKOK/^R_"_ANWBT^QMEU8*ZB,*J/+A<MMP,D[<Y [5B:+I
MFJ7GA?4+;7[*.."]BDEMXWA&VW>4,RG:1@%=W7BL\/.,DU;8FC2CLE<Y?QKK
M@U"\T.2UC=)81Y\DQX&P;T$*\#.20W>O:QX0O?%7@6VUG5[9[F6]D=UC0@^2
MH",5QSQSQ_6O#I[G4+F32]ENFJ:=X:W1787_ %DDK[Y%;: Q("R*,\],5]*^
M#_B59VOAZUN=*\Q?/DR8),IY8&TC.>@&?3BN7&S;@K%U'46D$>$>)K6'X;Z*
M=.M[B:.XNWW(D@XCW MCH/[U8\%POA>ZCU/7%5[W4E%O'(%9@%7YRWRY]37H
M_P 8=4O]8M%\0W]I816D4ZYFGF25'C*G=EF4!2,<=>*B\=:;?6FLZ'+IEI!-
M;1DA4(5H7+*065L8*X/! ZBJPL_W>J.^CF%3DY+Z]BCX@NC<:?:K_9,.JP3Q
M'9<'*;64#NS+Z^E7K(^-+K3SX4\/I%HX*@"8?,H)Q(1N#$8(_6O1O$.C:?J/
M@@Z)<*-/DCC\]1%T.Y<MMQC"_2O/]&UQ=5T[['X8E%S';J81&#M+2(<DL1G(
M^M8^TYI6V.*I+FU:-G1++P?X=#:;JURKZ@%4S[?O2D9&0<$9)!K,@\*ZSX>?
M6_$.ANBVCVTL]F+MAS,Q#JK<KA>O7'UK0\,7FA:A"VI>(M-LH-:LXU^UL=CP
MQR\[AO*@*X.>.O2LKQ5K6E:EX=U&..^EF#R*85E),!PK@H%)VM&3C/8X%9T^
M?G<3E:YU9*S);:*SL_&%]KU[<)"&L/L;QQ(_FBZ9MRN3R&P"O*C''L:\]U:+
MQCJ.E1^![V(7!N-0BD>4''F+YG$DF6^8X.6VX^E>T>!+&36-*35=6CAEO&W;
M2FU@4' (/YC%8WC_ $'Q$TD&OZ$ZJNFA3-&C8<G@HH YPVT@CO2G%2ERO0UP
M_+!OF6MC%U>+4/!<=BVI::+WR8S RH04!9MZN!G((48R3CFO1=6\?6&E:=IU
MY!:M/!,<,5'W,;>#^=96AZ@GBG3(8O&D,MGJT$@DCA0%?M-N 5*R=-PR1P0>
M@KD?LGB>6_MM"@BM[.TMKJ0F&8J?MEK&%;S$SC# *20 V0 ,T1A%^[82KJ3]
M]6-GXCRZ3XIT'37O&>PMKIF:-D_UP<8"L.#P,GG&!Q63#X2U/Q*++7?#>K*L
M6GI]FC5^(YD#%C(<X.<L5QP>.F*Z&/P]+XIU\_:"$TVWB>*%<;F4/M#!?13M
MX XQBN\T_P %#2M!B\/Z>K16T9+%S%LP22>&[<T8JHZ=HH>,3IVL>'>/[76[
M[78+.YTV.UTZ2 I+<1\-Y@SR,L>IQVKR?P[XX.B7=W;SHR7NG*RQJ>4GC+ Y
M)'&>G<<=J^J/B#J<-OX>AL(HOML\$.QB1N??@#<3R<Y&<UX=K_@30+1]'OM1
MGW-<+B95?RMKL2R[B"<\#O5N3<4F>_EU2G4IVFK'9ZKXD\4RMIVHZ#"L?FP-
M(YSCG#<$$@]A63(?&WCF*SMM9L8=/$0\QKE77YCQR1O8^_2MS3+6[UC79K&Z
MF^SQ)%E!&NW@Y'W@:Z,>$FETVYTMKJ0JP(5@Y! P1@'/O74YJ+Y#SZM**E>+
M/$?$&@^*/#$$<PNXM1G)5HOL^2^"^T[N2.!GT[5[+X.;18M?U>.*6Z:668E1
M,R^6BQEBH V@\_6L?3-"A\(W]G'))F&2)F:61LMM+$9+'_:XW?A6)XAAD\)S
MS:SJ-^IG,2RP+NP)$!)&3GG/][O4.GSNR)QDN=*)T/QB?1U;1&OI72_DG7R\
M]",<=OIWKO#I5I<^++V_-FJE@I24$9+]SU]*\CU#5=/^*'AC2\K$VK6=RGWG
M#-&C;L')&0.%KU#P]?B6]N)DN4NXRVU3'@J.!T()%36@HJUSS5AXK3J8>MZQ
MXCTW7YG@L4DMXHV6W<L 1<@?NV^\.C<]*T?#VBV45N^KRQ^3<J2)5'S$2/\
M.7XSQSBL/QI:ZY9:A]K:2-K-<L?-?8H)Y&2>!]:W=(O+ZT:22:*6>WFVY=(R
M8^57CS1PW^[Z<UAIW%&FXO1GGUQX9ETR75/$][>^?&6+_9]C.74').%&>A_2
MOK/X#S1W'V:XA79'*B,JX(P&&0,'D8]#7E7B&ULS:1ZQI%UY2P+NDQ\A?U!&
M>A'&*]<^",HFNHYAC]YAN.G/->;F51N*3/+S2I*2CS'WC:?ZA?I5FJUI_J%^
ME6:\@\<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH'3D=^65)U(<L59G/3PLG>1[CI_PXTC3=4L-3EN9)X;2)H7DE<J5@RSAE5
M3O.WD=*\)^,?C&UO]:3PQX?A/V=\I')@9R< EB3W[8%4M \6^,O%6DWE^E]:
M:K!)(T;IY+1.80H+1+OD/R]2#@C)]:Y^_P!5T/2Y;"]L-D4$)2(V[L"]NJ8
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$AE,R2)  X621@C*>> ,\GKS6YX[^ 5CHMI)<>#]=N;:SFD9[BT6SCO P?+
M*9I"4"9*Y7!YK%\2_"?4K'3#>0SK"L#O(S\.^Q0"AC*< Y!QD&O%=6MO%%O?
MG7EO[F&2W6.1[M02S1HHQ&X .<@#.!_#7%AJO.[H\G%9?*I\$K&_X5TFR\-1
MC6-%UR74+O2IC%?1W$*6JSPE0Q>.&-GC&-P&0!G:>:OW/P]/C;QF=;\-+YMC
MJ4*SDDL(MS#<%(7*Y7..*ZGPAJVO^*/"&RU-I#KT4FP3HCJ6B5@[<,W=25^M
M>A>&[?5M+\2V&H&RN9'U!_(6!70(H! \P^WS9ZUMB<3R'G8JG/"KG;/NG]D3
M1M9T+X=?8]7@6&599 H7(&!(V,DJ#TKZ?UJ(SZ7<Q(?FDB?:>P^6O./@["+;
MP\\9&"&Y'N2<UZ=J:[M.N8P/F>-@,>I%?%XBO>K<\QU.>:F?A]\1;O4/"WQ'
MNK#3K>?5&OKZYDN&C!>*,1R]&SG!.\XX[&M>ST[XFZJPG+-#;7!+,8D\S"JO
M .54 [@,D=ORKJOCEX^L?A5XD^RZ/!%+J=]=31BXVM*T=Q*VZ-?W?3))SGH1
MSBOF\>(_B!X@\47^FW^K74ZPA0D5Y/#%#YK!3PK;&*[6XYZ]Z^GPM:I*":6A
M]AAU*5-.YZ!;:9\1;"8DI91S7[O/"A<R8E?F0H'BY7IM'0],"N]AO?'[7MYX
M?\::T;<W)A>%[=SG<(@ I7$>W@GIFOG7Q-87X6>?5-;.EQ>'9+5-0T]8998"
MR2XC,7EACE64_-N*\ GC.?J7PC?^&_B+HUIK]G,-42+%O+>2H\31[00"3($!
M5=NW@&JQ=:<:;;1QIN-5.3NB+P3!K/A7PWXP\7W5K+>:K;NUG#')N>2.1P@:
M02/EE0*^=H&,@\<DUXS\/=%76-+O8[W6HKS5]$NDU)Q*JR%Y2TDK0Q%LG#MP
M3@8P,"NP\/ZSXE2:]T2\@@N--U4>5))"VY9)(_G4D!B1DA020.*XG^V/"FGW
M<6A^%-*DL=7%Y]FU\6$,J,T!<J&#2*RLRKNVE25YSC&*BA4O[S-,7A%17-#J
M=SX2\.>--5O8O[<L['PU#=,ZW DD9T*#)6)X'B6.,-A7RO).#U8FMSQ+X?UO
M2)8M*T_2K=[>XACM+-K5VS#%.3%<O(0@.%B((.3C!/'6L?Q?\1Y_"/V7PS!I
MZ7&B!!-#/*&^TR*V5RZY!XE.W&P' STYH\::U!!X2\.67B738-4\6B&8Q6D9
M+1PW%NB/*L;ABJD''RLY)P .:VDZJ?,MCSXOWHW.I^%^G>(]+G\2^ 9%?3M*
MTNV\R*>2%=C2RC?D.1N</N9OF//I46J"&'Q5K]SJSQ7NERJNZT=MKAE.1M '
M!S@Y!!KT'X,6=QIVA7/B_P 51/9R7J12>3<$;AY:L,+CL!P,]L5X0=,TZ'6E
M\1V18:=K\,GVDJK&5'568R$XQD@ <#D<#FN6C+GJZFM&#YI'?_#OPG=ZY?R:
MW+;)IUI&_F6X$CDJ(SE%(P S$8Y));O3="/AC2M7U+5/)FL]0@D=9'FXC*G'
M(!8J,Y]!7F.FQ^+-.\.WGB#P_JKRZ5(LMM&SD(WE8*APC;6!C'(!'/8&N]TG
M5?#^NZ-:Z9K$\]])>RBTD)&T^8(S,#\RCC:O7IGC.>*VJT_,[,-)V<;Z&OXL
MTW0K."P\3Z7-+&]IM>**S=@LJN0%!C5E0C\#6!XQNKNR\5Z%XL\-V#QS2+!)
M+C*.SA4+*Q&<?-GZ>E9MM/HMNPTRTEELY[81?9V1T9F2!BP0D @$XQSCK5^?
MP];1:$@UF_DE77)IF=G=2P5W8F/@=1NQGIQ649/X3LIT7*-I'IWCZ6QTKP]?
MWEXRP07*KL"QIO5<C)$9PIY!YS7A]JTFIZ=X8U30[B6VM4N)A+)L!E;88]G[
MC)C96YWY/ [&K6A#2UT%O#VFO+<E<J+%@0AC)SN8D#/S=@V>^,5<UN\MM)\-
M6G@\:5#%JEVDL*Q(K'8L@"J002._K3DN570Y048>S9>F>YMXKA[.]DL=-GC9
M5FGA0.UR6^\A).0!N&S=CVX%;FCV/CN/0YM$D@GU6X:3R/.5,[%&!G;C ZFN
MRTS0K;6_ 6GVOBFW1;B ^6RCA6P6VMCD[@N!G.,9XKS&X_LOX?\ BFXU&.\\
M][O!PH8 ,68="/>L?;"BVMCD-1UC6/ ^KS>$M:1C/>R(I*PIOCB;)+-"0%8
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M2M>SNETV_P""BH54W:Q[]1117R)H%%%% !1110 4444 %%%% !1110 4444
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MYGZ'J_\ P34M(+;]C'P%+"@5[I]6DD('WF&IW2 G_@*@?A7QQX M+>7_ (+
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MH'&1_P ([J!_$0L1^M?.7_!*X_\ &)6G?]A;4O\ T8M?6?[1_A'Q#X]^ GQ
M\%>$[7[=K.MZ+>VEG!O2+S9Y8F5$WR,J+DG&68 =S7B?[ 7PC^(7P3_9WLO
MOQ.TK^QM<BU&]G:W\^"XQ',X*'?;R21\@=-V1WKX##8RDN&ZU!S7.ZL7RW5[
M<KUMO;S-VO?OY'VM1117PAJ%%%% !1110 4444 %%%% !1110 4444 %%%%
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MYDM)T2&148J@<<[CM49.>M;>GZ#XD\/>'[SPW>6:+<73[(X[B17*0# BASD
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MG\'>.O#.G#Q!;-M( &-PRK#^':?EPN>?;UJ/PQ//J_BL1YOK;4M6M&AOHX!
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MEK'?P3PI<0RO:H;:XC>.0%"ZP%)(PW#$<'Y21]CZUXC_ ."8>C^ )?B*NE^
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MZM(9;B&_-C81*)82D,F8T8;CD;3_ "JU#6QI&:3N>B?V;)<7KZAX?;['-/\
M.T3#:[,!MSGDXP.G2LFR\-^.8KC4)9+ES;7,MN4V@B561R6"L!DCD9&<'H>#
M6(WA7Q/JU[I4,S+J%M;ONDO(B&E&58A60'<.HZKZ5U_B^_U3PA/I\EKI?VA0
M9"#T8E]J@\D8QUY''>LJT-7$Z'64E8]4T>6UU 75BUSYNJ:; JRROA)$CD4,
M> 3G& .?2FW=EH>C:8+WQ':QW%W<HS&1%"K*RC(SC R<8SBO,9?%MSH>@+JS
M6T]U'JVZ&2 8)#/DG.!D@$$#VKI-,^WZQIVHZ%&EE>Z) %$$<6Y9,Y!Q('?J
MO7H*\Z>':]YGF2IOGNSC;G6])\1Z)-K-W:2V+VNZ&"(DDCLN%R PX&0>*PKW
MPKH,NF6S6VJ"U2:+S!:*=CRR>8<R* P]P0..#6UJLEYX71KLZ;');00F&)G'
MS>:PPJ+@\!R,$D<=R*JV[7%WH]_?:Q"B7$C(8,*?DBVKD*>0,-GK[UUQCH=L
M;.21Z)XSDUJ[\.%M!G O0LEQ%N8LFS:#M7(;<<*>2,]*\BU.:"STFWOM20-+
M>1*MR+?YI(W*_,\B_+A<YYKI]%\76/B31+SP_:J6+'R@V#@M(-K/S_#C''6H
MO#7PZ\/VGB#5[!5N)Q;V\"DLRB%GD0$^5E0=P.1DDBB@KNQU5:_+)Q'V=SKE
M[J5K8Z&IDTNWMS]J94!92I9\=#R?EZD<&N$U:\U7Q7XRT[[%8W$5K9%E.X$[
M@I7(]LXXYJ_;ZO!?^,F\ 6UU;Q-J""?S((Y%E:*+YMQD;,9)9-A YQV[T_7)
M;WPIXUB$DJQ6MZF+= "TKS_PHK+E5Y(!+#'O6D)+V@4J]W8Q-3T^W?5D6_U)
MM()5D*R?(WWN">1CC\^M=5'H^C:)=H+C4)GBN'2(B5V5&WMM=E;>3]T\#C!Z
M8ZUTCQ:QXCTJVTB_:"6-Y3]HLY2,;SN*C(8 DKSP:\O\3:QINJZU#I-I>/::
M?#$YFC)!C22(,Y' R.@'-;1KINQZ-/#J1Z'_ &9I6G>+$DM+ORK6V0&&.X;S
M"R#;D[G+$ \$8SP:X/P]J5Y?7.NC2;N\U">%M\.(P0N[8A$9#'. 2>W>HY+-
M-?L=.O=&TG^T&3]QYB2(!(C8 /)!XVUT]]I<%AH0\$P:0//OG59@9$!15839
M!W 'E .,U-69E*IR-I=# GN;^6^TG1M-U*33[NSCB6YDD8E6D7_6%F))+-@Y
MR*]X\5^(-*2U@\/DBX>:  E\>7+D#<4Y.>>O YK%^$>GZ':Z]KVE"'?/<S&1
MS*RM,H)?AG'R8X/;UKE?B%KUKXEU,:5I\'EW$9-N73E[6,=2IZ-N(#<9ZUQ0
MF^8X?:.K)Q9S4L&CV'@.Q?PI/&DEO?EY("JM+,I5 0N=Q '7(KT2]\9:#>>'
M)#KUB;9;5,S13@!GC .$!)SRHZURVHVD&EZU_HT<NK7$4$5M]E\V,(OE2&02
M=LG)P>>W2M_1/&T<<K-XQTU(T,\BIYP)W3;SL7 /*CD9Z8[UU25E=#E*H_=I
MD?B/4=%32H_#VG1>;<W$0N+>W+%H)1OVX4DGD#/1>QJ31/&,.@:E!X4N%^RW
M8M5D:-2%CP%;.WH25VG.0,<5IR:S8>)6O([WQ"+-A$6CM;(?-!@@9!*N-QY[
M]#TKR.UF\*/-:Z='IMW?:C=%+=Y-2DC+R#."^5" [MQK/V+EJ<M.O+6,MST;
MQWXEN;G2[6&UO!8QWCE5DE; ?J#@G/?TKC=/\0:A'=/IEG.+1.=\B'SFDR,#
M!<97GT-'B?1/[=OXX;*!K>TTR,0Q0IP$EPH+#.<_,IZ>M7-!\+^-[/P]=Z7:
M7]P;B5LLVZ-=R\8R" >W:NA1Y4>YAJT(T_>,U=)\1:VM[I[WYM()(GC8RQ@E
MV (5SGKMY."<'/-=G9:'J-Q-:R274=U!#&L9:10<A1M^Z01C/:M?0?"%ZMC;
M0W+@RI@3..,OQG.>N3GI7HKV,.F6)DWIM'W5'?UX'OS7#6KVV/-KUJ=[I'(7
M<&CV3FUN8$N 648*C'RMUKZ5^"?E_;%\I=J9&T#H!V%?$.MZU?:S?R:5IR.E
MW)&29"I$8?D_>/R]O6OM+X!)/%'9Q71W3)'&'([L%&?UKS\QI-1C+N>)FS3C
M%H^^[3_4+]*LU6M/]0OTJS7E'AA1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?_5_?RBBB@ HHHH **** "O$?VCL?\ "D?&&8S+_H3?*.I^9:]NKQ?]H>Y:
MS^"_BVZ1=S1V3$#U^9:UH?''U1K15YQ3[GXQ:CX8:*P&F:$[QW4X#,F2#COQ
M^%8/]@W=K?6$MTZH4(189E$J+," K ,0%;()SC-2Z-XO%]XKBN[R +:XP\@R
M".#T&<=Z^@[>+1M9M/MEHWGVP<LB/P=R$@-D<_K7U\\7.&S/I958P]Q'S;;"
M]TF6>TAC:XM$1IDGD<RR+*3@@9Y48SWK+\#:!!XE22>\N69FG6ZD!YPT1\SN
M?45[5-X6L=(%]KCH7>1<.2QR5R. .G45YOI][<Z?-Y^F6(C@O&8N2?NJPP?X
MNF#54L7*<;MF]&$>1TT]&='8>,0OB6ULHX#>:<C-!<L?E"(3]_."#C;C\>M7
M]:\"W%K.GBCP*3]CD+=!Y>>/O<=<YQFJ6E:9/.7O]$'E_: T<B-@JXW<XSDC
MD>U5M*\6:SX4O+FSM)5DLX 1)$XSA7&W ./?UKGJ*3ZF"H>QE>)C/:6/B'6[
M"U\5F:U:+#L.8<G@\OWJ#Q#HE[8>-9FL;MFLV53%&Q_=@[1TYQZFNNMM7T+7
MWN?#-T7NM,U") UO& KH[@@@.<-D9_O8K*M](O-7\-7EA9V1MY--/F6Z[L@D
M,%VLQ9B1M8GKU]JZ:=62C:YS/%3]K>43.'AG5KVV.K:W:@F-V5&$>\;8P&Z?
MC7M_@KXH^&6L8?!FH6-R[3+MC=(V:' .UA$ ,*^6^X.6.3VK@_#GBBTGTZ+P
MWXC5XE7]X0H&#@#'.<]5KE/%"PWVHNEN#<6KKM4GY&5  -HVXZ^O7CK7)'FE
M/E;T-<4U67.E8N:QHOA#Q3K1TN;59M6MKY]]O;6V5AS&N[YPK,O53G(K!\<^
M!_ /A71+:]U32K=KIY?,%M%"C7!VD$E6 W=_2K/A7XC>'=6O9_#WB!;R'4[7
M,>;:*()(@ DW9)X;!V\8&!ZY-=;XN^,VF:-IVG6/A[0GN#(5@$M\HVH(]JE@
M8Y,[CG/((R*NI!TYJ,7N>52KU(/E7Y'8_#S1]8T/X>6P\,+-)97C/(JEV62$
MEW.W'4#U'&3S7.^,=6\0:[H^DZ5XTL;S3KQ[E3;+;1O=LIC:-RLH 0J'QM8'
MMG.>E>?>*/B=K5]=6ZZ#:0^:VQYC^\4 JNT$#=CI[59TSPAX>U"5?$VNW%V^
MJM<07;7#OA88FD!V1(AP2^&4;E.,C)'4.6'BI\TV14H56_:7+^BZO8:+K5]?
M6L_GW5C)^]C9]ACD))""+G&""/;%>GZ_XSL[S2TGNRRFW *@=F8X_P#9J\&U
MOPEXVA\=W^I:1#_:'A[4KB"ZMIGV!D,(.Z*4+M.27P< _=X/K[?#X=O+KQL-
M&EL95TI[1;B5B4\Q9MVW PQ&S@>^?:L<>J7\2!V4<9*2_>;G()<66@V"?V[:
M7KV'B$"*:X2W=4C$GRX9NC;M^,DC-0_$34K30[_PWJ'AV[N9M'MRL5X C2H]
MO@DJ8P<9#!>>>GO7N_CJ_P!%TCPYMO[8SQQNAB5LC#JR[.A'0XKY@TZ#Q!XY
M\43V* -:R86-0 !&<#\?7KFLL*HSBYRZ%573:YIO0]%TO7O!FK/)X@2TCQ=3
M2S)&D*P29GC$,F[ )^Y[5S6B:MINCW6M:#=O%;Z- H_LX+B*64D,3$K=6/0
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M7,S[JM/]0OTJS5:T_P!0OTJS7GF 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGID\7D3& JZ1\YR-O ;C^=:R_"[2OA!\/KQ_#DGFO 'N3&"LAFEVJ.0F,LV
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M/!^Y[4GPM\;6WB'XDR>&[V)0LT4T@:,-U$J@ [CZ'M2Z]XG_ +-G32A;!S+
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MBV,?F&-N[)'*\8S43;<FC3"59113U;QF+354M[>U+PQ,'D9B0Y'7Y,-C'/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<=C] ^%?C-XH^/?_  36\:>/O&8$FO'PUX@M+R9(Q$D[VL4R"957Y1N0*7P
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M9<@#.20 >M?1?4X4Z7,M7YBIRDI.#6AIVOP+7P['J.N>&-0BM]=E8J9)4DD
MMANPL:IZC;UR>!7HWPV\.>)_#FC3GQ]K5LL;R%K>ZE0I/SM'EI&,'!PW)0]3
MS5KP1XF\1Z9X,AU_QK;00ZAJ#2+91&013[ QP-Q&[IL[5\_0^,/%7Q*U^UM_
M$.F3?:(<B+?,UPQV,Q&"5&.":XZ4:LW96L2Z45.Y[-'X:TW7?C!;ZS%<JL5L
MNUK7=EHSE]K-Z9/KZ5Z3\;='U36O"]A:^'YUM[JSERTBC=O7#<$<X'(YXZ=:
M^+?&VKZY\-/BNEYI]C=LOB=Q'<AI'WR2%V!C7Y<C9YGZ]!7U]X"TOQ#-J?B:
M)C<I&EG$ULM[([AG=(F*X?' )/Y5%7#RHR53FV+K3]VT3YF_X6M-)XOUK3K]
M#?16+I')M "'+  M@#N>U>Y>"/%_B75--U35[O18K>#3Y0EE(X)#Q O\V%;/
M 5>U?.UM#XBTB7_A'?$7A6)+O7B!)?6:# "'<&8JG^SW:OI.Z\8CX;:%H?AR
M6'^T;C75^R0!NBJN$8GAN<L*Z,3B[P4EN71G)1L9'PNM-'OHM?\ BEK,4<*6
MC?9Q(I8 R_)R%R3]TX]*]&UC4)YM)L=>\-DZE%"X C4A")&*X)#;20.#^%9V
MN2:!X)^&4I?34E@GDRMLH'S,S<EQMY&>F1Z5;\(^+=*@TFUM;N*VM6D1G2-0
M@F7Y1N9A@'9Z=N#7@8FE*?OO<X*U>SY3-^('BCQ=HOA.WNM(M7-_=2*7VJ'V
M J2QP/0XKRV[L-*\4ZQHWB/Q5JX3Q%H.GO&FF.A5))F$H#$A><;^,-U%>F^&
MOB1XC\7^(KS0'LXX;"S\PQ2Q*,81@@$F ,A\[AD]N]>!_&GX9:UI7Q!M_%\>
ML/-%J#;O+4GS+0C<=J?,3CTP%Y->GE<DFKG'5V;/1_"WBKQ;KFAMIFKQ1V]W
M;*8+L31.A>%AM(B.0. #SSVKH[#0+*34-*N]4U"T6;3HV.$)69T+-@%22,?-
MV7/'I6QX=\3^&+W1K9-1U>&^O(+=24N"OGEHE&[.YBV<_?\ ?K7CNG6,?CC4
MM0O]'-G;,X"B>9D^T6P0KG:#AB#CKD?>Q]7BL-.+<NADM7<^DO$'A^XU:PD6
MVE\F&8E^!\P?@C(/.<XSQBN$U3PC&U@(-?G%Z=1,<%P2X7Y%4HHPFTCY16Y)
MX7\=ZKXML=;TG5U.D" SW4;-@G;N?.=W.?7'.,5%XK@T6*>PUN6\>[A$WSQ+
M;^0,YR>=S>9C!'0?K7ER:M9'94J77,3S^!?!&J6EG#XGM9)(K,J\=W;L0S[7
MR$<'=P"2> /K5:+1/$6@_%(:WX>DFNM-OA"L4H:+R%MR?WD+1L/,W*I #<?C
M4GA.^N_[-*(YDMV<L Y) !XX![5QUK\8])LO&EWX.LX)_P"V(LHBR(4B(8D!
MHR1@].HZ<5E:25T90IQDKL_;?X?[3X1T]D7RBR9('KD^N:[&7B&3C@*>GTK@
MOA=+=2^ =(DO5V3M#EL'=SN/?O7?R8V, 1T/'KQ7R]6+]J::W/RD\6> /A]8
M_%O5M:BMTDUC4+N4AI'8A2SY<[5(ZL1UKYP^/]OIFKW,5O/)"HL+I4$<Z2O&
MX:(@$>5AN"_<]J7XK:3\2KKX\^()[*:2"R@OKR2-E+8P)N!P1VKS_P )7'BS
MQ3XO;3/&L4CVUJ&=FD@, +#[O[TYSU%?2X7"\L%.74NI-MV/7_#>C-I6A:/I
MI82R6T$<3,#@'8H!(SZUSWC7QKJGAO4;72]!@BFFNT9 9@=BY.>6RHSQZUB?
M%6[M[ :=J2ZG<V<%FX9H[;=^] 9<J=K#MQSGK74Z;>^$O$?AZ#6-2VB%_N-<
M*!]TE3RW?-;<DK\ZV-8-)6,-_'6I)I6F3"W1+I]P=G!$0"J2<9(YQ[UZ!H%Y
M%XHTBVU%XE$NX[&SV!QGK["M1_"]EJOAT3V<4.H16K']T0IC#D ,1U'W3Z5P
M.H^.-!\)QOI]K9>8;&-3)'"NU8$VY!*J".GTJI5'/W8[CYH]3TR=XK&9(L>8
MY7+#T.?7ITJ#Q!;Q:W#=6@C$:7<+0D_[X(/\ZY;2O%$6LJUQ&G!(QSN["NTT
MR2*]=8[LF)<@9/'7\JXG>E*S6IW*M'D21YSX%^'=EH%OX@BU#9.NIP[78[@D
M:1 H">>#M[UH>$+#PG907-MX21(XY'#7(^<DR<#/S_0=.*I76K:VOQ,U?P$D
M3W>A:C8[TE&<#:L2O&>H.XR'OVZ>E^S\.Q>"6GNH89;J2ZP !G'!Z=ZJM77)
M=G%3=JG,SO;G5H-%M9]N0-@5B 3R0< <<GZ5Y1>>.38ZPLJP&Y@>/<4'RMC.
M,G.._M7;/*FKZ>]I>I/&\A5U1-P,1'\0(Z8_"JVL>!]"TO3X9=8NXK5'8*ES
M<SK&[2L"0OFMRWRY^7/;VK/GIM=2:N)=[(\T\>Z?IGB.YTG6/M A%U;A@&!
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MM<UZ:==8UL+:6<I7#8QOSZ+RW3VKUZQT73O$\,FA7=E]D:$Y9%'EIE<$ <
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M0\=V0QWE>1Q\QQAASGM4U,O7)>&IS.FF=]J\-UI/A^.**X-M*C;RV 5$7?&
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MYHY;A'.'E5I 3@[6^Z%/&1UYS4GBWX8^!?#D>FZOXFOCI^L0Y:.XB9@QDR<
MA5P1CL1CBMK1_&OAJ\U6]M],U4KJMOY<4L$9R5R6 !(]3N&:^6OC/XG7Q?;S
MZQJ>F7ELWARY6*-V;.]65B6(*9//3':N&E"O6DXO1;F<8-PM<^T3<QRVMOKG
MA[44NH;^)HFD"X_>H"V3E01U'2O%=-\:R:BUYHE^R2:M(9DLY94S'-+"Q1E!
M R"C%0,@"L;]GJZ63P=K&CKJW]HSPZB\I@D1E,.Z.)<88\]/O#C\J]&L?!^G
MZ1J[ZU;75T[?OO)MYY%:VMI;A@\CHH48RXSP?K7,U&G*TM3E5*3=KG+)/XIL
M].U"^,+QFV4-")-B[I<J#DQG=@*6(&>PK2^'_C _$GPYK'A3Q%<&=[:02Q7)
M78[$\A1M '!0=5SSU]/;-*BL];DFNVP608,AQR0 ,Y/Y5PUS+IVC7,F^1;<3
MS&88^;>[$9)V],\9)J*N-IO2$=1JFKZG.VNA6.@V<T%NS-.Y[DG/4Y].]>M7
M_B.2'1[/0M-9EFA0+(Y ^7!S@'KBN;N(UU&U.MPJ)@RD )S]S@\<GM7SO>7N
MO:]\0-VFR21VA+$;V,8"A2>C8HI4U4NI.QI4J622/9)H[K5=1$6FXDV,9))3
MPWF@Y'MR<]JXJ?QIJ%XNH6NF*[W>F3!%<JH1CM!;&>XW'MBO1=)GU#3=(GCC
M997N2-I"G<1SUYZ'/XUE:OX>BO=(^QAFMFDPQ\LA6)W;CBE2BH2LV3)MHPM.
MU_3_ !+HU_;:K+*YN RJ60!PCC!!P-N?I7W1^SY;PVEK86MOGRH88D3/7:J@
M#]*^5UUC4HX9;>VGEE&<,A8[5/H!Z5]9_ MF:2!G^\54GZXKSLSG=(PJ,^];
M3_4+]*LU6M/]0OTJS7D&04444 %%%% !7R)\//VQ/!'Q&_:(\3?LX:9HFHVN
MM>%_MGG7DWD_99/L4B1/LVN7^8N",J..N*^NZ_#;]ES_ )2F_%S_ +C_ /Z5
MP5]GPMDM#%8?&U*RNZ=-RCKUNOO,JDFFK'[DT5\+_M*?MR>%OV9/BOX6^'GC
M#0);G2]?LQ>W&J1W!!LXC+)$<6RPNTI^3/#KUQQUKY-U?_@JSXTT^./QC'\#
M-33P#/,(H=4N;F6$3*W0K+]E:WWD<A!(WIN[T9;X?YOBZ4*U"C>,E=-RBK[K
M2[6NFVX2K16C9^S5%?EAXP_X*?>&]272]+_9V\ :O\3-=O;)+V[MH8Y8_P"S
MPPYBD6&*=Y)$/#[0(QD8D;H/2/V3/V^O#_[2'B_4/ACXD\,3>"?&5C%+*EI+
M/Y\5PL!"S*K-'$Z3(3DQ,A^4$[C@@9XG@/-J.&EBJM!J,=7JKI=W&_-;SMY[
M JT6[7/T'HK\X_CE_P %&/!OP"^-VM?"+QAX6N9K72+%+I=1M[D.\\TULL\4
M"VYB 7<S!"[2@#[Q]*\<O?\ @I]\0_";:?XG^)/P UOP[X(U9T6WU&2:969'
M!8-&9[6&&5F4;E3S%R.0Q'-;83P\SBM3A5IT=)).-Y17,FKJUWJ[=-UU0.M%
M=3]?Z*\?M_C5X0UWX)7GQV\$S#7="BTB[U: *QB,RVD3N\3%@3&X9"C J2K
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M!-$9 T94=P0WD'[=_P"U5K'[56DZ-K7@SPUJ&D?#+PU>FVCO;Y$5KS5+J)F
M8(SHI2*)]J*[$ EG(W*H^AP618ZKQ7'-J3OAY:J=U9Q<;*.^]]+?,AS2I\O4
M_H^\"_\ (D>'O^P=:?\ HE:ZJN5\"C'@GP\#_P! ZT_]$K755_-N)_B2]6=R
M"BBBL "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"Q12_P#$RCHIZFO#_"?@G3O%?C27XAZ1JG^CS&69[>5W29+B56)@54&S8I(
M^8]3R:B&-J5(NH]T#M&7*<I9?!;1M=O-1TN_UBZGN;:3S80&9$3.2Q*;B&))
MKC;/X0>)?%.O:;INI,B6^F!8O,$F]E122/3DDXZU^@=IH%HENMVL*03",!RH
MYS@=2<YKR3PY\'[+0?B'_P )RVIW<JW6[S+<N#%R&P0N.Q(/7M6:SI0IS32O
M9FOL[V:/;_"?P]T3P%X9@MM/@#NQ,K[@"Q9L%B>I.3^57;[PKX=^(&@7&D^(
M;.WN;2YX9+B))4&T\?*W!.1U[5TDFHQ7TJ641(9%QNQQC%>%>+/BS!X/\41>
M'+*U>X5L;@JY.6!;^\*^=]O*:YGN=2=M"G<_"JW^'VB1?\([/<&&RD=X;9I&
M90&"J%!S@*0,8QBIOA?HNHW&JWNO:QHMI9'J+A(46612<E&<*#C@<Y[5[UHA
M_M6TEDU",_,N0K=AC-<Y>:M#9"6P@'RDD;<8%:4<?.:]E41+H._.F8LGBGP1
M?:K+X;DUFTN-2*[FM6G1IROH5)W9[].E9>J6&EW"&SOE%M9NCHBJ!D'&.!Q^
M-> ^-=-\(>#O%DGC>.V^R:Q=!5$I9F5BWR<#)QP/05SFMR_$S4;^&?PY?B**
M=$+B0*Q(['E6 7KMQ\Q_BYQ7J8;+N7WD]#">(4I<DCVC1M"U'PEJMRVG:H][
MI<J96%\X#'!Z%B/7M7.Z_P" _"7BG5HM9N-,AM[J.3S)#$BQM(Y.=S2 9))[
MG-;>B6>N3:-'8WLAEOPA+/P%+$\8P >_I7DO@O2O'MAK]RUY$ZR6Z.;EI7#1
MO)M8*5 )X#<]!]*UIQDI/D9M[-1V/2/BC\)]"U+2H-1C^UM,ML@B59FEB^6-
M05V] 00!GMS7S5K'PPOX]"AU3XCZNVBZ&C^7:)+.<-/SM5E9E R"3]*]L\?O
MXQ\<^!M-L/#\I&JVEV\9"ML4L68<X[$K6S\1?V>O%'Q=T?P^/$5X]I'I:"6Y
MM87 5KD&10XRIR-C+WZCI79A<PY:;A4M=.YR5*;;T/G+PMH6MW.E_P!AW6FQ
M:E:7E^5N;BS FC\N!D8QM(@("J">IQ@GBOJ^+QQX TO0GBM-2\B^A00P_.(D
M3;P0'S@XQC'%>@^$?AKH7A7P.OARW22.%_/>[F9OF!>-1*V>V0.,#Z5Y-J'P
MX\"VND2W-C)):VJLSQL,2,X!(8?.&ZMSV_I65;,*>+:C/IM8RAS03L=9K6C?
MVY+9ZA%J!GL95$K;7\T3*20,<XZCWJ/Q'K4O@[0VU>V2:VA@/D)%#(R_-*"1
MP!Q]WEL5J^&+>QAM[+1+3S6ATF$1))+@ \G!.WKR?2NMU+2/#]]IDG_"2A;B
M&3*!=S*I;!&1C'7M7EU:S4N5+0]%N*A='B_C7XF>$[KP=!XA\<7LT%EYH6$Q
M,?/CE (VQL""21DDC'!(K,TCQ)H?B>SM;+0K@O:7:*F,[08VZLR_Q2%3P#R"
M!S6CXZ^$FF:]%I%W-&DOAR*4L]NC'*2@. X[D<@?>[]*H>(/#^D^ M>T74--
M@6TT[9 95R2%C5OF;KUVG]*]>G3I^RM'XA0@[<_0[7Q'?^&/ 'A=KB9D@LH4
MR2,*SD=<CU)R:^;_  MJOA?7/B6+_0K<7L^H1,YE\X QX5B0(<'.0,$Y& ?:
MM3XU^(M#\;Z#9Z/I;S/!+J2@, !N3;)N_6N)C\ Z'X%^(<6JB\GTK2XK)Y#>
M,01#)(LD:?* V06V@_*>M>K@\/&-&5_B-56;?N['T_K/B:V^&NF_\))I&@&\
M66)A<2JVQ4=QU+A&SM.>.*\R^&OAS1KZ8^(M+LXY+J[WO*GFBX"'.W(;'H!V
MXSBN5\&Z=K7Q.\/ZOX7UKQ5_;XD8I&EHHA"PON"L3Y47..:W_#7P^E^!5S/K
M]YJZQ:7+$;6*U9GD?<[!]WW/53_%7/RP3M'<26MSI_B9>>,/#5QI5]X8M9)X
M$N52<P!LA@Z[,A0>A.3Z"N?UN7Q</'^F>)/#)N%G=$EOTBC8^>5$>4=E/ SD
M9(/TK-\":3XVMO&NLM?.]QH.HK]LCD=]VUV+E5 /(^ZO:OH33)-&T#0&U>XD
M+7EX[11A><N2W'/TJ9I4G;J.O&+7-U/D4ZY-KOQYLYM'L&FDTM?+:?:7" HS
M,2<<9#[>O>NR\9V.M:MXNEFE@NTLHI!(\RAVB$9;)4= " .F:].M[>VT*] M
MK)(;FZ.6< $L#ZG.>U:VOWDUJD=K!;"Z>[23*,<<J!Z$>M<;QMW9G'&"M=GZ
MV? V6SN/A?H36#,\'DX4OU.UB#G\:];<$HP^M>5?!>*V@^&6B"U3;'Y/*#/R
MDL=P&?>O5)\B)@IP2*^.Q#O5;1'70_%;XPW&DZ;\4=4T;6O*\V_U6X-K$[#]
M[(920JJ?O-\PX'->3^+6\*^";^&;Q#$D$\I4PKM!7<V1@1_WL GZ<UU/[3GB
M+2-$\=7%Y>6SW6JC5[E;210"8624@OR0,@[<=?I7/_#WPQ%=V/\ :_B:\?4-
M1OG) NU1UMP,890%[@;>_7\1].N7V$9,T:D]$==XIU>;1M%2_P!*C\XS1K*N
M!N.UL=?0XJ3P+J1\06,U_- T8B8*1NYR1GICBD^(][9Z6(;R[A,B1!HL1<(.
M@'&1W-/\(>(--;1II[;")(<G"XP1QS4.-Z3=/<Z</&SM(]'T[12M\=1:+$9R
MV<X/ KB/BQ8:9XS2.T>;E5QD?,%.T#D=Z[+POX@&H6DF) ZJK8X]J\0G\=:*
MWB5]$D8I.\C(#MXW!@N/Q)KSZ$9>T4I;E.S=I&CX&T?3?!MHUO:RDB23?(2-
MJ[L <C)QP!71_%+XBGP]X5EU_3M ;77C9<K"<#8&7>V\(^ %.<X[5RNO^'V\
M1RIHUK-)#.V)&,)PP0=2=PVX_6N"^)&A_$/Q/K6D^&?AU!<G1K!!:WM\#"+4
M)D*SL)#YI(4$\(?I7ISHJ=3GEU.>M:+M'8T?AG:7>N:U)\2HUGTY;A009+MF
MB,9(+H20H^0J%_#H*]%\.^#]>T"PLK%]0FU.VMRQWS;MRA@0%&6;(SWKQ;PC
MXET?P:\?@^%I;MXS<6D\DG^K+R2Y9E&1U.<?*.*].^&?C+QE>7]UI.LVIN)[
M1L&0!1&P[ <@Y_"GC,+.-G1V'AU=ZE?4O"%Q-KZZFLIC@20R2C/]TYYYKUS0
M;G0+8Q^(?,7S+<&-3D;2>F,^N.<5QEQX@\$_$$ZUX-6Y?2=6;SK!P=R[9OFC
M8AEW# ;O7G?AKPOJ_P /-?GT;Q!<)<C[,?(CM&>7<I<8E;S@%W=0<=NU8U8W
MA[Y?UKEE9GKFL:A_;MW)J<,Q22V)D*1_,SCJ1@8. !S6UIUY;6L4>H7<'FSW
M"[H8.N0/[W7&>.U>*^-+UM-7^P=-ODM=9GGL)Q&N3F"6XVR*YP0"RJR@ XS[
M5!X]UO75DT^2UG-G:-N61HP"_P"XPA3D$!CSC'''-94:-XKD(KXA2>AJ+\:/
M%%CKAT_5\Q:=*&4*L9(5L$\GCTK ^(%]-XXM--L=*U>2/?AI##$?-9/ES'O5
MP0&'!_D:]#T/03XR\-VUMJGR:E*AG4A4!+!BN"0#_"*R[S2K'PEI4DOV=ENK
M=R%8X/S?Q=#C''%=2A3@G_,0H3:*E]=^-/BA\+=+TWPQ<M:ZEX:O-MP\F5F:
M-!(%;DACA2JYS_A7DG]N^'OB&ES8ZGKDJC3D?=8M;'<7 ).V0OD_='&WM[UZ
M_P##[Q/?7?G:Q;0BU*2^7*B@8E3G)(R1V'I6X_PU\)V.NGQ7I.@@ZC=,7>5I
M'QN;/ 3?LQR?X:UHXBG"U^AU4E**LSXM\ :/HOB_7-4M;ZWNFLM$N4:)E=D"
MA6<8*XZ\5]WVFC:7J>FS2V=V;75=JH1&VP",$8WH"-P^O?GM69#H7A31++5+
MW7+:"UU*^61A%!O50<DJS8XR0<]3U-<-\#_#?C_7-<MO%'C74[2/P]ILDZIY
M)99Y3L8!7!3! WYZ]J6+K*JG(:J6T$\0J=22?PU9R2W6MVD;I;S02%%5L$#,
M2Y[KUW5WZV>L:!X TRVU5FN+ZUE&/-)#NSAV^\<G SC-4/&'QB\-:#<R:5\+
M-%CU?5[HLAN'0^5&^<9+,ZOGDG@$5I^!-.\=:II&K>)_B5?QW5ZZ^5;VR*JI
M$3@J<*BCHO7)ZUS_ %J2I)2VN%63:/&?"R^+O^$W1=4FN9((962:$*_V8(RX
M5@V=I^8^E=9\3-?N_"C_ &?1LI.TL@=@2ZB//&0/;M75Z1HVKZ;.\]W,QGB7
MDQ[3NP<\[ABLOQ-X=@\22K?2W<EE')\T_"')8=/F#8[]*UHU4Y6.7E:CS'H?
MAPB7PG9:CJRI]HD5G<[ BC#,!QVX KRW7/'&F3P75KH%PRWB;OG5,QA!]\@@
MX;"Y('>O2[1Q?_#[2[>W)$C[][#'(61UQSVP :\WTOX>:9I.K/J5O=3R+DM%
M XC,9#Y#!L#/ QCGZURX7D=6;UT;_,52KLK'-_#:[DNKZ]DUA7O+=9HFMS<*
M4\TG)=DW9P >#C-?4WBN.SUBRAU*U&R49#%5VED(QM('UKYMN?#>HS^++6>R
MG,=C%.CF(8&W&-X7C^(Y.":]\O\ Y=/D$;D[E7 Z=ZC&MU&K=Q-<NQ\V^'O#
M7@^V\<K<6^LQO=PSSN]BH5RC.P+([;N@(QM*\UWFJ65A_P ) VHV%BL21,"@
MBPD?W<$% ,9)).:\M\:>%O#7A_4?^$C^W7%O>W4C%8AMV-<.<YR!NP&/<UZ)
MX>NWTGPZFK^(;A&$K85QDEO08QCH*ZO8MPT,J+Y97,ZS\5>*=2U_4K?5],D@
ML[<[+>=I#B0*6S(L94;21C<P)R, ]*^^O@.V_P"S/UW(A_,5\#^"?$X^(WC'
M4/")6*.QECGCCN4#*X)C?:>>^0.U??/P)L/[*:WTLR&7[&J0[SU;RQMSVZXK
MQ\PA9+6Y4YW/O>T_U"_2K-5K3_4+]*LUY9 4444 %%%% !1110 4444 %%%%
M 'XXZKX6\3M_P5ZT?Q.ND7AT=;1@;T6\GV8'^P)H^9MNS[YV]>O'6OU\@T;2
M+6^FU.UL8(;RX_ULR1*LK_[S@9/XFM*BOH<]X@ECE03CR^SIQI[[J-]?G?8B
M$+7"BBBOGBPK*CT+0XM1?5XM.MTOY/O7"PH)F^K@;C^=:M%5&36S ****D H
MHHH RAH6AKJ)UA=.MQ?MP;@0IYQ^KXW?K6K1152DWNP*5_ING:K;-9:I:Q7E
MN_6.9%D0_56!%6(((+6%+>VC6&*,!51 %50.@ ' %2T4<SM;H 4445(!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!__0_?RBBB@ HHHH **** "O)OCG<O9_";Q-=1DA
MH[0D;3M/WAWKUFO)_CE%:S?"?Q-%>IYL#6A#KN*9&X?Q+R/PJZ?Q($KZ'Y!Z
MYXJ:+1X=1@,,!F8PBY=&6WCQR69201D' ^8<_E6/IGC;3;+38;K5[I)V$CI#
M-;@^5*%8C>%RQ!&!GG@FNEUS5= M(8M 72)+FT8[1%$@N5"_[0<C/LQYS]*Y
M?Q!X'TS7H;&+0O\ B5I;<0Q",<!\;]Z9P&R 3UYSSZ_505H7D8N34K'J5IX7
M\(>+O#\=S%:PZC:22'<DL8VEP#\Q##KVKS?2/AG/X3\2W'B_6KHQV]HW^@VT
M)$<,4//R,#NX (QC&*[GPSK/A_P8MOX8-_\ :9%)+9"H5+9;)7<:]3UC2M.\
M5Z>MH5+)*N&//.>O0]ZX'B)0ERVT9U*"DK]3S+P'\9_"_C/Q)<^#K"$1SVJR
M.[#)#A'"L>@[MU[]:]NO8[&/8+(*P[HN#D>H KYHN/A/I'PVO&UCP[NAU'4!
M(CS $_(S!MOS,0,8 X'.*[OPDWB*%)-3U=&58F(B(+$%2!R<@#N?6L,51IS7
M,I:E0<HNS1W-QJ%S8&1;.WW.ZG8&!"ENV>G>N+\,1WNFQ3>)_B%:VL&I2,?+
M%N 95CSM!SN<YX/X5WDVIQW^D2:M"H?R-ZE1@D%/\>U?/.D^.6\2:PT5U$T4
M<LI6)IC@G:GIR-G!Y]>W>C T)2TL:U)=CT7Q!\6+^]U6'3-HMII$;8N3N=.=
MI/N3G->87GB3Q#<ZXMO*SJ-P0Q['5,MC!\TG83_GM6)+H'B*^UXZE<!0B2AH
MW<E9E4-G:JA<%3T'//-4O$&C>)H_$'GCSU$\\+K+N<P(@7D,OW5/(Z#L>?7V
M*5*G%Z[F/+4.M\2>"K?Q1<I-/?[8XU\IX2P=.Y#JG57!(Y.>.U>C^'K'3M.T
MJTT&TN][6<<:.9/F:38, KC'/'S=>W2OFS1[7Q38>)VGN1<6_P!CRMPPW3).
MK+Q( ^ &RP7 '09SGBO7M"6Q%Q-J,-U(UR N8I!MVALY((8_>[\<>]/$MVY8
MLUA9/5'N=Y]G334>-TCD*G.Y2>G'3(KP#Q!XJO=/U<PP?O1(%#DJRAM[%6')
MX&.F?O=!S5GQ!XEOM/NS>-*ZP1@8B7]XIX'5FP1S7,Z'X@N/$]]>_P!MVUK"
MFG%?+>*3>I&3RYV)GIQG..HYKFP="<4[LN=2/<^C/A-9"'5$OK>!8H;B%RQV
MX#.6& 1_L\@5Z/X]^)WA7X=6UKJ'B+(-XZV\>U23\Q) X4X&037GW@W5#:6=
MOYS&UB(8Q28&Q@YSP3USU'M7H7B#PUX;\4O!;ZW%%?\ V9PRAP&&X#((_ U\
MKCN957-RT''8B^)/P_T_XF^"-4T"YE:S34[>2+?'C(1EXZCWKXXUSPW?>$-"
MA\.::K"UM0L2HB$M(5&.-O 8]<XK]"?-B,)BB'R8QCTQTKQKQ78V"B6Y=59H
MSOVGC...#U'U%=.4XWEG9K<RJQTL?(.A>--4T+6+K0K. -+)L!BNHG-QAFP1
MORH( YQMKH?BAX=U?4M*M!IP>Z6U66::UD8!)6X*DYP J\@@\\]178>.M7T*
M/6&GLM!CM;JW9"TUS(8WRS;3M8!BW!XSWJSKFLQVFB7>H?9C<EXUVQNY0L60
MDY89(&?O8_(U]#+$<LKSC8RI.-FFSAO@U?:KI>ESZ?K>6B7=L'(3:2&X4YQ@
MY%,^(/A=/B+X.O\ 2-/U$+)*4>UD#J4&&#,G7G< !D$8]ZDTG7;'Q!X1U:"\
M==,NUD"1W/"93"G&T8 .21QU'/M7@OBC6]<T"STGP/H$AN[N:Z,HDLSOCC$+
M1L5=\!E# $8P1UKT\-"]3G9KAZS<.3H>HZ9X.\.Z3X)LO!WFI#K,0(@EDVB7
MS\DL4?@=SC';O7'7'B:PU_1X=*^*5K C27+1PP3)\TJHH88#D]\\XK.UR#6+
M7XC^&KO4@]]%:^3*\"DCRI)(E8DL,$C)/6NL^,GA!/B7HNEW>FVVS7M*1F$H
M!C&Y@5V@)QD YR1FN_VUJROL:1BUHMBY-X*UGP-X.EU_X51P:-=7KJZ$.BEE
M.2@(1HS@ UXUIOQP\7ZMKEKX4\8:9%K&JV[D22*KS!L@L-I!?H".Y[UK>"+C
MQYX2T6'POXEM;K6=0F4D M(P3 &T ,.O/3%>B1?"+P3X+\;)KQ\4QZ5>7$0D
M="%E6,L N(VD?);CD8&.?3FL-&"<IMZE.:6[-?4_!/QOO;S6;7PY=L\FHL$L
M[<R;8X(MQW_Q@*0AXSCD#BN@O_#VJ_#_ ,.:%X5:[;5-5M!)/>R%P[0S2-YG
M\))4#>1DGG&0<5T/BO6?$9\.Q^#_ (77K/J=VR?;-8N3Y>%5AN\O:)>7 8#&
MWJ*\MT[PEXD\,^/]1O[_ %6XUF/7-/2.5WW-%%<1)$F68D\GYL#'S#)/2O(Y
MIU&Y5%9G/.3;]W8]@\'!;V,76J&0L^=AZGC\#7H6N>"=-UG2DU4%C+9_Q #(
M#]1G'?%>3>%->.CR+<ZO&T-G;R;")%"]1GO]?6NXU7XFV>KQS6WA^46UC\VX
MDKE]G7IG\.:\C$4*G/>*T)MT9^J?PJMXK3P'H\$.=JQ=_J?I7H$V=C'T!KSG
MX12/)X TAY6W;H003]37H]QQ&WT/\J\>I?GU(V9^)WQJ\(V'B/XG2ZC=DDZ;
MJE]*(^-CDSYRP(Y(QQ]37FMW\1?#UKK9T9&<30G:X.5 &W=W%>Q_%I[D>-]=
M6TYE6_O< ?[4I(KY@M/"=]XNDU&_DL9(;^%"=P0[7Y"]1CL?2OI\'RSHJ,W9
M(56LX>\MSTRSUKP]\0DO+&PN1(+=PL@^ZP;)Y4-UQCJ.*K^(-)M-*T Z%9W$
MEO+?9C27&XJ22=V5 P>,9KS/X9: ?!5G<ZQXAF-HL\K1_.-K#8/[S8/5JL^(
M=)^(VAWFL>.?#]XFO:9/:@PVC?.RR#9_JU*.HX!R00>:VI.,-(:HNG7;CS/<
M[OX8:+XG\.)<V^IEI7.56,2!ST'S94G'N/:M?4_ -IIVKQ^*KV.6.XE_>!#(
MGE;TP=ZC;E3GGDGK3?A-\24\8)/IUKX=ET[4D+F[DD=G15"#!#,,CGM@#\ZI
M>.]+UWQ$T5KIEW*1$VV3]X_[R/@-M SM)QVQ]:\_VJ]I>6B*7-+8[NQU;6+*
MR&FVUS;R(^79XXV:;GU=7(/ITZ<5%IGB&VL-2M=-U#55FDF**4FE7>JL<< G
M/';WKH/!^A6FA>#Y9]4(AGR5MO,XD92<E>>2V=QYSQ^5?.7B7P5J>N>,[3Q'
M8&.$V:([!W;(*$MRN".>@]35I*I.5Y:=#:4'8]8\0^!O#::Y_:DUE!-<&82)
M*P0LQ/*DGZ8KR3Q/XJ\5?\)1I_A[POYH#7,4DLD(>3: XW*0G1=HZGCFO6=-
M\:Z5XD\=S?#:-I$U&RMK6>::6",0!3%'N"N"6)RX_A'0UV__  BWAO0M1:\M
M-=M[.\.?WFQ#GZ@G&*<,6Z:<;Z&<HJ2Y;V,GQS\#-&;Q"GCVUNH[6WN6B-Y;
ML@,$KR'+G((&XG/7)S4:/JVDV$U]H9D%O$X$-K&VR' ^4L!ZGFNPN)[_ %FR
M&D1ZU9W@E*9&\89QW"!2 2>A%<OXV@\36?A6XT?2K1Y;D,I1X,G [YP,^M8Q
MK.I+WA1AR>9X/XH\%^ =3\>Z5<:.FHZ9KFI>7?EK?]Y8O-;.9Q%.$BX^88RT
M@Z^U:WA^YU3P[IMUX'\3W@M->U>[O;NW6/.%\Z=F0JX)4 "4<9J;X;V&JGQ(
MUTEI=VC002+YET7/[PHV,1,60C..3U].*Z9_"]L;^W\3^+]M]K%H9F%UO:,(
MF\%(_*7$?W0.W\/UKKE45+X2:E*[YBGX=T[7=-U:74+V#[*K$!6$JN"<#G"\
M@UZE>^+_  UK4(T:Z5&N1F.0@@[B..>._I66EB+QCJ.E7ACA"[@-BRJ>=IP&
M)&:\X;X7WUEXC_X2F?49)H)'\]8X%)4L3NP^" /?&:Y?:P;YY/4WIU9)6L;6
MH6$UO#/:Z,B6Q<'85& #UZ BO5;G4+C3? -EJ5]F?4+.T7<L(.YV4 DD_-DG
MUKSI=1DEE:6^MS9Y("-)PC8&,@_SXZUVME=2/;&/S@YV\+@,N".F#_*IQ&&N
M:U*R:LMSPGXD_%FUN_!5FUS9?9=3U'S?L<4T3S&8P?(^X+M.=S+M'&03C->K
M:3!X/LX8=/U32;6\U69!(R7@1MN5Z*A ;H,]:Y+XC>#CX^L;+3)[N/3VL)A+
M#)%;QB5./F52-I&XX).>"!6)H_@[6S\0AXDU>X$D(<%29'=BHA\O&UAA1WP#
M[]36T'&-.U]3C@W?4]322PTN:W-A;6UH$/*QIL ^G-=M'<//H,\EM+^\F)+X
M.-V,@9]>*Y[XI^%YI+"'4M'80+L#?*.3R#SBL"SN;ZULXK191YCJ/O' )Q^-
M96]I!0\[G;-VB)H-O<I#''?HI;C<003N'XFN.^+?AZ]\30V(M/G\MW\V-N%.
M,!3S@$@9Q7GW@&^\1KK<<5Y=SRN'8W0E&(PQ7CRSSGG'9:^A=44B%%?'F1E7
M=NHPPS_^NMIP<6G$YG5]QE;0O#LNB?#AWU*_DG19"R J<Q'I@'G"=3]3UKQ[
MP1JZZMJU]+YLL20E=D<T@*S#YLO&I )('+$9[=*]D>;[7X*U2SN6,<@D$V Y
M.Z+"IA5X^7<<Y]>*\2\+V?D>(G23+QV4?E09C"!,A@W(Y)88SGIBM<%4@N9M
M:NYS7NT6-5TSQ5=_$*SN+.\FBTF*>"8(K$(2JKD8SZDUL^%[3QT?&>I2:S?W
M$NF/N\J-W/E+P>A)VY]NM=W9+&;J(.WW#^')]:Z>2^TVUB%C=2()0>$=MA8'
M@,N.H)XS[5SU*\M;1.N=CA-=\&6/B:W-I?IYJVZ%E;@LC$<,I.<'(SFO._B-
MI&EZ%X$L[*21H8;&0&)<@D.Q;+' [ACVKZ#%K?V8N-H1DNXP(43YC'M!R7)&
M?FR,=>AK@/L?]H_Z/JMNES!(2"DJ!N5/4@@XZ<8[5CALQ?-:1SU8:>Z1_ Z;
M3;[0GU&WME22TE,'F'&]V15);H",[J^ZO@NQ;4-QZELU\.>+9I/!W@F_OO M
MLL=Q&5D=(U!9=S*K/L(88"Y)]A7V3^SI=37VFZ7>W+;Y;BW@D=L8RSH"3QQR
M37+F/,[-D\]U:Q^@UI_J%^E6:K6G^H7Z59KS!!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?__1_?RBBB@ HHHH **** "O)_CE((?A/XFE.?EM">" ?O#N
MW'YUZQ7COQ_LDU'X.^*K%W6-9K-E+,=JCYAU)Z5I25Y)#B[.Y^34L.EZH?.M
MKQ[>8,=SP.GW<<*V\,.#R<5:TZ^T30(EGEO#,EO\S29!W-U8\#'7TKYMFU&R
M\,ZK_9*"2Z!BQ*QE-O%E\KO7A@Q]_:JD7PZ^)%C.VL6M^VHZ%J:XCMF!1$C'
M&1EF&2#R<#)YK[&>!O!79C)\U0^ECIOA#Q?JJ:];2/N!^9E88; Q@\5Z[HU]
MY.Q83Q'@ 'GBOSVT_P >WO@;6;3PUI6E3QO+(<I)(TB2$J3@97%?5?PTU[QE
MJ^M7MQXATY],M+:4)''+"4+@YR0Q R!QVKBS/+[03BS;#RM*Q])BU@U6)9IT
M&5_+FLBZU70M-TZY^W7!A6(#E@>-Q"\#%;\#*UE(5PN[YE.:^._VI;EM)TW3
M;^/6GLI2Q1+>,&1KAG^4*4#+NP3GH<8S7S^7X=RJI-]3NQ.US:TIM6.N^([6
M2_2ZT]]DT03 PLV]DS]16';S>$(=6_XEW[Z[!V X=HT.,E01P3WZFO+/!$7B
M?X?6#:OXPCN&M-?;2XAYF[S&W[@1ALF,+NZ<X_"MG2UL_"OB'[-/,ZV-K+D.
M@/E"61-P9L'&=K8_SBOL%@U"_*SSHXE\VQ]7:;I?F646J*=[[5(?8P '4#GC
MY>IKQ7Q3J;ZMXH_L^T+3RQ96:/(5)"=N"I..WOWKW71=2O'TB2TDNBD11T\L
ML<*77:2!GTKS5]#L[>_6Z!CWKD"0@;A@CG/7/%>#A9251J1VU&Y+F/)_&'B#
M5/"6J>'_  ]%IJZA%J,@6XE.<0QG><LP8#@J/SK>^('C_2/#"6^D^#O(UG4K
MIUBEAA5V\M,@#YLX!Y..:X>?Q7"?&6J0ZI'+-HL%JJRNI)"9<?<7IG)&2#T)
MJYX&\2>!8]<N+/PWHRPW+N728QC<Z1DE7;Y0<\Y/-?03IQMS''";<K'M'A?2
M[GQGHL4US93:=+-PR2NA*D97/'&*\NM_ &J^$/BCI.G:QXA@_P"$=4MOMHE_
M>.Y#*@)()V[@OZ\U[MI_B6,CRKV(QKD;&CX&X]B0.IY-8=M\*[+Q/XON-7UF
MYDDDC?,!0G.,L0&.>@/;ZUXE&I.E*4JFQO*&I[?XB\+Z3J<>D7/VM[>W@V;5
M R"%4#'W3Z5G:5=S:A>)>11[[3#?.QVCY<COBM6YMM5BLH=-4Y6 *B,>1\@P
M*^<_BG:_$R[FL-"\*ZE!I-O(<RYG$(V .Q*C(ZD#ZUXN71]O6E":T"K%K5,Z
M+1OC?J-I\1[CPR9[632$+KE8Y/M E7> H;.PC('\/KS7I7B#4;F=(M6T[$$@
M;+.P)51@]J\D\*>%M":"VU.-[.YFMH%66X2)/,DG1>7+ D@D\]37I/AS6+&]
MG.AZE,@=_NH6&7']W;W'.:[,30Y9WIK8N,+P;N?)/ASP;<IXH35?$ODQSQR,
M?M,Y97G!7 ! 8*O)XRHYKOOB$VNFU1+ (VG#(PTT2@Y'?<P)(YP1Q^E?3_B?
MP3HOB:!EU"RA8L%.9$5B2#D9R.<5\G_$'X&_VJ^[4=6G6W@+M#!$S(BKV'#8
M(Q@8Q7IX3,:=9<LEJC&5#2YPGQ1T;PXFF^&M#T^^C\R>Y$T,<3[E1@K[F Y;
ML1R<>G:O8-4MKF;2'NK=A<3K&P61EQ]X8.%&":\_N_AMX<F\2Z1XAAMTAU*P
MC\F*%2(XF!W9P@&,X).<5ZW)IVM:21<W<(DCAR\<2G,GECGKC.2.G'6O3GC[
M+W5J;8.45I(^?O"VC:TWB*]UO65-IN3R][8VN%( 8#J,!<?C5_Q=X(NO'$D6
MK6GBN&VM=,94>,#EKC=DD<=PRCTKU^QU+0?'J7>DQ1M]I@W)*C':T0<Y^7T/
M STYKY"^(7@G6?AW?6_AO2-?BN1JEU'<2EW -O$C@[B^\X)V%>U=.#J^T:YT
M/%U]?<V/J/1;#QQH]H/M4\4]HI0>;&T8FR.F Q/7_=KCXO#?ABU\71ZAJ@:X
MN(FVY8DD,R9P57V/I7(:UIGBAI+9M!N[J\M[EGDCFMV>5%D8@@M(I(V@GY.P
M&<5]'^'_  C::I<+J5P@DN< L^S#%@H7);DYQQFN7'5N26@J=/F5V>0-X2\3
MR^(&UF%\6\5SE)5(PT08$@J>1Q[=ZZ/4O$MU#KCZ2;!WM28P9<Y!WJ"2,'/&
M>:]WFL-'TV ":1;<'=D%@=W'3'%>-W-_$^IS_9E5XHV^4@=,>E<E*LYNYO3P
MR:NF8%E=KXH4Z=:%8!&WF)N.02./F.>/S%9FHZ1>>#M1LDO;B!+SQ%-L@6)A
M(FY6 YP6Q]\9R17265AI<'FV-E$L)N$=3Y0 /S \Y'3'6J/@OX0#PV+O6M0U
M:37G)5[6"X4NUKMR<H[._+<9P!T'6M*V(45RG'4H24[L_:GX1)<P^ -'2^V^
M<(0&*\J>3C&,]J](GYC;Z-_*O,/@K--<?#?1[BYA,,KQL"A[;78#L.H&:]/F
M7?&03C(KY:L[U".I^(WQXU34M#\5>(]0TR(2W*ZG/M4JS<>8^>GX5Y#X&^+?
MCBU\465K<Z2@L+UFBD;RG_N%NN?85[#\8S?P?$#6;#3[Y5O+O5+UD25N&6.9
M@0 3_M"O)KK7?%MIK\$%K9R20QOOBQNVEBFULC&.!DU]'0BO81\Q58]3WSXI
MVG@O5?#U_H=Q-]D6W628")7).WYCR0W]VO"/ 7C/1]0AF\)V"2^9;1E@9.2\
M>0"0< #EAUYKT.Y,5TTL=S(;DN"K*3NR#PP(YZCK7(W7ARQTFPO9O#<'DWUT
MFPL!B15X.$(Y R >*B%.4%RKJ.E%=3N_M3^'GGMM(BQYR[3Z@'^E1:#J,.F7
ML&HW[J+>W.9&P>Q!/\C7)^"?$C>(]-AOKAC)-!%Y$I!ZRCDD^V&%3>)YK+^R
M)K663R8XU<R;!['L,9[_ %K.-+G=F=<GRJZ$^)_C!?&FES77A&Z+36Q51$F!
M\H.68!ADGG']*A\!7^LW-G$VK!U@N;@K; E-_DOM$6\#G@GT!KQ3P9H=R=1N
M9M"N'E@P71WRCXRH(5<G(SGG-?1NFQSQ[K^W*M=V=N94B= @>2-2RC!)SR/2
MNN=&$(V.>%24G<3QEK=CH6M;(H%FO@L<;$'9QL7NV >U8=_-J.H^';DZ?!Y<
MDH0*"RDY#@DCGTJKXTCN;JSM+S4[6.2:<^>T@0-AB,LI..BDX ]JGT"[_M&T
MMXDD0E1\NP!-H], USRI)+G!4^::1FR)KNG:%(XB=I9X1'_"1NVX/3WK+^'>
ML?$BROIH)9Y;.W&X\JA4]/4%J]6O)FTZUC+9D / /(S]*M16IO;);M)-R@[<
MCKNZXJ/K,8]#JJX:S6IYGJGQ7N-7\0:9:96-1.UO.XBD ?&,=?0G)Q7._$CQ
M/K=GXCL]"M=+2YL=ZO),N[=(K '*_-V!(Z5V<_A?3=2NX]1B,D4B2,=@)$8=
M\;OEX&?>NE=]%DD^RW#)-=::@+=#(HP, 'J,\5:J1FCGQ$FG8WO%.DWO@[P=
M!KW@:,WUN0A6-N3M,F'].G-3Z'XAO;O1QJL< 69U+&(\<D9[FI?AAX^EO;H>
M%]2L@+&Y5EM@6R,D\C!7I]XUXN+WQKI/Q=UGPYJ-I+'I4$\JQ$*PA\HN1&0<
M;<D=JX'&+GRD49OJ>=VE_P"/O'>K-/J6G-9&WN)!Y0Q@(K%0V<G((P>#WKWS
MPYHM_9V+P37 ,T,64QC!;!X.?I6G8W(LVU X4M'&3&#@+V.,]J\^\"?$,>*=
M<EA;36M_*17W%_D(;=U&T#/%>A7ES0NC2FK.Y>U;1M9N_$UKJ@D5(4BC#+@[
MMX50W?&,@XKC?%\GQ&N]=2UTB9DTXD%C^[QPI_X%U%=QXS\82Z9JC.L*B-%4
MG:1@C P!@=3WK1BD-TPNHSOB89!'3D8QCUH]K'V:TU-%)<QZUJE_+;?"JQ>9
MQ+=3VL S_M.JC^9KYQ\,ZCKD6HW::LF8HR"KD8&..E>T>&-6N;_4[#PKJ$,,
MFFVH=79P&XC7Y.ONO%<SJNGQKJ%WIELWF1JYV=^&^;I[9Q7'3KOF=D=+<>4P
M+?PG!IFL7%Y!*^+G,X##^%OE&.!W%;.N6M[J_A>_M;2;[/<RH(3+C.5*,IXY
M]JNSZV+G49M)*,9+4>6&;G"KS@>W)XK4L;^SM]-EA>,/+)D8///-7*JSDI6D
MFCS+X:Z-JN@F,ZM.9FE#V^V3& C'?GC'<?G6-XQ\8'P%KJ>'M/B#F$><V\$O
M+$QPNW&.3M/;\*XW7]:\=ZOXFEL]-MKFWBMF0QD(_ER# SDC (&3^(KTSQ-X
M @\8:SIFO2W/EZAIKHGG,-^] P)# D9&,XR>,FN^DH1BF<JB[V.;\1^,_$L+
M6.I64&VU*I*8T7YVWJ&VMGOU'%;^OZ!'>ZD=42^: SJDDN1G(+?<''&#S73/
M:-92RQWHCN6A ,!V!?F4<$=<5\_:O<>,M9UQM)L;F03WA!FC6-C';[#N 5P0
M!N(VG@9!Q6\.25[&E5-)'U'X::*XN($ANL>2DB;00PDW !23S@KCU'6LCQ-K
M(\+7\TEX?LT"1B5B1G))"CUKYYL['QOX,OV;4'N;+[;-(\4>7\MI%;/RG@!2
M6'&.17MGB:6Q\:Z6]MJAVE((Q<9.?F!7I[<BO/>"2E<F,F>7:C\9-1AU!Y=%
M@C"O ))6:-V+"/<Q0'.T'&>HYS7Z9_L[7YU33],U,KL-W;PS;2,8\Q V,>V:
M^ _"_A;0M/>TT8YN8]1E"B5HO,52V "<G'!P>M?H?\$;-=.NH]/5MXML1 XQ
MD)\N<=NE<N9SI.,53WZE2A;4^\;3_4+]*LU6M/\ 4+]*LUXQ 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% '_]+]_**** "BBB@ HHHH *\F^.EM=WGPF\36
MMA&);B2T(13T)W"O6:AF56&UQE3C-73E:28'\XOBOP7XV?QEY<'A_P R/37\
MI2Q_U@3YF_BP>#Q[U],6/A[QA'96R6NG/'Y\$<BH=I\OS%#;<$D<9Q7[.@(H
M4'C';MS44B*1@*,?I7KSS2<E84(KF/P#^,'P\\2RVEMJUSH"S&R96DDW,DO)
M*C9Y3*.K#KVS7U#\-_ _B,>#+!VMI7FDB1W:5@QW%1GDG/TK]74!"= !]*&9
M44DXSGOSQ7/6Q\Y0<1PTF?G=:^'-<AB,,MN0 .G'6O//%WPOLO%MY;3ZYI)N
M_L;;X]Q(*,.A&"!^=?JK"ZGA>.].<*&Z9KSL+>+YCIEB'M(_&R^^&2:=-?/'
M9W5U)=NLN)GWH'4DC )PH!/&W%<+XF^$!OM3/BF&TN=Y108"V(Y'7Y<NH/&
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M3-#*O)<9SU':LL#C/8:Q6I%63ENS\1O!_P ,/'&B74\&TR03.[(">?F&!D
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M;O\ FP5SSTQVK]J$C1,JJ@9))X[GD\U*?;!/O7=#,'%*+Z%.5T?SN^%_A_\
M$V+Q;:))87I;?*)FD:+R3QP5PV<9SVJQKOAGXJV_BV4&SDA3>@B&5*F+:-Q.
M,\[NGM7]"GV: G_5KWZ#GFI$CC&=JC/?BNJ6;MZV$VK61^+VA_#G4+'2+JWM
M-(DA>YD,YV%< D $<GIA>/>O+?%G@#7X-/N&U'3KN6VG)91$R[@<'K\P]>G2
MOWS:)&.YEYIJQ1(Q*H 3WKGCFEG>Q<JGNV/PI^&/PYO(]%N8]/TR9)=C$&X;
MG;N&>58]ZWK3PIXGTZ^M]1MK658"5$B\,& ZCYLG&#[5^W.T<' I1M/7&?YT
MJN/E-W84ZME8_!_7?!7BW54O[1/,ABEG#VX7'R(P8N#D'^(C'7BL;X>?"'Q[
MX<\M+UC?,P(R#SG!]EXK]^O*C)SBF,JY^X"#P16O]J24>7H0YJ]T?BIX@TGQ
M59Z"MU%ICRS0RA%! QOS@ \],U9\*V'B^Z\/3"\T=XI$8L%7;]_/^]TP:_:,
M +@ <=!["DVJ1O91Z8K"687W03<I:MGX\:;X3U^"1&N-*DVS$3./E^N.#WQ7
MSH_@WQ;X>\7>*_%>IVLWDR3Q"&*(AOW95F <,?0#&#]:_H1(5#\J@9_"F,B$
MY;@<]/Y?C2AB'>Z%)WW9^,_A?PI-HGB+09+;2;IFDDD"ERI5<Q/UPV?_ *]>
MD_$#P5J98:K;V)^U2;0QSDD#IU..]?J?M5%+ =./Z]:4;70[!C/>LW4M+F0D
MF?B[<>#?$AN&:.QDQ)$>!C<7X]3C&*\PT;2?&]IK4#VNF^7'=$$J(T!,B98#
M_=SC\,U^^2)_?YSP>]*5SG=@@C\#6]/'.*Y2IU6FK'XF>*O!VKWEL^O:OHL@
MO+>)YG"[1$/+ [!N?I6-X)TOXAZQJR:!K6AI!<,K,I@XC$84E<Y;.<^@K]R1
M H! 0 ''3V]/I3C$A5<@?*<CM[4UF26EB6_?\C^?G2_#?Q*LO'DL0M)C;Q2W
M ;!7YA%D@+S_ #KT/Q)X%^*%]IT]_P"&;+R-13:4:8KL((]!GGIU%?N#L!^7
M&5!X[  =*<D4:JRJ@ /ZU-3,DEHBX5-&F?A=XKTKXDV&DV%^VF26&J3JIO);
M=8GPV?\ ED)-P(/ .X9QG':M;PYX<\<ZO8K/JEA(QWC:^$5SDGE@N%_*OV_5
M<?< 4>E*54\L,GW]J7UWR(I-Q>A^*%YX.\36DPFM[!W ^4YV]^N.:L7_ (2\
M3:=8G4++3Y/NY"D@G/YU^T?E_-@#Y*DQ\IR<5,\=S:-&CFUJC\3-$TKQ%JKB
M>_T^0..,87'7'K[5E:C\*O%-MJTVHVT3!+CAD& 3]3C(/T-?N.0&7:<,/I2(
MJ1CC@>GI5T<P</A*J5[QLUJ?@7XQ^&7CO5XH(;)&2*)2@#L6(R -P)R<\597
MP/XJ33A;O:R&Z$:Q[N-K 8Y;OFOWK$2[MP--:(.X8'I6[S*4MQ1FD_(_%?P7
M\,-7TZ>SOKZTE>WMCYBJK98MM^7.3CKCH:^P?@V6.IL74HQ<Y!Z@YZ5]U_*>
MC5\9>!/^1ZUK_K_N?_1K5Y]2LY[BG4<D?9EI_J%^E6:K6G^H7Z59K(S"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH __T_W\HHHH **** "BBB@ KP7]I[Q+
MK_@_X">-?$_A>8V^K:=8-+;2#JKAE /0^OI7O5>*?M%W-K9_!/Q?=7MF=0@C
MLF+VZMM,@W+P#D8K;#QYJD5YH+VU9^*_PN_;,^*ECX9NM$U/7IM?\6/,KH@9
M"(XY2J",?+EBF&=B5X4YK2\9_MF_%'5?$VE^"_#6H7,5]:-]EOG1@?-N)BBN
MT8"G*PN&';.1D#H/FE[/PW\/-7A\06P\H12&$+.2S/O&W)VX&5W;L\#BJMUX
MIT31M:M=?\,7WGZG%</]IZ9+2N'5\L N25)!'RC^(=*_0GEU&,=4817M9^Z?
MJ/X3\>_$F?PG'<:]XPDO-0U5FF@GD86JQI&?+*!8_E)^0GI[U\R>(?CU^T+%
MXNN=+T+Q:\]G!,R>?M1HH;8DA'9MASN ;)/3&037AF@_$N_\&KJ7ARUU38-4
M83M#LWMO954N'VE1P,>GX\U[A\.?#ND^)+!K>P>"&\6""WCE+'$*)NWL$)W,
M64X)P0, \<UPQP<+-N.A[%/#/#J\]4^IU7AGXA?M-Z_)<0:;XK;4=[ .UMA_
M)4YVMQ&."*]"M?BA\6/">D(_BCXB?;+XC;Y%HD4V0.3EG"$'KGC@5X/J&J?$
MGX%RZG=Z/>6VI:<\J12.+>5D+R*7C!P0W"[@2.,_A7,?"_PCXF^+/Q#N;;Q/
MJ#::PB$EVBJ%=ADD"(,&QSC.0>,U')26J1V4*%&WUBH](Z_=J>AWG[3/QWUK
MQ,MGX8O[^YMP\:>3'"CLB9QNR%);>.F?3BOI'0/$_P 6M2TVTN=8\2WFFW5U
M,?W)C4^2@4C;D[2Q)&[D<9QVK"U70?#GP@MY+G0I7^U1P\*2&ENO*7[K\8R>
M@*A0,G/:O%/&OQ"\2>%;]?'>H:<;B;*RJP!1!E?*"C) &!USWK)PIS7NHX\?
MC8XA?N(V3/JGQY\5]>^%GP];4X=9GFU6%8O-:28NT\A8*Q5)"P0=_E%?).G?
MM6_&SQ=XBBA/B:2PM)2#\L4)V8PH'W!GCDY->%>+OBWXE\36VI>&->@$,SB(
M1G(RWEN6Z@D<8R3T/:N7M_#4=G%!K+W2W"I$TCI&<'Y<9Y/!(Z8'-=6&RI-7
M<3IP6#AAJ%\3+WF[_(][U?\ :M^)_A;Q%IMVOB*^NH+I3_H8"&2=/G"[<Y(/
MF+DD<[0>>U=3X'_:,^-_Q \=-HZ>([FQB=_.FC94\VTB4Y>-$"_O,#(RQ4\#
MUKYTL]$TJPL[C4M,WR:K=1.%<D<1D8R P^7)&#GG]#7-^%;W6/"<$OBC4K=-
M,G9$LVF(9CY*@J^W!(^<'EB#^%>E4RZBJ;TU/-K2]J^2"W/L3XX_M%_&7P%X
M[UCP[HFN7UHTEE#]A=8H[C:[11,S.DHQ\Q+'^+&<#BM'X%_%/XZ^.(U2\\43
M_OVV&9L#9E<Y"A<?RKYH\<^&]<^+U\/$?P\LEEM7$$ A1P/F2$!F5I&^7+(2
M=QQD\8&*Z'X"?$^P\+^(+:\\01&:+<3.Z!@+9]AZ@<GGTS7B3P\4K.)[-?#0
M^K\E/6?8_3[1=+\60%/[7\6WVJ2Q$[F#-"N2>GR/SZ<BMC5OB'J'A6\^T75[
M-#IT2@22S2L45FXY+D^HKR*__:%\"2:8;K3=0%S-M8J/]6<GD !U'ZU\6>/?
MBYXTUW3]9T)9O(M)9DEG=D_=2'Y %52-_&%.0<<&N&&!<I7Y=#Y&EEF*G.\H
MV/K#QK^TC\1O%.N3>%?@_#/J(LT<W%^7Q:#&<;9460DX4GD#J/6OE*S_ &CO
MVEAJ=WX(EOKBVO[J0LEU<GR_+C'#*B^6V[D@@G!P/PKF_!GQ?\9^'(4TY+>T
MNX;:2-F>-6)"1G]T6P_))!X'([C!JK\([D^*V\1^+]>7(S/-:W$B2*(ITE">
M6(QAR"-QS@CCKTKV(Y?&,.9Q/5G65%<DD>B7GQN_:,T:TNHI?$%]&LN(//G@
M0+#+&0[<E3G<N%&>YKNOA'\7_CK=7*WOB'Q!=-I]PIQ)=(L-L2K8.V903SZ8
MKROPAI][8ZM)9^*S*  7$4Q5V)885BT0QU_ES6CXP^,6A> Y;?PSI5@LTX^>
M><OO<%L,^ IVJ 6/4>E<\J$);1.ZKBI5H1IT87\SUKQ=\?\ XF^$]>_LN\\3
M7"6B('#0A)3ENZ;]N_KT)&!GTKFK7]I[XIWEO<:?HVL7E])-,_V*1E0)Y,&&
MED=P&.94X5,%5(X(R37SIHVIZ;XTU:"Z\0"6]LR[F40$++& AVE<@@G.,\'C
M/%3:1XQT;3K---CL)[[3H\PM,K+'G PVX-AB7!'W0/:MU@*:U:,<7@O96A?7
MJ?4G@SX^_%/6;C[/=>)7\PPW#1I$RNRO'*JE6RJ\\GUZ5[EK?QA^*UIH/]JR
M:G+#$SDPJ(T,DD9  !RO&ULL<$U\Z>!/"TU[8QWVHH!!%MN5A)&8X3GRU!4Y
M;*,IQR?7O7HGB'QCIUMX9LTD CC+-%)&JLWS$8*D\XV@[LUS.C2YTK'AXBLY
MU8PIZG$ZM^TW\2M U>UB?Q<7DO8G1H5$3R1RS ",[&7'4G([8XS7&:[^T3\9
M=<UV-?"'B>^@$6$EAN(T5 ^-Q?<-YP1@8QUKPC6VLM?\4O8O)*]K;R2K!$NW
MRW2)L*&.-V7&.=P'TKM/"ZZ-X5G5+BR\PI(9F)+.&)7:,[#G:,_7(KO6!I-7
M2/:J8:,:5[^\>X7?Q<^.]]8O._BZ6*Y:/S$\I5VV\6,L7PHS@9Y([5QL'Q8_
M:(\.:++?7'C6?5[CS,JZ8,?ER;G1E^7G:N 1C&?6O3=$:\\26=RD4R7( M$W
MVZF&.%8)"Y0>=RQ(.&8$J1C'.:Q_%EM,BVL.GPRW,)^T-<3P%1,'5\(IW IL
M )'"YX'/7.2H4?AZGST,3*]I;HY?2?VJOBU+:V@O/$,L3(I>0 (SD!CE2"HY
MQS7TSH/QK\=^*M"CNM-U?)G2-DD,@#J&&<,BJ1D]^:^!?B%>+X=T5YW"17,I
M5@T:L9&=CL+ G*8V\;<9X)Z5UGP5U^*^LEL+#8TD;H9)I<@98_-N&1P,=%P:
MBM@8N+LCV:N%E*@ZR6G<_=#X7:EJ6L^!],OM5F$UW(KAY%.02LC*.P[#TKT!
MVPNX=AFO)_@NL ^'FEI!&8HT$F$SNY,C$D'T)R1]:]2;G<0.<'\J^+K02J6.
M2]HGR1\3/VF=5\!Z_=:'8^'4OV@?&Z2=H@1C.1A&KQR#]N+4VBD2Y\+I#>8W
M*GVH[, XX8Q@],]JS/C1'9:GXXU-9E4RQR-NVM@@#@$Y_I7QKK=AHO\ :$=W
M/="T,0V['YYR>./KG/X5Z5&E!]#TLLC&2:J;H^W-5_;A\1V6C-KEIX2ANX2L
M9$27;;QS\P_U7WL'IGBLC_AO?6Y=.:YL?"4#W*KO>(WK95/;]T<GIP1^->,#
M1M,O?"TMY]H C2V29MG ,4*[^IR.F?>OGZ^GT:_U">/2[&*9IX"())_,$@E!
M4!E*LJ;0,C!%;NC32V.G 8>%6;@C]%? ?[;[>)-2L;7Q)HMEH\6IY\@C4&=]
MJJ6RZ-$H!X.,$U]-+\5+W5)?,\/P6%]9;<B3[6PDW>A18V YS_%7X7^(K[PC
MX8\.VUWJ#G2+F[D$CR1[I=T#$+\P ?'(.<8.*]#^$/QXL/!EK>:=X=FCUG1;
MN4D+Y<L83YF.1OVL1\QKBK4H?905\CQ,YN%&%S]%/&_[5/C7P+9S3ZOX)"W,
M4XC""X?#PLF[S!F(?Q<=/QKQ-O\ @H@ZWPMIO"PB+JI0_:CSDG(^Y7E_C?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M =WRD-C:,9PS>N371?#+P#>^./$45M?M<+:#S%F.Y<Q#8=B<YR,_6OT4\%^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]7]_**** "B
MO#?CM^T5\+OV=/#MMX@^).H21-J,AAL;*UB,]Y>2KC<L,0QG;D99BJC(!;)
M/@FB?\%#?@-J'A3P[XVUV#5O#6C>)=9O-$AGU"VC M[BR2)W:Z\F63RD/G*
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MC!*CD[5P?E!Z$YR>E?7NI:UX6\*V8$E]ON70;68Y9Y2,LK$#@AN"QX[U\G_
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M'$BR;"D:ILP!O;Y3\WH>O'6OO[XL64-QXEU>YMY6CDC?/EA1B5L<+NSD'C@
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MS71.4(PT.:KC'3=J:L?//A6PN-)^)GBD2+)N%J3'\I\V:-,!E!].G8]J[_P
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MGA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGDU1:U*7PG#;WSA%/ W'IN/IGO7F0G&,&GN?*1@TU;<^8/VB["#PWJ4&K6L
M2\U+8NY.1YNSN.>, \_@>:^;I]2O+;2KK>GVF:)W<2(NT,)@$R%;D9P>#S7U
M7^TKJ>F6L5H=4F9(H(O,E>"#[2Z=L*004'/+CH>,<U\?^)M:O!J5E)H,9N%8
M1_:(E.<.K993@'/Y5[N CS4S[S+)-J+9?\&_&=?",+1,XW"0;HF4_*R$XR0
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M)-TDK$C<H8#/0#Y.<9]ZQ+_PIXUUB>&R\,6B".WCG$QD;(2U+C:7;'RLJX#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOI7W+\&I$EU)I8T$:.Y*J.B@G@#V%<F.;TN?-3KRFES(^ZK3_4+]*LU6M/\
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M.2 >/85Z3\5_#%[>V\NBO<.DZW1>.95"1EEW!=S$8'!YR0,]*Y"T\4VW@3Q
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MJMBWC:K]WFT-/XB6]S=7EQJUMIEREL(XX,LAE@20,&\Q'8GY2IVYP,'.!W/
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M\.RZ3K5TT\2[74N>4DR!L& ,KP,=3DG)Q3OC%\=]/\2^'UT_PC,EW)"P^T(
M59$VD,OS8SZ9'I7D2=2;LY'R:PN86]E*_P!QL^,?C+IFB^(+RTTG8)XPI5;4
M(SR J,_+@<#.">O%<1<?&*.&?2)I;'[8T4<91S,1&DF>0\8!3Y>"&()^F!7Q
M/XBU#6[-WL="1-0N;Y1(D(!.W!P>01C&.YKK?!?A#Q-I"66O^.-0^SG56D,*
M$+(0^T;U9XMR '<H/3CIBO1AAX**31[V*R&C0H0=6.K/H;Q1^T)XT?6&L;IY
M8M-AN8(Y((521YH9T+MY3%5;<.@ (SGJ,"O"M0,[_$%(BL<6A0;'G>9B]Q.
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M?O)YH7+!.,8,94,2  =V!FO=O#'@CPT/M*V8CEFNY3<1JN\99&(YW'ALMQG
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ML^&[70XUNX]8FEDDFGMF'-Q:HSHREH]OW7VC"D-QZ9K"^'OC_P"(&L:IJ/\
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MYC>".\Q]H15$F.F\#YL=.]?%7PI_9P\3^,A!XBLKT:98AHMRS?,75?F^39R
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M/^V7_P FJ_%/_L 7O_H%?,W_  2>_P"356_[#^H?^@0U],_ME_\ )JOQ3_[
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M>)%\07/D^)M&N)))5"V_V,S,RJ6&[S,]#C;C&WOUKJ_B/I7@^SUZ$6$@DO\
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M 5NI,$-D,YP RCLO6O,G@I-WB?<T.-,%2E?$4U=^5S$\'_V'H>DR2I(&\07
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MU@W:B.=FG9N@W-N/WL^OK57P+)?^#=/O-3N=)\JTE6"XE<P>1(6D;:6'&<'
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M)4J-L)7:,=2 #77AL,I*YX>+<**<H*SV/IKQOXR\&>";>S\!R6XDOYHMT:X
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M^?[+]E+]FC3M:7Q#8_"_P[!?(P='738 J,.0R1[-BD'D$*#7OR(L:A$ 55&
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MZY%XZT_4;0(UI##*EY/(2"1N3F!,%<,1DC*UV7C/Q/$DD=H_RQ;F(P 22!D
MYZ9(Q7E5'*3NCDJ75K'-_9) ]NVJRQS:'/>1HD?F+A92^(U7D@J3P !\@ZFN
M1\=^,F\$VC:;%#!K4%U("MO/$TCE2#DI(#LX(Z;<]:])LM \.R6UKJ=Y(R23
MO!>&"5BL*29W[4&[ 8DXX4=*\O\ C/XET#3='OM0TZ"%[E)8U@LK@+%)(NT%
MC&P#L.<_=]_>NJBI!&3/&_$&L7']BP7=I9&RE)DM[= W[Q'15R\> /[PX XQ
M3_"6FZWH=O(9?MDVH7;P2#[4CK#*'4LP&X#&21N)8@]:ZKPSJ>@?$/2-%6RM
MXK&^$HD\EY"[Q*0AE///W0>>^.<5['-HC3ZE+91WA*PP_P"B?:"<"<!0KG);
MY!SQR,$<=*[Y5HQA9[CEB+.QE>'M"O/$%[.^FV,?E3*1-%@;%( P0V=N[..?
MTKV7_A7MS9>#$>^>99(HBS*SK)T7G"@9!]3WKM_!7@W2],\/0H)!*97+%XF9
M5)SZ@C/2NLUY VBWD$+;6,#H,G)/RD#D]?K7@5,;>=D<$Z]YVL?3/PH6T'@;
M31:.7B\O /;()!_6N_<X1U[$$^O->5_ ^&>U^&>D07!RX\_G_ML]>JLG# 'K
M7B5=:EV?11;4$S\#OBIX371_C_X\U>:Y9XIKSS0A'(=RS#CKW.*^K/@O\6M&
MC#7/C!DM=1=2@<'YG'"@[.6Z<=>V>E8W[3/P@&IZ_KOBK3KJ:"],WF?Z.AE8
ME <90L%)] :^(-$\1RVTILM6@^TW-MN*R;R@SC RX 8-S]SIWKUJE&-6FN7<
M[Z48U8VJ/;\#N/VA/!^FZ!\0+[78M0CO--O);ARD.'>)IG(X"DGG(W\=!VK1
M\')9:/X4GT\0G4QJC+ \A812>0XWDAF!R5( "]<?2O.=-DD^(NFZG::G97UI
M=V[1J9A&7S(&)8YW+EG(P5Z?G7<_#O3Y=;GM-(N+>3[%8S%7R[H?)&=\@*G.
M0Q"]>,XS6BPSC2:>Y[%.M"--*#_X)I?#?P5#HVJ6E]IDW]K9#B*2)-D<0D4H
M[/&=S;V4E<9!'!(QP>]\<^";?3G$ERWG1.\9CCEPD4;D9C"AND@'!/KDX%0W
M&M1>"A?WEG'&K+<?N3 ^%9<*&4+@*6 R3WQCFN_\,S:5\8]$N%N[6>W-I/"8
MY'+,7=MX)V[L9!'O7#)\IY6,Q,W)3>R/"4O-8U._C?4HWTV9/ECN+=65#(/[
MZ<L1LS\V0.@J2^\,637T\[O;WD4[EY9[51.8@#D$K&6([]:^G_&7PY&GZ+=:
M7*XB=8U9+@+M&<@[2W49'&.:^5KJRUJVTJ]MK&)=+VYA;[+EVF<_*H8E5/!/
MOUJ5B+GJ8#,G6U0MI#H,&MSPZ=J9M//AV%'C:))@-H8EVPJX/][IFO0]:OM7
MNK.2*&S>*VBMA(S!Q*J[B5;]ZOR;0O*CLW//2O''T(ZP\*:58S1/ B"=;EG)
MFN%4#"Y+81R&) P.G![5=0OO%VB:+<I.MQ=*)BPLX'<LL#A4!*\;D#9//'!K
M:DKNYUXE.JU*6URSI6LZ.]C>VMI;7'B1(#"Z)>3*\4K1;BJ\H $7^+GD'J*Z
MOX>62>.=;_MF\@,MU;!I(Y6=6MP$/E>0$(RNW/!W=N!S7&?#UI+QM7_M&%%S
M%%%:H$6V*':P8;8P S=.N:]@^&GC[0_!-[%8W442Q!GB,:QQE&F<[\EFP2^/
MX2,8Y[4ZJ['%CZ+C&3HGLGB_Q/%X?TR33=9NWA^T[TAPK>8I P=O7('&2!@B
MOFI[+2];U>+5-.N9+BWT^2.9U9"HE\H8< L!P3UZ\UZW\9Y/$9U#3M;TBQ%]
M)9;Q-"L8GD=G(#_NV4JJXZ$>_ Q7D)T#5K/PI/JI,UO-<7#!K<)MG/V@O((8
MXQ@=L @@\#'6LXM6.?AOEBG*74^D/V;_  5IL$VJ^-+_ '"QTXO&IX1<@(Q+
M%AR &/3'-<YXU^,=_P"./%<VA>'O*N]"6X:&Z>*WEC98PVV++LQ4[QNR<=J]
M%^'&L:.?V=KG5/WL<$\DC2HX"2*00N& ;GD#J:^9;7Q!I47AV66Z$UL;BY1(
M#%!';HWF,1 9'C92P3OD'\:Y&I-W1K3IU,1B'5@KI'%^)GU(^(;F#385EU/4
M\)*84+-MC 2-692<?(J]:Y2X\$:UI<PAU?43;^?+#!<,JDHD4L@1L."5(()
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M@:>$PV*QV-]G[9724')JSL[ZK1::[Z[:#=5W:2V/V1IDDD<,;2RL$1 2S,<
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M=;VOE*\?VY5N%E;._9,%*JQ1OX1@G -<=%_P3\\1P1K##^T3\0XXT&%5=5D
M '8 -7ZE2S^G'#TH+&^RG%-3BZ?-[W-)MWMV:T6BL8<FKT/T*\/Z4VA:#INB
M/=S7[:?;0VYN;AM\TQB0)YDC=W?&6/<DUKUD>']+?0]!TW1);N;4'T^VAMVN
M;AM\TYB0(9)&[N^-S'N2:UZ_)ZKO)N]SH"O-?C S+\-?$#(=I%L<'CU'KQ7I
M5?/W[4^H2Z5^SYXYU&"4PR0:>S!P<%3O7G-5A_XD?5&M"#E.,5U:/YT=:_MR
MUO;V*VV&*Z=?-5P"^48.HX.,Y Z<5[5X8O\ 1AJ>AZ=?/+9W^JVT_P!KDCP6
M@16C 8#:P+8;(P"..G:O+_!%A::GJ%Q?W]TTT.S=N<_>SP&.3UST^@KTCX=V
M-B?B:]P\RWXM+78H8@L4DV%LYSMD^4;%ZMSCI7Z)A+I,]+B5)4O8=4?>'PKG
MO7TO684C=IM-F5$>7:99$9$;+%<(?O=ATX/.:^@]"6Y?3X[FXR)'Z@X]J\J^
M"]LRZ;J=T[+/ UQBW9>?W>Q<[QSR'W#)[8%>TI@A4)V@>E?)8^HN9W/S&5-\
MUA+D.]NRC(8 _C7YI?&O3]>L?&RVNC ?9KIO-DP1G<I)8@L< [5K]+Y"0'P<
M@C K\V?V@9=:M/&.AR:1;-?07=[)'(@<H&VQE@"X#8&>O%;96^QZ>#:UB?3'
M[/\ <3S^$)KFZMY(YHIW\OS2I9H23M8LF%Y SC@^U>\,QC7IYQ'R^6ORG)YW
M;F^7';'7-?'_ (0\<:MX.NQ8Q:=(;;4D0Q:>]P<":,?O]KE<&,,P"D+C%>A:
MO\;%CL)9(+(QK;R+%,<^>$D89"LFT<;2#D^U7CL).<KM''7H-RT/1/B!=^1H
M5SHZ.K2W8\H@<@#.&)(Z @X'O7YQ_%R;39VLO#MMYTEU92X>9"&*G'R  #
M!P<C)Q]:][\5?%#PWHBWEKJ^N0OJFG1C9&+A5,[J3NWC)W*,<9SSFOG;X3&#
MQ!JVL^/-4BEN7U"YV1QJI$)8.P3;U#$!<8 YY->OD]+V<6I&T82IQN>2_$;P
MU'=65MK,-FEE>7\(F=$W,I0.T88G) .5Z9!]L53_ &;-=UWP=X^GN1$TUB8R
M+A2\:J2<[3N; SUP,\^E?7%CIFD>*;Z]T6UA MC&R*CJ 0& Z*>AR<CWYKR'
M3_ WA7P99ZYX>UDQWUPT^Z&*2[%JR_8V?!:0AR[C</EQG/?FK^JVFY+J?H='
MBQ5\N>$K.[M97/J34[CQ#XGT'3=?\+W*6LD_F@1RHS-A9&4DD8'4<8[5P7B:
MPU%O%^FVEV\4$-U/)%<7I.]3%!AT4JI)5BQ(Y ZBL[P'XUU""6+P9<6]S9Y7
MS(UN69&BB)SN0L!D,6!!&,YKU>2+1;Q)9[:UMY('@1RLFUS+)DEVD8CY)2,9
M!!/3GI6;I-/0_.Z3E3JZ;' W'AK4+:]N(M.B^V6\QD4S*1LVL?W>X9SC;V'-
M<1H7P_O==\6+YLA%Y*"LLLD95 JJ3O4$# X"_-DYR?2O9M$NM5-U_9^E6?V.
M8JSI")O,C>-2,%@% 3&1AL'&37AEKXR\;>(/'TNE2P7FGZ/>AH5NXY9,*47=
MM+ *&R5QMR.#GVINK+X6SW</.-:HIR9L:]HNF-=QHEM%+)H=U)]F+EB#AE!E
M0J0IWA1UZ8KIEN-)M;:RO+6[>ZCU)B+ED3:JS*2H3#KG&T'GIQUKQSQ#HWCJ
MW\46US;+,VFZ<[V[!2RP%4.,%!\O(XSVZUZ4!+I4$UA>61B@O-D9C+;S'YB[
M_.08&TC&..N>M:1FX:IGT>,PU%15K'D'Q%\,^$?B=J$<4%Q(LMBWFNKAL2A>
M1]T#OZ5QNOQV]A:Z1#H]M=Q7MK<I(R;)"HV'(DY&"O< '.#S7TO9Z18:7XDL
M9EM4A"Q3AV:,;1;&)PFXXQO#Y.#STK(LM<.JK-HNDBXU748@ZPND3,R\X16
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MF68VE6CR-ZG#Z?-;Q>+](BU"0,-3#^7*Y^3<-N!\N,'YN<UN^*=&O?#&N?\
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MJ$$QM8(IYK*YD(" 0@E5?&.>F.E?H5\%O#HUKX6:_:SHD\US=S*T,BA8XY!
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MBBOR,Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_4_?ROD_\
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M&T,&; WC#.FTDY)'3K4_C?P'\,;W0Y?%WV[[%<7)\JW3Y9&**<YGC50Y!8$
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MGK7<HN";?4]VCA71@G'9(^HOAEH:>'/"\EI!=?;_ #C)*P0XDFDVX#'<$4#
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M>&W!67*M(<>9R"2HZ8KCH/$*>-KT:1I[?\3"T@D?4+BZ5GECC24J!&#L)'*
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M/M-K"T@A9651QD9;H>W .?3H:VIT9G72I-:,ZCQ'K8LX0MB_EQ\M-,#D*<$
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M)*Y(7/%9QI.^AY^?9IB<35C%:7U.^T+P'HVGVUS9V>R..'?E@@#OM'S9Y^4
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M*Y)1:;N<TL4ZM64NA]MVG^H7Z59JM:?ZA?I5FD4%%%% !1110 4444 %%%%
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MQY[UI:?;:AH]O<6-A9-]G/F",>9MV@KA<#'%?H%_PJ32_P#GDOY4?\*DTO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?__7_?RBBB@ HHHH **** "BBB@ HP*** # HP*** # HP*** # HP*** #
MHP*** # HP*** # HP*** # HP*** # HP*** # HP*** # HP*** # HP**
M* # HP*** # HP*** # HP*** # HP*** # HP*** # HP*** # HP*** #
MHP*** # HP*** # HP*** # HP*** # HP*** # HP*** # HP*** # HP**
M* # HP*** # HP*** # HP*** # HP*** # HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>ck0001824293-20241231_g15.jpg
<TEXT>
begin 644 ck0001824293-20241231_g15.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0! 17AI9@  34T *@    @  8=I  0
M   !    &@       J "  0    !   $&J #  0    !   !WP    #_X@)
M24-#7U!23T9)3$4  0$   (P041"10(0  !M;G1R4D="(%A96B 'T  (  L
M$P S #MA8W-P05!03     !N;VYE                        ]M8  0
M  #3+4%$0D4
M              IC<')T    _    #)D97-C   !,    &MW='!T   !G
M !1B:W!T   !L    !1R5%)#   !Q     YG5%)#   !U     YB5%)#   !
MY     YR6%E:   !]    !1G6%E:   ""    !1B6%E:   "'    !1T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D
M    9&5S8P         1061O8F4@4D="("@Q.3DX*0
M
M                            6%E:(        /-1  $    !%LQ865H@
M                     &-U<G8          0(S  !C=7)V          $"
M,P  8W5R=@         ! C,  %A96B        "<&   3Z4   3\6%E:(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(&2!GJ:ZNO%OVDO^3=?BG_V*NN?^D,U<N7T8U,13IRV;2^]C;T/(OV6OVT?
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MV\-^)[[S%L;BS+I:3S1*6>W>*=GDBEPI*?.P8@K\K8W<U^TC_P %*?&'[/\
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M?9IE^'>)Q$%RJW-:2?*WMS)/0F-:+=D?8=%?B;K_ /P56\:^$?B_XR^'NJ>
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M\K8+D(QW*5)R01FEB?"O.J4*DYTU[BNUS1;MW2OJOUT0+$19^GWQC^/'PI^
MGAT^)?BCK\&D0N&\B GS+JZ9?X8(%R\AZ9(&U<Y8@<TSXL_&GP[\)/@WJ7QK
MU6TN=0T?3;:VNC!;A!</'=21QIM#LJY!D!.6Z9K^=K_@I3\3?&GC[]H&[T7Q
M5H/]CV?A%[K3-,F\N6/[;:K,6$^9.&R>,I\M?H5H'[3?C[QK^Q+\1_%_Q?\
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MRBORY_;4_;V\9_LM_&+0OA]HGAS3]7TK4-(MM4N)K@R_:%\VZN('2,(ZIPD
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MJSTB_@66UU6_\,PW*, 5D25+>)@P[@IP?:OLW_@L/:VZ_!KP),L:JT.NO&A
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M'P 8R <8&<=ZY2'_ ()U_ML_#&UUGP3\(/B99)X2U]W6XCBU"[L/-C8;-\\
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MR<UV7[5O[1_QH_:<T[1+KXC_  _M]!'A<W#QWEG97L+>7<! Z2O/(Z[,HI'
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M(W@F'PS=:?9II[36EI=01S1K(\D?FFX=P6!=@,$<<<X&/W$^#'QH_P"%W_\
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M#9U^@W_!4SX+?\+'_9]'C_3(/-UCX?3_ &W*C+MI]QMCNU'LN(Y2>RQFN/\
MC=^PC\7/B5^V7IW[1&AZOH<'ANTU/0KQ[>YGN5OC'I@@$P5$MGC+-Y3; 90#
MD9*\X_4_7-%TSQ)HNH>'=;@6ZT[5+>6UN87^[)#.A21#[,I(->'G/%]&A+*,
M3A)J4J,(J2731)Q?JKHN-)OF3ZG\J7Q-_:AUGXG?LL_"W]GF$S37WAF\N%O0
M%8F>*#$>EHN/O!8Y73;ZHIQTK]JM:O?!7[!G[#^AZ=XNT&#Q%<V<,-O)I\JQ
MM%>:U?[IY1(SAAY:/YAS@GRT  Z5\L? ?_@ECX\^'/Q_T+QYXWUS1=4\&^'=
M1>^@@@EN7OIS;EFL_,C>V2($2"-I )&'!49SFOTG_:S_ &=;']I[X/7?PWGU
M#^RKZ*YBO]/NV3S$BNX RKYBC!*,DCH<'(W;AG&#[?&'$N35,3A,#AYWPW.Z
ME1J^\I/MKI=[:I-6U1%*$K-O<_*#P'XG_;V_:%^%&I:W\*;/PQ\*_A=<1WY8
M6-I;:?:2QIO%UL7R[FXZA@\BJH9L\]<8_P#P1SS_ ,+8\?<\?V)#Q_V\K79_
M#S_@GQ^VSIGA^Z^#FK?$^R\._#?4)3]O@L;RXN?-BD_UHAA,,1P_\:-)&K9^
M8-T/T!^Q#^P[\9_V6/C!K?BGQ#K6A:KX8U?3Y[ K:3W1O,B9)8)#');)&#A"
M''F'&XX)Q7JY]GF5QRS'X2A7I>_9P4$TVD[^])_%-^NGS)A"7,FTSXA^%'_*
M6N^_[&SQ%_Z3WE?T<U^3G@C]A'XN>&_VX[G]IB^U?0W\+S:WJNIBVCGN3?\
MDWT4Z1J8VMEBW@RKN'FX S@G@']8Z_-O$K-L-BZV%EAIJ2C1A%VZ--W1O0BT
MG?N%%%%?FQN%%%% !1110 4444 %%%% !1110 4444 ?_]+]_**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'/C_\'M/^/OPBU_X2
M:KJ,NDVNOBV#W4*+))']FN8KD85B <F( ^QKA_V4_P!F?1_V5_A]J/P_T76Y
M]>@U'5)=3:>XB6%U>6"& H%0D$ 0@Y]S7TW17J0SK%1PDL!&?[IOF<=-]%?:
M_1=2>57N%%%%>64%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ?_]/]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'*QEXY&8@G)Y8TW:UVPU;T/TI#')3.6'- DYQ7ANL?M(?!GP_.;?5/$]I!(
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M"".^GBMI")9I85E6")4R%XDYXP"<XT+[X?\ BN6X^";06 V^$&']I_O8A]F
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M]2C$90G')4C->.6\_D?M:WMI9C"7?@N&:\V\ RPZ@R0%O5BCR#GG KZ0!]:
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M 'U-_P )9X:_Z"=O_P!_!1_PEGAK_H)V_P#W\%?+/_# W[*W_0HS?^#74O\
MY)H_X8&_96_Z%&;_ ,&NI?\ R30!]3?\)9X:_P"@G;_]_!1_PEGAK_H)V_\
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M6D'2EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXXK[?%=E.IS),^?S3 O#UY46[V"BBBM#S@HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#__T/W\HHHH *3VI:QM?T^YU71;_3;.Z:RN+J"2
M*.=,[HF=2 XP0<@G(Y% 'F?Q+^/_ ,(/A'I\E]X[\4V5BT9(^SB99+EB%+86
M!"9&./1?3U%?#/\ PW;\2OC1XDO? _[+?PZFU6>SQYFJ:H[6<,654G=;W"0O
M_&N/G&0<CBO%8_V;/C'\$/&=_P"-?B#X'A^/.EW$\CQ27T_VFZMPS^8"EO)%
M=,<*-@ (Z#Z#J/V:_P!I#X2Z'^T;\1;GQ7"/AG'X@D@:TL-6B&EK&$M+.(X6
M818RT;$?+R.:: _5GX=1>,8?!&CQ?$&2&7Q&L %\UNNV$S9.=@WO@8Q_$?K7
M:53T^_L=3LXM0TV=+FUG7=')$P=&7U5AD$?2KE( HHHH **** "BBB@ HHHH
M *_/_P#:O_Y+W\ /^QIM?_2>\K] *_/_ /:O_P"2]_ #_L:;7_TGO* /O\=*
M6D'2EH ***:W:@!V1TI,CUKG_$'B7P]X3T]]8\4:I;:18IPUQ=3)!$O!/+N0
M.@)Z]JY[PA\4_AI\03(O@/Q3I?B!H@2ZV%Y#<E0" <^6S8Y(_.@#T+-%1KG@
M=<=ZDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M99<?B:]^'/->!Z:,_M Z][:99?S->^9H 6BBB@ HHHH **** "BBB@ HHHH
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MY1U^Z1ZBLWQ-K$N@Z%>ZM!:27\MO&62"$ R2OT55!(')]Z -O=VH+8&<9KX
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M1Q'QS7W2.@J,+44HJR.O/J<H8J<9N[%HHHKI/&"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /_TOW\HHHH *S=4TVSUG3[K2=2C$UK>1/#
M(A)&Z-QAAD8/(/:M*N,^(5_<Z7X'U[4K)RD]K8W,B$=F6,D'\* /Q<^+^@_\
M$WOAWX_U#PC9?#B[\8>)TD+WEMI4]RK1,X#_ +QYKB)#N+C[K'\*YSP.?^";
MWB'Q59>$O%GPPU7P3?WK;(6U.XN&1F/09MKF4#(SU]*_0+]@#P5X2TKX)Q^-
M[>TB&N^)-0U1[^Z;'F3&+4+A4W$_W5X'M7I/[8W@CPCXW_9[\86VN6<-RUM9
MF:!SC=%*I #+[@$C\: /H/P=X3T'P+X6TWPAX4MQ9Z1I<0AM8@S/L0$D#<Q9
MCU[G-?&?[1MQJWBSXP^'_AE/XXO/!%A<6+7-BUE%$[7]Y^])C<RPS!1%Y4;?
MPYW'D]![G^RKX@U/Q9^SQX#\2:O,;B^O]-1Y9&ZLV]AG]*]+\<Z7X2.E/XH\
M5V,=Y'X>BFNT>0$M&(UWL5QWPM 'YD>-O@QKWPQ^'][\8_B7XUU!_B3IEV?[
M(F(A*7+02J+6+9'%MQ.Q5&) P&ZKU'Z>?#W5-5UOP#X:UG7!MU+4-,LY[E1@
M8GEA1I /^!$U^:>J>,?VMOVEY;+QM\,?".@:=X0@F-QHEYJZ-/<RQ[E>.=1%
M=Q[=P5&PT8/J.M;][\6/VYO@=9OXN^+N@Z)XD\'Z<OFZA+IB-#<6]M$-\LH\
MVZ?(5 W"H3G& : /T_'-.KFO"7B;3?&'AK2_%.DL6L]4@CGCR""!(H;!R <C
MI72T ?+7[0/P7\6>--<\,?$SX67EKI_C?PC.9+9[[>;6:"2*:%XI BLWW9F8
M8P<@<XXKSWPU\!_B9\1?C%9_&CX\RZ;:SZ%8S6&EZ?I)E\L+<Q313RR^<&.Y
MTF &'Q\O0=_N5ESS1M]Z /S;M?@#^TQ\/O#OB_X/_#;4]"E\%>+;F_:WNK[[
M0;S3X-29Q*H\M0A9(W CRK<CYLUW?C']E;Q!:_##X>:7\-=4M[?Q;\/+F&\A
MGO"QMKN48DG1]B%MLTR*> IQW%?=&WG-+MZD=30!\.>#_@?\7/&WQMTWXT_'
MFXTR)O#MG]DTO3]*,OEB0R12F:3S023N1L8?&&Y'I@_M6QQI\>_@!M4+_P 5
M1:]!_P!.]Y7Z ! ,>W;M7P%^U?\ \E[^ '_8TVO_ *3WE 'W^.E+2#I2T %(
M3C\>*3</RZT9)[<?SH ^<_V@OVH?A/\ LU:);ZU\2=0:W>\8K!;Q(SRRD!B-
MN!@?=QR17C/P+_X*(_L_?'OQ1#X*T*YNM,UBZ)$%O>1X,QR,!6CW*,Y[D=*_
M$#_@K5/XND_:LU&'6BQTJ.VM1IJM]S8;>(R8Y_YZ9SFOSV^&4_B*V\?Z#)X0
M+KJZW49MMA^;S,]NG;- ']W*DDGG.#3ZJ61F-I";@ 2;%SCUQ5HD#K0 M%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[M5N<?E'Q7W>.E31J1E%.*L=>?494\5.$W=H6BBBM3QPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#_]/]_**** "L+Q%HT'B+0]1T"[=D
MAU&"2W<KP0LBE3@^O-;M1XP2>N: /R>\9?L=^!_@MH'V_6/COXL\'Z'-<RBW
MMXM7DMX?-G9YFCCB0#))W$!1D\UY3\4?A)\$_!6JOX ^(O[1_C>6ZN[=)YK,
MW][>1K!( 5,_EQNB Y!^<CJ/45]<?MP6]KI^H?#/QMXIT"X\2^$?#^N13:E:
M6]JU\4 !<3- %8,JHKCD?Q8SS7R=HM[X>U/PK\5/VIOB1X+O;MO'-TFE:%ID
MVFO)<^1#:V\8"QLFY%,EM(>%QS[T ?K-\&/"7AWP)\+/#?A#PE?_ -J:/I=H
ML-K=;UE\V,$D-O7@]>HKK_%6@V_BCPUJOAN[.V'5+6:V8@9($R%,CZ9KQ?\
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M(1\X! &0#WQS6S0 4444 %%%% !7Y_\ [5__ "7OX ?]C3:_^D]Y7Z 5^?\
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M TW_ ).!UW_L&67_ *$:]^[UX#IO_)P.N_\ 8,LO_0C7OW>@!:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *B7<!S4M,'IB@+BY.#7!?$32M)UCPCJ>GZU
M+Y-G/$5E?!.U<CG P?RKO<XZ5XU\=BW_  K#Q%LSS:MT.,\BLJDE9M['9@(-
MUH13L[HY[]G[PCX/\'>%[G3O!]X+^TDO996<*Z8D8+D8<D\8%?0_;-?$G[%C
MRM\/KT39XU2XZG/9*^VQR*6'<7!.*.O/*,J>)G&;NPR.M+UIK,%X-(&XXK8\
M@?10.:* "BBB@ HHHH ***,XH **!S10 4444 %%%% !1110 4444 ?_U/W\
MHHHH *R]834)=+O(M'D6"^:%Q!(XRJRE3M)!R" >M:E,. ?7_P"O0!^/_P <
M-5_;W\%ZIH7AA_&&A:U/XQU(6-C:2:;:O&JR$@-,3;L0BY4,VTXS6[\0?!'_
M  4"\(?#F;6HO%?AK4TTA?/.GC2+,HA&<F%?LI&[YNRCJ:^P_P!IKX(^*_BQ
MI.A:S\.=930O&/A2\%_IUS* 8F=%)$<@*2#:7VDG83Q7Q>MY^W%\8]2UCX*Z
MCXD\,:2UCMAUBXL9WEO(D=$D $;V@4,4D1@#C@T ?H;^SUXWO?B/\%O"7C;4
MKT:C=ZO9+-+<+&D0D8L06"1_*O3H.*]D/3 XK@_AC\/M$^%?@/1?A]X>!73]
M$MQ;P@Y)V@D]R3U-=Z<XH \V/PG\!CXB)\5H].$7B5(C"US&[)YB%"F)%4A7
MP&.W<#C)Q7H_&,GZ_2OFC]H+XZ:K\";OPUKMYX?N-4\'W3W"ZU?VR%CIR#RU
MAD?)5%0EV+%F&%4D9Q7D_P 3?VY/ EGHNGZ7\$%/Q#\7Z]$#96&F%+HP&1!L
M>Y$;ET0,ZAB V.>O< ^[UQU%/KF_"EUK%[X<TR\\0P?9]2G@BDGB (\N5E!9
M2" ?E)Q724 %%%% !1110 5^?_[5_P#R7OX ?]C3:_\ I/>5^@%?G_\ M7_\
ME[^ '_8TVO\ Z3WE 'W]G KGM<\7>%_#)B'B+5;;3//)$?VF9(M^WKMW$9ZU
MT!("Y->#_';X;^ /&7@W4/$'C726U23PY8W=S;A;B>':R1%R/W3IG.T=<T =
MC<?&7X36BJUUXPTF(,< O>P@$],<MUS4R_%KX7N,IXKTMAP>+N(YS_P*OXC?
M&?CW7O$/B?5-4M;RZL[2[NII(+83R%849RR(,L3\H(&2<\5^DG_!+#3/#_Q7
M^,FM_#WXDV]QKMI)I;WL/F7=PAB>VD1"!Y<BGYO,_2@#^D__ (6U\+P!_P 5
M7I9_[>XO_BJ^2/V(OB1\/]*_9[T2TU'Q'I]M.D]]F.2ZC1AF[F(X+=Q7P-^W
MY\0OV??V9M0M_A]\/_!JZAXKN%$MP\FHW92TC9"5)'GD[SN1@&7!&:^'OV/?
MVAOA?9^+=&^'?Q?\)QW>C:A,T8ODO;F)X&E?<"566--HY&?>@#]8O^"J":+\
M6?V<(H_ WB2PO[G0=2AO9;6"Y622:(@PD!$)+;3(&.1P!FOY?8U9R(E&2V!C
MJ2<\8K^TY_V.?V<+F+#^%B\;KT:_O2"/<>?@UB#]@[]D]6!7X?VPP.T]S^&/
MWO:@#P__ ()DVVG> /V:/#OA/7M>M&UG5)IKZ*S\]3,L5R%D1-C$-E0<$8[5
M^EXP<>U> >$?V8/@EX&UBS\0>%O#QLKZPY@;[7=.$XQ]QY67IVQ7OPXX Z4
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MCC*G!&>E:&1C.>* &LQ!KEM"\<>%O$NJ:GHVAZA'>7NC2&&\C0-F&0$@J20
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M?&NM:JEOI$5QL3R)F!Q-O<;1A]H^\O7K7GL?B7]OHJK?\*[T-#Z>;;G Z_\
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MG//-#]HKX=^!?!W[0?P(O_"N@V>ESW/BBW61[:%8V;=!=DY*@9R0*_3+:*^
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MOKC0]!T;PUI-IH>@6<6GZ?91K%#! BQQ1HHPJJJ@  #H!0!JC\Z=2  =*6@
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M **** "D!S2T4 ,/6ES@4ZB@&,Z]:?110 4444 %%%% !1110 4444 %%%%
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M["MRN?\ #?\ ;YT6S_X2D6_]JA!Y_P!F9FBW#J5+*I(_ 5T% @HHHH ****
M"OS_ /VK_P#DO?P _P"QIM?_ $GO*_0"OS__ &K_ /DO?P _[&FU_P#2>\H
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M_?RBBB@ IIQU],TZF]\4 >6?%WXQ^!O@AX3E\9^/[];'3U;RT[O++L9Q&@)
M+$*<9(KYQT']OCX-ZW\/M0^)5U::GI.C:9JR:1</>1PJR2O;BX#D)*P\O81S
MG.>V*R?VUED\/:C\-_B?JVERZOX9\):U%=:E'" [P1H"_GB/(9]BHPPH8\\
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MG E*]!7YW_LV_'[QW\#/B9I'B7PSJ4J0?:%%S;Y+)/&Q&589&1P.XZ4 ?VV
MY_SVIU5;287-O%..DBAN>O(JU0 4444 %(0",&EHH :%P<]^_O2'=GV'7Z4^
MF$#.>AH 0Y(R*\]^+*D_##Q6&Y']EWF?^_35X=XI_;*^$'A'Q#?^'-4_M W>
MFS202>793NI>-BK88)@C(ZBO,_B!^VM\'=?\#Z_HNG)J+W=]8W$,2FQN "\L
M9 R=GJ: /7?V,\C]G7PR%''G:E^'^GW%?4O>ORW_ &;OVM/AA\.?@YHOA#Q-
M;ZA#J5G)>F5%LIV&)KN65<$(1]UQ7O<'[<WP5NIDMT_M'?(0/^/"X R?^V=
M'V6&8^V?7UI0@!R.._YU&CI*BS)R& (^E3?6@!H4 D^M.HHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJZ2^TO1+&SN8\[98;:*-UR,'#*H(R#B@#\LOA7\;_#/P7^ _C#X'>.TN-/\
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MJ@ D@Y]1UYI](.E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M":#:BU5]-L]P#,V?F)[DU]1C.[(Z?UKP/3>?V@=>]],LOYFO?AP<"@!:***
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]3]_**** "L
M[4+^TTJSN-1OI!#;6J-+(Y!(5$&6.!D\"M&LC6='MM<TN\T>_!-M?1202A<
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MUKZX%1[3G=Z<>U24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY^%MVNF^)_'-^+2.]=$E%I;96.6;RW5PQ1I48 @ XY(H ^N1CZ_C7P#^U?\
M\E[^ '_8TVO_ *3WE9?@3QQ\:?@5\=-%^#OQF\5_\)UI?C&U\W3M1^R063PW
M1ECB\EHX5 ()9R#O)P!\OIM?M41%_CU\!6 W!?$UL<>G^CWG- 'WR.E+31G'
MI3J "BD!]:,T +10:3)H 6BDS1GVH 6BBDH 6BBD)QVH 6BFYS[?A3J "BDI
M,Y]J '44F<<=:6@ HHI* %HI#3-S>F/K0!)12#..:6@ HHHH **** "BBB@
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M;N_S[4 .HIH.>G2G4 %%%% !1110 4444 %%%% !130V>,<CM3J "BBD)Q0
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M/_C-?0%% '@)^'WQF_Z*1-_X!VG_ ,9JO)\._C6?N_$J8?\ ;G:?_&:^AJ*
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MSN(,$,1.[(ZYZ5[Q10 @&!BEHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEB3P.E>L_LR? _Q5\/\ 4-?^(7Q"NX[OQ/XH6!+GRD:)%6V+B/"'./E;L>:
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M_2XQ-?SK IXRWO7.^)= TOQSHUO:2R;[=9H;E&4D9,3;EYH \T'Q-^+1&?\
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MLI!/'X5N3^(-'MKP:?/=(ER>D9^\<#/\J+ >-_\ "S/BS_T3"Z_\#X/\*/\
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M HHHH **** "BBB@ HHHH __T/W\HHHH **** "BBB@ HHHH **** "BBB@
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MC]?2I0 .E "T444 %%%% !1110 4444 %%%% !1110!__]']_**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KSWQ]X"F\:#3;O3?$&H>&]4T>5Y;:ZL'0\R)L9)H
M9D>*6,CG:R]0"".:]"HH \W^'7PUL?A\FK79U&ZUO6=?N!=:CJ-Z4\ZXD1!&
M@VQJB(B( J*J@ 5Z,B)&H2-0JCH ,"G44 %,DCCE0QRJ'4]01D'\*?10 UE5
MAM8 CT-.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!C $$=?:F@' RO/UH9F&2!]W]:^)/A?\<O&%U^T7XK^$/C
M:4+!86=M<V?RJ,FYD8*/E&>@'4T ?;IR<<4FX_PC/.#_ (U\!_MI_M)>*_@U
M:Z=IG@09U59H+FYX0_Z&5DW\.I'51TYKZ4\%_$G^W?@78_$N[D$EQ_8B:A..
MFV3[.)6' QU]!0![0O#' ^M/XZ5\:?LF_%SQS\8H_&>M^*)1_9]EJ2QZ:-J#
M%JZ%ARH!/U(S7UXNIV#7!M1.C2KU&?QH O@$=3FEIF50DDX%4H]5T^68VT<Z
M-*N,KGUH O$CO2$$D$#\:^3/VIOB]XG^$\/@&7PQ*(SXA\0P:;<956S#)&[$
M?,#CE1TYKZ=T>_\ M>CV%[<L%EN8(W.3C)90?YT :P'.3U]:?52>\M;2/SKF
M18U'<FG6UY:WD8EM95D1N00: +-%("",BEH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]+]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!ISU
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M 4444 %%%% !1110 4444 %%%% '_]/]_**** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
C **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ck0001824293-20241231_g16.jpg
<TEXT>
begin 644 ck0001824293-20241231_g16.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0! 17AI9@  34T *@    @  8=I  0
M   !    &@       J "  0    !   $\* #  0    !   "D     #_X@)
M24-#7U!23T9)3$4  0$   (P041"10(0  !M;G1R4D="(%A96B 'T  (  L
M$P S #MA8W-P05!03     !N;VYE                        ]M8  0
M  #3+4%$0D4
M              IC<')T    _    #)D97-C   !,    &MW='!T   !G
M !1B:W!T   !L    !1R5%)#   !Q     YG5%)#   !U     YB5%)#   !
MY     YR6%E:   !]    !1G6%E:   ""    !1B6%E:   "'    !1T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D
M    9&5S8P         1061O8F4@4D="("@Q.3DX*0
M
M                            6%E:(        /-1  $    !%LQ865H@
M                     &-U<G8          0(S  !C=7)V          $"
M,P  8W5R=@         ! C,  %A96B        "<&   3Z4   3\6%E:(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?&_XCZ9J?Q:/A:S\7VMC'#;PPZMIUC=/;++(T;^5YP=@'+A6QV('2OKGX_\
M_!-KQY<?%Z?XW?LN>+8/"VKWES+J$MM<S36C6]W*29&M)[>-R$EW-F-U &2-
MQ1MJ\C\,O^":?QB\<_%>V^*/[7'C"WUZ.WEBFFM8KB6^N;WR?N032RHB10#
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M>[?!?_@E%XRO?'$/C7]ICQ1:ZI:).MQ-86,T]W/?L.2ES=3+$44D#=LWLPR
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M"Q_].%M7UYH%A+I6A:=I=PRM+9VT,+E<E2T:!21D XR..*\2_:I^$_B+XY?
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MXEO/&\3Q:_=%/*2>)XVB6")>66.-7;:22Q9F?C(5?@(_\$X_VK/@9XUO]?\
MV7?B/;V^G7F44RW,MC=M#N)2.XC$4EO-L_O$C)R0BYQ71E7&-"KF..J_6X+G
MY;*<&J<^5)7>K<7^>CMT2E2:BM#GOV6OVY?C)X2^/FF_"']H7PW;/J7B/4;;
M3+N]FTR/3-:M[J[*QP/<>6D0E0EDW%TW;"'#'&&\]_;JX_X**Z$3T^T^&O\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]/]_**** "BBB@
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M) Z<UP\%<,8">'PE/&X6"]JF[SF^>>ETX12T7K;3SW=6H[NS/N[_ (*1>/\
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M(;&,=Z^?XDPF58++<%1IX5.KB*4&YMOW6U'WK=6VWV_0NFY.3=]$?EC\>/\
M@J;JNE_$&X^&O[-GA.#Q;=6EPUK]ONEFN8[N="59;2UM6221 1Q)YGS\D+MP
MQS_A%_P53\1VOCV#P#^T]X*C\)M-)'!+>6L5Q:M922$;6N;2[9G6+!!9@^5'
M(5NW@_\ P1\M_"LOQD\93ZDL3:]#HR'3]^-ZPM.!=&,'O_JP2.<$CH37=?\
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M@D=0:R/VT?#FCZ3^PCXO\.V-K'#8:7HVGQV\2* D:VT]OY84#@;=HQBO@?\
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MS/#)X?VD%AXR?--QBG=^])N_NKLO6VC(C-\KUZG+V/\ P5(_:(^&OC.QT/\
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M+>(Z6XD(4DHJR8P1EL9KSG_@L/#$OQN\%7 4"1_#H4GN0MW.0/PW'\Z^X/\
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MM"^'VB>'-/U?2M0TBVU2XFN#+]H7S;JX@=(PCJG"0 KGN>3BOSS^/\.GVO\
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MPCD8G:6CL0>>,C.*_H7HJ^&>,L;E/M/JC7OVO=7VO;\V%2DI;GX$6'_!)_\
M:&\8:U:R?%WXFZ;+8Q'#30SWVJ7*H3\PC6ZB@4$X_OX[X/2OUX^''[-?PS^%
M_P $+GX">';:3_A']2L[JUOY79?M-XU]$8KB:5PH!D=3@?+A5"J!M4"O?Z*Z
M,^X]S/,8PIXBI:,7=**45?OIU%"C&.Q^"_AC_@G1^V7\$O'.HW'P%^(NFZ9I
MNHJT!O\ [3/:R26V<J+BW$$PWC)QL+X/(89KH_"?_!,GX]_#GXZ>%?BSX?\
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M_5\5\VGS<W)>2Y9/D5Y+;5[^FRUV(^KQ/Q^_X*2^&?V7_B!XGT?P]\0/':^
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M>Y\._MR?LGZG^T]\+='\,^"[^TT?6_#5X+FR6Z#):21-&8I(&,2L8^-I5@C
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M2)&Q7GNH/M7L]%%? XO%3KU9UJF\FV_5NYLE;0****YQA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__U?W\
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M __6_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#_]?]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /_T/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH __1_?RBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BDR,X[TN: "BBCK0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% '_TOW\HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9,=.M?<?[/?[5I^(\MOI/BA(X[Z\94B,";8]Q+?>)8G&!7\K_@[7&%PCL?\
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M!76&%5WB-,<OSD8 \_37?$FH'PMX;\1:G)K@\)?%9-(M;^8AII[:&SG=!,X
MWRQ^9L=L#)'KF@#]"\49Q1G-% #\"DV@"G4A.* &@>E)@]Z<#2X!H 9G%'7Z
MT_ I-HH %QVIU(!BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJO@[78A+;:C;RPY*JQ0R(4W+N! 8 \&NWV[4*=_YTR9Q$OFRG]VHR>VW'<T
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MK2,0J .<>K=LT 39&0/6EJ)@=W7GM3@ &Z=NM #Z*** "BBB@ HHHH ****
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MJ;=['J?P_P#C'X#^)5_>Z5X9O9?[1TY%DGM+JVFL[E(W.%?RYT1BA/&X9 .
M<$UZI7SQ\5/&/@'P=KT^K+:Q7'Q%LO#NK7FF!8I'<VUK$TS)*R?*L;NGR[R
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MG@8 /T4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M_];]^\ ?6F=.7ZT%L'&TFG,549;@"@"%Y88SAI%!]&(J/[5;]4D3(_VA7Y3_
M +5]]^T'JOQGETOX0?$'3M"M#:VP%C/9QW,P<KAFR03AFZ5XS%\+O^"B\T8>
M#X@6;H_((T9"/_0: /U"_:BG@D^ ?C0+*O-B^,,,GD5XE_P3Q^;X'7S]/^)Q
M=#C_ *YQ5\)>(_@5_P %!/%6BW?AK6_&MK/I]XACE4:.JY4]1N"@BOTR_8^^
M%'B+X._"0^%?$LRW%])?2W#NL9C!#QQC[I]U- 'U8@/!)X'Z_6I*8H]L4^@
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MA.33ATH 6BBB@ HHHH **** "BBB@ HI#3.3E4&TCO0!)14;%N.,T@<8Y/\
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M,&N=T;]GCXD^%O"VBOX=N-(75]'\42:_;Z6\]U_9=K;2P- ;6&9D>; W;\E
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MHKT91W(YZ5!!:6UK"+>UB6&(=%10JCOP!Q4_ Y_"@!U%)NXR* <]* %HHHH
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MM[8-MD"E V3GH237H>0#@F@!U%-# ]#3LYH **0D#K1D4 +12$@=:,@DCTH
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M5Z1\(?":^$M%O;N^MA,9A)>2^;+N957!; X^6@#U,<'%.IBC!Y[T^@ HHHH
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MO38O;A/,CW8WA\XY]A7ZP?$\G_A6_BH=<:7>?3'DM7QC^P+DZ3XNZ?ZVT_\
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M^SOC9X'^/G@_QS-\6/A'>G5K988UNM/U"\=;1((1O=XX589D)4#W!->/VO\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__3_?O
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MKZ2'>@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#X+;LX(X/->2_"S_ ()^_M!^/?$,6EMH(BM P\Z3[1""N 2, MSG% '[+?\
M!*CX<^&[OX!:1XYU"P:35[F2[#3R,S*WE73A,*>. !VK];TB\O"IA4QT [UX
M_P# ;X3:/\$_AII?@#2%"PV1E884+\TKEVX7CJ:]GH @>WAEP94#D>HS0D$<
M6/)14]< #-3T4 -VC-#*'&#TIU% $$EO%*<2(K@=F -5+S3[*ZLY+&>%7AE!
M5D QD$8K2IN#NSCCUH _*?XB>&]=_8J\?M\2?A]9S7?@'56']IV4*F5XDBC"
MINFEW;-TKY&,9Z5^D/P]^('AKXD>&K7Q)X7O8KVVF1-YB<2>7(45FC8CC<N[
M!%;?B/PYH'BO2;C0_$EA#J5A< "6"= \;@$$94\'D U^6QE\4?L._$C#F2\^
M&WB*8$O(WR6UQ<REG"0QY/R1H,$CVH ]A_X*(8/P?'./]-TW_P!+8Z^]M+=3
MIUIMY_=)_P"@BOQ@_;F_;(^ OC3P!'X8\/:ZUS?/<V4BI]GE4%(;I'<Y*XX4
M&OTS^"?[0/PL^-.BQ7/P\U7[<(8HPX:-XB#RO <#NIH ][W#G!Z4F[)&!UI,
MJ.W)XH'RMCUZ4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY
M7$<;2'HHJ2FN-RE3WH _*/X0>*?B-\1OB_X\^*.I>*+BT\/>#+S5-&73R T3
MM#ED?=P01G &#]:^4/!O@CXE_M%^'_%G[1A\87.FI96DUQ8H$60":S)C^5B5
M(/R^E?0_Q._9/_:0T+Q#X@MO@[?Z9%X>\4ZC-J-X+N>59Q+<.=P3RU "[<=<
M\UZCXC_9Y^+'P_\ V>="^!7PJ:P#ZE)=6VIS7#/D0W1+$QR(HP06ZD4#9]%_
MLC>.-:\9_"RQBUZX>[OM(AM[>:=SEI7V?,Q]"2*^I,C>8\8]/K7B7P ^%+?"
M+X<Z5X6NY!+J$5M ETX;<K2QIM8AL D?6O</F')Q0(<.F/2EIJDGK3J "F/(
MD8R[!1[TX]*_+7Q]X^\>?'[XNZA\/?".HPZ1X7T5)HKFY>5[:;[;:S,C*)$8
MKM*,#CKF@#]25='Y4@_0YIC/&A^=@/J<5^?OP#7XG?#GXAZEX)UJ^BUKPR3;
MK9W2RR7,HW*SRF21CM^\<#Z8KRK5_$7Q,_:A^,'B+POX5O?[-\.>$[V\TJXD
MCDDMYC=6DA*X9"P*D,,YP31<:1^JZO&W*L&^E?/'QUY%E_NC_P!#KY7^!'Q+
M^('PR^->K? /XD3QW=K:Q6OV.X1GE=Y;L[R&DD89 #=AQ7U-\="#]AB)PNT9
M/T>A274?)K:)[_98-I ,\^6G\A5P9Z5G6,J?8H-QY$:_RJP+F(GKR*;F@49=
M46\GTHYJO]I3UH^TIZU(<C+'-'/I5?[2GK1]I3UH#D98YHYJO]I3UH^TIZT!
MR,L<T<^E5_M*>M'VE/6@.1ECGTHYJO\ :4]:/M*>M <C+'/I1SZ57^TIZT?:
M4]: Y&6.:.:K_:4]:/M*>M <C+'/I1SZ57^TIZT?:4]: Y&6.:.:K_:4]:/M
M*>M <C)R?44TFHQ.K=#3B ^#G\J<6GH+;<<6R, 9J/8/O+S[4X_+UX%)NX'O
M2EIJ@;:V/S+N/VC?&R?MN^'/@Y'+(NC7Z:D9$$GR,;=6*Y7'MZU^G0Z"OQAN
MO"?B0?\ !2'PIKZZ?/\ 8(UU?=.8V\H;D?&6QCGMS7[,@90=L<^].]PYKDN1
MG'>C(IHVXS2;<'&>#^= A^X<>]+4.5R5YRO^>*<O]X?3F@!^10"#T[5$Q3D'
M/R?K0"!A^V.G>@":DSVJ-@#RV?PHZ+ST[>M $M-W*<\]*:0 <\\TA.,A<9_2
M@"7WINY>.>O2F<@;1UZG/2D.""J]^E $V:;O4';GFD4DC ZCCFFMDG"_CGTH
M EI,@U"6_A3[WOTIY.<<<9H DS14'7<%R&]_Z4\8//(Q0 XLH!)/2ER#31M)
M)_G4*E)<D;A@XQ0!9I,]J8-HRW-+N&,X- #\]J*C5L<=AWIPS^% #J*9&H1=
MH)/UI] !1110 4444 %%%% !1110 4444 ?_U?W\HHHH I:A<QV5G/=R@E(D
M9FQZ 9-?B%XD\)^,/VVOB5\1_P"V-2^Q^%_AO?7NG10QO);S.4W/$=T>X,!M
MY)P:_<&[MH[RVFM)AF.9"C9[AA@U^*OC%/BO^QE\1OB%X@TK0_\ A(/!WC^\
MO;V5C<QP+;RS;DB01J9';AB<D#WH \N^!WP7\0_%?]C/1-3\/:JUMK'AR/4)
M())II=I=[N0#=M!+8QWK]3OV-OB9KGQ.^$1OM>96N]%OI=+=@NT-]ECC!(Y/
M4GJ>:_&/]F_X_P#Q7LO@8GP'^''A'[3KFHK/ +D7:PO$TT\DBD!UV'[W]ZOV
MW_91^$>I?!SX6?\ "/ZTQ>^U&[DU"XR%!62=$WC*LP."IY[T ?3*D'IT_G3J
M8N!@#I3Z "F\XPO44ZB@"(B3(*\*.H[TX9P=W>GT4 1@8QM&,TXY.<4ZB@"%
M5V_( <GDGM2R#]VY[D&I:9+_ *I_H: /F_\ 9R_Y FJ_]A.__P#1YKZ2'>OF
MW]G+_D":K_V$[_\ ]'FOI(=Z %HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBD.,<T ,ED2-"\C!549))X '>OS.^#NNZ*
MW[;GQ@*WT)$]SIGE_O%^?%HV<<\XKP3_ (*6_MO>)?A1J,'PK^&MS)9ZA>VH
MFEO89"CQE9GC>/:T94@A>N:_!S2/V@?C%HGBZX\:Z9XGNX=:O'5YKA2H>0HN
MT9.W'"\=* /[D0RD @C!IW7I7YE?\$\_VPV_:%\)'PSXK.WQ'I4#RS-)(SL\
M4;K&&+;%7YLYP"37Z2/J-G""\DR*J@GJ.@[T 1:SKVB>'K-]1UV^AT^UCY:6
M>18T'..2Q ZFOS&_8O\ 'W@D_$7Q7;?V[9>=<WFH>4GGIN??<)MVC/.>U?GI
M_P %,?VQ/%FM?$K4/A#X+U*73]'TDQ^?)$_%P)H8I0&1D&-K9Z&OR=\+?$KQ
MQX'UN/Q#X;UB>QOTD#^9&0&/S!LY(/< T ?V%_M ?M1>%/A/:_V%I.[7?$EX
MNV"RL3'-<!MX1B8MX8A,[FP. #7C'P#_ &8?$&M^+?\ A=WQTN$O_$CO'+;Q
M0&2.&,Q;D&^"1<<ICZGFOG?_ ()K>'/#7QQL=5^,GQ!G'B;Q7IES&B7%RA\V
M W,!:1%8;0<DY/%?LV@P",8/I]* (1;V_DK (5\I1M"[1@8X''3%-M[.T@+>
M3 D;'J54+G\JMC.>1@4Z@!HYY-.HHH **** "BBB@ IDBAUPW3VI]% $9W9#
M#IW'>OSI_P""F/Q.E^&O[/\ (;>%96UZ:73R617*>;!)\P+$;2/4<U^C1YKX
MJ_;J^ 5W\?\ X+7.@Z<W^F:29KZ! %/F2)"ZJN690,D]: /XXI9YYV'GNT@7
MC))-?6G[&'Q5\0_#+X_>%)K"Z)LI[Z+[1'DL'15<@*"0.IKYN\6>#O$'@KQ!
M>^&->MFMKVQE>&9.&VO&<$94D'GT-?:G[ O[-7C3XN?&;0?$-O8DZ%H5W#->
M2DQX6)_,7.UG5CRO8&@#^M[PYJ@UKP]IFL8(^W6L4W_?Q W]:VO[M9FB:9'H
MVD66DQ',5E!'"O&.(U"C^5:F>A XH =1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %(W0]J6HYI%BB:1^BCG% &7J&JV6E6QO-2E$$*G&YNG-0V/
MB#1M0@AO+.\2:"X;;$1T+#@@5^.FNZ+\2OVPO&/C:_A\4:EX:\,^"[R_TQET
MN]DM7>:S+.A:,D@Y! ) K$^%WA'X@>.?V'M"\7Z%XKU2/5_!\NJWRR&]>,W)
MAF<*DSYW,O'3-4D-G[@<=<8-!!X!;IS7S/\ LI?$35?B#\*-,G\0G?JFG6]O
M#=-EFW2E,L=S$EN>^:^FL MBDT(4'/TI:0$=!VI:0"'D<5^$_P"SK\-/'_Q0
M^,WQ2T6+Q(=)T9/$>M2>0T"R*TBSJ V>#RK8Z]J_=@]*_,SQI\'OC7\%?B_?
M?$_X'6=GJ.GZS',;J"^G\M/M-U,TDCB.,KDX5<,>: .8T'6?B!\ _C:?A/=:
MT^M:1XEE@MK-%B2);8K'YLAZ%FW%NF>*ZS_@GZ8DUOXX0RR!K@^/-5W=CG"9
M_6M[X.?!_P"*'COXK7/QG^-MK:V4B/!+IL%G*)8UDC0Q295]Q7(53P1DUQ_B
M;X3?'7X%?%K6?&_P5LK*_P!#\2W%UJ%['>S[!]MNY#TCC*Y 4#DY/O5Q:5[@
MSG/C9)(G[8FE/I2F:YMKW3GDB7J5\M,#GIFO0OVBOB#\49#Y=IX0NHDA.V-M
MRD2 /P1\M7O@#\#OB;KWQ7UCXZ?&R"WM]0U.&W2&WM9A-!&]H=@*JVYE)4 D
MYZU]"?'6.)ELAM!^4=O]NN:K2<MF=^5XJ%&HIU8\R/CZ#XU?M.+#&$\%:BRA
M0 <Q\\?[E3_\+K_:;."/!&H@]QNC_P#B*_3&RTS3?L<'^BQ?ZM?X%]*M#2],
MZ_9(N?\ 87_"N6>";=^=GTO^LV&_Z!HGYB_\+L_:>_Z$G4?SC_\ B*/^%V?M
M/?\ 0DZC^<?_ ,17Z=_V7IG_ #Z1?]\+_A1_9>F?\^D7_?"_X4_J<_YV'^LV
M&_Z!HGYB?\+L_:>_Z$G4?SC_ /B*/^%V?M/?]"3J/YQ__$5^G?\ 9>F?\^D7
M_?"_X4?V7IG_ #Z1?]\+_A1]3G_.P_UGPW_0-$_,3_A=G[3W_0DZC^<?_P 1
M1_PNS]I[_H2=1_./_P"(K]._[+TS_GTB_P"^%_PH_LO3/^?2+_OA?\*/J<_Y
MV'^LV&_Z!HGYB?\ "[/VGO\ H2=1_./_ .(H_P"%V?M/?]"3J/YQ_P#Q%?IW
M_9>F?\^D7_?"_P"%']EZ9_SZ1?\ ?"_X4?4Y_P [#_6;#?\ 0-$_,3_A=G[3
MW_0DZC^<?_Q%'_"[/VGO^A)U'\X__B*_3O\ LO3/^?2+_OA?\*/[+TS_ )](
MO^^%_P */J<_YV'^LV&_Z!HGYB?\+L_:>_Z$G4?SC_\ B*/^%V?M/?\ 0DZC
M^<?_ ,17Z=_V7IG_ #Z1?]\+_A1_9>F?\^D7_?"_X4?4Y_SL/]9\-_T#1/S$
M_P"%V?M/?]"3J/YQ_P#Q%'_"[/VGO^A)U'\X_P#XBOT[_LO3/^?2+_OA?\*/
M[+TS_GTB_P"^%_PH^IS_ )V'^L^&_P"@:)^8G_"[/VGO^A)U'\X__B*/^%V?
MM/?]"3J/YQ__ !%?IW_9>F?\^D7_ 'PO^%']EZ9_SZ1?]\+_ (4?4Y_SL/\
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MOAUX,O\ 5M;O!<?:X(#'YD!0CR]VY2/F'3BOCV+]H']OO>%?X5ZVPSSS!_\
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M#RF4PE2,<XS'GK7ZYK&B?=4#Z"FM#"_WD4_44 ?G'^SO\7/VL?%'CD:=\5?
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M?0 4444 %%%% !1110 4444 %%%% '__UOW\HHHH H:DDTEE<1PLJ.\;!2W
M#$<9]J_&#X,_&[PE\*/VF?B7X6^+NMV$BZGK-[/;.T\9MX8XV*[)#.ZA6R>
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MGBV[>XATO77@M@TLD@2,*2%4.S8'L* /TN7D9ZTZFJ0?N]*=0 4444 %%%%
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MOG_:FBX.,8VCTK]W2G0MR1WK\N_B'Q_P4@T13T_X0C/X_;VH ]V\#?L3> _
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M4;SQKXX_9*\>>.]&N/"NI>(O#OB^]U'4C/96Y$44MT61%:5E;YAC. >:\/\
M@E^TAXLT;]FF/X%^'/ FL7.OZM]OMOM$4/F)&;N5BC-'L)P-WXU[I\/OV@_"
M7A7XT>-/!7[2>MR7EG+J]_)8V]]'+>QK:JY6,*$5PH!!P.,5]@:)\>/V)?#=
MTE[H#V%C.""LD.F3HP(Y!!$55%C9ZG^RE\.]4^'_ ,*=+37E:+5-1M[>:[1T
M:-EF"88%&^Z<GIQ7TS@=/3^=<OX4\8>'/&VC1:WX:NOM=C.JNDFQDRK#(X<
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M_L[:WN7_ *?K;G_R%7Z$_!/Q[XJ^(_@Q?$'C#PW/X6OS,T?V2XD61P JD-E
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M(H #U%?EM\11G_@I#H?MX(_]OVK]2"1D"ORU^)$RP?\ !1W1IG;8J>!\L3V
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MX0?MJ2GP?"NGVWB.73+.2"+Y5*A%)R><Y)S7VY\=#E;+/!VC/_?= 'T#9_\
M'G!_US7^56QTJI9_\><'_7-?Y5;'2@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#XF_;<('P\MAW^V0?^@R5V7[)0"_!C0^F?W_\ Z/DK
MBOVW4_XM[;2-]U;N$D_19*S_ -F/XD>%]'^$FC6EW>B-D\_LW_/9SZ5Y4[JN
MVWI8_0(X6=7)HJFFWS=#[F^4G'<T  #:*\H3XP>"%QG4ESC^ZW^%._X7#X&
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M<)+>M-+/';7#%O+5L#: !PO0&OV0)(&0,U4N+:.ZMI;6Z^>.<,K#U5A@C\J
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MZG'=95'0J6U<=26BBBO4/@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/$VI6;6@2^E@@4Q"+,*(A1@ 2""&Z]Z /I520VT]ZEJ,!MW48'6I* "BBB@
MHHHH **** "HY?\ 5O\ 0U)3)?\ 5/\ 0T ?-_[.7_($U7_L)W__ */-?20[
MU\V_LY?\@35?^PG?_P#H\U])#O0 M%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4ASCBEI& (P>] "
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M65E['/:OHI6&W .<=^U$MP)1@<#M2U&F#D@'FI*E %&:*8=I.,4P'YIH92<
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MY^,9)Z>))./^ &OUP\1VEEJ&AWUCJ4@BM)H765V;: A')+=J^3_V8?A?\)?
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M- 'U/^V/:07W[.WBFVFP8W^R9!'I<QFORLM=4OM<\#_ 6QU-C) /B)"N"<@
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MK>QDO%&X/*_-U(&?2OT.P1D@9/\ .J.F:;9Z+IEMI5C&(K:TC6.-5  55&
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M0:A90@O$EPD4R1PB592P??&WS #FOWOTG2K#0M.BTS285AMK90B(@"JH48
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MM-N9K&Z\:Z>L\60093G./I7V#/##<0R07"K)%(I5U<95E(P00>"".M?SS_\
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MMJEY=8!598WD7[ZJ<A"#T)[U^7_B_P#X*JZKX&OCINNV=B)P <1VTS]?7$M
M'[=GVI@.&..3WK\8/ 7_  4Y\1_$5BOARPL92'VLK6TZMG )P/,]#7ZM_"KQ
M;?\ CGP!I'BC585MKK44=I$160 J[*,!B2.!WH \E_:$\1_&K1+2V;X1Z/=:
MI(TRB06X4X3822=P/\6*_-OXI?MJ?M#_  E5/^$KTJ[M+@R+%Y<AB4Y8[3_
M>AK] ?VWOC3=?!'X'ZMK6ERB'4-1AN;2W;YLK*UO(R,"A4J05ZYK^0WQC\4_
MB!X[U&YU/Q1K]]?2S2F79+<RR(K$Y^4.QQ@]* /V^\??M2_M/?$"&P^%_@^R
MO&U7Q06CA:-8G93#B4_*4YX4]Z_6[]FGX0V7PA^'4&CQV_V74+Z0WMX""&-Q
M,B>:2"3@EE[5_-!^P)\>-3\%_M#>'#XPN6U2RN99!YET7N9(-L$O,1+?*22
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M;_9'_H= 'OUBH^Q0*5P/+7^0JQ'G<RXP%Z57L5Q90#/_ "S4_I5P4 +1110
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M,O O[=WP,^(?BBT\(^'EUC[=?[_+\[3GBC^12YRQ/' -?9D;B1 R]& (S[T
M.(#?+FOSB^#P/_#;?QEZ8%SI>>/^G1J_0>77M#MI3%/J%M&ZG#*TJ!@>X()K
M\Y?A)K&E1_MK_&&Z:^MUADN=,PQE4*V+1NAS@T ?I@"0V,Y]J &R23D>E9EM
MK6C7<ODVM]!-)CHDBL<?@:TF!]<#UH @\JW/6%58]!@?X4IMK<'>8TQC!^45
M8PK8..G2E(SUH ACCB4@QQA0>X%/(!7#?=IQ7C:./I1M&23SGMVH C**1\F
M![4@CC)#LH)7H<>M38'2C _"@"/:@^4C KS'XP:)X;U[P'J>F^)YTM;:6*18
MY7W824HP5OE()QD\5ZE@'KS7%>._ ]CX^T!_#VHW4UK#(VXO"0'Z$8Y!&.:
M/Q^^$_[9]Q^S/#_PJSX@C^WO#>E@6]AJN]+6$11@Y8*(V8AF('))%0?&_P#;
M1\._M&Z(WPP^'5@L$.L(]K<ZI'*LT=M'<+L\QHS&I(0\G!&:^M]8_P""<WP@
M\01^3K>KZE?1#HDPMY%'?HT9]*KZ-_P3;^#/ATL=!U34=/+=?(6WCS]=L0H
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M0Y)96(P0,GFO1O@)\<?V/8_#T$=OH-AH6OV$:1WL,&G.HBF"_.JOL&X CJ*
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M^56QTH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$/(I?K2'I2 'O0 I -1X%2<"FX- #<"C IV#1@T[CN-P*,"G8-&#1<+C<"C
MIV#1@T7"XW HP*=@T8-%PN-VCTI<#H*7!]*!P:F:NM17(V09R*=M'6E)[TH/
M%5+1 ]3\J_VOE!^.'AP?].D?_H]J_4^T_P"/6'_<7^5?EC^U\V/CAX=/_3I'
M_P"CVK]3K3_CUA_W%_E7B9;_ !ZWR_4_3^,K_P!BY9?M/_VTL4445[1^8!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]#]_***
M* "BBB@ HHHH **** "BBB@ HHHH *_-?]NR[?5?&/P7\*S?\>L_C.P$@Z!E
M>*0$&OTHK\Y?V_\ 39--@^&7Q$0%;;PMXIM=1O'4<K;V\,A8G'S$#T )]J /
M>/VEO ^BZG^S_K>A3PK]DL;"1D7C(,$+%<<>U?C?^S%XM^)'[+OP?\.?%71Y
M4U+PUXQ2=Y],@C:>^"V<TD2A5;:JG<^[@G(K](?VB/VG/AU>_L_P3Z9J1FNO
M$T%M!#&(Y@2;U=B\E/5N^/?%=Y^RQ\%/#EK^S7X*\->.= M;^[TV"YP+B-)"
MIEN)'XZCICO0!^<_@']O:]U#P[?^ O!/AC5=-UK5[FZ OKVV0V<!NG(#2$.2
M C,"W' !K[=_9:\$?#/X5Z?JOBKQ9XLT>\\3>*IEOKUQ=H8UF=3Y@"28* D\
M"O1?@7\ OAS9Z;J4NL>#M.\Y[Z\VEH(V/EF4E>>>,5[P/@M\)><>%--P#T^S
M)_A0!YA\7A\$_B=\/=8\"R>(-$A&HHB^8;F%=NV17^\,D?=]*^*?V4_B_P#"
M#2K35_A5\69=,TV\L[RYEMKRZ-O;V\MLI2*)5>0AF8\D8&"*_2;_ (4Q\)PI
M\SPEIN.Y^SIS^E<+XM_96^!GBN/?)X-TF"ZP L_V*-G7&<8/'0G- 'EGC[XT
M_LL_"[PS<ZW8ZEHNLW04".TLY[2:YDWG9E$)!(7.3[5Y!^Q$G@7P]X2O_'7C
MK6-(M-9\1G;)!+)'$\:P2.$)C?&W*D=.M?0WAO\ 8R^".D78N=:\.:9K;J3L
M\^QC^08Z#.>_->QI\$?A'$-L7A#3 A["V0 ?I0!R'C_6/@GX_P#!NK>#;[Q'
MI(@U.UF@)2ZA0KYL;)D,"2",]<5^:FE?&#QA^QI,/"NFW<7CCP1#^ZTZWT5?
MMMW!!%P!-(Q4%BSY!'4 U^KP^"_PE5N/"6FC/;[,G^%(WP6^$Y#?\4?IA_[=
MTY_2@#\IM9_:;^)/[4D8\%Z+CP+X>U',&H'7H/LTDEM*/+=8I$9L-U.>PK]'
M/A5J?P?^&/@C3O">G^*M+(MHHQ,QO8F#RJBHS D@\[>_-=VOP5^$RJ-GA/32
M!T'V9/\ "G?\*6^%!7'_  B>F\G)_P!'3_"@#YO_ &K++X<?&/X4ZAHF@^*]
M'AUK]T;622[CVC;,COD)ECE5(XKQ'X&_MV^ [S1QX;^*FFG3=:TYC&9YX[>W
M@DB4[$V!WR> 3G'(K[^D^"OPE*X'A/35QT/V9./TK!OOV;?@'J4_VB_^'VBW
M,A !=[.,G ^HH _.OX\?M=:7\7+ZV^#?PG0V,-])&;K4IEC:Q$"R%9E\R)FP
MS1_=X]Z^[_@[JOPG^%?PWT7P'9>+-+=-(C=5VWL;#]Y(TAY)!ZMZ5UFF_L[?
M O22S:7X%TBV))YCM(U_I6O_ ,*7^% 'R^$=-4]\6Z<?I0!:E^*OPMF5H9O%
M6E.CKAE-W$<@]006KY\\8_#C]E?QK?MJFK:Y8Q3,Q8^1?PP@DG)X%>[_ /"E
M?A.'W_\ ")Z:V>#_ *,G^%/;X+_"AOE_X1/31CI_HZ?X4 <9X&O/@#\.K$:;
MX8\0:5#'_>>[A:0\D_>R#W->@_\ "V?A=_T-FE_^!<7_ ,55$?!;X3'YO^$1
MTWV_T9/\*?\ \*6^$O\ T*.F_P#@,G^% %O_ (6S\+O^ALTO_P "XO\ XJHW
M^+WPKC9$;Q=I2F0X -Y%D_3YJ@_X4M\)?^A1TW_P&3_"O%/B1\&/!8\>_#\:
M-X3L!8F]F^V[8D5?+VKMW#^+F@#W0?%GX7KG'BO2SD_\_<7_ ,53O^%L_"_H
MWBO2P1_T]Q?_ !54/^%+_"</@>$=-Z9_X]TZ_E3A\%OA.26;PCIN3_T[I_A0
M!=_X6S\+O^ALTO\ \"XO_BJ/^%L_"[_H;-+_ / N+_XJJG_"EOA+_P!"CIO_
M (#)_A1_PI;X2_\ 0HZ;_P" R?X4 6_^%L_"[_H;-+_\"XO_ (JC_A;/PN_Z
M&S2__ N+_P"*JI_PI;X2_P#0HZ;_ . R?X4?\*6^$O\ T*.F_P#@,G^% %O_
M (6S\+O^ALTO_P "XO\ XJC_ (6S\+O^ALTO_P "XO\ XJJG_"EOA+_T*.F_
M^ R?X4?\*6^$O_0HZ;_X#)_A0!;_ .%L_"[_ *&S2_\ P+B_^*H_X6S\+O\
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M?_PI;X2_]"EIO_@,G^% %S_A;/PN_P"ALTO_ ,"XO_BJ/^%L_"[_ *&S2_\
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MPN\%6?A'XM^.VT?3XM.TRX2Q$*0JJ)\L?S84=.2:^CJ "BBB@ HHHH ****
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M*:VHZ>1DW,?'/WA7S_\ \*.\4_\ 0]77_@.G_P 51_PH[Q0.OCJZ_P# =/\
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M%<PSG$+B0=RIR*EB)9=S5\W?LY?\)%!;^,M/\1:G+JK:?KEQ;PRR@*1%&J@
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M;5+B8POE%4AXT5E()!X!%=G9_P#!-;]DBUNH;V'P<T;P,"G_ !,+TX*G(/\
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MG9@!)$A $: %-NTX7 K]"O%O["?[/GC#Q!=^(-1\.DW.JR&2[(NKI0[=N%E
M'X 5]&^ ?A?X+^&WAE_"?A#3_L.FN6W1[WDW%E"M\SLS<@>M 'P5^P%+\*;7
M]G+2])U;3+*/5;"*3^T&NH85>4-/)LR6^9L#^\*S_P!BBW27XE_$#4?#*&UT
M--?U)&B \N,R$C!55^4C'0U[[XT_88_9_P#&>N77B2_\/G[7J!!NL75ROFA0
M HPLH"XQV%?0OPV^%_@KX5: GACP58_V?9?*YC\QY#N50N=SLQZ#UH ]& P*
M6D'3BEH **** "FY&XTX]*A*L< -P.OO0!\I_M#_ +2MC\"-1TZ#6+%[FRU
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M>.*=@$D'D=\T^B@"//S;<< 9I3T)4#=3Z* (QEN&X/M2!2'8Y)!['I4M% "
M8I:** "BBB@ J,[AP!D_TJ2B@"*11D?R['ZTO*CCK4E% $;*.W&.N*5<<=\]
M*?10 4444 %%%% "9YQ2TTX/'>F ;3RWS'K[T /S@?-2#.>:,,!ZT8&<]Z $
M._=\H&#2X&!NY^M ())Z8I#\PR./7Z4 *>3C./I3A]:BY&$QE3^E/X?@C&*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  GF^$7Q]\4>(?B)\>/$;P274R36,-OJ'V/8)%*N'0, >5&/2O4?@YX^\+_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=\-Z)XFLFT_7K&"^MV()2:))5.TY'#@C@UI065M;0K;V\:PQ)C"(H5>/8<4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_U_W\HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ck0001824293-20241231_g2.jpg
<TEXT>
begin 644 ck0001824293-20241231_g2.jpg
M_]C_X0#H17AI9@  34T *@    @ !@$2  ,    !  $   $:  4    !
M5@$;  4    !    7@$H  ,    !  (   (3  ,    !  $  (=I  0    !
M    9@        "0     0   )     !  B0   '    !# R,C&1 0 '
M! $" P"2A@ '    $@   ,R@   '    !# Q,#"@ 0 #     0 !  "@ @ $
M     0  "^"@ P $     0   ZZD!@ #     0          05-#24D   !3
M8W)E96YS:&]T  #_X@TH24-#7U!23T9)3$4  0$   T887!P; (0  !M;G1R
M4D="(%A96B 'Z0 !  , "P - !IA8W-P05!03     !!4%!,
M            ]M8  0    #3+6%P<&P
M                                 !%D97-C   !4    &)D<V-M   !
MM    ?1C<')T   #J    "-W='!T   #S    !1R6%E:   #X    !1G6%E:
M   #]    !1B6%E:   $"    !1R5%)#   $'   " QA87)G   ,*    "!V
M8V=T   ,2    #!N9&EN   ,>    #YM;6]D   ,N    "AV8V=P   ,X
M #AB5%)#   $'   " QG5%)#   $'   " QA86)G   ,*    "!A86=G   ,
M*    "!D97-C          A$:7-P;&%Y
M
M                    ;6QU8P         F    #&AR2%(    <   !V&MO
M2U(    <   !V&YB3D\    <   !V&ED       <   !V&AU2%4    <   !
MV&-S0UH    <   !V&1A1$L    <   !V&YL3DP    <   !V&9I1DD    <
M   !V&ET250    <   !V&5S15,    <   !V')O4D\    <   !V&9R0T$
M   <   !V&%R       <   !V'5K54$    <   !V&AE24P    <   !V'IH
M5%<    <   !V'9I5DX    <   !V'-K4TL    <   !V'IH0TX    <   !
MV')U4E4    <   !V&5N1T(    <   !V&9R1E(    <   !V&US       <
M   !V&AI24X    <   !V'1H5$@    <   !V&-A15,    <   !V&5N054
M   <   !V&5S6$P    <   !V&1E1$4    <   !V&5N55,    <   !V'!T
M0E(    <   !V'!L4$P    <   !V&5L1U(    <   !V'-V4T4    <   !
MV'1R5%(    <   !V'!T4%0    <   !V&IA2E     <   !V !3 '0 =0!D
M &D ;P @ $0 :0!S '  ; !A 'ET97AT     $-O<'ER:6=H="!!<'!L92!)
M;F,N+" R,#(U  !865H@        \Q8  0    $6REA96B        "#J0
M/;G___^[6%E:(        $K0  "Q8   "K5865H@        *%T  !#G  #(
MO&-U<G8        $      4 "@ / !0 &0 > ", *  M #( -@ [ $  10!*
M $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"C *@ K0"R +<
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MCPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N
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M]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?__<&%R80
M P    )F9@  \J<   U9   3T   "EMV8V=T          $  0         !
M     0         !     0         !  !N9&EN         #8  *X   !2
M    0\   +#    F@   #T   %    !40  ",S,  C,S  (S,P
M;6UO9         80  "N.B8]/M/>+*D                      '9C9W
M      ,    "9F8  P    )F9@ #     F9F     C,S       ",S,
M  (S,P  _]L A  ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0'_W0 $ 7S_P  1" .N"^ # 1$  A$! Q$!_\0!H@   04! 0$! 0$
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H _]#^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M_]'^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]+^_B@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MY*U*I1E_+5IRIR_\!DD_P-4T]FGZ-/\ (U*S&% !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M *.+T#_PD_B-_P#,;5?ZKY]_T+:O_@RA_P#+3?\ XE.^D+_T;7,?_#MPU_\
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MK&:36J:VZ6Z%FD9A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__3_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * ..\8_$/P!\.[!M5\?^./"'@?3$1I&U#Q?XDT;PW8B- 2[_:M8
MO+.#:H5LG?@;3Z5UX3 8['S]E@<%BL;4V]GA,/5Q$[]%RTH3?IH3*<(*\YQ@
MN\I**_&Q^</QD_X+5_\ !,GX)&:UU_\ :I\%>,=62"2:WTCX0V>O?%QKQXMF
M;5-<\ Z5KGA&QNCO 6/6?$>EIN5U,@:-POZ'E'@WXD9Q:5'A?&8.DVDZV;3H
M92HI[2]CCZM#%5(^=##U=-;6//JYOEU+1XF$WVI)U?\ R:FG!?.2/S1^(O\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M?$F02A\:SG),RRWEM;?ZYAJ*6Z_ ]*KG/F H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#__U/[^
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0!_]7^_B@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M]EK9'MT,_P )4LJT*F'EI?3VE/Y2@E*WK31^]?PI^-7P@^.OABU\:?!CXG^
MOBGX4O%S#KW@'Q5HOBG3D<?++:W4VCWEV+&_M9 UO>Z=>BWOK"Z26TO+:"YB
MDB3\.S3)LVR/$RP><99CLKQ4'9T,=A:V%J>4HQK0ASPDM83AS0G%J4).+3/9
MI5:5:"G1J0J0>TH24EZ:;-;-;K8].KS30* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0!_];^_B@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H _/;]K?_ (*E?L0?L5"?3OC1\:]"?QS%%))%\*_
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MU*RNJNC*Z.H9&4AE96&596'!4C!!'!'3BORNUM-K:6['ICJ "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MK:P(,0R:A(@Q7V>!R7+,N2^JX2FIK_E]47M:[_[B3NXK3X:?)#KRW/[L\/?
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MM&K&-2G4A).,X3C&49)Q:35B[2,0H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M.G]<6!APT\(JW/4G?V'UO$^SM:WMI_+]^:^&/X&"@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M;X5VK8#-,)5PE;E;:A6I*I%1Q&&K)<^'Q>'E5PV)I<M7#U:E*49/NJP/ "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MLMCBL5&LZKK58>Y5Y(\L.5+11/QGZ,WT9?##Q3\,*'%G%='/:F;5<\S? R>
MS=X+#K#X*5"%",:$<//WO>DY2<FY-]$DE\A?%'_@MW^UOX\TOPYHWP1T;1_
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M;6&F(1!'MA^$,CIQ]C453$UE&\Y3Q$X35TO>5*C*"C&_PJ2ET3<CVN'/H9^
M&6X;^Q<TP^/XJSZAAH3QN*QO$N/P./IRJ0BOK-/*\CQN7T<)AW.\L-#$T<5R
MP<85:^):YY?J9_P3 _X*M>-/VHOB//\  /X]Z5X6M/'FH:)J>M^ ?%_ABTFT
M6W\3R:#;_;]9\-ZMH<ES>VZ:U'HT=_KUEJ&EO8V,NG:1J-O/I\-Q%!/=_-<2
M<,4<MPZQV!E4=",XPKTJC4G2YWRPJ0FE%\CGRP<97:E*+4K:+^6OI/?13R7P
MNX<AQ[P%B\TK9#A\=A<#GV3YI5AC*F5QQ]3ZO@LQPF.A2H3>"EC)4,!6P^*5
M:O#$8O#3IXB=.4X4O2/^"NG[<GQS_8RB_9_3X*S>$[9OB4_Q3;Q'-XF\/?V]
M)M\&+\.AI,5@K7MK%:HY\6:DUX6BFDF,5F(WA6.59N?A7)<%F_U[ZXJK^K_5
MO9JG4Y/XOUCFOH[_ ,*-MK:^5OG/HC>!O WC-+C]\:0S:HN&H\+++899F'U"
M-\Y?$7UN5=JA5E5<5E.&5%*4(P4JW-&;E!P^8]#_ ."G7[3]W_P35\8_M0W-
MUX$D^*NE?M,VOPGL+K_A$530[?PK)X5\*ZZ__$F345BEU(W6HWL7VN:5U%O-
MM$ ECBE3T9\.9:N(J66I5OJLLN>):]K[_M/:5(?'RZ1M%:+JM[:'Z;C?HQ^&
M%'Z2F3^%].EGL>%<5X:5>*Z]+^UKXZ>:QS3-,#'_ &QX=RAAE2PU&7L80B_:
M0OS\LI0?\U?AWQQXA\,>/="^)6FW,)\6>'O%^F>.+"\N;6"6W/B'2=9@UZUN
M9[)4CMI(3J5O'++:JD<#Q[H0BQG _1*E&G4H3P\D_93I2HM)M/V<H.#2>]^5
MV3W/]*,PR++LSR#'<-8FE-93F&48G(J]&E5G&HLNQ>"G@*M*G7;E4C/ZM4<8
M57*4U*T[N1^[>E?\%5OV]M=_98\5_'S2KWX83_\ " _&70/ 7BMD^'@<VNB>
M,?"US?Z#J!C&KBU@M+;7=)FTRZF:)YYKO7M(A1TCC</\3+AG(X9G2P,EB%[?
M!SKTE[?>=*HHSC\%V_9R4DKV2A/R/X3Q7T5? 7 ^*65< XJCQ/3_ +?X-S#/
MLI3XAY?:8W)LTI4,?AU+ZG[2=6I@,7#$TH*2IPI8#%R:<I1M]\?\$F/^"BOQ
M-_;!\0_%OX>_&^Y\+OXS\+Z/H7C'P:_AO14T);WPR;R;1?%,=U:K<SK*^DZG
M>>&&AF7YF7694DVB"/=X?%&08;*886O@E4]C4E.E5]I/GY:EE*E9V5N:*J:?
MW%W/P3Z67T=>&?!_+^$N(>"*>9QR;-,9CLFSB.98UXYT,S5&&-RITJCI4^6.
M*PM#,U.#TB\%%QOSRM]&?\%1_P!L?Q/^QM\ -'\3_#J711\3O&_CC2_"_A2/
M6[!=5L[;3K2WN=;\3ZO+IK36ZW,-M86-OH^3)^XN]?L9@A*97S^&LIIYMCI4
ML0I_5J-&52KR/E;DVH4X*71MMRVU4&C\Y^B[X.99XR<?XO*^(H8W_5C),CQ6
M:9K+ U_JM:IB*M2E@<LPD,2H5'2G4KUYXNRC[]' 5H75[/YI_P""37[9W[67
M[97BWXJZQ\7[WP:_PQ^'WA_2=.MQH'@^/0KR^\<^)+_[1IZ1:BM[/YMKI6@Z
M-K+ZE:)&6675=&E=XU9%E]'BC*,KRBEA882-7ZS7G*3YZO.HT:<;/W;*SE.<
M.5]H3/TOZ6/@QX3^#64\*X/A"CG*XGX@S#%XBI]?S>6.HT,BRW#^SQ#EAW0I
M\E7%8_&8..&JN5G#"8R$8R:;A^X%?&G\0A0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M_MYM+[*B?F)7Z.< 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M!]F?LD?M_P#[6/[$7BBV\0_L^_%OQ!X<TO[6ESK?P\U6XDU_X8^*DWI]H@\0
M^!M2DET6::Y@5K0:WI\.G>)].AFF?1=<TNZ9;A?DN*N!N%^,\-*AG^54,34Y
M.2CCZ:5#,\+;X7A\=37M8J.C5&I[7#3LE5H5(KE.K#8S$X25Z%1Q5]8/WJ<N
M_-#;7NK271H_KL_88_X.5/V??B_!I_@K]L?08OV=OB&6BMHO'VAQZIX@^#/B
M*1C$@FNR%O?%'P]NI))2OV758_$?AZ.WMIKZ[\8:>TT.FI_*?&OT=L]RESQG
M"-?^W\ KRE@*SI8?-\.ETA?DPV/A;[5)T,1=\L<)-)U#Z;!Y]0JVABH^PG_.
MKRI2_P#;J;\GS+KS=%_2GX8\4>&?&OA[1O%W@WQ%H7BWPIXCTZUUCP]XG\,:
MMI^O>'M>TB^B6>RU31M:TJXNM-U33KR!TFM;VQN9[:XB99(970@U_.^)PV)P
M5>KA<9AZ^$Q6'J2I5\-B:4Z%>A5@^6=.K1JQC4IU(-6E"<8RBU9I'OQE&<5*
M#4HR2<91:<6GLTUHUV:T-VL!A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MV]@JAGP%WL  6VCA=QYP.!T%?Y8.U]%9=%V7;Y'U8Z@ H * "@ H * "@ H
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MN/4\U^NXY^TRG&-_;R[$-_\ ;V&G<_V9\0JO]H^#G'%>LK_7O#/B6K55DO\
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M(Q.5TH9Q@?JFFLLTP<*N INVM/'R^&]U]A?\%U?CC_PL']JC0?A)IMYYVA_
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MCPAE%G>G['):E6&858->[.&)SJKF=>E5BK3PTZ"O)1C)_H]7SY_.(4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MG=O\C:_5#S H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MH4,/AL/2A1H8>A2BHTZ-&C3C&G2I4XI1A3IQC"$4E%)(ITS8* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MG#5X4ZU"O2G%PJ4JL(3IR3C**:L:52<P4 % !0 4 % !0 4 % !0 4 % !0
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M#?\ !X1I6EZ7^V5^RVNF:;8:<MS^S3?7%PMA9V]FMQ<-\4_&0:>86\<8EF8
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M\CH4+KE<,#Q!C\'@.5W<HY=B+7Y'->G5QM\FC._[RI%85]^9>[-O_%3BY?\
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M $BD?QC?M5?\GK_M(?\ 9TOQ@_\ 5L^(J_7<M_Y$V _[%F%_]1:9_LSX5?\
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M$^9_]@.)_P#34C_5[QT_Y,QXJ_\ 9ON+?_5'C3^['X__ /)!_C9_V2/XD?\
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M$*=.$:=.G&,*=.$5"%.$$HPA"$4HPA&*48QBE&*2222/"WU>K>[*E4(* "@
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M%63X>JZ6$IN7*J>>X"]2OD]6+Y$ZTY5\LJ>TI1H9A.NZF'H_HS7SQ_-84 %
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M7E3JXGW'4J_O').I)G#7?^UU76N_W\_:+9M*H^9+MIHNBTZ']DW[8W_!6/\
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M5+KFPM6G-I-M+Z3"T)4,K]E)6J.C6E*/9S4FH^J3BFNZ9_GN?\$FOVG?AO\
ML:_\%$/V8/VE/B^^LP_#3X9^,->G\877A_3&UG5K#2?$_@/Q9X);4[;2HI(I
M[^/2Y_$D&H7EK:&2]DLK:X6QM[J[\FVE_P!1_&[@[-N/O"OC'A'(EAWF^;X#
M#1P$,566'H5*^#S+ Y@J,JS3C2=:.$E2IRG:FJDX>TE"'-./RV!K0P^*HU:E
M^2$GS65VDXN-[>5^G38_N._X*P?MU? C_@H;_P &^'[;GQ\_9UN/%5U\/+3Q
MM\)/AY]H\8Z"GAK5I]:\*_M2?L]SWMQ'I(U#4)X=-N[36-/N]/>^-G?R03@W
M6GVCCRZ_SG\$?#?B7PL^E'X=\,\51P4,TGEN>YKR8#$O%T(X?&\%\4PIP=;V
M5*,JL)X>K"JJ?/24H^Y5FM3Z/'8FEBLJQ%6ES<G-3A[RY7>-:ET[:GX5_P#!
MGK_RD)_:%_[,T\5_^KN^!=?TA]/#_DUO"W_9?X'_ -9WB0\W(?\ >JO_ &#R
M_P#3E(_M"_X*V?L9P?MY?\$_OVA_V?+/3XK[QW?^$9?&WP@=E3S[;XN?#\_\
M)1X'M[:=\_8E\27]A)X*U.[57:/0?$^K*J,7VG_/WP.X_EX:>)_"O%%2K*GE
MM+'++L]2;Y9Y'FB^IYC*<5;VGU2G4684872>)P=#56/H<=A_K.%JTDO>Y>:G
M_CAK'TO;E?DV?Y#<7BKQAHGACQ-\.8M8U?3/"WB+Q%X;U[Q9X4\R6UL=3\2>
M!+;Q5I?AF]U>Q8(TE]X<M_&?BRULEF ^RG6K_,?F,I3_ '2E@L!B,9@\UEAZ
M%;&X3"XO"X'&VC.I1PF93P5;&4Z%172IXN67X&=3E^/ZO2ULM?A+M1<+M1;3
M:Z-QNE]W,[>I_I8?\&MW[%__  S5_P $[K7XW^)=*^P_$?\ ;$\1K\4;J2>#
MR;^V^%'AU+WP[\(=+F./WMG?V4GB7XAZ9,KL)-/^(=NK!7B*+_D9],KQ _UN
M\5)\.X.O[3*> L(\F@HRO2EG>*=/%9[6C_+.E4CA,JK1MI5RJ5KIW/KLEP_L
M<)[1JTJ\N?\ [AQTIK_TJ2\I'X"_\'=/[*OB_P "?MC_  K_ &M+;3VN/AK\
M>?AAI/@&\UBWMY-FE?%#X5M>V]WI.K3)OAA;6O ^I>&;[P\TSPS:DNB^)HK>
M%X]!GF/]._09XTP.9< YUP/.JH9MPSG%?,Z="4E>MD^=*G*%>A%VE)8?,:.+
MI8I13C1^L8-RDGB8Q/,SVA*.(A7M[E6"C?M.&EGVO'E<>]I6^$]N_P""/_\
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MZD^:O5?[R7UL%RPC%1C!*,5R1^&-DERQLH^['9>ZM%LMCLJX"C_)^_X.*_\
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M//O]\I_]@T/_ $[6/ZV?^#=W_E#5^Q-_V+7Q7_\ 6@/BQ7\/?2I_Y/[XA_\
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M:E.K'2>&>']Z2C%GV>54/88*G=6E5_>R_P"WTN5?*"CIWOL?MY7\['I!0 4
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MC6SS+L[Q..]MCG3=6#JY?Q#EF']E%TU[-?5N=7?-4EI;[C^"?PD\-_ ;X3^
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M,?[.?Q@\$?&KP3XX^.VJ^*? .H7>I:/I_BKQ/X O?#]Q<7FDZAH\BZE:Z/\
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M?"SP&,S'$87$5<3+-<3@,3&GC<)'+J<Y83!NO2I?6/[1QKC%QHQE+TK_ ((
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M'PBJ6O=4O;U(.HTD_=IJ3LGIH[:4Z-6KI2ISJ:V]R$I6?9\JLOG8_5;X*_\
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M@^1);^\KQLO6Q\V A@"I!!Z$$$$>Q'%?1VMIL<XM !0 4 % !0 4 % !0 4
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MFC*,XJ4)1E%J\91:<6O)K0Z2N<H* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MG'YG.4JM256I*52K-\TZE1N=2;>[E.5Y2;ZMML=02% !0 4 % !0 4 % !0
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M:\==4UY$T[1[?XK.>#\/BN;$99RX7$:N6'^'#57O[G_/B;VLE[';W:?O2?\
M!7CG]"3AWBM8KB/PI6#X4XBY*E6OPS+]QPQG%57FE@K7CP]C*O\ #C&C'^QI
MM45+#9=_M.,J?T^?#3XH_#SXQ^$-,\??"[Q?H?C?PAJP;[%KF@W:W5MYL80S
M6=U$0EUIVI6N]%O=+U&"UU&R=A'=VL,GRU^:8G"XC!U94,31G1JPWA-6=NC3
MVE%VTE%N+Z,_ROXGX4XCX*SG%</<5Y-CLBSG!M>WP&8472J\DFU"M2DKTL3A
MJO*W0Q6&J5<-7BN:C5G'4[ZL#Y\* "@ H * "@ H * "@ H * "@ H * "@
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M.X@S*A[*7M9>TC]6YW:/+.%G?FPN58?"5?;4YUG+E<;3E!QL_*-.+Z=S[/\
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M97NMZE/]JU+5M(\'^(M*>]\,7.HW<ES=76GZ'XCM?#44L^-,\/Z;&K))_0?
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M#8FC.#JU(5/:T*E6C/IQ>"HXV$85>9.#;A.#2E&]KVNFK.RNFNBM9I,_(O\
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MIR]2KF/EPH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M))';3W4FG07$D?B#PK-<RP?V7XPT)KG2;F*[M+74AHNO_;=!L/X7XX\.^(^
ML;]7S;#>UP-6=L#G&%C.>7XR+3E&*J.*]ABE%/VN$K<M6+C*5/VU#DKS^TP>
M/P^-A>E*TTO?I2LJD.FW6/:2TVO9^ZOT"KX0[0H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#,UG6M'\.:3J.O>(-4T[0]#T>SN-1U76-6O+?3M,TR
MPM(S+<WM_?7<D-M:6MO$K233SR)%&@+.P JH0G4E&G3C*<YM1A"$7*4I/11C
M%:MO9)(ZL%@<9F6+PV7Y=A,3CL=C*U/#83!8.A4Q.*Q6(JR4*5##X>C&=6M5
MJ2:C"G3A*4FTDC^<3]N__@M%.7UOX4?L>70@1';3M;^.US:I))*HXO+?X::3
M?0M'$K'_ $,^,-9M7EV?:Y/#NEP2_P!D^)T_0\CX.2Y,5FZN[<U/ IZ)]'B9
M1?3?V,'ORJI)KGI'^EW@']"&$5@>+/&BCSR<8XG \ T:]HP<E>C4XHQF&G>4
MHIJK_8N"K149^RIYGBI*.,RI_P Z&LZUK'B/5M2U_P 0ZKJ6NZ[K-]=:IK&M
M:S?76IZMJVIWT[W-]J.I:C>RSWE]?7ES))<7=W=32W%Q/(\LTCR.S']!C&-.
M,80C&$(1480A%0A",591C&*48Q2T2221_I-@L%@LMP>%R[+L)A<OR_ X>EA,
M%@<%AZ6%P>#PN'@J5##87#4(4Z&'P]&G&-.E1HPA3IPBH0C&*2,RJ.H* "@
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MOPTXQPG-)0AAL_P495IY1B6W"-.K*I6R[%<\(X;&2Q'ML+0_1BOGC^:PH *
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M[NRVV/W'K^<ST@H * "@ H * "@ H * "@ H * "@ H * "@ H __]7^_B@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M&<WHE%MI&M*C5KRY*-.=1Z*T(MVOM=I6C\[)']#G[+G_  ;+_M$>/(]+U_\
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M?8+K4K36+-G6WU/3+&\#VR?T7PSQUPEQ?3C+A_.L)C*LE=X&;>%S&FU\4:F
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MV3Z0F^WP2Z<K:@?TPU_.9[X4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M.GQ!QQ6P[IYCQ7C*"4Z/M8VK8+(L-)U%E>!M>G.I"4L=C8N7UO$.C*GA,/\
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M551@*H&        !@<5X1_.[;;N]6]6WNV+0(* "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /#OC)^S5\!OV@K%+/X
MP_"SPAXWEAMS:V6M:AIB6WBC3+<MN,&E^+--:R\2:=;EP':UM-4BM9'56DA?
M KMP>8X[+Y<V#Q56AK>48RO3FTK+GI2O2G97MSP?+=\MC[_@?Q3\0_#>NZW!
M/%V=9!"=15:^!PN+E/*<542Y54Q>48CVV68JHHMQC5KX2=2$6U"<4S\=_CW_
M ,$,O!VK/<ZS^SA\3;_PA<N))!X'^):2Z_X?\T[?+CTOQ?I5NFOZ59H P\C5
M='\573N^XZG&BB*OL,OXXKPM#,<-&O'3]]A[4ZD59_%2E^[J-NVL9T>5+:;/
M[=\.OV@>>X*-+ ^)_"F&SNE%PB\_X7<,MS+V:OS2Q638J<LMQE>7NVG@\7DU
M&,8\OU:4GSK\3OCW^Q7^TO\ LUW-U_PM/X6Z[8Z!;L_E>.-!B_X2;P)=P*Y2
M.X3Q1HPN;"P,P D6PUPZ3J\2,OVK3K=CMK[7+\[RS,H_[-B8>TZT*G[JLM+_
M ,.=G-+9RI\\$].:]D?WIX=>//A3XI4J"X2XNR^MF5514N'\QE_97$-&JX\T
MJ/\ 96-]E7Q7L_AEB,N^NX*4DU2Q51*Y\LUZQ^P!0 4 % !0 4 % !0 4 %
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M2J1E"I3G&,H3BXR2::+5(R"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __UO[^* "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%1BO1121Z+7G%!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M&49QC.$HSA.*E"46I1E&2O&49+1Q:LTUHUMH-IE!0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!__]?^_B@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M%Y5)Q^9Q>58G"WDE[:BO^7E-:Q7>=/645YQYHKK):7_(,8(XY';'2OUH\P*
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M:JM858><)J%6$Z<?N,/B*6)I1JT9*4)??%]8R7V9+M\U=69[]7A&P4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 4K
MW4=.TV/SM1O[.PA[2WMU!:Q\#)^>=T7@<GG@<]*3:BM6DO-I(N%.<_@A.=OY
M(N5ON1\"?'G_ (*@?L<?L\1ZRGCGXH6T^HZ-&3+IWAVQNO$,LL^_RDMXFTI+
MA'D:3";58MZ*>*\'&<3Y)@/:?6,=2C*DKRBI)O3M;^NENA^@Y'X6\9Y]5PD<
M)D^)5'%./+6E!J,8R5U)W7;;[M#\M_&?_!Q)\-X+D0?#GX0:[XLMYUN/LU]=
MRW^D_<1FA+V]QIZNID(5=K?<).X'!%?$UO%K(*$Y+2<87UYWJNFRT_R['['@
M?HL\75U3E6GR7:O3Y$FUU5U+2V]UVZ'Q;KW_  <@_M*/%.^G?LGZ=I<:NPCE
M_P"$PANIMF[Y-\4_AR51)MQN52RJV0&91N/B3\8\#4E)4J4*?-\"YXRY4NFL
M7NN_;0^\I?105*,77Q$JUDN;3$1UMK&T*\=F<S:_\'/'QK\-2PGQ=^RI#J-N
MDJ"Z:'Q++'(8BPWM&ECX;A!=4^XNZ-2W#, <CLPOBK2JRIKZK2JJS4OW\(<U
M]I:)6Y>VE^SV/-S+Z,.%I0JJGC:V%FE[CC0Q5:SM[L;2JS6MNJ=KGVE\*/\
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MFKJS7=;?@?(2A.#Y9PE!]I1<7]S2-59$;H?\*9))0 4 % !0 4 % !0 4 %
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MH05.CA\-AJ,84:%&E3BH4Z5.$80BDHI)&15'8% !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % '_T/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;/A395@PXH =0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H __1_9S_ (B(_P#JS_\ \V __$E7Z)_J#_U-?_+'_P"_
M#_2S_BG?_P!7?_\ .?\ _P".P?\ $1'_ -6?_P#FP'_XDJ/]0?\ J:_^6/\
M]^!_Q3O_ .KO_P#G/_\ \=@_XB(_^K/_ /S8#_\ $E1_J#_U-?\ RQ_^_ _X
MIW_]7?\ _.?_ /X[!_Q$1_\ 5G__ )L!_P#B2H_U!_ZFO_EC_P#?@?\ %.__
M *N__P"<_P#_ ,=@_P"(B/\ ZL__ /-@/_Q)4?Z@_P#4U_\ +'_[\#_BG?\
M]7?_ /.?_P#X[!_Q$1_]6?\ _FP'_P")*C_4'_J:_P#EC_\ ?@?\4[_^KO\
M_G/_ /\ '8/^(B/_ *L__P#-@/\ \25'^H/_ %-?_+'_ ._ _P"*=_\ U=__
M ,Y__P#CL'_$1'_U9_\ ^; ?_B2H_P!0?^IK_P"6/_WX'_%._P#ZN_\ ^<__
M /QV#_B(C_ZL_P#_ #8#_P#$E1_J#_U-?_+'_P"_ _XIW_\ 5W__ #G_ /\
MCL'_ !$1_P#5G_\ YL!_^)*C_4'_ *FO_EC_ /?@?\4[_P#J[_\ YS__ /'8
M/^(B/_JS_P#\V __ !)4?Z@_]37_ ,L?_OP/^*=__5W_ /SG_P#^.P?\1$?_
M %9__P"; ?\ XDJ/]0?^IK_Y8_\ WX'_ !3O_P"KO_\ G/\ _P#'8/\ B(C_
M .K/_P#S8#_\25'^H/\ U-?_ "Q_^_ _XIW_ /5W_P#SG_\ ^.P?\1$?_5G_
M /YL!_\ B2H_U!_ZFO\ Y8__ 'X'_%.__J[_ /YS_P#_ !V#_B(C_P"K/_\
MS8#_ /$E1_J#_P!37_RQ_P#OP/\ BG?_ -7?_P#.?_\ X[!_Q$1_]6?_ /FP
M'_XDJ/\ 4'_J:_\ EC_]^!_Q3O\ ^KO_ /G/_P#\=@_XB(_^K/\ _P V _\
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M_P!^!_Q3O_ZN_P#^<_\ _P =@_XB(_\ JS__ ,V _P#Q)4?Z@_\ 4U_\L?\
M[\#_ (IW_P#5W_\ SG__ ..P?\1$?_5G_P#YL!_^)*C_ %!_ZFO_ )8__?@?
M\4[_ /J[_P#YS_\ _'8/^(B/_JS_ /\ -@/_ ,25'^H/_4U_\L?_ +\#_BG?
M_P!7?_\ .?\ _P".P?\ $1'_ -6?_P#FP'_XDJ/]0?\ J:_^6/\ ]^!_Q3O_
M .KO_P#G/_\ \=@_XB(_^K/_ /S8#_\ $E1_J#_U-?\ RQ_^_ _XIW_]7?\
M_.?_ /X[!_Q$1_\ 5G__ )L!_P#B2H_U!_ZFO_EC_P#?@?\ %.__ *N__P"<
M_P#_ ,=@_P"(B/\ ZL__ /-@/_Q)4?Z@_P#4U_\ +'_[\#_BG?\ ]7?_ /.?
M_P#X[!_Q$1_]6?\ _FP'_P")*C_4'_J:_P#EC_\ ?@?\4[_^KO\ _G/_ /\
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M8#_\25'^H/\ U-?_ "Q_^_ _XIW_ /5W_P#SG_\ ^.P?\1$?_5G_ /YL!_\
MB2H_U!_ZFO\ Y8__ 'X'_%.__J[_ /YS_P#_ !V#_B(C_P"K/_\ S8#_ /$E
M1_J#_P!37_RQ_P#OP/\ BG?_ -7?_P#.?_\ X[!_Q$1_]6?_ /FP'_XDJ/\
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M_P#YS_\ _'8/^(B/_JS_ /\ -@/_ ,25'^H/_4U_\L?_ +\#_BG?_P!7?_\
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M #8#_P#$E1_J#_U-?_+'_P"_ _XIW_\ 5W__ #G_ /\ CL'_ !$1_P#5G_\
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M7_RQ_P#OP/\ BG?_ -7?_P#.?_\ X[!_Q$1_]6?_ /FP'_XDJ/\ 4'_J:_\
MEC_]^!_Q3O\ ^KO_ /G/_P#\=@_XB(_^K/\ _P V _\ Q)4?Z@_]37_RQ_\
MOP/^*=__ %=__P Y_P#_ ([!_P 1$?\ U9__ .; ?_B2H_U!_P"IK_Y8_P#W
MX'_%._\ ZN__ .<__P#QV#_B(C_ZL_\ _-@/_P 25'^H/_4U_P#+'_[\#_BG
M?_U=_P#\Y_\ _CL'_$1'_P!6?_\ FP'_ .)*C_4'_J:_^6/_ -^!_P 4[_\
MJ[__ )S_ /\ QV#_ (B(_P#JS_\ \V __$E1_J#_ -37_P L?_OP/^*=_P#U
M=_\ \Y__ /CL'_$1'_U9_P#^; ?_ (DJ/]0?^IK_ .6/_P!^!_Q3O_ZN_P#^
M<_\ _P =@_XB(_\ JS__ ,V _P#Q)4?Z@_\ 4U_\L?\ [\#_ (IW_P#5W_\
MSG__ ..P?\1$?_5G_P#YL!_^)*C_ %!_ZFO_ )8__?@?\4[_ /J[_P#YS_\
M_'8/^(B/_JS_ /\ -@/_ ,25'^H/_4U_\L?_ +\#_BG?_P!7?_\ .?\ _P".
MP?\ $1'_ -6?_P#FP'_XDJ/]0?\ J:_^6/\ ]^!_Q3O_ .KO_P#G/_\ \=@_
MXB(_^K/_ /S8#_\ $E1_J#_U-?\ RQ_^_ _XIW_]7?\ _.?_ /X[!_Q$1_\
M5G__ )L!_P#B2H_U!_ZFO_EC_P#?@?\ %.__ *N__P"<_P#_ ,=@_P"(B/\
MZL__ /-@/_Q)4?Z@_P#4U_\ +'_[\#_BG?\ ]7?_ /.?_P#X[!_Q$1_]6?\
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M-5^IGA!0 4 % !0 4 % !0 4 % "JI9E1069V5$51EF9B%554<EF8A54#))
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MQ%.[7,DX5*;G1K0J4:DZ<NC#8FMA*JJT9<LEHU]F<>L)KK%_@[-6:37^C_\
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M3#\+1E3A*GC<QI6C3K<11<IQA0E[;#91:-6#GF2C4P'X25]N?WV% !0 4 %
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M&*LIRA3>(Q,E[;&U\3B)3K2]QKB/@ H * "@ H * "@ H * "@ H * "@ H
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M5*>1<01IT94Z&.C3C-8+&IPPV<4:-2O1IX?$4\5@<+\Z?\1HO_6-G_S<3_\
M)8K]D_XI_?\ 5VO_ #0__P <S^3_ /6#_J$_\K__ '$/^(T7_K&S_P";B?\
MY+%'_%/[_J[7_FA__CF'^L'_ %"?^5__ +B'_$:+_P!8V?\ S<3_ /)8H_XI
M_?\ 5VO_ #0__P <P_U@_P"H3_RO_P#<0_XC1?\ K&S_ .;B?_DL4?\ %/[_
M *NU_P":'_\ CF'^L'_4)_Y7_P#N(?\ $:+_ -8V?_-Q/_R6*/\ BG]_U=K_
M ,T/_P#',/\ 6#_J$_\ *_\ ]Q#_ (C1?^L;/_FXG_Y+%'_%/[_J[7_FA_\
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M_4)_Y7_^XA_Q&B_]8V?_ #<3_P#)8H_XI_?]7:_\T/\ _',/]8/^H3_RO_\
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M0_XC1?\ K&S_ .;B?_DL4?\ %/[_ *NU_P":'_\ CF'^L'_4)_Y7_P#N(?\
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M_P!0G_E?_P"XA_Q&B_\ 6-G_ ,W$_P#R6*/^*?W_ %=K_P T/_\ ',/]8/\
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M_%/[_J[7_FA__CF'^L'_ %"?^5__ +B'_$:+_P!8V?\ S<3_ /)8H_XI_?\
M5VO_ #0__P <P_U@_P"H3_RO_P#<0_XC1?\ K&S_ .;B?_DL4?\ %/[_ *NU
M_P":'_\ CF'^L'_4)_Y7_P#N(?\ $:+_ -8V?_-Q/_R6*/\ BG]_U=K_ ,T/
M_P#',/\ 6#_J$_\ *_\ ]Q#_ (C1?^L;/_FXG_Y+%'_%/[_J[7_FA_\ XYA_
MK!_U"?\ E?\ ^XA_Q&B_]8V?_-Q/_P EBC_BG]_U=K_S0_\ \<P_U@_ZA/\
MRO\ _<0_XC1?^L;/_FXG_P"2Q1_Q3^_ZNU_YH?\ ^.8?ZP?]0G_E?_[B'_$:
M+_UC9_\ -Q/_ ,EBC_BG]_U=K_S0_P#\<P_U@_ZA/_*__P!Q#_B-%_ZQL_\
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M_P#-Q/\ \EBC_BG]_P!7:_\ -#__ !S#_6#_ *A/_*__ -Q#_B-%_P"L;/\
MYN)_^2Q1_P 4_O\ J[7_ )H?_P".8?ZP?]0G_E?_ .XA_P 1HO\ UC9_\W$_
M_)8H_P"*?W_5VO\ S0__ ,<P_P!8/^H3_P K_P#W$/\ B-%_ZQL_^;B?_DL4
M?\4_O^KM?^:'_P#CF'^L'_4)_P"5_P#[B'_$:+_UC9_\W$__ "6*/^*?W_5V
MO_-#_P#QS#_6#_J$_P#*_P#]Q#_B-%_ZQL_^;B?_ )+%'_%/[_J[7_FA_P#X
MYA_K!_U"?^5__N(?\1HO_6-G_P W$_\ R6*/^*?W_5VO_-#_ /QS#_6#_J$_
M\K__ '$/^(T7_K&S_P";B?\ Y+%'_%/[_J[7_FA__CF'^L'_ %"?^5__ +B'
M_$:+_P!8V?\ S<3_ /)8H_XI_?\ 5VO_ #0__P <P_U@_P"H3_RO_P#<0_XC
M1?\ K&S_ .;B?_DL4?\ %/[_ *NU_P":'_\ CF'^L'_4)_Y7_P#N(?\ $:+_
M -8V?_-Q/_R6*/\ BG]_U=K_ ,T/_P#',/\ 6#_J$_\ *_\ ]Q#_ (C1?^L;
M/_FXG_Y+%'_%/[_J[7_FA_\ XYA_K!_U"?\ E?\ ^XA_Q&B_]8V?_-Q/_P E
MBC_BG]_U=K_S0_\ \<P_U@_ZA/\ RO\ _<0_XC1?^L;/_FXG_P"2Q1_Q3^_Z
MNU_YH?\ ^.8?ZP?]0G_E?_[B'_$:+_UC9_\ -Q/_ ,EBC_BG]_U=K_S0_P#\
M<P_U@_ZA/_*__P!Q#_B-%_ZQL_\ FXG_ .2Q1_Q3^_ZNU_YH?_XYA_K!_P!0
MG_E?_P"XA_Q&B_\ 6-G_ ,W$_P#R6*/^*?W_ %=K_P T/_\ ',/]8/\ J$_\
MK_\ W$/^(T7_ *QL_P#FXG_Y+%'_ !3^_P"KM?\ FA__ (YA_K!_U"?^5_\
M[B'_ !&B_P#6-G_S<3_\EBC_ (I_?]7:_P#-#_\ QS#_ %@_ZA/_ "O_ /<0
M_P"(T7_K&S_YN)_^2Q1_Q3^_ZNU_YH?_ ..8?ZP?]0G_ )7_ /N)_]+X_K^B
M#_I8"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M7TW/Z'?#'B2'4K>)ED5LJ.A'^?I7UA^/'?(P8#% #Z "@ H * "@ H * "@
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MA_&84 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M5F]:'M:^1XVISS7#^=UJ453]OR0E4RW'2A1AF6'A4BH+%87$Q/D6OW4_D0*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H __T_C^OZ(/^E@* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H S]5U33]$TZ[U75+J.RT^QA:>
MZN92=D<:X'106=W8K'%%&K22R,D<:,[*IZL%@L5F&*H8+!49U\3B)JG1I0M>
M4GYNT8QBDY3G)J$()RDU%-KP>)^)LAX-R#->*.)LRP^49%DN$GC<QS#%2:I4
M*%.R248J52M6JU)0H8;#4(5,1B<14I8?#TJE:I3A+\]?BG\3M1^(&J&-"]KX
M=T^:3^RM/!*^9U0:A>@$K)>RQDA0,QVL3&&'):>:X_J/@W@_"\+8.[Y:^:XF
MG'Z[BM&H:1;PF&=ERX>$UJ_BKS7/)\JIPA_@G])CZ2.?^/7$KI4G6ROP_P C
MQ=;_ %8R"[@Z[7M*,<^SF*E*%;.,50E*-.";H97A:DL'A;U*F-Q>-\IK[,_F
M$* "@ H * "@ H * "@ H _9O_@F5_P1G^.7[>]_I/Q&\6?VE\'?V7HKR8WW
MQ,U+3\:[\0$TZZ>TOM$^$FCWJ!-9D-[!<:;?>,[V/_A$="GM-3B677==TQ_#
M<_X[XD^,.2<"4ZN7X7V6;\3."]GEM.?[C .<5*%;-:L'>BN1QJ0P=-_6JRE3
MNJ%&I]8CZN RNKB^6I.]+#[\UO>J+M36UO[[]U=%)Z']XW[,G[*OP'_8^^&&
ME_"/]G_P#I?@CPK8)"^HW42)=^)O%^K1JXF\2>-_$LL:ZGXH\0W32REK_49&
MCLH'33-'MM,T:UL=-M?X9XEXHSSB[,ZN;9]CJF,Q51M4X.\,-A*3M;#X+#)^
MSPN'C96ITTG-KVE652K*=27UM"A2P]-4J,%""[;M]Y/>4GU;U/H>OGS8* "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H P/%/A
M7PSXX\.:UX/\9^'M$\6>$_$>GS:5X@\,^(]+LM:T'6],N,>=8:KI.HPW%C?V
MDFU2UO<P21%D1MNY%(WPN*Q.!Q%'%X+$5L)BL/.-2AB<-5G1KT:D?AG2JTW&
M<)+HXM,32DG%I.+5FFKII]&NWD?QU_\ !4#_ (-[-8\$Q^(/CK^P/I6J>)_"
M<;W^K>*_V;3/=:OXL\-P,7NY+OX0WMU)-J/BW1;<;X!X%U":\\7V:BW&@7OB
M5)6T[3/Z\\,_'ZCC7A\CXZJTL-BW[.CA>(N6-+"XAV4%#-H02IX6L]']=IJ&
M%E>7MX8>WM*GS>/R6UZN#6FKE0ZK_KUY+_GWOLH?RG\ITL,MO++!/%)!/!(\
M,T$T;130RQ,4DBEB<*\<L;J4DC=5=&4JP!!%?U(FI)2BU*+2<91:<6FM&FM&
MFMFM&MCYS;3:VC6S36EFNC6UNA'3 * "@ H * "@ H * "@#Z%_9<_:@^,/[
M'OQH\(_'7X(^);CP[XQ\*W:>?;,\[Z%XKT"6:%]7\'^+M-BF@36?#&NPPK!J
M-A(Z21NMOJ.G7%CJ]AI^H6G@\2\-Y3Q9D^*R3.<-'$8/$Q?+*T56PM=1:HXO
M"5'%NCB:#?-":5FN:G4C.E.<);X?$5<+5C5HRY91^Z2ZQDNL7V^:LTFO]*S_
M ()X?\%!?@[_ ,%$/@98?%3X<SP:%XQT46.D_%KX4WFI07GB/X:^+)K8R?9;
MC:EM/J?A;63#=7/@[Q:EC:V7B"RMKN%H+#7=(U_1-(_SMX^X#S;@#.IY9F"=
M?"5>>KE>:0IRAALQPJE92C\2I8FE>,<7A'.4\/.47>=&K0K5?O,#C:6.H^TA
M[LHV52G?6G*W_I+^Q*UG9K>+2^]Z^'.T* "@ H * "@ H * "@ H * "@ H
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M>CE63X637+@<HP$9.E@\/%1CS-<^)Q,U[?&XC$XF4ZTO<ZXC\_"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *6I:;IVL:=?
M:1J]A9:II.J6=QI^IZ9J-K!>Z?J%A=Q-!=65]97*26UW:7,+M%/;SQO#+&S(
MZ,I(JHRE"49PE*$X24H2BW&491=XRC)6<91:335FFM#?"XK$X'$X?&8+$5\)
MB\)6IXC"XK#59T,1AL11DIT:^'K4I0J4:U*<8SIU*<HSA)*46FD?SV?MU?\
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M6 ^6*_:C^5@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /__4^/Z_H@_Z6 H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M>MR]+=;M]_Z_ \4,EN@Q[^GX_I0DHWN_DOU0"+WZ@''/3I[_ *4Y=-M.C_R
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M[R;9?J3G"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * /S3_;G_P"";/PS_:WT^^\8>&_[-^'7QXM[5C8>-H;0QZ+X
MO>"W$=II/Q%M+&"2XO82(HK6U\3V<,VO:-"06@UVQMH='/TF1\1XG*)1I5.;
M$8#52P]USTN9W<\/)Z1:=Y.E)JE.\OX<Y>UC_5'T?/I2<5^#&*P^2YG]:XF\
M/*M5+$Y!4K<V-R6-2HY5L9PS6KU(TL/47-*K5RJM.&78Z::Y\!7JRQT?Y*OB
M_P#!KXD_ ;QWJWPW^*WA74/"7BS2"CR65ZJO;7]C,TBVFL:+J,)>QUG1;[RI
M/L>J:=//:3-%-!YBW%O<0Q?K."QN%S"A'$82K&K2EV^*$K*\*D=X3C=7B_)J
MZ:9_LUP1QUPKXB\.X/BC@[-\-G.3XR\%6H/EK87$TU%UL#C\+/EKX''4.>'M
ML)B:=.K&,Z=51E1JTJD_,*ZSZX* "@ H * "@ H * "@#FO&'A#P[X]\-:OX
M0\5Z;%JV@:W:M:7]E*60E3AHI[>:,K+:WEI,J7%G=PLLUM<1QRQL"M>QP_G^
M:\+YQ@,]R3%SP69Y=65;#5X6:3LXSIU*<DX5:%:FY4J]&I&5.K2G*G.+C)H^
M8XQX.X<X^X9S?A#BS+:6:Y#G>$GA,=@ZKE!\KM*E7P]:FXU<+C,+5C#$8/%4
M90K8;$4J=6G)2@C^?[]HGX >(/@'XR?2+MI=2\*ZLT]SX0\2;%"ZE81F-I+.
M\"*J0:SIGG16^HP!(XY&V7EHIL[F$C_4?PI\3\J\3>'XX_#^SPN=8&-&CGV4
MIRO@L5-2Y:U#G]ZI@,7[.<\+4O)QY9X>K)UJ,V_^?CZ17@!Q#X!<9SR?&.KF
M7"N;2KXKA#B3DBH9G@*;INIA,8J<8PH9SEGMJ5#,:"A3A4DZ>,PL/J>)HV^?
M:_43^?0H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZ)^DA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MRJ04O>49RIN44]4FDS>J#@"@ H * "@ H * "@ H * "@ H * "@ H * "@
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MJ4:M-RIU:4HSA)QDF??4:M.O3A5I24J<U>+7Y6Z-;-/5-69ZK7F&@4 % !0
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M7.U6,+0:5V[HX,7E]7!TZ52<X25790YKKW4];Q2^X_(2OW0X H * "@ H *
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MJ%2$Z^ GC/KN%NHUZ%.3C%_./[3O[#O[2/[(EQIK?&;P+_9WA_6[@V>B>-=
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M&CS5'4KU?L\!E]+!0Z3K->_4M_Y+#M!??+=](K]<Z_)ST H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _#W_@O)_R;!\*?^R]:3_ZKWXA5]MP+
M_P C+%?]@,O_ $_0/[O_ &?O_)U>+?\ LWV,_P#6CX</+_\ @@)_R)'[2O\
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M23PF$E>,$XXC$Q]E[&CB?@/_ (*__P#!9*;]JZ*/]DO]DBV?X6_L0_#Q-/\
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M5HU%.CFO$3HSG"I64H0JX/+(5*F#RUJ,E+$XR+QC_2VOG#^5PH * "@ H *
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M.G*=*M1J1Y:N'Q%"=3#XFA.G7H5*E&I"<L*O2/""@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MY774?5!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M4Q.%><<)83#U\;3BU!5,1&6(G7O*:YZOO3DVV>J>'_@%_P %!O\ @IUK-_\
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M;Q+>W"^%3SNID?%N9UVW+"5LRQ='%T8]:7UB=JL8]:E%WG'JUS0NE-V^[Q7
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M6I*M>M]8J6E:2Y8\OO=T>-E^7XC#8A5*B@HJ$EI*[N[6TL?V=U_GN>\% !0
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MJ64[2P+PWX@5_HT?X>!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M']+G_!J/XE^#/AS_ (*F"+XIW7AZQ\5>(OV?/B5X;^ ]SXA6U4GXLWVO^!+B
M>R\.W-S@6?BG4_AA9?$C3K!XG2:^TVYUC18/,N-4AMYOY&^FKA,_Q7@PWDL,
M54P6%XHRC%\2QPO/_P B.GALRC&>*A#^)@Z.<U,HJU$TXTZL*%>5HT7*/L9(
MZ:QOOV4G2G&E?^>\=NSY%-+RNNI_>'_P5S\2_!;PM_P30_;9N_C[<:#%\/\
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M#.EAH0ITHX>"/0Q-"J\JJ4\4X5*U*#GSQ;?\-MQE>48OF]G>,G;77>Y\J_\
M!9?XN>,?^"8/_!"W]C?]F;]FG6;_ .&.M?$[1_A7\&/$7BSPI=S^'O$T'AJU
M^&>H>/OB]JVEZGHS6L^G>(OB1XUCA'BC4K2:&2\L/%/BJ%?GU+S8?M? +(\!
MXQ?2/X^XOXNP]+-\/D]?.<_PF!QL(XK!RQ<LWI99D5"M1Q"G&KA<IRYOZE2F
MFJ=3!8)[4>5X9A-X/+</1HMPYU"FY1T?+R<TVK;.<M[=&S^.#_@F;_P4?^,/
M_!,S]IK1/V@?AS'?^+] FL=7T/XG_"&Y\57OAKPQ\6/#NIZ9?6]KIWB*\AT[
M6TM[W0-;N+'Q/H&L_P!CWUYIVJZ8D: V-_J5M=?WKXO>$^1>+W"&(X7S5TL!
MB8U*&)R?/88*GB\9DF+HUJ4IU<+3E5P[E3Q.'A4P>)H>WITZM&LV_P!Y2HRA
MX&#Q<\'656&JLU.G>T9JVB>CV=FG;2W:Y_1I_P $4_VU;C_@H3_P<%^//VK=
M1^$WA;X-Z[\1?V7/&]MX@\*^$M7U+7-/N]0\*:;\-_"MMKUUJ&IP6<DVK7^B
MZ1I-OJ#V]C96\\MB+K[/]IN+F67^4OI!^'T?"[Z+V6\%4L[QF?X;*>,<NEA<
M;CJ%'#584L;6S7&RPT*5&4U&A2Q%>M*DI5*DHQJ<G-R0A&/K9=B/K6:2K>SC
M3<J$KQBVU>/)&^O6R6R6QYE\(/\ E;]U;_LZ/XX?^LY>/Z]C/?\ E!2A_P!D
M9PY_ZU65F=/_ )'K_P"O]3_TU(^$_P#@Z!_Y3$_'C_L0/@+_ .J@\)U^D?0Z
M_P"3#<,_]C/B7_U>XXY\Y_W^I_@I?^D(_:G_ (.M/^3!/^"9O_8:?_U2_AFO
MY]^A7_R<WQ?_ .O"_P#6@QAZ&=_[M@_7_P!QQ/>_^"R_Q<\8_P#!,'_@A;^Q
MO^S-^S3K-_\ #'6OB=H_PK^#'B+Q9X4NY_#WB:#PU:_#/4/'WQ>U;2]3T9K6
M?3O$7Q(\:QPCQ1J5I-#)>6'BGQ5"OSZEYL/S/@%D> \8OI'\?<7\78>EF^'R
M>OG.?X3 XV$<5@Y8N6;TLLR*A6HXA3C5PN4Y<W]2I335.I@L$]J/*]<PF\'E
MN'HT6X<ZA3<HZ/EY.:;5MG.6]NC9_'!_P3-_X*/_ !A_X)F?M-:)^T#\.8[_
M ,7Z!-8ZOH?Q/^$-SXJO?#7ACXL>'=3TR^M[73O$5Y#IVMI;WN@:W<6/B?0-
M9_L>^O-.U73$C0&QO]2MKK^]?%[PGR+Q>X0Q'"^:NE@,3&I0Q.3Y[#!4\7C,
MDQ=&M2E.KA:<JN'<J>)P\*F#Q-#V].G5HUFW^\I490\#!XN>#K*K#56:G3O:
M,U;1/1[.S3MI;M<Y'_@HQ^VK<?\ !0G]K#Q]^U;J/PF\+?!O7?B+8>%+;Q!X
M5\):OJ6N:?=ZAX4\.Z?X5MM>NM0U."SDFU:_T72-)M]0>WL;*WGEL1=?9_M-
MQ<RR]WA3X?1\+N"<LX*I9WC,_P -E-3&RPN-QU"CAJL*6-Q57&RPT*5&4U&A
M2Q%>M*DI5*DHQJ<G-R0A&,XO$?6J\JWLXTW)1O&+;5XI1OKULELEL?#=?HQS
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0!__T/C^OZ(/^E@* "@ H * "@ H
M MZ?J%_I-_9:II5[=Z9J>F7=MJ&G:CI]S-9W^GW]G,EQ9WME=VSQW%I=VEQ'
M'/;7,$D<T$T:2Q.KJI"<8RBXR2E&2<91:3BXM6::>C36C3T:T,<1AZ&+H5L+
MBJ%'$X7$T:F'Q&&Q%.%:AB*%:#IUJ%:C4C*G5HU:<I4ZE.<90G"3C*+BVCZ^
M\?\ _!0C]L[XH?#ZX^%OCK]H'QMKG@B]L?[,U/2MNB:9=ZWIK*J2V'B#Q!H^
MD:?XC\06=U&OEWUMK6K7\-_&SQWJ3I)(K>30R'*,-76)HX"C"M%\T9>_*,)=
M'"G*4J<&OLN$(\OV;'Y#D'T?/!CA?B"GQ1D7A_DF!SNA7^LX7%7QN)HX+$)W
MA7R_+\9B\1EV7UJ3]ZA4P6$H3H249473<8M?&U>N?LA^JG_!%[_E(%\+/^Q9
M^*'_ *KWQ!7S'%__ "(L1_U]PW_IZ!_*WTS_ /E'_BG_ +&?"_\ ZT&7G+?\
M%?\ _E(K^T1_O_"C_P!4?\-*UX3_ .1!@/\ N:_]3<0>I]$#_E'7P[].+/\
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M'U,WAFRG@'1Q%:IF6"<W+.,##!5:5&+Q.,Q>+H595:=&G*G7<7/YR_8L\+^
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M)EF I7A@,IRZD_X. R_#\M&C'6I5:J8K$SK8O$8BO5YZO3/A H * "@ H *
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MH^RHX/+H8>A"'*I-PE4J<U:=2<O=?^'MW_!/?_HX#_S%/QM_^=M7%_JGG_\
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MMI=(J44?MK7XV>L% !0 4 % !0 4 % !0 4 % !0 4 % !0!'+]S_/H: /\
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M:7X)'[M?"*-DTNUR/^6:?^@@4SF/H6+[@_SV% $E !0 4 % !0 4 % !0 4
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M<)Q<9PG%\LH2BTG&46FI1:335FCW2>I * "@ H * "@ H * "@ H * "@ H
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M$%>26(]I'EPF?5&O;RCG&"PN&_..OZS/\X0H * "@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M#G'!0]E4H4JD*=:<X2G1JQ=;]Y5A5;DI>^?MB_MM?%7]MOQ1X/\ %OQ5\/\
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MJG_IT^F_:$?\EOX?_P#9*X__ -6\S][J^$/\^3^3W_@O#_R=?\,O^S>?#?\
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M</0A$^JP.#AA:45RKVTDG4GN[_RI_P L=E:R=K[LU_\ @K-_P2X^#7_!2/\
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MV0:;J=DQ_9LCSFCG&%52/+#$T^6&)H)_!.WQPBVY>RG9\C=[6E!R;@V?[K>
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MITZM6G&-&69Y743P&:4X1I/VU.GC(X>CA,=@^;PBOTL_" H * "@ H * "@
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MQII0OZN*YK>5[>12_P""!?\ RF _8:_[*=KW_JM/'%:?29_Y,3XC?]B?#?\
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M:%6+A5H5\/6C.E6HU(-QG3J0E"<6XRBUH<J;BTXMQ::::=FFMFFMFNEC]S_
MO_!R]_P6&\#^&1X8?]I/0_&<=O906&FZYXZ^#OPGUSQ-IT5O&L4<IUN#PCI]
MQKEZRIF>_P#%8\07MU(6EN9Y96+U_..9?1%\!\QQGUQ<(XC+W*I*I5PV6Y]G
M>&P=5R;;C]7>.J0PU/7W:6"^JTX*T81BE8]*.<8^*M[52[.5.#:^?*K_ #N?
ME[^UA^VW^U7^W)XZM_B+^U5\:_&'Q?\ $>G175OH,.MRV.F^&/"EI?- ][9^
M#?!/AZRT?P;X0M;Y[2TDU"+PYH6F#4IK6WN-0-U<1)*/V+@GP\X+\.<MEE/!
M?#V R+"57"6)>&C4JXS&SIJ2IU,?F.*J5\?CITE.:I2Q>)K>QC.4*7)!\IQU
M\37Q,N:M4E-K9.RC'_#%)1C\DC3_ &1/V\_VN_V#_%VJ>-?V3_CAXJ^$6KZ_
M:PV7B.QT^#1/$/A/Q-;VSE[0>)/ OC'2O$/@O7;BQW3+IFH:GH-SJ.E+<W8T
MR[L_M=QYF7'/AKP-XE8&CEW&W#F"SRAA9RJ82I5EB,+C<'*2M/ZIF. K87,,
M-&I:/MJ5'$PI5N2G[:$_9PY2AB:^&ES4*C@WNE9Q?K&2<7Y:770_03XW?\'%
M?_!6[X[> M0^'&N_M-'P/X=UO2_[)\07/PD\!>!OAMXJUFV8 3M_PF_A[0H/
M&&@2W0&R[/A#6_#D=Q TMK)&;2:6!_R_AWZ*O@=PWF=+-L-P>LPQ6'K>WPL,
M[S/,LVP6'FOA7]G8K$RP&)C3WI_7L/BG&24T^>,9+KJ9MCJD>1U>5-6?LXQ@
MW_V\ES+_ +=:/S;_ &4OVQ_VD/V(?BTWQT_9@^([?#3XJ/X=UKPF_BM_"?@;
MQP[Z!XBELI]9L7TCXC>&?%V@,U[+IUF[7K:4;^$Q?Z/=0B682?K/&O 7"?B)
MD?\ JWQCE*S?)5BL/C5@EC<QRY+$X2-2.'J*OE6+P.)2IQJS2IJM[*5_>A*T
M;<=#$5<-/VE&?).SC?EC+1VNK34ET70Z/1_V]/VL- _:_E_;UTGXJ_9/VL9_
M%.N>-)?BM_P@WPVGW>)?$GAS4/"6M:E_P@MSX.F^&R_;/#^J7VG_ &-?!PT^
MW\_[5:6L%[%#<Q\M?PTX)Q/ D?#2ODO/P3'!8;+XY+_:.;1M@\)BJ6-P]'^T
M88^.;?N\31I5/:?7_:RY>2<Y4W*#:Q-95_K*G^_YG+GY8;M<K?+R\FVEN6QP
MG[4'[5'QY_;-^,6O?'[]I3QW_P +(^+7B;3]!TO7/%G_  C'@WP?]ML/#&CV
MF@Z'!_8/@+P]X6\,VWV'2;&UM/,L]&MYKGRO/NY+BY>29_2X.X+X:X R'#<,
M<)9;_9.1X.KB:V&P/US'X_V=3&5YXG$2^LYGBL9BY^TKU)SM.O*,+\M-1@E%
M36K5<14=6M+GFTDWRQCI%66D5%:+R/:_VK?^"F'[;?[;O@#X9_"_]J#XU_\
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M(S/)([%W=W.YG=FRS,S$EF))).3S7]$))))))))))622T226B26R/-&4P"@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ&4_\C7+/^QA@O\ U(IGZ/X._P#)W?"S_LX_ _\ ZTV5G\N__!%7_D]_2/\
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M<E%:1345HCI:S/,"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH ^-_P!NK]B7X3?M[? /Q!\$?BA NGW9\_6_AQ\0+2PM[[7_ (8^/X;&YM='
M\6:1'+);->6B_:&LO$OA[[=80^)_#\][I#WVG7,EEJVG?8<#\:9KP)GN'SK+
M)<\/=HYC@)3E"AF6 <XRJX6JTI<DO=4\/7Y)O#5XPJJ$XJ=.?/BL-3Q=&5&H
MM'K"5M:<TK1G'TV:TO%N.S/\U[]I[]FCXK_LB?&OQK\!_C-H$NB>,?!NH-$E
MRD<_]B^*=!G9WT/QCX5OIX81JOACQ%9*M[IE]&H9,S:??16FJV-_96W^C7#7
M$>5<69-@L\R>NJV#QE-/EO'VV%KQ2]M@\5!-^RQ.'G[E2#W]VI!RI3ISE\-B
M,/5PM65&K&SCL^DX_9G%]8M?=\+M)-+P"O>, H * "@ H * "@ H _?7_@@U
M_P %,9/V,?CY'\#_ (J^(_L/[-/Q\URQL-7GU*;;I7PU^)MTMOI/ASX@B65A
M!I>CZH$LO#?CNZ)AMETA=(U[49O(\)Q(?P[QN\.5QAD7]LY7AU+B/(:$YT53
M7[W,LLBY5<1E]EK5K4KSQ.!A9R=5UL/3][%)'LY/C_JE;V-1_P"SUFD[[4ZF
MT:GDGI&?ERO[)_H9 A@&4@J0"I!!!!'!!'!!'0CC%?P0?;BT % !0 4 % !0
M 4 % !0 4 % !0 4 (1P?I0!^!W_  7X_95B^/W[(FK>*]/:1?%/PTEBU'2?
M)MIKIGM);J*:^C,$)!='2WVMCYD!W @=/C^-,LCCLIE7]HXU,+;DBHN3DI/7
MT2]+'[5X(<2_V'Q-'".G&=/,;1ES24$G"+4?>>SU_"VNB/X;/V1?'/\ 8OB+
M5? >I2&(:J[7$ F!B^SO8IM:$J^-CE\J4;YE88-?RIQGESJ8>GC81?-A_<FN
MKYGN]+I_\-8_TOX!S14Z]7+I3BXXI*M3=](\D=D]O+2WH?HISQC@=_TQ7YD?
MK&BNFM>@*2K ]>0<?0COZ#TH'T6B5NOIMI^O_#'YC_M5_#23PSXG'BW3H6;1
MM;(^URHG U2=B\BL!]T;!][[OXU^J\(YFL5A/J=27[Z@O<3M_"CI%KOKT/QS
MC7*'@\8L?2B_88CXW%7_ 'TG=KRV_ ^2\\#;T&&_'\:^P5[^]U5E_P ,OZ1\
M0#<@,/QHB[>[YNW]?(!>5P%[]_7'Z"EHTV^GV=K?,!,GY<\=>?\ ZWZ4[+WD
MM=M-OQ =CHIZ?S[_ (8J;[R6^G_;O3YW_ !G?.>A&..N/Y5I;2UK*WW &<G(
M'3G'T[U-K1M?R6GX?UL!T'A;P[=>*_$.E:!9QM+)J5W!;OL!)BCF;:9& Z*O
M')P/<<5SXK$PPF%JUYOE5*$FO-Q6B7J]#IP>$GCL50PE.-_;5(PE;[,6[7^7
MW:'[6>$O#\/A7PYHWA^)%!TS3[>TG(XW31)L:3C@YP*_"\9B'B\57Q#_ .7M
M24UY)NZ1_0N!PL<'@\/AH[4:4*?K**2?33^M3H@/PY_R?_K5S'7_ ))?E^5C
MR#XY>+QX-^'NL7<;_P#$POH#;Z7&#M>2<L%*)CDL0V !R> !R*]KA_ O'YG0
MI6]R,DZFETETT/!XDS".791BJR:A5=*2I7E92:7O:Z6T/NS_ ()P_ W_ (0'
MX:6WB"^B(\2>-KB2_P!3S;M$XMY;@W-M&=PR5 EP 2<@ G/6O[<X)RB.795"
MLYWJUURR@X<KA&-N7?H]/0_R9\;^*EG_ !++"4X\M++Y2?NU>>G*=1>]HGRW
M5M_,_I&_9M\(L#9R&(\;#]W'I_G_ "*^R/Q(_6?PI8BVLH5"X(11TQV_3_"@
M#M1QQ0 M !0 4 % !0 4 % !0 4 ?GO_ ,%'_P!LW3_V._@3>ZIH]Q%+\7?B
M"M_X9^%6F$0R&TU(6R?VIXSOH)DEC?2O!]M<P7?DO!,FHZW=:)I,J16E]=WU
ME[_#N3RS?'1C-6PF'Y:F*EJKQO[M&+7VZS3BMN6"G/>*B_Z+^C1X)XCQGX^H
M83&4YPX.X=>'S3BW%+GC[7"^TE]4R3#SARRCB\YJTIT.=3@\-@:6.Q<9.K0H
MT:W\0NIZGJ6M:C?ZQK.H7VK:OJM[=:EJFJZG=SW^HZEJ-[,]S>W]_?74DMS>
M7MW<223W5U<2R3SS2/+*[.S,?V>,8PC&$(QA"$5&,8I1C&,4E&,8I)1C%)*,
M4DDDDE8_W6PN%PV"PV'P6#P]#"8/!T*.%PF$PU*%##87"X>G&CA\-AZ%*,:5
M&A0I0A2HT:<8TZ=.,80C&,4E1JC<* "@ H * "@ H ?&CRND42-))(Z1QQQJ
M7>21V")&B*"S.[$*BJ"68@ 9P*"92C",ISE&$(1<I2DU&,8Q5Y2DW91C%)MM
MV22N]#^L7_@EY_P3SMOV=_#EC\<OBYI$<WQU\6:3NT/1M1L_WGPE\-:K:[9-
M/CBN4$EMXYUNRF>#Q+>".*XT?3II/"UJT:S^(&U/\FXGXAEF-26!PDK8"C/W
MI0E_ODX/2;:T="#5Z,-5)VK2;?LXTO\ &WZ6WTEJOB;FF(X X,QDZ?A[DV,M
MCL;AJWN\99I@ZMXXJ<J4N2ID&!KTXSRFAS3IXS$0AF]92G#+88+]B*^0/XC"
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^2/V\?VH=$_8O_8]_:#_:
M;UIK4M\*?ASK.K^&[&](6VUOQ[J0B\/_  Y\.R\@B/Q#X[U;P[HLK)N:*&]D
MF".(RI^[\,>"\1XA\?<*\&X=3MG>;8>AC*E->_A\KHWQ6;8N.F^%RRABL1%.
MR<J:C=7,,366'H5:O\D&UV<GI!?.32/\A?PSXD^*FN_%./XG>'8M9\9?%&Q\
M7I\4I]4/AN#QS=W/BBV\10>()/$>NZ#J&E:UI.M6\WB&6"XU.UUS2K[1M2DN
M?L>IV=S;7;VTO^\>,P>28;)7DV+>'R_):F >2QH_6Y9;3A@IX26%6$PV)I5L
M/7P\HX2,H49X:M3Q%%0]I1G"=-3C\2G-SYUK/FY]D];WNU:V_1JW2Q^UW_#]
MS_@OC_T7GXA_^(B_L\__ $/=?SM_Q+-]&#_HF,J_\3OBO_Z*CO\ [1S'_G[+
M_P $TO\ Y4?/G[3W_!3/_@KK^V7\(]6^!7[2OC;QQ\3?A9K>J:'K5_X:N/V8
M?A%X9E_M;PWJ$6J:-J%AXB\%?!?PWXHTBZM+J+:\NDZU9-=V,UYI=[]HTR_O
M;.X^JX,\'/ CP^SVAQ+P?EN6Y-G6'HXG#4L9#C+/L9'V&+I.CB*53"9CQ#B\
M%7A.#NHU\/45.I&G6I\E:E3G'*KB\;7@Z=63E!V=O94UMJK.---?)KML'_!#
M;]LQOV'_ /@H[\%/&NOZFVC_  T^)NH/\!OC";B0VUG;>#?B/?:?866MZFSD
M+;V?@KQS9^$O&6HS-&\J:9H&H6T2AKEJ/I(^'R\1_"3B++L+1]OG&34EQ-P_
MR+FJ2S#**56K4P]%+XJF8Y;/'9?2BFH^VQ5*;=H(,OK_ %?%4Y/2$OW<_P##
M.ROZ1DHR?E$_O0_X.&[G5;3_ ((Z?MFR:.A>Y?1O@];3A205TJ\_:&^$EIK3
M@#[P32)KTN"5 C#M\VW8W^8WT4H4)^/WA['$.T%7S^<>WMZ?"F>SPR\KUXTT
MM-[+3=?29G_N->W:G_Z=IK\C^9/_ (-!+33W_;'_ &H[Z2. ZK;?LSVMI92M
MC[4FGWOQ2\&3:G'"-A/D2W-AI#7.'4"2&URCY!C_ +'^GI.JO#_@NDG+V$N,
M93J17P.K3R3,(T7+7XHPJ5U#1Z2GJNOD9);ZQ5_Z\_ASP_R7];?Z"%?Y9'TQ
M^-?_  <$:7IFK?\ !'[]L^#54B:&U\+_  VU2U:5<^5J>E?&WX9W^EO$>"DI
MO[>WB5E(R)&C;=&[JW] _18K5J'CWX>RH.2E/&9O1FH]:-;AS.*59-=8JE*3
M:_NW5FDUP9FD\#7OV@^VJJ0M_7R/YY_^#.G_ )*)^WC_ -B7^S__ .GSXL5_
M5GT_/^13X9?]C'BC_P!1LC/,R/XL1_AI_G,_H[_X*P_\%>_@A_P2N^'?AR^\
M5:#=_%3XV?$=-0;X8?!?1=9M]"N=3L-*>&'4_%GC#Q#)9:M_PB/@VPN)X[&&
M_&C:MJ6NZL6TW1-+NHK'7M1T/^2/ [P%XC\:\UQ=/!8F&2<.90Z2SGB'$8>6
M)A1JUE*5' X#"*I0^O9A4A%U)4OK%"CA:%JN)K0=7"TL3ZN,QM/!Q5USU)?!
M33MMUD_LQZ;-MZ):.W\6GQ"_X.+?^"Q_[4?CF]T#X">(+;X<1ZO+,VD?##]G
M?X(Z%XWUZ/3D98X475?%OAOXD>/+N\16B-[J&EWNE137;LT%E86TD=E%_H=E
M7T3?H_\ !>6T\5Q/A)YNZ"BJ^<\5\1XG+<*ZS5W^XP.+RC+*=-VE[.C6IUY1
M@DI5*LXNH_ EFF.K2M3?)?:%*FI.WK)3E?T:\K;$5K^SI_P<N?MMC^S?$=I^
MWQ=>']87_2].^+7Q(\0_L^>!I+2;!>XNO"_C[Q1\-M N8!$Q=$M]$NKB6',=
ME;S;UB:I\6?0^\.?WN$J>&%/%8?X*N191A>*<R4X;0AC,KP6;XJ$^96?-B(1
MC+6I*-KH]EFN(T:Q-GTG)TXV]).*_#T/Q=_:T_9D^)W[''[0?Q"_9O\ C-/X
M=N/B=\-Y/#2^+F\*:S-XAT.*_P#%G@WP]XY@M+?69[+3VOKNQT_Q-9V6K2);
M?9TU>WOH;2YOK6.&]N/Z%X%XQR;C_A7*N+N'HXN&39O'%O +'8>.$Q+I8''X
MK+93EAXU*JI4ZE7!SJ4$Y\SP\J4IPIS<J<."M1G0J2I3MS0M?E=UK%2WLMDU
M^A_L(_ W_DBGP?\ ^R6_#_\ ]1/2*_P/XE_Y*//_ /L=YK_ZG5S[BG_#A_@C
M_P"DH_S!O'/A_3/%G_!P]XE\+:R471_$G_!8^^T'53)C9_9NK_MH-I]Z&S\N
M#;7$@^;"<_.53)'^R^6XJM@?HI8/&X=-XC!_1_I8J@EO[;#^'BJT_P#R>$=M
M>RZ'R+2EF;B]GCVOD\18_P!4NO\ $T^Q"@#_ "5_#B/IO_!:S08_ L<8?3_^
M"I&EIX-BMP(X=]K^UC OAZ. 0@A(\QV:Q"($*NW8, 5_NABVJWT=\2\R;M5\
M%ZSS!RU=I\#R^M.5[7=G.]_F?%K3'KDZ8Q<O3_E]IZ=#_0%_X.&_^4.7[9W_
M &!O@Y_ZT3\(:_RU^BE_R?\ \/?^PC/_ /UD\^/I<S_W&OZ0_P#3L#^;[_@S
MX_Y.-_;%_P"R)^ ?_4ZNJ_KGZ>__ "2/ '_91YG_ .JR!Y61_P 6O_U[C_Z4
M?V+_ /!1S_E'G^WC_P!F9?M0_P#JD/'%?P#X2_\ )U?#/_LX/!G_ *T>6GN8
MO_=<3_V#UO\ TW(_@*_X-;/^4KGA7_LAOQF_]-6E5_J+]-+_ ),?CO\ LI.'
MO_3]8^;R?_?(_P#7NI^2/]$K]J'X!>%/VIOV=?C5^SIXV5!X;^,GPW\5> KR
M[:!;B31[G7-+GMM(\1V<3$*=2\,:S_9_B'2F)'EZEIEK)_!7^3_!?%&-X*XL
MX=XLRZ_UOA_-\#F=.FI<BQ$,-6C.OA)M;4<9A_:X6LNM&M-=3ZBM25:E4I2V
MG!Q]+K1KSB[->A_F<_\ !'?XX^*_^";_ /P5W^''ASXH;_"D#?$WQ5^R)\?-
M,GF,-MIL7BGQ#_P@MT=2N'$833/!_P 4-)\*>++ZX>/:;+PS(P50X=?]B/'W
MAO ^+G@/F^+R6V.DLFP7'G"]:,;RK2P6$_M*FJ,%>];'Y-7QN!IP3TJ8Q*^E
MCY/ U'A<;!2T]]T*B[7?+_Y+-)OT/Z?_ /@['_:X_P"%7?L@_##]DWP[J?D>
M)OVFO'0\0>,;6"7]XOPG^$-SIFNS6MY%&1);KKOQ&O\ P/-I\LI\J\@\+:];
M)'+Y<Q@_C+Z#? G]L\>9SQSBZ/-@^#<M^J9?.2T_MS/H5L-&=-O27U;**690
MJQCK3EC<+-N-XJ7KYS7Y*$*"WJRO+_!"S_&7+;_"SCO^#2C]D#_A OV<OC-^
MV9XETORM>^/?BM?AI\.+NXA_>Q_##X7W<Z^(]2TV? _T3Q3\1[J_TC48B7_T
MGX:6+KLYW^A].CCW^T^+>'O#W!UKX7AC!?VQF\(R]UYSG-.'U.C5C_/@LHA2
MKTI:>YG%1:])R6ARTIUVM:CY(?X(;M>L]'_@/+/^#Q:\OT^'7[!VGQJW]EW/
MC7X_7EXX)VK?V.A?"F#35*]"SV^HZL5)Y 1@.IKVOH!4Z3S;Q-JNWMH9=PO3
MIKK[*IB<\E5^2E1H7]41GGPX9=+U?P5.WY_@?S;_ +!/P._X+'?$'X5^*?$_
M_!.K4?VM--^$8\?WNA^,'_9\^.NN_"WPU<?$73O#WAR^O4UO1=%^(GA%;[7H
M/#6L>&F.I7.GSNVG3V-M'=LEOY4/]=^)W$?@!E6=8+!^+%+@6KGO]ET\3EZX
MJX:PN<XR&4U<5BZ5-X;$8G*L<Z>&EC,/C%[&%6*56-2;IIRYI>5AJ>.E!O"^
MV4.:S]E4<%S)+=*4=;./3:Q]Q_\ #+7_  =(?]#-_P %,/\ Q,+QS_\ /NK\
MW_US^A=_T!^#O_B!99_]#AT>QS?OB_\ P?+_ .6'FOQ6_P"">?\ P<7_ !W\
M+#P-\</!W[<WQE\$C4[36AX/^*W[1&H_$/PL-8T]+B*PU8>'_%WQ9U?21J=C
M'=W4=I?"T^U6R7-PD,J+-(&]C)/%3Z)O#.-_M+AO,/#7A_,?8SP_U_).%:.4
MXWZO5<'5H?6L!D>'K^QJ.G!SI<_)-P@Y1?*K1/"YI47+4CB)QO?EG5YE=;.S
MFU<_H1_X-A_V%?VR_P!BCQ-^V2G[4'P*\5_!S1/B;H/P,;PK/XDO/#UPFOZI
MX*U#XK"^BM$T/6=696TZT\6QO,UP(%Q>1B(R$N$_E7Z97B5X?>(F"\/WP9Q+
M@>(,3D^)XE6-C@X8J+PM#,*62>R=1XC#T%:K/ M14.;^&[VT/4RC#U\.Z_M:
M;IJ:IVO;5QY]K-[)_D?UPU_"9[04 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % 'A_P"T/^SY\.?VF_A;KWPH^)FF?:]'U9!<Z7JUJ$36_"?B&WBF32_%
M'AVZ8'[-JNFM-( D@>SU"SFN]+U.WNM-O;JVE[<OQ^)RS$PQ6%GR3AI*/V*M
M-VYJ56.TH2LM-XR49P<9PA*/WWAGXD\3^%'%V7<8<*8OV&.P4O98K!U;RP&;
MY;4E!XO*<RHIKVN#Q481NXN-?#5H4<7A*M'%8>C5A_$Y^TK^SE\0?V6OBQKO
MPH^(EHGV[3MM]H6O6B2C1O%WAFZ>1=+\2:)+*B,]G=B*6"X@<"?3=3MK[2[M
M4NK*51^UY9F6'S7"0Q6'TBWR3INW/2J12YJ<TMFKIK;FBXR6C1_O5X4^*'#?
MB]P;E_&'#55JCB+X?,<NK2@\;DN:T8P>+RS'0@VHU://"I2J+]WBL+5H8JE^
MZK1/ J] _2 H * "@ H * "@ H \"_:.^"&F_'3X=7_AUEB@\3Z8)=4\&ZHY
M2/['K<<1"V=Q*V NF:N@^PW^X[80\-\ TME$*_4O"+Q&Q?AMQ9ALT3G4R?&N
MG@<^P<=?;9?.HKUZ4=OK>!E_M.&>CFXSPSE&EB*C/Y_^DCX'9;XZ^'..X=<:
M5#B?*_:YKP;FDW&'U3.J5&2C@\14E9++<W@OJ&/YGRT5.CCE&5;!48G\\6IZ
M9J&BZE?Z/JUG<:=JFE7ESI^HV%W$T%U97MG,]O=6MQ"X#Q3031O%(C %74@]
M*_U5P>+PN883"X_ UZ6*P6-P]'%83$T)JI1Q&&KTXU:%:E./NSIU:<HSA):.
M+31_SNYGEF89+F6/R?-L'B,OS3*L9B<NS' 8NE*CB<%CL%6GA\5A<12FE*G6
MH5Z<Z52$DG&<6GL4:Z3A"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M0C%:%5J]7$3]I6ESS:2ORQCHM%I!16GH?.M?5&(4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_T_C^OZ(/^E@* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MC]4UHPKJK]1D^7^S2Q=:/OR7[F#7P0:_BOSFO@TTC[V\ER_UDU_*I] % !0
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M.H87#N484X5:_)/%XB-*G]:Q%>4%(^@Z\\_.@H * "@ H * "@ H * "@ H
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MJ\G%R?QV94/88NHDK0G^]AZ2W7E::DDNR1_9U^RC\0W_ ."S?_!!?Q/X$O\
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MZ._9#E_9\_X* :7^T-X7T]]-\$?M:>$H/&PNK-#;6]G\7?A\FE^%_B+:VIB
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MHY-F<Y2Y'4_LBI&$:E3%U9_E?7]J'^5@4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % '_]3X_K^B#_I8"@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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ME_SC^/?A%F/@EXF9[P1BY5<1EU*:S+AK,ZL>66:\-XZ=1Y9BY6C"#Q-)4ZN
MS%4H^RAF6#Q<*+E2C3G+QJOOS\:"@ H * "@ H * "@ H * "@ H * "@ H
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MI3E9N+Y9P;B[23B[/1IK=%:F:!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M=^SH4*484:%.[]G2A"-W:Y]U2I0HTX4J:Y80BHQ7DOS;W;ZO4]<KR30* "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M7G*AB)2YL3*,/D,WP'U:I[>FOW-66JZ4ZKN^5?W9).4>UI+1*)^"E?NAXP4
M% !0 4 % !0 4 ?U:_\ !M+_ ,% 6\!?$77/V#_B-?G_ (1+XJ7FH^-/@EJ-
MS=$1Z#\1[+3_ #O$_@WRYB8UT_QOH=A_:VF&%X19^)- FM4M;ZX\6F;3_P"8
MOI$\"+'Y=1XWR^G_ +7E<*>#SFG&.M?+IS4<-C+K[>"K3]C4NO>P]>,N:"PM
MI_1Y#C>2H\'-^Y4]ZD_Y:B6L?2:5U_>5K/FT_MSK^-#ZT* "@ H * "@ H *
M "@ H * "@ H 3':@#G=:TR.\@=&4'*D=/; ]O\ #D4 ?S??\%9_^"2'@S]J
MBQN?B5X*M8_#/Q6TM))[K4+*WC!\16B&6XN$N_-RKW3A4C150>80"/W@7=\9
MQ/PM0S:#Q6'2I8R&LG%?Q5O)O^]HK);L_:?"_P 5<=PA6CE>.;Q63UO<I0J/
M3"S=HTTDK?NKMR;;]WTT/XTM8M?B[^QI\2+SP=XNTS4H=(%VZ&QU&&:&"[L1
M(5-_;(8U!G6-#MB!VXY'&0OX!Q-PK&M>CB*4J%=)NA7<.64DMHN^EF_+KY']
MZ<#<>1J8>EBL#7AB<-+E^M8>,U*$>9)RJ4E'65E9+I<^YO OQ#\+_$'38-0T
M+4('FEB5IM.+HM["2 6)MA\X09QDCKQ7XSC\MQ66U94\13:BG:-1+]V_26W3
M[C^@\NS;!YG1A4PU6+E92E3;7M8:;.-[I+3YG=$8&,;3D@C&,8Z9Z5YYZ77>
M]K;_ "T_KL5[JSM;ZVEL[Z".ZM9UV30RHI5T]#QD?GZ^M5"<J<E.G)PE'X91
M=FC.I"%6#IU(1E"6CBUHSPGQ+^S;\+_$+O+!HT.A2R$EWL8BQ=FY)^8^OS>U
M?087BC-L.DI5W72V532WW+MH?.8SA#)L4[PH4\-)[NE:[]5M]VG8\VF_8M\%
M3S>:OBW6X47K EM!L^;ISG/'],5ZD..,;&-OJ=!OOS-/_+^F>-/P\R^4E)8[
M$PCK[L8QL=%H?[)?PZT=LWMS=:\NY6(OK=5!"X^3]V0-K=#_ #%<U?C#,JW\
M.,,/V]FV[7^73_([L-P+E-!>_4EBO*K%+3MI_7R/?_#G@_POX0@%MX:T*ST>
M$CE+9,YP,<[P<9[X/KQ7SF)QN+QDN;%5ZE:7>3^[8^GPF78'+X>SP6'I4$E:
M2BK<WIYG3<_Y[=.*Y3I$ SCY3PN25&=OU ' ';/ HV+46[VUUVULUWT_K\"_
MHFB:SXRN#I'A&%KJ_FS FIK&)--MIFV[=]R$*1219;>&Z''&!FOT7@OP^Q_%
M$U5J1JX;!<RA"IR6<ZGGS*RI6^TGZ'XKXI>,V2^'6'=*%3#XS,E'VM?#\Z<*
M="S35-QUEB4U;V.Z^X_0K]GK]G33OAU8 PHVJ^*=5&_7/$%Q$#>3F;RW>PC<
M$C[';2AA"0%9QRWI7]@\,<-X#A?+Z>#P5.,9.FE7J\JYINRYDWU5U='^77B)
MXCY[XAYWB<RS+$5(X9S<<+@E-NE2I*3Y'RO[3C:_;;T_5GX+?!^6YFM99+8D
M90\I]/:OHC\[/UF^&'@"'2+2W_<A=J)_#Z >U 'T=:6ZP1A5& ,=L=* +E !
M0 4 % !0 4 % !0 4 ?-/[77[1_A[]E/X!>.OC'KC6$]]HUC_9W@W0KZX\D>
M*?'&JK)!X;T"&..2.ZN4DN5?4=52Q)NK7P_INL:F/+@L)IHO2RG+JF:8^A@X
M749OFK3BOX5"&M2IM96C[L;Z.<H1U;2/T_P<\,\R\6_$+(>"L L13H8VO]9S
MK'T*:G_9.0X/EJ9GF$Y2C*C2<*3CAL(Z_P"[JYCB<%A;2J8BG3E_!;XV\9^)
M?B+XP\3>//&.J3ZWXJ\8:YJ7B+Q!JUSL$U_JVK74EY>W!CB2."%&FE816UO%
M#;6T(2WMH8H(XXU_<J-&GAZ5.A1@J=*C"%.G!;1A"*C%>;LM6]6]7J?] F1Y
M)E?#>397P_DF$IX#*,FP&%RW+L'2NX8?!X.C"A0I\TFYU)*$%SU:DI5*L^:I
M4E*<I2?+UH>J% !0 4 % !0 4 >X?LY_ /QK^TQ\7_"/P?\  D.-4\1WF[4M
M7F@EGT[POX<L\3:YXGU80X86&D66Z01;XWOKU[/2[9_ME];*W!F684<LP=7%
MUK-4U:%/F495:K^"E#?63WM&7+!2FURPE;\^\4/$?(?"C@G.>->(9WPN64>7
M"8&%2%/$YOFE>\,ORG!N::]OC*UHN?)..&P\:^+J1='#U+?W$_!#X,^!_P!G
MWX6^$?A'\/-/%CX9\(Z<EI',\<27^M:E)B35O$>LR1*%N=;UV^,M_J,_W!)*
MMM;+%96UK;P_B&-Q=;'8FKBJ\KU*LG*VO+!?9A"][0@O=BNRUUNS_ #C[CG/
M_$CBW.N,^)<2\1FN=8J5><(RF\/@<-'W,'EF!A-MT<!E^'4,-A:5[\D.>HYU
MIU*D_5ZY3X\* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M,\+*3JJ/.X^Q7)LG+<^0?^(ACQG_ -&N^&/_  Z6J_\ S$5ZO^H5+_H95/\
MPEC_ /+S]?\ ^*>F3?\ 1T,S_P#$6PO_ ,_#\4/VK?C_ 'G[4GQ_^(/QXO\
MPS;>#;OQ]/X>FF\-V>J2ZS;:8= \):!X418M2FLM.DN1<QZ$EZQ:SA\I[EH!
MO6(2/]CEF!66X&A@54=54%-*HX\CESU9U/A3E:W/;=[7\C^UO"GP_H^%O '#
MW >'S.IG%'((9A"&95L+#!5,3]?S;'YJW+#0K8B-+V4L<Z*2K3YHTU/1RY5Y
M[X3^$'Q9\>PF?P+\+_B)XT@52YF\)^"?$OB*$(OWG,FCZ9>(%7'+9P.];U<5
MA:#M6Q.'HOM5K4Z;^Z4D?0YMQ?PGD$E3SSB?AW)9MJ*AFV=9;ETKO9*.,Q-%
MW?16.9\1^%O$_@_4I-%\6^'->\+:Q" TVD^(](U#1-2B4DJ#)8:G;VMT@+*R
M@M$!E2.H-:4ZE.K'GI5(5(=)4Y1G'[XMH]/+LTRS.,-'&Y1F. S3!S=H8O+L
M7A\;AI.R=HU\-4JTF[-.RELT9EAI]]JMY;:=I=E=ZCJ%Y*EO9V%A;37EY=3N
M<)#;6MNDD\\KGA(XD9V/ 6K;C%.4FHQ6[;227FWHCIKXBAA:-3$8JM1PV'HP
M=2M7KU(4:-*G'XIU*M1QA3A%;RDU%=6=_P"(O@Q\8/"&FQZQXL^%'Q*\+Z1-
M$9X=4\1>!?%&B:;+ .LT=]J6EVUJ\0QS(LI08ZUST\7A*LN2EBL/5DM.6G6I
M3DGVY8R;_ \#+N,^#\WQ,L'E/%?#6:8N$N26%R[/<KQN)C/^25##8JI5C+;W
M7%/R.T_98^&]A\6OVCO@7\/==T/4M?\ "7BSXO\ PR\.^-;+3!J,;_\ "'Z]
MXXT+1?$#3WVEE+O2K=M-OIXGU..>V:S,BRQW$4BHPRS+$/"Y?C:\)QA5I83$
MU*+ER_Q:="<Z=HRTD^:*]VSOM8\;Q3XCK\)>'''7$&!QV&R_-LIX/XFS')*V
M)^KRC_;& R/'XW+U3H8J]+%5%B</3E'"RA4591<'3E%M'Z6?\%J?@9X6^%?Q
MZ^%.@_!_X76/@[X?:#^SIX<2:'P=X8:ST.VN(/B#\2TFNM7O[*U*7.J/;+:O
M?:GJUU/J5V#%/>W,SN)&^=X/QM3$X'$SQ>)=6O/,*EO:U+S:=##64(MZ1O?E
MC!**VBD?S3]"SCG-.*N N*L?Q?Q17SCB#'^(N8N$LXS-5L;4ISX>X:<*6#P]
M:JG2PL:CJQH8;"4J>&I>]3HTH)<J_%6OL#^U#]>O^",G[.WPZ^//[3VNCXP?
M#R+QUX+\&?"O7_%^A6VNV=]-X2D\;Z7XR^'NE6,>J0*4TG7?L^D^(=5E/A_5
MA>6$^Z*ZNK"86T97Y3B['U\#EL/JE?V%:KB:=*;@TJJHRHUY/D?Q0O*G!<\;
M-;)JY_(?TS/$3B+@/PPP#X0XAGD6=9SQ5E^3XZI@:U"&;1R3%9-Q#BJ\L+-I
MXO ^TQ>782"Q^$]C7IVE2I5X.I*_QE^VUX-O?"O[5W[2B0>%;KPWX8'Q_P#B
MW:>'5BT.71]!&GQ>.=>-C:Z*$M;?3_L<=FJ?98;']RELJ^2HB KV,GK1JY9E
MW[U5*GU'"NI[ZG/F]A3YG/5RO?=O6^Y^S>"6<T<U\*?#5SS6EF69_P"H'"57
M,7+'0QF/]O+(\![:KC;U:F(]M*LW[6=?WW4;YWS'SUX5\$>-/'5ZVF>"?"'B
MCQCJ*>7NT_PKH&J^(+U?-+"+=::1:7<X\PHPCS&-Y5@N=IQW5*U&BN:M5ITH
M]ZDXTUIYR:6A^A9KG>2Y%06)SO-\KR;#/FMB,UQ^$R^@^2W-:KBZM&G[J:YO
M>TNKVN@\4^"/&?@:^_LSQMX1\3^#]2^8?V?XIT#5?#]]\F X^R:M:6D_R9 ;
M]W\N1G&112K4:RYJ-6G5C_-2G&:^^+:#*\[R;/*'UG),WRS.,-I_M&5X_"9A
M0U^'][A*M6GKT][7H<O6IZ@4 =5;>!/&][>Z-IMGX-\57>H^(SCP]I]MX>U>
M>]UTA(I,:-:Q6;3ZH1'-#)BQCG^26)ONR(3DZ]"*G)UJ2C3^-NI!*'3WW>T=
MNMMCRJF>Y'1HXS$ULYRJEA\N_P"1A7J9AA(4<#K*/^V595E#"^]"<?WTH:PD
MMXNT7BKP9XP\":HVA>-_"GB7P;K:1+,VC^*M"U3P]JBPNS(DK:?J]K9W:Q,T
M;JKF$(61E!RI =*K2K1YZ-6G5AMSTIQG'_P*#:+RK.<GSW"K'9)FN6YQ@G)P
M6,RK'87,,*YQ2;@L1A*M:ES)2BW'GNDUIJC9\*_"GXH^.[:>\\#_  V\?>,K
M.T226ZN_"O@[Q#XAMK:*'/FR3SZ1IUW%"D6T^8TC*J8.XC%15Q.&H-*MB*%%
MO95:M.FWZ*4E^!Q9KQ5POD52G1SOB3(,FK591C2I9KG&79=4J2G\$:=/%XBC
M*<I?944V^AQVHZ9J.CWD^FZMI][I>H6K^7<V&HVD]E>6T@_@GM;F.*>%\8^6
M1%/M6L91DE*+4HO9Q::?HUH>QA\3AL91IXC"8BABL/57-2KX>K3K4:D>].K2
ME*$UYQ;19T/0-=\3:C!H_AO1=6\0:O<[OLVE:'IMYJNHW&P9;R+&PAGN9=J\
MMY<3;1R<"E.<*<>:I.-.*WE.2C%?-V2,\;C\!EF&GC,RQN$R_"4K>TQ6-Q-'
M"8:G=VCSUZ\Z=*%WHN:2N]$=3XL^%'Q2\ Q)-XZ^&OC_ ,%PR+&\<OBSP=XB
M\.12)+CRF1]8TZS1EDR/+*DA\C;G(K.EBL-7TH8BA6M_SZJTZEK?X),\O*>*
M^%L^E*GD7$F09U.#:E#*<XR[,91<;\RE'!XBLTXV=TUI9WV.(M+2ZO[F"RL;
M:XO+RZE2"VM+2&2XN;B:0A8X8((5>665V(5(XT9F. H)K9M13;:BENVTDEYO
M9'MU:M+#TIUJ]2G1HTHN=2K5G&G2IPBKRG.<VH0C%:N4FDEN=1I7P\\?:[KQ
M\*Z'X'\8:SXG C8^'-*\,ZUJ&O!9E5X2='M+*;4 )4='C/V?#JZLN0PK*5>A
M"'M)UJ4*?_/R52$8:;^\VHZ>NAY>*XAR# 8#^U<;GF3X/*[R2S'%9G@L/@+P
M;C-?7*M:&'O!Q:DO:>ZXM.UBIXI\%^,/ NI?V-XV\)^)?!VK^7YW]E>*="U3
MP]J7D[VC\W[#JUK:7/E[T=-_E;=Z,N<J0*I5J-://1JTZL-N:E.,X^EX-HUR
MK.<GSS#?7,DS7+<XP?-R?6LJQV%S##<UE+E]OA*M6ES<K3Y>:]FG:S1S5:'I
MGIY^"7QF70O^$G;X1_$Y?#0Z^(3X!\5#0@-N[_D+'2?[/'R?-_Q\?=YZ5S?7
M,)S^S^M8;VG_ #[]O2Y__ >:_P"!\PN-N#'CO[+7%W##S+_H7+/LJ^O;\O\
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MMTF"Z^+_ ,2=!G\,_!6PU2!#_9FD:MJ\>A>%C%;R;'=/%'B2'_A+]>VL'NO
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M^] O(]O_ -5?%XC+,=A6U5PU5);S4'R?)]C]!PV:Y=C(Q=#$TG)K^&YQY_\
MP%.Z?R1VZ*TB[HU+)@$,HRI'L>AKAT6CTMTV/0MHFM4]K#2K#^%L^F,9[>G:
M@:73_/3Y 48@@*V?3'3&* CNM-->GD*X\I&EES'$O+2R JB\=2V,#@?YXH6N
MBU\D#34>9IV6E[;>3[>7X%?3[B#4YQ;Z1YFO7)AEG^R:3F>;RXL;ONQ.,YRN
M%!Q@YQQ7T&4<+YWG=94,%@ZB<H.<:E:$H4I)=I6UOTL?'<2\>\+<*826+S;,
M:"A2JQI5J&'J4YXFG)K>=-OW8I:N^Q]!^ OV>/$WC(VUUXD!T?P_=V+/'% O
MEZPMRY7;%<0,JX79UWME3PO4FOZ#X1\%,+A_8XS/JCK2J8?W\+[LZ=.MY1Z6
M\]4?QAXF?2MQ,XXG*N$XQH>RQ//A<PHMJ=3#JZC"K.+:O+>26UMC]"OA1\"]
M-\-V%KI'A[1XK*W C\YX80DEW.%59+FX*CYI92,MVSCT%?O. R_"9;AJ6$P5
M&%"C2A&"C!)7Y5:[MU/XGSSB'..(L97QV;XZOC*V(KSKR]K-RC&4VW:"Z)7L
MO(_1/X3? J25[:2:U/\  >4]Q[5V'BGZ6_#?X7VVD00'[.JE0O\  !Z>W_ZJ
M /I73[".UB5$4   =/;M_G\AB@#5H * "@ H * "@ H * "@ H _CZ_X+(_M
M;_\ "]/CY_PISPG?&3X<? :[U'09G@F+VWB#XD2,L'BW53L81O;Z"T,?A33D
M>-WBN=/UV]@N'MM8CCA_6^$,J^HX#ZW47^T8]0GM;V>&6M*'K4O[672SIJUX
M'^S'T*_!]<!>'G^NF;4.7B;Q!I8?'PC.'+4RWAB%YY/@]=54S'F><8EQ:C*E
M7RZC.$:N#DY?CI7UI_: 4 % !0 4 % !0 JJ6(5069B%55&22>  !R23P .O
M04";44Y-I1BFVWHDDM6^R2/['_\ @F1^Q9%^RG\'$\1>,-/A7XV?%.SL-6\;
M/) GVKPEHNU;K1/A[!.2SJVF!QJ'B8P^5#=>(YGM6^VVN@Z3>-^-\2YU_:N,
MY*,O]BPS<*-GI6:;3Q#5E\:TIIKW8=G*1_AU]*[QVGXP\<2RW),3/_4/A&MB
M,%D$(S?L<XQR;I8_B2I3LE_M;C]7RM3YIT<KIPJ6H5L=C**_3"OFS^50H *
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MG?W94W)*ZO?E3Y?EKJ>0_P#!TI_RE\^*_P#V2CX&?^H!I]>]]#7_ ),5D?\
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M2JRJ3:A!2DTBZF7XVE%RGAZBBE=M6E9+J^5NUO,_,VOUXXS]'?@3_P $A_\
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M^!OVE/@II^N0'4;1&GNK?7/!NCV_BV[\-P:JL4.HZOX'\<:'<S)HECJQNO\
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MF5T<<JL8_7,+,_J=K\N/\APH * "@ H * "@ H * "@ H * "@ H * "@ H
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MY+KK?"GX>^/?AQXAT"[N[C^V+8^)]2MY;*:P']L:1J@BTK]TXT^C/X=^(O\
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MFZE:G5QDK[XA^UTEJO?P_P#M&1UH2U]C&K;R]DU6C]RLO338_@QK_2L^9"@
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M8DDDDDG))/4DGJ3W-?<']ZI)))*R6B2T22V21^F'_!'K_E(K^SW_ +GQ:_\
M5'_$FOG>*_\ D08__N5_]3<,?S3],'_E'7Q"]>$O_6XX:.U_X+7_ /)_'CK_
M +$?X:?^HK:5CP?_ ,B.A_U^Q'_IUGB?0I_Y,)D7_8\XE_\ 5K5/R9KZ@_K(
M_63_ ()&_L7^ OVNOC7XMO/BQ;7.K?#7X1Z!I>N:MX8M[JXL(_%6O>(;ZZLO
M#ND:I?6-Q:ZC;Z-'%IFLZG>II\\,]W+I]I8O/':7%RLGR_%.;U\JP=)85J.(
MQ4Y0C4:4O90IQ3J2C%IQ<_>A&-TTDV[72/Y.^EOXSY]X1<%911X3J4\)Q)Q;
MF&*P.$S.I2IUY95@,NH4JV8XO"T*].KAZF,E+$X+"T'7ISIT88BK6C!U:=)Q
M_07XL_\ !6K]F[]EGQ]XN^%/[,?[''@>5OAYKFJ>#Y?&4<?AOX;Z;/K'ARZF
MTG4YM/TCP]X/U/6=6L5O[2>.'4]0UK2K[443[9+"IG!/@X7A;,<RH4L3F.;5
ME[>$:OL?WF(DH5$I14I3JQA!\K7NQA*,?A6Q_/O"?T2_$CQ2R#*.*O$WQCSN
M*XAP&%S>.32EF7$F)A@\QI0Q6%IXC%YAG&%P>$K/#U82GAL/@L50PSE[&$VH
M'V5>?'GXG_M/?\$E?C_\:_BEX1T'P7K'C/X3?&>XT'1?#EIK%I8GP?I5MJ6F
M:/J+KKFI:G>W$U^;"]N1?*]K:7UF;6[L[.*VECDE\E8+#9;Q3@<'AJLZL*.*
MP:G.HX-^UFXN<?<C%+EYDN75Q=TW?1?C='@/ACPP^EGP!P5PMF^/SK!Y+Q9P
M73Q^-S&K@ZM=9OBJF&Q.,P\7@<-AJ%.&']O1I^P<:M6A556C6K2J0E&'XB?L
M1ZK_ ,%#/V4?@IXM_:W^"GA71];_ &:;FVNM5\7:/XLUW0M6\-^(5T#7_P#A
M%-4UNT\':9XGLO&VDZQH5U;W-M=:W:6VE%M+LWN+T:MI%G;HOV.<QR',\92R
MK&5)0S%-1I3I0G"I3YX>UC!UI4W1E":::@W+WG:/+-L_MSQMPOT>O%;C7*?"
M3C3-<7@O$NE4I87*,9E. QV$S++GC\O_ +5PN!JYSB<KK9)B\'CJ-2G5I8&K
M5Q26*JQIT?JF+K3;_2_X-_\ !9?]GG]IS5O"OP7_ &FOV<(M//CC7-*\*VL\
MUOH7Q9^'L^LZ[=P:793:MH>O:1INK:/97%U<Q0%K.Q\3SVN]7DD,(DFA^=Q?
M"./RV-3%Y=F'-["$JC2Y\+74(+F?).$Y0DTE?5TT_P #^:>,?H:^(?ACA,UX
MS\,O$>6(61X'%9K5IPJ8[A/B&&#P%&>*K0PF-P&+Q&$QE:G2I2J)5J^5PJ6<
M8QY^6$_FO]K']CWX7?LI_P#!3#]A?5/A!9OX>\&_%WXZ?"C79/!?VEKFP\+^
M(-"^,7@ZUU2/0#,S75IX?U&#5=.GLM+N)+A=/O(]1@L;A---EIVG>CE>;8G,
M^'<ZCBWSU<)@L5#VUK.I3GA*SASVT<XN,DY*W,N6ZYKRE^D^$_C!Q1XJ_1H\
M<\-Q?6CF&<<(\"\68".<^R5*OF>7X[@W.*N%>/4$J57,,-/"XBG6Q5.--XBC
M+#3KTWB56Q&(\^_X+^@_\-:?"LXX/[.OAT ]LCXE_%+(_ $?3(KHX&_Y%6)_
M[&%3_P!1L*?0?0"_Y-+Q2O\ JXF8Z?\ =M<+6_+\#\+:^T/[H/W'_P"" N/^
M&POB6/\ JVOQ=@?3XH?![^5?&<<_\BG#_P#8QH_^HV+/X=^GW_R9[AK_ +.5
ME'_K+\8',?!?Q'9^$_\ @N1K&IZ@R1P77[7?Q[\.1F4HJF[\:7OQ&\(Z8H\P
M%=\M_KMHL( WM(Z"(B0H1IC*;J\&0C'=95@*FG:C'#U9?=&#]#T^-,MK9M]!
MS!X7#)RG2\(N LQDH)M^QR6APYFV*^'6T</@*KGTC%/F7*FAG_!=+P1XCT#]
MLVW\7ZC97*^'?'WPR\)W'AK4F#&RN9/#:W.A:WIT$NYD6ZTZYBMKN[M1L>*'
M5[&X:/;>1R2'!=:G/*'1BU[2AB*JJ1TNO:6G"37:2O%/O"2^SH_H,9WEN/\
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M'6?\%M],U;XG?L=?LS_&;PS:RW_@^PUS1M<UBYLMLMMI^G?$CP19S>'=3N1
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M $GX0IPH\)<+TJ45"E2X=R2G3A%6C"$,LPT81BNT8I)+LC]OO /[37_!1O\
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MCB"62QP<\T]AB\MPD<'''O$QP?//,<9@X2==X/$\D:4IRM0FVDE<SK_]KO\
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M*E:6:T:V:TM;:QA"<J<HSIRE"<)1G"<&XRA*+3C*,HV<91:3BU9II-'\C?\
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M *"5(925*D%2#@@CH01T([$=* /X O\ @O=_P3Y7]DW]I,?''X<:+#9? ?\
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MR/[NJNU2&C?_ &^K3792MT/T@K\\.\* "@ H * "@ H * "@ H * "@ H *
M$(!X- &9=:=#<*0R C'I[?I0!YYKG@*PU!7S ASG^ 'V_7VH \(\2_ W3[WS
M-MJA/L@_3C_/M0!X'K_[-UO*7V6@[](_\!_2@#RO4/V9<L=MGW_N=!^7I0!G
M1?LR-N_X].__ #S[=NW7_P#50!VNC_LT(K(6M/3^#_ZU 'M_AG]GNSM3&6M%
MXQ_RS'M[?YZ?0 ^AO#GPKT_3@F+=!M _@4=/P]/TH ]<T[P_;6:J%B4$>@'^
M1_G% '1QPK&, #_/^?I0!-0 4 % !0 4 % !0 4 % !0 4 ?QA?\%=/VIA^T
M/^T[J7A+P_<&7X>? DZEX \.LDV^#5O$:W,)\>>(EB4%(_M&MV::!9O'-/'=
MZ1X;TS45^SRWT]M%^P\*99_9^61JU(VQ&.Y:]3^[2L_J]/Y0E[1[6E4<?LW?
M^VOT._"?_B''A7A,XS&CR<2\??5N(<R4H<L\)E3I/_5[+=4I-T\#6GF-?FC!
MT\7FE?#6E'#0JU/RLKZ<_K,* "@ H * "@ H ]A^ ?P3\8?M$?%WP1\'O \*
MMKGC+5XK)[Z<?Z#H6D0*UWKGB/4V!!&G:#I,%WJ=RD>;BY%NME913WUS;6\O
M%F&-I9=@Z^,K7<*$+\JWG-M1ITXZ.SJ3<8)M<L;\TK13/A_$?CW)/#'@K/N-
ML_FU@,DP4JT,/3?[_,,=4:HY?EF%5G_M.88R='"TY27LJ/M'7KRIX>E5J0_N
MH^$/PJ\'_!#X:>#/A1X"L$T[PKX'T2VT738Q'%'/>/'NEO\ 6-1:)46XUC7-
M1EN]8UB\(WW>I7MU<.<R5^&8K$U<9B*V)KR<JM:;G)MMVZ1BKMOEA%*$%?W8
M1C%:(_Y[N-.+\[X]XJSSC#B+$RQ6<9_CZN.Q4W*<J=%2M##X+"J;DZ6"P&%A
M1P6!H)\M#"8>C2BK01Z/7.?,!0 4 % !0 4 % !0 4 ?SO?\%6_^"_WAS_@E
M[^T?X<_9VOOV7M;^--]KOPE\.?%27Q1:?%FP\ 6EE#XC\3>,_#D&B1Z7-\/?
M&,UW);?\(?)>2W[7EHK?;DMTM/\ 1VGE_J[P0^BYB_&?A'%\64N,\-P[2PV>
MXO)(X*>15,TG4>$P>7XN6(=:.:Y?&FI_7U3C25.=O9.3G[RC'S,;F2P=6-+V
M+J7@IWYU%*[DK6Y9?R^1^M7["7[55M^V[^R5\%OVJ+/P1/\ #BV^,.@:KKD7
M@FY\01^*9] 72_%.O>&#;2:_%H^@1ZD9FT,W@E71[$1K<B#RW,7FR?A?B9P1
M/PXXZXAX)J9C'-YY!B:&&EF,,*\%'%>VP.%QG.L*Z^*='E6)5/E]O4OR<UU?
ME79AJWUBA3K<O)SIOEO>UFX[V7;LCZWKX4W"@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _#?\ X*)?\%_?V(/^
M"?/B?5?A1J%WXC^/7Q[T5_L^N_"OX3_V:]OX*O&MQ<0VOQ#\<ZO<6_A[PY>.
MI5)]$TD>*/%FFL\+ZKX:L;:>&=_Z2\)_HN>(_BG@J&=TX83ACAC$+GPV=YY[
M52S&FI<DIY3EM",L5BZ:M>.(KO!8&JDU0Q=24917G8K,L/A6X:U*BWA"UH^4
MY/1>BYI+K%:'\^OBW_@\*^.UW?ROX#_8N^$OA_2_M+&"W\6_$[QCXOOQ9[SL
MBEO-&T'P/;FY\O :9+ 1!\D6Y7Y:_J? ?0&X9ITHK,_$+/<56Y$I2P&3Y?@*
M7M+:N-/$8C,I<E]HNI>VG-U/,>>5/LT*:7G*4OR4?R/9?@Q_P>%V,NLV]E^T
M/^Q==Z?X>D\O[5XD^#'Q/AUC6;/!Q+]G\$^.- T.QU+>IW1B3Q_I7E%-C&82
M^9#\_P 0_0&J1P\JG"GB'"KBU?DPG$.3.AAZG\O-F.6XG$U*-MG;*Z][W2CR
MVEI3SS6U7#Z=Z<]?_ 9)?^E*Q_55^QA^WI^RU^W[\-F^)O[,7Q.TWQOIVG?8
M(/%WA>YC?1?'WP^U/4(II+;2/'/@^^VZIH=Q.UI?1:?J 2Z\/Z[_ &??7'AS
M6=8LK9[H?Q+XA>&/&OA=FZR;C+)JV75:OM)8#&P:Q&5YK1I.*G7RW'T_W.(C
M%3I.K2O#%8;VM.&+P^'J24#V</B:.)AS49IV^*.TH>4H]/)[.VC9]AU\ ;A0
M 4 % !0 4 % !0 4 >%?M$?M,_ 3]DWX:ZK\7?VB_BGX2^$WP_T@%)-;\47_
M ),NI7OE/-%HWAO1K5+G7/%7B&ZCBD:R\.^&M-U76[U8Y#:V$HC<K]+PGP=Q
M/QSF]#(>$LDQV>9I7LUAL%2YHT:=U%XC%XB;AAL#A8-I5,5BZU##T[I3J1NC
M.K5IT8.=6:A!=7^22U;[))OR+O[._P >OA]^U#\$?AK^T#\*KC5;KX=_%?PS
M:^+/"4^N:9)HVKOI5W)-#'_:&ERO*]E<I+;RI)"9) -NY)'0JQSXLX8S7@OB
M/-^%<[A0AFV1XR>!QT<-66(H*M",9/V5:*BJD'&46I<J[-)JP4JD:M.%2'P3
M5XW5M/0]HKYXT"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(Z4>(<.HQ7[F682KX;/$IVA6Q&88]87]WA9T</\ #%?T@?PN% !0 4 % !0
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M5ZD?AG6JS7I*;:_!COV'O^3T_P!D'_LZ+X ?^K7\)4O$7_DWW'?_ &1O$_\
MZI,:&'_WBA_U^I?^EQ/Z=O\ @\@=S^U;^R#$78QI^SWXH=(]QV*\GQ'U%9'5
M/NJSK%$KL "PCC!R$7'\??0)2_U)XZE97?%.#3=M6HY31LO1<SLNEV>SG_\
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M%SG2PU?%2PM1*?N?6\1DN;Y/FN58+%NGRJO6RW&5:U7V<&Y/V=*,?"OVP/\
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MLEPV)KYG#%XG!2A/ QS;&8K"X3#TLMP4X\T,ER[#2PE:T(3KPP_M\+7^$_\
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MS)<3^$=<\.^*]0L-!\4>&8I+B9M*+ZGIE[H5NJV$2:G9)IT&EY9SPO/%XO\
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MO"DZ_#'".(Q5;+L3/WJ%6<<#+A;A2,8VM&I7R["8K.XQCI1K87FE*4Y1E/\
MF2K]&/\ 34* "@ H * "@ H * "@ H * "@#YL_:.\8OI6@V?A2RF"7>O-Y^
MHA& E32+9_E3"D21K>WL:J''RR16EU;L&21Q7ZWX3Y$L7F5?/*]/FHY6O983
MF7NO'UH_&EM)X;#N4K?\NZE:A4T<87_SL_:$>+<^&>!\H\+,GQJHYKQU/Z_G
M\:4TL12X2RVM[F'DHM5:-/.LXI4Z7M$U#$83*\SP,XU*->M%?$5?T*?XU!0
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MD?U%^T._Y$OA=_V-.*?_ %$R0^O/^"[/_)H'@/\ [.(\'_\ JN_BO7D<#_\
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MA,LC@>+.&L:Z#JXUPH0PV,S7"8.HE'&Y-F:E[2I&G3J0P4Z\L!B]J=2O],?
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M3_F1_9*_9#^-?_!1+XM^+M:U'Q?=6VEV=];ZY\5OBYXK%[KMX;W69W\BPTZ
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MN.CF=;-X5HU'2P\J7[45\8?PB% !0 4 % !0 4 % !0 4 ?YQ'_!V;_RDT\
M_P#9H7PN_P#5F_&VO];OH-?\F<S/_LO,Z_\ 5/PZ?+9U_O</^O$/_2ZA_7W_
M ,$$?^40_P"Q-_V3_P 6?^K6\?U_!?TGO^3\>(O_ &-,!_ZH\K/;RW_<</\
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MZZO7\)?2+_Y/?XE?]E)7_P#3&'/;R_\ W+#_ /7M?FS]2J_%3L"@ H * "@
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MJD,<5G%2M2="A26'IM<KL[R<=N56C&,(M:-)-VZI71_+W7]C'C'J/P/^)/\
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MP1XUTC_A((IR(;KQ?X?\0>'V>SM[ ?\ ".2W=M)=7/XOX>_14SG/^!.$^-^
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MFV.GB,EK8RO@72Q^(56C&-3'8'+Z_M(Q5JB>&C%/2,I+4^&J]H_<@H * "@
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M5(?O\;"G*]XY?AVZRFXNG'$2PM.I?VL8R]'*\)]:Q,5)7I4DJE331V?N0?\
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MAG1:^&N47\[<3\7I'XM_\%=/^4@GQW_ZX?"O_P!4W\/J^QX3_P"1!@?7%?\
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M'^>)/]!_V=W^^>+/_8-P3_Z=XJ/LC_@BU_R8[X?_ .RC?$+_ -.5M7C\9?\
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MVDZOX5\&:V(%&3P=8O-:N>,#-P>,@D_%\;THPS6C4BK>VP=-R\Y0JU87_P#
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MK!VE!I?HF!Q"Q6%I5EO*-I]+5(^[-6Z:JZ\FC[0KX\ZPH * "@ H * "@ H
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ML1B*LZ^(Q%6I6KUJLG.I6K59.=6K4F]93J3DY3D]92;;+-(R"@ H * "@ H
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MR;]Z.FL7%VV=FC^^_P :?'OQ)^V3_P $N_B#\?OV);SQ(WQ!^.'[*/Q \0?
M1= U*RTCQKHGQ1U3P3K>G:1X=M=5EN[33])\:^$?'L,WANYO5U"&TT[Q'I$\
MT%^L4$=U7^7F7<,8/P_\:,JX7\1:>#65<-\;Y5A>)_K5&I7R[$9+0S'#5:^*
MG04)U:^78[+)1Q<*?LI3JX2O&,J3<G ^E=1U\'*IA[\U2C)T[-*2GRM)7V4H
MRT\FC_,>_P""AW@?_@H5X"^+WA+2_P#@I%>_&&^^,EU\-]/O_!TOQI^(47Q'
M\1K\,G\3^*K?3H]-UB'Q+XHCL]$'BFV\6-%IOVV!H[YKZZ-JHNEEF_V0\*<Q
M\*LSR''5O"*GD%/A^&;U:6/7#N5/*<(\X6#P4JKK4'@\$ZF(^I2P*=7V<DZ2
MI0Y_<Y8_)8F.)C.*Q7/S\BY?:2YWR7=K.[TO?0_7+_@FW\%_^"^FI']CGQ9\
M*-8_:UC_ &+)/''PJU72[70/CW::5\,Q\&+?QYILOB2*#P6WQ%LY8O#3:/%K
M(O=&_L%&N;8W,(L9?."/^$^+G$'T7Z/^OV!SS#\"OQ#66YW0K3Q7#,ZV<?ZP
M2RRK'!N68?V3-/&*N\/[/$?66H2Y)>TCRW7;A:>9?N'!U_8<T&K5;0Y.;7W>
M?:U]+?(_NJ_X*"?MY?!G_@G1^S=XH_:)^,DT]_!8SP>'_ G@/2KJTMO$WQ,\
M?:G%.^B^#_#YN\Q0M)%:W>JZYJLD5Q#H'AO3-6UE[6]>SBL+O_-+PL\,>(/%
MGB[!<)\/QC2E4C+%9GF=:G.>#R;*Z+BL1C\4J=G)*4Z=##4%*$L5BZU##J=-
M5)5:?T6)Q$,+2=6>MM(Q6CG)[17YM](INSM8_P \SXM_\%5_^"P/_!5[XW_\
M*S^"OBWXOZ0/$]Q='PG^SM^RC=>(_!NCZ7X>MIO,,GBC6?#=Y8^(?$5AI\3V
M\_B#Q3\0_$3^'[2<?;%A\/:<+:QM?]6<A\$O 3P/X<_MCB' 9!6^I1@L=Q9Q
MO#"8_$5L5.-DL%A\73J87"5*K4HX7!95A%BIQ_=WQ57GJ3^8GC,=C*G)3E-7
M^&E0O%)>=G=I=7)V7DC=\6_\$Y?^#A7]EWPM-\=I?#G[6WAFST:)O$&JZO\
M"O\ :3MO&_C71HK5&GEU'5?"WPK^+/B3QFT$%I&]SJ$XT>[MK&S64:L]LJ31
MKRX'Q:^BKQIC8\,K%\"XRI7:PM##YWPA++<NQ#FU%4J&-SO(\'EW-*;4*4?K
M$)U*G+[!3O%CEA<SHIU.6M&V[A54I)>E.;E9+RT/U-_X(S_\')?Q0N_B9X+_
M &7?^"A_B>P\7>%_&VI:=X4^'_[2VH6VG:'XC\'^([Z;[%H^D_&&:RCL='US
MPGJMR]GID?CQK.QUSPW?.-0\97FO:/>7VM^&OQ7Z07T0\EAD^8<9^%&#J8#&
MY=1JXW-.#Z4JN)PF882E'VE>MD$:CJ5\-CJ$%.L\L4ZF&QE->RR^GA<13I8?
M&=F S6?-&CBFI1DU&-;1.+V2J='%Z+FT<=Y-K6/]TM?YJ'T1_EE_LA_\%U/V
MXOV>/VC+;XQ?&3]H+]H+]H_PEH'A_P"*<5M\&O'/Q=\67_P^\1^,O$/@?Q-H
M7@2;Q)HMYJS:?'X<\-^+]3T?Q%=V^FV8O(;72?)T5;2[^RSV_P#M5QY]&GPV
MXKX2GD'#_"O"W"..Q6*R1SX@RW(<#2S7"9?A,RP>)S*.#Q%.A[5XO%X"CB,)
M3E5J>SE.O?$.=/GC+XZAF&(I554G5JU4E/\ =RG+E<G%J-U>UE)IZ=M#TIM6
M_P"#@/\ X*^/KGQH\%Q_M-^/?AO=7FJC2K;P'XI_X45\ K.%+JXCNM!\!Z=J
M/BGP+X-\4MHK6QTB[GMKOQ7XJWVL%MXCU>^U-_-F\A4/HM> RPW#V8/@W*\W
MA3H>VGF>"_UEXHJ2<(.GB<SJTL%F688)8CG]O3C.&!P5IRGA*%*@K1N^98Z\
MX^VE#^Z_9TM.D5>,7;;2\OYG<^:_ ?[=_P#P5A_X)8?'\^%?$WQ/^/?@'QGX
M*O=)F\5_ ;X\ZUXH\6^ _$>B;UNH+/4O!GBK4K_2;C0M>L#+#8>+O!ESI^I_
M8+F2[\+^*+.4QW:?7YGX9>!WC7PO]=P>3<,9IE^8TZ\<#Q/PSA\%@<SPF(MR
M2J4<PP5&E7AB<-5Y95<!F$*M'VL%#&8*:O!Y1Q&-P=3E<ZD91WI5+N#7^%Z6
M:VE&SM\,C]E?VZO^#DK]IW]KRV^$'[.W_!-/P?X\^&OC/XC^$?!W_"QM:\(Z
M#<^)OC/JWQ5U_2(KGQ%\)_@Y':V5[>V/AWPOJ#SV,GCS3M*M?%_B:XM#=Z(W
MA;1;&:?Q%_/OAI]$3@S@.6?<6>+^/RS-\ORC'YA_9.&Q^)A@^'L/D>%KN&$S
MS/W.I3IU,7C:2C4665:T\!@X35/$+&XBI&&$[\1FM6OR4L)&4'*,>;E5ZG.]
MX4[=([<R5WTY4M?RI^,_[)7_  7E_9Y\'WW[3_Q=TO\ ;?\ ">@Z1;R:GKOQ
M/A^.'BCQ'XG\,6 ;SKK6/%8\)?$?7/&_A/2H&'FWVL>([+2].M#MDN[J+<I/
M[=P]QU]&7BO'TN#,AK>'&.Q->2HX7)GPW@L)@L95MRPP^!^O91ALMQU>2]VE
MA\)4K59K2G!V.*=#,:4?;36(BMW/VC;2[RY9.4?G8_;W_@WC_P""X_Q\^)_Q
MV\-?L+?MC_$/4/BM8^/M'U:V^!7Q9\8&?5?B19^.-$LY=<_X07QOXOEE-WXM
MTCQ%H5CK<FB^(?$QU#Q1:^)+33]$GUC4=/UBRAT7^</I6?1MX7R;AG&>)7A_
ME5+(ZF5UZ$^)<BP')0RBIEN(J1PW]I9;@(Q5/ 5\)B:F&6(PF"]E@IX2=7$0
MP]*KAZCQ'HY9F%2=18:O+GYD_9S?Q<RUY9/[2:O9N\KV6MU;^X*O\X#Z * "
M@ H * "@ H * "@ H * /P$_X+9?LJ'7?#?A_P#:M\'Z;$VI^%$L/!?Q7CM8
M=MS>>&;JX\GPAXJN-A59SH.J7!\-ZA.R27K6&LZ F_\ LW1&^R_>\%9I[.K4
MRJJ_=KMUL,_Y:D(?O:?I.G!3BM%%PGHW/3_1WZ!7C LNS7,O![.\5)8/.I8C
M/.#Y5IWI4,VH4N?.<HI73=-9C@Z2S/#TU*-!8C 8ZT?K6/7M?YJJ_2S_ %3"
M@ H * "@ H * "@#\%_VV?A1'\-/C/J.HZ7:FV\-_$".3Q9I:*O[BVU&>;9X
MDL(7^YMBU8OJ$5NBQBSLM4LK54,<22R_Z<?1WXWEQAX?8/"XRJJF;<+RADF-
M;DG4JX2E3OE.*G'XO?P45A95).<J]?!8BM*7-.48_P""'TVO">GX9^,^99CE
M>%>'X;\0*=3BS*X1@U0PV95ZO+Q)E]&7P<M+-I3S"EAZ<:<,'@LUP6%A#V=*
M%2I\?U^\'\?!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MT(PPE5RDX2P57%4K*52$X]6#K4\/7A6J4W45.[C%-+W_ ++=U]G=>:3Z'/\
M_!0W]N7XH_\ !1/]JSXC_M._%$OI\WB>[31_ G@N.^DO]+^&OPRT26XC\'>
M](F:.W26+2K2>:]UC4(;2Q77O%.IZ_XDELK6YUF>%>KPL\.,F\*N"LIX/R:U
M6.#@Z^99@Z:I5LWS?$1@\?F5>*<G%UIPC3H4I3J/#8*CA<(JDX8>,FL5B9XN
MO*M/2^D8](07PP7IUT5Y-NVI\25^AG,% !0 4 % !0 4 % !0!__T_C^OZ(/
M^E@* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M1C-31]QEF$^J86":_>U/WE7RD]H>D(VCZW?4_7NOR4] * "@ H * "@ H *
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MHGB#1X%D)X"&2\4,>@7-?&9M55#B7$5GM1S&G5=NU.=.3M\D?PYXOYO2X?\
MI3<29]6;5')/$[+<WJN*]Y4LMQ^78R;BEU4:+LNY_*+^QA-\,=,_:K^#MK\<
MM!T'6/AK?>+I/"_C'2?&-J)-"A3Q%IFI>&[*\UF*;:MM#H>N:CI^JR7$YCCL
M9+ 7%PR0PR$?J><+$O*\6\%.<,3&E[2C*D_?_=RC4:A;?GA&4;=>:RZ'^N?C
M=#BG%>$G&E;@+'YA@N)Z&31S7)<9DM7EQ\WEN)PN9UJ.!G3NZL\=@,-B,)"G
M3YI8B.(]E24ISBC^PW_AWU^Q/_T;+\)?_"8M_P#XJOR/_6#.O^AEBO\ P/\
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MBS_V#<$_^G>*C['_ ."+/_)CN@>WQ&^(0^G_ !,;7^F*\?C+_D=U/^P?#_\
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MTJE.7*W&S?P%>C+#UJE&?Q4Y.-^C7V9+RE&TDNE[/8\8KV3$* "@ H * "@
MH _J\_X->OVO+7P?\4_BU^QEXJU7[+IOQ:M'^*_PLMYY=MJ_Q"\):7!8>-]&
MM8LMNU3Q)X$LM/UI7V1QBQ^'5U%+,TTEC"W\P?23X3EB\JROB_"T^:KE4UE>
M9\J][^S\74E/!5F_^?6&QLJE%KI/,(-+EYVOH^'L2H5*F%D[*HO:4UTYXJTT
MO.4+/TI^A_;97\;'UH4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M9U_O</\ KQ#_ -+J']??_!!'_E$/^Q-_V3_Q9_ZM;Q_7\%_2>_Y/QXB_]C3
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M/^"D)\'>#C&[B6RTKX:?M-?V-X=9)-[2;H;'1K)D8NS' )8DYK_=:&8U.+O
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MC+$_V70I*'$^$IS:YE0J91!YG7HP:]O6R;!>[4J4J4'^"M?Z:G^"04 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_]3X_K^B#_I8"@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _/OX]>*F\1>.KJPB?.
MG^&E.D6X!^5KI2'U.8CM(;O-H2IVM%90-@-NK^G_  UR595PW1Q$XVQ6;2^O
M5F]U0:Y,'2Z>ZJ/[_753Q$X[11_@Y].#Q/GX@>-F9Y-A:W/D/AW1?">70C*]
M.IFE*I[?B3&N-VHUIYF_[+DXOEJ8;)L'/EC.4T>)U^@G\=!0 4 % !0 4 %
M'ZX_\$4_V,+?]LK]MWP98^*] .N?!_X)0P_&'XKV]Q&IT?4+70[V.+P3X1U5
MI4>"YM_%_C,Z;!?:(5,VM^%=+\61QB.VM+V[M/R?QFXQ?!_!6,GA:_L<VSEO
M*,K<?XM.5:#>-Q=))IQ>$P?M'"MM0Q-7"O64H0EZ>4X98C%Q<HWIT+59IKW6
MT_W<7TUDKVZQA+IH?Z/#,69F8Y9B68^I)R3^)K_.\^U$H * "@ H * "@ H
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M%[/^2"_!+_LKMY_ZANM5]SP)_OV-_P"P2/\ Z>@?W_\ L^?^3@<=?]D=0_\
M5U@CK_\ @@__ ,FD?$C_ +.,\5_^JS^$E9<<_P#(UPW_ &+Z?_J1BCQOI_\
M_)X.&/\ LVN4_P#K4<8'XN?\%=/^4@GQW_ZX?"O_ -4W\/J^QX3_ .1!@?7%
M?^IE<_M[Z'/_ "CKP!_U\XL_];7B(_L2^$O_ "2KX9_]D^\&?^HYIM?D6+_W
MK$_]A%;_ -.2/\7>+_\ DK.*/^RBSK_U98D^6?\ @I=_R8K^TA_V)%K_ .I+
MH->GPY_R.\N_Z_\ _N.9^L_1>_Y/[X9_]CVK_P"JO,#\.?\ @@Q_R<G\7?\
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MV8^RIW\F^2;^ZWE8_/,J_9_>'&&Q4:N;<8\89IA82YOJF&CE.6>T2^&%6O\
M4\;4<.D_8JA.2^"=-ZGY_P"C>'/VNO\ @I#\:FN_^*C^*WC6Z^QV>J^)=0CC
MT[P9X!\/O<RM#]NN+6VMO#WA#P[9M+>7-OI=A;Q7&H3_ &H:9IVIZO<M'<>]
M.IE/#N"M^[PM%7<:<?>K5YI=$VZE6H[).4FU%6YI1BM/Z(QN9>#GT9>!E1_X
M3.$<BH^VK83*\-*6)SOB#,(TH1G["E5JU<QSG,JRA1I5,5B*DZ>'I^R^M8G"
MX.DI4_[%?V2OV:_#'[)WP,\)?!OPU='5I-)%UJOB?Q));):7'BCQ=J\BSZUK
M<MNA?R(2RP:;I5L\L\UEH>G:78S7-U+;/<R_D.:YC5S7&U<947+S6A2IWNJ5
M*&D(+\92>B<Y2:2O8_Q;\7_$[-?%WCW..-<TI+"1QCI83*LLC4=:GE.3X*+I
MX' 0J-1YYI.>)Q=6,*<*^/Q.*KPI4858TH?2=><?F1_$E_P4W^!4W[/'[8WQ
M)L-'@ETSPO\ $*4_%+P:]MNMHUTKQQ)>MKVGVPBVI#:Z;XIB\3:+!:1MM72[
M>T5D2.81C]HX:QRS#*,-*;4JN'_V6M?7WJ%O9R?G*E[*;?\ ,WVN?[H_19X]
MAXD>"W#-?&SABLUX;BN$\ZC5M5D\7D,:"R_$5>>[G5Q.4SRO&SJR5WBZE6S<
MJ?,?J?\ \$'O@+]A\/\ Q8_:1U>SVW&NW47PJ\$S2)M<:1IC67B#QI>0[@?,
MMM0U5O#.GPS1[0EQH&IP'>=P3Y?CG'7J87+H/2FOK59+^>5Z=%/SC#VDK=JD
M7H?R;]/_ ,0/;YCPAX98*O>EE]&?%N>TX2O%XS%*MEV1T:EO@JX;"1S3$2IR
MO>EF.%J)17*Y?T/5^?G^<!_*7_P6&_8F\:>!?B[X@_:?\#Z)=ZU\,?B7<VVH
M^,SHVGSSO\/_ !G!IUM::E>:XENDI@T+Q7):'6H=?E*6L6O7>IZ9?&S>71CJ
M?ZEPCG5&OA*>65IJ&)PR<:/.TO;T>9N*A?[=)/D]FM?9QC)7][E_UO\ H8>.
M>1Y_P;EWA5GV.HX'BGA>E4PV2+&XBG3CQ#DE3$U:N%H8&51Q4\?E,:RP,\OA
M>K++Z.%Q.'5:,,:L+=_9U_X+A?$WX8^!-)\#_&'X7VOQCG\.Z=:Z5H_C6T\8
MS^$O%-W8V%OY%JOBO[7H/BBT\0ZEL2&&36X?['NIHX_M&HPZIJ,EQ>3K,."L
M-B:\JV#Q+P?M).4Z+HJK23>_LK3ING'^X^9+:+C&R6/B5]!#A;BK/\9GW!?%
M57@J&98FKB\;D=;):>;Y31KUZG/5>4>QQ^55LMPUW.<<!/Z[1A*7L\-/"8:-
M.A3X;]L'_@L7\1/VCOAQKOPB^'WPYL_A'X.\6V3Z5XQU.X\2R^*_%FO:-*X-
MSHUG=PZ1X?T[0=*U2#_0]9@6SU:\O[-I;2/4;6UN+JWGVRCA##Y=B*>+Q&(>
M+K46I48JG[*E3FMIM<TY3E'>&L5%V?*VE;W?!CZ%O#?AGQ-@.,>(^):W&.=9
M/6CB\EPM/*X9/D^7XV$?W6-K49XS,<3F&+PD_P!]@INMA*&'K*%:6%JUJ5*I
M3^Q/^"+_ .Q-X[\":OK7[4?Q4\/ZAX5_M;PS<>%OA5X=UFWN+#6KK3]7N+:?
M7?&E]IEQ%#<Z?8W-I96^E^&OM6)-5L[[5M3%JE@=%OK_ ,CC'.J%>$,KPLXU
M>2HJN*J0:<%*":A1C):2:;YJEM(N,(WOSJ/XQ]-WQSR#/\'@?"CA+,</FWU/
M-*>:\6YC@:E/$8&CB<%3J4\!DF'Q5.<Z6(Q%*K7JXK-/9>[A*U#!X7VKQ"QN
M'P_H/_!=[X8>)?%'P6^$'Q)T72KO4M(^&7C'Q%8^*9[.%Y_[&TWQQI^CQ6>K
M7RQ@F#31JGARTTV6[<"&*\U+3X793<IGGX&Q-*EC,7AIR49XFC3=)/3GE0E/
MFA'^]RU')+M%]CYSZ /%.5Y5QQQEPQCL71PN,XHR7+:^4TZTU3^NXG(<3C)U
ML'0<K*>*^JYE5Q,**]^5#"XB<4U2D?D5^R!_P4]^-7['OP\U/X7>%O"?@/QK
MX2N]>O?$FFP^*X-;BU#1-3U*"S@OXK6]T;5K!)],N3917)L[JVDFBNWGDAO(
MXI6AKZS-N&<%F^(CB:E6O1JJG&G+V7)RSC%OE;C.#M)7M=.UDERZ7/[&\9?H
MK<#^,_$F$XKS7-\_R/-Z.7T,KQ4\HG@98?'87"U*U3#RJT<;A,0Z>*I*O.DJ
MU*I&$J*IQG1E*"F?TB_M/? '1?\ @H?^QMX2^QS6.A^+?$OA'P=\8OA=K,NY
MK#2O%&L>%8M3M=,OYU26Z'A_6M/UFYT34GB$LEJL]KJXM;VYTJWMI/SK+,?/
MA_-ZMU*=*G5K8/$P6CE3A5Y7)+;VD)04X[;.%TI,_P R_"OQ#QOT;_&O-_;0
MKX[)\KSG.N"^*\%&RQ&+RK!9M+"U<5AZ?-"C_:.!Q&!I8["QDXQJNG5P7M:%
M+%U*L?Y:OA?\5?VHO^";?QUU>.+1[[P1XNM/+TGQKX#\7Z<USX:\:Z%;7;2P
M).(I$BU+3)9$DN-!\5>&M15U26672M5>SN[N&Z_3\3A<LXCP,/?C6HOWJ->C
M*U2C.UG;^62VG2J1Z)2C=)K_ %>XJX2\*/I-\ X.4L;A\]R>KS8O(^(,FQ,:
M>:9%CZM%0J.GSQ<\+BHQ<:>891F>&<6X0AB\)&M1HSI?J_/_ ,%_9F\-S+;?
MLQ10^+C!)%;RS_%1KGPW%<F/$-]-;Q^!+74YX%FP\FE)=6[O&/*76(V;S5^5
M7 2]HKYE>CI=+"VJ-=4G[=Q7E*SM_(?R+#]GA!9G!U/%.4\F4XRJ0APDJ>9R
MI<WOT(5)9_5PL)N'NQQ3I5(QD^9X*27(_P I7@_:C_X*9_M'OJ0T^[\7>-/$
MES8Z?<W=G8ZA:?#[X7>$HYIVM89Y_P#B80^%?!^B1O>3Q)<W%SJ>KW\ERR'7
M/$^K/]O^J_X3.&\NY>94J-).23<77Q-6RO9>ZZE6;LM$HP5O@IQ]W^N(U/"C
MZ+?AG'"_6*.3Y'EE.OB*5&M7P];B+BO.)0IJK.G3_P!GGFN<XZ4:-.3I4Z6%
MP>'A236!RO!Q^K_V2?LS_ ?P[^S/\#_A_P#!;PS/]OM/!ND&#4-9-JMG-XA\
M0ZA<S:GXBU^>W62<P'5-8O+RY@M7N+EK&S:UT];B6*TC:OQ_,L=4S+&U\947
M*ZTO=A>ZITXI1IP3TORP25[*[N[*]C_%3Q1\0,R\4./.(N.,TI_5ZV=XSGPV
M!55UH9=EV&I4\)EN7TZCC34UA,%0HTJE6-*DJ]95<0Z4)59(_CB^,7_*23XE
M?]GK>*?_ %=UY7Z_@_\ DG,-_P!B:E_ZA(_VGX+_ .48^&/^S&Y5_P"L)1/[
ME*_$C_!D_(G_ (+9_P#)DTW_ &5CP#_Z)UZOK.#/^1TO^P6O_P"V']C_ $%_
M^3YP_P"R0XA_]+R\^5_^" /_ "+'[3W_ &'OA3_Z;_'M>KQ[_$RS_!B_SPY^
ML?M#_P#D;>%G_8NXL_\ 4G(#^AZOSX_S@/X<_P#@IG_R?;^T=_V.6G?^HGX=
MK]LX:_Y$>7?]>9?^G:A_O']%S_DP/AG_ -B3$?\ JWS$_N)C_P!6G^XO_H(K
M\4>[]6?X/2^*7^)_F/I$A0 4 % !0 4 % !0 4 % '\B/_!S/^Q?;FW^&W[<
M_@K2)8[B.73_ (/_ !RDM(@UK-%('D^%?C"]6.,-;7,4BZIX&U34;AWAO$F\
M!Z9$+:XME&H?UG]&SC%WS'@C&54XVGFV2*3]Y-66:82%WK%KV6-I4XI.'+CJ
MCYHR]SYW/<,N6GBHK6/[JK;K%_PY/HN5^Y?KS171(_D%K^M3YD* "@ H * "
M@ H ]N_9L^.?B;]F;X^_"'X^^#U$VO\ PF\>^'?&EK8/.]M;ZU:Z1J$4NJ^'
M;V>-'EBT[Q'I'V[0M1>%?.6QU"X,)64(R^/Q!DN&XCR/-<BQGNX?-<#B,'*H
MHJ4J,JM-JCB(1>CGAJWLZ\$]'*FD]#6A6EAZU*M#65*<9I;7Y7K'TDO=?DS_
M %@?AC\1?"OQ?^''@/XJ^!KXZGX,^)'A#P[XX\+7[H(I;G0?%&DVFLZ6]Q &
M<VUV+2\B6[M&8R6ERLMM+B2)@/\ +S,LOQ.4YACLKQL/9XO+L7B,%B8)W4:^
M&JRHU%%V7-#F@^225I1M):-'Z13G&K3A4@[PJ1C.+_NR2:_#[CN:XBPH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /YK?^"]'[0EX;SX5_LR:'>>581V[_%7Q]'$YW75W(]YH7@;396B
M9-L-E"GB?5+RQN!-%=2WN@7HCAETZ"23]%X&P"4<5F4XZM_5,.^R7+.NUYN]
M*">EDIQUYM/].OV?OAS25#BSQ2Q^'YJ\ZBX1X=J3C[M&E"-#'Y_B::::=2M*
M658.E6AR2HTZ684&YQQ,E#^<&OT,_P!+@H * "@ H * "@#[@_X)Y_LTC]J'
M]ISP5X-U:UEF\ ^%V;Q[\2'1?DD\+>')[9TT5FRNT^*=:GTKPV[1L)[>SU*]
MOX0QL2*\+B+,GEF5UJM-I5ZK6'P]U>TZB=YI;7ITU.<>9./-&*DFGRO^?OI,
M^*O_ !"7PGSW.L'5C#B+.$N'.%XOXH9KF=*K&>/2U_Y%& AB\SAS)TZF(PV&
MPU2RKG]MRJB*J1HL:(H5$0!41%&%1%'"JH "@<   5^*'^"+;DW*3;E)MMO5
MMO5MONV.H$% !0 4 % !0 4 % !0 4 % '^<1_P=F_\ *33P#_V:%\+O_5F_
M&VO];OH-?\F<S/\ [+S.O_5/PZ?+9U_O</\ KQ#_ -+J']??_!!'_E$/^Q-_
MV3_Q9_ZM;Q_7\%_2>_Y/QXB_]C3 ?^J/*SV\M_W'#_X9?^ER/Y+_ /@[J_Y2
M*_ O_LROP%_ZO+]H:O[F^@A_R:;B7_LXF9_^LUPH>+G?^]4_^P>'_IRJ?V#?
M\$488X/^"4O["Z1($4_ G092!T\R?4-4GF;ZO+([GW8U_ _TB9.7C?XE-N[7
M$N)C\H4J$8KY122]#W,O_P!RP_\ U[7YL^O?VOO^33/VH?\ LW;XU_\ JM?$
MM?!\!?\ )<\%_P#96<.?^KC!F]?^!6_Z]5/_ $AG^<%_P;1?\I@?V=_^Q1^/
M/_JD?'=?ZX?3!_Y,'Q9_V'<,?^M)E9\KE7^_4?2I_P"FIG^H-7^,9]>?P=?\
M'A__ "63]B'_ +)E\8O_ %*?!5?Z:_0%_P"2>\1O^QSD'_J#F!\YGG\3#_X)
M_G$_H$_X-PO^4-'['W_77]H3_P!:C^-=?RU]+?\ Y2"X]_P\*_\ K%\.GIY7
M_N%#_N+_ .GJA_!=^TY#'/\ \%P?CQ!,@>&;_@J5\1(98V^Z\<G[56JHZ'V9
M20?:O]..#9.'T;^&91=I1\%<IE%KHUP10:?R:/FZO^_U/^PR?_IYG^LE7^&Y
M]H?S=?\ !U)_RBON?^SB?@__ .DWC"OZZ^A/_P GKA_V2>??^EX \K./]S_[
MBP_]N/SZ_P"#.?\ Y$/]O;_L;OV>/_3-\8*_5/I^_P#(R\,/^P'BS_T_P^<N
M1;8GUH_E4/[2J_SQ/?/\G[_@N]_REP_;=_[*;HG_ *KGP57^X?T9O^3$^''_
M &)L1_ZM<P/C,Q_WW$?XU_Z3$_TC/^"H(S_P3-_;ZP/^;+OVDNGH/@WXN)_(
M#/L*_P B_!C_ )/%X8?]G#X1_P#6@P)]7B_]TQ/_ &#UO_3<C^%'_@U4E2/_
M (*ELC=9_P!F[XNQ1^[#5/ L^/\ OB%_RK_2WZ;46_!6Z^QQ=D,GZ>QS*'YR
M1\YD_P#OG_<*?_MI_I1U_D&?5G\FO_!WIJEO#^PW^S;HK$?:]0_:NT_5(%W
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M\=_ZSO#9XV=_[S2_Z\+_ -.5#^O/_@B9_P HHOV&/^R&Z-_Z==7K^#OI%_\
M)[_$K_LI*_\ Z8PY[>7_ .Y8?_KVOS9_";_P<R:;J%C_ ,%?/CU<WID-MK'@
M?X$ZEI =2JKI\7P>\'Z1((20 T?]JZ5J9+#($IE3.5('^EWT.ZM*IX"\,0IV
MY\/F/$U&O;?VKS_'UUS=G["M1T_EY7M8^=S:_P!>J_X:=O3V<?UN?7?[+O\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@#__U?C^OZ(/^E@* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * .7\:>(4\*>%=<U]MF_3K"62V63[DE[)B"QB8 @[9+R6"-@"#M8
MXKV.'\K>=9UEV6*_+BL3"%5QTE'#Q_>8B<7LG"A"I):632/S3QBX^I>&'ACQ
MKQU/V3K</Y'BJ^74ZZO1KYSB.7!9)AJL5*#=+$9MB<'1J*,HR]G.7*T['Y>W
M$\MU/-<SR/+//*\TTLC%GDDD8L[NQR69F)))Y)Y-?V-"$*<(4J<(TZ=.$:=.
MG%6C"G3BH0A%=(PBE&*Z)(_YJ\9B\5F&+Q6/QM>KBL;C<37Q>+Q-:3G6Q&*Q
M-25;$5ZLWK.K6JSE4G)ZRE)MD-4<P4 % !0 4 % !T]@/TH _P!#;_@@O^QW
M+^RW^P[X;\9>*-*33_BA^TQ-8?&#Q4DD")J.F>#[RP\GX5>&KZ38L_F6?A6X
M?Q1/83[6T?5O&>KZ:\,=U!=-+_G]XZ<7+B?C;$8/"U?:99PW&>485I_NZF*A
M4OF>(@K\MIXJ/U:-2.E6CA*-1-Q<4OM<IPWU?"0<E:I6M5GW2:]R.RVA9M=)
M2DC]LJ_&#TPH * "@ H * "@ H * "@ H * "@#S7X@?!CX/?%E]*D^*?PH^
M&OQ+DT)+R/1)/B!X%\+^,GT=-1-LVH)I3>(M+U%M/2^:RLS>+:&$7)M+8S!S
M!%LZ</C,7A.987%8G#*=N=8>O5H\_+?EYO9RCS<MW:^UW;<^GX=XVXSX0CBX
M<)<7<3\+QQ[HRQT>'<_S7)(XV6&558=XM9;B\,L0\.J]9476YW25:JH<OM)7
MV? _P\\ ?#+13X;^&W@;P?\ #WPZUY/J+:!X'\,Z+X3T4ZA=)#'<WYTK0;*P
ML3>7$=O D]T8//E2"%9'98T"Q6Q%?$S]IB*];$5+*//6J3JSY5M'FFY.RN[*
M]E<X<]XCXAXIQRS/B;/LYXBS)4*>&689[FF.S?'+#4G.5+#K%YA7Q%=4*4JE
M1TZ7M/9P<YN,4Y.^3\0/@[\(_BR-)7XJ?"SX<?$P: ;XZ$/B!X(\,^,AHIU/
M[&-2.DCQ'IFI#3CJ T^P%]]C\G[7]AL_/\S[-#LK#XO%X3F^JXK$8;GY>?ZO
M6J4>?EOR\WLY1YN7FERWVN[;G9P[QIQCP?\ 6WPEQ9Q+PN\P]@L>^'<]S3)/
MKJPOMOJJQ?\ 9F*PWUGZM]8Q'L/;<_L?;UO9\OM9WV_!?@+P-\-]"B\+_#OP
M7X3\!>&H+BXNX?#O@OP[H_A;0H;J\?S+NYBTC0[.QL([BZD >XF2W$DSC=(S
M'FHK5Z^(G[3$5JM>I9+VE:I.K.RV7--N5ET5[+H<.=\09]Q-CY9KQ)G>;\09
MI.G2HSS+.\RQF:X^=&C'EHTI8S'UJ^(E3I1]VE!U.6G'2*2.LK(\@\,TO]F#
M]FG1/$5GXOT7]GCX&Z1XMT[54UW3_%&E_"7P#8>(K'6XKC[9'K%GK=IX?BU*
MVU6.[_TI-0AN4NTN/WRS"3YJ[99GF4Z;HSS#&RI2A[.5*6*KNFX6Y>1P=3E<
M+:<K5K:6L?>XKQ4\3\=EM;)L=XC\>XS)\1A'@,1E.*XOXAQ&6U\#*G[&6"K8
M&MF$\+5PDJ/[IX:=)T73]QPY=#W.N(^".#\>_"SX8_%6PL=*^*'PY\!_$C2]
M,NSJ&FZ;X]\(>'_&%AI]^T+VS7MC9^(=/U&WM+MK>22 W,$<<QAD>(OL8J=Z
M&*Q.%DY87$5\-*2Y92H5:E&4HWORMTY1;5U>STN?0</<6<4\)8BOB^%.)>(.
M&<5BJ*PV)Q/#V<YCDN(Q&'4XU%0KULMQ.&J5:*J1C45*I*4%.,9<O,DR;P'\
M-/AQ\+-(N?#_ ,,? '@GX<:#>:C+K%YHG@/PKH7A#2+K5Y[:TLI]4N=-\/V&
MG6<^HS6>GV%I+?2PM<R6UE:0/*8K:%$5?$XC%24\37K8B<8J"G7JSJR4$VU%
M2J2DU%-MJ*TNV[:D<0<4<2\68REF/%/$6>\2YA0PT,%1QW$&;8_.<91P=.K6
MKT\)2Q.8XC$UJ>&A6Q&(K0H0FJ4:M>M4C!2J3;XKQ=^S7^SI\0/$%_XM\>_
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MNK_O]3_L,G_Z>9_K'5_AP?:'\W7_  =2?\HK[G_LXGX/_P#I-XPK^NOH3_\
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M86=*O%P=!^V48RPSJJ22[\!C\+'#4:4ZBA4BN3E<9?S/ELTN6S5NNG4^)O\
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M)Q%*#T46VXI^S+&86$.=XBER_P!V<9MVZ*,&V_1(_P [_P#X*(?\%6/VGO\
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M\HTYW_V8S,O_ %@:Q\93_P"1C#_L-C_Z?1_K#5_AT?9A0 4 % !0 4 % !0
M4 % !0 4 <AX_P# OAOXG^!O%WPZ\86C7WA;QOX<U?POKMM$RQW!TW6K&:PN
M9;.5D=;>^MDF^TV%SL?[->103A28P*VP]>IA:]'$49<M6A4A5IO=*4&I*ZV:
MTLXO1JZ>C/:X<X@S3A3/\EXFR6LL/FV09G@LVRZK)<U..+P&(IXBBJL$X^TH
M3E35.O2NE5HRG3;2D?P6_&GX5:_\#_BO\0/A)XG^?6O /B?4_#UQ=""2VBU.
MWM)B=-UFV@E_>1V>MZ7)9ZO9!B?]$O83N8$,?W? XJ&.P>&Q=.W+B*4*EE)2
M4)-6G3NOM4YJ5.6UI1::35C_ **. N,<M\0.#.&^-,I]W \193A<RA1]I&K+
M"5JL.7%X"K4A[LJV7XR%?!5VDOWV'G[L=EYA76?7!0 4 % !0 4 % 'Y<_\
M!1[X:&:P\%_%G3X06LI'\%^(RJ,76WN#/J?AV[8J"!!'<#6+*>23:$FN]-B0
MLT^%_M'Z)7%\:=?B#@?$S:]O&/$&5*3BH>TI*E@\TH1NU*56I2>!KTX03_=8
M;%3E90/\L_VD/AI*M@N"_%G 4E+ZE4GP7Q$XPDZD:&(=?,^'L4W%.*H4L1'.
M,'7J5'%1K8S+J4.9U6H_D[7]OG^384 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * /Y'OV\_V2_P!M:]_:<^.-
M]X"^&OQL\7?"[XA>/+SQ#HDO@_\ MSQ#X:U2#6K:VU"47>G:+>7D%C%97MQ=
MV(75[2T2$6^R,"#RB?U?(LUR6.68*-?$8*CB</0C3FJO)3J1<&XJTII<UXI2
M]QO?74_V'^C]XO\ @;0\+. J'$'$_ V3\5\.</T<MQT<Y^H9;FF$J8&I5PT/
M8XG'4*,Z\ZU"G1KWP=:LY^TN[SYDOJW_ ()B_P#!+3X@>!_B+HO[0W[2_AV+
MPQ-X/==2^&OPUOI[.]UI_$NU38>,/%$=C<75KI$6@!FN-"T2>0ZP==%OJ6H0
MZ2FCV\&K>7Q+Q/AZV'GE^6U/:*K[N(Q,4XP5/K2I-I.7/M.:7)R7C%RYFX_D
M?TI_I8<.Y]PUCO#CPOS&>:0SF+PO$_$]"G6H8&.5ZK$9+E4J]*E5Q<\PM&GC
M\=3@L$L ZF%PT\7+&5*F#_HTK\\/\U H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@#^('_@Y;_9&E^'/[0GP^
M_:V\,6!'A'X^:+'X/\>RPQ.4TOXL^ =/AMM/N;N7:(HXO&?P^CTP:7 "\QOO
M OB>>9UBGLXE_M7Z.'%D<PX?Q_"F)J?[7D59XO IM7JY5CIN52,([WP>/]I[
M1[<F.PT4KQFW\MGN&Y*M/$Q7NU5[.?E4BO=?_;T%;1:<GF?S*U_29X 4 % !
M0 4 % !0!^X?_!OO^U-<?LZ?\%"? W@_4KPP^!/VDM-N_@MXEBDE<6]OK^I.
MFL?#G6$@!6)[Z/QGING^&UN)F"V>D>*]<E7<Y"-^,^.W#4>(. <;B:<+XWAV
MK#.<-)+WG0IIT<QHWZ0E@ZDL0XI7E5PE".BN>MDN(=#'0BW[E=.C)>;UIOY2
M2CY*3/\ 1EK_ #]/N@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _,O_@K?\;'^#7[%GQ M=/O#:>(/BU<
MV7PDTCRQND:S\3PW=QXM#)AMMO-X,TS7]/EG91''+J%M%O2:>#/TG"F"^MYS
MAVXWIX1/%S[)TG%4?FJTJ;2ZV>Z5C^H_H><"_P"NOC?P[6KX?V^7<&TJW&6.
MYE^[A5RJI0I9.V]G..>8O+:T*?VXT)Z.$9V_BCK]D/\ <4* "@ H * "@ H
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M  5U_P""!O\ P]2_:*\"_'W_ (:O_P"%$?\ "%?!70?@_P#\(G_PHK_A9_\
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M_P#"1_\ "+6OG[/[2_L&'=_9Z_TWD_TSO[)\-LM\/?\ B&_M_P"SN"L+P?\
MVO\ ZX>R]M]5R.&3?VC]0_U6J>SY^3ZS]4^NSY;^Q^LRM[4\V>3\V(E7^L6Y
MJSJ\OL=KSY^6_M.FU[?+H?UCU_#A[1^;G_!5+_@GQ_P\R_97E_9G_P"%N?\
M"D_,^(G@_P ??\)K_P (#_PLC;_PBD6L1_V3_P (W_PFG@+/V_\ M7/V[^WA
M]E^SX^QW'FYC_7?!/Q4_X@[QJN,/[!_UBME./RO^SO[4_LC_ 'YX=^W^M_V=
MF?\ "]A_"^J^_P W\2'+KRXS"_6Z/LN?V?O1ES<O-\-]+<T>_<^??^".?_!(
M+_ATQH/Q[T3_ (:&_P"%_?\ "[]7^'FJ_:?^%3?\*K_X1C_A K/QA:>1Y/\
MPLSXC_VU_:O_  E?F>;YND_8?L&SR[S[5NMOJO'[QZ_XCGB>%\1_JI_JO_JW
M0S:CR?VY_;?US^U*F7SYN;^Q\H^K^P^HVY>6O[3VM[T^2T\L#@?J2J+VOM/:
M<GV.3EY.;^_*]^;RM8_:6OYX.\_D^_;O_P"#8'_AMC]KCXW?M3_\-P?\*S_X
M7)XFLO$?_""?\,T_\)G_ ,(Y]C\.:+H'V/\ X2?_ (7_ .%/[7\S^Q_M?VC_
M (1[2]GVCR/(;R?.E_N'PS^F9_Q#K@3AS@K_ (AO_;'^K^#J83^TO]</[/\
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MG&X>_;ZU6K9?4MY_4_\ MWH>6\CK7]VM2:Z-J2?W)-+[S[C_ &2?^#1SX/\
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M^('F?8?^$5^T_P!I?VY']I^W^3_9]O\ 9?-N/"\<?%K_ (C-QEA^+?\ 5_\
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MU(22E"<))QE"23C)--)HCJC,* "@ H * "@ H * "@ H * "@ H * /[I_\
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MJ/'5_P!]B6TX_O:GO.UNACBITZF(JSI+EIRFW!<JC:/;E6B]#XZK[PYPH *
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MK$/$T?KV#M5M.;H2]C\-3D5_A1W9?5P]#$<^)BI4^22MR*?O.UO=>G?T./\
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M[%3#9SQ96A52=N;"9DTU)4[/7^'MFO\ P4>_X(\2^#,?VQ\7O@QH[Z#I2_\
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M*KU:[E["FX_BE^WW^SW%^S%^UA\6_A9I=B]CX1@UT>)_ $69GA3P-XMA37=
MLK:>X9Y[J/08[N;PS-<S.\LMYHET9'=\N?L<CQ_]HY7A<3)WJN'LZ^W\:E[D
MVTM%SV51):*,U8_M7P"\09>)OA/PCQ3B:ZKYM/ _V9G\K0C-YYE$G@,?6J4Z
M:C"E+'RHPS.%*$8QA1QM)1C%62_4?]E_]DW]G+X8_P#!,;XC?M?_ +2/PLT/
MQUXPUJR\5^(_AM%XBO-;L_LEH\T'@3X:Z,MKIFJ:>I3Q)XX5]5ENBDTDFB:K
M8W$:^5;_ #_,YEFF88CB/#Y3E^)G0I0=*GB/9J#N[.MB)WE"7\.A[J6W/%KK
MI_+OB?XL>(O$_P!)SASP@\-^*<;D63X*ME67<22RZC@JWMJL83SWB7&.IB<+
MB+2RW(VL)&DG",<;A*].3YJGNX__  3Z_8!_9L/[,'B#]N']M(W6I?#>UB\0
M:AX9\)'4-9TK18?#?AO4IO#TWB#6%\/7-AX@US6]<\46USH_ACP[:7<%G/Y-
MF\L6LR:Y;6^G7GN>9C_:4,ERBT<0W3C4J\L)3=2I%34(<Z=.G"%)J52HTVM;
M.'(W+L^D#X_>)*\3\O\  _P65+#<1U99?A\RS98?!8K&3S+,<-#,(9?@WF%.
MOE^!P6!RNI3QF9YA5HSK4^:K&$L'' U)XCVCX2_M.?\ !&3XO>-M ^"A_9 7
MP+;^+M9L_"_ASQAXM^'WA:VLY]2U6\AT[2X=4\3^'?&FL>,M$.HWDT$$&HRO
M+:V?F^=J=_IL"RS+QXK+N+L)1GC/[5]M[*#J5*5*O5;48KFERTIT8T9\JO>*
MLW:T8RT1\5Q;X9?3,X0R3'\:_P#$7GGM3*,%6S3,<GRCB#-*E6GAL)1EB,5/
M"Y7F.2X/)L:L-1A4G/#PC"K64.3#4,3-P@_#OVG_ -F/]CC_ ()\_MJ^#M;^
M*OPW\8?$G]E[XE?#CQ)K.@?#C2KLZ[K?AOQW9WUOI4]C'<:OXN\(3ZEX=TR*
MXL]1L)]6\1WNH1OJC6\Z7\FGPW;=N6YCFV>Y/5AA<12P^98?$4X3Q$ER0J4'
M%R3M&E54:DK.+4*:C[MUR\S1]SX7^)OC'](+P6SC \*<29/PWXH<-<1Y;@\P
MXCQ5%8# YCD5:A4Q5.NZ>#RC-X8;,<3.G5P]>&$RVAAW'"JI3=".(G17ZL_\
M%7_B?^QU\.O"WPQMOVJ_@YXK^*VK>)=-^*UI\(KOPS96%W%X0UJUT[PA'K-[
MJAO?'G@LPPWESJ'A>6$P0:XQ72[G=;V^U$O/F>%\-FV(J8AY9BZ6%A3EA7BU
M4<E[6#E5Y%'EH5;M*-5:N'Q+5]/Y3^BCPQXQ<19IQ/4\*N,<JX4PF68CA6KQ
M=1S*M7HRS?!5<1F\L%0PJHY#G*G*C2P^:1FISP*3Q5*TZEVZ/Y"?\$V_^"=/
MPC^(GPE\1?MB_M?ZA<Z3\"O"W]NW>@>&KB]O=#TGQ+I'A5)HO$/B[Q'JVER1
MZY)X=L=2AN]&TG1M!EM-3UK6]+O(VFEM4@T[5OJN(<_Q6'Q5/*<IBI8VIR*I
M448SE3E4_ATJ<)>XJCC:<IS3C"$EI>\H?U[])'Z17%W#O%F7>#OA!AZ6+XZS
M3ZA1Q^94Z-#'8O+,7FLH2R[*,NPF*C+ QS&OAIT<9BL9CXU<+@L#BJ,E"%5S
MQ&$^C/!OQ]_X(C_&3QGIWP/G_9FE\!Z3JVI'P]X<^)FM>$[?PCI%[>W4AL[&
M:]\6^&?',_C[2H-1N3;KINH>([6."V\])M=;1(DN-GGU<#QCA*,L8LQ]O*,>
M>IAH575DDK-J-*I05"3BKWC3?2U/GT/SG.. ?IM<&Y-B.-X>)D,^Q>$PW]H9
MCPS@LVJ9OBZ%"E%5:T*&4YGD<,@Q4\/24WB</EU5SJ<CA@5C9.GS?F9_P4C_
M &";W]BGXO:%I/A2\UOQ1\*/B7:W6H?#G6-3AAEUBVO[&ZBMM9\%:K-910PW
M^L:-]MTJYM[Z"RLTU33M7LFCMENX+^.+Z/A[.UG&$G*HH4\5AVHXB$;J#4DW
M"M%/X8SY9)QN^64'K9Q/Z9^C=X]4?&KA#'8O-:."ROBOAFK2P_$>#PLY0P=2
MA7I2J8+.L)"M*<\/@\9['%4JE"=:L\+B,)63J>QG0<OUA\-_L:?L)_\ !.']
MG7PK\6_VW?"J_%KXN>+DL8I/"UQ9#Q.L?B*\LX=1O?!'@;P;+JNF^%;Z+PU
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M4A5S#-LTQ,:5/$9AC:E.%*E[65*A0H4Z=*E3IT<-AZ-*,6X2G/YRKT#]&"@
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M[P4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MU04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M)*%6*MLVW%^ZHQDG9^\XJ6G+LD?YIO[:/_)XO[6/_9R_QV_]6CXIK_7+P_\
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M*7L%P?A,ZXNCAG+DB\PX4YLJX@PN%Y_XM?,Z5/*98*,(MU:>$E."FI*WG/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M:IAZ4WWA*5/\&I_A8]3_ .(L+Q!_T8WHW_B0M[_\YFO-_P")7<+_ -%MB/\
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M.EE^49-@L/EV78*@N6EA\)AJ:ITJ:ZRE9<U2I)NI5J2G5J2E4G*3Y:M3U0H
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MKL_AFPTBXGT,K;V,V@^'M6O@@>WNOM/YUX[^%'CSDV#POB+XI9O@,_\ J=3
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MPK_E(M\ /^S*O!/_ *O/]H"OL?H(?\FIXF_[.%F/_K-\+F6??[U2_P"P>/\
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M4ZF;PS3+J=/"T<SP&6U(\N983&Y?3HX+-LIIJ6(J<E27U3%TL;BUA_0_"?\
MP2Z_X)T>"/&UC\5/%W[<7@3QE\&M+U'^V[#P5J7CCX765MK-O83_ &RWT?6_
M'&F^*I5\0:;)&D=MJ-GH7AW1=1U2(O%:W-G).H'/4XDS^M1>&I9-6HXN4>1U
MHT<2^5OW7*%&5)>SDMXN=2<8/=-(^=S;Z47TBL[R2OPIE'@?GN3<98K#?4:^
M=8;(^**]3!SKT_8U,9@<CQ.50>7XF,G*IAJV.S'&X;"R2G5I5HTW?Y!_X*R_
M\%!/"7[4'C?P#X ^!-[=/\+/@W?76M6/C&*VNM'_ .$L\;7,5I;6^J:+8W=M
M9ZEI^C>%+.VELM$N9X;*XO;O4=5NA:BRCTNXE];A?(JN6T:]?&Q7UG%I0=)M
M2]E15WRS:;BYU&[S2NHJ,5>_,E^O_1.^C]FWA?DF?Y_QU0I+BGC&A2P5?)YU
M*6,_LG)*4JM2IA<;7HU*V&Q&,S6M4C6QM*$ZU.A2PV%I>U]M+%4X?HG;?&[]
MC'_@K5^SAX-^'_[0/Q+T/X(?M"^!EBNA>:KJVB^&+NR\5&RM;#6=<\%2^(KB
MVT/Q3X0\8K#%<:CX22^76=/DMH8Y5MGTG2]=NO ^I9OPMF%:O@<//&8"M=<L
M(SJ)TKMPA65-.=*K1O:-7EY)7=KJ4H+^=JG!'C-]$OQ'SGB#P^X9QW&_A[GC
ME2]CA<)C<SI5LJ]M5KX+ YU#+J=3'97F^3.4J>'S9T'@\1&I.474CB\3@:7;
M_L=> ?\ @G9_P3J\=MI$G[5WPZ^(/QI^)T&I^&K_ ,;ZMXM\#Z/H/@CPOHUC
M)XDN],U1[7Q%?:+X%MM8U#2=/MS_ ,)!XBN-:\1ZT="L=*LUM;>]>/'-J^?Y
M_0YO[+KT,'AG&I&C&E6E.M4F_9J4+TXSK.$9M_NZ:A3ASRD[M'B>,6??2(^D
M3D*Q<?"CB+A[@OAB>&S+#Y)A,ISS&8_.\TQE:.6T<3A8U,NH8W/*F#P^+Q%1
M?V?EM/!9;@ECJV*K.K4HQE_/O_P4=\5^%O''[;?[0?BOP5XDT#QAX6UKQ;I]
MSHWB7PMK&G>(- U:W3PKX?MWGTS6-)N+O3KZ%+B&:!I;6XEC6:*2(L'C91]U
MP_2J4<FP%*M3G2J0I-3IU(2IS@_:3=I0DE*+M9V:6A_H%]'+*<TR/P2\/LIS
MK+<?D^:8+*,12QF6YI@\1E^/PE1YICZBIXG!XNG1Q%";ISA-0JTX2<)1DERM
M,^)*]D_;3^S?]HCXI_\ !.K]IKX+_#3]FSXP?M%?"I)?%7ARSUCPMXQ\+_$C
MP9J"?#3QQX,T'2+2"ZUK7;35K_2?">IWUKX@U*PL;+Q?'9Z5XALK?Q%I*W,.
MJ160/Y'@,-G^78S$YAA,!B;4JCA4HU,/6C]9H5JDFU"#A&56,73C)NE>5-NG
M*SC<_P 9O#OA;Z1/AEQIQ+XD<'^'7%4HY5F-;!YID^:<-YSAWQ+D><X_%U9T
ML%@:V$P^+S7#4*N7X:O6K9/*MBLOK5,NQ3ISPLJQ\W_ ;X-_\$[?^"7UUXB^
M/WBG]J#PY\:OB1!H%[:^"].T35/"&H>);72=83RI(/!?@+PUXAUF\O=;UZW=
M-*G\5ZIJ-KHMKIL]PK3:'I]WJ5Q+WXW%Y]Q(J>!I9;4P>'YTZLIQJQIN4-O;
M5ZE."4(?$J48N3DEI)J*7Z/QYQC](CZ3]++N ,K\+\QX*X;GCZ%7.L1C<+F^
M'RVKB\'+FC/.<^S++\%1H8+ 5(O%4\JPN&JXVIB:=-J&.Q%+#4X_SM?M3?M
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M^/Y_:6_:S^,'Q-M+PWGA@^(I/"G@1E?=;CP1X.7^P- NK5>?*CUR*SE\2SQ
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M(YJ]>CB*M2-"I[*C"[A&%248N%%PA"/[N4N:$.3GM)L^/X3X"\=,P^D5X?\
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M_#=;'^A57\ GV(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M.:C2KI:TI<DVE]B>U]-HS24=4ESOJT?Q<U_8Y\J% !0 4 % !0 4 % !0 4
M% !0 4 ?7/['G[</[1G[#'Q,L?B9\ ?'-YHDHFC7Q+X*U.2ZU'X?>/-,!43Z
M/XR\+?:8+34K>6(&.WU&!K/7M'D87FA:MIE_'%=)\MQ9P;P_QIEL\MSW!0KK
ME:PV,IJ-/'X"I]FK@\3RN5)I_%3:G0JJ\*U*I!V.G"XNO@ZBJ49\O\T'K":_
MEE'JO-6DNC1_HO?\$W/^"C7PA_X*-_!-/B%X%7_A&/B)X372M)^,7PIOKN.Y
MU?P%XFOK:5X9K2<;&UGP7X@DLM1G\(>)1!;_ -I6UE=V=_9Z;KFEZMI=E_G_
M .(?A]FOA]G/U#&_[3E^*]I5RC-(0<:6.PT)).,X_P#+G&8=2IQQ>&O)4Y2C
M.G.K0J4JL_N<!CJ6.I<\/=J1LJM)[P?2W>$K/E?R:332_1&O@#N"@ H * "@
M H \(_:-_:-^%W[+?PPU?XI_%;6UTS1[#_0](TJW,4NO>+-?FAEDL/#7AK3W
MDC:_U:]$,CD;H[73[*&ZU34[BSTNRN[N'NR[+L3F>)AA<+#FG+64GI3I4TTI
M5*DOLPC=>;;48IR:3^^\-?#7BKQ6XIP7"?"6!>)QN(_>XO%U.:&7Y1E\)0CB
M,SS/$*,EA\)0YXK:57$5ITL)A:=;%5Z-&?\ '%^V+_P47^/G[7^LWEEK.LW/
M@3X417,K:'\)_"VHW$.BK;[_ -Q<>+-0B2SNO&FL"-(MUUJL4>F6<HFDT/1=
M&6ZNTG_7<HX?P&40BZ<%7Q5ESXNK%>TOU5*-W&C"^RA[[5N><[*W^TO@M]&S
MP^\&<%0KX'!4L^XO=.'U[B_-,/"6.]JE[]/)\-*5:CD>"YW)QI824L76CR1Q
M^.QOL:#I_ =>Z?T*% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#\4_^"W?P4E\9_L^>#_C-
MI=GY^I?!KQ:EGKDJ !H/!/Q :ST:YNFP-TBVOBVS\(VZITC35+F?*JC[OL^"
ML<L/F%7!S^#&TOW>FJKT+SBM[*,J7MKZ-N<:26ES^\/H"\>0R+Q+SK@?%U_9
MX7CC)75P$'\-3/>'%6QU"DM4H.IDU;.I\WVI8>E3M>2M_*W7ZJ?[ !0 4 %
M!0 4 % 'BG[1?@=_B'\$OB-X8MX/M&H2^&[O5-)@ R\VK>']NN:=;Q ?\MKN
MYT]+.+.%WSKN*KEA^C>$G$4.%?$;A/.*M54<+#-:.#QU63M"G@<R4LNQ=6?]
MRC0Q,JTK:VIZ:Z'XE]([@>?B'X(^(W#&'H?6<?5X<Q>:930BKU*^;Y!RYWEN
M&HK;VV+Q67T\)2O://77,TM5_.%7^M1_S>!0 4 % !0 4 % !0 4 % !0 4
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M#_I8"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /I;]D'X7?"CXT_M#> /AC\;/'[_  O^'/BH^);?
M6/'"ZOX?T!=&O+#PCKNKZ DNK>*(I]$M(]5U_3],T8?:XF-Q)J$=I;M'<SPR
MIYV:XG%8/ 5\1@Z'UG$4O9N%'DG/G4JM.$[0I6F^6G*4]'IRW>BL?FGB]Q1Q
M7P7X>9_Q-P3D$>)^(LJ_LRI@\C>#S#'O&4:^;X#"8]PPF5RIXVM+"Y?B,3C/
MW,DJ4</*M44J5.<)?OW\<_BG^R5_P3/_ &,/'_P _9;^)VG?$/XQ?&)=6LGU
M:Q\6^'_%_BNTG\2:?'H6L>-?$^H^%(X-*\-6GAWPVDECX+TF.WLY9-8>UO(+
M2_8^(]8'PV"PV:<19O0QV98:6'PF$Y)<KI5*5)JG+GA1I1J7E4=2IK6E=I0N
MFX_NX'\!\#<+>+7TE_&?(./O%'AC$</<'<'/"5EA*^4X_*,JJT\MQ$L=@\DR
MS#9JYXK,JN8YDXULZQ4JE:$<&JM&=6A'^S<&?RW5^E'^HX4 % !0 4 % !0
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M);O[+)TYM1@8Y/\ 3GAAEOU#A:A7DK5<TQ%?&RNK-48OZKAX^CA0=>/]VO\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M*4Y8>IBWC<;3O];<G\!5[I_0H4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % ']/_\ P0T^"H\.?![XF?'34X"NH_$OQ3;^#_#1E@VM
M%X3\!QS-J-]:3D M!K?BC6+O3[F,919?!\!&&+"OR_C?'.KC,/@(_!A:;JSL
M_BJU[:26W[NG"/)HFO:SW35O\E/V@7'G]J<<<+>'V$J)X;A/**F<9HH5+J6<
M<12I_5\/6I_"IX#*<#AL11EI+DSFJGIRG[HU\.?Y]!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!
MY=\;OAE9_&;X/_$WX47WDK#\0/!'B+PM%-<()(;34-4TR>#2;]E/?3=4-E?Q
MLNUXY+9)(V21$=>K!8EX/%X;%15WAZU.KRI\O-&$DY0OT4XWB]+6>Q];P%Q5
M7X&XUX5XPPW.ZG#>?99F\H4Y.$ZU#!XJG4Q6&4ELL3A56P\D[Q<:KC).+:?\
M!^JZ7J&AZIJ>B:O9SZ?JVC:A>Z3JFGW*&.YL=1TZYEL[ZSN(SRD]K=0RP2I_
M"Z,.U?O=.<*L(5*<E*G4C&<)+:4)).+7DTTS_HYP6,PN8X/"9A@:]/%8+'X7
M#XW!XFB^:EB,+BJ4*^'KTI=:=6C.%2#ZQDBA5G4% !0 4 % !0 4 ?S4?&SP
M?_P@/Q;^(?A%(!;6^C>*M5BL(0NQ%TJYN#?:28U[1/IES:/#T_=,AP.E?Z^^
M'F>_ZS<#<*YY*I[:KC\EP4L54YN9RQM&DL-CN:76<<91KQG_ 'DS_F@\;>#_
M /4'Q;\0^$84%A\/DW%6:T\!1C#DA#*L3B)8[*/9PZ4I99B<).E_T[E%V6QY
M=7V9^7!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M*JT94)\ZC3<7[LXV?->WOQCT['\UU?UL>0% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__]/X_K^B#_I8"@ H * "@ H
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M,^*^+*W.JG$G$6<YVXU/C@LSS"OBX4Y?WJ<*L8/_  F-7:?+!0 4 % !0 4
M7=-TR_UK4=/T;2;=KO5-6O;73--M$!+W-_?SQVMG;H%!8M-<2QQJ%!)+  'I
M45*E.C3G6JR4*5*$JE23VC3IQ<IR>VD8IOY#2;:BE=MI)>;T2/\ 5A_99^"F
MC_LW_LW? SX#:'!%#9?"CX7>#O!D\D4/D'4=;TS1[;_A)]>N(BSE;_Q)XFDU
M?Q#J7S'=J.J73# (4?Y;\3YU6XBXBSO/*\G*>:9EB\7%-W]G1J5I?5J$7_)A
M\.J5"G_<IQ/T.C35&C2HQTC2IP@O^W8I?>]WYL]ZKPC0* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* %5BC*R\,I#*?0J<C\L4 ?YEW_!6?\ 9WB_9C_X*#?M)_#K3+,V?A'6/&\O
MQ0\!1K T%K%X/^*MO%XYL]+T]6&7L/"FIZQJ_@J"7+^:?#+NSNY8U_I-X5<0
M?ZR\ \.9A4ES8JC@EEF.;:E)XO*Y/!2J3M]O$T:-'&26EOK%DDM%\-F='V&-
MKQ2M&4O:P]*GO-+1:1ES17DEJ?G/7Z$< 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?Z-W_  ;X?'G5OC=_P35^&NE^(+N>_P!;^!GBKQ=\$);VZD5Y[C0_#DEA
MXC\&0A555BM-$\&^+-"\*6"!?^/3P]%N9Y/,<_Y^^/624LG\1<QJX>"A1SO#
M83.N2*M&.(Q$9T,:_.5;&86OBI_WL0^EC[K)*SJX"FGJZ,I4?^W8V<%Z1A*,
M5Y1/VZK\9/6"@ H * /SQ_X*F_&-O@Q^Q-\6]1LKW[%X@\=VMA\+/#C9*M-=
M>-;@VNNQQNCQR1SQ>"K;Q3>6TD>YDN+6(E0FYT^@X7P:QF=82,H\U/#N6*J+
MRH1YH??6]E'T?E8_I#Z)O!4.-_'3@[#8FC[7+>'ZF*XLS)6YE&GD-!U\N4XV
MLZ=7/9Y1AJJ;BO9UY6?-RQ?\/M?M!_NP% !0 4 % !0 4 % !0 4 % !0 4
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MFH4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M#RWV%:.*X8EF-?GQ,L$\<W/&2]K=8I.*4:<;4XJ)^#U?;']WA0 4 % !0 4
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MGRZ\U!?"O>CZ&54?;8Z@FO=IOVTO^X>L=O\ IYR7Z6NO)_Z6'7DU_G"?<!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M[&GQVDFW_8)/VC;U;++@Q^;'\.O _P!L\M <H?GM]Y*KN^7&=O'\3?28</\
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M73NZ6+S&C6ERIM4Z<Y:*+DO[H:_#3_GT"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#-U/5]*T6UDO=6U"
MSTZTA!,EQ>7$4$2 #)RTC*.@)P.<#I1HMVEZZ%PISJ/EIPE.7\L(N3^Y(^0O
MB+_P4*_8U^%@NU\9_'WP'ILU@,W5J-2\ZXB =8\E$C"-^\8)A)"=W&*\S$9S
ME6%<E7QV'IN.Z<UI]W]=CZG+^!>+LS]F\#D&85XU=(2C0:3\M;/\#YX_X?2_
M\$Z!>-:R_M"^&[95('VN<QI9GMD.L[R!1U),0P.:XUQ/D+=O[2P_KS:?D>V_
M"7Q!4>;_ %;Q_P#A5-\WY6T]3ZH^%W[;O[*OQH6#_A6/QS\ >+GN(TECATW6
M8O-*2#Y#LG2'K[$XQSBO2P^8X#%?[OBJ-72Z49;^FB/F,QX4XBRB_P#:.3XW
M"I-INI2=DUTTN?3=MJEG=QQS6]Q!/#(JM'+#(DL;H<897C8H0?:NW\O+\-CP
M&G%V:::Z-6:^1>65&Z'_ #_GVH$2T % !0 4 % !0 4 % !0 4 % !0 4 %
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M4\ W;D$<AOZI^B=GZP'&N<Y!4J1A1S[)75HQ?Q5<PRBLJU&$>R6 Q&9U)?\
M7I?+_/3]HUP<\W\)^&.,*%)SQ/!O%D,-B9K14<FXGP<\)B:LWUMF^7Y#0IKI
M]:FTU=I_B[7^@Y_BT% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % #D7<Z+
MTW,J_3) I;+T _J7_P"#B[_@ES^R?_P3'^%'[ '@[]F[PSKB^(/&L_[1L?Q2
M^)OC#7[W7/&OQ,OO"UM\"6T2]UY4-GX:TN'2F\0:T-+TKPMX?T+3+2+4+C=;
MW%U-<7<_\:?13\9.-O&#.O$_'\68O#?5<NCPF\ER? 86GALOR>GC9<2+$4\,
MVIXNM*LL+A_;5L;B<36FZ4;2A",*<?:S7!4,'3PL:*=Y>UYYR=Y3Y?9VO]E6
MN[**2/KW]E7]GKX!ZG_P:K_M!_&C4O@C\(]2^,-MIOQMNK7XKZA\./!]]\2;
M2XTWXQ6&CZ=-:>.;K1Y?$]K)8:5#%IUFUOJ<?V:R06T.R(E3\+QIQ3Q-1^FA
MPOP_1XBSRCD,ZO#L)Y)2S;'T\HG"KD-2O5C/+85XX.:J5I.K44J+YZCYI7=C
M>C2I/)*M1TZ?M$JEI\D>=6J67O6OHM-]C^*FO]!CYX* "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /Z(_^"Q?[<7_!
M,W]J']F?]DCX<_L._!O2/AI\2?A9=+_PMK5=.^ ?@[X2R:W91^ -'T**&7Q!
MX<1;[Q.J:]:75R(]0)&7^V_ZV5J_ECP&\.O%[@[B[CG-?$7/Z^;Y3G,?^$.A
M5XFQ^>+#3>9U\3*4<+BW[/!WPTZ<+TK;>S^&*/6S#$8.M1H0PU-0G#XVJ487
M]U+=;ZKJ>\_\%$O^"7'[)_[(O_!![]A_]JKX=^&M=UC]HK]I3QI^RWXX^(7Q
M2\5Z_>WVI6VE?&+]F?XE?$[6?AYX8T2Q.G^&-%\&:9KJ:8+(#1KGQ'??V39S
MZUK^I211"'YGPK\9.-N.?I*>(O!>:8O#8?A3A'+^,LNRO)L%A:=.E.MD/%^4
M9/A\UQF(J*KC,1CZV&=;VG[^&$I^WJ1P^%I)RYM,5@J%#+,-6@FZM65&4IM]
M*E&4W!)6BHIVMI?NSP;_ ())?MQ?\$S?V8_V.?VOOAC^V+\&](\?_';XJ77B
M7_A3WBB]^ ?@[XHW.@V5U\+9/#^A0P^+O$*-J/A5;3QC<7&H)'IVT6LDK:FG
M[\C'TWCAX=>+W%_'O F;\!Y_7ROAK)8X3^WL%3XFQ^30Q,X9S'%8F4L#A6J.
M-Y\!"-)NK\:BJ+]TSP.(P='#UX5Z:E5GS>S?LHSM[EEJ_A][L?SN5_4YY(4
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MKX*GA:,8MUJM/2_WM7A'\^A0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 07-U;64$ES>7$%I;0J7EN+F
M6."")%&2\DLK)&BJ!DLS  "C;R1,YPIQ<ZDHPA%7E*<E&,4NKD[)+U""YM[F
M&*XMIXKBWGC2:">!UFAFAD4/'+%+&6CDC="&1T8JRD%210.,HSC&4&I1DDXR
MBTXRBU=.+6C36S6EB8$'I0,6@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _
M%+_@X$^#W_"T_P#@FI\4->M[7[5J?P4\5^ ?BW9*BN\T=K9:]'X*\07$2H"
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M/B[+<UX3K59.RA7QE*GF.5I*VL\3G&59?@8_#RK%MWLG&7\6M?L)_MV% !0
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M-_VQ/C_^SY>QZ/\ $UKGQQX,CEGV:G<,]U=PQM+$JM#>@JQ4<.L<@R/.?^
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M?TF>%/&D.I*I64'..,Y]/\_RK\G/UJR>WW?U_7II?V"UG$R*0>#C%!)<H *
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M8*/-)UN&N3B&GR16LIWRSW(QU<K))O1_SF5_K(?\XX4 % !0 4 % !0 4 %
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M/7C2Q2<<#4H4Z.(^Q_VL/^4&/[.O_8.^!W_N2KR<K_Y+3'_XL;_[:?COA/\
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M58-\64,]S;#8BMBJ.,S"/#F*=64*]?"X.K45/2B^;"T5&5)PA#DC%OP7X/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * /B;]IS4#-XIT'30?DL=$:X(XP);Z\F5O<'R[.(X('!4CKQ_0OA!A/9Y+
MF6,:M]9S'V"?>.%P]*7W*6)EMUNNFG^-7[1[/WC/$_@KAR,[T\CX,>8R@K6A
M7SS-L93E>VTW0RC#OE=K0Y)+22/FBOUL_P [ H * "@ H * "@#_ $%?^#=G
MX6GX>?\ !-OPKXED@>&?XS?%/XF?$QRP4">*UU"P^&-I/'@9*M:?#B&/+Y)\
MOY?W>ROX&^D'F?U_Q%Q.&3363Y7EN6K^[S4YYE.+[6GF$G9=]=;GV>34_9X&
MF[6]K.=3;S]FOPIKY6/W3K\0/5"@ H * /E']NO_ ),S_:?_ .R'_$7_ -1J
M_KU<C_Y'&6?]AN'_ /3D3]<\ _\ D]GA5_V7G#/_ *M,.?BC_P $A/V._P!F
MO]HGX"_$7Q9\:/A7I/COQ#HWQ=OO#NF:G?ZKXEL);31HO!O@_4H[%(M%UO3+
M=XUOM1O;@/+"\VZ=E,GEJB+]GQ;F^8Y=CL/2P>*E0ISPD:DHQA2DG/VU6-_?
MA)_#%+330_N7Z9/C1XG>&WB!PUE'!'%F+R#+<;P=0S+%87#X/*\1"KC99UG.
M%E7<L=@<54C)T,-0I\L)QA:FGR\S;?Z)_%#_ ((]?L3>._#.I:7X4\ :C\*?
M$LUO(-)\7^$O%7BR_ETV\QNMY+G0/$VO:SH&I67FJHN[4V5I=S6QEBM-2T^=
MH[J'Y["\79S0J1E5KQQ5-/WJ-6E2BI+RG3IPG%]G=I:7BUH?S;PI],[QSR#-
M,+BLWXAPW%N5TZD?K>39OE.3X:&)HWM4C2S#*\OP6886OR-^QJJM5HPJ*$JN
M%Q%.+I3_ #!_X)G_ !2^)W['W[:7BO\ 8;^)^IM/X5\3>(]>\-1V/GRMHVD_
M$+3M-;5_#7B_P^+M$GM],\>Z'9P6'V>."WDU,ZQX9O+R..332M?3<287#9MD
MU+.L-'][3ITZG-9*<L/)\M2E4MO*A-M[VCR5$KJ1_5'TH>%.%?&;P/RCQYX5
MPJI9ME>69?F<J_LXK&XOAS$XI8+,\FS'V+E3J8KA_'UIXCVDIU(858+-*-"4
MHXFYZK_P6,_:-^(7C7XI?#_]A?X0W=WYOB9_"D_CBQTB\DM;WQ5XJ\;:C_9_
M@CP!?O&\0&DPVT^GZ_?6<[266HW&MZ)/<*O]CKNY>$,NP]'"U\[Q:5J7M50<
MHW5*E0C>M7C_ 'FU*FFM8\DDOB/DOH6>&G#F1\)\1>/?&5&ER94LVIY#7QE&
M%6AE.49%AEB,\XAPRE&7^V3JT\1EU"O!0K8:G@<=3IM_77R_=_[.'_!)K]E3
MX->"])L_'W@+0OC3\1);.W?Q1XM\;VTVJZ1-J14O<6WAWPK=S-HFE:/;2R/%
M9M-8W&L7,*1R:C?S/LB@\+,>*LTQE:3P]>>#PZ;]E2H-1ER]'4JI<\IM+750
M6T8KK^ >)GTO?%OC7.\76X>X@Q_ _#<:U2.59/D56GA,9#"I\M.IF6;48+'8
MO&U(1C.LH5Z>#I3;CAL/"-Y3^3O^"CG_  2L^&\WPQU+XO\ [*OPZO/#7Q'\
M'S65YJOPW\!6>JZE9^.M%FN[:RNF\/>&()+N33?$NAI*FK01>'H((-3L+34;
M=]-N=4EL[A/5X=XHQ"Q,<'FF(53#U4XQQ%>4(NA-)M>TJ.RE3G;D]]WC)Q?,
MHW1^O?1H^EGQ-#BK#<&>+7$M'-.&<YA7H83B7B"MA,-6R#'0HU*U%9CFE2-%
M8G*\>X/!U)9C4J3PN(K8:I'$TL)"M3?Z+?\ !/7Q)\?]?_9C\(6G[2WA'Q?X
M6^)WA6ZO_"TUWXX@^R>(?%WAZP6VN/#OB;4+65VU&*\.G7L>A:C)K$<.JW^I
M:'>:K>([WXFD^>S^G@*>957EM:E5PU51J)4=:=&;NJE*+LHVYH\\>1N,8S45
MM8_FOZ1N6>'>7>*6<UO"_.,FS7A7-J6'S6G1R*?M<NR?,<0ZE/,LKP]6,5AI
MT%B:$L?AHX*4\)A\+CJ.$HN,</R1^WJ\4_"@H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@!"0 2> !DGL /\* V\DOP*
MEKJ%C>QF:RNH+J(,4+V\J2JK#JI*$A2/0XI)I[-/T,Z=6E5CS4JD*D;\MX24
ME==/=[%CS$]?Y?TIF@\$'I0!\._\%!/&6H>$OV?-672YYK6ZUG6-%TQKBVGD
MMYX[:>_@CN1&\15_FBD(;!'&*\#B;$3P^45W3;C.3A!23LTFTG;3>Q^2>->:
M8C*^!<<\)4E2K8FMAZ"J0FX3A"52*FXN.M[-;-:'+?L1?&:Z\7_!+2[36[PS
MZQX:NI])D:68R2_V=$WEZ;O+Y=B88R [$DXYY%'#6,>,RJBZDN:K2;I2[VAI
M%OKTW>Y7@QQ!4SW@S"QQ-;VN+RZI/!U)2DY3]E2M"BYZ-IM1T;>J\SZ-UWXV
M:1X?\9^"? _E"[UCQI)<M;(LA'V>SLI+:.YNF"_W/M"E0>..<"O7J8FG2K4:
M#NZE?F<(K^6%E*7>RNNENY]YF.>X?+\TRO*)+GQ>:>UE2A_+1HN$:E335<O.
MMU;N>Z)<JP'([?\ ZO\ (KH/=+*L#TH =0 4 % !0 4 % !0 4 % !0 4 %
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M8B-2M4PF$Q?P;_P3C_9O_:J^.7B.T_:L_:A^,_QIM/!6IZM_PEO@CX<OX_\
M%V@Q>/[V:Y^WVOB'6/#^G:G8Z=HGPYBE*/H/ANRL;.U\1VZ0[;2V\'I;P^(?
M=XBS'*\#3>5Y9@\&ZT(^RK8CZO1G["*7*Z<*DHRE/$6TG4;;IN^KJW=/]_\
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M/*.*P#K6JULMQ.#KR5ZI\P5Z1^J!0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MO1OIW:Z;>?\ 7^06TLTM[Z?U_2VZ#C@\;5<$897564J>Q4_*<_3]*-5Y:O\
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ML/B:=_\ EW7I6G'L[Q>S/M'2M3CO(E96!R!Z8->T?)6MH;OTH 6@ H * "@
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MP=O&3C_/;'MZ<5\D?8.R:MI\MOZ[=+'W3H9<VR9]!_+C^F.GTH)>^ATM @H
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MAG_U$SK_ "(X@^/#?X*GYP/2O^#T#_D#_P#!.?\ ["7[5_\ Z2_LY5Y/[/\
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M62A#*I2=/VBA[=U*=D^=+5QLU9WA96=[GY5_\/VO^"%O_2"SX-?^&*_9*_\
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M7+_]]PO_ %^A^9^J7_!V_P#\I2/"/_9I'PF_]3[XPU^+_0=_Y,UCO^RXSO\
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MG2)8$\+#\2YWA*$,+B,FKUL12BJ<:LJ>(IN2BN6+J4U1G[26FLH3@I[I+<_
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M1\M;CS'PSB+Y?LNG/&PDMG3NG[I_477YB?Y2A0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &5K>G1ZMI&I:7)
M))"FH65S9F6)BDD7GQ-'YB,O(*9W#'/&*4HJ491V4HN-^UU;\/(PQ-".)P]?
M#R<HQK4ITG*+M*//%QNGW6Y_.I\0T^.W['?Q,NK?2_$VNVVFM<M/IFHBX-YI
M>N:=YAVJ;:]A>(2[%V7&"D\CEK@ER7 _+,7_ &KP[C/W=>?LI-NG)^_3J1;?
MNRYD[-ZZ65EV/X;SN'&_A/Q#4IX;,<6L)4K2J82M.<ZV&Q5!RYN23K)VDU>_
M*H^ZC[L^!W_!0[POXP%CHOQ&BA\+:VZPP_VG&Q?1;F9L1JKR!I)8;B1ANPT:
MK@@[>N/J<KXIPF+Y:6+MA:^B3?\ "F]O=W:?R_(_<^"?'#)L[]G@>(%#)LP?
M+"-9W^IUY/1<K;E-2D[*UDETTV_1O1/%NFZO;PW-G=P7,$R*\4T$BR1NKC*L
MK(2.1]/0\C%?5)II-:I[-;6/W:G.%6$:E*<:E.:3C.$E*,D]FFM#\V?^"H/B
M&WB\#^ =(^U@-J&K:E.UH&.94M8[%TD<#M&V2N<8/..!7QW&=3EP.'IIV<ZK
MM'OR<CVZV/YU^D7B5#(LGPBJ6GB,75E[)/XXTE1:;79:V/B7]C3XC7'AR^U_
M0)+HB'6;2VN[>+("QR:;]J67:.#C8T9&#DEGSQ@UP<%XGEJ8O"-WYN6I#RM?
MF_/^NGS/T=<W]EF6<Y'.32Q%.GB:$=+7I*<ZLM[W::V/J?X0^-U\<_M(^)_&
MU[=*="^'?A_^QK&6;8UK!+J-L%U";?)G8\;V6[*^F?X<U]%AIK%9SBZR?[K
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MK<0UJLZ]#%1E^\_M7,L+BZ7]<B(D:)'&BI&BJB(BA41% 5415 "JH "J
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M84J-"C#W*.&PU"%+#X:E'2G0I4X7;5WV]<Y\T% !0 4 % !0 4 % !0 4 %
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MB=?57B9E-=RU5U9KNK-?@?.RC*#<91<6M&I*S7R9I+*C="/P_P _TH))/I0
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MQDN6RM&_+I:UNA^O_AS68[^WC97!W*"#GMCK_2O1/ECL@<C(H$+0 4 % !0
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M_P ]7$@N6W^:')C4?*/CN.^)*M6H\FPD9X?"T.6-3W6O:<OP\LM/=M_*?:<
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M?M[?MM_"C_@H;XE_;P^$_P /O''[27Q8U[4OB!XZ_:.\$^%/#'BC5[3Q_P"
MOB5K\-SX_M_$4'@C2-5F\(Z$GB34=$U+PQJQTZ30?"GBO3/!Y.FZA8V::'>_
MUWXG^&GAYG?A9A/#7.\SR[A+(\-1RO+.%,PQN,P=">5YEE&%<,KEA)9C7H1Q
MV)>$HXBCBZ'M5B<;@JN.7M:52;Q%/Q\+B<1#%/$TXRJS;E*K%)VE&;]Z_*O=
M5VFM+1DHZ:6/Z0_C[^VY_P &NW[>7C-OVC?VO?AG\4OAS^T1966F6_CWP;=^
M!/CWX/\ &'C+5M%@2QF\-^,I?@?=7?@;Q'J^B/#_ &*WB37=;\/^(I].TVQT
MRYU>/3["STVU_DWAGP[^F/X:9>N%.!<WR7-N%9U*LLLQ\,RX9Q^ P%#$2]I'
M%X"/$4(9CA,/B$_K"P>&P^*PD:M6I5A0E4J3JS]>KB,FQ,O:UX3C527-'EJQ
MDVOLR]G[C:VNVG96OLC]5/&G[8?P&_:F_P""!'[=?Q3_ &;_ (/WOP0_9O\
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M?7D?F?%/_!:7_@NO^S[\<?V9M&_X)P?\$W/!EWX/_97TJV\*:)XQ\=2>&YO
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MZA^LA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MF5/*N(LCRS&9CE6:8=R7U>:J82E6>"Q<XN*JY?B_98BG54XTU6HJ%>I\6?\
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M9RI8*E0IPPT/959T*<(*K7NW4;<$E+V?NT[N_O1GK:Q\#]+K/^"<V\6<7EG
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M6#QF&Q^&I8O!UH5\/5BI4ZE-IQDFDUJO)HV5D4CKC^7_ -;^59'424 % !0
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M\.SR2PIOST'ZC_(_SR">G]>1V8Z#Z#^5 A: "@ H * "@ H * "@ H * "@
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MI/LITFOO;C^2/VFC^T+X'=*+Q'A_Q72K?;A1QV45Z4?\-6=7#RE\Z,/0K?\
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MH_\ R8?\5"N /^B#XP_\*<E_^:P_X<#_ !Y_Z+C\(O\ P \9?_*>C_7K _\
M0%B_OH__ "8?\5"N /\ H@^,/_"G)?\ YK#_ (<#_'G_ *+C\(O_   \9?\
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M^,/_  IR7_YK#_AP/\>?^BX_"+_P \9?_*>C_7K _P#0%B_OH_\ R8?\5"N
M/^B#XP_\*<E_^:P_X<#_ !Y_Z+C\(O\ P \9?_*>C_7K _\ 0%B_OH__ "8?
M\5"N /\ H@^,/_"G)?\ YK#_ (<#_'G_ *+C\(O_   \9?\ RGH_UZP/_0%B
M_OH__)A_Q4*X _Z(/C#_ ,*<E_\ FL/^' _QY_Z+C\(O_ #QE_\ *>C_ %ZP
M/_0%B_OH_P#R8?\ %0K@#_H@^,/_  IR7_YK#_AP/\>?^BX_"+_P \9?_*>C
M_7K _P#0%B_OH_\ R8?\5"N /^B#XP_\*<E_^:S7T;_@@#\6YKI4\0_M!?#G
M3+'*[KC1O"WB;7;H+AMQ6SO9_#L+$$1A5-\@8,Q+)L >)\=X1+]W@,1)]IU*
M=-??%5/_ $G_ (''C?VAO"$*+>7>'7$F)KV=J>-S;*\#1;]WE3K4*>8SBG[U
MVL/*UHV3N^7]"O@-_P $5/V4?A6VG:M\19/$7QV\369MYI3XJ>/0?!!N[=V=
M9K;P7HLKS202Y47&G^(O$GB6QF6-4: (TJ2>#CN,LTQ-XX94\#3>B]DN>M:U
MM:T]FNCI4Z37R1_.OB!].+Q;XMC7P?#,,L\/\KJJ<(_V/&>/S[V<U:U7/,='
MEA5BOX=?*\MRJK"_,GSJ,H_JK=IHO@GPS8Z-H-GI7AS3K*VLM \-:/I5C!I^
MFZ?#'&EI8:=I.F6%NMI9VUE;($M+:&WBLK:.&.,K%;KQ\G*4JDI3J3E*<FY2
MG-N4I2>[DW=MM[O5]3^.<;C<9F&*Q./Q^*Q./QV,K5,3B\9C*U7%8O%8FM-S
MK8C$XBM*=:O6JS<IU*M6<ISDW*4FW<SR<DGU]  /P   'H  !T  J3SQ* "@
M H * "@ H * "@ H * *=_J%CI5E<ZCJ-U!96-G#)<75U<R+%#!#"A>21W;
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MZ;]S]%AA<)1BH4L)0IQ248J%*$4EV]U*S5K+L4;KP1X,U$,M[X8TJX5A\ZF
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M * "@ H * "@ H * "@ H * "@ H * "@ H * /_T?C^OZ(/^E@* "@ H *
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M2[-=.B[>GX:!0%GW]/*_^70ZKPGXRUWP9?QWND74BQAU-Q8LQ-K=1@_,CQY
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M?3L]5_E_F?J#X=NO.M(C_LK^0'^%!+5G8ZB@04 % !0 4 % !0 4 % !0 4
M% !0 4 (> ?\_2@#\1/CSXBN-=_:!^+$4H94TBXT32;7?L(-O;V>]MKQD97S
M6;]Q*H>(K_="U_,'&.,EB^-,\A):818;#TU*WPQ@VVFDM+WO"2NK=58_O'@'
M*J>6^%O!=2FU)YB\QQN(Y>9<M25;E@I1;T?*E:<;PE>VDDSS#'3&,<9Q]>O_
M -;_ "/!M?;RTVZ;GOGYW?M$7<ES\3;^-RYBLK&TMH5SE579N; PI4EB258'
M'!5L&OR/BZHYYS4B]J5*G!=K66OEZ?=H?UWX14(4>"\+**7-B,37JU&E9R:E
M9=T[*R4HM=FCP['' /;G/]/\*^8/TT=[9&??Z<8'TH 3MD\$<9_'H.<<4 !)
M&.AS^@[?Y_#M0 A+ ;PP5E(=3_=*<]/T;C@<_0_3^OE^@TDWRM73]UKR>G_#
M?<?J/\,=2DU7P#X8O969I#IT<;$\L3#\@RW.Y0!A7[KUY%?M^2UO;Y3@*C;Y
MO8I/OI=6NKWZ6?9_=_#O&N#A@.*\[PU-6A'&3E%)6C[_ +SLOLM[N'3IHSGO
MC5;B;P?;L$!D@U_2W0E2ZK^]SN;:-T6/X95QM.-W'!]"G0G7S3(53BG..<X2
M5G?E24U>]DY1LM5-?#]K1GF8+%T<)E'&+KSE3HSX3S:,G!QC)R=%QC%<[4)J
M3M&5&7QQ;Y?>2/?OV<]4=+FT7<>J#EL_=QR3W]>W2O[!M;1[K3O^)_G!*SNU
MLXNRV5DTUIT\E\C]F? =SYNGVY)/^K3]!_G_ #U#-VTMVU]3TY>@^@% CP?X
M_P#[2'PM_9M\$ZMXT^(NM")=.L9;RT\/::8;KQ'K+)M2.WT[3C+&Q\V5TC\^
M9HK=,DF0E=AZ\'@<1CZT*&&IN<YM):.R]6D<F+QN'P-&=;$5(PA"+>Z3=ELD
M['\Q'[1O[;W[6/[?.J:A\._A[IFN_#3X22^>?^%?>#+V>/Q%XCL(LLLWQ \8
M6XA,-O+"H?\ L>Q>UMG&\10W+%]WZSE'!V6Y-0689]7IQE'E<83TU?2,?)]=
M?4_)<ZXQS+.*TLNR"A.47=2E3N[+;WY*RO;[-]]$CPS]D']J+P%^P1\4=4_M
M7P-J_C;5-1T>XTO4++P<D*7'AF;[3$V_R7(>Y5]K_;Y+J192J121QR/D#T.)
M,+/B/+H87)Z=L-A9^UYU&U&I%1:?*[:M:/F7NVTNCSN&<73X:S&IBLYFY8G%
MP]FX.?-6I2YO=<[/12U2B]4]HG]7WPP^->D?$30=$\2:5)(MEKEA:ZA;17 ,
M<Z0W42R1I*C<HX##(/(Z$ \#\0K4I4*LZ,])4Y.,O6+M^FGD?N=&K3Q%*%6G
M\-2,90[6:7W/_ACZ,LKL7,"LIZ@8]>,=C_*LB]OD?(?Q&_9L^#-WK/B+QBGP
ML\$S>+/$C)+K.O3^'[&ZU+4/)=I88IKBXBE8V\4Q,BVXVP>9\S1EB371]:Q/
M)&G[>KR0^&',U%?)&/U7#<TJBP]'G>LI>S7,_P -E\CX1\<?!J*.\E&E:'I]
MC&)VF5;/3[:V"RG@.##"A5@#L5AR%PJX4 #%SG+>4GTU;9T1A"/O0A!=U:*:
M?K;3R_!' 6WP4U>5A_H\FW/'! Z^P_/'Y5)=WV27^)6.#^-W[+OQ-\6?#G5-
M*^'4\=EXC;;/ )Y9;=+M+8-/]B\Z)=Z_:GC6#@I_K X8;:]C(<PHY7F6'QE>
MA'$4Z3UIRBI+72]GIIOLU^!XV?9?6S7+,1@J%=X>I55HU*<W&22W6EGK:VGY
M'XT:M)+-JS_!OX^Z;JFEZ?HDBV]SYEI)!K7AR75"MU!J&B7\L(DU""WU"%9&
M$#3#;]H) V-N_9HT,!FM"OF_#[IX?-ZBIS4%)0YY17*Z,X725U\/NKI?1'XE
M*OF&3UZ&3\11GB,FIRG3]HX\WLTVI1JQG9RNFKR3<NNA!HMY\3?@=XHNO'_@
M/5;N7P/:75FWAKX@V2F?98W\#.+'Q!8[3)!+:7-M+#,T\,8RBE=KLPKH6.PF
M-C3R3B:G2IXV:CSWTCS12BY1G;1ZIV3V9S_4,9@:E7/N%JM2I@J;ER:-M1D[
M\DJ?79I-J^A_2W^P#^V3>?M$?#)O$>KBT^T:;K,VB?VA8EA9:G]GC0M<6ZL%
MPH;(!3,3QM&RDYK\<XHRC#9-F<L+A:_MJ3BIIZ>ZGM&ZWT/V?A;-\3G65QQ>
M,P_L*O/[-]$VEVZ;:KM;L?JOHFLQWT2,K9R >OMV_P /Z5\X?1VL=4IR :!"
MT % !0 4 % 'X-_\%X?"OVWX3_ 7QH$RWAWXA>)O#1?!^2/Q?X<M]289VX >
M3P7#P67.P8#;?E^[X$J)8O'4=;SP].HETM2J<K^:]M&WDV?Z'_L\,W]AQIXA
M9#S6CF?#.5YIRZ>]/)<TGA8Z7O[L,\J;)VOTOK_,G7Z:?ZPA0 4 % !0 4 %
M 'Y4?\%+=*Q)\)=;"_?3Q;I3/QSY3:%=HI[\><Y7/'+8[U_;GT/\9^ZXXR^^
MD:F1XR,?\<<RH3:Z?8@GITC?H?Y1_M,<JM5\),[4?CI\6Y5*:M_RZED6+A%]
M=/:S<>FL[=3\KJ_M0_RK"@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M /_2^/Z_H@_Z6 H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M87 XV3=NR]HO)-KR/=R&-\35E;X:-K]N:<=/FH_AY']TU?Q"?5A0 4 % !0
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M49+JFM+:'U6?9-A\^RO$9=7;BJL;TJT+*=&M'6E5A*SY7&5G?R3Z(^1_@_\
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M1IK66W5*_*O.5D=(K@_YX_\ K5F=!)0 4 % !0 4 % !0 4 % !0 4 % !0
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MTS4H1<:=?V5_;MC;/8W4%U <C(Q+!))&<CD8/3GI6;36Z:]58#165&Z'\O\
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M^A_7!7\K'TP4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % '*>,M=@T#0[N=IVANKB&>WL?+*><;EH7V.B
MM(C!8VV;Y4#^1N1S&_",?U_2)D[+\ON/F[P 7OO&33R.TCVNGW]Y))(Q=WGG
M>"U9F9LLTCK=R$L22V'RV>KZ?UL[67X$-6C]W3KK?\-/EML>^4B H * "@ H
M * "@ H * $Z>P'Z4 ?RW?\ !6S]MO4?BI\6YOV0_AMJ#IX \$PPZG\6]<L9
MP(]8UAIYH[?PN'BD.1IMW90S3*=N5FY^]MK\A\1^*)86G_9.#DN::_?U$_\
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M:C:Q.KA@R@C!^G^/\N:]P_/'Y;?U]W]:L]!4A@/\_P"?\B@0Z@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * /_3^/Z_H@_Z6 H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MLZ"?,J<(QY;QYMT^NA]$6&J"<J ?U_S^'Y5Y!];:QT\397]10!+0 4 % !0
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M=WI_GO\ _6Z5H>@U;0ZE3D"@0M !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M]+VNO+7\S[%"C<!_#[] .O!_"O&OU[]NZVNCZ&+NNB?X^MO+^K'FW[*^@O\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M3^)M[\-K?X;Z/X7U%)K#PM!XFFU:;Q+>ZQ;+$RW&NZ(EG%9IHTC$C[2T[7"
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M87P)RFA%V68^(^08*?Q:QIY'Q1F"6C2^/ 0?O*4=%9<W*X_!]?T@?XD!0 4
M% !0 4 % ']PO_!KMX3BT_\ 8^_:%\;'B[\5?M-7'APKM/.F^"/A3\.[ZRFW
M^>R$/?\ CC68?*^S02Q_9M[S7,<\"6O\4_2:Q3GQ=P_@5\.%X:CB/^XF-S3,
M(2C:W2G@Z,K\S3YK*,7&3E]9D"MA*K_FQ+MZ1I4E^=U_2/Z8Z_FT]P* "@ H
M * "@ H * "@ H * "@#-OL")]V-F&#9Z;3P0<\8(P*%Y?*P:6UVZ]K'R9\4
M?@7X%\8RRZDMA_PCVO+\\.M:"%TZX6;DB67[((3.VX+NRX)"X)(XKW<OX@S#
M KV?/]8P[^*A77M(6[14[J/R6A\/Q!X=\/<0<V(>'_LW,59T\QRW_9,1&;>D
MYRH>SE4=[7YI:K0^3]1E_:"^#ERQM]?D\<^%+=Y)G%Q +F^DC<;"C!FFFMTC
M5-W4A.H&.1]-2GPOGR4*M-Y5C)+E3C)^Q<OLK[,=7_PQ^88RCXJ>'\O:X3%+
MBW)*5252<*D%]=5/1-.ZJU+02NM>[LCYY^,'QJA^(^EVZ3^$K;2];@GA8:HF
MH"2<6XD59H#!Y*/^\16CP6Q&6. .E?29%PWBLEQ2K4L>JV%FI<]%*REH^1Z2
M?5WV['YEQ]XFY5QKE+P.(X?>$S>A5I^RQE1WE1Y)+VM-WIQMI'ELY*VRT/B'
MXA?&@>&K?^Q+1_[2U#8@%N)YS;V808C\P&1XMR_W#&N,%1UKZ6HZ%*5Z=&E[
M;K-4TI*^_O+J^OY'YE@Z./QE%4\1C<7]222CAYUJCI24;<BC3<N5*/V;+3R/
MEC6/'OBO6YGEN=6N(5?.(;1FMXT4]@(V ]LX[5S2J3E*[D^^CLE;LCUZ.#PU
M%)1I0=NLES/\3"BUO6X)%DBUG5%=#N!^VSD9'J-_/X_2I3EW:]&^FQLZ-%II
MTJ;5K6Y(Z>FFA[Q\/?C7J-NZ:#XFE6:TNI(XX=2(99(7/R@38?#CJ?,<_+QC
MK6].K'GBZL*<I)VC5<5SP7E+=??VT/-Q>!J*A5CA*U:E2E[U3"QJS5&JUHKT
MT^1M+17CL?HU\#->TG0[^ZU>]E26]4PI8R32YQ%+$DC3+O\ E9RR@>9PP4;<
MX%?$<>XS%+ZI@J*E["I2=6JXIN\E+E2<EY6]W_)'[E]'W)LH<,VSO%>R6/PV
M(A@<.IRBN2E*DJLI1@^JDFN9:J]MC[U\*_$%-3EB_P!-B"DJ.95 Q^>/\XQ7
MYE[*I_)+[C^G_;X=*ZKTK?XXKTZGU-X7US21'&TVJV"D!<[[N >V.7]<U7U>
MOTI5/_ 7_D1+'8/KBL.K;WJTUVTWWO<]5L-7TR[/EV=]:7+H,,L$\<A'U"$X
MY'?C^DRI5(*\J<HKNXM(JEB</6;5&M2JM;JG4C.W_@+9LAU/0UF;#J "@ H
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M2;NXI14<0W)MV4;NTK<KYL;'FP>+25_]FKV5KW:I2:5NNJ5D?Y@%?Z8'P 4
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M_1#/V:__  5_$G_YX-'_ !+/P?\ ]#KB+_P9EW_S '^L6*_Y\X?[JG_RP/\
MB*7_ &TO^B&?LU_^"OXD_P#SP:/^)9^#_P#H=<1?^#,N_P#F /\ 6+%?\^</
M]U3_ .6!_P 12_[:7_1#/V:__!7\2?\ YX-'_$L_!_\ T.N(O_!F7?\ S '^
ML6*_Y\X?[JG_ ,L#_B*7_;2_Z(9^S7_X*_B3_P#/!H_XEGX/_P"AUQ%_X,R[
M_P"8 _UBQ7_/G#_=4_\ E@UO^#I;]M0JP7X'?LUHQ4A6_LKXD-M8C ;:?B#@
M[3SCH<8H7T:.#M/^%GB)KM[7+E\O]P#_ %BQ7_/G#_=4_P#EAPUS_P '//\
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M;_QG_P#/)H_XEOX"_P"@OB+_ ,+\)_\ .X/]8,=_+A__  7/_P"6!_Q$[_\
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MJ_\ #?\ C/\ ^>31_P 2W\!?]!?$7_A?A/\ YW!_K!COY</_ ."Y_P#RP/\
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MO3E=.+4TVNBYO4^.?$_P'^('AV20Q:>=<L4&Y+K3<.S* _WX3A@WR#H,#=V
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MMM._8M;E]: '4 % !0 A /!H S+K3X9AAE4\<<>E &4N@VROO"#J#T';_/\
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M7K-.I+KQV#^I5*=)SYW*E&<FH\J3<I1:6NJ7+HW;T6Q^45?M9PA0 4 % !0
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MXF=3$8=)1C^[JSE)=68XJG"EB*M.D[TX3:@[IW7JK)_(^.J^\.<* "@ H *
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M7HXG$87+J^6TI87#8/#8N:Q6-H2C#&4Y3C"FZ<Y_RH5^FG^JQ_1K_P &\_\
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M$H^5_P!;,Y=/ZU')']2MS>TY,2X\JWE]84/9\JM\7L^5;7/Y#C],'QOJY?\
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MSA_:2XR4/#CP]R[[.)XWQ&-?OV][ 9#CZ$?W5O?TS*?[R_[NW+9^UT^)J_H
M_P =0H * "@ H * "@#^_3_@VZT)])_X)PQZBT3HOBGX]?%378W;RMLR6L'A
M;PL9(_+^?8LGAN2 ^?B7S(9-H\CR:_@OZ0^*CB/$.4([87)<LP_72[Q&(Z]_
M;\RMI:2^U<^SR:/+@8]+U*C_ !/WTK\+/5"@ H * "@ H * "@ H * "@ H
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M % !0 5Y.+J*4^5?#!6^?7\K?*Z>IM!:>O\ 2$/ /TKRJC_%G4M$EV/[D/\
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M<P-<1*VTR2;XI&G5 YC. Q&17\[YE@)82M/EUI.3M*W\.2WB[;6TC?3RV/\
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MGLO.Q^-_2'PWUOP+\6J"C*7_ !@/$U6T;7_V?+*^(ZZ62I7?]U.VMC^;JO\
M7$_YLPH * "@ H * "@ H ^L/V*/V+?CK^WY^T'X2_9L_9YT*QU;QUXGAO\
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M(WQ5\1_$;PU\7_"'C[5OAC\)]:\.Z_96W@SPUJ<_PQTK7= \1>)?#!T:6_\
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M6K6&@:3;P:)>7^H?C^5^/7TF_%S"8>IX2\(X.C@\GR_ 87/LX^J9/RX[B&&
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MUCK'Q$_:EU'3K"?QE!#XD^*^E:#X)U+6[)+VQ@;1?@=X<U*W^'&G_8;JQO\
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M3JR52_*GS5%S/LG.'LWY6WTY;W1_-K_P5?\ ^"7WQ3_X)7?M'Q?!KQKKT/Q
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MT*M7DG2]CB:#JT,13KUO;/\ @O[_ ,G:_"S_ +-T\.?^K+^*E<? W_(JQ/\
MV,*G_J-A3XGZ 7_)I>*?^SBYC_ZS7"I^%U?:']SG]&O_  ;S_P#(Y_M0_P#8
ML?"S_P!.OC>OS_CS^%EO_7S$_P#I- _SF_:%?\B;PN_[&?%/_J+D9XC_ ,$?
M?^4E?Q _[%;XV?\ J4Z37;Q9_P D]0_Z^X/_ --2/M_I?_\ *-7#_P#V-."?
M_57BCZI_92_Y3F?M0?\ 8+^*?_HSP17F9G_R1>6_XL-_[F/ROQ6_Y0;\+_\
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MW]AO_@LA\/OAMJMO\7;WP5\4O"ECJ?\ 9'AFP\1:#8?$'PM=:\MA_;N@^(O
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M 2QE7 9?0JTL)7P$</@IRPU%Q4X4:<%S/F_DSK]1/]9 H * "@ H * "@ H
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M!7D^51C=)M.44_EZ&%KXERC0I.HXJ\DK*RV6[2/H7X/?\$H?V^_CE\5/B/\
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M1B*3M*EEM#%YDN9;Q6(P6'K8/FC:THO$)Q>CLST:64YA52E'#RC%[.HX4_\
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MP[_Y/=@?^RDS_P#],9J?6X__ )$TO^P?#_\ I5(_SG:_T /AS])O!W_!'_\
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M(TEV]V5UWV^5S] \-LV^L8.IE]7X\-I35[72^S;IU:T\O3^E?PIXPM]6"%)
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M;U+4,3B*'):NV>SBJ6%E@Z%'$5W1I6I\KA)1Y^2%E'WH27+;WK66J3Z'X8?
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MAO\ ]CCB#_U"RTSX?_B8G_!3_.1_*9^VIXYUWXF?MA?M3_$#Q-?7>H:YXO\
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MO_Y/X\=?]B/\-/\ U%;2L>#_ /D1T/\ K]B/_3K/$^A3_P F$R+_ +'G$O\
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MIUV7*UN?U(? >[EDTZVW%ON1?R7\J\\B3U?G;\D?95H<Q+_NC]/_ -=!);H
M* "@"CJ8!TW4 1D&QNP1V(\B08JZ?\2G_CC^: _R/O$4<</B#78HD6.*+6=3
MCCC0!52-+V=410. JJ H X  %?ZOX9MX>@WJW1I-ONW")^<R^*7^)_F8U;$A
M0 4 % !0 4 % '^E'_P0<\'VO@;_ ()4?LR,\$-I=>([3XG>-]8N%C2(W3Z[
M\6?'5Q87ERR@&1XO#<&BVGFR%F^SV<* B-$1?\\/&[%RQOB=Q&DY2CAY9;@J
M4;M\JH97@HSA%=$\0ZTN5:<TV]VV?>9-%0RW#]+^TF_G4G;_ ,E27R/\Y_XN
M_$/5OBY\5_B=\5M?E:?7/B9\0?&?Q UF9LEI-4\9>(]1\17[G<2WS76HRG!/
M X[5_H!E6 I95E>6Y705J&6X#!X"BNU+!X>GAZ:^4*:/AJDW4J3J2WJ3E-^L
MFY/\SSRN\@* 'R2232/+*[RRR,7DDD8O([L<L[NQ+,S'DL223R:22222225D
MEHDEHDET2 _JU_X-3O\ DO'[67_9(_ G_J97U?S#])W_ )$G"W_8UQO_ *B0
M/I.'/XN)_P"O=/\ ]*9^VW_!4;_@JY\)O^"5MOX>\'>!_A;HWQ(^.OQFO]7^
M)-_X+AUP>$]/TW2;NZ&DW7Q(\=ZI:Z3K&IZC=^(=0TJ3P]X<L8X(YK^#PWJ,
M1U/3=/\ #MG9W?XWX:^%^:>)KKXO&YG5R_),HA2RZ&+='ZU4J5(1]K'+\#3E
M4I4Z<</3JJOB)MM4WB*;]G4G7E*/K9AF5++N6$*:G6JWJ."?(DMO:3:3;<FN
M6*Z\KU2BD?SG?M@_\%,_B)_P6]O?V._V*?A]\*9_@KKOBGXVPR>.XV\4GQIX
M8U'7;Z"#PWX7\46DT&C^'M5C\/\ @;PUJOC[Q+XCTZ^L9I5BD@^QW-U)IPN)
M?Z X3\.<O\&8<6<8X_,UG%'#9,U@FL-]3Q-.A3<L1B<+*,JU>DZ^-Q%+ X?#
MU(32NGS1BJG*O"Q685,V^JX2%/V3E5]_WN>+D[1C+:+Y81<Y237Y']0GQ2\=
M_LE?\$+OV$-/N/#/@B1O#?ARYTOPIX5\+:1)IEGXZ^-_Q:UJRGE?5/$WB&YB
M N-5U*'2]1U[Q1XAN8+R+P[X:TN:R\/Z--:Z;H'AF3^;,LP/%/C5QM4CB,8O
MK%>-3%8G$U54G@LFRJC.,53P^'B_=I4W4IT,-0BX.OB*JG7JJ52MB%]#4GAL
MGP:Y8>[&T8QC93K5&MY/N[.4I:\L5:*TC$_F*_XBA?V\/^$X_MT?#']FS_A"
MOM.W_A O^$3\=[O[+^T;MO\ PE7_  L/^U/[<%I^Y_M,6XTG[1_I/_"->5_H
M=?TA_P 2V<$?4O8?VCQ#]<Y?]]^M8'^)RVO]6^H>S]CS:^SYO:\ON_6+^\?/
M_P"L&,Y[^SH<G\G+/;_%SWOY[?W>A_3C\+?'G[)7_!=/]A#49O$G@IX_#WB"
MXU3PKXH\+ZO)I=]X[^!OQ<TC3XVBUCPOK\,+)!JVEV^K6.O>%?$4%K:0^(?#
MFJ166OZ-%;:AK_AF/^<,RP7%/@IQO3CA\8G7P\:6)PV)I*I#!9UE56HTZ6)H
M-INE4E2G0Q.'<I.AB*3E0K.5.AB']!3GALXP;O#W7>,HNW/1JI:.+7574HO:
M47:4=91/\^KXA?LJ^+OA9^V/JW['?C.^ALO%&B?'33_@S=:^D06RN(M6\56.
MA:/XMM()9AMTS6-(U+3_ !)8Q7$R.+"]@2X:)]^W^[\!Q-A,SX2I<68.#GA:
MV2SS>%!OWXNEA9UJN%DU'^)1JTYX>;C%KG@^5-6/B9X>5/%/"R^)5O97V7Q*
M*DO)JTEY'^@!^W)\<O#O_!&;_@GCX?OOV8_@?I6MZ/X(UOPE\)_ WAN[%_\
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MZ!8+IG@;XC60\;^ KD*S6IOYS(OB;PY<B7<BS6<SQ7-CD_O;.2+:#Y#D?N7
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MXKXH_P#*$_AG_P!A/"__ *3G)VX3_D=XGTJ_^V'\R?\ P6Z_Y2S?MY_]E_\
M$O\ Z2:;7]??1W_Y,CX:?]DQA/\ TNJ>/F/^_8G_ *^O]#^F?]H3_E3P^$/_
M &!?A#_ZUQ7\A<+?\IX9[_V$9[_ZPY[%7_D04_2G_P"GS\(_^#:;_E-)^R!_
MUY_M#_\ K+WQGK^D_I<?\H^\=_X^%?\ ULN'CS,H_P"1AA_^XO\ Z8J'Z_?&
M/_E<F\.?]E$^"W_K"'@VOPG(/^4!\7_V*N(/_7DX\]"I_P C^/\ BI_^HR/S
M=_X.H?\ E+EX_P#^R+_!'_U%I*_6?H8?\F-RS_LH.(O_ %,1QYU_OTO^O=/_
M -)/V _X):?\JKO_  4%_P"P+^V=_P"JO\,5^$^,O_*9_A?_ -A' '_JXQAW
MX+_D2XKTQ'_I$3^3S_@EA_RDT_X)Y_\ 9[?[+7_J[?!-?VUXS?\ )H?%+_LW
M?&?_ *SF8GAX/_?,)_V$T/\ T[$_J]_X+E?M*^&OV/O^#B'_ ()L_M&^-5E_
MX0CX;?L]_">X\;W$$<TUQIO@GQ)\;OVFO!OB_6K>UMXII[VXT'PYXBU/68-/
M@C,NH2V"6491IPZ_Q/\ 1RX1Q?'?T6/%KA/+VO[1S;BC.X9=&3C&-7,,)P[P
MAC\!AY3DXPIPQ.+PM'#RJR?+2C4=1W4;'NYE6C0S3!U9?#"G#F\HNI5C)V\D
M[KT/M#_@K?\ \$)O#?\ P6&^)7P\_;;_ &1/VGOA9H]_XH^'GA[PKXBO;]KO
MQM\,_B)H.B7$\OACQGX8\7^";O5VL=6L]%U&71[_ $U-,OM-U:#3]&9;K1+R
MWU*;4?S_ ,#_ *2.+\!\HS3P[XYX.SFO2P6:8K&82G24,NS?*L3B(1CB\OQF
M S"G052A/$4E7I576IU:$JN(7)B*<J,:6^.RV./E#$4*T%>"BW\4)I?#)2C>
MVFFUG9;:W^W/^":7[(7[,7_!//\ 9"_:D_8G^#GQTT'X[?'3X>>&=8^*'[5N
MNZ2EO!=Z/XW^*?@/Q+HGA#2KW2+&]UFV\'V<.@?#"\MM'\&7NO7_ (BL[:RE
M\4ZW;6"^,-/-W^>>+O'/&'BEQUP9XA9]PWB>&N&\TQE#)N"L-7YI0KY=DN98
M/$8ZM3KU*>'ECIO$YS3E7Q]/#4\).=2.#P\ZGU"KR=.$H4<)0K8:G452I!.=
M=K=2G%J*LK\JM#2-[Z7=N8_GQ_X,S_\ DLW[='_9,?@M_P"I5XZK^H?I]?\
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M^*+J"VM;GQ)XV\1ZQXJU^XMK*(06=O/K&NWE_J,L%I JPVT4EPT<$2B.)40
M4J-"AAZ:I8>C2H4DVU3HTX4J:;U;4(*,4V]7IJ1DF09%PU@*>5<.9+E.0972
MG4JTLMR3+L'E6 IU*TN>M4IX/ T:&'A.K-N=24::E.3YI-LY*M3UCLO OQ%^
M(/POUS_A)_AGXZ\9?#OQ+]CN-._X2'P+XGUOPCKG]GW9B:ZL?[6T"]T^_P#L
M=RT,)N+7[1Y$QBB,B,8TQC6P]#$P]GB*%&O3NI>SK4X58<RV?).,HW71VNCQ
ML]X=X?XHP/\ 9?$N19-Q%EOMJ>(_L[/<LP6;8'ZQ14E2K_5,?0Q&']M24YJG
M4]GSP4I*+7,RU%\4_B=!X]/Q5@^(WCR'XH&_FU4_$B+Q?X@C\>G5+BW>SN-2
M/C!-0'B$W\]I+):S7G]H_:)+>1X'D,3,I7U;#.A]5>'H?5N51^K^RI^PY4[J
M/LN7V?*FDTN6R>IE+A;AB>0KA6?#F0SX76'AA%PW+*,OED*PM.I&M3PRR=X?
M^SUAZ=6,:L*/U?V<:D8SC%2291\;>/\ QW\2]>F\5?$?QKXM^('BBXM[:TN/
M$GC;Q'K'BO7I[6RC$-G;3:QKMY?ZA+;VD($5M"]P8X(P$B5%XJJ-"AAH*EAZ
M-*A23;5.C3A2@F]VH048IOKIJ;Y)D&0\,X"&5<.9)E'#^5TZE2K3RW),MP>5
M8"G5K2YZU2&#P%&AAXU*L_>J3C34IRUDVROX/\:^,?A[K]EXJ\!>*_$G@GQ/
MII<Z?XB\):YJ?AW7+'S%V2?9-5TBYL[ZW$B?)((IU$B$HX*G%.K1I5X.E7I4
MZU.7Q4ZL(U(/UC).+^XTS?)<FX@P%;*L^RG+<[RO$I+$9=FV!PV8X&ORN\?:
MX3%TJU"IRO6/-3?*]59GTIK/[?/[:>OZ*_A_5/VGOC/+I<L!M9X[?QQK&GW5
MQ;D!7BNM2TZ>TU.Y25!LF%Q>2>>C.DN]7<-YT,CR>$E..6X-23NKT822?E&2
M<5;I9::6V1^:X+P#\%LOQL<PPOAAP9#%0G[6$JF1X/$4J=1;2I8;$4ZN%I.+
MUA[.C'D:3ARN*:^1W=Y'>21VDDD9G=W8L[NQRSNS9+,Q)+,222<FO5/UR,5%
M*,4HQBE&,8I)125DDEHDEHDM$CZ#_P"&M?VHO^$&E^&G_#0WQF/@&?1Y_#LW
MA)OB-XK;19?#MU9OIUSX>DLVU0HV@3Z?))83:(?^)7)92/:-:&W9HSP?V7EO
MMEB/J&$]NIJHJOU>ES^T3YE4OR_&I:J?Q7UO<_/O^(2^%_\ ;D.)?^(><&+/
MZ>,IYA#-EPYE*QL,QI5HXBEF$:RPJ:Q]/$1C7AC5_M4:T8U554TI'SU7>?H1
MZ/\ #SXQ?%SX13:I<_"?XI_$;X87&N16L&M3_#SQOXF\%3:O#8M.]E#JDOAO
M4]-?4(K-[FY>UCNVE2W:XG:$(97W<]?"87%**Q6&P^)4+\BKT:=90O:_*JD9
M<M[*]K7LNQ\YQ#P=PCQ=#"T^*^%N'.)Z>!E5G@J?$.1Y9G4,'.NH1KSPL<RP
MN)CAY5HTJ4:LJ2@ZBIP4[J$;4?!_Q/\ B5\//$MQXT\ ?$/QSX&\8W<5[!=>
M+/!_BS7_  SXEN8-2E2?48;C7=%O[+5)HM0GCCFO8Y+IDNI422<.Z@AU<-AZ
M]-4:^'HUJ2LU2JTH5*:<5:-H3BXKE6BTT6QOG'#'#7$.64\ES_A[(\\R>C*A
M.EE.<93@,SRRE/#0=/#3IX#&X>MA82P\).%"4:2=*#<:?*G8U=)^-GQFT'QS
MJGQ0T/XM_$[1OB7KBW2:U\0])\>^*M.\<ZNE]Y'VU-4\6V>JPZ_J"WGV6V^U
M+=ZA*+C[/!YH?RH]LRP>$G0CAIX7#3P\+<F'E0I2H0Y?AY:3C[.-KNUHJU]#
MDQ?!/!F/R+"\+X[A'AC&<-8%TG@N'<7D.58C(L&Z'.J#PN4UL)/ 8=T?:5/9
M.EAX>S]I/DMS2OQOB3Q-XD\9:[JGBCQ?X@UOQ5XFUNZ>^UKQ%XDU6_US7=7O
M9 HDO-4U?4Y[K4+^Z<*H>XNKB65@J@N0!6U.G3HPC2I4X4J<%RPITXQA""[1
MA%*,5Y))'LY;EF6Y-@,+E>3Y?@<JRS TE0P679;A*&!P&#H1ORT<+A,+3I8?
M#THW=J=*G""N[([+0_C7\9?#/@C5OAGX;^+?Q-\/_#?7EU%-<^'^A^/?%6D^
M"-935X$M=635O"EAJMOH.HKJEM%';ZBMY83"]@C2&Y$D:*HQG@\)4K1Q%3"X
M:>(AR\E>="E*M#DUCRU7%SCRO6-FK=+'C8[@G@W,\[PG$N9<)<,9AQ'@'AG@
M>(,=D.58O.\$\'4=7"/"9K7PE3'89X6K*53#.C7A["I)SI<LFV>=6=Y=Z==V
MNH:?=7-C?V-Q#=V5[9SRVMW9W=M(LUO=6MS R36]Q;RHDL,T3I)%(BNC*R@C
MH:4DXR2<6FG%I---6::>C36C6UCZ*M1HXBC5P^(I4Z]"O3G1K4*T(U*-:E4B
MX5*56G-.%2G.#<)PE%QE%N+33L?5EE^WI^VGI^C'0;7]J7XZ+IYP%,OQ'\37
M.I1*J[5C@UJYOYM:MXU7A(H-0CC4!=JC:N/+>1Y.Y<[RS!7\L/34?_ %%0_\
ME/RJOX#>"V(QBQ]7PMX&>(ZJ'#F6TL-)MW;J8*E0A@JDF]Y5,/*3UN]6?+NL
MZUK'B/5;_7?$.K:GKNMZK<R7NJ:QK-_=:IJNI7DQW37=_J%[+/=WES*W,D]Q
M-)*YY9B:].$(4XQA3A&$(JT80BHQBNT8Q227DD?J&"P6#R["X? Y?A,-@,#A
M*4:.%P>"H4L+A<-1@K0I8?#T(0HT:4%I&G3A&$5HDC,JCJ+=A?WVE7UGJ>EW
MMWINI:=<P7NGZA87,UG?6-Y:R+-;7=G=V[QSVUS;S(DL$\,B2PR(KQLK*"$X
MQE%QDE*+5G%I.+3T::>C36EMC&OAZ&*H5L+BJ-+$X;$4IT*^'KTX5J%>C5BX
M5*-:E4C*G4I5(-PG3G%PE%N,DT['U5#^WG^VE!H;>'8_VI/CE_9C(T>9/B-X
MDFU,1LGE^6FNS7TFN1QA#M1(]154&-@7 QYG]B9/S\_]F8+F_P"P>GR]_@Y>
M3_R7R/RN?@-X+3QRS&7A;P/]934K1X=RV&%YD^;F> A0C@92OJW+#-OK<^5]
M1U'4-7OKO5-6O[S5-3U"XEN[_4=1NI[V^O;J9B\US=W=R\EQ<W$KDO+--(\C
ML2S,2:]*,8PBHPBHQBDHQBE&,4M$DE9)+HEHC]4P^&P^#H4<+A*%'"X7#TXT
M:&&P]*%"A0I02C"E1HTHQITJ<(I1C"$8QBDDDD>@6WQK^,MG\/IOA):?%OXF
MVOPJN%F2?X96WCWQ5!\/IUN-2_MFX6;P9%JJ^')%GU?_ (FLP?32)=2_TYP;
MG][6#P>$==8IX7#/$JUL0Z%)UU:/(K5>7VBM#W5[VD?=VT/GJG!7!M;B"'%M
M7A+AFKQ53<'3XFJ9#E4^((.GAOJ=-PSF6$>8Q=/!_P"R0Y<2N7#?N(VI>Z>9
M5TGTX4 >X?"?]I;]H#X%17=M\'_C%\0OAY87\PN;[2?#/B?4[#1+VY"[!=7>
MB"=M(N;I4^1;F:R>=4^02!>*XL5EV!QMOK>$H5W%6C*I3BYQ793MS)>2=CX?
MBOPU\/\ CJ5*IQ?P=P]Q#7H0]G0Q69Y9AJ^-HTKW]E2QO(L73I-ZNE"M&FWJ
MXER7]JK]IV7Q?=?$#_AHGXX0^.+W26T"Y\6VGQ4\<67B&3P^UY'J)T :M9ZY
M!>QZ"+^&&]318I4TR.ZABG2U62)&5++,M5)4/J&"]BI<ZI/"T73Y[<O/R.'+
MS\K<>>W-;2]C*/A7X8QRBEP__P 0[X(GD=#%K'TLHJ\*Y'6RZ./5&6&^O_5*
MV!G1>.^KSG1>,E!XF5*4J;JN,FGXAJ.HZAJ^H7VKZM?WFJ:KJEY<ZCJ6IZC=
M3WNH:CJ%[.]S>7]]>W+R7-W>7=S))<7-U/))///(\LKL[,Q[(QC",80BHQBE
M&,8I1C&,591BE9))*R2T2T1]OA\-A\'AZ&$PE"CA<)A:-+#8;"X>E"AA\/AZ
M$(TJ-"A1I1C3HT:-.,:=*E3C&%.$8PA%121].>&?VX_VQ?!^C#P_X=_:9^-=
MAHR6T=G;6#_$'Q%?Q:?:PJJ0VVDMJ-]=RZ1#$BJD<>ER6B(HVJ .*\ZIDN4U
M9<\\NP;E>[?L*<;OO+EBE)_XKGYCF?@=X.YQC/[0S'PSX*KXQU)5JE>/#^78
M>6(JS;<ZF*6&H488N<FVY2Q4:K;U9\^^,?&WC+XA^(+WQ7X^\6>)/&WBC4BK
M:AXB\6:WJ7B'6[TH-L?VK5-6N;N]F6-?DB628K$@"1A5 %=U&C1P]-4J%*G1
MIQ^&G2A&G!>D8I)?<?H&3Y)DW#V7T,IR#*<MR3*\,FL/EV4X'#9?@:%_B]EA
M<)3I48.3UDXP3D]979TWA+XU_&7P#X9USP5X$^+?Q-\%>#?$S7K>)/"7A+Q[
MXJ\.>&?$+:EI\>DZBVN:#H^JV>E:LU_I4,.F7IO[2<W6GQ1V<^^V18QG5P>$
MKU(5JV%PU:K3M[.K5H4JE2GRRYH\DYQ<H\LO>7*U:6JU/,S;@K@W/\SP.=9[
MPEPSG6<Y8J"RW-LVR'*LQS/+UAL1+%X98''XS"5L5A%A\5.6)H+#U:?LL1*5
M:GRU&Y'F5=)].?27P]_;%_:J^%.C6WASX>_M"_%SPOX<LK7[%I_AVQ\<:[)X
M?TNUP0(=)T2\O+G2]*"@_(=.M+9D."K @$>=7RG+,3-U*^ PM2HW>51T8<\G
MWE-)2E_V\V?FW$/@[X5<5XRIF/$/A[PCFF8UJOML1F-?(\#',,35T]_%8VC1
MI8K%7MJL15J)[-6/*_B)\5?B;\7=;7Q)\4_B#XS^(NOQP"UAU?QKXDU?Q+?V
MUH#N6SM+C5[N[>TLU;E+2V,5NAY6(5U8?"X;"0]GAJ%'#PWY*-.---]VHI7?
MF]3ZKAWA3AGA# O+>%>'\FX=P#G[6>$R7+<)EM"I5M9UJM/"4J2JUFM'5J<U
M1K1R-"P^-GQETKP#=_"G2_BW\3M-^%U^MTE]\-[#Q[XJL_ -ZE]<B]O4N_!]
MOJL?AZY6\O +NZ6;3G%Q<@3RAY1NJ98/"2KK$RPN&EB8VY<1*A2=>/*K1M5<
M>=66BM+1:+0YZ_!/!N*SZEQ5B>$N&,1Q1AW2=#B2OD.55L^HNA2]A0=+.*F$
MEF%-T:/[FDX8B/LZ7[N%H:'F]O<7%G<07=I/-:W5K-%<6US;RO!<6]Q ZR0S
MP31%9(9H9%62*6-E>-U5D(8 UT-)III--6::NFGHTUM:W0^DJ4Z=6G.E5IPJ
MTJL)4ZE*I&,Z=2G.+C.G.$DXRA.+<91DG&46TU8]"^(?QC^+OQ=ETJ?XL?%3
MXC_$^?0H[N'1)OB'XX\3>-9=&BOVMWOXM*D\2:GJ3Z?'>O:6C7:6AA6Y:UMS
M,',,>W##X3"X126%PV'PRG;G6'HTZ*ERWY>94XQYK7=K[7=CY[A[@[A#A&.*
MAPGPKPWPQ#'2HRQL.'LCRS)8XR6'518>6*CEN%PRQ$J"K551=53=)5:BARJ<
MK]7\*OVF_P!H;X'6TMA\(OC1\2?A]I4\[W<^A^&O%FKV/A^XNY%"/=W'AX7+
M:)/=LH"FZEL'GV@#S,"LL3EV QC3Q6#P]>25E.I2@YI=E.W.EY7MY'E<5>&7
MAYQQ4C7XNX+X;X@Q4*:HT\=F64X.OF%.C%W5&GF'LEC:=)/7V4*\:=_LC/BO
M^TM^T#\<X;:T^+_QD^(OQ#TZRG%W9:/XF\4ZK?Z%9WBK(@O+30FN%T>VO!'+
M)%]KAL4N/*8Q>;Y>%HPN78#!-O"83#X>35G.G2C&;7\KG;F:TVO:^MA\*>&G
MA_P+.I5X0X-X=X>Q%:FZ5;%Y9E>%P^.K46XMT:N.5-XRI1YH1E[&==T^9*7+
MS:GC%G>7>G7=KJ&GW5S8W]C<0W=E>V<\MK=V=W;2+-;W5K<P,DUO<6\J)+#-
M$Z212(KHRLH([&E).,DG%IIQ:3335FFGHTUHUM8^SK4:.(HU</B*5.O0KTYT
M:U"M"-2C6I5(N%2E5IS3A4IS@W"<)1<91;BTT['U99?MZ?MIZ?HQT&U_:E^.
MBZ><!3+\1_$USJ42JNU8X-:N;^;6K>-5X2*#4(XU 7:HVKCRWD>3N7.\LP5_
M+#TU'_P!14/_ "4_*J_@-X+8C&+'U?"W@9XCJH<.9;2PTFW=NI@J5"&"J2;W
ME4P\I/6[U9\NZSK6L>(]5O\ 7?$.K:GKNMZK<R7NJ:QK-_=:IJNI7DQW37=_
MJ%[+/=WES*W,D]Q-)*YY9B:].$(4XQA3A&$(JT80BHQBNT8Q227DD?J&"P6#
MR["X? Y?A,-@,#A*4:.%P>"H4L+A<-1@K0I8?#T(0HT:4%I&G3A&$5HDC,JC
MJ"@ H * "@ H * "@ H * "@ H * "@ H ^0_P!J7_6^"/\ KGXB_P#0M#K]
MR\&_@X@_Q99^6./\H?VF/^^^#?\ V"\>?^G>$#Y+K]N/\M0H * "@ H *RJS
MY(-]=EZ[?@5%7=@KQYOIV-C_ $=O^"%?_*+?]F3_ *]_B9_ZMSQW7\!^,FOB
M-Q!ZY?\ ^JS!GV>7:8*@NRE_Z<D?KE7Y@=H4 % !0 4 % !0 4 % !0 4 %
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M<QZ+W]-/2QV<,(0# X'^<?3_ #] 19H * "@ H * "@ H * "@ H * "@ H
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M^[8?_KQ1_P#3<3\YE\4O\3_,PZW)"@ H * "@ H * /])/\ X($^.]/\=_\
M!*W]G2UBO(;W4? UQ\4? 'B&W4B0Z?>Z5\4O&&HZ787"D<.WA#6O#5[Y9&/(
MOHL?*17^>?CG@9X'Q-X@DX.%/&QRS'8>6W/"KEF$IU)Q\EBZ.(AZP9]WDTE/
M+J"_D]I"2[-5)-+_ ,!<7\S_ #N?C5\-]6^#GQC^*_PDUZW-KK?PP^)'C?X?
MZK;D-^ZO_!_B74O#]T%+ %HS+I[&)\8DC*.N58&O[ZR?,*6;91E>:4)<U',L
MOP6.I2TUAB\/3KQVV=IJZZ/3H?$5:;I5:E)[TYS@_P#MR3C^AYE7I&84 ??/
MQ@_X)<_\% /@1X%3XF_$O]EKXF:7\/AX8A\97_BW0K32_'&C>'_#,FFIJTNK
M^+I_ VI^(W\&6NGV#>=JQ\61Z,^D>7*NI):M$X'PV4^)7 F=XW^S<NXFRVKC
MOK+P=/"UI5,%5KXA5'25+"QQM+#_ %N4YKEI?5?:JK=>SYKH[*N7XVC#VE3#
MU%#EYN96DHQM>\N1RY++?FM;K8_;_P#X-3O^2\?M9?\ 9(_ G_J97U?C/TG?
M^1)PM_V-<;_ZB0/8X<_BXG_KW3_]*9\)?\'%?B*_UO\ X*D_%?3+R>66W\'_
M  ^^#7AW28Y&W):Z?<_#W1_%DD$ _@B;5/%&I7)7_GO<3/\ Q5]MX 8>G1\-
M,KJ0BE+%8_-Z]5I6YIQQ]7"ION_98:G'_#%+H<6>-O,*B_EA22\ER*7YMF-_
MP;T:-IVJ_P#!5/X$7%_$)9="\+_&;6-,#%-B:B/A+XOTM92CD;S%9ZI>/$$5
MWCF$<ZJODF1-O'JM4I>&6=QINRKXG**-3_KW_:F$J6\KRI03VNKQZV:R1)YC
M1_NQJM>OLI+\F?J!_P '7GB;59/%G[%G@[?/'H=IX>^-GB;RU:5;:[U74=2^
M&^E;Y4P()I]-L]+VV[$O+;1ZI<@"-+H^;^;?1?P])87C#%VBZTL1DV'O9<T*
M5.GF%2R?Q*-2535:*3I1W<=/0XCD^;"1^RHU9>3;=-?@E\KG\AM?U8?,G]=7
M_!J+XFUB+QO^V=X-47,F@7WA7X->)I"79K.RUC2=6^(&E0!(RVR*YU.RUJX\
MUXU#7$6D0K*S"VA"_P J_2?PU)X+A#%^ZJ]/%9OAEI[TZ56E@*CN^L:<Z,;)
M_"ZKM\3/IN')/FQ4.CC2EY)IS7XI_@?F[_P<#;?"'_!67XM^(_"]U_9FN_V!
M\#?%+WM@!!=6'B33OAIX2@L;T.HXO8K?1]*O$EP6SY3')%?H7@3_ +5X795A
M\3'VE'V^=850GK&>'GF.*<X6_D;JU(6]>AP9U[F95)1T=J,M.DE3BE^2/Z8?
MV(_^"Y/[#_[97PCTGX;_ +4_B;P!\'_BYJWAZ#PO\3/ ?QFM--L_@]\0;B6T
M2RU;4/#_ (D\113^!IO#7B-VWMX2\97NF:M92W4^D)9ZY86D>M7W\Z<9>"_&
M?".:U<QX9PV.S7*J5=XG+<;D\JD\VP$5)SI0KX?#N.-CB,.E;ZUA(5*4HQC5
M<Z,Y.C#W\)F^$Q5)4\3*%*HX\M2%5)4JFEFXM^YRR_DG9K:S2N=Y\8O^"#7_
M  2W_::TH^+/ O@&7X4W&OPO=Z?XV_9P\<C3O#]VCY,$VG>&KX>,/A@+%9,Y
M70_#-AYL>8A<IMB:+ARGQO\ $OARHL+C<<LSC0:C/!\08+VE>-K753$0^J9E
MSV7_ "^Q$[/7E>M[JY-EV(7-"'L[[3H3M'Y1]ZG;TBNQ_-__ ,%%?^#>GXV_
ML>_#WQ3\=?@M\0(?V@O@[X-L[K7/&FG2>'I/#'Q/\#>&K4>9=Z_=:/:WVL:1
MXM\/:':J]WXBUO2+O2;_ $NQ2759_"\>C66IZC8?T)P!X]9-Q9C\-DF<8!Y#
MFV+G&A@ZBKK$Y;C<1+2%"-64*-7"XBM*T,/1JPJPJS:I1Q+JSITY^%CLDJX6
MG*M2FJU*"O-<O+4A'O974HQ6LFFFEKRV3:^$_P#@D_\ \%#+O_@G)^T[%\4]
M4T'4?%WPM\:^')_ 'Q;\+Z.ULNN3>&+K4;#5;/Q!X96^GM=/E\3>&-5TZWO;
M&UO[JTM=4TZ?6-$>^TPZJNJ6/VWBAP%#Q X;>64J]/"YE@\1''95B:O-[".)
MA3G2E0Q/)&4UAL12J2A.5.$I4YQI5E"I[+V<^/+L:\!B/:<KE3E'DJQ5K\NC
M3C>RYHM:7LFKQNKW7]R>G_&#_@DI_P %7_"^A:-J^N?L\?'^^^S2+HG@WQ^E
MAX;^,_A9M2$?V^UT/2-?_P"$>^*'AUY9HHX+V\\+/%I]]-;PO!?WL2VTQ_BV
M>4^*?A?B:U6E1S_(H<R]MB\!SXC)\2J=_9RK5:'M\LQ%HMN$,2G4IJ33IP?,
MCZY5<LS*,4W0K/[,)VC5C?=13Y:B\^71V6KT/@']H;_@V&_8U^(,5_J/[/\
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M $@^':<?#[@2,DXRCP9PLG%IIQ:R/ )IIV::>C35UL>6UWGV(4 % !0 4 %
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MP%/&S^/&0P>'CBI_XL1&FJLOG,KGG;EYI<O:[M]VQQM=Y(4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % '__T?C^OZ(/^E@* "@ H * "@ H * "@ H
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M7'ZRKZ8:A+W;JZE"HXWM&2NC0OOAKX=\(:,='T&PCMX_F>:0*IFN)GQOEFD
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M=.E '/?V#$9-Y7]/Z=/R]*!W>W0W[2T2!0%& ,?I_G\/K0(MR1AEQC\/_K4
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MRT5N]OT1^O/@#0UT^PMTVA=J*.F/X1_GTH,WT7]?G;[CUM!A0/\ /^<4"'4
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MBB/XM9S#_@-=?TG8M9[PO+H\IQD5ZQQB;_"42.'/X.)7_3R'_I#_ ,C^8_\
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MXJ\;(N/'N+EI:IEN5RC;LL.Z?R]Z#^1]-E_^YTO6K_Z=F?NM7Y*=H4 % !0
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M\?[(_KZ4"-2.WCC   &.P% $X '2@!: "@ H * "@ H * "@ H * "@ H *
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M'33:VZ['ZIPUF];/,NAC:U!T'*3BE*+@W:VKC)+1ZM2V:[V/TWTO58KR-2K
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * /_2^/Z_H@_Z6 H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MO#]W-#/>PVUS<K'<ZSX@URXMK:[\3>);R*"XU:XMK.WM[33-%TS1M&TW^H^
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MWY1;7-[_ 'LOQZ'P&;>'&5XV4ZV$YL'B)Z^Y+W%)*T7RK9)OIKH?#*?LH?M
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#_T_C^OZ(/^E@* "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M9%EU3=6TK8VCI;5:TGI+6_\ =L?595_ND?*<_P S^@FOQ0]$* "@ H * "@
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M?$4<SK0RWVGL\1FF59C@Z%#VN'R_?,\OQN'6+P%/#XNM5Q3="IA:7'_MM?\
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MGR9KWN%</]:XHX:PMN;ZQQ!DM#EUU]KF6&IV]WWOM?9U[$57RTJC_EIU)?\
M@,&_T/\ *2A79%$G]V-%_P"^5 _I7^I;W?JS\Y6RZ:+0DI#"@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H *PK2T4>^OR7_!_(N"UOV"O.J/?RT7Y?F:A7'/H:4^OR(W[#_/\
MGBN-O=^K-5T1'7GU7O\ <;G]PW_!KCX@-S^R%^T5X3WDKH?[3#>)!%MB 1O%
MGPI^'^E-(&7]^3*/!"(5E_<H(%-O\[W6/Y+\>Z27$F35[?Q,BC1OK_RXS#&S
MMVT^L]->^BB>_E?^[2_Z_P __3=$_IJK\+/1"@ H * "@ H * "@ H * "@"
M&6%9 00.?\_Y[4 <9K7A>UOT97B4@]BO_P!;'3_]5 T[>G;\#Y]\6?!BPU#S
M"+5><_P#_#^6*"EY/_MU[?Y?D?-WB3]G&*0N8[/KD_*G7\,>G0=^/P![=&NN
MFWW;(\DO?V:WWG%IGG 'E_X#TYY_^M0'-_>^7+_E8ET[]FM]ZYM,>WE\?J/P
MX/TXH#F\_DH_YGLWAC]G2" QM):+P1U3@=,]0,?GCI0+Y;?S>>FVB/ICPG\(
M;#31'FV3*X_@  Q^'\N.G2@5^[OZ;=?^'7W'NND^';:Q152-1MQC"@=*!?U8
MZJ.)8Q@ ?A0(EH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\5
M/^"UWQWC\%_ 70_@AI&I7EEXI^,^LI;2"P%XDL?AG1'CO=7>2\M(Q]C610B)
M_I<,DIPBQ2J<'[#@K*Y9AF]&7*G3H24Y.2T5FNGI_6A\?QKFL<MR:LE*U6O%
MP@KV?;3SUT]#\./C%X4OOA/^SE\+O#^C>.Q-<_&V\C\8>,O#^GK D4'AC2ED
MATS3[AI+KS<S7$*2S&2TC+?9_+^5BDJ_J-+$K/.*'AZF#BL/DL7"%1]9Z<O1
M)J.RUOKT6A^65<-+(>%(XFEC6\1GCC*I3C:RI;/S][KI:ZTUV^U/V1/ *^#/
MAG9W[QR+J'BUHM3E\T!6CMC&$@AC C3$6T9'#9.>1S7YMQYFSS#.)T(M>RP5
MZ$>6UKKXNKUOITVM8_2N <I679+3K.+57&\M:?-NE;1;+3[_ -#].OA5X,&H
MR0O)%NW%3]W_ "?\D5\.?>?"E;=_ET]#Z_C^%UE+9*/(7.SKL [>W^% M.^O
M?I_G^AY9XC^"Z2,S1VX(_P!WU^G3ISQV]J!INVMFM/ET12\+_">2RO$)@V@,
M/X?3MT&!C% :[)<J^[^EM_PQ]>^%-$%C;Q+LVA5'8#T]O\X^M!+Z);(]&0;5
M H$.H * //O'GA'0_&&C7&C^(=)LM8TV4J\EE?VZ7$#/'G:VR12 P!901@[7
M8=":J$Y4VI0;C);-:-$RA"<>2<5.#WBUH_D?'WC/X5VL2I8Z7IUO9V%LBPVU
MK:6Z0P01)\JI%%&H1% X"@"E*4IMRDW*3W;=V_FRX*-**A&,537PQBDHI=DD
MDOE9%'P;\+I;:YC<P$ .#]W''O\ YZ4BKWT227W?UW]/0^R_">D&QMXDP0%4
M#&../P]/;I]:"7V6R_K;H>AJ,**!#J "@ H * "@ H * "@#EO'.H1:1X)\8
MZM.RI!I?A7Q#J,S,DCJL5CI%Y=2,T<*M,ZJD1)2)6D8#;&"Q K2C3E5K4J4%
M>52I3IQ5TKRG)12O*T5=M*[:2ZV1ZV0X:6,SS)<'33<\5FV78:"3A%N5?&4:
M44G4:IQ;<DDYM07VFD?Y[3L&=F'1F+#Z$YK^A#_I8@N6,5VBE]R2&T%!0 4
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M,=E].&,QF(S?.\9BL74S;(,IRJV%S' _VU1JU,PCE2Q3H8>C@L-.,JN,K8?
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M)XC 2KTI1=.FU'VZU*G@LH@I4X.O62CS.,7).K>4M6KKDI^[IL[-=S^&ZO\
M1@^;"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@#__U/C^OZ(/^E@* "@ H *
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M%T>RMM-TC1["STO2].LXD@L]/T[3[>.TL;*T@C 2&VM;:&*"") $CBC5%
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M.<94Z>88V>-J5:V9K"N68-3QN"R_G@JKBU+"X:&#<G)T&_?/I#]H*R@\=?\
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MZU#$+)(YCB,HS#!1S&M&O7Q.#P^%K8:O.&*E@?8TZV+H?N-7Q)_!X4 % !0
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M\_Z%W"W_ (;\Q_\ GN'^KV#_ .?F(_\  J?_ ,K#_B%Z_P"">O\ T4;]J_\
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ML@$Z+LLT;'WF8\UPU/I%>(<Y<T7D=%?R4\KO%>GMJ]6?WS+60X!+:L_-U/\
MY&*7X&A_Q#9_\$S_ /H!_&G_ ,.M=?\ RFK/_B8?Q%_Y_9/_ .&JE_\ )C_L
M'+_Y:O\ X,?^0?\ $-G_ ,$S_P#H!_&G_P .M=?_ "FH_P")A_$7_G]D_P#X
M:J7_ ,F']@Y?_+5_\&/_ "#_ (AL_P#@F?\ ] /XT_\ AUKK_P"4U'_$P_B+
M_P _LG_\-5+_ .3#^P<O_EJ_^#'_ )!_Q#9_\$S_ /H!_&G_ ,.M=?\ RFH_
MXF'\1?\ G]D__AJI?_)A_8.7_P M7_P8_P#(/^(;/_@F?_T _C3_ .'6NO\
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M#:_N1['T&;?\B[!+SH_A0D? ?_!GL3_P\=^/0R<']B7QX2.V1\=OV=P#CID
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MU'XS+I]W'QCY9K2ZFA8="KD$$$BO<X\IPJ?3FX4C-72Q?"M1+^]2X?=6F_\
MMV<(M>A&'TR*K_AJK[ZEC^77_@C%Q_P58_8%QQ_QDQ\-AQZ'5E!'XCCZ<5_9
M'C__ ,F5\3?^R0S;_P!,'BY?_ON%_P"OT/S/U2_X.XKFXG_X*C>#8III)([+
M]D7X3VMHCME;>W;XA?&6\:&(?P1FZN[FX*CCS9Y&ZL:_%_H.0C'P;Q[C%)U.
M.<[G-I?%)97D%-2?=J$(1](I=#MSW_?(^5""7_@=0_2O_@AL2?\ @VI_X*Q
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M*_M,3&BG[M".O;GG:3^Z/(O)W6FI_*W7]H'B!0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M#_S7_P#_ !VT?Z^_]2G_ ,OO_O,/^*B'_5H/_-__ /Q)#_B'<_ZO _\ -?\
M_P#';1_K[_U*?_+[_P"\P_XJ(?\ 5H/_ #?_ /\ $D/^(=S_ *O _P#-?_\
M\=M'^OO_ %*?_+[_ .\P_P"*B'_5H/\ S?\ _P#$D/\ B'<_ZO _\U__ /QV
MT?Z^_P#4I_\ +[_[S#_BHA_U:#_S?_\ \20_XAW/^KP/_-?_ /\ ';1_K[_U
M*?\ R^_^\P_XJ(?]6@_\W_\ _$D/^(=S_J\#_P U_P#_ ,=M'^OO_4I_\OO_
M +S#_BHA_P!6@_\ -_\ _P 20_XAW/\ J\#_ ,U__P#QVT?Z^_\ 4I_\OO\
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M _\ -?\ _P#';1_K[_U*?_+[_P"\P_XJ(?\ 5H/_ #?_ /\ $D/^(=S_ *O
M_P#-?_\ \=M'^OO_ %*?_+[_ .\P_P"*B'_5H/\ S?\ _P#$D/\ B'<_ZO _
M\U__ /QVT?Z^_P#4I_\ +[_[S#_BHA_U:#_S?_\ \20_XAW/^KP/_-?_ /\
M';1_K[_U*?\ R^_^\P_XJ(?]6@_\W_\ _$D/^(=S_J\#_P U_P#_ ,=M'^OO
M_4I_\OO_ +S#_BHA_P!6@_\ -_\ _P 20_XAW/\ J\#_ ,U__P#QVT?Z^_\
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M(=S_ *O _P#-?_\ \=M'^OO_ %*?_+[_ .\P_P"*B'_5H/\ S?\ _P#$D/\
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M_P#+[_[S#_BHA_U:#_S?_P#\20_XAW/^KP/_ #7_ /\ QVT?Z^_]2G_R^_\
MO,/^*B'_ %:#_P W_P#_ !)#_B'<_P"KP/\ S7__ /';1_K[_P!2G_R^_P#O
M,/\ BHA_U:#_ ,W_ /\ Q)#_ (AW/^KP/_-?_P#\=M'^OO\ U*?_ "^_^\P_
MXJ(?]6@_\W__ /$D/^(=S_J\#_S7_P#_ !VT?Z^_]2G_ ,OO_O,/^*B'_5H/
M_-__ /Q)#_B'<_ZO _\ -?\ _P#';1_K[_U*?_+[_P"\P_XJ(?\ 5H/_ #?_
M /\ $D/^(=S_ *O _P#-?_\ \=M'^OO_ %*?_+[_ .\P_P"*B'_5H/\ S?\
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M^*B'_5H/_-__ /Q)#_B'<_ZO _\ -?\ _P#';1_K[_U*?_+[_P"\P_XJ(?\
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MU_\ _P =M'^OO_4I_P#+[_[S#_BHA_U:#_S?_P#\20_XAW/^KP/_ #7_ /\
MQVT?Z^_]2G_R^_\ O,/^*B'_ %:#_P W_P#_ !)#_B'<_P"KP/\ S7__ /';
M1_K[_P!2G_R^_P#O,/\ BHA_U:#_ ,W_ /\ Q)#_ (AW/^KP/_-?_P#\=M'^
MOO\ U*?_ "^_^\P_XJ(?]6@_\W__ /$D/^(=S_J\#_S7_P#_ !VT?Z^_]2G_
M ,OO_O,/^*B'_5H/_-__ /Q)/@K_ (*9_P#!%B?]E_\ 8O\ BW\=X/VB_P#A
M8/\ PKX^#[R;PM_PJ%/"GVVWU?QKX?\ #DDO]MM\4_$/V7[)_;"W.U='O'G\
MOR L6_SXOTSP@XT6-X^R; _4/J_UN&8454^M>UL_[/Q-2W)]5A>ZIV^*-M[W
M21^*?2"^F!'Q@\+\YX&?AS_8'U[%Y1C(YK_K=_:OU=Y;F6'Q=OJ/^K&6>U]M
M&FZ-_K=/V?/S\M3EY'_)17]L'^=P4 % !_G'\O\ /^%9U'9?IZ?D-=$%<,OA
M?]>1N%<D]TO+^OR *XJFWJS=:)+R1_6'_P &K?B]K7Q[^V;X!+937_!OP9\9
MQH7/R-X.UWQ_H4S1QXVCS1X]@$SJ5+>3;JP<(GE_S-](O#IX/A7%VUI8G-<,
MVDO^8BE@JJ3>^GU67*ME>5K7=_=R9_[Q&_\ SZ:7I[1-_DON/[):_EH]P* "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MN-S&4,/EDX9WA7A,XR3'8Z3A3R]UG&GB\KQ5=QI_6:^+IRQ-&M]1IU?,Y/\
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M=?P8?;!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % &;JLQ@LW*.8V9E164E6R><*5Z'"G).!M#8.[:#4%J3+1'D>JOR_
M..#T]<[01^.<>U:+;^NO]?Y$ST45I_PRZ'F^KO\ *?<$].W(_P#K#_\ 54O?
M3JVONC9+]!/2"_K1Z_HCR_67^0CU#?J0/Y"H_5O3\OS+@M%Z?G_PR^1Y)K3C
M]X>QW<=.FX#\_P"E5!>]Z?\ #%'C^MN?WGKEOY#^0.*E]/0:VE\OZ_!'O7['
M6HA/&7C;2\\W7A^QOT''33M2^S2$?CJ<8]!@4NGW?U^1%2^GR_)6/T'H,0H
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MQE\4?"OPXUNZLD^4WT/A/2O"WQ'MD:1@6M[2X\40.T)1YY+68O;Q_P!JY5]
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MTNMM+I75_P"8?_@\4_Y*_P#L._\ 9-OC1_ZD_@.O[*^@)_R(/$?_ +''#_\
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M!!_N#_/^<4"T\_+]#UW0="CL(T 0#:,=/;'IU_S] &_N6R['9J-H H$.H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M6G&>G\R9NP6\%K!%;6L,5M;6\:0P6\$:0P0Q1J%CBBBC58XXT4!41%"JH
M%0VV[MMM[MZMG!4J5*LYU:LYU*E23G.I4DYSG.3O*4Y2;E*3>K;;;>Y-2("@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /YQ/\
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MM0Q%3^:M&'_@NFI?^Y#^IFOYE/H@H * "@ H * "@ H * "@ H * "@ H *
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MNL\$* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@#_]?^_B@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M7P\OL[5'BO3;)CQ_J]3=M-E'((^:.[9,]LYX(HZ?+_VY+]"9?:^9^SM2<X4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_/K_ ,'._P#RB,^+_P#V
M4SX'?^K'T>OZG^AK_P GUR+_ +$W$G_JIKGF9O\ [E/_ !T__2D<A_P:Q_\
M**;0?^R]_&3_ -*M KO^FK_R>W$?]DOP_P#^DXLG)_\ <_\ N+/_ -M/Z.:_
MDD]4* /\_+_@YOT;5/V?O^"M'[)W[4O]CZI)X7U#X;_!SQG!J4=LQM]2\7?
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M:C.5*K2J<*<*TZE*I3DX3IU(2R-2A.$DXRA)*49)II-6/:658#I2TZ6JU/\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M/__0_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;:5?^'_'NI:IXR\!:9JNDV5O/JEU-<W%GIC1,+A;2><R-</ 5555#^[4!,
MU^><2>&E'B*EB,9EBAA<52A.2@HJ,*U7I'HES=79^G1?99%QG5RJ=/#8URJX
M=R@G*3UIPZNUM;:::77HC^QWX1?'/PG\3_#^G^(?#.J0W^G7L$,B,DB,T;,B
ML\4@5CM>-LH0<'*G('0?S9CL!BLMQ-3"8RE*C7I2<90FG%JSML];/==U9K0_
M9\+B:&,HPKX><9TYQ4DXO2WW].WD_(^BK.^CN$!4@@@=/Z?C_D5QFYH?2@!:
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#_ #\?^#BWXC)XS_X*3^*/"<+[H_A%
M\*/A5X(G3>C[-0UK0I/B?*<+S%NL/B!I?[N3Y_E\S[DB ?WO]'O+G@_#G"XI
MK7-LTS3&QTM^[HUUEB];5,!5U7^'H?'YW4YL;R?\^J5.+\F[SMZVDGZ-'X2U
M^XGCA0 4 % !0 4 % '^I#_P2A^'[_#+_@F]^QCX8EB\F>Y^ W@GQG<PD,)(
MKGXDV1^(L\,ZO'$\=Q#)XI:&XA=,P2H\.YQ&&/\ FIXHXY9CXA\88B+YHPSS
M&8.+5FG'+I_V?%Q:;3BUA4XM:--/J?H>6P]G@,+'_IS"?_@:Y_\ VX_0>O@C
MM"@ H * "@#Y<_:&_;._9N_9;B@C^,?Q+TG0=<O+3[;IW@[3H[C7_&=_:%VB
MBNH_#FCQ75_:6,\J2Q6^IZJFGZ7/+;W,45ZTEO,J>GE^3YCF?^YX:<Z:?+*M
M*U.C%]G4G:+:ZQC>25M+'ZMX<>"7B;XK3F^"N%\9F& HUOJ^)SG$2I9=DF&K
M<JE*E/,\;.CAJM>G"4)U,-A98C%4X5*4Y4%&I!O\@OB1_P %_?!UAJ,MI\)?
MV>]?\2:6N/+USQ]XTL?"5TY7AE_X1O0=%\7)L?K',?$J.J@;[;+%4^MP_ =5
MQ3Q684Z<NL*%&55+R]I4G1U7E3:[,_LGAO\ 9Y9U6PT*O%WB/EF6XIJ\L!P[
MDF)S>E"ZT3S+,<7DKYX;3A'+)P;^"LTDWY-I?_!P'X_ANE;6OV;/!^H665W0
M:7\0=:T>Z*C.X+=W?AO7(@2-H5C9$)@DJ^0%ZI<!X>WN9C6B^\L/"2^Y5(?F
M?78K]G?P].E; ^)N<X>M9VJ8KAW!8RE>RL_8T<RP,K+JO;JZLDXVU^YO@I_P
M6Y_90^(QL]-^)5CXO^"&NSB)9I=>LQXK\&+/*VT0V_B?PY"=4Q'C=-<ZMX2T
M6SC0H1<,Q=8_%QG!>:8>\L-*CC8+94Y>RK?.E4M'T4*LS\'XZ^@KXN<,JKBN
M%\3DO'F7P3E&&75GE&=\D;W=7*LTE'"MO3DIX'-\?4D].1:7_7;PSXH\->--
M!TOQ3X/\0:+XJ\,ZW:QWVC>(/#NIV6LZ+JMG)_J[K3]3TZ:XLKR!L$"6WF=,
M@KG(('R52E4HSE2K4YTJD'RSIU(N$XOLXR2:^X_CG-,JS/),PQ64YSEV-RG-
M,!5EA\;EV986O@L=A*\/BHXG"XF%.O1J+2\*D(NUG:S1NU!P!0 4 % !0 4
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MQ#*7+]B=3+LWRSFT3<84WMRGPE7]*'\(A0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % '__T?[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M _S=/^"_GPI;X7_\%0OCQ<P:>VGZ+\3].^'WQ3T0-NQ>#Q#X)T;3/$U^CN3O
M6Z\>:#XM;Y<)$X>W4?N:_P!#/ S,_P"TO#/(4Y\]7+9YAE5;;W7AL;6JX:%D
ME;DP&)PD==6DI7][3X/.:?L\QK]%4]G4CZ2A%2_\GC/\NA^,5?KAY85G/I_7
M8 KGGT^?Z&E/K\@KEE\7W?D:!7%/8N&_HO\ @#7^[_G_ #VKDE\3^7Y&I7=
MZ,C#Y75D(]F&"/RKDJZ/3HU^1M'X5\S_ %(/^"<GQ??X\_L&_LE?%2XG>ZU3
MQ#\#/ ^F>)+J27SI+KQCX(TX> /&MTTA^8FZ\7>%M:N-KEI8Q*(Y7>5'=O\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 UF502Q"@=2>  !DD^@
M _*@"I#J-A<[Q;7=M<>6Q1_(GAEV,N,JPC=MK#(RIP1D<4W&4;7BX]KIK3R$
MFGLT[=BR)$/0_P OZ4ACQCM0 M !0 4 % !0 4 % !0 #'&6"KW9B JCNS$X
M  '))( %']: ?Y8_[=WQ5;XX?MI?M3_%@3_:;3QM\=OB1J.BR;A)L\+V?B2^
MT?PA;"10JR"Q\*Z;HUDLBJHD6W#A5#8'^GW V5K)>#>%\JY>26#R/+H5E:W^
MTSP\*V+=NG-BJE:5NE[=#X'&U/:XS$U.DJT^6VW)%\D/_)(Q/D^OJCE"@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M222\$K]-/P0* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]+^_B@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * /X@_\ @ZI^&W]D_M!_LN_%
MI+<)'XX^$7BSP')=; #/<?#;Q=%K?DF0 %A;V_Q,A8(Q/E^>2,>97]F?1CS'
MVN0\2Y5?7!9KA<:HWT4<QPCHWMYRRYZ_W;=#Y+B*G:OAZEOCI2A_X+E?\/:'
M\J?]/\_R_0U_3GZ'S@5G/I\_T *YI[KT-8;?/_(*Y)_:]/R5BPKDGLO7]"X;
M_+_(8_0?7^E<DOB?R_(U(JY*WZK\C:'PK^NI_?#_ ,&U_P 6X/'G[ 6L?#V2
M[B?5?@E\:O&/AF2Q\W==0:#XOLM'\?:)?/"6)BLKW4==\2V-G( D<UQHNHJH
M+P2D_P :^..7/!\8PQBBU3S7+,-74OLNKAIU,'5ALO>C"C1G):V56#ZH^CRV
M7-ADO^?<Y0]-IV_\G_3H?T'U^-'>% !0 4 % !0 4 % !0 4 % '@O[2GQ:L
M/@M\(/%GC>]>:-[+3[B.Q:%%D87C0NT659E&W"-GKCTZ5[_#.35<]SG!9=25
MW6K04E_<OKM\CR\YS"&69=B,7-M*G!M-='9V_(_SK?VD/VZ/'7B/X[^+=1BT
M\'3(-<D-U#>3S&[E67RV=1YJLX\KY@@#;1D[0N[;7]EX:LLHH8?+<-"/U?!0
MC2^%0<]+MM16LE)NS;;LC^<L0Y8ZO5QE:7OXB;E:]TDM(V;>FB3LM+Z6L6D_
M:Y^&]]+'IEQ:ZM%%>0""?4/('EPRSQ^6W_+;;M1F/)Z =*]7^U<,WRN,DIJS
M:6U_GTT>GD<7U::UT:73KM?;^D?,/B#]FCQ]>>(C/X9CL]6\+Z[<B\TK5UG<
MJ;"=P292J,JL%W_Q-\V *\R675^>U)1E2FUR2O\ 9\]+=UM^!TJO327-I):6
MTT[>>FGR^X^O&^)/@3X ^'?#O@+6[RXNM2L=.@#QV,:SB(89?WA\Q"""#E<=
M!7K_ %FA@:=*A-WG"*32V72^GI_6ASNE*M)S6S>G]?UV/A?7]=\>>*OB/=>*
MM N/$FJ6MWKIFT2337NOL]M8O<(;>UE@AE6%713AU*]#ACBO#J3KUJM1TW4E
M&?/&%KV49KE2LGIIN=D>2G&*?*N7E;Z7<7T_KT/ZTOV1;B#Q#X+\#37,@?4H
M]"T>#6(7(\^WU%+6)+F.:/DHV\$C/X=*_D#C#*,;E&?8^EC*$Z7M<15KTI2B
MU&I3J3<HRC)I)_(_HKA[,,-F&4X26'J1FX4:5*HHV?)*,8P::Z;6/W9^$GA#
M3Y],MRT*-\B#H/3'']?3M7RY[3W?:.R_#^O^!8]-\3_"O2M3L)H);&WGAFA:
M.6&:&.:"6-P0\<T4B&.2-P<,CJ5(.&&*J$I4Y1G"3A.+3C*+LXM;--;-$M0D
MG%Q7*U9QE[T6NS3Z/3T/Y(_V]?V"/A[\"OCO<>-M)\$P6FA>+7EUO1&@-Q):
M6FH(46_25 GV6&1KOS[B"V8#]T3L)487^N?"O/<-Q!DL:6*FIYGEK5*MSNTJ
ML/>=.I"/VE3@E&4NDC\!XXRBIE.92J4(<F"Q=YT^5>[3FK*46^CE*[2V/Q-\
M??LM>.]2\>ZCK7AR[L)-+U.^BN(KB>X:*XLU54!W8C8CRRI\OYS@!<8QBONJ
M^5UI5YRARRC/J^BM9II*UNQ\I#$Q4$I7YH[6_#[O*WWG]8G_  3H^.-Q;^"=
M#^'FK:C)<ZGX4L[>TAGED=WNK) H\YWD8N0)'V+DM@8^8U_+OBIPI+A_.OK-
M*/\ L68+VU&>UY;27+LM5+;I9V/W/@;.UFF6+#U';$81\DM;Z='=^\[IKTT/
MW[\!>)X]3LX7#YW(N>>^!_/'/%?EA]L_^'VW]/\ @'K\;!E!'H/R[?X4")*
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M+&R*(Y&,:LX^:ON8^"V;5^?ZIF&$G&$4_P![+V4KV5[QM+1.Z33>BOY'S/\
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MGD.9)IG.Z65SQEY'+.QQU)K_ %'2C%)17+%:1BME%:)+T6A^>:]=^OJ-I@%
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M[7P.)RZFDU_RZE9O6,/WOKY@_EL* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H XOXC^-+7X<
M?#WQU\0KW_CT\#>#O$OB^<?+\T?AS1KS5V3#LB9?['L 9E7+?,RCD;8:A+$X
MC#X>+495ZU*C%RORQ=2<8)RLF^57N[)Z=&>YPQD=;B;B3A_AO#_Q\_SK*\FI
M/72>9XVA@HRT3=HNM=V3:2T3V/\ /OU"_O-5U"^U34;F:\U#4[VZU"^N[AS)
M/=7M[.]S=7,\AY>:>>1Y97/+.Q/>OZ A"%.,84XJ$(1480CHHQBK1BO)))(_
MZ3,)A:&!PN&P6%I0H87!X>CA<-0I1Y:='#X>G&C1I4X_9ITZ<(PA%;1BET*=
M4= 4 % !0 4 % &WX9T#4?%?B+0?#&CP_:=6\1:QIFAZ9;C/[^_U6\AL;.$8
M#']Y//&@PI// /2IG.-*$ZD](4X2J3?:$(N4NWV4^QQYAC\+E67X_-,;)T\%
MEF"Q688RHDFZ>$P-"IB<3-)R@FX4:4Y).45I:ZW/NW7/^#-&YU_6]8UV]_X*
M3YO-:U34-6NS_P ,=YS<ZE=RWDYR/VI5ZRS-_"/H.E?T3EOT\Z.5Y=@,LPWA
M);#Y=@L+@<.O]?+6HX2A3P])?\D:]H4XK=G_ #*9YA<5G^=YQGN.QO-C<ZS3
M,,VQDO87YL5F6+JXS$.ZJQ6M6M-_"O1;&7_Q!=?]9)O_ #3O_P#*FKM_XJ _
M]6E_\WS_ /$P\K_5[_J+_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?
M/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\
M$P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3
M_P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+
M_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[
M!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_
M !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$
M%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\
M-.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#R
MIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_
M (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@
M/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?
M/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\
M$P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3
M_P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+
M_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[
M!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_
M !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$
M%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\
M-.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#R
MIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_
M (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@
M/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?
M/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\
M$P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3
M_P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+
M_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[
M!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_
M !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$
M%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\
M-.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#R
MIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_
M (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@
M/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?
M/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\
M$P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3
M_P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+
M_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[
M!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_
M !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$
M%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\
M-.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#R
MIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_
M (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@
M/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?
M/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\
M$P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3
M_P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+
M_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[
M!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_
M !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$
M%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\
M-.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#R
MIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_
M (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@
M/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?
M/_Q,#_5[_J+_ /+?_P"[!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\
M$P/]7O\ J+_\M_\ [L'_ !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3
M_P!7O^HO_P M_P#[L'_$%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+
M_P#+?_[L'_$%U_UDF_\ -.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"[
M!_Q!=?\ 62;_ ,T[_P#RIJ/^*@/_ %:7_P WS_\ $P/]7O\ J+_\M_\ [L'_
M !!=?]9)O_-._P#\J:C_ (J _P#5I?\ S?/_ ,3 _P!7O^HO_P M_P#[L'_$
M%U_UDF_\T[__ "IJ/^*@/_5I?_-\_P#Q,#_5[_J+_P#+?_[L'_$%U_UDF_\
M-.__ ,J:C_BH#_U:7_S?/_Q,#_5[_J+_ /+?_P"['__3_OXH * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#^<?_ (.;_@U'X[_8-\)?%6TM4?5_@;\:
M?#6I75X4W/!X.\?:=J?@W6K6/&&0W?BFX\!3L^2NRP9&C8NDD7]!_1OS?ZCQ
MOC,KG*U+.\EQ-.,=D\7E]2ECJ,O/EPM/'02TUJJSTL_"X@I<^#A46]&K%_\
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MY4$&O0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MB,<NHJ^RFUC*DH+>U.3C\#:\G.JOL\#*%[.M.%/U2?.U]T#^ .O[S/C0H *
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M%^S24:N:XFA''9SB=&]<7FV)QN*:YI<OMN52:BCYYKO/T4* "@ H * "@ H
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M#O0 SS$'?^5 !YB?YQ_C0 X,I[_Y_E0 Z@ H * "@ H * "@ H * "@ H *
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MB^'JN10Z7_UCKT,AE'3^:EF,U;MOH?W75^(G^!P4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?_U/[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M*^-=GXR\,Z%K(E$,>I:;9WI21Q^X,\$<KQ.2>/*+%23QQUQ7\6YA@IX#'8K
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MGOJNGJY)6YLWP=2$N5TJRY+.WV6OFO+;;<_LY_9Q\2-OM$+\9BQSCT&/Y_\
MUJ_BD_IB77Y25ON/UJ\)W?GV4)[E%/7U H(?S^9W H$+0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M4SO+J3C>V*I-K5:*:[?U\C^NKX2?%H7UOIUEYP*P6]M;*NXM@0Q)& "3SPN
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M/W:-?*Q_M1]!R4)> V7J+3<.)N(X5+?9G[>A+EEY^SE!_P"%QZ6/R2KZH_L
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M4E2,$'!!X((X(([8K\E/\DA* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@#YQ^.W[5/P;_9ZTB[U#QYXILHM0M[(7T'A^SF2;5KN%I3 GE0KN5-\HV 2
M$-WV;<$^;F.;Y=E5*57'8JG0C&/-RM^\^R45KK:RO;H?4<-<&\0\68NGA,DR
MW$8J4Y^S=2,+4H.W-[TW9:+6RN?B9\;_ /@LU\2]7:YT[X$_#_2/#UF480Z_
MXZ::6:0_.HDMX=,O"5  5X]\ R3@YQQ^79GXLX:G*4,KP4ZG*VE4KVL]-&N5
MIVZKW;[?+^G^&/HJXF<*=?B?.:=+F2E]5P2:FMGRR]I3>MKJRENNA^9_C_\
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MJ<J.)PE>KAL11GI*E7H5)4JM.2Z2IU(2B_-'TJ:DDUJFDT_)K3\#7K 84 %
M!0 4 % !0 4 % '\W_\ P7?^*L4VO_ OX(V5TQDTW1]=^*/B.U4GR@=9O&\+
M>$M^!M%Q%'HGBZ0QL=Z07EO)L5)D:3]%X$PSY<?C'%6;IX:$]+WBO:U8KJE[
MU%O9:+>VG^HG[/'@Z5/ >(''U>BE'$XO+^$<KK.W-_L5&.;YTDM_9R>-R1*2
M2BYTJD;R<&H?SWU^AG^E@4 % !0 4 % !0!^\O\ P04^%T>O?'3XM_%B\MX9
MK?X>?#ZS\-:8TT3;[;7O'NKHZWUG+P@E@T'POKFG7"_,5@UD94>8AKXCCG%>
MSP&%PD79XC$NI-+K3P\/A?DZE6$O6FNQ_ /[0/BMY?X?\'\'T*CA5XEXEJYK
MBU!ZRR[AS!2A]7JK_GU7S#.,%B(:?Q<N6J46G_577Y<?Y*A0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0!__U?[^* "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MM_\ MK_"Q^S_ ( =CIUM_P!<D_PQ_G_"@R?3T_)M'J@Z#Z#^5 A: "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#!\3Q&?PYKUNOWKC1M4A7'K)8S1
MC]6%:T'RUZ,OY:M-_=-,SJJ]*I'O3FOOBT?YZ'[97C#0X=;^*OPXT;Q%;?\
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M[>=C^R;P'XU?Q]\+O!?B_5-&L=#U_P 2^'+#5=6M(;6&V>"[NH 9ED<()<'
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M4Y6J=:.ZE#UC;0^[=.U.*[0%6!SCO[?Y_P#U8KL/ -D$$<4 +0 4 % !0 4
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M$4\+3QGM52H?PI>SG.+M3<?E<%6KT:LJE"C[:7)RM<DY<MVG?W-K\MC^B/\
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M7.>;.\3R23M)/+<7DT):)PK4ZL'K&R_9JOCS^)@H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H __UO[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M4>D6^I^5&]WJ>UX9-A+Q6K!2J D;<9P1@]\=%-?S5XN<3XC,,\JY33E5IX7
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ME.;8.AC\NQV&FJE#%83$04Z-:G):6E%V<7:4)*4)J,XRBN<K0](* "@ H *
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M_4?2@XJWY)?G8I/T_&HGMZ?\,>?+[7S*$G1OK_6LCR,1O\_U9GOU_%A^A_\
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M3R23R2>2:_>?^&^X_P"B=)12C%*,8I*,4DDDE9)):)):)+1(2@84 % !0 4
M% #D1I&6.-6=W8(B("S,S'"JJCDDG   R3P*/P_)";44Y2:C&*;;;244E=MM
MZ));O9(_T'OV:/AE_P *9_9]^#?PN>WCMKOP3\._"VBZK%$%"?V[%I=O+X@E
M^0!6>XUN:_GDD 'FR2-(0"Q%?@F98GZYC\9BKW5;$59Q_P ',U37R@HI+I:Q
M_P Z?BAQ2^-_$3C7BSVDJM+/>),VQV%G+?ZC/%U(Y?&WV53P,,/3C!:0C%16
MB1[A7$?"!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!_]?^_B@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MSIZ!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MT;QSRZ2EMRTIPL^9./O</T.?%SK-:4*;Y?\ '4]U?^2>TT].Q_>M7\/'V04
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M_+HPY\7AL,\TR]\MY1QN5WQ4(P[/$T8U\$]':&)G;6Q_H#5^8'^8P4 % !0
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MU\'%];PP<;-Z65DN)93@4[^SDU_+[2=OP:?XG[>?"OX2_#'X'>!- ^&'P=\
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M^WC%\#-O[5Q\03>*3\5?^%F?&$_\3Z?PH_@B6^_X09OB"?AO\WA>1],^R_\
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H _]#^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M!-&>SQ2(KH>S**Y*T(SBXR5XRBX23V<6K-/U5T"TVZ'^I#_P3[_::TW]K_\
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M^>X?\.#OV>/^BQ?%_P#[]^$/_E'1_KWC_P#H!P7_ )<?_+0_XJ%>(O\ T0?
MW_@?$/\ \]P_X<'?L\?]%B^+_P#W[\(?_*.C_7O'_P#0#@O_ "X_^6A_Q4*\
M1?\ H@^!O_ ^(?\ Y[A_PX._9X_Z+%\7_P#OWX0_^4='^O>/_P"@'!?^7'_R
MT/\ BH5XB_\ 1!\#?^!\0_\ SW#_ (<'?L\?]%B^+_\ W[\(?_*.C_7O'_\
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MN+XPS>FI+GE["-7*,C32UC33K9Y.497C4FJ,DE*@F?TJ5^<G^8@4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__1_OXH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MR<PG&.KP&+G*K@Y5'TAA<:ZE*&GQYBTWK!']9E?%G\9A0 4 % !0 4 % !0
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MDK'[&>"+KSK"W.>L:=_;_/Z>U!F^G6Z7^7Z'HXZ#Z"@0M !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Q3_P4*^/:?L[?LG?$
M_P 9V>I#3?%GB'3O^%=> 3',(;V3Q=XS@NM/BN=-;*L+SP_HD>M^*E9#NCBT
M&1E^?97LY!@5F&:X6A*FZE&,O;8B-KQ]C2LWSZ:0G+DI/;^(HIIM'[O]&OPY
MEXG>,7">0UL+]9R?+L5_K)Q&I4W/#QR3(YTL15I8I)-*CF.->!R?WO==3,:<
M7[K9_$+7[>?[\A0 4 % !0 4 % !0!_=M_P3L^"%M\ ?V/O@UX--H+;7M:\.
MP^/_ !C(\"07=QXG\=!=?N8KX1X5[C1--N=+\+Q2$"1K'0K,2YE5V/XCQ!C?
MK^;XRLG^[A4^KT5T5*A^[BU_C:E5?]Z;/\"_I)<=U/$/QFXUSJ-9U,NP.92X
M=R2*ES4J>4Y!?+J,J._+''8BCB<UJ13<?K./KN#Y6C[:KQ3\+"@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H __]+^_B@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@#/EZO_O'_P!"K7['R7X$/1Q^[]#^7K_@YO\
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M (.7O!5WHOQL_9:^,R221Z9IVFZCHM\PB/E+/_:L=S#NF!"A_*LF_=GDH<]
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M+BV?WLJJJH50%50%55 "JH&  !P !P . .!7X8?\^[;;;;;;=VWJVWNV^XM
M@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_T_[^* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M '11[>PP/IS0*_96_JQZ%::;#;J J*,#T^G^>.*!&H%"C H 6@ H * "@ H
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MT_5?@?,XN%XM]+?II;^NQ_6U_P $ ?VJ8?&WP?\ &7[*WB:]QXH^#]Y/XQ\
MB>=<ZI\-O%6HLVL:=:Q'Y_/\(>,KB>XNFW;9;#QEI<=O$/[-O)6^#XEP;I8F
M.+@OW==*,[?9JQ5M?\<$K?X9:*VO\+_2+X1>7YY@^+,+3_V3.H1P68<L?X6:
M8.DE2J2:TY<9@HP4.JJ8.NY/]Y!']#=?,G\VA0 4 % !0 4 % !0 4 % !0
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MI]*"'V[)+\#T0< #V%!(M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MI^TQ==5LNR*C4MK#ZKAEFV(E2>E18[#591_=4I']&%?GI_FP% !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?__4_OXH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M?Y_E0 Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MI"*]G;^6S;NUH^ZTV/OCX/?#)KJ: SVQZKC<G?CV_+^E?FI]BWUZ?95M_/\
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M=\<#I^7/0@5Z!X;Z+YOU[?)::,_0K1;006T:XQQ_G_"@@WJ "@ H * "@ H
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % '_]7^_B@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M-YP_>TO*=.^B2WYHWA;S79'^;B"" 1@@C((Z$=L>U?Z#-=/D?%BUS26C_K8
MKEGM\RX;_(0C(Q7+-:_UT-2"L)K1?<:0ZH*X)K3T?_ - KGFM/0 KSJJM+R?
MR_JVQM#;TT/[Y_\ @WF_;@;]HS]E%_V>?&VM1WWQ8_98AT[PY:/=3_\ $V\0
M_!?4I;A/A[JLB2/NO3X.:"Y^'MY<VJ;+32]*\&MJG_$RU@7>H_R5XM<,K)\^
M_M7#4^3 YVYUFHK]W1S"'+];IK^55KQQ44WK.K6C!<E.T??P57VE&SUE2]U_
MX?L/[KQ\^6_4_H)K\H.L* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@#__UO[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MSR:IY[0K<091FRPR658?$N<<+EN%H5,&WBIU(?OI2BDO9I<T;GZHU\N?R8%
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M25KO]?J^1/XU"@ H * "@ H * "@ H * "@ H * "@ H ;N'J/\ /Z4 +]*
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MUW]J5O[TKR?J>_5X1L% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MY8_P_P \T$%V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M,O4+6%X9&EV+&J,SNY"HJ*N69F. H4 DL> !G/% ?UV/AQ_B5\#?BOX\\9_"
M[PEXRT77/&O@IXH=>TRRFCG6WGF@%P;9;B(M ]S C(;F ,)(RRK@G.WLJ8#%
MTL/3Q4Z%2-"I=1J.+4=/5(Y:6/PE7$3PE.O3>)IVYJ<9*]GTLNW;Y+HCP3XA
M_L^6EY)+(MC&Q5V=3Y(;!]N,C/4]CWSTKSJM"C625:E3JI.Z52$9I/;[2?33
MTT/6P^-Q>$<GAL5B,,Y)1E["K4IJ45:R?));;KMNM;'REXE^ FJV$5T^G03I
M+';W'V>.*1HT:3RW,4>"Z1HN\CG*JF021CCS)\.Y'6:57+,(UMI22LKWTMM9
MZQ22MTLCWZ/&G%6&@U0SO'JWO+_:'.\HQY?>Y][Q]V5[W3UN]3\4['X^_$+Q
M2/%OAWQ2R6]XFI>)O#\-HB75LNG7.G7\L$*1;2[7*SQ)YBO+Y<9=Q)$6! 'Z
MUEGA#X?TLOR[-L'DN'=7VE"IC?:I5HU[?&^6<^6G>34I*&GE:Y^39MX^^*N(
MS#'Y+C.*,;&C3I8BCE_L&L-4PZE%>S]^G34JBC"/+!SES)-KF,_]EK4W@^,?
MB7P9)\D?BCPZFO02S7 ,MS?Z9<&"\C6)Y?,+QQ9D=O+'^L7 !)QV>(638/!3
MPF+P.#PV%IRIQIVPV'IT5RJ_*KTU\/9=#Y_PYS[,LQIXO YEF.-QLX5)58O&
M8NMB/>DTI/EJRMS^ZDY;O:[/V.^'GPK;5I8?W&[.WMV/OCT[5^8GZGHM%OU\
MO7_(_0/X:? 2&);>62U&,*=S(./Y8]OI03?Y^;T2Z:+I;34^W_!_@*TTB&()
M"J[5'.W!X'YX_#\J!7[??^7]=_1'K]K:I @    &!C'3IQ_G\NH27* "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!__U_[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MT_X8\:M'?YZ>NWIT,^=>0?7CVX^7_ _@*P9Y.(BK)]OR7^>QFR+V[G^?;_\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!__T/[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M<05S36J_K8U@]+=AKCCZ5RR5FRR&L*D?Q5OFOZ_ UAM8*X9K2_8L*YYK2_8
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M3^917;^NG0_=;X?ZFEUIULP8'=&O/'H/TQTQ7(=';^O^&/6$8$#'^?I0(?0
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__]'^_B@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_1)XW_Y$OQ?_ -BOK_\ Z:;NOSZA_&H_]?:?_I2/\W<@_P"1YDO_ &-LN_\
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M:8MHT4%U:ZGH,?B::V,+.UMJNIH]OYP6+Y[,\FP]+B2CEU']UAL75PTE%/\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % '_]+^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MNG=7"N.2L_485SS7W, KSJD;-KO_ %_7D;IW2(V49Z?*W!';G]*X*D?Q_/\
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M!*UK+C@O#L?'&:^-Q%2<,5BN2<X*5>LGR2<;KVDM'9JZ/X:XCS/,<!Q5Q='
M9AC<%#$Y_G4*\<'BZ^&C7@LSQ+4:RHU(*K'JHSYEY'K( 4!5 55 "J    ,
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M;,J5)>[@<SJ-R=7D2_=X;'6<DU>G3Q2G!NFJ^&IO^A.OG3\ "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * (9E!0C\/PQ_]:@#\6OCO_P $J?@5XM\:^*/'NF7&M>&;CQ3J
MEWK^M6&E3%[:[U>]D\V]NR+@R,#>.!YWSC'6+856ON,KX\S7*\'3P=.%&I&E
M>,7..T7;MNU]E]+=CX7-> <IS;&U,;5J5Z4ZCBYQA+=KM?9/[459=3XWU[_@
MGI\*O#]X6CDUZ[$:I'Y,MTQB?RS_ *QQ]YI6X5SR'4#NHKHGXCY])2471AS-
MNZAJK_9[)=5IIML94O#3((<DFJT^5)<O,[:=?-]'NGVT,BP_8T^$]FLT<F@7
MUXLWF(YNKN1V\MW+>6/E 4 '8=@&4 !Y&:XJO'G$53E_VJ,.2UE""2TTZW_X
M<ZZ7 '#=)37U24^>]W.HV]7?32RT]W;1(_++]HKX>:BOQ;NOAO\ #BWCT6>\
MUW3/#VF&Z<-#HMI?LL=Q>R22EI/+LX6DF2)QYKE!@EG 7]/P&;5Z/"?]L5)J
MKBI0FYU.5)N3TYEM[U^VE]C\NQ^3T*_&"R6C#V6$C.$:=-.ZC%*]O[L5YGV7
M\)+[X5_#'4M$_9Y\&"Y&I:>LEI=ZC/%LFU[6H8UN-5U*ZF?;NN+NX=IC&6,B
M)+$H3  'Y/G.59K/"PSW&24J.*=X>]K%-Z1MV71[.Q^OY)FV3TL5/A_!1E&M
M@THS]VRDTK.5]M6MNG2^Q^JWP:^&(O9K>:6'=ED^\OZ_E^7'%?*GU3?7Y17Z
MV_(_3_P%X)MM+M8 (E! 7/R_H,?3D#Z4$MM:=>O^7EZ+_@'S5_P47_:8U/\
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M33TOI]M:1J2WD2,ISD#I_GO7.;;'0"@!: "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#P[]HWX^^"?V9O@_XM^,'CN5CI?AVU6'2](MW5-0\4
M>);[?%H/AC2]P(^V:K=KB2<J\>G:=#?ZM<*;33[@CMR[ 5LRQ='!T%[U1^])
MVY:=..LZDKM*T(ZVO>3Y803G**?W_AAX<Y]XK<;9-P3P[37UO,ZSEBL943>&
MRG*\/:>89KB[6_<8.AK&":GB<1/#X.C>OB*47_#=\9?B[XU^._Q.\8?%CX@Z
MD^I^*?&6K2:C>L7<VUA:JB6VEZ)ID;D_9M'T+3(;32=)M1Q;V%G!&=SAG;]P
MP6#H8#"TL+AX\M.E%1\YRLN:I-I*\YOWI.RUV25DO^@3@7@K(?#OA+).#>&\
M+'"Y3D>#AA:*M%5<36;=7%X_%2BE[7&YABIUL9BZOVZ]:;2C'EBO,:ZSZT*
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H _]/^_B@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M.K&=-ZQ/HJ=2-6$:D-I=.L6MXOS7Y6:T:/L*O"+"@ H * "@ H * "@ H *
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M9]E%&,\MS#'U'AJTLVRW+:U3#YSEF;XG 5GA%5=&G2J-RA*I33^1/A3\(?\
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M$Q6*CE6/RW*L)B\/C9/+N?-,+6BYVPV*R_#XF=.K^[Q%+ZI5K,^^/B-\#?\
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M;1RK*\/ALKP6/QOU;!X#!4\'AZDZ+2HX6'MZOM)<TOMK]C'X>>,/A/\ LL?
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MU3GLE&M2LZ.)IV7)6@W&]*5*<_M"N(^0"@ H * "@ H * "@ H * "@ H *
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M/#O@NTSY>GVJ"90=R_:I@'N?]YC*3O?DNVYL],?A6=9E/-LRQ6.GJZM1V?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!__U/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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ME2K4:BY9TZD'RRA)=TU;31[IM69[VG1IK1IIIII[--:--;6Z'65B 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M>6#Q&(=;$RA&=:2/?JX#\\"@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#_]7^_B@ H * "@ H * "@ H * "@ H * "@ H *
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M^]M_73H?HEH=N(;:-?8=/>@@Z.@ H * "@ H * "@ H * "@ H * "@ H *
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MX]M/\ON_X8EZ-/T>FAB7"8_#C]?\_E2AU7]?UL2U9V^[T.?OXNI ZCM[=/Z
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ML24""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M7&5(Z$CFO&E%Q;B]'%V:[-=#UXR4TI1=T]5Z'=KLD7'^?_K?YP:0R&2RB?\
MA7\O\_SH @DTZ"2":WD1O*GBD@D\MC&WE3(8Y KQD.A*,1N4AAG(.0*%I\@_
MKY'\:G_!13]FKQ)^R?\ M&WFLV6I^)M=^'WQ-U2[\3>$];URY6^;3=3NY9VO
M_"D^H:>;>Y%M$F]+&.^B1C&$C#3_ "FOV_@K.Z6:9=+*,2H1JTH)4^516D;M
M22DGK=K:]NEM#\*XZR.KE68QSG#<SHU9<U1.4M'LXZ:6:LK;GQ!;>)/$/P[\
M4^'OBE\.YH+/Q/X:N%U?09F'FXN(HPU_H\RVSVUZEO=H,;3)W4D\5]5CL#2S
M; XC+<5']]1B_9RY&G;>$D]NRTT\CY?+\PJY-F&&S3"/_9ZS7M(\ZE%:^_"4
M79JVZNK>I_5=^QI^V-HO[1/PU\+^.+&[@2]O;>.UU_2TDE$^D:Y:[8-0M+B&
MZ2*YAQ<*[Q^8A!1EVRRX+5_.F8X&KEV+K86JK2IR:7FNC_X'0_I'+L=2S'!4
M<72:E"K%-I.[B[*]_O\ ^&=F?J#X>U>.^MXW5@<J#GUSBN$[;6_3H=<#D4"%
MH * "@ H * "@ H * "@ H * "@ H * "@#\E_\ @J-_P4*L_P!DSP$?AM\-
M-4LKC]H;X@:5(=("!+O_ (5IX8N_.M9/'.I0L&MO[8G:*XMO!NF78D26_B?6
MK^SN-+T];/5/H^'LD>9U_;5XRC@:#]^27\:HK6HQ?;9U&D[1M'W74C./]/?1
MN\":WBCGJSW/\-6I\"Y'B8_7)7=+^WLPI\E2&38::]_ZM%.$\UQ%+EE"A*.%
MHU:6)Q"K8?\ D,M&NIEEO;ZYGO+_ %&>;4+V[NII+BYN;F[<S2W%Q<3,\L]Q
M.S&:>:5C))*[M(68DG]@I04*<8I)+HELE9)+RLDD?[:\.X"GEV58:C2I4Z,'
M3A*G1I14*=*BJ<88>E3IQ]R$(4(P480C&,%[B5HHMUJ>Z% !0 4 % !0 4 %
M ']3G_!%/]BMO 7@R7]K#X@Z:8O%OQ#TV;3?A5IMW !)H?@"<J+SQ:1*OF1:
MAXTD0P:4R(GD^%+<7D5S=6WBIX;/\RXRSCVU595AY?NJ$E+%23TG77PTM-.6
MBM9?]/7:R=/7_)_Z</CA_K!G4?"'AS$J63<.8JGBN+<31J7AC^(J:?L,H]Q\
MDL/D4)\^*3<N;-JLJ$Z5*IE49UOWTKX0_P ]PH * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /__6_OXH * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MO9P>*51*E/2I%)1E?XXI;?XHKSLTNC6O]8=?BQWA0 4 % !0 4 % !0 4 %
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M#&OV?T>18#GG]<J+W*;:HI_:J+1SMVI[1_OZJW(?V[5_&A]:% !0 4 % !0
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MXV_%#QQ\ _AO'-87>E>&]-O/%.K:EX=\:ZS-=2+I=SXXUB)K>X\+V=U,-/\
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MUQ/%N14+-*5;/<#3ZV^/,Z%.UKI)O'PBU>WUJ,')XB3_ *JZ^5/YH"@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@#_U_[^* "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H :PRI'MQ_2FG9H#-E3*D?4?3\/:M9;)]FON,[6DUW6G]>6QC3
M+\IX^[U_P_I[>E3-:)]B5U7]:&-,G)7L?\__ *ZK>/Y>O]:"B[-?UH<O>PX)
MS]/TX]>W;G@@4UJKES77L<C=Q$9[$<C'J.1CIU_0$4I+_)^CT_ 4.W1_U^1_
M$/\ \%T_^"<?_#/WQ*F_:L^#WAZWM/@K\6]<*^/=#T:W:*S^&WQ4U'?<75VE
MDH,5EX5^(DJSZM8-;-]CTSQ6=;TC[-I5A>^&;2X_L3P2\0O[=RY<*9O7<LYR
MFC; 5JLKSS'*J:480YW[T\5EZM2ES+FJ83V-7FJ3IUY1^9SC ^QG]:I*U.;]
M]):0GI[W:TWTZ2_Q:?SUU^[2CO%GDK5$;COZ<5SC(ZQJ1^Y_@S6#NK=OR"N*
M<=/0L*Q:NK %<E6%UZ?U^'Y%1=GY!7!..GIH_0V(L8^7U^[]?\\5Q3AT^[^O
MP FL[N\TV\M;_3[JYL-0L+F"\L;ZRGEM;RRO+65)[6[M+J!HY[:YMIXXYK>X
MA=)89422)U=5(\^O2C.,H3C&4))PE"23BTTXN,HM6<9+1IIIJZ&M+-:-;-:6
MMM8_O(_X(D?\%@;3]KGPUI'[+_[17B".#]J/P?HIB\)^*=3FAA3X]^$?#^F1
M--J!N9KCS+KXLZ)8VMW?^,-/6$/XDTBVF\:6!N)+?Q7!H_\ ,_B!P-+(JT\U
MRRDWE%::]K1C=_V;6G*RA9+3!S;C&A-O]W)JA/\ Y=2J>YA<4JZY9:58K72R
MFE9<RMHG_-'1=8Z:1_HGK\O.L* "@ H * "@ H * "@ H * "@ H * "@ H
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MIRJ9C@J4%;*JLG&]>E%._P!0K3DWRQCRX.7NW5"5-4OZ)J^=/P<* "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H 0@'J* (C"A[=/;_#%  (4';]/_P!= $H ' H 6@#^5/\
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M)?KZ?Y=-C]VX9P?*JN+:_P"G%+3TE4E\-OY(1<9?SIK:_0UN?6A0 4 % !0
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H __0_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M;UIR]ZE.WQ+33_%':7W[21\45]9-=3 @(QQ635U8:=F)7)-6_)FX5RR5GY=
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MW';V"=O7:_\ E^7]:>UV=LL"*H&  /T_S^F/H$EZ@ H * "@ H * "@ H *
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MR*C.KD56;GB<-%.4\GG*6V[E+ RD[4JCUH.U*JVN2<OWSKPC\3"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%SUZ^W3M[4$OIZ:]/P]+'HJ_=% AU !0 4 % !0 4 % !0!\\?M.?M._"O\
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M-"/V(+F>W--ZS?SDW97=E:-[(GIG4% !0 4 % !0 H&2 !DG@ ?H* /[ O\
M@DO^P.W[-7P^_P"%T?$_2);?XX?$_1H!'H^J60MKWX9^";ATN[;PXT$N;FV\
M2Z\8[34_%8N!;W&G"+3?#C6=G<Z;J\FI?DW%6>K,:_U+"R3P6&EK.+NL372L
MZEUHZ5.[A2MI+6I=J4.7_&CZ7WT@UXG<1+@CA3&1J\!\*XV;EC,+6YZ'%&>T
MHNC5S)3@_95<KR_FKX3)W3=2GB5/$YFJM6GBL)#"_L;7R!_%P4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_1_OXH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M_+>/GN?OS7YR=(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 >8?%[X<:1\5OA[XJ^'^M37-MIWB;2+K39KBT=X[BW
M,T;"*:-D>,DQ2;7V%@K@;&^4FNO 8RIE^+P^,I*+J8>K"I%22:;A).UOE\C#
M%8>&+PU;#5&U"M!P;CHU=6NMMO\ @'\T'CS_ ()(_$WPA<7=K8_$7P_JGARV
M\V&QN;^T OYK%=X@BN[18F@9_+PD@#;2.N><_P! TO'.FL/!5<G4L0H*,TJD
MO9MVU:[+LK:(_*Y^&=;VC]GCTJ7-^[NHW2Z73OJM+[]CXB^)_P"R%\8_AMI,
M]SX6&@^*9+&XC$FA65K_ &:TEJ7(G>RCM(<-.L:Y1-JJS%03UKMRSQLP>)Q,
M*&,RV&"H2>M:%24N7;[+LOZ\CFQGAQC*%"53#XSZU4A_R[<%'\E?YH^.;UO'
M<GBS3[8Z-IUMX7@29-<M]5_Y#6GZI!Y:^4EL\#H-DOFJ)?,5N 1@Y _9L'CJ
M694J&+P-2E7P5:*FJD6FUIMMNKZ[/3T/SW$8:IA*DZ->$J-:G[K@UUU^=M%;
M0R?%$VD>$?%&F>(X/#5_K.J^(;JWTJ>]3S+BTTFVXMUO6B>3R+001H&,T:*R
M\G/>MZG+2JQFJ<I2G:+>\817VK;1MWMYF,=4[NR6W];]59?H>F^)_ 4WC/X?
MW%[KFDZVO@B]+>;KZ>=;Z?NB9HB1<1%)@@VL#].1V'@3XMX=KYC+(GF%.6,3
MY)1YTH7=O=YT[WZ6TV?0]59'FD,&LQ^JS^JM74[/IY67;STZ'%7UYX-T$^&/
M"6HK#,MVT<6@).B7<)E1&6-_-GWL'*HP5OO<@5]%)TJ?)3E9K[.SC[JOOZ(\
ME<S;LK/1?DET_)+KT/TW_9Y\,/:>$S(;&WBDUB\^T07<$CR&[LO+2-';<JA0
M&4IM7Y/W8( K^/?$_.EF_$N)]E6G4PV%_<TH323I)6;A[K=];O7N?T%P1EKP
M&3TW.DH5:UJDI)MJ>EDU?R5M-#]"/A]\&WUI(W-N6W 8)4_IQVXK\X/L6_DM
MK_Y+R/J+PW^SN(I(7-H>"O\ RS '7Z?E_+I03>_\TK?)?@?9GPY^'<>B1Q#R
M0"H7^'&/Y=N,?I03MOOLNEON_K;<^D;&U6&)5"@8 Z#';I02:- !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"?[?G_!03X'_\$]O@_/\
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M384 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % '__2_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M-S@G47M8?$QJVA*T:NB[*?2\>TGU@M+OW%;W8_TPXQP1@C@CIC';%?E9U!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MOZ4 /H * "@ H * *,B8)7L>1]/_ *W3\*V7O1_ B6EI+IH9,T>UB.QS^?\
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M4P:>L\/%2J86]X<V&3^K_P!*M?.'X"% !0 4 % !0 4 % !0 4 % !0 4 %
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MBHZM>O7JS;E.I4J2<I2;W?8VJ@X@H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * /_T_[^* "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MO)'/;7,$DD,\$B2Q.\;JQ_$G%Q;C).,HMQE%JSBXNS33U333371JQVEFD 4
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MT;?J::.W]>7_  /(_*[_ (*"_L40?'SPW+\1?A_I\%O\9/"6G/MMXQY*^/\
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MJUYU:L_6:Y3Y * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H __U/[^* "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@!" 011ML!GNO53VX_P ]*V:NOQ1F]'Y/1K8R98\9
M7\OI^GTI?%'S_K^O^&%\+MT_0R)X\<^G^'^'Y8I0>EON):L[&)>0!@3C\O\
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MSH/V1^$G@I-*L;;,04A4_A^G_P"J@#Z;M81$@&,8&/\ /^?Y4 6J "@ H *
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MRY8*I6EI4QV-E3C6QN(O4FH4HT*%'Z?KS#\K"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_]7^_B@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *TR]&'T/]/\
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M3:]6E5A55X/5;Q>DH_+JO-:=[/0_32OEC0* "@ H * "@ H * "@ H * "@
MH * "@ H * /.OB[\2]%^#7PN\?_ !7\16>I:AH7P\\)ZWXNU6PT>.VEU6\L
MM#L9KZ:UT^.\N;.T:[G6'RH/M-U;P!V!DE1 2.C"8:>,Q.'PM-QC/$58482G
M=03FU%.7*F[+R3]#Z7@WA?&\:\5\.\(Y;6PV&Q_$>;X')L)B,;*I#"4*^/KP
MP\*N(E1I5JJHTW/FG[*E4GRJT8-V1\E_L<?\%$O@I^VAJWBWPUX%TWQ3X/\
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M $3Q*XZ?X4 9[Z9"YR4'7T'2@"Q#9QQ=% _+V[#C_/2@"X  ,"@"O/;K*I!
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#__6_OXH * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(*E.=*<J56$Z=2G)QG3J1<)PDMXRA)*49+JFDT=IL5 !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?)G[>'_)F/[3W_9%/'W_ *8;NO5R/_D<99_V&X?_ -.1
M/U_Z/_\ R>WPK_[+GA[_ -6%$_CB^"-[\:?V=;3X<?MI_#V/9H/A[XNZW\.?
MMR-.UE)KVC^&/#?B+5/"?BF.-4":/XV\*^*KJQM0DOG7,6FZX\#6EU86D[?K
M^-C@\P>(R:O\=3"0Q%M+J$ZE2G"K2_OT:M)2?:\-TVC_ &GXZH<#^)-;B;P.
MXCE?,,QX.P/$GL)*FJ\<!C<TS/+L)F^4RGS7QN19KE-*O5;AR4I8G *:JTJ]
M6"_MK_9_^./@K]H[X1^#/C#X!N?-T+Q=IB7$EC+)&]_H&L6Y-OK7AO5ECP(]
M3T/4HY[&YPHBN!%'>VAEL;JVFE_%\?@:V78NM@ZZ]^E*RDE[LX/6%2']V<;-
M=OA>J:/\+O$3@///#/C'.^"^(:7)C\FQ3I1KPA*.'S#!5$JF!S/!N7Q87'86
M5.O2UYJ7-*A54*]*K"/X#?#W_E/AK_\ V,7CW_UG+5:^]Q'_ "0D/^O6'_\
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M$V-GJ$Q2!OG:W V,A2<J&,P]>HE_"<)4DVOLQG>:OT7.H*^[BM3^:\Z_9_\
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M?1=/Z_#^M@KU\'3Y8N;W>B]%O;NKZ>J9A-[(*[3,* /T'_X)W?\ !./XY?\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 ?_U_[^* "@ H * "@ H * "@ H * "@ H
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M1@L4VB7FG)!-I5Q!;RV;1-$F/G\/PEG^%Q$<71QV!A7C+G]I[?%-R;=Y*?\
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M_J\2E;1;_D%=\(6Z6MLC(*WC'J_D@"NVG3[_ ->2\OZ](E*VBW_(E1<<G_\
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M0#I^% 'TSI&A6]C&BI&%Q[ =/Y?E_2@#IU4*,#_/L* 'T % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MY<9G.)HPA]<QKBHIWH8.GA\*E2/MNO%/PH* "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /__0_OXH
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M9S:YJ-:*^U1K1O3J16SY97B_=FHRT.Z,HS5XM->73R:W3\FETZ6/J"O+*"@
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#"\2^)_#7@O0=3\4^,?$.A^%/#
M&B6LM]K/B+Q)JMCH>A:390(7FN]1U74Y[:QLK>)%+/-<3QQJ!R:J,93DH0C*
M4GHHQ3E)^22U?R1T83"8K'8BE@\#AL1C,57G&G0PN%HU,1B*U23M&%*C2C*I
M4FWHHPBV^B/Y\_VQ?^"\_@'PC%J/@C]C[0HOB3XG\R:TN/BQXNL;[3_A_I*Q
MMY?VCPOX=E:PU_Q?=NP?R;O55\/:):JL-U%%XC@G,$/U&7\,5JK4\<_8T[)^
MQ@TZTK[<SUC26S:M*=O=Y8/6/]0\ ?1HS3,94<PXYQ$LHP5E.&38*=.IFE?J
MHXK$6J8; 4[6YH4_K.)E[U.2PDX\Y_,Y\7_C7\6OV@?&M_\ $3XS^/?$/Q!\
M7:BS!M2UZ\\R'3[4L732] TJ!8-(\.:+;DG[+HN@V.G:5:Y8P6B,\C/]KA<)
MA\'25+#THTH+>RUD^\Y:RD^EVW966R5O[3X8X1R/A;+Z65Y%E>%RS!4DOW6'
MA:52223K8JO)NOBL1))*=?$U*E65E%SY4DO.(XL]L ?Y_P _KZ'K2^_IY>?]
M?+7;[;#X?RTTZ:_\!=MN^FQ>CC]!_G_'U/;Z]-$ON_/_ "CV7Z;^S0H)6;6G
M1=_)>7YFC##T)'T'K_@H_P ]A5'K4J.S:]%T2_K^K;WT3_ZP_P ] .P_R=HQ
M_KM_P?\ AD>G2I;::_U_27]*VB?_ %O?W_W1^I'<=-.B7W?YO]/+\?6H4._]
M+^OE\M[T4?\ G^O^'^%:1C9>?]:'I4X;:>B_7^O4O(O3T'^<51Z6'H[?Y?U_
MPWJ:]C#E]YZ( ?\ @7\/Y8)^H':MHJWK_7]?TCZ++:'/5YW\%'7UF_A^[67J
METT>O5'T 4 % 'TS^RQ^R=\7/VNOB-;?#[X6Z.&AMQ#>>+/&&IK-!X5\%:+)
M+Y9U+7+^.*0^=,5DCTO2+1)]4U:>.5+.U:"VO;BU\W,\TPF4X=U\5/?2E1C;
MVM:5OAIQ[+3FF[1@FKO5)_EWBQXN\'>#G#53B+BO&6G4YZ.49+A7">;9YC8Q
MYOJN H2DDH03B\5C*SAA,'"476J*=2A2J_VF?LD_L?\ PD_8Z^'2>!_AMIYN
M]6U$P7?C3QYJD%O_ ,)1XTU6%7$<VHW$2_Z+I6G^=-%H>@6K_P!GZ3#+/(HN
M-2O=3U*__'<US;%9OB/;8B5H1NJ%"+?LJ$'TBGO)Z<\W[TFEM&,8Q_Q"\8/&
M7B_QHXEEGW$V(5'!X;VE'(^'\).I_961X.;3E2PM*;_>XK$<D)X[,*J^L8NI
M"$6Z>&H87#8?ZKKRS\E"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H _]'^_B@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MZ'\*/LJ%/D]U1WI4X-^ZDO>;/E.._&3Q(\2\MR;*.-N(_P"VLOX?E*648?\
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M.)IN="I;3FC&?-"ZYXQ;L?258'AA0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!C^(/$7
MA[PEHNH^)/%>O:)X7\.:/:RWNK^(/$>JV&A:'I-E A>>\U/5]4N+33["TA0%
MY;B[N(88T!9W4"G&,I-1C%RD]%&*;;?9):OY&^&PV)QE>EA<'AZ^*Q-::IT<
M-AJ-2O7K3EI&%*C2C*I4FWI&,(MMZ)'X5_M9_P#!>'X%?"^+4O"O[,VBGX\>
M.$>6U3Q?>_;M!^$VC21[D>[2YDBMO$?C9XY5"P6NC6^D:+>1-]L@\6/''';W
M?T>!X;Q5?EGB7]5IZ/E:3K-=N6]J3MO[3WHNUZ;U2_HG@CZ./$F=RI8OBJM_
MJYES49_4XJ&(SFO%VM#V2;P^ 3B_>GB)5<12DE3E@;N3I_S0_M*_MD_M'?M=
M^(?[<^-WQ%U37M/M96?0_!.F_P#$D\ >&(R^]8]"\)V3+IZ7"_*LFLZB-1\0
MWJ1PK?ZO=^1#Y?V.!RS"8&%L/22D_BK27-5ELFE-[1MTC:/]V]S^P^"_#GA;
M@G#K#\/Y52H5YQ2Q.8UO]HS'%.UG]8QE1>T4.V'H^QPL'=PH1<I7^:XX@,<?
MX_\ UJ])173^OZM_5M/TJAAE'6UW\OP_S\GYEV.+.">G;']/\1^'J-%'^NW]
M+I]]EO[%##[76W3I\_ZTZ:W+R1]/;M_G_)^@R=$K?U_5O)=/P7L4:-DM/1?U
MM;\/4OQ0CC([<#U^OH!_]8#C%4E]W];'J4:-K7WZ+MI_7];WT3N?P'\N/3T'
M^3K&&WE]R\_^#]VR/3I4OZ_K\$6T3]>WK_\ 8^OKVXYK1V5OZOY^G9?T_5H4
M>K7]=W_E^A<CCZ?YS_\ 6'Y=JN,;:O?\CTH0V[=%W+R)V'XG_/Z"K/0HT;V_
MK^O3KZ%R-,8X^G^?Y?\ ZJTA'J_E_7Y?\,>G3A9**W-^"/RHU7 !ZMCU/^'
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * /_2_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@"M,G\8Z=_P#'_/\ ^K2#^S]PFKK\C/FBW#(Z]1]?3Z'^?Y4?
M"[_9?3M_7_ (^)6^TOT,N2/(/J/Z?Y_+\*)*ZNOZ1*_E?R\F9<T>.?S'^?\
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M  .  . !P!P*_F(^C%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * $P/2@ P/0?D* %H * "@ H * "@
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MMJ]EH[?@G$' 7%'#7/4S#+:D\)3O?'X*^+P22^U.I3CS8>/;ZS3H>ETTOO\
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_3_OXH * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H __U/[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * &.@88[]CZ4XNS\@*+IU5ATX_S['^5:M<RT?H9VY7HKJW
M](S98]IZ?*?T]O\ #VH6JL]UHT2U;5;=#-FB]N#_ )_S_P#JJ-8/R_K\?ZV!
M]U\_)_Y&9)&.58<?Y_S_ )%79/5?)_U^0D[?Y&%=VV/Z?U!_S[CC(H3OY-;H
MU:4EI_7E_6QSMU;=2!C'4?Y[C_ZXYZT8F!<6X?(Q\W;W_IG'^<8(S:M_A_\
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MA2MOOV_K_A_0R<^B^\*ZXPMO]Q 5JHWVV_#^O( K>,.WW_U^0!77"G;R\O\
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M0\^=!QVV[6Z>CV_+U*S0YZ<^W1A_G]*S<'_7]?=Y'+.FGNK?E_P+>:WV14>
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MQ7E'X\% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '_U?[^* "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"*5-PR.H_4
M>G^%5&5O3\@MT*#H&'3VQ_GTK1J^JW6QG\/NOX7_ %_7X&9)'CY3T['_ #^H
M_I1I)?IV)UB_ZLT9TT/_ -;_ #_+\C4)\CMT!K2ZV_+^NAFRQ!@5(^G'\O\
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MAD>TC[OY5@X6V^X!O'<;?IT_*L7!>G]=@ KCW'J*PE3\K>:V ;6$J?E\T F
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MIKV<<7AY4,;1C94<1!:'\^'[2O[#/Q8_9]FO-<AM9?'?PWB!F3QIH5E('TF
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MXCCN+3X4_"?X._#"WF79'JFMP>(?B-XBM>O[VSENM2\-^&DD/R_)J'A;58E
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MTMH6$C)Z#C\OU_\ UGVJE'_AK=/P_P O,]*EAWVM\M?^ _37:Q;2(#I_G''
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M0]"T3PQH^F^'O#>D:9H&@Z-9PZ?I&BZ-8VNF:5IEA;(([>ST_3[**&TL[6%
M$B@MXHXT4850*_/YSG4E*=24ISFW*4YMRE)O=RD]6_-G^=&/Q^.S3&8G,<SQ
MF*S#,,;6GB,9C<;7JXK%XJO4?-4K8C$5I3JUJLWK*=24I/JS5J3D"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H __];^_B@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *\L?\ $OXC^O\ C^=:
M0ET?R_R_KT$TFBC)&''^>OK_ /6[TVFGS+YK^OZ1"VY7\GT_3^M#-DCQ\I_
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M(65A=Z?\#? CW*A>L875+34[38_1RUHT@ _=O&<FM(^&W#*U='&2\I8V=O\
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M ."\7_!2>R??/\2OAUJZ^5Y?E:E\&_ *1!LH?/\ ^)1I>DR^=A2N/-\C#O\
MN,B,ISOAW O_ )_1_P -5?=[U.7](\^?@IP+-66#QU+6]Z>9XJ]M?=_>.HK?
M*^BU.AL?^"_O_!1:UG6:XUGX):G&JL#9W_PCM([9RRX#%])US3+P-&?F39=H
MA( D1URM+_5O ]*F*7_;]+\O8F4O [@:4;*.;TWI[T,QO)>2]KAZD/\ R3;:
MQHWO_!P-_P %#+N#RK>7X"Z2^]7^UZ=\)[N:X*J#F+9K'B[5+3RWR"Q%KYHV
MC9*@W!C_ %<P'_/W$ORYZ*M_X#01$/ K@F#O*6=U%;X9X^E&/K>E@Z<O3WK>
M1@W/_!>K_@H[=0/##XU^%E@[;<7=E\'?"QN(\,"=BZA]OM/G V-YEK)A2=FU
MMK*_]7, OM8E^3G"W_DM)/\ $Z8>!_ L6F\-FDTOLRS*JHO2VO+"+\]&ONT.
M-U3_ (+=_P#!3'5-ZK\>M)TF*2)8S#I'P<^#%N 58GS4N;KP%?7\4S<!C'>)
M'M4!(TR^_:.0Y;&-G1G4?>56HG]T905OE<[Z/@SP!35GDE6LT[\]7-,T;Z>[
M:EBZ=-I=+POW;T/-M5_X*R_\%&M;W_:OVIO'5MYGF;O['TWPAH>/,()V?V+X
M;L?*VX_=B/8(AD1!036L,ERV#NL+%_XIU)_A*31Z5'PHX$I6Y.&L)*UOXM7&
MUEI_U]Q,[_/?J>1ZY^WC^V[XE:1]6_:S_:#+2EB_]G?%7QCH2_,TKG:FAZMI
MRQC,\F/+5=J[$4!88E3>.68"+NL)0\OW<7;[[K[T>UA_#[A##V]GPQD:M;X\
MMPM7:V_MJ<V]EW^]N_SOXI\7^.?'UP]WX[\9^,/'%W)/]IDNO&/B?7?%-R]R
M1M-P\^NW]]*TY  ,S.9"  6P!73"A1I:TZ-*F]O<IPA_Z2D?2X/)L#@;+!8'
M!X-)<J6#PE##)1O\/[F%-)7Z;'.QV848550>@ 7]% K4]..%V]V_36_]>A:6
MU _R%H.J&%?;Y)6_#38LK;XZ+CZ#^I_2G;RV.B&&2MMK_7Y>6GW%A8 /_K#=
M]/8?YXJE!]=/N_K^K'1&BOLQO:W1K_@W]%;\BPD)XPH'N>?R[8JU%(Z8X:3Z
M66VW]/[K;%A8/7GZ_P OI]!5I?)=+Z([:>#\OPT_#^ON+20^@_3'_P"NFEY7
M_!?YOY6.^GA8KI\K?TE^1;2#U[=@/\/\^U6H]_N6B^Y?UH=]/"RT]WE7I_6_
M2Q96(#' &/SJ[=EZ'?2PL5T^<EZ=/Z\M"PD1_A'^?Z?YQ32VZ+_AMO\ @?<C
MT*6'>EE\VOR7IM?3I8LI"._/\OQ/'X=!VP:M*WE^>EMHZV_&W9'?2PR7]/\
MK[K)%E8_Z <<#\/Y<?\  :I+Y?F_G_7J>A3H66NGE;7HM.R]-%]Y:2'/3\\8
MX P,^G\QQTJCNIT6UMRKM_2_"WR:U+J1!?<^N/Y#^I_(TTOG^GJ_\O31G;3I
M6T2^=OEHBRJ>OY5K&'SM]R_R.ZG1MT_R^?\ D3HF?3 _(?X_0?\ UJUT6W_@
M7Z)?K_P#OI4+_P!?AY?UMH6$C_SW./Y#V''Z4DKZ;+]?\_R/0ITE'1+Y?U_P
MR+D<7Z?D/PX_^M6J26QU1AVU9:5>PZ4SMHT;[K\/Z_X/H643\!_/_/\ ^JKC
M&^^QZ4(**\_Z_'_AD6548R> /P&!_(?YZ5J=-.FVUIZ:;?\ ![+^E^HG[(/_
M  2N^/W[31L/%7B2VF^#GPGG^SW"^+O%FEW/]N^(K.7#@^"_"4AM+S4HY(2K
MQZUJLVD:"T<@DL;W5)HY+,?+YMQ3@<NYJ5%K&8E)WA3DO94I;)5:J32=]Z<.
M::M9J-TS^8?&'Z6/AYX6*OE.55*?&O&%/VE/^R,HQ5+^S<LKP]W_ (6\X@JU
M'#SC.Z>!P<,9CHR@X8BE@XRA6/ZHOV4/V,/@1^R?HGV#X3>$HK;6+FQBL/$/
MCW7#!JWCSQ3L,4LJ:IKAMH1;6$MU%%=MH>CV^EZ%#.D$EOIJS0I,/S+,LVQN
M:5%+%U7*,92E3HQO&C2O?X(7>R]U2DY3Y='*VA_E?XG>,OB!XOYC]>XQSB57
M T,1.OEG#^!4\)D&5.2G"'U/+_:5%.M3I3E16.QE3%9C.FY1J8N49-'V/7F'
MY>% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__U_[^* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *
MLL>WE1\O?V/]!_\ JXXK6,KZ/<35U^11EB##CM^G_P!;^5%N75;=5V\U_7_
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MH24 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * /_0_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
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M:+=O^&^1?E:WY?UY'.W-CZKM/]X#Y3W_ ,\?3W+]]OZ_JVPS N;(C(*\=/\
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M!G\",8Z$BE*71;?U_7;\"XQZO<TZ@L* "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"K)'MY
M7IZ>G_UOY5K&5].I,HW]2E+$&'^>/_K>H_R!JVL?FB/[LOD^QG/'_"P_S[>W
M^>"*>DE_6@OAT_#HU_6W8SY8>Q_ _P O\_IVJ$^1V>P-:76WY&?)$.A'M_\
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M?F&6YS@Z68Y3C\%FV7UU>CC<OQ-#%X:HK)^Y7P\YTI-)IVYKQ31@%/\ ]?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 ?_]'^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MTFH-NG+HX5(QG%^[**:LO)J4JE)\M2$H/:TE;;MT:\UI;;0X"NQP:\_0@*D
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % '__2_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@"K)%CE>GIZ?_6_E6L9='Z"<4RI)&''3_/MZ
M4./6._8SV]V6W3^NW_#>F?)'MX/3M_A[&A-25OZ^7]:":<7IM_6A0DA]N/\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M '__T_[^* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@G]!]/?W_+WF4KZ+8M))61-4#"@ H * "@ H * "@ H * "@ H * "@ H *
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M*(^JK^7\/U5Q/)_W?U_^O_*CE79_A^C0OJW^+[Y?Y">2?;_OK_["CE\OZ_\
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M2AU>GE_6W;\#?@M0F.,M[=O;M]/Y8Z4K7WV[?U^6PW+I'0U(H">W_P!;_/\
MG%2Y?9CZ?\,1:_\ F:<4/8#)]?2BRC:^_P#7Y?UT&NJCM_7]?TS3BA"8]?\
M/Z>WTS3M?5[=%_G_ %_D-=HK79R-".+&&;KV'I_]?^53*71;&B22)Z@84 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_U/[^* "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MOCR5(J=*I"I"23C*+4HN+V:E&Z::V:T.5IK1IIKHU;\"M3Y)=OR$%39KH 4
M% !2LNR^X I<L>WZ?D 4<D>WY@%')'M^8!1R1[?F 4<D>WY@%'+'L 4[+LON
M *8!0 4^5]OT *?(_3^O( JO9KO^@!5*"Z*_X@%:*#[6_KR *M4_5^@KI$D4
M4D\@A@C>:5ONQ1(TDA^B("Q_ 5IR**O)Q@EU;2_'_@D\ZZ:_U_70^IOA/^PY
M^U_\<!:S_#']G/XK^(=+O&5+?Q)=>%;WPQX0DW*')3QCXM&A>%GV1E7=(]7>
M0*\>(R98E?YC->-N#LCYHYGQ'E5&K!/FPT,5#%8M6=M<'@_;XJ.NBYJ2COK:
M+MT0PN,J_P /#U+=W'D5O*4^5/\ [=U/TA^%?_! ;]L7QI);3_$'Q-\*?@_I
M;A'NO[4UN_\ &?B&%&."MKHOA2RFT>ZN(Q\S0W7BO2XCPHN<D[?SS-/'SA#!
M*4<OPF:YO46D?94:>"P[LOM5L5-581Z)QPM1_P!TZZ>2XF7\2=.FOG.7W+EC
M_P"3K0_4GX1?\&]G[,/A=+2?XK?$GXH?%[4(F#745C_9GPS\,7>W9A%TG3#X
MB\16T+?-Y@7QG+*58"*:)DWM^89KX_\ %&+YHY5EV5Y13:M!S53,L3#S]K55
M##R>UO\ 8HKO%]/1IY+AH6]I*I4?574(Z>4?>7IS=M;'ZS_!3]A[]E/X 6T$
M'P@^ 'PU\'W4((_MZ/0(M=\7SJP3*7OCOQ4^N>-;^$&-6C@O-?GMX6+M;Q1>
M8^[\NSGC'BKB"4I9QGV8XR#VH2KO#X.-GO3P&%]C@Z;UUE##IM))M\JMZ%+#
MX>A94J,(M=5%.6BZS>K_ .WGV/K>&PYRY+'C/.?S8\_@*^95EHEVMIMY67]>
M1HY=W\EK^.EC7@LB<*JX''3'(]__ *^.3Q3MW_"VGZ+;Y::$N3>VGIN;5OIW
M3(S[#'^'KZ>E-=E_P+>;T?W67Y H=]#>M[ +C@#IP /\_P S[4[>5_/:*]%U
M^XKW8_Y+^OZ^1M061/1<#_.?K_+MQQ5I6_K\ELB')OT[&W;60XPOXXY_#^7Z
M?-1_7H"BWZ:?TC>M[$+RPP/\_I],?@12O?X?O_R7]?Y7[L-M_P#AON-:*#C"
MC _S_GIZ4:1[_J0VW_DC2B@ '3 _S_G^?I46<_)!9+??M_F:,4&<<87L!U/^
M _\ K8JMO=COW_K^OR';K+;HOT2Z?UZFE%%CY5'^ _SCZFC2.KWM_5AI7\H]
M/T_K^E=2,(/?N?\ #VJ')OT[&EK:(DJ0"@ H * "@ H * "@ H * "@ H *
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M>C*4E_A]-ON_X!DSZ=G^$,/5>H_S[>O%&G1_)_U;\B[OM\U_E_E?R,>:P/(
MW#^ZP_S]/_K4-6\O(:L]C(FT\#L5_(@_YQP./7I1_7;\OZ_0,R73V&?ER/\
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M0_\ )&_,_?\ A[Z6GBAE*I4\XCD?%%*%E.>/R^.7XRI%*UO;Y/+ X:,M-)O
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MN,HN:::LTUHUJM"MY>./_K?IMIE.E+M'YK_AM!GEC^[^BG^HH,_9/^5?)O\
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M$YZM^@^G\O\ #I4.5].A:26B):D84 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % '__5_OXH * "@ H * "@ H * "@ H * "@ H * "@ H
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M/WGE^.PN/NNZIXFGEEO\/M'_ (NW-/)I?\NZ\7V4X.*_\"BY_P#I)\M>)?\
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MB)QV7U^GM_7I^6*5U'1?<4H]9:^70MJH48 P*RO<L=0 4 % !0 4 % !0 4
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M%)_=VL?'8WZ2W@C@&T^-:.+<5=K Y5G>*6[7+&<<M5*3TO[LVK-:]O=/"_\
MP2(_:?UHP-KFL_"OP= PC>==5\3:QJM["K8WI%!X;\-:M93W$8/$;:C#;.5Q
M]K48-<%7C/+:?-&E2Q55JZBX4Z=.G)[)WJ55.,>M_9<UOLWV^&S/Z97A/@54
MC@,NXQSF<>94OJN58#!X>HU\,I5,RS7"5Z5*3ZK"U*L5_P N&]#Z7\*?\$6[
M0+%)XU^/-W=.<&:Q\)^!8K.*/A05AU;6?$-Z9NX#R:);XXS&17EU.-:C?[K
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M_/\ 0?7I3O?X=%W_ ,D.UM]7T7]?D7XXB>@P/7_#Z>@_2AM1_K^OZ]"E'O\
M=TT+BJ$&!^=9MW+'4@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * /_6_OXH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * &E0PP1Q33ML!5>(KTY
M'\OJ/Z]*T4D_(EQ3\F5GB5AT'TZ?EZ4./6.C[="+V]V2T_K^M"D\++T&1^OI
MT[_A3YEL]/7^OZZ"Y7TU7E_D4VB4]!_G_/K4N';[O\@NGNOFBG)![8Q_G\/Y
M4E)K1H'&WIW13>,CJ./\_P">*TT:[_U^ D[;%*2U5NG'Y?\ UOTQ]#4ZI6^)
M?B:*:ZZ?D94UGCMCGTXZ?@/Y52:_X .*>WX;&7-:>JX]P/YG^A'T]F9N+7H9
MLMF1D@?3'\N/Y<_3M2L@6FQG2VP[KW]@?Q_+N/I4\MMON>W_  "U/O\ @9TM
MD.<#\ .GX=/R/TXJ;:_R?E]_3T[%:-6,N:P']W&.P'L.JGI^'^%%O+3O';YZ
M6TL3R=M/(RY;$CH/TX_+M[8[<FEH]%Y;:=EMM?T9-I+OIV*#VI'&W/L0/Y'I
M2M;;_+I_7]6!2:TW]2A)9(?X-I_V?\/\_E1KU7W_ -)E*2_P^G];_(H2Z=GI
M@^QX(QQ_^KTYHT\U_7R*3OV?X?AK\C.ET[&?D9?IT]/3'Z46]'Z?U^8_P,^3
M3SC&%8=,%1T_S[4;=U_7X#T*,FG#O&R]_EQC]/Y<47]'_7R8%*33QSSSZ,O/
M_P!;_"C3T_KM_P $"J^G-V7/^Z1^@_QHLNC^]6_S J-IYYRA_%!^&2*-5_P'
M_D!6:P7^[^7 ]/\ /:G>2[_<! VGCT/YJ1^1'\J?._("$Z;Z#\U&,?@11S^7
MZ 1'31V _!?Z_P"%/G\@&BP9.5RI]02OZBES1_ET^7Y $MG)/#);S,9K>5=D
ML$LC20R(>"DD391U_P!EE(]J$X)J2C:2V:237HUL!R=]\-O!.IF0ZEX,\)ZB
M9?+\TWWA_2+LR^4%6+S#<64A?RU1%CW9V!$"X"C'53Q^*I6]EBL53M>WLZ]6
M"5][*,TE?K832>Z3]4<_/\"?@]=2>;<_"7X87,I 4RS^ _"DTA5>%4O)I#-A
M1PHS@#@5TQSO-H+EAFN:0C_+#'XJ*^Z-9+\"72IO>G!^L(_Y&'<_LP?L^WT[
MW5Y\"O@_<7$FS?-+\-O!SNX1%C3<QT;)VQHJ+Z*H X%;1XESZ"489WF\8K9+
M,L8K7=WI[;OJ+V-+_GU3_P# (_Y#8_V6/V=5967X#?!L,I#+_P 6R\&Y#*00
M0?[&X((&/>J?$_$+5O[<SBUK:YGC/R]L'L:7_/JG_P" 1_R.EC^ 7P9C=)$^
M$'PN21&#(Z?#SPBK(RD%65O[)RK*1D,/ND CI7,\]SEJW]K9FTU9IYAC&FNW
M\;;R#V5+_GU3_P# (_Y'067PI^'FGDM8^ O!EDS%6+6GA;0+4DH<QDF"P4ED
M/*DGY2<KBL)YGF%16GC<7)+I+$UI>N\]+^1:C%;12]$CNK'3A8Q&WL(Q90LY
ME-O:C[/"9"JJ9/*AV(7*HH+;=V%'917'/FF^:=Y-*W-/5I=KO49=^Q3/][S&
MY[]1^+$U*7HE\OR_X %A=-/< ?CG\1_D4]/^!;^OR N1Z:./O'_=7 /X_A[T
M:=OQ_P D@_K^OP+T>F=/W8Z#ER/SQZC\/I1?Y>@?U_E_7_#&C%II/&#]$4#^
MAX. .W\J+/2_X_U_706B_P" O\OZVN:46EXQ\H7W;!(_KD4:=7\E_5OS\M ?
MR7K_ ,#_ (!I1V"#L6_(#\L9]^*%V2_7[EM^!/,N_P EI_7]:&C%9XP%7';@
M#\>G7U[4]7U_7\$3S=E;IY_UHC2AT\G&1CI_G'?GU(QQ0K?Y=?P6GR;\K"Y9
M/_@FM!IV.B],=0,#\!T]N_'6G;Y+I?=;;+1?<M"U!?UH:T5BH[?3&/\ #''L
M.U-+R^<O\@YHK;[EL:D-F3C"X'M_CU/_ -;I5**ZZ_E\ET(<F_+T-6"Q''&?
MPP,_R]./TJA)-FQ!8G^[GZ=/_K_3_P =I7M_DMS3D2W_ ,D;$-HB=LGMP./Y
MC_/:E9OR79?Y_P"0G/HE_7H:$<!/; ]/R_S_ %I.2CHON1&K\R_';XZC _S_
M )[#ZTK.6^B]!V2WU\ET]?\ (O10$X &T>N.O\OSZ4](Z15_(+7U>BZ=O1(T
M(X0N !D_3K^G/].PH2ZR^[HBEKI%66S??^OZL74A[O\ ]\_X_P"'3^52Y=(E
MI)%BH&% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 A
M (P1D4;; 57B*\KROZC_ .M6L97T>A+BF5FC5AC'^'_UOPH<>JT9-^722NOZ
M_KR*3P%>G/MW_#'6A2Z25OR%R]8N_P"?X?\  L4VC#>Q_P ^U)P[?=_6PKWT
ME]_5%.2#V_S_ $Z=12NXZ/45NJU7Y?+H4VB([9'X?Y_STJ]&OT%ML4Y+9''
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 ?_U_[^* "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!$\0;D<']#]?\
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M_G\OR%1>4M$M!\O?33^M"['".BKG\.W\OZ>E4HJ.K_KY!Y)?Y_>7X[?NW/\
M+_Z_\O:C5^2[];?H.R7F^W0NQQ$\*.!QG_/\A1I!%<K?Q?<6TC5/<^O^'I4.
M5_)=BR2I * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H __]#^_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M+,CH,_A@_P">/4TK"VV*<EKZK],C^HQ^F<4N7L[?E]Q:FUYE-[-?[N/PS_\
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MGKTB_P %V\E]R97)Y_@74TT?W/S'Z<D#Z4K>:7IKU_K9CY(K_@O_ "+T=BH
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M7_7HAI-_W5V_#_@?H6TA Y;D^G:H<^VQ:26Q/4#"@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0@$8(XH3ML!6>$
MC[O(].__ -?^=:J??3\B7%,KL@/!'MT_#!']*;BGK^*)UCINO3^K?D5)+<?P
M\?R_^M2O*.^J[_U_7F*T7MH^W]?U;H5'CQPR_C_]?^GZ4_=D+6.G_#6*[P@]
M/RQ_3_#\JCE<?A_K_@?UT#W7_=_+_ARF\'7C'X?Y_7FFI]U_7]>@K->GX%9H
MB.HS^'\O_K57NR\P3:V*CVZ-VQ^G_P!;\P:+-;/Y/^KEJ??\"C+9=\9]>,?K
MG\.#]!0G;=6_+M\BO=EI_7R,^2S(R,?@1U_+Z>F.U-??Z$N';\3.DLQ_=V_@
M,?IQ^GM3(LUT*4ED>P_3_(_4<=J5A;;%)[4CJOMR/QQGC\AFERKII^7W%J;7
MF4WM%_NX_#/MT/-)Q?E+\.W;39%*:[6*DEB#TQ].GZ'@?G4V6NDH_D/1]G_7
M^7W%)]/ 'W/R!7^7'^12MVL^EMO\A<D>WW?U^A2?3AZ'_OD$?IR/H:?JG^#M
M]ZV^8N3S_0J2:>>PST]OR4\4M'V_+_[4GE:Z?<5FL6'\)_+_ .)/Z4K?UHW]
MV@>\NZ^\KM:,.WTR/Y#K3Y?/[TU^@*31";3U0<^B _RI:_=MKL-3\E\M"$V2
M<_NQ^1!_^M_2G[W;_P E7^0<R[?CI]VQ$;)/[F*7JOT_*P^=6ZKTL,^PQ_[?
MX<?IMHNNR_'_ #'S+^9KY?\  ?YC/[/3W_[YHNOY5]["Z_F_#_@"?V>GN/\
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M?I]PTFU;X46TA[M_WSV_'_ZWZBH<^B_KT+44B<  8' %0,6@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __1_OXH * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M6^,<8_"IM-^2^[_@CLEN_DO\]BTD/]U<_P"?\]:?+&._]?(:N](JWI_G^7_
M+B6Q_BZ>W _/T^@IW;V5O-]OZV_JRLEN[^2_K^ONO;2(#A5S[ ?T_P :.5+6
M6OZ6+U>RY5_7]>7R1:6'^]Q[#_'H/UX]*3GV^\:BD6  HP!@>U9E"T % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@#__2_OXH * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M[)_LK_WQ_P#6I<OFU\Q\[\OZ] ^R?[*_]\?_ %J.7SE]X<[\@^R?[*_]\?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H __]/^_B@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M[@Y6NGW$)@(Z<>W_ .O_ !JN=>A-K$1B;TS^'^15:/L_T_R#;8B,0/!3^O\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?_]3^
M_B@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M5M+#4$O/^NQ.L2#MGZ\__6_2H<F_+T*)*D H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
H "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ck0001824293-20241231_g3.jpg
<TEXT>
begin 644 ck0001824293-20241231_g3.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0! 17AI9@  34T *@    @  8=I  0
M   !    &@       J "  0    !   &SZ #  0    !   "N0    #_X@)
M24-#7U!23T9)3$4  0$   (P041"10(0  !M;G1R4D="(%A96B 'T  (  L
M$P S #MA8W-P05!03     !N;VYE                        ]M8  0
M  #3+4%$0D4
M              IC<')T    _    #)D97-C   !,    &MW='!T   !G
M !1B:W!T   !L    !1R5%)#   !Q     YG5%)#   !U     YB5%)#   !
MY     YR6%E:   !]    !1G6%E:   ""    !1B6%E:   "'    !1T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D
M    9&5S8P         1061O8F4@4D="("@Q.3DX*0
M
M                            6%E:(        /-1  $    !%LQ865H@
M                     &-U<G8          0(S  !C=7)V          $"
M,P  8W5R=@         ! C,  %A96B        "<&   3Z4   3\6%E:(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\4VB2Q,4927R&4X(^[ZUW?ASQ=X7\76SW?AC5;;5(HR YMY5<H3T#@'*D^A
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MW5TL<L3C<CH\Z!E8'J".#6U^T'\)?A/HWPOU;7+;2;71K^S5&M9K=?*9IBX
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M_P#T5-7TYH'_ " M-_Z]H?\ T 5\Q_ME?\DJL?\ L+V__HJ:OIS0/^0%IO\
MU[0_^@"@#Y,_:O\ ^0S\-_\ L*/_ .A0U]DU\;?M7_\ (9^&_P#V%'_]"AK[
M)H ^%OVB9M+;XX>"+3XB,X\$_9]S@[A$9R\@?.WGKY._'1*](\8_ ?X6?%#P
MY!<?#M].TB[MY$>&_P!,5'C('WE<0LJMD="3N!'7&0>V\=^+/ACJWC#3_@[X
MZT\WEUJT8G@\^)3;Y8.%VR[@RN2C*"HSDXSS7SS\9O@IH'P?\.S?$_X8ZK>>
M'M0TZ6$" 3EXY%DD5-B%OGSSN(9F!4$$=Z /MW0[2_L-%L+'5;K[=>VUO%'/
M<;=OG2(H#R;<G&X@G&3C-:E<EX"UR\\3>"- \1:B@CNM2L;>XE51A=\L89BH
M[ DY'M76T ?"G[2\ND:/\8? OB'QFB:CX:CB*3698,5*RL7D,75E(9.V&V;3
M7M>A?!GP<GQ$TKXN^ [V+3M/-J5^QV,2+:W*RHZ[P4( !#*<!<94'J2:\%^!
M?A'PU\8_$WC?Q7\2X1JNKK<F 6LS,!;12;AD*"", ;$/\&WC!P:SM<UWQM^R
M;J-WX=L)EUKPOK44\FEK.X\RUG ZE>N%9AO  5^H*MN% 'Z%T5\X?LT>!#X<
M\$_\);JEP+[6_%A%]<3[_,^1\M&F[G)^8L_^TQ!SM%?1] !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>7?%OXIZ1\
M)O"K>(-1B-W<3/Y-K;*=K32D$X+8.U0!EFQQTY) KU&OB[]J\II_B;X:>(M5
M0OHNGZB_VKC<H'F0.01W+(CX'L: +MGXS_:UO;%?$\?A73%LW D6Q?Y)VB//
MW3-O#8[$@Y_A[5Q?[/OBL^-_VBO%GBA[-].DO=*8R6\ART4B2VR.I.!T93U
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M1S;<.WL'15_X%0!V?P^_9M^'7A31((M>TJ#7M7E0&ZN;M?.5I#RP1'RJJ#D
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M?M:^ /!/A/X>:9J'AK0[/3+F758HFDMX5C8QF"9BI*CIE0<>U?>%?'W[:O\
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MAO4I8+'6]QFTW8OD!B=P*D'(VL6VC& K%?>O:20H+,< <DFJ?]I:=_S]1?\
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M3K.J0V4JRO:SR2&*8+_ X,K#!^AH ^DZK7O_ !YS_P#7-OY59JM>_P#'G/\
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M"/\ K@E?-MEBY_;-OS!\_P!ETL"3'\.8$Z_]]#\Z '_M%?\ )8/@]_V%4_\
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MH!Q7J'@'X+^(O!GB6#7]1\?:MK\$*2*;2Z>1HG+J5!(:5A\N<CCK7FO[8/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQU7Q+>^)GNI1(LMZS,T8"XVKN=^._6@#YX^-G[//P[TGPAXJ\?6:W8U55EO
M3.3'YLLFYOEQTRQXJO\  []GOX>:[X*\+^/;];LZJ^VZ)6?$?F12G;\N.GRC
MC->]?'[_ )(WXK_Z\S_Z$M5OV=O^2*^%?^O9_P#T:] 'M->6?&[GX2>+ ?\
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MAP<_\M#7%?%KXX^"-<\?^$?B1X$%TNI:$^RY6:(1"6W5MP0$,1R&D4^S=>*
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M?%KPE8:!X?N;:UGM;Y;EFNF=4*+%(F!L1SG+CMCWKWJB@!!P,4M%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/>+M(N/$'A36M
M!M'6.?4K*YMHV?(17FB9%+8!. 3S@&N#^"WP^U/X=_#NV\'>(9+>[GB><R&
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MMD_L^'$A4]1E(K<D$<$%\>U>]?#;X9^&?A;X?&@^'(V.]O,GGE(,L\F,;F(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]7]_***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /_UOW\HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_.>,#ZU\KG^ H8RG+$85ISCO;JO\S2#:T9^QM%%%?G)L%%%% !1110 4444
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MBQA@!]]#(I([_(7[2'@&X^&'[(/@7P1J%[#?:AI^OL;MH'WQI<317<KQ@_\
M3,OM/ R1G S7+_MX:UJ?A[X]>$]?T.Y:TO\ 3M L)X)HSAHY([NY96'T(KP,
M/@U7=.,):WJ-2\TU9FC=C1^!'A/7? GPI_:6\(>);<VNIZ5ID4$R'IE8;W#*
M>,JPPRGNI!'6O5OAY\&Y?CA^QS\,?"LFH)I>G66M7>H:A<,1N2TAGU!'\O/&
M\F10">!DL<XP?2(_B/X3^,?[+_Q!^)^FVT5IXCOO#\MAK<:'!$]E#*8\C^Z1
M*S(W7:0I)*X'ROXQUG4]+_X)Y^ ;?3;N2V34=<N+:Y6-BOFP>?J$AC?'5=Z(
MQ'J!5.I6K2;^";J17HU!I_\  %L:W[9'C#7_ (46&F?L\^ M);POX*6T27SX
MC\VIAO\ 6 R#G"O_ *T$[G;EOE*Y^5O@EK^H3?$GP=9M=2KY>KZ>-H=@I7[0
MG;-?87PFUK1_VN_@O<?!'QM<I%XY\*P^?HU_+R\L2 *I8]6V\1S#DE2K\L"1
M\2?#K1]6\)_';PSX?UR!K/4--\0V5M<Q-U22.Z17&1P>1U'!ZCBO:RV,8T*F
M&FK5(WOYW^UYW_ F6]SZ4_;%U"_@_:!\10PW,L<8BL<*KL ,VL78&OD"YGFT
MR_LM;M25FLIHY%(.""C!E.?7(KZS_;*(/[0WB/\ ZYV/_I)%7RE?Q^;9RI_L
MY_+FNS)K+#4O\*_(F>Y_1!\(_&2>/OASH7BI2NZ]MD9PK;L.!A@3ZY%>CU\-
M?L">(AJ?P6_LJ3=YEA?7"#)R-FV-N/Q>ON6OR+-<+['$U*2V39TQ>@45AW_B
M?PWI=V-/U/5K2SNBH<133QQR%22 VUB#@D'G%7;75-,OL?8KR&XS_P \Y%?^
M1->==&CIR2O8OT444R HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /_1_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHKSSQ1\6/AMX-WKXD\16=I+']Z$2"28?]LH]S_^
M.UK1H3J/EIQ;?EJ%ST.BOG3_ (:!EUWY?ASX(UKQ(I^Y<-"+.S;TQ-+G]5%'
MF_M->)_N0:)X,MV_OL]_=K]-N83^E>A_9%6/\5J'JU?[M7^!/,?1=8>L^)_#
M?AV/S?$&JVFFIC.;F>.$?^/D5XC_ ,*+\1:U\WCKXCZYJF[[\5FZ:= WL8XP
MPQ^5;FC?LZ?!O1I//7PY%?SDY:2]>2Z+'U*RLR_^.BCZOA(_'5;_ ,,?U;7Y
M!=D.I_M)_!G39/LZ^(%OYSPL=G#-<%CZ!D0K_P"/5E?\+]OM4X\(?#WQ%JN?
MNRRVHM(&^DCEOU%>Z:9H6B:)'Y.C:?;V$>,;;>)(ACZ(!6K2^L82/PTF_67Z
M)+\PLSYW_P"$R_:*U7_D&_#_ $_1U;HU_J:3_B5@P?PH_L?]IW5>;SQ!X>T,
M-_SY6LURR_\ ?_C/XU]$44?VFE\%**^5_P#TIL.4^=_^%5?&"]YUCXLW;9ZB
MTTVWML?0JW]*/^&?YKSG6_B)XJO<]474/*C/_ 0A_G7T111_;.(^RTO2,5^2
M#E1\\?\ #,OP]E_X_P"]UB^]?/U&4Y_[YVU)%^RW\#T;?-H#W#_WI+RZ)_24
M"OH.BC^V\9TJR7HVA\J/"T_9I^!Z=/"T7XSW!_G+6SI'P(^$F@ZE:ZOI/ANW
MM[RRD66&4-(621#E6&YSR#7K=%92S7%25I59?^!/_,.5!1117 ,_F'^(,4^F
M_M2?$JQO4:)WU*^9=X(W#S^",^O:MGK@5Z)^W;X1D^&_[4@\4J6-IXG4S?,N
M%W'!<!LG/+CTQ7G ;.".0>GTK\.XDH.&*E<_L;@K&1KY?3E'LOR/J?\ 8,1Q
M^U7=2'[C>%+T#ZB\M<_S%>0_"G_E&+\9S_U,MA_Z4:57@/C'7?&?@Y(O%O@/
M7-0\/ZE KV\EQIMS+:3&"4JS(TD+*Q3<BDC."0/05\ZVGC3QC8>&+WP18Z]?
MVWAS4I5FNM-CNI4LKB5"A5Y;<-Y;L#&A#,I(*KZ#'NY1F,5AHPMLI+[SY+B'
M(9RQ\ZW-I)TW_P" -M_?<_8K]@WXI>&?CQHGAGX1?$R3=XO^%EY%JWAJ]8CS
M9;*+Y)+?)^]Y:'85[Q[& S$36_\ !#4;S1_VQ/VH-7TZ3RKJRTZ]GA? ;;)$
MZLIPP(."!P1BOQ(T'Q!KWA75[?7_  QJ5SH^J69+0W=G,]O/$6!4E)(RK*2I
M()!Z$BN@L_B;\2=.U;5=?T[Q9JUMJ>O(T>HW45_.D]ZC\LMQ(KAI0W<.3GO7
MK4LVM&"DM8O?OI9'SV*X5YJE:5.5HS5K=GS)OY.WWL_4;Q#HGA#_ (**_"U_
M&_A*"WT;XZ^$+95U&P4B./58$X5ER>C?\LG)_=L?*D.PHX_-/X6Z=?Z3\:O"
M.EZI;R6=Y9^(+"&>&5"DD<D=VBLCJV"K*0001D&N,\->*_%'@O5DU[P?K-YH
M.IQ*R)=6%Q):SJKC# 21,K $<$9YJ.^\3>)=4U]_%>IZM=W>MO,MPU_-/))=
M-,I!64S,Q<N" 0V<C'6N.OBE4<9M>]U\_/U/7P663H1G1C+]V_A3WC?IZ=NQ
M^C/[8KLO[;WBM5SA[+3P?H+&$UYEP17CO@'4_$WC/Q'J'C;QAJEYK>I3(L3W
M=]/)<SR%0%7=+*S.VU%VC)X  ' KV(].*^1SZNJF*E-=3] X3P4L/@*5&3O9
M)?=H9OAW1#XG^.GPST"')DEU:"7Y1DA8)%E/X87GVK^FV"/R8(X?[BA?R&*_
M!S]A_P !2?$']J!O$\\(DT[P/:R3!R3C[1,HA5>#U^9C^'2OWHK]+X-P[AA.
M9]3\!\6,>JN8^SB_A7XF/K^@:/XHTBXT'7[5;W3[L*)87SM<*P89P0>" :\I
M?]G#X)/][PK;CZ23#^3U[=17V]#'5J2M2FXKR;1^6M'@[_LR_ U^OA>/\+FY
M'\I:JO\ LM? I^GAK8?5;R[_ /CU?05%=*SK&+_E]+_P)_YARH^>/^&8/A;%
M_P > U&Q]/(OYQC_ +Z8T?\ #..AQ?\ 'AXP\46..GDZH1C\T-?0]%/^V\7U
MJ-^NOYARH^>/^%%:_;\Z;\3_ !.A'3S[M;@?B&49H_X5E\;+'G2?BO*ZC^"[
MTJWFS]7+9_2OH>BC^V:_6S]8Q?YH7*CYW_L7]IVQ_P"/7Q'X>U3'_/W:S0Y^
MODBC^W/VF]/YO/#.@:L!U%G=RP$_3SR<?C7T111_:E_BI0?RM^5AV/G?_A;W
MQ/TWCQ%\*-2CV]3874-]GZ! /YT?\-*>$;/CQ'H.OZ 1]XWNFN@'_?!?^5?1
M%%'UO#/XJ-O237Y\P69XOI/[1'P6UDA;7Q5:Q,?^?D26V/J9E0?K7I^E>(O#
M^NIYFB:G:Z@N,YMYDE&/JA-0:MX3\+:\"NN:-9:B&Z_:+>.7/_?:FO+]5_9P
M^"^K/YK^&XK24'*O:22VQ4^H$3JOZ4?[%+^:/W2_^1#4]PHKYV_X9];3/F\(
M>._$>C8^[$;S[1;C_MFZC/XFC_A%?VCO#_.B^,]+\21KTCU6Q-L<>F^VR2?<
MFCZC1E_#K+YIK]&OQ%=]CZ)HKYU_X61\;= X\4_#8ZA$O6XTB]2;/^[ V9/S
M-2P?M+_#NWE6V\5V^J>%9V.-FJ6$L7/IF,./Q.*/[&Q#^"/-_A:E^3;#F1]"
MT5ROA[QSX,\6*&\-:Y9ZD2,[8)T=Q]4!W#\0*ZJO.J4Y0?+)6904445 !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0/)7,.W/4*BD^M<D;7]MKX''?9W&G_'7PQ#SY4VW2=?CC'97&8)L#NV^1ST
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M;S2,"0B*68X&3@#D\"OTQ_9+_92EL)D^*/Q5L)$OAQINFS#:L2@AC-*G4NQ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@XR,'&5)'->J5U0FI*\7H>%7H3I3=.I%J2W3T844451D%%%% !1110 4444
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MV'^U*^7/T+8]J[NBL*^9UJD>2]H]EHOPW^>HT@HHHK@&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !4%S;6]Y;RVEW&LL,RE'1AE
M65A@@CT(J>B@$S\JOVD/^"=EMXGO[GQU\#;N+1=<D^=[.0M'!(<DDJR [2<@
M8V]NM?F_KVB_%/X8W;Z7\5/"MYI[02>2;J-1+$S<X.4XP0,YK^G6L?6O#V@>
M)+0V'B'3;;4[<_\ +.YB29<^N'!&?>OFLTX7P^)][9GZ)P]XD8W I0G[\?/<
M_F;L?$FA:DFZUO(V[$,=A!],-BM87-N1E94(/HPK]OO$_P"Q1^S'XL>2;4?
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M0EM);/\ R:ZIZHTZ***W/,"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+6\AD9X0PE:,>8Q)!0D;?,4[0P). ?E]FCD&+G3=2,-%KY_=N3S(^UJ*0$$
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MQ34RFHJ\G9&M"A.K)0IQ;;Z+5GI]%?G-XP_;,^+EQX5U7XG_  P^$]RGP_\
M#]M)=7&K^(Y3I[WJ!2J?8[9<R%2Y5O,.Y2N00AP1M^&_VV=4\)Z?I<G[37@#
M4/ EOJ<,,L&O62-J.ASK.H9&,L(:2$L&&(V#L/XB*Y/[0I7M?\';[SW7PIC>
M3F44WM92BY7[<J=[K2ZW5S[^HKF/"/C;P?X_T:+Q#X(UJSUW39ONW%E.D\>?
M[I*$X8=U.".XKIZ[$TU='@3IRBW&2LT%%%%,@**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@"IJ&GV&K6-QI>J6T=Y9W<;130S()(Y(W&&1T8$,K
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MH **** "BBB@ HHHH **** "BBB@ HI"0H+,< <DFODGXA?MF?"CPIK3>"O
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MJOYO-?WNZZ]-=S8^JZ*CAFAN84N+=UEBE4,CJ0RLK#(((X((Z&I*\0H****
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MHU9_B%%%%:& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&Y'1NH(-7Z*\M-IW11\IVMYK'[..J1Z5JTDVI?#2^EVVUTV9)M'DD/$4IZM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ****  G')KXP^.?[7?ACP!'-H7@R
M:/4]< ;YMID@3!V_>! )R<@\J0#[5XE^US^U-JD.I77PB^'+"&,18U/4>&)\
MS(\F#&0" #O8\\C &.?SCNKJXO;F2[NY#)-*Q9F/4L>37PG$?%GL&Z&&^+J^
MW_!/V;@3PT^M1CC,?I![1ZOU\COOB%\6/'OQ.NI+GQEJLMY%*0?LVXK;K\H4
M@1#"X.,D8ZDUYPJJBA47:O8 8 I>A^E0SW%O;(9+B01J.[' K\QKXBI5ES5)
M-OS/Z"PN"HX>'LZ,%&*[*Q-U/TJK=V%C?)LO;>.<?[:!OYBLS_A)_#N[9_:,
M&[T\P9K6@NK>Z3S+>195]5.16;C*.MC;FA+1.YR(\,7_ (>O%UOP!JEUX?U.
M%Q*CVL[Q*77IG:?J,=.<=*^Z_@!_P4,\3>#M2LO O[0RO/:O(L46JI&&*1E0
MH:1@<O\ -RQVL0#]*^2LUCZUHEAKUE)8WZ;D<8!'#*?4&O;RKB"OAI*SNCY7
MB'@["8^FU.%GW/Z9-&UK2O$&G0ZOHEW'>V=PH:.6)@Z,#Z$<5SOB;X;?#_QE
MJ6FZSXK\.V&JZAHT\5S97-Q;QR3VTT+B1&BD(WKA@#@'![U^&'[('[5&O_ 7
MQM;_  N\?R?:O"NI,L,$YPK0-G"-DX!'.#SQGO7[^VMS;WMM%>6DBRP3HLD;
MJ<JR,,@@^A%?L&79A3Q5+GC]Q_+V?Y'B,KQ#IMM=GL3T445Z1\X%%%% !111
M0 4444 %%%% !1110 5\0?\ !/G]U^SR-/\ ^?'7=:@QZ8NW;_V:OM^OA_\
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M#Q'XBTO7M>\1V>G7&ENCPS0F(%#&_F*?+BA"OANS<'H>*_3&!9$@C29M\BJ
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MN*7MJ;A56S6Q[#XW^+>F>*_#+Z:\!2Z(7#YX!R">V.U?+^H>(["R'ES2[L=
M.:X#Q%XKDF<VNG.40<%AP2?PK@V9I"6<[CZFO2I4XTERP/F<77JXJ2J5WK:Q
MZZ_CW36PK!B%Z<&O1_!OQ+B\VSLGN#]B@E1S$0 ,!MQ&>O-?+-.1WC</&=K
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MZFQBCU&(K'*OWHIE.Z*0=>4< UA4QLJD8TYOW58WIX.-.4JD%J[G%:-^T#X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'RV-SB=2'L:2Y*?\JZ^<GO)^ORL%%%%=)XX4444 %%%% !12,RJI9C@#DD]
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M ":)04445Y104444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG3TON^R\O,X3X<?"F#1"=8UQ1/?2,6 91A<Y]SZUR'Q]@-UJ&E6</RLZ%1Z
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MG1*_WD8B?UJJJ5%67W?,^2?AQI%MXB\<>'?#\\=T-.GEA$A_YZ),P!5BV6W
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M8G:T("\LK=L"N_*ZU*G7C.M'FCV.;%TYRIN,'9GX-ZCK.IWEY?7EY%+=W/\
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MZ]X#T3PA<:QK6F7CVUK#;S\3I$7$DLC&/$2J0O\ >SNZC'.UX1^/6H3^,H/
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M)[!Q\I/8&O-?[,^&NF^$]/\  ?Q:\&7_ ('U>W:-!KL, D2213\SF;G<&'4
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MA0,D\>P-<V&Q<:E)5=KG#@,RA6P\:^R?YWL=?11176>D%%%% !1110 4444
M%%%% !1110!\C?&>.U^"6KI\8O!]Y#876H3+#J.D2$K#JH)Y=%4';,@)8OC'
M<\DA^'_9O^.OB+QY\4M=T_Q9<Y&MP"6S@!/E0-:DGRHE[ QLQ)ZDKD\U],_$
MCX*^ _BH8I_%5M,;NW0QPW$$SQR1J3D@*<QGGGE#7S;8_LG>(? 'C32?&?P^
MUV.]73+E)C;7BF&5H@<21B5-RL70E>50<U]O@,9@:N#E2Q$OWK5DVNVJ5_U?
MIM8S:=]#[JHHHKX@T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *^=_V?\ _B7S?$#PR>!IGB:^:,>D
M,^UD'Z&OHBOG?X<?\2WXY_%+2#PES_95[&/]^ B0_P#?1%>I@M:%>/DG]TDO
MU$]SZ(HHHKRQA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=<U]P5RX5<UZKZ[>G3_/YGN9W)4N3 PVI[^<W\7W:17DK]0HHHKK/!"BBB@
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M8"J2 2J\\D9)+'C.!X+^U5_Q+_C)^SGX@Z>3XLEL<_\ 7_;[,?CMK[@KX?\
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M&>/E]C2/G-[?^ J\O5)=3[0T^PLM*L+;2]-@2VM+.-(88HQM2..-0J*H'0*
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M0,D\GK5NBBLP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXBR&G3H2K4)<MNG1_P#!.7$44E='Z T445^;'GA1110 4444 %%%% !1110
M4444 %%%% !7SQ\4/]%^-/PEU)>/W^JVY]_.ME _K7T/7SQ\:_W'C/X67W]S
M7A#G_KM'C^E>ID_\>W>,E]\63+8^AZ***\LH**** "BBB@ HHHH **** "BB
MB@ HHHH **** /#OVD_^2(^*?^N4/_I1'7D'BOP;J]K\-_ 7QE\"IM\1^%-(
ML'F11_Q]V0MU,D; ==H+>Y4L.NVOJ7QOX0TSQ[X6O_".L2S0V>HJJR/ RK*
MCJXVEE8=5'53Q6KH6C6OA_0M/\/6;/);:;;0VL9D(+LD*!%+$  D@<X &>U
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M8B08=$LI 4@8C[IN9@%'<$(3\K5]UVEI:V%K#8V42P6]NBQQ1H J(B#"JH'
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M;H2O]X5R5*+CN>5B,).F]3ZMHHHK$Y0HHHH **** "BBB@ HKYY_:9\;^)_
M'P[AUSPE>_8;U[^&$R!$DS&R2,5Q(K#DJ.<9K@?$MI^TOX>\+7'Q+F\66C3V
MD)O+C1ELX_)B@4;WC$A!9F1>O(/!PYXR ?8E9.O:O#X?T/4-=N8I)XM.MY;A
MXX5W2.L2ERJ+QEB!@#UKY8\/:A\=_C3H0\=^&_$-MX,TR8L+"R$"733-#E'>
M65UR%,@8 !3Q_#T)Z/X=?%7Q3XG^%OC"XU\):^*?"*WMM.\87!F@B9DEV8V@
M[@00 5)7(&#@ 'LOP\\;V7Q%\(V/B_3K6:S@OM^V*< ./+<H>A(()7((/(]^
M*@^)VK_V)X$UF^!VM]G=%/\ M.-H_4U\\6WQS\2Z%^S_ .&O%5T/[9\6>(YI
MK.UW(JJTWGRHKLJ!5PJJHP ,DCU)JEXL\"?M)VOAIM;NO$]MXHN$V37&C?8H
M_+?# [(V"J7V]> A..,G ,5(MQ:6YCB(2E3E&.[1WO[/7@,Z/I$GBS4HMM]J
M6[;GJJ;OZX!KZ3KX]^+GQ/\ B/X=TCX;3>$+1M&U+79O*GTR>)#NE7RE6!BZ
MA@I9B,J5)!SQ73:UXR\>_!'X:ZCXG^)>J0^)=;O;E(K**&,10QR2(<1_*J95
M=K,3@$@8ZG(SPV'5*"A'H8X#!1P]&-*/0[[XR^ XO&OA6801@W]I^\A;D$X!
M&./K6#^SUX@DU7P8VEW.1/I<OD8;KL5% _7->>MX5_:H_L/_ (2S_A,+<ZKY
M?G_V/]EA\O&-WD[]N-^./K_'WKE?#WQ=T3PO\+]6^,VE6@34M7N5T]K _P"I
M340&D)!&#Y>P[\=<#;G/-8RPS5958^C.6I@&L7'$4^JM+]&?1'C/X=7-]XAL
MO&'A>1;35+=QYNXD+*@'0X#<\#M7H/B7Q%9>$_#>H>)M51WMM,@>XE6(!G*Q
MC)"@E03Z9(KYHL/#G[4]MI \73>*K2YU)D$[:)+:Q^6RCYO)\U5&U\?+P1S_
M !]ZY'PE\0/%/Q&_9X^).L^*KHW,T)O(H041?*B\A'$?R*N<%CR1FNF%*,6V
MNIWTL-"$I2CUW/>==^.7AS1?"_ACQ:-.OKJS\531Q6ZQQ*9(_,Z>8 Q&?102
M3VKVNOB.?QIXF\&?!;X2/X:O39MJ5W9VMQA$??"X;<GSJV,^HP?>O0OBS\1O
M'$_CK3/@]\*VCM=;OHA<W5_,JLEM!SP%8,,X&XG!Z@*,GC0W/IJBOAKXHZO^
MT5\'?"4NHW/BB#7[*Z,</VP6L45Q93%U8':5*NC@,F6SC/8XK[$\(WMUJ7A3
M1=1O7\VXNK*VEE? &YWB5F.!@#)/:@#H:*** "BBB@ HHHH **** "BBB@ K
MS_XH_$WPC\'O NJ_$+QQ=BTTK2H][8P9)7/"11*<;I)&PJCU/) R1V.JZIIN
MAZ9=ZSK%U'96%C$\]Q/,P2.**-2SN['@*H!))Z"OS\\!:7J7[9GQ,M?C1XOM
M9(/A#X.NG_X132YU*C5[V(E6U2YC;K&I!$*D>QQB0/S8BLU:,/B>W^;\D>OE
M> C4YJU=VI1W?5]HKS?X*[>QV/[.WPR\7>/_ !C+^U9\=+0V_B;5XC%X<T:3
M+)H&DOG8,$#%S,IS(V P#$':69%^X:**THT5"-E_PYSYCCY8FISR5DM$ELDM
MDOZUW>K"BBBM3@"OG?\ :VT[^U/V9/B?;8SLT"_G_P# >(S?ILKZ(KS3XTZ=
M_;'P=\=Z1C=]NT'5(,>OFVLB_P!:RKQO"2\CNRRIR8FE/M)/\2E\!=1_MCX&
M_#O5<[C>>'=)F)]WM(F/\Z]8KYJ_8ZU'^U/V7?AG<YSLT6V@_P# <&']-E?2
MM+#RO3B_)#S6GR8JK#M)K\6%%%%;' %%%% !1110 5\/?"C_ (I_]N+XWZ&/
ME3Q+I'A[5T7M_HL)M78?5F.?>ON&OA[6?^)#_P %"O#UZGRIXH\ W5BP[-)9
MWWVC=]=H ^E<F*T<)=G^=U^I[N2:QQ%/O3?_ )*U+_VT^X:***ZSP@HHHH *
M*** "BBB@ HHHH **** "BBB@#__TOUUC_T+]J>9.BZCX45_J\=YC_T$5]#U
M\[^+/] _:0\"7?3^U-,U*T^OD+YV/UKZ(KU,SU5&7>"_!M?H)!1117EC"BBB
M@ HHHH **** "BBB@ HHHH *\Z^+QQ\*?&1_Z@]__P"B'KT6O-OC&<?";QB?
M^H1>_P#HEJZ\!_'I^J_,&3_",8^%7@T?]0;3_P#TG2O0JX'X4C;\+O!R^FC:
M?_Z3I7?4L;_&GZO\Q(****Y1A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !114%U=6]E ]U=2"
M**,%F8] !0#8V[L[2_A:WO84GB;JLBAE/X'-?(?QW^%7@G1M!E\1Z:T>FW4>
M-L"A5$N74': 1T!]#73>//VC=+TB673/"<)OKJ,[3(R'RP?;)!/Y5\RWNG_$
M_P"+-^M_+;/>%C@<I&JCKC!*UX&9XVE.+I1CS2\NA\7G^:X>K!T*</:3\NGS
M/D'XB:.ZS)JT*Y5OE?'; &#^E>75]J>-? 6M>$I4TSQ/:^2UTI(4LK9 QGE2
M<=17S?KW@.[M':?21YT'7:2-P_/%?/TJCA^[GHT?"TYNF_9559KN>=T59DL[
MN)S')$P8=L?X5O:1X3U;595 B\J'/S.Q' ^G7]*Z9325V=#DDKMFU\/=/>?4
MY+TCY(%Z]MQ((_E7V]\&M \;W%S/XA\$RQ"YM"5:.1P"X !QM[@YKQ?P%X'E
MU&[L_#&C%5GN&5-SG@LQQD_B:]POOAA\4OA?,NM60!6'YS+"R,HQZJW)_*L*
M'-*?MN5N*[!@83=3ZSR2<(]5NC[=\ Z[XLU>":V\7:2=/NK;:-X)*2DYR5^4
M?S->A;$!W;1GUQ7QEX'_ &F9H=FG^-K<DJ /.C3!X.,L,^GH*^N=&US2_$%B
MFHZ3.)X).C#(_0@&OL,%BZ=2/NRO^9^H93F5&O32ISYFN^_S+UU:6E] UM>P
MI<0O]Y)%#J?J#D5Y3KWP$^#WB+<VH>%K.-VYWVJFT;/KF ID_6O7J*]6ABJM
M)WI2:]'8]5H^=?\ AGZ31_F\">.=>T''W86N?M5JOI^YD S^+4?V/^TQX=YL
M-?T3Q9"G:^MGLIF'MY'R9^IKZ*HKL_MBL_XB4O5)O[[7_$7*?.$_QB^)?AB"
M2?QW\,[V.WMU+R7.EW,5\FQ1DML&"H Y.YN!UKXT^$G[47B?P1J\UMXH,FKZ
M!?3O,\6<S6S2L69H2W5<G)0G![%3DG]-/&>@3^*O">K>&;>[^P-JMM+:F?9Y
MAC69=C$+E<G:3CD5\\^&/V/?A1HFR76OM>O3#DB>7RHLCT2'8<>Q9J^@RK,\
MMC0J+$TK.5M%=[=5=Z;]R91=]#Z,\,>*?#_C/1H/$'AF]CO[&X'RR(>A[JP/
M*L.ZD CN*Z"N?\.^$_#/A&R.G^%]+MM+MV(++;Q+'N8# +$ %C[DDUX\WPP^
M+'B9BWCGXEW-I;N<FT\.VL>FJOM]ID,\Y'T93^/-?*2A3<WR.T>E]_P-4NY[
M/KGB3P[X8LSJ'B75+72;4=9;N9($X_VI"!7SWXK^,_PC^(&FW'AG2='U'XC1
M.<-%I%A+/$CC@-]J?RH4(_OK+D5VNA_L]?"'0[P:H_A^/5]2X+7FJN^I7#,/
MXM]TTF#_ +N*]EBBB@C6&!%CC0 *J@  #H !T%5"I3@U*-VU\O\ /\QW2V/R
MTO\ ]EWXP^(+BYO_  QHUKX9T_[T-MJ]^MS>$'M_HL9C!] S\=S7B_B/X"?%
M;PXS'Q;8:D\2=7MD'V?'N\&X8^K5^P'BSXE?#[P)&7\8>(K#2"!D)<7")*W^
M['G>WX UYG_POZ+7OD^&?@W7?%V__5W*6O\ 9]@Q_P"OF],0Q[JK5]/A.)\7
MO.'-'SNOQV^\Z88B75'Y)6NA:3I[9M[1$D!^\1N?/^\V3^M:E?IOK'@OXT_$
MS/\ PD6F^%O"5K+_ ,]+7^W=03_@4@A@!]P&K'T[]B[X6-NF\776H>(KB4?/
MOF6SMP?5(+18E4>Q+5[T.,J$8^]"S[)W_P D;+%1ZGYE7>O:/9-LN+I _P#<
M4[W_ .^5R:SIM5N=1A>WL]*FGCE!5C/B%"K<?Q?,1^%?JFW[&?P<B!&EK?:;
MG_GA-'^N^)B?Q-8UQ^QEX/;/V37[^/\ WTB?^06MH<7827Q2:^7_  Y7UJ)^
M.>I^"M<L%\Y(1/&><1$N5]B, GZ@5S/V*\W^7Y$F_P!-IS^5?L[)^Q9I9/[K
MQ5,H_P!JT5OY2"H/^&*K3/\ R-SX_P"O$?\ QZN:6;Y<W=56OD_\B?;4^Y^1
M^G>#-;NU%Q+;;(U(.R1O+=QW R#CZD5ZG%KD=A$D%_83V*1J%!V>9&H' &Z/
M/\J_22/]BS2P?WOBJ9A_LVBK_.0UJV_[&7@]<?:]?OY/]Q8D_FK5O2XBP%)>
MY4?W/_)#6(@MF?F[9ZIIVH#-E<QS>RL"?Q'45>(# JPR#V-?I,/V*O@I*P?4
MHKZ_;NTDR(W_ 'U%&C?K65??L8>$+*<7O@;7KW29EZ0WT<.JV>/0Q3J'_*44
M?ZYX6]M?N#ZW$_-6;PWI%U('6U$4QZ/#F-\GW3&37H/AOX$_&3Q"R'PK8WLL
M+=&OH0L)_P"VTGE\?0DU^B.CZ7\9?AJ +;P+X:\36R<"70V&D7F!U9H;A6B9
MCZ"89_GTD?[1_@G376W\?Z=J_@>=B%!UBPDC@9O]FYB\V CW+C^E>=B>*IO_
M '>DO6_Z*S(EB7]E'Q5IO[.GQ+\+ZC#>?$+PQ<:]I" -*/#EU!)<9_NF*Y,3
M'WV;O8CK7V+X)^,_P*\-VEOX/MYCX'EBZ6.LVTNF2!CU+/<*J.Q[G>Q/K7N6
M@>*?#/BNT^W^&-6M-7MN/WEI.DZ<^I0D"KVIZ3I>M6CZ?K-G#?VLGWHKB-98
MV^JN"#7RV.SFKB;1Q%].VGX'-.JY?$36=[9:C;)>Z?<1W5O*,I)$X=&'J&4D
M&K5>#7G[-_PP%R^H>%+>[\&W\AR9]!NY=//_ 'ZC/D$>QC/Y5J>&?!GQ8\,Z
M[:BX\=KXC\/ L)H-2L(UO53:=NRYMVC5FW8R7C/&?:O-=.#5XR^]?\.9V7<]
MEHHHKG)"BBB@ HHHH **** "BBB@ HHHH *^>/V@_P!Q_P *[U#_ )]_%VEY
M_P!UO,S_ "KZ'KYX_:3^3PCX?N1UM_$.F2 ^A#L/ZUZF2_[U!=_U0I;'T/11
M17EC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N?L/"OAW2];O_$>GV$<&IZH%%U.H.^4(,+NY[5T%% !1110 444
M4 %?!7[3=Q/\<?BOX._9)T:1CI=P4\0^,'C)'EZ39R P6K$=#<3 >Z_NVZ$U
M]D>//&N@_#CP9K7COQ/-Y&EZ%:RW=PW<I$N=J@]68X51W8@#K7R]^QKX*UZ3
MPSKGQ^^($.SQC\6[H:M,K<FTTT#&GVJD\A4A(8=\,H/*UQXGWVJ2Z[^G_!V^
M\^@R;]Q">.>\=(_XWL_^W5>7KR]S[)@@@M8([6VC6*&%0B(@"JJJ,  #@ #@
M"I:**[#Y]L**** "BBB@#PK]H/XVZ'\#? 5QXDU*13?W&Z&Q@/)EGQD#'H.]
M?SU>./'_ (J^(OB&\\3^*[LW-[>MN8 _(H'15'8 5[/^V!\8;OXN_'+5K:";
MS-"\)2-8V2J?E:3@RR?4D ?A7S-7IX6E9<Q])EF%48\[W85S^I>*-%TIC'=3
M@R#^%>37%^-/%\EO(^D:8VUAQ)(#R/85Y(Q+$LQR3W/-:5*UM$;5\;RNT3W/
M_A8F@EL?.!Z[:Z72]<TS6$W6,P<CJIX(_"OF:IK:ZN+.9;BU<QR+R"*SCB'U
M,(8^5]3ZJK,T_7/$OPU\36OQ$\"SFUU&Q<.X7HZ@@D$?A6+X3\2IK]H4FPEW
M"!O'J/[PKK"H8%6&0>"*Z&E)'?)1J0/Z,/V7OCYH_P"T)\+K#Q?9NJ:C$/)O
MH.C13+UXYX8<BOHVOYW?^"?WQ+O/A=^T9'X#N+IUT'Q=&R+$3\@N3C8WL>N:
M_HBKR*L.5V/E,12<)-!11169@%%%% !1110!\I_MA?\ )++/_L+6O_H$M>Y_
M$[_DFOBS_L$7_P#Z3O7<T4 >&_LV?\D1\+?]<I__ $HDKQ;X> BT_:#_ .O[
M5/Y7-?;=% 'Y[6OA#Q'KO[-?P^\4>%;?[;J'A.]GU#[,,EI8TNI2VT#EF!53
M@<D9QS@'U'5OVM/#%WHJV_@;3+S4O%5T%2'3I+=_DF)PPD*'+;>>$R3[=1]<
M5&L42NTBH [=2!R?J: /CKXN3Z_=>(_@?<^*H(;;5Y=7C>YA@R8XY&DMR4!)
M;.WH3D\].*])_:3\ ZYX^^'8@\-)YVIZ1=QW\40^]+Y2.C(N>"V'R!W(QWKZ
M HH ^1&_:Z\)GP_MBTJ^;Q64\L:7Y+9^U8QMW_W-WMNQ_#FO.Y/@'XWC_9V_
ML_RL^)5U7^WC:C!D_P!5Y7E8Z>9L^?;_ 'OEZU]]^5%YGF[!OZ;L<X^M<?\
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MKM*RCV XR,D?;/@/CP/X=!_Z!UI_Z)6NI1$C4)&H51T &!3J "BBB@ HHHH
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M?=;.)3^HKV^BG+FBI=Q8RBJ=6=-=&U]S"BBBK.<**** "BBB@ HHHH ****
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M2O#Q\+:3\)KI+BU\2:8MV98)864;1,\N=QZ$!P"#@YS7UW110 4444 %%%%
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M3RA/H?SKXCT3XG:/J<ZVMY&UF[\ L<H2??M7?WUC::I:/:7:"2*0?_J(]ZC
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M45U2P\-1-/&VY//EFN$4CIA)79..V0:]M QP* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"&"YM[E6:VE2548J2C!@&'4''<>E3
M5\\?LY?+H?C"'_GCXHU1/R*'^M?0]=>.PWL:LJ=[V$F%%%%<@PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBOG_QE\6]3U#6Y?AY\'[9-;\2#
MY;FZ;FQTU3P7F<9#..R#//!R1L/5A<'.M+EA\WT2[M]!-FO\5OB9=>&VMO!?
M@J$:GXUUP%+.V7!$"GK<S]E1!DC/4CT!(Z+X7?#RU^''AH:7YYOM3O)&NM0O
M'Y>YNI>7<D\XSPH/;KR230^&GPLL/ 276K7]T^M>)M5.^_U.<?O96/\  @YV
M1CLH]!GH /5JZ<5B(1A]7H?#U?\ ,_\ )=%\WY"75A1117F#"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@"G?Z=I^JVKV.J6T5Y;2C#Q3(LB,/=6!!KQ7
M4/V</A7+=OJ?ARQN/"6HOS]IT&ZETUQ_P"%A$?\ @49KW:BM*=:<?A=AIM;'
MS1K.A?%_X;6$FK:;\2['4M+M^!#XJM47 ]#>6AB<L>V8V)/8]*\4N?VX+S28
MIK;4O!7VZZB)47&G7AEM9"/X@LL,<P'L4/UKYO\ BE\1?$GQ%\476H:[*Z0P
MRNEO:$D);H#@*%Z;N/F;J3[8 \UK],P'"5-P4L5K+RT_+<]"&&5O>/H/5_VU
M?'>OR-!I%W9:%G@(L/[X>Q-SN!/T45YWJWQ7^).O9.I>)]0E1NJ+</'&<_["
M%5_2O.+BTM+Q/+NX4F7T=0P_6L1O#=A #)833:?CD^5(0GXJV5_2OH*&5T:/
MP4X_=K_7S-U32V1KZEI]EK$C3:I"MU*_5Y!N<_\  NOZUD?\(^UOSI=_<6N.
MBEO-C'_ 7S_.L2;7;W3I/)@U&WU5O^>81O-^F8MR_F!4TWBC64A5SHTD&[J\
MFYD7W(1"WZ"NAU*75?U\BKHOW%WXATF![F[6WO((AEF5C"^!W(.Y?UKB]0^(
M]TYVZ9;+$O=I/F/X 8 _6J/BK6+N\LX$;48;A)6)>*!2H4KC&[<=W?OCI7!5
MYV)QDD^6#T(E+L=U;_$'78G!F$4R]P5V_D179:7XIU#Q"S0Z7!!;O& 6\Z1F
M.#W"JHS^=>)UI:1>7-CJ,%Q:.4D#!00N[AN"-HZ_2L:.-FG:3T$I,]S_ +%U
M"YYU+5)G']R "%?ID98_G5RUT#1[-O,@M4\SKO?YWSZ[FR:YZ'6_%KV[/_8P
MD(Z-O\K/_;-B6_6JB:M<W3!-9U)]*+?\LA 8O_(C[A^5>M[2GV^__@FET>T:
M?X_\7^'%$FF^(;W3HT_YYW4D:?B P&/K7=:-^V%\3-%<10:O_P ) $_Y9/:K
M/GZR($;\WKY]M- T*7%SM%^W_/25S-G\R1^E= D:1*$C4(HZ # %9ULOIUOX
MD(_=<3@GNCZT3]MCXBZA:Q6UOX3T_3+AB ]W<S22QA3W%M&0W'7!FYKW'P9I
M5]\8[8W6K_&"^U%0 TFGZ%''HGE ]5?A[HKVW;P#V-?F[6AI>JZEHFH0:KH]
MU)9WELP:.6)BCJ1Z$?Y->+BN$Z#C^X?++[_^&^1C+#+[)^M_AOX"_"'PK<_V
MAIOABUGOR0QN[T-?71;^]YUR9'!^A%>N !0 !@#M7F7P<\8:EX\^'&C^)]8C
M$=[<HZ2D#:KM#(T9<#MNVYP. <@<5Z=7Y?BXU(U)0J.[3M]QYTKWLPHHHKF)
M"BBB@"&XMX+N"2UN4$L4JE75AD,IX((K\<OVJ_\ @GS>I?7?Q*^ \8BNG;S;
MC34#8?/WB@Y'X8K]DZ*J,FG=&E.JX.Z/Y*(]6FM+^71/$-M)I>IV[&.2&=2A
MW*<'&<5<O-,T_4DQ=PI,.Q(R?SK^ECXH?LW?!OXOPRCQMX<M[FYD7;]JC'EW
M"^X<5\1^*/\ @EUX+N)9)O _C*_T56;*Q31BX11Z9+ UW0QB^TCVJ6:Q:M-'
MXT#P3X<W[_LW/IVK?M-.LK!-EG"L0]ABOU+L?^"7VLB11?\ Q%'E@\^7998C
M\6'-?1WP_P#^"?OP>\(S17FO3W7B.XB;<//(CB..@,:YR/QJ_K4%L:O,:,=8
MH_)7X5_ WX@?%K58;'PUITC0.PWW#JPB1=P!);&.,U^V_P"S_P#LO^#/@C:_
MVC#"MYKUQ&JS73#)7N0F<X'TKZ&T'PYH7ABPCTOP_8Q6%K$ JI$H4 "MNN2M
MB'+3H>7B\?*KIL@HHHKG. **** "BBB@ HHHH **** "BBB@ HHHH *KW4"W
M5K-:O]V9&0_1ABK%% TSXG_X)VSM-^R#X&BD^_;-JD3>Q74KD@?D17VQ7P__
M ,$]_P!S^SM'IG_0.US6K?'IMO';'_CU?<%<F _@0]$>WQ.O^%'$/O.3^]MA
M11176>&%%%% !1110 4444 %%%% !7Y_?&?Q3X@_:9^(MW^RW\++Z2R\+Z25
M;QUKMN?]5"3_ ,@JW?H9I<$2]<#*G(61#W?[2?QE\5PZQIW[._P,99_B9XOC
M):X',6A::>);^<C.U@,B(=<\X)V*_M?P2^#7A3X%?#^Q\!^%%:18B9KR\EYN
M+Z\DQYMS,W)+N1ZG:H"C@"N*J_:R=-;+?_+_ #/H\'!8*DL747[R7P+M_??I
M]E=7KLM>[\*>%O#_ ((\-Z;X1\*6,>FZ1I,"6]M;Q#"QQH, >I)ZDG))R222
M370445V)6T1\].;DW*3NV%%%%,D**** "BBB@ HHHH \I^-GBF3PA\-=9U:W
M?9<-%Y,)]))3L4_F:^#["W%K906V<^6B@D]SCDG\:^L?VKK6:?X274\72VN+
M>1O]U9%S7RDCB>V62,\2("#[$<5^?<2U&\7RO915OFW?\C]=X0H1CEJJ+>4Y
M7^2C;\V?-/C[Q'-K6L26R.?LMHQ1%'0L.K?G7!U<U%'BU"ZCD^\LK@_7<:IU
M^4UZCE-RD?TY@,-"C1C3I[)"U]!_#+Q))J-DVCWC[IK4 H2>2GI^%?/=>A_#
M O\ \)3'LZ>6^[Z8KIRZJXU5;J>7Q-@X5<'-RWBKKY'N.N74^B7^D>*K)C'<
M:5=Q/N'786 8?3%?JKI]VE_8V]]']VXC20?1@#7Y6^*(3=:0]DHR]T\<2C_:
M=@!7ZCZ#:M8Z'I]D_#06\2'ZJH%?K'";?M*JZ:/YZG\T\>\KPV'D_B3DOE[K
M_-L^'O NO_$K1/BI\5!\/O"T?B03:J/M!DNXK7R2LD^S'F$;MV6Z=,>]='\'
M[S5M>^/6NZW\38CHOB^.P$-MIBQ;83:_+F1)=[^81CZ')(.!A;&AZ1\<?AW\
M0/'FM>&_!,>MV/B;4//ADDU"V@PD;RE3M,F[YA)T(!&*Z_P'X"^)>N_%(?%S
MXI0VFEW%E9&RLK"T?S-JL6R7<,PXWMW.2>P %?;'Y@>\^,M=;POX1UOQ(B"5
M]*LKBZ5#T8PQLX4_4C%?)'PM^!_AWXN>$5^)7Q2GN=9UKQ$TLH<3M$MO&LC(
MJQJF!_#G!!4# "C'/V3K&E6>NZ1?:)J"E[74();>4#@F.52C#\B:^2_#.F_M
M!?!NPG\#>&_#MMXPT6"1VTZ[:YCMWC21BVV1'=3U.<< $G#$8P 7)['Q]^SO
M\)/%]Q+K2:Q:6;1#13(&::V$\HAP^X;<*&5@HRN0>QQ7SGH3_LRZCX:6Y\?:
MWJ5]XLU!/.N[[;<EXKB09(0 %&"'C+!MQ&> 0!]9>&OA/XV\2^ _$VC_ !@U
MR6[OO%1#"".0RPZ>$;S(Q$"=N0^"0ORX4 $]:Y31[[]IWP1H$7@2R\*V6N'3
MX_LUGJHNHT3R4&V-GC=U)*C'7:2 ,@G)(!Y1H_CK5_%O[,/CO2=7O&U+^P)8
M+>WNG!#RVS31F/?GG(P>3S@@'IFNQ^*O_)*?@M_U]:-_Z3+7HFL?#7XEW/P#
MUSPIK>I2>)_%>K;),-*H1")8V\J-Y"BA55223C))QVJI\0/AMXUUOX??##0]
M+T[SKWP[/ICWT?G0KY*V\ 20[F<*VUACY"<]LT >??'NSLX_B]9:G\6K34+W
MX?BS"VYL]_DPW)X8R["""3G."&(VXR 17I7[//A_PWI6H:[??#KQ:NL^$KO8
M8=/;?YUG-P<L),,N[YARHW#&<D5M^/K7XXZ#XX/B?P(D?B?0+N 13://,D(B
M<  NA?:/FQG[QY+ KC%8WP4^'7C33/'GB/XE>+=+M?#7]M0I!%I=FZ,BX*$R
M-Y9*9.WUR2S$@<4 ?4-%%% !1110 4444 %%%% '_];]_*^=M/\ ^)'^T[JU
MJ?EC\2^'X+K/9IK27R<?4("?I7T37SM\4_\ B1?%WX8>+1\L4UU=:1,?[WVR
M/$(_!\FO4RK64Z?\T9+[ES+\43(^B:***\LH**** "BBB@ HHHH **** "BB
MB@ KQK]H0X^"_BP_].F/S=:]EKQ;]HDX^"OBL_\ 3JH_.5*[\J_WJE_B7YH3
MV/1_" QX3T0>EC;?^BEKHJP?"PV^&-(7TL[<?^0UK>KEK?'+U&@HHHK( HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **P_$/B70/
M">FR:QXDU"'3;.+K),X09]!GEF/8#)/85X(WQ0^(GQ.8VGP9T;[#I3':=?U9
M#'"1_>MH"-TA]"01GAE'6NW#9?4JKF6D5NWHOO\ T6HFSV[Q;XV\*>!=-.K>
M+-3ATVV&=ID;YW(_AC099S[*":\/_P"$U^+?Q7_<_#;33X2\/R<?VSJD>;F5
M#_%;6ON.0S<$=U-=5X2^!7AK1]3'BCQ=<S>+_$AP3?:C\ZH1SB&$Y2, _=ZE
M>Q'2O;ZZO;8>A_"7/+N]OE'K_P!O?<+5GC_@CX)^#_!UZ?$%T)=?\12'=+JF
MHMY]P7]4W9$?MMYQP6->P445Y^(Q-2K+GJ2NQI!1116 PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ^>/V>ODC^(EO\ \\O&&K#\/W7^%?0]?/'P%^35?B;#Z>*[]_\
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MM,5H=D,!7@AY=KX*G ;Y=H)P3NXH ^AJ*^:M$_:+BA\26OA3XF>&;SP5>WY
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MGD@%L^RLHKYO_:1\0ZAX[\<W&H6+;M \'WEOI*M_"]Y/O>4K[@Q%3[*OK33
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MQFM-^W5%8_+:F':Y]8O9K5->3_-;KJD.HHHK8\\**** "BBB@ HHHH ****
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M%50 *NT5R8K'5:UE-Z+9+1+T0T@HHHKC&%%%% !1110 4444 %%%% !1110
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M\^(?[3?@CQ+'I=QINCF*X@L&N4V27"1Q3,\NWJ 6; ZC ZYR!]^/&D@ D4,
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M!"]-KJU]$)?%>N1<KHFER8W1*P_Y>IU.%7((!'3<7C^L?AO\.O"?PH\%:5X
M\$62V.CZ1$(HD'+,>KR2-_%([$L['J237 ?L^? O1O@3X).B17+:OXAU:4WV
MN:O-EKC4;^7F25V;+;020BD\#DY9F8^[UC0I._M)_$_P7;_,[\TQM/E6%PW\
M./7^:7\S_**Z+S;"BBBNH\4**** "BBB@ HHHH **** "BBB@ HHHH ****
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MATVT7&5B7!8C^)V.6=O=B3[UTE%<V)S"I57)M'LM%_P?5W8T@HHHKA&%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1165JFO:'H<7GZWJ-MI\?7=
M<3)$N/JY JHQ;=D@-6BO$M8_:+^#6C/Y,GB6&\F)PJ6:2718^@,2LOZUA?\
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M^'M*M-,CQC%M D(/UV 9KT<T^J1J1<N:3Y8;6BOA7J_P%&YXC_PNKQKKWR^
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M7;V. ^/7QN\.? ?P'-XMUB-[_4+F1;32M,AYN-1OY>(K>)0">3RQ .U<G!.
M?-/V:?@CXC\+SZK\:?C)(NH_%3QL!)?N/FCTRTX,6G6W)"I& -^T_,P RP4,
M> ^ W@?Q/\=?'L7[6/QDL7LX@C)X*T&?E=,T^3I>RKT-S<## ]A@CCRPGWK7
M'23J2]K+;HOU_P O(]_'5(X.D\'2=YOXVO\ TA>2^T^K\DKE%%%=I\Z%%%%
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MW^T[XA3_ )Z^';5_^^9PM?0]>IFOQ0?]V/Y(40HHHKRQA1110 4444 %%%%
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M]S&LT4MK=*Z. RLI7D$'@@U^A>E>"/!NAWK:CHVAV-C=-G][!;QQOSU 95!
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M][4;<?69/\:X53EV&:M%8;>)_#:?>U:T'UGC_P#BJ@;QAX27[VMV(^MS%_\
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M.OT%KZWBG$8.4:2PL>B=_+HOEU,X)]0HHHKX\T"BBB@ HHHH **** "BBB@
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MMO)6"BBBNH\8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KQ#]IK_DW'XI_]BMK7_I%+7M]>!_M4:CI^E_LU_%"XU*YCM8I
M/#>JP*TKA%:6>UDBB0$XRSNRJHZEB .36.(_AR]&=^5)O%4DOYE^:+O[,O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/;DCD01'YR/]^3@_[@KZ\H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^>?VH/^237?\
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M%: NH6\TBPVS2LZRS,V!]Q>F3T'7'7'0<Q^UP9SJ_A@W059C9R^8$)*AMRY
M)YQGI0!:_9)\9_9=4U/P+=OB.]7[7; G_EK& LBCW9,'Z(:X#]IGQE_PDWQ#
MDTBVDW6>@)]F7!X,Q^:8_7.$/^[6+XGLM1^&&M^"O'6@@1_;]*L+V+(^0S)
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MR5SZ 4 ?I!17EGP3U+4-7^%N@:CJMS)>74T4ADEF<R2.1*X!9F))X '->IT
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MNWQOSQVQ7K=% 'D?BKX+^$O%_A31/".J3726V@)'';31/&)]D<8CPS-&RG<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPWH_BGXHV6G:[;)>6D:3S&&091V13M##N 3G!X..>* /K31_VAK2/X8-X_\
M%%HD=S+=RVMM:6Q.960 @9<G  /S-T'89(!\3?\ :[\:F[\R+1=/6TS]P^<9
M,>GF;P,^^S\*O_M8Z);:,?"\&D645CIH6[VQV\:Q1B4F/<=J #) ';G%=IH/
MBCX6Q?LY/IES<V8?[!+'+:ED^T-?%3R$^\6,F&5L<#!S@4 >O> ?C1X:\<>$
M=1\3E6L9-%B:6^MV(=HE52^Y3QN5@IVG .000*^<[_\ :O\ &5[<W,_A?PY
M=/M26=IEEF=8\\,[1LJIG\0.F37GW[/T>F'_ (3)_$T[6OA]]':WO)E5FV&>
M5$0X4,<@;L<'UZ9K-TOPUXET'^V]4^%'BBWUFPM82UXL1,+M; ,?WUM<JJ2
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M0;02 <9.2.*]"KY.\<?\5E^T[X,\,C]Y:^%K.74YA_=E?)7_ ,>6$_C7UC0
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M48!Y;T)Z4 :WPJ\07UU\%?B+X;N'+VUA;)/ #SL\_<' ] 2@./4D]ZX'X/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "LW5]'TO7].FTC6K2.^LKD 20S*'1P"&&5/!P0#6E10!6LK*TTZS@T^PA6
MWM;6-8HHT 5$C0;550.  !@"K-%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '__TOW\HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ck0001824293-20241231_g4.jpg
<TEXT>
begin 644 ck0001824293-20241231_g4.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0! 17AI9@  34T *@    @  8=I  0
M   !    &@       J "  0    !   &;Z #  0    !   "F     #_X@)
M24-#7U!23T9)3$4  0$   (P041"10(0  !M;G1R4D="(%A96B 'T  (  L
M$P S #MA8W-P05!03     !N;VYE                        ]M8  0
M  #3+4%$0D4
M              IC<')T    _    #)D97-C   !,    &MW='!T   !G
M !1B:W!T   !L    !1R5%)#   !Q     YG5%)#   !U     YB5%)#   !
MY     YR6%E:   !]    !1G6%E:   ""    !1B6%E:   "'    !1T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D
M    9&5S8P         1061O8F4@4D="("@Q.3DX*0
M
M                            6%E:(        /-1  $    !%LQ865H@
M                     &-U<G8          0(S  !C=7)V          $"
M,P  8W5R=@         ! C,  %A96B        "<&   3Z4   3\6%E:(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M7PG^UU^TSX^^ ^O^']*\'6>G7,6JVLTTIO8I9&#(X4!?+EC &.N0:[O]DCXY
M^+_CMX2UO7?&%M96UQIM\+:,64<D:%#$KY8222'.2>A'TH ^L:*** "BBB@
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M\'OA9X*U5=<\)>%=.TC4%1HQ/;6Z1R!'^\ P&<'O7X.?\+K_ &BO^AR\1_\
M@9<__%5^J/["GBKQOXM^&.MW_CO4[[5;R+6)(HI+^22618A;PMM4R$G;N)..
MF2: /MJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4PN4)RO'.,U^5'_!0_\ Y+GIW_8"M?\ THN:^ZOV%/\ DW/1O^ON^_\ 1[4
M><:'_P %"_ FK^)=/\/W'AN\T^*]NXK5[J:XA$4"R2!#*_3"H#N;GH*S?'/_
M  47\%:+JTVG>!_#5QXCMH6*_:YK@64<F#]Z-?+E<J>Q8(?:OR+FBDGU!X(5
M+R22E5 ZDEL 5^S_ ()_8&^$%EX)M]/\;0W.H^(KB$&YO([F2(03,OS+ B$1
ME4/ +JV<9/7  .D^"7[:WP[^+FM0>%=3LY?"^N79"V\5Q*LUO.YZ1QS@)\Y[
M*R+D\*2>*^K?%>OP^%/"^L>*;F)IX='L[B\>-" SK;QM(5!/&2%P,U_.G\5O
M 6J_!GXI:OX+-TS7&AW*-;7*?([1L%F@E&/NL492<'Y6R,\5^V=OXTN_B'^R
M5?\ C/4"K7FI^%+Y[@H,*9UM9$E('8%U/':@#R;X=?MX>$_B)XXT7P/9^%KZ
MSGUJY6V2:2:)D0OT) Y(K[MFE$,+S,,B-2Q ]AFOYW?V8_\ DO\ X$_["D/]
M:_H<O_\ CQN/^N;_ ,C0!^?OAS_@H5X.\1>(=+\/P^$K^%]3NH+59&GB(0S.
M$#$#J!G-?;GCOQ[X4^&GAFZ\7>,[]=/TRTP&<@LS.QPJ(B@LS,>@ ]3T!-?S
MF?#'_DI7A/\ ["]A_P"E"5^D_P#P4H;6!I'@5(V/]E&>^,H'3[0%B\HG_@!D
MQ^- %G7_ /@I+X=MKJ6+PSX)N;^!6(26ZO$M69?4HD4V,^FZMCP=_P %&? V
MK:C%9^,_#%WH$$K!3<03K?1QY_B=?+B?:.^U6/L:^)/V=?&G[./AF.^M/C=X
M4GUB[N9@;>]7,T,,.T#8T =,'<"=X#DY P,<^ZZG^SQ^SK\;?&<%[\$_B)IW
MAVPO(U$FES1RM<B?/)@AN9(I"K#&5!(!Z'!  !^N>F:GI^LZ?;:MI-S'>65Y
M&LL,T3!XY(W&596'!!'0U>KRCX*_#!O@[X LO (UF;7(;!Y6BFFC6,HDK;S&
MJJ6PH8L1DD\XZ8KU>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]+]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@_P#X
M*(?\D-TW_L.VO_I/<U\I_P#!.;_DLVO?]@"?_P!*[6OLK]NWPKXH\8?!NPTS
MPEI%YK=Y'K-M*T%E;R7,HC6"X4N4C5FV@L 3C'(KYI_8)^&_Q$\'?%G6M2\7
M>%]4T.TET2:%)KZRGMHVD-S;L$#2HH+$*3@'. 3VH PO^"C_ /R4CPK_ -@E
MO_1[UV/[#/P;^%_Q&^&NN:OXX\.6NL7EOJ[P1RSABRQ"WA8*,$<;F)_&C]OS
MX=_$#QEX^\-7OA#PSJ>N6\&F-'))8V4URB/YSG:S1(P!P<X->W?L#^$?%?@[
MX7:[8>+M%O=#NIM9DE2*^MY+:1HS;P+O"RJI*Y!&<8R".U 'O5C^S?\  73I
M1-;> ](9EZ>;:I,/RD#"O8[2SM-/M8K*P@2VMX5"QQQ*$1%'0*JX 'L*LT4
M?FE_P4E_Y%3P5_U^W?\ Z+2N-_X)J_\ (7\??]<-._\ 0IZ]8_X* ^"O&/C/
MPSX0@\'Z%?Z[):WERTJ6%K+=-&K1J 6$2L0"1P37)_\ !/KP%XZ\&:GXVE\8
M^'=1T)+J&P$)O[2:U$I1IMP3S57=C(SC.,C/6@#],Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#\<O^"CO_ "5+PS_V!A_Z4RUU'P[\
M'_\ "9_\$_?$ME&F^XTZZN]1A[D&R=)7Q[F-77\:M?M]?#KX@^,?B/X>O_"'
MAC5-<MH=)$4DMC93W*))Y\K;6:)& ."#@\X-?2W[&G@S6M&^ !\+^-M'NM+F
MNKR^66UO8'MY3#-A>4D"MAAG!QS0!^&4=]>16<UA%,R6]PR/)&#A7:/=L)'?
M;N./K7Z7?LF^#_[._9>^+_C:9-LFM:?J%K&3U,-G92'(]B\K ^ZU\8Z_^SU\
M9]'UW4M(MO ^NWL-C<S0)/#IEU)%,L3E1(CK&596 R""00<BOV%\&_#O4_!_
M['LO@:*QF.KR^&+]I+58V,YO+ZWEE:+8!N,@DDV;<9R,4 ?DM^RA_P G$>!_
M^OT_^BGK]"/^"AGQ*_L+X?Z7\-K"7;=>)9_/N0#R+2T(8 _[\I4CUV,*^.OV
M9OA%\5]!^._@[5]<\%ZWIUA:WA>:XN=.N888U\IQEW>,*HSQR:T_VI_#'QJ^
M*?QJUW6[+P+X@N=+L'&GV#II=T\;6]L2N]&$9!620O(".S4 ?+'A'X??$+QF
M)KOP/X?U'618L@DDL;:6;RF;)7+1@[2<$CZ5WDGP9_:+E1HI?!WB5T<$,IL[
MH@@]005Z5^Q'['_PON_A=\%=-M-8M'LM9UJ1]1O8I4*2QO+A8XW5@&4K$J94
M@%6+#&<U]1T ?R^ZMH_B#PCK4FE:W9W&D:K8LA>&=&AGB8@.I*L RG!##V(-
M?T0_!3XBO\6/A!H?C2SD0:C>VGESY&52]AS'+E1@[?,4L!_=(]:^$?V\_@5X
MJ\0^+]$^(7@/0;W6I=0MS:7\=A;27+I);\Q2NL2L?F1BF3P-@'>NJ_8%@^)W
M@UO$?@#QMX7U?1],N NHVD]]8SVT*S@K%-&'E15W.I1@N?X&- 'S)J'[<G[1
M6G^(?LNJW=I;#3[K9=6L5G$-WDOB2(LX=AG!7(.1V-?LSX1\6^&_'_AFR\4^
M&+M-0TO4H@\;K@\,.4=?X67HRGD'@U^<O[5G[&6O^)?$E[\2OA';17$E_F;4
M-,W".1[@G+S0;L(=_5T+ [LE=Q; ^ ;?P]\>/AT\D5EIOB3PTTI^<117EGO(
M]=H7=Q0!]X?\% O!'PD\/:#HNLZ+96>E>,+V\PT=HBQ-<6?EOYDDL:8!VOL
M<C)R1R,X\P_X)TF]'QFUM8<_9CH4_F^F?M-OL_'KCVS7S3HGP9^.GQ.U@R6?
MAK5]3N[AE#W5W'(B9/ ,EQ/M4<>K=*_8[]EG]G6+X">%;HZK/'>^)=;,;WTL
M7,4:QY\N&(D E5W$LQ W$], 4 ?F?^W=_P G$ZK_ ->=C_Z)%?I!^P[_ ,FV
M^&_^NU__ .E<M?#7[:/PM^)OBGX\:EK'ACPCJ^KV$EI9JMQ9V%Q<0LRQ , \
M:,N0>",\5]^?L=>']>\,?L_^']&\2Z;<Z3J$,MZ7MKN%X)D#W4C*6CD"L,@@
MC(Y!S0!]%ZY_R!=0_P"O>7_T U_,WX-_Y&_0_P#K^MO_ $:M?TSZQ&\NDWL4
M2EW>"15 Y))4@ 5_//X3^"/QGM_%6C3W'@'7XHH[VW9W?2[M551(I)),>  .
MI- ']%-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y%_\%)/^
M1R\&?]>%S_Z-%>N?\$W_ /DG/BK_ +"R_P#HA*Y+_@H!\/O'OC+Q7X3N?!_A
MO4M=AM[*X25["SFNEC8R@@,8D8*2.@-?!UC\)/VA=,1H]-\&>*;17.6$.G7T
M8)]2%C&: /Z-J*_G7_X5O^TO_P!"OXN_\ =0_P#B*^N?V*?!_P 9=#^,SWOC
MK1=?T_3/[,N5\S4K:ZA@\PM'M&Z90NXX.!UZT >$?MPHR?M)>)688#PV!'N/
MLD0_F*_53]D*^M[_ /9S\%R6[A_*MYH6P<[7CGD4@^AXKY:_;B_9N\9>,M?M
MOBI\/]/?5Y!:I;:A9P+NN,PD^7-&@YDRIV,J_,-JD @G'P]\.]1_::\(_:/"
MGPWB\0Z>+USYEI;6T^/,8!2^TH0C8 RXP<#KQ0!ZG^WUK-EJOQ]DM;.596TK
M3+2UFVG.V3,DQ4^X649K] _V%/\ DW/1O^ON^_\ 1[5^7GC_ /9?^._AMM-U
M#5/#^I:]J>N1/=W0LK:>_:W=G(VW$T2NIE;[S#)Z]2<X_5S]C+P[X@\+? 72
M='\3Z9<Z1?QW-ZS6]Y"\$RJTS%28Y K $<C(Y'- 'X26M[_9FOQ:D%W?9+I9
M<>OEONQ^E?TV>']>TKQ3H6G^)-#G%SI^IP1W$$B]&CD4,I]C@\CL>*_F3M=/
MDU;7XM*A8))>W2PJS= 9'V@G'89KZ)USP]^U/\#8[SP$DFNZ9I4C.!_9[SO8
MS!^KPR1_*-_<#:W.& /% #/VQ_$FF^)_VA_%-UI,JS6]FT%D77HTMM"D<H]]
ML@9?PK],/A9HT^E?L-KI[ M)-X7U6=0>I%VEQ.H_*08K\Z?@-^R5\1OBEXDL
M[KQ+I-SH7A:&59+NZNXV@>:,'+1VZN S,_(W@;5ZDY 4_N=)H>E/H;>&Q;(F
MFM;&T\A!M00%/+V #H O ]J /YX?V<[ZWT[X[>!+JZ<1Q#5[5"S' 'F.$&2?
M<U_0AXQUFR\.^$M9U[495@M=/LYYY'8X"K'&6//X5^"'Q;_9F^*GPG\1W5D^
MC7>J:0DC&TU&TA>:*2+/R%S&#Y;X^\K8P<XR,$]_X<\+_M<_M"6]IX(U*[UF
M7P^KIYL^IF2&S55.0TKN TY7J%^=LX('>@#YP^&/_)2O"?\ V%[#_P!*$K]Y
M?CSKGP$N?#L_@/XUZS8VD%_&LZ02R[;I "52>%5S(I#!@K 8."IR,BOQR\%?
M SXP:-\4-!\[P3KIL['6;7=<MI=TD7EQ7"YD+%-H7 W9S@#OBOU(_:W_ &:Y
M_CGH-EK/A>2.#Q3H:NL"R$+'=P.0QA=_X2"-T9/ )8' ;<H!\50?L4:!\3-(
MN/%?[/GCZWUW24GDMPFI02VSI)& 2AD5,L<,"#Y*@Y!''-?*OQ7^"7Q&^"FH
M6=CX]T];0:@)&M9HI4EBF$17?M9"2"NY<A@#R#C!KO/#\'[4G[/6IWL?A_3M
M:\.O*0LX6S-Q:2E>C?,DL$F,\,,]P#5C4?"?[4O[1?B&RF\0:7K&M3J"D,]W
M;&TLH$;!8AF2."/. 3C!; X)Q0!^C'[!OQ/\1^/OAEJ.B>*+M[^Y\,W200SR
MDM(UM*FZ-'<DEBA# $]%VCM7W-7SY^S5\$(O@3\.8_#5Q.MYJ]]*;S4)D_U9
MG957RXR0"4C50 3U.6P,X'T'0 4444 %%%% !1110 4444 %%%% !1110 44
M44 ?_]/]_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH _F1\+_\CYI'_82M_P#T<M?TW5YY'\(_A1#<)=P^"]$2=&#K(NG6
MP<.#D,&$>00><UZ'0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!__U/W\HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH __5_?RBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_];]_***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHK&\1^(=&\)>'M4\5>([I;'2=&M9[V\N'!*
MPV]LADED(4$X5%). 3Q0!LT5R_@OQKX6^(GA73?&W@K4(]5T/5XO/M+J,,$E
MCR1N 8!L9!Z@5C>'/BK\/?%WC/Q)\//#FM0WWB+P>8!JUF@<26AN5+1;RRA3
MO )&TF@#T&BO/O&GQ5^'OP\U?PUH/C36H=*O_&%ZNG:3%('+7=VQ4")"JL Q
M++]X@<]:]!H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_U_W\HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!_]#]_**** "BBB@ HHHH **** "BBB@
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MM"[O]'7[-<>:B_=9]R_O Z[?ER?E_P#X?DQ?]$4?_P *'_[W5^^M% 'X%?\
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MT4 ?@5_P_)B_Z(H__A0__>ZC_A^3%_T11_\ PH?_ +W5^^M% 'X%?\/R8O\
MHBC_ /A0_P#WNH_X?DQ?]$4?_P *'_[W5^^M% 'RK^QY^TZG[6?PDD^*2>%;
MCPCY.I7&G&UGG^TK(8$C?SH9O+BWQGS-I.P8=77G&3]5444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]']_**** "BBB@
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M7X8?\..?#?\ T5Z[_P#!-'_\ET?\..?#?_17KO\ \$T?_P ET ?N?_;>B_\
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M /?U/\:/[;T7_G_M_P#OZG^-?AA_PXY\-_\ 17KO_P $T?\ \ET?\..?#?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#[+XC^+#KVIRZT;B6%EFERVE63-YBP"3S&$9;:<A1Y@(VOP_Q>_;Y^.NE_M
M>'O$%SXG\/>,;[X;7&K0V6J:2MTFCW\>I1E$,T2^7YRVN[Y2BX;;]Z3[[?T,
M_#O]D3X-?#OQ-XJ\60V#Z_?>*/$LGBL'5DMK@:;J;NSAM/*P1M"JEL+EF8
M;C5?7/V./@?K'Q%\%?$6UTH:._@?^U3;Z780VL.EWC:S&8[MKR P,92X8]'7
M/\61Q0!V/[,OB[Q!X[^!'@_Q7XJ\4:5XSU?4+0M<ZMHH*V-U(LC*3&K)&59<
M;) 43$BL-B_='NU8?AKPSX>\&Z#8^%O">FV^D:/ID8AM;2UC6&"&->BHB@ #
MZ5N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
MTOW\HHHH **** "BBB@ HHHH *_#/]C+_E*O^T5_UY:S_P"G2QK]S*_#/]C+
M_E*O^T5_UY:S_P"G2QH _<RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&^*?_!?;?_)=?:__  Q[^RA_T1[PE_X);/\ ^-4?\,>_LH?]$>\)?^"6S_\
MC5 'Q1_P^7_9+_Z!OBG_ ,%]M_\ )='_  ^7_9+_ .@;XI_\%]M_\EU]K_\
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M17_7EK/_ *=+&@#]S**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K\,O^"(/_(B_%7_L)Z=_Z)FK]S:_
M#+_@B#_R(OQ5_P"PGIW_ *)FH _<VBBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8?V($AF2;_A??Q:?8P;:WBQBIP<X(\CD'O7W$.!BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^%'QR_X*X:E\4O!VG>.]&\0)X:NM9T^+5&E\+6D$:V+W"+<%Y5LU**(BV6#
MJ.01C- ']#5%%% !7Y^?\%2O^3%OB1_O:-_Z=[.OT#K\_/\ @J5_R8M\2/\
M>T;_ -.]G0!W'_!/7_DS#X4_]@IO_1\M?9=?&G_!/7_DS#X4_P#8*;_T?+7V
M70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?#'_  3B_P"33O#_ /V%?$7_ *>;RON>
MOAC_ ()Q?\FG>'_^PKXB_P#3S>5]ST %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %?AE_P1!_Y$7XJ_\ 83T[
M_P!$S5^YM?AE_P $0?\ D1?BK_V$]._]$S4 ?N;1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)IHQ'>26Z7'R0.%9F"JH^7.W&?TUKY'_ &RO&/[+G@[X807?[56GVFL:%+=
M6%C-:F[N9[P(V!:HOS+($+ ON0 '#, >0#Z<\.>)O#?C'1K;Q'X2U6UUK2KQ
M=\%W93I<02KZI)&65A]#6Y7XJ> _V;OBI>7T?C/]CKP%JO[-EG>2).;KQ!X@
MEE6^BR.+CPZT5^N<9PLLT17J..OO_CSPM_P50M;R)O _C7P#J5FH4$FPGLY6
M(QDM'*MPN#U.V7Z =* /TLHKF?!:^+4\(:(GCY[23Q,ME;C4VL-_V,WHC'GF
M#S '\HR;MFX9QC-=-0 5^&?[&7_*5?\ :*_Z\M9_].EC7[F5^&?[&7_*5?\
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M^"<7_)IWA_\ ["OB+_T\WE?<]?#'_!.+_DT[P_\ ]A7Q%_Z>;RON>@ HHHH
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M.C_P7!_Y'_X6?]@S4?\ T?%7C?PT_P"2=>%_^P79_P#HE:]D_P""X/\ R/\
M\+/^P9J/_H^*O&_AI_R3KPO_ -@NS_\ 1*U]#P]\<O0_?/ /_?,3_A7YG;44
M45]6?U %%%% !1110!\#_M8_\CII'_8/'_HV2O[ /@5_R1'X>_\ 8NZ3_P"D
MD5?Q_P#[6/\ R.FD?]@\?^C9*_L ^!7_ "1'X>_]B[I/_I)%7P>:?[Q,_AWQ
M+_Y'N*_Q?HCU2BBBO//A0HHHH **** "BBB@ HHHH **** /_]/]_**** /S
M\_X**?LTZY^U!\*/#O@W0?$ND^&)]+UM+]I]8E>&"1%MIXMB,BN=^9 0,= >
M:_*W2/\ @C-^T=I\D>JZ#\2/#EL[IE)[:>_0E''\+I;C((]#@U]??\%LO^3>
M?!/_ &-,?_I#=5T?[6WCOQK\.?\ @F7X#\3> ->OO#>KQZ7X3C6\TZYDM;A4
MDMH@ZB2)E8!AU&>: /D/_AT=^U]_T5_2_P#P/U3_ .,U^NO[$_P$^('[./P7
M;X=_$KQ!!XEU@ZG=7GVNWEGF3RIEC"INN%5\@H>,8YXK3_8B\2>(?&'[*'PS
M\3>*]3N=9U?4-*62YO+R5Y[B9_,<;I)')9C@#DFOJB@ JE=Z9IVH%3?VD5R4
MSM\U%?&>N-P.*NT4 8W_  CGA[_H%VO_ 'X3_"OQ'_8LAAM_^"J?[1$,$:QQ
MI8ZR%50  /[4L> !TK]T:_#/]C+_ )2K_M%?]>6L_P#ITL: /W,HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^&?^"CW_ ":1XG_[
M"7AW_P!/5G7W-7PS_P %'O\ DTCQ/_V$O#O_ *>K.ON:@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P",4 ?<U%4M-O[?5=.M=4M X@O(DFC$L;12!)%##=&X5T;!Y5@"#P0#5V@
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M8U^YE?AG^QE_RE7_ &BO^O+6?_3I8T ?N91110 4444 %%%% !1110 4444
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MX([+_P"1Z]SHH_U=7\_X!_Q "E_T%O\ \ _^V/#/^'H'[>__ $,J?^".R_\
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M,:_/?]GW_DD'A_Z7/_I3+7N\/_QGZ?JC]L\"/^1M5_Z]O_TJ![+1117UY_6
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M* "BBB@ HHHH **** "BBB@ KY#^&O\ R=_\8_\ L&Z!_P"DYKZ\KY#^&O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M $N?_2F6OT(_X+=_\DE^&_\ V'+G_P!)C7Y[_L^_\D@\/_2Y_P#2F6O=X?\
MXS]/U1^V>!'_ "-JO_7M_P#I4#V6BBBOKS^L HHHH **** /B[]KSKX3_P"W
M[_VA7]/?["7_ "9[\)?^P!:_R-?S"?M>=?"?_;]_[0K^GO\ 82_Y,]^$O_8
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MG0!W'_!/7_DS#X4_]@IO_1\M?9=?&G_!/7_DS#X4_P#8*;_T?+7V70 4444
M%%%% !1110 4444 %%%% !1110 4444 %?Q6^#_^3L=4_P"PQK?\KBO[4J_B
MM\'_ /)V.J?]AC6_Y7%=6!_C0]5^9]+P;_R-\'_U\A_Z4C[VHHHK]"/[W"BB
MB@ HHHH H:K_ ,@N\_ZXR?\ H)KF?^",G_)V.K_]BIJ'_I79UTVJ_P#(+O/^
MN,G_ *":YG_@C)_R=CJ__8J:A_Z5V=?,<1;P^?Z'\V>/_P >#])_^VG]2-%%
M%?-'\[!7@?[5G_)KOQA_[$WQ!_Z;IZ]\KP/]JS_DUWXP_P#8F^(/_3=/0!_+
M[^P)_P C9XK_ .O&#_T::_4*OR]_8$_Y&SQ7_P!>,'_HTU^H5>KAO@1E/<**
M**W("BBB@ KP']J3_D@GB[_KA#_Z415[]7@/[4G_ "03Q=_UPA_]*(JBI\+&
MMSV/_@AY_P B9\6/^PAI7_HJXK]UZ_"C_@AY_P B9\6/^PAI7_HJXK]UZ\8W
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OD/X:_\G?\
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M_#3_ ))UX7_[!=G_ .B5KZ'A[XY>A^^> ?\ OF)_PK\SMJ***^K/Z@"BBB@
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M@1E/<****W("BBB@ KP']J3_ )()XN_ZX0_^E$5>_5X#^U)_R03Q=_UPA_\
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MX(@_\B+\5?\ L)Z=_P"B9J_<VOPR_P""(/\ R(OQ5_[">G?^B9J /W-HHHH
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MG_SUNO\ OXO_ ,17E7Q(\(:5X3EL$TQI6%RLA;S6#?<*XQ@#UKZLKY]^-_\
MQ\:1_NS?S2OF.,,AP=#+ZE6E22DK:I>:-\+6FYI-G]='[%7_ ":1\(?^Q8TS
M_P!$+7T]7S#^Q5_R:1\(?^Q8TS_T0M?3U?BAZP4444 ?SH_\%P?^1_\ A9_V
M#-1_]'Q5XW\-/^2=>%_^P79_^B5KV3_@N#_R/_PL_P"P9J/_ */BKQOX:?\
M).O"_P#V"[/_ -$K7T/#WQR]#]\\ _\ ?,3_ (5^9VU%%%?5G]0!1110 444
M4 ? _P"UC_R.FD?]@\?^C9*_L ^!7_)$?A[_ -B[I/\ Z215_'_^UC_R.FD?
M]@\?^C9*_L ^!7_)$?A[_P!B[I/_ *215\'FG^\3/X=\2_\ D>XK_%^B/5**
M**\\^%"BBB@ HHHH **** "BBB@ HHHH __2_?RBBB@ HHHH **** "BBB@
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MI?\ V2>\_P#3[!7W/7PQ>?\ *2K2_P#LD]Y_Z?8*^YZ "BBB@ HHHH ****
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MMXN^'<&H:WKES+>7MP;V_C,T\S%G<K'<*@+,2<*H'M7V/10!\*?\.T/V'_\
MHE]O_P"##4O_ )*K[)\(>$_#W@/PMI/@KPE9C3]%T.UBLK*W5G<0V\"A(T#2
M%F.U0!EB3ZFNBHH **** "OPR_X(@_\ (B_%7_L)Z=_Z)FK]S:_#+_@B#_R(
MOQ5_[">G?^B9J /W-HHHH *_!O\ X+C_ /(O?"#_ *^M:_\ 0+2OWDK\&_\
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MOYA/VO.OA/\ [?O_ &A7]/?["7_)GOPE_P"P!:_R-?#9Q_O,OE^2/XJ\6_\
MDH<3_P!N?^D1/K*BBBO,/S@**** "BBB@ HHHH **** "BBB@ HHHH ****
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MRAXV^&OPS\<_VSXDU<Z8;6T_LS4K?S/L^HVT\G[RXMHXUVQQLWS,,XP,D@4
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M==-JO_(+O/\ KC)_Z":YG_@C)_R=CJ__ &*FH?\ I79U\QQ%O#Y_H?S9X_\
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M )$S2O\ KF?_ $(UV=?T]DW^YT?\,?R1\_6^-^H4445Z1F%%%% !7S[\;_\
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M!!&L442#5+'"HB@*JCT Q7[MU^&?[&7_ "E7_:*_Z\M9_P#3I8T ?N91110
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M_A^%X%_Z)5J7_@SA_P#C-'_#\+P+_P!$JU+_ ,&</_QFOR5_X5OX)_Z!:?\
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M2[\\'S8[E<8]MGZU^[E?AE_P1!_Y$7XJ_P#83T[_ -$S4 ?N;1110 5^#?\
MP7'_ .1>^$'_ %]:U_Z!:5^\E?@W_P %Q_\ D7OA!_U]:U_Z!:4 ?E9\/?\
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MN_ZX0_\ I1%7OU> _M2?\D$\7?\ 7"'_ -*(JBI\+&MSV/\ X(>?\B9\6/\
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M$S4 ?N;1110 5^#?_!<?_D7OA!_U]:U_Z!:5^\E?@W_P7'_Y%[X0?]?6M?\
MH%I0!^5GP]_Y$S2O^N9_]"-=G7&?#W_D3-*_ZYG_ -"-=G7]/9-_N='_  Q_
M)'S];XWZA1117I&84444 %?/OQO_ ./C2/\ =F_FE?05?/OQO_X^-(_W9OYI
M7R/'7_(KJ_\ ;O\ Z4CJP?\ $1_71^Q5_P FD?"'_L6-,_\ 1"U]/5\P_L5?
M\FD?"'_L6-,_]$+7T]7\^GM!1110!_.C_P %P?\ D?\ X6?]@S4?_1\5>-_#
M3_DG7A?_ +!=G_Z)6O9/^"X/_(__  L_[!FH_P#H^*O&_AI_R3KPO_V"[/\
M]$K7T/#WQR]#]\\ _P#?,3_A7YG;4445]6?U %%%% !1110!\#_M8_\ (Z:1
M_P!@\?\ HV2O[ /@5_R1'X>_]B[I/_I)%7\?_P"UC_R.FD?]@\?^C9*_L ^!
M7_)$?A[_ -B[I/\ Z215\'FG^\3/X=\2_P#D>XK_ !?HCU2BBBO//A0HHHH
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M"F_]'RU]EU\:?\$]?^3,/A3_ -@IO_1\M?9= !1110!_(?\ \%)_^4@'C_\
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MV$-*_P#15Q7[KUXQN%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT?\ @N#_ ,C_ /"S_L&:C_Z/BKQOX:?\DZ\+_P#8+L__ $2M>R?\%P?^1_\
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M?9=?&G_!/7_DS#X4_P#8*;_T?+7V70 4444 ?R'_ /!2?_E(!X__ .OG0_\
MTUV59=:G_!2?_E(!X_\ ^OG0_P#TUV59=?K_ (8_PZ_JOU/,S#=!1117ZB><
M%%%% !1110!SG[(O_)]GP\_[&J+_ -&-7]D]?QL?LB_\GV?#S_L:HO\ T8U?
MV3U_+F9?[Q4_Q/\ ,^BA\*"BBBN(H*_BM\'_ /)V.J?]AC6_Y7%?VI5_%;X/
M_P"3L=4_[#&M_P KBNK _P :'JOS/I>#?^1O@_\ KY#_ -*1][4445^A'][A
M1110 4444 4-5_Y!=Y_UQD_]!-<S_P $9/\ D['5_P#L5-0_]*[.NFU7_D%W
MG_7&3_T$US/_  1D_P"3L=7_ .Q4U#_TKLZ^8XBWA\_T/YL\?_CP?I/_ -M/
MZD:***^:/YV"O _VK/\ DUWXP_\ 8F^(/_3=/7OE>!_M6?\ )KOQA_[$WQ!_
MZ;IZ /Y??V!/^1L\5_\ 7C!_Z--?J%7Y>_L"?\C9XK_Z\8/_ $::_4*O5PWP
M(RGN%%%%;D!1110 5X#^U)_R03Q=_P!<(?\ THBKWZO ?VI/^2">+O\ KA#_
M .E$514^%C6Y['_P0\_Y$SXL?]A#2O\ T5<5^Z]?A1_P0\_Y$SXL?]A#2O\
MT5<5^Z]>,;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MR'\-?^3O_C'_ -@W0/\ TG-?7E?(?PU_Y._^,?\ V#= _P#2<UZ.!^"M_A_]
MNB?6\,_[MF'_ %Y_]RTCZ\HHHKSCY(**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K\,O^"(/_(B_%7_ +">G?\ HF:OW-K\
M,O\ @B#_ ,B+\5?^PGIW_HF:@#]S:*** "OP;_X+C_\ (O?"#_KZUK_T"TK]
MY*_!O_@N/_R+WP@_Z^M:_P#0+2@#\K/A[_R)FE?]<S_Z$:[.N,^'O_(F:5_U
MS/\ Z$:[.OZ>R;_<Z/\ AC^2/GZWQOU"BBBO2,PHHHH *^??C?\ \?&D?[LW
M\TKZ"KY]^-__ !\:1_NS?S2OD>.O^175_P"W?_2D=6#_ (B/ZZ/V*O\ DTCX
M0_\ 8L:9_P"B%KZ>KYA_8J_Y-(^$/_8L:9_Z(6OIZOY]/:"BBB@#^='_ (+@
M_P#(_P#PL_[!FH_^CXJ\;^&G_).O"_\ V"[/_P!$K7LG_!<'_D?_ (6?]@S4
M?_1\5>-_#3_DG7A?_L%V?_HE:^AX>^.7H?OG@'_OF)_PK\SMJ***^K/Z@"BB
MB@ HHHH ^!_VL?\ D=-(_P"P>/\ T;)7]@'P*_Y(C\/?^Q=TG_TDBK^/_P#:
MQ_Y'32/^P>/_ $;)7]@'P*_Y(C\/?^Q=TG_TDBKX/-/]XF?P[XE_\CW%?XOT
M1ZI1117GGPH4444 %%%% !1110 4444 %%%% '__T/W\HHHH **** "BBB@
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M_;CZ>3BA_P!EW]F:1!')\(_"#(,8!T#3R..G'DT?V[7\ON'_ ,1MSO\ N?\
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M4_"3PB7 P&_L'3\@>F?)H'[+W[- D,H^$GA$.1@M_8.GY(],^36)Y!\(1_\
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MQU%9_P#PL#P;_P!!6+_Q[_"OZ,?^'6G["_\ T3AO_!SJ_P#\F4?\.M/V%_\
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M?^BK:3_Y'_\ C5<'_P .M/V%_P#HG#?^#G5__DRC_AUI^PO_ -$X;_P<ZO\
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M /)E>?CLPE7MS+8^$XSXZQ.=ND\1",>2]N6_6V]V^QWG_#P?]C'_ **MI/\
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M[5]:T %%%% !1110 4444 %%%% !1110 4444 %%%% !7R'\-?\ D[_XQ_\
M8-T#_P!)S7UY7R'\-?\ D[_XQ_\ 8-T#_P!)S7HX'X*W^'_VZ)];PS_NV8?]
M>?\ W+2/KRBBBO./D@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***_+_P#:H_X*:>&_V7?BY=_";4_ 5]X@GM;6VNC=P7D<*,+E
M-P78T;'*_6@#]0*_#+_@B#_R(OQ5_P"PGIW_ *)FH_X?>>"_^B3ZI_X,8O\
MXS7P#^P7^WGHG['F@>,-%UCP==>)F\275K<(]O=);B'[.CH58-&^<[L@T ?U
MET5^%$/_  7 \*-;&2;X1WZS 'Y5U6-DXZ?.;<'Z_+Q[TG_#\'PK]C\W_A4=
M_P"?MSM_M:/R]WIO^S9Q[[?PH _=BOP;_P""X_\ R+WP@_Z^M:_] M*NS?\
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M-7 'KYZ__$4']K/3%QN\-7 S_P!-U_\ B*?]KX?^?\_\A_\ $5,@_P"@I?\
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MH2&.&&82"01Q#.)0"N#C&<G(H ^O**** "BBB@ HHHH **** /_1_?RBBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^-G_  5JO_AQXJL?&WPPL+/P[<:3?1ZE.EI"&BLG@<7#@B\8@K&6(P"?8]*
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M^WI\6O"?[)G[,FG_ -LZ'H6H&5]1C!^S3W"(8&N%(X2SM8V?]Z?O[CM!&PN
M?T0>#_%6B^.O"6B^-O#<QN-)\065MJ%G(05+V]U&LL3$'D$HP..U=%7#?#'P
M-8?##X;^%OAOIDIGM/"VEV6EQ2L-K2+9PK"'(YP6V[CSU-=S0 4444 %%%%
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M HHHH **** "BBB@ HHHH **** /D/\ 8M_Y)AKW_8SZS_Z.%?7E?(?[%O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^0_V+?^
M28:]_P!C/K/_ *.%?7E?(?[%O_),->_[&?6?_1PKZ\KT<W_WFIZGUO'G_(YQ
M7^-A1117G'R04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\A_#7_D[_XQ_P#8-T#_ -)S7UY7R'\-?^3O
M_C'_ -@W0/\ TG->C@?@K?X?_;HGUO#/^[9A_P!>?_<M(^O****\X^2"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__6_?RBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^0_V+?^28:]_P!C/K/_ *.%
M?7E?(?[%O_),->_[&?6?_1PKZ\KT<W_WFIZGUO'G_(YQ7^-A1117G'R04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5\A_#7_D[_XQ_P#8-T#_ -)S7UY7R'\-?^3O_C'_ -@W0/\ TG->
MC@?@K?X?_;HGUO#/^[9A_P!>?_<M(^O****\X^2"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#__7_?RBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ^0_V+?^28:]_P!C/K/_ *.%?7E?(?[%O_),->_[
M&?6?_1PKZ\KT<W_WFIZGUO'G_(YQ7^-A1117G'R04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\A_#7_D
M[_XQ_P#8-T#_ -)S7UY7R'\-?^3O_C'_ -@W0/\ TG->C@?@K?X?_;HGUO#/
M^[9A_P!>?_<M(^O****\X^2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#__0_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^8/V3O"_B+PG\/=:T[Q-IT^F7,WB'5;A([A#&S0RR@HX!_A8<@]Z^GZ
M**ZL=4<ZTI/JSV^),9+$8^M6GO*3>@4445RGB!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S!X!\+^(K
M#]J'XJ>*+W3IX-(U6PT2.TNW0B&=X(2LBH_1BAX..E?3]%=6&J.,:B756_%/
M]#W,HQDJ5+%1C]N%GZ<\'I\T@HHHKE/#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ck0001824293-20241231_g5.jpg
<TEXT>
begin 644 ck0001824293-20241231_g5.jpg
M_]C_X  02D9)1@ ! 0  2 !(  #_X0! 17AI9@  34T *@    @  8=I  0
M   !    &@       J "  0    !   '-: #  0    !   "X0    #_X@)
M24-#7U!23T9)3$4  0$   (P041"10(0  !M;G1R4D="(%A96B 'T  (  L
M$P S #MA8W-P05!03     !N;VYE                        ]M8  0
M  #3+4%$0D4
M              IC<')T    _    #)D97-C   !,    &MW='!T   !G
M !1B:W!T   !L    !1R5%)#   !Q     YG5%)#   !U     YB5%)#   !
MY     YR6%E:   !]    !1G6%E:   ""    !1B6%E:   "'    !1T97AT
M     $-O<'ER:6=H=" R,# P($%D;V)E(%-Y<W1E;7,@26YC;W)P;W)A=&5D
M    9&5S8P         1061O8F4@4D="("@Q.3DX*0
M
M                            6%E:(        /-1  $    !%LQ865H@
M                     &-U<G8          0(S  !C=7)V          $"
M,P  8W5R=@         ! C,  %A96B        "<&   3Z4   3\6%E:(
M     #2-  "@+   #Y5865H@        )C$  ! O  "^G/_  !$( N$'-0,!
M(@ "$0$#$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U
M$  " 0,# @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!
M%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:
M8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.T
MM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_
MQ  ? 0 # 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$
M!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*
M%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ
M<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"
MP\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_VP!#  (" @("
M @," @,% P,#!08%!04%!@@&!@8&!@@*" @(" @("@H*"@H*"@H,# P,# P.
M#@X.#@\/#P\/#P\/#P__VP!# 0(" @0$! <$! <0"PD+$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_W0 $ '3_
MV@ , P$  A$#$0 _ /W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /_T/W\HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"0!D\ 4 +10""
M,BB@ HHHH **** "BD)"C+' ]Z6@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HI 0PRIR#Z4M !1110 4444 %%%% !1110 4444 %%%% !1110
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M?5Z /V[HKS#X,?$.V^*OPQ\/^.H"OFZC;+]I1>D=U'^[G3'8"16Q[8/>O3Z
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M?36__!Q'_P#)->F_\$W_ /DH?BS_ +!2?^CUK]@: /PQ_P"%"?ML?\^FM_\
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MBS?:+0,3@>:2J/$/?# =6('- 'Z%T5'%+%/$D\#B2.0!E93E64\@@C@@BI*
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M^\5O!,F2NZ.6\VN,J01D$C((/I7ZR_\ #%'[,W_0GG_P8W__ ,D4 ?,FN_\
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MLY'ZT ?KOX'_ &>/@YX!T&+0=)\+V-TJH%EN+RWCN;B<XY:22123D\[1A1V
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MN=4\/3OIDTKG<\J1*KPNQ/)/EN%)/)*DGFOS4\>_\GN2?]C?9?\ I3%7U_\
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MS/*=\#2$EM\:8X?C&:^YJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_T_W\HHHH ***
M* "BBB@#\"/VT_\ DYGQG]=/_P#2"WK]';;]O;]G^.WBC>XU(,J*#_H9Z@?[
MU;WQ/_8M^%OQ8\<ZG\0/$6J:S;:CJOD^;':3VZ0CR(4A7:LEO(PRJ G+'G/3
MI7 _\.Z/@E_T&_$/_@3:?_(E '3_ /#?/[/O_/SJ7_@$?_BJ]:^$G[2'PR^-
M>J7VC>!Y[I[K3X1<2K<6YB'EE@F0<D'!(X]Z^?O^'='P2_Z#?B'_ ,";3_Y$
MKVCX)_LN?#_X#ZWJ&O>$-0U.\N-1MQ;2+?2P2($#A\J(H(B#D=R1CM0!^9G[
M??\ R<!-_P!@RS_]GK]K/#G_ "+VE_\ 7K!_Z *^;_B_^R%\-/C5XP/C7Q3J
M.K6E\T$5N4LIH$BVQ9VG$D$C9YY^;'M7U#9VL5E:064.?+MT6-<\G:@P,_E0
M!\2?M[?#?_A,/@^GBZRBWW_A"<7&0,L;2?$<X'T.QSZ!#7Y&:?=>+OBGJ/@S
MX<I+]H:T*Z5IR8.$%U<O(2WT:4Y/&$4#H*_I"UO1]/\ $.C7^@:M$)K'4H);
M:=#_ !13*4<?B":^6OA=^Q=\)_A-XUL?'>A7NJW^H:<)/)2^FMY(5:5#&7VQ
MV\9W!6./FP#SC.* /IKPKX<TWP?X9TKPII";++2+6&UA'?9"@0$^YQDGN:^!
M?^"@WPDU+Q-X7TGXGZ% UQ+X<$D%^B#+"SE(99<==L3YW>@?<>%)K]&:9)''
M+&T4JAT<%65AD$'@@@]0: /RA_9"_:\\+^#_  M!\+_BG=/8V]@S_P!G:@5+
MQ+"QW>1-M!9=K$[&P1@[3MVC/UE\1_VR/@GX)\.3ZEHNNV_B75&C/V6RL6,A
MDDQ\OF2 %8US]XL<XSA2>*Y+XA?L&?!GQEJ$NKZ$]WX5N9VW/'9%&M23U(AD
M4[?HC*H[+7#:+_P3B^'%K<++KWBC4]0C5@?+A2&V# '[I)60X/0XP?3% 'SC
M^RMKGQR^,/QNBU*?Q3K(T.TN6U+5Q'=SK:8+%T@\O=Y8$K@($ X3=CA:^T?V
M^/\ DWRZ_P"PC9?^A-7T]X#^'G@SX9:"GAKP-I<6E:>C;RD>2TCD %Y'8EG8
M@ ;F). !TK%^+GPH\.?&?P;+X(\4W%U;6,LT4Y>S=$F#Q'*X,B2+@YY^6@#Y
M _X)Q?\ )*O$O_8:;_TFAK]#:\;^"OP/\)_ CP]>^&_"%U>W=M?W1NY'OI(Y
M) Y1(\*8HXAMP@[$Y)YZ8]DH **** /Y_P#QU_R=_J7_ &./_MZ*_H KY!U7
M]BKX5ZQ\29OBC=:GK*ZI/J0U5H4GMQ;>>)1-M"FW+["PZ;\X[]Z^OJ "BBB@
M#YK_ &OM"U/Q%^SKXPL-(1Y9XX;>Y*("Q:.VN(II.!SPB%OPK\W?V&?B]\/O
MA;XQUZU\>3IIO]NV\$5M?R ^7$T+L6B=@#L63<IW'Y04&2.*_;5E5U*L 01@
M@]"*^'/B!^P-\'_%^JS:QH%Q>>%Y;C+-!:%)+7<>2RQ2 E<_W5<*.P% 'L'B
M_P#:H^ G@_29-4N/&%CJC*I*6^FS)>SR-C(4+"6"D],N54=R*_#OXT_%'4?C
M'\1]6\>W\/V5;UE2W@SN\FWB4)&F>YP,L>A8D@ <5^H/A?\ X)U_"W2[V.Z\
M3ZYJ.N1QD'R%V6L3XZAR@:3!_P!EU/O7L_Q)_9%^#_Q)TG0-#EM[GP]9^&TF
M2UCTEH8 5G*%A)YD4NXY3.>N222<T >N?""]AU'X3^#+Z!PZ3Z-I[ @YZVZ9
M_(\&OQ5^/6HCP5^UWK.OW\3O'I>N6>H,BXW-&ODW "YP,LO3/K7[9_#/X?:5
M\+/!.F^ ]$N[J^L-*$BPR7KI)/MDD:3:6C2-2%+$+A1@ "O(?C5^RE\,/C?J
M2>(-=%SI>MI&(C>63JK2HGW1*CJZOM' . V.,X   .S^%_Q_^%?QCN[K3_ &
MKM?W=C"D\\3V\T#1HYVCF5%5L'@[2:_(?X!_\GDZ9_V&]2_]!GK].?@9^RCX
M,^ _B.\\4>'M8U+4+N]M&LW2Y:'R?+9TDW;4C5MP*#!W8P3Q5+PC^QQ\,/!?
MQ,@^*NEZEK$NK074]VL4T]NUMYEP'# JMNK[1O./GSTR30!]95^6W_!2W_4_
M#O\ WM6_E:5^I->!_'']G7P3\?ET5?&-[J%F-"-P8/L$D,>[[3Y>_?YL4N<>
M4,8QWSGC !R/[+>CV7B+]E/PUX?U)=UIJ>GWUK,!U,<T\Z,/R)K\G_#^I>,_
MV1_CWYFI6SO/HLSPW$6=B7UA+QE#R-LB8=#SM8#(RI%?NE\-_ .C_"[P3I?@
M/0)I[C3])1TB>Z9'F822-(=Q144\L<84<5SOQ7^"'PX^-&FQV'CK3!<2VX(M
M[N)O*NH-W79(.Q[JP92>2N: .%T#]KO]GS7=$36SXMM].R@>2VO T5S&3U0Q
MX.XCI\A8>A(K\S_VO/VDK/XYZUIWA/P.LS>&](E9T=E*M>W3_(L@C^\%521&
M#ACN8D#( ^HKK_@F[X&>[WV7C#48K7/^KD@ADDQZ;QL&??9^%?0GPB_9'^$'
MP@OX==TRSEUC6X,F.]U!A(\1/>*-56-#Z-M+C^]R: +/[)OPIO\ X1_!O3M%
MUN'[/K.IR2:A?1]3'+. $C/^TD2HK#H&SCUK\MO'O_)[DG_8WV7_ *4Q5^[U
M?)FK_L;_  QUKXI'XN76IZPNL-J46J>4DUN+;SHG615VFW+[,J,C?G'>@#K?
MVH_A9>?%WX-ZOX:TA/-U:U9+ZQ3CY[BWS\@SW=&=!R.6&>,U^6W[)?[1<7P$
M\2:EX;\;13CP[J\BBX"J3)9749V>:8SR1CY9%'S<*0"5VG]SZ^8OB_\ LD_"
M/XQ7\FNZI:S:/K<W^LO=/98WF(& 94961SZMM#$<;NE %S6?VN/V>]'T1];_
M .$PMKY0C,EO:AY+F0@<*(L J3T&_:/4@5^0WC7Q!XS_ &M?CLKZ)9LL^KR)
M:V-NS;EM+.+/+L!PJC=)(1W+8["ONBT_X)N^!DNM]]XPU&:WS]R."&-\?[YW
MC_QVOL?X4_ [X;?!BPEL_ NE"VFN0!<7<K&6ZFQT#R-T7OM4*N>0N: .'^-7
MP*M/&W[/[_"CP\H6XT6TMO[*W' \ZQ0+&I/0>8@9"3TW9K\OOV8?VBK[]G+Q
M+JOA;QGIUP^AW\X6]@"[;FRNHLH9!&V,G'RR(<'@$'*X;]C?BM\3] ^#_@NZ
M\=>)H+FXT^TDAC=+1$>7,SB-2 [HN 3S\P_/BOF:T\)_LQ?MH6U_XKL-.N(M
M4T]TAN;F,?8KT%URGF %XY 0" S!B,$ C% $GC#]O;X':+X?EO\ PK<W'B'5
M"F8;-;>:V&\]!++,BJH'<KO/H#7XW:YXGUCQKXXN?%NORF;4=7O?M,S=MTCY
MPH[*!PH[  5^ROAW]@3X":'J*:A>+JFMK&VX07MTGDY'(R((H6(]BV#WS7YN
M?%T:)XY_:JNM)\%0Q+IL^KZ?I5I';*JP@6RPV>(POR[,QG;CC'(XH _?NOBG
M]N[X;_\ ":_!B3Q+9Q;]0\(S"]4@98VTF([A1[ ;9#[1U]K5YS\7O$F@^$?A
M?XHU_P 3QI/IMMI]P)87.%G\Q"BP_65F"#ZT ?SU1:UXM^(-IX/^&,)^TIIL
MTEIID//$FHSAF'_ G(K^C#P+X2T_P'X-T7P9I0_T71K2*U4XP7,:@,Y]W;+'
MW)K\=/V!_AL?%_Q>D\8WL6_3_"$!G!(RIN[@&. ?@-[CT*BOVVH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _!+]
MCW_DZ?PK_P!=M2_](KFOWMKY'^&_[&7PN^%WC^P^(WA_4]8N-2TYIWCCNI[=
MX";B)XFW*ENC'"R''S#G&<]*^N* / _VCO@GI_QQ^'-UX=(2+6;+-SIEPW'E
MW*C[C'^Y*/E?TX;!*BOY[M4TS4-%U*ZT?5K=[6]L97AGAD&'CEC.UU8=B",&
MOZC:^3_BO^QM\)?B]XOF\;ZW/J6F:C=1HDXTZ6"*.9HQ@2.LL$IWE<*2" 0!
MQG)(!9_9T\1:;X1_91\.>*=8?R['2-*N;J8]]D,DKG'N0, =S7Y0?!W0=2_:
M%_:1L9]>3SUU;4I=5U(=4%O&QGD3V5L")?3<!7[*WGP"\)W?P6B^!(U'4H-
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M,"9[() ) /K(U+X0_P"">?PDT2]CO?%&J:AXB6/_ )=V9;6!C_M"+]Y^4@H
M^;O^"?OPEU/6_'L_Q9U&W*:1H$<L%K*W_+6]G78VSU$<3-N/8LN.^-/_ (*1
M_P#(\>#_ /L'3_\ HZOUGT?1M)\/:7;:)H5G%86%F@CA@@01QQH.@55P!7@O
MQM_9B\ _'K5-,U?Q??:E9SZ5"\$0L)88U9';<=PEAER0>F"* .F_9V_Y(1X!
M_P"P+9?^BEKJ_B=X)M_B/\/O$'@:Y<1+K-G+ LA&1'*1F-\=]KA6_"M;P;X5
MT[P-X3TCP=I#RRV6BVL5I"\Q#2LD*A07*A06('.% ST KI: /Y_?@O\ $OQ-
M^RQ\8KI?$NGS+'"7T_6+$8$C1@Y#1Y(4LK .ASAEX! ;-?KUI_[6'[/6HZ.-
M:7QI9V\>P.T4V^.X7C)7R2N\D=/E!YZ9K5^+_P"SI\+?C8B3>,=/:/4H5V1Z
MA:.(;I$'12V&5U'8.K <XQDU\G-_P3<\$?:]Z^,=1%KG[A@A,F/]_I_X[0!\
MR?M!_M0^,?B]\1["Q^$&H:KIFEV)^RV"64TUO<7MQ,P!E*1$-ECM6-3D@#/!
M8@?KO\(?#WB;PM\-?#^B^,]2N-6UV&V5KZXN93/*;B4F1T,C$EA&6V*?117F
M_P '_P!E7X2?!FZ36-!LI=2UM-VW4+]Q+/&&&"(U54CCX)&57<0<%B*^D* "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *\!_:F_P"3>_'7_8/;_P!#6O?JY#Q]
MX*TKXB^#M6\$:W+-#8:Q"8)GMV5954D'*%U=0>.ZGZ4 ?E;_ ,$W_P#DH?BS
M_L%)_P"CUK]@:^;O@G^R]X ^ VLZAKGA#4-3O)]2MQ;2+?2P2($#A\J(H8B#
MD=R?I7TC0 4444 %%%% 'X9?M@?"#Q!\(_BY<^/=%CDAT7Q!>'4+*[C)_<7K
M'S98BP^ZPDRZ>JXQG:V/JSX1_P#!0;P??Z5;:7\7K2?2]4A54DO[6+SK6; Y
MD:-/WD;'NJJR]P0, ?H1K_A[0O%6DW&@^)+"#4].NEVRP7""2-A[JW<=0>H/
M(YKXD\5_\$]?@WK5T]WX=O\ 4O#^_/[F.1;B!?H)E,GYR&@#O-5_;C_9OTZR
M:ZM/$4^IR*,B"WL+I9&^AFCB3\V%?F#\=OC-XJ_:H^(VDZ?X>TB6.V@)M-)T
M]#YDS/.PWR2$?+O?:N['RJJCDX+'[1LO^";G@J.8-J7C'4)XL\K%;Q1,1GLS
M&0=/:OKCX3_L\_"KX,JTO@S20-0E7;)?7+>?=LO<!R $![J@4'N* ,CP]\#;
M73_V<(_@9>3#=+I,MI+,!E5N[C=*\B^H6=RR^P%?D=\#/B=KO[*WQCO[;QAI
MLWD*'T[5K1<>:JA@RRQY(5BI 93G#(3@C<#7[ZUX1\8?V<?A=\;42?Q?8/#J
M<*A(]0LW$-TJ#D*6*LKJ.P=6QSC&30!F']K+]GG^Q&UT>-+,PJF[RL2?:3QG
M:(-OF9[?=ZU^2OQ(\2>(?VN?V@8T\)V4BQWS1V-A&XRT-C"2QFFP2%QN>5\'
M SM!)P3]IQ?\$W? HO-\_B_4GM/^>:PPK)_W\.1_XY7US\(?@#\,_@G9/#X*
MTX_;9UV3W]R1+>3+D':TF%"KD [455R <9YH ^?_ -LGX&R^*/@CI2^#+5IK
MGP"JM;VZ#<[6"Q"*5$'=E5$? ZA" "2*^5?V./VJM!^%MA/\-_B-+)!H<\YG
MLKT*9%M'D'[R.1%!;RW(W J#M8G(PQ*_LE7Q[\4OV)?@Y\2=3GUZUCN/#6J7
M+%Y7T\H(978Y+/ ZLH)[[-F3R<F@#?\ &O[8OP&\(Z#+JUGXBAU^[V;H+.PS
M)+*QZ*3C;'[ER,#L3@'\H? /AWQ9^U5^T$U_J<)E35+T7VJ."?+MK"-@"@;T
M$8$48ZD[?<C[GTG_ ()P?#ZWNUEUKQ5J5[ K ^7#'#;D@=BQ$G7U %?;?PZ^
M%_@7X4:&/#W@/2H],M6.^0@EY9G_ +TLC$NY],G '  '% 'S7^WLJI^SU<H@
M"JNHV0 '  #&N%_X)Q?\DJ\2_P#8:;_TFAKZ_P#BY\*/#GQG\&R^"/%-Q=6U
MC+-%.7LW1)@\1RN#(DBX.>?EK)^"OP/\)_ CP]>^&_"%U>W=M?W1NY'OI(Y)
M Y1(\*8HXAMP@[$Y)YZ8 /9*_ SXZ^#/%7[.'Q_DUW1%:V@^W'5M&N-N8WB:
M3?Y9['RR3&Z]2.<889_?.N'^('PW\%?%'07\->.=+CU2Q8[E#Y5XGQ@/'(I#
M(P]5(XX.02* /!_AQ^V9\$?'&A07NL:W#X9U/;_I%G?MY>QP.=DI&QU/\)!#
M>J@\5\K?M;?MAZ-KNBK\/O@UJTSF659+[5;5I( $C.1# _RN=S8+N,# V@L&
M./0-9_X)P_#RYNVET+Q3J=A QR(YHX;@KZ@,!'QZ9!/KFO0_A[^PA\%O!6I1
MZOK/VKQ3<18*1W[(+96'\7DQJN[Z.S+[4 3_ +$FD_$W_A6]SXO^)>LZGJ,F
MO2HVGPZC<2SF*SB4[94$K$KYS,3[JJD<&OL^FJJHH1 %51@ <  4Z@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#_U/W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#A?B9X!TCXH^!-9\!:X62TU>#RS(H
MRT4BD/'(H/4HZJP'0XP:_'>3X&?M7_LW>*I=5^'MM>7BN"HN]&0WD5Q&IR!-
M;;6;CKB2,@'[I/6OW"HH _$_6?B;^W1\2+&3PPVFZY%;W(\J;[+I#618'@AY
MQ$A0'//SJ/7BOI']D_\ 8XU?X?:];_$OXIK$NKV@;[!IR,LHMY&&/.E=24+@
M9"JI8#.[.X #]'Z* .(^)<.OW'PZ\40^%))8=;;3+S["\'^M%UY+>5L_VM^,
M5^(&O:#^UY\7KNV\(^*=-\2ZJ(9%VP7MO-!;1N 0'D,BI$IP3AW/0]>:_?:B
M@#P']F_X*6WP,^&]OX9ED2XU>\<W6HSI]U[AP!L0D [(U 5<]>6P-Q%>_444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_U?W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /_UOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /_U_W\HHHH **** "BBB@
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MC.3QOK^JV\4.L7=Q*UO<1!3N$3Z;D?9U#YVEU=CSME937Z?4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>1>(OCU\'O"/Q,TGX/>*/%=EI7B_7;;[796%R_EM/$7,:[
M78"/>[ A$+;WP=H.#7KM?SS?\%5_V1?"^FZ[K'[2LGQ2MK/6-8"$Z!K4@\^X
M\A%C6/2_)4N0JJH\MX]JDEFE7- 'J7Q(_;R_:(\-?\%"K3]FW2KK3D\'3>*M
M#TIHVLE:X^QWYM3,/-+9W%96PV./PK]:D^/7P>E^+,?P,M_%=E/XZDMIKK^R
MXG\R9(X "ZN5!1) IWB)F$A0%PNT$C^(9_&GC&7Q-!XTEUV^?Q!:O!)%J+7,
MIO(WME5(66<MY@,:HH0AOE"@#  K]:?^"8?[)GAWXL>-]+^/&I?%6"UUOPO?
M"_30M+FSK'F12??O3.ORP2\AMB2"5&*F13D4 ?T(6?QZ^#U_\5M1^!]OXKLO
M^$ZTN**:;2G?9/MF3S%$>X!9&"$,R(695(+  BOR5_9V_;R_:(^)7[>K_L]^
M*;K3F\)1:QXBLGCALECG$.F0W;P#S=Q.0\*9/<9]:^-O^"DG[*&@_ ?Q_>_&
M+0/BQ#J.N>)-1;46T>_F(U^.:>4R&>!K=<-"C9*NZP[ H52[8K\MK?QAXLM-
M>N_%-KK5[#K5_P#:3<WR7$BW,WVQ66X\R8-O;SE=A)DG>&.[.30!_;YX.^/7
MP>^(/C[7_AAX)\5V6M^)?#$23ZC:6K^;Y".YC_U@'EL4<;9%1B8R5#A2PSDZ
M+^T+\)_'6H^-/"'P\\5V&J^*O!?VJ&^L%<B>&XMU(;]VVTR1J_RL\>Y V5+;
M@17XZ_\ !+/]COPQ(UK^T59?%B.]U@6<]L=)\.RJ)+(7L31M'J)G3?YBYW+'
MY042(KJ\@ KX$_;-_9LL/V./BC;7GPW^+<6N:G-.\J00W+P^(M-9@6WW3V_R
M#<#CS-\;N3D1;<F@#]0O^"<'[=WQY_:6^,WB/PC\7+[33H6D>'+G5 UO:):E
M)XKNUB#-)N/R".63(/'0]J_5[X7_ !S^$GQIEU^+X5^)[3Q+_P (Q=K97[6C
M%TBF9-Z[7P%D1AD+)&61BK ,2K ?PYZ7KNMZ1#?66E:E/I]OJ\/V6\6&5XTN
M+?>LGES*A^>/>BMM((RH.,@5_3A_P2^_9'\+_!_0[CXTZ'\3[?QO=^*+(6D]
MMHD@;2(0&63;(77SI+B,C ++"4#.I3G- 'ZZ4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!_]#]_**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MGQ3=^-OA;H4]OKEY:M9&ZN[R:Z9+=V5W2-7;8NYD7+;=V!@$ L#]=T %%%%
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MPT?^SQ_T5'PM_P"#NQ_^/4?\-'_L\?\ 14?"W_@[L?\ X]7Y6_\ #D3X2_\
M12-<_P# :V_PH_X<B?"7_HI&N?\ @-;?X4 ?JE_PT?\ L\?]%1\+?^#NQ_\
MCU'_  T?^SQ_T5'PM_X.['_X]7Y6_P##D3X2_P#12-<_\!K;_"C_ (<B?"7_
M **1KG_@-;?X4 ?JE_PT?^SQ_P!%1\+?^#NQ_P#CU'_#1_[/'_14?"W_ (.[
M'_X]7Y6_\.1/A+_T4C7/_ :V_P */^'(GPE_Z*1KG_@-;?X4 ?JE_P -'_L\
M?]%1\+?^#NQ_^/4?\-'_ +/'_14?"W_@[L?_ (]7Y6_\.1/A+_T4C7/_  &M
MO\*/^'(GPE_Z*1KG_@-;?X4 ?JE_PT?^SQ_T5'PM_P"#NQ_^/4?\-'_L\?\
M14?"W_@[L?\ X]7Y6_\ #D3X2_\ 12-<_P# :V_PH_X<B?"7_HI&N?\ @-;?
MX4 ?JE_PT?\ L\?]%1\+?^#NQ_\ CU'_  T?^SQ_T5'PM_X.['_X]7Y6_P##
MD3X2_P#12-<_\!K;_"C_ (<B?"7_ **1KG_@-;?X4 ?JE_PT?^SQ_P!%1\+?
M^#NQ_P#CU'_#1_[/'_14?"W_ (.['_X]7Y6_\.1/A+_T4C7/_ :V_P */^'(
MGPE_Z*1KG_@-;?X4 ?JF/VCOV>20!\4/"Q)_ZC=C_P#'J]BBEBGB2>!UDCD4
M,K*0592,@@C@@CH:_$M?^"(GPCW#=\1]<*YY M[8''UQ7["?#CP+H_PP^'_A
MOX;^'I)YM,\+Z=:Z9;/=.))VAM(EB1I& 4%B%!.U57/W5 P  =I1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% '_TOW\HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /_T_W\HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#_LO>*M.\&_%6YU"'4M4LA?PBTLVN$,!D>($L",'=&W'I7S_ /\ #WO]C?\
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MDP2+?[,W_!1OP9^RE^R'I_P\\+Z1)XE^(<^H:C<>1,KPZ?9K-(/+>>3AI20
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M?DM^VE^R%^T-^U3\8UL[KQD?#GP4T;3K>XDMA-O:XO8Q(TIBM(\!Y/N@23L
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MMHEC)+9Z?:0O<237!PD>Y(P6\M&8/*1]V-6;M7\VOB;_ (*=^./BU^S+XW^
M?QTTD:KK>M6L45AKEDD=NQDAN8IMMY;C;'T0_O(@N. 8R26K^D_X[_$V^^#/
MPA\4_%+3O#UQXJF\,V;WATZVD6*26.,CS&WL&VI&F9'(5B$4X4G /\@'QP^(
M?Q*_:V\9^)_C6G@>STRRT>!9M2?1+#R;:VA:3:DM[<8S+,[,%WR-N<\* !@
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M7^!/A/\ \%D)_A_\/M*71_#^A6\S65JDDLBPF?P\LDF&E9W.YI7/S,>O'&*
M/Z):*** "BBB@ HHHH *XCXE?$#P_P#"KX?^(?B3XJ=H])\-V4]]<[!N=DA4
MMM0=V8_*H[DBNWKB/B5XWT+X:^ /$'C_ ,407%SI'A^RFO+N.U@-Q,T$*EI-
ML0^]\N<YP ,EB ": /P.U?\ X*N^&OCE^SW\4/A7\8/#X\,^(M<T74[?2;K3
MQ)<6-P\L;^1!*IW2Q29VKO\ FC8Y9O*'%?.'_!//]LKX;?L>^"OBOK'BNTNM
M9U_Q"^C)I6F6R[/M!M%O?,:6=@4BC0S*&/S/S\J-@X^7_P!J3XJ_#'X\?%"Z
M\4?!/X8P^ M,5)I)8;4L\MV$&][F:"/_ $>WVHI9EA7 ^9G=^H^=]":/3[ZT
M\0:EI UC2;*ZA^TP2F6.WG&2_D/+"R.GF*K#Y7#8!*]* /Z8?A%_P5)TWQ?^
MRS\1_C+XVTFVL/&'@6?R8],M1+]FNFU%F73,,[,V-P*3G/ C9P!N51\/?M!?
M\%)O"'[4G['7B3X9>-=(;PU\1#-ILL26ZO-IU_Y%W$\K0O\ ,\+! S&.4D8&
M%D9CBON3X#?MT_LMK^R;XJ\3Z5\*[OPQX:\$):VNL:#9:?'=V<LNHDQ1A9R$
MBF$C+B1[C8W(W@[E+?SQ?&KQ=X0^*'Q"UOQK\,/ ,/@+PZ0LG]F64LMS% I?
M;YLCO\L>]G5=J*D:DJJKGD@'Z,?L:?\ !0+P%^R%^RIK7A*VTN;Q)X^U;Q'>
MWUM88:&TAADM+.%)KB<CE2T38CC#,=I!* AJ_<K]BG]INW_:L^!>F_$:YMXK
M'7[6633]9M8%988KZ$*Q:(.6;RY$=)%RS;=Q0L2I-?Q]?#G6=$\%^+M#\9>-
MO",?C#P[;W#&73;J6>UM[T1 ;XQ/"0P*;E8XW#H'5E.#_8C^QQ\<_A?\?/@O
M9>)_A'X9F\(:%IDS:=_9CVL=K#;S0JKNEOY/[J2,;QATQS]Y5;( !]54444
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M%/86T*S6LEQ;L5F@+HRLA9XR"2A!(:ON6B@!J(D:+'&H1$   &  .@ IU%%
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MN:ZNB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%&E:1^QCX@^!'[*7@B#^U=2N=,D:)9X(;J]^S74<KRW%W=R1B1@JDC>^!]U
M!A:_3NB@#\GOV%_V+-0T?]E/Q#\$/VMO =J6U#Q)=W\%G<3VUVR02V=I$D\,
M]G+)Y,F^.104D608]#S^C_PI^%W@SX+_  ^T7X8_#^R^P:%H,/DV\9.YVRQ=
MY)&_B>1V9W;NQ->A44 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^0*_=K_A&_#O_0+M?^_"?X4?\(WX=_Z!=K_WX3_"@#\)?^'Y=E_T1B3_ ,*
M?_(%'_#\NR_Z(Q)_X4 _^0*_=K_A&_#O_0+M?^_"?X4?\(WX=_Z!=K_WX3_"
M@#\)?^'Y=E_T1B3_ ,* ?_(%'_#\NR_Z(Q)_X4 _^0*_=K_A&_#O_0+M?^_"
M?X4?\(WX=_Z!=K_WX3_"@#\)?^'Y=E_T1B3_ ,* ?_(%'_#\NR_Z(Q)_X4 _
M^0*_=K_A&_#O_0+M?^_"?X4?\(WX=_Z!=K_WX3_"@#\)?^'Y=E_T1B3_ ,*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ?FG_ ,%:O^3+/$?_ &$M*_\ 2I:]Q_8(_P"3./A-_P!@2'_T)J\._P""
MM7_)EGB/_L):5_Z5+7N/[!'_ "9Q\)O^P)#_ .A-0!]=T444 %%%% !1110
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M[ W[5]S^UI\%3XK\0VL-CXJT&[.G:M%;Y$,D@19([B-22525&^Z2<.K@< 4
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MO2RRQS*=07[0ELP3*BW@21;AG*NX);R]OS"3P/Q)X!\;_P#!._\ :Y\ ^/\
M]H3['\4[*^5;F'4)IKF:6%8G6*2>+SF#"YM,AHQ('C(88VOAH_T'_;M_8F^/
M'B#X\Z-^UI^RS+'=>+;'[(]U8M+#!.MS8A8X;B$W&V&5&B4)+%(PR%P X<JO
M@B_LC?MR?ML?&[PSXT_:[TRV\)>$_#HCCDC5[=-]M')YDL%K;0R3OYLY^]+*
M0H'(+!52@#EOCF?)_P""SGAR>^/[B;6O#)A)Z$-8VR+@]_WF<>]._P""SH:Y
M_:&^&%E8<W[:*NT#ELO?2"/CK]X'%?7_ /P4._8@^+/Q5^(WAC]I/]F^2-_'
M/AQ;5);$RQ6TLCV,QFM;J"6<K$98R=K+(R@JJXR00? _A7^QQ^V'^TO^TYX?
M^/O[9=E#H>E^%WLY%MV>V+W2:?(98;6&WMGD$<339>5I"N0S;<EOE /W3\<V
M7B'4O!/B#3_"5P+37;K3[N*PF+;!%=O"RPN6P<;9"IS@X]*_$'_AFK_@L%_T
M5^V_\&[?_(E?O/10!_+W^U[\%O\ @HCX*^".I:_^T3\0X?$7@J*YM$N+--0:
MX9IGE A;RS!'G:^#][BOVZ_X)[17D/[&'PI2^??(=*+ YS^[:>5HQ^"%1^%>
M._\ !6K_ ),L\1_]A+2O_2I:]Q_8(_Y,X^$W_8$A_P#0FH ^NZ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\PO^"DW[&OQ8
M_:ST?P8WPOURTMG\,RW9N--U":2"WG^U",+.C1I(/,CV%<,OW7.&'(;\F?\
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MO;4O_1-M7[T5^"_P"_Y3(?%'_KVU+_T3;5^]% !1110 4444 %%%% !1110
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MG-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 ?_3_?RO+/C?X3U;QS\(_%GA+03C4=2T^:.
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M %%%% !1110 4444 %%%% !7X,>'O^4X6O?]>Q_]1N&OWGK\&/#W_*<+7O\
MKV/_ *C<- '[ST444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?,/[9GQ>\6? ;]FGQI\6? ZVSZYH$=FUL+N,RP9GO8+=MZ*R$_)(V
M/F'.#7T]7PA_P4T_Y,<^)_\ UQTW_P!.=I0!^)O_  ^/_:Z_Y]_#7_@NF_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M117YA_'K_@J?\&_V?OBUX@^#_B?PIK^HZGX=>&.:>S6U,#F>".==GF3HW"R
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.S,([Q4G$*#.T*/ER>K,,DXP![E\2_A+X!^+FBC1/'>E1W\<8D$$WW;BV:0
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MY@= _:P_;G\5^>/"_P 0O&.L?9=OG?8Y[FX\O?G;O\L-MW;3C/7!QTK^EO\
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MZ[_8-^*=I\2UT)?$4?\ :CZF=0$']H>7]F'V%K<R?O>&X@\KGSMVWYSSXO\
MLF>&_&'C+_@G-^U%H5NDDVE6[Z=?VJ#<5\_3RMY>E1TR(8(2<<],]J_2GQE_
MP1O_ &7/$_BR;Q#I.J>(/#5C=2M+)IMC<V[6T>XYVP-/;RR1KGLS/CH,#%?H
MI\*/@M\-O@I\.[3X6?#S1H]/\.VJNK0/F8SM+_K9)V?)D>3^(MV^4 *   ?B
M5^P;^T!\-? __!.[XM:'XDU^ST_6=#;6S'933HEQ<"_L8UM?*C)W/YLQ:,8!
MPP.<"NX_X(?>%-0LO OQ3\;RQ%;+6-1TRPB<CAI-/BGED /? NT_.O;?&O\
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M@"T_D:\K$?&S>.Q]84445@,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M;WX6^,;.S\3Z7/<3Z-J$<<<=[ [N[V[A550^223@ <DUR?\ P1,_Y. \<_\
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MCD=1S0!ROP%\1_L\>']<O?@O\%Y(Y[S2[9KJ]N(EWB=HG6)B]R<><X9Q]W*
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M "BBB@ HHHH **** "BBB@ HHHH _-/_ (*U?\F6>(_^PEI7_I4M>X_L$?\
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M_P#2:2O(/^")G_)P'CG_ +%AO_2VVKDQ-)1:L7%W/Z8****YB@HHHH ****
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M<?V9O@G>?!?P3<V_B*[74/$VOW)OM3N%)8>:PP(PYY<)R2QZLS'IBOHZBB@
MHHHH **** "BBB@ HHHH **** "BBB@#\%_@%_RF0^*/_7MJ7_HFVK]Z*_!?
MX!?\ID/BC_U[:E_Z)MJ_>B@ HHHH **** "BBB@ HHHH **** "OX]OVZO\
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M_P &,/\ \C5$Z\I*S!12/M3]D7_DU7X._P#8GZ#_ .D$-?0]<CX \%:-\-O
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M#/@_XB?M%>*/A9\1M3O-+ECN-16U>W:-))[JWG^X?-1P=T8=QP,XZU]HWO\
MP3Q^"VG6<^H7_B;6X+:UC:661YK551$&YF8FWX  R30!<_8$^+VN>-_!^K^
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M% 'X+_ +_E,A\4?^O;4O_1-M7[T5^"_P"_Y3(?%'_KVU+_T3;5^]% !1110
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MW_I;;5P8S=&M,_I@HHHKB+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO4445\Z?@1\3?\%&_P#DRCXI_P#7A;_^ED%?S\_\$^_];X[^FF?^W-?T#?\
M!1O_ ),H^*?_ %X6_P#Z605_/S_P3[_UOCOZ:9_[<UOAOC1,]C](Z***]4Q"
MBBB@#\Q?V_O^1B\(?]>MU_Z,2OZ1OV%?^3/OA)_V +3^1K^;G]O[_D8O"'_7
MK=?^C$K^D;]A7_DS[X2?]@"T_D:\K$?&S>.Q]84445@,**** "BBB@ HHHH
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M262&,^88IB[L\3_*%   )/.* /T=HK\$/^'Y6F?]$:F_\'R__(-'_#\K3/\
MHC4W_@^7_P"0: /WOHK\$/\ A^5I?_1&YO\ P?+_ /(-?KS^S9\>_#G[2_P?
MT7XO>&+*?3;;5?.CDM+G!D@GMY&BE3<ORNNY<JPQE2"0#E0 >[4444 %?EO_
M ,%@/^3.[G_L.Z9_.2OU(K\M_P#@L!_R9W<_]AW3/YR4 ?B/^R?_ ,B-JO\
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M:@L$5["]OY[?9Y/E1SE"Q[*6#'H 37FG_!-[_DGWBW_L*1_^B%H _1RBBB@
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M$VFI/;P6TRP;3O9XH8XRH8D8#C=QG &,_5-5[>[M;L%K69)@O!*,&Q]<58H
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M1_X)L_LQ_ 3X@V'Q-\(V&I7^N:4'-F^I7GGQV\CJ4,J1HD:EPK$ MN"YR &
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M@A WS8"@'^D.B@ HHHH _-/_ (*U?\F6>(_^PEI7_I4M>X_L$?\ )G'PF_[
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MX[DLQ+,Q)+,2Q)))KJZ* "BBB@ K\M_^"P'_ "9W<_\ 8=TS^<E?J17Y;_\
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&FU_])+JOQ;K]1X,_P!V?J?V#]&G_<<7_C7Y!1117UY_2YU/P_\ ^2G>!?\
ML8-+_P#2E*_JGK^5CX?_ /)3O O_ &,&E_\ I2E?U3U^9<:_[Q'T/X6^D%_R
M4+_P1_4****^,/Q _*7_ (*5_P#(0^'_ /URU/\ ]"MJS_VAHW^!G[4O@CXS
MVBF+3=;2WENBHX)B46MXH [FW9&]V8FM#_@I7_R$/A__ -<M3_\ 0K:OH/\
M;9^'W_"9_L_G6[6/??>%6AU!,#YC 5\N=?H$;S#_ +E ':?M@?$5/ ?P$URY
MLY@MYX@5=+M64]?M8/F%2/2 2$$=\5^</QC^'O\ PKS]E'X807$7EW^N7]QJ
MMSD8.ZZ@!C![@K"(P1Z@T[_A-[_]I_4_@G\&6,CII,(AU0\C<8G*R/G^(K9P
M!PW]YV&<YKZ8_P""CT44'@/P9!"@CCCU"9551@*HAP !Z"@#VGXC?\F2S?\
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MX]_[#.G_ /I-;5]45\K_ +>W_)_OCW_L,Z?_ .DUM7U17U/#OPS^1_3'@#_
MQ?K'\F%%%%?1G]"!7#_$W_DG/BC_ +!EY_Z):NXKA_B;_P DY\4?]@R\_P#1
M+5E7^"7H>9G7^YUO\,OR9Z%_P1(_Y+=\0/\ L74_]*XJ_I2K^:W_ ((D?\EN
M^('_ &+J?^E<5?TI5^<'^>P4444 %%%% !1110 4444 %%%% !1110 4444
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M9*QPIY:#)R<*LH R>:N?\.]? G_0YZ]_W\A_^-T?\.]? G_0YZ]_W\A_^-T
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M"7_/_P#\E_X)']H+L>O?\/@OVPO^>V@_^"S_ .VT?\/@OVPO^>V@_P#@L_\
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M>_Y24>&O^P_KW_I+>U_6U0 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ."YXJ3E8ER/Z"Z*_GT_MKXP_P#17?&/_@XG_P :/[:^,/\ T5WQC_X.)_\
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MR@_FU?HO7YT?M/\ _)3C_P!>4'\VKQL]_@?,_(/&[_D2_P#;\?R9_:+\/_\
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M[_TGN:^#J]O#?PH_,AA1116HC!U'_D:O 7_8T:1_Z/%?T15_.[J/_(U> O\
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MXT9PME?3">&5%'+>5(@C?&3P^ > 0#]5_B#X&T/XD^#=6\$>(H]]CJT#0LP
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M>8^#T_W\_-7V-X!\'6'P^\%:)X)TR1IK;1;2*U61^&D\M<%R!P"QR2!P,\4
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M )-%N/\ L9-1_P#15O7ZM5^4O_!''_DT6X_[&34?_15O7ZM4 %%%% !1110
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MJ_0>#H9HZ,_J$HJ-];][>AQ8IT[KG,O_ (75X?\ ^?*Z_)/_ (NC_A=7A_\
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M1^T__P E./\ UY0?S:O&SW^!\S\@\;O^1+_V_'\F?VB_#_\ Y$+PW_V#+/\
M]$I775R/P_\ ^1"\-_\ 8,L__1*5UU?&'\A!1110!^7?_!2[]D#XR_M5Z)X,
M'PHU>V5/#<UVUUI=[.UO#.UP(Q'.K!64R1!&7#@?*YVD<AOR,_X=!?MC?\^>
MA_\ @S7_ .-U_5O10!_*1_PZ"_;&_P"?/0__  9K_P#&Z/\ AT%^V-_SYZ'_
M .#-?_C=?U;T4 ?#/_!/G]G/XE?LQ_ =OA_\4=8AU+4[G4[B_BMK:5YK>P@F
M2-1!&[A<Y9&D;: H9SC)RS?<U%% !1110 4444 %%%% !1110 4444 %%%%
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M0+N?7K/X0VAOM,FO)&DD>)K6>467F,=Q5'@4("?E$@4':%"_#7P$_95^(_\
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M6M?PG>,O#L7A;6VTJ&8SJJ(^Y@%/S>PK^ZWP;%';^$-#@A7;''8VRJ!V B4
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M_P#^1"\-_P#8,L__ $2E==7QA_(04444 %%%% !1110 4444 %%%% !1110
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M &+)_P#2VWK\^]>_:=\2:_H6HZ%/H]I%%J5M-;,ZM)N59D*$C)QD \5]^?\
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MSR$#.$CCD9F./04 >G4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
MFG_P5J_Y,L\1_P#82TK_ -*EKW']@C_DSCX3?]@2'_T)J\._X*U?\F6>(_\
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MU^>U_ERO\S]/OM%O_P ]5_,4?:+?_GJOYBOR.\2^&$\.?9]FLZ?J_P!HW_\
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M% !1110 4444 %%><?%WXI>%O@I\-/$/Q4\:2M%H_ARU>YF"8\R0C"QQ1AB
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M .(DX#^2?W+_ .2.;ZA/NCZPKB/B/_R)6J?[B?\ HQ:\7_X2_P"+']RY_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#9?_ $JFK[2H \3_ .&:?V<O^B5>%/\ P1V'_P 9KVF**.&-(84$<<8"JJC
M4#@  = *?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME5D-A;[PIZ@-LR ?2K'_  KGX>_]"OI?_@%!_P#$4 ?CW_P^Z^$/_1.-=_\
M BU_^*H_X?=?"'_HG&N_^!%K_P#%5^PG_"N?A[_T*^E_^ 4'_P 11_PKGX>_
M]"OI?_@%!_\ $4 ?B?X]_P""TO@37O WB+0_!W@W7-#U[4=.N[?3[\RVSBTN
MY862&<KNY\MR&QWQ7X07/Q2^)MY<27=WXOUB>>9B[R/?W#.[,<EF8R9))ZDU
M_<?_ ,*Y^'O_ $*^E_\ @%!_\11_PKGX>_\ 0KZ7_P" 4'_Q% '\)VK^(O$'
MB!XI-?U.ZU)H01&;F9YB@;J%WDXSCG%:5EX\\<Z=:Q6.G>(M1M;:$;8XHKN9
M$1?155P /H*_H*_X+0^%O#.@_!?P%<:'I%GITLGB!U9[:WCA9E^R2G!**"1G
MM7ZM?"WX>^ 9OAEX1FE\-:8[OH]@S,UG"22;="224Y)H _DG_9?_ &LO'OP$
M^,^@_$35M?UG5-$LG==1T]+MY!>VSQLIB9)G\L_,0P)^Z0&'(%?L?_P^Z^$/
M_1.-=_\  BU_^*K]A/\ A7/P]_Z%?2__  "@_P#B*/\ A7/P]_Z%?2__  "@
M_P#B* /Q[_X?=?"'_HG&N_\ @1:__%4?\/NOA#_T3C7?_ BU_P#BJ_83_A7/
MP]_Z%?2__ *#_P"(H_X5S\/?^A7TO_P"@_\ B* /Q[_X?=?"'_HG&N_^!%K_
M /%4?\/NOA#_ -$XUW_P(M?_ (JOV$_X5S\/?^A7TO\ \ H/_B*/^%<_#W_H
M5]+_ / *#_XB@#\>_P#A]U\(?^B<:[_X$6O_ ,51_P /NOA#_P!$XUW_ ,"+
M7_XJOV$_X5S\/?\ H5]+_P# *#_XBC_A7/P]_P"A7TO_ , H/_B* /QLA_X+
M??#5KN1+CX8ZNEJ,['6^MVD//&4*J!QZ.?QJ_P#\/NOA#_T3C7?_  (M?_BJ
M\R_9&\->';W_ (*K_'+1KW2K2XT^WM]>,5O)!&T*;=1LPNU""HP"0,#O7[H_
M\*Y^'O\ T*^E_P#@%!_\10!^/?\ P^Z^$/\ T3C7?_ BU_\ BJ/^'W7PA_Z)
MQKO_ ($6O_Q5?L)_PKGX>_\ 0KZ7_P" 4'_Q%'_"N?A[_P!"OI?_ (!0?_$4
M ?CW_P /NOA#_P!$XUW_ ,"+7_XJC_A]U\(?^B<:[_X$6O\ \57["?\ "N?A
M[_T*^E_^ 4'_ ,11_P *Y^'O_0KZ7_X!0?\ Q% 'X]_\/NOA#_T3C7?_  (M
M?_BJ/^'W7PA_Z)QKO_@1:_\ Q5?L)_PKGX>_]"OI?_@%!_\ $4?\*Y^'O_0K
MZ7_X!0?_ !% 'X]_\/NOA#_T3C7?_ BU_P#BJKW7_!;SX6) S6/PTUF688VK
M)=VT:GGG+#>1Q_LG^M?L9_PKGX>_]"OI?_@%!_\ $5\!_P#!3[P7X.TC]B3X
M@:AI.A6%E=12:1LE@M8HY%W:I:@X95!&02#STH ^<+;_ (+>?"IH$:\^&NM1
M3'[RQW=LZCZ,=I/_ 'R*G_X?=?"'_HG&N_\ @1:__%5]7_\ !.OP1X,U3]B_
MX8W^IZ!I]W<S6=V7EFM8I)&(OK@#<S*2>!CDU]J_\*Y^'O\ T*^E_P#@%!_\
M10!^/?\ P^Z^$/\ T3C7?_ BU_\ BJ/^'W7PA_Z)QKO_ ($6O_Q5?L)_PKGX
M>_\ 0KZ7_P" 4'_Q%'_"N?A[_P!"OI?_ (!0?_$4 ?CW_P /NOA#_P!$XUW_
M ,"+7_XJC_A]U\(?^B<:[_X$6O\ \57["?\ "N?A[_T*^E_^ 4'_ ,11_P *
MY^'O_0KZ7_X!0?\ Q% 'B/[)?[47AW]K;X:WWQ*\,:+=Z%:6.J3:4T%X\;R-
M)###,7!C)&TB8 =\@U]05FZ5HNCZ%;-9Z)8P:? S%S';Q)$A<@ L50 9( &?
M:M*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** /YO\ X_L==_X++^&-.U0>9;Z?K7AA85;D 1VEO<KC
M_MJQ/UI?^"RC'1?VDOA?XETT;-1BT6)E=?O9MK^62+\F8XKL?^"E_P -_B'\
M%/VK/!G[:?A+19-7T"SETJXOI(P2D-]I<H BN&4$QQSP+&BR$8SN'7:#X;K7
MBKQ=_P %1_VSO!>K^%?"=UI'@[PS'807[2GSDM;""X>YN99Y5 C$DQ9HXD_B
MPO\ M$ ']*_CG7;[POX)\0>)M+LSJ%[I&G7=Y!;#<3/+;PM(D8V@M\[*%X!/
M/%?B!_P]5_:K_P"C<[G_ +]:E_\ &*_>BB@#^8_]J3]M3]I3]IOX/ZC\)=<^
M!E_H-G>SVUR]W!;7\KI]ED$H&UX0,'&"<\5UWP(_X*%_M,?!WX0>%?AAHWP'
MNM:L?#EDMI#>-!J"F=%)(8A(2N>>QQ7](5% 'X+_ /#U7]JO_HW.Y_[]:E_\
M8H_X>J_M5_\ 1N=S_P!^M2_^,5^]%% 'X+_\/5?VJ_\ HW.Y_P"_6I?_ !BO
MSM_;!^)?[17[7WCO2/&WB'X6ZWH"Z-IRZ?%906=]/;C]])*TRAX1M=]X5O4(
MOI7]?5% '\*'_"E?C)_T(>O_ /@KNO\ XW7-:+X(\:>)+RZT[P[H&H:I=V)Q
M<0VMK+/)"<E?WBQJ2O((Y YXK^]2OP8_X)3_ /)TG[1?_7S)_P"G&XH _#?_
M (4K\9/^A#U__P %=U_\;K]3_P!FK]N+]J+]G#X/Z/\ "&Q^"6J>([71GN#%
M=7D&H*X2>5I1&JK 0J)NP!D_T'],%% 'X+_\/5?VJ_\ HW.Y_P"_6I?_ !BC
M_AZK^U7_ -&YW/\ WZU+_P",5^]%% 'X+_\ #U7]JO\ Z-SN?^_6I?\ QBC_
M (>J_M5_]&YW/_?K4O\ XQ7[T44 ?@O_ ,/5?VJ_^C<[G_OUJ7_QBC_AZK^U
M7_T;G<_]^M2_^,5^]%% '\]WBW_@KU^TKX6TZ/4-9^"$'A^&241"?4EOTA9B
MK,(U+K$-Y"DCYCP#QW&]8?\ !5_]J6^L;:]M_P!GN2[BN(TD2:&+43%*K@$.
MA$+ JP.1R>.YKW/_ (+5_P#)K?A7_L<K+_TW:C7Z,_LX?\F\_"[_ +%;1/\
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M&5*K@$@8' - 'JO_  ^X^#/_ $3S7_\ O[:?_'*/^'W'P9_Z)YK_ /W]M/\
MXY7Z[_\ "LOAM_T*>D_^ %O_ /$4?\*R^&W_ $*>D_\ @!;_ /Q% 'Y$?\/N
M/@S_ -$\U_\ [^VG_P <H_X?<?!G_HGFO_\ ?VT_^.5^N_\ PK+X;?\ 0IZ3
M_P" %O\ _$4?\*R^&W_0IZ3_ . %O_\ $4 ?D1_P^X^#/_1/-?\ ^_MI_P#'
M*/\ A]Q\&?\ HGFO_P#?VT_^.5^N_P#PK+X;?]"GI/\ X 6__P 11_PK+X;?
M]"GI/_@!;_\ Q% 'Y$?\/N/@S_T3S7_^_MI_\<H_X?<?!G_HGFO_ /?VT_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ-@@E6!&>Q%?7M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /__6_?RBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __7_?RBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!%<(TDCG^%1GD^U 'K-%%9VKZMIF@Z7=:UK5U'96%C&TT\\K!8XXT&69B>@
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M5[;6;&&5H'FM9!(BRJJL4)'<*RG'H10!U-%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 45RWBWQOX0\!:;'J_C/5[;1;*640
M)-=2"-&E8%@@)ZDA2<>@-7_#WB/0?%NCV_B#PSJ$.J:;=;C%<6[B2-]K%6PP
MXX8$'T(H VJ**X;P_P#$WX?>*]>O?#'AKQ!9:GJVG"1KBVMYEDEB$3B-RP'0
M*Y"GW- '<T45YSXL^+OPP\":FFC>,O$]AH]])$LRPW,ZQR&-B5#8/."5(!]J
M /1J*:CI(BR1L'1P""#D$'H0:=0 45Y[XV^+'PV^' 0>./$EEH\D@W)%-*/.
M=>FY8ES(1[A<5PVB?M1?L_\ B"[6QT[QQIZS.<*+AGM5)] TZQKSVYY[4 >]
MT4U'25%DC8.C@$$'((/0@TZ@ HHHH **** "BBN-\6_$3P'X"CCD\:>(;#1/
M.!,:W=Q'"\@7KL5B&;'?:#0!V5%</X0^)?P^\?"3_A"O$5AK31#+I:W"22(/
M5D!W*/<BNXH **** "BBB@ HHHH ***0D 9/ % "T5Y[X3^+/PS\>:C+I/@W
MQ-8:S>P1F5X;6=9'$8(4M@'[H) S[CUKT*@ HKAO%_Q-^'W@":UM_&OB"RT6
M6^#&!+J98VD"$!BH/) )%=S0 45A>)/$_A[P?H\_B#Q3J,&E:;;%1)<7#B.-
M2[!%!8^K$ >YJCX1\=>#O'UA-JG@O6;76K2WD,,DMK()%20*&VDCH<,#^- '
M5T45FZOK.C^'].FU?7KZ#3;&W&9+BYD6&)!ZL[D*/Q- &E17SM-^UG^SK!=&
MS?QQ9F0$C*),Z<?]-%C*?K7LOA?QCX4\;:<-7\(:Q::S9YVF6TF295;&=K;2
M=K>H.#[4 =)1110 4444 %%%% !1165KFNZ-X9TFYU[Q#>Q:=IUFN^:XG<)'
M&N<99CP.2 /4\4 :M%<_X8\5^&O&FD)KWA/4H-6TZ5F19[=Q)&60X8 CN#P:
MZ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BO/O%_P 5_AKX O8=-\:>);'1;JXC\V.*ZF6-VCR5
MW $YQD$9]0:Y/_AI+X"?]#[I'_@4G^- 'MM%>*Q_M'? >:18HO'>DL[D*H%T
MF23P!UKVJ@ HHHH **** "BN!\6_%7X:^!)A:^,?%&G:/<E0X@N;F..8J>C"
M(G>1[@5<\)_$3P%X[61O!?B&PULP@-(MG<QS/&#P"ZJ2RY]P* .RHHHH ***
M* "BBB@ HHHH **JWU]9Z997&I:C,EM:VD;RS2R$*D<<8+,S$\   DGL*\<_
MX:2^ G_0^Z1_X%)_C0![;17B7_#27P$_Z'W2/_ I/\:[GP=\1? OQ!CNI?!&
MNVFMI9%%G-K*)!&9,E0V.F=IQ]* .THHHH **** "BJ>H:CI^DV4VI:K<Q65
MG;*7EFF=8XXU'5F=B  /4FO+K#X_?!+4]2&D6'CG1YKIB%51>Q8=CT"L6VL3
MZ F@#UVBD!!&1R#2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% '_]']_**** "BBB@ HHHH **** "B
MBB@ HHHH *_ W]K73+W5_P!ISQO::?&994$<Y4?\\[;3HYI#_P !1&/X5^^5
M?D=?6-IJG_!1FYTR_C$UK=RO#*C='CDT4JRGV()% 'V-^QC\0/\ A//@-HB7
M$GF7WATMI4^3SBW ,/O_ *ED&?4&O8?C#X[A^&?PP\2>.)& DTNSD> -T:X?
M]W I_P!Z5E'XU^>?[&M]=_"7X_\ CGX#ZQ(=ERTOV8O_ ,M)K!F*,H_Z:V[E
M_HHKO_V_?%-_J=GX-^"GAX^9J7BB^2=XU/+*K"&W0^TDKD_6.@#\[O@1;:C'
M\>/AW>ZDK[]0UBRN$=SEI%:YVE_7EE;KUZU_117XX^._"MAX'_;*^&7@_2Q_
MHNC#P]:H<8+"(A2Q]V(W'W-?K?XJ\1Z;X/\ #6J^*M8?99:1:S74Q[[(4+D#
MW., =S0!^8'[7>HWGQL_:)\(? +0[C9!I[QQW+K\P2XO ))G('WO*MU5A[EA
MQ6[^P%XXO_#NN^+?@/XE)AO+&>6[MXF/W)H&$%W$,^X1@!Z.?6L3]AKP]J7Q
M)^+7C'X]^)D\R:*2586/*_;+]B\FP_\ 3*+Y,=ED%<[^TS;7G[/O[5>@_&/1
MHF6PUEX[^14X#NF(+Z(>\D9#$^LE 'Z_5^).B_#'PU\7?VS_ !CX*\6&<:=<
M:GK$K?9W$<FZ)W9<,0W&>O%?M5IVH6>K:?;:KITJSVEY$DT,B\J\<BAE8>Q!
M!%?AI>_$3Q)\+OVN?&OB[PIH_P#;NH0:KJT:VNV1MRRR.K'$>6^4<T ?>W_#
MOSX"?\]-7_\  M/_ (U7??#+]D/X3?";QC:>./"KZB=2LEE2/[1<+)'B9#&V
M5$:D\,<<U\I_\-Q?'C_HEO\ Y O/\*^N/V;/C-XV^,>DZW?^-?#7_"-RZ;/%
M'"FR9/-6122?WH!X(QQ0!\22_P#*2$?]?R_^FL5^N5?D;+_RDA'_ %_+_P"F
ML5^N5 !7XP?&#P7H_P 1/V\[WP5X@,HT[5KJPBF\E@DFW^S(6^5B#@Y'I7[/
MU^1OB;_E)##_ -?UA_Z:XJ /HV7_ ()\? >1"J7&LQ$_Q+=QY'_?4)'Z5\>?
M&7X&>.?V/_$6E_%#X8:[<7&CO.(1,X"RPR'YA!<JF$EBE"GG: <8(!VD_M17
MS?\ M<Z;:ZG^SKXTBNE4B&VCG0L/NO#-&ZD>AXQ^- 'HWP?^(]C\6?AOH?CZ
MQ00_VG!F:(<^5<1DQS1C/.%D5@I/48/>O2J^#/\ @G?=W-Q\#]3@GW&.UUVY
M2(GH%-O;N0/^!,3^-?>= '&^'_B)X!\5ZG<Z+X8\1Z=JVH6:LTUO:744\L:H
MP1BR(Q( 8@$GN0*[*OR-\4Q_\,W?MP6?B!/]&\/>+9A,YZ((-28QSY[ 17 ,
MF!T 6OO/]I_XB_\ "L?@GXCU^WE\J_NH?L%D0<-]HN_W89?>-2TG_ : /3?#
M/Q%\ ^,[JXLO"'B/3M;N+1=TT=E=17#QJ3C+"-B0,\9-<_XL^-WPC\"WS:7X
ML\6Z=IUZF-]N\ZM,F>FZ-=S+^(%?#O[,/A+6?AA^RAXV^*FE0LOB'7K*]N[1
M@/G2"RBD2!@"#G#^9(/[P*UX%^RIX1_9H\>6VK3_ !RU59?$\]VQB@U"^ELX
M9(G56$BS*\?F2O(7W!GSP/EYR0#]?_"?Q$\!^.TD?P9XAL-;\H!I%M+F.9XP
M>F]5)9?Q KLJ_-6Y_8[\3^"?C-X?^(?[/6HV]GH,#17$J7=XY"C?B:%'5)&D
MBEBX^;)Y.3TK]*J *>H_\@^Z_P"N3_\ H)K^9CPO=:[X<O;3Q_HRE3X?O[-U
ME[)<$O-"#]?);\J_IGU'_D'W7_7)_P#T$U^&G[.7P_\ ^%D_!_XSZ#!'YE];
MV>FWUH ,MY]HUS*%7W=0T?\ P*@#]N?"WB+3_%WAG2O%6E-NL]7M8;N$]]DR
M!P#[@'!]Z^,_V_/'[^&_A';>"K%S]N\7W:P[%^\;:V(EEQCGE_*7'<,14W[
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MX8\1Z=JVH6:LTUO:744\L:HP1BR(Q( 8@$GN0*[*OR-\4Q_\,W?MP6?B!/\
M1O#WBV83.>B"#4F,<^>P$5P#)@= %H _7*N-\,_$7P#XSNKBR\(>(].UNXM%
MW31V5U%</&I.,L(V) SQDUYE^T_\1?\ A6/P3\1Z_;R^5?W4/V"R(.&^T7?[
ML,OO&I:3_@-?)7[,/A+6?AA^RAXV^*FE0LOB'7K*]N[1@/G2"RBD2!@"#G#^
M9(/[P*T ?<7BSXW?"/P+?-I?BSQ;IVG7J8WV[SJTR9Z;HUW,OX@5T'A/XB>
M_':2/X,\0V&M^4 TBVES',\8/3>JDLOX@5^0'[*GA']FCQY;:M/\<M567Q//
M=L8H-0OI;.&2)U5A(LRO'YDKR%]P9\\#Y><GZ'N?V._$_@GXS>'_ (A_L]:C
M;V>@P-%<2I=WCD*-^)H4=4D:2*6+CYLGDY/2@#]*JAN/^/>7_=;^535#<?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD>A!P: /B[]A'XG?\)O\'E\*WTN_4O!\HM""<L;23+VS?0 -&/9!7S/\%/\
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MQSUP ?3E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;4IEN+N2SMVFE1E=9)#&I=@R?*03D@C@]N*^,/\ AWE\"_\ G_US_P "H/\
MY'K[=TG3;?1M+L](M"Q@L88X(RYRQ2)0JY( YP.>* ,7QQXG'@KP=K7B][.3
M4$T6TFO'@A($DB0(78*3QG )KR;]GK]H/0_V@-!U35M-L&TFYTJZ$$MK),LT
MGEN@:.7(5<!SN4#'53S7OMQ;P7<$EK=1K-#,I1T<!E96&"I!X((X(K\U/$7[
M&WQ6^''C:Y\:_LT^*H]*ANMY-G<2-$\2N<^2"4DCGC!^Z)0",#[Q&Z@#V/\
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M05\MRDJD,"I!D.,=*^\/B;\.] ^*O@C5/ GB56^Q:E&!O3B2*1"&CD0_WD8
M\\'H<@D5^>&A_LV?MA?!PW.B_"/QK9RZ)-(61#(% SU<V]S%(D;'OY;-GCDT
M >4^'+[XQ?L?_'+0/ASJ&N#5]%UB2T+6J2/);2VEU.8=Z1/S#,I5L;>X RRG
M!_:&OST^$O[('C9_B3;_ !>^/_B--?UFSE2X@MHG>8&:+F)I9'5 %B(!6-%V
MY YP"I_0N@#SKXP?\DE\;?\ 8#U+_P!)I*^%_P#@FS_R*OC;_K]M/_1;U^@7
MCS0KOQ1X'\1>&=/=([K5].N[.)I21&LEQ"T:ERH8A06&< G'8U\W?LC_  !\
M8_ 31/$6F^,+RPO)=7N()8C822R*JQ(RG?YL41!R>, T ?7E%%% !7YD?M,>
M"M?^)'QBO/#OBGXJ:3X,\&6\%JR6=]JD2.Q:,%W6Q\Q-QW9PTI7_ &217Z;U
M\K_%3]D'X6_%_P 8W'CCQ3=ZI%J%U'%$RVL\4<6V%0BX5X7.<#GF@#RCX7?#
M']B;X9>3>GQ;X?\ $6K1X/VO4]4LYMK#O'#O$28/(.TL/[U?6^D_&#X1ZW?V
M^C:%XTT2_O;EA'#;V^H6TLLC=E1$<DGV KY:_P"'>7P+_P"?_7/_  *@_P#D
M>NK\"_L1_"#X?>+M*\:Z'>:O)?Z1,)X5GN(7B+@$?,JP*2.>Q% &M??M5:%I
M?Q_B^ ^K:)-9323I;C499T6(R30":';'@DB0LJ#YAR>G:OJB80M"XN IB*G>
M&QMVXYSGC&.M?(7[3'[*6G_'"6V\5^'+]-#\6V$?EI.ZGR;E%.468I\RLASM
MD4$@'!! 7;\]ZA\"/VY_%6D-X%\1>.[3^PR@BDD:[;,T?0JTD=O]HD!'42'Y
MNAZF@#@?V.H[/_AK/Q?_ ,(,1_PC:1:MY7EG]W]A^UH+?;C@C[FWVK]@Z^>_
MV>_V>/#'P!\/7%CIL[:GK&I%&O;^1 ADV#Y8XU&=D:DD@$DDDDGH!]"4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '_T_W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /_U/W\HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
MU?W\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ck0001824293-20241231_g6.jpg
<TEXT>
begin 644 ck0001824293-20241231_g6.jpg
M_]C_X  02D9)1@ ! 0$"X0*-  #_X0'X:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X])^^[OR<@:60])U<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"<_/@T*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN
M<SIM971A+R(^/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R
M9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D
M-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N
M=',O,2XQ+R(^/&1C.G)I9VAT<SX\<F1F.D%L="!X;6QN<SIR9&8](FAT=' Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^/"]R9&8Z;&D^/"]R9&8Z06QT/@T*
M"0D)/"]D8SIR:6=H=',^/"]R9&8Z1&5S8W)I<'1I;VX^/"]R9&8Z4D1&/CPO
M>#IX;7!M971A/@T*/#]X<&%C:V5T(&5N9#TG=R<_/O_A ")%>&EF  !-30 J
M    "  !@I@  @    $          /_B#%A)0T-?4%)/1DE,10 ! 0  #$A,
M:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%
M0R!S4D="                  #VU@ !     -,M2% @(
M                                                $6-P<G0   %0
M    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H
M  (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M
M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X
M%&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\
M   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE
M=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q
M.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                      !865H@
M        \U$  0    $6S%A96B                      6%E:(
M &^B   X]0   Y!865H@        8ID  +>%   8VEA96B         DH
M#X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M       6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                     &1E<V,         +DE%0R V
M,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M        +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@                            !D97-C         "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M       L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V
M+3(N,0                                  =FEE=P      $Z3^ !1?
M+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M          $                        "CP    )S:6<@     $-25"!C
M=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/
M %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
M A$#$0 _ /U3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKFA\1/
M"K>&[WQ$/$^CGP_8LZ76JB_B^R0,C;7$DN[:I5N#DC!X- '2T5C>%_%FB>.-
M%@UCP[K&GZ]I%QGR;_2[I+F"3!P=LB$J<$$<&MF@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KQO]J+XA:O\-?A_INJ:5JL6@6UQ
MK=G8ZGK1MENIK"SE<J\L$#9\V7=Y:!0KGYR=C;<5[)7G/QD^%UY\2M/\-S:5
MK,6A:]X;UF+7=,NKJS^V6WGI%+"4FA#QET:.>0?*ZL"0P.10!X%X=^/WC7Q%
MX=BT31?%,.K2:YX^7PEHOC*ZTR.&[6T6P-Y=336>U46:,PW$*;XT#?NW,97[
MWK7P5^(VJ3>//'/PV\5^(+77/$OAJ[CDL[YHXK:ZU&PDM[>;S7@3"[HGN!$[
M1J%^:(X4O@\_<?LNZSJ,>J^(+_QG:GXD77B2S\46^L6FCF+3[6XMK46D<(M#
M.SO$UN9(WS-O;S"0RX4#7\-_LK^%M3FUS6OBAH_AKXG>+-:U ZA<W^I>'H6M
MK7]S# D%K#,9C%&L<$8.79F8%F/0  ]CTG5;+7]+M-3TR]M]1TV]A2YM;RSE
M66&>)U#)(CJ2&5E((8'!!!%7Z\I_9._Y-9^#?_8F:-_Z0PU@?$S]J:V\(_$6
MX\!>%?!'B3XE>++"SCU#5+/P\D*QZ="_^K\Z6:1%$CCE8QEB.>.,@'NM%?..
MK_MO>$8?@SI/Q"TC0]>UM=0\01>%V\/1PQP:G:ZF[%#:S1R.%216 !&[^)2"
M0<USGBO_ (*)>#? O@GQ'K7B'PAXLT/6/#>JV6E:QX;OK:%+ZU-W'))!,,2F
M-XV6)R"&R<=.1D ^L:*\OTWX_P#AW6OBIX;\$Z:D^H2>(/#3^*K'5H"IM9+0
M21HO.=V6\Q6'&,=Z]0H **** "BBB@ HHHH **** "BBB@ HHHH *^;/B+\<
MO$__  NSP+I?A6>WB\$CQ6OA;6KF2!9&U"\>RNKAX86/W5M_L\:NPZO*R9!B
M<'Z3KYY\8_L3_#_Q%KWAC4M-AN=#;2O$3:_=P0WUX\=X6CN!)&J_: L):6X$
MA=!GY2N,.: ,3XE?$KXBZEK'QGU;PGXCM]#TSX86\?DZ1)I\4\>LW*V"7\RW
M$C_.D926.)?**$$,Q+<+69XA^,_Q \=6/Q/\8>"_$$'A_1? .F6MY:Z+-I\5
MPNKSMIL6I2I<R,-Z(8YXXE\HH0P9B6X6NW^)'[..N^*]>\=_\(]XTA\.>'OB
M!;0VOB:RFTHW-R=D MGELYA,BPO);JD1+I*!L5@ >#6\;?LOZIJ5[XRL?"/B
M^#PKX4\;Z?;Z?XATV32C=7 2*W%J7LIO.00N]LJ1$NDH&Q6 !Z@#-4\>^,?C
M!\2;;PQX)\3_ /"#V%OX/L_%$U\-/AO9IYKV69+:!EE!41(+>1GV@,V]0&7!
MSO?LS_M,>%OV@/ GAVYM_$?AVX\:7&EK>:MX?TO4H9I[212L<S>2',BQ^81@
ML.CID\C,OC#X(:]'XRL_$_PY\46/@[55T%/#5U'J6DMJ-N]G'(TEN\:+/$5E
MA:27:69E(D(93P:Q?"/P_P!/^%'QB^#?@_2GFEL-%^'_ (ALHIK@YDEVWF@@
MR.>[,<L<=V- 'T!17 _'#XMZ;\!_A1XB\>ZM9W6H:=HL*S36UGM\YPTBIA=Q
M SEQU/:JG@WXV:7XV^*WC'P':6%Y#J7A>RTZ]N;F;9Y,JWD;O&$P2<J$.<@=
M>,T >DT5S'Q%^(&A_"OP/K?BWQ)>"PT/1[9KNZN-I8A5[*HY9B<*%')) [UQ
MGP9^-FL?%BZG&H_##Q9X$LVMEO+.\\0Q0*EU&Q "XCE9HY,$$HX!QGTH ]:H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'OVEO$GB#2?!EAI>@:
M7KUW_;M\NGZCJ7AVS>YN=-L2K-/+&J?,)&5?*1OX'E#_ ,&#\F?##4-'F\*^
M%M#A\/W^@>#+'XYW:3V>I6#6UND+-?FR@(;C]W<I:J4/W7\L=:_12N<N_A_X
M7U+P_JFAW7AK2)]&U6:2XO\ 3I+&)[>[ED??))+&5VNS/\Q9@23R>: / / E
M]XRTGXZ?'!/ASX<\.ZYH3:U8F\75-=FTN&'4/[.@-QY7DV5R'=@8C)G80P&=
MQ8X]T^%'CD_%#X6>#O&0LO[,_P"$BT:SU?[%YOF_9_M$"2^7OVKNV[\;MHSC
M.!TK1\)^#="\ Z)%HWAK1M/T#1XBS1V.FVR6\*ECEB$0 9)))/4DUPW[)W_)
MK/P;_P"Q,T;_ -(8: /5J*^3OCQ\5/%?AC]I"_T#2]<N++1X_A3K.N+9Q[=@
MOHI<13\C.Y1T[>U>H?LX>/IM6_9<^'OC'QAK<0GN/#EI?ZEJ^H2I$FYH59Y9
M'.%7DDD\"@#V&BOGGX_>)M'\;?#6#Q3X<^*?B33O#>EW1CO+CX7)#J=U=R.4
M58\I',0$W;B%'1LG@5\N>%_BMXK\9?LYP_$#Q3\7_B5:6&GZOJ>CZ9_PANDV
M\VH7$<+NT$VJ1)$_E2[!M9&*+@(2<ON(!^E-%>.?LB^/O$/Q0_9K^'WBKQ9>
MV>H^(-4TQ9[NZL2ACE;<P#$)\JOM"[U  5]PP,8'L= !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 >#Z]^UUX7M]3NM/\(^'/&'Q1N+65H+J7P3HS7=I!(IP4:[
MD:. L"""%D)&"#R*L^$_VL_"NLZY8Z+XET/Q7\--7U"9;>QM_&VCO8Q7<K'"
MQQ7*EX&<D@!/,W$D  FL_P".&I>+V^)'P^\!>%_%T?PPT'5K2_GFUZWTZWN)
M9KB P"&P@$ZM%&[I+-+RI8K VWHU=/\ #CX2>*_"NM7%SXH^*NM?$/3I;<Q+
MI6LZ;I\,,<OF(ZS P0(Q9=A !./F)QD @ ]8HHHH **** /*?V3O^36?@W_V
M)FC?^D,->)R:UK7[+_[4'Q;\3:QX'\5>*_"/Q"33+_3]6\*:4^IR6UQ:VY@D
MM9XX_G3/#(Q&W!QG.<>V?LG?\FL_!O\ [$S1O_2&&O5J /S;U_X$_$#Q)\&9
MM7NO#GB#PYJ_COXU6?BL:9IL!DU'0M/>0(MQ*%5UCE15\QF8%5)7=W%>B_&S
M]DJV\%>'_#,NBQ^*?B1X@U_XD^&]0\2ZMK)_M&[GM+:1DS,(XU1((HV8?="J
M&Y.,5]OT4 ? O[.?P3\=?!W]MZ7P[>:1J=U\-O#?A?4;7POXA:WE>V%G<WD%
MQ'9/.1M,L3&9 I;<50' 7%??5%% !1110 4444 %%%% !1110 4444 >#Z]^
MUUX7M]3NM/\ "/ASQA\4;BUE:"ZE\$Z,UW:02*<%&NY&C@+ @@A9"1@@\BK/
MA/\ :S\*ZSKECHOB70_%?PTU?4)EM[&W\;:.]C%=RL<+'%<J7@9R2 $\S<20
M ":S_CAJ7B]OB1\/O 7A?Q='\,-!U:TOYYM>M].M[B6:X@, AL(!.K11NZ2S
M2\J6*P-MZ-73_#CX2>*_"NM7%SXH^*NM?$/3I;<Q+I6LZ;I\,,<OF(ZS P0(
MQ9=A !./F)QD @ ]8HHHH **** "O*O$?_)TWP\_[$SQ-_Z7:#7JM>5>(_\
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MOA/P[9V>L:]=>+M:A1XYM>O[>"&YN5,KNJL(41 %#[0 !PN3R23U- !1110
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MDR) AMX8Y&C4;8'>, [,@!CP1G!R!Z30 4444 %>4_LG?\FL_!O_ +$S1O\
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MP,8^&^N&PTN#29;.ZTZ,WNB-Y5P[W$HD8*T:@*D6S800W4 'VG1110 4444
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M(P&%' '7K7VU\'_%U[X^^%7@WQ/J$<,=]K6CV>H3QVRLL2R2PH[! Q)"@L<
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M*$_\G@?$#ZV'_I!;5^K?[,__ ";K\+_^Q8TS_P!)8J\3!_[S5]7^9^D<1?\
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MXJD^,?QL'C#Q%\2_AKXA\0:1H=UI^F>%_AWJWV];:VGGMWN+JXD<B1R6AMT
M"*BY[ELT ?5E%%<=\4O'Z_#GPG)J,=JVIZM<S)8:3I<;;7OKV4[880>P)Y9N
MB(KN>%- '8T5\B>&?C3\2M0^&FA:'?:_8GQUK7Q'U+P2VOP:>@BM8+66\:2>
M. _*6\JS94#Y^9U+;L$'LO!/[1.E?#OQ-XU\$?%GXC>';'4O#^I11:?K6N7=
MKI<FJ6LUK#<*3&61#)&92CF,!<;#M7=0!V?[)W_)K/P;_P"Q,T;_ -(8:]6K
MRG]D[_DUGX-_]B9HW_I##7JU !1110 5_*O7]5%?RKT %%%% ']5%%%% 'YR
M?\%>O]9\*/IJO\[.OHS_ ()W_P#)H'@/ZZA_Z7W%?.?_  5Z_P!9\*/IJO\
M.SKZ,_X)W_\ )H'@/ZZA_P"E]Q7CTO\ ?I^G^1]_C/\ DF,-_C?_ +>?1]%%
M?-?[17Q2_:*\&>.K:P^$_P (M+\=>&FL(YI=3O=4BMG2Y+R!XMKS(<!5C.<?
MQ'GBO8/@#T?QGX!\'>%O%^J_&FYT62Y\8:-X<GL?MT=S*"UC&7N#"(]WEY+9
M^8KNYZXJQ^S_ /&*Q^/WPA\.>/\ 3K"XTNSUJ*26.SNG5I(PDKQ$$KP>4)X]
M:^2/%WQ=_;4\7^$]:T*?]G/0H(-3LIK&26/7[8LBR1LA89NNH#9KZ%_8@^'?
MB+X2_LL^ O"7BS3CI/B'2[>>.[LFECE,3-<S.HW1LRG*LIX)ZT <7\3OVI=(
MNKBU\'>+_P!G?XA>(8]:FDAM=)N]%TV^COO*Y=UA-VV44%2790%W+DC(K?\
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M$_:&^*?PDURRUC1;OQ$/A_KTFN:7I-]'.=/N6O=#4JZ*Q:-6:.0IOY*CO@T
M?6E%%% !1110!^5?_!<[_FB?_<;_ /;"ORKK]5/^"YW_ #1/_N-_^V%?E70
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MORKK]5/^"YW_ #1/_N-_^V%?E70 5^JG_!#'_FMG_<$_]OZ_*NOU4_X(8_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+5[]D%?'WPYT%/AAX]\!7.D7.GG4-2A\4:=>17>D7PFOWF,:,")8I!]IX21
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M ,FZ_"__ +%C3/\ TEBK\I/^"A/_ ">!\0/K8?\ I!;5^K?[,_\ R;K\+_\
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M"K0O@E\)?#W@GPWJ-WJNC:4DJPWU].LTTS/,\LC,Z@ _.[\ 8 P.U>AUYS\
M=+AT;X2:#9VO@+_A6-JGVAX?"WF12&R1KB1EW&,E0T@82LH)VF0J22":]&H
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MTTV@SWES9B87<<DNRY-H [1O$T9"9'S-S7Z95\<?!M?CA?1^,;GX9/X#T/P
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M0 4444 >4_LG?\FL_!O_ +$S1O\ TAAKU:O*?V3O^36?@W_V)FC?^D,->K4
M%%%% !7\J]?U45_*O0 4444 ?U44444 %%%% !1110 4444 ?&GQ\\3>%?&6
MMZ(/C'X9^*7PYO/#<\\FGZQX2DO+G39&D 7S4N=/5VW;!@"1(W4.XQ@FK'P/
M\2:=:^-H+CX:67QH^(4%XHL[G4_'6JW\&AV<#2(TDZ_VAAGE4)\HBB9CEE)4
M,37V'10 4444 %%%% !7E7B/_DZ;X>?]B9XF_P#2[0:]5KRKQ'_R=-\//^Q,
M\3?^EV@T >JT444 %%%% 'Y5_P#!<[_FB?\ W&__ &PK\JZ_53_@N=_S1/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >4_LG?\FL_!O_L3-&_](8:]6KRG]D[_ )-9^#?_ &)FC?\ I##7JU !
M1110 5_*O7]5%?RKT %%%% ']5%?$WQ,^)GQ(N/C;\2M)TKXDZSX<T;1M4M;
M*RL-.L-+DC1&TNQN&):XLY9&)DN)#R^,$   5]LU\%^.O^3A/C+_ -C!9?\
MICTNFMP#_A._BO\ ]%F\4?\ @KT/_P"5U'_"=_%?_HLWBC_P5Z'_ /*ZJM%7
M9 ?3O[*7C#7O'7P3TS5?$VK2Z[K(U36+*34)X889)DMM4NK>(LL*)&"(XD!V
MJ 2,XR:]AKPG]B?_ )-]L?\ L8/$?_I\OZ]VK, HHHH **** "BBB@ HHHH
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M'QI-H@\#_$>QLY+'^T].U5_!U_<1:C:%@JW$44$4DWE/N!5RFT@C)4_+6/\
M#9OB'K'A/6_%GPLN[76OAWJ&J7VM:7X:\66T*W.N)>7$ES>+#<Q%/LD1EEE\
ME;A))-Q;S2$*!-'X:_LD:GX9T[^QI?%,\/@*^FMKNYT*^L ^N-#"J_9]+N=1
M6YD1[6$(L82-!E0R[R&8N >[>!?B5I'Q#^W?V5:>(+3['L\S^W?#FHZ1NW[L
M>7]L@B\S[ISLW;<KG&X9ZZJUU=16=O+<7$J001(9)))&"JB@9))/0 =Z@T?5
M[+Q!I5EJNF7EOJ.F7T*7-K>6L@DAGB=0R2(ZDAE92"".""#0!H4444 %%%%
M!1110 5XM^TIK.J)'\.?"VFZI?:'#XN\60:/?ZAIT[07*6JVMU=2)%*OS1M)
M]E$>Y2& =B"#@U[37%_%#X9Z?\4_#]MI][>7NEW=C?0ZGIVJZ:Z+<V-W$28Y
MH]ZLA."RE75E9792"#0!X=X#^,0^#OQ8\?\ PUUF/QUXIT#2YX+S2=6M]*U'
MQ%+8QRVUN[6=S-"DTY)D>5XFE!RBNI?Y5#<(WB[2]6_8[^&'PYUCP3XWO]2T
M^'P?;:WHMW\/-:FA\JSO=/>_C?-D8Y%6*"?*@L'"D+NR ?J?X8_"NS^&D.M2
MC5-0\0ZYKE[]OU76]6:(W-Y,(TB3(B1(T1(XT141%4!>F22>YH ^5/[$_9C_
M .B"?^80U3_Y65SW@W4OV8?&5OJMQ%^SK<6-O8ZG=:9'+-\&KJ=;HP2&*26,
MV]E*%7S%D39)LE5HV#QH1BOKGQ!97NHZ#J-IIFHG1]2FMY([;4%A6;[-*5(2
M7RV^5]IP=IX.,5Q/P(TW7=#\#RZ;XB\,P^&M8AU*]GNC8W8N;/4)Y[B2YFO;
M<EVD2.:6:1_*D"M&6* ;54D ^?=63X0>%?B1\+?$7@+X0:QX=N-(U^XGU/4-
M$^$FK6,T=F^D:C!@LFGJSJ9YK8;!GDAL84D>Z_\ #2WA+_H#_$#_ ,-QXA_^
M0:]6HH _GN_:#_9Y^+7CCX^?$KQ'HGPF\?WNBZQXEU/4+&Y_X134(_-@ENI)
M(WVO"&7*L#A@",\@&O-I?V9_B_#JMMIC_"?QNNI7,$MS#9OX<O!-+%&T:R2*
MGEY94::(,P& 9$!^\,_T8?$;XD>'_A+X1O?$_BF_;3-$LS&L]TEM+<%=[JB_
M)$K.<LP' .,Y/%?+WA'_ (*#? CQ5XB_M_Q)=W?ASQ5HHO\ 2+/=8:A=++83
MS0N9D\N#&R;[);MB5%=#&R@8R6 /QW_X9.^-_P#T1OX@?^$O??\ QJOV[_9\
M^->B^!_@'\-?#FM^'_']CK6C^&=,T^^M?^%>Z_)Y4\5K''(FY+(JV&4C*D@X
MX)%>X_#OXA:#\5O!VG^*?"]ZVHZ'?F3[/=/;RVY?9(T;_)*JN,.C#E1G&1P0
M:Z>@#X*^,GBY_%7Q\U3Q'I7A#Q_=:--X9TO3X[G_ (0/6TS/#=:E)*FUK0-P
MMQ"<XP=_!)!QQ_B3QTWA;P[JFM7W@_QY%9:;:RWD[R>"]6A58XT+L3)+;+&@
MP#\SLJCJ2!DU^DM>7?M#>*-%T7X<W.A:SHMQXF/C R>&+/0[>7R3J4]Q;S?N
M#-O00JT:2YDW+M .#NV@NX'Q%XI^(D_AN&UC3P+X]O\ 5;Z0PV.EIX.U2&:[
M<*798_-MT#;45G8 DA58X.*]+_8E^/6EV'@GQKJVK^%?'FEIX@\2G4;&./P5
MJU\LD*:=8VK.);6VEC/[ZVF7&[/R\@9KM_B-\#_BI\5(M-\,^-=8L]0@<MJ-
MCXQ\+VWV"30;SRGCFM;BV>XW75G-%+)%F-PY#$.!Q(OKGPM^$^I^$=6EUWQ/
MKEGKNO&QCTNUCTC3?[-TW3;)#N$%M;>9(5W,%+,SL6V(!M5 M#=P/0=)U*+6
M=+L]0MUN(X+N%)XTN[:2VF564, \4BJ\;8/*.H93D$ @BK]9=[X@TS2=0TS3
M[W4;6TO]4D>&QM9YE22Z=(VD=8E)RY5$=R!G"J3T%:E( HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *^'OCE\!]9_P"%D>'? GPX\;^.(O%6O6M[K-SJ6O\ CO5OL&GV
M5O)"CE8(9E:1VDN8U5 R@ $GBON&OD_]KW4_!=M\5OAE9^._%R_#BPGM-3;3
M/&6FZL-.U6QOE:V'DJ[$I]FEB,F_S(W3='$"5++N ,C]FGP+XW^!OQ\?PA\0
MO$^I>+[W6?#]U?Z/JB>(=2NK-HH+BV6XCEL[N:41S RQ%95;!5G7@DU]CU\W
M_LXZ'\(K7QQJNI^%_C /C#X^N-/\J?4M2\46VK7UO8+(I:...#:L,/F-&6VH
M,L5R2<5](4 %<+\6/B]HGP9T*UU?7K?5[FUN;D6J+H^E3ZA*'*LV62%&95PA
M^8C&<#N*[JO%/VE/%7BBW7P+X)\(:POAG6O&^M-I)U\Q+*^GVT=K/=3O$K?*
M9F2W*)N& 7SU H \)^$/[67@[PC\0OC!JNIZ%XWALO$GB*#4-.=?!^HL9(5T
MZT@+$"'*GS(9!@\\9[U]E^&]>MO%'AW2M9LDGCL]2M8KR%;J!H90DB!U#QN
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^%?VJK[QSX(^.7AOQ-X@UWX:?V,]AJNF:!I^J>&=1U:[D62:SE*M:P
M2M)-*%@!\V-51!N##]XN/NJODG]LSXE:E\ _B+\-OB1I&DZ7J]W';:CH,MCJ
M&HR13744[6TOEVT$4$TKR[[=6\Q5(50P93O!4 POV2]0C\<?'2[\2:C>:;'K
M5EX<N-.MM/\ #_@'4O#UG]GDNK:2662:[&))=T4(5 >%WG'6OM.OF;]EG]KG
M5_VC/%FM:/?>"[#PF-)M!-<1-K<\M^DC.HC5K2>RMW$;*7/FC*@H%ZMQ],T
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MQC%?,6K_ +-OQE\"Z9/XCTGXGZ#X[U2QC:YD\-:YX(TZTL=0VC)A26!1) 2
M0K;FYQNSR:^B/ASXTM_B9\(/#GBCPY NFP:WHL%_86\H&VV\V$,D; #&$)"G
M QQQ0!^>OBSXK>!? ]C\!?AU\=-!U>ST_P $V]UIWB+PW?:;<7%K>WBP1QVN
MJ*RJ8[RW)2X. 68-< E#@X^G/V/='T9?&GQ%\0?#WPQJ'A#X1ZM%IQTFQO+*
M2QAN[Y!/]KN[6UD :*)D:U3.U0[1D@<5X9\/M2_9?\&>%[.P^.OA7[)\7&B7
M_A)I_'?A^[O[N\O\8FFBN#%(DD3ON,?E-C85P!7NO['>FZ5!XJ^(%]\.]%UG
MP_\ !FZ6Q.AV>K6\]M!+?#SS>3V4$^)([=E:V'*JI=7*C@T ?4E%%% !1110
M 4444 %%%% !1110!@>-(_$<WAB^3PG<Z9:>(F4?8YM8@DGM$;<,F1(W1F&W
M/1ASBOS@T'Q]XB^',WB#PU?:E\+=9UNTU_5I=2:V^&^M:X\,\U]/.RO<VS-'
MG][Q'DM&NU&RRDG]/J_.>W_;$U[]EWQ=X^\ VG@/2_%.C:7X@U&_2XT_6+R:
M2PCN;F2Y9;N2WT^9%;=*[;20R*51MQ7<0#ZT_9(T73_#_P"S_P"&;73+^?4[
M9Y;ZZ>ZN-(ETIGGFO9YI]MI* \*"620(I'W I&00:]DKA_@UX^NOBE\,=!\5
MW=G8:=+JT+7 @TG5!J5L(][",I<"./?N0*Q^0%2Q4\KFNXH *^)OVH-=\/?#
M7X]:'J'@_P".&E?"7QKXINTL/%,=]<V5U9K;Q6$\UO>75E.P*N?)AMUD#QY$
MJ#)X#?;-?)/Q.\76M]I'[0WBW5/"?AO6]8^%=S)/X>FU#3A)\PT2&;]^0P,@
MS<RKC(^4C&" : .9^%GB/0+[]HCX?7.I?&C3OVA_&]\U_9VTNC36EO8^&;06
M<LLMREI;&0;Y&CB@,DCY(EP#Q@_;E>%ZYX@3P%\1O@KIGA_1](TFV\97MY;:
MM]DL4C=XX]*N;I K* 1^]B3UX!%>Z4 %?%_[<7C3X 6WPU^+>D:M=^!A\4FT
M&ZC2*ZAMCJOVEK7, #%?,W[3'MYSC;BOM"OE/Q?HOC;]HGXL>,](\'ZUHOP\
M\,>$KR+2K_7SH%MJFJ:KJ!MHIY(T\\%(HHXYX5W$,Q;..,8 -KX(>//V:M7\
M0>'+#P)>?#R7QL]N?LL>BP6BWQ80,9=A10V?+$F[!Z;L]ZW?VH+?6M(D^'/C
M33]'U'Q)I/A#Q%_:FL:-I,9ENI;9[.YM_.CB!S*T+SI)L')"L1R*XOP+H_C;
M]GWXP>#_  _XQU?1?B!X>\6S7%AI?B*/0;;2]3TR^CMI)Q#*( $EBDBAF <!
M6##!X/._^V=I<NI^$_"1U72M;UWX<0:ZLGC'2O#RRO=7%A]GF$9:.(B22!;@
MP-*B9)52<$ T ?(>@?%#]G+XH:U\6(/%OA+5?B;\1M<UR_ETF:WT"\N+^YLW
M_P"/&"U=HPUHT,>R(AO+VM&S9((-?H;\$=*\1Z%\&_ ^G^,+AKKQ5::)9P:K
M,\GF,UTL*"4L_P#$=P.6[G)[U\7>(M>_8G\0:#/IGA+P;#JWB?RB-/LO!OA:
M_M]9^T ?N_*D2%&CD#8(9V !'-?:?P6M/$UC\(O!-MXUE,_B^'1;--7D9P[-
M=B%1*68<%M^[)'!.2* .WHHHH **** "BBB@ HHHH **** /EW]NC3_&MQ\/
M8;^PUWP3H_@72[[2]2U8^*K*XF??!J,,P(*2JK1_(@,.PO)RBD,ZX\&\+>,!
M\5/B#X%TO7+WPQ8Z=!XDTW489/"OPGUO3[BYGAN4D@C-U< I#$TBIO<@84')
M S7U5^V5;RC]G[7=4M?[/%]H5W8:Y:R:Q?BSLXY;2\AG1IG*L&0&/F/&7^Z"
MK,&'B7P@_P""A?B/XF_$#PMX4N?AMI>BR:W<1Q1WU]KMY9K/'D>9);+<:;&L
MS!-S+$)-S8P#WH ^WJ*** .!^.7A_P &^*OA3XBTOX@7UMI?A*X@7[;J%U>+
M9K:D.K13"9B!&Z2"-E8GA@M?$W@'XH:AXQ\+SV^L?MP:#X>T2/4=0TT6<T6D
M#6GLX+N:WBE%\9%.Z:*-)5E$.<2@@MPQ^O\ ]I?QE=^!_AG#?6EI8WQN=>T;
M3)K?48!-"\-SJ-O;RY0G!.R5L9Z'![5R_@W0/"MG\?/%_P /+7P/X9MM!TO1
M;'7X733$,[75[=WQGW,V1MW0A@ !@LW.,  &Y^R1?:#J/[/OAA_"NDG1_#D;
MWMMI\37#7!G@BO)XTNC(RJ7-P$%P21R9CR>I]DKRG]F?QYJ?Q(^$5GKFK"W6
M].J:O8A;6(11K%;:G=6T("CIB.% ?4@FO5J ,/QE>:%I_A'6;KQ.]E'X<AM)
M9-2;4@IMA;A29#*&^4IMSG/&,U\*^)OB+^RK)^TUX#O+6_\ AD?"D7AO6([]
MXK>S^R"Y:>Q, D 7;OVK-MSS@/CO7VA\9/'FG_"_X4>+O%VKV?\ :.FZ+I=Q
M?36>!_I"I&6\KD$?,0%Y&.>:^=[#]F/XT>+M/BUW5_BGH/@O6KI!./#FA^!M
M.NM/T\D9\DR3@RSXZ%BR\YQCK0![U\%=>^&7B+PM=7/PHF\.W'AU;UH[AO#$
M<*6WVH1QE@PB 7?L,6<\XV^U?(?[57C"Z^#.B_'G1O%4.N6=GXZU.PU72?$5
MC!/);WMBD5G#=Z49H@?LTQBMKE%W[583@[ASCZ:_9F\8:IKGAWQ+X?\ $FDZ
M3I'B[PGK,FC:O_8</E65Y)Y,,T5U$G51)#-$=IY!##H!7@'Q._X5-X=^/OCK
M5/VD?#UUJ4,]S!_PB.KZSI=UJ.AQZ;]EA#00B-'CBF$XN&DWJ"=R$$@B@"G\
M$)/A1\0/C5\-=?\ V=?!%[X>T_2_M8\4:U:Z/-IEB]@UI(J6<Q<*MS.;@V[K
MC>5\MFW8K[QKX=^$Z_"SQ!^T%X)U7]G'P]>:9ID3W0\8:KH^EW.G:'-8_991
M%!(LJ)'+/]H,#)Y:D@*Y)QD5]Q4 %%%% !1110 4444 %%%% !1110 4444
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M38W-U\#;B[CT^XUC3M)UC2-8U?2[6,R27>G6VH03W480?>_=1NQ7N%(K5?\
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M%% !1110 5R7C?X3^"/B8MO_ ,)AX-T#Q6+?_4_VWID%YY6>NWS%;'X5UM%
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MW3=*\&6=EHMM=6NBPI%91ZNOVLW"QK& @D$+6OF <@[0>: /IJBBB@ HHHH
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M^'K>&]!TB*QNM0\.^+1>W82"W$:RBV6$#YY!&&^;CS"<D]?K"OC+3_@GX$^
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M*VM\DTMK=PJ3DJL\+I(%R2=N['/2O3Z* /,OA%^SC\./@.M\? WA:VT2XO\
M'VN],LMS=3@=%>>9GD90>=I;'M7IM%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?/G[7'[7VC_L
MBZ;X1U+7-"NM9L==U$V4LEK,$:T15#/+M*G?@$_*,9QUKZ#KX[_;L\/Z?XJ^
M*G[-FBZK:QWVEZCXMGM+NUF&4FADMBKH?8J2/QH ZOX_?MN:+\#]:M+2/09/
M$UI=^%;CQ7;WUI>K''+#&RA47*G.\,&#9QCM5'Q=^VX[:QX=\,?#+X?7_P 5
M?'5]ID&KZIHNFZA';1:+;2Q+(OVBY=2BR$LH"'!(Y)&5#?G1\:M#\4?#'QUX
MO^$_B5I;RV\"^!]7LM!U28Y:\TF::.:U)]2@9HSC@;-O\-?5'[*.LO\ L(CP
M_P"%_'=I:?\ "N/B"MMJ>C_$** 1F"^FA5S8ZD_;&3Y<C'&,GIN\H ]@^"_[
M9WC[XU>))['3/@'J]MI.F^(6\.:WJS>(K-DTNXC=!<;DP&D\I9 QV9W= 37K
M_P )?CM;_%?Q_P#$[PO#I$NG/X'U6/2Y;F2<2"[+QE]ZJ%&T#&,$FO(/^">.
M&T_]H(@Y!^+_ (@P?PMJ/V-_^3B/VJO^QNMO_2=J /K:BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *\I^,'QWM_A#XR^&?AZ?2)=2E\;ZU_8T4\
M<XC%HVS=YC J=P]ABO5J^2?VTO\ DN7[+/\ V/!_]$B@#.\,_MU>.?'&FZYK
M?AOX ZOK'A;1[^ZLKK6D\16<<:_9V(E?RW ?  W8 /MFM'X>_P#!0SPQ\2/V
M7_&OQ?L/#US'<>$F*:CX;:\4SKEE\MA)MQM=6R&V]5<?PYKY[_9?_9UTWQI\
M#?B3X[G\8>-=-O-.\1:[*FDZ9KDEOIDQA8N!+; ;7#'AP?O#BO#_ (A>!=8^
M%O[$?@OXG^&+;S-#\<>$QX6\8VB<+YBSL]C>G_:4IY18]BJCE\T ?L)9^/-)
M7P#9^+M7O+70-'FL(M0GN-0N$BAMD=%;YY&(4 ;@,G%<Y:_M'_";4+&:]MOB
MAX-FM(8/M<LRZ_:E(X=_E^8Q\SY5W_+N/&[CK7Q!^T%X+^+Z_!7X;ZWX[UC1
M_%_P8TS7-#U/6?#NAZ-*MXND(03YYW-YZ(A4.H49.&X"UX#\9OB]\.IOVIM7
M\0_";PWX?'@;4M"TRPU/7-2\+O-I>FAKZ,2ZJ+%D42"+;%&,K@N#C)P2 ?K!
M;_M$?"JZT>'5X?B9X1?2IY'ABO1KMKY+R(N]T#>9@LJ_,1U Y/%,D_:.^%,.
MC:?J\GQ-\()I6H3-;V=ZVNVHAN)%QN1'WX9ER,@=,C-?D/X!T7PEX^_;X\(Z
M*FL:7\1O"=[K-C+->V_AN+1]/U&2.VN"2+-!L90Z[2V,.5;.1R?I*'X%_#V3
MQ1^W:[>#-%/]CZ6ATQ38Q[=/+:7-.S6XVXB8RA7RF#E5]* /NW5?V@/A?HFL
M'2M0^(_A.QU3[3]B-E<:Y;),)^/W10OD/\R_*1GYAZBFW7[07PNL=0U>RN?B
M/X3M[O1QG4H9M<MD>S&X*?-!?Y,,0/FQ@D#O7Y:?LX_#GPQXR_8G_:/\5:[H
M6GZSXCMM'M_L^J7UNLUQ 8]*AE5HY&!9#O.XE2"2!G.!6M^U%X3\(_!SP7^Q
MUK&B:)X9\-_VAI31:MJM_H4=] 4EMK(R7=U!C_2C$9I)P'R=XR.: /U3\$_$
M7PK\2M+?4_"/B32?%&G1R&)[K1[V.ZC5P,E2T;$!L$<'GFNFK\Y/^">>M:?-
M^UA\7[7P[XLM/&&A7&A6$[:OI?A^/0[.]F20IYD=K& GR[W3S /F(8\]3^C=
M !1110 4444 %%%% !1110 4444 %%%% '@?[1W[0WC3X$_;=2TOX0ZAXV\)
MZ;I3:KJ.OVNLVUI':A#(94,4F78JB!\J#G> .17A?BK_ (*;:Q\._#G@OQ5X
MT^!VL^'?!OBH0S:?K(UVVN/,@D19!(L2+N/[IM^UMIZ#@]/I']L+_DU'XP_]
MBEJG_I+)7R)X\\/V'BOX6_L$Z)JUK'?Z7J46FVEW:SC*30R:3$KH?8J2/QH
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M;6);(*L1X%\/[JUNOV'_ !3+K<,VHV'_  G_ (<6[@3+230K9*&1<<DE!@4
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M[]J<<Y&6 /TMHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQHH =117AO[57Q\UOX&^&_"\/A3PU%XI\7^*]<@\/Z/8W=S]GMA/*KL'E?\
MN@)TR,YZC!H ]RHKYA\ ^(_VM[KQIH\7C#PE\,;+PL]T@U&;2[V[>ZC@S\YC
M#.5+@=,C%?3U !1110!Q_P 1OBAX;^%>D0:CXCU./3H+BZALX%<Y>:6218U5
M%ZMRPSCH,FL#4/VB_!.F_%:'X<RWT[^*9#&#;PVSO'&9 2F]P,+G!ZUP7[;G
MP]L/%'PMM=871!JGB'2]9TDV$R1F26!6U*U\TH!T^0-D^F:^>_BMX7UR?]K&
M:R^'=QXX\->+=>U@0:YJ7#::-+:!D-S%_"&C))7/(8#M0!^AP:G5\A_LI?\
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MJ6B@ HHHH **** "BBB@"*2%)"I=%8J=R[AG!]14M%% !1110 4444 %%%%
M!1110 4W;MZ'\Z=10 W;[TR12(V.><&I:9-_JW_W30!X7^QU\OPWUP?]3+JO
M_I4]>[UX1^QW_P DWUS_ +&75?\ TJ>O=Z; *3:*6BD 4444 %%%% !1110
MF/>EHHH **** "BBB@ HHHH **** $/-&._>EHH \Y_:*7_BQ?CO_L$7'_H!
MJI^RS_R;3\*?^Q6TS_TECJY^T5_R0KQW_P!@BX_] -4_V6?^3:/A3_V*VF?^
MDL=/H!ZC1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *^<?$7_ "?QX2_[$FY_]*7KZ.KYQ\1?\G\>$_\ L2+C_P!*6H ^CJ*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY#_ &^FL_ >A?#?Q1/9367@
M^S\=:??^+[K2;9O,>S5)ANN/*&YXMS88'.=P&#G%?7E?&_\ P4U\6)X7^%W@
M%-7\2ZEX;\%:EXQL['Q+)HTS17DVGM',TB(5!) V;BHR3M'!QB@#YF^'>GZJ
MWQ/^$GQL6[U33==^(OQ-FL])\+2JL5DOA@*R[Q;;>&0!6#CCYE?J=Q_6&OSG
M^"/A?]B.#XL^$KGP/XWOM0\9+J,+:3;S:CJ+^;<[OD!61 IR>S<5^C% !111
M0 4444 ?+GP?_P"3]OV@/^P1H/\ Z3U]1U\N?!__ )/V_: _[!&@_P#I/7U'
M0 45Q7Q.\<:OX&TFTN]'\'ZEXRGFG\I[33717B7:3O.\CC( ^I%>5ZA^U%XL
MTNXL(+KX(>+(9+Z?[-;J9[?YY-I;;][T5C^% 'T317AFE_'[QK?:I9VL_P $
M_%5E!-,L4EU)<6Y2%2<%R W(%>XJ3MR1S0 ZBBB@ HHHH **2EH **** "BB
MB@ HHHH **** $8X%49M9L;>%9IKRWBA9MBR/*H5FSC .>OM65\0]%U#Q'X*
MU?3-+U231;ZY@*17\2[GAY&2!ZXR/QKX+\<:3X/M_P!F7X?Z=XKU*_U+Q&;S
M4-+\/V37AC%W?2/Y:W,YR.(R%<MVR3WH _0IM5LX[A+9[N%;AQE86D =A[#.
M:2+4K6^6X2VN8KAH<I((G#;&YX..AXZ5^?6K>$[WX;_&CP_XLU?4M&\;3VMO
M8:%$MMJ$CW]M<&U<B41@[2I/.3VK0^ T_B+P?JFK7OPMTRU\2^(]:T"UU'6[
M.^OR(S>&XF#.Q).U^7X]O:JL3<^C?V._^2;ZY_V,NJ_^E3U[O7SI^PK<:I=_
M!>]FUJTBL=6?Q!J9NK:%]Z12?:GRH;N!7T72>Y04444@"BBB@ HHHH ****
M"BBB@ HHHH **1?NBEH **** "BBB@ HIC,%4DD >YP*\HT/]I[X=Z_?>*;>
M#7XXO^$:622_EN$:./RXW*.Z,1AU#*02N><4 :O[17_)"O'?_8(N/_0#5/\
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M?\%6/^3BM"_[%BW_ /2J[K]%_P!FC_DW3X7_ /8L:9_Z215Y.'_WJH?=YO\
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M1U;0;*Z@O3&8B\U]+,-IQGAF([5Z5110 4444 %%%% !1110 4444 %?$/\
MP4*\ _$37OA_XSU#4_BGX>\*?!Z.WM9IK"]T9I[N.:.2,H8Y4^?>TX3: >I
MZ9K[=7.T9ZUX3^VM\)/$/QO_ &<_$?A/PG;VMQXEN)[*XL?MDXAC22*ZBD+E
MB".%5N""#TH ^"? O[7'[2-GK7A6U\:>,-?\%^&M4NH+2V\3>+OAW':V5SN(
MVAYU)P7'1@".=Q(&37ZA_$+Q]:?#GPZ=5N]/U;5V:58+?3]#L)+R[N96SM1(
MT''0DLQ55 )9@.:^&?C9X#_;,^/OPYMO!7B?P?\ #J/1GNK6YU(V&H21RWP@
ME24)N9V$89D!)49]"!D'Z:\+:;\</B3\-[ZU\9ZCI_PF\6KJ0-M>>$1#J0>T
M$:\,+I74%G+9XR JXZF@#/?XT_'6[E-SI_[.V--^\B:GXULK>^9>Q,*1R1JV
M/X3+WY(KT3X7_%E_B(U_8ZCX3\0^"_$&G*AN]+UZT"C#;@'AN(V>&="589C<
MD8^8+D5\A>%?"_[6_P 5H]9U;PC\<;33/#EKK%]I-K_;^G6!O9S:7,EM)))'
M%I^V+<\3D)N8XQGK7V%\$]"\;^&OAGH^F_$;Q!;^*O&4/G?;]7M(EBCGW3R-
M%A5CC VQ&->$'*GKU(!WM%%% 'G7[17_ "0KQW_V"+C_ - -4_V6C_QC3\*?
M^Q6TS_TECJY^T5_R0KQW_P!@BX_] -4/V7O^39?A7_V*FF_^DL=/H!UTGQ'\
M,0R/&^N62.A*LIE&01V--_X6;X4_Z#UC_P!_17\TWQ(N)?\ A8GBC,C'_B:7
M0^\?^>K5SGG2?WV_,T@/Z./AW\1/#,7Q#^),KZW9HDM_:E&,@Y'V9!7HO_"S
M?"G_ $'['_OZ*_F!\Z3^^WYTOG2?WV_,T ?U$Z/XOT7Q!</!INI6][,B[VCA
M<$@=,_3D5MU^+O\ P1:D9OVDO%(9F(_X1B8\G_IYMZ_:*@ HHHH H:IJEGHF
MFW6H:A=0V5A:Q//<75S((XH8U!9G=F("J "23P *YKPC\8/ OC_4I-/\,^,M
M!\0WZ1&=[;2]3@N95C#!2Y5')"@LHSTRP]:Q?VF&V_LZ_% '_H6-3Q_X"2U^
M=7_!*?C]HK7?^Q7N/_2JTKCJUW3JPII?$?08/+(XK 5\8Y6=.VG>Y^L=%%%=
MA\^%%%5-2OHM*T^ZO9]WDVT33/M&3M4$G [G H MT5^?7@?]J+]IK7/A_:?'
M@>$?"_B/X27T\TS^$M',O]N6FGQRO&9T<_+(Z[&)&3D#[J G9ZU\!_VLD^/G
M[3>LZ-X6URUU;X=#P;:ZU9+' JS173W'ER+(?O*RC@H>AH ]A^*'Q>N/ E]:
M:-H?@OQ%XZ\2WD1FAT[1;=4AC3)4//=S,D$*D@@!GW'!PI -<)'\:_C?I\GV
MG6OV=I#I2_-)_8?C&RO;U%[D02)"KG'\*R$GH,U:_:MA\8>&_ /B+QYX>^(^
MN>$K#PSHMS?7&D:1IEA<_;6B5I,E[F&1D) "Y'  S@UX?8?!C]MS4+&WNF^/
M/AZR,R+)]G-A:3E,C.W>NG ,1Z@8]* /L?P)XVLOB!X9M=;L+34;&*8NCVFK
M64EG=02(Q5XY(I &5@P(]#U!(()Z2BB@ KYQ\1?\G[^$O^Q(N/\ TI>OHZOG
M'Q%_R?QX2_[$BY_]*6H ^C<BEKY._;Z_;&U3]D+0?"%_IFA1ZX^M7-Q ZRW'
ME",1JA!SL;.=_MTKXQ_X?7^+?^A L_\ P9#_ .,4 ?IC^T/_ ,D\M_\ L/:-
M_P"G*WKTU?NBOQB\;?\ !7[Q/XXT-=-G\#VMLBWMI>!UOPW,%Q',!_J1U,>/
MQK?_ .'U_BW_ *$"S_\ !D/_ (Q0!^O]%?D!_P /L/%W_0@6?_@R'_QBOU5^
M%WBR7QY\-O"GB:: 6TNL:5:ZB\*MN"&6)9"N<#.-WI0!U5%%% #,]J-WOSZ4
M5XE\0OVR_A!\*_&%_P"%O$_BTZ;KU@8_M-K_ &9=S;-\:R)\\<3*<HZG@GKC
MK4RG&"O)V-J.'K8B7+1BY/>R3;M\CW"BD4[E!'2EJC$**** "BBB@ KS_P".
MB_#MOA;K@^*W]D?\(,47[?\ VV0+?[PV=>=^[;MV_-NQMYQ7H%?%G_!4;5-.
M\-_#/X:>(=7@LM8TO1_&UE>S^'-2D\N#5T2&=F@+D% =H8_O/E(##DD*P ?L
M?P_L9P_$.X/P.?13XS\J0)]H>^-WY>/G^S_;3G&W.[ROX<YXS7V1J$/VK3[F
M'?)'YD3)OA.'7((ROOZ5^>6A^(KO]L?XM_!G7O 'P/U7X=Z'X4UN+7+[QMJU
MC%8B6TC4AK.W*#]\DI(!VDXP. ,FOO3Q!X-@\1:WH>IS:CJUI+H\LLL4&GZA
M+;P7!D0H1/&I"R@ Y4-G:>1S0!\A? 7Q<_PO^$_AWPGJW[+?CB>^T>U6SDOK
M'0M,<7Q0;?M,F^Z!$LN-[KEL,S#<W4_9/A>^&J>&](O4TJYT-+BSAE&EWD:1
MSV89 ?)D1&95=,[2%) ((!(YKY%U[PW^SYX7U:YTS5OVF/$VGZE;.4GM+CXM
M7*RPN#@JZ_:,JP]#S7UEX%731X)\/_V+JTFN:/\ V=;_ &+5)KPW;WD'E+Y<
MS3DDREUPQD));.<\T <;^T=\-=3^+'PMN?#FCR01WTNI:;=AKEB$V6]]!.XS
M@\[8FQ[XKY]\1?L/ZSXH_:#N]5U.ZTNZ^&UYX@E\3W5K+N^TS3RP^2]L5Z;"
M.=V?XL8K[4INT\<T ?'7[,/P^\.?##]M#X\^'_"FD6^AZ+!I>B/%9VH(16:
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M $4S7O\ O^/\*]]_8/\ VHOBSXZ_:S^'FA:_X\U?5=(O+J=9[.XE#)(!;2L
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M_P"Q8U/_ -)9:_.C_@E-_P G%:[_ -BQ<?\ I5:5Y&)_WJD?=Y3_ ,B3'?\
M;I^L=%%)7KGP@M1R1K*C(ZAE88*L,@CT-244 ?/FH>%=/_8E_94\:GP&)[VS
M\,V%_K.FV.MS&XBA<AI3"-FQO*W[CC.?F;FJG[,/[/O@CP_?6WQKT'2O[ \2
M>//#UG=:KIM@^W3DDFCBGD:&(@E,OVW$=>,G-?1,T27$;1R(KQL,,K#((]"*
M\4\/_&K6-0_:V\3?"9K'3X= TGPK:ZW!=1HXN3+)-Y90G=MV = %!]Z .I_:
M(U;5M!^ OQ$U'0I;*#6+30+Z:UEU)HUMDD6!R#(9?W>T8_C^7^]QFODSX>Z3
M^SO#X)T5;#]K7Q/:6:VL?EV\WQ-73FB&T?+]EW)Y('3RPH"] .*^HOC_ .&=
M4O\ PO<:]8>/=2\%VNC65S-?0PZ1#J]G>V^T,ZSV;1M)+@(<")E8[F'.17Q3
MI_[=G@;PF-.;7?A[X8^(VCWTRP6NL^"_"M]83SL> !:7MJ(V8^B71Z'B@#]+
MJX+XP?&#1O@MX6_MS6H;R[C>9;>&UT^ S3RN1G"K] 33O@]\8O#7QV\!V?BS
MPI=M<:;<.\,D,RA+BUF0X>&:/)V2*<94]B#T(-<I^U-KMQH?PLOHD\,:GXDL
M=2#V%ZVC-B[LHI8V0SQ#J6&?X2#[T <]J'[<OPOL6\)G[==SQ^(H%NHI(8-R
MVL+2>4'G.?D!D!3ZU!XB_P"3^/"9Q_S(]S_Z5-7PW-\!_B796/AVTN/!FH22
M^*?#=GHT!C@ %@T&I-*#/@80^3M8^K$]Z^F?AO\ !F?X/_MU:;!/XRU[Q>=2
M\*75XK:[<>:;8&Y(\N/T7CI5"1Y!_P %P/\ D2?A7_V$+[_T7#7Y'U^N'_!<
M#_D2?A7_ -A"^_\ 1<-?D?4C"BBB@ K^F']F_P#Y-Y^&'_8L:9_Z2QU_,]7]
M,/[-O_)O'PP_[%C3?_26.@#T>BBB@!!7XL_\%"/^3P/'_P!;#_T@MJ_:9:_%
MG_@H1_R>!X_^MA_Z06U>1FG\%>I]]P7_ ,C"?^!_FC]I(O\ 5I]!3Z9%_JT^
M@I]>LCX)[A1113$)S12T4 %>,?M3>.=(\%_#N"/5_AEJ7Q;76+Q=/MO#.FZ8
ME_YTICD<-*K@A(P$;+X.,CBO9Z^-?VI/@'\;SX=\0:M\*OB-XLUG5=4\00:F
MVAIK::<;*R2&Y5[:SE8%5#/+$2K\'RE[B@#R_P#9S_8W^*NF?';2_B/8:/8?
ML\^"EN4N;WP-I.NW.H2ZD@.2DZA_) 88&!C;_<R*_0_4(?M6GW,.^2/S(F3?
M"<.N01E??TK\T?V=_&EU:_&SPGX=^(_Q=^-?@OQO]NB,7@_QI&7L=78-_JDG
M0;9(VZ;F" ]J_2_4/M/]GW/V,H+ORF\GS/N[\';GVSB@#XA^ _CZ'X5_#'PS
MX)UC]F3QI+J^E6:VK3V>BZ6[:AL&W[4ZO=JPDDQO<?-AF8;FQFOM#PO?#5/#
M>D7J:5<Z&EQ9PRC2[R-(Y[,,@/DR(C,JNF=I"D@$$ D<U^;_ (=_X9?A^%XL
MOBAI^I/\?6MLZY'>6U\_BB76]OS-;.H).91F(QGR]NS/&:^_?@:GB:+X,^!D
M\:M(?%RZ'9#5S,09/M?D)YN\C@ONSG'&<XH [NBBB@#Y=^$'_)^O[0'_ &"=
M!_\ 2>OCW_@N/_R,'P@_Z]=4_P#0[6OL'X/_ /)^W[0'_8(T'_TGKX^_X+C_
M /(P?"#_ *]=4_\ 0[6F@/R[HHHI %:&@?\ (>TW_KYC_P#0Q6?6AH'_ "'M
M-_Z^8_\ T,4 ?U ^$?\ D5=%_P"O*'_T6M:]9'A'_D5=%_Z\H?\ T6M:] !1
M110!^3G_  58_P"3BM"_[%BW_P#2J[K]%_V:/^3=/A?_ -BQIG_I)%7YT?\
M!5C_ ).*T+_L6+?_ -*KNOT7_9H_Y-T^%_\ V+&F?^DD5>3A_P#>JA]WF_\
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MJ/[+O_)LOPJ_[%33/_26.@#^<WXC_P#)1/%/_85NO_1S5SE='\1_^2B>*?\
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M2QT >CT444 (M?BS_P %"/\ D\#Q_P#6P_\ 2"VK]IEK\6?^"A'_ ">!X_\
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M!\)>$OC9'KWPKT;Q;J?[:5KHNL7FC1:E<^'Y%\.O<VDSPB1[4C[.'+JQ*8V
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MG/X=+('1K[Q5%>^(]03WBDN2EN#CHP#*?^>@K]9/@#X/\(?#_P"#?A?P_P"
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M,#:,)/$FFH=9_P"0<&N5'VK_ *Y\\UXYXB/_ !GQX3/_ %(]S_Z5-0!\J_\
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M[(+87 N-X79O\S<,9WXQ_#GFO1J* "BBB@ HHHH AN+A+6WDFD.V.-2[''0
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MR=!/_DO7Q_\ \%Q_^1@^$'_7KJG_ *':U74#\NZ***D K0T#_D/:;_U\Q_\
MH8K/J_X?XUS3C_T\Q_\ H0H _J"\(_\ (JZ+_P!>4/\ Z+6M>LCPC_R*NB_]
M>4/_ *+6M>@ KR#Q=X0^,-]XDO[CP]X[T+2]&D<&VL[K16FDB7 R"XE&[D$]
M!UKU^B@#YF\-V/QY\1:YXETX?$/PU#_8MXEIO.@/^\W0QR9_UW^WC\*]8^&?
MA_X@:+-?'QMXHTOQ"CJ@MAIVG-:^61G=NR[;L\?3FHOAG_R/7Q-YS_Q.(/\
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M[_R;+\*O^Q4TS_TECJ]^T5_R0KQW_P!@BX_] -4?V7?^39?A7_V*NF_^DL=
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MKX^_X+C_ /(P?"#_ *]=4_\ 0[6OL'X/_P#)^W[0'_8(T'_TGKX^_P""X_\
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M^%?>%O\ H7-)_P# 1/\ "H_ _AG1]%_:8^$DNG:59V$KOJRM);0JC,/L3<'
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MWY&*]\KP/]I_]G36?C]<^#I--\7-X:C\.WK:AY'V<31W$P*&)G4\'85) /\
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M>+KRS\5>)M22\U6YU+[*J*KM"B!8P<X $8_.O5/V7<?\,R_"O''_ !2NF_\
MI+'5[]HK_DA7CO\ [!%Q_P"@&J'[+O\ R;+\*_\ L5=-_P#26.@#^<[XC_\
M)1/%/_85NO\ T<U<Y71_$?\ Y*)XI_["MU_Z.:N<IL HHHI ?H)_P1:_Y.4\
M4_\ 8L3?^E,%?M)7XM_\$5_^3E/%/_8L3?\ I3;U^TE 'AO[87_)+=,_[&+3
M/_2A:\P?K7IO[87_ "2W3?\ L8M,_P#2A:\Q:J0F)1113)%7[PKO/V%_^2)3
M_P#8<O\ _P!&5P:_>%=Y^PO_ ,D2G_[#E_\ ^C*3&CZ&HHHJ2@HHHH ****
M"L7Q=X7LO&WA76/#^HAVT_5;26RN5C;#&.1"C8/8X)K:HH \-\6_L?\ PZ\:
MZQX7U+4K"X>Y\/V\5I#LF*B>&(@QQRC^-5(!&>]8?B#/_#>WA,?]2/<Y_P#
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M[_R;-\*_^Q5TW_TECJ]^T4?^+$^.C_U"+C_T U0_9;_Y-E^%?_8JZ;_Z2QT
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M+^UTW]H[Q/)=W$5M&WAJ90TSA03]HM^.>]?LK_PEFB_]!:R_\"$_QKYCLO\
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M;MT<B6Z*RGCJ""*^B_\ A37@+.?^$+T$'_L&P_\ Q-)_PICP#G/_  A6@?\
M@MA_^)H \N7]OSX"LP'_  L33,_5O\*^0O"/[3WPQLM9\;RW'BVSBCO?$E_>
M0%@W[R)Y24<<="*_0[_A3'@'_H2] _\ !;#_ /$T?\*9\!=/^$+T'_P70_\
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M !1110 5%-O\EQ$563:=I8< XXS4M5-4:Z33;IK(*]XL3F!7.%,FT[0?;.*
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M 'PKH'A#6/AQ%X<CTF'3;?5-4-X^LZ+&L8C-M<6J((I+JWP8R2R!FCRRCD$
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M7UZZCCNHC'*J2:S>NNY3RIVL.#7T#0 4444 %%%% !1110 4444 )M%+110
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MT <]\6?AG\?[J;X>R>(_&&A^,]$M?'&@7EWIN@^%I;>X2./487:8R>?)MCC
M+,2N H.2.M?9%? WQ2\3>*OA[XA\ _"37-5F^(&DKX_\.3Z)XJCG2XOK>*/4
MX&>SU55.5E1<E)R )54[L.#G[YH **** "BBB@ HHHH **** "BBB@ HHHH
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MM92MI$"\)C^0QG&5*_+@C'%>B5C^%[Y=4\-:3>)I5SH:7%G#*-+O(TCGLPR
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M7EW%'M;+10-(^<';C=CY:\%;P#^R_'HIUT?'_4EOO+\W_A(E^*<YO=V,[_\
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M\5]HT %%%% !1110 4444 %%%% !1110 4444 %%%4M8NI[/2;VXM8?M-S%
M\D4/_/1PI*K^)P* /F/XOVH^'O[2DOC_ ,3_  SUOXD^&K[P]:Z7I=]H.D#5
MI]"N(I[A[A3;#+JLRRPGS4!.8MIXK6_9BT&>^^)?Q*\=Z;X"U+X9^#O$$.G6
M]EHNK6:V-S>W4'VC[1?/:*?W&\2PQC.&<1;F XKLOV2=:NO%7[-_P]U^_P!=
MN?$>J:QI,6HW^H74QD<W4PWS1C^ZL<C/&$& H0#'%5?AYXEU"3]IKXN>&AJ]
MSJFB6>G:+J26\\QD73;N=;E)8$SG:K)!!+LZ R$@?-0![71110 4444 (P#
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M.Z=H6B6,&F:1I\"6MI9VZ[8X8D&%51Z "M6BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KRSXR?L[^&OC1-I>H7U[K7AOQ+I(==.\2
M^&-0:PU*U1\;XUE4$,C8&4=67VKU.B@#PKX=_LD^'?!/C2Q\6:WXL\9?$CQ#
HIH<:9>>-=8^VKIQ==KM!$J)&CE>"^TMCN*]UHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ck0001824293-20241231_g7.jpg
<TEXT>
begin 644 ck0001824293-20241231_g7.jpg
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M0R!S4D="                  #VU@ !     -,M2% @(
M                                                $6-P<G0   %0
M    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H
M  (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M
M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X
M%&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\
M   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE
M=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q
M.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                      !865H@
M        \U$  0    $6S%A96B                      6%E:(
M &^B   X]0   Y!865H@        8ID  +>%   8VEA96B         DH
M#X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M       6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                     &1E<V,         +DE%0R V
M,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M        +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@                            !D97-C         "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M       L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V
M+3(N,0                                  =FEE=P      $Z3^ !1?
M+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M          $                        "CP    )S:6<@     $-25"!C
M=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/
M %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M&,LP&1D@'&1GK68W[3GPH3P=I?BQOB#X?3PWJEW]@M-4:^0027&"?*+9^5P
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MK2?V*/@MHGA'P_X9LO UO;:1H>KQZ]91QWERDGV]!A)Y)!('E8#C$A9<8&,
M"@#YD_X*/_!7P)X=\'_!K0-#\):1X?TK6/'VFV%]!I%G':">'RYD"L8P,X61
MP">1N-4?VD?V>_ANO[?7[-^@6_@G0['0]2M;[[;IEG81PVUT+:-Y81)&JA7
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M,30!^<'QT^"?@;PW_P $G? _B/3_  MI=MXBD33-0DUB.U07DDT[_O2TV-[
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M@CR5RN'7UK[J^+?[!/P-^-WBR;Q/XI\$QS:Y<$&YO+&\GM#<D#&9%B=59O\
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MT>70/^";?[2&ESWUKJ4UCXVL;9[ZQF\Z"X9+BV4R1R?QHQ&0W<$&OTF\9_\
M!./]GKQ]XNN?$>J_#Z);^[E,US'8W]U:03.3DL8HI%4$GD[0,YR:Z6P_8C^"
MVE?#/Q#\/K/P6MMX/\07L>H:EI<>I7@6:>-E9&#^=O0 HGRHRKQTH ^7_B+^
MSYXRN?C1-\5/AC_PKCXC:FWAO3M/UKP5XV"32V&VUA93$"<1%XPC9=D^^3\P
M:OH;]@OXN>'/C)\!5UCPWX+L/ *6VJ75E?:)I806<=VNUY'AV +L<2*W X)8
M<XR9?BC_ ,$__@7\8O%!\0^)_!C76LM%#!)=6^IW<!ECBC6*-7"2@'"(JYQG
M '->P_#GX:^%_A#X0L?"W@_1;;0-!LL^39VH.T$G+,S$EF8GDLQ)/<T =311
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  >^*>G?&7P#IWBC3;>XL5N#)#<Z?>)MN+*ZB<QS6\H[/'(K*?I7<4 %%%%
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M7]F_X6ZOJUY-J&J7_A?3;JZN[AR\DTKVL;.[$]2222?>M;X[*%^!_P 0L?\
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MVR:]VKY_^ __ "7KXS?6Q_\ 2K4Z^@* "H)+B*&6&-W5'E)5%8@%R 20!W.
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MGF?/K%VM\TOU/T;HHHKO/F0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#Y_P#@/_R7KXS?6Q_]*M3KZ KY_P#@/_R7KXS?6Q_]*M3KZ H
M*I7.GVMY=6=Q/;0S7%H[26\LD89X6*E"R$C*DJS*2.S$=ZNT4 %%%% !1110
M 4444 %4-0TFQU@0+?6=O>K#)YL0N(ED"/M*[ER.#M9AD=F([U?I* %HHHH
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ML^#='T'1_ L7AVXAN_MD3:@KVCQ^6$B6/[1"&;.W:3MW8(H ^U?V<[/4]/\
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MXK\">%[7PV^B:6MH8'U"QDEG/F6L4K;F$J@_-(V..F*\-_X?)?'K_GR\'_\
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M\0-+M/$<V\HGV/YV99&[+@,WUC![5]IUQ7Q>^$?A?XY> -5\&^,-.&I:'J"
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MXA_M.7.N0^-Y].G^R).\365H("-AM0 <'D?OG_3TK[PK\HO^"*O_ "$?%/\
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MX>\7_M)^./ \VM:?:Z-JGA#QUH-OHNMWEA TODVQU%_EESY\REX\M('.<C%
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M@# IU% 'S_\  ?\ Y+U\9OK8_P#I5J=?!_\ P6\_Y'KX:?\ 8+NO_1R5]X?
M?_DO7QF^MC_Z5:G7P?\ \%O/^1Z^&G_8+NO_ $<E 'YCT444 %%%% 'ZE_\
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M &*&D_\ I)%0!^,?_!4K_D^3XA_[FG?^F^WKY0KZO_X*E?\ )\GQ#_W-._\
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MMY183Q1DAE7=P.-RYZC(!S7P'_Y+U\9OK8_^E6IU\'_\%O/^1Z^&G_8+NO\
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ML? OP%=?"WX,^!O!U_=+>WV@Z+9Z;/<1Y*/)%"J,5SSMR#C/;%=W7SI^Q_\
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M"OOBB@#Y!_:W^)VB>-/A+JNJZ?\ :9].^&GQ TJ3Q*CQA?W5I<6TUQL4G]X
MD\9 ')(('2O+OV.O#5A^T!\?/CE\0+.WU"S^&_BBQTF+3YK&_FTRXF:%0A(^
MSRK-'A[>0'YEW ]PQK]#F 8$$9%(JA0 !@>E 'S'^RWX-TWP3\:/C+8Z:^H/
M;[K#G4-2N;V3BYU)1^\GD=N@]>3SUKXM_P""WG_(]?#3_L%W7_HY*^\/@/\
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M(AX4M+H:AJ*I!;P&V4S86WCD2UCW%2S99\':=M?;<<201JB*J(H"JJC  '0
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M  6\_P"1Z^&G_8+NO_1R5]X? ?\ Y+U\9OK8_P#I5J=?!_\ P6\_Y'KX:?\
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MX??L^?#?PUJRM'JNE>'K&TNXV.3',D"!T_X"V5_"O2J "BBB@ HHHH ****
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M-5^#O_8GZ3_Z1Q4 ?C%_P5*_Y/D^(?\ N:=_Z;[>OE"OJ_\ X*E?\GR?$/\
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MDTW0=2\#0:?/<ZII"37,$RW9RO"INR!+ O"#JV>F: /1?@/_ ,EZ^,WUL?\
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MJ^KQ6<>J6VKZKI,[:>K+;R&TOY[421AF8X985;[QY)YKTF@"#['!_P \(_\
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M (07PWYA;_A']*W$8+?8HL\=/X?<_G3_ /A"/#O_ $ -+_\  */_ .)K<HH
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M&;PUJGQ4M/ 6GW)U+5;G1KC6Q=6<L4MM'##/!"R,RON#EKA"!MQ@-R. >_H
MQ;?P?H5K-'-!HFGPS1L&22.TC5E(Z$$#@UM444 %%%% !1110 4444 %%%%
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MV,D)DA01PQ(9)=Z[F8O&HP,' !]1T444 %%%% !1110 4444 %%%% !1110
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MV48/#VB_$#X87_\ P@/Q'\$Z1XBT^23PG>:UXW.J:9=J;%I4A-JLS!,VQD=
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9** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ck0001824293-20241231_g8.jpg
<TEXT>
begin 644 ck0001824293-20241231_g8.jpg
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M0R!S4D="                  #VU@ !     -,M2% @(
M                                                $6-P<G0   %0
M    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H
M  (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M
M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X
M%&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\
M   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE
M=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q
M.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                                      !865H@
M        \U$  0    $6S%A96B                      6%E:(
M &^B   X]0   Y!865H@        8ID  +>%   8VEA96B         DH
M#X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M       6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                     &1E<V,         +DE%0R V
M,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M        +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E
M("T@<U)'0@                            !D97-C         "Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M       L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V
M+3(N,0                                  =FEE=P      $Z3^ !1?
M+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M          $                        "CP    )S:6<@     $-25"!C
M=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/
M %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MMXC=EY]I[/YZ@D9&Y7&3BOVPNK6&]A:&XACGA;[T<JAE/U!J15$:A5 50,
M8 H ^1/^"HWPW\0?$;]F R>'=.FUFX\/ZW:ZW=:; A=[FVB65)%"CE@!*'('
M9">U?*O[='[1GAW]O#P%X(\"_!?1M8\7>)K:YDU^_MX]-DC?3HHK60-"Y8 %
MB7_@)4E% )+*#^M%5;>QMK1I7@MXX'F;?(T:!2[>IQU/UH _(WXA?M*^!?'7
M_!,RX^%6F7MXOCGPOHNE'5=-N;&6'R!%J%K$YWLH4_-(G .>?8UZK?>-[']D
M/]M@?%#XB6M]!\/?&_@JPTVQ\16]I)<PV-Q%#:AH7" L,_9BV%!/[Q2 1NQ^
MD]075K#>0O#<1)/"XPT<BAE/U!H \U^ _P"T5X._:2T'5M;\#7%Y?Z+I]Z;#
M[?=6;VR7$@17)C#@,5&\#)4<@U\*_!3XD:!^P'??$_X(_&W3=4TGP3KVKW>H
M:'XEM[.6>UOK2XB6)XRT0+!O+CCX4$JQ<'& 3^FT4,=O$L42+'&HPJH  !Z
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M*.#XM^"KJULM9L8V9M&O_+DD_LUSSM#90,!D%A&02(V(_;:N'^-7PY_X6_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRUO?$.FV,^HR76J75YYKK$6!43R.$YE?[@&<C/08]LH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%?.O[8/A_Q==^%8-=TKQ]XF\(^%]$@FN-1L/!&G_:-9U*=MJVZQ-@X16.6
M4+R"22 ,@ ^BJ*_/"R^-GQ)^*7PE_99\'3^/9-)U_P")%Q?#7?%'AF2(W8@L
MT9_*5PI6.8@H),#*NC#U!I#]K;XA^$_V-_BOYNNOJ?CKP?XHN/!UEXEN8T,L
MBB\BA6YD&-ID6.;@XY*@G/.0#]'*^-+'_E+%J?\ V3!?_2U:P? _Q[U']E'X
MJ?%7P7\2_&WB#Q[X3\/Z5I>M6>K:A;BZU&%KEUAEB/E@%T,CJ0,?*!]:YOX!
M_';PM^T'_P %+M2\4>$FOCI?_"NFLC_:%HUM)YB7D;-\K<XPXYH _0VBBB@
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MOFJF2/LTQ;]XR ,"Q]<2?K310!\6?%#QYH?P=_;9\,_%_P 67:CX8^)/ ?\
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MC[_&?\DQAO\ &_\ V\^CZ***]@^ "BBB@ HHHH **** "BBB@ HHHH ****
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MIOA[]G:#2]!T_P 4PZ+8>-H]7GD:'43,XM9/)8[=K/$2!N./?&" ?K#1110
M4444 %%%% !7QI8_\I8M3_[)@O\ Z6K7V77QI8_\I8M3_P"R8+_Z6K0!]ET4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\Q
MGQN_Y+1X^_[&#4/_ $IDK^G.OYC/C=_R6CQ]_P!C!J'_ *4R4 <51110 5_4
MOH'_ " =-_Z]H_\ T 5_+17]2^@?\@'3?^O:/_T 4 :-%%% 'YR?\%>O]9\*
M/IJO\[.OHS_@G?\ \F@> _KJ'_I?<5\Y_P#!7K_6?"CZ:K_.SKZ,_P""=_\
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M_P"Q@U#_ -*9*_ISK^8SXW?\EH\??]C!J'_I3)0!Q5%%% !7]2^@?\@'3?\
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M5 !))X %7<_-^->:?M+'_C'/XG_]BQJ?_I++4R]V+9I2BJE2,.[L;'A'XO\
M@7Q]J4FG^&/&>@>(;Y(S.]KI>IPW,JQA@I<JCDA0649Z98>M=H*_)W_@E/\
M\G%:[_V*]Q_Z56E?K!GCDUSX:L\13Y[6/7SC+HY7BWAHRYDDG?U'T445U'B!
M7SI^UO\ \C;^SS_V4FS_ /2*]KZ+KYT_:W_Y&W]GG_LI-G_Z17M 'T71110
M4444 ,_G7Y/_ /!5C_DXK0O^Q7M__2J[K]!?VG/C=J/[//PQF\:67A;_ (2J
MVM;N&&]@^WK9_9X9"4$NXHY?]Z8DVJN?WF>BFOR2_:J_:*_X:;^(ECXJ.@?\
M(Y]ETR/3?LGVS[5NV2S2;]_EIC/FXQC^'KSQX^8U8*G[._O:'Z%PA@<1/%K%
MQC[BNKW6]MK7N?K_ /LS_P#)NGPO[?\ %,:9_P"DL=>D]<U^>G[*/[?.H^(+
MOX:?"'3?AL+JXCMK31VU'^W%3$,$($USY30 ?+%$\GE[\G;M!)(S^A8Z>E=^
M'JPJP3B[V/E,TP.(P.)E#$1Y6VVM4]+[Z-CJ_F-^-W_):/'W_8P:A_Z4R5_3
MG7\QGQN_Y+1X^_[&#4/_ $IDKI/(.*HHHH *_J7T#_D Z;_U[1_^@"OY:*_J
M7T#_ ) .F_\ 7M'_ .@"@#1HHHH **** "BBB@#\/_\ @LA_R=Q:?]BS9?\
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M<HNGRZ+J?7<9Y?"C66+=3WIV2C;MN[W].G4]PKXH_P""O/\ R9OJ'_8:L/\
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M60_Y.XM/^Q9LO_1MQ7PO0 4444 ?LQ_P13_Y(#XR_P"Q@/\ Z(CK]$*_._\
MX(I_\D!\9?\ 8P'_ -$1U^B% %6^^T?8YOLHC-SL;RA*2$+X^7) .!GV-?,V
MH:E^UAI]C<W<FF?#4Q01M*X76;K.%!)Q_H7M7U'63XJ_Y%C6/^O.;_T T ?*
M'PL^)G[47Q>^'?A[QGHVD?#R#2=<M([ZVBO-7N5F6-QD!PMFP!^A-?7&FB[^
MP6WVX1B]\I?/$+%D$F!NVD@$C.<$@?05XS^PW_R:!\(_^Q>M?_0:]SH ****
M "BBB@ HHHH **** "BBB@ HHHH **** /GS]K[X3^(OBAH/@N]\%7^D0^./
M">OP^(M)TW7C_HFH/$CJT+@<CA\AAT(ZC.X?*/PO_9Q^-S:UX-TGXJ67@WP%
MX*T_QZGB\WJZ@DU_>W[3M)%9VY#L '=]N.&(]2,'B_CY\(5^,'C[]K'XGZAK
MNI6WB+X;3VO_  CKPW$BBS\FW$AV88;<[.PX+$]37K/[+_[*GQ'^,WQ"\,_'
M;XY^))-0,9AUKP]X=BNWDCM6;$D3L@PD>T%/E7.<8(&* /T,HHHH **** "B
MBB@ KXTL?^4L6I_]DP7_ -+5K[+KXTL?^4L6I_\ 9,%_]+5H _.O_@K9_P G
MI>(?^P9I_P#Z(6OC:OLG_@K9_P GI>(?^P9I_P#Z(6OC:@ HHHH _;/_ ((Q
M_P#)J>L_]C5=_P#I-:U]ZU\%?\$8_P#DU/6?^QJN_P#TFM:^\)IEMX9)7.$C
M4LQ]@,F@ D5FC=4;RV((#8S@^M?,GQ%^%WQM\+^%?$_B*U_:*U+9IUE=:A%9
MMX2TPKB.-I%CW;,XX SUJ?0_V\_"'BC2;;5=%\!?%#6=*NEWVVH:?X,NYH)T
MR1N1U&&''45E_$?]KC3O%'P]\4:-9?"WXM&]U'2[JS@$G@B\5?,DA9%R=O R
M1S0!4^#O@/XY?$WX4^"O&,_[16HV,FO:19ZK)9Q^$=,98FFA20QABF2 6QD^
ME?6<*M'$BN^]P "Q&,GUQ7Q_\"/VI+3X=_!+X?\ A;5OA;\6%U71= L=.NUA
M\$WCH)HK=$?:VWD;E.#W%==JG[>/@[P[:I=Z[X'^)?A_3C-' ^H:MX0NK6WC
M:1PB;Y' "Y9@/J: /I>OBC_@KS_R9OJ'_8:L/_0FK[*TG4H-8TRSO[5M]M=0
MI/$S#!*,H93CMP17QK_P5Y_Y,WU#_L-6'_H34 ?A=1110 5]^_\ !%S_ ).?
M\1_]BK<?^E5K7P%7W[_P1<_Y.?\ $?\ V*MQ_P"E5K0!^U=?.UA_RD(UG_LF
M5I_Z=)Z^B:^=K#_E(1K/_9,K3_TZ3T ?1-%%% !7SI^Q/_R*_P 5/^RE^)/_
M $L-?1=?.G[$_P#R*_Q4_P"RE^)/_2PT ?1=?S&?&[_DM'C[_L8-0_\ 2F2O
MZ<Z_F,^-W_):/'W_ &,&H?\ I3)0!Q5%%% !7]2^@?\ (!TW_KVC_P#0!7\M
M%?U+Z!_R =-_Z]H__0!0!\N_\%(/^26_#_\ ['>Q_P#2:[KZSKY,_P""D'_)
M+?A__P!CO8_^DUW7UG0 4444 ?.WQF_Y/%_9R_Z]_$W_ *1P5]$U\[?&;_D\
M7]G+_KW\3?\ I'!7T30!^'__  60_P"3N+3_ +%FR_\ 1MQ7PO7W1_P60_Y.
MXM/^Q9LO_1MQ7PO0 4444 ?LQ_P13_Y(#XR_[& _^B(Z_1"OSO\ ^"*?_) ?
M&7_8P'_T1'7Z(4 ?/$W[??P(AGFB_P"$[\UH9'B=H-'OY4W*Q5@&6 @X((R"
M>E9_B#]O7X&7F@ZE;P^-)GFEMI8T4:'J/+%" /\ CW]:O_\ !/\ S_PR?X0_
MZ^M5_P#3G=5]$4 ?#_[*/[97P@^'O[-OPY\,^(O%-QIFN:7HT%K>6;Z-?N8I
M57#*2L!4X]B17J__  W_ / 560/X\\H,ZH'FT>_C0%B ,LT  Y(Y)KZ)KYW_
M ."@G_)G_P 0_P#KE9_^EMO0!]$4444 %%%% !1110 4444 %%%% !1110 4
M444 ?)OQ._X)I?"7XL>//$?BS6;WQ5#J7B"?[3?16.JB*!VVA<!/+/&!T)-1
M> /^":'PJ^&OC'0?$FD:OXQ:_P!%O(;VUAN=:WP%XF#*K((QE<@9'I7UO10
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MW_KVC_\ 0!7\M%?U+Z!_R =-_P"O:/\ ] % 'R[_ ,%(/^26_#__ +'>Q_\
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M10 4444 %%%% !1110 4444 %%%% !7QI8_\I8M3_P"R8+_Z6K7V77QI8_\
M*6+4_P#LF"_^EJT ?G7_ ,%;/^3TO$/_ &#-/_\ 1"U\;5]D_P#!6S_D]+Q#
M_P!@S3__ $0M?&U !1110!^V?_!&/_DU/6?^QJN__2:UK[IUC_D$WO\ UP?_
M -!-?"W_  1C_P"34]9_[&J[_P#2:UK[IUC_ )!-[_UP?_T$T >$_L!?\F:_
M"?\ [ R_^AO7T%7S[^P%_P F:_"?_L#+_P"AO7T%0 5\R?\ !1S_ )-1U_\
M["FD?^G&WKZ;KYD_X*.?\FHZ_P#]A32/_3C;T >\?#G_ ))[X6_[!=K_ .B5
MKY+_ ."O/_)F^H?]AJP_]":OK3X<_P#)/?"W_8+M?_1*U\E_\%>?^3-]0_[#
M5A_Z$U 'X74444 %??O_  1<_P"3G_$?_8JW'_I5:U\!5]^_\$7/^3G_ !'_
M -BK<?\ I5:T ?M77SM8?\I"-9_[)E:?^G2>OHFOG:P_Y2$:S_V3*T_].D]
M'T31110 5\Z?L3_\BO\ %3_LI?B3_P!+#7T77SI^Q/\ \BO\5/\ LI?B3_TL
M- 'T77\QGQN_Y+1X^_[&#4/_ $IDK^G.OYC/C=_R6CQ]_P!C!J'_ *4R4 <5
M1110 5_4OH'_ " =-_Z]H_\ T 5_+17]2^@?\@'3?^O:/_T 4 ?+O_!2#_DE
MOP__ .QWL?\ TFNZ^LZ^3/\ @I!_R2WX?_\ 8[V/_I-=U]9T %%%% 'SM\9O
M^3Q?V<O^O?Q-_P"D<%?1-?.WQF_Y/%_9R_Z]_$W_ *1P5]$T ?A__P %D/\
MD[BT_P"Q9LO_ $;<5\+U]T?\%D/^3N+3_L6;+_T;<5\+T %%%% '[,?\$4_^
M2 ^,O^Q@/_HB.OT0K\[_ /@BG_R0'QE_V,!_]$1U^B% 'SO_ ,$_O^33_"'_
M %]:K_Z<[JOHBOG?_@G]_P FG^$/^OK5?_3G=5]$4 %?._\ P4$_Y,_^(?\
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MG<;G!^88H _4ROG3]B?_ )%?XJ?]E+\2?^EAKY]_X7)^WY_T2SP9_P!^9/\
MY*KCOACJ'[<?PIL==M=(^&7AB6/6M;O=>N#=HS%;BZD\R0+BX&$#= <D#N:
M/T^K^8SXW?\ ):/'W_8P:A_Z4R5^LW_"Y/V_/^B6>#/^_,G_ ,E5\0>*/^"=
M/[2'BSQ+JNN7O@-5O-2NYKV=(;J,('D<NP4%C@98XY- 'R'17T?XT_X)\_'/
MX?\ A/5_$NN>#FL]'TFUDO+NX^TQMY<2*69L Y. *=X/_P"">OQU\>>$](\1
MZ+X-:[T?5K2.]M)_M,:^9%(H9&P3D9!% 'S=7]2^@?\ (!TW_KVC_P#0!7X(
M?\.Q_P!HG_H1&_\  N+_ .*K[MM/BY^WS9VL,$?PL\&[(D6-=T+YP!@?\O5
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M@^,7A'XQ?"?PM\2!X!\0:3\1HY/LC^#S<QWNGLL(D#2QRNP*?, 2/1CGY<$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ck0001824293-20241231_g9.jpg
<TEXT>
begin 644 ck0001824293-20241231_g9.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $U G # 2(  A$! Q$!_\0
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M6QY9VD$C VXK])OB/\#_  !\7=&LM*\8^$=)\06%E_QZ17=LI^S\8Q&PP4&
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M!JVJB>W(DC*,638,D G'/6O??$W@SP_XUM8+;Q#H6FZ];V\HGAAU.SCN4CD
M(#J'! ;!/(YYK8Z<#@5PO%S5"-"#LE>_G<KEUN?CIKDB_P#"B_V[OF'_ ".-
MAW_ZB;BJ7QD\5_!_QI^RG\!?"WPPL[,_%V'4+&(VNFVGEZC#<!"MP9F #'?.
M4922<\$<"OUQ?X6>"Y+/6+1_"&@M:ZS*L^IP-ID!2^D#;@\Z[<2,&Y!;)SS3
M;'X4>"=+\21^(;+PAH5IKT<8A34X--A2Y1 NT*) NX +\O7IQTKT8YE!._*]
M'??^ZEK]Q/*?!OP#^%GA3XE_\%%_VB6\6Z#IOB,:;' 8(M0MUFCCD?R@SJK
M@-\F >HR?6N#^"/B;X0_#GXZ_M)VO[1]KI__  E5WJLTEO+XALS<?:+%FE.R
MWRIP64Q%=N"5V;3\O'Z?Z;X-\/Z-KFH:UI^A:;8ZQJ./MNH6UI''<7..GF2*
M SX_VB:S?%WPG\$^/[RVO/$WA#0O$-W;<0SZIIT-R\8] SJ2![=*P6/3;4D[
M-):/56[>H^4_(WPOX3TFX_X)\0MX[UC7/!GANX\>R:AX0U!=,>^CA7RMH\]
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M5GO0&#.H$*8^;<QZ?*Z#+;,5]'T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%-WKN*Y&[&=N>: '44WS%VD[A@=3GICK2JP8 @Y!Y!% "T444
M%%%% !1110 5YW\8OA[XO^(%GID/A+XDZC\.);:1WN)M/TZVO#=*0 JL)U.T
M+@GY>N>>U>B44 ?-?_#-_P 9O^CG_$O_ (36F?\ QNC_ (9O^,W_ $<_XE_\
M)K3/_C=?2E% 'S7_ ,,W_&;_ *.?\2_^$UIG_P ;H_X9O^,W_1S_ (E_\)K3
M/_C=?2E% 'S7_P ,W_&;_HY_Q+_X36F?_&Z/^&;_ (S?]'/^)?\ PFM,_P#C
M=?2E% 'S7_PS?\9O^CG_ !+_ .$UIG_QNC_AF_XS?]'/^)?_  FM,_\ C=?2
ME% ',_#CPUK?A'P?8Z5XA\577C35H-_FZU>6L-M+/EB5S'$ @P"%X'..:Z:B
MB@ HHHH **** "BBB@ HHHH \0^(W[5FE^ O'NH^$+#P'X[\=:OIEO!<:@?"
M>B_;(;03 M$DCF1<,RJ2 ,\5[+IE\=2TVTO#;SVAN(4E^SW*;)8MR@[77LPS
M@CU%?!'[6$,MQ\=/'6M>&-*\73OX6T&RO/%]]H_CG^P0MIMD>)+>$(?.=461
MLL<9.T<FON?P3?6NJ>#- O;&6ZGL;C3[>:"6]),[QM&I4R$\ER",^^:[Z]&-
M.G"45OO]W]?(E/4VJ***X"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK6FR YO5^;_8/\/R>V_=C*BL#_ACG7_^CC?C!_X-K3_Y&H_X8YU__HXWXO\
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M'5OG/'Z"^+8+FZ\*ZS#93"WO)+*9()F8*$D,;!6)((&#@Y((]C7P/_P3^N-
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M87=AJD0ANK*ZAD,<T$J@D!U92."1T(-?&^A_L+_$&'3]:UNWTOP-X(UNUNM
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M\-=9N_$?PY\*ZM?R"6^O]*M;JXD50H:1X59B .!DD\"NDK@/@PHHHH ****
M"BBB@ HHHH **** "BBB@#!\?6T=YX%\1V\J-)%+IMS&Z)$TK,IB8$!%(+'_
M &003T!K\Y?@?I.O>)/''PDTOP/\;_"7B+6?#>C7,.EP6O@B16TVT,:QR_;F
M613%*1&(PLF&+$G:2=U?=GQV^(TO@#2_"EG#;22MXL\0VGA@W,%QY,MF+I9!
M]H0[3EDVY ]>]?+_ .SGHO@+PG\3/@[JO@?PSJ?AN\\5)XET_5;B769+A]1_
ML^4IYMX"-L\CR%I _P I0G'(Z>OA7*%&;MO>VS6SWOY7V(EJS[J7(50QRV.2
M*=16''XX\.3>*)/#<>OZ7)XBC3S7TE;R,W:IC.XQ;MP&.<XKR4F]BS<KXI_9
M:_Y2"?M6_P#<&_\ 1!K[6KXI_9:_Y2"?M6_]P;_T0:0'V3K?_(%O_P#KWD_]
M!-?*G_!*W_DROPC_ -?NI?\ I;+7U7K?_(%O_P#KWD_]!-?*G_!*W_DROPC_
M -?NI?\ I;+0!]<4444 %%%% !1110 4444 %%%% !7FW[2'Q0O_ (+_  -\
M8>-],M+:^O\ 1;+[3%;WA81.=ZKAMI!Q@GH:])KE?BEJ7A;1_A[KU[XWBMY_
M"<%LSZE'=VQN8FA&,[HPK%QTX -:4[<\;J^NW<1YS\+?VK/"'Q%\?>,O#1U_
MP[;MH^I6NGZ9+%J\+MJOFVL4Q:)<\X>1H\+NY3UXKW"OS]\2_%;]G?4O%?PS
MM/@SHOAM?%LWC'2XI7L_")AE2S,O[YEDDMP$XQ\P(([5^@5=6*HJFXM1:OT>
M^G^8D%%%%<)04444 ?/Z?\G]R_\ 9,D_].K5] 5\_I_R?W+_ -DR3_TZM7T!
M0 4444 %%%% 'X\^/O\ D[K]H#_L.6__ *)J:H?'W_)W7[0'_8<M_P#T34U?
M0X7^#$_K;@G_ ))_#>DO_2Y'GO[0/_)'?$O_ %SB_P#1T=?L]\-/^2<^%?\
ML$VG_HE*_&']H'_DCOB7_KG%_P"CHZ_9[X:?\DY\*_\ 8)M/_1*5Y^._B+T/
MR7Q+_P"1K1_Z]K_TJ1TE%%%><?D84444 %%%% !1110 4444 %%%% !1110
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MH/[:'[3%CXQ\00>*/$<,>D"]U:VLUM([EC$Q4B)20F%*K@>F:^_*^*?V6O\
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MF-8L&8*+VW+$X"^:N3^M7* "BBB@ HHHH **** "D9@JDGH.:6D9=RE?48H
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M + -C_Z3I7Q%XE_Y.@^-G_80L/\ TC2OMWX,_P#)'_ O_8!L?_2=*^(O$O\
MR=!\;/\ L(6'_I&E?"1W/X.-&L#XA?\ )/\ Q1_V"KK_ -$O6_6!\0O^2?\
MBC_L%77_ *)>K*/M+]F7_DW/X8?]BUIW_I,E>EUYI^S+_P FY_##_L6M._\
M29*]+K(D**** "BBB@ HHHH **** *6M:?%K&CW]A<2-%!=6\D$DB$!E5E*D
M@D$9 /<5\S_L\^"_AGX%\::1I/A']H37O'$UE:R6EKX3N_%UOJ-L(T3!_<1K
MG$8''.%Q7M'QV\9>&/ OPE\3ZGXQU&;2?#K64MK=7EO$\DD8E4QC:%!PQ+
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M.Z_: _[#EO\ ^B:FJ'Q]_P G=?M ?]ARW_\ 1-34\+_!B?U[P3_R3^&])?\
MI<CSW]H'_DCOB7_KG%_Z.CK]GOAI_P DY\*_]@FT_P#1*5^,/[0/_)'?$O\
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M14'P7^"&E_!_P#)X<:\F\2SWFH7.K:GJ6IQ1^9?7MQ*9)9F10$7+'A0,  4
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M_7K_ (;=^ 7_ $5WPE_X,X_\:]:_X1;1?^@18?\ @,G^%)_PBNB?] >P_P#
M5/\ "OF\;BI8VO+$35F[;>2L=$(\D>5'XP^-/BYX*O/VG/C9K4'BC3)=(U75
MX9K&]2<&*Y018+(PX8 \5)_PN#P1G'_"5:9G_KM7[-_\(KHO_0'L/_ 9/\*\
MD\>?!NYUK]HSX4^*+#0]/;PYH=CK4.IR;8E*O<1P+ -F,ODQOTZ?C3IXN5.*
MBEL?I^4\=XS*,%3P-*C&487U=[ZMOOYGY$?&SXD>%=<^%NOV.G^(+&]O9HXQ
M'!#+N=R)4)P/H"?PK]6O /[:'P)TWP+X<M+GXL^%(;F#3;:*6-]2C#(PB4$$
M9X((KWC_ (171?\ H$6'_@,G^%)_PBNB_P#0'L/_  %3_"L*U9UI<S1\UQ!G
MU;B#$QQ-:"BXQY=+]V^OJ?F5^W%^T-\,_'7[1OP.UGP]XZT/6-*TFWU5;^\L
M[M9([4R)&$$A'W=Q!Q]*R&^/WPV49/C?1<?]?(_PK]3?^$5T7_H#V'_@,G^%
M>3_M5?!R?XE? /Q5X;\*:'I\VOWRVPMHV6* '9<Q.WSD #Y5;^5*%1P5D?+G
MP;'\?OALLB$^.-% R/\ EY%>C?\ !-S]IKX4?#/]G_4=)\5_$'P_X?U.3Q+J
M%TMIJ%ZD4AB<IL?:3G!P<&OT$_X171?^@18?^ R?X4?\(KHO_0'L/_ 5/\*4
MZCGN!\,_\%"OVI?A#\1OV1?'?A_PQ\1O#NNZY=BS^SZ?8WR2S2[;N%FVJ.3A
M5)^@->[^%_VUO@-9^&=(MYOBUX4CFBLX4=&U) 58( 0>:]O_ .$5T7_H#V'_
M ("I_A1_PBNB]?['L/\ P&3_  K(9Y$O[</P!9<CXN>%,>^HH*^9?#G[3WPE
MM_\ @HGXM\82_$3P]'X7N? =M80ZLUZ@MY+A;I&,0?H7"@G'I7TY^RS\&KCX
M;_!NST+Q5H6G0ZS'J>J7#(JQ3#RYK^>6([@".8W3CMT[5ZW_ ,(KHO\ T![#
M_P !4_PH \E_X;=^ 7_17?"7_@SC_P :]JM[B.Z@CFA=9(I%#HZG(92,@C\*
MSO\ A%=$_P"@/8?^ J?X5J*H50 , < "@!:*** "BBB@ ILBEHV ZD8IU-D&
MZ-@&V'!^;T]Z /S=\ Z=\8_V=]?\(SSQ_#)8M!TC4/"MI;ZKXV6U%X\EZERS
ME2F!*GR*4&2!)SC(K]&M+DNYM+LY+^&.WOVA1KB&%]Z)(5&Y5;'(!R >]?EK
M;_#6+Q/\(K7P*/@MXD\<^-X4URTTOQ9I_D7/AK4IM0EVG5I+W<<2((XF'1E*
M%?I^GG@W2;O0/!^AZ9?W/VV^LK&"VN+GG][(D:JS_B03^->QF%M&[7U_X?=D
M1,;XQ?%#2_@K\,?$GCC6HYIM-T2T:ZDAMP#)*<@+&N>,LQ51GCFN;^!'QSD^
M,/\ PE&G:KX8NO!OBKPS>QV>J:+=7,=R8O-A2:%UEC^5E9'!]0016G^T%\)4
M^.GP8\6>!'OCIC:U9F".\V;Q#(K*\;%<C(#HN1GIFN9_9U^#?B;X=:EXZ\4>
M-]5TO5/&/C"_M[J]_L.&2*RAC@MTMX4C$A+$[4+$GNV!TYXHJE[!M_%_PW_!
M_ K6YE_'+_DX[]GC_L):Q_Z;GK\=_P!JBXBA_:J^,@DECC/_  E-V<.P!^][
MU^VFJ?LQ_"_6M7&JW_@^RN]261Y4NI7D,B._WBC;LJ3T.,<5@7G[$?P'U*XF
MN+OX6>'+NYF<O+//:[Y'8]2S$Y)^IKOR?,WE.+6*C#FLFK7MN!^#OVRV_P"?
MB'_OXO\ C5/6KN!M'O56>)F,+  2 D\?6OW&U[_@G?\  S6/$WAK4[?P%HNF
M6FDRSR7.FV]DOE:B)(BBK+SG",0XQW%="O["_P"S^N0/A'X7Q[V0-?;UN.JE
M:E.E]72YDU\7=6["Y3N_@+_R0WX=_P#8NZ?_ .DT=?DM^T;XGT?P_P#M>?&Z
M/4]4M-/DDUBU9%N90A8"TCR1GZU^J,/[+OPMMH(H(O"%K%#"H2.-)I@J*!@!
M1OP !Z5CZA^Q7\"]6O);R_\ A?X>O[N4YDN+JU\V1STRS,22?K7YMAZSP]15
M$KGT619Q4R''PQ]*"DXIJSVU373U/R3_ .%C>%/^AETO_P "E_QKG?B)X[\-
MW_@/7[:VU_3KBXEM'2.*.X5F=N. ,\FOUC\0?\$\?@=K'BKPQJUOX$T33+32
M)9Y+G3+>Q3R=2$D115FSV1CO&.XKH_\ AAGX ?\ 1)/"Q_[<%KTI9I.47'E6
MI^CXGQ.QV*H5*$L-!*::WEU5CT'X,_\ )'_ O_8!L?\ TG2OB/Q(K']J#XV8
M&?\ 3[#_ -(TKZ\C_9@^%\4,<2>$;9(HP%2-9Y@J #  &_  'I5.3]D?X/37
M$T\G@'2Y)YB&EE<.7D(& 6);)P/6O&3L?C!\P^6W]TUS_P 0D;_A7_B@8/\
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M^/- &;\7/B]X<^"W@^XU_P 17L4*_P"JL['SHXY]0N#]RW@#LH:1C@ 9]S@
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MUK@KN@M$=F9(LJ6P3]YVX J?X)? Q_AM?ZQXG\0ZA8^(/B%KJI%K&OZ;I_\
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MNL_VAH6I:I&/"U[<7(TVXM(!-]GGG9!%.&!*[X3P5/&""<K_ (6U\0O'FH?
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M?)\"Z;<:5I[_ &_F>.6R-DSR_N>2$;>-N.0?6O?**'6K2U<W^'GY>;#VT/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
$% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
MB5!.1PT*&@H    -24A$4@  #+(   "R" 8   #LD >O    "7!(67,  $SE
M  !,Y0%USO"5   <N$E$051XVNS!,0$   #"H/5/[6$-H
M
M
M                                  !N    ___LW3MK%%$<A^%#&A'!
M"UAY::QL!,5"K/P"%I9B)5IH8RLV@B!BI6"O%F(32"O8J)V-8"-I1+!1@I?*
M2Y1XB;]AL[ NV:RSF]4<\SSP$@+9.3-GEE3S9TH!
M
M                                  !@56U+)]/=-)O>IH6EG\WO,^E,
MVKT&SG5/.IUNI<=I+LVGQ:5J=B!=3 _3R_0Q?4VOTY-T(QU-4^OXN_HO[_]T
MSSJ+_FVL:4?2(_<)             &"X.^7WA^7;]*#E6EO2U?3A#X__+=TN
MG6&"OVE[NI">]9S+S_0T74LG2F<(9&ME^]^U/]UOL<[S='R,:SPXQC4.ZU+E
M]W^08\M<ZWK9_YKT#K 8. (             &&)O^EY&?XC]<(NUFN&)%R.N
M\[ETA@<FK1E,: 85OO2L_:9TWEJRJ_+][SI5.F]=Z1ZCN=;KZ5#I#!IM7#JO
M\^E]WWK-4-&&$=:\628W2'&NXOL_2//&HKFR>H,LM>Q_398;8#'( @
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M\U(YP#2[CS-<5-F_6&_!F+[_3C:USG%?&LV 1)W[WP3KDD$6
M (">%!?VB\&22Z9YGT_3T:^PW-AG[2F1=U/G899KACA7\=R_5M8KSCJO8?T_
MXJ5,_^;W47]FIGY'#W4OM_[V\\@%0S[#XY7]7QWC]Y]S;>L<VR-STF@&).K:
M_Z98E@RR              !T=7F:F:^!+&WM\T_DN@'7*(8M=J;\9?&- ZYY
M862BLM;NR.D-ZW^[W6FX0983,_6376H61?9'/DKE4-(PBJ_O[*GL?].8OO].
M_\Z_BQQ,Y7!$2L,/2-2U_TVR.!ED 0            #HZKTT,U\#>3"5E[H?
M&7*=%2E_6?R+ =8J+O=_6UGG0"J'&YK6_W9[,_WKYYD79.KW=:E9G\KAAU$,
MB%Q5V?NW5 [7C./[S]G0.LL3;3\;=D"BCOUOFOG)( L             P)2N
M3C/W-9 W4WF1?NX(UMJ:CKTL_DN?:\R.;,NL\U!#^]]N?^:Y[^^C?FFF_JLN
M-;LB:T9T_DV5O9\?8(TZO/^<E:D<;/H^,J_MY\,.2-2M_TUT0C+( @
M       PI8]3>=%Z^0SL]5/D@1&M=6<Z]K+XWWVNL3ZSQHY47D9O8O_;[<D\
M^]>1.3W6K\W4/]6E9N&(SEX,0DU6]EXYP#IU>/]5)T5VM\YR?>5WPPY(U*W_
M330K&60!             .AH=3IZT7IOY,/(TY';(V?7_.RY+X),]%&_)+(O
ML\:JXZ3_;Z7\A?N[>JS?7*D[U'HG,^'FRMX_I'* ((W9^\]YLG6.5S*_J\N
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M2?>?G.'A8H[-!<?462#1B_-/6]SA?6XL.<_J]KA/&_1]J9 %
M * 'DDX)CX?.A0#+^K2/B6&X<TC21:-,%X;U.?M..F)<6W(/UX?_=H1)YZH!
M/_\9,;^$[L4L2=''^#Y__E9F]O!,A3F:=/]+V\_O*7&6=19(].+\TY).-_MR
MWN?E$G.,#JUN.LFXNQOT7:F0!0            "@A]:$_!]J_Q0SI@_K;TJM
MN:;DV"TY^]Y6<1\/=CB'K0-\_DEGF\VA>Q%+NA/.4)\^<Z-B=F?6GU=AGJ;<
M_X5AN*O+;276K*M HE?GG[6NPSM-+3A^81CN#C.A0=^1"ED
M 'KHN)CG0OZ/M1<<Y;6O",.=,-X*K8X,9>S*V?/JBGM)UOZZPSG,',#SGQ*S
M,PP7Q21=2IX*W8M9]L;,[L-G[NJ<=4^J,$\3[C^YOS?;SVTIN69=!1*].O^L
MH9#?V69]P?&OMY]_HF'?D0I9  "@Y5\   #__^S=2XA651P \!,V8J]1 [-,
M:E$&A;4H@E1Z0M BHA:Y*R,)>E@4(?2"7!2V"$*( FE1T0,JBI9ASTWT6)2B
M%%E!+:1"TD8=FR:S\S%7YOON=^Y,\]U[9^Z-WP_^B_GNN?_S&N[J_#DA
M      ! 19;$V!OC:"Y>JK'/DV)\F_7S:XSE ^1(C7E=B3'=F<C7B8=;MOZ7
M=^4;C7%9U[/'"^9X+ [$N*KF^6[-];EUP#Q-V/\'LC:'8YP[P_Y2?<V&JM8_
M95MB3B,Q3I[FO0NZVE_1L._C7.T3             ,#_6NH0_XX:^WLAZV,L
M#'YP?2PQYDM+C&DXQI^)G-M:M/[7AHGBE6,Y;DFTN37&>"@N9ND4'EQ4TSSG
MQ_@]UU];]_^<&(>R-H\,T-]<%$A4N?XI-Q;,ZZYIWMN2M?NF@=]&A2P
M         #58$..WT'M8^X^:^EJ?Y3\28VV)/*EBC*4EQ_9.(N?NEJS_JM!;
MQ/+N%&VOR[7-QX]AXM:<JMV4Z^>G&,>U</\[8_XX>[XSQM  ?<U%@425ZY\R
M+\;/B7GMG.*=$\)D<<W]#?PV*F0!             *C)\Z'WL/;?-?2Q)DS>
M>K&A9*[]H?^ ^?R2.1],Y-S7@O7O%'#LZ7KWGQCG3_-.YR:.@Z&XF.69&N;X
M5JZ/S2W=_[N[UGGU@'W-18%$E>M?Y-&"N5U9T'Y=]OQPC%,;^%U4R (
M        4)/.[2C=A[5'*LZ_(L;>+/>F"O)]'_H/F ^5S'E-(N=8"];_M=R[
M[__']ZX.DX5%^>C\OK3"^2T,$\4*W7VL;.G^'PC%!4!U1!/7O\AIV9KEY_!&
M0?M/L^<O-_2[J) %             * F%X?>P]K?59C[C!@_9'F?K"CG>Z'_
M@/F2DCG/3N3<T_#U7YD8\TQNN[DY3-PLDCJP_U"%\UN?R[V]Q?M_-+2OD*7J
M]9_*JXDYC,=8EFMW8=?S-0W]+BID 0            "HR5FA][#VVQ7E71QC
M1Y9S<X7C?3KT'S!?53+GHD3.[0U?_RV),5\RP[Z?"ND#^Q]4.+\/<[DWMGC_
MVUC(4O7Z3V5UP3PVY=H]F_V^J\'?184L               UZ;X=H1/W5)!S
M88POLWQ/5#S>&T+_ ?.R8SX^D?/%AJ__KL28%\VP[Z$8NT-]M]&<&>-(5][.
M#3#+6[S_;2MDJ6/]I_-5P?_34/;\Q!C[L]_O:_!W42$+             $!-
MK@^3![7'8RPKF6\XQF=9OL=J&.\I,49#[P'S-TOF7!SZ#ZW?UO#U/Y08\[P!
M^M^0R#-6T=PVYO)^9/]GM4"BCO6?SAT%<UR;/;\]^WLT6_>F4L@"
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M<;;4<&\S2F,>BDRJ:=ZZ>?V/]9)V:.?\]V=ED_N\O^'?UP_S[\9.K1,
M        P(BR(IUX2?O1"N-<%-F>\J:,&RK6-"KR7F1]/\=]G'J^9/Y%A6NN
M:ACG:&16%\S_JG3RB_8+6ZAA8B_C+*OAWIXMC;FNYKGKUO7O5(-$N^>_+].*
M>2S?Y\'BY]==\-VHD04             H&;WI1,OFW\:&=/B.-,C.R.;(U,K
MUC0YY0TL64WW]'-L]K+\\1?CCV=>B]?<US#&BUTR_S>FDU^T7]]"'>5QLIJN
MJ'AO63/2CM*X\VN>OVY=_TXT2'1B_OOS29-[S;)DF'\WCFI2]RA_-@
M      " D>KTR.+(PY&9+9S_0.1(RE_.WA89WV(=LR,_1AY/@VO$&%W<P]DI
M;TBX/?)"9&]1T][B]_U9FGJ^:+ZS&',P7FHX?T=D7!?-?WE7DG\C,P8YQMK2
M&&MJ^'S>5!IS3V1L&YZ#H5K_*CK1R-*I^>_+O";W>B#ENP -9Z<VJ7U, @
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M     !AV_@,  /__[,$Q 0   ,*@]4_M80V@
M
M
M                         &X   #__^S!,0$   #"H/5/[6$-H
M
M
M                                          !N    ___LP3$!
MPJ#U3^UA#:
M
M
M;@   /__[,$Q 0   ,*@]4_M80V@
M
M
M                 &X   #__^S!,0$   #"H/5/[6$-H
M
M
M                                  !N    ___LP3$!    PJ#U3^UA
M#:
M
M                                                    ;@   /__
M[,$Q 0   ,*@]4_M80V@
M
M
M         &X   #__^S!,0$   #"H/5/[6$-H
M
M
M                          !N    ___LP3$!    PJ#U3^UA#:
M
M
M                                            ;@   /__[,$Q 0
M ,*@]4_M80V@
M
M
M &X   #__^S!,0$   #"H/5/[6$-H
M
M
M                  !N    ___MP8$     PZ#Y4U_A %4!
M
M                                     / 90S $1 #Z,80     245.
%1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_02.jpg
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MUCK3 J1JK8JGARS*,BC0;3-L\N0B>X_E&:6TN,3MZ_8(_+^LG2I0M#)=<K7
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M\A%!3\A1.$ZJ@<(J(J\*JJO*JJ_/WX7\O\?\RKSUZ1.$1$^R(B)S]_CX^?\
M#_'JO1T='1T='7GQ1555^45.../Z?_SK!D1T)%=14 VT) (6P]Q2^1'DU144
M$'\/BH*2?<31>HO?43[%J7N@UV]L/6^.46+]X6F'ZC/.W'<<*,U&RV@RO$#&
MSK<?DV;11I3]#D(1I]3,KY[\J/):>;/E/PM](%A?>!7=_P#K[MCTSCOA4[#V
MC(M+CNMU\VI#-UM$[?+JGJMH8)DS;01G*[][,^MJF/7MR&(JV6-%*-EEYM3
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M(1@WK==A?<AN3<&G-[=HE0;E_M/'<F[2.Z:J"JK;6;9=N6T(L*+;7#L><;K
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MV[!^#'A9+C\WZZML7581"?1EU 5 5"#D?)%7RZZO:.V\ TYKW*ME;)RJ!B6
MX15/VV395/\ JE@5E9%-B-&80/9^HEV%@^X42!%CBZY+DM(T!DX^R)QOX_WP
M=S7=.RR?9?VHSV,&?=4:[N#[HY_^3W#WH$I>8MWCVN8S?[YY,+40VIM0,IZ$
MS(8-E7Q;4C%%\PWLTR'+9U?D_=]NC(^Y>]9<9G0\4&JCX)I+%KJ.J.#^R< J
M)7U%\\V^BMQY>23+(R: %=9]Q357Q0!9J6(K+,"+35=9&-@'/IHE;4PH[ >R
MW$CMJ,1Z#'8:!&F4:;6"VT#8,DK0CTUO<_?=VD=OL)R3M?>>NZ63'&0TM- N
M6LLRR=*;4@;KZO'L6*VMYMDXZ/M+&^D847>0\E5$ZC$S23O3U:\CP7$:C6F:
MZ"]/.CSBAS;*\TV352Z3;'=*WC%@];4N,X?AC@A<XK@,QU*Z>_8Y2VTU)KV0
M#Z8E-$8GHIH[59$A0X,2%%KX<6-#B1H7L-QHD2.R#,>/% "5L([#0 TPV!*
MMB* 2BB*NU<99<0UD$IC[A&X!$"@8N#X(V3?DK3@DTJ"JF)&@+X":#PG7+8_
MAN)8L]*<Q['Z:DF2W3>EG40(L-N2XZ2N.F4=MP6!=-Q54W!%.5)>$^43KMT5
M4$>/+CA!^4'E./M_"OBJ\?\ 9^%_+^7CP!#(D-%<3RYY)11$55YX0.$1?G[J
MA%S^:+\]8(QVFW#<0W354(38 VO!P#\E]QP%X<+A%15<-Q5/A2(4Y5$9GO\
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>R?T3_5U7HZ.CHZ.CHZ.CHZ.CHZ.CHZ.CHZ.CK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" ". 1L# 2(  A$! Q$!_\0
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MTWC_ ,IU5_Q'#@7^:I_X!_P0^IU#^;6BOZ2?^(13_@F-_P!%-^,W_A4:;_\
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M"_Z^2_\ 20P?Q,]RK^</_@[_ /\ E)7X'_[(;IG_ *>=9K^CROYP_P#@[_\
M^4E?@?\ [(;IG_IYUFOS7P0_Y+N'_7NI^2-\5_!/RGK]6/\ @T _Y25^./\
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M2%2<N?F)Q@8 _,7_ (.,SC]MSPMG_HE=C_Z<M3K[\_X(H'_C61\,_P#N,_\
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M451E:]PK^R+_ ()@_P#*-3]GG_LAOA+_ -,UK7\;M?V6?\$W=#UOPQ_P3N^
MGAOQ+H]UI^I:?\%_"UMJ&GWUNT,UM-'I%LKQ2(P#(ZL"I4@$$$$ U^<?2#:_
MLC K_IY+_P!)1T8)>\SVBOYP_P#@[_\ ^4E?@?\ [(;IG_IYUFOZ/**_!N!^
M*O\ 4W/HYE['VMHRCR\W+\76_++;T.RM3]M#EN?PUU^K'_!H!_RDK\<?]D-U
M/_T\Z-7]'E%?I?$OC=_K%D.(RW^S^3VL>7F]KS6\[>S5_O1ST\'[.:E?;R/Q
M:_X.-5+?MN>%<?\ 1*['_P!.6I5]^_\ !$\8_P""8_PS'_89_P#3U?5\!_\
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M,8HXF-M90*EM:EUACWF*-/,9=S[F)8^34^VM[B\N([.T@>6:9PD44:EF=B<
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M** /Q9_X.-03^VYX5P/^:5V/_IRU*OO[_@B>"/\ @F/\,P?^HS_Z>KZO@/\
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M!@LC;2:]5\3^*O#'@GP_=^+/&?B.PTG2M/A,U]J>IWB6]O;1CJ\DCD*BCU)
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MW,V_O=S^6>(\WEQ!Q#C,TE'E>(JU*K7;VDW.W7:]MV%%%%8'BA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7R;_P4!_X)$_ ;]N?56^),
M.LW'@SQ[]EC@;Q)IMFLT-^B,@7[9;$IY[+$K1I(LD;@% S2)$D8^LJ*Z,+BL
M1@ZRJT9.,EU7Z]UY,]SAWB7/N$\TCF.45Y4:T=%*-M4]U)-.,HNRO&2<7976
MA_/[\=_^"./_  4$^!$]U/-\$[CQ=IEO/#%%JW@2;^TUN6>,-E+90+L*IRC,
M\"J&4\E2K-P/AC_@GK^W;XN\06GAG2OV0OB-%<WLPBADU/PC=V5NK'O)/<(D
M42^K.ZJ.YK^D"BOJ*?&6.C3M*G%OOJOPO_D?TA@_I:\:4<'[/$8*A.HE;G7/
M%/31N/,[N^KLXI[)1/R'_8X_X-Z?B9XFO[/QG^V?XKB\-Z7')OD\&:!=QW.H
M7(!E79-=(6@MU)6&0>49R\;LI,+C(_5CX5_"OX>?!'X>:3\*/A1X3M=#\/:'
M:BWTS3+-3LB3)))))9W9BSO(Q+N[,[%F8D]!17@YAFV.S25Z\M%LEHE\OU=W
MYGXGQYXG<8>(V*53-Z]Z<7>%*"Y:4'KJHW;;U:YIN4[.W-;0\U_;,T+6_%'[
M'_Q6\,^&=&NM1U+4?AKKMKI^GV-NTT]U/)I\Z)%&B L[LQ"A0"22  2:_([_
M ()"?LH?M3_#3_@HC\/?&WQ'_9K^('A_1;+^UOMFKZWX-OK6U@WZ1>1IOEEB
M5%W.RJ,D99@!R17[=T5K@<WJ8'!5<-&*:J)IOM=6/2X.\4LPX.X1S/(*.'C4
MACHSC*3;3CSTW3;26CLG?7J%>(3?\$XOV+Y_VT(O^"A;_!:,?&"&/8OC!-=U
M!21_9YT[YK43BV8_9&,63$3C!SN 8>WT5PX;&8S!\_U>I*'/%PERMKFC+>,K
M-7B^J>CZH_+&D]SXA^&7P5_X**:W\??VGOA%^UC\-_ >K_LO>+/#NJQ_#_PA
MX!CMM/U+4VU!IGN(8'62!TN+J.>[>^FO9DW7UQ');R)$TI7Y-_;:_84^(LG[
M$7[(OP2_92_9*^)5C9Z/X;U7[;X9UB&34=1T2ZOVTZ=QJ=Q&OE0227#W$C%A
M#&GS@1P+&8H_V0HKWUQ5C%435.,4G%\L;QBY1IRI\SC>SG)2;E*UV[ZV;1]7
MP'Q9BN N*L/GN&IJI.CSVC*]GSPE#5K6RYKV7:Q^*/[.W_!OM^V#\1=:M[KX
M^:EHWP\T6.\:.^CDU"+4M2DB$>Y7@BM6> AGQ'F2=&7YFV, JO\ K9^S%^RY
M\&OV0_A38_"#X)^&%L=/M5#WEY-A[O4[C #W-S* /-E;'H%481%1%5%]"HKS
M<RSK'YI95G:*Z+1?JW\V?2\?>+W&WB-&-+-*L8T8NZI4TXT^;^9IN4I-=.:4
-K=+7=RBBBO)/S __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_1.jpg
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M!#(D'N7/K2'F[$F^'*X6LI93=:9M+J+^"3#FK+ /;:(YQBHKK1H!I[Q:P?\
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MG6K.FEBH0L;%6ZP9*'%7F(@!#@D8,AG'ZL5.KBUFL^TX5K;]S'1FI3&PS%(
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M"7HV26;*&!$BC$N_(#T 3?\ >M)K7PXVWJXA#S,8X-%3<<K\2P7C# FFJKW
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MD_-)&<2%JJBFP< .""!NXX\Z-:N%NTM=)4LG--UB2*:7((J142"!?7I2-@M
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MU1;D9.+1?6_$M3@Y/(N@^4 %Z[?O6NTTL"-OJ_;QE4F1_@'"90CY0OT','?
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M4:;?D/";95C&W,I&XV_+4 GA-D!SUJX-E6^6!M.&BAR4K%L1$_\ J$H &?\
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M'M6BN9NZNVXKC7N>RI"0,R>'(R6+T B8#T&M+IA<[EUJG%),8ERD91P1)5X
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MTHN"?FINZUTN)R2D7*!E9-5TFF&!%0>U<5GSY%4 (ME(>ZVX,A[5]^*>?%I
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MWOUI83G#I;D^LDX>N'1!14YQ#I*;1 ?O2ULI]H[:^L*K,)APG<J"HE*I(.
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MYG$QB@!2 H'J-<@ Q4^A0*/I70Z6731^2F"W]P#6CNB7/9EIR,D1$'!6R1W
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MD% -9 >4)21*@824SY#7G9<7#QJ3%0R]WZ?6\B[8/50=R#,JFTK<X]3%*'F
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MF\@J<O\ A[CI:_1N!ZNI\,!Q.9$I\$.;R$0\Z:,C*,;;9 N\<)-6Y"@F3F&
MN[ = #WI)ZJ:O0K&/-<LLW63MV&\;Q)<N!5*/3P@/>J@<6W#1=/%=>=M7SIY
M,L'%FIL"J*)MG'B1+D#"00+^K'3%0:VM4+HT9UC@(2S(EQ_#,TLE%N6LBB)G
M*)N@'4 /T@(]AJT4YPF0]E:MHW#"34N^O*:.*K<'KHRC=L./$&!^D,9ILL.$
M2UV<"Z2(=9K+/A%9TLW/MWJ&^KMY9I-VGPKZR:275=9[%F8PD'+M^20KY014
M)ZB'H-61T4TP_P"%%KF5EGI59=T4%9%P=3).8'<2B/E28UKMPG%5>D9;J3\
ML>$<IR"[ULIM+SDQR)3&#ICV&E/Q4:@,.(?4.UM%;!,#Z);. 0EW3/!FY$Q
M.QB] [5=[3732-TVL"+M:,2(W08HD2$R)=N\0\Q]:E@-Q*8%,^/&T?M7P$3I
MJ ),8-]>:R:*****ZU<[<^7G724>603E#<'F4*H-^(5PD3=[/(_5"P"F3NB)
M5!T"2)<G5$G4 #'N%95M1]O\;V@)+0NI0L)JJS;E(N9<1!9-8HYZ@'L%./AG
MO.Y(*&+I]?C54LQ&#\,T55# JH$#:4_N& JPB::;4VS.W=Y_W>U912%Z /A
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M\/>M27%]I$LDZ4&!U*B2BUYR7194Y"]A$?(1[U*.'KB#FX6Y'&FFJK,D9<;
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M?'^,Y4QP)1R/:O0,$U%T2F43 %?_ ,:R4R[2X'J/F-<Z*********XF*!BB
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M(N*7F4F +$(3X=N8Z9BD,/7(>M6_T;_#QM.T"M)RYW;RX+I$H'6^.7%9 !]
M*:K30D'&P;<&S&/;,"%#!BM4@3*;_'>MBFK_ # IB00-C(&QTQ6511111111
M11111111176JGS.E E, 8 >E?3%W%P(9K&314*N;?XTOTE]*Q)2-)+(J1SQ
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@BBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBBO_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823826016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 11, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GRI BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2223 Avenida de la Playa<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-1170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GRI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823794144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Sadler, Gibb & Associates LLC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Draper, Utah<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">3627<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823721136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 5,028<span></span>
</td>
<td class="nump">$ 1,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,615<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,739<span></span>
</td>
<td class="nump">2,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">691<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,636<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,707<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 13)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.0001 par value; 250,000,000 shares authorized; 525,485 and 2,909 shares issued and outstanding as of December&#160;31, 2024 and 2023, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">43,772<span></span>
</td>
<td class="nump">31,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(39,740)<span></span>
</td>
<td class="num">(31,533)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">4,032<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 5,739<span></span>
</td>
<td class="nump">$ 2,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269909964144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">525,485<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">525,485<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823714144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 3,768<span></span>
</td>
<td class="nump">$ 3,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">4,467<span></span>
</td>
<td class="nump">8,155<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">8,235<span></span>
</td>
<td class="nump">11,387<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(8,235)<span></span>
</td>
<td class="num">(11,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income (expense), net</a></td>
<td class="nump">25<span></span>
</td>
<td class="num">(2,082)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,207)<span></span>
</td>
<td class="num">(13,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">Deemed dividend on Series B Warrants</a></td>
<td class="num">(1,911)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (10,118)<span></span>
</td>
<td class="num">$ (13,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in usd per share)</a></td>
<td class="num">$ (55.21)<span></span>
</td>
<td class="num">$ (5,018.09)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in usd per share)</a></td>
<td class="num">$ (55.21)<span></span>
</td>
<td class="num">$ (5,018.09)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">183,278<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">183,278<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemablePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemablePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269818935120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,207)<span></span>
</td>
<td class="num">$ (13,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Change in operating lease right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition', window );">Change in operating lease right of use assets</a></td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">313<span></span>
</td>
<td class="num">(547)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(387)<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(479)<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">105<span></span>
</td>
<td class="num">(57)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(8,611)<span></span>
</td>
<td class="num">(8,990)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ProceedsFromAdvancesFromEmployees', window );">Advances from employees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_RepaymentOfAdvancesFromEmployees', window );">Repayment of advances from employees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of bridge promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="nump">762<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PaymentForFractionalSharesReverseStockSplit', window );">Payment for fractional shares in connection with reverse stock split</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CashAcquiredInReverseRecapitalization', window );">Cash acquired in reverse recapitalization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PaymentOfReverseRecapitalizationCosts', window );">Payment of reverse recapitalization costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred stock issuance costs</a></td>
<td class="num">(2,033)<span></span>
</td>
<td class="num">(517)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">11,831<span></span>
</td>
<td class="nump">10,797<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">3,220<span></span>
</td>
<td class="nump">1,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure or noncash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedForRepaymentOfNotesPayable', window );">Issuance of stock for repayment of bridge loan</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants', window );">Recognition of debt discount and additional paid-in-capital for warrants issued in connection with promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization', window );">Net liabilities acquired in connection with reverse recapitalization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid', window );">Debt and deferred stock issuance costs included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts', window );">Issuance of stock for payment of reverse recapitalization costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantsIssued', window );">Issuance of warrants for payment of stock issuance costs</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember', window );">Through Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing transaction / under ATM facility</a></td>
<td class="nump">9,499<span></span>
</td>
<td class="nump">12,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing transaction / under ATM facility</a></td>
<td class="nump">$ 3,604<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CashAcquiredInReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Acquired In Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CashAcquiredInReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Issuance Costs and Financing Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Liabilities Assumed In Connection With Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Periodic Addition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PaymentForFractionalSharesReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Fractional Shares, Reverse Stock Split</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PaymentForFractionalSharesReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PaymentOfReverseRecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Reverse Recapitalization Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PaymentOfReverseRecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromAdvancesFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Advances From Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromAdvancesFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_RepaymentOfAdvancesFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Advances From Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_RepaymentOfAdvancesFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Payment Of Reverse Recapitalization Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedForRepaymentOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Repayment Of Notes Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedForRepaymentOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269817004464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (1,625)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,871<span></span>
</td>
<td class="num">$ (18,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issuance</a></td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise', window );">Warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises', window );">Warrant exercise</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing', window );">Issuance of common stock in pre-closing financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing', window );">Issuance of common stock in pre-closing financing</a></td>
<td class="nump">11,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt', window );">Issuance of common stock for settlement of bridge note (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt', window );">Issuance of common stock for settlement of bridge note</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization', window );">Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization', window );">Issuance of common stock to Vallon stockholders in reverse recapitalization</a></td>
<td class="num">(2,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,037)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,037)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,792<span></span>
</td>
<td class="num">(31,533)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment', window );">Fractional share adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">330,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">11,166<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">11,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise', window );">Warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises', window );">Warrant exercise</a></td>
<td class="nump">666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,207)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">525,485<span></span>
</td>
<td class="nump">525,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 4,032<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 43,772<span></span>
</td>
<td class="num">$ (39,740)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Fractional Share Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Pre-closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Settlement Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrant Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Pre-closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Settlement Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824593744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT I) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Merger with Vallon Pharmaceuticals, Inc.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to an Agreement and Plan of Merger, dated as of December 13, 2022, as amended on February 17, 2023 (the Merger Agreement), by and among the Company, GRI Bio Operations, Inc., formerly known as GRI Bio, Inc. (GRI Operations), and Vallon Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Merger Sub), Merger Sub was merged with and into GRI Operations (the Merger), with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company (Note 4). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and amended its bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Splits</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, and immediately prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of its common stock, par value $0.0001(Common Stock), at a ratio of one-for thirty (the April 2023 Reverse Stock Split). On January 29, 2024, the Company effected a reverse stock split of its common stock at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 14, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split). On February 21, 2025, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen (the February 2025 Reverse Stock Split and together with the April 2023 Reverse Stock Split, the January 2024 Reverse Stock Split and the June 2024 Reverse Stock Split, the Reverse Stock Splits).Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, GRI Operations. All Common Stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio (as defined below) and the Reverse Stock Splits for all periods presented, to the extent applicable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824102224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text">LIQUIDITY<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $39,740 in accumulated deficit through December&#160;31, 2024. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of December&#160;31, 2024, the Company had cash of approximately $5,028. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, the Company, GRI Operations and Altium Growth Fund, LP (Altium) entered into a Securities Purchase Agreement, dated December 13, 2022 (the Equity SPA), pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes (as defined below) in return for the issuance of </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of GRI Operations common stock (GRI Operations Common Stock) immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued 4,387 shares of GRI Operations Common Stock (the Initial Shares) to Altium and 17,549 shares of GRI Operations Common Stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 164 shares of the Company&#8217;s Common Stock and the Additional Shares converted into an aggregate of 656 shares of the Company&#8217;s Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Company&#8217;s Common Stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into a securities purchase agreement (the Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering, (i) 1,495 shares (the February 2024 Shares) of Common Stock, (ii) 21,131 pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock, and (iv) 22,631 Series B-2 common warrants (the Series B-2 Common Warrants, and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Annual Report on Form 10-K for the year ended December 31, 2024 (Annual Report) as the &#8220;February 2024 Warrants.&#8221; The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $243.10 (less $0.0221 for each February Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The February 2024 Pre-Funded Warrants have been exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 and expires on February 6, 2029. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 and expires on August 6, 2026. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the securities pursuant to the Purchase Agreement, the exercise price of the Series A-1 Warrants was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants. As of December&#160;31, 2024, all of the Series A-1 Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0&#160;million shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company has sold 325,618 shares of Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3,605 of gross proceeds and net proceeds of $3,467, after deducting commissions to the sales agent and other ATM Offering related expenses. On December 20, 2024, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $322, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3,605 that were sold under the ATM Offering through December&#160;31, 2024, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering (the June 2024 Offering), (i) 3,529 shares (the June 2024 Shares) of Common Stock, (ii) 125,047 pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of 125,047 shares of Common Stock, (iii) 128,577 Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of 128,577 shares of Common Stock, and (iv) 128,577 Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants) exercisable for an aggregate of 128,577 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Annual Report as the &#8220;June 2024 Warrants.&#8221; The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $31.11 (less $0.0017 for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants have been exercised in full. Each Series C-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 and expires on September 6, 2029. Each Series C-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 and expires on March 6, 2026. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the June 2024 Offering. Pursuant to an engagement agreement (the June 2024 Engagement Agreement) with Wainwright, dated as of May 3, 2024, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,002 shares of Common Stock (the June 2024 PA Warrants)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The June 2024 PA Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$38.89</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, will expire on June 26, 2029 and are exercisable beginning after September 6, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 21, 2024, the Company entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of its issued and outstanding Series B Common Warrants to purchase an aggregate of 44,842 shares of its Common Stock, offering these Holders the opportunity to exercise all of their Series B Common Warrants for cash at a reduced exercise price equal to $17.00 per share. In addition, these Holders received new unregistered Series D-1 Warrants (the Series Common D-1 Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock and new unregistered Series D-2 Common Warrants (the Series D-2 Common Warrants and, together with the Series D-1 Common Warrants, the Series D Common Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $17.00 per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We refer to this transaction as the &#8220;Warrant Repricing Transaction.&#8221;</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pursuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $25,000 and non-accountable expenses of $10,000. The Company has also issued to Wainwright or its designees warrants to purchase up to an aggregate of 3,140 shares of Common Stock (the October 2024 PA Warrants). The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $21.25 per share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross proceeds to the Company from the exercise of the Series B Common Warrants were $762 prior to deducting placement agent fees and offering expenses of $154. The issuance under the Repricing Letter Agreements represented $1,911 in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#8217;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824567472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this Annual Report to &#8220;authoritative guidance&#8221; is meant to refer to accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly-owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of December&#160;31, 2024 and 2023 included investment in money market funds.&#160;The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $4,521 and $1,217 at December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&#160;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&#160;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs that are generally unobservable inputs and not corroborated by market data.&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At December&#160;31, 2024, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the statement of operations for the year ended December&#160;31, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost. The Company commences depreciation when the asset is placed in service. Computers and peripheral equipment are depreciated on a straight-line method over useful lives of three years.&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to use, or control the use of, identified property, plant, or equipment for a period of time in exchange for consideration. Lease right-of-use (ROU) assets and lease liabilities recognized in the accompanying balance sheet represent the right to use an underlying asset for the lease term and an obligation to make lease payments arising from the lease respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the Company recognizes an ROU asset and a lease liability for its operating leases, except its short-term operating leases with original lease terms of twelve months or less. The ROU asset is initially measured at cost, which primarily comprises the initial amount of the lease liability plus any lease prepayments. The lease liability is initially measured at the present value of the lease payments not yet paid, discounted using an estimate of the Company&#8217;s incremental borrowing rate for a collateralized loan with a similar amount and terms as the underlying lease in a similar economic environment. That discount rate is used because the interest rate implicit in the Company&#8217;s lease contracts is typically not readily determinable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease modifications that grant the right to use an existing leased asset for an additional period of time are not accounted for as separate contracts; however, the lease term, classification, discount rate, and measurement of the remaining consideration due under the contract are reassessed upon execution of such modifications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the May 2022 Warrants (Note 10) in accordance with ASC 815-40, and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the accompanying consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with changes in fair value recognized in the accompanying consolidated statements of operations in the period of change. The derivative liabilities will ultimately be converted into the Common Stock when the warrants are exercised, or will be extinguished upon expiry of the warrant term. Upon exercise, the intrinsic value of the shares issued is transferred to stockholders&#8217; equity. The difference between the intrinsic value of the stock issued and the fair value of the warrant is recorded as gain or loss on the exchange in the accompanying consolidated statements of operations in the period of exercise.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's Common Stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.&#160;</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;As the Company had a net loss in each of the years ended December&#160;31, 2024 and 2023, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">359,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">359,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2024-03). The amendments in ASU 2024-03 require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, for all public entities. Early adoption is permitted. Management is currently evaluating the impact of this update on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-09). The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. Management is currently evaluating the impact of this update on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, FASB issued ASU 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-06)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-06 represent changes to clarify or improve disclosure and presentation requirements of a variety of topics in the Codification and align those requirements with the SEC&#8217;s regulation. For entities subject to the Security and Exchange Commission&#8217;s (SEC) existing disclosure requirements, the effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited.</span><span style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. Management is currently evaluating the impact of this update and its effective dates but does not expect the update to have a material effect on the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824602384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER WITH VALLON<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">MERGER WITH VALLON</a></td>
<td class="text">MERGER WITH VALLON.<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into GRI Operations, with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Effective Time:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each share of GRI Operations Common Stock outstanding immediately prior to the Effective Time, including any shares of GRI Operations Common Stock issued pursuant to the Equity SPA, automatically converted solely into the right to receive a number of shares of the Company&#8217;s Common Stock equal to 0.0374 (the Exchange Ratio).</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Each option to purchase shares of GRI Operations Common Stock (each, a GRI Operations Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the GRI Operations Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#8217;s Common Stock, and the Company assumed the GRI Operations Plan and each such GRI Operations Option in accordance with the terms of the GRI Operations Plan (the Assumed Options). The number of shares of Common Stock subject to each Assumed Option was determined by multiplying (i) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Common Stock. The per share exercise price for the Common Stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each warrant to purchase shares of GRI Operations Common Stock (the GRI Operations Warrants) outstanding immediately prior to the Effective Time was assumed by the Company and converted into a warrant to purchase shares of Common Stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Common Stock; (ii) the number of shares of Common Stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Common Stock; and (iii) the per share exercise price for shares of Common Stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of GRI Operations Common Stock subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Bridge Warrants (Note 9) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of 272 shares of the Company&#8217;s Common Stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants and have an initial exercise price equal to $22,787.31 per share. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All rights with respect to GRI Operations restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s Common Stock. The term, exercisability, vesting schedule and other provisions of the GRI Operations restricted stock awards otherwise remained unchanged.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI Operations was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i) the equity holders of GRI Operations immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately 85% of the outstanding shares of the Company&#8217;s Common Stock and the Company&#8217;s stockholders immediately prior to the Merger owned approximately 15% of the outstanding shares of the Company&#8217;s Common Stock </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) GRI Operations held the majority (4 out of 5) of board seats of the combined company, and (iii) GRI Operations&#8217; management held the majority of key positions in the management of the combined company.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plus: Transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net liabilities assumed plus transaction costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>In addition to the transaction costs noted above, at the Effective Time, 19 shares of the Common Stock were issued to GRI Operations&#8217; financial advisor for services related to the Merger.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823360976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS.<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the year ended December&#160;31, 2024 and 2023.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2024:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2023:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes is the fair value of the Level 3 liability:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in valuation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.429%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">166.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.26&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823345600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT.<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:9pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $4 in each of the years ended December&#160;31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824605488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES.<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office facilities under an operating lease agreement. The lease agreement requires fixed monthly rental payments as well as payments for variable monthly utilities and operating costs throughout the lease term. The Company evaluates renewal options at lease inception on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the operating lease assets and liabilities recognized on the Company's consolidated balance sheets:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance Sheet Line Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments are due as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">137&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs were $62 and $59 for each of the years ended December&#160;31, 2024 and 2023, respectively. Operating lease costs are included within selling, general and administrative expenses on the consolidated statements of operations.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities were $59 and $58 for the years ended December&#160;31, 2024 and 2023, respectively. This amount is included in operating activities in the consolidated statements of cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824590320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES.<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Payroll and related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">337</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,270&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269909962912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PROMISSORY NOTES</a></td>
<td class="text">PROMISSORY NOTES.<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Financing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, GRI Operations entered into a Securities Purchase Agreement, dated as of December 13, 2022 (Bridge SPA), with Altium, pursuant to which GRI Operations issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $3,333, in exchange for an aggregate purchase price of $2,500. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were issued in two closings: (i) the first closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on December 14, 2022; and (ii) the second closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#8217;s assets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the funding of each tranche, Altium received warrants to purchase an aggregate of 809 shares of the Common Stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $2,057.51 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants were freely tradable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1,250 of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $679 and $571, respectively. The $1,250 of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $718 and $532, respectively. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered into the Equity SPA (Note 10) pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations&#8217; Common Stock immediately prior to the consummation of the Merger. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $22,787.31 per share subject to adjustments for splits and recapitalization events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred debt issuance costs of $294 of which $90 was incurred during the year ended December&#160;31, 2023 related to its issuance of debt under the Bridge SPA. Interest expense stemming from amortization of debt discounts and issuance costs was $2,104 for the year ended December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824092432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS EQUITY</a></td>
<td class="text">STOCKHOLDERS EQUITY.<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Purchase Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered the Equity SPA pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations Common Stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued the Initial Shares to Altium and the Additional Shares into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 164 shares of the Common Stock and the Additional Shares converted into an aggregate of 656 shares of the Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Common Stock issued in exchange for the Additional Shares.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell (i) 1,495 February 2024 Shares, (ii) 21,131 February 2024 Pre-Funded Warrants exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 Common Warrants exercisable for an aggregate of 22,631 shares of Common Stock and (iv) 22,631 Series B-2 Common Warrants exercisable for an aggregate of 22,631 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $243.10 (less $0.0221 for each February 2024 Pre-Funded Warrant).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The February 2024 Pre-Funded Warrants have been exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 and expires on February 6, 2029. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 and expires on August 6, 2026. The February 2024 Warrants were classified as equity and the allocated fair value of $4,279 is included in additional paid in capital. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the amount paid for the February 2024 Pre-Funded Warrants approximates their fair value. The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156.3&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.63</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.65&#160;%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants issued in connection with the Merger was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants. All of the Series A-1 Warrants have been exercised in full.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company has sold 325,618 shares of Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3,605 of gross proceeds and net proceeds of $3,467, after deducting commissions to the sales agent and other ATM Offering related expenses. On December 20, 2024, we filed a prospectus supplement to our registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that we may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $322, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3,605 that were sold under the ATM Offering through December 20, 2024, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company issued and sold, in the June 2024 Offering, (i) 3,529 June 2024 Shares, (ii) 125,047 June 2024 Pre-Funded Warrants exercisable for an aggregate of 125,047 shares of Common Stock, (iii) 128,577 Series C-1 Common Warrants exercisable for an aggregate of 128,577 shares of Common Stock, and (iv) 128,577 Series C-2 Common Warrants, exercisable for an aggregate of 128,577 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $31.11 (less $0.0017 for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants have been exercised in full. Each Series C-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 and expires on September 6, 2029. Each Series C-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 and expires on March 6, 2026. The June 2024 Pre-Funded Warrants and the Series C Common Warrants were classified as equity and the allocated fair value of $2,908 is included in additional paid in capital.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the June 2024 Engagement Agreement, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, June 2024 PA Warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,001 shares of Common Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The June 2024 PA Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$38.89</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share and will expire on June 26, 2029. The June 2024 PA Warrants were classified as equity and the fair value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$229 is included in additional paid in capital.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the amount paid for the June 2024 Pre-Funded Warrants approximates their fair value. The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants, and the Placement Agent Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.1&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.65</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.92&#160;%</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">October 2024 Repricing Letter Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 21, 2024, the Company entered into the Repricing Letter Agreements with certain Holders of its issued and outstanding Series B Common Warrants to purchase an aggregate of 44,842 shares of its Common Stock, offering these Holders the opportunity to exercise all of their Series B Common Warrants for cash at a reduced exercise price equal to $17.00 per share. In addition, these Holders received new unregistered Series D-1 Common Warrants exercisable for up to an aggregate of 44,839 shares of Common Stock and new unregistered Series D-2 Common Warrants exercisable for up to an aggregate of 44,839 shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $17.00 per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rsuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $25,000 and non-accountable expenses of $10,000. The Company has also issued to Wainwright or its designees the October 2024 PA Warrants to purchase up to an aggregate of 3,140 shares of Common Stock. The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $21.25 per share.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds to the Company from the exercise of the Series B Common Warrants were $609 after deducting placement agent fees and offering expenses of $154. The issuance under the Repricing Letter Agreements represented $1,911 in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.</span></div><div style="margin-bottom:9pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Series D-1 Common Warrants, the Series D-2 Common Warrants, and the October 2024 PA Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174.4&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.65</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.16&#160;%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had the following warrants outstanding to purchase common stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">210</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$243.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$464,100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128,577</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$31.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,839</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$17.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$43,548.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$94,970.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$243.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,002</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$38.8875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128,577</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$31.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$17.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$21.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 2029</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824619888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK BASED COMPENSATION.<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Operations adopted the GRI Operations Plan, which provided GRI Operations with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Upon completion of the Merger, the Company assumed the GRI Operations Plan and 57 outstanding and unexercised options issued thereunder, and ceased granting awards under the GRI Operations Plan. As of December&#160;31, 2024, no options remain outstanding under the GRI Operations Plan. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan had previously been approved by the Company&#8217;s board of directors, subject to stockholder approval. The A&amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving an amendment to the A&amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by 109 shares to 140 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s Common Stock</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for issuance as awards under the A&amp;R 2018 Plan, (ii) to extend the term of the A&amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#8220;repricing&#8221; of an award without further approval by the stockholders of Company and (iv) to revise the limits on awards to non-employee directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;R 2018 Plan generally have a contractual life of up to 10 years. As of December&#160;31, 2024, awards granted under the A&amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of 142 shares of the Company's Common Stock were outstanding and 256 shares of the Company&#8217;s Common Stock were reserved for issuance under the A&amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;R 2018 Plan may be increased pursuant to the A&amp;R 2018 Plan&#8217;s &#8220;evergreen&#8221; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#8217;s Common Stock outstanding on the final day of the immediately preceding calendar year.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the GRI Operations Plan and the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and nine months ended December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">388</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">388</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the year ended December&#160;31, 2024:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,376.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,376.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,475.38</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.57</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested and expected to vest at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,376.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.63</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, all of the outstanding and exercisable stock options were out of the money and therefore had no intrinsic value. At December&#160;31, 2024, the unrecognized compensation cost related to unvested stock options expected to vest was $240. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of two years. </span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 141 stock options to employees and non-employees during the year ended December&#160;31, 2023. The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.84</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of common stock on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,298.42</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No equity-based awards were granted during the year ended December&#160;31, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected term of options is determined using the "simplified" method, as prescribed in SEC's SAB No. 107, Share Based Payment (SAB No. 107), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company's lack of sufficient historical data. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected volatility is based on a weighted average of the Company's historical volatility and the volatilities of similar entities within the Company's industry which were commensurate with the expected term assumption as described in SAB No. 107.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The risk-free interest rate is based on the interest rate payable on US Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The expected dividend yield is 0% because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823363184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">ASSET PURCHASE AGREEMENT</a></td>
<td class="text">ASSET PURCHASE AGREEMENT.<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2023, the Company entered into Asset Purchase Agreement (the Aardvark Agreement) with Aardvark Therapeutics, Inc. (Aardvark), pursuant to which Aardvark agreed to purchase (i) the Company&#8217;s license agreement with Medice Arzneimittel P&#369;tter GmbH &amp; Co. KG, dated January 6, 2020, (ii) certain patents related to the Company&#8217;s ADAIR product candidate, and (iii) files (of contract manufacturing and FDA correspondence) for a formulation described in IND No. 133072, ADAIR for the Treatment of </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADHD and Narcolepsy, filed with the United States Food and Drug Administration. Under the terms of the Aardvark Agreement, the Company received an upfront cash payment of $250, which was recognized as other income. The Company is also eligible to receive potential additional milestone payments contingent upon Aardvark achieving certain future ADAIR regulatory and sales milestones. Other than the upfront payment, the Company does not anticipate the receipt of any milestone payments from Aardvark in the near term, which potential milestone payments may or may not be achieved, paid or received in the future.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824611008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES.<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with each of its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Separation and Release Agreement</span></div>In connection with the resignation of David Baker, the Company&#8217;s former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269909998656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX</a></td>
<td class="text">INCOME TAX.<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected income tax benefit at the federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State and local taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-deductible items and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(26.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accruals and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation - Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization - Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14,521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2024 and 2023. The Company increased its valuation allowance by approximately $2,163 for the&#160;year ended December&#160;31, 2024. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had federal, state and local net operating loss carryforwards of $52,369, $58,254, and $5,563, respectively; $46,245 of the federal net operating loss carryforwards do not expire and the remaining $6,124 begin to expire in 2029. The state losses also begin to expire in 2029. The local net operating losses begin to expire in 2024. Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (IRC), these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the IRC.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the provisions of Sections&#160;382 and 383 of the IRC, certain substantial changes in the Company&#8217;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the US federal jurisdiction as well as California, Pennsylvania and Philadelphia. The tax years 2021 to 2024 remain open to examination by the major jurisdictions in which the Company is subject to tax. Fiscal years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early years, which have been carried forward and may be audited in subsequent years when utilized.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2024 and 2023, the Company had no unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#8217;s uncertain tax positions yet to be determined would be related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823347504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS.<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recapitalization</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2025, the Company effected the February 2025 Reverse Stock Split. Stockholders&#8217; equity and all references to share and per share amounts in the accompanying financial statements have been retroactively adjusted to reflect the one-for-seventeen reverse stock split for all periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824632880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,207)<span></span>
</td>
<td class="num">$ (13,037)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269818010800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824607712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269819113632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the critical importance of maintaining the trust and confidence of patients, business partners and employees toward our business and are committed to protecting the confidentiality, integrity and availability of our business operations and systems. Our Board is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. In general, we seek to address cybersecurity risks through a comprehensive approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy; Effect of Risk</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face risks related to cybersecurity such as unauthorized access, cybersecurity attacks and other security incidents, including as perpetrated by hackers and unintentional damage or disruption to hardware and software systems, loss of data, and misappropriation of confidential information. To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity program to ensure our systems are effective and prepared for information security risks, including regular oversight of our programs for security monitoring for internal and external threats to ensure the confidentiality and integrity of our information assets. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. As discussed in more detail under &#8220;Cybersecurity Governance&#8221; below, our Board provides oversight of our cybersecurity risk management and strategy processes, which are led by our Chief Financial Officer.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our incident response plan coordinates the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, which include processes to triage, assess severity for, escalate, contain, investigate and remediate the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our processes also address cybersecurity threat risks associated with our use of third-party service providers who have access to employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, in Item 1A. under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">We may be unable to adequately protect our internal information systems, or those used by our CROs, clinical sites, or other contractors or consultants upon which we rely,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">from cyberattacks, compromises, cybersecurity incidents, or other disruptions, which could result in the compromise of sensitive or proprietary information, lead to operational or service interruption, harm our reputation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">and subject us to litigation, fines and other significant financial and legal exposure, and other adverse consequences,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; which disclosures are incorporated by reference herein.</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the last three fiscal years, we have not experienced any material cybersecurity incidents and the expenses we have incurred from cybersecurity incidents were immaterial. This includes penalties and settlements, of which there were none.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">In general, we seek to address cybersecurity risks through a comprehensive approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity is an important part of our risk management processes and an area of focus for our Board and management. Our Board is responsible for the oversight of risks from cybersecurity threats. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Board receives periodic updates from management about our cybersecurity threat risk management and strategy processes. Additionally, upon detection of a cybersecurity threat, our Board receives an update from management of our cybersecurity threat risk management and strategy processes, as well as the steps management has taken to respond to such identified cybersecurity threat. Our Board also receive prompt and timely information regarding any cybersecurity incident that meets establishing reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed</span></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, is managed by our Chief Financial Officer and supported by consultants with experience in managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs as needed. As discussed above, the Chief Financial Officer reports to our Board about material cybersecurity threat risks.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Cybersecurity is an important part of our risk management processes and an area of focus for our Board and management. Our Board is responsible for the oversight of risks from cybersecurity threats.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Board receives periodic updates from management about our cybersecurity threat risk management and strategy processes. Additionally, upon detection of a cybersecurity threat, our Board receives an update from management of our cybersecurity threat risk management and strategy processes, as well as the steps management has taken to respond to such identified cybersecurity threat. Our Board also receive prompt and timely information regarding any cybersecurity incident that meets establishing reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, is managed by our Chief Financial Officer and supported by consultants with experience in managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs as needed. As discussed above, the Chief Financial Officer reports to our Board about material cybersecurity threat risks.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, is managed by our Chief Financial Officer and supported by consultants with experience in managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs as needed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, is managed by our Chief Financial Officer and supported by consultants with experience in managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs as needed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our Board receives periodic updates from management about our cybersecurity threat risk management and strategy processes. Additionally, upon detection of a cybersecurity threat, our Board receives an update from management of our cybersecurity threat risk management and strategy processes, as well as the steps management has taken to respond to such identified cybersecurity threat. Our Board also receive prompt and timely information regarding any cybersecurity incident that meets establishing reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823287600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text">References in this Annual Report to &#8220;authoritative guidance&#8221; is meant to refer to accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly-owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of December&#160;31, 2024 and 2023 included investment in money market funds.&#160;The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $4,521 and $1,217 at December&#160;31, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&#160;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&#160;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Pricing inputs that are generally unobservable inputs and not corroborated by market data.&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At December&#160;31, 2024, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the statement of operations for the year ended December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div>Property and equipment are stated at cost. The Company commences depreciation when the asset is placed in service. Computers and peripheral equipment are depreciated on a straight-line method over useful lives of three years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to use, or control the use of, identified property, plant, or equipment for a period of time in exchange for consideration. Lease right-of-use (ROU) assets and lease liabilities recognized in the accompanying balance sheet represent the right to use an underlying asset for the lease term and an obligation to make lease payments arising from the lease respectively.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the lease commencement date, the Company recognizes an ROU asset and a lease liability for its operating leases, except its short-term operating leases with original lease terms of twelve months or less. The ROU asset is initially measured at cost, which primarily comprises the initial amount of the lease liability plus any lease prepayments. The lease liability is initially measured at the present value of the lease payments not yet paid, discounted using an estimate of the Company&#8217;s incremental borrowing rate for a collateralized loan with a similar amount and terms as the underlying lease in a similar economic environment. That discount rate is used because the interest rate implicit in the Company&#8217;s lease contracts is typically not readily determinable.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease modifications that grant the right to use an existing leased asset for an additional period of time are not accounted for as separate contracts; however, the lease term, classification, discount rate, and measurement of the remaining consideration due under the contract are reassessed upon execution of such modifications.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense for operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the May 2022 Warrants (Note 10) in accordance with ASC 815-40, and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the accompanying consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with changes in fair value recognized in the accompanying consolidated statements of operations in the period of change. The derivative liabilities will ultimately be converted into the Common Stock when the warrants are exercised, or will be extinguished upon expiry of the warrant term. Upon exercise, the intrinsic value of the shares issued is transferred to stockholders&#8217; equity. The difference between the intrinsic value of the stock issued and the fair value of the warrant is recorded as gain or loss on the exchange in the accompanying consolidated statements of operations in the period of exercise.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's Common Stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected </span></div>benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;As the Company had a net loss in each of the years ended December&#160;31, 2024 and 2023, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.&#160;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement &#8212; Reporting Comprehensive Income &#8212; Expense Disaggregation Disclosures (Subtopic 220-40) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2024-03). The amendments in ASU 2024-03 require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, for all public entities. Early adoption is permitted. Management is currently evaluating the impact of this update on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASU 2023-09). The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. Management is currently evaluating the impact of this update on the Company&#8217;s financial statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, FASB issued ASU 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements: Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-06)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2023-06 represent changes to clarify or improve disclosure and presentation requirements of a variety of topics in the Codification and align those requirements with the SEC&#8217;s regulation. For entities subject to the Security and Exchange Commission&#8217;s (SEC) existing disclosure requirements, the effective date for each amendment will be the date on which the SEC&#8217;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited.</span><span style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. Management is currently evaluating the impact of this update and its effective dates but does not expect the update to have a material effect on the Company&#8217;s financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269909896752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">359,406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">359,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,501&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823093792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER WITH VALLON (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of the Net Liabilities Assumed in the Merger</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Plus: Transaction costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total net liabilities assumed plus transaction costs</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5,923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823916768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2024:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2023:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.902%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes is the fair value of the Level 3 liability:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in valuation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Balance as of December 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.429%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">166.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.26&#160;%</span></td></tr></table></div>The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:<div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156.3&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.63</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.65&#160;%</span></td></tr></table></div>The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants, and the Placement Agent Warrants with the following weighted-average assumptions:<div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.1&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.65</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.92&#160;%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Series D-1 Common Warrants, the Series D-2 Common Warrants, and the October 2024 PA Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174.4&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.65</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.16&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824095120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="padding-left:9pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824516032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Operating Lease Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the operating lease assets and liabilities recognized on the Company's consolidated balance sheets:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.919%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance Sheet Line Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Total operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments are due as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">137&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Present value of operating lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">119&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269909982352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consisted of:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">342</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;Payroll and related</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">337</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;Total accrued expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">691&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,270&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824820432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.429%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">166.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.26&#160;%</span></td></tr></table></div>The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:<div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156.3&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.63</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.65&#160;%</span></td></tr></table></div>The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants, and the Placement Agent Warrants with the following weighted-average assumptions:<div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159.1&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.65</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.92&#160;%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes option-pricing model was used to estimate the fair value of the Series D-1 Common Warrants, the Series D-2 Common Warrants, and the October 2024 PA Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174.4&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.65</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.16&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding to Purchase Common Stock</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had the following warrants outstanding to purchase common stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">210</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$243.10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$464,100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128,577</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$31.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">March 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,839</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$17.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$43,548.05</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$94,970.33</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">210</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$243.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,002</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$38.8875</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128,577</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$31.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">September 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,839</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$17.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,140</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$21.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">October 2029</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269920831376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the GRI Operations Plan and the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and nine months ended December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.316%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">388</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">148</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">388</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Activity of Stock Options Granted</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the year ended December&#160;31, 2024:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,376.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Outstanding at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,376.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exercisable at December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,475.38</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.57</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Vested and expected to vest at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">142</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,376.92</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.63</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Volatility</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">129.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5.84</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Dividend rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fair value of common stock on grant date</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,298.42</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824403136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Federal Statutory Income Tax Rate to the Effective Income tax Rate</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Expected income tax benefit at the federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">State and local taxes, net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-deductible items and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(26.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal components of the Company&#8217;s deferred tax assets and liabilities are as follows:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Federal and state net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,537&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accruals and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capitalized research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,099&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation - Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization - Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gross deferred tax assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,684&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,521&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Less: valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(16,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14,521)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net deferred tax assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823813792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th"><div>Feb. 21, 2025</div></th>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0769<span></span>
</td>
<td class="nump">0.1429<span></span>
</td>
<td class="nump">0.0333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.0588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269813587328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2024</div></th>
<th class="th"><div>Oct. 21, 2024</div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 22, 2024</div></th>
<th class="th"><div>May 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,740<span></span>
</td>
<td class="nump">$ 39,740<span></span>
</td>
<td class="nump">$ 31,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,028<span></span>
</td>
<td class="nump">$ 5,028<span></span>
</td>
<td class="nump">$ 1,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,485<span></span>
</td>
<td class="nump">525,485<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockHeldIntoEscrowAccount', window );">Common stock placed into escrow (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds', window );">Sale of stock, aggregate cash fee, percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds', window );">Management fee, percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses', window );">Reimbursement of accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses', window );">Reimbursement of non-accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 762<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember', window );">Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember', window );">Series B-1 common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember', window );">Series B-2 common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember', window );">Series A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember', window );">Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember', window );">Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PriorWarrantsMember', window );">Prior Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantOrRightOfferingCost', window );">Class of warrant or right, offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember', window );">Series D-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember', window );">Series D-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember', window );">Series D Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember', window );">June 2024 PA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="nump">$ 38.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
<td class="nump">9,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember', window );">Series B Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_October2024PAWarrantsMember', window );">October 2024 PA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series B-1 common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series B-2 common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="nump">$ 3,604<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="nump">$ 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAgentCompensationPercentage', window );">Sale of stock, agent compensation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">At The Market Offering | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.07<span></span>
</td>
<td class="nump">$ 11.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ConversionOfStockAdditionalSharesConverted', window );">Additional shares converted into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClassOfWarrantOrRightOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Offering Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClassOfWarrantOrRightOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockHeldIntoEscrowAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Held Into Escrow Account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockHeldIntoEscrowAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ConversionOfStockAdditionalSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Additional Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ConversionOfStockAdditionalSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAgentCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Compensation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAgentCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value Of Shares Offered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockMaximumValueOfSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Securities Issued Per Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Reimbursement Of Accountable Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockReimbursementOfAccountableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Reimbursement Of Non-Accountable Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PriorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PriorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesBCommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_October2024PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_October2024PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269813647008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">FDIC insured amount</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Uninsured cash balances</a></td>
<td class="nump">$ 4,521<span></span>
</td>
<td class="nump">$ 1,217<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824574768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ck0001824293_PeripheralEquipmentMember', window );">Peripheral Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ck0001824293_PeripheralEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ck0001824293_PeripheralEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823453888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">359,548<span></span>
</td>
<td class="nump">1,501<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">359,406<span></span>
</td>
<td class="nump">1,359<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269822923616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MERGER WITH VALLON - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockOwnershipPercentage', window );">Ownership percentage in common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses (in shares)</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_GRIOperationsMember', window );">GRI Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockExchangeRatio', window );">Common stock, exchange ratio</a></td>
<td class="nump">0.0374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockOwnershipPercentage', window );">Ownership percentage in common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 22,787.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_GRIOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_GRIOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823293024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details) - GRI Operations<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(4,190)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net liabilities assumed</a></td>
<td class="num">(2,939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Plus: Transaction costs</a></td>
<td class="num">(2,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts', window );">Total net liabilities assumed plus transaction costs</a></td>
<td class="num">$ (5,923)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_GRIOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_GRIOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269822658976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantLiabilityFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantLiabilityFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Other Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantLiabilityFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269825778448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in valuation</a></td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=ck0001824293_WarrantLiabilityMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2023</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance as of December 31, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ck0001824293_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ck0001824293_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269822903680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details) - Weighted Average<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0426<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269818279088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823692672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824607712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Operating Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Non-current operating lease assets</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269819192816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Schedule of Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269822908000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease, cost</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269920321696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 342<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent', window );">General and administrative</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 691<span></span>
</td>
<td class="nump">$ 1,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued General and Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269811744192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTES - Bridge Financing (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 13, 2022 </div>
<div>USD ($) </div>
<div>closing</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember', window );">Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares) | shares</a></td>
<td class="nump">272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 22,787.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember', window );">Bridge SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
<td class="nump">679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,057.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 22,787.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Bridge SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">$ 3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentAggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentNumberOfClosings', window );">Number of closings | closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Aggregate Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentNumberOfClosings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Closings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentNumberOfClosings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269816100672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2024</div></th>
<th class="th"><div>Oct. 21, 2024</div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds', window );">Sale of stock, aggregate cash fee, percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds', window );">Management fee, percentage of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses', window );">Reimbursement of accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses', window );">Reimbursement of non-accountable expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember', window );">Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember', window );">Series B-1 common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember', window );">Series B-2 common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember', window );">Series A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember', window );">Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember', window );">Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember', window );">June 2024 PA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,140<span></span>
</td>
<td class="nump">9,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.25<span></span>
</td>
<td class="nump">$ 38.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38.89<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PriorWarrantsMember', window );">Prior Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense', window );">Proceeds from warrant exercise, net of offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ClassOfWarrantOrRightOfferingCost', window );">Class of warrant or right, offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember', window );">Series D-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember', window );">Series D-2 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember', window );">Series D Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series B-1 common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series B-2 common warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="nump">$ 3,604<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="nump">$ 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAgentCompensationPercentage', window );">Sale of stock, agent compensation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">At The Market Offering | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.07<span></span>
</td>
<td class="nump">$ 11.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ConversionOfStockAdditionalSharesConverted', window );">Additional shares converted into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settleable in cash, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital | Pre-Funded And Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settleable in cash, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital | June 2024 PA Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants not settleable in cash, fair value disclosure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ClassOfWarrantOrRightOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Offering Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ClassOfWarrantOrRightOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ConversionOfStockAdditionalSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Additional Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ConversionOfStockAdditionalSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Warrant Exercises, Net Of Offering Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAgentCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Compensation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAgentCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Management Fee, Percentage Of Gross Proceeds</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value Of Shares Offered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockMaximumValueOfSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Securities Issued Per Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockReimbursementOfAccountableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Reimbursement Of Accountable Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockReimbursementOfAccountableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Reimbursement Of Non-Accountable Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_June2024PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PriorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PriorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD2WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesDWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedAndSeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedAndSeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269815371536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details) - Weighted Average<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>year</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.660<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series B-1 Common And Series B-2 Common Warrants | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.563<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series B-1 Common And Series B-2 Common Warrants | Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.63<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series B-1 Common And Series B-2 Common Warrants | Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series B-1 Common And Series B-2 Common Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants | Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants | Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0492<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series D-1 Common Warrants, Series D-2 Common Warrants, And PA Warrants | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series D-1 Common Warrants, Series D-2 Common Warrants, And PA Warrants | Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series D-1 Common Warrants, Series D-2 Common Warrants, And PA Warrants | Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Series D-1 Common Warrants, Series D-2 Common Warrants, And PA Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269814584640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member', window );">Warrants Expiring In August 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 243.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member', window );">Warrants Expiring In February 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 464,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMarch2026Member', window );">Warrants Expiring In March 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">128,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 31.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2026Member', window );">Warrants Expiring In April 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">44,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member', window );">Warrants Expiring In May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 43,548.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member', window );">Warrants Expiring In July 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member', window );">Warrants Expiring In April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 94,970.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member', window );">Warrants Expiring In February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 243.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member', window );">Warrants Expiring In June 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">9,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 38.8875<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInSeptember2029Member', window );">Warrants Expiring In September 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">128,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 31.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029OneMember', window );">Warrants Expiring In October 2029, One</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">44,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 17.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029TwoMember', window );">Warrants Expiring In October 2029, Two</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">3,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 21.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMarch2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMarch2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInSeptember2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInSeptember2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029OneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029OneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029TwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInOctober2029TwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269818452336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_GRIOperationsPlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum', window );">Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan | Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_GRIOperationsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_GRIOperationsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269920308736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824790032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Activity of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Ending Balance (in shares)</a></td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance (in usd per share)</a></td>
<td class="nump">$ 4,376.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance (in usd per share)</a></td>
<td class="nump">4,376.92<span></span>
</td>
<td class="nump">$ 4,376.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending Balance (in usd per share)</a></td>
<td class="nump">5,475.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in usd per share)</a></td>
<td class="nump">$ 4,376.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (years)</a></td>
<td class="text">8 years 7 months 17 days<span></span>
</td>
<td class="text">9 years 7 months 17 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (years)</a></td>
<td class="text">8 years 6 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (years)</a></td>
<td class="text">8 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824792976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129.54%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.34%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of common stock on grant date (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,298.42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823353376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ASSET PURCHASE AGREEMENT (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Aug. 22, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ck0001824293_AardvarkTherapeuticsIncMember', window );">Aardvark Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Upfront cash payment</a></td>
<td class="nump">$ 250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ck0001824293_AardvarkTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ck0001824293_AardvarkTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823446640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Former Chief Executive Officer<br></strong></div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_COBRABenefitsPaymentPeriod', window );">COBRA benefits, payment period (in months)</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PercentageOfTargetBonus', window );">Percentage of target bonus (as a percent)</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_COBRABenefitsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>COBRA Benefits, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_COBRABenefitsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PercentageOfTargetBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Target Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PercentageOfTargetBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269817992032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at the federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes, net of federal benefit</a></td>
<td class="nump">7.70%<span></span>
</td>
<td class="nump">8.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items and other</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(12.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(26.40%)<span></span>
</td>
<td class="num">(18.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823794288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX- Components of Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 14,537<span></span>
</td>
<td class="nump">$ 12,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share based compensation</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals and other</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">1,846<span></span>
</td>
<td class="nump">1,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation - Federal</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Amortization - Federal</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">16,684<span></span>
</td>
<td class="nump">14,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Less: deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(16,684)<span></span>
</td>
<td class="num">(14,521)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269823053824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance, increase</a></td>
<td class="nump">$ 2,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would affect effective tax rate if recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">52,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards, not subject to expiration</a></td>
<td class="nump">46,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="nump">6,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ck0001824293_StateTaxAuthorityMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">58,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=ck0001824293_LocalTaxAuthorityMember', window );">Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 5,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ck0001824293_StateTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ck0001824293_StateTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=ck0001824293_LocalTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=ck0001824293_LocalTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm46269824633648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br></strong></div></th>
<th class="th"><div>Feb. 21, 2025</div></th>
<th class="th"><div>Jun. 14, 2024</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0769<span></span>
</td>
<td class="nump">0.1429<span></span>
</td>
<td class="nump">0.0333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="nump">0.0588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>102
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MN="FYMVP,DT6I TP^SLA]'%B#^C;=O874$L#!!0    ( !J(;EK*9ZT*Z 0
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M[\C%AX_D ^$E^9;+K69EIF>^00;KR4^;\6[K\<(SX]&0?)&ER37YM<P@>^O
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M*&N WU=2FD/##M#6M8M_ 5!+ P04    "  :B&Y:0#8_B!,(  #Z)P  &
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M,N=.G!KUD\Q]<=1[U6.Y6/!:^5NS^DXT]CPG>9E1+OQEJV9MVF-9[;PIF\U
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MX.1ZG"(/&'I,7LHRM08$@0@3BFMM9I/IWQI=K[4RIDT]?IY"B]C!DE%IXKB
MGK]OASWBGMR#&PMY%IT%Y^'%+NRU3GS16+??TN!4)"=@K!J$Z 7<,)Q,%ZWG
M!$QSB;T'.YP%Y],S7&-%X22 ]C%(W;-@?KX8IFZL4L"6R&)J$?B:I)1!.:9#
MLQ9V<M+D>W(H)Z-QKUI)5"I&.&5P*%2!R*JB2*T+81XO,7BL)0X:2>%N\.:2
M^=W)C!V] 4#0B$_8;#8[B1:7L_G%L:T#8BTP?"%6GJD*-ZYVJ6(PJD/W(FMR
M!32K=MFL'14 \3*FR+Z#[&'WY8RUUF[MC#.HQ6J/KPEW$S3@*JT2T6MD.JQ
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M%\#WE5)E\X (W/^;>/E_4$L#!!0    ( !J(;EI*8C!4Q!0  "(]   9
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M3]J0T9-_)[Q%=^L'YG8X3>L6=FK9:]Z'4#ZX&2J[Z5K]6]\8=78<(WY@&3#
MA[-5L&Q&?0L"#IF>?AO+18"+36J^C@XQ10\/=1J7SWYZLF%*67W(<6LS(*U%
MXO4_&#?B[\'&YH 0U]/O'(PH2W"4G)[+M BH=&IEIY+B?Q&(MOW^\2C[W>K2
MM'/^=2[_#J;IY">LZ6GZ ?"%_.YU&"Z_'OZ@VSG]L*,V,TP]GOSX9$^.QN,7
M>#/_"G;JNLXM^>/":*!7&H#W,P=L%+[0 NEGT:__!E!+ P04    "  :B&Y:
MTA+*T D(  "Z&0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6S-66UO
MXS82_BN$NU?8@.$7V6G> RC;W#:';M=(<KL?#OU 2V.+74G4DI2=W*^_F:$D
MO\1.G.T5Z)?$ELCA,\_,/.30%TMMOMH$P(G'+,WM92MQKCCK]VV40"9M3Q>0
MXYN9-IET^-7,^[8P(&.>E*7]8##XJ9])E;>N+OC9Q%Q=Z-*E*H>)$;;,,FF>
MKB'5R\O6L%4_N%/SQ-&#_M5%(>=P#^[?Q<3@MWYC)589Y%;I7!B87;;"X=GU
MF,;S@,\*EG;MLR!/IEI_I2^W\65K0( @A<B1!8G_%O >TI0,(8QOE<U6LR1-
M7/]<6_\G^XZ^3*6%]SK]HF*77+9.6B*&F2Q3=Z>7OT#ESQ'9BW1J^:]85F,'
M+1&5UNFLFHP(,I7[__*QXN&0"4$U(6#<?B%&^;-T\NK"Z*4P-!JMT0=VE6<C
M.)534.Z=P;<*Y[FKCS=W'V[NQ)?;AU_$Y_#77S_]=M%W:)?>]J/*QK6W$>RQ
M,0S$1YV[Q(J;/(9XTT ? 36H@AK5=?"BQ9\AZHG1L"N"03!^P=ZH\7+$]D9[
M[%V7%I]8*][K;*IR20G1%:&UF/5A]*U45OE',H_%O[3*G?@,N2L-"!][2J#_
MA%/K#*;1[[LH\@#&NP%0:9W90D9PV<+:L6 6T+KZ\8?A3X/S%]P;-^Z-7[)^
M8!#?:J,G/N4B+(Q*1>!#,>J*HC2VE,B/T\(E(#Z"F8,1X=P 8*VZ;OWDOIR*
MI;0BHZ\Q9K5+F%WD5HL/=[?B4P&&B;5=_W;S(<J$6:B%RN?KZZ!!*9:)3M,G
MH9<Y&K;EU*I8H: (/>.A&.-"YD\]<9N+2.=Y5?^\!K]/-6;#O+L^6$@$C[DK
ME+,B N/43$72 =E4>:1-H3TN]F'ZE,JE)0JB1.9SX%DYFA SHS/QXP\G03 X
M_RS3%"=,$HD9%$'IT&**SM[F48^'#,_)1#6:O+]6>O-UZ!CDS6P&K%[B 07Q
M3+1E1]S(*!$6;3/&+>[0JPR7OG<Z^BI0BJU#V$2ERC) LAP@?QA9;>HX;B[1
M):?3DJ<0.[R.?6TA96V)%&ZGR W6EWL2]Y,0ZZM$09/,!"+ Z"R0:XJB3@D2
M)P?-,22F9,! !(1*BKS,II@!B&&%9BV"1-GP^'P+$GPK94IV!KW!Z'@LV@SH
ML0K;'7G1Z8GVM.)3%QQC'(].X" +![K>!IR.[FT/^L0&.QLQH PJ<W@$$RE+
M*7=83'!.C/[3BXU<P<(<'M4DXP,L0IHR227IF6TRNUW/7(-'@SI8?@G@2^36
MB%P[L0"+,>FNA8?CPID/$:6YS%^FZK6X>*'=J#_,':1![ ')XX%3OHR>285G
M&5'B)H^U&DMD857O#DS6H-IEFYD)*P#>EL6L>,"GNY)N(_ H/W]@D(@'AK=I
MAA4P!D*@2*RF3R+#XX(JTB?*A+;J,*A=J[R4;2Z13BP!2W]M^?W$<!H@.<#Y
M=+@&(-JVJB!NUHR/G]&ESVBN6+#D&7ZKO(E1GVO+.9!;CI7[=5(]]>A%I6]U
MJ1!:#.Q,FSIU-K5'3M%X6>"S9@9:/BPL,6XU[$L[] [O79Y@E\],_AF.KW=1
M_!+#>[&5Q6[&211Z(L0ZHX<XE%F@\DU@@RPJQ2VN4 5PT9)50,S*-*4 1. K
MTGM;%S,1VJWMR:E*49*Z+">$FAJ*N$S!)P^MI%EU"J,7RG*^[N;6CUL21 /4
M:  )J"<K1O6.*O5>2F.J?>>M\KU#&KYX:[;S/1LH9UBM:1CC#:E#[[>E]17L
MS\'6#*U05D' SFR&<6!MV4C]:F0MX4V4,#VJW9<*ZYF&-^N>K\3@NU6QQO"*
M+(9_L2Q6,/[O-?O7RN(Y6\<@J%<4:C..WR.3^^/T3">WUEZ!>B58?\<0O4E-
MVW&']ZEKHV*T7A>B:/^FL6\X[?A,A&KUF*.R; 9M(%L5\7KYTZEGCGW5O.I#
M@N/@#4<LOXD^6X+E'"64^R84->(,R;0J4ZDTU5FI\GK;,V(ND0M&IG+LF/%H
MO459<]Y^%P3=XY/CWFBX2@GD##HBQ!V$C_?6']'0GZ)*A*T<J/<JZ@\X9R3R
M%UM/[.'B6K_::ZX^*#XKP&T9VVVAUBZU0G/X5OY=JG!8[ _;C1G<KHUXQY:X
MC\&7]^>'5?O.NR(>T<O<517!#;T!C!?/CF2AG$S5?WVS[5N>#V$XX6VKQ#&L
M?$;1#2+E #@&6_7:G!F1M/ZJ@3]@1JJ%3+%D;8\N<^KU^1Q58E]O 7OR+4>W
M= \#,_4KKTV6=&]DP%\*QEY0G[4;];5%P_%,1DX;N^JOSYHN 'P+AU%'IW=M
M=GO5KUJ%+T2ZU,4ED,9UD='QPD.EKMY[T<B*+##HC\@F&STY^D<-?/W,\X9^
M>ZNM:P9QNM2>'>3'%K3AGX;&IY<M1IDGFIG)/[0A]MMCLD\&CSKT=ZJIPBU(
MUZP2\1TBD,[P<MVU?7G3?@4$K>=RSM=C.U9$JU\!B=#^#M+605J;M&=A7UHS
MC:F_9&7QA[E$T]T4"XD3J?*5KV!U'JT6\&R?;5WQB??[RD>\$Z?CH9@8**2*
MUW*Z*L/1<"!"7Q]6%/*)T?!1/XH,]0_P6$".Y88D=X>G ]P^-=;Z7ICMH'LZ
MPGUTDI;V3#S@'F1E5+4DEO90?'\R?LU*@;.%>S;YG6@?=4^#46?7]6M_[3Z=
M[R_I5P/:.M$U?[7>/&U^F C]??QJN/]5XZ,T<X5!36&&4P>]XZ.6+\SZB],%
MW\Y/M7,ZXX\)2*P3&H#O9QJ/$]476J#YN>;J?U!+ P04    "  :B&Y:;V0,
MO=,%  "D#P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6S=5]MRVS80
M_94=I4F=&4472G$\CNT9^9*I9^S&M6/GH=,'B%R)B$& !D K^OON A1%V;)G
MVK?V1>)EL3A[=L\N<; P]M[EB!Y^%DJ[PT[N?;G?[[LTQT*XGBE1TYN9L87P
M=&OG?5=:%%E85*A^,ACL]@LA=>?H(#R[LD<'IO)*:KRRX*JB$'9YC,HL#CO#
MSNK!M9SGGA_TCPY*,<<;]+?EE:6[?N,EDP5J)XT&B[/#SF2X?SQF^V!P)W'A
M6M? D4R-N>>;\^RP,V! J##U[$'0WR.>H%+LB& \U#X[S9:\L'V]\OXEQ$ZQ
M3(7#$Z.^R\SGAYV]#F0X$Y7RUV;Q&];Q?&1_J5$N_,(BVH[&'4@KYTU1+R8$
MA=3Q7_RL>6@MV!N\L""I%R0!=]PHH#P57AP=6+, R];DC2]"J&$U@9.:DW+C
M+;V5M,X??9F<7\/=Y.+V#"[/)C>WUV>79[]_NSGH>W+.)OVT=G0<'24O.!HF
M<&FTSQV<Z0RS30=]0M5 2U;0CI-7/9YBVH/1L O)(!F_XF_4A#H*_D8OA2JD
MA3NA*H13Z5)E7&71P9^3J?.6JN.O;4%'E^/M+EDQ^ZX4*1YV2!(.[2-VCMZ]
M&>X./K\">-P 'K_F_9_DYE\YZL&W'.'$%*702Q!EJ23QX>G9O)*9T"F"U#"Y
M.8&]9 #>D(124VD/U M@)C592*% .(?>@= 9*"FF4DG/?@H43' &K#W2;UI9
M*_6<-21=#T(V'D,V9,M81 "EE;2[SX4G55<J@RFR"R0%9XR$9$T;Z[@W$)Q2
MR/"",JG=#"UMN0*SY"C(UM@,K5I&$Q&;PA3] E&3HNP].2J%]3*5Q <'Y .4
M&AHU(@^9\-B#B:,>EN9=F&W$(&HO'[A+9!OK0B!DDJ%'2RJFU]'(A!"JHF0T
M+MIMPQ))J%S(")/#3+;C;X+=3"JM8& MH+E$*VR:+[NPR&6:0R:=)V^5I";B
M&D+:J!JH-3)B0<".F7*]BZEB3&7EW?M0 @2*(B8@OSHPBTU'.Y5^OBH";BK.
MXD,E+=9<M("W^&28D"IR+6>2BX;VS:*DZ8X8,AK!S$+Z9D;1X&&Z1I!2^N;&
M4G7NPP4^HH(A[,.M%MD/ZK2T]*$R_!>JSX6R"4.C#KS&)"RR$I!VYS!>*),@
M$IDQ%ZE07:@T!>7)L0]5'B33RAMAZM68$L+TQU,@SQ!HXVMT7?83R:Q3RN_7
M1'<!)2&T1!%)R),"@OWJKAN0NHJZ()4:"9HEPL15)#$NUQ63SVJMA7E$F*\B
M6!,3)H*^/*:YE@_5*I]U=E=PFVBFQN?@Y%Q30E/!BC$1Q-;\AX1OU-*.[&&O
M2U&4I;',W'1),+VG5X1'FU7I!L:H.*GJ3FLM<FE$VNKR6&X7%F%1BA@F+BD?
M#*Z1TKIHVR'\J+(YH]U4)$9R.*M$P-I%UAI)* B-10Z%T95HI<F"&Z)J@2'[
M3:=;:[8N:1J8@: 19%7HN(QUB<*2,&DR4^ I%E.JA]5L#=9T,8I(UXKQ@=LP
MV4ATL5 "MI6VMK054(S"K2CA/%';74V1;EA7<_'NS5XR_/39;8R-IB36(V&C
M#6R;)CPU"-*SP!H=734ZFD1!7]9RVJDY>P\WK<Q]#7+YNBZO\UBNM76RS?JV
M78Z;]J/W<+&.<!^^"VMYX;JT?H' 1?)YZ]7_*BFC_WA21J^F(S"9YD+/.3+W
M-"%UBE8]L]EKO?U%LWWK ^D%)@.:D[ 9L[CNNCL4W+%089Z^((TGY76L1'K_
MX2;-C2+@:T^%R0CI@IQ4+GYYT1"3!<^W[:$M8ARQ3SX9P*U/@?TMB.Z,HDU#
M[,/=W=X WL+9SQ+#P QSB&+D-N8@Z7VD3_A'GJX96 8S".;7TMU_F%ED.F@%
M08UOQ[UD%]YN^R+OMTY.!=IY.!\Z")^Y\1#5/&V.H)-X\EJ;Q_,K5>]<TD>.
MPADM'?0^?>R C6?">.--&<YA-.OH5!<N<SI&HV4#>C\S)(OZAC=H#N9'?P-0
M2P,$%     @ &HAN6DI%+Z&0 @  L04  !D   !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&ULG51M3]LP$/XKIPQ-(*$F30)#K(W40M'X4-85V#1-^^ FU\8B
ML8/MT/+O=W;2T$FETB;EQ6??\_BYL^\&:ZF>=(YH8%,60@^]W)CJTO=UFF/)
M=$]6*&AE*57)#)EJY>M*(<L<J"S\, C._9)QX24#-S=3R4#6IN "9PIT799,
MO8ZQD.NAU_>V$W.^RHV=\)-!Q59XC^:QFBFR_(XEXR4*S:4 A<NA-^I?CF/K
M[QR^<USKG3'82!92/EGC-AMZ@16$!:;&,C#ZO> 5%H4E(AG/+:?7;6F!N^,M
M^XV+G6)9,(U7LOC!,Y,/O0L/,ERRNC!SN?Z";3QGEB^5A79?6#>^,>V8UMK(
ML@6377+1_-FFS<,.X")X!Q"V@-#I;C9R*J^98<E R34HZTUL=N!"=6@2QX4]
ME'NC:)43SB2S^=?99/[P$T9WUS#Y]G@[FT[N'@:^(6[KX:<MS[CA"=_AZ8<P
ME<+D&B8BP^QO I]$=<K"K;)Q>)#Q&M,>1/U3"(,P/L 7=9%&CB]Z+U)%-UF9
MUU.8%4P88"*#R7/-*[IB!GZ-%MHHNB._]\7>,,?[F6W=7.J*I3CTJ# TJA?T
MDH\?^N?!YP.ZXTYW?(C]'T[H?WAZ0'G&<H&JR[7]1' ERZHV-(U=CHX@[#>?
MFUH);FJ%+HM+OK%C#?W(/E%LGU&:UF5=,(,950GE)>7,U>%Q%)S <7A^0E0Q
MO1>D8&<9-]1O-%+!-U@CH6I/SFWV)F?--!S%P G#TASD$DR.\(I,:4!["?>$
M9AEL>+U]!^/OE%&):N6:A894UL(T%=7-=OUHU)3AFWO3S*9,K;C04."2H$'O
MTYD'JFD0C6%DY8IR(0V5N!OFU%-160=:7TIIMH;=H.O2R1]02P,$%     @
M&HAN6M1'52R0!   (PL  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
MG59M;]LV$/XK!S7HOF1^D9W$36T#29IB =(U:++MP[ /M'26B%*D2E)QO%^_
M.U*6G31VBP&&19%WSSWW*DY7QGYU):*'ITII-TM*[^OS?M]E)5;"]4R-FDZ6
MQE;"TZLM^JZV*/*@5*E^.AB<]BLA=3*?AKT[.Y^:QBNI\<Z":ZI*V/4E*K.:
M)<-DL_%%%J7GC?Y\6HL"[]'_4=]9>NMW*+FL4#MI-%A<SI*+X?GEF.6#P)\2
M5VYG#>S)PIBO_'*3SY(!$T*%F6<$08]'O$*E&(AH?&LQD\XD*^ZN-^@?@^_D
MRT(XO#+J+YG[<I9,$LAQ*1KEOYC5;]CZ<\)XF5$N_,,JR@Y).&N<-U6K3 PJ
MJ>-3/+5QV%&8#/8HI*U"&GA'0X'E!^'%?&K-"BQ+$QHO@JM!F\A)S4FY]Y9.
M)>GY^>WUQ?WU_;3O"8MW^EFK=QGUTCUZPQ0^&>U+!]<ZQ_PY0)](=$S2#9/+
M]"#B!\QZ,!H>0SI(QP?P1IUGHX WVN<94K(<_'VQ<-Y2\O]YS<D(,7X=@AOB
MW-4BPUE"%>_0/F(R?_MF>#IX?X#@N",X/H1^(/0_H]>#AQ+ARE2UT&M0T5FS
M7,H,82DRJ:27M--0=BP(#=3&5GBIBR@+HK"(U%T^ KW8I'[[UDCR&9;R"7.H
M.-=J3=O:"P6U6+.4 ^%@11W%SVZ/)@4\"BO%0F&GV/@-(Z'S'3*9<:3B2VN:
MHJ2A0<L-&8^V>NXE/@K5"$\@Q -71,34W-L$ZELEJ3,,>\ MS_^%83O4N3+:
M)@G5Y*]@^))0)/WX2#BCR8$U9&@]S3;P!O );2:#$9)S]%[3;*'H;/E2.$K4
MD"GAG%RNNW!'TQ4M&[O-@:(8M6'IP>WS##@HB)\5BCCD!K3I<D+M3Z8D,>^B
M'.$V&3@F22?S)DBH!J%HA!7:(U>(Y4-O99B&%/Y'U'3D8J!]0%OPJ(90\3HD
M![^O'N?01Z=VG"#HS!1:_DLQH?#[;>I^<61*.Z-D+CAB"Z$$90K"X'+G0,V/
MU8(JE0? 97MX'[Y*MU3^<..Q"H.!_T;PN]&_9HWE:MQ'[3-9MYN7(QBF _X?
MP^<7XCOTS^%J#^:NCQ%X8WWW9#QA X>X?8^SNW,VA+=O)NDP?0\/QH?*W*].
MS@S?19<^-K[ALI!:5DWUHAA T%'><%RH,Q5E]F6X-V$](;33 :].X33EYQD,
M3UHJ9&AT1C7J2/NFJAM.HJ22XF*"X03N8K6T!6>6/\']92;B*%@1)!R1?:ZM
MHY-W89R@R$H&Y8I:H[#4>_S5><4/UN(2"3W [4E5KM:]/<8X-NT\R.G#ZTOJ
M;+HQT,0MCC?]%R!%SM'E#TEH&^Y\'09NK/)GM>T\/6+LMW$@@1Y<"5=28F0>
MG!*5:5BH(R C6)P2<0S_() Q6!2D&*Q)P/W_07HH>48&6CP%=XEM681[5#0O
M?^A]QAXON>AZKWTQ^SL7EPIM$:YG/"J(0;S#=+O=#? B7GRVXO'Z^$G80M(4
M5[@DU4'O["0!&Z]D\<6;.ER#%L;3I2HL2[K%HF4!.E\:XS<O;*"[%\__ U!+
M P04    "  :B&Y:=5(L&G<"  "%!0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6R-5-MN&C$0_971-NI3Q%X#"865N/7RD I!TU:J^F!V!W85K[VU
M34C^OF,O;&D*J"^^SCD^,_;Q8"?5HRX0#3Q77.BA5QA3]WU?9P563'=DC8)V
MUE)5S-!4;7Q=*V2Y U7<CX*@ZU>L%%XZ<&MSE0[DUO!2X%R!WE854R]CY'(W
M]$+OL+ H-X6Q"WXZJ-D&EV@>ZKFBF=^RY&6%0I=2@,+UT!N%_7%BXUW UQ)W
M^F@,-I.5E(]V\BD?>H$5A!PS8QD8=4\X0<XM$<GXM>?TVB,M\'A\8'_O<J=<
M5DSC1/)O96Z*H7?K08YKMN5F(7<?<9_/C>7+)->NA5T3&\<>9%MM9+4'DX*J
M%$W/GO=U. +<!F< T1X0.=W-04[EE!F6#I3<@;+1Q&8'+E6')G&EL)>R-(IV
M2\*9=#29+!YF4YA]G\\^+V?+@6^(U>[YV9YAW#!$9QC"".ZE,(6&F<@Q_YO
M)SFMINB@:1Q=9)QBUH$XO(8HB)(+?'&;8^SXXC-\<_;"5APU,)'#*,O4EG$-
M/T8K;12]BI^G<FX8D].,UBE]7;,,AQY90:-Z0B]]^R;L!N\NZ$U:O<DE]O^Z
MDXL,I_6]INTTM< <\)D\KJE F22W:4-+<MT'N@>L5JC:N[!-_ ^J#PLZ@JFL
M< 7.\8FL7I-Q#5Q!G$34WL7P 04JQET(R^DEE[;ZUI) +RA)0J!K4I(W$0HY
MLS+BN >]N M?I+'8UWJOH'L74AM>1[T 3I7>/[)&A6KC/@";Z%:8QB7M:OO'
MC!IK_0EO/JA[IC:ET,!Q3="@T[OQ0#6F;R9&ULYH*VG(MFY8T#^)R@;0_EI*
M<YC8 ]J?-_T-4$L#!!0    ( !J(;EI^TA.-7@8  %80   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;,U86V_;-A3^*X0;% G@^B(G<=(F 9)>MCZT
M">)NQ3#L@9:.+;82J9)4'._7[SNDY%N3;,4>MI=8E,[E.W>>G"V,_>IR(B_N
MRT*[\T[N??6RWW=I3J5T/5.1QI>9L:7T.-IYWU669!:8RJ*?# ;'_5(JW;DX
M"^]N[,69J7VA--U8X>JRE'9Y1859G'>&G?;%K9KGGE_T+\XJ.:<)^5^J&XM3
M?R4E4R5IIXP6EF;GG<OARZM#I@\$ORI:N(UGP99,C?G*A_?9>6? @*B@U+,$
MB9\[>DU%P8( XULCL[-2R8R;SZWT=\%VV#*5CEZ;XK/*?'[>.>F(C&:R+ORM
M6?Q,C3U'+"\UA0M_Q2+2)N..2&OG3=DP T&I=/R5]XT?-AA.!H\P) U#$G!'
M10'E&^GEQ9DU"V&9&M+X(9@:N %.:0[*Q%M\5>#S%S>WUQ_>3R;7M[^)C]>?
MWD[.^AY2^5L_;21<10G)(Q*&B?A@M,^=>*LSRK8%] %GA2EI,5TE3TI\0VE/
MC(9=D0R2PR?DC58VCH*\T:/RIEZ\42XMC*LMB=\OI\Y;Y,,?#UD;91T^+(MK
MY*6K9$KG'12!(WM'G8OGSX;'@U=/(#U<(3U\2OH_BL:/2>B)*ZNR.8EW2DN=
M*CT7[[5(C=9-62R4SX53<\V??$[B ]DY67$YMT2H/M\5/]V^%]<56<D,3N =
M6<J$TMX(*2:4UE9Y14[<U#;-42*;S)GTH)5.F)E 8*F<0OAP%(*;B/T&W>3F
M\J ;L5P67M5E5U2U=;747D#+(E=IOHM#.5=#M".M#-H,P\"QLJ;$%V.70AL/
M4*V*CWPZ .I@I9P#XAS8P*#@ETH60I:FACX W1MU1R-@!#'=PR0-?C1 (?4F
M8VLM)*04V)+NT6#0$Y^@8%.K6,!A+5X&L#""DQ$N=R_%OCH(D&;*.M^^#^KV
MAMWCXS%S/ %W_T=!#KO)T> @* (<I, Z+(<Q+*\@(X/@!AA<:W#^#Y!]D* 1
MIP'5Z#&_MI&?+I&-A2+-G+(H6"3#?VW*2NKE\V<GR7#\RB$7'6&0<1W(+%.<
M3%U15R8FQJS6&5L)9I)0CD:A,0F[35YB$*6$.9*)A;3XY!WGY\J6+0LAXF1P
M*EPNT2DVT)10-?$F_2KV_=JBSXV\@RT[V[<BEQE+IWNRJ=I)NL'1N'<T%"B-
MJ*P;'=/0RFD!8![<2^$Q4-D]'(P9RCC60E45*@UDG*.PET+9ABP(>@5(2U9V
M/!!E;/8SU%G@CI1P=V,G_$>V6+;M9->.@&R&]E LV;<9JXT6Q_"S%M1P2I1M
M*-FNC2 #*DT:F@L"X'<S@Z'OJN;I'=(*U,HBDH7D*X&829SN9%$SWRI0*0*E
M/#>Q8&(7] ZCGO5SVNL6 #=1#L/Q^#1HW3L:#P-Q1>'&42S_WKR="OM?VC<>
MGC3VC9)=^S9*:0<M&GLWL,G"&1;\8Z-GHWZ_FT,LM2G*K9'$/&^_U<HO6;O8
M9X>)(?K*]Q.E89>L,/A9Z3M"HNT-DQ LQBM='E2E7!=%J")<;IV7L4]L=#VV
M,DUM;/(,")*:KK(5.\7765];'9HB?UZ5'1R];A?;]C;]:[N!J+*D3"%\J"8@
M87&FB:X.]^PV?&OW]L2U%I<@+D02[UBC+3]S8E0%A<1;QX2-X^._-'V!_(N.
M+/A6T A]L$>TDR-;>>EM.TM:PEA8W[UFXSWV$6P:4P8;LQ295JI"VM#+W$Z:
MMJS=IN?=A5:N-%(:YNTT7?I6XR4$["5)=WPR[HTV>B\K_8($Y^\R^X(;/&>R
M"T8X]%D?$Q=C1%;*RT+]&6-$=[2RZ/L9!^?R2&V< 2<&72\PR#P[,N,;;FB\
ML:%':H[1O%99R"RXXW+R6IR,CEZ,!@RA&\34:1ZCW]JJL0BF\$9HX'&0KS%8
MVNA'*#@JJ[A;-72U:TN99K/8'M;Y4)+/318M;',-"51;VUJP*H/4.._B<#L]
MY-]8KGNG@Y!!:R[</!N%2T)HB3>0]7VFV2%&L14V%>[=5KGMN&[=MKBK-<CI
M'CLPPN\\H6?R%8@;-XRVO@U?*RG#FA%]P5'>,8BQ8UP/!X>KG'X*=N^AC:*_
ML>N57)N\T7+*0VE<^U9O5TOS9=P5U^1QX\;M:J[02 N:@770&Q]UA(U;;#QX
M4X7-<6H\]M#PF&/Q)\L$^#XSR-#FP I6_TJX^ M02P,$%     @ &HAN6N+C
MY=Y+#   _"H  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULQ5I;<]NX
M%?XK&-?;269HFC?=TL0S<N)TW6XV;IS=G4ZG#Q )26A(@@N05MQ?WW, @C=1
MDI--IB^V) #G\IT[R)<[(3^I+6,E^9REN7IUMBW+XL7EI8JW+*/*%07+864M
M9$9+^"HWEZJ0C";Z4)9>!IXWO<PHS\^N7NK?[N352U&5*<_9G22JRC(J'Z]9
M*G:OSOPS^\,'OMF6^,/EU<N";M@]*W\I[B1\NVRH)#QCN>(B)Y*M7YTM_1?7
M$>[7&W[E;*<ZGPEJLA+B$WZY35Z=>2@02UE<(@4*_Q[8:Y:F2 C$^+VF>=:P
MQ(/=SY;Z6ZT[Z+*BBKT6Z6\\*;>OSN9G)&%K6J7E!['[D=7Z3)!>+%*E_Y*=
MV1MX9R2N5"FR^C!(D/'<_*>?:QPZ!^:'#@3U@4#+;1AI*=_0DEZ]E&)').X&
M:OA!JZI/@W \1Z/<EQ)6.9PKK^X_OG_]]Q_?__3FYL,]N?G'+[<?__GRL@3"
MN'P9UT2N#9'@ !$_(.]$7FX5N<D3EO0)7()$C5B!%>LZ.$KQ#8M=$OH.";P@
M.D(O;-0,-;WP +V;WRM>/I)_+5>JE. )_QY3TI"(QDE@=+Q0!8W9JS-P?\7D
M SN[^O.?_*GWER,"1HV T3'J3[7#%Q-Q2:WZ/8LKR4O.%+FK9+P%3R;+C60,
M(JPDMSF)19[7H;+CY98HOLEYOB'EEI%W3&Z8;/<[^M?7(BMH_NB0OWZX)>\+
M)BF>5H3F"5FF):\R GN99(G>;@6Y6Y*BDJJBP+<49+?E\=;NI\@AP9]Y_L!4
M2<[]P DF'GPE,55;33NF><Q2^/A((,VH$GY#00O)\Y@7--6;:!S+"DAQ+0%0
M KU0BFO)DPTC/XL2D."86,I*Y@32FU[F"@6+&1%KHK843N*G@8*@> ;D[DL1
M?R(\RUC":<G21Q0!Z0A-"@#5J4Y#"D1:(%TT00- 'QOG,,'7J5"@Z![>*'.-
M\6T.)@8$[HWH<- "FYL-RR3A>*K= P )PE2,#JL-3W/[%;(RB(C0Y% >"BEB
M,(X&Y-SWG9D7.82N 5Y(@TD%K@-&$.LUD_B!?8:ZH0Q\YY-HZI)E:6"Q6A0#
M# PVSI@> .4#DZ4QIT )Z08\90,@(7U_&G6,5;MF:Z'#NI^@.YU,C]!UR?N<
MO*./9*[35.B@.X';"9EH#])@XB% *&LH="W=":)NT-"JW K)_UO;M&>,4CA0
M0%?_@4A%W%8L9VL>(U1BES.IMKP@*<]X:7S#(0E7*P":=7TA3:TT1U"KO0IT
M8I\A7>00-#9(]H!TR5NVDA54=9VP3R0;@*W97J?X/A8V:VBCX$*?^CY)9R2C
M],!MTPIJI<&&SB ES_AS$"%:3(8*:+4<6(<-@>_XH3\40K*+MQ66._(;E1)8
M*P"*R9@KNDH-5D-_J@FUH'<!U\R06^!,8=,]A!%LNK[P[:ZGLS$4QMEHW9_Q
MAWU&P3=F-)HW(B><+YZ:-@ NWW/)1W34UJ-VX!OF@''/6&0KGM>Y$(X]H\\A
MV0^=1EN4@$C[2_NF!'<4&P8>)$T4/UL9D@>-HE'M[1BBZ1@$:VF!56&]&'*\
MJ3?G012ZOD>>I4PI<NZY7A#X^ABCX-"GA'YND#KMIEOZP"!SL-P:V."XKM(4
MV@5D=5A/WO<*':&HMS+P#GT-@*GU@W+5;K*:(FI@<:[=IY,5ICHK+(;2##']
MOM(LJPWTW[4LTS%P&T2U2\8I58JO.:!)02Z3YVWM@9PK8HJ59DVY) \TK5@=
M$,%L@8I \Y)6B3$%;1-L0;GQ<EI 4D^-&#:O)0QKBW:G<DM-?:69J  :?<XF
M[-,^00L(T\\<NA5L&[8,9&P%-4RO4QI_NKB/MR)%@ H4\ +AQ+C-1 (MV0X4
MKY3)M-!S:7):@+[2^,N^BR%41Y)14T[7 K#<(=.=GKE8<@$.+:$^ N[0<6G!
MU ORJT@A*:1H!7\R=4/R [F![!*C$1 V1/614:F([TY#\H8_\(2!#!*%AN"#
M_1^X^G2QAMK1MI%Z-7*G$U@>Z9J'/639SUW#GN=T8=,=0!VF;:KH(+@$!!N0
MVJ(])EC=QJ.5)*9>8ZB"0M,%CH()Q_.@(+?!,12WU\F,\(<FK^TMQN0[FGJP
ME](X0*>(#O>.RD]0/][;VE"W6X'WI)[AGJ*;MEV'1N$WRO.=1*\YU3)DP$FW
M".B6&M9>XX5;.WT6*C'"U+&UL2KPT+F/;I7Q-*U'@GZ]E"(C$#.Z5=/_:Z++
MC^\:$%SR"P2N'&?6:J<S8U[R,C4VAJJ#=;6914+7^\'::2.%4FT%[I9K[!0/
M5'<E4DPZ4E2;+>'EGJL,A //T#1@L&?9"A0(1SL_\'Y#.0PFSM2?'^(^@HQ)
M[WLIH:VNON]ZL]:Y'0AECI,(.0^=J3?!/0:*!@$T_5X'$SK1=+;?P0#"&;B)
M=H8: J4A,'V[[@]T0]&36;)4%P7;]NB9HL&H]?0=I#V.ML0")A1FL0J0JHHB
M-=Z-A:^20&_#\89#VQDFX]*L8FT5D/'N+T+R["T0@OG7)6$87D#Q":/Y<S-Q
MQY)A]NE4D=X4W+. KC<@%L:)]IVVJ:X.>:@9S$%F'NMZ?4#:_4FL<<W:EG4X
MA=" UJ%;RYL(X)>+TE;3P9#3TP!RD7:;+BOC ,9P#;=.;821O/:66G](DMI?
M6YU[]K4!,F+2 \-B-ZDHIJ=O6('-MSE 59F,?NM>NU,4S5K5)7^KH.]YVO!E
MMDZ?E$5;LE\^==7%2/L%8.38J&UI6IP</8B%SB18=!7I#F$^) 0OFG4%^HH)
MS%(Y/H+YP=R9S&:V@KW^BAG,DCC$J)G"]GCM=3[.'V0V/HB%CC\+GCZ(>9/9
M5P]B XO:(>R8)4\,8/L6&0Y@^S@^90 +?=?W._.7Y\_:^>N8O/7L==PYGSQW
MC:CWC28=H^!@T+EG16FRT^C<M0_E=Y4&NC[@W9NZCL-J1RPK[O[D\/736> L
MO/F73&?#B]U6])M\ ZV SL&'[M$/M.UC^=+>^8I>2PNNRD'AA.'E/</<V8%N
MV2*"7;_U?E-+AREEX8#S'THH>U99#IR<YB,SRWDX=^>+C@L@^CMHAFOKH_&[
MI6EQC,UIFPXM&7SW*?N$F_Z?)NR1ZN7TUT<JC@7Q#B2R/HM_O]$TOG#]H]/X
MY NG\44 R^_C4I@6"RSP@5G<?F)EV7UVA1U0L_5IU\^'B=5 Q$R6$(;D1VAS
MF-0!P]MI7)>FSH,J>\FQEZBZ83D,R"ARYE'0B4ADT.\I1-MU,J!@A4$-1%%
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MDQ8',/ EG/;5N!>K$0<QZ_1?7D*#QI8F#JQ-/HA8&HP'#\Q^ EUI9>.L^@C
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M^[VC@X[_/A)OG%GPKUL3XYS)^7*N) Z6M #OI\:X>$,*ZI\[S_\+4$L#!!0
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MCR.PS47>?'A3A<MS83Q=Q6&9T[\/6A:@\Z4AQ]L/-K#YFYK\ U!+ P04
M"  :B&Y:2X]X0/<"  "/!@  &0   'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6RE55UOVC 4_2M7F;2GBH1 MZH#)+ZV\0"M"ML>ICT8YR:QFMBI[4#Y][MV
M(&52BU3M!?QQS[GG7MLG@[W2CR9'M/!<%M(,@]S:ZC8,#<^Q9*:C*I2TDRI=
M,DM3G86FTL@2#RJ+,(ZB3V')A Q& []VKT<#5=M"2+S78.JR9/HPP4+MAT$W
M."T\B"RW;B$<#2J6X1KMC^I>TRQL61)1HC1"2="8#H-Q]W;2=_$^X*? O3D;
M@ZMDJ]2CFRR281 Y05@@MXZ!T=\.IU@4CHAD/!TY@S:E YZ/3^Q??>U4RY89
MG*KBETAL/@QN D@P975A']3^.Q[KN79\7!7&_\*^B;V. ^"UL:H\@DE!*63S
MSYZ/?3@#W$1O .(C(/:ZFT1>Y8Q9-AIHM0?MHHG-#7RI'DWBA'2'LK::=@7A
M[&AZMUPN-LOY:K.&\6H&T[O59K'Z-E]-%_/U(+24P@6&_$@W:>CB-^BZ,2R5
MM+F!N4PP^9<@)&VMP/@D<!)?9)PA[T"O>P5Q%/<O\/7:@GN>K_=6P:HLA:5K
M90TPF<"4Y J9H>0"#<R$X84RM4;X/=X:J^G6_'FM#4V2_NM)W$NZ-17C. SH
MJ1C4.PQ&'S]T/T5?+I30;TOH7V)__YG]!UT'YF55J(-K&(PSC=BT;I,CM:ZL
MF#Q S@S0(FI,0$BK %\@G-KKFFCH7ML<D/$<5 J"%E2:"H[:@,V9A4JKG4@0
MR&? X XUDQS]"7%_0C7SKYBP6Y28.@(A"8I P92(-D@!O9 V[DS%]N C3X*=
M%#(HX*PV")3PN-\@L!&1*960[3"C9 <6Y!])(ASUU3ORIJH@UZ/K!0QXSNB:
M.;#OB2JN/,L.C;M_#DC-L&2C@$^UL =@>Z830X_]0"63?7&R,LTL)AU88\5T
MD]!UZ(%VR)E>SN>U2Q:>F42).O-6:$A,+6WC%^UJZ[;CQF1>PANK7C*="6F@
MP)2@4>?S=0"ZL;]F8E7E+6>K+!F8'^;TQ4#M F@_5<J>)BY!^PT:_0502P,$
M%     @ &HAN6@E0+L6+"   O!4  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&ULG5AK;]LX%OTKA"<S: #5#_D1ITT"I&F[6V#;*9)V=X'%?J MVF(K
MB1J2BNO^^CWW4I+E1&EGYT-B/<C[//?<2UWLC/WJ4J6\^)9GA;L<I-Z7+T8C
MMTY5+MW0E*K FXVQN?2XM=N1*ZV2"6_*LU$\'B]&N=3%X.J"GWVT5Q>F\IDN
MU$<K7)7GTNY?J<SL+@>30?/@5F]33P]&5Q>EW*H[Y3^7'RWN1JV41.>J<-H4
MPJK-Y>!Z\N+5C-;S@G]JM7.=:T&>K(SY2C?ODLO!F Q2F5I[DB#Q<Z]N5):1
M()CQ1RUST*JDC=WK1OI;]AV^K*13-R;[ETY\>CE8#D2B-K+*_*W9_5W5_LQ)
MWMIDCO^+75@[G0[$NG+>Y/5F6)#K(OS*;W4<.AN6XR<VQ/6&F.T.BMC*U]++
MJPMK=L+2:DBC"W:5=\,X75!2[KS%6XU]_NK=AYO?W[\1GZ[_?3'RD$=/1^MZ
M[ZNP-WYB[R06[TWA4R?>%(E*C@6,8$AK3=Q8\RK^H<37:CT4TTDDXG$\^X&\
M:>O=E.5-G_*N6)M<B4_RFWBMW3HSKK)*_.=ZY;P%'O[;YW.0..N72#7RPI5R
MK2X'* *G[+T:7/WVRV0Q?OD#>V>MO;,?2?])-O[LWJ&X1KVL3;'6F98,?K,1
M.L3"(Q;J&VK:*?%LI0JUT?Y42"]\JL3G.[%1B;(R$\Y+7WEC]]V-5GHE9)'P
MXL[STII[S76J"WZWT86$^EJ.0A5[)[03THF-R< $[H5 LE6^4K9-./V;BC<P
M;NU5TI5?V]F8^=A&-BR>#,?BU^;GSC?&9F:-Q9"C7"0*$!VBT8AH))\-S\1R
M.!,?3/$<6*Y %JL,/L)VQT(,%%OQ;#R<G8IGDW@X.16WR+^TZY3?)^H>#%>2
MIV)M5:+A\+/)\.Q43(83<9/*8DLA$_<RJT).),4!44(>XD40NZ2?WQM-TU.X
M\=LORW@2O\35)^-A\.'^</5:;92U1R%3CBB3N(\C1EZKS0:WCKR'5Z6Q(&&1
M:#RU"E8XQ,+OE H)7$MK][K8"IF;J@B[I'/*AV@ 5RN RVM%";6=?%L%R9YV
MEI4MC5.N!4PCJG(PE79U$50O'HI/6%E:O-(EQ&%!:0I56T!2;O!$%GOV_NRE
M(PH.SI.8)TR4J/H_ ;W7CT6]$&]KI)!,!G. 4(F'["9(Q85PP:6=M(D3)V(R
MB^;3,[J(H^5L*>Y2,H':1\(NH?P""- \Q62Q$-?KM:UDUL7:.:R:S\6-+#42
MK[]CJWT2<<;![0ET+?!_?'[^-#C)MP:@#80F<W(>A+:N^>)YZW;<+KK.*;'?
M'RZ8MPO^9BD4??E '!;18CFK(Q-/Q#^40VR/UG83UHAL?L/RWMH)DJEZ6/*I
M^(#T]!O12#M<O>*,F*(76:EV3"X 'B69V*.SC"G6@BN$%)LJRWJMDUO,1<X+
M"G8O4!G6C^%(22-(AG)H-*(H,'B1Q22O3]]J+V0)-OZF,;"H;"].XFBRF'*U
MD>U[8$(HZM:/E3[4Y;'."6\$S78>?W"T3R=J6H.+J\U&KS4A#(6L:=82ZEXG
M1"UH.)KP"5FN*HD?(,H"D]8!0'5=MP+1OOJC<AS^5"8-BT=U81[(_J<E"ODG
M\SB:+LXC7"RC> [QM/]D'LT7TXA*C?H0W,CV0,QL$<6S>6-KTSU^JB8QHC">
M&JZVA\YI%864MIPLH@G2O5);:IRF6:B)&.+SD)'@6T @HN3,CY<_%0 F^+Y]
M2/QG("( I.WD'**[,#L[,5W&;/UT.6UB\ X L054W2*1146)212]G)PO%Q$A
M6^8!:<_>W=Z<<O)<'WE2705">A"\ Q5RQ7AO]:KR\".7>_@"+*V^<(,SX(X<
M),G 7#4E#3J[UZ9RPNEMH0%.243)C=B1ZV97 ("I+EE1A3:#.O8T(/YTPW$K
M8F=1W1C($JI CL[MS5\,Z^T-PJ$L%QP\1/917]0)#X;TD=7!.(I.*E%^'!25
M1 +%3P_YOIW0V-6HTYC)@AY DWV]Z?&II$<%I8);.O)@:71JA!^/(YK]P]-4
M$A(5T<GC0/^E.+\-ZG@?.:O^J+3?"XC8@'76ILJX=>*@1N(/6'$$D__#Y6.&
MW.B,TW&8CA7,*-H,=8;I+Y75+M'U0=2)'4ZA]'N#O@[AA9:1^*B*PNVS>XD[
MMN!CJC.9J*Q,M0R:20DQN*.RG5"\N5D$.B$GZN*6."C6Q1"BE,LO"$O7"K9R
MEVH,"%U2Q8C>J2KH0W!Q<((+02^.]0Z<'F9*.A4W0SA7?J<*']@D*PHF64.5
M7/G4V-#H$Q!'T-0M\"VF<AKIDQ!+#(8"ZM'.V(JH-IQ!SDBB+.DP5%*B.'PU
M2;#F((BJ"="@%A6\V:786Z%[T7!UG%P5.AULX>F4.QI%C1HI-7[@EOVL' _)
M K.1>I[IK^@6SU$8Q7.B_>Y"GP*!J<F2J&X#Y-2Q;)7I+9\Z'BJAV3%'XZ]H
M>I".HY])"S;PG=KM'I2X-I',+>8%SQR$.IV/?Q7!1%J^4F0YWH?1DOF/!(=C
M K5O3"@^X[.;V&F/29)4L+MU O=!#Q4T3T!?"[/+5+)E,*"?0WJ&0!94=N'[
M$;QYLKVW0\_C/E\83!EU1+[W'@UK.MIQK4MVH9<F#]ZUYUD0TT'T,0IV-774
M;\7*4!AH5&<C$%E. >P&SF7&B(;/C%S_P.;64%WTG,6/]+;65D73"8Z1LE=<
MGX!WHF!$SHP8C%VIK@4!YQR:NB([Y?V *-ID/:C1H;C3-,0]X F>!Q^-/*V1
MT</UH:8S@.]I$Y@VAW?#IP>[3N2Z-$(50X [,&1+;WU&TI>(>PEZ1;4-^[[;
MC#I?U'*%2J/OAMQ*"A\^KK5/VT^3U^&+W&%Y^*[Y'H6*,X#(U 9;Q\.S^4#8
M\*TPW'A3\O<Y@,N;G"]3!>*WM #O-\;XYH84M!]LK_X'4$L#!!0    ( !J(
M;EHP?Q85N@(  .D%   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;)54
M35/;,!#]*SMFAA/$B1,^"HEG"(1I#[04%WKH]*#8ZUA%EHPD)]!?WY64F'0&
M,NU%UFIWW[Z5_':\4OK15(@6GFLAS22JK&W.XMCD%=;,]%2#DCRETC6S9.I%
M;!J-K/!)M8B3?O\XKAF743KV9[<Z':O6"B[Q5H-IZYKIERD*M9I$@VAS<,<7
ME74'<3INV (SM/?-K28K[E *7J,T7$G06$ZBB\'9=.3B?< #QY79VH/K9*[4
MHS,^%9.H[PBAP-PZ!$:?)5ZB$ Z(:#RM,:.NI$O<WF_0KWWOU,N<&;Q4XCLO
M;#6)3B,HL&2ML'=J]1'7_1PYO%P)XU=8A=CD0P1Y:ZRJU\G$H.8R?-GS^AZV
M$D[[[R0DZX3$\PZ%/,LK9EDZUFH%VD43FMOX5GTVD>/2/4IF-7DYY=DTNY]F
MLZ_WL\_?8/9 :S:.+<$Z9YRO(:8!(GD'8I# C9*V,C"3!19_ \3$IR.5;$A-
MDYV(5YCW8#@X@*2?C';@#;LFAQYO^%Z3[=S@4XO2PFQ)JX$?%W-C-?T2/]_J
M-Z"-WD9S,CDS#<MQ$I$.#.HE1NG^WN"X?[Z#ZZCC.MJ%_F\/\I\0/;C#G#7<
M,L%_,Z^&+Q*N<:Y;$B(DX::/#L!6")>J;IA\ 2Q+4@X6_O UEN((;8G:(&16
MY8^0-8+;7C J)0IR[>^=)H.3<Z!+Y_8%F"R ">%$C!IEC@:L E,QC=[7H-Y8
MM6K=^W#IR[(\#VRX7$#))9,Y9P*,919K_Y 56R+,$=V$L%H%D0LJ6?PB\3CV
MRI5U0\ C*HF'-,H.#;H?(>2%9HQOQKAF@"(\82+&56' OS.%%[VW7CC>DE^-
M>N&'C('<M1*4V)UV<^PBR/<U/ S!&Z877!H06%)JOW=R%($.@R485C5>S'-E
M:33X;46S&+4+('^IE-T8KD WW=,_4$L#!!0    ( !J(;EJU#8AT00(  )H%
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;*U476_:,!3]*Y9739NT
MXGP!59=$*K"I>^B$RKH]F^1"K"9V9CO0_OO93DAI%= T[87XVO><>X[QO?%>
MR$=5 &CT5)5<);C0NKXF1&4%5%2-1 W<G&R$K*@VH=P254N@N0-5)0D\;T(J
MRCA.8[>WE&DL&ETR#DN)5%-55#[/H!3[!/OXL''/MH6V&R2-:[J%%>B'>BE-
M1'J6G%7 %1,<2=@D^,:_GD<VWR7\9+!71VMDG:R%>+3!MSS!GA4$)63:,E#S
MV<$<RM(2&1F_.T[<E[3 X_6!_:OS;KRLJ8*Y*'^Q7!<)OL(HAPUM2GTO]K?0
M^1E;ODR4ROVB?9L['F.4-4J+J@,;!17C[9<^=?=P!/ G)P!!!PC> J(3@+ #
MA,YHJ\S96E!-TUB*/9(VV[#9A;L;AS9N&+?_XDI+<\H,3J=+^HQV"BU!NA?!
M,T +IK)2J$8"ND0/JP7Z</$172#&T8]"-(KR7,5$F]J6@61=G5E;)SA1QP_0
MG>"Z4.@+SR%_34",Z%YY<% ^"\XR+B ;H=#_A (OB 8$S?\>'IZ1$_87&3J^
M\%\N<NB^6KIHF,XV[[6J:08)-MVI0.X I^_?^1/O\Y#7_T3VRGG4.X_.L:??
MS:PQ-@<?18N<.J0=*+OT\BKPIC'9':L?R/)#+WQ):W61HV=>@=RZ[E<H$PW7
M[;OI=_L!<^/ZZLW^S R>=DZ\T+13ZX[*+>,*E; QE-YH:OI<MI.@#;2H73.M
MA3:MZ9:%&9X@;8(YWPBA#X$MT(_C] ]02P,$%     @ &HAN6BQU:+Y# @
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MVCI%QB(X(7:X$"YK<NU<P5@5\$<,??O-D\7B_&+;SX;<S8_G%V))M>F,B8:
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M41T1\$_8C)@.?A^!WO<6*-?!CR9F=^N\E*V3]*&N)*V.1B54 ^ZFODD6N1!
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M R#HK"JVAO2T(#B,^R6D4" [HQY[L#\]#T%'?6IY>C8;[9$YN5FHH6%BFFA
M#ZDP#?K(^[E;:"N@1F/1S*>^RZI"69Z%X$2E&W9_4EHEG6>_0G#7%&/%1DD;
M*C)VD\9XX@K0I^TY>UA?%-[5QG).P^FTL7$AE_!I6-)9;G FL@16DPAU(H-R
MM]0N)0WJ*6$F3E&L?.5]*/$(,T54"&E.A8,:TZC3B4G9HWY2]NBK3,K><D_$
MFO_UQTJN]DZ_IDFA&%(3'#_N.7[\U3D^,+6;)G@_ OKZ(Z )''S?X^#[+\#!
M1VXWWG/2?M.L<'L*N-.4#@#W2<_PDV,9'G/YKJ\[2,5Q%$VE,]ES@/7=0DQ3
M/R#$#[T0/QRO];Z&>#&J.:Z&>N.GOMZXM1;+5IH*"]CL;M&F>2I0AT[)-C\?
MOA,Z/U:Z,!B!B[U&8Q?J@\%2AP++4>3TSKAZ/!/:';AL=T78AOPH:3$'E+X!
M#,RS7X]FVEL#^-@Y:2JXTM1EJP0^-",9GP<-*80%GI!JD^L,Q5/.;1CO'T^,
MEJ;S>R9+H[[A\(#I5+R(Q3XA:A8JM:&YIM)Y[_'CD5?/,I08F+W%Z]X1V%&,
M[DQ"D$2\:MUX7TD/T)CR>'C4A/*8YD#O,+8 MV11)J)?MX$GK^OP+<N0(X:9
M )4_^R-W2"2U4HCAZ$OAS=J584)+, W)"NR6ILJWI33-RM#C!(!M:D&L1*2#
M=*CE@Q:62C4IN4+@=U]A^+@U+5V1RJ@ #P-3 /$&E:E.UC@TIHRU<4OBA\7C
M7B&,2_K*DJ>SZ3O$?3,/&CP@C9KV=L(=NJU^W$>+AEG,[B!L[Y2>1SN-4KG*
M=P;'47!"XUVB!B/WT\6(,/;<.ZKE<=L_E>3GHZ_IY[\O)+^*7UMR+_2A6V;]
M]=5.2#LB7A_#R_]JO)XRRV(PR^)8L\0:A;EZR]@DO/Z!QIKF\#XKW6>E/RHK
M3;G0\-[-?/(5F'TN=&4JGO.,&IF#7C!-Y#Y]_E^FS^%%J/D7O0EEG [C<$3>
M/D:[K:!\=U=V@/2!CG,^C*CF7S2C^AP9#CG1- /W3O35G&@*$,,$</XE(\ W
M)+J/$_/1_:, ,<W /2#^(X 81H'SHV>!^ZO1$1R^(%I,,W-?>-X7GO^-PG.8
M0\^/'D0?F4^O6%PR2%#S1(WP^Z;29Z,7^^EU*/[Y KW_ MV$=_S[N_U/)%Z$
M'P8,R\/O*WZ6]#:5$Y4JL/7\]'OD>AM^LA NO&GY9P)+X[VI^2-]-:TL+<#S
MPAB?+HA _\.1RW\#4$L#!!0    ( !J(;EJ:..RE+10  .@^   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;,U;:7/C.)+]*PA/QXP=(1^2Z^JZ(FQ7
M58]WZUJ[/+,;&_L!(B$)723!)DC;FE\_+Q,'09E255?OQ.Z'[K(D,)%(9+Y\
MF0!?WIGFJUTIU8K[LJCLJ[U5V];/CX]MME*EM$>F5A5^69BFE"T^-LMC6S=*
MYOQ061S/3DZ>')=25WNO7_)WGYO7+TW7%KI2GQMAN[*4S?I<%>;NU=YT+WQQ
MI9>KEKXX?OVREDMUK=J;^G.#3\=12JY+55EM*M&HQ:N]L^GS\^D3>H!'_$VK
M.YO\+6@I<V.^TH?+_-7>"6FD"I6U)$+BGUMUH8J")$&/W[S0O3@G/9C^':2_
MX\5C,7-IU84I_J[S=O5J[]F>R-5"=D5[9>[^JOR"'I.\S!26_R_NW-C'C_9$
MUMG6E/YA:%#JROTK[[TAD@>>G6QY8.8?F+'>;B+6\HULY>N7C;D3#8V&-/J#
ME\I/0SE=T:Y<MPU^U7BN?7U]\^'#V=5_B4_OQ/7E+Q\OWUU>G'W\(LXN+C[=
M?/QR^?$7\?G3^\N+R[?78O^S*72FE3UX>=QB:A)PG/EISMTTLRW33&?B@ZG:
ME15OJUSE0P''T#DJ/@N*G\]V2GRCLB-Q.IV(V<GLT0YYI]$0IRSO=(N\LRPS
M7=7J:BG".L5_G\UMV\!Q_F=LQ4[>HW%Y%$W/;2TS]6H/X6)5<ZOV7O_Y3],G
M)R]V:/LH:OMHE_37Y])J*\Q"]&J/J;A;R)5:J$95&5:J*]&N(/&LJCI9B"M5
MFZ85K1%__M.SV>SDA>S:E6ET*RF&Q++3N<1S_./TA<"#I9(5/]"04/I#]@:M
M&UUENBXPT5)5JI%%L:;?5=VJW,VMQ$VEZ=,UYE!N::5J=";%_B]G9Y\/A+1B
M 8%Q?+)A>*;*99-;<6%RO<!#'/'[9]<7> Z/C(Z]J7.>"L-N#FA"DOI.5UB9
MA@U&GSDW^$?LOSN[/C\XVK&/C^,^/MZY!9][RT"!"U-9^%[.ZH_MYP\+$U^P
MMBQ^ SLOXD(M61Q VY(;9$67*[:$WS^6]<O5I3C79B(N*T0=653CA[N5P48>
MFKL*\FPWMSK70/9)&"X^U=AKFM[Z)\^* G.TJLE,6<MJ#4 M)#L@R42H558R
M6ENQDG"TN5*54(4&\)'2NRS^)%K\R4XCW5A%*WIK6UW2]H^9^?=)8-LBQFOI
M%DL_;K$N;0%E4MVN@?/M2I!K(V1^ZS0P KA>(1/28 J@4GY50L59R$+2(GO6
MSD#M2K9"+A9(;[Q?#<<L=D*6<=\P7K7NT4++N2YT"UR;.&OCF5S;K#"V:WA%
M4([<G:8??U!(-Q5Y4 B8T94&^6,ZJ7LP"@MA>==0</7C&"H0\R8_2JR[N6[9
MD+7Q8Z.!(J6$NVHB"(4S/@Q'$F]ET<7=L"MZR-3>%>]DTQ!::4@E[^,IR'^Q
M#[3X1L6G,;J7!-@R=\Y=W72DO2$.H)H&BVSEO3?<A**GZ?!=7"W-X3?3:T5J
M(N :MAGL-S<-?)F$-F1?^ D/,2Z(\'6A0#^.Q.6"N S!-'P&Y .6U L"W45C
M2G[DPD47P?/TZ0O;.]%$F"982-VW[&@K)*?4S6 IF?\*YN&@>=&UY!YN7R!@
M3/X 6()26*&)\8\A70$#P.>AZ!Q)8*%;5IA5FM.<MZH!6UM[GX:D^9H\=8VM
MR58B6TFX)FD4=-V%!D\C&CS=&<L7TJYX:_B/MXA#;#>Y\!@L_* H]X5*OB ;
MKT 7 9Z%QO=DZ%LLRP6/"^R&HD+FY.,P+VS3ZGE!Z\?V9220\0,Y>8D +! '
MV"87I.Q:C5*B=(P+]D5*(+@&F-9= TM:"DF.*QH-*J7*.?8ET"G^#7^<AH20
M*DA; ,F*8J_YBKIA@:1LCQ@%O6,(*@=:_&<Y3V3!,MG0$ GZMR(W)6ULE@ *
MGF]UV[$#'8ES67U%K-7&<NZAU=]<0T3UU1D4HSN*PJXF#_]I]O@$#N1RNLJ)
M<V"=_N%+&LJ1?V$:( _[Z' %*TD6$ET5Q++N46%8[:='D\>S*:_KI^D$@4"K
MV&[*"05&K;@(*=:[?/=9]-UG.QWNG=2-^!O028D/0(;. <FHY_Z0(,'?W_+W
M8'B .4V)7EHV*B X4\Y7[SBVY^2PF<+R<H=$".:"8 MF9%0D1ZPEG)T B%(]
M89:,^65-CH6QIL%NP>L3-@#9[1U1 >]QR+3P%(V-:F-.*GO-.3]A.XV#5W@[
M(Y0&I%79VGDB;7.33+SHUUJF-J#!#/9859\M@8/@EN+9[&0BQJW'Y),&'$P(
ML.2\T"C2("^=::7AEXA'D(&5!L;!ID2R]3^4]=FA[@@03)*$6I6M*H &AG04
MQD04W+2I9(8)AP+SQL"7"P6W\U'JOG??,%D9TRAL-V+(KX2C+%<V:_2<?J"*
M_KEX3V+$5#P7_]$9LE+8(_(/K/=6ZD(ZY/(EN!]A.</I',8"82\"Y2"T2AF'
M#:FRYPAN>]W$,TP,WIO1]]Y<AG,,/+,2OSF5O"X/-4C@+2QDXO>"%NO350YR
MEK5P2=*WZC_-J:KCM7U+R].'6D:4[RNBKDI$^F'D?Y5IX; @!W."*K<GWLJ8
M1()6C\/X>+(>XFO3#9B_P[G))E+#WYG@Z@U"XTR==: _D31.^LJAEFM:RQ8V
ME"&G(4<D ) 5$('Z#2,]1_,>F^'3FK'$\\A(+'TQZ(%9<"/$>=:_8"$N9SY8
M2UTWYIXI">F"6$H":LZYUC@M+6KH]A#E3QGR]=K[C57I;@Q3$=S-+"L'"AXV
M;43$/HJ9C(]%LI\\)>UXJ&(\[EE5IINL*X%4G-_8.S/I$(8@PT\,7QM)<NQH
M<.4[^E]E$A<;#VH/6#EA=Z(R46Q:+7:!]GKN>AQ]-),BWW"6RTI\D&M2:C8A
M4"X@\S/8?RDSU3'.A%)TW_UZP%5 (D/LTS1!B/B[__K 5V^5[R8R_Y#(<5F@
M78%9";D$O-(^'@4-?#WA;?E M@,F1#@W59QHQMSIX\-'R#!OP+UON?/BG/6O
M*E^2@3BD9R^HTN<N%0MZ"SAM^VC_=%<Q%X7!]GN9!Q.?!4/4.S1";)A;S0U7
M'U</=0W)T%<1V,4N2RL:=8_J7MM $,AJ/LZ''H8PC'./S<,48JXXZ%T8$J^
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M;K9B'.;TBFG"-VP25P$I.<J,;2=]<>A[GK1IL%DL$OE)3XT#8&VNLBXZRYG
M&Y](\#HAFYOCMZKD:G_G&@.(W-A5*EK67*OK?,*EL\_A/A7V?;P@8+-0^49O
M5,(.!7$1%$_LU(61/2_3)<K.)AB%^]&\);Y[D3BPTYLH6'P*_E.94F? Z%O=
MF,J1N2^4<<)"G![:%^%SQ5S9[P=FPMK\B+*FP\0VA-SF(H-#1P8'_=8U$578
MG6P8FH !Y%S.<@A0)J==GK,O.3V-Q:RZU[9WVSP)7 ++/-<D!:;>@"+)E+Y]
M2,*L._!(E'\A5N8.B;*9;&#!)))UI^MD:$9'1M,D'8MI:B22S@, 9+[@V,4
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M.!XQ85GP3$?K ]B_,,9M-K[ ]E]B] M02P,$%     @ &HAN6H=B E1T!
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M\XM=E12?TT\ES@<,HE2^Y+B5A?T^F85!+(+G8_*NZ)[>B#]1(>5W0:'GALK
M*L"B)G80LEAFW]#D8:.E3$FP,#2M96R7:O]C'I]43$X=8_5VNU*#7V'XFM'
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M:'X02@W11(XKORE;9\C+*<XM[V]7V]LM_/#(,H'VQWGL"-2[XKP!6-< Z06
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M!WI\T?@%Y-]I[4Z&3] ^Y\N_ 5!+ P04    "  :B&Y:A4'?HX@"  "(!0
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MVW!4'\>N)KP)<I,.-6M1P1LH/X [4>E<P:)*,?T?X)*N7ERP%S<+3A)O,+F
MT#^'P NB$[RP+S:TO/ -WI*]V.* 52E,DT0VC"OX-=TH+>GW^'VLYI88'2<:
MRXQ4S1*<..0)A?()G?C].W_@?3JA-^KU1J?H\9HLF#8<062M7$QA\4Q^5*B.
M:3U).ZYUC\4."XD@PRE-4R(; =T EAN4_2V8)H3762-8$9#))+='F^(3N;TF
M[VHX@S *J+T.X18KE(S;$);2SUR8<S>N!/IWHL@'NB I>!LAD3,C(PR', P'
M<"^TR7VM]PP&USZU_GDP].#8H;L'[BA1;NT;8 IM*MT:I9_MGYEIZZY_X>T;
M=<?DMJ@4<,PHU;L87CH@6]^W RUJZ[6-T.1<V\WIJ41I F@]$T+O!V:#_O&-
M_P)02P,$%     @ &HAN6ALCD2(I!   )PH  !D   !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&ULK59M;^)&$/XK(YI6/8D8OV$@!23RIDO;-#3D[E15_;#8
M U[%]CJ[:TC^?6?7X(.$H$;J%]N[,_/,,V_>':Z%?%0IHH;G/"O4J)5J79YU
M.BI.,6?*$246)%D(F3--2[GLJ%(B2ZQ1GG5\UXTZ.>-%:SRT>U,Y'HI*9[S
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M'5,]J.I5476,+-Q-OI6&W@6NF=)##)4UH/E$2M-T[ +MTV[Q/U!+ P04
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MRT5/9YN28\XVA?G&&45+1JB6H9I -8EJ"M4TJAE4LZCF*,V/<EDR&IRJ9#1
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M?+[:_F$]P/?YXNO#9K_[%U!+ P04    "  :B&Y:VD\X)G<"  #\!0  &0
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MO_VSS[&/1VLN[F4 H,AC%,9R; 1*)4>F*?T (BH[/($8_RRYB*C"HK@S92*
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M"\V6)J MM>T9J&1==N.*7Z71'(0^DHJDR*=A" LR_TG6A0_\[>0I>J@>/<[
M>1:^S<-X+>93AF4WIC!>X<^X'V%\,CQG$\'P)-9DJ5SHJ,T)]\GO2H982YMW
M=%BE=0;#0<>UGR.WFE69E=1:WVLNJ;ACL20A+%'>ZNB+@,BO"GE!\23+MN=<
M8>Z>?09XO0*A&^#_)>=J4] )?'EA\_X 4$L#!!0    ( !J(;EI,QE]WW@(
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M4=\?ONO4=A/)4M/L+)A4K9,91JJ[!:X7J/LKIG[B^43W3T6_'/P#4$L#!!0
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MX):I&;THK8/YOA)"[PV;H!KFT4]02P,$%     @ &XAN6JC\-T[] @  -0L
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MHP 6,LDX[LMCF&4-8S81-$Y[KCLJ9 >7#E>RR0:F N3[!:5B.U%M7-&V._\
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M?I.=-'HN:CW>'CU32$Z1[[Y%GN,%/?#)\^'^)MQ6F6G3X[7I\0R?OR\]VK]
MW\=S(;EJN1]]CFJ*H)]"?X9#4>($1I;ZS@3P%5CQZU?NP'G?Y^^%R#;<^JU;
M_Q![_(45)TG%.102L;8'J.D!;'J@SW[-&1I.?6BL8M=S(GO5==43$[0A&UJ#
M5FMPL#+76_KHG\8<]JD,7K)(+T2V8?RL-7YVL$B3/07J)*#/?TTZZ%0@.-\J
MTF[(OB(-6JV#_VZHO^@=[(@)W2V]NR%.O]RPE1L>E'O')*;_*C3<;6WWW9;2
MGICMS-J=,US?GY\Q7Y)"* T+!7).0U4=7M])]42RTASK<R;5)6&&F;K&@>L
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M.HG6^<!U591 1E5+Y,#QS4K(C&K<RK6K<@DTMJ L=;UVN^]FE'$G#&QL+L-
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M?6=(L2!A/A(6(&$,"0M!,$,L@XU8!NA!GQ785"^#O2ZTZU&S$_5KRO1=LTR
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M_LK$X[(K>M:R"RU)H%J,:@FJ"523J*903:.:035+:>X[8.M>1=0CEUT16K%
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M3/))\&F]V:R7NS_>9.EEEF^_H/S\U7J]>?C+=H OZ_SWW<-^]_]02P,$%
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MXX&X4VG> >833C+51-T3+EHR-0Q%UPQ4!HCW"T+X=B(W*/MPYQ]02P,$%
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MFUMZ+*$T!C2_%D*?.F:!^OD5_0U02P,$%     @ &XAN6O.FO.0U @  S00
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MB0,  *T+   9    >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;*V6;6_;-A"
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MU5WJ >IYPIA\NM .FK\FPM]02P,$%     @ &XAN6JUJGO>G @  8PL  !D
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MMW3W!=K]A(J74<)UBW9-K.]8**NYH$4KEBLH\K)YXJ?6ASV!&QP1>*W >ZW
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M/K=<+W]9?NV<W.,7G--M17W^"U!+ P04    "  ;B&Y:I7\.<>X!  "0)@
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M^4]9[YU;_W'\^"P[V_1O^6S\(]KB!5!+ 0(4 Q0    ( !J(;EH'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ &HAN6D_-ICWO    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ &HAN6IE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  :
MB&Y:(XEP *<'   ?,@  &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ &HAN6O7Q 6L_ @  P@4  !@
M         ("!ZP\  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( !J(;EK*9ZT*Z 0  (P3   8              " @6 2  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  :B&Y:%LX+ Y\"  !:!P
M&               @(%^%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ &HAN6BE&_P5*!   XPX  !@              ("!4QH  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !J(;EI -C^($P@
M /HG   8              " @=,>  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    "  :B&Y:NF?(5X &   ?+   &               @($<
M)P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ &HAN6FP9
MY@N9!P  7!,  !@              ("!TBT  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( !J(;EIMY_J[\PX  $,Q   8
M  " @:$U  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  :
MB&Y:2F(P5,04   B/0  &0              @('*1   >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !J(;EK2$LK0"0@  +H9   9
M          " @<59  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#
M%     @ &HAN6F]D#+W3!0  I \  !D              ("!!6(  'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  :B&Y:2D4OH9 "  "Q
M!0  &0              @($/:   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;%!+ 0(4 Q0    ( !J(;EK41U4LD 0  ",+   9              " @=9J
M  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ &HAN6G52
M+!IW @  A04  !D              ("!G6\  'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6Q02P$"% ,4    "  :B&Y:?M(3C5X&  !6$   &0
M    @(%+<@  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M !J(;EKBX^7>2PP  /PJ   9              " @>!X  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ &HAN6N1OOYQ8"@  ^AP  !D
M             ("!8H4  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    "  :B&Y:G]=4!ED$  !9"0  &0              @('QCP  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !J(;EI+CWA ]P(
M (\&   9              " @8&4  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ &HAN6@E0+L6+"   O!4  !D              ("!
MKY<  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  :B&Y:
M,'\6%;H"  #I!0  &0              @(%QH   >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( !J(;EJU#8AT00(  )H%   9
M      " @6*C  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ &HAN6BQU:+Y# @  B@8  !D              ("!VJ4  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  :B&Y:/*4S.!$"  #=!
M&0              @(%4J   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( !J(;EK*D:D9"0P  $0R   9              " @9RJ  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ &HAN6IHX[*4M
M%   Z#X  !D              ("!W+8  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    "  :B&Y:1B_S![D"  #*!0  &0
M@(% RP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !J(
M;EK-+H(5W@(  #$&   9              " @3#.  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ &HAN6H=B E1T!   70T  !D
M         ("!1=$  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    "  :B&Y:,\H#K7 "  !/!0  &0              @('PU0  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !J(;EK-EUDT+ ,  -H'
M   9              " @9?8  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ &HAN6H5!WZ.( @  B 4  !D              ("!^ML
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  :B&Y:&R.1
M(BD$   G"@  &0              @(&YW@  >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( !J(;EJ[\R3YLP0  "D+   9
M  " @1GC  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M&HAN6OIB]VPK!   Y@D  !D              ("! ^@  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    "  :B&Y:R;Y5VTD#  !"$0  &0
M            @(%E[   >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( !J(;EH$R+!U^A<  .NC 0 9              " @>7O  !X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ &HAN6MI/."9W @
M_ 4  !D              ("!%@@! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    "  :B&Y:2_3.V%T"  #+!@  &0              @('$
M"@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !J(;EIS
M2"0!+0,  +@+   9              " @5@- 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ &HAN6G1%3H-Y P  O T  !D
M     ("!O! ! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
M"  :B&Y:3,9?=]X"   :!P  &0              @(%L% $ >&PO=V]R:W-H
M965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( !J(;EJ.MIX\Z@(  #L+   9
M              " @8$7 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L!
M A0#%     @ &HAN6N?+HAW@ @  V <  !D              ("!HAH! 'AL
M+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    "  ;B&Y:J/PW3OT"
M   U"P  &0              @(&Y'0$ >&PO=V]R:W-H965T<R]S:&5E=#0V
M+GAM;%!+ 0(4 Q0    ( !N(;EJVKFO^ @,  ,(+   9              "
M@>T@ 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ &XAN
M6J/=K-QO @  MP4  !D              ("!)B0! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    "  ;B&Y:WPW)8*0"   D"   &0
M        @(',)@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( !N(;EK1G3!4P0(  ,T(   9              " @:<I 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ &XAN6JBIN"5N @  - 8
M !D              ("!GRP! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    "  ;B&Y:!#X _8D"  #4!@  &0              @(%$+P$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( !N(;EK>G>O7
M<P<  /E(   9              " @00R 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ &XAN6N+0Y'8L%@  ;70! !D
M ("!KCD! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  ;
MB&Y:87D+&CH%  "=)   &0              @($14 $ >&PO=V]R:W-H965T
M<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( !N(;EJ@IMTE(P4  !@B   9
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M970V,"YX;6Q02P$"% ,4    "  ;B&Y:\Z:\Y#4"  #-!   &0
M    @(&8:P$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    (
M !N(;EH4PR0960(  .T$   9              " @01N 0!X;"]W;W)K<VAE
M971S+W-H965T-C(N>&UL4$L! A0#%     @ &XAN6G79N#9Q P  < H  !D
M             ("!E' ! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"
M% ,4    "  ;B&Y:C.U+#XD#  "M"P  &0              @($\= $ >&PO
M=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( !N(;EJ(YV,8NP,
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( !N(;EI]2-/_@ 4  '<K   /
M      "  3J# 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  ;B&Y:'M^9
M7AP"   ])P  &@              @ 'GB $ >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  ;B&Y:I7\.<>X!  "0)@  $P
M    @ $[BP$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     2@!* #T4  !:
%C0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>152</ContextCount>
  <ElementCount>298</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>66</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Changes in Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - MERGER WITH VALLON</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLON</Role>
      <ShortName>MERGER WITH VALLON</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - PROMISSORY NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROMISSORYNOTES</Role>
      <ShortName>PROMISSORY NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - ASSET PURCHASE AGREEMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT</Role>
      <ShortName>ASSET PURCHASE AGREEMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - INCOME TAX</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/INCOMETAX</Role>
      <ShortName>INCOME TAX</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - MERGER WITH VALLON (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONTables</Role>
      <ShortName>MERGER WITH VALLON (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/MERGERWITHVALLON</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LEASES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - INCOME TAX (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/INCOMETAXTables</Role>
      <ShortName>INCOME TAX (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/INCOMETAX</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITYDetails</Role>
      <ShortName>LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LIQUIDITY</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - MERGER WITH VALLON - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails</Role>
      <ShortName>MERGER WITH VALLON - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails</Role>
      <ShortName>MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - LEASES - Schedule of Operating Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>LEASES - Schedule of Operating Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>LEASES - Schedule of Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - LEASES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LEASESNarrativeDetails</Role>
      <ShortName>LEASES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails</Role>
      <ShortName>PROMISSORY NOTES - Bridge Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - ASSET PURCHASE AGREEMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails</Role>
      <ShortName>ASSET PURCHASE AGREEMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails</Role>
      <ShortName>INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - INCOME TAX- Components of Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails</Role>
      <ShortName>INCOME TAX- Components of Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - INCOME TAX - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails</Role>
      <ShortName>INCOME TAX - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ck0001824293-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ck0001824293-20241231.htm">ck0001824293-20241231.htm</File>
    <File>ck0001824293-20241231.xsd</File>
    <File>ck0001824293-20241231_cal.xml</File>
    <File>ck0001824293-20241231_def.xml</File>
    <File>ck0001824293-20241231_lab.xml</File>
    <File>ck0001824293-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ck0001824293-20241231_g1.jpg</File>
    <File>ck0001824293-20241231_g10.jpg</File>
    <File>ck0001824293-20241231_g11.jpg</File>
    <File>ck0001824293-20241231_g12.jpg</File>
    <File>ck0001824293-20241231_g13.jpg</File>
    <File>ck0001824293-20241231_g14.jpg</File>
    <File>ck0001824293-20241231_g15.jpg</File>
    <File>ck0001824293-20241231_g16.jpg</File>
    <File>ck0001824293-20241231_g2.jpg</File>
    <File>ck0001824293-20241231_g3.jpg</File>
    <File>ck0001824293-20241231_g4.jpg</File>
    <File>ck0001824293-20241231_g5.jpg</File>
    <File>ck0001824293-20241231_g6.jpg</File>
    <File>ck0001824293-20241231_g7.jpg</File>
    <File>ck0001824293-20241231_g8.jpg</File>
    <File>ck0001824293-20241231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="488">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>109
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ck0001824293-20241231.htm": {
   "nsprefix": "ck0001824293",
   "nsuri": "http://www.vallon-pharma.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "ck0001824293-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "ck0001824293-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ck0001824293-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001824293-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001824293-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001824293-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 246,
   "keyCustom": 52,
   "axisStandard": 19,
   "axisCustom": 0,
   "memberStandard": 21,
   "memberCustom": 44,
   "hidden": {
    "total": 9,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 5
   },
   "contextCount": 152,
   "entityCount": 1,
   "segmentCount": 66,
   "elementCount": 575,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 488,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.vallon-pharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.vallon-pharma.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952154 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
     "longName": "9952155 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "longName": "9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.vallon-pharma.com/role/LIQUIDITY",
     "longName": "9952157 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLON",
     "longName": "9952159 - Disclosure - MERGER WITH VALLON",
     "shortName": "MERGER WITH VALLON",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "9952160 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT",
     "longName": "9952161 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.vallon-pharma.com/role/LEASES",
     "longName": "9952162 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES",
     "longName": "9952163 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.vallon-pharma.com/role/PROMISSORYNOTES",
     "longName": "9952164 - Disclosure - PROMISSORY NOTES",
     "shortName": "PROMISSORY NOTES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952165 - Disclosure - STOCKHOLDERS EQUITY",
     "shortName": "STOCKHOLDERS EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION",
     "longName": "9952166 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT",
     "longName": "9952167 - Disclosure - ASSET PURCHASE AGREEMENT",
     "shortName": "ASSET PURCHASE AGREEMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952168 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.vallon-pharma.com/role/INCOMETAX",
     "longName": "9952169 - Disclosure - INCOME TAX",
     "shortName": "INCOME TAX",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS",
     "longName": "9952170 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9955512 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONTables",
     "longName": "9955513 - Disclosure - MERGER WITH VALLON (Tables)",
     "shortName": "MERGER WITH VALLON (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9955514 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables",
     "longName": "9955515 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.vallon-pharma.com/role/LEASESTables",
     "longName": "9955516 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ck0001824293:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ck0001824293:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables",
     "longName": "9955517 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9955518 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
     "shortName": "STOCKHOLDERS EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9955519 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.vallon-pharma.com/role/INCOMETAXTables",
     "longName": "9955520 - Disclosure - INCOME TAX (Tables)",
     "shortName": "INCOME TAX (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
     "longName": "9955521 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
     "longName": "9955522 - Disclosure - LIQUIDITY (Details)",
     "shortName": "LIQUIDITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-30",
      "name": "ck0001824293:CommonStockHeldIntoEscrowAccount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails",
     "longName": "9955523 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:CashFDICInsuredAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails",
     "longName": "9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentUsefulLife",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentUsefulLife",
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
     "longName": "9955525 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
     "longName": "9955526 - Disclosure - MERGER WITH VALLON - Narrative (Details)",
     "shortName": "MERGER WITH VALLON - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-75",
      "name": "ck0001824293:CommonStockOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-75",
      "name": "ck0001824293:CommonStockOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails",
     "longName": "9955527 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)",
     "shortName": "MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-72",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-72",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails",
     "longName": "9955528 - Disclosure - FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Assets and Liabilities Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-76",
      "name": "ck0001824293:WarrantLiabilityFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-76",
      "name": "ck0001824293:WarrantLiabilityFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
     "longName": "9955529 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
     "longName": "9955530 - Disclosure - FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
     "longName": "9955531 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails",
     "longName": "9955532 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:Depreciation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R49": {
     "role": "http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails",
     "longName": "9955533 - Disclosure - LEASES - Schedule of Operating Lease Assets and Liabilities (Details)",
     "shortName": "LEASES - Schedule of Operating Lease Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails",
     "longName": "9955534 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)",
     "shortName": "LEASES - Schedule of Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.vallon-pharma.com/role/LEASESNarrativeDetails",
     "longName": "9955535 - Disclosure - LEASES - Narrative (Details)",
     "shortName": "LEASES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
     "longName": "9955536 - Disclosure - ACCRUED EXPENSES (Details)",
     "shortName": "ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
     "longName": "9955537 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)",
     "shortName": "PROMISSORY NOTES - Bridge Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:ProceedsFromNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9955538 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-65",
      "name": "ck0001824293:ProceedsFromWarrantExercisesNetOfOfferingExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
     "longName": "9955539 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-84",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-105",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails",
     "longName": "9955540 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-123",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-123",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9955541 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails",
     "longName": "9955542 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails",
     "longName": "9955543 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
     "longName": "9955544 - Disclosure - STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Assumptions Used to Estimate Fair Value of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-146",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-146",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails",
     "longName": "9955545 - Disclosure - ASSET PURCHASE AGREEMENT (Details)",
     "shortName": "ASSET PURCHASE AGREEMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-148",
      "name": "us-gaap:ProceedsFromSaleOfProductiveAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9955546 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-149",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-149",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails",
     "longName": "9955547 - Disclosure - INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)",
     "shortName": "INCOME TAX - Reconciliation of Federal Statutory Income Tax Rate to the Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails",
     "longName": "9955548 - Disclosure - INCOME TAX- Components of Deferred Taxes (Details)",
     "shortName": "INCOME TAX- Components of Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails",
     "longName": "9955549 - Disclosure - INCOME TAX - Narrative (Details)",
     "shortName": "INCOME TAX - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9955550 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": null,
     "uniqueAnchor": null
    }
   },
   "tag": {
    "ck0001824293_AardvarkTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "AardvarkTherapeuticsIncMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aardvark Therapeutics, Inc.",
        "label": "Aardvark Therapeutics, Inc. [Member]",
        "documentation": "Aardvark Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r54",
      "r57",
      "r746"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r559"
     ]
    },
    "ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Accrued General and Administrative Expenses, Current",
        "documentation": "Accrued General and Administrative Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses:",
        "label": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Accrued Research and Development Costs, Current",
        "documentation": "Accrued Research and Development Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r116",
      "r431"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in-capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r697",
      "r698",
      "r699",
      "r700",
      "r755",
      "r782"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r261"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant issuance",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r27",
      "r87"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r647"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r607",
      "r617",
      "r650"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r681"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r642",
      "r651",
      "r655",
      "r663"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r302"
     ]
    },
    "ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "AmendedAndRestated2018EquityIncentivePlanMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A&amp;R 2918 Plan",
        "label": "Amended and Restated 2018 Equity Incentive Plan [Member]",
        "documentation": "Amended and Restated 2018 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discounts and issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r539",
      "r540",
      "r692",
      "r764"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSET PURCHASE AGREEMENT",
        "label": "Asset Acquisition [Text Block]",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r754"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r100",
      "r117",
      "r135",
      "r167",
      "r170",
      "r171",
      "r172",
      "r174",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r348",
      "r350",
      "r384",
      "r424",
      "r479",
      "r532",
      "r533",
      "r559",
      "r571",
      "r716",
      "r717",
      "r771"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Assets and Liabilities",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r121",
      "r135",
      "r174",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r348",
      "r350",
      "r384",
      "r559",
      "r716",
      "r717",
      "r771"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.vallon-pharma.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r600"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.vallon-pharma.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r600"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.vallon-pharma.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r600"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Accounting",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ck0001824293_BridgeSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "BridgeSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge SPA",
        "label": "Bridge Securities Purchase Agreement [Member]",
        "documentation": "Bridge Securities Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_BridgeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "BridgeWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Warrants",
        "label": "Bridge Warrants [Member]",
        "documentation": "Bridge Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Plus: Transaction costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r344"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLON"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MERGER WITH VALLON",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r345"
     ]
    },
    "ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable and accrued expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42"
     ]
    },
    "ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total net liabilities assumed plus transaction costs",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_COBRABenefitsPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "COBRABenefitsPaymentPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COBRA benefits, payment period (in months)",
        "label": "COBRA Benefits, Payment Period",
        "documentation": "COBRA Benefits, Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_CashAcquiredInReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "CashAcquiredInReverseRecapitalization",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired in reverse recapitalization",
        "label": "Cash Acquired In Reverse Recapitalization",
        "documentation": "Cash Acquired In Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r114",
      "r524"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r74",
      "r132"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r74"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FDIC insured amount",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Uninsured cash balances",
        "label": "Cash, Uninsured Amount",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_ChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "ChangeInFairValueOfWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant liability",
        "label": "Change In Fair Value Of Warrant Liability",
        "documentation": "Change In Fair Value Of Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r169",
      "r233",
      "r234",
      "r235",
      "r237",
      "r240",
      "r245",
      "r247",
      "r448",
      "r449",
      "r450",
      "r451",
      "r541",
      "r686",
      "r693"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in usd per share)",
        "verboseLabel": "Exercise Price per Share (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares called by each warrant",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares called by warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r248"
     ]
    },
    "ck0001824293_ClassOfWarrantOrRightOfferingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "ClassOfWarrantOrRightOfferingCost",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, offering cost",
        "label": "Class of Warrant or Right, Offering Cost",
        "documentation": "Class of Warrant or Right, Offering Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrant shares (in shares)",
        "verboseLabel": "Number of Shares (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 13)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r96",
      "r426",
      "r466"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r186",
      "r187",
      "r520",
      "r708",
      "r713"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for future awards (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ck0001824293_CommonStockExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "CommonStockExchangeRatio",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, exchange ratio",
        "label": "Common Stock, Exchange Ratio",
        "documentation": "Common Stock, Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_CommonStockHeldIntoEscrowAccount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "CommonStockHeldIntoEscrowAccount",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock placed into escrow (in shares)",
        "label": "Common Stock Held Into Escrow Account",
        "documentation": "Common Stock Held Into Escrow Account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r565",
      "r566",
      "r567",
      "r568",
      "r697",
      "r698",
      "r700",
      "r755",
      "r781",
      "r782"
     ]
    },
    "ck0001824293_CommonStockOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "CommonStockOwnershipPercentage",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage in common stock (as a percent)",
        "label": "Common Stock, Ownership Percentage",
        "documentation": "Common Stock, Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r467"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r63",
      "r467",
      "r485",
      "r782",
      "r783"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.0001 par value; 250,000,000 shares authorized; 525,485 and 2,909 shares issued and outstanding as of December\u00a031, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r467"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computers",
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r528"
     ]
    },
    "ck0001824293_ConversionOfStockAdditionalSharesConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "ConversionOfStockAdditionalSharesConverted",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares converted into common stock (in shares)",
        "label": "Conversion of Stock, Additional Shares Converted",
        "documentation": "Conversion of Stock, Additional Shares Converted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock (in shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r18"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r209",
      "r235",
      "r408",
      "r417",
      "r423",
      "r525",
      "r527"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r674"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r674"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r676"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r676"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r678"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r587",
      "r676"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r580",
      "r669"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r581",
      "r670"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r581",
      "r670"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r668"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r668"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r579",
      "r668"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r582",
      "r671"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r673"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r584",
      "r673"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r585",
      "r674"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r588",
      "r677"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r586",
      "r675"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r583",
      "r672"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROMISSORY NOTES",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r133",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r194",
      "r195",
      "r205",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r221",
      "r228",
      "r229",
      "r231",
      "r392"
     ]
    },
    "ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of debt discount and additional paid-in-capital for warrants issued in connection with promissory notes",
        "label": "Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants",
        "documentation": "Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_DebtInstrumentAggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "DebtInstrumentAggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "label": "Debt Instrument, Aggregate Purchase Price",
        "documentation": "Debt Instrument, Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r93",
      "r95",
      "r140",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r557",
      "r694",
      "r709",
      "r710",
      "r711",
      "r763",
      "r765"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r392",
      "r393",
      "r537",
      "r538",
      "r557"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r557",
      "r694",
      "r763",
      "r765"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r140",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r557",
      "r694",
      "r709",
      "r710",
      "r711",
      "r763",
      "r765"
     ]
    },
    "ck0001824293_DebtInstrumentNumberOfClosings": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "DebtInstrumentNumberOfClosings",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of closings",
        "label": "Debt Instrument, Number Of Closings",
        "documentation": "Debt Instrument, Number Of Closings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r30",
      "r33",
      "r50",
      "r85",
      "r86",
      "r140",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r212",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r230",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r557",
      "r694",
      "r763",
      "r765"
     ]
    },
    "ck0001824293_DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt and deferred stock issuance costs included in accounts payable and accrued expenses",
        "label": "Debt Issuance Costs and Financing Costs Incurred But Not Yet Paid",
        "documentation": "Debt Issuance Costs and Financing Costs Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r763",
      "r765"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r94",
      "r324"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization - Federal",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development costs",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation - Federal",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals and other",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXComponentsofDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r25"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liability",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r44",
      "r45",
      "r46",
      "r47",
      "r139",
      "r154"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r263",
      "r294",
      "r295",
      "r297",
      "r546"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity of Stock Options Granted",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r35"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r600"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r600",
      "r643"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r155",
      "r158",
      "r161",
      "r162",
      "r163",
      "r166",
      "r342",
      "r347",
      "r360",
      "r361",
      "r421",
      "r435",
      "r529"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r158",
      "r161",
      "r162",
      "r163",
      "r166",
      "r342",
      "r347",
      "r360",
      "r361",
      "r421",
      "r435",
      "r529"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r165"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r309",
      "r550"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected income tax benefit at the federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r309",
      "r334",
      "r550"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r313",
      "r550",
      "r696",
      "r747"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible items and other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315",
      "r696",
      "r747"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local taxes, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r312",
      "r550",
      "r696",
      "r747"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXReconciliationofFederalStatutoryIncomeTaxRatetotheEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r696",
      "r747",
      "r749"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll and related",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation, weighted average amortization period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r296"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r110",
      "r125",
      "r126",
      "r127",
      "r141",
      "r142",
      "r143",
      "r145",
      "r150",
      "r152",
      "r154",
      "r168",
      "r175",
      "r176",
      "r177",
      "r249",
      "r332",
      "r333",
      "r339",
      "r340",
      "r341",
      "r343",
      "r346",
      "r347",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r394",
      "r396",
      "r405",
      "r434",
      "r440",
      "r441",
      "r442",
      "r454",
      "r507"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r604",
      "r614",
      "r647"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r644"
     ]
    },
    "ck0001824293_ExchangeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "ExchangeWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Warrants",
        "label": "Exchange Warrants [Member]",
        "documentation": "Exchange Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r377",
      "r551"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r363",
      "r364",
      "r377",
      "r551"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r553"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r553"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r553"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r376",
      "r377",
      "r379",
      "r412",
      "r413",
      "r414",
      "r537",
      "r538",
      "r542",
      "r543",
      "r544",
      "r551",
      "r553"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r378"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r420",
      "r551",
      "r554"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r251",
      "r256",
      "r364",
      "r377",
      "r412",
      "r542",
      "r543",
      "r544",
      "r551"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r251",
      "r256",
      "r364",
      "r365",
      "r377",
      "r413",
      "r537",
      "r538",
      "r542",
      "r543",
      "r544",
      "r551"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r364",
      "r365",
      "r366",
      "r367",
      "r377",
      "r414",
      "r537",
      "r538",
      "r542",
      "r543",
      "r544",
      "r551",
      "r553"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r378"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r378"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity for the Liability Measured at Estimated Fair Value Using Unobservable Inputs",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r373",
      "r378"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in valuation",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r369",
      "r378"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value as of December 31, 2023",
        "periodEndLabel": "Balance as of December 31, 2024",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r378"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r362",
      "r364",
      "r365",
      "r366",
      "r367",
      "r376",
      "r377",
      "r379",
      "r412",
      "r413",
      "r414",
      "r537",
      "r538",
      "r542",
      "r543",
      "r544",
      "r551",
      "r553"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r651"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r651"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r651"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r651"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r651"
     ]
    },
    "ck0001824293_FormerChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "FormerChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Chief Executive Officer",
        "label": "Former Chief Executive Officer [Member]",
        "documentation": "Former Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_GRIOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "GRIOperationsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GRI Operations",
        "label": "GRI Operations [Member]",
        "documentation": "GRI Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_GRIOperationsPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "GRIOperationsPlanMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015 Plan",
        "label": "GRI Operations Plan [Member]",
        "documentation": "GRI Operations Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r489"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r600"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r184",
      "r185",
      "r369",
      "r373",
      "r378",
      "r437",
      "r439",
      "r492",
      "r523",
      "r552",
      "r780"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r185",
      "r369",
      "r373",
      "r378",
      "r437",
      "r439",
      "r492",
      "r523",
      "r552",
      "r780"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r309",
      "r310",
      "r319",
      "r329",
      "r550",
      "r752"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r309",
      "r310",
      "r319",
      "r329",
      "r550",
      "r752"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAX"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAX",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r306",
      "r309",
      "r316",
      "r317",
      "r318",
      "r321",
      "r328",
      "r335",
      "r336",
      "r337",
      "r338",
      "r453",
      "r550"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r307",
      "r308",
      "r321",
      "r322",
      "r327",
      "r331",
      "r447"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r691"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r642",
      "r651",
      "r655",
      "r663"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r667"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r667"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r578",
      "r667"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income (expense), net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r689",
      "r702"
     ]
    },
    "us-gaap_InvestmentCompanyCommittedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentCompanyCommittedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in cash",
        "label": "Investment Company, Committed Capital",
        "documentation": "Amount of funds committed to investment company from investors."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r767",
      "r768"
     ]
    },
    "ck0001824293_June2024PAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "June2024PAWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "June 2024 PA Warrants",
        "verboseLabel": "June 2024 PA Warrants",
        "label": "June 2024 PA Warrants [Member]",
        "documentation": "June 2024 PA Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r395"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r400"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r61",
      "r135",
      "r174",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r349",
      "r350",
      "r351",
      "r384",
      "r465",
      "r530",
      "r571",
      "r716",
      "r771",
      "r772"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r97",
      "r428",
      "r559",
      "r695",
      "r707",
      "r762"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r113",
      "r135",
      "r174",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r349",
      "r350",
      "r351",
      "r384",
      "r559",
      "r716",
      "r771",
      "r772"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_LocalTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "LocalTaxAuthorityMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local",
        "label": "Local Tax Authority [Member]",
        "documentation": "Local Tax Authority"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r193",
      "r303",
      "r535",
      "r714",
      "r715"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r193",
      "r303",
      "r535",
      "r714",
      "r715"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r258",
      "r303",
      "r367",
      "r418",
      "r436",
      "r438",
      "r445",
      "r457",
      "r458",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r521",
      "r522",
      "r534",
      "r541",
      "r545",
      "r553",
      "r554",
      "r555",
      "r556",
      "r560",
      "r718",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dividend rate",
        "terseLabel": "Dividend rate",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r759",
      "r760"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected term in years",
        "terseLabel": "Expected term in years",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r759",
      "r760"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Volatility",
        "terseLabel": "Volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r758",
      "r759",
      "r760"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate",
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r759",
      "r760"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r553"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r365",
      "r366",
      "r367",
      "r553"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r109"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r76",
      "r98",
      "r111",
      "r122",
      "r123",
      "r127",
      "r135",
      "r144",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r153",
      "r154",
      "r159",
      "r174",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r342",
      "r347",
      "r361",
      "r384",
      "r433",
      "r487",
      "r505",
      "r506",
      "r569",
      "r716"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss available to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r146",
      "r147",
      "r148",
      "r149",
      "r155",
      "r156",
      "r160",
      "r163",
      "r347"
     ]
    },
    "ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "NetLiabilitiesAssumedInConnectionWithReverseRecapitalization",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net liabilities acquired in connection with reverse recapitalization",
        "label": "Net Liabilities Assumed In Connection With Reverse Recapitalization",
        "documentation": "Net Liabilities Assumed In Connection With Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r608",
      "r618",
      "r642",
      "r651"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ck0001824293_October2024PAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "October2024PAWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2024 PA Warrants",
        "label": "October 2024 PA Warrants [Member]",
        "documentation": "October 2024 PA Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r531",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r558"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails",
      "http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liabilities",
        "terseLabel": "Present value of operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities:",
        "label": "Operating Lease, Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "verboseLabel": "Current operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "verboseLabel": "Non-current operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LEASESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r402"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LEASESScheduleofOperatingLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Non-current operating lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "OperatingLeaseRightOfUseAssetPeriodicAddition",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in operating lease right of use assets",
        "label": "Operating Lease, Right-Of-Use Asset, Periodic Addition",
        "documentation": "Operating Lease, Right-Of-Use Asset, Periodic Addition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "ck0001824293_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, not subject to expiration",
        "label": "Operating Loss Carryforwards, Not Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Not Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_OperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards subject to expiration",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r606",
      "r616",
      "r649"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r652"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r609",
      "r619",
      "r652"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PaymentForFractionalSharesReverseStockSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "PaymentForFractionalSharesReverseStockSplit",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment for fractional shares in connection with reverse stock split",
        "label": "Payment For Fractional Shares, Reverse Stock Split",
        "documentation": "Payment For Fractional Shares, Reverse Stock Split"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PaymentOfReverseRecapitalizationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "PaymentOfReverseRecapitalizationCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of reverse recapitalization costs",
        "label": "Payment Of Reverse Recapitalization Costs",
        "documentation": "Payment Of Reverse Recapitalization Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of debt issuance costs",
        "terseLabel": "Payments of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of deferred stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ck0001824293_PercentageOfTargetBonus": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "PercentageOfTargetBonus",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of target bonus (as a percent)",
        "label": "Percentage Of Target Bonus",
        "documentation": "Percentage Of Target Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PeripheralEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "PeripheralEquipmentMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peripheral Equipment",
        "label": "Peripheral Equipment [Member]",
        "documentation": "Peripheral Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r682"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ck0001824293_PreFundedAndSeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "PreFundedAndSeriesCWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded And Series C Warrants",
        "label": "Pre-Funded And Series C Warrants [Member]",
        "documentation": "Pre-Funded And Series C Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prefunded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "ck0001824293_PriorWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "PriorWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Warrants",
        "label": "Prior Warrants [Member]",
        "documentation": "Prior Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_ProceedsFromAdvancesFromEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "ProceedsFromAdvancesFromEmployees",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advances from employees",
        "label": "Proceeds From Advances From Employees",
        "documentation": "Proceeds From Advances From Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Proceeds from issuance of common stock in financing transaction / under ATM facility",
        "terseLabel": "Proceeds from issuance of common stock in financing transactions",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of bridge promissory note",
        "verboseLabel": "Proceeds from issuance of notes",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront cash payment",
        "label": "Proceeds from Sale of Productive Assets",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant exercise",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "ck0001824293_ProceedsFromWarrantExercisesNetOfOfferingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "ProceedsFromWarrantExercisesNetOfOfferingExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant exercise, net of offering cost",
        "label": "Proceeds From Warrant Exercises, Net Of Offering Expense",
        "documentation": "Proceeds From Warrant Exercises, Net Of Offering Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r404"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r104",
      "r107",
      "r108"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r115",
      "r432"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r404",
      "r422",
      "r432",
      "r559"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r104",
      "r107",
      "r430"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r404"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful lives",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Offering",
        "label": "Public Offering [Member]",
        "documentation": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r250",
      "r258",
      "r289",
      "r290",
      "r291",
      "r303",
      "r367",
      "r415",
      "r416",
      "r418",
      "r436",
      "r438",
      "r445",
      "r457",
      "r458",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r521",
      "r522",
      "r534",
      "r541",
      "r545",
      "r553",
      "r554",
      "r555",
      "r556",
      "r560",
      "r563",
      "r712",
      "r718",
      "r759",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r192",
      "r250",
      "r258",
      "r289",
      "r290",
      "r291",
      "r303",
      "r367",
      "r415",
      "r416",
      "r418",
      "r436",
      "r438",
      "r445",
      "r457",
      "r458",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r521",
      "r522",
      "r534",
      "r541",
      "r545",
      "r553",
      "r554",
      "r555",
      "r556",
      "r560",
      "r563",
      "r712",
      "r718",
      "r759",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r601",
      "r611",
      "r644"
     ]
    },
    "us-gaap_RedeemablePreferredStockDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RedeemablePreferredStockDividends",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deemed dividend on Series B Warrants",
        "label": "Redeemable Preferred Stock Dividends",
        "documentation": "Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r19",
      "r87"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r257",
      "r406",
      "r407",
      "r425",
      "r429",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r484",
      "r486",
      "r512"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r490",
      "r491",
      "r492"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r257",
      "r406",
      "r407",
      "r425",
      "r429",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r484",
      "r486",
      "r512",
      "r770"
     ]
    },
    "ck0001824293_RepaymentOfAdvancesFromEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "RepaymentOfAdvancesFromEmployees",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of advances from employees",
        "label": "Repayment Of Advances From Employees",
        "documentation": "Repayment Of Advances From Employees"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r209",
      "r235",
      "r408",
      "r417",
      "r423",
      "r526",
      "r527"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r523",
      "r532",
      "r779"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r304"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r602",
      "r612",
      "r645"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r592",
      "r603",
      "r613",
      "r646"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r610",
      "r620",
      "r653"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "negatedLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r87",
      "r427",
      "r443",
      "r444",
      "r452",
      "r468",
      "r559"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r141",
      "r142",
      "r143",
      "r145",
      "r150",
      "r152",
      "r154",
      "r175",
      "r176",
      "r177",
      "r332",
      "r333",
      "r339",
      "r340",
      "r341",
      "r343",
      "r346",
      "r347",
      "r352",
      "r354",
      "r355",
      "r357",
      "r359",
      "r394",
      "r396",
      "r440",
      "r442",
      "r454",
      "r782"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ck0001824293_SaleOfStockAgentCompensationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SaleOfStockAgentCompensationPercentage",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, agent compensation, percentage",
        "label": "Sale Of Stock, Agent Compensation, Percentage",
        "documentation": "Sale Of Stock, Agent Compensation, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockAggregateCashFeePercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SaleOfStockAggregateCashFeePercentageOfGrossProceeds",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, aggregate cash fee, percentage of gross proceeds",
        "label": "Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds",
        "documentation": "Sale Of Stock, Aggregate Cash Fee, Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from sale of stock",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockManagementFeePercentageOfGrossProceeds": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SaleOfStockManagementFeePercentageOfGrossProceeds",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fee, percentage of gross proceeds",
        "label": "Sale Of Stock, Management Fee, Percentage Of Gross Proceeds",
        "documentation": "Sale Of Stock, Management Fee, Percentage Of Gross Proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockMaximumValueOfSharesOffered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SaleOfStockMaximumValueOfSharesOffered",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, maximum value of shares offered",
        "label": "Sale Of Stock, Maximum Value Of Shares Offered",
        "documentation": "Sale Of Stock, Maximum Value Of Shares Offered"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SaleOfStockNumberOfSecuritiesIssuedPerTransaction",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities issued (in shares)",
        "label": "Sale Of Stock, Number Of Securities Issued Per Transaction",
        "documentation": "Sale Of Stock, Number Of Securities Issued Per Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockReimbursementOfAccountableExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SaleOfStockReimbursementOfAccountableExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of accountable expenses",
        "label": "Sale Of Stock, Reimbursement Of Accountable Expenses",
        "documentation": "Sale Of Stock, Reimbursement Of Accountable Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockReimbursementOfNonAccountableExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SaleOfStockReimbursementOfNonAccountableExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reimbursement of non-accountable expenses",
        "label": "Sale Of Stock, Reimbursement Of Non-Accountable Expenses",
        "documentation": "Sale Of Stock, Reimbursement Of Non-Accountable Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/ASSETPURCHASEAGREEMENTDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r344"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Net Liabilities Assumed in the Merger",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Federal Statutory Income Tax Rate to the Effective Income tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r550",
      "r747"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r404"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r490",
      "r491",
      "r492"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r262",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r83",
      "r85",
      "r86",
      "r87",
      "r118",
      "r119",
      "r120",
      "r169",
      "r233",
      "r234",
      "r235",
      "r237",
      "r240",
      "r245",
      "r247",
      "r448",
      "r449",
      "r450",
      "r451",
      "r541",
      "r686",
      "r693"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Outstanding to Purchase Common Stock",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ck0001824293_SeriesA1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesA1WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 Warrants",
        "label": "Series A-1 Warrants [Member]",
        "documentation": "Series A-1 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesB1CommonAndSeriesB2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-1 Common And Series B-2 Common Warrants",
        "label": "Series B-1 Common And Series B-2 Common Warrants [Member]",
        "documentation": "Series B-1 Common And Series B-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesB1CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesB1CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-1 common warrants",
        "label": "Series B-1 Common Warrants [Member]",
        "documentation": "Series B-1 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesB2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesB2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-2 common warrants",
        "label": "Series B-2 Common Warrants [Member]",
        "documentation": "Series B-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesBCommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesBCommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Common Warrants",
        "label": "Series B Common Warrants [Member]",
        "documentation": "Series B Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants",
        "label": "Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants [Member]",
        "documentation": "Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesC1CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesC1CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-1 Common Warrants",
        "label": "Series C-1 Common Warrants [Member]",
        "documentation": "Series C-1 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesC2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesC2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-2 Common Warrants",
        "label": "Series C-2 Common Warrants [Member]",
        "documentation": "Series C-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-1 Common Warrants, Series D-2 Common Warrants, And PA Warrants",
        "label": "Series D-1 Common Warrants, Series D-2 Common Warrants, And PA Warrants [Member]",
        "documentation": "Series D-1 Common Warrants, Series D-2 Common Warrants, And PA Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesD1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesD1WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-1 Warrants",
        "label": "Series D-1 Warrants [Member]",
        "documentation": "Series D-1 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesD2WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesD2WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D-2 Warrants",
        "label": "Series D-2 Warrants [Member]",
        "documentation": "Series D-2 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesDWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "SeriesDWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Warrants",
        "label": "Series D Warrants [Member]",
        "documentation": "Series D Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r279"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r290"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r289"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r291"
     ]
    },
    "ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r262",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term\u00a0(years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable, Ending Balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable, Ending Balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r270"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r274"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r272"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares outstanding",
        "periodStartLabel": "Outstanding, Beginning Balance (in shares)",
        "periodEndLabel": "Outstanding, Ending Balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, Beginning Balance (in usd per share)",
        "periodEndLabel": "Outstanding, Ending Balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r267",
      "r286",
      "r287",
      "r288",
      "r289",
      "r292",
      "r298",
      "r299",
      "r300",
      "r301"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock on grant date (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards, contractual life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONAssumptionsUsedtoEstimateFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r288"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r284"
     ]
    },
    "ck0001824293_StateTaxAuthorityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StateTaxAuthorityMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State Tax Authority [Member]",
        "documentation": "State Tax Authority"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r63",
      "r66",
      "r67",
      "r110",
      "r125",
      "r126",
      "r127",
      "r141",
      "r142",
      "r143",
      "r145",
      "r150",
      "r152",
      "r154",
      "r168",
      "r175",
      "r176",
      "r177",
      "r249",
      "r332",
      "r333",
      "r339",
      "r340",
      "r341",
      "r343",
      "r346",
      "r347",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r359",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r394",
      "r396",
      "r405",
      "r434",
      "r440",
      "r441",
      "r442",
      "r454",
      "r507"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r168",
      "r396",
      "r419",
      "r446",
      "r456",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r467",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r488",
      "r489",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r564"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r168",
      "r173",
      "r396",
      "r419",
      "r446",
      "r456",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r467",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r488",
      "r489",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r507",
      "r564"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r605",
      "r615",
      "r648"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuanceCostsOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuanceCostsOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses",
        "label": "Stock Issuance Costs, Offering Expenses",
        "documentation": "Stock Issuance Costs, Offering Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesFractionalShareAdjustment",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fractional share adjustment (in shares)",
        "label": "Stock Issued During Period, Shares, Fractional Share Adjustment",
        "documentation": "Stock Issued During Period, Shares, Fractional Share Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r62",
      "r63",
      "r87",
      "r448",
      "r507",
      "r518"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesPreClosingFinancing",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in pre-closing financing (in shares)",
        "label": "Stock Issued During Period, Shares, Pre-closing Financing",
        "documentation": "Stock Issued During Period, Shares, Pre-closing Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock vesting (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r62",
      "r63",
      "r87"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalization",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization",
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for reverse recapitalization expenses (in shares)",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization Expenses",
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesSettlementOfDebt",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for settlement of bridge note (in shares)",
        "label": "Stock Issued During Period, Shares, Settlement Of Debt",
        "documentation": "Stock Issued During Period, Shares, Settlement Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r62",
      "r63",
      "r87",
      "r273"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercise",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise (in shares)",
        "label": "Stock Issued During Period, Shares, Warrant Exercise",
        "documentation": "Stock Issued During Period, Shares, Warrant Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r62",
      "r63",
      "r87",
      "r454",
      "r507",
      "r518",
      "r570"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValuePreClosingFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in pre-closing financing",
        "label": "Stock Issued During Period, Value, Pre-closing Financing",
        "documentation": "Stock Issued During Period, Value, Pre-closing Financing"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueReverseRecapitalization",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Vallon stockholders in reverse recapitalization",
        "label": "Stock Issued During Period, Value, Reverse Recapitalization",
        "documentation": "Stock Issued During Period, Value, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueReverseRecapitalizationExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for reverse recapitalization expenses",
        "label": "Stock Issued During Period, Value, Reverse Recapitalization Expenses",
        "documentation": "Stock Issued During Period, Value, Reverse Recapitalization Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueSettlementOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for settlement of bridge note",
        "label": "Stock Issued During Period, Value, Settlement Of Debt",
        "documentation": "Stock Issued During Period, Value, Settlement Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedDuringPeriodValueWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise",
        "label": "Stock Issued During Period, Value, Warrant Exercises",
        "documentation": "Stock Issued During Period, Value, Warrant Exercises"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedForPaymentOfReverseRecapitalizationCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock for payment of reverse recapitalization costs",
        "label": "Stock Issued For Payment Of Reverse Recapitalization Costs",
        "documentation": "Stock Issued For Payment Of Reverse Recapitalization Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedForRepaymentOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "StockIssuedForRepaymentOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock for repayment of bridge loan",
        "label": "Stock Issued For Repayment Of Notes Payable",
        "documentation": "Stock Issued For Repayment Of Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r66",
      "r67",
      "r78",
      "r469",
      "r485",
      "r508",
      "r509",
      "r559",
      "r571",
      "r695",
      "r707",
      "r762",
      "r782"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r134",
      "r232",
      "r234",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r246",
      "r249",
      "r358",
      "r510",
      "r511",
      "r519"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split ratio",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r410"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r410"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r410"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r410"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r410"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r411"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIQUIDITY",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure or noncash activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ck0001824293_ThroughFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "ThroughFinancingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Through Financing",
        "label": "Through Financing [Member]",
        "documentation": "Through Financing"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r769"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would affect effective tax rate if recognized",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r549"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r102",
      "r103",
      "r105",
      "r106"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/INCOMETAXNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance, increase",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "ck0001824293_WarrantLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "label": "Warrant Liability, Current",
        "documentation": "Warrant Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantLiabilityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantLiabilityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSAssetsandLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "label": "Warrant Liability, Fair Value Disclosure",
        "documentation": "Warrant Liability, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liability",
        "label": "Warrant Liability [Member]",
        "documentation": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r565",
      "r566",
      "r567",
      "r568"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r759",
      "r760"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights outstanding, term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r759",
      "r760"
     ]
    },
    "ck0001824293_WarrantsExpiringInApril2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInApril2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In April 2026",
        "label": "Warrants Expiring In April 2026 [Member]",
        "documentation": "Warrants Expiring In April 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInApril2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInApril2028Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In April 2028",
        "label": "Warrants Expiring In April 2028 [Member]",
        "documentation": "Warrants Expiring In April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInAugust2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInAugust2025Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In August 2025",
        "label": "Warrants Expiring In August 2025 [Member]",
        "documentation": "Warrants Expiring In August 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInFebruary2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInFebruary2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In February 2026",
        "label": "Warrants Expiring In February 2026 [Member]",
        "documentation": "Warrants Expiring In February 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInFebruary2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInFebruary2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In February 2029",
        "label": "Warrants Expiring In February 2029 [Member]",
        "documentation": "Warrants Expiring In February 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJuly2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInJuly2027Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In July 2027",
        "label": "Warrants Expiring In July 2027 [Member]",
        "documentation": "Warrants Expiring In July 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJune2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInJune2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In June 2029",
        "label": "Warrants Expiring In June 2029 [Member]",
        "documentation": "Warrants Expiring In June 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInMarch2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInMarch2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In March 2026",
        "label": "Warrants Expiring In March 2026 [Member]",
        "documentation": "Warrants Expiring In March 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInMay2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInMay2027Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In May 2027",
        "label": "Warrants Expiring In May 2027 [Member]",
        "documentation": "Warrants Expiring In May 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInOctober2029OneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInOctober2029OneMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In October 2029, One",
        "label": "Warrants Expiring In October 2029, One [Member]",
        "documentation": "Warrants Expiring In October 2029, One"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInOctober2029TwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInOctober2029TwoMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In October 2029, Two",
        "label": "Warrants Expiring In October 2029, Two [Member]",
        "documentation": "Warrants Expiring In October 2029, Two"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInSeptember2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsExpiringInSeptember2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In September 2029",
        "label": "Warrants Expiring In September 2029 [Member]",
        "documentation": "Warrants Expiring In September 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20241231",
     "localname": "WarrantsIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants for payment of stock issuance costs",
        "label": "Warrants Issued",
        "documentation": "Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants not settleable in cash, fair value disclosure",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r761"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r367",
      "r416",
      "r521",
      "r522",
      "r553",
      "r773",
      "r775",
      "r778"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r163"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r163"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-25"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>110
<FILENAME>0001824293-25-000050-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001824293-25-000050-xbrl.zip
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MRZM>"PR&;\W.:?OR&SN[ZOP.?Y;/KZY^X&<:"'@A1<RLG'TD.6(A,2QL5+!
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MJN [0WA.22I&<#TM&2ZVK;]"RP0R8M: W0,Y@FJ46HWX*\1?<0_PH!*['UG
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MD"YU4*L9![54K.&E :TZ^=G3(:VZ\KT7<0CXAAK+@BPAZP#$.?(J,Y6!XHA
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M!SX"3$'!UBI!NC]5[@GU6Z=-S@29VA&W=- -+(&*$T$G<T[]3[:[,"R_'(C
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MW8H2;D$\=-AW ]_6MUWC5D<WQFHL$QW-ARDRR*A["5SHFCYFNXQ+R=%*JM&
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MJ;>"5.U_%5I2G)77[/8Z5ZW+7JMP)Q4Z0 &I_$#J8VM+O2M0E-X\OVF#R:>
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M('E&]%$P8+D6CC- Q+IJ;H$KF_A/A$%M^.6^<&Z4Y88^0,</^W!\ [D5/?>
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M >L^<UQFH/,13[;"-\YCU*HY3F_TT)<<^41L:R"(3)6GQZ<EC80]8<J@ 0B
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M5++A3]ILBG4$ZTF[3YA!Y7"DH(ZI0_D/5.NZHKCNNEKWS Q6S<.^7]\%=Y_
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M0$J0OR%$^31%2+NJNA"I;&0N'TV^ZEDQA?404QF>)DR"&X5$T30R/D^>#&6
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M^4VC.E$I^7)(E^@']YEG#L.[\U?\\ZFESU@:IOG/@>V!V NH[BV#$A5F-VI
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M+ASLR+Q*&1R2)+6Y>;NLN-@?E(2T +Y74KB?0;HT.;IX__/QQ-KT."_(A$R
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M[J4)(X/:1H\I=>H695W<Y9:N[5*G)AGQ!_\&9I4SEED2Y'&"HGY&C&_<$94
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M#)8+7=Q[RQ?!";HI-$FA9AH6HVS-VBJ%T>CXM)-^\D@/458XIPG@(M&C00;
MZ4S.EQT:6W*PYY6P8ZCDS_;%H^+B\L*%=J^N<MUYK[CT7SSF*%Q!ZFL?VK4]
M<*V7])0=)B0\11\]47[[$F] <;*D]G)5Y7-:A+2)6/[%'9. C"&VOJ @2KI"
M89AZQUJN3Y)Y+M8(P/5^)WM:K>5BR"BHR\\%2'ID(9J4[R;D"?R:4I'_J>EW
M^V"1H^=(!F5P7M/Y'BU=LIALA 2EB=+DZ7?"W%6H,B8H)D0,985P>DSS4 X
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M3IT1WP\=U,3*T+(OMU M9JOFF&18E^A2B)XYJV#>\>G7PGXRIC.F^P) .H(
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M=RT:ZROB0P['?=B*OTYX[3S/=YAG.6+#+!8=G8"._I,;TL3W+9NIW8D/1V2
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M3G3HHO#)(V&/0*F9Y+LVL?E)NAIBCR/W1TV^121;O>=#)FWTKI=\75("A)(
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MF5*D;)RQN9GGV O^ _.O"&#(%CJ9AG253_AO.?2KH]ZCG4+(]-L>F':K1!3
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MN0+$+5!#K*G+A.@Z_:UH3,\3>V_3KWEQU%"$^4\#DK(B$$;!G16(&,X:O\=
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M15%9(5NB-N!G!C_^6+*_)7GA45.6V^CYU[Z:^752\>$V$.FEYB*F-F13OPE
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MUN7RN:%%0M4HPW'A2IX[1 LV8O@ [)D'/@;T9<EOY4HB(/P-)J<J+NN.92"
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M4)F82>953^TV>*U1&U<LE=,Q6C:<X+.O"1A*LC>YM;T1,2"H'>]X(\+WQ72
MZ=;PFC2%T+2P1 ^2T@&-A_;T#P)*,-+9">LSNTX)XU<T2-&XX%Q+5QR?F\<Y
MGTU(6]KJO6L#FQH\,X]L$;9&UH-31[[NDPE)XB!].-]X:"ULP4BM&%L3:X 7
M6NJQDXTO@N\ICF+B1/-TE4.1;;'^UZ7M[^0*> &7L88YJK2QD#M3NR98(5K(
MG.(/9V394H%D: SP;M))16BKX :W*)W;@[CA$C0##?$53.^*\0LF!A46?UC>
MFR[*#<C:0+6O6JL""&F'U0(]3)U1 B;Q&PQ@3BWH6#TD"?,K !S_2NCXM,&"
MVX"G$$7'%3?NHO\EW+#E3#(=)4(,6K1TVLD$";K7D43$91:M;4Z4G3A9@+J!
M4B4+(_ (WIBE-3&V<$4TOFI%.5EZ]6;S!./.CP]O6J;Y8%-F!+4X-B BLP_A
M]\$MP/0R8\_+9T"MG_14@CKO[(C& ZU/*%@1FR #%ZU^$+L0-J.@9"[5*(DX
MZ5F2;:#9778D2QB"<-3O6FY5$ TB[Z$!&E"TB57X1\Y2QBUZ7@\#W$E?,2#>
M+LWIZVDS^$A>4T JHA')WFNGBK,CO-<1">#'WG,=\/B&YTSU05HR,D(_NP%<
MLUH=,AUZEO EH>TG5)(Z#+;S,)6K127A7!\>HH>CTY4-\O<TG*V&HV,+*2C=
MX,8Q;S&[2,Y2?,'+RGQDG\:=EP]RL:^[+#F2+5K[TFLF/JFGEXG4Y,E?&6B5
MNO,7BQ_%I]/B*_8!9J(P3>HI7=HQS^R_!M5+"1%>?#*DBV *B3-=!.@B/J>1
M2*?:.PQ".Y1NB]0'2KB+AN&@E:UEI89K7=?;ONI$FX_8505FEA(B_<LD+N?Y
MOGV^R10D1XN+8&9*3&/3<IZA!YPAX9,D*G::A1"P=7)"7=7;=3N6##]/Q\,:
MR$W?4DA^\/UE<H)3T7P]2 JW+ X5_A!WF!WXR?>HQ0EPD/X\A0\YA6W?$E("
MG@Z$R.JH%)'V8FF>^#P=#S@==_,")!!E#"NW; X+6>=9>L!9ZNJ.$XA \%$C
MG=M%EG3Z-92ZYUFX?18,AEJ4_T,!*+0(.T8OLC'CTXG[)G?"3T:A'1-C%>_Y
MO^92E[^*D.\\@;=/H*,%SX9IH4R;S]-0?%5>E]MI#O'3S[NG3>J2LFF)PD?[
M38$L9 (WZI*Y?ZI(:/-,ZHI2A:STB;Z8O)-,S9RZ5MIGIBUF4SCGV80_513+
MW8@-T/K6I;4Q2?,<J37/3^L90_>?'[TX8^C.&+H/&$-'F)1+2JY7.Y92<U(=
ML!2DWA:LQ'59:]$E_'6;WTCGY%(I"[G>G)*H"1[(%TB,G2AR$B$)S> DIRE^
M652%4!:PG38WFP7H9K+>=P&OIW2#C++"/>A?PC.4ZH9Z$KZ45M@G' TC1N)[
M$3%&!:6\XX>BK'L;AVYX7U!=C)J!M3.YC@@*7'MCN>]9;6]I=>9W-$R(FW!?
M39/25CC/>3KYW'-4LYD<+"8Z/=/+,*<R]XNU2.[IT)0V8[!#E5=UO<[T@(1S
MJ#P3DT_+3P<(#[%]<D)7P%5;PF)H'W^3--Y?\\%-0UN40L?G\>("*:5?+9LZ
M7VO'%&JI1.U3-XXL-U_G>X;Z10'YXGW9=D,$H?I2^;K>Z\X:)3N!FN*I'FCI
MHD-/[FEM$S/H.6G3VD+-?8@-Y!GR?(TH>T;"I)1 EGIUB^N"<T8M[@HGHILM
M<IY\M^FK.57$_RMZ3;7=:!)89#Q."C!L)Q:'$>"0?<4:ES7 _6-$O!-1-TIG
M327BX#(;+"T"QM!\'^N:^_Q0-PXZ9NT:VO0H>+;PU4@LDS8Z*Y#IE-;>]-&J
MDS$A_:N@G6Y2\O>^4U61;LI5 55-G;;+ 37YG2=, "K#.8M8P>\Q54+@R_\H
MUY$6+&I_KADE4C>7>26;33K!;IG[B3-0R#U$PG43B;*1^1XM,#G)]%"E;YE=
M!H,<'Q0>S )>H)U2.*6D&.&PZ@6& C;C\ #NI\9.-=7)'V=R72<VE4(P9;!F
MZ#EY6S8]2;^M^4+>DXHI26A_M$/CO22\4&$&>WL:C-BW@E6.V9BY-LE$QF%D
M+W)0"!$T=%W 'P6M$TLITR6I@(P5;G".?UU9]M.1!L0?-YJGEG+ZB--O2>M?
M1&,$5SBLZORR:)-^:##]5.RY62?^KY!2.4_0K1,$>^MD+JBK=@"L<-LMPWZC
M3;;(NP'I2_FK5&_.4W7K5#%;@/ 3@*NQG2+$.V^H/WQ#T?D3/O#DAUT8V:*S
MUHI]O;?8EH3O#H@0R5/*]]9OL7$^&]-U%>VJ*9=P3MHB?OT\H0\\H4,XMF N
M6Y7OF$G.E]+$LX5R0L1\!P]5)6P</VOB.P\HBON8;YHHG9VG_V&G/]C6HKJD
MA&/2@E(-&JB$6.4\';^COS*2Y?(!H@6.G!*5 *PIRMVR;UIDXGZ=#MQYPNXT
M8911#CZC.BX1'\\AGB_*CD0)MGEUV>L<MBMJ:9*?H99)'$^,3VP7CSQYR'OW
MR6-J)RY6>2]IB5H[NUUGT>D'S&_#$,*?T!Q*+$50:UF,=R=<D"..1'0,M8&U
M;$WIJ:;,RC)OE1]9^9+9=6$D(I5KW.65$SD^G72A9N*P"-$IM?PHV;'46MHN
M_FDB+U0J#3Z7#.P?KO&,H=Y&XN9.7V-<3L_?V%U[V=3]WJ@0%M3$+TS94+7?
M;'M5ZHLO2[U74D2:&'3)^-UEZ*?*)3=7Q> "KAFX%0ZM8<;MJFXA\$:K'+_F
MW%7:PI7Y,HMU8@&"4%XS@W+KF Z,))LGM^Z[7SNYM+DM3F$2!(XEJ0'%XA3D
MVB9S0+1$(P=S>!YC'[MCQHV6 #>O$:9,.HI'&3B4OAHF7+0#1E)PVE406V('
M=->#U!P@4CM?5=ER,M%/A;7'3:0Y):4HDWB7LXU?/!*5V*3=I,*113:1?DNK
MGYJ(C]5,3I.N3\)LWK-P\DVL)JOD91-+;3-C67M=2AM\1=(,.?N39O42JSB3
M\JI45=.:LXQ_=U6WDZEEYJIG#9WA;VVYRLH\B2FY-?5+"2-A%N.QS 0ID SZ
M9G)TW9BBM7J9;%#'52^4P+J(F9K$LQE,B9W$MMVD$!'WV2JM2HP?>[).X3L(
MXYX7;K.AX64% VK[XS,'#&]D0JURPT>S%:?IS=;F&7@;:F[#+2/ID^:)>%/&
M5&QKTO=1XX[!0-$\4X]#:OCA82+="%G].]^;&L&INH0]U<0AQ7DM)1CLTJ+B
MHHFO/&5*HWXPR@(XC +'<Z<@_TKV=')VAILZ8^S*ESH[_"=8[2.SKT7\,Y3N
M")3NHS.4[@RE^X"A=$Y#E[RK)M$KKECR"R<] 6U87SE+8#@XI98A] 6PK#&_
M+H8RW#V.#Y-*KQG]5%UC%JEV^O[ ,-)C_09?_^XK$6E#XXT!?#@J''EE8YN\
M@33WC=>OL.&A0'.$"A,T7A/.['(/0N25=,[G2PJ ;K^7 ,I!+7+8R[D)(C=I
MX'OU_=L,<0H%8 >EJO[VV[?(@81/<=,U 0LD$LR9O>*&A<1QW.91D4P/494,
M3YYL+7WR"N@@$A9_J"U4@IC9J.3TEG=,W\\@BH.0FIX89/)>[(PK_&&,0<!!
M@D'$P=U)*"QQ;G@=^K%X(/3.HPS[Q!#7%-5-^,J*70E[0' 2=(/T JN:QO4(
MWYJQGL?BY^GOHQ_[#KFTB=4,P1Y.VQ!LDU&JRM?"$<2653N5Z212/";>*@J]
M2L/G76E\\,2Z^"/Y=80"W5"+Q-809B(*"O;'77#?VI)[BJGY6UHP!*<<3 .<
M(Y14ONZ)MB4C\%Z^]F++*S*SH"LCKAW<D%:4)RW<(W=1L&:'.*X2B> '?4OK
MG9E'*$_# $[L9-B)'0@_]3YF)%;L8<<=[\;Q.F\.S./A!BYXZ@0C+=L=.DE8
M''*SL D2=[<]M%VQ:R]$4M1&W9@P'!957\/!9HU0"U/"(0W.(D.%>C&><*WF
M<D1$:%[Z@"_2"*5H&\TNNU0!05,G@M@BR^VC-@MDXUD&QJ*\K2O1>N+?"_%4
M</(_@,,M:O'X]2Z1Z/(P'PN*89[$+,?XR^@@.68"=LU%.QR!#5E@4J:-Y"Q#
MSET39D</MFJ=,6TB7QF3?3 _!1?UCHWE5<)[V>6F%]HOVF>@?06BRJ!+7'<P
M!B=LBDKH31WESYKW^\#,4!V/1NPF;R)P,8Z6#]$'OY0$,./2QL'HL'B;0O -
MHWZM:H^BK[BN;RH\B[=)H]FC,C);:*-Y'=@F%9AE?8O,[%\PJ+YAPUM"5636
M]<4HR;#)_8PF / QY8HE881-E.@QDR->L[&J$"+D=>%^NV,2"2>QJ?]U\8<)
MK6VM61VGM,3>*;!O^!)>Z"1U\#O5WAXU!(HQ%MS)P!Y[AM+)1&18$WI]8H,.
MH87F)LV,G\3LW!9/&*NE9K9]_ON6,1+"1J<.+/S6VG=4]6$F:L%DZ/D^UX1D
MA:#HGD01YPDRVXO%JP%]5A3*IE1U5<B5#DE,B,P].^(S+4+TX_1!-.4ZI4N?
MW,C**[LBEVZ<J5]I!&(M)D)9[6]+?D2BE\,<WC2*0L<5QPGC'FY85M?U]CH1
MM-65+\3",A/;<AT96]VW!UU!JC9#ZDZ0Q2Z*=Q#&FZ"F-<+F(3NI#T_1($6Z
MU6K\;'#9@M-1URM</NH-)^]3#(6"IYC4A-M3BS!"MIP+#S?:NOOPJI<77FDM
M)1H-XXG!OJ'2Z('+6#K/."/X/V-SWJA!F8_&+A)T#PX&/E*8?5"FDM+07=EN
M#G*TMHYM?';G0 F+7C ;O%T6\P%"%VW>=LK$Q_,R*"5#CF]4 IK9!='?/XB6
MK@P&DCA5<<DKRB2,-:1@(:A-*AF5;*]T*\+ID1(?ZQQ.2@2EP'< <>4A_]DW
M9;LN5T,9E33P$Y?=PC%_1^=HT?,M53)HY@4F+ZPM=-J9<@>.PMEK"2FY'H78
M.V7"0![)D=OLR$$V?8R-5JU:+ZHCG$BT?T\?Y!<OD<L+M!X UEJN!CEO%7_6
M+WL)M-8QJ)95XG\(+Z7DSWXIQ")I8I,;BQ,+&3N 78<M&X)5ON=Y8X4.:X2,
MK9?Q))YZ&?][($-H,=&2"OXG)9]XE0D[;TG.-M?\$^^ 4$DD;)U2"DZF72U,
M'33EB";P47YF:V1=%A]07NF7PA:([%3NM&FS."'(@R=PR'1>W36@^G9LJ274
MCYGT&PS1ED U)<K)26LVIY&1B_'+$"VBXD_ /UGVY7:M"PHA(?XQL5&\51T8
MF["L"M+,,DL5ODE6YIHLD,C@"9%UB(5[V*O8YQ63('Q38IUNLW'@#,":<+3R
M-_F9=4N$\6PI&-ZJ/UDHMS*'NN&M+@NJ<>^O)!T=!I1^5*PGK]<5Q*3J^^^M
M%UPF*5%'Y$4_7!?CB4OV*QN.V!HO6KXIFXGKWITY%FU?#0(GTW=D]O6KNFX+
ME9//ES7&?\HRL/#[-86S#7D6/#P@J.91\KGO% 3,*3MK.2<KU%_R"!$_P$WE
M+S8!(N;?,]XDQ&A%KR-[UY\FFI;.;CF[&%]?:0)I!;.#M:74?:M=^;S7B^:Z
M7'D.<&;T#3<GM[:L[C#K&R4? I"0<4:0@R@I@0)]U*+9<16>R..WVPFW;;(-
M4CZ(B8I18H($GAM39@RK#&Z:GW#AG"=N 7M.J%/SCU2?GM\OX[,B><7$88OJ
M+GK242VB"":')T?0E5'!(CQUMXW)8:3.M,?#/6:45M0DBF_>#O>J170V]E/'
M<Q<_[92QBTR(OH32XGIGR%D/?R;3DG*:#Q-N 3W=$334B(_ -DI=V2K'9+ 8
MQAE$<01$\?$91'$&47S(((JFH62X<]"]T-+ ]-WBC.=1;VOHETNLRZY&\,S(
M2YD6LMW61%-_$@[Y/4._'_N&@1%T=%V5^T3!8XC^3A#E"DC'!^&H(%FN9I+*
M(T.)D*'+$P4/@R9.R..Y;C;*SSQY5Z[>+?/5NXQDN/NUU+/Z)"WDGGU*#V0@
MM_4><A=,165TA6&,C?$07(;&7YB9ME\/Y?8=-:.3"[_O.RO"ANA"3GFD#Z\*
M*SMZ8HE"NDQ.8MD<W6_?WK(:9NA YDN0Q;8M;A!H[2DJ("::<@>WH]Y:92EM
MGAQ7L.8#N1!\C"S$#,/,JF_#V*H>CJR&P653H0T"T%(!E3%!NCI_Q7*TZ)"U
M" @E%'7ZN!3^\N]OK<BJTL;?A-"D6+S:YF7P^E^NK L'C%[APHCZ\ O3OR9D
MF+G-B1'-E:K8S( Z4GQ1D]]F]2-R 3.?!''^[.R<?)?6&GF*V[ +5E?'ZEN#
MOBY3[\DF8T^KLF+ 2X1$G*5!*))>3W/!-D#)F,CH^<M5Z[!<FD,VQ&I$S NF
MV-/":/(;"R1;J %K$0QLPOF?;S7N$84C>AHP(Q )V4I*ONV,N)%4Z!FHP55S
MB!V%/46)^@7>AX$I@IN'4$Y?<8HD#;S\V'9-KY(9VM+!*GB/J"U.1TZWCR4N
MBI3DAU]I>GP-/40($<IY(*)RH]JYUZ8P7,LY0C@+$:9%SV0&B2R5*R-Q0H"B
M* R"*12NFIY%4ID))BV7H++#+*Z"$*!WZZAI$-V23Q^Z6W+V$)^I6X9EOGAV
ML?A2QQE-7L^_6/PUPM+?1'@/38PRF5E-37_" C@_7[R]6#BS_P]=>_$R[1_7
M,?IO_WF!>7AVCY;I/[!EA;M/<>ZQ5IGFO4C,2D)R7>AE.U^C(M*&M;(UZMKF
MO'VX\G79U)5>V1DMYJRZ6'RM0LG3N]%77-RY-CB]$O/)A)QKR2R&D[,MESB^
M'3WH *KD"\L9CESJ: P#_D0L&V<=GEC)SFJY86[#J,1\K_0QMBXW@3RZ&%$
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M*)>V64PCW&(L'U-%/ UUXX!'*9N4P/2Z-N*R4&T?$*T('D3OE#.G;HI\0]J
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M)HLV'DA2P2''C#A1V#1&TK:A+EBP'?CM?IM7#"@DK/1BS)T]U*F1X#O*=\2
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MNFF4>FK.=M>\YNGXT/%@4%+&P'7,$CEZ5:0S++%JF#C,L6= WE 3W270'P]
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M_AZ*GP]S]SYSET.H9G%N:2U:X!_1FP>'R?16E72@V5>5@6) 4L(<-;&1'U;
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M-+K/]%A)B65ZO.">.G13AJXW6ITD&*3A/WI!Y 1:>&5ZW'[Z>77]L: P1SB
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M5?EW.\U^B-)V)>N@R6\),FM1F/OS(0OPXAX9_H=IO_^T6]5W6KR8:7.@DX)
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M_^UIAI.BT2S7]+#L+;?CDA,2-/_7ZZ_>4.GWR>*;N2$E@R@B%^6*D'O2+80
M^@:@-%>$1E 7['(OVQIG$:H292\)W_B5$ESY*/T#/^9;&5^BDVCNC:*Y&&0J
M?78WIY:33# :&'M)%N7UICRQ(0G7T2+UO>4A9B^[E1B^J?-55I[FW,5V6-+^
MM[V+8JU65W9Z4D2,8/ZT5)E"GH:R71<UQ]%A?]4])1!0(J*<Q_13 37GZENF
MXB[D)I?T9W!UELNK'4.M^,YR,-Y0V7JS-^*V/!-?WCEWW"*]85T:E+54.);7
M&&?SCEEFTB9]PV6JBN%3L?(-K.,:T#E861[Y;+7)6KWG\J2E7<PG)53LX$)^
MUZGQBK=E)GVW6%/D1_X>]W1/^DG_0=6RI"B<.B@09NCO=%"FK_Q/>B8"*SO:
M)SEY\_SMKJ-1*,RTG#]]]NCB\:/SQ^HXJ?65[=[/GVML"0Y;NFRWN,S@O'D>
M;X5'6)0URI9M7[G]1<ONJEQADAUL-D8(P:FW @PGT@T?).BB\S]_]EF*+AI_
M[_'C8 V6FY+>,&X (LAJY1'@-7&;/-6W' H)SX4,W#3RZ?&H')H?%?<:1$9>
MVRR*K(GL:R,"P $*6\>J=91S''0) ."]4K0T=Z>+!AW7^-+'2\X!OHT:*2I[
MS*\?$!JK_H$^CR*EY9'J$*)UX<U;^%FP-HF=IM%/WP!7._ *HMI2E=HQ@ Q_
M:2.(6_;HY/=VGMIDN?P4;;HX@!RVYE:=_BM?R73.W'T4:2$"Q\[4"K!'U3."
MP3\3.R=?6G=>DI9/W<>0EH^)NH\E^,F#A4M(C2!$TA-#U/+"25W57+J9??GP
MV@<_YDN!@.1:.E?HL5BS]HZEZW5>G:BKEVI$VCQR]<H\+SE-()N-JFS.8O4G
M(J%X5-^'%)<.#'!<4%79D4#=H#V^3#.Y,J+SX'V&,=J'K]'@\,2X&@LA%ZI8
M'4.4P\>GV/+%5;5!48)LA.L!J7[C5A2*,V-P:NDJ]P@]*0.M]$E$B5C:;X]Y
M6G7YN)59(N4P'JCK2KP<?O]OYT^>??9\<2&/HNWT*V:BA;5QE]=6.,#=2W9Y
M[78P*Z[G_=_.[;+AJ5 C=DWTJ^I"6D^&JZZJSO#TO)A1HT-SV8$7C60Q_,D:
M6[0!D0HIZLE/^"GUYUW/??234^=YJTH/&7J_P_=17K+_XO%)[*5[YA->IJS>
MH[ >;I+ !CD',"D7YE#GLP0482$0V8OOWW''C,[;F&E!'5CSF[7YP=TTQ)-
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MP30C 3C0F:G7^UY. GSA^?/G3Q^5CQ\]>VS!(R#.X@=<U"OG"XS[45-S#Q]
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MEFA;S4[R[56+Z$U..9EOBEIK#D8Y8<+S^!B6=$@G:T47J/O*V@!RB0304JB
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M:^!NA/8V1%WGS_\O2\9.]+.(YZA]R/ QHL"Q(L%84!UPX[I2/EG72QO"XUX
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M(FE++27OKJ7.?O$H00,\-EW2F)$!8."6L%=4^B#UA-A?2C.N)JEG-J4^1\=
M2B<8BUE_@5M::>%Q/2<LH8<%\A$7",_L(FSQJP9G15^NPY$ <?7)/:SV/7=%
MU.4Z=#Y$GVH=5M5M\"OP1\H3<I&/<QNZ"BHU/'9L4=_UV99"8;2K<XMP])78
MIU:@WAT8_8?%\^%0QIUD?94I(V9PHV[+C#-*^(%M57+7.YF;:SK]M[S]H^\^
MM"V3=DSG\1(7A$^:[:Z1PB<]D#9Z3KK\T3(":TN+OW!G&;LU8C)/WS-\C9W)
MCI6X7@1]VI14+F<FA0'VVBOXD/_%KE>K,1+-9B&[L/ ^'+MT(%:9VN[>J?/2
MU]X[H&.@+DGS1\)!2!W1KW%3RBA3,%TH9*A0TN1+9?YCL@#Z%R=3^9[I^91Z
M'(;OW20()\9+>?H%EUBM-&H6!R>I0D0N@=-?%/]$5OXM'?,_DD;2:PW$7C8K
MJ7X)'#$6R([)TI_S(G4[C$3$=&=_D )"?.AO@,T_KGSP[ ]_F;(K%AJGQ"&T
M($#PLUYX(2GQ?=07ZOH\(0[T/Y,Z\(%%ED\L)OL^BN35VE/2G9 ^H<;]NG8C
M[51$SR";E ?1]WKD\0+_ER_C\^><<5.Q^ @D"F]WU=[Z^%023G65U]@F7)%,
M;X.!SRQ9.F_8,'LC 2JJ#'7PF%BH*MB7O>/2' M6[>9)@#6#,4-7!+#T)-%'
M".JIPK\X?_G$X9^N*B;KD&3,1_8D9E/$L[,J[;A1^[1<!6<@C,!FG[F<DD&;
M\#V%&8TH]%&ETQ3/3Z\ISQINRPYN/0B5@J:_./QI61>/]E,8;B"W0=G,9QAD
M@S?[XN,,W+/W'+C%:<UC= 8DCUUP0;7=ULC S6XGFXR8F3;O0=MLE(6?$Z5Z
M599!;*@LR%1BG)>N!E8WL#52A'.^A/=B>XC)/M3T86')O0OP^N1\00]3?^!Q
MF!^108PL/1MA^& D2HBQ/"]7-&(@=(8W5OUVW5)6W#,M*^N1$12%H_,CS<EQ
M9U$J3DI)\ T>FLL.$6O)EJBKUE4'!(RT@\R<J'/HQ?\^_N0/=@R^E%/S=?>3
MG9??X[A\V^;?^JFZ1$]),\QY<NO@1497[C,@0<A84+^CM#>N:PHLE!8[V'2<
MXR 4=;TNY )8UGL.(J'X5:.5TZO]'_;>O+EM+,D7_2J(FKHS<CR(Q46K?:<C
M:$FVU65+NJ)</?U>O#] $I30!@$V%LFL3W]S.PM @")EV0)=[(BN*I'$P5GR
MY)Z_#"*%1K_$-.)^\L%4O4:*%,122@TJ&KOM_2QCARL5@9F$XT0:TT><X?A8
M4H8=2=[(Z+&)&KVQ@LC/E>]'8:?+R:DJ\-'FSD+6T][>)N3M?>M6G$B&G7^9
M#/*ARK?SK]FE@&5$[^)DR2;MES>I>)A!*<_-#CN68WI%9XQ'$/\>9\./\E3[
MG3APR%7%)AFND+F7F-GKP%G!-GHLS+5PSYSGHC\QHF%3STEQ 7W]6<[A\!E3
M]"KF:"[B9:*GFEJS6YS10=7U^?%2O"O>,B8. 6!+I2@>-B:?$=PC$X,=82;D
MZL5(M.4M>#P@7:Y!(6/#^+RY;TK%\':(7$\9]HTGNS#7RI#Y6A,MQ7RP2M^?
MI?9S6(F(SL-(N@TH1R'%^!ZQQ>WK26X@A8.'"OZ,YY3!@8<%==[R*Q-8=J64
MY0 &@IZE#E;$$-HS9W10YRY*W83I8FU+<95Q=!M3_9 00/%MO"SUDAQ6%V)Y
MI:['%$>6/UZ>%EF1)EFO C[]QE['H7\YL3QCY=NXW_[)A9E9^QEJ>1F8C?:&
M+.54WRF]6?)8TY4YYE%Y'I?/D =32-Q1_2 E=X<ZP[LH,7E([4[Y(1NPBK=V
MOX-MD"K3=Q9$-)NG!"'"*['=/!QJT@8 93%)-4=EO,A5\,"+82WCM=,Y$O@C
M$\<JA[HKL]DH+!;Y_M@?/YIZ74S DE/[(6=T35ST)B;>O=*!=3$AP:_+N3+M
M(V);F2-96V..V>[Y%>R?1[CO-DG=)*D?U2>IKU$[=ZAKY[:9[0V82Z,RVW^Z
M:LIN;3'EU?7EU=GUS?G9.M6T+Y@]X'\%!LL.=6+-TA0N'I$S$QANM]OM.?U[
M/PK&V._#^>@Y5Z$W]YS_Z+:/7/SS[W$8>JYSTG>.N^W>(6H=[*U"/WPJI55?
M"0$?-/N."S?;2?^=4]H!-@A&LX7>[< FC"0W%"RB4+H.>^2R"Q)N.?>)6K]T
MV]W#$LJ.P&-/O!%FQ0:R$A5;HJ <O0V5*0%<0+E;E>6Q&LO#"K2?E<![M03^
M\>Q]_Z,#9'YR=G9Z?O%^ ^@<VZ<D[/N5D\>PK,/Q< ' TEI'#:;.@QF#01U4
M_-CG"CMR+Y%:C<ESY4$L,!U= *@HUV[\$#W:\$%"6F392JRX,CA<A4.W(EGW
M?EZRWJLEZT_G%V?.H/_N[.:?SNGYX.3CY>#S]5I,O+PA+X: D%DI3_7SWVJ^
M?SLX?@[-=^]@J_EN-=_GT'Q__+VHYI=7_>L;YHKGYT^6(L<_KQ39KY<B_>O?
MSVZ<=Y?7SO79^_/!S77_XD8@_@:$LW-YX9S]G\_G-_]TX1<?^S<$PG-Y\ON'
MRX^G9]?.I_[-S=GUP.E?G#KG@\%G^.CJ\_7)A_[@;.!<OI-G'4%K:9B54;UO
MG[@EYGG)&_:!4:8:-/UZ(ZG0#1+AP[06&2)L)X%$('+7A9>.O7\[)]X,@]Z.
MK-QDYJ7SZ3 .56+>^^OSEDHLZ5/.']LVG3T7[9M]UP[[[\/?O?VCNA;'=W[(
M8+)%6ZM71/2B7J8(W48G$,76:#-*6L%<!NGL:<"HUX$T_N%*4#7-V1!PI@X;
M8\#G*>+>CA &'4]%NL_"7A*^*U$GF+?1&G39$+UOX/L.)D$[Y^?GKJ2%=EN-
M2P*UCV?N7#X@$M!=,"."%GSSMQHL7;XG:BT!"5Q+!?[ ZGGTB5OIO5SIC$D4
M*Y><LV+-2"Q4I,)T-[+I#LLVUJDY:<A=N_9167$&7LB<Y'.44/Z6C\S$7,0&
MKVLE0VKSF.!5#M*$X9@GBM%9C/$M8X B0Y3,^OYD$H1<]*">74= -^;<&M);
M>>GAG 98?0&;?H4%:?,&S;?6AZ83*+&!-0%K8 ZV%W 6)?46M9*[>7FZ*GBQ
MQ;I!W<5XK#1IYY%YX/G2<24]'%BLG_H,!LU]8I_LS\68Y<]JLAS4FBS_WTNI
M!C72Y&QP=OW'V6GKQTCQZDG\_S\8B'9__^>EO,,EQO)%__T9(L]J"QD]KY\'
M@W.PDM$"AA]\_.?@G"S?=^<7_8N3\_Y',*,O3L'VE=\ P7S^>$,_P<A;'[]H
MIMMVS3*+FP(PBN1]Z+ZKD1?.TT#WX*V( "@XEL6",C#[*.9 ';^I4N:6R^MT
MJ:,9CM"E3;]C!7P%;-O'%#C8.:H&1_45:V??[7:D1A(LKRC"+KN<.])R!MBA
MO (0L=0I($CKUXHE/!FR?$SB"5.? XWJL<+[[&([^VVT1,Q;%(E#:!FH>!=S
MJ%26<:D(F!<ONX,8C3J+'QY _-+=,(Z_<.<FO6^,*,G@H:J\E!"[%%QZX*<%
M='T&6 79-_&D&XS5;9AJWN0+:SM$'*:24HK)2!EB'XG]I\L$"93M'3^NC!6<
MC4)N\J@].59476 _S&N=#?E.%OA1%CC0"U3#5)Z[])#AALN*&CGD-0ZH-[Q5
M*DD)K804+C]4!:",N9I0IE5@\.N7;+JAJKH:G%5Y\]&3>/,+\5U,#;\/_(<F
MZY.4BRTQ64\7:P)[1 8R#.(95N1Y(S]G1"N%668!LE+G%@01P"MH$O0$:1<T
M33]!YA7\R;<_BJ6Y$S(Y;Z81;#+8"[A N *L (91?3*7RL7?XWDJV%E(B(@V
MX6NPA92*#<6R!T83>ECH$R=SK(0;)C&L@:<%%RN69^%%<3*F3C+H7;R-L<8U
ME7XG6"<1C7/@1',:VD='@IV%:"U"(>QPQQLS?T[)#K!P4N#^0TH=MP"9G33'
MVT=('GCK*-%9C="$$G"5L$^UG+"0<8Y-,] C.2:TB/?7Y[OM@V['E>*2.*%*
MX;M@2,A6V +AXO<;!QLAP3ZK7]./"8% GD#)(*T(B(%Y?WI8@HRMI#PGG4>P
M>7"$SG7_>G?H"[3:+9ZQJKG'L/UMC$V07(T=3%[8>]/[IMARD4I1X"R1N.G\
M5/+^#,@B\-) *E]&8,>*8_C4'_G3(9!"KT.^X3VWD(7NWWMASM0I/6(Z+O '
M<]B>V2*UE3B+?(9TLM^%4_"_,+8@8P!I8M/[INIG"A,F) ]?$[H3YJRI,!DJ
M+,SSJW>XF6$P\7=5C@1WY(MO,7F>^JNH(>1II2C0B Q.1 D1:=G#O==VV[A2
M/YZ%?N5^NWR)>:WR\PCHDSM5@5)$-8*5CXK2@F D4X8?@8G <O1D>@Y0?4C.
M.Y[ ;1@/493!7MX%H2\>?,(PUS&#["$V%&)N<^4.T_II<X L7)AW0(J:J3\H
ML2JY\RP#A1BX3PR(A7O$R4;2 NY_9[V9#/O*X>SB78*1]&7A%M.;Q3QQ&(Q8
MMN.-[[C\E< L9J U!=. 5 H"O"!V0Z@4*/6)BU$U"[W0W&K"T/02$/?ZEZR>
M(A';UU058\9#K.^&F6N:98:*A1X@ED.?ZW,5<V1.89B$ LB9<T\I*F^6*Z'J
MDF6G0'M^$!QO>H8O'HZ#YYS/+%D1,?%?#4Y<YU-_\,%U^A]/76?P\0S^'KC.
MYQ,+(=\N2J%3QKYSC+G"N"#2V$Q?ZN++B=,)7'ZB5%7:,L+IE+LJ]XL[S;P[
M[1,IC> X$VGQ<@XVE=U\#LER.1>@"\$.'4(>0H@384@6WT4\UP1^%D\Q%@-B
M.\Z'H;\[!*X/?W%3-XYZ.U?H>72Z'BH#4XRA85I%/D:1JOL\/7!7 *[B]:,$
M#*6I])W4S!(89:_EO/5$:Z"*AFTZ3*V+[["]12O?9K:LD=GR,DJA2MX%0?<O
MMG:YOE][D6?XC#8AQ:9$_9KR.T7+9OQ<HS(PP"5F)2,'@FW#"'RY;C-6Z<=:
M"R.L&"IB) V?(LU:F22_]TW?F+6B7/P.DA/XH//IPW6?91&\0\&;U3$_Q5,?
MU\J0'Q>U&7DAF!N1,_!GF;#'O<I5D&:"FK&:]8?KLY/J:3[#+/MHZ0#S0[QQ
M9"<:D(D:6."<*'VVN+71XM;J<2+:UB>T8=X0- Y!4RN:0PZZ6B8Q:*)LW6BW
M%)W!4;O'%D4!,2<$K=+CMG7[[?;_0W9V#,Q&64OP%+=Y) ML"@K4"+NWLMFC
M,"_8MJ2!V!!SP-CV0];2Q"XB1'G+%JNQ,G"6E91293F+4C_-N;4R Q+[&OCI
M(4Z^('6!HD4-$/-9+ED$ ]*DZ ->G8S,N%*(=T_5S:'!Y\<&BZCPW?E>F-V!
M^AY@Q!3;X%(7;')<_2L.E(<T_8(0AL.<3D>!?WGA-(:-0!4,.S+>>I$4.^-0
MRM89QN.Y= #4/EP<8XC^ODSI[O$$^R%BTSX?_6,$ <[W#:OGR%J$7P>WN8#@
M>T&D\'H)<A5L".KXBR"]M+MC]#AJI9).%;>/$G\^\L:)T@\&\ -:"9T#MJ+(
M;=]Y TQ$C# UR!(S#-1VH#'GJ#A"9Y41RBZ++\$X\N>PGMD=AK0Q.3[2FTG[
MK3P[<.G ^$PS<7_#3T@#S^9DA MH)+QR@J8H(<9P?V#O-D*[BPZ%>UQ&,1IR
M#"<A1(1'C?B4U"0+U3<!MF5R".G%P"$T?C8>Z9T?SG23^0"=XT"HANBE'S2V
MB@;#,P$F0OX,I-082UN5U3Q.\EOM7V9[QH+Z-.V';!)'(2!&*#]N67_**-6K
M4^<P0UR=_;9"TZ'L,6!GUC6=R9+1TH@1/DT5M3H#TX0;;0NR-1AY_L%7#5<7
M3 9D!F0RL#CLL..E,Q0ASJ((3XY]>.20_GA&O,5$DR<!]82GUY;]_J01U TN
MPO\?TF)>]7(K3-,RS@C_@-@BWV,X<'@WNU@F><*!:^9VBJ?1IG(%,%,0 ][1
MJ@3H)*#8.1U#\],9) GHU*RR$9F=ZP:??2Z^X9S* 2B2S5C&<H4@<M[YPR1'
M6=[IJ-31A6ZNML?)/( _=BJ6K3@BV>RWQ%4Q4R,D"-,[]"7"-("^=\F91<FD
M&?L9"M]V6?$P)=YI/F1$MRR<KSLE=G0[9!:1T)>7= Y;SCL=*&4GB=)BV31
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M_*42--QZ1O&.&$I*G0Y[?A"P 2X"Q2JX)X31UO89%=@UJFDP?<( AZY.UY8
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ML(OC8J.Y5+IH'%J#5S:.8X2J6\D[H38CBYVG82S571I!82?8$&8X=SQ\0\>
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M-F")$TRG_ABC(>$<IX#CQ"KV0L "!7.0]Q3?MJ"(@U9_^,A-J_-0[C_U0C4
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MX\:4X8MHKW>ZZ+"07:>!78VRK$J^%JK!4DDZ,LV3CES&YOZFK9*)*C&5 #?
M&$_HS5+_M?H/+&^?A=[\=1#1PNFA-\7AD0\CKB["&,KEI'O*7QL6W6HSF\X2
M^/]8O5F^;L%7ORU^OM=I=8\/*[]JMSIK?MX[VEOKB;I)';0.]HX:-J>]P];^
MT?*-^HTVGC<?SA=)Y[]_Z?UB!#!IJ*^[LZ].I\AK46DM'S&?[G-?N:.56-$%
M&#.:]K/Q8RMJXWID9]9;. N9)BV]?_M77?F5*-"%Y3]"TXOA:_3R@98E_([8
MX2S#QI3!V%%+6/,FP"#?;4=J,=QJT%?*I;#I"L12NTDK4M&W;?)3!_^QDUN;
MSB1-HD&DM!S*%7-=DI'S >;SI^M<W;5.6T\BG=*ZUSZ=Q_>MFC.]V,[M[S=T
MG^KIZ_E#B*MMU57BIYB&FKE+*_=/127^WG'/QYEL]3)VKG2%[<("7I5,VF^1
M49O".S[ZV'3*^=T/P_E+BIO-X1E[1PW=I^;QC!H8CPW@#6;.U._19',])ZO8
M,#7CCV 61,[O^=1#\!8ORY-[?QQL]8TUMO!@\_2-%V,; VJ3APV/%OC&7T$P
M]\,AMKOJPR*^Y8K]Y<3S0;NA^]0HZN(K]@GX]ZA"+EOWJQ1 [7"H^X48UT_S
M_ ]E7B^A8-6X?N-H]VPZ"^.Y[VM+,74J=*D7NK:->?Z'ZI(O91Z<>O?!V!G\
MZ7_QD^_4FV*_U5TEO+Z8$H*NQ=UNZV@Q/(;IQIP%L--YM=.ML@2:H]<U3#CO
M=[;Z[PKW0C@C>MJ\(%&)X&\1L.TOI0,S@WCK?2GI)LU1ZAIVOPZ>=K_^8LKO
M@H_ZAWMO7LPAAV.&GO-'RQD$TUF*A22?6H/1ILK>G=Y6_*XC?GM;\?NCV$-#
M+;;ES9]C/\1T^SBZ]:/-Y G?Q!#^<OK"_O%67_@6AO ;I516Y' 6*D8Z.OM9
M58QTOD.=Q&IK@3OR72[V*F\OUM$<M0YH%SY139HR<@ATA1!9"**S/DNVN3O<
M;?8.8VVO'Z6<R[S1&]UK]D9',;=G%X FW8O6N<7:;8857V'_7SYS?NUTQ1>L
M$5O3([TL=>[[;FHU3;L$.@8/WS.,+=84Z,PKJS5*=?(5(9!.-1'BP^0T0D@]
M(+;^+ E"+#[HM6#!0'N[$Y3*\*;WU^?.I0$_"B+X5?N8 >?T7):]>82.*H8]
M4#"_B_T%9!J, 8R *?"R JH!(?8%!2!XI0FFKG.:M/B<"/TVB/,TG*OI*<0'
M?&=:?"G\\=Z?_N%]=?H#[O@,:]O'5^$:7>?L/OYS/G7>!G#$M\$HA0F-6J[Z
M96>/?]DY8DP+Q$.#>:DWIX4W+[SX4QXB1 ,6]<+XB&K@S7S8O1'V:$"DO'OJ
M%0 T$")^6.H#+=XQ!*%_#[KXC/9@"(_ZH[L()SA7?1Q<V4U8Q%'+VAN"Y<86
M6C1FBB@>B*'E1X3*IW;3(0QTP1)2F(K%]P"#S],LF<M[.L?'A?=0&P#<>CPP
M*D>[3;PQ 4X(C@2,.@QX+-K,M_'#.(8/3^(P]&\9%P(?IDM'$,P(P\8/$%QU
M,$KBP@@XR<\1O#5)I:?$"=Y+;QSK4.9@=!?'8<OYAX$4TW/6>&MX=$"Z2-1%
MRE?0B_IJ)(_>.6IM]#4#B8K?6%!ZRS?UWSEPJ EN_ETP11(C<JJ]P8VHOUV3
MMU:E%KX$3ZU@J77]I9C424L*X]3"5/T$Y$T )@4F.L#S1<0%@3#OMITY7&&Z
M^A8EA#Y7P,M]YT8 A!,&5Q_+X_VQ=1D]H/HT=8 Z?"<EB')$*+=HB% 8=U%S
M0&Q46!FS&T:+=(AN5?OZ13BREO,.;](G;XYKZ#CX:5B_8A>A2ZW-(_3"FLV#
M!__ 5I61O .8Y@$SSVZG<IR84%]"N4CF>BE[BUAW& \+^7C7IF% !C<W"RYB
M[-;!3!ON#G+<7?1RX@Z,L1(.\=GN_2CWN06I%R+0YIV73+T1\6)"I"*>VF($
M,M:2\X1!;!"X9N0!0Y/-0&HBWCI@GOH'<A(CHV.U-3"IT@KK-LYP93RQ!2*Q
M:(,0,N'][\+X 1Z\3+*[>(:<#RCD/(F_Q,!,[87!QQ\_GK#D>N]''O YF!3K
MH21\/Z4MOJ# +6_A:IK%$BN*- @F4=?O5Y_>PX!7P%[O@I#/DZ!V(NFP XM%
M8M6C_A>0)79 T/T$*H]'(,#@&L&C_^E-9V_Z",$;W-+M(24DGW%+.;QQ+-T0
M.J+ ;*V&220@@ %8+4JX68W\48GJ/XF!ZKR4_Z#F/58.J!?.TX [ZA$D%B+#
M1B#^"1_4G)1ND&GO+,VWJ"V\5=K"J:TM_ .D0X:2\Z:@*"C2+K.,&K7 T_14
M)%?F;7_W(BY#Q1)4:Y)&G,/1O_5&\ A?P &S($NHO\UA*(1'.AO%:..,-.^A
M'JI \IK]6(FS), _^G=P+K8,IS9-*/1@:2!#80(G5WUG!S&EB1<@@E.>OE+2
ME "=<%I7?A2E\_ >[H6WB<)QI63:'SW5&IODI:93O7/.2^H2=:K$8K+J-]A<
M;I6A1#?%2.NQW(."J-83LW7(&EM,[,4*PRTU:_'&]T$: [N@ 5C]-]1JO;!:
MC:[=&V6&'8MQ=<@,ES_M=O%3>^-*KRT>@H<-Z1$UF_D5&0)P;B#YO"'*.9P^
M?'Z.QH5O0PD)"&')H$"U/$Z J[C. .CK-/!OX])9=O;):L7_<,MSLPYX$$R)
M.[K.Y]]=PK6?JE>G\21[\!+=E*]D:7L$OFVP!-2I::.4S->_YR'Q\6ZY473]
M=BTU5O\(QD#/V'X=!2CUQ6'E ?DZ8B0C&U^T/H\7SB<>"DCS,M-P"]6S!*JG
M4PIB;9N=;$%WG@2Z\T($O."U^=V+9L!<#*]%M7:,3);]?8B>;<'AHVX+*N@T
M0%^)ZTS!K$!@_T0[E$AM-.XB_9[S"!3X+&?9J'Q"9^.<VZ Y9%R #&!'FY[#
M@B?*?KT]./PZ*KY#U&,9:A,UT?I"D[^&^ODTWU&I=.)Y/.Q:TF(S"Y#PI8<T
M%"^07^C73(2HM9_?YFG&FA7KC&5U"H^;%D? XLJ0+WAX%OV=0.]_C]%&]F!_
M\R06]]1Z%JHR1',&'>7VCA]\X[@V^[%:Y(/=P/ET&'@%RYFF53Z8#E]V;[G'
MKM)W2W9^T6\D[EQRXWJT@U5>]Q'0%?V\[-BW@AOL(<$1EBQS@/L[14UU<9T3
M=NMA_ "C%045NF/M7YE>0 L^F4?>+,U3'H,.!H8@+7P Q@=;$NC-LTBGX/ZO
M\N!KKGF*38<SU>U&J>?XWD^C3\3X+;'0J-:XZQ2Q_#B<]]79.W5M_0%%%H_S
M4IK)@MVV6J3R$Y"<FOYB^$TX5L'_>H+=RD<9AMSXOCH?XG!,;GJ"]$>T^ 5F
M!59::]""&7MCZ8^ P.'L?587&/8>&Y$-U;B+_F/A8P3PGMUAFX>'&*[\R!O[
M-3Q&7E%P]YLP$>T3.R+9$SI4SC>;CVA+T86/L<DH9LR[3NC?TMSR*/69^;#A
MQ_M>VME_Q62R?? 3T),6'9 X7<U=#BHCPY>Z[:L='_L &VHYQ94X4@(*3_C*
M=")#'VLA4,!#:Y>CC.PZ5:7ZK-TM%NLK]S?QY!.U'1G[ H#MU3!3*_A[4-JL
MDIRZDS6R(R85S #=4)RBK1_Q@&^4-$&)83GBM4/D2/>)0D^,U90<FP3@/*<Q
M+#A%)ZWE5H&S,?B",.O'+DV]&P F.O 0ZW ,>YY$=]X4K]9P#L=RDB?^)R]#
MM9G6%P7 $3)RBDOJ063!'Q8]1^JJH[")L:,>' 3<3D7O=&]6<5&<@?"(\2BQ
MQ4&%V-L3\JK8O/,05 0@%5:]0$#BK*^\S$L\"9KP6)?P,I%W2T:[CH-[5-(&
MYL;2J*6=7RE(/DJ *;'4A#OK/?#EBF'DK#[N;;FISE%W,^'TOZ,LIL=.\R^%
MYS@VCH]_]!X*(7+JJF#/7-MBE:'MA<,6;D#APTB:/53E8M3J5<-B=L2C<?(X
M6A8;7ZFI;G,MLHJRIP;8/M7RFE5&"2JA/Q1NP7&)R??X4V84NCL+F3K3::'U
M*8A9:LLAX;1X,O$3B4DOM.^,+:;7Z;H29H9!L,VE=XNHK=YL%@?<NI$Z@@L=
M$KM9S"&"WW#\6A/_:O;'TBT@14:F)\H,':PQ=ZH,L-*+C5&((<.WEF)S8CRS
MXJNU%8DECMN2I5JY&^SSX([DRU)@^+L33D@H903TPU$\!!;[,1NWG)TH?G"^
MP#\B'+Z?C+(\R=-7+C97Q$97/H=N@05R.QJCX>!(I_WS:TM90(6%&G18;^#S
MCY,ON #@SG=PXN60.+57ZXC=9QM>>/X+L7QK50,,;/K"L/".::U$V%K!)M9?
M @/.*%Y 3!8CY*Y%!J$_5EFYZCVFR3E.(+('Y2 IW0@*B.=X7]!1SQES8WL8
M?X(0QB3L9\&,2B0<CLZ&,&AR#Z>M.B'MG%P,7F%3GW$^RD2@JXG!?;C=I?X,
M*:\?[B4V,(LXHX7Z5.*I*/HIZ6^2OZ&T+^[)F= 9T.GHN_;'' 1J"G]W#O?>
M&(+0T_#R"&0\ABGXAWJ2HD"#>(*/D9>HA9N3I?Y :3K)X6<IINR#!J7VUZ.N
M43"[]"Z8X4G^W4->2Z/3.UFXG\#$QQY]_#;Q_@S"@MJ*S>7-F5K\9(&>0%7Y
MXG- /.9F1&C7%W:B?_KA5!^&Y-)TCH_;6C4$/7'/?I\A>%! @3.R'GP2MZR+
M17X)DVB"H;YHA V[<"K8GPX^#89!B'H"+'>JI@G\P@N9PO 3G:3HUEHCE1F=
M>.GAL"3KSU(ER*<%Y.=,R2\AWA"]-DL/,:UO35-=HS#@;L9 S#%<BYA2-:8!
MZ%H4""3-:#Y#W_T,#F(:>-I0(^;+<B'$A=_'X;W=7EOO ^[8!!F?-4])>^#&
MD;1-N'7^UY'TCOJUTVJ#9L.Y+MCGQ.;_2A$< TG<@EIZDD]!+<-6DY),,90D
M#+T%1F,TB1<L'JA_=:)3-:J4/UHQG!RU<7/$[Q);EE5_#$IHD%K)&Q:IJ@'U
M7-[EH)A9"J4:QEYA1=Y+M5;_%F9]AT1L)[M(&A285F%VARE):%(0"1"OQMR@
M>;4.:Q..G>K)PCU=4[K7Y'BJ+LQ_[13/[U\P^)RZ:J7F0\E'*7?>1.GH@RJ$
M,M?5_NIA'H0J$_C:SM$^-4SO-TM/L#ZFU$]?LN>J32G.]ISBBRR&AAT0/;[>
M$Q!"*J<,J)OWNK3>)3[C_AB/P$>=L>C5@5'\77[E0E*Y3BUPG7><!_W;DE><
M1U%\SZT4/W&DSD]M+[]1_DG\X_TUE3)]X$377Y4);NFS/$#! 7VD\BZZI&6H
MV HYYI,8N"-UVOZ$3BC8%%BQC+H33_U;;[?'4AV%P.XH =4'-2$OBJGY>C *
M0>5,<FQU'B+7G&/2&?;L+:9ASIV=BW\.SEY_NKEX^TJT_#MJ786C8#-!VU-V
M5#BT!X][?=^B*B3-8&TME\N$%"$%?VK;2&D#.@'T0SX-$D^4)7SL(YS G_*!
MI9K0%M&&ES?%M2=F*,D<<$EW >9ZD\QO;PO.$EAA6UQD7:-K3+P1*A(DW"[B
MY,$SG<[[*!C>@QHS,Y(]0F9)6TUM)N&-HR3@G"=U;DK/$!,2BRI0.*#,Q=>_
M^W2"?2<Q@Y/>X)8W_8\K4A#.K]CK ^KA) :I;+>()W\@]KS,%@R&'7+^2+OO
M]Z'W-1Y,X4+_CFSHE5DVL&B=Q&@?A]94[:/>IK\L27_I;M-?MNDO&YS^P@+)
MWQ6CE5*9R5!O.6<>;"%7DJ#44(4%)7XE5O,5LWU3$(%,;('UL[OUW(1>KU 6
M>E/RYK_M#]XIEEW@8_TA;M-O\*_[P']5$%,@&)-,G-8SSJVDW$*[,L"NT;.2
M%N"-_22[PSS"EO,QR++0V PW1D=6&D,<V2QXEN!.2:"+7E+0K'];"+K9K\5&
M3O\(PB^<RDHBIKC@\[>?BLO4SGG;'E(V%%I9$1"3SPY(E.DZ"4D[_7=(KWM;
MF"3\M7O%;A%[Q9-XA&GL)#7_@=9+0'.PO//:B83'&<(62([N"L::2;/RP<0!
M&:U_*!8:[,\%]K-Z\'&HJ& 75IE0O$-%X[N<&5&="O%$CWWS39TZZ*1MMM0W
M6V$#*5.I?G(P2_*1;X<+ZTN+K>#=(9Y3,?6'"Y/D](S[9XEE\__Z=Y%7BH9C
MY N8^-S1R0 5.4Y\<],9T#(VB],7]"1$'9#\#9134)XD&DJ5DZ0\_Y+U1+JL
M[5R\1C?)0+EI*7U;U-.4-.OX/D#'F7'D8I16^*T5*A"?28J7MVIY),CL64KN
M0+V'YW1^7SQ!8".J&S4>35O<G'H;#NW\I?*FH(0<_''EZMP")2>-8F_;X!YE
M@H!)!B\UNX&#:+]GZ)-H-1 -RVQ]"[_!9;O3FXJACSYD^NQ?F']B1"0[$_PL
M( )#$S"4\C;XM9ZTG,N\Y%NEZC.D/=FD0H3:WJ;#Q6UB.5@RY42[D%((#-+W
M)Q,OX/"_VBK7E&18X75XG?WZQ1>67E7QCK//]FNLDKYTAD^ (<D9>2I^HYS8
MI.1S >$LE%+#I7YL5QN*<%G)_TWVI2J.HXJ'LGN^:KYTV4]+9KJ6L*>VY[MP
M=>,017AE,1UMJR7[54G\>[)A,*1/3,*U'D_MYW<^Q!%\)/K$[YC:E,51(;T:
MPTYP)_&[<3R5)(VH0M,A'68<8.'CR&@3Q72#CW$T1H'W^?<*?<&L>7G6@!7C
MM+,'7%/>8O$AU.I6=J_ZR;.Z5QL"L/*.!D6O!(<;@+>L ;'2G/ZJ"3E9H]CA
M%Y@B60RX#?WL >4;"LVQQKU=:*.*_>6E2DU@=5#>8/!\A*E )K://UQX>O/.
MGE4EC.R4&R<VU>:]A(OF 1=4#MG$3]D#B"UT,4M-"A:!RUAY;\25JIX:SD/O
M(54Z"W,: E7*U<VV%(S(5B_O,*@Z1,<J1JU),6'U"U9+3E?\]Q#)D!QD5O:)
M5&4G-%J*22;(P_U$W(X4IN=4.@=WIJC6 HE+?! GF#;"Q'G:@<G6DTPN['^Q
MY?'40]  >&P:WZL]YOO&(D5  U#]'7EY2GM^'YNJ5=E;CL%/O7_%B0@;JO,&
MXY+%.YT#.HFQYH'N/ TBLL$'FUP=H9[:9NR](B6.\5#DH*I[-*;6!;<1W2!,
M]97,\U2).[X6(+]!"U([881>D]+IZ[="WR"87X#T*-$ #'>/0LJ'89I"D^N6
M,K/IRUW4%!V\YJ"#]#.*L:MX_-37<?OB5>;M4E3\0+@5- 1^@WK)#).&'@+F
M(FD^)%T^PY*'74UN6MTP%=D9**OC\MM-:W'K:9@K*BE X*#HN,"^0"C&D2RU
MR-K4-.A1SO&H6>0BS]))#.P@5!L)"A8\DZL4%/P!W&$O(+0COGY!0JJTSQ ,
MBUM]6>Q]GOCZX+QIC&W4[_S2Z7FI;$7Z>@U97 #9ZQTL0 _V6OLO1K>HZW8/
MWKR<NZ6X.ZRKL(L!J>C<:$1PKZR,4E/M2$E=3.ZIXB/++P]K7&Q+4<)S]_#-
M]CA_R'&>ERY<(?."$UCJ')1:>PF29SGS?0H[;,_]QYQ[^>"K$"OYA(N57L]]
MZ@>;H55]9Q.$9;5664 E ZT?1/2]-\(BI!+"DYU=/,[)^A!OE0%=5):$?@BT
M W0@:T0/<_[H !"M06?E>9$>4HWHY:!U)S#LN-):>HAS.%0XW%GHC9:([%0E
MMH+LCMCC#?\%]BCY2UW60UAE09]-D&:DN\24512P$_CQZ32"JM:MSU"2]1R(
M9H:4@^ZM)BQDZ?7X3!H>)5.3MP]U4@J/HN^2S@YCJ!=>.O;^#=)DAOLA2:!(
MR&JIF6T#8GT'NK833(<LFG$>O49#&YH<H(H0 :JJ0+V=K@/$F-VE)F"B<(YD
MRH7D8M?6S@G;;Q+X8TK G4DB,1'I-M=F2:Y-;YMKL\VUV>!<&^/JKV4XA&'I
M%H'O4=*O!= NS&[H%UCA&HRK7^QLH!R%/"P'P& NZ:0@^P-;PHR M6*BLJU6
M,.YFZF=HS(.]#Y.YSH$&.NW^;H]+3FDZ9U]'=Q[8"DY_I/-,*]H +)D5U^=5
M3*?R[2>[G9JWPTX8VY3\&Z14<3AG+M$A4LO;;ZJD#GW5>>,$$U=I//$LB+0?
M5R-;+Y,X+O]00@KCV,< 188@'CYY9JP(!?V0E29"$YWXB6]\*_Y73-9-1:\T
ML_U7/KZE8"$6^'I),B<E.\_$WV+%*0-??*"F/!%D7)R,.:HUY"H^T$ 3<HR9
M5Z#W9I8#S:8\PJ/G[A8B8PK<U3K\BDM$;E[8&E>\2 1J(,EK\'[&BYUY(\+R
M+(;>*MIYN+4Y @E%@*S*8?/0:V>G\PHAC$&JNZ98!ST;D?K+I<=-#H-K"M#1
MG\\.,$7Q^.G$]\U=+2U934;@$/,A['[@,2*>M0N%&X2'P?.6[(DW.,Q.]Q4>
M(&[U!.R$@.P*@[:XUKN_D2S@0M;NOJAQ/!PAX;+B9//6&GY103(NE;5-/$G,
M8;ULY#'*;.C?"[B1BL_@Q7BXHZPW.XY'];&EFQAS_KO:JX>[ /XB_+","SBD
M&*_ *U@$2&D;[UQANY (K&1&O*^,'X(+U?=\G)N+NI1U6LS9=89PX9&OA P[
M J]_S48?F) CVKS"6$(2)@YJ%:<6R'L5ZIYY >4]%K9,%1WH-Z H4+MO?T-U
M,89F]3X\3J?TE7JR&?;=B@$()#DK:DB4A*2L9*)MI;MB9E3Z8RQWC/*Y)GZU
M"66?<?GFDJC()<VEUC;3L<G!V0GQB*GW18I>[XH"6ZW-8^/)<F,83L+BR<HX
MX&T@=D"@I KYJ'!1B3QR25A%B4[TA"R /QL%R2B?IIE'R5\ZF,AO'_MP\\:&
M-\ -M'D#N[#LA13U'TQ'B7S@, 3]_: J>24D,I*]XC B7(?ZE;1HCT<FYEXH
MO[+"+#QM*F3UN":9WF0T11P#N!T7<B):^&P6 @=$W7QEDUL?*U, >Z84=JTF
M#SSS!MVPFM19LS/%2/NDM@E\X_D$*3=&J.BR<IL,%-*<_I(\C(LZ4:U$X2S2
MM<P4^@GJ;&9&6CZH>6%=F"[1DC)G+?^$FH>FH%>XGT[CA@?2@F&D8Z <-PQN
M(Q%GB7Q%,WA +=EBK\.Y':>^+-PKE"G6"]# 4([J= 3;2%="RN&54DT!2MH@
MW&/J$1 C%A_W?%#/"X\"(PC>_Y#@"TC@IUH7L/-$R/D)MS>)9PF*LR;=M=I\
M*WOGF&4DI'IAHJF<'QR4*4I1.T)\112$20YL2X[FK*@*LM_75@ -3S0Y>6S&
M58D\Y._8CR09>SK]T'9*HI08*^B@6O8HTZJ9!RN/^GCO",]-+#EUHO=E&FS\
MV9Z G2LP<K1V61;J%K.8-'#)A'KP01W+*#GDX>&A=9N I1FW8*\LPU L[&95
M+YQ+3XV7PBDT(<'.&VJL(QW*0#.;*N8<";AY::\#]B"8V!*35^*COX K9P3A
MSNESZ(T[V5!"+?D==).4PA&.QXF&F"D_2QA(,#4P[W9_!Z,B],.YOGG20 ,]
MBSEU.I&)-(+.U\4H)I&I]8@FK.!1+FQ9#7B@95_+0A#??2R"7X[O/MS%2'5D
ME16[.%1X7AIQZH]';\N;E$I<47-V$A>H'N@F/P8[# OK)?B$#YC^/130)97[
MC5+59UCJK<0/ V5:*C;:T+:F_H;>(-)-H]04C"NJ^?03XA31R#>S,A(0!D='
M"9I9"WVY8+;)](T@ J *)1#GLY!FX-FI?5;[HB#]8N-%T1+P,Z/0M9P^!7B5
MXXK;+%519+!8$(.H3OZ#TCPQR3!/J=*",SQA$$MS)*H;PZYY(VE2-IEP"EDD
M@#B<0)IBI[&<FE]0>ZQ4 3B,0+%+?,DO6R %U.AD!BH=L#0!VK%U]MM.A.#W
M(;(5YUR.XAE[M^ASHRVY\A699PC<J#NF%09:0H,FFYAC^6GARKJ.P,^2SH;;
MGRX;S.$RD8*6Z@J.7D99!DC%W.01Y ]F0A R'F7W58SL<=7+9K*+"@K69I B
M8N(;OJ_1RXCDK$S(D1^@FSGQ,7ZFG !9XGL:PII=<7 S82,S4K&!,='PFKKL
MQF.&Y#2]QS)U_!#TBHQ3S$UK,34;>&!"I4F!L"<OBJ/YE)#;\N$TH+KL5&FQ
M)C68_(K A)+(GMZ_<]@,#"OAWEC3JIA-*<Q>Q2W(648J?1D^3,U>T!>M^C>Q
M<,N[N\#*J6><D.9:%[J:=5!M:1SJ5!0VV<4(X%ST(+&9W!W1^.V3IL#>;YZ"
M']UJYD@9QN104JX!_-T,K6'.J"&G%#^W35A8DK"PMTU8V"8L;'#"@F$*5D</
MF\5(R\UJ7J94 DN4I<1)B N8Z&*6P!254Z?"XX)\;18#_U(.($O_:KSL+WFD
M:I19>T^-W^,Q=[I6SM;S1]D^?A0NU<D>MI^S*MI4-/$6W&GE48W:QIB$*AV%
M7+J^IV(6N"I[L>0B]OV,;4=+JXQG=[AH:9:T>JAB8:OL.%3&Z&@UH2?<!2O\
M5(%!CE"05-2I"HE=JS1^E$\E_=TVQEHPN-#X>O8 .\\-( V\,1Y+[)IW3/=L
M-]=HXRSM<@6WBNL^$O8J4Q];T<H6>R3.-9" ^EY[C_Z\_!]7*T'68^H"UM-:
MY?TE)QJJW!%5"-KQ-RFM*\Q'G-Q4I4[+G^M"XL(MSIO!"]=%JK&#2=IGUOP
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M'U&"]K&\/@PI;?2$,J6TNY.4.225@Q&V@>P3CU&?7"%%1S9_) &#.QB;,?(
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M"XQDYB.K'\EB(T"X+T*"_B]LNN.+539196Q]4>\\5T6E"K.8N\7O<]B%>E
M@A%&3MQ)8'I73956$1LHKI$DZM"GA9+B33<OY9AJ])CR@<?]YV/Z@&K;QLQ!
M'H9R!\@1A5Z(B7<1U63"5**1";:9*"?I/..UE ,T.U@AQ#$K\9W]'@?B6W:
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MQU:QD!KF !YAPVXQ4:X@%XYC597HPPF%==.BPQMIC2WN$X/&>P);1Y.\+1!
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M:#QP,1(]6]%G:ABYDQ 3[>UI4P?N^;%>J^MH;(OG"*LJ'@:\.!#!I,+XRK^
M KTZ'Q.,@D.U+#_"(QD;[&N>[*+86,S:CS "U[(GZ'\S'>$IA2$R'_<L%KHQ
M_D:C0H-Y+$8E$%'Q,]*7#]*WQ@_&6:2>I$&4F-U@BSJV$!O%4W-!G,?G%_"^
M=R::HT.R1<D4M%VQ1+^!_6L0$*OGUO,W[)B(#O]S,UW45YT';FZ7EIX[E90O
MCUWLY-.).687Q$UR@@SBIE<J;DQYHA-F]D.-P>W ,1%R#'Z),B$^<X!]XL&]
M/QJU5BH;8-M:(Z[1Q6,3G5+2UY-Q3IF#1V)3L1M;ZQ(LVGS!H:]7<$AG&9I
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MKBAFSMLXQLH@HBI.GUJY!#PN>E[P2'H*UF'G3QI5:[8'/',4&E=U%T?X25,
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M&^"-!]]&D-#4Z]_^Y-\;NO3ECD4C8%3>MYP"M ?L#.E.Q8THMRZ-!K%)SP>
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M36%[G.8H^M(=@E'_6K/]ZE(M*KZS@KRT0-:NFY<:1Y^ZFMZ:S8G=_32KW2G
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ML[M;[Q.8"R#%U/T,-)4$QG_?2/+F\5X*']18Q8TE8J>,L#$O.Z79!BMF%-<
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M\']AN=U&X_\ESL8X%N@KOU7CIX.4G=LFF_C@6;H,_D'Q&1X,/SUZ$"<P!'-
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MDO:PUN^DIZR(OCGY E+&\ 8@JF/[3\]!^H5?RK2Y1]I)$Y=SMPBZ,9-''"J
M<QQ&)HRS/!X=AN[R#7A\1J1H$C_K+47KWQ@3[T!L8D&P>+&44'Q-<2_Y61>8
MY<CDBX5C_P+:4$BXVYFE07-'5A(-=^1=ZXZ#)304B.4^K7860G4Y?,J\\3D)
M?3R9%&3E8H>6]'"(!T:F9_AS[0_'?H5G?0;7K*9]N=?.^>\O-+IS9B+5I6N/
M ;=H][X#O@8HJ<C;N"I.Y11%],\Y[_%^=!%/6'(%*U:BX]/X58GUPEPO'T.U
MNZLYZI:>B8L51$$'S_ (<IF$*3<W8?%<J]92C"U-S-L"^3-)2X/-1R^ [JO
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MW2[:LI&D5NR&1$&,=>6PD1L-%2D51JO\]OA.HINLOYP "?,HYONJ.S^9I\D
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M1B2P>7;5J@W;:8SJS24PUUE75C*O*VKZ[@?M.\)\";XC?+[*+N[LBD8RE-=
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M%$R!;?M-3J^^>6]>7P#(+9A68;":C;.K3E%%5R7P[4Z54Y))AP-[-IMP2K-
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M]FS?Y5A;V.SJ:FP_E'DOJFGSJ[%6JY!+ZP(/Z?U -B;[6SADVBM8]7R0C&M
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M5MJYR=PU=W692\QJ-MVQXB"]?G":&O5&JZ4PH<$\HG7R>)'.$QP\0&ZV1&G
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MK07Q9:=3&W32LA*Y4T.JQ<O![;"KB@%9)(7Q6.S%PG8\),22@G=YE17.L(,
M/I/8F)?@$U:Q-$)":R3NP]B_?=U<V\B7?3-UJ$*)%A;G]B$^7M&^BW/$@YN&
M6H*>CJB#UBP0,M_B;8\D!8* GS9H7\BXB,['N;UR#0CJMOJ<<=N*:YP5(Z&R
MZ;A^Q%(Q="S9G7IKD)>._%)2TBU%-4SB1D<'1ZF()Y!]Q;V5,/<.-$ZCVQIN
M(LM1TBA%4][S!K:NQ:]Z:\G2)S5'RJ^/@&JF_'(O";:^O;=R]-OQ""J)3KD$
MW16X31/3=T$7:HL@51O.A<9/R++"T"V(E&&#!3_F!7A8NX2<'Q8LZ4&#^YAY
MKUA;FQPP&Z$'O__122"3KE)=&[EQW!8DB^M/GE/T@BV\ ->[B6&VP3C0A;Z,
MOC6F[\@RSUC$ N?T_'MYJ^Q'\MUTO<]8" YS-_L#F]IEH[DJ#F@WSJ[ZZ[%B
M@O:FP-R.ES'B<+"==3Q6 U+[H  U8!=YP >EU=?@O;D)A2G+ Q(*.=MAQISF
M',^E%&,/OF_Q^XNM^[#B5%L/U_ 07<;=;!2N(5]+5F@IVJVS*VRH59D*\D%L
MZ[(,6_UF6T7L%OLM&\K=<G,8A1F"A=K*$LM4A25Q42R"S5EGF3<P^__;N];F
MMI%<^U=8WCNS296LDJAW4N4JQ78RWMW8OK8S>_<C+;8LSE"DE@\[GE]_ 70W
M'R(EBA1E418_S"211+*)1@-H-'!.M2AN>QT"RVEW4W1H75BV4F)KPK)&9EA2
M<LQ64-@%@K9.#XF"FVH*:$@8M%60"3WSF#_6E2OR(0DC'$S7$BE >E%]/M/3
MV\#T1#%@Q+/D'+K7#"S04O-K2JE>!W;0_5;*WF2Y@3<1%:(-H13/UIV]&[UK
M>AN[>#9V^J:]W  /"KLK[&8 ?1KBV:S+>#GP'7,Q2::7XT7D6ASK6-5"#WFP
MQT%)Y*UFZ%AT2?60XK5Y V3>9H?.$%N81VGM)/$B3%[U 6J/)SRZ5'O#>F:N
M9SNNA$SBF*P(Y\/#90U>#X2D*[H\&N(8AW/"C@+3.>/9EN:FE1IK:S)&"3-1
MK0*AG=3>I.QU&QF;V7##N])GY:^]*6[(ZZJ9NFJF/BI>>V8WVFG53(?R:]UF
MTAV^\Z/BNFIF3=6,VMIEU4RW55?-U%4S^4VAFG6(LZTQ[+;KJIFZ:B:A=NI.
MJV:Z*E;-M/OE5<W4?7&9?7&CNB^N[HO;=WM6W1=7]\6MZ8M;VP%7I8I'Z0$3
MB3SP9M?^'!XS6?:I"52SR8SI?G!D)E*#E]19CXJW?.KP /?Z8A*>N72C$)4P
M\*X+U#/'9]7D1LY##Z(O)^%D@BY:/AD]DHLF5_/4IAQ*'J[3;@[;_5QYN-6?
M=WJ]4C)Z51W4J+<^8UE\_\(-V]N$]*/-7!,%[KBR.#IZCIU+"]].R.G0Q2!/
M^93; -J,Y'&TXE@8@JOD8GD[6S2Y)$PC'F"T,63 .$C!-UF7=MJG:,J!I%*W
MAQ-/9@&[6"203+:4D0;+4./W/KW%RD.*37*!\I NEH=T.\UZ\G<Q^6/_R7<]
MC"A[VYD\48)\4"^?V[!EP2T7,6S]D[/5H&BY-'MI"G)K]B%.84'C56@BLXU7
MOO+!+K;']+L-OL&I=:"H#D1)I?N[/A6LWNOGMF*%(-FW8'OI#E>SFNS3A1_4
M+!<T=&\%O]\=K8*;KF=XPQGF.-S;V[!#-.&Y;5@A;/TM;%BOM;(%L_;3NS5A
M;T6CT&NO:AZM9WC3W23O>*W#L$U,6"& @_6;R1XB3"5K0VH7O%L+M2.HBIP>
MJ@,>JM. :+N9PK]<J\#&41CM(P=U#)9IP HU"&88,"3 K/WO&]NOM^KT[/6H
M8K:>X,(3_ _?+,,\':)ASFV>1CLP3TBJ5?O6-S9/A2:R]/!J<'(VZC9&@U:S
M4ZO ]CO$81U@95FP3B$XMPP+-BRQCN(8/7 Q&U9L*HN$6*-RJR6.<8JCYXFC
M.M#*-%.%T!*WR,7W6YQB, F'6KOAW5JQMV(+[+<Y6^!P4&>RMM@K<M:@+4W8
M(5KPW":L$$#I-B9,+;DDXAC]=$$C]E9@M/U.J241QSC#(5]]'8IM9,>VK[S/
M:<>ZY99%'*.?+FC&WJK^OM\KM2SB&&<X IY6!V/91FS[*ON<1JR_"L:U=M2[
MM6$[*L-/SO!@%<1L/<.EV+ DR$S8S5]#S&0F'$_5UFJ(&7P%U.-L;!.U-3RI
M@6EJ8)I=:6\-3%.I5ZD2,,U>T5/2Q=-N-Y5\N#(7ACLQ;<1@NYF>1WA:[M ;
M,1T1PEV*9+YH+M-OM5<.N)U E^D/$S3A\!D^+XXY<_]P<_Y/Y<OX_O)".;_Y
M?GMY?3]^N+JY;B8]:%3BZ2! X@DISU4/!1I(;;5["H?Q06,"PD4NH5M3LW+!
MT^S#A:,1O($%1S/B*IIN+P@N=L:4I:_P=20*>@"3OO2; %1;>R3<8[173\35
M0G ] A$<UCS"+X*"X*/X-]J+YN@"5!]NX""Q#=S@]!$U5GZ+D.'SA6F_,F08
MT@V'33@V.UX&"N3ZIH<A=5/YL0#]0LHBDY&J"43Q[\QY8LX2.1&"?*]^9;IW
M[JU@5OM:N!JCZW6,.P).LO/E-;%@QRB$&R[!R*[Q6N Y)C</HY.S7C)-'P-6
MPI?S+<GEH,L)"FA48"88!05"QHRF@Z:4+N?S$I((I B0V*/6P$'EEFU67\T.
M9!O=ET^-GTP__8LY=HK,!ZV3,\M.D;F0J\/F2!H:G8(,X57!@N0TAV.0J"Y(
M4.]@H5.D C9R>* V\B:@Q.-*V^$&)$KO( U,8%06:"*%54F51RSZ7".=!BD?
M1.6<#.MWS31AD=R" L^U"?-IF^UFWD7Y0 /Y59LO/M_QW^'''SD;2.)SPF5;
M..S9@"@-GOR([''!.\5YN7[]VU!M#SZ[RJ,-:P@%$3',KO_X!_P=+7=$7.)6
MFKGJ\8]L DM:8=,I7(SO8">G(/ UL7G@=^:F3=%0\,3;(N@\DD_R8 :TN0V_
MYV['F\&U,/ /QD>\R+ F#MH\[M0"#B@K@.(2?$D@DMQV+*O[IK =D\11(9\*
M!PP;^Q!U.Z#X>IKEPB["-#(<\8;K*.96O6%6??[6;[C)>^&)=1K351IEX]X9
M*D/ZK7TR2J:M[B@=6"5%1RQ_ :\14O,L!R>)U8_+G*]ST%HF&&.(*4&8\Q1[
M,8-W?)HI_] L*K4C<]3IT)WXK<#^S(Q' \DM7Q6Q4KR9YBDOMF^"\80G@$GQ
M)'T0"EAM?78D^Q+]N_T91X 6#-^!3!V$#,K4=\A(2?,I+?&R)XIR?'XPGFE8
M:,R%'3.-.=+AV58DKD;>0!E;AP8\!WW9'EF'DK,D]B=NS"=OL3DILBM);DKN
MHX_ACTZR7*Y15^6)61 =FN:K(,TC@XL&#3E 36-*.3A.6;@^@= 9I9KBQVQ3
M_+ALBD/\P5MXDATGZ()9G7S2?8?3;TB+3*2.RZD"SDR2M5D0(I>R6R>L@+-,
M,,DKG LR"B6+=/"4=B!6M^![04!:$OEC-ZN$^DV\(/8G=I.%IQ&^QX@2_CUN
M[CF%W_*VL70Y\$?2$P7S&W\Q")F9 W'G5]OYZGN^PZZ$D4][3P3=ZR4[R=/?
M,]6Y\;=UQ$/C7F6-OO%0-A$8YKZ/,M<PW@XB3QW5-6!X3KTD> WA2]@S<Y"[
MSY*^A,RA2WD03@(]-1P7.9]?<:1,F\P4%*2E:PXM0W@^&'<+9SKFY]0NS3SC
M2F#SW @,U/3UQ&_1)X)ITY(BL6R/NUSD;\S+6[RD1@%I3YR6MNB*NA)"O[(2
MJB>5;NQ&R8]#!NE0>:/,&-I/8^[/TP@Q!OV3LR0=5<")O&:OL8D.1Q=K,.=(
M<RCFG+@-(XRM"[1Y].N8(B19"XN G5\*[WC/R<%7S [L:R?TMYOI'9O83Q::
M,NY3*(&=3%</!H< AAZE*0Z8(RFN$&%$C%G=X2E[6B IL8;(RZW-&07<ATG;
M8EA+:.N"MQ1FW6-/-M$I@G9@=(@DTC1H4HKHF9,;G#3A;^WPX6CB*(*>(<L.
ML5&#-!302F_F*CP'DN[8Z<>XK<]!LW@H>.Z#;K.3$SI]):]BNZGV\Z*M[QJ%
MO=UJ]OJEH+"GUJ.,J@;+/=SH$.^K6 O_07=Z&5-]!;2^",E65KE.><"^<(_]
M2 UMP2:539FO>ARRZKP?*L'-BKDP'B.T0?07.L2YIKU 3[2L,UFOO-G\M]*8
MWM)$L@,=V+1\<=5B4<M" I>$=ZU,NKN]22$/(7F[&^L%3&$DYW$HT]/#U(!-
M/N-(,&0@'PQ/SBA(5S_OO!*]UOM:[U?IO?K6>C_:4.\/@6-TLPGYQO.SY)TT
M?6Y8ANLY5 ^\0Y;1 U&_3CGJEU"S(=(L=X=%3&L!.J!W.#'=74T,]<)G3$Q)
M,:LB:<JK;!T>;$\S"T:J(D^!1.RZ[6/6@QQ6[<]+$M%[\_:[6M-J86.[BSBV
M7A7UJLBQ*D:[6A6=33W=^G:SM:T-XA.<L6J<9<PYZ[N;>DXA#^BCM1'\1"!2
M9^(J_!I^0&4XRE2#_SUKIL_DH94N#MWQ[[Q6 V_BR/,A-WYX(D\S^$&$#7\3
MP[&?Q7&)@X-U#;BIRP^CL-G$L'4L!8"_T>;&FC#Q,OP[6?1NN)$"#+S9,W.I
MN$#>8BH>X2Y$U2(]G1\,"VE1,2*]%(Y1C$$\C<LQ/.F)"8!>GA=A+[6QU#V*
M63V*[=4]BG6W827&4G<;5FRT=;?A3KH-5W? 9?6Z5</_QUQ]S/5.L$1#T:AR
M2A9O8(&K=,F9'IB[R7BAA!OSZ$G_+%UEO/<")(P5253]J7F*X:$O73CV(]D-
M^@Q_'KD=7L)+Y947PS2Q_$J;S SVS/1M*F"B;9F9)4GNJIJD9-W+L'LH=2^\
M0..1F?9+6(_) QN,D9\QWL'"IM3"V(S845:;4,':NN*2=UA3TALTU4ZGK)J2
M8<[RE#>H*:GDH#K-OKK^5N54<AQ4H<MU4)XHUN]N$N^5E\._Z1_HE&!0L)=0
M9%.M@HT=>0Z BDME;<9[O[NU@D+D_;*B!#%H=< 6'6[C/U#7P%+0=BS5,#?1
MBGPO5E^F)*J#=D(3G^<X[("@W';6MYBC>W_82^_8./"2D?V"O56H:J22RV$-
MZ-TPM>UB!RM"^H Q=P$QU+R\"(E#;+)H= ;]YJA:H/OOTKRF;XO+:S7,U)4[
M&2V<A\'" \0*:G93XA!IDIK]SDH$HQW!GE;-1G[CF^\RX"4/4(,W;F;<<8!
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M"Z[SV7 1DQWGZY[1 %VE,U1I!CK#CIS'*\2TL^!1=V#]+1_MI$Y8ONW1L-]
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MA_K%SDRXBN-^[H?1EW?A L_*N\DP_7;R1W_<4S$I&U0!49#1:D0!+[F!$GA
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MQK0/B?Q\^K]_/7UY^OZ?#>(>]SZK57#C<9"-(ACG>%'??MH()E_>C\)@/"O
MNZ&+B=YI.F0@,TT[@4T6 HH$7!8>.)T3 EO/C'L*4[NXQ@-/&O_XY<Y/ICY:
M#$9H01NAT-,J5T]&F$0'PKB23:$_FP]-V0KHOF(A39GS<%BD*Q4]EX#)>NN;
MN@'*V)2UK,V3Z\!L'@7$E!Q8483-13L4>3^OX@ITAP^K=,:4>WV&.M%8)UVG
M;O L?(DU$'44?+F/YC!1EZ[T]PA-=A#^?F@1.:(0@NQ]6XW"4!BX(!5$56QD
M0EBK6U_Q[8L.3\1<#L>&363> 0M.R50?TZ_,0P(R%B\D"O"%@*A:QAX#][5M
MC5 *C0F^]>RSNPCV[Q_MJI-[;<6V%F@G+O1CK551FRQJMQ:M,IME,7EM.$1>
M<K(1#??-C=EGV8YZ[]9#.[UTT#QJ=5/&=4!]ZUVK-U+<6KV*MY'ZWKI6,\>X
M8DX NIH2))%PJ<CH#= EL!1\4JUK];^6KM7MF;")L/?2M1IYTK+V ,!4N[0&
M%R#6:A*3LR[,>\3FT=9GV[5Z(^4\V;5Z$\EV831<Q7$_]\/HR[MPG:DPNX+4
M)G*>ZIUC$;6 R)(U@P6X2\HG%C7RUGU&'P3S#1D+3?31P:SS6W#>A$OZ\I84
M%ND&:R#L*LWC272'R_=HH,YEDG2CBRZN_)]&&C+3*M8&X))\)<43 Q_)B9(R
M&>D9,P&;[S,'8LL:R2 '(<LF*NAJLO+;JWC13V>E8"V=6&0M&">%)R1\-M(!
MZ7!D4H!+F+F((@N^W93:54\[0 )(8]6LJDK96:X-C8X[P$XF[S_B+V'T6^VQ
M> >=%L7+Z!#03!/T,]G3AFO(@0N6D@G!;]>8X,%''J?JVTBX"_]BEJ8P[_-S
M-CKO?_@XF6YT);OH;=$@@R!7BA8-,0H!.L148E&>A^;-[1\"\^T8G6WTT4$3
MWI7 YJ_'.M ZLC8?@748,[.1 M>AQ0[2W]=.,H=H(_?:9P_,<0153 'OIO.
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MD9 1,ZW6[K&3X#GH<(,X?1,5;B*R?<;IK0K,VAA 24_;C#05$AU6SI;(!>U
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M1QY>8)(3?6H@2)&;9[VTQ-20L?FQ\C2J=F, 'WS6+ R&(B9:)[D4)=K:62E
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M0V8RX98VHY&M;,]5S_^6"+*=T/<V0^?VK,P0B[/%DS$D6-WAF"8+F4O@*OF
MFG&=6T\N^5IFE.Z2B-%4[OMJ9?+D1"C#,^I@,]!KD$DBNMX2Z@"*2^5I'R03
M:B\#;;^6F5W-&=140P_>H'24E/CCR;M7+U^<_?+VU9MW)^]/S]Z\J? G_<_8
M*M_PZ2<T327<<$&-L@1?D5B&7Q#?X>@SL6 ZV>;',,9\>Z+)R<7T@Z83V,\Q
M#3\,^O^:#H[L#W-MW#N^(6F061?O'$11"BB!=!22APS,BQ)%3#XO&XX[O]2-
ME] N,[$-L%D&5N0*DR2;@NM$+V D"?OD0O4SZVNHG6&M6XEVLI!]94,>DM</
MYU$>BA'/)0/S[448O F7LU)298-Q*6FPJC8*\$F <X(L%YZS+5HF;F5C2M]^
M_N'S+ _&AF$CK720<[? ,O>LUD'341[F722'2;W<7C,/J'@'L7:O[&"428E)
M2*9.2[/5BTF._M"*Z<@EYZ)UV>P^E/Q$&F57.MY$FEVE/_UT?GKV:3ZI?ESQ
M+=H1)2UYX +\]#HM%H(5?(8D"::,/BFSW47V P_<OPNWBS)618A:2+*K],>3
MRZDG4NO<<#P)$\R"?O;JOZ_ZDR^G@SJ9C)R86YA-3L9A=)"24W7(%(.8BP$T
MG$?DR42Q78;3AD"^?E9T*?D.]ON3W\,H7[<2"<4Q28N!R/RT4Q6'6,AN,2XJ
MXTN=(14;;_=W /QI .ZNEPXJX!^00HU-S08>CG_\<O,[;\.7:<^[NH*;94R[
MX=UYT]984T=V9!?K.8PUN@--ECWBYZ+C#C:Y3M:&:'4J=?QX5C53-7H(J".4
MR-#(E&-AK<OUOQ[>/F%@/W/:;J+:#NAZ?0;5RX:SZ:2D11*D*=(69B':0L",
MD1"4KT6?CN<0H^/+W8+;A7*7P>S?5#N\KH==**JA#W!WS$;-7'"*T](\)]-2
M"@:^U*%K)BI=A#<FK+5#?3V3?@YMO6TO_X:U#,LC.M:!<7PS@C82_@,S9K:1
M7(<S@CCYE=%(/I^U$I('PA& T__)($OFZWEGAU;@6C."6NAO$X$UUMLOX8_^
MY=6B^1WGS&$6"FPQ I2O"4(I6$#EM=;((BVH@>;N//1P,X$V$ONPA<PZ2*"9
MGAWQ$6-C;FO$95MCFC V_>79D=+SFGFK@P;%-/TAZ QQ*D5PPGGF.687FH]C
M; 5^_T;>L[HE/@@'NB+S8Y;S0X;SS*B]W33KS=4L<9K$)UT@L:I,;Z=!"X$G
M TEQRT.MO5'-&SJU7L2?Y#X<)PX1Y7EH03/X9^5FB/7T]\8G5Y./PU$5?D^I
MQ JM#RP3=72UB^"1\VE&>&:9DSG2R1[>S7+^)/YSX,DA O5/+>W>@K@GY,XK
MLN5*)B]8TH(,CR!4$=HZ(5+SIJ3-%_$GW0_'B0Z:ZMYJUODB?.I/%J_A.8Y)
MW)A?#T>OKR97(SP=CZ_"(&%/&N$LJ@22"1*?<1R<-1%2R,59+XQ8SFW8/:U]
M4Y#?-DF[U6E7W2&V?K5.!VF$],W3P;UE+A9X,B8AUW2!\ 'IR/GP880?PN1V
MI]K;O8MGGG,OQ4+PZ,WDUI&;8;@!SY!\C52,]98GNSQ0:=UY7,]LI=_FV_*L
M5;(1^1IVZ.C GSD=3$;]P;B?_AXNKK 7??(L\CJN7-'"LC,0F-7 4G(Q&<VE
M;9T$V=EBOLT7YWEQI&$WDHV$_&8X^(SC.G2]+FG\?DC'[.V?5T&_&4[^B9,;
M%=RZVASWG%%>D@]#2\L6E"P:HD:R_I+,CH[<J&SK3N5[6=BW_5(\/^XT;,K2
M^2)GZJ"S<_ZM^GN\QY.D]88"Q7)?LPH4."DTR.0*@6,F^M;AT?VN\,]7YIFR
MJ6$+FYU/S476\W@RNIKFYYQ-/N+H_<<PF.\*/TVKFT\7MR2:O#AG;01:5:[=
M6 PX93T(JUT*AGEC6I>?[VMMW_;[\BP9U+"?S\[K?!WZHZDA>4(>V.5L::LF
MHM%6X!@W)H*+DA;(:6U.U08$!H-'Y5RTS^8567=1?[X;SX<S#S<QVE?3B)N1
M35/[\=[U>UWB8-Q=2XD-G]]MPXE=A/%,VU$8C3P&(8#4$$!I:\D'H'?%>PST
MLMB@5>N1O=]$.PJ)DH6@'7A64XX%JSVIE(?HDZD.EM.E=>W^G^THMN3U?MI1
M;,*(Y]*.XG1 .R*^JX63]>-^GJ]SFA(J<\F2)4;&72 WB+E$YZV(D%F*')G0
MLGD2QB-PCBO;?2.N#+O160<Y00] F]=^K .NHQ+$1X$=II:PF1K7H\<..M@[
M46)FABG':$</$I2K&<V&(V@FDD+4S(?6X;P#$.2)HKW#\&,3T7? BWHY2A_X
M\6207^)GO!A^JACG9O>BA)]YXR0MV5D5:?%!0T3!@,E$@G!96-DZ1VH-6/OW
MJALJ<MBM%CI(L?X)!S@*%X3P)%^2J,>36:? NR!+D#RK[$!CJK<@](?C=.I&
M)M$[453 UKWXU@)V3&1IKXDN^F[,S#+,JZVV.=:>B)[IZ#-XSNNU,D/P10M(
M*F+*7K*<6CO+ZR'[^F-VN_AK'6AOWQ/D[X6:;D41?Z7U3(:OQI/^)2WR.LXX
M+/.@>V>QMRTP=!M_VU4H_W][U];41JZ$W\]_497NEY>M M;90]4&]H"S>]XH
M75K!NP2S8SLG_/O3,I 0L&$&:\:&[$NJ M1,J_O32%^W]'6E'-R+<\3?X!YT
MT#F")X'EHC,4@=@H#6%&NVB=X3KLS(6='C)M+]<.N.''&:B/.3$B7>DBXD3
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M;Z30LD/_\_=_X9$H!0"8-,2E>'\YIQZ#>)0R (C%_>7<G@, L$$- "H2!7W
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MZT5NAQD[-,2;U[9'WA_])$TSO9DLO'XL'^6:W5];-W9-GR#<%?4]B#]\7BX
M1+_K^(U20 R%X2XW0_3]:Q2I._CRN@:E"S-Q.0TK;PN +ZT5:<?<N(WH,MHB
M\/NX_*YO8/\C[A64$W R.&@L 'X5^YL6_SVK[C&OP2TN/A  #'$0]A++:!8
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M<S_I,YMB>D_&@Y')>V<'NJH%@!QAS^AA4?22%=*DO!PK& C@:_1CW<"J8F1
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M</VP .CZ(6)7Z'<9C_WW ^G_BDA"1^!M* =A]$B? .A@"H \ IJ17*$]Z"T
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M>V^J!X52X(FWP6M"E*.V@87TR42IN7YV]9O]M6-PR9"U/L]GR:J')J)W@*<
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MP5W5=*9U+OLX]Q2-N^?.\[P2U;1LUX9,-[WMK,X;!.7YQL-(#)H8U(QO<A,
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M"1(1'$!R70.WX71%>4(7@2KX9:J2S-DIB!+B $^I6:%VEA@#D10,::)"6K%
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M"^XR_3[E/RCX%U;//E(\G+Y+NIXD5$>/D3"&R/E+'UYF@%$$1OI#B#NP0WH
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MOX>0=;[PYYJ7.F=6A"]$96OB:VC@ A44ERN:F'?<E.K.%YP47AG0T=.^/6)
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M+?+I5.6;2@RA9CEF"2$K5!6]T8OR4J**$[R@0&<BA6ITL(DE<V#.W+Z^YH/
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M[:A17?(-#J'%*F1,"0F<)X&[!\OH] [IXB(LLL/(5;1Z6]R[?[46B-&/:?P
M?SB^F-$MWB,DK&W_^T;;8#'+2U9&_<+E]-X)]QQY6YM]C[G-H75WLI_'U109
M@=V:Z70;6R!3%73G^",^;.IN[J',-:.#1#>EH^=.80!@]7^Y^J'1A?_/%NQE
M.,#9@MT-9@6".483H;<)4_<)?#E(YO67*TY$Y/4@W:<V]."C8^ 7W2?(U5'E
M*"=7J$ +DW\1!8K3U#6='$W/.>K1)_<O3%-96(8CSQ!*HG]%I% XO1"4/OC[
MF+7P/WUX;>POAO]Z&VI47\L?U!#J-I*N\6:?["*R=.G4=MDNILB,OFS]H;9N
M4'M5-L\57O,.[&EN5IA6Y\ODU;H?3B<&O1XH?]Y!N,MU//1S?VNWY0&>YG;:
MB-"\/+,ZQ<.^I;W9PLDT^SGV3KJ!2M#8S=%2[64U$!W$CX%&JB3+E'EZ.DMR
M>EUXH)@O!'H9#U^<TL$IE^"N5&"4J">8.K Z%1V4LN^;\8N[/Q$?$2]UU$/%
MS>5W0Z?'Z(H>X5Y#?L'OC1_>Y)UC6'FH&#?*,*CL)!7CX@D;_O)? ^ %(6*@
M)BK8;4C?)3,+Y3*T5FJS\'-I:84__VI&ZUY2:E)63'[ZL*Y2,&'?AWZ:FW).
M"@,(/-8*Q+=NO*D4'A_T?/9MYC7S=&_;#3*[?+CP\IL9Q1!73;,'*<OJ7[[L
M:[V<:D2OW7 C4XY7UTPT._9JITV8LV>8#>08 C< 'I?)E'OA.WD2#:AU)#4?
MPV)]_X*&"F6'I-@G*JS1BB<MN$X1P"9$A4'3R@^75L>+H]XO;0@_U7=NI/Z&
MVAT7N&'"@TG4V^A="^C?AR,4"2WG0Y"/-J>(H-HD>D3H6@7D&[;_X'61$W3U
M_'$X<U)KL\S :E61U+EKW&6AZFA#4Q-J.U$\[2BLDDS0^(9U*Y0$^E\'U8HI
MO;H=E*U]>_ 60KK&.=2'5>@8'Z2G,5!LON]R<5Z^GXYAD+V:Q;NFPP\R7J0>
M,D\]GLT??8"V0BQ:4]%F@+Y #_][WR/5EP!HQ74$)I*J*>R=9+"/M!\B3V^H
MU7ZX/T0D*')[$C8A+VN1Q86.E4 HPQ3]$;ZO1N9)1,\3/>W(2U7M18U#)A;A
MD6D\5)M]TU_#S4?(@U3 0,P2(+A#;Q\#:(<Q3X:D\J3K>&+3R86\Z^R=E#$U
MWC>D;..5O/FN$A%)=-(/S2W1H\;=&4#_7!;L]8V\6"F07D(=.%<B'<1<E[WS
M@7#JV]EGNOS9&*S3]V],!X68= : 1.1'%RW?*+:MT?ICCNGWJ<;I2T_VK<YL
M[8SKCPLU=%^[#2K/+Y3-*!NLWQMS"4BM1MC\;IL"^6T'O9=Z&PYH+4-TR,-%
M-\[9G"/G^4ZH.8B\9R6S?<Y-IS]4!K I%.4V7@CVPUU_Y\=/:U9L: 3'!TUN
MU];BE9O]$7W@NFNU)'PS@IA"992IPKGW=(6RD:2-=*1[,G)IRL1<I#G$(*^E
M7J%)O+E9?*/[C)N^^_N>L>YG[WLD=78Q ]D++U(E.]9?*7X(CYQJFK$8;G*\
ML&,#7EN36N[\8.+!HGZND#-7$G4(2O4D;G;T- '00 N5%IG$??/\S>:8<-ZN
MI06!-?6Q9H/IQ3E0#SA:,M82N?.S >4A13["-7U,6^>1?%KX+<\_R6\)C$5M
M)9NFWZB(GG1UIFE_BA9<%*H,5!=EJGBFCA-9IBHLELHKKWY]ET7$J_:I.Q=^
MK91<1:U1YMJ?W!*2N 4#<A8/@N^<_X6@#;Q([N6G^-CEJ_/S;#(BC[FE_%+2
M#&[0U%TZ7EK0R8V$GR6T6+B20 FK+=BNT<\NP37"!U_4!6:$1^K(>&0GR88$
MB@LP;Q>HW& QH5SP=>"5%AEQRH<D8:(M3R-P=*MZPCT9%JO+CQVL@W(VICD.
M5-Z?,MM&&YRCQHP7!==*4Y<6E^B_WIS?+F^BI[SG+DZ!9:GQ5BVBJA757L_[
M=G1'TUQ_&CQ#+D?)[$;_LW35\F D)J1F<[;S3]]U%YL)$RAK"7Z91. $E->8
MGE&Q-D*--I%FA1K;WI:1#T$@%.K^@:Z].*MWP)#_Y1ZWWH.14BI;,!H_W=GK
M]<ZRNFE).#NQ1S[36%.SR]O%2)EU2)^-_P_^*[+6D9,IN(:[*"J ^/IC6?Q'
M0J58B^YH4_/IR7GT/JH/*=DPHN8M219_I-V?_Q1G+WK$1.V;V]5YH_%[J"9R
M'Z$5^7N&4?6/RF$MW9J&5>KP%JRJF(F5.?;)ZY;VZUG$T=GP9#OFD./SNZMS
M=K3>0BVS4'/9ME<C=S?\==WC2I\5QH+#'W_:>VO:%?OAA^2.QOWUKK9D_I>.
M_:$[]+[URE[UJ#MD[QTU56...;-4+DH;R<_A0AE]F,SSMA!5-JL)58$<P=46
MP5$WXE/%V193E6DSKLZK@$9C;J;#=]P9]YW=<<PLVY]1DC1Y(]/207[I6U']
MAG3V\%U<#9\H5 HE BX$KM.5+9CC,NL9@6G-,Z):\\P%)RAB0=FJQUL=/WI*
MMF[!_J.6<IMG%]S&Y,K]NG>K?"3B5Y9E?Y8S-OS!0$JQ_3ICN)K4MG&ZVVW8
MA2"K?' H86%*.M&:4S#4ZT.X<<"1MV^>E WGWD!MZ&5%@E]E6@FBFT8[\;&Z
MA-PMF,:F5J#PA1 )Y7/ 40A8#QVIIU[=)+Z=1QN=6^D$)=$]POU$_A)R+7#R
MS/1W?PIY5@D4#X8J@1&/Q+DJV('O1A\NI3(*T+7DEE)UEGF,?I,%1!GU>=FE
M^8!,:VU:LP%/YZ7HY;^^4]R78R[.+K?*,OD-+7R3S+$Q]GTL2.;2VM28/8_#
M"^ZLW#.(VH.*_]Y2HJ)1XG,YA;3'C#J49[<PDOE%2S6'O>'Q]L?&"P><_KS@
MEF7^0VI8O:/ H6J08.6Q[@**BZ A:8K^@:I3PF8A1R9W<>H@ HGO54Q13,JG
M?M)-!C7*>2I4YH?0SFWN9-*>FSZ;*H\*7/PB..4&Z>"Q(3L7GOE(P/+JHNF#
MSFL#H4J:4]VH$=T6$#X(%?19%* QG%BC?):^[LP-:Z&*T[$/?_Y4\ (_I;<;
MR7]4T/<WZ^C:HUVCE&1HX7I\TCFUX: AA>^2E,I9H&2E \^S>2N\XJ?G%"L^
MWLAC7M5*UVYU]] (X3JA-GN>]SM%G3([$ZJJ@7UVN1AQ\WU9DXU/:TKJ>9^Y
MRV_*%Y!>CD-=E"^1?&?.V(2;%\026)_Z:*"T I0LNHL/T\K'%C)(<;BH//34
MQW_=7.=K4=//=S[Y);,16@M.#$DD-P22K][%$:!(/8F!<QW01/1.).,%LER7
MO<'3Y ]R#6DBPXNB=X1[NDE&,9^2WK9#[.AC<UC,TM%>G#53DN-BP_VVZ?VW
MT" P &<57H;&9,CP3Y"8<M]Q:J*Z*/;,H8.R)E^Q^PL"2:P'*@H?L1=>>WR@
M*,72W@,9K[W@R>>TCI\^X,'&#*!OMO?H.N99VLWDL_\EVRZHH4<%+E=M@,_Y
M7;G _K!!W\[>!K5U^!M(ZIC]WNBEV(]DE%"Y5Y.N@!)G>(9\;QX\69]$1]/D
MMV RS<KX+CJBPM>3VT.KPMT"+KB7&,:'$O;Z. <TO2>T7B]Z[OLVBNPPK'6/
MRCPX?#6&9SC,P/\-#I(J(+0J@NB3%=('JES@[@Y!!+Y[,Y"#*L*B:1%(CH=
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M+[#"TZG5/4)9\VO HC\WO=WM ,_[(^D1Z0 .Q20D(0\T'QH7&@$5^3Z((^4
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M.K8U*P0"KQ<I;L:#JV&5-4!\5*1'%)3OW@GL$$D.OO,2.0O<Z4NM14!*5LP
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M]O!&4)%OS<V8-P7IW ? +M@"6N RF_6QK<>P:I5UIUY-'\-L!V\_]N*C3GZ
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M#_RM1[KW.NLWV17EV-W ECXX,-N>_L8X54U[_,?GKT6O89_I6B<W]MOV)CH
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MO(TTCJ63YXMXE%&R@ P%<F9I*.(!]X5-4\R=&%61@4HJI<1O+:TKAQ.DZC9
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MQNT.S8[/1_B?YXWE#,^V]%]]UU-L4U41HCF L]">V<>C6TU?FPG[W1#Y*K-
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M"W=9MC,\[JN7MLOZUM*1FTLV]-GWA&C]OC[K<8NI8B?\-354"^\))E,5<>(
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M;*]PL<6'T_9Z[&P,4<VY--RW,RC$X5%M :'KF;?.ZVZ4IN#E5VHB?#;AT0#
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M:AM65GL XRG\^G&_%_Y.@5VQ,\Y9$_6>PCN-#0>4,(JB6_ Y-4RQY&F*Q-]
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MKSIX_8\ZVX:NJ(,)OU\4//Y>>3R;?2VM, EM^*3+ZJM+*JWE@U]FOMMG8*0
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MPJG]^LHKIJ1?1[B9Q9,,9QNQX_UW7WSJ*3)]-)BA 0_"!V^5V-UA](@$.X[
MXC-G,RJ*?C9I<W6!Y?>NJ'B>Z&,^:PCST<)S DI.:]8<]K\6H#F%Y*GP!G7U
MY&V[8><62Y<N13!A? W0JH8A%T(.D\C)I-^;%3&M!B3R!RN:S=0!B+K8 DW
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M?#3Q@%<(B2_"Z#/C!9H/]Z.<5+Z5CY1WG&JC!%U</63=)+V]F; 39#'43I%
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M)#XV;WGT<0A><C5;,KYR-?_D2%<.8S?9BQ^R!R@CGM O ]DRY@1'S(>"Z3@
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MX?V+)Q_K/':(T+Y4J_2RS.5)T76PE47@QQ4=:8N3"3\#TVL7+'.0"@PVJ^(
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M'.=/AF9<X>A/IF8R486R%'Q7>ZDN?L+8[ /\Q++=RJ3T+9<7$[NZU/]6'AR
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M/-%F>[\Y,"KVY]$Z#\T1]C8D4;1;2,$SO_8?Q&H+RRS.EF)M04_^$5&'*I2
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M6.W3Z3&M9W.]$9]:]G^RS%4!$?_>P5H6W*H=R^.:R*2;I9%&EYA@,K2@O?(
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M%<#)KA#'Q% TR-A//8(-!LOY1U%P*2,4@X-,8>P-H7SH%>9VXL$KN+$2#TQ
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MNS?I&0;M-89G5C" 2\OIT,2M^:1@ZG'<(*WF00G0M[76N9F7D\]:E1,$U W
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M_L<?3F!,/!C(I">8P8FA>^U06&[>XQOK[-_E_&HVK6\X>OS,=<S$^.,BH.*
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MU=$V+\D8X:_Y9DT(6LZ@Y*0(YG_A_>C-'*>97/M^[@.[JW6$,JZ5ZI3_Q +
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M"%4:K67I?^0C\[-M0PZ\3QNQ$XH<'>_!G^NZ5?^6)^%$=YN(#,OU]+X.H6B
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M?77K6TXK2;YU=L*O$2N!;4&4CL\,%;M!B0S9F090ED&_KYDVJT;:CM&%K!G
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MPB9JV,:74Y6=5KE(OD-]@76.?A?T_NP<WLH@A#M2'P*MYVGR=PN>>D%OE1L
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MR]'(09356KS4* T7E#Y/_;)V-"?>@W#1*1K%X0DW[N/MYP=#.WA&_/7=US$
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M0EL6#&SKX+B('=)ZG:S%/XV+(VQ=Y>\5&QKVL0CTKSRN*PNP$8%^IW3  &L
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M,4]*@#$*Q0F:;>7'>88669E_+)!#ZH4<Q6H)1Z]SF\'QVR41I%C2 7/]8J"
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M64.0(#P50#H2W&KMQ_D)E4PIQ#A3H2=P?WX*-$!#A+*_-QD[?S!$K.TM =+
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MS>S\J+OA6F4"Q!8E^RX4D0:$F'==D>CE*W?6H[M_*75Z_K6S^^Q@^1-B4M=
M;:/>\08/9A G0B.%>[WH>MJ",S>W1\P-K4F 1N,CHR'/KO;S@@HCA!2ZUC)O
M9AFKQI%8DV6C_IC<RJ5H#'G&7+$9Y^OO?W7K0D-W*O*MQDG8/Z=6$(-::ZH,
MRAZ^&;##P740I,POF[NSZ5T(67/'EVA5<NP-:L1H.>!Y==(_\?<VX<?1X+75
M"!P,;OQ^O&[&%QF!KY]^=LEHB:UTA ,^S"K5F4LE)H2_.A/A$OQ@UX9OIAW=
MX.'Y:D?,#DDJ&!^.=9)!#O97/X-N]L:_N+H:3-#@O7_.*%2KC\FF%"95.A6=
MX83/Y*0;+[S._ Z7?TUR@K5>_E_; '[T_UTC"T+O(E])@NLN*,;]29]99$+X
M2GNY%]BZ?>2CYN# (D_LV!QXK&XE=;K\)GLQ_ENKQ%MT(9G+/;[B).8?2GT0
MB8K<#I_C'(7,C,KNW'()!TXPYR1W;-.>5\OHXQ^3%*_D-9#(_D+I@1V!G@06
M&=9IDUVG(P@)ZF<!. ?20ZM3R?X+.HI\"60P\?$8?V;P@S&[UY,T^]EAL47.
M3<>WC1OJ2I6O%>&_O?\&&L*$LNG=!2<9.>%A#J<8GS)#)0Y_%H'<7\63!? S
M)1+/?4\/RE[/OU"40.;9\B<LOKK@:_!UL:\Y7-+ULO7P=E-NB\=:0\FII>*2
M%@AED:^H)3RD6BP&F@>86VP)KJD8)>YA*025=IT@GY\X<\1Y._S1Y8?[VA\K
M5NN5O\%UF9N72ZR9:'2K@ZG!Z])SE?.52<V5<75KYK=0X>M5(A!QBDYGH^_7
MP4"X6Q^3NHD]E*2_"&_95BGO*1B%%3%UK:3>-T\5_#:O7PC?<V>Z79%X^+,I
MZLAF'@]\^<T9YT&EPXSJB+- I',^\4-5YB]BYK9\V<DQ=<=-9]&I7"<F0OD^
M9?HMO5)?5P2"=PC[B;6UXSHGZMH;4I;'EB7JF^J;'M]I:&I\85[R,D?Y\1/T
M':\G;Q3\3#NEIH4'84'K^] BD%"Z4[S("N *]PWP:Q'2G@<23M"*/ON< U"O
M?S';G__&#JN'/<[7>3+QP,,329<)J8<!-T2@G[Z%X&IQ+/MHK5CJM3;JJGDX
MBK1WUV+^;%1%8*^ZRIV)3/,6LH/"T'V^DD61%$S6KX[XPL_T?6_PJ8'SA3Y*
MUT/NO\Y_+E\XDY:^EF1WPR:X:+[6(Y**3>)1A#(DCMB2H.)HIT?R@R23P/4"
M@Q[LWA^7\-JQ*;U0:0X4;T(@(MM5.4H=D*<Y#?BR&UY/&[(?^@V5+YMXQ_U4
M.H+]B"8*#X[RC@KG?EP5N/IW!,\=(T?%ZGMA]('33&W$GL%H%EX=0/#VPY30
MVAW/@,1^\?_4(@N5>3?&\0F&/D:WT'<MDU5P']MG<=R^9)::F,B8Z[))Y_X]
M5S-HL!J;AKE,M+V6H%+NI?NPJI_]3RJ5[%QN66)E]&M0G?^Q!4B,EM+1L.NE
M6O[J?^C.-0_,&&X%!H<0;D=V(@ -!%\.S[T[@;G' C_"U3[-9 _VP YC%=$S
MC)VD5DO?>41R@493;D>!Q9,Q\)$ 5E]O^UF.7M(^1FWUWQ7IR:W[J0'9OMX2
MPA 8(QG2B.K6!S0H*;@@.G#2GR_OYD4"9,L!DWF?-HX&<XH,EP50B.Q.G].)
M3J-;,*F@JAG[HL#F^*&L9%:P2:=0C4/O;D.L-N:<;/$M7WE'FWWZLCDBJWXM
MM#BL%VH6VIBB!LOQQ36:KBO(@"DU1R?0.M)78]12%5[<JI4R,E)!7Y7WLY;.
M)=K _V[.2,UT<!V26@3?,M-GQK^I:[&I1^\\W/#F>LND]+&&DW]<$2FV-(%P
M&':$Y.]MX,,!KXH!Z>?MD3J8(I*N4"\MYSAFZ!W6XZ/$.=DRCP"O-(>;99:7
M#[WDX,F&[,3$5JW"Y4'?<D1 ^P$..#6A8-+8A&OL#>8KPG[G5/+ED$+)B[R3
MN,Y;SLS&9/X]GD700ZM\1F4:C9B@:_X=<X'ER"#(\56F5BL7^[A^Q44E_-,<
M*WP9^F!$:HNJOMP*5G[*$-SXHZ1":6)7W=NJX%*?N193YE92-[-ZNU6* D@8
ME9X9"3^+N=)3]6&S,;OYKY!\F\OU5Z&RM@8IN242!Z/MG,]Z;19S#D:_>YUC
M@^K_1D><H'MZ?HG&\17W"B5)O'U\L>,\B<$X 1#>:8Q+*C<.Z.,Y 79"!?^X
M5E4F_@!Z<FRS^R$N35]WBW(8J:[7P-&/WVIITW*I'QM:R$YH-0X&IT20Y.:^
MVA&7^HFJ:V'P#7H*K![>HP_\@N(?CN5>!J3E3[_&SB#4#%%),';21Z19: OD
MD!X_>%[:F55)QLLM[P;_VTS5BUB/:_8GKQ\$S*@VS28-8(ZD(W6]<M7\TLNE
MW=EX^HON=B5?MII^A[K\O7@5]P?(/G5]7-F-,CDRL]06+\7NM4& _W')8V^7
M.J:M&)E8.69^+OI9J*2XZ+UYG=P371U?EUZQ[A=LV)C#UT7%B[G64WH]@2^+
MX)J<YGEBIQ!U]%3ACQL6+V%/""K)<[J<QE2H-":44X<X$(&2+R$@1OGG2N&,
M-M>(]:1L'+*EEC/5HQ$=$_5P'S>6Z3ECL:=R'>,J2!5V$]C.\(_KPD-B_),T
M(MVF)*LTDC4!"Q'H@#]?J]N)#4[GRPJ>0G_!=?TXG]/4B%(.4 %S7[6J2W&.
M] N>H10'5^VX8X2[U9O8L"5E9E_RLP^;!<:4C0\G)>/N-XT.O,<^584DE$HU
M'B]\FK!7I\A.^LIL'-%3UJ$M0E6X(ZOM$/ZR*:+3%:\UL?UECCN[KC744E_7
M5M;B7E#/N^\O/%K);1$+PWR!-9>Q$"H"+[%/2'(PQG@%C/&<"RS# G!I1T6@
M#M0!$<B67ZM5:@7=SZF7.,6[:@T)O3VO7I$O183%T3:<WF8T9O\],B\<M12!
M'HA-]#.)3;_W/5/L4G"Q1:4)9R#2(M!=W%.$A/D>WB7T5"==AF]209L)>*B4
MT)O\II]H"4WW_[6Q<:HLO#0&MSX;,B.H"OVH58!D(WO533B-9,1A'Z"P3WB6
M@\";NV*K3KYBP530J6X<6!)J\E.P:_M$/2_?SNF]Z]$](17 WD.@2AK:Y)?^
M^Y\(.KW,LZ&%:3TWV37WL4*2VY=<-Y*^P<3W[1$1Z!6]$!?;*M&%D>SX9/_7
M[?<J[NNR[&*[U ]A!YE+%%FG=FV)A!XWG\G0Q2<%O\Z=MAU=6M!_8BXQ#T_V
M.376JL#F=='6TUK=R[UZ@HN R.Z<\-WVHDC#)DA38^-GCUA"@W>5HK$&).1_
MH^Z]HYI<OS;A>#R*@A 5Z4@\(B U(B!*RU$/<  ATCM1$2D1(DTBA.2H-&DY
M%D!I46E20F_2(OT("E(#00@)(AT22G@D;>([W_PSZS?K^V:^]YUW)BOK7EE9
M*<^SG[VO?5W/?=][2W?C A ,"RJ@:$I8+<:]Y7W!08)6,>;,QHD@QFYLX-N&
M%L9&9\&H1DK+L]YHXP:*'O1X=/K]JJC^$(V[U78=^F=F""+=7FJ=MR=U^NZE
MG6"^JIZOO3WR1L[$I["O;R4H?2AO<[!(*O5BT/Y9#?B^^9?O1NE>&AV#:IEO
M;,W01W*P&Y"DYS$5A\?XH(@"D6)-Y:Q$WVVC$V>%0: C^QZF'C2(OEC0"SAO
M/N&=#-+\KU6B_R\:[&[])9D(XE"X-;#9#$B-U-H24XZ6@<?Y[0+%]!P(K>"%
MDS9':8BGB%20!8SGT&_(9$0E*J$-/'RKOI&IRS+X^W.SJ-='T<(5]2&EK$#4
M%ZY!1_^UFIJ1L!6K*$T8O"&NIZ.G;T;=W<K0RN5 :UU=[=%]!P2C]*.928?3
MH!*0[=/M2PV2WR<'S#M;8%[YL"I!UKX\/Q'I$)VS\*I.P]IM?3/-K:7O6'+A
MLR(;HTJKS(@3CK6IK9%[[M8&>]Q_QM^VH?^-81\DM)#PFQ7?%'EB&#[HZ2 +
MQ@=51<TY\W*P$LZ+,Q("*NS_@@^*%[QX-S:X GL#X>3C?N&#R*F* IX6<0&6
MENC&:\RM3-O9]=K;]F6O/8E1B2^5Z=#!UV3-O[!WNSQEEMFT5!C/>L[VUX8P
M@D@=.T:^LT*KS@W< MXP8/([:XH7Y=R%8/P.GT#-]G9'2]$SU@*9I,XF2(H&
M5A8H@>_GP!C4)ZNS8QB]O  *-#Z,)('.ZC$H3XML< LJ"!7+HGL*DSN)]\D7
MFM1-RZC1>+8W6YD-Y^S?]Y)^ONU7>B*@\C&QFVFBOO^PNIE35S]8SK3.!VDR
M;M%,!&\JQ@']D':8*4I6_5M(.D1_L,5_ (C0ZAJJKKC*=OU6&QR4XJEBB?JE
MRJ&X3^Q\D9WEO>!GUMA'O,]4AC-B,HDGO)]]=9K78Z+*?57+1L1C#>.[FF"=
MQE$]Q_V\5(<Y@6*/\Y8C:UFYIQAZO7'$688SJR%NN[F4>\J\="7W-A]T9R2?
MK?#:T?P?W"^X6Z1]/YM',+S 1SC*#&),!$&XQ9W1V4,2YPC1N/Y2SG#1Q;93
M#'+B]A0>7#=>J!6DIQXMU^4FE:!9FY3UD-7U9;[2BCTEX,\-,]3-ZW&^'?9T
M^<1"@W+E5)U8YL4=58MB\V.!#U J9^C<O-UHN+IF']#_07A&'8!G,154=#N#
M??_Z096AJ1QVRMLQ6L\5/S[5^7XTYT^GUXO?@XO=<ES4OM:N6*H5:7BS(M8R
M!"A[B?L*-IM#J"-SU%*D6(AA(]-R]":UHTV5^[I-&1U=2Q(-R#1-K? M1.,L
M4GMM3&1&RS'>406 U961<,,<U7!K(=-)+L';-UJY(HKHX4^"_2QA#O,>C/':
MS\V#W810IFC.\;KXPUZ8/[C%)F! B"Y*B-==#./*=<NF5M"M#;NQ,DQWEPDY
MI'MT@.%)H2[)I@):'6Q*72]VFJ;O=OL6.TNE(/.;2ZI"KV.O0[&8\L>JSQVH
MS*-\D,_S3M<+8]3U<,MEB\FZ,WB13HS02;1/+MJ^1X9\S#OT2$VOV&'Z74GU
MPT]*G4KBI, O1EU-99_E6";F_YA/=\QS-+61[+K\T:QV2 #H[>&:M/?<,MCL
M\PL-Q\R#4:%,7\\X.N7/&*;UKX1C)-_8=+F$/R\U](CX)B<')_Y<<SV%MNHT
M0*T%"GA>7GTEX_MCGX-5S"C;^M&UU=HLN8MU<BC E0"RB-L[JWEE>DH@?*>_
MSRS,^[2T8)X_]WPEZBN, ?=]Q=$4$V?P)7O=]2N%.<1%/*JCK%<J]LTV(E;>
M.M*!>@!@31N$^]@<?P$;?W(E--G-+FQAP_Y%Q3_#P36^%!C#GC E,@OFB*=O
MS1*Z^"#@#N(PQAF8FFO$6- &#WXV7,H]IB#/0,5E_3':XAD!2<#19)EZ SEZ
M T7EZ!"*H2;TSX;&\8FDTOZ1P->NE*\8O, ARACZ[7 *E'>XES'(FF$L/"0:
MP>:L%GEB +73[<=(F0;':08,U'C[?@>LNO3K+U"7QM.IC.?^Y)Z^A4C*BML5
MN0L09+/[H'I\Y8_O4E(=E[YMJ0VD![Z"JU]__OQ1@;QI5L2+%]O-UDLE-??-
M>P'S#.:&B"_)'"59&AQTTPLOSTSW[PB[)U'J5/;N-F T+!..=@H/L-1[DU1L
M='?XA6Q2K&S5,Z+->80C1XI+"(3-ON2#*A<>&ID+-*U="S<?YH\_X3]S%">;
M(JFI;_US.AU^;.GY<M-,007P;'.8QP==8>C'2*TUW7F:[W_??NW.2)GIR[;Q
MNIS[;5&"JYK-^Z0 YA)QLSD9I'KP$Y)O'EN?-T(5PV@'ST4CKHS.CF1T2T8&
M/2SW7)K18?@F[HC*SOS*U(I]M^0?32<<"HA,>>OE)C12=S13>'F/1PCS^3&C
M;&3^F"[[H&Q> & PUNUJMI<Z-/S2;\8OCCNQ5#?5VU 7F#2HN$[$G#X8: +(
MX@F#C8][+C+6O3LL\_/?M$^LAE5N9^URL]J'\MS0!@[<1_,9RJ?/IT2L09B^
M/-S@#TXI&\<X# C _5<!?WIT!Q"?>X91&N$@F8][9:7^FO)J3%?WU.F:,0">
M,X6L94?\W(J2[@S7J6Y#A-$V70&5+F[=M\>#7?RHFLE-ZS51#Z+WXI^D:4\T
M/3AXV2S_W:#A9V+""^-)S0RU^GIGF[Z/FY.+.[SO>TBZ#E;Q#0T<>\G$I-Z=
M#SH&2:Z<T,">?S$/8<G:QBI9%EQT<U3MGAN+$$.KMNCZ]S&R&B9@##B54D/#
MKV6P53!P@,K8I6D]841TN:62Y@*EZ-2XL(MWE5(WZ)(IL]PCHD'1OO#AL O,
MRZ.8D[ 83([;\C]>E)ZGBRE*P_ZWED@Y<."T;P]^DDJ3R.CRSV(Y R/LJ]C1
MK:\>RPJ048X(H]F&V8.G;0B[+UV?6C2!5)')=N\S/IQ?B6P<BR/1D6M0Z\K<
MH6VDC)X(K=#T-LRX+^33H$@&D^4./X?VIP5/>LE))#^O;2N%E)D@F_M-3XS
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MEM4C.^^\ S,YL]C8WI?)7M8?@CMI8_"ROEQQT _QD 9H2VWS5,E*81)J=;!
M.3P'[;WM$G?Y$=&M$";^XE[# ;,Z8;N%%+51_R^? BPNO^_,$DHGYTEFO5!R
M#&FX@WWU<^4K;C8CDKK&!\V=A#HPX]?"Z8@#'#U&08M0._50+>R@7T.;_%"=
M;='+</@QZE</(!&Z1A5'?#7NFPS8O1\0YBDSD%34*9-QO6T4IL0'S29#Y-MD
ML#V0>I6U:/91SA_ 0V^?0B1)? <LA-%A$A),R^,+T8][("(81SKI(+SPFO6G
M<98!-:7V1RV[]?0P/?CVKIN.7[I41F;L.L$G_$>;!;YKH44\A]$CHIRF]O*(
MZ)&HT@=F+HF-'I;%J@4&P=CM[/J0IHQFI#_'](.\9PI3?Y%*5WDL SL UR*V
M<Z#I3$<-:^$=;>GL#<A?='G2N4_YBU:B\,GQKHZ+397)ZH[9N(>6QVN/[56P
M]7G=D'VXV72>-K<<AT2=Q(0/G6$@NK*F<A#7 E'6#8R=BD[<(8\52D,"N0.)
M:1H@!M,_(VS'PCVA9L-DFYKJUK$!?*';A-]N9%Q)_04^*)? ,(<\0H#YH+LP
M2@:KX-\:>5L.KX6#5>8RGKP&-&F!4:NA17'AK=<KGE ]1XE/&NN;QCF:--&(
M#@-H/-2[^:9W="A=I-Z\N?9+Q5WM.&06?;-<BQ[@8OG2+:WZ4X7B&SFK5Q;1
M7MGS$CZ&42W]Z>,U\$"C594$><]L!BIUYCP?Y'LKQ,/F04>+#"T((1Q<#/4W
MNG8.+;]>(#N,U]>3)PD9U"=Z$#QC'.'^\!S>:US[%=)LULSIGSUE IH47M'A
ME!J$0(T1.B596TLXX18]FJC6KEDS4[AXJ\61;K6"/^9N3=>\?MBDOT!I_O5(
MK?IEWD-OUM2T%_LZ1XD;0_(! RJDOW!!8(HW2XM+7*T%)_#.,BJ>M.@58H28
M"RD[K:'MZ0K*82.3 N8K8IWO[Z4^PCDW<ZJ--_)%J\78/UQBC=58O_=-\N'I
MQ(&!K=)8 '_!0SOSV_L+PF@/+R%HG$FNRO-<1W6[[IO3]]]<#%@PM3CSGK"Y
M\F8#4*?S02?YH*X3<T$@1N=OI9WO!8J+010[EXZS,#^9^+ET9+":M)8U6X46
MLJ*,]2_?BDXSI*M(=^@6FV>>0^[XLBP%5O#B2/WL.<X)!L;8-X \5MP0OF,%
M(8(F6#*\4BHFW-%!@[3=QW6? \A>+?5,2 (*<[E8/Z'NY/E.RQ$.K ".#"S"
M!:A1$:T/6TG5U2-\T+,-X*SOVLFWV#$^J![>"T]MDWI$!Q\&>KN<)!6.L_]P
MEB3KYTHR(N)JX0<7,[OJG;7-PXNLRR?00=0NYPL13Y5V_FYS5[[NC"^;-;JC
M\Z21(-/56&94R0<Y]I][Y9']/*G4V5R5,N34$AAM/(5P+^ *;</I)LK,K)X!
M-6;%Q8]%&3?/S^SK0XOESQ<8.=WF%3WI'LU;-W^E>F/%X1E\]UZ%J:$ X"GJ
M+.O:55S^OY[P 9UPJH6EF//:!.<S_+0_E0\*Z<%-:"GR0=9_<E<%]H+S01\?
M_:SL6K&1C-AK;5-Q7BS ^O3P09MNP3ANF@P?Q",&^W)J[Y V=3[A5F&"-XHE
MP/R1_[EIGUB)'^V5_W55\']WIT95.Q%TSL ;;^GVGWW'Z-]C\&?W WR0&N\*
M;'9A\(<\'R2@R6RI-CW<$IGFB$VA(3CIK^! ,&(OQ8-7LW>,#^HS9T"Y:#J,
MZQOJ_</E+:D<O[M]]IW#4K>E=HRBC&>?FK:E]<:G9S4D]^PO[335X=(KN5)@
MFQ1_2\?B*[$7[4M52VT<?Y-^-V!OH7I)^=NS:Q-MY/!6L[Z^3KOQ'2OV24/>
M99;47AIW/B<7S&ET'XQ@N=OS05Z/%UM7MJ&\PS"V*4>-FP8+!/_"\0$^$V?0
MN ]N4G&<B*)E@Y3TI#+@T7?US[X=E+A7-W-T_JAN&U/1UY>2L=. _"JFWCVX
M^0\=B+K0SQA=LL_Q*)*P"&F_8C3BM9*A@2(]O]]:CO6F#QX8'> H,Z5B&IVA
M';0:A5.SG"FU=KN\*ZD*>E7 UVJ'XN+&#E4O^%.+HMM3B=6:@AQG!PN [L,.
M(^K)7;@4ZCXC5^(T6KT+*\?PBK]97E"1@%$,1^M6"/GOV92B]%)?-YD5L5 F
M(DEF4O=/>4:/_?A]\/O+'C!JTX2P0#YQ;\#Y2/.9_G//"JRFS%4Z[8K/MJNH
MVEL1O!R5:]EN%/*B\R..E/MCC.ZL!U[_P\U[KV:<VU^9P+-L3IP=R"^9K6ZT
M*SWLF**G]M3>J:7B,[*V7LXT2BU%J3_ @7PZ0#+&62VC*Z^HB>! Q!8M:?=7
M U%:U\3$%+IM=!_<JU5<S7/B#>L2#ZR.6;6%RZE.;WG13!7ZGME:9A]_W")U
M)E!H1FUF9<M)]L,-![_+-RH3I?TOT5Y7;CO<VPI:#SO])L NL'[>VG3Z:X,W
M+KI@YBJN<,9CJ8$U\J"^@24.]WWP:Z?BFN2NY-R:$VEAY$0&F4Q)^T1N2IO_
MS)W_N!547E'8V-*2&418DI*"+"'@O%:%G@Q8+<N!6[ Q^%$A:O=[W<;6>5>O
M ]YMM94N>HG4%2O1R[>,HTOB:\>B2)*4NXZE>T'%Q7Z[%M'YR_H4:XX)*@U7
M-#WH^P!,>!C,>RJT!X?;!!1)C^(U_^P)#EK7L;1%M>:,#21[@<&I'6QY:^&+
MF9'Z-JUGG1[7DV/_[-/WU!TZ\>K52_&M9CZ(T%&^U%28ES=C^LY?GTQQY$"6
M*U:A*M4M\;S6]5-\D 7WXO8[UHGCP0[^9UOEH[,UAB?UD(;R(Q\W/])4KERZ
M?\"NY,V:OX;R2?N2XJ4#=L($C?<2[R\]GW<_7=>U*Z5C'1JNVZ#O?/Q'];25
M?H[NB!4?!!5888%1O!HN>M6J.8X/LB(UC:"(!5N!%67*N0.;,HU\$#XJ"[>=
MA1JI$X[]-=M1UO+\L*W#[/-ZLE,->/5NN;3_<*K[7\D!/>=*#SSN?.<0HY<<
M8&IOFWVSQ?O,<&0/131J9;("<CUS?3GP\CS;H6'S<[ >K45PJOA:/JCWG_?%
M=<;N]N/EA.OC>II7'=K0;Q*MN#:;4<TD-0BPRP?]V<BV'C<,Q@.B=Q@O?9%?
M\H<G#1Q6,VZ_#_/Z$QZ_^< A>3YM?O"9_-,VD2,_O(.\7&9RG]8@TUQ=.<G+
MZF]53<]VG\U_9IM8;7'WF=N9IC,1(P4V+WZS%#RS3[\1OI=\T^:8V]D>;4OM
M1,_C%EIQJ3FE 9%*0\U#=7)<M8V/F9"ZI8@,R8BV/ZA,)FIA*@N9:UXDO>3U
MGH%B)0,K;!BPP9/T;1]\PH,R5%+.I'B3R+IKO]OH13E>LH(>7]K#LW)?T0,O
M'3J2B4@@0HG'_O*I%I*F=]^>N-87B]$+.!&]4@SU 3^P</.@>&YI*@T1MTW<
M$]#@QXUY^U_-OU\ SVJ_-)J#\OH_KVCHR8:KQ$>R;=#V]O9-<(KIUA8TZ6H,
M4W!U6CR9YCT"_8Z?^WQ_X6>_H#92";JH*W.>/$G/Y(/<QJ#8J2C]Y^#)M;7
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M-P_U%GT?$\A/\=+%BNM7;+\(!ERR4Q7("PO'.I![!-;<.1:^&W&7">1ASM>
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MW1W-4(VYWE5$.*+BUG)QN1H^Q1 UV#-4'U@IU\Z^BY*S5PF9LF7BU<7[P0"
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MBLPDFT4&"^2_1-LLCS,7Z/I1O#<Y]\T.[?)5:+=FN*>[%"B\4CNBBE8HZ;Y
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MUT2Q#V=O*(4%OIK4_VYAA^J(]BXJKO\BJ=3[B'#&6<'F4SE9G?!-8G_ )4$
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MIM+>LN!8N:3/-36H+5B2BR#L3FQV^IM&<BK.?;U$]L3H?K&MG% V!?X=6U=
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M82N 9TMU*F7+C,$/H;:* WB[X8Q8JEC5@Y"<G9G!53P41ZX$F<+;*>PN/PN
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M_)?0:Y*_<6ZBO=@A8:DLSIZR_!K\:84J_4C;)=A).YK$$J9*_D5B9!C,Z]!
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M;[UZ@U"TZ<%+W:=BQDHGWI6K9NW^#G>P=V?#'!=4JE OJP_S\E0/M_3Z]8O
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M=D+'G.FH15765XXZ:Q1/:I!Y@1U$51T@<G]$B]!#8UZA+UT97NT.:Q.EF;2
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MP0XAA'381 AYO70+IR[ML-8O$/Q'//\#'S(E4(852+U2"%G-N\.@?"PC<"3
M(#1HC8A 3#\30KY=HXC@OG(9L@)28-SPIBKJ>1"%EY:% O/-99#U8A='(413
MCL1+7(%QH1VX!>-+PM'_Y!MMF;%;FQZ#E(."2)PXS>@8\-48<)^&RF-,V#KL
M26]%41;Y+;TQ8-;4G_E40?O"P%*5\SK7>)7#2:-]7W43'G)7H8CY(4D^ZNM@
M3&N#W2TM183,O:$3Q:BPLYWFCE\+,A3&;^XI\'Q^[=N"50-[^$WM6<<S_&J5
M??+23ZOKWIO_6+IJ"IN-X+H+!A2/\$LHWM0X,"0;_%!C#P;NY\"C)>2>>3V;
M\,[6J?V#N#X#Y1=OY*HDB=YI(]6C'7V9ZLP+)-*&AMBF[%;]^AUHZ#6]G9=9
M5RF9K;@]&"DO3SKB\91R5&]WFN$I4LF+&I8@]4AWWKV1.AGR[]V#2-GU%TX3
M[_8)(17LVL>L]%WO7P<+NIKJ;$,=_"/=1C:6TI*7WH^B5I%MSPMDF^"Y0RN2
M\!876.HT:XB>BO!):@7K27T=FG1&8M%U.YF14_4I_+;/N!>Q8"T8@]T!Z$UG
MB]#66TF2\SD'6,18':X%W'0@.$$]XKQY1,05^QU/TF10^CXL^=F9E9"0(UHS
MU+L.>2OU61X/\,@ ?1RA$VB5B<M1V6>=;_ZV^VU7*<4P6 @Q'!%"5FHR9M&O
MOY[L]))+<DHM"\_V&2VVSOM(/#?T+"4S++0^=8!2?TCYY?&FU;SO_0WV9)_J
MG''IS,*"1MU\'3>=ZB3*1$Z[.C-(S25[NLSX+S!*GL=S"TW< W?DX:0:$!Z0
ME6#7"_LNO&5+YI?4\&QJ A#WC":OW0V*\#J&:&$.R1X( __]W*!G/X#T"Y'.
M77_3#=TTX$P'K2ZCAK'[YY9/_F[_G?_[4N=$V[FPL$7-W/I1SRZ_)=)+;R$D
MB/R K(HKG3I /XLX0U(;KQ%AL#9"X-[+YSY7J8Z6I/8@?2)4!T@Q_MS>)V81
M8&M8A@3TSG/(Z1U3$#9U,8X^N1&@2WJ4UMH)>NS4;$3<C5K6F4)<(-%OXB>)
MT]$[2(\PQK@"E\G/3]_1'\8Y'+#TV\3TB"G<VV&3?!N*_&U][C=2JX%)%_$^
M_</[I&.I^L,CNNK'&G..$JHP19.J9%=]=6=S^ ILWJLEI1;166K89.U[5@-[
M7J+MX-4.\7U6O;>ONGC:OGPA<[!SGU.EM;G?F4E+S@E2+"+K8CP$&.04\),,
M1+E6Z'1.,/"@")W93ME#5L5VH0X&+R=0Q<C*Z'V5";C]\]\R;PY@/*</<49T
M2JPGK8 0MMX/2I?9<[$6#1[.Y16#*^&R8QZ]8V,P%W[_*@_1:[86]+SQ%M8Y
MQ7--JMH4";LDJ>6)*_8(*N]4.V-EGWA*JKU'Z]L=SA+\BK%((B+==CEB'M?E
MKSE^]">HF=.W^W\;J?U@TKMSD,!JQ]QE57"T6;*M@1/%G$?\,GB#";U7$7,=
MX.<"\&8)')TSH#Q(EN%ILB2K@_&/$+O]7^MTF?0U:!;YM3>@Z+KU#>1ZMFB<
M<4[^*\3$8KI1J6.6P_O;XV3%*(>>\B\S,L1 [$$<<_<>HX"<Y(%7K+T/ZUZ=
M<_QHCP^LMTSR"T19X,N_D$YX2CP^\O;15:TC\=['DZ_,)!OO[SQV)ZJ\\YC!
M3GOK"_9?L^Y%\P!?!"L M?@VL C-N 0X<ZVP4Y1M6 CORHBNOT<'H;RSF3(!
M$^Q#/=!OR!CM>C6OU"JK"!W60KR!^S>5UU4,DZHR>]_ WEQ=.'#&:J(31KT-
M>_R<M,WD3+*L:#I]?FY_TU#Q)=CELQG!*QJE =56OUHE"&1<#ASA6CYY]12O
M>ZXHQ#W[RN7\48WJ*7A:_\!\O6]60,G@!WXN/QOAA8RFEN.:\=L$O4+(=P:'
MO*:1,51H\(M\]-T+@ZVF6O/'(TI,'(:79V[6C^A^NFN=L^+(WEF!7=?;)!/#
MPR,CE Q*"&%-DU^71%?G-QPZ;H:GJ9_[4/9VRL/>3GOWG)2#3KMIHZ=3Y<:"
MD=U2A\' 0,;ZD4.7U?K+1XW]C$U^K"9GZZT>>_EVN_2O(K^U0S3_W9%>&^U@
MY;WUGN0.&BH0UZ;!OD-#Z2J=L(GS6U/\,2J1] MT0]EIE39U^/9QL%-93O /
M+G9%M<#V:^C"H.A,"[9BU+N\"7[RR,+OD3$!59+U,30)#K09%4W8>NE/B7';
M!BBS\"V<'"C@S^ILV41%8Q1HDS#]JY5,)9.:DQ<'>\\;3N6^<I7QZW:P;7RR
MO)9T<6'EYR$X'$Y2--G\$"8[6TO>]^[LN<LII[.(IS]HWY@NL2>K'Y)5O->M
MD_>JQ:TG5N<&36ZH\FFZ*N%8)%%/G8*-<_Z1TLM:N#<C\^WF V.(]*^_[=@:
M6@7YIP^E@R*E)C]0?MN:#KY 2A(8"3JPVP$F>Y#CQ ?[$)HR.["5FB"$E-<D
MA63?;<%JLFR\V2X I2GGY, >/%N$)IK$7(O4MHFU9<$2;XWT?5+3S*EY,356
MLAY;I:D_N\0G&;K@]4B_,#P37KSG%[@^][13[5G*OF44F$Z_\YY=J)"7JG$I
M2RLOU5C,L?:%J0K'F1F0I#.XX5S&<=MY"K\U4BI79F:WTPE(GE+TZHO@;R(,
MY#B2H\."+I:5"/IR] 8PIG3J8X(TPH>:J-_9@4@@2!F@@^,:;(JG7)KY!!IL
M^UAU4H'/F;K ^X+#7W[X0M[!^E15B/^QO(X\,4G*(Y5U;(,$/>@);^I%SC,'
MJ^Z%3P4Z&WXH]OCJ/2<N[7[HDW5NNON7F5HGTV^=&3HL 'WAO)M+O'5#YO5X
M<^_)XGD<0KTF(GCU2EK\RLX_CC3^\X\=D906$P5]QMG# A->_.VSB.<J^*8(
M'/RN95]JAL!5<X2/V"YVOO(38T?(UW<[-A'S4E97_@L7*.XD-%#PWTB?E01[
M,$+(DUX. LP0$0P'0396QN'+E Q8[/BD""&QX ^OAGN_(E[ >'FX[X20T60E
M(60D[ PB-5Y]\XL0@ONO6E(Y$LM^!9*?P&U:GPNB+EWMY>YHP\T7PAH)6P^Y
M-DZB'E#6^&S0[AQJVA;XTJ0/M52!N258E)7G@JP/EX(M>%KBJ.!R.)X?RT"L
M'7TA[/M/UG)[UUKF$J.CH#-,060Q.U8@T<@V^1G8>K:[ *3FSVOG5^>RS[>1
MQ8#;6CG*&3\.KOEC#?U<HI1S>A;Z(BLN](7X:U3]GK#(6<<KIP[=NU\NN9H%
MN_35Q>*I>\:Z9^8USD1_1KI I'\#5@) 4P=[#&ZR.C6*7Y]R"6K5O5G"MFFY
MJ5.V/\&^1B/+_\2XD3.G3K!-__8](41-"+E  8X2%QM?8'L195ZM0LA>R:,3
M@YV4@\&3R,/ G-4G/TWFNSHI2FSE6Y)&4&"(W\MYAZ>=GA5'C(=B$7JP/L73
MC+E'M(F#YVN+:JLNE]3EY2ACGN$SON"*4)7(QV5RR(?G]* 7<Q/1T7%?K%ZG
M#9]\&WJ ?/KG>QAU61/QU9EA]1"3Q3W]HPA^(*@-=\#VJKB8*(QY31!-6.E4
M$$+2CU8M1^K[ET[B6F'TE(P!FX&3S'G^O7"IY.@O)PP1XC_8!9&/)D4Y*MS#
M-.XR".;F"5(%83#65?QX#Y43Q*\E*_OH&R>EXF,$WY\#TFF SE=3?QVN-\\\
M+"S\;OZD<U=8:.V;NDN!=RO'QE.#. J&V!NP<O0I_"9IK\=MITG9!RD>56]I
M\!!J5S9_DX/H@X\/M\'&!5I>;V5\GUKUU"*ESEUPO!A27@?XQH<Z]T@'H9]?
M[ H(N=N!F\Z&536F+UIP[=%2C)PJ(I#@Q K-]*<KB';4J3SZ2;/45Z PNEJ<
M:>*LKLX/O#08HEK)=#*$V==4#E==KN :/^,]XHU-C0DA/Z/8^T<7/;X1 %M8
M)5OIL!#2HL0BUK@A:,'<L'E4(!T*N7G8/-NJ\YK"LQ:^F],K\BV$KKFF/*7"
M]]WRH"W.)%++*+[!BR'Z>#Q0AI7X;30&O_O:-U[8R,)(*\7_?@?#R\SGYY;K
MTLNQ)6:2[XC>QLX7A!#V?NJBJQ#R8P2' -[/G.8@A!AE(.C*E+$:P>-U)N@E
M#]-;2()(71:"O7-E>39?"'F $/PH +N@.!%VA2 /!SB##</<-5R;.:XLD+]O
M>0+LDL3@,2C>)EAP/DX#NSWJIA(5[+<$^U'BE(W5?M#T_(P$OJBM-W.?+PF.
M03MZ-Y^ .2) 10C)C@+IH,K"8&SOK7461-Y1F#@."33:_G$9)"^$3$1/"E1A
M,0@2SRWG4YEUPY%>WW-G>]+?8OW.^UA07X?T!W.UP 8@;CN[HAIL(6-J"8(P
M"2%DGZ:@G;)J0@&I\HZ197 K\[F"H\[\!-P7/'90" %,,:"/S W:@=P%_C-W
MX/?WBS*\^%? 7J@&O-#3]/=$^C/RWX]$\H8H+%"LWV-Y5V!)A#4P#+9\1 HA
MYT7^[-XFO!]KN >$D'Y%/A&\X5, 9*:W  ]$.ZZO6 LA3:"&CL+8WV//X(;P
M0HA$$(*W*/4''<H_T;G"^X,.?B!=<-1IZ_(OV,%IW%@NBXA(YVGE"J01N[2_
M=&BGS#OY?=K019I?NKPQP R\@/@-EA0JA#R79PHFMW3I=>T?DG+JGZ7$_ZDR
M_V847X607?B61# 1?\G?(D^YOKP)PO%/Y'$;JT*(ADWZ0[E-JSLE9H.5'J0)
M@9WO/=/U\6"_'T!M?L<&Z<02^9?IN(U/0LAN&'M_[Z(S:+C1G-^V=H;23+8,
M-Y#W8]76F))^&)](83T!K!'I'1EQZ LYJMQO+XLBU-L-/\*,NW:2/C,!L4A(
M@]_(\K%O0LBM-F<BW]SD?]N"AW%M\KT4, YO!W,,:)%M#X!Q(<0:P=-L YO#
M-W_B/3I_A[8N :<+YXD)(=^._+_=TJ! 7"!'4PAY:<A%;A5TK*T-$A:PK?CA
M_._CAZ07M=L<K,UQO,>XO^#Y!^$A;<$CA# O &@3FB5B+<1J2RQL>RT#[!_^
M0 W?0A!$VE*C><:*SK6UW5VIG^Y,9),&%O1#1ZNB_XT3OO@;)M3_=>PS_]>^
M_'\#4'_9T7\+/)3K2SAZ'W9P:UB#-&AZMU:!8=._F21XQZ<(+I(A: <S,F_3
M![&KHN.MLCY*\FG]U-  2F*=I),[%VGW('*;@9\04@A++:O%"T(7X7\'F#^3
M'?'_+%QA_PA<S7]X;[T(3%0(\6%__0,ND)+M,A#GQ=%D"#1 \LM_7,U:90C\
M'#845'%M1WI?ODR9C^@)K1 X9=5QZ]S\:S>,HG _(.6'*9]-&RG4H#-@DGKN
M3?@[4OU[QH60?RTJ^-L/O%M;Z L.@-ES[.^A\V< _$N>V_M_J.![\+]=FIGP
M+KSF;A3BID%-/X$"OR .(1;^J< +%?T'# K&WEGQSX4LXB]L_C^'33T&E+23
M__[O4:'\"Y782D$WA>6VM9DH"Z"Q5J9-H@1R/%P_QH:M9$\P'M!%2@,>M.[T
MV)* DLK)3RY=19]\$#)5)693DXOW/,<EO?*FTCTE:C+X;=MO&U8,)F<1<$1:
MQRF49-M'W<>T+$^- T<_]F2^>AO8Y1GB&5QI;D[H480#Y]O(N[UJM13H(3%7
M/V"=#T\0AM6&2BSZ<HY6;<]72SEA%.![VM*@W*4:,S%N88P9W_C^O_"5W.!Z
M.EM@QWN(:^XE?#LGZ!1".'",KQ R2&HIXA]JH6QHGB:PZ)0U^;=\KU4POZ7@
MIU&;[#;<9L]LY[<R8YQK, 4)I@6</Q^'^OYE0CC.561S0Q,A&14?&BDU:$&!
M5)5$PFMXD)>_A*Y,"L![.GW2T#(L5!V?]/*O'NS[+M[-S:$F?6,'A?3#RVR"
MUV1@TW?Q&EQ$_6^WI*W?+(Z:K$<V&Q^0,.I=XD;%[Q!")#=Q3>(G:M+3>1!Q
MU7%.Q&1 8R,F.E =N\WX0"3!,ILCA-R'L1#OL/KPVA/Y7I/^WTUB8?E;S! ^
MPD8_2EM7,&O6-B%6)E\4&C@;@8'FX!>W!7Y#$;](6P76;[[9(8UUWE$Y:3[Y
MGM^(B8K7'"0% MLV_SM>&_;_IQXU6?^\77W=9/>]Q B11?45N$ \E;MS:Y&0
M*$NOF2+&TV.+6  A8314@CRBS6?-POQ")JJFH6J@08'1*PDRI9DH7Y VA5DW
MTJRNXR(G93RX$I"'J2+C-%ZWY[D.U*^Z^>+Q);G]G7[*P\<7F36VD6 PR7*_
M=-_@(DU1I^0A>@%CF.U^]YR[]%OEL[39 MH'4E=PR0RH?E%G@60J\.K5(8%\
M0LLML0Y96M*&4LWWP!!6<9A_G7< "!=M0<;@H *YR5Z%CUA15G(LK;?*V%\A
M3Q:>[]/G9&Y@S]HZ;=,G0SNHRJ0KZYX\-\"(\=[%/;:I(TG&9-RTIKB1(2NQ
M\#2L3@BI"4:\%*00S';#\<]18M,G/J>>CGDRZYAVW,PN\O6-LE-FF?/AQJIN
M[('-\XIEQMAK./F8(]-8Z6V0<\RQH"^G!$@S@09B>N9&&7+"9MHQALCUPVB.
M"$;K'X?B6DSEHM]M3BYSKPIF>]17>\4^CQ[\.6KB[$_F:9GJZL[#WQJ#O_;#
MQB@7E%7Y1VNO2USI@M/%P,A*"F;I\NJZK>TC=1"9T8EK*JNK# I8"8SD"2%K
MD8A>(:2(4I+U:I C50SW@;]>^9)1Z3]AJ)C@%LN=)I>$K87FBW6.J1<KDRHB
M."&:^=6[&<F((P)IK_D-**M@(S#/0; ]D6DNP"%X8$C_77N5%PM8$8B?$2U)
MB%3<M#<B1 A!$ 02N,]RF]A+O!.]@]]@-+-^ <C9@^_Y5![HN("($/+]']<O
M8PF_""'B]W!@#FGJPW[]QZA>)KRGL'1@H!H(6Q,%*-]V\_^9TWPPI!\+GIQR
M$EVBS'&%D.9 7C0"^3LNYH_OJ\[SP&PC<H%+V@ 98CG_&WX,J3,H8#_T$ZYW
M70B)HF[L_-OE/[BRKL0]1?R]_[09W' 0[(Q>1ZUL""'3-8(+?XB0^ =;/O_A
M+77^ .@W_BA/@ / K/C+'U+D_L&R_'\]/+E(4$+Y+2'F_IT05L1O))[D%FXK
M_Q:W$_^Q?,CEV#]#^W_QK?_K45%U0H TE?G!6V((_D2,_T/VO47TERVBE']+
M-.>_7?7_UROQ#_FV2XR[8K>>!*8'\O#]R\ QL+%*^@7[/I)")U.$D"%X.XH?
ML .7^_Y^T:E)<>TON6#EAZ"A/N2<T7(10C0*!ER>_W1]8GFMCD^I!X[A$JB5
M\3H,^J@H]^RKHJQ]XD\K9BL$4SV_I7_R.]HN [P5A/T7+2KZ-^N<UO_..J?1
M?[7.B7!1&9>'^PZ^>;<-;--T/XX)[/&'<2"N0:!ZXZEO])H0DT07_HM%(_UQ
M=!H'^BA#K]7_4JM2*UFYGK6>JA</-PC?\QING'4GDDB CD>FW[VF=7L;:=Y(
MM]OW,^;<KQXG.7>(:W:*[QJ,)5!V^<Q(^_0J/ <^K]+1<(%&BLYR;.=I.Z4>
M'E3*<98_70+U@7(2&1I-9FP;HLK2NW%5$^=@2T&]$+(=5%24CZ ;44EBIG,Q
M&"B )Z+?\J2XAI@?V=!' H76/*!4"#%OJ!D(IL;E&+'RXQ<<HE1O#)7:F/2]
M#@I7FF.*CSX,3\S#@-W(#E>0&-9%T(RHW*X/BQFT;01@[.,M@?LPZJ-KIMV?
MNFLXZ*IJMEYTR/G![5"C,MHGRPCGMKK0P&KOC-F$X-[C+Q1_XZ!4GK'3SI .
M-B1(,W8Y=)U$9R',Z6KN)X$<8ZKQF=2T)_>J%W$((&(UB:[1.2]ZJ56#<S4L
MU6M*\<;5Q>+4B'.#O:>RSJ4%:>G1"Y750G+Y+]XI.K<^/=50.L%5X92 # 8*
MNK=F>$^G('90_)9%YZ?@L0S19)X$U\!O8G%]2IU"Z5,>PBJC[UZDL%7Q%X//
MA')F(\W8):$_)=QHDSE_&3I!J4CG[3<7B+6_PK8B=@HAOK@)N!W;X>$UMDHK
M; >ZDPY-6$/&C;H=9G5DOP**#AVZ4%M5><8I)+^'6#0Y;Y]67(;#>>WE+WT$
M#DZ=H<N?VT^*2N=>5HH/>G[C>HISC4:69F3FM\6!N WH/OYQC#OA4;A;R#.'
MEMZX"IA<!0'*,CL;&%H@(19MTW7[32)[KUEQFRW18J30R'ZUW*F4< &4\13H
M?NH(7YPDD 8;-^'@ATD&R)<3(ISE[3P;%JD-S3,,#Y(3]&2VY<CEO&<X^.O/
MW]] 5*Y>;OP!VXXEA./2\!,H3@1[;K&8O;44Z#LC9:>.G!.LXR0.M'JB76_,
MX$+>E#.?\@/[3.J<=C<_N\0[_4S&:XBVV]4JAL\HD<F1'?'X-*VE^4%; XM0
M[_58+$LY&:SNS@A,UIFYW*/JR_]=1:6@O#JMG)_YA;1ZGY%\AIZLPNIJ=ZE?
MP#@^Z<O-G/9<_"2&%)&[));8:O:0:),SV#8]AY2ZG#<_1$1]LN4_S4;M8@JP
MA+F-,*):&C<79^ Q20*CSS#11A)V@];U*"8P^?7L6Q_J>POX<W[WX[9+4!F#
MF\<?R2?IZ8><DED8;!U\-9MZ17THR/RYO]=OA'2132[NEQ.W1#I_"A(@YXW-
M<GKV<FKK?*-2\B^FOUVVBR'I&A4-NO;+G-IP%0\N&NYP/[G"0<>OGF/KV*K_
M?*<8K"^?$33M3)6Q#IJ:*OX[U!R6,8T;#,5/B%[?2P+TO! RRFM\%?+F;D'9
MOD*+.\B%U:_<*]_J#/5?S:_''^11%G[I:+#<@T;YG&CX,2@82[+<CWUO'6*[
MH345K^5P^/UUK?SO]$6:F%^T>R*")O-QET"=;$V)0%6@\)1IO. 4OTJ7"SUH
MP2XV <+976W5#C^CRSF]K5:^""C/CF$!O2#QXO'%R&Q_#.(&W(8)FW=("FWC
M#;-Y'CD>IS%&KFN[?]1,ZBE?T%5O3;-ZVC94(EY<7AZYF(V?@^=YQ<L1M]U>
MCQWO%;UY5@5YGGT^!HTZ\SI_MX7:<ZS'87\7NX-U(?L3/[]2?\^T&3;U#YS#
M28YR>;<1AR.UY_NP=MRMR0'V6_,VMU;NUAC%<B\MH!1N8>PB]5K!T!A;+9!+
M:"6KU+-6@TAQ.D*(7'>AYI>*>%1EH;_B6)/IANT)QK'AH)SPN'=H+X7,:V5[
M<XXF%D[/6!\NC^>,-:BE/:FK2PB=M-A#RL/';:1# ,TVE["6@Q\4;DVJM[$$
M!Y*/:YTM.IFF=[[KVVO;.<LD[V+N;E=GDYPS(4?7K+Q7E@&5N<5)D,,Y((9.
MF8C^D5]!5O4A[ '3#GJALU4($6.&+"?H.[2.Z[J>UC3I"-W\0)FO:.>_O2L^
M/R$ZL?3&XGG=P1NROP9VH@XY?ID(3&QP) (!L^J]T*OH7+?*OH#<7]TNA.6.
M+ZS;;QH((=X,YM&%P47<O)< $6'U;%:NLB)Q]B#13,ZI^5J./3\?OA&^2T\U
M7^6$GJHNMUUBTGS)@Y:NP.X(H0?&G4/)]*3)/KR36!%UZC#\<9;/0-0FYTKQ
MS9Z0R%SKH+;W)T=T2HZ_W)A\V\V\NXZ;>2Z$P K.KQ^&^GI&AJB58A<]+2D5
M"<BTH*J#Z\^0Q'7\%_3-JTY+C;N/>\84:ABD5W-TO8?3E0VM@QX63!-"GQY3
M"UWJA(T6F-SR2LYIK=Y[_]0CT=&:  *2.%!^]?5AY]L=%QM#XCGB^X(F/KY_
MI]>/?9G_W--NSEKGKL%AAEG^V59)T%]#U!P*<JT;3[SJ[K$P"[AC&A$W/JY\
M@V&(!SUB8765>,)+Z_W]Q<[,#0;860%8)UN2N9C*;N?8BL*717,'\^-"0ZD%
M(V.#^_!-T_RLK_0WJP?4965BVZX7V[1>_CFM[*&=CW%$_2G"'(\SQV.;*)R/
M-*3D&YN59B3D:&6\.,;^.946^&D^EUR(LQ>;E;M([(KKH,G\Y!K@9(G.T*%9
MISHNS)MV7PYZ259M69BLW^-YPY_X.> 310O!MU4[X%^\XE&K@$O?.&S#63J5
MDJ9%*"O4T$Y6^?AYELC<>#I/U DDS7MO"G[^$F'VZ\>C+0,DR_CVR)OXX<E<
M5,Y^#F\AK4KUVR2AI!KQ$@H<B^5)F7!\MAZQWX0EH0Z0M1W1+2OM6%$@C@2@
M+AG!V)Y+L<1VXCP*RE.GFP?JOQ]1'?&+?N4W2O#^=#Z@>NRL#&\)K,>$$#L,
M#NH5GN:>P[XL,5$$8'9J;W]EIB:_8E.LY^?C1WGK^*F8T#.U!_V<P";%&YUC
M37D^?H'2FDYD'.VJO;O ML^/(5V2LZ]R2E4ZUU)<:)TJ1Y39_BS([/W<JCOH
M!NY;8X6Q'Q UT&9"@M$9@.G!.)1]MYDBA:,='+C!HL:3#!#>.AXT^![?INX=
M>7>4VYOJR0W=_>>3=TX](L^PH+S]7,&N!'9KVS*+04-TSF.,&>]&V+=X"!I\
M0L1X"&.B,O8&3K48T/(/S/S9/*"&%.@9^J0T+%5$=Z-S7Q!!UOTN;UTL];UU
MRPQ24N/2SS$,:%&'17UICB!^?=!\F1=(7Q_0FQ=] N330^V:4[Q':4O;2%%I
MNI=V?>W:D>YQTC:H+.>(B8Q8S_ZGI3-JMD)(F)GD^W?G8"FP2I"U"@M^.F[Z
M):K"89%&Q^_UG=('H-P+P$K+F2EYME+7G@1Z! $ZA2Z8_)'M]6C-9Q4X$@7=
MZXWS?=-3DN?4[A7I7N(X59*?-%U?73Z'FZZ E4&;X6.Q#%@+7 0#+6/+%. 9
ML-CTG&,C2FSH8ZV&"W>U"F4?!P9W604:?C3E1(14/X[V)96]@=@UDXK? U/5
M7IFWJU2LW-\XDDWCVCQFM)S5QNSBB%[JQ4;HR4\F2P;0U2<]Z-XVY/;;Z2TS
MO%.= MALPX6VL[X#IK0*@X)J]^BVCARU$'>HAR794<O-U_=NM--%BPY$$FX.
M[!0(1.DU>_>JGXTB\0'C D*.*&K0J"(FU]0^BZ:OFYFOUN.KRM7UUS5?&IF
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M7R* PNL+#*!-\H&B[D('_7E%6J5 ,G.WH8#CF6OU)?*D?15^X/D,>J#O('Z
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MSZD[F:Y'B"8T$T6M+C>S1I-*HZZ)8AVYXFNL&X>-;IV- ]Y==JP8,&I5]YK
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MF:G/T&<R'-T%)01N)?- +:X;6(8Y+9HXDM2FUC4BOM:VG]4$STB0_T*MS]?
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M$:5\G(;/#-Z'_P8Y ?AS!0OX<#4$--/$1+UZ_97+WK%AI Y]^B'BPP #9LL
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MIX M6B88!^82N*W!4RM<V26I,+9N6HE'(\Y59\@';M%4M*C^T#6Q<VXW0+7
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M[HG-("N9.?))(Q>878!_13,U &/J)Y04!2N%3.V6-^BD;CTQ>18RKH?>C./
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MUO&:YHP0S< $!08^(^QP7R,%)P-8>(9I%;U]<Q$R'2]9R8QCB=PC?J9IBPT
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M[+> 0[\TUYIZ-H\NRF;JB#Z8#'_EMQ>T<'ZZW$\_);3"<'P][K!P7,>H5==
M$,1?RZ6ZF>[B^S>@3Q%X\LV6*/N-EM0P;TA=SOX<I/[TQ?:-53_Q@34KE%/
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M_SB:L[3VZ8-AW!N%JSK:,4U6V/D/+OE]Y"-'4Z1-CGZA9_4'#R[<6#?Z_.'
M-$H,>R)N&LD7N#\Q&/OR!+.XK+/A972RG=7;H%OEQXL<1UOUBWSVYM@DV,J)
MF4D(5'B9&J]C> (+S.96BBQE*EF6KX?BH2H);C?@9N-%.>H]NM)Z9) ^$)P@
MT<P[SA 9F6-5ZJKT*:G:;$Z:,*NBU9Z,NA1&31P+?K/>&LOZTO'E=2^SK0J>
M2<*@+?L YP+8R;;B42=?MC>&$YI'$?>6UY=W>I%VT)B?XX[&^INDQ-!F*ZK
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MSXB<BW["MDH451KE^T">S/LCNU1$?3ZOKRK8U;QP6592F4EDF<\DSTU9QCT
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M-^D]<5#3TYFZC)-Q+1K#^H29>(U/9-CT+1MN6UUZAPE5'[GWNJ?=@KS[HNB
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M)Q6_;-OU\:;QSZW*$FIK#OZ_-'S)B(: JW.3JS0/"+A=2F#6H%[>6-Y@E$'
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M"!60>11E,F_/<GR^69-KW55G;VR]Q4T7$Y;$CH/#WR3:4V5TLYJ04-(^)\5
M0+,"PMXS$DT82$ ,=L7RZ46MMR4M+=X#*ODS"E]1$62!/.2$%AI7_#R.BW.3
M!#&=N7XTKM$,EAO)X8W7$RPKJ <ZY\X%.$9?"X@1QI17:M>55*G:VYM$^/?Q
M,_F1X98!MJ?K.EFYC9XK?:I 0V=5,"-C%'ORN-&"MYGM)L<+6L>9-KF Z<IS
M7FPCVZ9#Q+[A)Y:\_E]C=(B5\7")@5,:'<\K^ MO:@-DPMO;3#0_DG!R2*\T
M\H[5BP1!1 6F*.;U4^5I #O;V]-T[AQP'1:^+ @TSW7YV5V7I#!4N0>G:1<L
M6EP<VS(P\OZAZ+)K194*G<)13,$\<3V)/9=0=4;6]1X/V9GF(O84NU]0,;Y<
MD,3 I3OVHCNVW4!JJG=(7N^OW-Z@(^BZ2+G-E&\'/;OO 9C[SY\X1LIK!XL
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M1V@?3&?&38;S%O@K@6IJ3^OGA"F^8'4U.',E"4U73*9]FCFMP#MU1+%/HE.
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M;BWK".VEA#T.]?7"D :&><ZMPFN[$OP@B!VT;@GJ8H]>[48A<YSF#OY1Z,V
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M+;]-33ZX;JRV\>!](6LZS!+-KD4;'(HN;CS;U>]JT(YI2,!"D\^Y<]-J^&/
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M-$#]%WAB"RZ(P'N.@G] :IU+D3U0D8K%Q>\VIO"S"6@42I4AJN/@!\/M!_+
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M3NS<W#,!=:%Q$A*YH<^6G0 O86%+1/OZ%*1'XL?UK0YT*_-=:I)F0]V=3BK
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M%!S@J*;=!#))'WCUY>"TDFRT?8+HP7%":MOT=>K57D:>K2^\S:5GB_C1\+Z
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M_>AW++]$XICT--?CO,_1'"E8%M4^GY[27_;O*8BV.D*-BJX7M?K8 G<LDZ]
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MM@5&U!C$J**"86]ZTUAQ/NCD,AXE#,>-NLRY=CI,."P-3G,EGI>)O]9 + >
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M=Y4)#W7F 2*@-\*:_;VA]KU8XL_YY\(;0W[LS'/_=01'-*/M]&TZ>Z2I@\I
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M5\8NS=3WWK^41O*][FCP*=T!!,_PM[%'46ASG$$ $;@Z$!-SBHDD N$E@1&
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M9B=A#V4X[[=.BAN4Q4YSOA]?$LO6I:6Y9J(EO?":2N07Y8\C"(GU!SVPF43
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MQ<'RQ25;!>W T#61&:TK;A'4]M6K@,2^U";O00R!8_(K6,;-MT1+1("SD+>
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M<ZSNR+)Y:N.R^79N07;FL/3%PI-(VN]OM2C(T[<>R@[?4)3*(0EA1EX5Y+=
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M6]Y=3X@L_O9A*':V%K/-TLH<[-^)4!V9-LS-DFQ*9!\N!X2OWJ!_YD_XDJ'
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MV 7X;R](A0<IK9/$!MU4C OU;V3(I-?8Q9/^<&&J:VYT<B0\$W-($K8#6+4
M!LZ+02D4;BF?E[#,%E]<&G5SE9*]A(E!W()R<I]'G*@VW8S]HPW:YCY0VD._
M*>8PQ$?_ND/5P4&=-$7DGBR PBNJVV;8=SEIHRI>DP'94#I)V726K]\>,JT/
M(^K\A'CC':F&_X=)"DAA$!NN*F3QM7SM;^\29?-XP2+IH1W!FEWSV&TOGINT
M.%1//P\E##S#H_X>C<TC UGG?.?1,;M@8^PB2=N(#*!>$C#^8UL4G!71IS#*
M<]=^4LK4*'J;D@1%;!?[3\^LH4]]+?[[G(4E&:B@)7Q&(,!;M)ED8'M&";TC
M=;(&"W G U=I1$@S%*02])JEQ(Q$'-:6U!E!!H:\MP.]%YF/E78BT(>24.2)
M4FN3)A9!2$6$@0YEY$GI*.@FBA/>/18@2P;*H$\H*GZ4K==J48V/D5@&7YI6
M>;9?\;< $71BLQ/L CF69^8,E 3OEW(?^C<_^Z=Z.RM'&-F4SPM#V UFM0U]
M(QDT<=K@K5R5_/&;YZI3OM\)\X&3!]RB5+\J-A%OQX($<6]^\YCO3RP,K?Q^
M.BKYQG,J\3M]?O;NA_IO8I'"BQ+ /#<.SA>81>*K7W2O/(8XDX$W5B9[ ;''
MKX_TZ]W\.KUB]R"68SV@2^!E/GX5RIT[F)&!WWFYU52[_N #)](:R>2$(MZH
MJ\E DA49J(TQH3Q$&"3Y$1DH,CC2WD6-0/!7T82T.>(O2Q3I/3=1)!H^0QG9
MF'V'S^'XC]@Y"H(O/:)$)7]W(NAJ("4K4"^1@83316;BZS7X">-R0,P\^'\[
M+\+W?TY[>/WSM,<\@:*<KI8OTA+C* .?G3(R2.J'[WJ3Z"BY@JF,#'RU')/%
MN!]+(CG!6TYPHG!5:>HAQ2R34%@#8K W@GAAM":'('3\LV"_ZO_@!M0IRZN_
MW)!#S$4O\5!,JZN7F0S<=Y)Q/U9A9H./)^60@777;:EMRN@*S$6"#M4<X2?&
M3^SY?_[K'B!-XU$)N^']])\Z;JO?4F"6LG658E??OKMC)W&>02DV;!_U'J5V
MD?1;CRU:$[.>%\U(TSFYKE6#:QPN>QO^Z_XLI%LF-K%ZLFZA==X'.%EIZ%HT
M(T2H<<#'YVA)"3-C8=8$'F)V;_B^^V*8K\?3*BV8=VKUJ>XE+72]H-0T9[8%
MU[C731?>5R@C?&HV/K>_ T0G/**B;A_X-$.H(MI*9Q^36-G\K999Y/.*[;DP
MN3D)CSO]K&?^5/S'5NE_2=[;5X,D"93DF: V1*JWAJ\_J%R;#Y)?"VI90!)B
M-\G &)I8)_(]J >]"X,PP;=XBBD._6%SFI)H=X[%D=3HS0@T)6N7B+>![2''
M*E*1X$/&4?C^ ^\_\&I?BOX-A1RT41!SP#19 7&$J-]5\T6 E[ZTPZ>0)_<,
MKH-?$1D#+4XOP+N_$"@<\$T"?G+9K,?A#_+KWR*$SXZY0>-S"S$HACJ6FR>A
M(Y^#(IN%)KTAEYVX6:/34@H<\NJ!GFKC8KM0#V9AW\5-TRWW[4IQ^YJ*FO@-
MFKZ)9QX]'AX>F@'E6(<6,G!9327@$A8978F,4^K-KILI5GI3Y5/'E+JL*?!.
M*?S:=!65V(&(PDI=X+7%KCEFN".*"F]LCH\+7%1EA@Q40FNW=_:+>&Q9JWJ=
MA>Q@@A2=+#DG@&LN54=J#/RSEOB$OTRZO]J^0TF3?XLXH,2P_ @<::QK\N:H
MVVI26U'!K.KTD;'EQ<,M.L@M88D6=;&R\U/@ZPY3]6QKH/,2!S&@*,CEYV.R
MRJZ6I_U#4345W^4*JK>RJ)XE'!_-W.$C Q2X $7<TY=#YML(Q^;S]S#+T#B<
M_[(WG,)69.M]N*F0M_NB>H\FH& ,BBKCBPNB#;B[Y\T<Q:^0B-D],:4$!H0Q
M[]P#&O9=PR\ GA.P78<\A;>(O/@<)!F@725O9C05Q]2ISGMTZSX53U2(D!<O
M[YEC,_3;[HT%;$+G?=T\5]FFW$O%.3?N1?]_XP%3\![=+M%@G2*2A4%$"J]4
M9W2=/H-W]\#,2!T\**)$=(-7AW6 /"4=W*#X;@[6K(PT#ME]^7<'5YD6Q2SU
M!%&\.#,((R7'_,R"KP>P=3 OW*:X^N%8%^)8%'F6HID]DLB OMG!1,#?LAS*
MB^A38(XR)"K)G008Y8,HK!2IBPZ\/P*W3NU$' LU47S@&^7G2$G=3^P9\5<I
M-^;0##X$*%%MT'&SLE1\/I60@ 0H_^\LY4EULTI'@_];.=7_;.)= ?8X^JX3
MYLY[@Z]V&'7S\=JG?'D<TA,Z"Z6(#ZQ<[[>-&^Z&2W_^?COQ["=/R'DU\0 H
M3B1&8HN@.[]3OH[(>_+@6LW0BV\6V=:=<GY<Z=W*K5W+R2_$ EJZ6,^L@YG@
M(P1#2A]$4_I UW43FZHQL'\TZ/JQ6-+BXT.++T8&(I-H]P;I/,+#W[0Q5'B-
M.^FG4*,THAP^6GV9-D+A$+G_4$<Z">E/V&VB2$)7@C4V<8W]\AS,<N% O'\+
M/\LS@8VW3;'N_:#PY)[V</3)IS".R%:33V6WOD/+ P/B+7'O$Y=5NTAT;.YL
MI2&X9U>B%0R=JQ3,AT7) ,)=W4;R7R8U4 5H6_3$&*9ZJ_H9YO1UKU2;C:#2
MP32'SNC)\#<_086&[WG>97W^8\F$A\3D(#%'?T1\@ZNGPT*WI*R^\Z(9NX=S
MDDQ927LA-1SWAXJM7R1ZOL FJ<NDB.-/U?81,LOCAGUXSVT.")^:SJ[L:_F2
MQ0FU#L1_FPPI@4]2D1YV=2$/J0;@AW_J4,'P<H,.>"@98+^&B^M,7_ALR25C
M\2K!B:E<QH5K-1IRV[-*"-".M6TTP"G/TW9 . ),</((#EWL3$G3U]P)*WKV
MT1P'@W*Z*->Y%\"?/2T:A:DGLF*:8UX&!GC:] [S'JX(3PA;>*K,U9\.A9/2
MUBY'VBEX;9)>5POBE)L".?ICE0=CL>"ES29NBBU5EL+7-B\<+RZ0@6;F:,O2
M6NS/KM_K:GQZJDH;JC#SG\4/OO](G.CEC$66/S,/_')Y[$^"S78)#(X)*L)Y
MM?'+0"[ @A0J7&^0@8=0.1Q#>(Z\E%M+6V J(/4.UJ7<6'0AT2AY8/<M^O0Y
M!:]J8&WK3A1G\A@K'^L#7<S&)Y_>";B.DX_8:N#[NH:2W1SGB4%=U%FPG-SV
ME1MPOE7\7&&U1G8K@V=4Q3:PX-AR->)5[[6N9V#'BE'N]2//\/&G#YE5_FP/
M?N<:^4<,_%NO.6I6$&^;!WL)9W8$30UN*&7[&'<MZUT;%FL7.WZZ[2 @^N)8
M7>4W;8'9OR$)2@.+[.QGP^=UVB@-%3?P3E+H^YCV@9V4XY'8=FQ%TAFN:70#
MC[\4;=K>SF68%"8"?2J%1RP$P)F-^/0>#[J_6MO)'G.-E6Y8N5L\SO--/G;>
M(1KJ 181(@.FR#^(94@A&JL'/Y9%GWZHA!!%97&OYKYI=Q:!+ZV?4*==BR-^
M]7-2G;X#O5[],SQ3NWNBY==Z2+S?/JH*; <^0S B?@JZB*#=F 5BS.I)0PWH
M4\WX6C>A*9GP5@)>D2JL(W#LXB)VO.YB'-V>#.&4UQQV7W)/:,'@_V:F!O<6
M;0^)@3/ONS*U&6$[,W9M((&A[)&6;\,D4$*E+QL8'*XU!1-3@RX3S/!T& ->
M9TMD"$6T$]39D;S7'4K5ZZ3*H]K<IFDA"K;\$4W/&\WO1\?:U($:<7)^*8LP
MGWAF9HO[V8&?1QN%' 8G^4W^]\24B5MM!4>=,-7B1+K,2!>J]<4-AX5'"=FC
M\[<ZSE='74BH/E=^287WI7@^W@D+Q72%D&XY\M^NP4I6=F1\SIVS4*U0VN*W
MK5AA*;[UY:F?MLH16\\RR &Z$71E^$B5AV1 U0$Y%%Z'GUB]UCO5A_^07^@B
M(M) I/>C;+%P%LD@>2B_O'O$TL2<([O_W2E&G[%?%E=J:I(_'4[>ZZ%5[$$Z
M=^/<WQ+\<%.M:K0C%>!(%BN+R<W)H";N/:M*4UC)RO0/0(3A3G,_?VZM5J"T
MYLLF9APH2K:^Z.U!_WG=A9JL.P,])V_DU: .R>T.0E2?TC;R_^V *$H:/T(&
MKB#"YP[E*=R0[>MMNXCNA+J'-%V(:>=0\G+.\)Z<%#Z[(#GFJ?TN)0'_J$JN
MJXC-YJ KP!2W,%K)'&D\#K/MX,!.;)JF=;17^4OL"?OL.("5DW4D&/+/4[_3
MW?_"[)O9=)M8%B1.<!BI0%]HP6IHXW+3%6MK2!-I8,8% E+"S_STGET@@3@+
M78KCZ$!6:4!3?0[]^]OK2S0>P#I&*M+L&S(%UVNILK34>SZ->3/P%G5]?"@^
MJ@MNCS)(GNS:XOM7J#M1/54EV.-<0#0!DJ#V'298ISN_9#FCI29V>MPIH+.%
M./Q:[<]<?4? N:R V[BY$ (7:]I.L(I)GB;#+FVBOMC=+S]?SIK_^//@K5IN
M!M.C-W.WJR(W9OD7/6IX6RMP)K;4"]#N;%0OGZPJ\R%%/22UXKW(P-,9!S)P
MK\MF]=07WOWD;TY]0B%K(IN3C3J6N<5&!@O>YIOO9]L$,3= 7#.=JBS?R\M3
M:27WR P(=LKE"R\5K"F@'A.+LL?41 CW\)!"_.MFTLW&L@'!D=$3C:\&7+']
M?#4Q9X(EDWCV^Z1[]9U$;-;7ORYXY@K&2ZF@K)AE%9JL9/XT<1YHIX'J@B*:
MLHE1X*5?)"Y*W#T#/W0^=N[KMQE&58J+0\[!OK]N5-.,^,,Z\&*&O@(J6.0Y
MG%44R&GV&_W]*/H/B8?4&T2+37VKPK/(H^KU8-!T=&,F .PEH*OF$MR38V#S
M9=@TT:<,=WX+_1QQ+ N* !W2Q!RG1791=# ,=!Z\98WC((4_>X+8.L!I@<)
MY:C@"BD./*1C\F%6GL64TYCH+*C6VRI*^%(FC8E BJ\)IZI.D8TD+KFOY%0K
M0 EG71W68'=R Y$%E4M-I6T;$^@2WG9\SG/_C^*NW1(#@]<HQ=BE-+UF67#9
M_#>MLFA2BYW0#F+,AU7IDAF$U3]^T?*VO(MY;+]__Z.8EM>\ 07?+Z,W2RF2
M+#LS"U?=N2EU+N Q%AGZ8DBD#FFC[>G-6ZA23#/UMK]71-37]?1+@2HT"8ML
M#Q\*$H1M/J[!(F.SRH>7OD,MP N\]<KM/J>@N(^<;HI?F+MV>.#=]W!H8FP:
MBI32"[$A RVBX*7O?RNU?SL727IO %'%;\[+=YQ7L<!8FT(B2&+1;48XQNF4
M<MU<I:ASO8O'5'SJ[M(TS#X=@9(4,4G$NL>2: )T<*6H1:E(THW!+6_):X.C
MDYH#+SXT1,D4MYVGXV1JA.[S=K'=S36X8)C_J83Q!BJGCI=U\:I)5?V'_SVK
M6N")"TAV*))730C6,]8<)*G&V\#N>\FF._-7V,^(7A93L3L"UTTWE!^C@0!Q
M#!F@)_CAX1@*?P'X.C#S>,Y^TDQIS.V%%Q6O8L,-=7_>7%,>Z_'JVIBN'B/1
M$2_NJ3"?I!X8N(.@W6XV]KVX.>B<[0C<1>I8T> "Q1"S_JJP!+-X6!$J@D)-
M]@/H_:8+!_V3BMX[;T$\*F ,X^7FV9OU@R4!JJIORN%/^])?0#_,F$%%19:-
MO&(];<R\,F&I'2G^?"M)\W#VV<FIS4,.%CW^&+FS5I KR/PEU/M%_J*0)PF)
MASZU>"GC;2D$:/?1W[>!CB^(D-)0F]__OM).V+<+?GB&HN,&_<2[FR3P&,AE
MV,\%$]+G!1!GO^M7?-P!_2%%.OBL!^0_1/J>=V&E)NQVWKSEU^\\A@_!H1[@
MD"$!O@LS0FT9-^HIL;/<38)[(D#1YX*^9)ET%LL'+I8KJ^47EKC60-3HI5@\
M+:F9'72BS^=3N00_U^!3-4N'-8@H)2AB L%&U8,E$GG07B:,Z/-$!39SF1R?
MX L)GS"-+_]GV/Y_V#B?:R78B>9JGM.P?<=TZS:>N0=)897N*[H^.YJ!);6^
M#/,G"/] 5D,JX;AK<5D)['_W,G)1^U\RR(P&KB?<?:=5UAG#+77F\5/F5N3_
M_"I7D^&*>DGG@1)O>N77FZ9BG3P?4NX)7U2?;(X-/<./*?DKO)'V7]9/W KR
M-^1&$]H"\RM<?940:<^CRN@#6<]84ESRL6POO0'N6MI)4($3W_;[^/C?/;=R
M$D9^DQ@*@S)1 _\Q)\@J\4J9\;;A,*K$U39TQRCA6OU'VM[;Q5#N\M=O-"%?
MV(*B1<_&EW\=AX7VNGJ+F^](CCJ6FBIJW4F\SJXSM5$:W39]H?%?EF(M7>7Z
M,">3NU8Z5QNJ& 1J8"V) LTT%]KM7P)]2ICB 4W :.35:\F7LPI2VXD;G*O1
MRRSJ[X3CVA.J1RP>(SS-'#.#Q3>4 JM*\F;,9^]6LZ<^DKE]EPQX#X28&F^I
M"R*A4+:X8KG?6H*AK.:+<?YB(<&TOR^D1 -B*8C,<7Q0NX73Z,"D97'B?<'8
M9[XZVT+(@A>V![(^E N24V)L\R#.'%6C VW>^3K?9^YG??S\R-9H=H'-;.V<
M]?][<_C_NX')$_\+4$L#!!0    ( !N(;EJP$JLHYXH( />@"  =    8VLP
M,# Q.#(T,CDS+3(P,C0Q,C,Q7V<Q,BYJ<&>LN@=44]^W+AJ:-!60+E5Z%>E2
M!%'I(M*E2R?TWHN@2)<F(%VZU$COA-ZEUU 3FO0$, 0(X<7?_YYSQAOGCG?/
M.??-9"8S:Z\],^?::WUK?GOLV\7;#0"YFI*J$@ '!P!0P;X MU# <T4_H"T
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M0A2:L]OK&$_9#W$9#2SC2%PQ[BB>SE#.H.+ 82\_E[T +1-Y'_%C*#@0\M_
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M;GWK>_5'2HK[ +R4A[2'*Q_V;@"#.*%2);,@;_K.N3('@W=G)X^%/Z@PLO%
MR>WH.=(LQT+B"BI$88>]]*I3(&V$LZ1]OY1X78JJE/'XS0713,P< 1;^Q=YI
M*5(!_KMJ, 1NL#N,A6I"/-5FA+X42WZ6M8,.B "EY\IW5-YL8$P^4-G%/;G;
M9FK(L*,S>N=J/^9D5%0:)8WHLR@>?7IX"ZB:V<^-TXYQ&$,7L=R3WZAX*!B.
M,E!'I4/C7T#D5_O+-1\V3,:YW?VL3L-9,YOJ,X&@'/X#7LI"\LUWT@0IMJ%.
M$"F#DF:RJ(10O*Z9[;1YHFT<0]WAL]$(')U'%+1A+("$21+^W^Y!SK%E2E[
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M_=1Y$N:_4EI6LR$-6A" ,3C8['#Y(C0&W?'W6WT+RG>;A 7,[$92 5$!<*7
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MO^6&#MF$.OY%QU[IZV'=$V_Q*0K*;U\Z"97./D_'9R$JB*!2N;*X!]#[*[;
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M_O.YHQ_CXB=CCPK[T7D5_8$+_DAANAV@+&8M'W5,NI(]QF,8K>LJFJ@9-QA
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M-*=RL.?'F7+M(K,0S-!$?EW4$'G 4#\B*3R8>Y]FE/SJ'J"6==5#^K$TC2*
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M_CFHFV#;5.+*4^V<71I>;@9H2N9N=!'NYA'CPI]&5>\9[!MG^$8>]>K\8%H
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MY?>#4\GFN?!_@,BG5YK/Y.&/@H?D\#0[18>73+D:WDS$_&3M+^=C-@ SPO\
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M:MO(9;KI?M;E>0QY"MKCB)H^NW)X6T9*HR-"]V?A>?)G*K;W#R[+JX/OBNB
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M?"P64$O:+6 0( RW]%VP[S^6>S6 O#5">H<U+5_3<#W*G_W*!&7]!R)X=_;
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M&W7C?O80%JT4*7O*FQ<H>/(ARYSVMK%R<J/C]^8T3>'):,V'SD/LU>;HA.1
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M0=+%&@-8/WYBO:;H^20_/&\S_[4FFS:U#[\ZWV?_;$W>E$#ZJFP/'<'K$6#
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MU8HA>0TRQ"&MJH68]APF/A?!N+:[]E@$P;AQJW?($!H=\FG?0);ALR I@L/
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MC5U%H35FYF2-$]3>4\3>-7TH?6LVUX,Y?=^3-5@U$:U -$[((_"MEK9[[7%
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MWJ#(^+N&K5\=Z;[CBPOP]A21-)GY9M[TJ;^LYH]ZCSQR?,,'2R21-;/!\8_
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M^L+]%^O(I+^G1=;OHVZ:.'GH-^XO$=/.0;"P@3L:1(Q1^MML1F1NY3.R9*%
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M%1-8):O?*J(,%WI@Z=NTCWKIU;CD#0T +R!:O@>-O[ Y(7EI&C-GM%W?]KM
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M?5G<-UHY03<>FLK.O+>8:PE[$3A;#5A&IQTPULT=,E(3'9+?DP(UAG*@JR+
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MC31F05%0U' -""SRI\@6S\9PZ:%TT7*G:4;P?SN2^#]!GGMSH>>YEF:N?P&
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M%=(JON UKM"Y*EA0^Q_L+R]H_E[?ISD5^85:6WWZ\6&<NC>!Y(>$4XE_WHT
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M^1H/D'LP+,C#9Z>T7I&.L3NO]^!Y"O_<6EY:45=)X/^[3W^G__>W?46H ,,
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MDNV1.Q<N$R>=:3Z/$1[I7XS$>Y ^\3C(UZ?5_*Q* /AG!?WQ+X"0MRF$\B\
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M[ 67<\1A5LABVH:PVW7H9+*]/:1K>U"5<HBX+JLS;<JD^P]G ]4L8EO9I\3
M<^Z BCG+4ZOO.SH^5W;5@>*]NI3!5EB2+7BO!R&NDNA(7HMB(F=\HF!Z'(_]
M1"%.7948\;JPHZH@T,@(21;UX58,=X8<?R?SCJ2Z;<R-9.P]I9%>F]I2N9+"
MF*V21Z'SWOYK>/?DPV"%J5M7GVJN#!%MFNV1H)C)'U!^?O<2H=?UE/U^._YX
MMA+]9CA&KS)@.FJ[+B@ &1/,R1\M"T\E[XH+X >?Q(C/R&@<*U(Q9#Y/>-7#
MDG>QXRAGYKU2VO878-&)+FA._'WDIMO.,]@I4)2NTY"H0R0<_H?PDN%4/IX5
M>V!]?_,7\,*2N" Z7OEFZ/8]+E?V"-Q'% Y:PL^B[^WU:7R=M4'V(:F@:;_@
M0:$.M-!H%LR)</-ZF@2<)'ZBZ$ZW _ Z,B<[HO+UJ@'N_]'9O>^I8U^6G#3'
MPJE=D8?9.8GG'_8\8YL(#&R7&1U_M .R)G4(1,]GC7[5A)0<[P6M1>/J)W7K
MIMFP3/ZI+K^3+AM,Z@ JSU/<2(VVZ;KQDEIK$+"<,A!2EN#BA%BE+;^Y.,3]
MD@:]+0;R%)2">-+*^(FF(4@\^&2"/]^94LF0<6?RJ/8(:A2^3"&EJ^AA7F[]
M?L\VN<$7( (F_<X-+#NUUZ=03HTX=-L/B[ED#S<1G614U1^/VU:M JV-CU\F
MVF)9AH]%O*365]H%U?GL9013;[ZHL<LFFMY/S<HPHT=]@@(+.&?<%Y3YMB.>
M":9>E1B.9 W0)C4>:0X6D.,BB?88+A*F5S*"1G_/CS3POC8;Y? ;^8(?>C%L
M[!QH?LH#U-66"H%>9GOXBXA;0=\D::A/XLLR8FN<^-.FDK0_S2?G7,B36KBN
M<\P53$<F)9>/>G%HC-['U=H))R1Y^\QT%N$8,?=+'52_@0<?.DP^4<Z<BLVJ
MD3SS5B$0:/\]\>#13 >B.Y1P_E@4RRLV<*/9%>6T;)#2U 'F?[O7FQ;H6&JM
MB.(+ZTX+Z^6WR5I=TYJV4##)$8#6+65L>.9!KJKJ0=NMSP=%"GM#5#%@JQ9<
M*GA1%64/Z6K&7+2-6\N8+'&,GS90NRL^[Z8^'VCUJ8*5F@\7F?'-7P*2Q-TJ
MU24X"JW'0[TT4=,;B5Z^VNP&<H[+GHF-S^39LF(5L!"XZ#DTNJ^0*EBA[I%J
M 4*M0<E*;HOSB?9@:BUK$9[1C_@>.?N7AXZ&$:&GBT/MM<FPAK=MQW4!0>66
MTJHA#P'8@!C%9^A*;G S3R&NMBTR3XYU]I;6,UT;G7W#D=V+9Q;N+G@#&KWE
M8 G-.*%P#HS<JDF[9V]MFVX\>DFW8O"V@AFF@7B>)G:H$W!571@%/P/FFOVS
MGWP[<^!@Z4^(Q<O9HKA^B-RPW5D@+;?$45)FI:&&Q_T#0W6+0IV# @;71$85
MC&]!ZR7CJ)-/8V6#!8<Z9'M2@N2K&E@"$]TO^9F,U$6.\;ZOO;,+$TAW?)GR
M+!+O*\'F\0" >B];3@K3E!W+>RY/_L >)/-6Y51%*VC-7TA5D [=<EG]%X"_
MV[:>*[O=\*38N:;L5[VZ2"S#@'VF1*RWQ( $!QS/_OCF8&P;FMX:OV%AU;_.
MA3U?OENUU9U%:$/.#A>WT $/@#U_ :[XV]?PWUSQR!M62BM<CY87 MKVSG/G
MD<O@2);LNY[;.A,Y_$1D8\&9D9V%Z_N44> />B.KC)>L:^\!3SJJT%:QP;(;
M?YC65LU-S7%EB$-M&<UM11K8:7O%AB ]_7E%0]ZJT097ZX]98-3Z;!\KN9L-
M_#RC$ 8Q?$(-#7Y\\]YM7QC.J(O?I0'!7&G7S7B48N;OH7=U<LG\BWA)3X8)
M-RO+?U5T5^>>),J3_,)$KOI=P8QR!A8'+X&_.$M2C9RZV9F#%MRS'9%A,0A,
MDLEBOVCB=G[#^[8L&>57TGY'CDSY@^"9QJULOK(<9>]AYZF##A\WE*R'15>\
M1J>VU*1&O964+CIE2+,CJ.N+VZ/"P 9,4&\G33U&&SJ?(+A.HF+4FKKY4'%;
MV/N!; :&)QL>3%MF HPC(5+&,N78[C]?6X/YO$JQ>-U,37J"/$IJ >O-1*5N
MA B1"+]OCUIR\ ?.D<0(>2N0O=6V-_0K*Z(Q."+]Z(2#OZ^?#>;Y/1[\-OR7
M8&I**^)T(]1W IA[XWC#WW_(I[?P-(&'N5<]EF]^I,(-^G17T$KZ?K;@N2[5
MLC%.6KT%Z(_?$M!;FW#80]02"*_%Z<T.WO-B#-,=*Y]-_:3!\D8X9Z'TOOB<
M>?Y,(0.9.TGH)R ^!#&^$_,/G(Q SIV/9V=3NE#V[<GQ,UYYT_TA[/X/X/H5
MJXU=<,3<%10C+R$-.9OL&DC3Y_ACQ8]JU%!53M>."=NN=^SOY_A%"\GJ-4GZ
M86^B-CI#K<D?27^T#\LTF[HUJ'&FY;'V+]6NW*4<JB@Q?WW<\IQ?\*6LX 1C
MRR\*KVGI='S'(CA.&E; .B-ZIZLW<T' [UXS36F<=_24O/FICG2>(_5V82-I
M1YO!0H1#CO,\Y=Z9_\.(UJ(AB@+IJE.YS D@VGB!"M7Y _4J_?TL>RTD3:!N
MI6RG5;M]+&FU9DH'<)#35X\M -58'K1MIDP&^5C;:=5:*+G-%ZGPTKR2EHHX
M(]V&%+\[>YV(T!UK43G2+J@HQI7W1?SO8>")"@GS%7/ZATE<1(D_!ND?L8*"
M#J=%=JN@Q<L]]>5X:,@4?-B2",L2Z8$YMF)Q7C9/6=N#$+*[QA*)]J:)?V^8
M?#WX:!FZ>ZLTLX.QZQ2:90N*^94<$$]GS]T0^&"N4&.S;\;?O&IH BK[>=%"
ML4]X[WI^,KK)> 9]HQV]:#"D!!RYW1\+JIALK?'H\3'%,<SJ38E"XI;I' -L
M( Z&*=5'+>@;& =:!IX8K(T+ESWN0N;S]#/X.$\W'=H0C:I2)<Z$UX4?+4#%
M31IF&H- FDI8GA4+A M6YCID:PHF4O2FKNM*8X-ZT'1MJE$O1#-3[F/NO@O0
M!FTP[WZ!X.E35LZ;47\6QL\W'6NGKC_K+GU>E26EDXT:)Y75M72<]V7\S_[T
M^R$/6WZ/K?X4Y1.2 /L$OU#:KIDF 7)<+.5@7PG?IN"O/N+(M_'!$=S./?BR
M/I8G: M\6%MY]$[VQ^_&JL0<?#.M"0/EG<B$N)S.PS1=;PZ0*Q.T,/J<)Y[H
M9MS*,DL XAZT^'CJ-.,-[ 4>YJ>GER4[ZJ06I]B#P'P%$B)N](B&+X<#S6+8
M]#O8A9G.F2@&7F(+$C&S)AC[Z!B;.>19XVR]8>0$1TP=L;F_A.Q!$8:UMS#J
MNF(>!0TX!I6>SJQ+EMH_7 /8OUS:9+72X:EDJM7P]I@9P$9F"]M9$?/;XN8)
MH!TY:&V&%VJ<32::/,,4S]4CEKXPN^[S.<+:Q&,^;\\TY5K[N,.<F2H&ZYCB
M_M#VW#_(&1RXGF,EEE&@&5@/<BI56Q1;?.:>0KLC<,N^#)6^C($[8"!?SX\4
M>.*_^UMR-H3\B,E<,&#_(H<=VC,Q*!TW41&">+#Q#/!K3 Q=_ 5\>\,5C]74
MQZPG!III-M?&Z=93M)BU,UF;GPW1/S\'@PZ084O9O??B,[>:7*V5%*2%%2N-
M::KRXY_MI/VR9+\P5QW'#;293TSLY,8;YH-](G!%OYURC&!'81^PSTE*5Y;5
MX ^R/07#AP8#;Q=P AL((EQYOU1VPE&$\;+QOKZN=4FTG=CF X9QWH#!DS?&
MI%^,=G<&&$>9Y9'1L1Z^TG[M35$3*FG4](Y6Q^'[KF?[\H]Q7=V!"7*O9UC,
M8GRWV3_413Y(6^;U>,=47O3^87/0#G43V5>-RT\'W<&4ZOL3$#1WWU\ D;.4
M+#S2,69?>-^=ERP+:1N%TO]&^@^"1T(]/AG1@VY%"[OE">[GO5 !6W.\W[S_
MS(;SZHI\3W@=M?FH_5'!'S#O/!52#H3N7VB\8W'3U:J+.-+K^OYQ.$ D@6FH
M_.3-R!?769%""N<<>/0_#F;"E5*O_[!W9KO?FK!]^K: @N=B]6?D==SNI0Z%
M.>1,>N[_4/&607%PP;;H)+A#<'=)<'<+P3\TN(:@PP2W 08($-PA0((&".[N
M[NZN,[C/!,G@+Z?.K5?W_NB?N_;NZNZU5U=U+S/=VFN[)& A$J>7K&GB@<O3
ME+]+22J):O_'0^U!5U '$@%?AZ6'?:YK?%"3]W>OV<!B_+0$57TZ$GOWGH^2
MJ9.\)V/R,#ZO>[ZH.?RP+]!BW#?F "C?B\5TVW.: YJ!R.[\<QEIJ$JE%%74
M[V1+E/18$_SU"O_P-*<X W802WV C/=RZ/21L8 KA\A0G]*1-&AHZ>=J+7ZA
MS4MVX4\TXZ[]%*O_%;>B6!*TT2%8^"@$MPSUPN-W.2^N6V>Y_U97YY+8=F'G
M=:L).$/GC$=TY4'IHYI-Z$,\U4<9%PI;R=$^QP[!>PD$U-S%AN5/,XX;+T/H
MR!:OT>89PCE<OM';@5J))X#,SBP\K8!ZE+]MT4N%ZNLY&I:F5)J%2Q5_"/"?
MQ[9PELX\$XA.)"HG3GGO#08_,3OL2<[JW5)KR;16!E$_3W?A*2U(R<,2"#6*
MP2)3'X.X8Y7'PC#U#;@,2_J^ODL8R(U=DD7KD";O ZG[7GK]KHF?F_),^&M%
M^\%-TKHMON6"T^=#Z' 7&3PVD C9P8 @BRE=&W6TU^JF_B+YQ@RN\"I,=FL0
M.&V\VNIP>WT1Q_JNTD+WF@LI<S _Z)?67@S&AXU;P!]'@409!P8^S>N4N#G&
M@)P!ZP23R44IW!< IA1YQ5.\\(*A61JGI+3$)O8P:EW5(G_*"&/=WC-I*%06
M"URP,Y2>!RXPFE\ZH?;UWHKY+^I74Z[K1%F'6"3I*(HX:GSCD>R;CB"KRCCB
MOC8U<[FU^&IKHFZ')M8FU506\Q< N.8_ CG??-UT"6V?A#N<["L3GB.MX$"N
M!$6D8UM07#0PHRG32\I]O?8%H.)Z?J"D]F?BK*KU;[484J%T%%8=3PP^>1[:
M1V\%^=Y:N6."@NK5K'LMHD4 &*U,G;+0[? .]M^;X/&A ^LJ1[*_U33+RV+,
M7ED<IN.T1/*["6JG7:0"Q[D$3AWR,-%HZ?<Z4LOSY]BDL5/O$;-R/;O5)E,>
ML;X;!O=8&CQV:0=:D1V@0O#]L@$\(:(P"A;M5=?2]CV8\$?-@-L+P#>*HCKY
MT6D'[QWOFT'H"^#U,/B^051IZH!"_ .K@J *!K6$S<-\%]%IAFU"I)1&E6/;
M8$E'4VLJVC>5JT%F!4X!LW<E/5^R.'VJ\Y\IC4%^W8.YA! Y"8VIA*)3"8T.
MJV+S<%#B'0_)'QF=>+]8N[843Y)6BY@K"69>6W@N;_4C^[]2@:A[_#:V9,NI
M'T U^$.#5?BVG3,!IA$1>H)9Y0W[^_QFDFP.AO.W<0%GE&5?Y>H_'4Y)IHM#
M0;0ISHL7 !D$!UX=5;1\X]']8&J<3/TM==V]5[J-1#<4J8 2/FSR^("P#*L6
MXO8?H*-/V^*DJ.3- \6<#^]]SP,OB=)OL0!D\MMK?OS0]S'-T*VFRBG*LF!8
M]J*E_B]!*US[I O8&"<RW>HZ\BL'TLAEVBR%/9OP#ZE#@P*<< 4=#6\O4,-W
M7L]$F)>U7C9N Q)**R^#34@/"A$:PMODCDWSZVNK/P_MQ.)V(15BSB164?3R
M%GD(7FAE85.I+P+E?4W&Z8<LKH_#C@HM1&TI3-9E*=,67Q<7!N2UDE+/=8%T
ME-"H!FYBH[JYPPS3)*D4R0^V0#IZZ:8PP L 2SOH,DFS:6ER..I+8R?V'.QB
M7*4E4;BB"J\CN9?]ATV*[-\I24/Z@E'TTOS3Y#6C+86JJ +3S'972H--FPWL
MT!%J# :/!4.K(MJ/_<^$"T6MC>&P@S4LJ8C05TV$1BH#<!_7@9R;BN03%U*;
M"Q#$&)D+DXWE T8F%689C'//N8^5K8?W:+WOI[E?1MN9#!IJ,E'Z?5K=%:\]
M4+U_KL47)KZ%L27.$.LM#+S!D7RBE)GUDDDO,R.//V=".?LC\$MR@2XF-SU>
M,-=DN,&4)6U;\0^5$:-^B[NA[-N/#]MFKN ]:])*"3>=O:9O\IPF:_1E0=@=
M0-!N-1KPOL-0U<N'"K-JS*W)"X6A^DLLT4T11!59#]4*\R:R!*<6>HBH];_V
M34ZE-778(_#[$[1ZI0:?_B8E"JRNO%S)'8K!7U=56;-K,'Q_I.R3 )25MY1
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MA+YM L<MYOD.R-KFS5"I(^EJLM&N*A9J,(M;R2[>5P)'^#3J\\0D3)K%\05
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MT'/9@7\(_*\&'2)&@3AUX:O[<0-7L:[\.8O(]9VEF('[BZI[O>C:K>Y5P_&
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MSOB[23S01;K880_=)@6C#(C,'4N<3Z3Y)*X,T9AO#A)+U'>Y47S \!EOR>Y
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MFJ^RP-?Z2>>C[#YH7Z"C\-%D^2\9Q;!/4II'-QC\7;CLP Z"N2H_";H<<*Z
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MC:'!%R:O1;^F4.1[JVRFY@+UT8)-[HEO2]OA: EG?W>CGCF ?_VJPR<3TMU
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M]!G@UTZ>&].\1WUEXB\3:;$;Z" Q0H7\T1!^7*MQR>F?2N=)))M61%^IP/\
MPLT^%-,CU;4-( L=4OVP+:;SI(A,XPSJHZ@'+ ?=]:]RLK^QU"U6]L;B.X@<
M9$B.&7'U!QQ7YV>*_&NLV_Q%U7PA\'-$BU068SY<[/.N^/(=D0<''49)Q7+Q
M_#;X^+H4WC VK?9 Q9K"W+P.03\Q6)",@_2O0G@(M)N7*SI^I\T4WH?2'Q \
M7^#O'/C8>&A;&\L;"XMH;V^VX@B6-C(Z!\CG=MY&>]8GC?QW\'K'0FCUBW75
MX;*[:2S^SR$2R;@0PE#8(ZD'/##%?-U[\5/%GA/0UT?6_#\UNEP#+&EXC"-U
M8GY][C?D#@?-P*Z7X=_L]>*_BE<#7_%.S3]$N9-[!5:-Y V#\BGMV!-=KP].
M$;U)62\]SLA@XQ2E-Z';Z-\5K:ZB=_"7@S7HM.3YD6VO6CB0KUX 8 'TZ5L2
M?'768[.3[-X9\00S%FW11[)U!SCF?87'T4?C7U!X%^$WAOX>><FB37$D,R[/
M*F8.F..HQSTXKT>WMK6SC:&TB2&-G+%44 %F.2<>I->94QM*[M"Z]6<E>O1O
M[L3\XO#UA\5OC$77PEHUKX>TUIB9]0F)-TS,,$[WR_3@X^E>NWG['?A,Z3;2
M6MQ++K;2Q&YG>=E1TSB4K@$Y(/ /&:^P+:WM[.(6]E"D$0R0J*%49.3P..3S
M5C ZUG4S.I>\-$9RQC7P*R/SH^*W[-\'@B\L=;\-7XL=$&4NIY9=LD.T @C^
M^S8.%4=N?6N__97ANK2/Q'XJO;K?I*@%#(B"4A1RS./4#ITYKNOVK/$$F@_#
MWRU:5O[18VXB1$:-B<$LS'Y@5'3;UYS7@WP'B\3^&-)OH=<LY)_#=Y'&S*W'
MF;),%8P,@LV<D>@KTE4G4PMV]?T.N-6<Z#<CZ0U3^R/#RM>>*Q+HUK,YN6>-
M5>*7/W8LC/[QL@?ABMWPW!9:K\.]+T;1TC9]8=I]\;8,*[]YE;."77@8/5N#
MQ4=[\0;#Q1<PZ/;6(2TMC;W>RY=5>Y7<0BQ(N[HPZL1Z5UG@/1O =IJ&K:GX
M<6/^UKV9I+U#+YLT+L<F(C)V*#_" !FO,JR:C[R=SSY-VU.^T72;;1;*'3[7
M+",?,[\N['JSGNQ/)->->$/%VJ_\+6\2>&KE[BXT<N6MIY0/)65%!DBC?.6V
M]QVKW;K\N2.HR.HS7R_XGT*'PI!<Z/H@;7IXK@36_P!INXUGAENMS7 =SMVH
MP[$<YQ4X5*7-%[LFG=O4^R_@M'IT>O\ B-M&"FVN/(GE=)-Z-<.&W$#D E0I
M.#SUKZ)KX_\ V3=%73]+UF_:!K*2[E4_9EG$L"1C.QD4<+D'GZ>U?8%365I-
M7N>=7C:31^<W[<L&AR7^A"_4_;Y[:X@M'"APDDCQ?,RDK\HQR<Y]!7Y>IX8T
M&X\]8KV&61 \;.BGRV;<<%=^#NZC/%?I7^WA?0Q>)/"-K<:'_: \B\GBNA*5
M\B:+84#)@@JQ."3T.*_-FPT-O$2I/I4,D,<;HEU;,JD(YP3Y9'/RG^(].PKZ
MW+':BF?=919X:-U<Z/P3?>);[1HH+>>2SFFCDMDNIADJAY1E'/((QN!_I7T5
MHMGJOAKP:HU&V^SW^MO$\5X3S&\>%RBOT,OW0Q'?G@YKH_ASJ?P^\+>"IM2\
M16Z6#Z<+DK$R[YBL0!#JK9&-Q_'-9LVC_&'6-%7Q/JD]IIVC?V?'=V?VAHX6
MGER6V*) 2?+09"J1G.3P:BK7YG:UM0Q>)3]VQ[SI6E77BVUL++Q/97-C827<
M>I27%M?R07,+QQ!(P&B4"2-FWHP.!Z<5H_\ "(ZP-(@U%;1FEGN'N9DE#/MM
MKIMP7 YRH0<\8W<]ZV?"_B*X/A_3[+2D-[J5S:6RAI#M"R)$/OE0=N]\DD X
MR<"O!?BEXR^)VM76G6'PQDNM1U[25>34VTX/=0+<2HI>!FX#B,+A0=O<@=J\
M>FI2G9:'G4E+F?0^@/$$LMS\,W\+7,D<L4<39D!(#V_S%4=2,A<<=2.!7S7\
M0_#>JS^ F\.VDLMX^JS,8;,E9?+MA$NZUB8 8*^7N <YR>">_JWP\\7VWQ#^
M#UWK^OP0B#3H;C3=6\P%(SL^9AAL<%6&<\ @BN5\=:I<Z<MQ(5@A%EDV,<"N
MQ:<09C8JH' QZX(XZ@9K#)PGR]4RZ+Y7;LS@_P!DR[\6:-\3?^$6NO+6QEM9
M'DV2*P8H!C !(XXR/:OTX'M7YC?L<ZOI'B'XJZO="24RVE@RVZ^2Z0;V8";:
MYX9B<E1G.W/O7Z;<CC/:N3.'^^.;-)J52Z[$HW8P#@\\THZ<\XIH/K2@@C(K
MRCS;#E(#@CUK\@_&_@?1_#OQYU3P?9VGV*SOKVXF =LPOYJF7#GDX8N>/3CK
MBOUZ9D0-+(P1%!))X  Y))K\@_$7B.V\3_M(:QXHTRZ6YT_2[P.N_+P2E64#
MG[I&%/0=.]>[DO-[]NQZV5+67H=OXEO]/M-/FT>&V?0]>DO;"&]$:-N_<Q;H
M)46/)4.Y(!3 ^;#5[=X*^+_C/PO<:?HOB1[8^'1=11QML8W4-J6\MHR5^200
MN<._#!<$C&37B]_90^)DTSQAJ]S)86OB+51!OMHM]TUC9N49I -Q5 X!!(S@
M'/&*Z35+76K[QE;>!G:VN/#UYJ,L]S) PCD8R1"&.= <J5(P6 X9BP]*[ZM.
M$U9J_P#70;49JUCJO&FO:;\.OB'XCTSP5X?L(-&M;!XYO,EDBM_-N(_/D=?+
M!P7.$RI^7BO-K)]'\4ZGI/@O2](N;)O%#PK90V3%8H[95\R6=E9L[(B[$ER2
M6'')KD_$%EJ.F3216+?VIX=TE+VS%S*8V07'F?)YI!$@!4[03NW*% YKZ>_9
M>\-Z'I_B76]92$)-=6=M_9ID #+:,SM+Y8;YD#.5+#TQ2JM4J7-N[?CYE3?)
M#F6Y[WH/PGL_" :Z\.:I=3:KY31"?4I'O(QY@ ;$;,-H) )"D#M7@FJ_ 7QS
M#KO]LZDD7BQH]-N(8H[0Q:3:0RR;MJ1098 9(+DY+'DGC%?4WASQA!XBEUV"
M+3;ZQ&@7;VCFZ@,8N"BAC);]2\9S@$=37EGQ*^-ESX4TB)-(T>YBU74)84LQ
M?Q^3%)&9%65R 3(@0'JR@9(KQL-7K<]HZLX*-6IS>[N><>!O%_@?X2_"JT\8
MV][%?>(]0"0WL*S1/--<P[U>%BH^6.%BQ&Q>@X!S7HWA+X^6%QX>3Q+XPM19
M7-]N-E%;*9GGC4XV\9(.[(P<8[U\V)\,=>^)OB!7\%7NGK=Z=<W$]_>- GD1
M.[$);JL8"L\;!ON\[?O')%=1I'AC3].MXHM6UN"UUR._D@AL[*6 32O%,?,=
M4*_*K[0JHHZ9.X9KT:E"D[\SN[ZG;*E!WYG>1\R:A;ZO<^(;.YT/38[C[9<W
M$UK:JP40PRRLT[L7*@.I8J225]<5]Q?LN^$O"VF>#96EG@U349)YMSF5;CRU
M+$F(')4E6R#MX].*^6[KP[9:AXBU6W\6BYTV+1D/VB-@(;.TAGR%C$J?(SOP
M^&8G<.>:T]/\:>%M*DLI? N@W<*00RS27(WV=M<-&0A(5\@@[3@Y]\8KMQ<7
M4AR)V+JOFCR(^OK]O#.F>/=0U7P3#;6VKV%JRZA<.,1HF-P7WSCG;7BEU;>
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M-+=I4M _EQ^;.A8JAY!3<2 .QP*]!5E7<H7T2.EUG-\G0_2_LRGD'CVJ3(
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M,W_)!O!?_7B/_0VKW2O"_P!F;_D@W@O_ *\1_P"AM0![I1110 4444 %%%%
M'\Q]S_R5WXV?]E$\4?\ I:U8?CW_ )%.^_[9?^C4K<N?^2N_&S_LHGBC_P!+
M6K#\>_\ (IWW_;+_ -&I7W6#_P!U7H?VUPG_ ,DU2_Z]/\F=A7T)^P)_R>_J
MO_9.[O\ ].]G7SW7T)^P)_R>_JO_ &3N[_\ 3O9UEG?^[OU1Y?C/_P B*?\
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M*GX0_P#2IZ^T]>TI==T/4=#>:2V74;::W,L1VR1B9"FY#V9<Y!]:^+/V\/\
MD7?@W_V5/PA_Z5/7W10!_.I^R=_P34^+/PT_;%MK[Q3K^GKH_P -)K/6&N;.
M20S7\5T;A;1$C*#9O,#"<,WRKD*7R#7[Q_&3_DD/CC_L!:G_ .DLE<GX3_Y.
M%^(W_8$\,_\ HW5*ZSXR?\DA\<?]@+4__262@#R?]B?_ )-'^$/_ &+.F_\
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MCG;DL7)4D@ [CTSQ7U=X:NO&^CZ5;?V_J,6J7/@Y&,_ 0S6\BL!*[DGE54'
M_'FO9Q\.9QG?6VQV8R*<DT>J>-M?\1:!X;N9+,0S:G(K"-H\@)N.U6PV><GZ
M>M>5^(];T34=2\,>(&O9;V[CMBL]JC,(W(&XF?R28SG! #'&>E8/B3Q!XUO?
M&+^*;6VCO?#5U9-#90%25N0RYW,X.-NX<#@\^E;%OK=K\.?AMIUB?#EQ;OJ\
MGD-%;H]PZQXWNWR@L1R0N>YS7-3H\D4^K_5'/&-DF9?Q8T&^\;W>@SZ)X>0Q
M:8#/+Y+H&*L1E"\?"C'.#SD5T7PY_P"$2U&_N=%UF&#61J+[K1YXS* D*X,>
MV3*_+M)W+U.<\UZGHGC?P)&HTC3;F/3C%%YODRQM;D+W.'"Y/KWKR;XH7/CB
M^TNS\4>!"FCK<QK! YA26YD:3>R)&O\  )#@DY!J8U)37LFK=B>>]HL^F[>"
M&TA2UM(E@BC&%2-0JJ/0*.!7SW\5M?U9[R^'AW5[2.+2+"26XA*>:QR""F0<
M(Q]QR*?X?\9ZQJ?@H:3K\TMG?V]ND5S=2LL$LUQ(2OEP\<,>/F Z]/6N0/PD
M%[?W&@VRS65A;6T,*>?,/M6UY/,D)[2*6Z,Q+=12H4E"3<V$(V>I[7\)M+T6
M/P?IVJZ?9Q0S7*,[LG)W,<GG^==WK>I-I&BW^K")I?L<$DVQ<;CL4G SQVKP
M3X/2R>"]<U7P1K-TTB:A>23Z8Y!\N5%'SJA['C...Y%-^+GQ5TB3PYJWA_PO
MJ4;WT3F"]PN[RHCE9!SP&/W0>F:RG0E*M;?_ "(G"\SB_#\/@C4KW1M/\77,
M,B6TIFNK;8Y#W]X<0_:& VOE2=N0>>]>_>-?#DTFCX\&QQV&M0A5MVA*PD1,
MZ^8#@'(*CN.M<CX:\,>"M1T&TNO%#6]S?2>5(CR2*LB>6H6+&T@!E'IT-5]"
MO;'QGXCOF\#7M_:6MDH@EO@I:.:57^909@0VT<97U[U=23<N9=.^Q4G=L/AN
M;1M=UOP)XSNAK>O6^)VDN0';RIAGRD;I^[XSM]>>:Z;3_B-X%\.M+X5B@N=.
M.F2FV6%X'VDYXV/R"&SD$GFLJ!+#P[<R^%]7AN=08W9DL;]E99'N+DLS(TJ*
MH4KT)S@KCOQ73^*[?3;?X>:A%K3;6AA62=H<-)YZ$,&XQN.1S[5E-*<M5HR8
MN^YT>F76C/K=ZPN8!J5PL9DA#H9DC484,!SZUPGC/Q#(OA_49/%R#3-$BG\F
M[,+N+A(-V%?<,?*_&=O(!ZYK$TGP?;:=IT7Q#T*SB\1:E>IYTI,NQY(FP4$,
MS< (.S=:Q--\,^(O%.I0:Z=1_LP:O%/.+&XQ>0/$7&Z*56X[\[#P,<4Z=.*;
ME?0=KNYT]_H_PEU;4=(MA#82VD<'G"5/ON6XB#3+R<KN."<FM3XOWL?AKP5%
MJVF2O97=M)'!:218(7SB%8$'C:5!&>W!%)"WAWX>_#[[7HVFVUFMQ(D(0G;"
MTTS^6"[G)"9/'MP*RM6^&-G+\-M5T:XU2;6) )KB":X?S1#AO,5$4<84#:.I
MQ3IR7-&4GI<2?0\*_9&M+S4=:\4>*)I"C&?:3\IR"6."#@CM@CTK[U5R!\IZ
MU\ _LNZ[X7\*:EKFB:MJ-K87-Q<?N//.R2X#?-@,QQ\O?U)K[WC970.AW*>0
M0>.:K-&_;.^QT8^5YW]"/4-+TG5U1-6LH;U8SE1/&L@4^VX'%7@,  # X  X
M  [5&"1QUI^:\QMG!S.P9[BCMQP:C)QQWH'?FB3$2D\4#)_&F@CO5/49TM]/
MN9I+E+-1&P$SXVQDCACGC@\T)7>PTM3\Z_VE/B#XGU#Q+;^ -=TZUC?3Y3<Q
M21EBP5EX;<QP<K^M>G?##PEXP\1Z/%JT)BFT^V3%M;S,\+*[8)! RI&.C5\U
M?%C5=2U;QQY>KW,-Y>6[[/MN ROM'!0(/ND=NU?7GPU\=>+-1\#_ /".>'M-
M%KJ&GVYD2:8?N#$G;=P QZX["OJ<2I0HQ4$D>_7AR4$HFMK_ ,*!+8Q>%/ N
MO2Z/K<6RXN,?O(CSQN/WDST&P@XYQWKO-*\,^(6L7&E7EMI>OV<LD4TRV^^)
ME?:<@'!<8 (R<^]9?A[P7J,?B"+QG]NBU2]O%:X6*65H_LRSA0RIMW;TXXW#
M(/0XKWA<CMSWKQ:^):]V]SQI5&0V$%U!9PQ7TXN;A% >0+L#,!R=HSCZ5S>I
M^&=(M[ZY\3:=X?M]0U>Z$<<I8JC21J>Y?*Y4=.,GUK7UJWUJZLQ'H%Y'972N
MK;I8_,1E'52,@\^M>-_"/Q&NG77B+PQXBUB;4-4LK^1W62.3]TL@!"J<$%1R
M1@XYK.G!\CFON(6JN?3?[/FHR:HVO3C0DT."*<0HI*B9VC+*Q=%& ,],,>*^
MEJ^7OV<Y;JY?Q#<&\^TVC7)$*/"8I4^9B=V>2#GC(_$U]0U516DT<-=>\?F[
M^W5IGC#5=:\+6_ARRDNK98;E[ET0L(U5H\DE02.,^W%?-OP>^$GB_P"QW"?8
MY!!(5@AE?>K3RSQLTF&8%=H&#OZ?P]:^_OVH?B-JO@=- 70;VV@F\YKB^AN(
MV<S:=$/WRQGA58DJ,L> :\L\$Z)\9-,T[2[7P^VGVNGI:W$\HFF%Q%+/,I:"
M-=@#H(R5WG)SSBO7IXJ<:"CHCZ'"XN<:$8Q./\(_ K11XUUWPCXOCD:.2SMK
MF%XYF*743;H9 -P!5DP X&>N:]&^,_AGPEXZTW0?@Y%(G]H1SP74,>2S6T%J
MI02,0<@'A>N6_6O%&^+/Q.\1:K%XE\)Z:NK7^A02Z;J"Q0.T5M>;$:9E#89(
M]PQ\V6/7&!5K]GW5?%GCCXI7GB;Q%Y7GI9Q-<30X5'D\L 0E< Y^8.20#@+Q
M@YI3A4UK3E\*_$*BD_?D]CUG_A6<_P ,9['Q3INH/JJ6B6T3Q3* QN0=AE0Y
MPJR*0-AR%(!'>M+X"Z3:>#M>^(?@N AI;35UO5DW9DDM[Y/-CWD\G:VY<]_Y
M=C\7]8AT_P &W5D 'O+Y?W /0&-@Q8\CIZ>M?/7P:/\ PCOQDLM*F=0=6T26
M-5C9W&RVD66)7:3YG=49LGU)]*XUSU*,G)_TA)2G2<F;'PU\*7X^)7Q2TFXD
MN)=-M+NXFCM$")83/?H& D7!+2(H&WG ZXYJGXQ^S:+X!U^YGF%VOD3RL=Z_
M.\P\D(1C. <<9_AKTSP3J%AIUU\5K>=Q$\6O2N>NYA+:Q,H'U.0.PKYY^(^H
MG5?@UK]E:+#'J(MOM7V8 K@0DNP.<<[>X/)^M=-+FE45_+\CIP]W*_H6?V#'
MTV\\.^(H5M(VETVZ1DF8$N'D#J<9&%XR#MZY.:_0(FOEG]D/4_#US\'M.T_2
M(8+.[A,DES!$P9LR-\KL>IR*^I<G[U>?F4KUY''C_P"*Q^34BC&0!461VJ4'
MUKA.0PO%M[9Z9X5UK4=1.+6ULKB27Y2_R+&2WRCD\=N]?C[\$;K1)=>U#Q#'
MID0TBT\R]98&),FR&1BA20G;R%&T]*^_OVM/&MEX?^%]SH)OA;W>ML(3$IQ*
M\')<K@Y&"!SC!Z=Z^9/V7_AQ:PZI8VFLQ;(KP-.T+C+R6[!AB4]/WA4@^H4X
MXKZ/+X^SPTIRZGM9?>%*4WU/4O@SIWB#XB33ZO:QG1-"DFU$K YQ.+'50IC*
ME1\KKM<I[-U]> \<?"'QAX2\675MH&M7-]H^AV\5TT^?+>/:O_'M(ZJP)D0<
M\#)._CH?ICXCWNM_"PO'X-T6VN-,\0O;1*9=_E6UW&1&J,%(^1U V\@ @CN*
M]0\ :9#=^#&&JVTL=]JKRR:F)T*2/=,=LAP2<*,8CQP% K%XV4/WBV>EC@]J
M_BZ'Y^:AX8TSQ9K?AK2;32FDT-K4QR:>)%AB=I(=L#JS.KM+',#EN3M4\YKJ
M/!$WC;5?%^B_9! ^H1V!L99[6+!BNU8AD:8G/EK&N&&>HR!S5C7?"-QX$\;Z
M]::'< 7VBO%<6$D_[PI!N$S Y.<RLY4MSD_W1FM/X470T#Q!I'B<Z1?:=%JI
M798%0OG3S#87!8X;=(268'W/%=U2=X76NFAUKR/O(W\FB^'_ +;KLB"2UA_>
M%6^5F1>BEL<L1P*\-U?PSXM^*&K^&-9\0:<UIHL]K=$P07.Q[<7,/RBZRNYM
MQ(&V,C:1G)JWXR^&OB3XH36I\::D='TZW=O*L;',JR[ESNNG8  JP!4KT/?F
MN>^$'B7XT:WIHT>\MK1K*#"_VO+-N*A3M\N.%$&]@HR&) R>:\:G#D@YQ:OU
M\O0XXPLG)/4YCX;7/Q8TOP]?_"_0-*EN(M&U&>REUC,,46T8+);]&<KGF5QN
MW$]2./-[K2O#%PSPM9S0W-NQM[(2%3&9%8B=F9@6+8&T$GC)/I7M]MH'Q$^&
M8O?#5M=G7=/U--2U*2Z3/V["OYTB1PJ IFD\S8I!QG!IGQ1\4>$?#OPNT?Q5
M-I-OI1N?)B%M=J!=6OVE#\OE*?FE4D94YY.37;2J_O/=6_;]3JH5E%^O8\2C
M\-^#OB#?:C!X5(BU#3M-ADN_#=K-]HL9]48LCK(S;HVD1=I#+C!Y)KVW0K[Q
MWX@T*^\!3>&[;PQH.E6:6=Q+>J!Y*+$KLJ+$Q5@0>"&&T<\GBM#X?7WP@\-M
M:ZUX?TZ[TY[*SEM(YO)D,5TH?=)RJ[99BPRQZUS6C_%ZWT_X::Y?ZE"]IXFU
MZ]N_*MWB.]VN'$44@4Y^5$VXSUP!U-$IRD[);-6ONC*4Y:I+8P]+D^&_B#X5
M7&G627EY:7K>1;&TAEDF@2-PL@D8J3L#Y8NPY6JWP@M?'^D?#O2I=#\7ZKK_
M /:5U<+N5(F%E;H'\MRMSEW&55=J'() Q7D_@SQ#\13XVT[0?#VC7/A/1=#F
MDM8K("6:_OTCP9I+B)3MP68.QP-I( /)%.^,>I?$+4;*YT#1S)H*6VIQWL.F
MLIAD&W<7E5\# =E#;>0&:NM47+]W=:ZZZFJ@Y*S?WFA\7= ?X.:?H?C*VGU3
M5=5\7RW%SJ'FL!)!(8(Q.<KA\9) 4G:HXK@OA_\ "3Q9KWB5?#V@7=G+I$=O
M'?WDKDQQ0Q709]LNX&02' 4E6QW/3B;PUX^\07FM6DOQ*NIKIH(+I[;[8?.@
MB:7^,1IR^"HP"PR"0:O^./B#XRGT34-&M;Z"RTSQ"+26^O[>*)_.BE@"K"B9
M"QQQA,L-QP7P3DUU0C52Y.O?^NR-[5$E%'V5\(=)U?6?$UWXMN)-/33-*@_L
M6W2S+S12^5@R-$SXV+G"G .[!)[5VOQM\3W/@[P#)+HFK6NA:A<R1VUL]Q'O
MC_>G8<(O/RJ=V0.,5\Q_#[XHW/PL^$^CZ?\ V5&M[JC7&HP374BQVOD*/FD!
M7+%R0%" #)8#.*^0/'OC[XD_'SXBVWA[3IWNY[DXBAMUV@1#.Y(!VQC+$D]^
M>,5YE+ 2G5=25E!?DC&.#E5JN[T1H>)/$G@'PQ;76G76M:AXJU5),RZAYDCJ
MB[61E13D>6>I3'& .G%><V>I:3XAO(M7?0KK5;(N[BZ\LQJ[+UC8+D;0!@#K
M[U^G'P6_9'\"_#G2A<>)K=-;U*[4&2*=0T,1;DA5R<GL2?PKZET3PSX>\.Z6
MFB:!I=M8V$6=L$4:K&-W7C'?-:SSNE'W81;\]C2KCJ4':*O^!^6'P1^-_P /
M? /B>UOO$.EW\]_/!+$&N5#SPI(1M-NK?,8V (8!B?PKT7QO\2=:\5G6+K3+
M-]7\,V*[AI]VPMO)CG951HTVEG968XQRHXZ5]F_%'X0>&?B1X=N-.-M;Z?JX
MMS#9Z@L"-);\A@!D?=) !QSC.,5^8WQ ^'?B7X9ZQ!X*\674U^J6T<_]HQ)(
MELLL[,%17X!9=@)![]!Q5X*K1K3YXZ2[?Y#P4J-1Z:2Z'NOA;3/B?X"N9O$]
MIX)FMK.RMG_LJYNYQ*#<S.,"95.4@*D[68 KWXKRWXK74^HZIX:N-=LXKC6[
M:94U:33KA)+>Y6X#.BML4 L@)5FQG [\5[[X/_:&T?XC>%O#_P .M=LM7N/%
MV4\Q=,?R?-DM?NR-(& \J7&64\'D&O$$^!&J:7H.M_$8.)M<BGOFN;!I/+D@
MC$F2GEDX)P=R$=..U=&%FU)NLK2V_,47)5+U5:QKZ9X9$OB"/4?$>IPZ!X9T
MRW-](+3;!<&$H<1.H4Y1\@(2#D^]=E\ (_"-EXU\*7>DZ9.]Q?ZG<*TC$*(%
M=)WA^7=C;Y:\[1@LQX[UX5J=OK'BFX\2^(=&COH+2TELDDB,@DM$,1X4-L!9
M550>&P-Y 6O8OV=;N.Y^,GAY1HKP1B.41R^8YMT**Q<H&SDG> .^,\X%:U_X
M<FW_ %_3(G)NG)R\S]8*\<^+S;;/3\_WV_D*]CKQWXN_\>FG_P"^_P#(5\A+
M8^5I?$C\U_VHO$\D&G6?ANS2-YI5:9BQ&0.@ /49KYQ^&QU$6VFBU80B639*
MKY.R)&.?N\Y/]:]#_:.T1+3QY-JER3)'J,$0(+8VJG'RCV/-=O\ "#P_HE[+
M;OJKA;>VD9;0H #/P"?,([^U>]&4:=!=3ZZ%H4%?L<_.ECX8\>Z3#<6!FC:Z
M:XOH5Q)^ZEC.,IZ# 8BNO'PPN_BY>7OBBQU3^R]!GED6WM8@5$P7Y59]O0+C
M*@=Z6>+PYXDN?$%\UI)%XA.JK';1@Y=HXPOWL<; N<\_SKJ/AIJ.I^&_!@UJ
MVA>[MO.<7-E]U[>1W+-Y?8KSQ^5<M2I+EO#XMCSIS_EW,2W_ &>-:T^>>YCU
M.VOVER%$L97"GG!/?'K7,>(/AQXH\.3I=7UK(\"(SBYL,L8V5> P^\![BOLG
M3=1BU33K?4H R17""1=XVL ?4'I7EGCOQU;VFJ6>CZ7<2;HQY]U+""52+^%=
MV"IWD8/H*YZ.+JN5AT\3/X3YWO\ 3+.3P5%X\U3SM;AO8XXYHI'9!;31M\ZN
M">CXQSTKT_P_XE\(>*?AXOA32;%K:V15B%EM"R*RX?8ISSD=&KAK?7[K7],U
MNYUC3GFT#Q'<Q.IM$.[]WPY4=SP,D=:Z/X?C0M#\6W=VEE--8B""!=\+?:$D
M1=I=D[*1WKHJ6Y;O?H.4=/,Z.YT+2?$VB6FE^(4ET9-)C:Z6T$AC8''+(P/S
M!1QBN!UK7/!]EX8U:Q\&W<^F2ZS)#.E[_P M%D1@&2,,,A<#  ]Z] UBW\+>
M,?$EC?:?=-IDJ&6%7N4/)(^<JK_*"-H'-:.A_#O3]1\:K>ZP_P#:MMHB+]F>
M554^?UWJJ<,N.GO62FHJ\[][$:;LB\$>+O%-G)JMF/#.I/IKQ&[@NIU"LTS+
M\Z;.H!;D>QK#^#.I:%?^#;D6^CP6^HJ\UKJ$,BA97EF8[,_[)S7K4\?BVR^)
MEK=-</=:!J-L\7D*,);2P@'>Q[[\X'TKQ3QMX6G\$>/)]<TFXBTFVU]/WE_(
MQ AN"6"(J=&)ZC(XI0E&=TM&]2(-.Z/1%M-/\.RP:-JFF6ZK81%R5(.Z!@ K
M@$Y^1A@CTKC= U?QGX@^%OB>6:W\RQNM\.E?9\I(VYL,,-RJ@YQD\"K!D\*:
MOH::UJ9GN_$\ES]GB+!C)(RG9@+Q^Y*@G.,<YJGX)U^YUK2]0\+Z_=/:Z'"D
MZ!VS%*L:L1M/0XXX;OTH4&E>VUOZ0TBGX UCP]!XJO?#7BW1GLI9;6,&>63,
M<*P( 8GD! SSD&O5]%U"\\&>"TL]!T2YU*.)Y5M"G216=C&6).<$8RQKY3\%
M>*OA?J.D:C8>*]/N-3DAFDDM'3S)!<;<J%;'OVK[(TB'2O#6A6OB35-7E2UA
MM$5WG?;"%.,$KV(Z"IQJ2EJ/$1M(J?#.?4-3^V:_KUK=Z;K-XL8N+660O F!
M\IB!X&1UKS2QM]>LO%NLS'9#>:RUS$TEJ<P,L0VF60'GS$'!%=7X\\7W/@F+
M1W\%H-1O-?E:** DR*[, 5E)'*J,X)Z8KD?&E_X^\+Z9IUWXAGL6U.\?RT6V
M7R@KS,H=0Q^\6X&36=*+O?\ F_0SBVCU'P//I-UI4.F:,N^#3F%NP="K!D&<
M'//&?I7))"?$'QT@O=$D4VOAZS:*[.,IODSA%/9AWK \1_$&^M)[CPQX7$C^
M)+U_)"[ !"2,$YZ$KZ_C7L?PZ\%0^!?#D>G-(;B\D_>75PYR\DIY8L?:LY_N
MXN3W>WZLUMR1YNYW;2I$CRRL$11EF8X 'J2:^6/B_J?POUJ)[#3(DOO$.[]V
M;-<D..1OQP16]X\N=8^('BIO!>@ZG]DT>"WWWKI_RT.[D#N<"MW3OAIX'\-W
M5O=:18L+GRU7SD<^:W/WAGH?4^E5A[4_>D]>W^8Z24&I2>I\VW/P\\7ZO!H%
M_(&BU;2]9U!44??FVTB2G'.2C&21' 4D"RBIR:AD6G)JH $!R1D$E"@Y@^0,
MDB5+;,G0C>2&;B0TT,#XSM2_IF;NK9G[Y7Y8GT[5J=J[]E[/^E4]YSE?\VS#
M"OXX/TH(^'0W_R<2QU_BG+6ZT'F3WN<Q1D*44;)ONP,Z24;^E@$(PN5D2HWV
M-*F#L 1XPW2P0P,4%K]DPG:E!S_8RSU*386N;K1@V+=9!*TW)#]#EQXM&S\)
M^-H6E;[KI1.\76"^TLMQH'U3&UMM<G++(A7E(\2DMP!K[)BSU359 6PZ$S[F
M)_UE=#DE!Z.!QM4)%2,? !'>I.4>\K,>/P)4Q*7MN!X 5 [=?B2!TWO#T.2@
M@(I!&(+"Y.D30$Q9L\-A?((4FZABR^]A[T)P_NB;A?,^2LG2@#+!6%?<A7!V
MW*7)CUMO<U']-2P\9247HOYNIX8QR(*HEO@"YDTG1:4D\<:.^7=/&7]29(VG
M)):[B1)<1R_U]&[^8"3Y)%=KH'/5)L3=#/06;Q@5EOZA(+"KBW5^[?NUSGQ7
M;LIM?)G)J"W3:]RQ'4M;W?O*\,D6T+J %.*/W*"H=PX1[.IK[$R?7'B2*C]Z
MC<;C4?(%?@SNJ$4]\[>^Z$X44)V$(D_[$50VO>DVZ,+R'_?<^3"S5Z(-%%Q*
MOM1D)_""6E=T+PF9-@HO?7N"0G3.G:)X01!AU.P2G_QTU>DZX*?"E&^G?V3S
MNSHS<!?B[VBHX'NQ1,\>'OJ?./ZC;^).V&Z?OXP[,DPUV7C^U2&=1;^R3NM]
M@<35'?$?J:(/9P^ Z"M&X*<++0B1[>Z8K=><I>G4T_=Z(<X<<AWCCLDNES6I
MUAK?#K.S8N2=/2NU2IX??"?)!+KY1294"*KD>R%N@+6YI* "&I1E7!Z3O.'P
M)G.S$MD1W3WMK-"J*=3G=[9SK>KC\ I 6$_[V)0I<B.^KC[R!*,<!",0_UM-
MX,ZM$<OPQ"Q,CD ^[^M(</57E'N$/$D)QK --=+&2%5I\3GOL6U4,I;=$U]\
MZ1MHY2&K"'+@8(KZT.T#KT&$$RZ783]!^M]@7#\Y;AI=&KNB#G]Y%,2J LW;
M_W[)2M2TID+(YS8#<%>T#?WCD(BG#O]9=[8W:HZ77*)0$,?HM!L'E<*"!==G
M# )^O$W/!<:9'^:SSY$F^]8/5[B8I+A\6%H: 4RFDH\GT'NI"$O+0_T+CSHW
M$[J-:_:S6N?-+,B$L@4R"'<WE?B,]K&O)&H.A%96;88JE?,WD9P#-Y))K4!:
MR6<KXTO'0X4SE.0!"K? !5_4WH"<.\U^ 347<N,K)1N^Q8H6QWB []=ES4BM
M/9>_U[#>P1J>O M_^6/#[KJ F6$$TVL4W2 ;Y;ZY[N9O$9'CTJBGJ *AW+>2
M<K!>;*1]4A?2;<'I:D4+*G+1D;<4!&3:=2J>9M!__ T[P>.YS;=_%Z;NI":$
M[0B:^2I67K)NW^[V8U+ 9?UT(AG,(9HL$6J%,JGG#"L7)+A-2QD6;[3_C)7>
M7L&\=-Z1RZB]?_RC4EI[E?4?LWRR(>\5/DK#Z+28S.ZU!-G:.PJX%HRWO1UR
M+&IBGG6O ,/-4&5?MZ41=>((-XNH!6$W7[)\GCVO$J+Y#P*C>KK![L[P30(7
M1D1?M* $W]Z"\#=0S*S,I'._#")9U4;*$D.&SBD$3\.'-RA1? M/_--,U68W
MY:W=5#D:X$[XR8$KF?SW"%VAAH.!-HEBKHQ6244^#/LOGU"LX*JY.7=*<)+<
M%_MHA-Y93D[!\Z#GZJ2B># \43E@D05Z[FIH@]B*R'JVK U%VE36>_2<[62B
MT_4M =R%EN&\:A8<^ #X<76#>V.U?B3;\Z??XK/CYFTZQ5_"RFV_[S8Y&)".
M*9VB."HDMGBCW[^$15&@NB/!M>4G?T,1@0:N10 7Z1'"5&M=H&O5(G?.[YI5
MXAW2K)MNFZ]; G>ALA:<:4CM43NH 6+E)'L6>FK'C@U]8DR6<&/I7@.V>87R
MG?3/6DG<R?2P6+$;MB6>?0R_EFV3;PV\K)L9"&%&X<?T<J/CE=%A%(O-"+S'
MA4U=J9/>S)C];:.P3!/VG-6-2@A;&]JJ"ITU5%IL>C&AJ^:F5GO4I.^\ XA3
ME1EC8("'91]<3DE)U?895J_TNOEYY^,U(ONB,?K_^52^"^;3.2>XUY VOF(T
MEA]0[&27F-$4N29]*5'[[_%FA#P#2L<0.5+OP8F\KVN]\C0MEAW&$ARTBR.=
M9?WSD^7,VQ 4@COK(Q(GJ] 7D2;1@>+NF42NK;$I\CG$<TU^>@#0DYS5!>VU
M<&+84'6)WK66,Q*MM>[BY&VK;G\4/<GOSCF9GS*,EFE6I<<'3OA0NNAO!!58
M6DS@_-(0JA9,R6 B9*Y\,X\#S-\X8'2/*$21)4*T*G4"L,)U>T,DS7\8G23)
M^[T/X,W/0)'&P^IC6MMH Y/"_(46TJPM%8;#)7\7ICDJV;TT7#25FBS^1M,"
MKR<&-SX U.9]A (O3]6[H2\T,@-F4D$.X]::ZP1W!VOMG%7A B(5TN-SJ9^1
M=20\TWW]G>N[D<BNP9NK09V@/'V;]G8^H?JA)+NV[B>B^/<!P\UB"4BLBWI]
MI/4G></ZPPW^MFSHX-69U')=35&$ZQP'I7[VU/AU,>GCRSJIP5 :044FL#8;
M#=$FHH]P/'R=(]E]Q?746)5ZU.X]F"5*0&DD1/0_?Y&W1;U?U8W6;EL0HM-K
M:^U5I]3O,%'ERI&^-D48!/1?UMKKZ;;0@"[NB#)X2N8L+A3+49#.R]CMK[XB
MQ(+^4N9&ZK;4>X_ Q9:=I\>:#/A+O8[Q,&#T/1_X<+B787/-J;.UU)[#:OR%
M,GLBMD7UT]MAT]2N.NEJ<[)A)0J(2MS@=MX0N3,P.T'7/<C#K+$$SS%I79/I
M >"'Q[3149]D0^9#]@D80H7.VK*0:LN?,(@B0+S#7?GS*!,+6 =OCDCJJ/$X
M+Z:;4(K=&'I3EM[<IAB!?K<=2JO2.5*/DMR8<[5YTZZ2R$")Y4Z)^Y+K$L=M
MM)*GNP_FGMC"U$=!AHO^^FWN ^+4.//P^:ZEH*$G3A79FL#5EXCA(*6/O=R_
MT9=[QE$LBGNZKM(#?E8CMGYF69Q/SF5^CI8)3/4YB6 ONV1*A@C.V]'>G*>M
M'A3>E+2V46)QB.X08W>!=[!,7_O5+!IWB&<GW)T'745N96^J-\7!W[A:71);
MB3)\U5>7AI>7AOAHU;G<DZ'.[SGG=Y(ALI^*=LU68Q-KT"MD+QY[CYU/!9]N
MU[+WLJ(?L8CI1/<%,\YIB,F,V3)F_;ADP6\)L;(9]J^)S],P]5>N6J6.&+>:
MO6OT%1/Y0K;.G5X)Q\D^'J\L.U3,87RWU'@<>#7P &!< TO!>.HKG.A@IVH+
M>XR?+D4G]M1M>QRX1M=D$>-)/<J' N=,ZBC62!B1IH0"Q\U3Q FU&/D/9M:O
M^"G!U7_]M_72OQU!G;(7/\L*W72:37!W(=Y/=7+\&7WTNA)-E6H]'WPKCHZ;
M,>XHT%S*?@#HI4E'I@K;9JX7[^65DS*?C=8R1#+J6=_^"?U2-6=N]?OFU "E
M$=T,7G$U-&AKU9Q>$N) !KX-FW89!Z>_D*.[U?[]5=0HH#H]/]>AUZSU[FO-
MJ2^1J]Z]H:,GVZFC74;I[<L2@*H L^NT?FW :<(]45]X,R@G45O9M^)0RIDE
M8U\H3" ]9AE__;5L4-Q.>60Q[WAY9:Y3__Y.2-B(*F#<BRQD4?2\?B89'_,*
M/5&^M@I64D^2ZU%<<1:R[>AFLN>68O;=P](-1-\522BPZGQ"\4;;)Y$(D6^L
M<Y(]A4PB?!6CV<(J*K.,]"9>9Q)J[9\$F^C+&SBV!+A'A3Q#8P]=4FPJ5ZFY
MG&B+&W[7 !J&DP;?0@O-#LU#BA^WSY_ .F*C5-6WH7_QNJ_?? Y>YLQ\#5*W
MX3*X U'N#9GC)O3J;A2[$UT!,Y3O?0<W,.^1))&K9KU%33^G.6*4O[Y*3DB1
M1#Z;3S?Z_C?SIPO)<;(Q/GZ<+S@Y+H3?I=7\Y54O[:_\,QC>BY Y&%<_IR?]
MF)P&+PUI%BK")&UDT&@)PQYJ_R[H28+E$TI^['\(S* Q27ZIF%'BD:Y][/(Y
MV;>4N#]*UK^>IQ<]O&T!_OD]:<\@%_#*XZ6R0:#;>H)#-WQ4B06B43A1$B]$
M="QJW1VE5<_].HR"8,]=MYMVREB>1<N,N^--(>^OF\_IT+GNF:$"&A\6)H1D
MYSO&EKM6XZ+8Q3=V^&[0%$R5]S"D-!1N)J_V[KV\&HRH@-SZD"P>%"R?XT2K
MD9J!]72,V9;K?+?SJ"!":*N A,3&L@MT4!<G].<S1)63JLMI1E!Y3<=7(0CH
M*T_]'BH'+9(P#0&>/O^^I,BS-D,L]0! IDNFRJYQ/5=F:?N2HM4#!#EF&79E
M,A/N"[IWJ\$LJIG1"6MF.16Q"2I"QI?:W<]SF1^) FZ7ZS_*Z\-R<!>$ZF!T
MB<Q I!9A[++)3SV:M#4^G,80A+_;(>B@@'3?^ADZ R;TW*"]*UIKOGGB%A1;
MRY,EQRR&SZ^\QZW*4=#5M0 -MN0/UW_[>M[VPCJ.KYX>^9\8R?\J,GQT$U+8
M/6ZE);.:;<B='BQH]N+=K5+4A7A#^(<&=S$C)VY!#%R&&?#,VKGP?I11. _.
M1HR>&&*CEO>'7<OSAG3F)>9W5 \&V EG/F4W8U1J+/RI9?F(GE5?XI*%&O!&
MC1H C+R?W#Q3[J9[ %AS/@!47:ZTD7W+.?>:4N$/@*.AT'W7%ZP'_Z>DU?\U
M-]5K[U[[=&3FEB^?[P$PMU2CQ/H ^%D>_ #XT'?N EQ_^P!8!Q;>M0R$GND:
M/ #J]<\<W]FH_'^)2[7/>P!T]1D%A#S_]\*X4%CR;LCQ&S5(,FKS\A?:^%81
M?#BZ#8T_[PDR7FHAD? U2E:?3T1:F'S=6KNUTKS^%3$BP_S7ACJ4.2>TY?08
M#KHUQ) O*E)K5>51GCA_ZV[L6M[58)EJH@PWPJ%5Q\WX[O6\W2[AW\JVOB@U
M#&TV745?/ !B;RZ[6*MKT-63\VE$=G;A*YOZG9E2W 6X&V:<,^M81EACO*S)
M#P R233W T#%,>G?Z<K+>@ D 3,@- ^ \%@(*[)@L)J%Z#4R*Y$WGRE/7>7R
MACAMZ.75_.0W4<\TFA_OEAOE#/^\#6F=M2E@9,-0%VQ9M\%<\0>FMC?I#K)8
M.1=<Q;O,W,]-6MMN=8^KJ95W D2Q'/8J1_1(0B)^_6(CNM]@.Q/&_)/(QO)M
MLCO^P-NB7KJ[;J4=*_2_DVZO/\!V8W1QI?9$7N3?]GOT4?0=$VP7W#%5 <W^
M?S:S+MYABN+4<2H!6ZE+'^7EX, (##=9?Q^K+FWL^S2>L"JQQM67CSF65!ZS
M@SFZE2Z)D&U1(GUV-E%7_IUJ>4-G9GKF6D)P?]O+CFA!HW1KM<K[09OFC:9R
MJP/&>H1%G969C1H7U2#/YS]<<<;\^X.W&BGCFIQS3?)/;P$AOS;PD'<%D?+L
MMV] C.K)Y4]U@BR"V=/X,KYT$!:_V:+ENI>X@?#].1+)I+I5EY_VS+AV.2[F
M=H^8'#C;[1/9"2DQ^[WLO'3D6+XZ"GKD^,'SR4L&&6EC '%Z=HNU!=+QQ[TP
MVA-YJHN,3H*\\X1/.8R5/P?1O:'G::></'MB)S:ID5E##MEC]QY5/C2^[N6G
M2#13?[ZKU>,+G;%0@"Q.I0 '"IJE(N6%@FK0T<8+'^!QGHZ[6C[5M[\XXI_L
M>/W&+H2W!$-M"OJ:0X?^X?$&'<JOLA"=AA'_:\&O!:+\ZG"VDXSSV3*7'"3K
M8CGQ^6C ID!U:X8&PMF+XOTD)&];K)ERZ.Y(,OYXX26Q 0^#6;3,&@'+=9W%
M#R46C#>R4R>8;*C5X51-B[Y!T-K>JONC*2I<#F5=J#3,1CR%O(!(^ =W_Y3/
MT?3\,^7M]I@"P>SZ9(LJ^V_\ZKK,"EQM23!K4LM6DS-_\T..:=[9(_TI>AGN
M:3R!S?( 7L*X_1OI,8FQYT<"9"L"VRTCZ>\J-PZ)'* IXJ=4N<W*WOVC!IIP
M%M 0Y-WM2Y<^RC8TY[9"#4H_B(/+?Q73U%;LF?S9+JR=$8YA0\;W=]8G\OR2
M5Q9GXLU8V9#A4<\T77#<,>;%GN=%UM>6HR6V!'05UWVL%(5DS\9@8+?/C>U.
M:Z*;S8D_X/3R0%S-[?T)A^49$7O\HB[YS:W3'ZZV/VZXKF[**I8V.+LI'\W"
MU!*T4OPI]2YY2?+7!6;E.;?U"9R\QBZEU3YE5ET&)OB_LD'P$_AZF6Y'F69(
M[WNN]+ !%^J:<S06*!?61Q_)C=-D6/(G_%%]RU8&FG(_!\VP;J)!0U*=A/V.
M?WZZ<71DF,#$4[!9C;T(6* *1ZG0SZO>@<Q>%3MW\$6W#^)Y%GJW.$@-B9P*
M+&#DZJK;FBVREH]2SM0V#JM5^H<QZT=B+&M[LF&11X,P);0*0D1JP[PX(%R<
MAT]26$7SCB:&&=LZ='LS09$#19)@ C0/=+KR>GZ=Y15R1I_283K='V[V7>:V
MN*/&A+&T]5>&GKYM/;H>"=5'9V8;24GMO>J8WWTNN%\UAV,=*(6?NAGWMWJ3
M'.1_3]N[(#[E)Z2J,[<78S'=P)XRP72L_!VKZ=U._I>]TF ZYY)5B_<P [<3
M,[_FL[=-V%#Z+>Q]Z3H-XW\S=I[Y-$JXMDW+D[H"QS3&X847P%KF"L>_E@]&
M>67?*"PAEV_#&R=/5+OI%%MA,897*/AKW5(&I\:@0K ]YN_M0#F.L!(SL!BC
MUXP\:2HR/TS?5.A>JDM70=HUIT9;H;X#_IAZSD=8\F1ML5@U;Q+F7/_YY?O%
MC.-KSE@6Q.3'MA3NG]RW8?DRE1B;X@,ELCIXM/8"=_C1,!$7E<)D)#SQO<&]
MT_I0Z+.Q4;RV+('LUX&'4@[G4I@WR"(A?\/YE@*"H_E_T %QC7^_J\G 8T#D
M.KWSX=D@V7C[#-/OHWP:Z#F?_#-"+87\ F8##O[NMD:Y#/X_'?Q51)1>6O+>
MAFB'VR$I18%0LOW 0Q>Z)93Z%56 <B%YU4>L5"!.P_XWU(S+$4;75NAT\-])
MT=>7LLY[S[Y^R28I\SEC;&01A_P%(IM31D5+:SVTP%.NEH%N@(0_X$/=6Y1Z
M[LB%R;\NKA.IRN?A19<T]!:>K+V!=(_!RZI 1PQDT>IEWDBL!HC@<*>/?2&@
M?O8*,^@YTV;M,F&Y<2CB+EE#FN@I\2F6&*7'BL5_-IK@]B9%_84T7KL-$:@M
MGV%^NU/3MJ,3)8[P]!9J:OD5_1[W^3.E@5ME0 IUK@EELL))V[Y.UP?$;F\\
MC.6X8;\SUU%M'NK9'G;O[64<M;X.>!4.BI]E/!JRIFZ('J+HS2DWEU/V?O[=
M/W,KI0CX9$M]+2P]7UFZ6E8D.H05[;=G&HTHDA-RH?"\##!]62MI9ADVR@7'
M_G;,OU10[9(OAJ*V?KS4'%%^8![<ZUY;RFS90&C[K!%22ZX$#D2M5*OYLF1Y
M)5LB$661Q;\UMFMQ7GX_B&FXYE/^_7@\XB"_Y6]6E#P-C,1F*+LOIMDU!+P]
M-[=WO!+ ->A>,5G#*)__"I3R8M\;83U<HZH863'JO@5R4FJN@]\A*CFD6Y\,
MC(]6<'Z#[[*]6IP!@/6N!I:HQJJM@^N-%KGHZ)( %-=# #\RO6>F _5<%OHA
M_X8" 8<9KKGNES>M'=N(YT,4>7HCA[R9J-;00HNU)U@4GQ-(2I@=*W=[]%8>
MSP])2>93]T7Q"1?]Y?TTNJN2%KP^BV!7?G>5A8+W<=>!3P=N['3KU1R%$@B\
M7%>\R4V%7RLNJV)!\7FY["CRHRHQZ@L^U?5DSID;N#U)3#.M6%3F'N_-J+/>
M&['$SWMR,O\U'R?5=0;=]<O)L>+#3I>;7G<\ #[]0RW=CEMM\_7NE'YFT_=)
M12JO*?5V>.E9U#P5J="K*,[MW>KM31)PYA_#P4!;G YP^F1&X0=XR/'W&\^D
MC"NECQBMTJD2+19X</R;5O?SH7S=R;FW(2@;+MGO@'!IA.5,]+LV%&MI]0IZ
M4[TY:<922"'[\_7DF\2DQF?8>UO2_?N@2EO+S\7F4@WSQ,99@HNS5J$N9!%E
MHXCZ&GJP4A?XMZ@TMS(\<1T7W!:K]*$B='9S8$4^:C-9ILPP[\<>H;I1);-#
M2XO21U:V'+/N10AOH8KX,W*G70=*&3M\OZ&W9HV!E)YKQJ;WM/N9*U0@;)/.
MS(W)K)Z&+Y5ODT)TJZH>LWS'TV?-\*G<-NELK*P2L+!<G5/Z$(J[[EQWTYOG
MZ5KYA#Y2W7CLPUNJ<.D]+N/KO@_ZT=IU0A_<ZQS>)*8.=^W"$\Y9'@#\^_+/
M2B'\J'/_$#;D/RE^S[;,S9X-:A\?:TXX>3$:%/1LBU%B)CQ0)%I$L*6 V%QP
M272L]V;)CW?*V&20X5E*]<+%6(WY8+DC;4%%R?Y%[#AHL^4!$$7RF6AK2C+H
M3EL+ .9595T<T83S2FS=RZ&[4+PP7^BE;VN>8D$I[G6A4ZS&SC.R0Z,D,IIS
MD9C3<Q$J)]CJH#5^A\77%27AD_F)J/6OI)JWVO9)C_Z>[354%Y!!@ [BZ%>A
MCAV9)UJN'YK'V/F/?"FX\\K3\9U9-U]!=7GU<@/@))!EGRK#N-TW"VB.6TVH
M&\>M[A!WG%9[S.@IP4$XGE]8OF9]@R(QN&BTWYIB0= WI\-- A0I0)O>D##,
M[#$;+@9T'ALU/_G@T^,^H%NQ"2X>[)0/K.OR(^E=#2O( 61>XP$./:%'%H[;
M)UFP9&:G;(SUD[^^P33<0;&"K9\(X1\\MS(!V 7>QG$C R6NW$4+4(HDP[C$
M9@75@1"\V?.@=HQ1VBNWO:8D.K&T1R/M[EVYQ,$">4L8U<HC5C(4:ZI[ $]&
MM84RY^J&M.;22T$_>7O3Q-I?K"T2IQ$MMT$QX@@YF[Z.6Y\$MVR/QA>M)9"?
MQ=BV!=OR5S5*E,+I,/<81L>(HK/>X<*RU9^.A)2AXGAQHB7VK7 /SH^@L7)'
M88?3!P#V3<.NA)\M1@J*L;)WE^1@C%R.DW&<S]YJCJ%XU)RBN7.Z,<@-WKFH
M&_V1+[PH$>QHG&DEOBI9+'#M5L<52_RLJ@SS+BP$\Y9<S<=:" WIY0!9Y-&]
M=B5ZW1#E]+:]3;GGY3<L:,(CK!U@AOG$=OPFWF$OR^QD ?*S1:S/ T!V,;8#
M%!-CRQ<B6GK_7D]!H$A8@NJSR0/@X[F_XV^V1^)W07H]2Z,QPK6GPL*O#*Y3
M.3F%86C5-"]J !;\P$83.F[3%%((ALJV1E?T3/TY*7!W$'9S>[0S>;@S>D;2
M\2;<\\C&9(F&JK<\QRKH&*US.=>$"AZ))S1#I _ZMS:NV+QL^.K@D*;YFV:E
M?.*1>+H853/S(YF:31*(!UIM.YA02'A$KD=L8)C=U-N9G8JKHI1[([[Y].?8
MC/F%S4J!]:]W2/O-B).+=[;5Z+@E"Q ]K4JZI1R-00P^%[F'1F$]$1H([W'4
MZ$;V#=33FPIU>RLKE'9J.$T1QY.RKJCR*9K79Q*FANL0HZPJO7]=94+/]@/1
MOH'\1[:A6[J78;!3M"GC5;1#^_R)KZN)708#X6,HCK)'JB:^&*==F@PG,ZRC
M/EPV*G[[UIU>L<AZ;XB5)G-?!T#_SHD^)CP-P#U YOFC+G 4QE,..TV2A4/$
MNIN:.LZ@JGVM"S0IS9D;H%&ON&*N\LDN"P8<[PC+XT[\1/%D2G!./RO[PK=%
MWJZNU@6>9TVK#/!\L09IW66E[IBH5UM( : &3'?E\M?!:]?F9??72Q@=.,(
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MQ4@]S>#/<(-"&V[LU/[+:LD"\A NYU:3[%=+;_3<R9:%A,<[;$6^S :DU;_
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MS&/)O\)8.VQ=W16CV&G>UD(@I-\XBDN1!45R&ME"K'"\="9;,YO)P"_720/
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M7OGG:'5I33^BK8?R%<'BZUR1CV<F&P[MRWK3[A$N&$B]Z0M$Y(]JKKP1-?3
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M9[IDQ74%E3VL#WF,A6O/WC%@"WH95$?7LCASWI[7I*1*&P?&&GH/;K$^P^L
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M.!NSE_1NR=/2(BZ'J"*'JD">"!Q'L'W14)6F-W=:E54O9^M+/!5.O+"1 +9
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M_QGFZY<E%X1S6XQYAO5%#.<KFU10X<DJ?/:IMT5#;;K,U_RNDA[C5'^G,W*
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M%Q[4Z@$)O0:TCSI1H%.^=PER4FO72I P"E6[KCHM&[9M#CJ^RS3_+-L_?NR
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MH&DOWH)\:=NQ8?ZJKA@T+9VQX$S*&EG"RE?_\FUSWC]8<D$ +ENG*<NE>6)
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MTS':X9,C+M$#01URW3OIC450DFQ#?%=JQ/Y1@D26-7D/6]0KLGVWJVKY'P=
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M9CD+N(/3"?)(W(YEF2[SVX\5I\TC*)A,A&H&31D!O+G=8F'(?[RA,/'-J6L
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M:UV11]W HH&:<9X8B7X6_@0'6KN10:[&2BK'7OR3.]@8%ZT9%R1/.((R7P)
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ML"[ 8SE8;KMD\&AFNQ(6:GH;Z_F:H45OQR#]+6171='+=+9BA BE1O]LL#^
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MX\#T31UXV32%5:FYC>I754G<X8)@6>R\>+3Y60]YPC2J()PGCBY2UKCSG2*
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MV:K)A(-V<T&Q&.SOARS+-R%,"AQ+@:K1/7#UJ'HD3T$P1'P>VB6V@,H?8##
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M)IR0.00?,:JHSKXD2%3UR<43%:<8VV#?J"C/J'?('Q$N+/M5HTQ52=G68_"
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M%\,0F6RHOU&JFQ;HV$Y=Q+>^\27(%<G6FT?E&/=[CQ&J[;^B%O&*O]";H@[
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M! 25&GA%<D)#GG:M3C+OU%;H9[X5D2C27>K-?7>N&]U!,.VER^(HP5AYQ3@
M*2S7<O+S=#N3,1\C)(J2T@-L6:^U\_:%D$!I$''_)>]M7W'^<\. [S;VA=XZ
MWQI_,+%>[,KL5%4&/D>#"Q!5ELM':]3S70Z" HADIPI3"B7BD99K\J]D?'_F
M@H7_704SU\#D\*U@17.V%-UX6ENBR!,R@YI/=RO>5;^3M36V\^0*LTV',&HX
MF^MPT7>H!T#4"=R9<]13H-!35 ":)7WVE!G7_W\[GO)3401=!T^TM##]%0=(
M[=:PT;YCVQ_:K*14I?_,I\YIKNX^,@8P?#;,5 \/GLFTZ"A!Q9E*4HTZ7PJG
M:W(I!ED^)BNT7C&.QG*B2]'KX0+>IIJ2[]DX/-169]C9I%CC"<7/TP=R^$P7
MH#@!Q?;&[DL?)Z8A&2_]8FIJ5HAOP7Q;P*B;ZHQ-0F\@D9./9O[Z7NCJ.\,F
M57?"CWYHUEZP<:FX^U_?-]V2)*S'4AL&4&]<Z&0O&TT@ ^)V</8\:_(\HIN$
M?:F9-4MSXTX&5L1G-)T9("JM7#48]'Q#S^YQ#?0#@H2-Y)]QYO'O[D_U*HN\
M:2ZQ!:M@0+FS@*F(L8]Z'E9I3M]D[BB0PHDM1_9G[H?XR'<;-L$-DOV3!):8
MDLWVDVBQ[X'+R1P4I>R43Q/6,W=CT:YA]\(RZ7UW7J#J;8X%P4VU,!X7E;3A
M-S>D[D!-T(%!RTR@J*_G)T^6HC7<GE/2ZE-_Z[46!ZW,,SM;@TUNZL"0C3O?
M;DMJC#/BB.=X92_SZ-<M_P0G=W=&8'.?B]]7#PT:.G P&Z:M>XV^)N?2<8WU
M&:O--_JW\?]$><BY:Z>\#IVF/J'DK^*P=L6FF'(&SMD_]N+"'/'EFJ_8K[E=
MD)S8G8X&4$&F1)2-<4(4@XD-Q5[L]VE],T9=BF'!*SG)C0 ,XYEJ<UXOG6N0
M_U_R^JQ(@^:8L,WWOV]#A=ZY+[0O F1([:H"]Y"3D2+V%*N@W<UL7UH%#I7H
MT49IL-5'EW6&VZX7<G9[EL,;PU@MS\U1::@YL_M^?$OJYT?JEE)<&\C2<5=5
MJ=O*'8A#P-ZO$"JL;L@FD&0XJ#B2CFHH[8#S/&X<&;)I2?$G\--,!]VJ.4;7
M=)HE&/9"%&C^8RVPOY:KFHP\7UI>1@]KUH2&];DR*V\F/H&/LZ1'#V>^1WZ5
MI'Q*;-MJ70JXV&GOU<3X%6GSWY1\/^)LS;S[_.7;_-NN;K>10F^6=K2I;L;<
ME3^3JHKPQ^4TK#[BU@@%']Y<'MIIF><R-W?@L%KTT\%SSVLS;0(2!HJ6@TS%
M2"Z\6E]6PKZO[^':[@8CL\\68=\L[8503<@W9CF'3WLWAD4$:N(IK9+2/UU[
M@(RVT+.Y\Y?Q5+WNQ..N',-,\14OACCG*(Q)6AH$(PP^UG[,T67#J*+^ *.B
MC9-/]&0:)@JX0CH_-<2[X]6_NI3+SKTXDL,YKV0!]LDHA,7Q5'BE;0X!1 #9
M"^U58Y+OB_K(6*4?;UMY$(K72QLB,B8EEG=L(552WL5D('%!M9=#S:'N6N_6
M GNR=$2R+TNFQ%@QD#QQW0113 !""\1G-OLNK2F9WTC4G$UDJ?;L.FX1U]TR
M'XW7OZ! B"JZ^BY49(+]R2'W *"./H[WO8 DRKT\:VPB[U_HT#8;F?X2KQ(=
M^&-84$,V!&Z=?6O,PU&4 [$NCY0MALOC78:B:%,K'27\M_\/7>\5U(07M?U&
M44"Z2%6:%)$N*+V)2.\@O42D$VG2 @10>@U-0#I(KY$:>N]=6B34)/2:4*.T
M[_^>\UY\Y^)</#/[<L_L-?MY?C-KUBK^M[@GE>Q'D1 ?EQBRV?&%:.RO<1/D
M==T,1'*=G'<2><@)5XW]FX&,#*"35MC)SR;!MC$3#033O+'D'G1N@I4-R$PG
MI41A4LDT)TM#1IOES0Y%W4)$[@ ?*6N=TX4"'3Y;QP 6O_U^=_ N<KK&<WF!
MHFHY^]#3SR"2-]1'=LH8\:::2#W+?$$0TU@+USK1W":A1XCV[<@S=++@H^S[
MC!)2C8&O-Y:KASED0:<E0"IPW:V+1F^NX!QW\ERN2Q$G>P.1,X 2>SD(^M$P
M/>:<YN$XD&S^UI3N!4I;#9!R+7/;*&^>8C&,V'ML)E[^;ZT,G/)^YB"XP0W&
M 5V+DW2E &U-Q>:* J,RW:[9[@"4HF_A(JIF:#LN^K$XVS*(UY0!WC@$[#N8
M>2V^AHW#USV@2[H#5(^,Q/EO(SH^@Z4'S(C"15>T77B?!#H$Q3-ZCD21'5UV
M2TS0>FC)&<.3:'[Y RLD9)6\8TEWO("T6A?Q7P_;M/)%,*S@>\.L:5+&EMC]
M?D0N%<Z[L_#>E7V*;?+1RGA5PF5[_4KMA,.U,LXX5*Z'-GRF?=3.U%:78H9X
M!]I^OF\144R8^D"W@;X:9-^M6L=']P68/P1S'O6VH<.09\PR2')NM_PS*+Y6
MP6K#4$TXE[3J1S.%PWX9(0^LK_DIGW>TSMU2XK8CVCW=1!&1@D&S-$0/FQ(I
MU!@9]R1@DVZ$.V)R(G/T?5+90DXVOC[$X2957^2(5\=RFV&_IPC!X@I8L22Z
MA +SJL?Y&]"JP DOE(>VOVAM7TR?<NZ05><9:_$7Y'$<1!;5'@RR)$ZPH%"]
MKO34F1/P-G\I^HSQP<+E2V8F+SO7B+8/LSXM@^LS;8(.L&+S6OG=7PZW_D*G
M%1%5IC:'_WNVS=U4HC&6"(EYF7__?T69UN7$2KECMMF9P]TO%"D>)(VM#GV$
M:9G.##X\?''N2RGUH GLJNGZ0W^A[F\%6+A5V'9;AO9* :^LQ3[6S?JP\QD>
MKI\Y8?3,4>C,_.;%*"&1]+$HN?8;$@*[C>#5\2%^:A4)N2'<)3KULF<M_%]D
M_%F\B*S#!_,<>9W:ADRW>D6!U7(_\CB6STOF8_&V/U[7LGJQ;!@/RU-T.>4A
M#?K7:" <J"E6<$ ?RU/LRAT@QCN/#+B\:+EB-8F$)H$\7S88)K\,"W8\:=^Q
M&R$41?98]B92_G81OU*YDD)<V8Q>!7_/<SP1]Y/S^=TUMG+Z>26G99L9-"2C
M=/463-J7]^R:^TI>_=02#QM(0_A&)?(V&+F;]7%67/*;T)R&Z1-_)3,II 8P
MPMQAHP+<Z[Z'BNLP)#TJ(<;[=SX8NJ^/HVBK $FM5#?]'"_W_#3]N=7SJMDF
MY@]I  W#V[W\(_Z!K_+&H-X[@$/7WR?>QU?/VH%W@-+]O9UV VQD7Z[0 B="
ME-F\7RQEM*)$5KY?JB;']3[9_5]F%@/4*<OA(S+9F>@[@+TL[YHBWK/"B:YN
MZHU8+B_NL_JEP9BW-"\(7D&6HCG%&?=V,R?VR0AG)N#?T__K8>_'\&T#D087
MA7B]*UZP&&(02%,CJ.D?MH4<G1SDRCW9,[0<YU &3S^P,LV95WX[::H ^,<;
M@\U;Q%S$X6VN=,  R'N\I>^;)AYIY/+2BO+SUL9F)2-AS6\Y"LC1[DJ11+#-
MI"SR*\G+G_^_DK^;_Y_93\JZHQ_.9'2)!NX 35U]\E'R#$$,CE+!/;MO&G!T
M\6A26?V%VW^[U1-A34X<G!<SSWGMR0Q]6NL.[:5]'W(,',@HW0$>2M8WQ"#7
MKR4ZDT4!$V]FHYF@!^Q)3[AO4@F0K; XUGK? SNLS87W?RQM@ ZQV)6G])IP
M=/Y=BCPJ:@[4!FNU5MF+S+383@U+ .@D $E_9RZ!6-74!]5YT:S,WSJW3SV
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M:>*U0!G&-'D>4UVX%BPW6/UT_IF3GL5%H9[H!%'Y9==_401==N["[L(8TK[
M^2OQ7DZ5OW@!C ,_@84?RHG7_KZ6P2T+116GF;J,Y4FM3/&/A  4LQ.#2;"L
M9&#,T"HC3K3KFOT]Z=7Y>!,N9)\=VI8"?;MK["7/@)]]C], HP7>+CL+B.W7
MLD>(*%..Y_8QD7D5:SOU)476?G>6BCV25Y?Y#RY:6<)=?NZG4P$%?K(KU8F(
M59"1'7%S^B.<>K,KUJ\\K+S7NYBX8V6$7-#//!^.6=Q_MR2'S;@JP*H1(63W
MP_&[:')EUC $(M-N;5%P(_EET0E7?PQCI]<[R645A84.*?TPZP),ZY?O!U/^
M\):8S0>)4JUGHXE]LG]I<:S1$ 5,UQ-\EQD.'KD%'=/ %D\MVGQ/$?/H2TU@
MD)RR0)?CW7JZ&ES#98OA84*?&J;=].P(%;<8X&6C#6YMH.WDMQPR\U>R&FCQ
M7EEE 0Y+5=&;%P>J*:9(XC%"SY;BCY79YY.HF,%JT-"JU*ZNGEMJR51^)S6X
MX-J@P!*$N$R>8A\V4OG![_$U.[GB%> <]AP_AM-06C@2N.8N9%\Q'[S:[*3^
MZU[T]4LH4S,RZ+.'E2@JCQH<V7_+TX;70UFJ:[T8,TXM2BK297[.NO\X./*!
M.^!^Q\7LA1&V,:=O5;#:UT-LAD:=9E!$>)@@T^HTDE=AC%@G4_.O0X\5 $L9
MV\FCB K0Z(6]<7'?$NMUL:!_',$9,H'_!BS*?8+5B;BF+Y7+RC<CQF3$:H[[
MMD\JDTHSI<E6HLV#%ST'@^CQJ3_WD0)[(Y\$^U.6WP_8JB*2BW5L9N,0.R]U
M8UXCXUXP#Z&YA6N*$'S3?U\/_B,?ZI7UG]7%"M9X7>D\L:RS,-5B2$:**&O&
MYK7>DY4WFY_N)%C9-XO[AT@0?=\5@0KE-]H#)"D,VP<'K5-DVY?>%'A/4=3D
M.167E)-)81,YJ5K_1LE,5G-S?&3VS.MM"GIR;3C3J"CT[9RZO-(1=WU(ZI>H
M&2,)7DJXVHI)BBGWK0V:<4W%=.WXKW;9N=FAR)4G9VA4?S8DZ0%ZXWB&U*]G
ML>D1,FZP->#^1;"CRXL>RRU>RO0F.9-RUU+F"-"^6U0>T^=B;$U^+D6$1FR8
M!]D$+XW)]^PGH2-3"E8/2_%71MC IAPT^1/_CA'P5EW2#[-A\W+'*8(]7KZY
M6$BT*X._?AQ3[K86]G)(CC+47(=.3?;P#O ]GJ3R!>HIW"*"S2:AVO8/.+3[
M@O5I Y\6@\6.F9-/LFF-G;1MZHDA!07@4\ 93'"FW;P8:05\UF)=EWOB*[#1
M#2F;AZKWOW+W/U'RZ:+RBG]Q];ZIKN.WH W8>*K)(41S=%RDU.>_2GZ*"E=A
M-./=.4Q]V>AS+KN$EA\P:5<+\%V_D7X;^R%F?C0V6E ,X$]WS_ ;R\K^8$.\
M=/\=@#)%:R%__I"[.>W<%MK[1UJ:_F,Q,9M'0_:G]J%>@WVKIVTA:Y9AN_O^
M):IT[WFG<E\!AOPOY,/-2D-@G9+F9BN%$SQ?;U*FDBRJAQD_T;H3,2+]WG"+
MBS.&%3 H+O^Y(6NTX>?AJYD9?414RYXG@S5_/SO%/O24K%X8<&]/K<CI@>J,
M\%]=ZJ#0S.M+?!N&,JJ+WKJ5E>)@.T]UQDYXV5Q9S:DIM^9K!!L&2@RS*M8V
MM&M!3Q=,GONH+ :]P!>B*,GP/L G'7M Y!![[\/"JH$2SW"=[^O4@:#-O,@Z
M_'^.)R>(<XA*[TU7N:5^_TKMS<!G3/Q;Y ^CX2_W]J008[G,6*$X[\I0-[N?
M*[NC<>1;>DETHI)NK[S8;$+C$'O'7\]M%ZZY2IQY=U_@/U!'\J4^TY8^IQUC
ME!R=V?&9+RGK6YZO'SBC7-SNO:7K:L0QWTP,[#:RHQUMDW)I,[XH_O3JEB64
MW>]LQD^L ^O_(EW^[9&IO4TB'/:X%D@*OP8M,/#Q& $B&-C.V+M>483$XWSU
M0U%GOIDE6?PSPPNZ([6/+#:^#S.07ZIMTQ9_6._HXZ6K6"J[D$O")0S=*&K8
MULY6YS>E?>Q7X_RV?.^F7V(YJ/!^JQLIA*\!Q_\(?0=@!-$CS\]Q$7MKA^2U
M_+V)/9^BW0MS2YD0D[5[5H_3T:)IC3@BI5"5]NFJ_F";EA]NB?"5%#*//)N_
M3_?D:,WP66C+B7UGN=?S9YSU+4)N+N2]D>"UQ$=L(3]VA$V5&HM5?%Q>7L$C
MHJ[,]6?XO0/H9V&84Y>BI1;/N/4-!U;MU$UNM%MX^Z.*%;S*  _+-[=2Y00W
M8<D8Q[62Z<J<ON:! /(&J_>/2%5GO@-</=,^^W+/(<:#&^ 1_-[FLGPFGJ0Z
M3ATR\$#HZ!])@Q!M271KA:F@30I%2_&P7V3"K813'JU@ 58EXA M!4'\>MG2
M0L90]ZOG9%+.X#B7+Q^/^PD1FQ<P[C'SABU"3,D\WF@YN(3U#(T]?Z9+>#G)
M)[;0U]<IC@7A \Q#EC06JNR6:'XE\&30V$K5?Z'<W;62K.B*A:@X^+ :7MG=
M9AI)U&@((<5XAO4_"*(2+!!YO!.K1K+JNGI. OR!!-Y7TLY2VN'%^-@^<>=5
MCAG:%U1A>C15[74;YW(9-WP+$ %<:9]O)BL28OW&C*(<X"%;5!U)SJJ;?\Y=
M=UY&U*_U@C)T&I\I:Z'TVIQ3>.RK+2@1\)+F#D"G@,'!:!+Q'"98^THTC,5"
M0RC*+IT_79B8"Y[TX0%)J3R/A77;MF@EI,GK4G+. G$L];H3ESXD3^\DQQ(Y
M("4>P:'U5.VM>=98^ N3!(;'SY>K_..V5UOROKFL)SP!YVX/^"*,*JNC[<1\
MB'T"<[@V,XP+7_O_\P"^<EX5E2HNO:!VIA;+XR!/;%@JC O-^\X2WG9J"?PJ
MQ[@_Y1* 4U3FT&FH^]S#Q-=JG&-"T,--+"DYPEW"]VB^K,*T&IH:67J0DU,3
M5.;HSC59:[?UY(=%\W;GC'QU@"R$ RN.(>Q"RS_91;*TE>0[:7YS3=-MNPA-
MV:2BK!6]]/;_L,]36=@/4_ZP.<:1@)NZ_OI?_ N4/WL.Y("\Q_]' C^J-Z'6
M(#^7+0 >-:-+P(?)=N?;SV.Z PQW"5WMW@$*2+"[T#\KWWI(5&4#C-5C/.I?
MAV5;_CXQ'F -?RH?=DV]*E:KV]H4]4MSE] FPB?^JPQEQA=9<O\^B"M6-KPD
MIK7X=\2I8031"0V]8]SH*R9H=B8:YM9NBFF;>N+X%(+3$ AO%\[R09GFJ+D5
M.BRT5Z(NPS^?=SU&@H.N=."_YLX624<\A%?<U9E2E4;T^VH\!KZ4EW5Y,Y^$
M?@^\K+U8J(3M/F6N;9VO03?&^2:%A.B\?;T/E-E=D%H;'+N<E]&<* %[JN9=
MBB7^LL\TE"3G""![O)MY48REC"AJ$X?_>G;!<<]5)S-_6_)>VU9SO/;@93>+
M8-/\F1/<\=_FI"CQ"PE5BF7^)'^F<^8!%]$7-1>O2E]6GASYT,M3R#SS$^TL
M=BL=>GA39&5!_[(YB>B3#H[E>H$E%7MJ%MM/Y6QVT?HO-2?K3=);XWM%KN$W
MZ;]@AI90VNF0(@_HC]*409":?ES5>*HI7\*#]5.\01M&LH1":K9M(<*FXVKF
M#J#N*-?0T/_G>%]=^O+-JJQ3]V6^PU0>==!C9K>!1(@"O#W3QHU:D2M),BI_
M_1>SY(,-F\QM" %: -1G]-_UO"H-W'P)-+@2\EIUV7T$&M;=Z>4%P8= @^/K
MRNT5P6.#!3G!*0<W]E@M22NU"S*JHJ]1XX1J4VS^]LT>5,[J:CG?*ZP$- K6
M[P -+'DU R!'9/'8RAZBXOVMR0D&RH66+<SUM<U,O_B,ST/'2MIA2VK)$ ON
MD*4_GE3<!(Q[?(?5#DHSHJHLEMJ3TGTDDI:CI!12)'_;NI'\3;,:,(52PM]F
M]%[N<@[>#U!?MQUW$YP'&WF45@E_5S,.SJC,9LI'>5GZ,9YE#1]!ZB.)N^OR
ME)DKP4SV7:_>I.$H0R%*W#%O>%8G^48XORLQ#".UUQG\2:[64.)QWJPL>,&Q
M_M:<TC];+8)BF#)%N#M+9*.;XI.I@HFHOB_.">J'$WJ=<Y_/EOQ<:VR1B>7V
M0]P$T]XP$OP(1H?&\1%%:*D:\_?6Y1!2OG!W5@\ E:^7I"PHH'OMD0M$=G,O
M\ZC0K]*Y_GVLNRNW?0)8NJXRVV-VUZP5>J$Z8J#.JY6\ O[T'RH(C+3AJ/G-
MV"3A< Y!#,/JXHZVOW'LWAV 5"6L8<6S^Y;<^%'E0-?XSEC#-N#L2!ET .%-
M."J[33W])!X=Q(7/LDQ1Z(C5:9I)2"%0#V]?P8!L*;Y^O/6>LDK1.UH2+S V
M[TA*N1+5<D,%/ON M2IV?WHTN;EE+TARP.8E-W_^,.>\I, U/>T))U;MTI+8
M3E[12CH?0H(MR9P!.A^^* AV+U+OR92H6_%ADQ_/W#RGI'-BO7^M()@42+O\
MC^OLON,#T-;W5&V2KU+WY5/-R] WFP4R27F]YZ_E'5D!3NAQ_-[@BE& G;6$
MWA@T?]U;%,U*AL*[K?\Y] 8R(U>R*O\^5>,VR:BV&?G+D13A_G;?:@HM'],*
M'( 16 ;W4C%9],EX_!4G;5).RG(N WI>5^[DL/:ET071-V$/5ZI<B+^J\'\D
M5/[4[#F\S2US7L6A%&#EY35&-<_UB)7M6C6A#_@$8E<,!J$:-'P]?.C,LWY,
MQZK:6(4O!U.=P7SP 5CQWM5'OUWY7>LK+-?*S:.+F2!K8.6NWM=X1+*SF7&_
M_-?:U_A/TN93CP:$K=OOR1\#PWSV5+D!"(29W2QP=P$^GFO:',W)&QSY)32A
M%YZ?G+5S*0*3_%(I2YG=KG;U"B]M/(N*F7'B:&U,'(9N\R[NQ,GR;>8$=],_
M59K_,X\*\(YO<K'OS2F]]^ULB+U+)^/K9(#Q>%Z#UX*8F6%VF6'-^?UI&:UK
M=PQ_8&WWA+:PG!7H3Q6M\N:8S5;9=H37K];&%I$5)^!><5S$57:3ZE[ ?5 C
M'(_#D;@?2T %I.@>_ZV+KWMM(UV[FQ2S?A;/?JP6LFH>M;"FW17'__D>L:7"
M<M5V,R;N5'</V7A]X9PN9IVHKIY;\-W+S2!$V.H#4WI;XX5#)1?]L9N-C@D^
MFC4:$_A^F?$HF@S]ZD/A':!UI?+X^#Y_^7HUN8-N<JR$^+T_!XRPR"#&_2!R
MG%OTH?7\F^'JZBH6T6;[N$';[&VGSQ?#L.FYQV&D+&)?A:$_#A.<CWL,U.!S
MI\+G+$FUW/ZYOVF/U@WN +)4_[S8*UEX5Z+O %JAMZU"IS"]7$_9T9B7-=;_
M]T0@%O(KK7TYP&\Y8GRR6W0F 1ZFV&X.XB@<N(7KMK:WQ)!*@Z$;?XZ_X,+=
MNP>#W)67$?VLA-ZLX0;7OM@IJ(PUUO^T>Y5OOM'%N*_I$@13JW2Z:+U-L?]H
MFT8U0HETJ(V?=WWOTN7T,)9Z>R]A*5ASH3%X,7:0SHIE6E!&+T@K=*#4U'S%
MPDK3IO/;I5EUWG$R6L8O296 W[5@PX#!&LA\.[9*C T#TC<P&_<;W0'HSW/>
M YV?EF1WBF /6GU22_>,FXXOLBHS"L/90>EQ;T <+983X<^BV C.9_ZG?Z==
MZ"+@#I D;G4'J&T;N /\"^J$><%(;W+O !M:B*X#5USP;1ZLC&#E_[,$#ZVS
M%'PA_+OK<_"#G5;.S%,\R ([WP^GH\_507Y:<J^H5^(WGTX-C%(D?*@.)>9D
M;=K?9$4B+MKQ?E?/P4+:.)5X%\%&T(HKZK#A1F[J8YI/M*+ZP=&[(H^0MJR4
M-%V:C74"^8M7-\E>.HL$J'#$MP/O#!G%\KW+^. RX!N@@\KWGX/1-.9YMHZ5
M@Z;17-%L5)7GYY#9*_Z@N5S 354GTPB.J/N7Q9]G?"5UG;7M)-Q-S8;&/2_5
M6T5^V;K[,3X@?$!9_+^;Y_YO=1$T"N'YZ:%574[1[<2YI+-+J//.)J3B?>[;
M/XX+P?59W[@S-HF&5Y^?M$*R3D\1Q_$ &CVE_T?!=PO_[P*Z4\PM":.=F]-_
M5A611P51*%&KPBOVR+V9%94-FF=_(G0!IE8^:7>(-+0G_H!=PH)'8+FB;M'!
M]5-]74B-(3/X@.KA4*\;5([R]WFUF-,!5X!&B@M18B43W^-D<7#LJ[^TW_A^
M9W@N!OT&-JT-P@CP\'=8:"HVM-_,LA5<0BZUYU<UL%+3Y9!!6W7 ^2K5S_4K
M^6/-IGL,DTK2 WD-6X48+1+$6QSW@0LZY\N4EBZ_BS<SZ503W%:WC$--@-D&
M ) S7">S83(^]!,SCR\,*=1NY.M55\=5/OAK4<AY[K.E'^.TLENH5IBF!53<
MH<1S!U7"_O.1.F!H"0)R 27LA/\*2,G(THG8>]^T<A!U7U "6<CTJ1,)R^JR
M3<=W"77+DTWA)I=-P75*V6.@"\?/$QWP;/0"Q\/6(H_4L!<T+WE?,;@2=B;!
MQL&Y/W/MHI.;ZM-[C^ !TGPP:;ZL6;RN\5 >K7=SNQ1$H6K*U;6PP8GY)X :
M(S$D8_S'^^\-+J];CA>W55NS(P(*7D1:S*H/6S]0!\JSM]RN'TDCHNDF\E//
M)8[)\,;]'GUE>V)B34:Z^QG?>PU-N'_\X#*A$)$<JE;#?EJ8[9%BW@YQ$Z03
MFSG:_+#Z9[G&E_K1GH@V;UZ?"DX^A!P><@UT1P@_.$$U!]%(V7X4WF,@@]Y4
MQN W40(. [E",RXR3ZBU@DGXX>MRO;_H_C[:>22SH&OE8''>&L#RMQI\^6[V
ML,1<([6YM<=D7N[CS/JA!522O=.K?MXK@>[//D(J%;$H8R<CWQ;!S6MS(K<U
M(^'0/7)=^:<!&.8O(^55NS<PCF"4_N3RDSU 4#K!;!@'ZSTFWLVES+R=%&ML
M_9UZE+;IE_KGOJKG7&CN]Y>39L/JNM D.8-<VK0=9>R$=)VK@RUG0WA=VYCO
M)&@WD !M>1%:N-OJT_&)OS#VLSYCIT5(D(7/)FA;B *BB1O,\BU5J5A<VHN9
MK#L\.>5]2_PPBC57*R"O7TOR5N09*\D?UH/-]OLV'O-Q;[WX\.X@:2Y!HX.)
M4M]*8Y6"72F?6'1ZWD RS]MQR(9B3]0]>-(22^HF"R/^/UBAP^^=6OWW<20C
M%01W4R-H*0Y738B6[Y-[T<N3RQA@QU#[3E8D"YK3YO;F>9(:FCC,ELG4">TV
M"P#7U(B:L//*$H.KB3)B[,,'1^Q6>[05;H4G> :1(A^7M ;R/!J2S+K-5!XQ
M:8P)=P-\7[1?6N$<0AI7I$[[5 PB?#M"#)]KK^?S<$4S 3H\K9[A8 .=[,DS
M@1S]/J\=6P&M4/G&]_T9Z?-1.R4=^SVY5-->Q\2F3J#208X N_B3>_;*3!&N
MI9(U4%_N4:B#EI*G?#<P/,N@&VG9,M?5:$5\#<^;_YXK3Y$:BS,VGD<N3/7^
MH\CR"/ HUZ+**'BF+^V^)K>](R(QX!\8D6-3C*PNR;EOWMOQF!!0&2JY_<VL
M1\[\M;CHQ'B":!.N\QNJ+0DU821_\*,Z59_.CEV$B&%2V"J+K';Y74HW"I-(
M:&20J+"C ./'SZ6PAN=RI<W=\Z#-JA/6566#YND-?&$AQ;D@0B#2J#5*D!B,
M+8"X)!GCHZ>Q_HNH61-='^O^^P H)-*Z?"8?9?4H:P"I$*F5X>*6FI2Z)/&<
M@8G)<TC/4BXCOX<PE"ZZ/+Q3ZT?Z^+/0W(W0/9#S(SK'!</U5\/_#)/^SE<X
M7_>K:R]78<[6(E=)9S)8QE2_D?D1JSLX<G,S[DZ Y0]U4,^D_RO3UK-W8*!J
M=F)391\?%$I?.V0U?VXRJ'#X/FF(EV'+T,NUHILJF$!GL:B1>,ZI!.)[)011
MFQ=MZL!"?S&VAYU6CU'[#%+,M,BEG@-CO&AQRN&>!6K22US3AK[:;2*DE/T>
MAF\2'H*![^8%&W/8>Z4UVFJ;E!7BXK:_+66N-LWQNVZD/0.%9:"D+0V_\092
M\#W5W32R6\C\7A,GCC6.6%-*>0\=?;F>S,K!+CJY_-&;]E1E !AVT?D8Z]VQ
M&LNG1?L]*N;%9W[I)<>71( -W/%$X+=L$BPLEH7[M^@*RR5JZX>Y[H(K\LVK
M[N)QSE?NXRHDRM*9AAS/*.(V/6<:'\ZG]/B2VE^)OCR(CH^4[_@P/(3FV[;D
MP,SG1<D]LS1]$W\'>*0:A63H36GU_2M.YN\-,\+J1'G?&/3YWK+BE J7]EN]
MVSC'0NB4>-])_5H_(H K E_>3MT!R 4W\+%^%1;+^4TSMD(;S>Q&GHD,Y0<\
M/):6KA8?4__&_[U]9 D1JP\=3#?;SO&I[$ A?54Q6\]T]#TMM,LI8G$!@VFU
M.S,6*GX^XZ>]&-#SX96&"XNMSB7< SK?6['?ZW.+2HVI[7 )R$.'Y8I[4R6O
MK?10I'F1G10XPI9JBRD7SVH-_K!8MU7U7Z^WG]/_&I[D+9HK6@YY[2S% D)K
M!6D]Z?< NWV8OAT"%=OSJ9%9A\5(";NN?QOJ\+RE;Y[Q+CLG#91US1U\EN+.
M;G%HO($*[NW,7L!,=_+3S3:<B)O^K%?'@&INOQ),2=1@E+%6X3^=U$JK5,.^
M,G:36': TA=+\G@J82"@Y]2U*.;9H9!JYL7Y+:+01)E4^S ZT?>ACH5QPQ^K
M)6<C=V>Z+X_8FI62&+SLK!.#>?'BF*FO1Q#BB]:F'%C78F- Y+>JXL^$QKIR
MNE+H3C1V,\[?ZENIR;M<,W,%&FN5CQ6$?"7?[9Z]&.<SK;%UN8J1+9M@WO<6
MT/XHRQM^5%JZ&\4U)V@#-Y@>[E&0"Q7-%UY&=*\]EI'%=-%>?YB%M2N0Q?^L
MJBN('B%.XF'[KC>'R?XW-VK44LT+&4*<0-YCT_:+X!WT6O8%Q:]"V6O\"/@&
M RO[O%F1REH$P&_>QY0K2SOB;K6"HZPKIWVOSF .>!!J[1$XH"^V%&QLVW05
MG3K\+%=QKJO#ES[3)Z^LY\+R'5+ZAPY6]5OZB6C.F\WJT2\Q+B9G"6&935DU
M3J=[F5J]EF;+#VR3* PC10]H3WV[6<E6P.^V^Y'O]<)G[%KIC<QUB.OO6\GX
M(!>'%CJ32F$&/)RYD6- QMNG*NBNZ$Y27/A*'U=7Q ):CSK;+[E6*^/B@>W"
MA<+^:ML4<]RR67#K'6"FTQ%?CB/#\R*1HP.%])>Q'*49PQ_BOOS9\V/S4-?7
MT];<*::75F(1OC*TVB=<TIKQ:DMYJD,S(V-[#=7[>J_V3T@P[]\@5BI\;&^Y
M"_G\F*G%JCGLNXO%D,A[U<'M=XSB%&]E$J6,ZZ_E\5FH\I_S$%.<!!%.-*R$
M^).?HO+NR]&*0356'B*/LZ$@OEX(W\]E_-)09OCX](0,_+7%:G^5O(_-Y%'^
MALM./B+=<A4R<Y7@&A8X:>Z84'!+<PV90^.HG8+>S,>E/7ACFDX]#*T\@8R*
M>*YU.%Y_N,F'G8]01@0Q':EV+_FY?XCVOQEN8<"4;]=([%N)K-)3@>I6EW\4
MU#7JO'J__LM>(96(":KL:<6#-DR;-:#:L<X]\CI=A-.\__3%(\'&D$<K(-'_
MYH)9BNK+=K)<5'O]0L/2F[E&RW=>@=*C8%2R_I%U\]BFPB=E)A8B FCJ^5$*
MK@UUN!#]<&3.DS>!5Q72Y&0XK[P^!LT^/P;FQ);OFWU-F[* :(_*!W!S"JZE
M:OAV#Q*70431:E6-6<&/EI1=8>>^]WP2SDV!_%1]QYMMK,Z9HA:2MA>?8.$&
M75[>UD?G.@RK8)MW3>EZ+0L.U Q4221TGE>]5-8^(;X.N;GS_Z0QQ**!E*C5
M M#ZGPL@TO1[T^.X5#: .N7QO>1./&PB*X"5%B]W!9SYS\K8U3E:6HPD*3"<
M&^Y )EIF:<1:,. <1@V2I_BL$]T_X6M_8OZHU#)!QB,O^9W$'L7K-<;*7BW>
M>*O+5T-*)X.!E).D2[+F5HB&&TV0+1#9<+#FUIPRNB-W.FS"&=<-H'@-]8A9
MQ*XFH0/-AQ3[D$&9XJ3?!(?M3/7T+>B>84:_:IN^7;=%+-8/%>"G+N([L3?7
MA+=3*C.&)2%Z5^&I/ZR;SB 1MX*>>.,J*_PG^?L[< X4,/+P^9S0E@(;0#E?
MG-!@^8"9QJ@^?PL9\$)CH*R2JWS@F@\KBN_H1,@XH&)=V,_MY=[&]W]+U1E=
MMVO*OI?G?Y&U1KXCE59*6!MLQW29-JPOR60;SBTQI#BE>5:M89_8]SC[D[+A
MLC3AD'RUMN0^LM5:7=A()4N_T/7@^@YP4W#+AA^08Q\J</+4*$7N*/.X;$2/
M'N4DBFWK!MGU#$DR3'P$+YFEHRG@+PHYIRB1_ *Q+EQZI3$"L[PI2Y(#@=$X
MC6XY:AQA2B Z7D?M:41YB:FF]<MQZ)+N+X.&^#^RK_'&VVY]61V6U]ZESJ_-
MO_\^?&M$EE_X'I?MN=+239 TTURKEYSZCZ636L^]=7F?>[XX2RUM4HWN-[<A
ME,XBD>,M3?HY-P.GC^@:GM5D5DY#(R!!U@5M8A=-(Y1L<U73O>[-@*GVZVPK
MV+EXVGY,,T5>[C0>Y"3/IIB\FJ7M,<M-.[/KVVJP-Q+L61+EY1U#DWE,SIKW
M?#?N<1H'!VN\@Y3+B\(O+0O)ME)Y\:*5Y$$+JS?;5_S'M>-%42<FKL(E8C5$
MUG/^"%,;$$;6TRRT3PRA>='IBJY3KC,+S"[96IESF#Z?\.AZ+&-0B"_]T*!!
M+N?".VJBU*!7?_^8BMOS\0C9V^,=R8K@^NK(_C;*:&17A"NILQ6KAB177"6A
M!76G[F<FGCWAM<SM'%D#\V>>2/)S)3_1%9%)OLKY"!M[NQ.7''=2ERD&[F_9
M)WS#HF.@&Q',E;DFG-]5E:M06O-SGSS/\3!F;JNS"Z?3#61V#I*<L<,>YOWQ
MD@!<J8Q_(]09UU/;Z\:4XHU_0$RQ5C!4_!>$0D-CFHG9;[L3U6>8,1;M66C'
ME5=-NDK2\='2J4BXMZA=R]G000>.&&1&=,UA5I]W^$R7I!X@,T>0'0 ]/\_G
M)P3ANE ),><=A!<(BP9O3[*UO=1.;\:>!U_ L#FWB%6)5ES)-[G"LC]9S[),
MK40R1ENAAHA.XCU93TL&L^RFT+],#*-RER*26N].+/F&Y!VQ\Q.5\-Q"W6\G
MMJ\D>HA5[LVM0]OO\R&Y8Z8^U*8A%;>6E@LY7&1$?O5L!#S%9^G.56]TI$V[
M1%@J7S@IC5.[)HL[Z3R YE/,PW%&.DP0L2R5E#[]L>"'JYCG%".1#+W9+&%Y
MHZD\;0V)'XJ;6G,$<[#BW7($N'AHQ;_ME*+=O\WP65=.HAMN>?X,[JT/S(2K
M'5HVD(^X.\ %>J34D50JZ\.X,?$[6$:BSH/080;:S:['QS;S6[\;F5WW1^=E
M(M:>JJ]^UKG%#E\_JKHA4,<I'?U(;_W@^B@I3>V94QQ;;PG:3V@O^&DXG_:(
MZ=-F*YD37\:"/1RX=U\3NP8-^EUF,4+SY0?FTSNJ\2?C'X5#!X^=83A*17SH
M?Q]#[1C7SI7+Q.^(=V&O(J;MDC@^*4@.32"@?#9J<_RWS#O&7QSAP4NM!S,B
MPP<*8NI_NWG;4\F'%EK_MLMB\N@@;"%# VE8H#/\"5'O!B1'+V)&SM7?WQU4
M0IEQ>I.5,7)RU:%#C;?&,-;(*# W5994-T*+&1L3.6Q=F8)PGCW2:E/^Y[$N
M\IJ(1LFCAN&(A-+!>/+F'FKU,I\V*BD*BM7 "0\IXQ"7H*<Y"M<*8%;]CJ9D
M1]1[MMXV;1/7X>&K_-D@I@:Z-)\F(Y'EE>J&! \QD[3FTSE,;IO*NX[A<CW]
MK0-#-;/)E_^Z4#6AOMCC;G$SXWYFUP5T+V[4E.,7]$V$4F\_J4T:=_YNYDG>
M5[DGO[VU](_N ,!?IAM&/_I3R$?-_<B6=)A@!!RKL.NW,\$H&P@K]K:^9(T3
M]G.TTU8A>"'QG4L/6X3NZ] ET=GKUY2%CIFK+<6PB[ +GUF+ 8"D[X\0]82W
MQ(.R^T]3)8NIXLS"JLYET:=6M=,UJ)FTWQCX^TV,IA)UV:3$ 5&Q>V;Z@!:1
M*18>93_[U)%K%L4H\EPQ6GO.^_S6^P1^L(US0R/Z8=%6G-C(N!J$\;1#;9J.
MY$>3F4GEYX8T942)_2Z?=%C-+@^-47(YJ"[ VBXB?6://D4]>4"0EC*#ZB^-
M$ =1]K9L8#A(;ZIDT#G.8#-M>P!(?BV*!D;E<N4IUPF5]9\675*RC=/M=[FG
M:>)2XAXR<EYTPV;N ,37_%AHJ*]CJR4L2:*UL3G94/YU1QLAJQ)W&=-3+&RQ
MR=SEB?;\V<J[WU5NQ["B[VE$H/5[7_\00/M*BP/]BG%EY@[ML0F3#7'L:Z)1
M,#,=[<@R1.]:T\/+02T6<P$;5,-B;<A$YV\R77X$.9L/6XT"F\O1ZS-8*VA(
MCBL>T;0CW1V P2?X+Z7]8_I0.L:7%R7.(HDS[H__-*6+"[RN"W:TX"KR<3[>
M4'Y$HM[OSW3.:=]9T'R3XM) &G (TL;QS_3^>IUE'D530NOK\H!%KADF@]="
MR1_(0Y&]X*,)%_N9W+U#$?&WAIW@3?)O*7#9RB,@ >0==KL?Q#=63:SZVVS8
M.LE>JT5B4H632D5](URB943M*("AZGVR-LDP+GBQ#761XU:8Q[0WW3A9Z:7I
M/B("L Z7T^4XF_)<;;^ZR,;;-U%9X+?[U#]OW*-6M;&#\I!%@E[IA3!X<V=O
M=6Y%,%07FGQ4BJ>R-GP+H-2DX$.Y(3U1EPF",IJY,K-S>TBF5_QNKNT=M595
M],W<R2JB,[]PNG7F3 VU^CFN]H>>VUV1"\:U3I>O39S%,Y4+^4A!8!?64;\Q
MK++**N-&[L_.;#P'MO[]0C@&).#!OO,O5#Z%XSC&3V6\QC/E)%<^!RST[7SC
M5W@C*;G5UI1I-/)5FXUW GA],(YXR&;?JA8+1].58O?VF$7.W_^3*_69L5C6
M-A]7Y.EM9?DQ9;C-,K^A7WELI5(=7<I-Q' 4V(;6JTF@7!,*3WXQ+_-3(*R_
M*F"X>X0EIW(PB!3"OW#-?QG$B9MY_^]FQ([RV=]\Y>7L)D*3O-F82[R=6J'I
MSX\[ZU0J[RBUG8/:+V">BP.+>=)/9V(\+'6R;U_O(",C13588S.9TI+$HI\H
MOO&L*-E(P:<VCSG$^1Y:K: $]$_-L1=YE<YT=P"[YM9P6\?3G.((9WAL.W,!
M&*/^5"@J_TKI1Q(73^XCQ43*1EO\'6! ^%H:J[0*=P!M!T;325CK:IM@"__S
MH@_J3'5;0EFYPB%FN6$^(:]7X]>*(7"4#O-U(,XU,]WG*5T6S6>*%RVGUF0Z
M.BG<]_R9[&%:E(>29567(8$<:LFT[-)>A.!--N_E/G?N7S(D', ,R^=C)+/U
MCB=K2'FEF>-V-YN+2 W&FB?)ZFWC@,%W%QQ-_HCXO5Q*A)=D0SA6K$Y8=C2P
M<MS3A=\9/.R%^IXP-I/C"\/#@#AG\0&E*[E"YZT7!B15L8L^7KW0=E;_BSL
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M82,+!@N6=BG.K^V9[,VAI6&OQ8MD94\KJ=7&<^$320;HM.$GN6 F6C."@:'
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MVX>K!L'ZC9^\4V:I^VI>SHW.X,0[CF 3,-K=G7>,ND"-^=)ED%C4N.HB2H1
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M3?[H\8Q@QBIOTR;CD6/,"N-$JU;YSG_^B=CL'J\0,CW!1NA 3L-K<0LOEGM
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MP^R$%KF]F7;SO9,6)$$DRH41DM<K;]S]4E(=GB4[^>Y$NG\MQOVK!FV_L?7
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MES[H?[?2EM>;Q8YN".8.[NN:]++@291N^.HBP0@$./$6'UCW%4>0C],K9E=
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MWCJBFM\#D8B\G_WB]Q*T*W-,(3YI]><D,+,[[AEKK ^HJSU2)ON1$RS]]51
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M@]^2.+D:A6KTX8K9OXLO\?!H;J3OZIK)"5RM:!*U^X4UO*5ULV=:79"@$-#
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MD/HJ9-2WHQH"^,%% I!=3M!&+'8D1C.1L: S8>/2L::AL&I5M043JG,C')P
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MX9;^!%2M!C\"!C;)1<WEMTX:?PW:=Y3_,#-?#SKY)9B?PH)+ORE96^*1'_%
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MJ9@0C%R'X#2_J\ F1%;03+9Z_?ZX'<D46:-2#;90_X O2(OO1?7%>D2S_?#
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M8F,H-#S"&]SQR?J?Y)9;PN5,5"%']AL(W)J>)X]0+KS@'4J+E-S1PCF_&)V
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M;> ^P[J;RSHH90H>-T,QYI8*&^_-K*Z\PU9[RM1$M<D6B7U"'\BZF &[2G.
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MI+=1\=R:*4*T4<\*?+QJ[>\+NY[?Q]>,5NRW]/%Z&D&>T!T9[>B=IT#NUAB
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M]]SVTD:<X$\ .TGU._IHB=*"RH#E_%49#J23NCNR1$.PKM./<DP)G=UZZA5
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M_:*5 !'4."SXU<;AFRFX@^?(>EKO:0#J/+3))BWO8B_40*MFN@84=C?8P]U
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M=\!#\^>!^7"'IN:,)T!CIB(>[Q_<&]$D<>G.K5J_^OV\Q;&.Z>$G0*P1=E*
M,&Q-80#IZ&=7,L".\8O%>YI22:'Y[063\,7#PDYS8N.:F<KK*#[#_"GTT ,-
M1USF9OY:7 _S]K/"Q'O[0$0PW.LT+D"AF%9!"XGIU@_TP?]AQ!P1,--A3:OI
MD0?MC>B2K;Q_CY@JAV^0.'4DIU2.\#4U;^R,O#(Y9A3"\/:WK_A^0&9.<V]-
MVMW<I2]#@3A*2BLYT5;=M>"#<Q%;TZ*)8>?<:D]!ER'+DL8J4 K+#Q55?%78
M;P%_.4E)V44\=0N9M5N[ A@0KIM<$JTQ)!"CR".?#M.2DVK,Q+VFA.\_]*?>
M?GR8R[F-'WH"$'AR<C,TF^,8K.Q+0#)RXPV+=!-LE2>I\ZS'+;\JJYT?Z^@C
M1L*"V)O\<"4\U*("U82_^I(KWGZ.^2KU>S65/P7:P1OSR(K8BY4A=Y)YW3@/
MQ7.6'DI@QJP>)WH"?.1 Q\4',0E5MAU2'^CJB[)-V[A3:?7GFL=T8 :Q0Z4^
MU@16ZYHW4<SN9_ZA;,?;+G@.+O<[EWT.HI9#!G4(.9L/(9NJSA2OR%J7IK?Y
MGT6YHS'EV2/ C5T, <M944+=<K69DW7<6U\'"KT%/M$06IJQ(LGUY)#4[QI_
M-[4+XPHI7.6V;49$KK$Q>+RF(,!^36^D:U%3<$R0Z+C^\?WB7*_=1K2(WY'1
MQ+Y;X+/625=K-_9,*+:TX<MKF8A__5^#4A@<1Q:M*-3/62\TW? MZJT8$O_^
M"0O'" /MJ.R;FQJ8E5[6^' D4KJE)O&-!>* LWJXS5<"A% _2N[?YXC_^-D6
M^KT#Z+7^QFV@)KY@]:7RCUJ.?K']WWG<AN)"&PI'6M@&?_87K[R]7Y9V$=GJ
M$GE7 /R>7XVA-F#!PTM>R53[/72+%WLS)UYL$U<O&,961\) (TH8>51WC"T1
M:48TNM_AEV)/ )HGP"]TK>NY)X \*3S"6_AO+^6]<3&(M:]5XJKM*'-&E?B^
MNCU>,N0[H8<YML:=EJ->HJ?KD=H[1KO('S+649"/AJ#M/+OJ%8B$P/Z'](Q9
M:2T(V?16OC<]^F#RT8H@*;3DYJ9-LBB&4 ^B]1V]VUG?*:0+P!^'TMF4'3(G
M-@^0[Z#*Z?H*RK\?#>C#8(XK83 !   6<7=-GJ.E2B:3#<B/;DTNH#W($E,;
MHH0H&Q;FYD'-D-]2^7'P_#!\I-?HAE>]JVW&"]?R9P^G2+%4"A,$+Z!R+"G/
M8])O[YBAK*4:;H[O*#BQN_')\G-]N9TO@'M_CO2/T?V+-+E6A:)5!2^WS^K5
M)NSCQ("1%O[^&OXV_S&!I')-JHX/;BG#(&6X]$:HYUVMQ)UF:WO/2.%7&',Z
MV;8]39Z[(+0UP!+I/:V#N%D,P*,OK%@S[NX<9D3_W;Y-+*V/?6C"FQ" _TC5
M^W->ROC5%R/S"=WRV%;2K_A5*8O8+?RS72Y'\K,:KK!SX=*5"8;!@G>?5]*S
ML"MI1YR^+2PH&;V8Z=XC\>C_Z90S<;Z$6K]QON@G$6(7DV4NKP.,4HZ.5OOQ
M7A5$.ISON\?G^I9^J4%C*,9 O:4<%?:CQP6V2KSJ@!1]9RD)Z<08M[#N+:>Y
MKA99#HZQ_CE7:R#%]VMNF#H$ASA$U"9A\XO\(JEA9:WG?5(;IY.]PQ, /T"W
M&B^\'/VK$L5XX9KQ" 4%A3<L]VYIT^).3S/QGX;MA^P*)?FO&!;QIRHQBHG=
M4!0HM]&KW?IKJR<J;]K5VKH884=/)#;FKVA_,"^O>--UMC5(]<G/MB6_QHEL
MW[\)ISAE01.*X8I=Z'=Z]=&1O9,I>;G;*/'/,(A)HP69G&];;/I0</+V+&0+
MDUBL3QHEI5\9@#LG?*A%OJ%:^78&!P[*CETMJ;:PN-JK]35=2\KI>9WV"3$T
MZ>I>\758 -&@ZGHFR$8_H*GDO[DXVTOXR (*<F"<;0XP/JA/M;'5J)IZ[/(2
M_ABN:IH-S:A+%3M-+.!%)A7"/R$>\Q:O,E.7JY>[$VP3%JE[#OFP0T-$[LY-
M9(<*T5;WB0V!;GW08NTH=C/ !K-/B$N&#D;">>A<;>" +CT0@$O[PFU=!C$+
M*A_T,+#--*#E8;2Y6X&+]]TF)$.J/(V[T@1+8YJ+9A ]Y;"VYL)FY0HU^9Y1
M(U)6'L'K]*3#]6X@;#$QP'7SCOT'-,$(''W,?$,C>_ON94$X=B9 ?Z8>I?X6
M*I0K&%S.3%+C)/><3&6%YHQ_NA8D&W\1/_G,;-!P3@I5] 9H>'P6YLK[_4O;
M(, 7^_6\/+':Z:XC1TI6A__PY%467/H5*%G^FSJSVTV*&#W("Q!WYA#L<!K%
MY ]4A"\<T<@Q8[V8XRPH);P6D.[)V'HD1 U7B,8+!6)K-1$Y$G=Y-[Y]E3?"
MP*&6-,0_*K-P*$L0@+;9"28!5M8LR54XZ8F:?1;5&,U<UU8CEOX8JNT_#RE=
M*X!Q!%0=78*Q4(_CPXL^RZ"6U+'=<>L;=\0T?CCGZRMI#M=8,^*Y+L?--66%
M>3D 9!8R)C#*;,TQ>*-'/T3D ?,]ZO(O,8Y-S"TA3ZDZ@\Z^+$D(]@G?UT$=
MPLVR-D\;]F?DWORH=E(S6EYF8?V"P?(MN:.XVU,YFQ?4SSF&D-*YTNN\,VV-
M>;62_G(41\]V?Y =KV#571IX4*O_O@%ZL9+(JIT\V=RAG<JC\DL&WD..H!_J
MU,"#7!MU\9/&ZT9]2AT@%L$==U5^*ZWYZ9IR6OB0:C%11M+0#(^H6(%^^>I&
M"Y];  *>\W YZ.Y';_\YNZ,I(E'_Z:9\*D=?])'QG@0A?)7B4\L6*&$L^4'J
M5V[B3_#XUS][-"3S\_2-O)$_9F3H\S75Y5Y,57L(E5D_-CCHM@R-2,?\Y:0>
M_L_P"%B( UQ^-O0QL*3_BHAG$V]5X#CE"A_F0R>;[Q\\J.[=A J$C=NG33K4
M<,^W5N((ZFI^3#])./10*N1*6D_+,7GT7$T%MNP!9MV!4T&L!U C_<C2@BO$
M<D("1^*LZN-80O@ETW>PTK33#38\.6IZ*/CE@;E5&!Q^J%J 9S#&T>1(@FYK
MAZ],W;$9/NP!9Y[WE/CR6]/L"G(=U26*F#T=!'O4&<A1C_*<WQV1<X=1;"8$
M<M::H\DD?W?BA.6[Z\VRKO&UR.?*AZ96\T M^/A-L@;!1 &O?H;Q8LFYN2P:
M&7PY,U%Z1:9S3GM\EM#Z]H6GW:E6DQY2)K;4S'#)A-S\0J=#_+>M#T5]Y-H\
M7?,H7L6!YWQG6OV!&?[<A;$LX;+ZC_W#LGY0O.2[ZJ;3+[C<JX7:P-J/!6W@
M_*!7H%W]1? ]=8U4_6A$P8R]DA['X*[)SP,Q,7"1$B',-#UW9U$AJ<F9:3R(
M38V'1 4Q](5>T+3C)>6 S;L8T7HN"6*L9WYY;#\A]>!W ,+O8 [HY0KU:5P.
M840QEGH\M>_ISNC-)X$;-^3#T=Y?SH614@GU]<]>U WO;7X/2OCZ$-54+N*C
MT:> <5&UQ;GF9"BFH<P<R^YW\[#6MD\T')TOZI;Z;S3\H4 ,LT6AAQ=-T'GG
MQ]DLGY_R\1",1EM5UCGZ?%.#ZF>431<RA45Q'._1_[>S:($,W^,\_?.>YX>9
M9OA(_(ZHQJT7VJNF2ZC@=S\+M1=XOO/,1*M8:E>5IJ0+)<1G,$GI9P2\_,_)
M<6]K+ZFN[F(:8 BBAEU'>4G6\AH\KG;Z!LAQ3XC %9.HC;W.+#C.AFS.F=U:
MOYCGEJ<^KLB^ZK7Y-^GJB+W0($D4D^'"O;U_^8A7\<$M#3K>7R;'LG=Q+^0E
M<QT7H.^\S\));_K[>13=>ALF-X; &/=638CI,.<>!@W$-43T.B>S]@F NQ&5
M-14'.QHEQZL=%+.R<;!\KT$2)D%[W!$B:_3?;NO_Y^SVM1JB]\_IX[LU_T?(
M*?D38/_V-D1Z]G_2<5_^4!6\6=GSXB&G1T@=X;W8KR_#4:A*MJ??8;S01 ;9
M%<[6QN17W^.+74@RXD]KE59YX$/()@AIQ03A_P[PAU52F;(.>9,M)Q9W''L\
M6U7GLLU"&0/QDT;B  ?_17,/>"@*WM[J87T"+)G1/X@NZX\$4\F0:B 55!JB
M!I"?3YOV:>$"859>7P%C*^[*:Y@O"<O$MXZTEED?-27AP0^1L"? 7&"I+VD@
ME#C!R;(8]_/,0^- NP:^SPL8XMNW=>*PCI7I<ZG<S>M!990MK+VIL[JYJZOK
MV[3@:T9A2?E(D[.W&)48XOOFMH]C3X SST+\WL/#3__>E#X&.?MG'8&? *RJ
MB/''GF:M!\'UV1'M!+Z&"&^5 L%QMDV42P\Y02W.P&C ]'K5O>$3(*SEH/"Y
M4*TU+**7W///I:F .N%+EBZ1=I*'\JDY'!L+Y/$ UBAW@EOX5\ZKG%Z:?WE]
M F!9H/[ "R-[:)S?[PO^V7]DZ(AS(\\KJ5FV(K5=+<<4WZ8C!*NA<APW%%#Y
MA6SW!.&;67$!:,[^B,5WK?'J4<JQ\/90HUUQ"&6FG?M.(3Z!S\]^"C%X!ST
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MO')VE<Q7]UJV0E3_2LL^?U! M".VJ2QFNP3=7D&7?<]61KV^,GDQQ%WO"=_
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M&Y[U*K$^!6<6;H1I=YT=/B$V&*X:RK=>&_3I3R=Z?1LLGLC8OY2#YML;MNY
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MMJ2.=J]GK-0^'&FW++.,,4>GFS2T*,I?66,0NV3_<EEJJJ+\ME'9L4%'J4S
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MUP+O_0M6>XV<S???;0N_/WD$S)>%ILPVL+DY5 Z$(T.NDN M!W&/ ,*GG?G
M>FX=]F[*1Q//*FZ#_SVC.?U;:!CD*P3#K-3PJ%M%8A?U0K=0RRW8>]OM9B$2
MV=%M1B@I5)B^&YKQ9O<M'NMOT>-RV<]I4O'&"Y5@?'A\J*1FP:%XR[YPE;X
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M!,3<9TU2>TT94S6] 'RH3BBJL;;JMZ=KKTWJ'Q)E/%"^DU_&BE"*"*7LX'.
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M[5CO+395M"SOD3;L-<]8?[L#Z.,?NOVX(!0G.+H#_.^E<C*EH<.2,[>MZG>
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M7;^OJF<__HY<6(AEU?L!_0[V+0<[8*$1T+>U :5]17OJ?#2<7!B&R_F#D,-
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M@[W'?%7_)/:C"2L4YRY3"D$> ZN/X35(G+W7!7TV(_4X'2+GGV'!Y0?-8:Y
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MW2;B/N(LP/Q]>H?CX70OT[NWN <RJ]1\';*L>!Z)K7<]6A=5ALR7[Y@N)$K
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M4?3!U/*,U4H/N67>=[R6U_W_JASB,XTL&'H40NH]DB,,>MR9A:I(FZK&N5I
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MH/>:X6Z[&0@C:SM/+O';A79G/F-M=/OU<0O('\-TUX)_DK%H-+)=X!]" IX
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MF/3.\O )\ RH",-] A"B#/L"F-K4S3D\71A.W!+KZ;RA-O0J2NB).1<]24^
M!G"\-QBJN)TR1(A^,#-4?"!9N>%P3OOY7>*C$0FOEK)QQ'V?9QK/%]01H@B>
M-; )I3B'7_>9\SR2%",ITH3O[O3;*5H$->(KZLO'=D.4@(&1R?BBX46R5]:H
M;.3FL&7#2=/6Z0N_S'YM*I2N>?ML4?=2R_C>BG)N&(9U9X41YI3?D?H=6I!A
M]\(],?R4X%Y]GM^[VO'NT\$N2'$BN2H^,:[OQ8]HYR(J>LQ \%\0 OL=2@51
MY]S-7$7)\'*AB3;)UHU*_0I4)A>NZ/LA<H^UC55D['%8!F?I$0?E"5/.0S*,
M&)F/5JTYJ%.]W#-50=-?B,%F(\(*S9,R_5AT@D^KJ5K-,G?%6&_\4@7'1;'B
MUX#U3G[K7F>'*<H29LKG<CT80KI(<'< SU17DS?2(;O?,&'6MY,]]I8^FKT7
MJ*:7FRP3^9K9/ZEK)8%I3BL^+('I'H'O?9^?5ZZLQ?K::^"7A9'8U01QT8CV
M"61"U&>-,,B;K+U8+!HR,E>8=/W1V'0735K%*9G'B-'$1U!MA)"K<5[$DM3R
MB$:KW.E6?S$*J.E0U[TM24Y0CP65<-$+GRMUK.]J;Y\_T7VK_N;5*+&_QF",
MXG=^,O0I_YUX.-@;68J*?+?X3:;L(XBTV]E(;2<VX\VO,<G60S*ZRU.SF'M>
M>JE!@_;%1JO6,T-M8[[&/PN%\]91YW=7VAD96O)F#VL,E\ZBPSZI*"MEA.9&
M4?4?T4/O)#.5O1,FZ8G1# 45ALXO/.]/=9% 0]\ I:OH)9_WPQB^[I*?V5$\
M;&].,+7?O\;YE=5_J_F5HGV]T5/;WZ7;N<IS[*30-^5#KX=[*L12=[&C \0A
MBAP7Q^7X;<8]5AE*A+T\FY?+4+5[&>RH@6C^AK18RQ9@X!"$T/AGD6S9/:<)
MFD099OFEP\3Z[R;?0]X@G5SMO4:+VJ)."_T*QWX,_EHGF%U5%6?:3S0T#H5-
M1VVP+YIJ2&8T0O?R":8%^#PI,>,TB]B(O\/C!Q'#155KF^S1+=LCO(VFI6GL
MF?X&/J#HMW]']D3195]AD,:WNQMTR#6N'7E)_6L=QWR.9+C2%P>B9:A@\AY0
MC21[V89"*[L_,GRUVL58TZ[*P3!+)_KLF+K:F,W,Q5I6Z,-Y8B+Z[ZO*6YOO
MBS&C2<S1\VYU@QUN'L'BD&T+.Y@8DKQ@$#<W"9,]QZ#V<T5#0;WSQL9'ZU,!
M (?D7BEQQV^57X<T^C5EI>/%T]T\H.A%8L'$C"E53'_JT_B.,M"5I.9W'YH@
M%ER_:'*5C_='V/TF.]ULB-WD)G>'*UTS9;S:D:HDNCQJ52<&PFHG]6!G^GD?
M5R92U9+^RQO#<IG(H\6&YD*;YGR1K%%#-&1KC;+[G/A1/"2U+-((%.$?!WS;
MBKV'^7STUH-G[-[?98.\:R&$Y<M2NUTZZ<80[^/[-YEAGP6YJ=C2TYY32Q\R
M1B?!$F@='PR->IP]IF!NB_7^L6]7VWGP?P"*\%17TU=SH'I5-<\9*KS\O(.Q
M_XHA_)6M^Z@'BD*?8WC9 ".7EP3+_/@?IR&I?AF7$J7-+7,&XR-!3CZ;'1-P
M5.N^M -/*!$J C=8VVB>K2%%HT6-^@W_G#HMA]J&%MD'J]W;\W@H@C+^N-/R
M!_N%+_&:V:I$2YL@T3MM*MI:>59L)H2VR21'9BX^:V.&_N^BI+$UXK^.>3+T
M<U5!0I[;ZZ0NZ2Z+9T/4L<Y$I^_%!#XF[K53ET23XTM5<#\B(>=@2<1T[(5B
MJ7JAA<.[4'NV.=-1C&36+U*9-@I5\K("VCJ37!NW.-M RF)S%':O3S<=HJ1K
MN,.1#O-3C[[<-&])[2Y5^8<J#[5CB^HRB/1Q5$99'%,<&-B5A=,#M(:#F=S<
M\U6PZGB]!:A 4/RAH9-L^KZ66&$6:JRK_MWP]X(0^<CI@)2!1Y+D_6%*2Q)+
M_<R#TV.K9G5K]RO[6:'O6];40GTBC4V&GSJZRQ098US9:COF3KVYB]6@NL08
M6)]E?#!=RL:GQXU"<*/*$"U7YMU-#T7EH%GIJNL-DVA_*]=<CT1^U8O;)1TP
M!*Q99M:W?? IXA+V18GMJ%LDG9%CEXK-+MW,=P#MU\$&KBF8Y"'^^<RNOVWC
M6.^?S^$<I@7M$AR%!Y4W24<>I>G;SX%"U=,UEH>:U0Z"DZR#=D'J]-5]U$ER
M1Q$R%M)1 7_/JW3B<*S2 .CE')W@(;Z/_M(M<1=DQB(=]NP4NN-D*0Y]83 #
M^>M@ @^)(450(&S2;HBH<RG$(*^DCW1M=8" )>U0SLVJU>J<)?*<7UQ\7UB+
M;R52.650&]N>@37XY:F^^C<7WAI6OQIG=/]?Q)%.8];''J_\MFS;C['^'!H(
M3;_4JAUG+>3KA>YBCW?0NZTK^P]9M/?<T:=V=R16Z; "BX.&])75("'2/&F(
MKL>.\L.6G!^LC\2YOY@S(5.*]/UMT]]P7!2L,*R?213E'/W^FK\DO;J=GUH"
M$MQ,>KTHY2JQ4,SU@]+)VVK^NZ_(8<9. =[EL:Q>Z[PS+^,T$<[R6.?PZGE_
M[=;%7I=+0^:>T_EI7(Y70%F4"U\)VI>@(:/[Q&>U \E'TZQ=(<:*2(*Y/I\0
MIH5[4U\/I>I&Y;[MNG5'$<A*9RH=B9.M>8D6UE^T]#[PG';2TCOC(.'%FIH=
MU>.BF-?9C./F_\:*S[3&W=+N<%*A7_HP R4J;^O83D?0>$7%L7IYQ:31$_A,
ME<Y?YQ3C1CNY,B57^KP@D"?EI(3CHFW41#M/B?$[S2EDFE;MCLQ/5E=R8195
MZU>_-Z:I#AA_R".C5E6__$ 7C;Y:[;[!O/C(%20Z7]5I##LE58,5H-=4.KL&
M4F;OC@5="%7&PED=_]H&N8PX81V9G51ON]+WW7'^Z:;L05PL+M'8Q1<7C#IZ
MM'A@1R4FKDA]=L"SPO!V:9I%C6T.;]()"%L^*_M<C,C/DSXTLU@_% ^KA,06
MXTS).YT !'BU?N._,57W#>1QN);BKN2X+2ACQ \1<#0Q3/'2CGBG\ 'Y%:HV
M7U@PDNRHU!3HD_E\![?!*K87KZCMHC0H ,EX;(.TZ@V@"-]V?2[OZ@[#UW$>
M6O^IGC'W=]G_O=F(F-CUR/HR5N\4OOQVGJE2&RJ#,[((T5Q2_J<.).-D\7K.
M]PE0)-AD1,)M!J JG1"]EO*'Q_]Y H!2$F0;IR-E2/P"(%LQ,;L+(DGFHFH5
M?Q9='A6XI.(5?L[SH)^E^;FHO)TFYBGC<4C*CQ]!I! \SA?0_]/LC/$6,B@!
MN/0_Q7U@@3W#/O^IH[69:-3U2C7+2</**7:Y_M>H^!B<6N0\N.>8\D[;3PNN
MB.J!=P4X)M'";-8876O5[;LGH,&_[6&O L3UOV# 3R+41L&**+OMA7DO0L;[
M5YT([+@@"9@ E9_+GT,&YJ69?,>C9JQWUAS <+;Q9F'%7HPT+4U_?K [,A32
M0R##^#A%DS+09;!D@6!?;X0FSD$?L@WZATJ,4FW$S\6R34'3&S>&(I.:'G?K
M:H9U/3#9Y'\6S.O!%$*CG I_ J , [0'=E.!$H7F)LK6W<U2>>BG-Z/9 ,!V
MS 2VEN-%;E\^5R>RH!^,[=<#:;?V>;^QNK)F9EJQ?7S)#VRV9B,J>S%&"/C2
MY7CF.D@3)$.$-!RVQ UR0+D&PTZICN;,%(L<B,N_FZRMX?_F_FK-^;6*%G>:
MUCT\YT'M(>V1!I6YOS65*INPY]^TRJ/*1*H588/_G(.KUW:P\)F\#^/@L_WX
MPX%Y4 NK1/-Z]I%/NVS*O=%M9K)U6M^EXS=XSBZ>@OUQN$+]C_27<HEYH\E:
MFL%H5MN$V*  GY8*/T4-FLGUAI&0$6L.H4#[(N*7HV?*'H"M#PR.>_2,D/30
M?B7PNEEPKM%\T'BEXZI4;NOQAA37EV'VZ%>KM6?<_6A=>F%H$#$9&E0@S'I&
M'B9 N-ZU%.U2UNQ>^@2P%ZXW40TCW7V[CZF+FK^<#L)SCB_=K? 13:0+R,\H
ML6] +0TU!Q@._CD5#G:0SEGOS@5)B52JT&*,C_V@'_E+_B6O.$S/&^SYU;[9
M0J"E/0>1I&XLH]_YON'U/] J&]]_!0J,>>Q8 7W!,HTS(I,JPXN/_)WSI\(I
M+,__VL:_:?%NB_$8JU?8HD@2\Q[!K'V-Q3/6:;EUS")+*P]'5DX'6Q4[B58'
M!AR3')+60<EK-73HN*SRVJA>2BZ1=FZ ?VH9@AK *# L%,OONC_3H'#ZW>(G
M9V\GV0;G8E$/RW&";3;-/>=SYEZV\PAL>IX^H&6@:\4D7T^2RR4?!RLMY"$%
MAT12W0E]@!&JY_\YC"R-8+._S974CQ+.EY5T<?S^3K^Q$8GU4V24]*"!U12"
M_46U?=5KI^A^5VMA_$-JF*/DU=SP!A52<S-)1-J8I;4S?X5?HUY%>G%EID@7
M*)@:MO(&KW48;3T<4A)=6/@$8+4?'K4LOY5 G&T:I/1?X5>N20\V*)+%&P'<
M9LK_"LU?[Q6V=LS<>Y8X@$#^_/E>X^75^&ML;+]'T9Z]3^S=$A5-3U8*ND98
MPI/SKUX=; CVQ"@T&8V9ROMV3/-7W_7:;O1%I$<(GB5Z!,SGTR!;!C;Q@[R1
M.YGGVI^RZDR*1\PUJR</SV:+0_V$8O0VKTVQ6\$O_4">HZ:Z8DBA5L1&E WB
M"+:P7^#N^ZN VE2Q_O8B9H6O\ O?_7G$$&2B?'0KYRB$J0?J7'U/7@2%KH>"
MJ-FZF[^^TK6M4$=$ CJCE+5[L+H5EYJTXV1XD_$#8=*-OLV+I&;K1DIE'4,8
MZF0_!F>GBD!IK(D?*%Y6O1JJA HGF!LW<G5J8]4C',Z@] IG8R?H=+X^ZE0&
M:#B;37K4STYNS-N&W<T]"R^^?LO=,YL\] ^)PX;@J_2'$,Q?! K4^;73EE<7
MMW?D>;J3C]^D20_BH.DE&;Z,P<.2-/S]^H\,7_32&Y0C[Z(/Q>V$[^RA)VAF
MFC3C;HHIJ"7S#)C-/]E1(W$PB/KE1ZJ$I(RP1=B6D*?$!2F%,/#TB)0D\9WP
M;8#8,DFV<3+DWO!*IDXI!0M\A.$SON]HKZOK4*OAM2::J' S4.A HI+]8'6#
M!ND-JA6SKGHA7G^@VBF/+R"8TW$6L,T!2?:#Z(W),#_VGFSM5-YD(Z$AAM=E
MP+I1ZII#R% W(V4 >)CVIJJFYF1_[K2*=YN7W^1$W(2BQ7Z5E;>FQMA_](+\
M<GJ0GF5I,,"[(.:2EJ.GL;--YV4%UO,FZM25E!?HX><^XN"";OJC6\;^)#:4
MZ7 ^0VM31W/':^KW@OYT)&;\'^4.?[8($T?;XB:MF.VUW,[;,00ZSL^2^V]4
M6C)OB"+MA@10;^ZEB\Q!F;4.+89UFB&NKCDK>KP)KU2-R:AU%'%6Q?<!LZ/;
MLG0@&8IYK"Y'U\+5QDE/1PRAKLGJ[&1G)"MIM)N:0", >YWN4S5J^%0#M5F)
M<AGH#^AJO**XOGY>#MBAK(TCWM&9^=SM 8DH2[XW_'G_9DZWKP?76WT3M^XK
MZ*U O!IO"MOH<SRKI %KJ2TF"=;O='NE(A(V5-5WU$N:?.2Y0-:M1%SOZH1<
MW.<7U:RJ'7<:<P]?5>B/IKO%(X;;O-F_-9#(_,'XQS':#*BIN5X&HOD@4U]2
M<[Z<I%3.C4P#*1ULF/\%^7E6/&%B".N]=%M30UT'PBZ.I2=:'<7\;8AO0IWJ
M":#[>IOVI=R[YX!DQ[#YBTE)6@'"(=>K?^RB#!1I>-N1<Z*2J4;7(#PK/O).
M/]K\0>C8="R^6A;$1ZG_X"MQ.*1D6NXQ/5@+3JPNBD?:=B\2KI["K<]R?#*:
MRT/YY%SYV?KM:LTNRQQH'I*.AYX <4 ^7EWC2I5Z(I/9S>D,HR= ,0_ [C76
MV*^3(K:+&K Z"2KR?;<D0Q0IM+KQU>@OMFI\Z+/-UT4?>!THOQ#M[%/3.W:F
M;U?')(-EQCFJ: >N""+4 YU_YN\:\K4K4;\O3FGW$%RL*%%5"7ZN;6<%!Y.B
MCF"45\FY/P^6T!63I_HE"C0:F_63M1L[7:I?:OA&MHU*O'OUO-H5!R6E@&HB
M;\ZN/.)V%BFY;S$D=*I/&'!^W5B>;3W@MH8>F9I(P+,JPQ$D5#!@(="(#,EU
M][HZ=76U3B&+LDWBBVQ+\)EK'?'9_K8?@24T!>XGQ#T2DQ%;\*Y^.RQE*E&=
MRA'<E@:2#1.J(?JJV)B!<9<(JUQ5%F[;NI^D-^HB$3>7[96D')3ZYK6)[A<-
MT]155[4 B>#D?3Q;B!=B,PVWY4E6XQD.R+FP)%V%'LA@S ,%8,;#E94F<0,/
MF5CFW7J?;%+5IB!0_1C./5A70K_EBR#ZK22/\T$:S YY3U^B,/S=HG@F^3.8
M5GP;8,L0'TGJ745)L]$C6%NWL+BQ^?>]:OQ,HU"$#5X96[LW1#[,,8<J/R".
MLY"]:2PH#P$Q1])ES1ZTEV=ISS4)"$P03_PX^43?&TO4]RUH8K?^^:Z'(_0B
M!=,Q8"/<5:#_.LZ9*:-S/$F9&W\\_3H'.T0>G96-;K_:^NB1LB/88EP5T314
M)3EXP#I-A^@(2Y;7I:O0.Z&_2IT_M]@5S0?JPLQO\<_,5X._!E=L*#(ETU8J
MK^(RXY40//1%1':4_Q%:2*BF&CNR^\73,ED'YX'A=/.L3B+V+;,;^<AGB#F(
MR^.W68/!Z"=C*=^( NR: F/Z-#F'&"A02=5^'A0-N?WNO?TK\%3H_E3B\*NM
MM") AOC.%T)Z'AAN053.Q ;WO 5J%00MC6\PY\C/PE+*4>::^JL71B;J<X)N
M'_+]Q:W E<&2ZR=4;J4?"Z[>X_1<XZE(S;LXC(:WGR3XQ3G3)#VP' 2]G)][
M_'6 [M;+*O!,RO!:=!=LB[;K9*@5;@Z'O-=R/[7(LC!$IIK?XWN2 -ZD*2=-
MX1B(LS'JS!M.LV8SBD_"J,OJ"][/;*L=_YU5R9I@US[I8S>DLWO6+=GZT-E)
MB=T7B2QX)*Y<:J 9M^^Q,GXWN<_%&>*>5$8OF',GIA\__1;1=,]E0&75D"?/
M2?TPYRNM!M[O5[+O^<2US_Q&&PY3#W#&7ZQ4-!:Z, E%<6E]R^G.WL[3[I5L
MB1;1=+!G;0S6P]GRSNC?:5Y@94($&"[X2#957X'+U7[8'_\R(S/H%B+DLV4C
M$CVE$J>7=CQWO%I!"D0&Z6SS"<G_%L$UMQR4S'N,S_$P54V;B&)9Y5C/9O8E
M/]H\L+0_DL4'<EHAK?HV)/X-*HX\,"C@_0!';-:+PET*T76QM! [5LX?Q\<F
M2B4_UMKI3P<)DS8)95[<2S>B4F!2H)BKHNJNDN_$)VTYM@=XCK^M[B_!PHC-
M8^FMS>0 V80@VJM@TUX+YM].C^ONF(<WE,^=6JU87O4-2R*_$\<W(1T'NW$1
MT5E;'3WQ/E?HFIU?^'.\J7)@ZN;J$<E4> 05:N('EGE90JB33;C <!+C</MG
M!C:D5MLV;?F'^2K18W6C#.WTW5(%6R#Z9DI %NWS<7/"EA"Z1V@/CD@*L;T,
M3:[J(E/]_/X=5@$,7X$7NKY6-B+GF88K1CUZ-.FU2?0$<"6,[D9#)M=M2SEC
M&R#I+&C=<JHO/\L?5RU_)YH(.)8.,.RUX$P?L$0,6:(W3A.L#?&W><.D5(B*
MP\N,%\9&S]#;W%8]AP*NAWM([E^V(T5;[F3O"6:\.K3)_:+B43'FW=D?&QK]
MPXR3S7O\!:C@/P^.=.=S"PI["(!VV[*QCTRY$ O2A:F?91O&IFQOX?9RXWLA
M?QF> &+3IQ"'*ZM0VW1:?UM]-S3F9,'\[Q?W/$,R)$&O$4^ ,)D7?[K1$7M%
M%#\)LC^QI+R+K7QNK9/.4K]CY>,^_?8RY264#S.RXMA(7=#ENP!;P9+P;KEO
M]XZN_?#V%)B:>).;C]:9JO=/L>\(7*2@YK#E;$4%@VGUH>E%5N*>TOJPW-_7
M 0NMEU)=ENI-6?(I06(Z8J<[4B^"6M^3):M)2^J;,N(IB7W.50XLW\V!K0VZ
M[#BM8;%2KR]'SI$MYB;O^61OCS\!",Q,JUI<@TMB^X6M;8K<L.A2Q]$W@7LM
M B= 6?QYD_[ZIH5?9\\&0SQH\Q(C"]QP:L3Z9?ASM>=EMS%ZXL]UV^8^O;RN
M"H^4=*]7[%U/) H@/C4 <I8<&':_7@1J>SY/T5=*WB0APAJB)DCX_F&?MAT9
M7VYI,)SRKKZKI:<I^6RA18EKK3A OQK2I$0'HOD;I5#V0=+SHNK84U^3\&V!
M?IJLX =JIEKY);JZK1>CRC#;UM$C,_JR..$\#\<[+E?G<26I@0AY]Y8(N=,4
MD\-&<R7O)/XE_3?++5RTU'@2QZE]#)?PC9>SC07X&P?-%F0M+?&@&J@C:N9-
MUK/U/KXF?U9/JVHSUNKX=&F6:>6YJ$'1:U'$\9SRD3?@@RN5':3\0.]3AR:A
M1?[XVQGKULAW+" 7YRLGP[MB&54) $'&ESK3313_WN/CIO=?A.JH:\?K'>XS
MF+@$9QC.924#/I(REF-6.$%:>T",)G@G\\]<Q;?[6-,YJ88")QT[Q[AK$>')
M3\[:[U*;*@5J>9T,<'8_W$!#D!! _D"35]:23W7IU-@!2_U7 )&\52\Z>>3'
MX!\6Z^O4*T&77X</.%25Z;O0?MU+%*,";&B:DKK9U&ST/^'\&;1&A_S^?4W<
M]+'"A#]GB9+PRNC8J'_O$Z4C\^HHT/O@R(CT:!%]<''11+UZ86$-S_S3RSYB
M[;$3E75J3H:F@"= ?R:TIHA]N%QJS5@RXXX8\F7"?V-\O0O?XQ$?D9^R=4IR
M1"'YIH*E-9GZC68DF_^(N&NGWM7T6Q*#@-ATA;9FA(;8.!Q?0<*U-'O'L5D3
M[!:3&J4S@[8:OJRW08O,Z$D V@3ER*PT=O"H^JRAI_*,J=-WA^'9=MQ45=5P
M) ?&OE?[A,'S"B-L/53R?'^ND3!&R *5*@HU6A<$92@4LDJ,.@0(WR6Y!+@[
MX:4!Z$>'/'+XBTJHP-X)']* UR0<GRSS$NT^H"_=&(HO9C*2%K7>^4)_S!ZS
MG\'T/$G6MM#W;+3>7C&^7?M?K+UE6Q3L%_8["H(*@G2'I'1WBY1(*LW0-0R=
M0PM(PU "2HJTE,#0#4-W#3CDT,T,$D.(^_[OY\6S/\!^L3[ ]>)<ZW<>Q[K.
M!4.[912:UF-#:)_9)'WFMG/-N4W\LW)9G$8V'71 &<I%+%_I7O^X_UHM<YWF
M$.Z/7\I=FR"F0 )Q? _=ZK_:^I@&CBW\_4HJR4[&'S-"L!+X,9^A&6/0%<W2
M05)]]XTAL2PPQH\3P"]<5%;##8'=="BY/YFL$%]L]OHP,@HXZG73X-QW2O[*
MPK/LJLH9U5B9+I8T6K_*LJ-GG&CU*$WW3RK0(O^* REY<9+_UHK[,TJ1H<X\
M-U06W0>F"J6=%TA;U)N;UN3U#BYHDV,C#-4G1K1,$6 W]^!(:'O81FS1@L]"
M'@O4:X!L_"E%TY6]OK#G!!%Q.6/63V5JA,_==JM=:Z*H#85M'&MH<6T=/6UW
M+9A3>6Y=E])['9?5QV]#).ITB<U#YKJ6;J[&U_(Q)/,(KD#6F.!'NZ&.$E(=
M<<=1*TBAY%55)6ZMU6'DFO,E& N146F/. 3-C;/;&7(Q.;PF4I<K_^)RN00"
M%8YB-<T;%M@2C!$[5K<5 <>9OL;W+;T]P")F2>H13HXV'7)L=_^M7)6M7J>Q
M3;;Z_"_9X'$\83D=BD(PZH1EU&&>G]7$D0 VO&%M)-7#0.XXVU$V)"ZMD]2A
M9%TX\3.!A\ '9$)J8-!"_UA2JN="L@PW9]%*/AX++(;XC<%OH47%*#?W(M+W
M%"/Z$)KE:?KGUX<W#1O_ +&R@@]LK>B:)%_"V:5E(E:K(2=F^K\O0CA-1D0O
MA;/G]V0MRTR=UZCG+\8NU]U]<08/G]$8TI]+U>8+7+Z.E(^Q=;O6H7\KK;HA
MZ@P8XH,&4%Q0);FSSW6P5UKV/ H* K$!(I20PA#ZBXO:":[&3C>"G&XR^?I4
MDWO%_*<;@(0 G_VEEY1BJ?X=5=\%"8O\%(]YW@FV+GPNFO@I+XU^;YK4?4]>
MH#YW&<)VX+T,T3]G>K5KDJW+7$ T"_B>-276]]"G\"*4$3*'*H/G)#-"M!>-
M2(\6*>O,@:II[.TWK[Z(,.H^7E5;FY3C.4KBW"#*HCIY4A+LTXSAVY[,Q-=H
MHAH@UZXO4AW8]JJI'[2SWGFR>G[96\O?^0\0X0Q)4$1G=A=A93:OZMS!/\>O
MYT!U\%=-+;E>$E'I9U: 9Q1:)ME:2'/$"KI@:4X9.[85%B4O@?5$Q\#]:+6F
M8BY'=F;=W&Q!\>40>(3XJSH2??4;G7'O06_+*K4>B35*]%3,O8YWN=D2.)^A
M\4ZUU9-6,.(207Q106/D%NH!]&H]";=DNY?ZF\C1BB6Q1C$0PR6Z\%O7V8X\
M7=XV>[XWD?V-6ZY7)Y$IP6F%!ZC]^4"L'(9:?V1ZL":#^6C:V/Z6.=[LMRW(
M$2IZOCQY\\W+0(G[V:&_][LI.[-(([T@'P7B!^E[(%IA,)G4*8RIL9:T![DZ
ME7!<[2+ZZ=12 XW('W^;5B,>DZ^S)O^,-=GTK@!5FK!!#%5H:C[!K\1F3\[!
ML]\Y46J6R&+B;"B-/%3?_HIAXK]@C@8P?<V_7+W7PK*BC:XB&]$/&1MGQ .H
MG&I\B_ACN9IOA#AZ35&?W4*M$O\SB()LG[P-_P&<UG][NLJZ^V*R4$-0_BY:
M^69KRJB?:J7+-R/>>%-\>BSZ.0H^\47TP=\3&5LEVY>V\FA4?A?D,9+.R+I7
M/XPSX7<X^_!TTV %4(N)C7H5H"9,3K1X#7H8:K/GA;,K\/[QDB3N8GWHD-^?
M>\6_];(^+CY<P4PEA[2/VM,&S=P;Q&>GN36V$P,<=)<_X:2$'!VT6X8KO+A7
M0Y/U%A"%/L;.?9R^5]X(JA!PY;>2$:"]4EU76&8>C:#I.>C;>)2:$F)TI8XE
MK@D6Q1 GROIC<(!9\'P%#-G;[(D+[.2TA#*]<@09-5MJY"? (Q5]-U:]7)WO
M'1KH?/!?EJL7SR] UUG4KC/$O%);KY;L[GNL<GTV6YA>F*P%BZ!7NN@6]5W5
MB]/46558;,XI.<';/*H_WY3I2S/VA.!78-O[I<E8CDQ+&G/>;8J:V!OP[D1$
MX;2.X# $4$P+JV+_D)-V)"9N'1B=N%6S6H!*'(*54-[VJ#P;5U;%^;*6>8?,
ME>J\<]?$JO4 "57!XN]NQ(]NAL3:B?NJE76Q)79_^O_&^8)YLQITP/Q:QVR?
M:AL^Y:@_'U629'6GN(B)E97Y/KQ(N[#PY26031BW2Y'2::SF&3Y#4/(;GGBL
M0?F*"7+I8,)1=AH8I\^U1^CVXV6M LB!4]Z:QI!ZBM[;;+1SSE/F57Q:LJS<
MTV#73:#8 P_$LL]T(.U&?\#7P[Y-1?PTM=Q*+Z<X=H,$"N[,&6J3O2V!9A1)
MSA>W?WT[16G"(LG)JWA1M9X0^G)6%KRAI3^FWR!!ANQE'RA250BC@#N;,')L
M1 \/63KOAA*N81W5T [))1/E;&T==3:HLL=2Q7D 89S\HQ0IJ2J8Y_M=3_T(
M3]/\_=&:$KJBX&X]RY<0"3@)Z!^ KI$G[,5^I;W'A+\]>VL&@MJ>N'LJ2^KY
M;'@^@!!/3>RBM!W#,?=N85D#NC)"K@NK7SD#UI4S$S*/-6D<XDD>6?@7!;MC
MW:M'_$N=,G^VC1^6%^DE'X.\O4;NRO,-]?TE#WJ'1\@/5E7V?:QM7U=P$JPR
M.$:%TH)HPQ(;PRA52)HE1BG2:'1^;_O]W8;61:@29&YO%+R[7*_O,0O[TOYI
M.:](\N+6*.U>$E%U@HH?,ESPV4/X$J:#RG[=B:H0A)Z*,X7,AVS-IV@_"?R
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M<:AJ_S[IFE10Z6'VY4_SOYES ?HIK9Y,IP:QNBF_I/SP931&AFL_H&N39;G
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M<A7[(MUI!R?!"=YD0)EM*6KJYU*VT]X'Q@_T3=%:F@:(ZL\C+[8&?Z:]?!G
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M)IMI?7.[SKJVTYYFLX)GW-EXX5())&"23]"44 %>%_LW_P#))K+_ +"6N?\
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M#N95"@!0.@ ^IY->@'2].,XN3:QF8'(D* N#ZY/-9&D65WI^LZI"<FRG,<T
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MP!99>-_'5]V[?/E FAKP464W[O4NU9,LF\Y.#"L)\3?)Y=*-X805.FGQ:N!
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MH/\ (^17TE)-+_J(:@B\J7^0///VA:>KO<NT/?,GF?T756M)'V9V^6:')\^
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M6O$$S.3=K&7'RZ6[?ME(_?1\W5\FP!?O?G@#J;4Q=")C> $(UG3;4!_4;6?
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M];%?$T+77E6'69:X86NZ25HO!,,A4SQP:('#$U$ZOEBK%5?/25IBBQ*(GTV
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MY S&D/*:H!+.0LBEME-']RS[[[:EW.1E^!E9OPY,?V_:S(LF$27!T3XU-W)
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M/QQL;USM;QG 35ZFHP-[8O'GO%3CYZ9150Z07[ 0K<E6<%ZG4_GM )=)UC^
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ME6FMOR(Q?#.>P#[].CMO$T$,J=(JA_F[?Z%O-YZ;]S'KK/_RQZYNME]<#$]
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M4]V\GS3\2<6) (1QZ<YY8W5M$<SP*X;NSKF(IL5PO].GE-6!6W8$> C>SB-
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M^7INVA?H?R&GH-:L:8#^:%((%;XP:YXG%M]_JJR5>>7Y0E[KTC\':&_9]F?
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M#+7%C\+8>"]2IJ3CS::JF^-])/JQIL&8@Z-9W,\T><3[I'J]CQA)C6@YO]W
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M#I>K^-_'&F7?A_7-'B\-V=]&Z+<27$<\I$R,R(L.,;DX)R2" >*Z'P])X?\
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M*^(/XS"BBB@ HHHH **** /"]$_Y.8\9_P#8H>&?_3AK=>Z5X7HG_)S'C/\
M[%#PS_Z<-;KX=_;0_P""FVG_ +*WQ3M/A1H/@S_A*]1@MH+S4I9KPV<<*3Y9
M(8L12EG*88L<*N0,,<[0#]5J*\V^#WQ/T'XT?"_PS\5?#,<L.F^)K**\BBF
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MF[:V:.X==L*R+E7(&<E&3^%AU]JO>+O@I\2/"5A-=P0F]L+6420K; O)'&S
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M^9-"IT[>VCF="QU8104ZQM"8H%NS8K+N4=#>[7@_&'#I]&,4LQ8GG 32C-M
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M+YZ\4_;A%FQ/;1;Q0M1:Q&])NH7CM/P<)86[MJ-\.&UPI@-2!MG24QB*1#9
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MM8A=4C#HCE&(QD]E!*KN4>OW)#16O[LTQXNMX-\A0CG"%"V8TLY2A%>*@^-
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MZF2.,C-3)WR]CQ8V0@$"(@+KN=-+CV[3E[ =S6T]13(8%;5WA]>$@Z=H\.]
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M&Z"@QJM85]-LC6+0M^V%A=Z"ADB9,$8ZPI?Z[U4:\Z*DQYYSF-N&)BUM29=
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M\SG)"A:'(VJIS$S>XA@QV\)P9E DCS,/V<4BA9-Y79Y9VQB:+)8#&452W8E
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MZ,WG"[(RY&1(QK^VZ0\!'(B!18M% MIHKJV!%X-WN==R)%K6_^>D6M8'/?W
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M5S#PK(CUH*V.OY/\]-?>LJJAXL\97OM?:[56_-WU1.3J;0">^;%S4"G0ZX@
MV^"S$$[?,6XZKIN5%<7I-'[$W^U&AV6@5=]4?QFT*0KO;P_[WU//R>WLG8N
MHVU;K]N4]5Y/IRI']@)T!O\>?%\WL><?K=>8Q+!.\IOBA0;CB!N(43WFS=(
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M]<9P )&7@_^]-FGX2(+J=RP W:;A<X)3-HU5S76<WF9_)OHDJ.Q+L4,!]]D
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MD9=^[3(#G=V:ZD^*\LRC;8\]&1#5YEP9;*;3ZPQ14A(0RY#O"8POXLT+QU-
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M6$]TV=NA<7CSZU[D.CJORKY\8$!UX]X3"K>+R0N@]ZWM=A"NT0KB2B4+\P6
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M1P[SJ^T)Q?J66K1=;L@&M5F<1(>DB7>YC>9AK7S#="OD8I?Z5T)FO.+^3%L
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M<Q2+(A^ZT^]->3UK=,2?TG!A-+@5:I:(82*BEOYJ.M/ .OC S4C:R\NZ6)9
MCILN&/Q#7F?GYNSC_6F^\&C%%^'B6/A6G"_NVR^;.6Y!NIO5#FY:_G;JU978
MSYLZ2<C1SB=UZIH-5J.<.]B10A3>*K+VV8[3S<!24!AII))O &.%@>& M?WK
M?- 2 3/>9Z8^XSM_EO3IRMTY-BO?1#KY'!)R<R>C)X#B?$-[7;-7Y!KDUSU,
M@BK+ ;/0+TN^I6'8YVHYGY_E0U(<IWP+RG@Q^G$;H[A2$X7_T.1HJ%]O):"X
M(>282$,.$V.9<LG&DQ[8-\J_225MB'*QM!=-6> ?[<942Z:9$<$\D?LJK*-M
M6\10TDY99L#XM3R;,GB/N-XFOZ^;CH#KHB9;$96YP%!*3(]OQ/U320U?#)M
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MLAW#Y;-$O[%M) [PP<FJAG0Q_[D1(CB2Z??S_Y\-[VGA__5]X16\'R-B7RQ
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MK( %%\\?:)KX!(KOH*SSQGQIV4;..^!T5"E @6&?B>YG(^,)@;,<<*6@QK+
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ME=6;XD>-O]=<K"8.HRJ;,BI1-$01_4W?CBDA(^5J?S*%0, ZGA6"J9ZUQ9T
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MFHJ0 )1%*NA9HZ&D>Y16 1DE'8:@&C-9)JJ@?,]2P+<B*?6O%[F$D:73UA8
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M-=9#KAB#2Y)92.#@P;U5.<^SKT7N$;LUCRGBH*+_#\C<=XQNVTX+GQ*8_3O
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M.MSJJNDI?/O"$#E7FJ)8L11'N@*4G 3)B'!,-^1E-\0SZ!T-FX*NQD67:!O
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M]O(G/L%;]2"2K?:?6Y"VZ!7&XCB01BV?3I[#?.&@';Z2JS8S%YM2L2=,W35
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M)MBUPO@;7,60B?3R-8,XG42-_)&(@D@J6@Y6^!0C8ANFU@V=@_,7'"Z%#A/
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MD7>?_SR&5Y@BI7P&BD3]AFAU0+".>%/Y**4\S@1(?O!4(^U_2EF+Z<(=Z\_
M32^-I+-*=^VS@Y,[3G*3'LAE37X\;%/^))K^X]B#L;)!'4;B14VX+U)),-Y?
MQCN@!3>HBR5:!6HNAK!P^F[,[*M1]6(S &Q<S/0R[[Q'"4'K,A'% (QJ7<S7
M+9&N]FEN%*@2<4.>7M@'Y;^(1^S\6U \_M0T<<0CMW&:5"GGY23 _&5A[_,?
M7"T-(7^?NZ+QC,T,!,G*U0X;?K+\A*_]R%EIE\3T._Y31"*P8>33&#2^BL>8
MFYNMG)-P^SX2UW(0[N>JOW AVA\NDS@TY^=P,$BO@J)SDV^J#YKS!$DE:K-V
M[(*!S##;2:B"4Z.FQNJ!K/)'B^5>VHB=8^X].6?=H9*&=(LYK@.A .W*I+XP
M+1>]KPX=I*YPYU_!X; &3_9!S1UMH[E.6C#&5RIQ@@UTV'(^Z5JG<A*^JLDO
MT@;UE94^IG$/>BQ"@FT?"L8+P-VY7H<\JA#NS;X.U('/Z4UU9>@HZBR_7\MO
MBWW$";?X*@^>34#5;ULDP']VH0%WEJ6V0%(/,PSN=5+J%)QN1:OS<WB(!B6Q
MA Z2X#*'>6B'XZTF3:Y%SCZ(=E;:S ]?ZB#XM&HTBB*G@.4C5-"+U$IAZ9\_
MW4Q02<GLBE\AFN[Y3#BJUD@EET 2+,@KH<[Y^:;RRQ*6[W;\Q_@S1S:2>/1=
M%7Q\MNN2!GK_[SWD%F%O/-@#WT\R*2(8W@',71X+>[=E+#(QQ2$8EKGPL\]$
M]=/%;EF?:77H=@FW#YC <RY>!%12+M8S>%:;$@(T-W?W=S5&HO.ZE/\\*/W^
M9>Z< J=DQ3]B^C<N3Y_L.GTW*UE9-9+R;_H3LAA3 DW&!KO*DW;Y:[VJZ$+!
M0R4Y?CF/:,#11+5C(XWR%%YY34'V7HTAB@6P\8/^T?#:S3"\?N [@&5XI,7]
M@Q?!?YAW4\581I02@T9J5_5$5=^T+&LRPD4\39A[L$?O/8F'@2Q/>@EM7DF[
MGOY+M['RV.NT"D6 Y2N3*KLS_VV-^8V _?&7J:Q*X]6EKU:16,>0./GD<&&X
MY-G;\E/G.B<SZ;D&:@STGW$+HI6"/W#+6 F1X/+ZRAY/M;Y58&UMX"RC:SSL
MD"MDY)V[QDW/BW!MGLYU3:X(Q\!O6XL+P/1O1J[)H]0&XH8W!; =G64$PXSS
MM,%1PM/=4>$OIEC-=Y*S#&V8"JI\4J%MP(LZ'-#:=NIXFQJQT ? =JZ'\>AE
MYH1!'J]<;NU TN4[ .[<^%ODWB$\/^VL$_'E'U#Q<_9^15>U]U2J6H.&&318
MGCE6#]X"Z/.?T]=^Q!?=8'<R/\5*T,(N3R?R6O'/%-(23ZT ^.QW&"J6I]^>
MHD+KM+%&%:ZNY\?O_"^!1;N%5\,.[=D2;X'8>7)58-(Q4?^H*$-@QIUTI.]Q
M(7]U*>4;(?U.\$ D0-@B=0%W>L"#!&.G(N$Z5&QI J[F<.)<G7% 1'L?VZW8
M6-\>>U*(>^KFVQ.9JVBZH+3UT=>JI$62=P">N]O+<1EGDQ.?01@UWQA0-0#S
MIEJNNIH*!>S@(HD4-@RXJ2X!!K1X,H[7^3;AN#&U^W7DV"&U/7=%[2I#?[?/
M2&%_&!6Z4':[#HH0KR]LF3/?!"'"M"<?M%-6ABE3K*UBIGH^/I%Q) G->N@=
M2&7+:('+JH]T.(N'B9PI?:BN<$ 2%CKIS 79!-J+"E6M'V ):P(O#'&V&?B8
M7;.].\QRF.!?]_QWQ;$.].MLD!%C&?</(3W#@^AMITI#%0KG:Y*$EB$6]5H]
MJF[-%XJI8'!:8_&T 6T:[+M]3Y+?2O/MT^Q%TI3@"B;ML+D%?,2?[?A9O,E*
M0Q,E-R>[%F6?QZB=R5^WI3-$J['DZ&N\)7@U#H#5?<=X6)1*67G5O;?_UW*4
MNRH"G5&NP(VU_X@>L+T#\:F^+4K#MJG2RN?'*!K,!_-Z2-O>[ FKXXR''/X8
MUO9'7=01V6EP"V0DK$*@^%]RF_-3WD N+^_%N2[(ARS/]R7"=DG>"@N5T4;;
MT[Q<1,:5XV&!L.3A/Y3_F76)8H_EMW >L1NIP T/;2$-*#-I=Z<I5K+8BX"X
M ;P#$55T-JROTV(!#6YBR2>38W$[MI&UG3FP&8JS["IBYE43H_^I&*+97R!E
MRFN8.ZOE7O32"5G64\6+C\?@FI"[J=)V81EOZCK)*4!-6UW=\307^Z;-F)-1
M@,)=>/9$%&2FZ>;:AW*$TJ8J@>#V,"^]EU7(#X4\LX?*]>&XW"U>!1%U0SW^
MP=F0]!I=1CGG9)(RELSE0O$IO\^K=>%>B9KKDH'[2%X=I'USIIU9/!3ZC<F[
M,O;6102O7_&N*'1=2(:*"H %P.O:4959<X,OF0PDTT-P^Z"\SR_'B6TSYLT<
MQ+-^U-%6^6*>J?%ARP70QH;VE(,_$[SI$JW;PC8^O_69P07::8S_!V5O&10'
MT*R-+L$E$-PEN </3B#!@SLL[N[N$!R6X&[!87%W9Y'@K@$66]Q=[GO.J:_J
M5IWZZM;]T?^F:IZIJ9I^NN?I;M\E#W99_IY%'<@H@ %YQ?>-X:9*YA;=VSY@
M#B/L3]A?+Q&.TO]0W.\JUGP>E5Z5GERL9LS49@Z;2"BB"]/_K'7U<WZ#V)''
MRH+NIQ@N\'FU3-%N/[OC:880ML9^%J=BZ62YV;JA##,?=7?(*D[0IQ%R2F 2
MD7D''%LD/=M<+5"0FNF@A6,W8SIY]9TN@AO74BC'KWZF?]:#C;T#PLQM]<H3
M0Y54DS9%"US9JKI&XJ",GO_AMI;O@ 5-<&&\9G>J>HQYHZF-\WC]@6N>S5]?
M4AUZ'5+VT=BZK>Q<:7+I8CWYCAB+*!IJ?K)3F@Y&.U?88DV>FK55%2[[M\0-
M.!([,V>F>#(^+)K-YMRO(&^Z<-@J'Q!%WCET*5Y%0]>5;CL3;XW5+!L:0AI2
M> %N:V+IHC/PIGK^CB,P1;6?)D^C**NXN YK/+594VB\\FM.0XR.?#/-3FK$
MTCT\LP]LK$J5TJ]'9"/%'F$5Q(8=&U@:G=#:J_93S\EHE_4]DH>CKNFL:L5T
M&MI7&.H<B>K__1:,[M9GG#*U*UZE-AUE1$>_(1KQO<I:US*BJHJN6RNGVDP[
MT -E,&[RW)R(=W*@V.9.;3RP^,L3D\%7#!;<2>AC@$4'XXL]WLPJW40,08K6
MA%J(JMKP-!;09\Y16*9ET=&DN8;,Y5,VA?-:Z6QE[OAW77=;29<FWW,7MTNR
M>P]K6P03U&RXE-T/R.+ZAOW%#$/=]GT;3M,RVL\X8D"M--CEE+D]"<_/R70-
MAFR*'/_C15$BVM(A6<Y']3ZJ%=A]X$BY7F7V0X5SK/F8_V=#03_]D,.'DOXM
M.<3:!F8ULK1KU,F E!M]OZG+4F!SW:5#3)$<V*R[Q?^7"YPF[7Z[$DEB4@"L
MSX%L9JD4+Z=!SOMT-D3[ @ #.C1L3^C>'>EUV%Y=-L\V7V$ER!!M/2^9%&&?
MRP&I2-/9O79G'/;G;5J%"H-FJEXDC;D'*O":X]:P.?RW>U8@-B=V$GH%S48$
MJO)?GW_<\IILGV+H[:_N<+=Z"N#OLX"G/,M&/7:T02?,7S<T8',78+T&P7DZ
MW5,6BF+7KRNGF_;A"H5GH)UZT2EW=[/H8"W77>0#U.Q8WR4.]ZR8J()?0MY&
M.5L7BB@C4ZW5S=9&T;8",[6)N)\,UF/C]U0//$U19YQF4I<46Y[K"7Y[8JQK
MA.GYRLC&23 >,>N:E>^+TQK^4T6>C_Z7X@!R6S/G/X&V)F\VJZ3'%6/RDQ]9
M_YE7^:XK5X^]*C[O+TF?P35A3OQ]+*[(A^M"4C]5!0&+&^-$U?DX>.ZRP"IF
MWY.[<8#,9?V;=N->RXA,+^V3OZ!F9V1B>;0&9EP?4IFV\;9L-AS-"X0\QC5Z
MFA9W@M'N9TZ3@.VXM47G&R0J4HWB]'6>(D\M<VVV<80GR]@1G9#5Y>^&]CUO
MX![;;P%8[LW)DVH<;<Y8B@74-+V]?5&J8F9 V!HM"(>KLTY$EM>?-G=<@VOS
M+P53(9Q7KUJN]&S]BPX;*+?9IWB&<9QKN @C1)O,DKS2@G^G/5P ^%@!K3'!
MTCVH]%U?E-]0_:H>@L2T?@_N$F0Z'5^5D1^BP'!0E%5;?F7B9=EO6L$@XJ),
M3YI1]UFLKE?I!#E:5B6 !8I'\(.WNPP4;!6?@=$51V<1CC2[)MP/MU4O3K8R
MC4/\_!V<@\Z+67.E/D!HM-!M00=>QN1#ZLP9V!2M(P5X#@&:MD"!]163'_2H
M5.MN3!/Q0,A+BUW(RGUS9YY.PLVBC^1BNM?/VCO-(.\!$XMO2#Y['2:=V6XB
MNS,S2*O2"I;-._TL9>97="CP<--YSI+K,[#[5&YBSZ;U7#7<Z9>B_]R_M0]0
M9?5S:[S=+]<IPZKO@?C-A9[V)<Q;NJTY($'\+8#_<7ON*(C-U<8MZ(,X^003
M3S:FS\SHA%N):_!>>9%I>*GK))/0-,0U^=*\NL$=,S-3@C78D<;Z/A#CNX#Q
M#:\'NJ_1;-=1>*Z4T%TB8>9:+F);\):)N@QG"C]UFS\U(DAOA"%I@I-O U(S
M6UL&7HSX:3Z![L'SQ<XHI#?K$U4"IGKH_$*,Y?*;^:)G+9QV?!IR;<4BO/_"
MH"MG(&-UKR\3?GNOJ047E@W3\-GAL.(J><U U@CIT$<;$(DX/ ZR<8+!JZ'(
MBY X84S:>"Q"XLK5\@%S?_>OJOQ_:JC%_IA:$,HK)IO6__D1J!:ZK0&_^#-&
M]+4WEA)I$V5G8_C;[LJ<596&GF++D+ '.*1##%I+_>T^Q8VSQ!612(>C8J4?
MHF.^8AWHU*V/^S.]327\8.3ZJYSSUP=N[K(29WVC%UW6 8CX//-[0.PLF_)
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MI5WEKUZ?2S"BO6CAN_I]M1A=H<!*6A:7*!7=-YF<HP[FV;TO'11!G*5:-N;
M;B?;GIIY^E M(Y5>&'BT;AA0_F.%7H"@SJ:HXBN7(NW:;.@5MB">MH%BB!Y"
M(LJ2S$@76;:^X?WL=2ZSR[WZ.X"K.DIO!E1'=.@:OOH.H+#+BNN--_HF,E;P
MD9EAF)B,\+["0(FEYU*H_9_#9D)-=$:<47Z[^[$I6-AVV;^54<P;6X?VQ=;\
MS%4>/V_]@*CTYZ?"YC1-)*N>.-/)R!V:]MDV+M:T]KA4\!<^:61<S$>*CMM_
M1 N,7 Y.*%BX]M3AF&Y#+V6G?Q>%H"T[[K+%<=L,+XQ*)[Y)GX5K]FS_G=PX
MR'GX<WZ4HK5NNT4&1^/<EK7<_\23M'/9%1E1[")0+FE??$;KB3W0#-]Y9J97
M89?:EIAS.SQC*9QQ][,C5E546GUVGAZYYM+Z:W]I^^5SYO),3?R;R$4]'Y.-
MES=;86 +"-'M1H0%&NF]*Y7 U4Z92[9 7N5-*W-)\)JY=[7%QA=P@I5\?6P4
M5L^Q(ETCWJHF ]"R91Z.8S42VB@EO[WQ]<^ U3$QH;"N2"N+A*G6S8LNXNPT
M)N.*$W-5(GV4\(6II4+-W5AU$),7;]#\M">P#5(WX5&*K4^[-M75[8>'YSE5
MH16G'D3C!D*#N_$^VXWY$"/)V(@LWX7/!>REKI'W@_'2KGK@-]HL,?G)+,]I
MY-1Q\[!Q?+YUA#N*^L0:'C TIGHS%N4=<#S_56.%7-U[ZI(6@].J4BRR;J\M
M7?GW2$.=5ZSED&/ ]:V8A/9-#).](HS+M-)*P))LT_-#U+4]6213HWT)&H<@
MFO$-FN)\Q8%!E-R1387S1[<W.G\I[CFE3X&9H"EJ\[UD].\#AY&\<R0:<=P5
M[D8MEWII1<5.Q<NMLEX"",Q8;7+X$YQ/$Z,^@RETAN'PR*+;>3/<(^;11LHA
M>@>/F=E9[1'3M6Y.7VU0"LL%E$11C?<5<ER S 7%'[.:7F*\")<=,IM'7:I$
M<ZRNR^KT# W6H.,I/]55$4J\D<F)_>:>%0I:X@+6"I71LG(BAS-%=4JA\M"C
M/VYG05(6JP-6%+GHHQFC6 Q%EZ\N^AEFM>>]7I.OD41(TB:NF)[!L_/7B_T,
M9=\%W@'QUW SPT[[+&OE!^^ <+75@6TD/7.=:''QKNYQ*7\X+:+<9*7Q_\5\
MDWW;7;X;Y+/?47MYDZ42ZN'C2;3B.&![*Z:XT!>XK%*:S3[FV1>B@!=.YQLD
MTII&QQU5C'3+*[I@7\?6F18B/8[G/#1@B%;?$/HIHE[HT*&JH.%UK_47K8F>
MK.GJYO7#_,,8CGU9I BRQW:&H%DBD!9_:[ID5"-V#K$W#A]7 =^!*R\!QZ7Y
MYPE7<.*Y1FQ2( %+4FMJC6V'7T.]=BUT.#IU%^[+.Z"MAY;L;LRXL=$=<E9)
M^7TZ"%/T*'@I<()'_LGIY%3":4_:SP=\E9&SJAH:WXOI$IFM-N\^QLR_VYY*
M,SQ<OG&> 3]@G]60\-M-.WN)?K8BO+!X=9%HZ>Z'^5KT*4-^ %*%OA0KX44/
M=Y9;?V3%0_\V$JJ8?JI; M/QHW:_H_(\^>!^N?%24;[]_'1--"X*RRRV*_/$
M? :GW[0U-8N]JXJ/'QF1H,4=@S?83#Y6')[J%>M J[ZY?@G O,$ZB++RNK[S
MM&!9_351^!DYG0IM;#5X4LMR^F9!/$M<-=]ZZ6K3SZR9[HL19LF\G.Z>L!S8
MQL..3*U<5AKM!V+-1,FIX6W2W1-[,UADK975N:"&-5(", @WSB\<''FL[UW_
M7)H#BU<8G!#SBM[,/M1K"1MLQ4PH:W;H\XSI\W16(9<R/67+G9$O5]M-&0BT
M\G'R1VEN]+]L%!?AD%'U[]-[TSIHI#\:]D@;%I_:^8B]92#R^A,J-/;EZ0[(
M!A&.+D5,VNL(?;DV4BNK<&T3:\^?W(C2F;'$13F0\SQ#8!J7Y:>I.TTSHE1*
MLTOI8M5#=LD*31N><K@9$YW[%*!G@>82'.VVL#CGH+^]HU6_Y)[:T!L4Y /Z
MA+R G]Y1!"G(: ;76,E&*CR2[ZJK[[#O]0=D9]K9\M:MZ+.FE#A^[[P-??@C
MDW,XL*5XD5<?0#*C&?L]:<+5>S/QIC)J53N^L*C(PU:_&+*7Q@O+M5U0<7!R
MQ=W;9=K#&8X.6?,9]Z[24DG^4@5PB;RD!'JC'<WHO@-^]/Q-8,NXR/6A76FW
M<)6@=7)8!%(M!&YE P\#:&=PG[V6BI'-JT>NVEPQRV2N[@IR\LX\P-53SEK6
MK0-5B4*XTFA9/TRN%Q=PRFS^3IV>_64=#Y[%=3X2BSB.?9M;*B67H?JOU-WF
M(?US,*=@4)U W*%%+,:",Z'<7 H=:>X)5WY*A;'AI&U]W><2=":%-)F86&6Y
MS$R76?-.;ABV\4H._H(GT,C@@H\.7L1;(+<K;:K-4N)UPY>]:GG)?;O"<'MX
MUB$J>(CJF7?Y<ZL0Q^P/\G%EOE$' '"Z#Z)]9]>6=.^8E%J<EH[&"BY&H]P\
M2HXQP&%:7\U$FW?Q@C?X^]R>LL)<<@<3C3[8+]5>,Z[B4Z2WOKH9S?67LK?;
MWST))O]*I)<9MA(.:G\K)B@L/KP*M%R5*OF<HM!'_]7T*A1&#)^M['_(O=+"
M$<M90.(62/NCV8Y?M6""M<W"M1F):WR5(I3_"&O/,/C2/Q.Z<K@POV&%9UZ>
MLA=,C(BU<'AH%)MI56Y=+=+^8OXW_2OK00! 8)EKA9PIBWOJQ$.(KGEFA\)>
M$7.>DFE5@C:[-<,J]L:-Y<A7U[:^O1@T-W/D^N2?'<DSP_)WH]5,/.GC(GDX
MUTJGL*_64!M3N;67J]'&_MLX]P!\O$$I?&XWP>P+SSQB?]:R1F_-D .D6=G+
M]XJ?Y["7R0@:CAQ-D=PFV[?OP3CGO*<MK-"3I=2&6UB?XQ-MCG#9ZK)+Z?+*
MHHV.RO/1DK0\?I]1"_PS2WHUH1?<?'A3[)W??3\U?J^/$+Z^')CE(9& <J0C
MVFX[$.9('BGE^IA%Q*Z \?%'9H[OY1@#J6U4N38[>P.?Y\3D"@=B < =I7.X
M8I:PF+<Z6_/;GL;\X",AOIK4A_^-38OJOU9_M]BN@O].:635(WBSC@?[K3?M
MX.'@NH[8G"X_[>@X+=1:+R.'C2\9<A*-_=G>)>WA^L[@<B#._#7/_?R#=]UV
M?_..OW&_&*&>71KB(2S&O9D[_6&KIA-B$L(YN;;2DMH32!JN;1HOVOM:W6:W
M'0CW0OQ;]^*L]%,$M))'B7-"9YYMDXCK4%]D;EK&WP=?L1)="D<XR2'H]\#(
M-]*WOFP@^XOI)4N/($-8FY??)9I0)D,OY"&SLJTUWSK-LX%C\IR^'8?E\9YW
M.K57:KA>/AKG"[NXF $+G]Z\>S;F(5'+6[L/87:13;6<FX>;T,^M<&+-M@39
MTZ"R,E10!H!%OD/UM9E;#.\AZD[](:+P092H:78L P]EY^?X&&+#+)<A',J^
M8E=<$I!55!7319P"=C&R8]6#%2T7$$!^;%<FFDIMEYJ%>FH9PR[)C4OL"(Y4
M85>M ,>S#P"2&0C"_C^#@<?R.]-+M4N&_D"@[@/+-D(G01M5!_GTWG]1(FM_
M?:B2C4?.LFFC>,##QNF#L)E(7;JG]K,0[SHZ1^7!3EQ0 +5-)U;:O<9#>IGM
M_)1M"XZ?7@5WR4X2N?8L8.QCGBR'SZ.N^\T8P#_]_R3E,?P4_4;W0+EUK,\0
M[:$YHW3AAF(.N?]YV?JJW_BYR>.V\B@2<&']#K#9",:=8*LW9H?YY*SLT_0)
MF*]RM@;%T=)"LAJ. X"7HF$[Y"18V-Z.)\:']W2]KF6UX8Q]I!%HWB8R-&V_
MNXAXIU^<'LH1U/-'L"?O<TSTW*P?!H]8UO]_F?'_'X;\^=>7 C-\0A%D[GI5
MY/V#@7? ,OS=]X>^"R*YR]>(OG< MC=R#_HVCEE:1QCB;</L D1_<']N"HS[
M*$7J0^=YIG7 <T%W__,=8)[I..[ TAO84-4;HZ+4HD'>5S]2VN;:O\K).01?
MBN LH2Y2?E-UM_, *?\._^"V>8[[(+VB4#VE$LF:-X]PEW(=5SU"EO>-?EF<
MK[D+U/?<113WVX7\+?/Y:T ?"33#:WZ=]\),AA$!]: .%@__^F]_\<@_,O1;
MS>[B?5CWET:2,#V-I$)'/8D&R_I$=^-.$3_:-)?6N7? -Y^%M^&!S<D'K"V_
MP""-(8_-*,TL4J;B6-G]/SN9\]MR7TM)G7Q"Z\AS< -4B3YTA%6J=%-07<A$
M"O/80;\+=E;/WJ".AJ#>#-&DS$4*Z/%R@W*INS_&/D[PS.OLZ67J""O)U<^X
M.JU[I?SWA$M&]Y[Z-X*TU3H3'4+I%$Q-/YG8:K#([JIRRO<#?]8:ZGJW[._!
M61?A( UN.>=8-E%"&AC7,AQ>!YNN<BR8T$476#D,R",:'*E06E4!0<[(IKKW
M*A8NMD,N+N'.\EF;L;Y:J>=:"8R)'P7@&8OY!]1=IFMCXS2\\&2I^D5L2$3V
M#%Q(,9TQN09\JSX.,:][H_WSC,=T]2]+7NLH]Z%IJ,^VE#I(# G(\822U=,F
M-E>/EA1FG *L&":U':!=-M$K0-/,ZK FT-/.Y%WQRO(J_XHW'  <#LKR ;D#
M"]J:V%P;95&9$5+)E87@])IY-<&32F:KJU(8IB'AR1(,&S0-R5_8IR8QM%QJ
M]WE$7,(I<F8)O8CX""-'@\8F[X#(R&GUR6=#_^0_G8[MZ++@<0;) C+@CWS1
M8).6)8O+0ZAI/C+G]*X##,*8@'(B59ZYBFK:1R6:^ JQ'W<\<O^P4NX^]^=Y
MD+X#:I;RY? 9[F/Y5?TPLHH/]5U7\+C%6M@CJ.)=ZCV Y++T-2\"'VRVE42_
M*(Y=U_3#T:*Y&&EO-B$$9R5_UM&Q3"9ISQ,VQX!T[==]*5SK[<O_]MF9H&:0
M4E_2CWE56 6;EDIF8G2 [$ $40F#2#4$:1H5%'T]T2[IM3C.TLS34, +2=W:
MY"(4.$@<*B-\2EZ[KCN\>P<T?='Y7FQJ)GAJB!?G%MD4Y=,B[5]1Z$R4BTPN
M1N(?V9\"J9!7<YF\?7$;MYVMJI&+'RKIL9?_1DD7\27@V*IH9CVWO0/6!$O@
M]ZJ/A*?&^0TWP"RHW08I.-Y3S-UQ1,N2*--&9MPE(S_!@G&G_T.;;VHD&O+#
M%O,T_'ZX9M!$-3WD=H"Z*65:_6-59MAM%LM8<(Y-QIZOG.M[.:N5VPV\52E%
M7E'CU61YO\HX*G+-Q'RMFQ_6[]* 95T0H@8P;D\TGX#\10<+QT^8M2<VL'6]
MQ'H*1:G_)0)RO_D$)FA"$3F6=[RLR:BWI"MPW6 B"7'P_F7H=ASOLEQ!R3ON
MO?T3J'8]>\7!U7VN\'%0A:/-/@"<\6'U8+F0#73=?R&+P)3Y5G#3AZKWL;JV
M,_(1O4Q8,0+1W*@"J]UXJ,^JVX'&V-!0%"L=1GR"#R[\AF 2JD__=;I]*K/L
ML+%E+'31V!&EE\/<H;+0ET D1L^&NBZHK8*042<%/(FY.Z=WR^+M--V=?A^;
M_I:QDPTUL-!!U/T [4:&Q!5*0@K3Y$2BHWP("K$R\G ER/[+H,?+E4-^3KN-
MUSW8^52QNIN>Y<PE0<P 9!-F]+\?DQY!6Y@BKH(!TGEC- 8L"L5?3!)/,:<;
MIW-_]0#\L&S-$AP12S\(?*]^A ]I%_%]4C<8<Z%EZM12A(.1D\Y>SQRJM]7$
M:(,&1_XN#CRSBO47\?H1#<LZ@.LL4JE3\:X31[ D(Z?D<+J8)29H( 6R"]]C
MJC$+LA M"UJ_+ZFYGF:<'OR7"(3G8U:^TI7Q!.T(O!QJEM=HF7C>#MB.UG7@
MQ66'K<%$N+3J\3\BW/?NG>U#AFX!I]\FT0J%(NA2BFL>T*$;+_!/"_DZZ0_(
MT(/_40NT,JY6+]X!47RU^FN'_[+[$]QF=PG^L8R?.*9<T7$RZOE"%B"K.N#+
ME/VS%<WIW1".?S7#8UFR@"H)8X6/HUZJT-O\A K?6-[J?E<65*4BSR\QFW^6
MAW 5PP62A!UF_RML3TX:R&E/!?W;,"=]?A1$)*,NB';,31O83G$L.7M^IH)?
MW&\,M8(GR+.5 #99CVLH)$SKK8Q296PA\0N<3T ]RO+#R%MT&+SRU@K0[PSE
M:<;'QY'<%CJ8^7D4PG5@R:FR 48YWWLR<%G8+0AMU,G6;W1/9;3#][UB-PYT
MI3'YZ=K=#C7S6ALMU3S%OZ6*>@^)O=K69E&VUV6FK++&<WV0$WY..VB3LW&^
M(U+7+_N3Z^$<+7J!# (?J@VOS![E*^/:HL:V7[)#<!]A=5%^YO%?(YR 8E[9
M'N7+W"T.C;4MT8ZY#:IE36]4R,/B;Q[=&_IKWG'B@EJGV1 63N68:("?OR_X
MGUW[Q4(8Q:#>NC%S_7QZ B]M<G1F#^5PO6:SUGB;%)KFX?J=G\'3M0@I_@53
M_>U  (M?MF#$CDBYZ+9.7:2-HR&GD,,O&>2L#P<+/ Y?MW4L3<#\RT)QAK,Z
MJFV-HV'P+=&EM/F>M.MY*E\BG\RC&^-E!.@&A3>OX_8,Q6)NY>K'G.1P7DK=
MR$H,2LW0M@)IE.W:H@V53'%^_:'[F\(J"H[-)Z\S-BJK[8S)J;9!@*ST,&H)
MAZU+R\S"Z;GY-8J0U6;S2"]/,3R2MX>EM?_BXZ>6,+R'7SBR^SGSG=3!8IO1
M D8O2XLD%>]I_[HQT-G@24/7%$_[,3)TG[:)G)/%\A,[RETODI\V]U%3.8E&
MWVQ10=X]H8&NE90--A _P\\W(%GWZW\1DGEX?:<$2L#@N+^IS?,.2*MHVT$6
M,YR5W0WI"/O=> T,K2$S2;#-OM-*Z[I<Y\#VWWY%)KO^K[_]'<!<K?1%!6N
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MNEF BF#N9?]>,?LX&D.:I,<(D<[^PN4].C>'3$TB<#WCD.B<NHA\OUJ+0"C
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M\&.CWBUV_79$9 (/OSGSQ$WPM6>E]6NU19[*YZ[CT"[*3)<WP@7[JA<EPLQ
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MRXI<B$H^%[>VY/^0@^_!&^#NB?!L\N>\=M:[G)YVXJFK,6/5XXJ5);T>HE?
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MN[KA2;5"\91>:UKI)WORDOLWH#H_)X,BLAPI5XCF\?<E>?EK%/]5%8,=FL!
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MN[A4=%T?&_/CZB Q?XU8G3.EF8+"LO?6@VMYF:[WHA)1Y@G 57$2U;J%T&F
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M*@?ST7*S=?/V[MBHYR%C!&E<E!*V7)ULIY!X>+.H[WS[$'%2.WD-C<GOJ.%
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MZ<]ME9Q0,#VH%[P'.H?7:A[#^,IFA139JNX3AHH7UEK3P[;#Z2J<Z];?7E5
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M]$CDZ!,J)"\AJ)4&&HDO(I'17@%0XS4B[NY M]],'0%LDAJMU0WU@77)RPL
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M++>$&& Y^1]ND?K68U_)ZB&VO65G6\PTC5I4Y:B<M>A3U=IDN<MZB]__SDP
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MO?2_4,+>%7/F.A [';M:>3DH<.JXR99S#F+/"W''"#X652_IM]>U-C3@8W
MPZR8L)KVP25CCJKNQ'W#\^ (^MU *31I#>,%@S6I2<56R 5DAGI&M,%M0H*G
M/J8E&XDH;KAL?,"VBNE L^Y 7TD3Y<1R/:>8F&J&^[#>BLS:*WEB+6;]S)NX
MS,KHLW>KM(<YI(*=0AT#HZW;\?8&M9YOY!1!R5R%946P]4LL61Q]3,V?;Z'
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M7P")$Y>6>).J0EMR$GX>X>XJ4':G>T4L!9.2G+4D>^5)Z"39#GA'ON&#I]G
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M+7K#+;Y-Y:,9N;>4$$=\<WM/4V&.JJO=#4BR4=3%,+-$';WK=*J#08SE7')
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MH8=_D[)?U0I5B#MI<3<F^*O*5_3K,T U"4]OWCTF\'[)$6WABTOGB)D)8=0
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MT!(:<'$3"PV*NQZB5QBJG9C:C$-))_XNW&>G<S@<<SZUR#\M<[H>XI9>ESK
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M]JJA\L0OY<5J#1^=YOTN13.MS [3N/BK:W-'*B%T^A93TM8R/0>9Z^.UR3Z
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M^/KP@<8:)0_)\B1*O$[5/6BQK4[@/*IZCPJJ^(O$%F8]Y?U9Z(7IFD[TR/C
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MY1U#C"?M9BO?!(EU<VQAL]QNKFM\:8.&NX\YU:MN?F12"%8*?:6P+@AN7N+
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M6K_\'S7,+V;^J9G^FW&ET0JIXR6\J1[S1JRP.43=Q_POG;> 2["_^;]<WFI
M<!/LI7B@!A;8N$MJSNDNFM=S/_9W7T/NLWU\VLP*T%?BX^&U--8"!,F3QN!5
MD3N=WP@BQF/--)C;(-E9@N7CRNEF-;^"ZU4X"T2 @X C^(5$^;)VGYWP 77"
M,3U9->VY*-:XW3A"V3+*@="Q!!@[!'[P;ZD$Y?IY>++:"G?U7>N(FM+&/$EV
MO4H?EB(BO_/N7VV6(1+H/">(88YX'UB52A3V]<E4G?EQ=O-.DHO\]JE[74+6
M3:L<7><(JO8#UA$4@.\7(NF$QP%;A^D)7VF[2NKCE\1IAZ$T'$KT5L#7" .&
M\D=@@N'1A[4##WX_X2^/[;2%;CUPY6R@#K&C]3SV<#"+1*D0'0ATN)'Y;NM;
M63C%KKHT?"KF D WV^\'JG+YJ<>+R/OR/-XE>O41CSL32%M%_\[X!< LJ M.
M?N1YE<A154U(_Z%'(0V-N #88$MCBCV:F[ ]Z3*B3NY"'U6$-KA\GO.(K[&A
M=J^3_850DB@(9=HX6!L'267XVZ5OXNZS[^IS.AWEI) Y[OK*)-1.4']L\-:?
M$YM!'HY5BC"(A8D6@"T, [\.]6RW![;B(#%'*H$\VA."LK9+=@/E[?0.<2.[
MZKP?J0H$& S]4GL9XUJ9",!O&VEEL7O"XY+R\U/CZ"GNL5UWN:WT]YZW O 6
M&GQMG]GHV&U3R,44[Y*\B:XXRVYP],RI3KOXX)1G=-NUU<H9S.^CVT_#.I=9
MBDM@Z9$ILU>]+:R>._ &.7,D#C0\ U EPEX14G$B7>Q+(MCC[K(/"B9$'ES)
M86-99QNWC4TG/+?]YQRD--O-M5#/<TVYZX="W8-$!;!HW_/W4G-M%67MQE%(
MY278?4+9G2R\,?-&[:[[]JY3FZ'+H_KT'5_NG0/;^PQW;O%;:S"I"T3Y +Y1
M\D5N;V%9VZ=7'A&ROKLJ1X:K G&W1I8?M1)\B^>T\&K@)RQ7 W(BU!_2:X:L
M%A9F LFI"_![1I3_GM+P?P/^+Z7C_P=LS?\?08ZC6AE]W^8*"0=SR$-HB \(
M8V^#&&&/,E](R#,RN5H@I^,HAR=DX4XO*_I7TY7FE2*@5@X QN0@3ZF-O3DX
M'D2(1%T &)] [^/36WX3W^1!R<WK)HET7H['SL<&<RDOFD\>O!(P91*2&(^E
ME[U;2'E.A6.,5 5C%F^N=))$)R1KXN[L>7YU\Z,UIDCG5-Z-5W^,#A84#"7;
ML@%0 LB"51Y=&?L/!?4?BFKLGQ+S/PSD%W/_"U!+ P04    "  ;B&Y:?7W"
M\;2A 0"T$0( '0   &-K,# P,3@R-#(Y,RTR,#(T,3(S,5]G,3,N:G!GY+L'
M6%-?ERY^Z!VD@X!!04!!4>E2 B)-5$#I($%1:=*[A 20)E5 1$$)"HC2(AT!
M";V*]"(@)5&1)@GU0-J-OV_FSG/GFWOO_\[<F?_<9Q;9#^OLL[.SVUKON_8^
MASI-702.7#$T,03HZ # F/8'4)< 78-0]_L <.T:<!H  %: +MX=8*1IM"+
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M3N6,X<Q9HO C/D.J8ZB  )IRW*VQ#H5>O;-EMV0:'ON4M*!VW';9.PQ7B_!
MS"V(:?EAS7A CJ4X5(BR_[6W93;NXS5SIQ0N'OIZ_H2PF1)N[FD2IN)5&M#%
M#IX3IE6L,RPY31_,$ WY/&OW+.78"P!?IC/^"'H"0VAUVT6>QPMBNPYBX<]Z
MKHUVB^ (*I/_#'SE0N/W[N*#EA^KF"7,S.8.FL*G>.&%C"P*PFB: 4SLIF$A
M!W0P*C#%!MWAUX4\7L";36?PS/#T^!F>*RWYP@S]IK("P]^\9F@T"3_SNC?
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M3P,?;#Y"[0C448'6Y[]HD=X7D!:-ZIGZD-A2(W7JW[080^I"VJJIP'F'VU3
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MM&CD!3RT"9LOH3-#!0XU2G<?=2*W%#V0NVMJE$C/+22%+9L*2"&[S XIF53
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M-3F&"GS'(4Y1@:D<Y(HN>GQ( -E;6T*[+%LXI$,/0*?-*-?5L"AR6#'E*3M
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MR5%;6>+DTY1'--?V"M1F3A&_N-L^].X!W;SRR1"7S&>2.)UVC"(5<#?[.NM
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M02'LZN?B))E%5VDA)0I.#Q83>4F.DV?659#,>F^2TIY&O'D &/=^8866(Z9
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M.DXOBVFHLE;,JD.@7@<>I\?)[:.F9G84NB]:2UE+&&P8K=!<QDZ?Q-VA>3=
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MFMXF0M.O?S-BEK=6VO&]^5ZK[1<9OJ\\H\M&:UC2.E/N9YTH9!].ZW/M:0[
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MEP\.T1^92 ;LZ&QX+/MRFY%#Y,*<Q^J+G#2ER<3G3X[G1$A>O+XM.$*)=TV
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MT/WHB:NWY@16)((!=C&>K$PEP.<MO1GK^+'+M[O%FBT,MBHD&0N^RXR W/8
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MG??6M+_DT[_])TJ$>,(!!/CG>PESE:/<J/L2P[1%G<T]OR*)[<$/:] _4SG
MW*R,DVC_;H9WK 99_=4>B::/@#*/?NQDYI5M;KRT:#@OFY@_X1(WX1@<7>YE
M5'5SOE;D9^GQ+^GP=QZSE[^7JVZ&N2 \C1AOXRCEF.%S]/K!<KO/R]H#4@W#
M@8U&A^@<0)#%PWJ(&LV!8#W6 YI0<=2N+1-=0<=FKMA=7>%&O'46MZ.7&I)O
M7F!OZ]TU>) .SA4/AI)"NK?G(QB31TK2<J+=2G9;QLI8B+Z6O'3Z^'[)C=L'
MMI_]+?^P+5E0N\NXY.W]RC(D\'QI^[CRZZ27#^O%;N"/< !O?*(_6YRZDM?
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M0D795;%>PSQ4)#(H2Q<']MP_<L/E"K!ZF/OXYS5YL!KVYC/KNM_?(0K%CW&
M%=J?4/BX"1*);(1)U_K0(LUH_,Q]Z0NH?9F?UFXQD_'^0;-$O/'LU)N+[PDO
M7S?=0&JV&.C&=FJNW)FSK1J=FW]-9)LU8"I7(Y@ZBG,+E(7MH7': SM5GX0U
M08O]2&]=(Q$'7:B0AN#QG=OC5\LV?C"%*X[DL'"H<0+B*@=P,%LIJ:0?5F!W
MCVSN8:ZI^4&-0H_ ,SE )0&^@4OENPGLL/)US5]=*>.A3_Z*Q-Y&_7(I]A'/
M;SDLX;=KL?_G-,9UNJ!@;Y5489O"\##?@6-S/9U'>#/]B@65 &RW-U&>WCF
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MAY6KR-#8;:AZ%/TF*Q+;U@/NLV:&!D:R>3E J=V<;!!"DSUVBD&2PX\7MG*
M^TAS<)B^Q@$>.M)B6#[0P6K2ES&V54T#;&4<_[%*X_?9UFI/6\\?G5)AY< J
M6EL]C$^['$^+6C^JFEUVQJOI/;^DW.<Y'3" *\0=0$D:I"V "+]OL-_=</Z=
MJ9 JD"DJ;>[%5:6S;&-)O QLM'#6L(40A1,C=GC>S7[]0=[UCO4QZ>RV<N05
MYB56#NRF=RS]G16E*YZ1J!UAFVM7?^Z'U36F^$"M)#6D^<%7Q'6J;?=8C/11
MY7O;>XZLVTW]+'I,A(RF)^*V/H7PNA>\[/RDMW;K_)M1YP=<<L0!G.%?U#B
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MK-WI*XBF/PNP^P00*JV-F0N@",K4SXXK_K%_5I1KBJ?^54NT+)($,!B@6-P
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MLSY%[$JZ-]1'&[L)5])TV T<8$KQGST%T%$7[""OQ1W+)"<B:G_,%V=^+!1
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MIS.&17_^ $ #^[)1P.J?M<*#>MRR(VFF?[69\S>"$J'OIF\"]J8&"RU@TU"
M?" 6#7_'\=-*W_V'8H!_H1@$T(0)>/BO>)XQ1([]U>4L_>VZF#6XMBV<S 9,
M#XDL(TA]T$M+#=0KV;#JR?FM:]XN-;9I"B+XN86S*1444=0LHA,G[^IY=M?9
MJOL3.HDKCW4%X_00@*V2JV9W3P8_RGH,FY^1"20L(+;!P!WJ5T^#;S[7BXW:
MA&'S4"U6X:.Y>??.+'3H=!! .9XO1TW2%YL'#C?FL(0QA5V8!![ > H3E;.P
M0'5C41D"=D6?AFC%!!'@0>J !<#_0H_1FJ[,(W3I*KVH92?OG'/>HS&=U:UV
MO0"WE*3#HD?H>2#\KY,\O_YEHA_CS9?&B DGF*I$_BZ](]L+YXM%3='!(\XS
MLNX9DTQTW&53X',EU2<(Z>IB>9JJU.Z -Y?*\'-A#X+"RB(315>/^_*;(ZH4
MH=BS(W W&2XSIPV43X ?]\$4_\*'F4<I2]TY=J#T#>M328*;2$'#J=#Q&K4@
MWX$O;_#E3@M8]"L7?2?Q$H<ML@Y7Q3^O-JB=4DM &-W:J#8=46>@B!/<]>J,
M +HV ZX(. 9E/AV5TX1@4[U?EX>2 :,K1\'81DT_ W2FS(M!QS;Q']-<QQ;G
MTD-*5W5:<78%J_HF+Y*O"XS1.>H7PJ_D+YTL453L1W8(()N?Q:-C8\AJ"S00
M"0HDQ%'#"5VYQ'$3!YAA!4^NIA;1NFX+(/94#P[!C>NQY5#9',SB@PUW2!N[
MVMA_H8@73:#T!P[$$L8/]@;:]<56.ZC??S/![IW6P>8!TU/=]$H .5I@D;+<
M#;S 2RQM/JD#'IP_6RW*LL#-+"V@<[\3)@]3/\?^>O<*[]^49?S![A6_*\H8
M_K?M7E&2T8,OPUVCR9X,]E YL_#LBR.!U:10Y5=KS6&%*7]UX5[J8O('^(7V
MU75P/FEO=X?^KH*55U95?E)(B.I:XEFGT3_J8LD/=DY4;5BG^U%K&WD&.'/I
M;<9' NL ?8GO,+#:1:@>BVK]FK?JYO0<^0OSEMY:/&(E<I(M@)JHZBP:NEBX
M1P!=OZAH[(U)?SAR\$WTJ</M'P]K+(CJ6D2I#C+I4+ ;,9RG>?SAP@T49M9.
M_B;$32YD.4LK$E_1>-W(4),QLDN\0SZ*(Z96ZCU&O$)A]1,CF9-[U]'&]1&[
M4<!IAUBO]R+:K"/EM 67 KY]I>HJ$E<<N5K7HNAY+KI]>LQ4I>4/<Z"D%O88
M)P/Q9(E9'Z$LJM/V2"W,O:LE<M?+1\5SQNX120,)>X@>8LV-9(M9%L4W,>R#
M=L?M-+O8%RRNI+2H*<C0YM^P4[F)SVS=?5\;MFR6>-OPQ=VJ"%VIA/'SK<<F
MCX,3(SBTU@;,^G4/CA_\#7-S J>+#*EB2YF[:PCK ?[L@ ('?LX1_YKTVU$9
M-\CU^/'M)9X"Z%@DG2_S58C-1*5U,,MP;@W ?,:0,OD\7*9#Z N/?0+SC,EQ
M/Z?\Q6+)]41PEALXZW4L?^[L[%BP+R"=P,*GP% 7B :&\<QF;T3E!P,,5D F
M,'$@%U8 K<<HPK[*"'&M=LB6^P[T> 1A"JW; GJCSS(M8_H2(^O.R2T[&20V
M,62JW.%'J78R68*D8"4/L,0! HN!SV,#LG2UL WCXGN=?-@NG!Q$-AO59XM>
M"XO0?/CR98'O9V&IP_5B "K*C&A]^!X;'@@X]XS)27:]^B-Z/#-T#>NH0@?M
M>D'SNFM?[FW]]#5#Q=!?@2\.H+J0#V+$H'L!,-HPI%[LBXS=U4%B?LU;^B+F
MMH>N:5IY :_#%M4HFLQ_/B@T-),\??8/4SD#)8<>D[2?G,0A$R_!0.QNI6D1
MCG^U08CP0FSO6R>F ]^*340CN#5\OW9XL)#Z@=+L@^UB5A+N"R 'B'\2D@J1
MR?^-YO]9:FOXM_:>*QDS W^:9&?I_%HB+/B;J"4)/7!3V=BX_,NH@\A!UR.*
MS5H7,EY1;W:/]?; U?1!6!'N.P("%2,<R\KY3 1QO,(9H\.3NMNX<+0>#6A9
M]H$B=-7"NX&$ZM(GF(^)+@(0:8T:$@O>_@<B/X>86X 8LVB<4,0]$^M4V8Q<
M\7N\M5AO*C'?<_<1J.L=SKE^H2>7\1V';B*, &3?MIV0!4;XJXS=QQOD9F)>
MW\1* BO1-.7=4N.Y@9X)7+MZ?[%P71N9H4W<L3"J*JWA1^C@P_!O\A=[@C;]
M;LP?*Z0]RCK3M/&[0VZY0^O;S#0KJ4;;S4:,NOVSEQ[1,5*KLMU@KG'#7&I+
MS!GAH?>H&P+$D!H%,!J&[_"8#7(.;IG 0L-A&S;UO8T2R0_Q">0=.FNB4=AX
M/%!O8-^+'UW9!O2=$)]WO]31IDV50[IX"-A@VJ(;4@8"2"$./D=L814R@?C'
MAX//$-<_HIS%N)Z/ES]3V+F<]6G$/R;5]_7]9-7$XT=^W;QF=QVKIXWO+*!P
M^YA<<>JY7\L*>SMDU:"_GS;O&YZM_1&]^ =J@2R.O:6-.V@1AJ,$T'M:@";M
M*_5+:<!50OOQ"93>7!I'&S_0)( 6$%0%G_F\E9#5H,;,;)5I/.EP";NHYN)G
M(U$7W>);MU7:_9RU/HG;6LZGJW'M)M^^W9AH+ F;P/@1$IZER&E_QL;R5NH?
M6M!@O<XTY./'V/Q8!P@)L$#N\#Q<_4F;_,FQC_P6J8OSKEN^'4(/#JD((<]Y
MYZU[W'2_YK^Q6JZUL7-[!CZ7S#I#+$QZR]]O7?0JUC:TPTEON<)V47-#Y];B
M5&W.<V3-H\Z:T\F?BG7#H+%# T7":6>$.TJD31Y=ZNJ0&#AZR-K\B*++2ZE-
MS^YD[.-=&?1Q65'L']K:,_^#[]/1H[L6O'\:D[4\,=1,K#XB^?=:(=3-+>#&
MDIZ5-Z4^WJ.E6N^ ;+':+P)HH [/X]"Z]U4X.Y_'3KTI\=3?_1B"-QS*3E_@
M\4^6!6KDEOVS]'T0P>FW]>&?FO269PSY.&28K7I7$/U@O-MQW.3S7?4?UN03
MR&M, NZ&Q<XF.5S.8O'L=Q1=)FZXF7TL:RDOE+9?8T(.DQ#M[I!W;;)[Y*Y@
MK7O.,=%TW3:5/5OJQ?)(0OP7^<Q8A4J'@[$A>N[+3XL\F:C>?5B^[^X"*;?1
MG>/4X&23.YDD31:M63->6BOE[(^#INL^R3LG,./=&L_\3='.KE;D@L8:ZO,R
M9A3X^;_^/%.Z3@!Y);WC4P=Y FB5,<Z*;/&=,%M^O=*Y' #^(.7]&P][ 71C
MQS3_ H!>,[T91[9.KUT,69K\@9.4MH"VR<[3U;-6\4I\[K.+QA;=Q$@?(FL?
MH?5]SQK-T^SH:H;HD8'S8<$&>C^ZX6OX[63[RK7-J 7R;2:/DX*)TV,1!X(*
M/**/QT*(3_30_20C_C/,$-5J+'CC5E:Z[%;Y<.5^_OVIQ-M^\4)1=U5@!5X
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MM/5;#2HNS.M;P/C$=N'=++48A2V8,VL&_7>-K^9GFL.G<CQX(E6SZ2K,\Z$
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M<>R?U,1!Y'B["39PW!L@7F; C(.SR2#8=.JW,SM7_K[N4X#-"(A.JW+*\5-
M:6'7B.VWAX@5+K\_:"HJ*]K8^";Z"2-ICVJHB*MRK-!!<RN"&7'I,+-(KGP4
M;__R\^CQ^*G<NOGKLE^AZ\\(CQJB@.<$WX#?T5D$K%H<GG1@@-]>X4LRHBN<
MI$WS8209Y?,+:*Y,*=(>-KY\)C_0Q-*9A3V=7KSDADG7.[%CZPW2<1UX*?B=
M\!X00, OG5QTY. ,\']RAY-0T><GHUD-JY@++,.DJ5O,=:;='&D>^##+S!3K
MFR#66 ,I=3T=5WP&J#<K=EX94WYRAFJT8?GB(Z(;JS\^L?.YIVS1[51ABH\
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MHX$YHW_7)L40Q=@YLGUG9ZGK7:&DG:4N1KS.I!PQ)^;N'^%7XK:J6(U[7=*
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M=%AQ^8K[S3B/AH4!YN\D,-3ERH4D?C 6;31:>P5WRZVG<([V\GO^Z#IQ!NA
M;UW/\1^]E\894JWT-DJX=OFR^L8@SQ)-\C&%<D+K<W993<?L(I?9#<>CMNKP
MB>LM-]SLYO9:$(/!WT6/(*GFT0S&+"/Q5 XH#4#NRGVL.8W969:Z;\O53L^
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M>08*D5;R+Y:5[/P6_#D W">%]6N&9D)-1F 2F1?)(V"6!B3L>1(6FH>'2;C
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M*U!S4DW5>XA]*=[$^'G<X?3!LK=??Y?ZXIZ?NU6^.L%/>T -)Q^G]+0A#@S
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MQK9H)&_O@C(]_HS\U[08QM0JO;G?<\Z_O/<'J4?A'O="'HCX#NT WF]ZXH.
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M,N#]@N?J49)LYKJ0ZSK;_&@2-)>B%X8/7VI-7G=5A<V<>W++A$<7X*>;P43
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M*)9\BY)!].X4VM\R#>7UM0TH=O_-L]'!=%NR19\,;*(?&._-Y'9]H!2W[8*
M\SK1-HH5"Q_5NMH"N>9^C4>MIP]S[-A12;3D 5,>F.]$N\.=<,/E\.0^X<K+
MRE&6!NJULO&=VM!\U&&(ORUJ7*7%"<7+DH-=MZ_&X)YX:#5<;+EXSG-E)\-E
M91<TC7(_]05 $79!LHSC0+:TGQHAEU25:E,0*U(AR3GL]6$AF2E,"6A9?<@"
MU4>M\OH$CKF:WE^J??YK*:Z=&&.,I[D 5DA*"B'M;6;9EVB;==%)4'V8MNKV
MQ:C48*CUWG0' 2R*]$$E@ODV2R&"2UOY]XI@_#R*)WH+/%<%*!=A<G[?D;Y]
MXSE6 "_!]LT@=H)A:^Q/@RF-?TN4ZKX\3"I@+)$T?CRGN8RRSL >P,.!.27W
MW+?:X^?4"8I.1DDJ0V_M+IN!/TC??A50>F>TKNC5,9DO65>Z6L:G3W<Q_*C>
M++XK$&+]0.,(,A,]UDD52M"1.]O6>BIJ?]'D '$<%R:)E<1^-0&) WN3SLIU
MH@#]]U0!+C[M,483)NTO K 9!&X#P2ZA\S+>8)2XW9DO=2!)NR#!$+P<0ZNN
MQE1QT/\0\<Q!A2=.^6)S.O ]XHY'0!NA(@\A!:-?K&L<7=;D4J=^O,V+Y8I_
MK*6V8C>F-ZV+;L4G8ML'NW(D#'=!JX_3PY0XL$KEP<C/$LM1GJ1FO!A+MDTN
M,;G,/(*OA+ERT18$2<&M+[V@/[,CG!M 6,U.6@>0!2PP^=#G^D(_"J?[4DU/
M,!S!5589CUO\_>_?T]G(E?)29-VL,8GWU-VIA_(AVE"BID> ^M8Z='S3D6M]
M<K@$=R.?E5NI"IE!77V7R0#=Z6=H/^S5^8L<)D'.+IWUA?.'WVZY-*3W<HS,
M^+_^M(&6 :Q<W78NE@>$%-;IZW!L,PE]$Q-VE<! *(6$'8?7.?ZQ=8P_ZM&E
MU\<@25D'+!"9XV[C^/&.*$\MU^N]KTA99P32R_<2(ETJ-SF4K@CS(^$?KNA^
M/R!);G"\E]I_T?!\4'H0PST1$PGXT;R8:$80)=$9&;L+$FNSF_E.BS)ZU#F<
M=FGZ\7U!0?,"H1&-=$R52BR+<QXRCE#.(>MEQ7A\2HK7C@NJ#W"]_2G F)=2
M2BND',@E@L5\3OJ'JHH/W+)3OU2F'7>^&UP$]YY>_9'8#@8W:>#ASD!EJ54Y
M[/[@BKGW/>WU8R,G2B=\&-1F]/!W%9NA#9,S$U:#!=?]C'2N$=,0BT<HH *A
M5F@&E'(!)0Y3NQ*0A.>]IY2%M_Y6*N +)Q<R,_LX\[6A$8AV?-5EAA5E FY,
M-7:8\&-)V]_K##3/\9G7_FFUL(%N,J3X?=<1BF<KDK$&D9VL2\U'*I^IZRQ2
MLC5>O/8TG/X][CP7Z0-MP4P^QT)\'9T"N8/<!],@FKZDS+E9^U?H\OY^A/"U
MS&9LFE0BO\$!)EM1\R!Q4+YJL&CKV+"<\ZGFWG#/I[)AI'5T3U\"YA-W$M*W
MD6^+6)->+9FKFVL\X7G&N19\FJ1"10]!QBNGJR!R"%%WGZL<4'OS7R[=W=R!
M,R!]@^GUA:N86\@$>37 B/*IIU7^Q+##SK6X*I^46!ZLDK&(G=1&!PAAC^C-
M K T/V9Q%3)!.F':[]3M7=#R=<Y;85[I,9E#18A\UA!4*&0"^L#T]$C#\3=H
M6@>QNCV#[[;EC>*@:>\E:.XN2,[S,6MR2FCL308Y0I#[W"CF!DN#X46!MMH=
M_/X>R+/X$G;6L])2WJNMG[-3E9.Z3K-@%C/X*4JM+)7JD8VH1\;FX2<O*/MB
MC+J2S4E2JPM0*U;7+H@C!"\+X-OQLO" -UH512'J(1NY?--='7U3LC'Z2E--
MJ12]Y5GZ&89MU5"3E@MPS.AZ8Y#I\&&KT!/?SALX^C?6AZ'192?]=7KT0^@\
M3_G]0GBE59L=W4%B'+<<[<^J-G."^$+%YY#BIDIWD'S&PN]@I&MQML_]0$6%
M*1S/@["7!V,,F<'7!QEZ;]R6ZD9:Q\=^6'H]==)WM&?!T!V0%)28J1+K!T18
M@H!L@ZF?8NAGZV@?/CBK!3(/,Q;<IHGOY!#ZQ.%ZS&*$Q$^7LZU+OX\J"/^<
M"&#..!MP)*WP<(5M5A03:EI6$S&\=]W;FO-^C[S_55-IGS,>HYR]+:C*2<'3
M/"DMS!<07QF[Q+P68=M0V-=VV>.W%!&)[+PYLN'"-(H?P"YCVR/A3GBOHZ_7
MQ<X,_@Q"N3#8^AB7"#B:@N'.%&1G]+[OK^DZ 4=[L)T+O^6>6@[D,&5LH8?!
M,;N@0P5 (075EJ^3MF4=??>M_8L/H4<OK@:GLG0X  SU_IP=X$B_#(NZ1'W[
M7&V^SOUMGZ27XN\G['ZGF$-[&_N(&JFG('<S4DPE!^#";R</"G9(\Y=XI?Y!
M[U@+:N8TK=YQHYZ;MFOM2TVYBQ'6T:^^[(TZGIMKLS*]]L:;6F[W$,_# L.5
MAHX.(L +P@M7AQX/<IWL2)*4.FE-C#G)T ?\",@$%CBC;4KR\[4CEYH\01QA
MG%*0?J<">ZN+%T!<I&QW80VR,&6)==B_N+54!E/CBQ/H^LXA)'LQ_NBU^.%P
MK,TV/^T+\X.&L4D8GJ])-"+'A4S0-!FI/3A[YO25&W/IO^H"QE9I=C4464XB
MMEW<[5Q'W6C/F^#'_:ONU@M9T49(!:'^Q2[<P]1Q72(LEIAQ$?;#6_O#-<:G
MT^&'IP4B1_R-.MQE1ZK5RL$7AA6_-'Y2N"!RQIEWQLMI1H5L2PTFJ73V/?*<
MUFNCJY4KG8_*^51[&_K40Y!3DVM+5G"8@V!J2)E+W@7=#DBM2VS'/*@81R5J
MK,Q^@?S8?G[\Y7NIPBYCOBVD/ )_FG$#\(R@#%E0\@LEDG1[0F-?M-/MVPZH
MR,!ZIX E:"$[WS#E]MD%\9M*N #\]NDF9YV5]FUV?;4!L%++FEB,[@" G YH
M1?,O%;:/2R06?![^XZGHOF_F2E(<CZ08JIQS^!]ZM&"[ASO*\B>I%G5GJB-$
MC'V[$^,#NWNM#O::E)+_'!]>"TB%2&P(Q9L>SNXP58B[GG1%D_?P@; ;+[*'
MRD.@0@PD ?_(5+J:"GE8<=@OZHF DT*5%_N9/!M!81O=RNF2X\[7CBATW]8'
M"<X,+<WUC7NWXH49-RGH*P--THM^;Q=%+.EKM7<DP*%V 4MF8!!B/!+?VC<N
MTQX&X86;>(0&B*SZ^52\LC^B]$62J^(BMTG0=W@W)9[DU D>&[)OI"0FAZ@Q
MS[:X6A[65_;:IST1WZNV@:;9,!]O]#TXA&P-(HEGV%-#*8)#A^R>VEWNHWJN
MH:L:SA&@0K"*?F?8PU:C>?,N00/PV=-6<V;@E!I372"#'@2WZ$]/*73S&;?\
M0^H8_7<-:7&5L.7'W'#O!6AEO@!EQEV84I%#>'9-:Z%?V5EVGY4#1!KSVD=:
M+_&DTX7^9=*GSW;3:69<)"F3[BWCT4:0F#W49!Y3E1,3"GWD@FWCS_&'. Q6
M2$_J?'MU.[0S;$LV7Y5SWF;;F];UYYD_4V(;-SRRAB-G[H*4):#D5N1_A@E'
M7&-AD=(,",7)C*J1I)N;Z>56=.0DIWZ;-V<C#-_^4H,(Z< G]0,IA/*$[PW@
M0\?\'@;)^.]_+IN985-$-T1\SV)$4A,*72=/1M[ZXUV.\(N7+<_',85@+CB$
MG<7^Y+2CS"4L*U57#WFL>2A:,FN[>T(-C//6OKCM@CX,L>I0!3 @BUAVJQ[=
M#3[(+HIB&4*%#,/ZH8;H?9-+><-\-8(%\+34F9T7F^(;=LOK=,@8G'M(]Z!6
M9TB>4:W6<PZ92QPQP?CD'=/D'4YJ\^MDZBK;@4D;ZU'\+E8.,ZP$/G7 >@NP
M,6*6'![M3%B!T,W7M1D\,,Q9:F^\/U%#R/541]'@0ZY#-EG:\>G$NDC00^*O
MJ5Y>]8K9:S<?V1K5\KTO+%&F@-"]J"2(. ($]P#013"?^36_R,\I(?O<S[XJ
ME'+0?LRK ';96ATO92=OIHIPPYPVZ,%JQ1NXJ*R%L-DWY^(:-D'"7:N9KG/+
MM?030/CTU1QF)5+:#7B_K1E\WX!3!:(>";YL)L]/U !4+R90VCKT\O>--(#?
M61_.5:AY^-NC9M48CHQL[J6\-51B77@*TB]C7.\"T'CLN>F3 L!EUCN%;/\I
M+1;AZ-#L]2($3(*^,U4'-"D]6)<L/_D3_3>:&LQCU>Y=A;BQ/6<%_?R@SG?N
M"S6#.E$A5975;IGM\7RO8W1B0#?^/%5(9?5_YX.+4N-=]=,U/68^ZF.5P.51
MNA%Z6"CG(D0$<0@H;A[_K75JW:G2QR.X_[1B?21)C -X15=C_<C;!;6!Y:P)
M 5(GMTQEZ[-['M6ND1RL>GDE213TI)NW-<6N,V"?R1_DPZ6O_4[/NO&$*L9*
M<7^4C9\,0:<V:-/WP518XMHPVPZB47DT.?GHN/==!_E$N>TEMB_V).AUK"9A
M/O:UYS8)P2W6=84.FC0__-'<;M_Y168@W21X*!.XQ*U)RGC WGV,1U]2C:D6
MX%4Y";M*N]!I=/Y'_&\&:V/J$5TS8+3-*!5''B$BT_)Y&P"[6X13EA.7<*_I
M:C:CO6*:+7T_-\7I]J_\ZB12-R1UTX[YK%8M 6L\;6K'I^,@9]64;(" :7_1
MJ_[!-@/E9/2S[%\G-E1*[ >0H#U/.$::3MAJ"4CX_-EE?'DD8$ ^I),/9'JI
M[>,F>+2I]G_3#E!]C=&!3!<BJQ$8NA%@]7L_0Z%/$(TNS3P!<A:3%9"E9@GZ
M<*XB90"_%LRA$",,%U!^L[X*XY;!J;5J G"_P/UR2D%._X$_J&OB[E?.02XO
M=YUU.-]+R'X1*#0'S?B,DMP%^46<Q!%?A(=[J&;DJ^\[8WH9%Q9U&W/-5 C9
M8E-6 %@%19 ^A,I%V56K?WK*YQ6H+V"TOJ'#048)0&[@8R"<8@"ZL]SK=G4@
MM4?II/TQ$UN2\H[3O%VBKK^0:_]R=<!!._'>G&"1ZH;'CSTU-V2"%H;DZIS6
MZJG\M%3F:X@?7M@T\ZUMV+A)#SG]-$K9%_G#G7N6I<N48G4W\8P@9%F]+![*
M[<^V[@N?%95/X8[F)O[:H[K/^QN0[C]_RI8:H;8?0M-IB_K.==PW#H(NXD9M
M T])$S4-%N0)#2PYWQ&$"6M"VJY3(X&=K"R;&L'XK_F5'W\CTLW%J1ZGS&-.
MCL_,@,[1])9+Z [S4#!#5U;B6A7UX!L;[X2D Q=/7^/HGWM7((0NI8B2MM)#
M^W[@:3G4OJ3IZMP*N&V@-*Z'6T7AM))4K]_62H,2,:,%$H\PH1Y((Z*37. B
MOM(AM369$[=I?&97631N4J=AD!DXC27*?,Q20PP_K<-VX$59Q%\K&EK-;NHX
M;>^"22N/B(75[XAT5H>[-- V[7^8W@(1'C2_^;;@\/<C6FG;]@D_)Z06H %W
M1FEG/I^^?B<I<[P]UN,:14QU_H"1X]=_4Z<3:;W%Q<ZV!QMGAR_9!K8H.066
M+4?NYYI!W;0-+[E# \E,)$WW75CF9A<)=A/%+6"Q(PV50#6%[BIR?6'=2C].
M-E?BJRLUG8<8 [EZXN4OE.>[SH_0YAR>5+ES[VY(ABB9+!'!8R1:[4> 2H"%
M9(CM@E[!*EIU)/C5A[6UO1^G],?&1/NMO =9.%KP%8("061H'%208478!1U
MC.V"A!O<B/S/"/&V]5I_W':\<[I13!27_X3>'1YUYR;OE\;<&ZFAWOKB0 D1
M,^;G"K30+P#/L6<D/J 35E<%RGI>9H@&?SPO9Z80>8G;81S?#IUP(CD^82=;
M=0'QQJ<,75\]$Y9R%?.H;3Z)E178V)!"X\A:K7(:=C5#!=WI/_<)K,$J[ C8
M-A0?0XWR$A5O+.=S2F=)<PWM\"VR4GYF%Z3.+?[S7T<!7Y;:AA[(#=5-7OER
M?JQ3\\4'V2 S>2GZ65:_J3@@3)"JON 0DN/XY>IU6\>;OXP\5_V78C=^853*
MX!+TRZRQ"\'$)9F%DSKO,,.G!C33VAZ7-KQ;=0_9VLGI$!H?C]8CT2&TT*))
M2XY >/7!VC]B,RSDC$":T&JVS:@RC)FH)EFYJXHB+M=_LRBJ4A;2C.D"]TS%
M0#0PMR 98!%3(?C-X28>AF/=4]KXH/U=B5]'](PLIPTZC7#D0:QTI>$[@9_G
M9?-8SHEDSM)%L$PU,BTR)U%]A8CY0C][0I7KD#F)6ZYT4Z,%2KG2E]ATY-"$
MG^GAQJ%[UWT\UA3<L/VR+Q Z')M.Y'/T,_,H^88CU#?V6/28FK6W)F<.EL].
M<J&%##V-Z)#7 SY.[X)$\7!!(+%XRL[_C8?D/0$M2=*MWH@6#CN$WP8G =7^
MDY.8'Z>["Q(J2^&6PJ<7F_ L#3:*G8B[QI$]W+_O7UMCCG)6]A^&3KFO.M2F
MC^Z7;:@0MB*>%V]G7 *>$] /6"(-5.]'MWG%ZS33C6.&]*5X:E?\J/?H1 DR
M+]T/ED7K:QU_D,?]\)6G,@^5>#KQQ:W(%P)>_;0O RV,:TV?AC%^YN$W#5W-
MMH*>A!A<7I-_X+2Z&H>9N3R(7)J"S$*_^\+47 !O*M:.@DVJZ'P5[7D_WZND
M_^4;:AYSFPIN?YZ1B.%4HI:GYYXITJU^?%S,3/;TY8=W474\Z&P"GD1$MO?-
MHV1PC&,S&)J0T#"R$_H0NK])V2Q/HSW[EMQ(KPCXS#5B[C/*%X'[D_G[$=XP
M.HMWE:K7?"<<2?&VCSUI(]=OD7FL98PS#BDPC.1 R,$=F&6F2EBJ']'QV^<=
M\:INXT ;OD]_&#VY(LCM_E.-UA74C"Z#O+3[U4?S )Z0^GYDD#:_X87+[OEO
MD'VLO$]F*5G)Z\EAE3WCXP&G#?]72W5VCW2Z=-,$5]0FC!*^VO(GGB,_40YR
M/T4W1_2Y"P"[((+E -SBWFO6#^>RE:!O#L*=T59KY.$AR.W5^+R<%J'$QS -
M^^&'KST\OEXY5))EW1D=; 8V_[=FQ7.X$W"3L)J2S]]$"4]Z+7+N?MKL1ZFU
MV?&S&$(>(Y3Y$7,7.GZ.K3N=?B_5SN7Y0\P>D<X_/ELD&=QKYYH>P;I69K<W
MIGJQZ=1X'U<=/G&ENM2X8BYY2J%,N^_;Z: E,]G>W!*&/3/.]%@/H=SE^#WC
M4^%'SJ9):\82@[<JN^:C-E:A7_ \#<'3J"1YG@^XA@-4I+<-9K%0[=F+M:\M
MD;(O<+/%[>")\&G,WGFY'0$L \BO#+JES=C>7TCZV<GK>M]0 -<*X4+ZFEC1
M7(%J9L8;:$H?']Y0\?-9J3,?E6?RISVYJT'1/;N@_>+I.-;AXKA[&E[7"'$[
M S]>$,Q$UK/=-#K[QB&=*)%J25->AJ2HS36L_TE:2Y[!D7L\)U]X!C1:TQWA
M.KN@AZV4G'AC/\KBHJ[>UN/K/8?O#ZPHIA,+"[BS)ZCHS^R2;_7'\U8HA[&N
MO\ AJV#T)P_B%K=R9I?KAGPQ9L%,#KF\3ODTQU[*5K)VR_B#'I/EJ*(OM^A-
M7B_-=D#<HXU-_]:!507]<_/(_8>["OWL+JC[Q"AR*1LY?^P3FF+;_S\'T!?^
M,]/@__D$^C 5.6[Y/WA[[Z@FOVUM-$BOD=X)55!4%!&0DM@ $14L"$H)BDH3
MZ1 @)'2D-P$%)"@B-HST(A!Z*#\(4J63 *)"(*&$%U+X<.]OWWW.[YQSOSON
MN./^L089[YN1A/6N->?SK#GG,W],C-$&$NQJ;B4_*5ZL1Y=BO^$F)SL<)89Q
M]WX=6PFP\(B_<AMDFJ$)O:T,[NV6VK59PI-;*)*DF2KJZ$8[2GKP,RV^&#%U
MOEW[!2]'2-3WA)V:=I@ VMU+% ANT/HXX6CAU.(;RX7OS0_<+@2_A<T]@W U
MB2)&MC!RC+/94],_,PMK$H)O&W>4$?J&!?RB\DFXU_QP,>#(C!3YZ%8H#RF)
MXZ(YB:_0&P2BPKMS(J "K,$]D%"I2P6E(V:QTH;;+X+=-PS-1]L'8FA:95Y[
M=CQ:<-ZT7]LH6PYUBXUI$LG#(1=E88^+5,9%M>0*R+S3#)6/*?]+ZEYTI)H
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MDFB%_R("UH^[K$,VQ=\NB[HQY++_,Y[](V%#TY='.?SX6 PRD%F(!%-$6X>
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M=@5ZA:Z=6<8LP6L.]@G^==CGR?+1&Z">'M]/X/,\OS78B5H3-VG:@] COZV
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MU+[A\]KYY@ \SC$N@1:BP9;^^F*BG-.1=\WLA0<P?[PY/._N&#EJ'AR#5@B
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M*GD)L*0'(17L/!8B FI+M\TR9"S<'ES/YL=SO^(N683S,Q28A4:A]$,,JUK
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MX"10@S@AH\.>\ZELRS62NU?;1(^]K'_Q166YSM0,1<)9,[CI)D@=)I8E\[M
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MZ+XB8_RXT_-8GH1\;LXN\D["!B\1>+D/VYA M\K=8!PE[K=O9<QUBXL#%*Y
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M_;_:N_*H)I)NWX@("A@59(>,XHX081!<@+AA5 81!>/VC XH*"(@,B!"FD5
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MI59UM/KJ2?G@@_4FLU9[,GX!'1@! G(!&"0@^1D.1I8?FJ%0<<5?6^B0(%$
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MU^8=F4W8^*-SBK'$J0*367"85G(8KTXM]FM#QWXV-/$;0R_ZPGI,SZX4)/6
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M7KMFK:I5JW:_++UL K#DI&2E # P (#,ZPOPL@7X*.EA90X *"@ & $  !(
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M"S38$];-WMDS4P*ZLV=]%SHYK 72)$M#ZS9]ZT@)YMCGJ*WLYO6; 5N<\KP
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MT'#4\R"'RX\=4*E(C%8_=M99O=RS&L96\N0NMO]Q8M^H\!@WHQ3@3]9C\P(
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MLFF<E^*@&89=PT"6%\ ,#8BV3S^ZE5;*LX^XMU9EP4X(&4(X,,8;\YI"+9C
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M)[\G;.8:8)UE;$'F/YCI%#_NN^%]R*^+79#)^;@<L\_L&&OH+S%R,4^Z#XW
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MO4=M&UI:QADEZ2YZG*2<_"1:$SNDG/5ZHIK?JO5G)"_P0J:V%%AGW@I)D"?
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MGQY(L(V8Z#AC6:T;1,<B3"KP:8Y6@7E=3T@3!WDW).-]HH>&4/4XW=(4L4D
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M.T"Z#Y*6R-A1'S7.OHOM9(&*'IDZ1IDH3WK08FLNPN3#8^&B2#ZRGEW2]PK
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MW80>D8HR.XEX['E+FDU=*/RF^38:^ 7.ZU3"+_M$/'^#+:F>QO%&A,/8B>A
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M\+@MS(6662=K._-X$W(6TI3_@CS)%XL$R>/XV^HR>[+H70>.U*%*$DT02(Q
M2C%OWKX,49A$M3ES.H])9<V.RR)?3&6,<6=,*NHC,_1KY?34I.!#IG/$T1KV
M^WDD?%V90S<@\19?J<C>XLPK?7+F!<&#YD>3Q:P7_XFM8,&?PV['&4O*9_M^
MQ<9;NS56F!X*&2<@'0<QV9%1^93RQPGUY'+!OP62MM0G+VDT-;_GO;<\'QS
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MNY,<%"*:32G(+B/WOO$EH=J;O; !2@CJ^L"L*2C\PN'M_F,#MQK>#V&*P?,
M42V&R=:D."O2!77KPZB;&+]30]!.W$$SZ0==BA@G2>X1&F;*]ZHFZZ?YX:^
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M<RD!'=WR^-O3M2VL]CV@H!=OV'$/, Q 9U8=Z>/(<WYL!SL(?1$CGUC@/PW
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MHN1RBG+^^%%PKI9'=VTBB5IET^"LJ-*$U;5*75&6D 9/@+#-AX,C$[00:^H
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M(7H'P'2UI#&GI-BO=6^^*KKAEC&=N(I3? DS:CB9S-Y79QL8559HOEG=FH4
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M;CWZ@'FB%I+#B"/I,3'Y<,-=9:8E'=16/I1OR-F$:YC-J&T[YVY0H<[O#>:
M@A@7G&MZN 'E+?2*.@1_)Q/;]MG''P+J'-:QYCW;.;Q,6[U';O2X5CAKWP<6
M57P5-P$85/2# 4KOF[R<\%4X2[J1\H*E%?]*KYQ[J7I7_;#OZ*._OE^E[UNP
M&2OB)-X_CV]US4R!:LC/5M_QE]1)S>X)?2JV^">$(_/!+"3G>/<ZEG/XKH&;
MPM#PD!:W:7$3E\U$)DO-TC;\?6>Z6)'SE('GF$E: ?NW?SRWQNZ78TYW$SMS
M[1ML'<O=:K?4O*W>>'=>"(5@._SL)2H1_R7T#.PQ^-<![ES!P(-#/OR7A\]0
M1OQBV*U5L'T3_]4SP*#^=V][AT(V*?P=?VNX_X[CSC@\V*H1Z]2E-I'JG@LR
M4,4P@><_>5R/U1;.A,L!8OX48=FV0R@IS796<T5'Z"AF&U%\F&F^W!HG]AT*
MO^EC?:++X_ZSC(6H>09@HN0@ ]"(QZ<*/YJ%8T=E5P,8#R$Z$(VA8&'"%#4,
M--?J+ 0C^[U\2NL#!+^3)A3KC@9:P'WH5'<RK*NK03&#HLLE5@)&CD:@N+UN
MQ&6*DF#)[(H)>QC+1H+*"Q%HOPE=F6 ]7!B(^SEN4(PS/:=[I^FGX6]K[!^)
MLF +M[Z33[TMTX-);ZD&ORN5?L#\S*9U&RW]K7QLCT;=W^>;E_HK:6(3E+26
M>5/<)3WY.>9<<G\,_=>OT'RCO!ZK]%NKJ85I021WG->)MTWCC'-I@LX[(7B[
MEEI8L@:/6(YF"XI;IZ$5"8IE;FI*Q6.-.7UMJSB\-26UN^D?_/GP26(A4!AQ
MU@_Q;TTPW9T[W3GGJ$D)5M"B>I<M-)8ZKKDN"(-^*Y""2'!NJ5OU>S,OKI*?
M"4:&O7-_)TY>\9:JK<_RW.-LM@&L_YG[=.EBW:( 2ET78S$OH5M9W!'<\!YQ
MOI4^> _W30<HR@-<V5<O>U%ZP70HWU@N3I8-KI/S:FMF93.5Z5)IRLTN"EAO
MA/2;0,URE+^(3>M"4K;+Q0"%[(=U,X@>$Z;;PMM6HZ$%*3PC*"I<$]W4T-2X
M8=GOB&\\PMKR';/@ZDC^5XGR.PB0K1*4?ODN,7Y64XV[JW%K31[<\QJ97O >
ML=N(*W!>K>E$]4$S/UOI1?TPO#,QO9#R2O(M3"BMU&!UDL-MTO4S4[.N*W4M
M8GRT)+ Q#Y[6=U/'$_; 5':@;8*2^BL/PS\OJ<WG3:EMA6)\<5>)<K?;G=B$
MQR_T8JP=<E;;Y^@J0XQJ:V@&_%PKT>7F3H$K YOAO"F%+NQ%AW^-2BUCZD@=
MF-J/KJ%76=$2O*6^P0&8F>/TC,*OQUK'O43[7VA.]DW3;R[ZQ BP7@ZW+GJ2
MVP@=O9?X)<!P\J['JGW$+*K6?SY8NA4B@5%J8.#H/2Q>=4M+0;GA]+%R(OKF
M5!2C,+Y<LG'(;VVX GFD%@G_&&L_U%U3> J+^&(;SX:'@Q<WI72C<J8A\"F_
MUJ-+IZ7\Y,%P:Z[B,.5!-66AJ\2 H9D[RV88!ZN"?@_E_VH=T1/Q0Z5BHMQD
MC4;'"4RA@,4K_SM5VYSC!<7M;TQ%?C/W'IY%O6> "F(O=M[0\>:#_%+ZV >?
MU_=I[O'(AZ"C.8$--#-?_P_ZX+M/9VYN4F-RH]]#>3^CW23RQ^>EI!G".+KG
MIPY]A\B-VQ?7 SD0N\TU0[4U&]=.+>C!GT?&;4P /_"[7=4"(*GK^QV]$5V:
MS"F6$JUZ=^&9?.:C;KNUJAF$!0;E5(W&ZUR-R-*P4B6GGW(-:PK\4C1A%H.9
M(Z;M8_ 6L46NDA\J<*#>M):2ZT$,NJ[0NCYCT!]DRHCH=+-=5#'<>QLH3Y#C
M[K)G56MT)"Q&D%;B.UE<2*_)6??=C"O6567SV]7(A*$^[:OY!]TR<\=@QH4T
M\!-%(E.BR''Q!5X$A7>]EW7_8=G7.=(UA:T:!KWVQL5FRXZ[26PEKGN=3VC;
M-KKAW^(]64AWG@&D@3YE&^I8H5VR0639/R8(\[W<M1_Z*=O1QHBJ0B;^(\SV
MMX/&<Q0?GI?ZM>7$LF=R+",&W0^%&@Z@'R/5WD8D<S2^!3B+Z(P4W?E,L1_1
MA;E2&=*W6'P:J/Q&DBH4;U%P=3M=XBL^X)_PU;=(N;<W%^RM$-C,I&=H^SV"
M0 8M4>N*AI#TC@F!KVW59'#C3#2,>=:=4$1Q<U5+?9W$EM0=I,DO4+E#7IK4
M<_(_BZ]>9NG-RI!&ES381J0\'!+9=!DW:/;&%Z*;ROCB]'+90*GC/[Q&XW8=
MG .*0 2FM.'_.E3IE,.< C.EO ?WT#?&:<T)BC"V=+1DRP\)\+,J*>GVZ^G(
MDA;BV2VX__'BL.%NN#*%?+XPW_7U>O>G.ACO&= O*H7M"X%G#65+.SP#$C"/
M].H1JZ[RQ:OF%=+ GG!>=)UWEE%J(G_=I7<JY%/'%^ZO/G-P< A4407QJ[4D
M3DW-"L:26\I2:P]_?14="_@,L #P8!C7UG+#8K-;.&%,M ;%Z5]:XO4U%V+S
MI3Y;_(IEWTEX^?_9.=VGF6=(OPBQG4Z0PGWLZ6$(=$(*1P6/;$[ZW)L?ZS\#
MG)K2)N\_#VJ^/;7*+C4=+WZ8B;?*H];?0)CQ)7!P65$V:KL7SW:JGAXIK-TR
M4%:LLR0]K;=XWR6=7-Q+&)ARH;A<!$36@CY?_<)^D*U;+GSS:VPKP4R80J^Q
M#9UV<WCAMOU>[VFJE[R'*7BI$".8S9==YFD&T?NM5B!&4&VZ&0J^]FI>P/]3
M-I[Y*>-ZZ"(P>GF?S[=N=M(=ZK1&HM788CH[#>*PY\,T3 [E\SW2C*F?K[1H
M6))S:.M?8\XO%#:;6AO -:1+#D$HH3T#R*9AY,^ \NZZI[1%[@>BUB<9.M+>
MHQO59\!?+J>-WLV<PL9GP-#T\C.@;YUOYHG+7GI).*>V"/UZYK$2>O0GYAUT
M,M?01OOK,/G7$\-"A#KW\@K\[?%C<:!,,ZK]1XBE6LV:@8JM%,3):[<85\0C
MU\$&-_SHYK>&[YFYS9!H#_&OJ<=\@QX?I<Q9S9QI,U.O5F.SM?\JANYS?"14
M]YYTN9V> 69VSP!M2.TSX/K;8_T3X\2]_"0"]UH'P105+>%19KM^]KDSS#J%
M$9O6'L8$,X!' XG5!')];+P1Y%>-P?_\6/CTR@IT+UL;5@A@JH\_-'=JWNJM
MSYFCL[L(GGEJ.WD&Z"<^ WQRD,^ ..E&T(DZ@N&Z>C'$H7 Y5ZD9&9048]V6
M<SJL'R\65(?O@5??E=S(H"HQNOYVE0 -CS#7G[3ACR(#_DD9CJJ(P8<*U;_7
ML4_'4'_!A]J-9"GK_,X\_9%G . ?L!6;0>'!/$CS$>YH,<64+4FI 94Z@3AI
M)ILV.9ES?J S&A8C88Z[9$* TK&.QS, '8($-2?%AES^USP2J(T"/@,P\![K
M'X2Y(WK>V7?H#SP#<%;DF3:6?K7IY^JVQ^#*XE4VCB]=O-Q4_J)PORW.%GM]
MMLRR63B\$?4,J!])?,(+E$?4SSPHN-$VTF83KG#LO54)<8C^-XRA3T4'PL9]
M&N(M+J=H0=]U##_:?ZY2^/3Y)\LKDXH/AQV!FIWJRT;'](6"5TOP9\!FTF(R
MR_$!+'='ACEW2)^WT2JU?FF9E.*::R/?S_R$WP'T[_(86BA)ZE&*X,EBE6<
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MY@QU-3@-50JUF_E[2+ZE]-N]=L@^U[HNS9#/>;^M#I-/"9$FO_<V<IO?HI+
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M30-JQ[X)H/U,OD6- 0[0K!RB^$6XYB]2-6?L=WODY&*Q#TL(KK^ -$VDX5_
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MT;(WW@"*1<R.J>/>AXX5Q#ZJ_0P[K__9TML.PKM! ]R#*$:1VYA&0ZWQ&16
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MQBN?DQ,CDD(*7/HM:^WP;I@9(%01QLP@#!;)D- P01R\Q)I@47(;WT)&6%L
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MJ)V?2N:9&AE2LN0KMRJ3B4C/2,O2?STN@,JSM%_@89Y)G7%FH^LMT8UF#/R
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M"GLS&QUZ5;]P1HOFKGB+.J%(:&^W_(U%W'77:"CWX]\#1PLR:O=Z6>:>A1?
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M6:5U^,.IVTK,3]YD[\UP0YI@,EPQ:)J9[.2B[^E-[-."]L M&FK*>@N";,5
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MR*F/B*[8BH.V\#HHL=I$X_<$E1D5BA= ^[ H3%S*]:L,.:R]G-]Y'RCJ_@(
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M_R@X5B ^I@7#"ZU!2EM=W56T4N.Z;9&5UJUQ*A\NR*TA6 "RY1 ZCCQRH9P
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MEA%37O/,.#LA7:8#>I.,H/#B\:;-B4K>=S4!SG+_/G&GGG%6"CS[G^^_RXW
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M+*GGL,??\W$C=1O##MUX[NN(V = P(;?XQ!BGLWJ-:KLWXWG<;),/:220@5
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M^*?+DO'MI\ KWX%[_E5%/^?P#A:?A/Y[IK8_]!/B#MSH7M(:]@'B$(S7@*&
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M6]\W+LR_X)T7@#Y?3SFO1O QD0K>E9YKK? O6%%OO>>&FGJFAJ<D3:OH?WF
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MJP2P[2C% V^3 &RA:Z*DS6< ]<2VS]"H /!E/N996,:>MM;XV&I0D? @Z="
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M-]NG'.R3Q;$4=:$Q CJCD :*!CQIB@M(@A\-T(BF=@'V0+292O0[*>@QC4N
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M-P1L[/U9#?7@C9.X\KG5<TXJJ#H0:$OG]B-7V[97'3["47(PB7#EKXK9HUG
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M9QI,'70=7-+;%V-/,]/6,L: 8$P754SO '68*B/6O)?77A"];TH\-7L&=$F
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M2CW^W3)]O\E)(Y%TD*O3PY2:)P$L1/O!U68:*U6QID_]]>%OQ5)W[83QG[?
M)0-6_3TAV8+^IB1_0;FEK>1D3P#+D17>57ZU*I@BQ@;6Z(MN&BR//(Z%1I8Z
M<F)[WE7%!7INBR2G)2HQ^D@9_RYJ_YE^J+->@YZ^E,:)3[Z-JA"MB.(VNT>K
MTC[\2RR2Z!6HXEI];HPWZ$*11(Q]A,J?U'QXP[(DZ%IV7!^%'>/2>-< FF[K
MH:"("0:5ALYE8WH8340A\!*)UTV> $[+!KU9;J9<B%2_Y-31W)B\'!O1 [$:
M1QK< 8GZ/4VIR4)I8GT<K\^=T%"+2 0YI_>&0#H%9G##$.F_1RET[J9IE.Y\
M6U1T/<%6-<Q?._7\S8=--2Q9H;TU@CF"XMRNG,%Y1HH!5JQ!0H\>*8]9?V !
M*+S/A JETN-2/4#Z!%C,X8]Z%KG!CW-/$% CD:GCX3[E]C<.H=[W((-P"1-2
M?;ZKVZ"JMJ8(A<=_M]HJNX: A28)UD&?/D;U9=G7-C7AO?G-P,6@ 19&4EQ.
M<%RPC4?W6D0'_!R4XIN&.0QX"[]D:?72M9UX*(W? A-I7)+._-CRM;&&\E?2
M< :$%X!FM*>:XJI?3@"FAVLI:GY[N$4ZONYBQ\'(<:J)0D1%>06J*#>^=?4O
M;M*WSIJ7?\;B_#(U!U Y1'\^J6$<!6X*?"EE7EH_9=G4!OW&)306*3(J/-,4
M8K%"*[!6=9@UYIW%LE9P9>EN(K1,U?IQ("DUG9+>YM3R3.B"O]]]Y#PAOEQT
ML62":F/NJK)XWV/_=LV 9;76G=B.H44KQVQ;2YH>;2S-B!9_ BC.7+ZJ5]8X
M_D98C$4AP&;B \"2I;@N%\SUAO?3OI[[!?.:X9[_D+R"S/SR?O!/"*$2M1?U
M'3 ,76BX((@GQ=9]BQEY<N)0^"YE[!3,AR<_8(RD_ 20YU4PN$!.=:AY.T15
MK8B)TQ:6@"3ZVM3#'&$TNT7B8Q^B65)M,R:'.370-!-\RQUN"[2LM0L7($](
MK&XMDY+[GS[,X7/ELH)(C-1U241#TY!0G&GTX]OVV?!U.8?M$>1[II$4Q;08
M3E[%82F'*O3P)B8ZX_>^CY]3\[B_LKSY.RR^UE#C7VR4@#UFZ_:'IDJ.(SN*
MIM]_6T7"FO(Q0.+&P9O:KK8+P)J:[^+OK<3>X<C';V"8")7<NZ*"JFL,T%J#
M;[\9#%8Z;RLQ5HY1T=<NR0:%@/<Z'$",6_"\-W_,D5TQ3LY-N1^MF)]/\WYY
MU@CH@TCQF<20]_)@HGD&AR%T)/!B$Z//S)X,5GJC@):$HH#TK>10<*!8E:!9
M3LE:L5AQN]"E#.:]2P=LWBE S'N2]7</Y_%8MF48%SP8%5+$L"6Z3<CQJPMY
M58G\CX-GD4<8'#>IZDXI21U%]#4***[9(%.T";:_Y;DEN1D3Q5[FO\XGA&\\
M 2(6JFYSE]F6A>)2=S9U(D]Y;#,RGH4,KOV&0=60&3&2 EL/\H]/ )V6><L%
MP0LP,'"<!/B:62G=0IUMMQL^QJ^N?"96JM&JK6LCN;U\[2T5WM/C8DEN4)#4
ML&=^ +HG\"-KW<@5T9].U7D1WQS<#Q@BFK6A09FH;JJ"_IUQ34"H/MFXL/8R
M?^V0]W\(=&B9"V)=/$"-.VW>R#4ECK>DM ;F^MD@=V'Q<B]SKF.GLCUM#O)[
M*T'5DMB%/83>5<:/I?LFH<+>?!=8L+U-DD2V$,&H-*CS]U?JLPN%*VY4@41G
M$-KBFTLFZR"V 'MD0E3T(YM*V6J*6G:%J3+3EF6JM'LW6!%.IV7BX(,B[YMO
M6_R3G*.*N[2Q\X'*QX?T*)@L;QNT;FRH9F5XM_+L<;8H]B9LIM=GC3M5HRME
M4-%E\Z,/IH1I4H>\!)WR;0 =Y[^R\44&G:K-4Z[)+PWS,"D4+@^G(_?GL-7>
M(>E#K.&=3UZ#XF#VKFC!;%6.#^*DN?WI9^O6@AE4L2E*JVD8V/'6L,G-])
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M$FC-'S!'5 S.WB0B/RB'&"K>A=YDZIG7\H4/^)TD!&X?Z:F_W@#X(KJD&I\
MM&MH*OU&Y'Q:L3K5*,.($I-BRINB#2LW4YU[P0685>4A$$K+,)/_I;'Y![/;
M*.['C3UF/@QZMZ66!LG.*37.92(.9?BTQ3R!+DN6)Z7I:-90VYPGEXA:ZYU7
M3X0%1CIV0C\/!FD7!H>^(A"O?5<K"WUZ5=SJQ*8ZX[(UGS>B.?!FC?>;0V3P
MC_<?1MLQ]PH&!4QE,C97*HK6M=J)F\:KWS=9UJ#!\RH7;3/KW_Y@=O>.=Z3*
M:.AYGX,^TA@^LJQWMF.;B7HG$/)KO^Z1NLTZF\240P1'S1-4HGLE(AL7EE6B
M?;-A@^LMKR.'X[E/<K:0U;E<CO<<"+H&=8'JA*I6PI";C_K$KM8]@][-,A,<
M1V0$'^^KS@MC I;I@'9MIIE69&6E_L>:=)8 [*]B6SL'#@,!6N6=U8C$H[N/
M,Z-DNK9GI,QL_RDE\-K#X:JGL3+J(H:+N>W]:P5USKK>#..BT'SE<^#4T?'I
M_#^*ZYH/2:$M9F"/!4E@>,2/-/DB[UEGE9]GP12@<&UD>OGF$X!(KJ2F@*R0
MWC!&S0W?QG>4UTR4749\#1VZ]<#4A^M2A)88FO?B*-4KCB3U/INA)\H6Q4X%
M.T3E#[CF4]HG'22/"L>]J*BJ*4K*=+LF+W&75Y3"K<S#0K&%6BYP<]Z+%'**
M<.],6U*L[%.R&'=^]9A0%[H@+J7RH';-=J\[IB6?/@FP^3T@-/YCR;/!=9BC
M@%T>*.D6>W88#+#O?(4N+-I?@D>;/0&^>ZFX-/]'[4X^L3]79'/>Z(((G2P%
MQU@RC71$#[92O97&VOJ;))ZG:KX<P%&/DHD[$0JTWE5B3CA_]M$CONX9V ]C
M^="$Y6UJ\7OEDL&SR%(H.J[W5JV4-MGC"@J%AEO/8=!'?.6[5B^VL0-ZV)/'
M^)+X'_.N2] 4[@R=QLZU-L]9U$>I:J6%L#/1*@SQ<NS)Q'IW$7/OUD[!.,IE
MBY:'/+AM7B6$2+PI9"K'.#3A-J9S,?B:-<4^4*TESD6U%51HAZ+=ZF/UUQ?\
MSMVJMWWW(<TGI*"A-C[T7AJV4 P*UVC-99QK/)*E=VRH9=$VNX(P(TLC&EG#
MEK42CDZLFT-U#;_'2 ZSR>V,/E=D/I]=*$)[Z-5UY/SS^S%$\WA 1NGVL-H!
M%ZL94R747\OZV]*+=-X;EJ9&.HV "H1,W]SP35+'!\V(6?GV& $^F%4.;[&+
MU=PAB!U*YMYT,]GU,1$(*A,J!([A,N6\AN^;JJ/S>\1Y8GY9S7(66/2H?9.S
M4!2C'-HC/0ONIPOM6H*T:\R5&H+P&GD_CT57_G7]RT1!,> '^C*8:S7*4L&7
M1L#MFD_BZ4+(FKU93:3>F3B6MZV*[R:](__R[B>A81UUCI\WQ&R.J\9ZFO9@
M-:+_D.I%<@8=R&Q3'A<BTXYVVAR&J12!(JD\HS1K$X=C21E%?](L]CZ+WTC-
M 58/ESH8*)&+N,8P1?%0*WNPI8L=QF^#<[P@:J ['B][I_ ?NBG20<CFA&J1
M:(A7AY5JR?;9=;-PBR; 3#S^!7P+>&^\$0>A5B*KMD.T.%5[#FJ#NG=J1+XE
MPUU'I#@6CKRXL.'E/D4#5($E!,/L?$M_L,5N HDPI,0@29T,(#9]M$^@RV8'
MDVGLMGV&QHJR<;<PBBF\I?,\S)OTV%A4O/-/C:>D<6#@>&+9A2$1M>U5^+'6
M@-3O'[2.3A393"48Q L/2UL(Y'HD5X Q;4$%5DM+3/-.#+, JZM.8&*Q^]OY
M3$1DRF(C57OEJ'^Z+U/6:IZV/D48GF)1PJ_\U%K*@4"Z_QP69\D^ Z_<B#YE
M#]!PU$?VDIRE50Q.66/DY:QDR^YYD[:X3;#)0SR*P)HW#S <\/B1IMCWF>+-
MRSP%VM7#PEF8BA=ARZU2K4\3*Z_5A.S:KQ1>CT%?B$]6G\*,V7,[LA6:Q1>A
MJ_ O;B8B'L'$!QX/F3J(A$Y-["]^0!;V">?="^1P98F9OC$DEF1_/L+L-?1G
M-EB6*?'G7N*8KG5AD0E(0J->93GZS7F_EF.HA3FCLRY&#AE\G7*8=%I?S\[5
MMUE8@Y-UDT;]!T"&5W+;$VY0N-'U'://XM1@5LA.:(_%9!XO@GN^W=T=/'$/
MI>RFP3:8;F:0<\_Q>J>D=O10COZ<P8O&4% Y[G3]CL4QDJ?&%W\%4<S_N?QO
M?036MU$U8Q0@\N>$VYQW!%7[SM_)&Z/V ,MA9M<8E:3&S[%3*3'+5(Y.0&UI
MSS;*D((2O\XPOEFI*96>8Q^'_[S91P.3T%2(=3!7@(:5@T?1K]H.ZUCYL_R[
MB+:]O\#:>TL19,"'>4?!NQW#T0[-RV069TK+S%  \>,4A+5M(<#0#M+SHCHG
MY1/5:1Q5<_K[IGH^,)9J( T.Q)R.3R=1:UWZ_1*(1P=Y^1CE)K)(MOKM)T[:
ML$20Y3#!PQ(R\1EH4F&6(;O7&Y<GTXG2[-LVS!>0Y K8B3)QF#KY E3E].&G
M2MFH?"]13X2/LU=V:)2P$,7IF8VW"!/!3@W\;_ LAA0D^E$,@YZ6G4'MJU%E
MV;Z<ET17DTQ4GK\3(Z?O:.-M2'"QW*\#WOV,6GN1D]]K*[OR/4>R,D,+;!OY
M;T2B+_ZZU% ,"[[V?9/D-R+&?&<>H8KPK>JJ9VU*5V<5G1O+QJX[XOM/QQE,
M"+:N9BZPC=1\1^=OO4"59 @M?'>.4W74^:P4>A:>;D;Q+<_M@9WNF>FAB+";
M<!6-66L+AR.NZJ/*\6L7C#S<"RR85D\6S?"LL_54#:T>KS'-66)\&0.0C4EL
M3^C".9L:==(%95_P]M[5CIFB]V72'.%5FF2:;MN3?Y4 !FG_R.U'I4,M"QP,
M&4.M._&H'647!P=._F(WF:^/EQU(T[2*!] :I7Q_B?=>C!"7*5^Y<DOQQ+GJ
MF$=(0F\[RV.O,13#/'KTO>B_H@TB^_P/[8]_&J$QS!^U ]H!JH4S@ 7)<N;6
M'JW=+'G'F)K])1(PHW<ZZ'-PK_QQBY34(<_F6AV*<>36]C_^).'6<E:F?7'Y
MHG(.PNHD/L^_F(31+1G_P#ZK6W(U[#RM.D*X FYO0Q0>\B5^JJAY.V[OFU>.
M,MD"HK R[=(2/A^[2$07/4/%>UVPL9%.W"NBI*$V" FIEPLJ*MDT!V=?VJ&*
M5<]&[E=#F8J]/="FJK,U6[,6_'*,BG S9GD:5/O.ALU:&S"03$EZU'58:#XK
M!/J),1X?X!>/TJV0M]WK5RJU]!\05ST-A]%@=6S8CE^VXN@*;Q_SFS^(>VC]
M"V+H:/\S6$G]S-J+TT+27=X_*V,S*K&XHXV6?+8JI*Y5U]#,D(GYC!=8NB:$
M0%P/MJD/K-KT9244U>U_56?O_U@;-<+]^1NUTS!-9>@@=T"11O:![VKQ$R 1
MYE,I>)N>,R^_AI#=P3=CK/NZ.#S$A!V^UG'>E\7UD!O7(]0M\(E,BZ+'D98P
M**W4TIUS^:NHYI_!+V8;/);_^;(TDJV?#Y'KKF>HZA#\GO2:_ ;':55^2F#
MCW1G'*]0V7YBY]A0?M[Y7M6A I>40;$0OT4"&O%U%14?'KL58,K6[]#AQ>49
MDRF(D+6\@[F6/KZ8!;IMR5"HE-C''[Z,_J.=6V06C_\L=/:ZFJ)(Y MWH03"
M/$E!39XOT4"J*C!K1DN.9<QOOCR8"]I;29[9#]5:ZA9XG*E(W'78H\,_$-\V
M2%BR'_Y92%^9' H6!S:"+'5;NV:/)#G*/N%G.95Y>;M212]L'Y[ @ (5^ZB:
M I\20Y',MZV+ZY$W;?XVI'"U]EUO!16W'5ZN>S:LS"HC$UD.Q)Y 2!_:<(=B
MPX>TH<9@[>"1O*NI,?OHFO_7]]'X'67^/+&KRH9#BSV-;*5W@RH:.Y'.KI43
MV%"VV-FZK@;HC%7$%A%G)H7D^;A114-*6E&6Y.AF34+%/U:!2C5KNT_+QZD4
M./ @$-SM9EXD/L LX$5-:50C.ORG0LYR#P_G%]=V-[#:S#*R1L1T_K_=0V<9
M2@DO[:YQ6'^BQ'DT"L<08P*$IJ)C+R:)0<^)*!S$K3NX)C/*[&IB]GC7.S">
M?WHN+R\0G\?OT)GRW2)SY/>I93:*+OY>!4_O0/>K4Q-[RL\_0=YK!<W-_I?4
MNH]=OQ3\RVDT>+(PQ(M2MFWHH2O4;N'CGI.V\YJC-/_ .P6 ;N\7-S]<%8R
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MIFT3Y)7=L'"A8,16BO5*,>$SK=D-_&2XP6/42SDV4<SP)/_P8TV<*3YF@'I
ML(#QFXD#4XL"6AU+Y*@*T@2Z.8H)[6K^T7;B>1;TSV:[G)J@ D1M0^,PV_C
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M#%7;\!8S/]U3_A]0$NO4,QG2>W)D'W"FM*&SLS'M^#CQ9T5U.A=T9T)-?*L
M4AM$D"Z>3:X9;[1-^VNO.'#A+"_!E!)$_*A0[?#8=1)\X0#,UVS(0^0J, =F
MVCT6!*595QK\[_T&JN)[_U_T./Q?[XTX\S\XYHN'4I@*!"VSP980H+[IF]!9
M7:HGV#Q-6+'Y V/J]A;8 8P-^N,CW!R,>6_JY6_MA<-4;W%UL/PEW!U)*,_A
M*.E;(>?[JZ/)!M'5>[HL@"A.C'1N5%4WR39%68[51%/B@,64?\4'M%K\M+$
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M!/ <7X3@[>>1(PAU1;$A.^PLT _8ZA!,$<1A8"NS5&_OWD<LQEN6@)\B_P%
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M&;D%BK?3O7[5&":8P#WL+4KY2+B"0B\DH3]M=H%A<AL7^?U7H3F-83@J)4\
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MWO^+-/'_YRGDR_^G7](E<- *)H!T/GA"P*TQXG3G^+(;@"A24A9]P&-F2HT
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M7M@IF&6,:H,W>P?'0OVU,A&5M1Z]>:K?'#0S!UPW=P7E1+%&2P[.\NZ/I=T
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M^D.+';'W^9?C>P$BU>Q.[N?[N:7$%G.X7 E=GC7_X$96]/C]N^(= LBXO@J
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MU?W1U7WOT\]YSCG5W=4/@)[Z@,+ZK&LA^Z%=]=;?MOQZUB=QWS\>3V"(_&7
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MZ2T.Z7E3^U5>+CM<?W@YKI<BL'->+-)E/&)5GC<-2_F]/UR@.&1-@PTV._5
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M0/Z;9U$YY%4(:'"=O4@;J;8YW&RE?L>95O";N_[W'<$_^ 4OWC)U,$(V$QX
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M25/%^5JC4T(8?3*<\/T0Z3>0K0D*1WX':ID?5!E[A[!>CW>AL34,.F\Q2ED
M.(R&W08,<#V&I4=F[E7]^0!P=22?5-D2Z<C42N$1'  DCY:U%^8#"#4E!O[#
MQY^G0?JEX)%)L[_T5@[_?%OL/,JX/SX !DKC[:=R&3IK6HVQXOJT'%%66P^
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MDQOX,L]'EXO#;OU]; ++['-XID_)J82W20;'\)1\J>;E,-R3N/*6E8?'TA\
ML!"95\##?\,3R'#4625('EX1>R P9;!R_&(U/9)C_T^.>0]S;IJO4-ULUL*Q
MOZWCGW1GFARNQ9G=UM+SAA,*X<I+3<$]];0-Q_D3JU3ME@ S]#YL(6H7T=!S
MA@\<W\)PXFTK7+)L??>Q?^$#2R'V26T]5W4)CXO+;Y>\ZIJHCPT-BO'B4_*_
MF/ Y2V@!@$Z,0BW+;_/?;23$N;C^MM"I< W*O#E(,YGH)GIYX*M1'1@CJL>2
M&-I(O[H 7:! X.(%0I\?SE\[5N!U*V"-3PM*GG3=EL+6RA1O\M3,RC.K;L\.
MQ0S)=2?\G8J%'";E>6/#EOQP%KME/N!>T0E]F?6R*(;C:37$!PEIUV7K?YV>
M(#IE]HZ]Z<H1/!F2Z*2BBS/3>JX,GGH = =9T1B;I!D1+WT=(RTU0DH[D^+N
MY*;;0>ND8!,1)SK_G)S\=]1=J/VB4E2<\U6 XIBGW7!E.J_E#GD?VM(<6Z&7
MASU6EUB*!H&,+R)#FCY+8N1($F[,-SZ2X;S7&E!++] _IU_E)^A]&4[<'XA_
M[)?SJULN2/?X],$4;*GU=[!GT]'&17D.<[6YEGJ:5OKVF([G&^57$<ZE^UA7
MT.08Q_KB,87MV=L1Q-QW&=:IPIJIW?K6N4\O"O8\:<;=^)YJ\1&6[5,-4DFP
MR[06]]P)]1H^ $BD)1R@:S?/YU_A(U:3HICC=EXFT)B=2S#2OPD+T.J#X%NL
MKXS\:NLI./*VD$B15S+V>[;:^]'=?PCC#=>W6H1&PQ?IM]("6QJF)TFM)<CI
MDR?,9L$__UAX=L:W'1WEOQY.KD?*Y*18KM6V,/R:<@C(SCZ>'"K= PR64RD^
M  SIY=Y*>?0KBU1/1/;:H^.]6L[ 14VR^,#V$<.9_*3#=^'ZRPELFX,3,Q)4
M&.P_*^O5GS6%GC2;):Z]@T1+D$7D_77:=V3+7CH7C_;R]%,LJ7S/.WH(  L=
M9+A'F0F;O@NVCD5DH6<_F-3T&MB_-_5G;>SGM$\!S0O^(>X7Y ^(WDTQ[1"B
MQK6/(A=MB#MEBB=]P?H]6,]GG\5P-)?:AX=>RECCO'_RYH]P,:-_8I)[HIA.
MKS6]DG@7U "5N&WO[?9\]9"<377=5@[3T7#?I>?U<Z%)<IG0K(71,3?V7II
MH9)QE],GJ5LT?IS:K#2FMH95XKCJ5NMM9F14YFK*+1$M)J?ZX::O")I1<2>G
MY)2C\/05)M9Q8FMQRTR'LXQ=[SAUF&M'N5RAI=F8CUVYJB0E3)_8>%1W;X-S
MF);RO-A58*"IY+@65M1>6'R"UG-=8<G"J!=C%K\&6%M;!RYD_<UA@. XN3C
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M65ZW[RK?@C57:>GE*/NE,HY %# B4@<<&RAJ^P-:8LY$ ?=%]0NTTI5=C"?
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M?9)2$O^FL$=R. 9[R%LJ@(>QI'" 5H(;;RTZ6\ITVK?2XOQ\UE2I"[L[GV7
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M#K7AQ8OP&[V!@]AS\:/$]PA3%/CZO5'M!-/X/,MWTY7LW9['@+6K2.SD!"Y
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M[6:GG;TM38.L@S2 C#:YB?6EMF4F3=A+[;?/'A^&AZG_;%CJ1Q!%UC+@V#>
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MM"? FQBHI-\@])XIF3CN7O=;HVXLH2H[I?B$1<K?W<5X%R+3)V(^7N/"&U3
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M2IX),Y8:]6B*_6FHU 69;W8/A.N:74$8V^?H2&D02Q!%@5[B$FC8_^!KS"5
M6H<@=8Y.4/32A+<Q(7'"> 'CQ/\$B!$#PB\R=C!DJLTL-19L*&T:?+F(NQI]
M8)N7\V-]+6ESNJY&!\Z1^80[=RX@EL<RUIQNWIX^0?LQHMBY)(JB[]=P8?4
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M1O"I0]+KY7U)8'_Q3]K^$9Z9H3J!/1VNN)1-Q<<=_7U52=P9X3\S-HKQB8.
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M>#*<Q#)IFTQ-# -L8EA2G#QB*Y?'%HATF#<VKIV/MY8F.(#3"?] P"R$CE"
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MH2X6]HDI]1#&4CI@"*+!<)R!>QC8/Q$7J+_.^^087R\>$:[IBR>40A$RJ@G
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M!1+@(A\Y/I!!M#S*A@,V]2 Q(*;%9K (%B<4J>L/PIR\]PWJDV"<![.6 C6
MT[_D]\YT%4]M>NO%@G'Y/=9(LN?;/Z>GO1R9FLL;/A<72_F;3R],(2,\M,2>
MUT-;23U:ZW2^:V7F%9"0],\D34&G!O?82!#(!JF'<+P<R*>;+8EV?,T[_BJ&
MR9V2?U%SW!UMQL4\?F6]) 0+W2#(3,I./9$;Y(O$+029ABY\.:L[+;W7:4S1
M9!__1_@ZTV+8A=:C4[-\DX'>_\F0NN%&.[A-2"'803#S+(< X$V7<)+>W+*U
MW73HQT35+ HVAK0D63/W!P4D#=SL)OPQ'PKW"7]?- ,F";1:^+(/GUU;^[C/
M/8$50J00R7) )6MMOAVF-UA%)JIM?[ <9*=7@*SD:8IH494?4Y70K5+_KME:
MB[\+Y'H@RKR)1!;>RQ\&$8",$$(:*A4UU^R*IYP_XF6='; '=H>Q<'*M/0RR
MDKP%_FHK:B@)HW8'B='!/W&M%/33D5X;3<<9[M=5+!^9 A:OCN/$_$7H51Q6
MQ:=>]H-=)DJ^O2#)# ULV3PZ1_ ]82G<JP'+H.NF]%WPI7XS5,5##L'3#FM%
M&^ZB-#3&3#*.VI$I"LOXUR@,^ N#()+PJEQ+'<K*/$HED?M.V8\I2E*^XX'9
M=V<5"Z#*8ZW;R-F_XQK1TQ;N-!/FZ1M$4<:)16R*(U4Z2.E[V4"(Z/F)/Y3O
M7OII0E)XL>8,Q#TS6B[MQ:C*$[*B,5:#X\X87=+K2YS<F,:8&O'FD0MA!P,5
MT$EM9TF^159:WI.6!)7)XIZXYZ*!6^?I0SV^BS,T9DKG1ICC"UPLM#.G+=+V
M8!"<OILOKV@;'X.Q; J=5C8MC<SH; A4_ WQ\G&R0C4QG<B EVWZDM/'(T:%
M7Y0D*N[)93#CQ?-2J$ECM L\/#T-%S28EMWK@SCGP/X(V.#J&%!%E<BAAWKN
M2TFBN!Q:/%/.UX:Q$/']Y ^8W5E*MK\ Y\BWX(!_9(IXK .)P1W-"(R/"[#%
M S@PT7Q4+X8R4[X3FA2Q4M]<6DU:8S$FI?Q(Q]R*@=_CGCIMPY<'Q>7XUY+8
ME2[.TFH?=SN- KB*+'7R4IUD;[,K!1YC36K"UN7;U+HRZ+<5]>;?>RAT!Q('
M]:FUT-&N!"X48!4A';PDVF+*YC@+YS[AH#XV^M_]C',YJ=V9 #"Z.<U[U2$9
M:Z.D@ID63A\"JC9!.OH]"S=W);)6 A<):X)IEPLJN#^U>,P#/?#7:PV-R4+*
MPB&6#<M;=J?ILQH>CE-3?VM(L\]K5W$7?!PXDU8HK5,4<)PYJ@E>$TX, U#F
M4YPN8$^8??]<IVH''_*/+NEV'D_:#&\AO#5,&Z,;[DPA!NC,5N.CJ#)'4VJ*
M[+G?]!^RX'-]O:^EMLNVB,6U8&8QIJR]\%L(/N[ZG:"H3=$;+R+"&5G*>OOP
M*G)\_K-$);9*09BM&_RIA$.>.5^TLDPMHJ/,COT2)%ZET@&JF9=HC1WWO%U=
M/5J]0>MLRF*)E$X'+O/67Z.Y.?H]8".O[Z6 <T^8,_Z%#SZ/>6";\@VDB\J?
MZA8)(8UD.M]4S\H)>GU8!H4,\70&K>"J3J.T67V0<] :A@:<ZZ0.:D8#>I]W
MM>&TDRLX63:A>'E2P])&1C32K9 =._Y:JG^ZG;J\HNJ71Y46[F.>CDZ907L%
M_\Z<406GLTUM9B>^L],E9])L:I!EFU-93O3@'*L[*6*?A$;1^( 663<2%$XK
MB,@[?R!AV6$)KQ-XE G 6YTZ&;1@FJ]QH-!W5F3'M*+<3I''\#3.A+@BF>2B
MX@*I5Y"P';O$ZRZI&,J]3K,L"_M-=K&8WZ+%3Y;-<R/A23P9UJ,C-$)T5(]A
M5P5TP* G+,P=,WS0Y^Y4381\:IFCKEZ;9D/R@9,K/6.F[QYDJ+(O)P.-:%3@
MVE=0.E.C?Y^W?R==CU)3U4-X9<.)=*USINIPKB/W@!GFY:S^1RWV7=T@WH__
MG57[_QS4Y[G'AUJ&'84P6V38MK-5GYN37@]-JFYPOP"NH"SN7L.(&-3]UBC>
M[O>2JZDOPFI'-P;N#YWJ1@@-9-R2&=I%U4Q.( S9^,]"0J%HB;%JZMXD"Z$Z
M)O9LV%N=;357#Q]OYA\.D$O;80&(I>WSD_Y )N2!8D\G?/U(P G7Z&1G=R7&
M6,6[&%7\XI4^J>ZZI'$%!D//,R JT*GWRFV+( CN\@R F;@.%:Q$]0>UMA9L
MX\?.(IN,X=W%AM9D?[VZZ]+JZ-;274AUIQY37[)5?^X--\]%-?YJ!E>?)NBC
MA."?$B'PA'];Z'@9  #> (' $A6I,FJ)=QRNC;E:6G%ED^>>2FW^WDYR/QNB
MF.MDK]@A?[7L#?%R?DJL+YV6K<FZN+A0@>;(O[%D,?CX#.G?,BYV6P.#5 +P
MI>>^*KGLS].IMT9NU/YWY_NWMRGR9^<)$_XI3J:]+)7GS.>>/]@G [GYN"!F
MKWEIBHVH:244ZD@.=2YO3]7+54H"I_-%YLW3((R4_MQN;MKGIIXZ44^, 9]K
M7HFH\9@82N71.-U[+-[<L#M'LI>9"1B_N)/'*PJ+W\7+U6L!6CX#Y"GSH\K,
MQ%M]_M8T/P.<4L1)0TB*4()7?[52,0 21;WKN.!R$:5EY<9F6QO\OT\V.J8W
MIU$2U8VO_F)=)45Y"[+L.*V+CP=R<GJ_L\0F3K7X<B!F?2<_>+0.*PF,">_\
M=-6>SJ2R[*6P28=UT!W 91#!X)VCFO69UJ34@""9BD/O5>"MQ5S8E-,?"4P7
M,_7$?1B]PA&>1-58#_8:[V%GWESC-*JQY49FP<:)\3GU!9W;Z&F(Z>SWMQIY
M/_ST1JV.WMMY7E)H@18)=\76&N,C 4\"=R6(.O6E:M"7UDYN.MM.5\%/!'EC
M2I;8U*@M3E<],A] U*'<[)=V-R&9ALV(Q"CFY"]+OTTV1ZFCJ7\X-V0 VG%#
M\L&Z*T8G?D#!EIBKX9-G@+OXT^OL_:--Q?U8GXN'V9)L0K5%CN^F'Z:$)1?.
M<88$#@\(+NZ<+G+S?5Q<,VD:E@00SX!P<?<JH.B)_F"9HG,+HRQI_BW&"_OA
M\YL.8W((-Y8,C.2/8>_08&*_P9M&GAIP'/&P)%")W)J=>69H%D^]Q50,4V3L
ME-KKCQ G_D=DB,^NO9ZHJ&ASF]78&P_ %'F*Z L\C.Y ]P?C'-6\:K"8\X&2
ME\U[6NNWL;F@8  W  .#@87.\+:7!*0!WXQNR^CLZ< ^ROYJ96T)U9XZ4CN%
ML7C$N^=>9M^M07G"!BA;FV"3FJPN9AH=*]2.Q3+Z8FAK\SPH[L$BNTMUJ;,W
M[H[R,^$50P<I#_+P>1]=W=4)00<;WZ!763-"O&EX,Y$LC*CIA]\"&K2? ;:3
M/B9PGZ2R#@+^16;>]\1@Q^+<4[$<5 DWONF2 '>K4@=:UI[N&6>+%\M#(^5'
M*"C!?\H*1T=N]\%1ZG"A"!"%72W0WX!GRYC_OC!6I<%Q_$801/HMZCW,[<X]
M]W:_[J@U)^4H,$HAC@34 647ZS(P_INJU8[ C[FB$3*#=X\9CDIEHWD4\5E8
MVS FA\R[)R[T ;,AGUW)#ELS78E?;Z@SZI$5GVL1DW_5K%32Y5#<Q?O9!,:
MF<A@6L)M!KLG\_4F$EP,DG]&YY[)_++F,9<FGW):V(V3 RO9M;:TI6"$4%?G
M&(\S*WDG1]\Q,5"@$<WEI^<4S_U^.$M-%^W\XB9$2SG/6>="/_?SW@8\),?'
M2B78\+@)S86Y6DRZ4Y)![C=\!N/V1^1V?U0WCE)H8U6J7:/AX+UX6!$9O:JS
MG7G?HN7U6%!B\)AH67WX*F<B :;)K?\2A2<YLF](%6A3%P]VWL&G4RE1>;E?
M4+09&>$"R_C$*K?17(]%Q>3>QA!6X.A2W4,Z[8,OO%A>QOS%:?7]]R7WGT9R
M'-DT\P6V[_7#(C5L9(I9-XF]#F,/,V!*+:V-X)8N__)K9OJ]9,'*B>+R3Z('
M5-('931.P^*R1<"CK4'2)<%Q/H=.S^ZNEQSU)++QQ'1<#/$WQZ9I:)W:1/JF
M!N0_P"L4\:V7=-^['G;)J12'A(_S6XIMH95V,S#N>6V=:E^, 3,<I,*.=R&U
MAK%BXW);]A&TX9VIP@9J;XE[YX/W#6GG1U&)EG6]UC96!N91K(0H>C5YK%L
M]?:EF<K*(2FE60R'K9%V.(=6E&V\,^D0"V8[C JRNWTYV\C1 JFL7GV?\E[
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M4,8S(2%ISU3DQY&="H(Y!VK4A3D<?04,4W";FA571%H2*.]1<4B:>XC0',]
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MR&"=*IN3W2#60?+[.B9NWLEL<?H?A[B3@_;,['Y@E<A9' C'W\RO0+*+L#%
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M$N_] 9=CROM;K?D&YRF2U6[KAFC%X3*Z/::V%XMHW$!HV]@3(#KP59KN'-U
MAGN&5XI][N>XD5U4KN]DIJ?411,3(1MBBVG>W=NXVI1N&W;'5_&F\#%<EV&O
M+Y\#R9Q^T-]>5=2HV;3*ZS%_-';3 B+<A3KMWL\%TMJJ>>=+<N.8;A;@&_6N
M\GBE4ASG2#VPSV\A8VW\\D>*D46]/QI#,8VMOG$.R9D"H::FRZO= G(?M)QP
MO;?O=&8<[MD1V*PJ.1L<[8;F%6S+3MN,SX5'J-T,@\ =K[?$Z51BC7Z=FG=%
M_DY)$K4AWO&/@Y<%JK<#%[,H3U,R6B_&GK-=_I0CJN1?4:M'%G_.&Q'(W&1V
MRK&7'VXE=U4L2_=!39Z=:;^YMR!M-_-@FEN8D;8G,>=^T\I3JT:,S]WBB)8X
M)'I5G5,P=U*L>W$G7W!NOQA-Q/(G]BW&64B$.7WP@,NA<4[&R>!4Q(5J%/3-
M2#%Z2Y)2>A75U%*?H!-WP;L8HV#-RUZ4EH!\)^E?$SRXG+2TT^7C)_<$VPZ\
M/=<ZM*24R4=M$SMC>+M?)9L>];/KWL>18"8^"RCVY&W>.S.Z3H!$N7^1B]F>
M(5.KG:-_35W#%KT,>_7!?EPMOA"3D5;^R&Z7!D=Q;J_!0%EBV^ B\G1W<[5R
M:+,=.^=+,2K@XK+:%]X]<$: #&3OC@H4J#<RD6\)XT5QJ9-E^^""CO_650F7
MNF:*AKUX1931'Q_XQB6Y7$7T42[B(%!H1@)8<6L%KE[795J%F;+Q#H6Y_L $
M/-<E4L6@N=,^Z]T@0G+)(L1/IJ)."D6,OWFMJ@(%2(#VP>CW-0"!^[#A&S=C
MV-\4*^0)\(Q?G$MW[I%(U==#"=/($JREJV.'B_>C+R*-8Q*+?,*_>WLJXC8J
MRI__>>&,G.5MAB*P&6Q]Q9M[6B/JO%L/7NZM-L[V5A0PR-(\^I5VFKK?A$S8
M+,JM6++K$K8;<>1;K2A%D:>8KOE"S"GHN@'"BZ/M+.^5 "#;C>%R WY<)TK#
MG(ZG7'B%)W'TT=L)IZ0L.%16?F;[I@*Y]A<;  >Q#QM$%W\UY/K: X==2?AS
MRE7SLB/-BLL:R^J-M,.D;Y5X^>&+.PYO]JVH 2P)QN-=O*XL2OF*N0'U JJ:
M%L#Y0 D&'=?'1,-YDF3KF.^[=*M*%GDW-(*Q06;5^-YA&IT(U> S\YGJRV!'
M+>;L!3Z?8"]+UHK[UA$*>JN0..QZN-65<4*O;_9&C+]7$'JSGR6Y ;VIF>ZV
MT7%O/%8_4:#]G9MQ3C<-7WLE-H4C7_B,Z1XKI6&X&@\Z&;:%$$7?BYQY6-M4
M7(?D(TO,[97\J;_(]/FO<I^B=P8O;@S2(Z=2'D]<U.(M5R]J-Q?'V>?B2L43
M@,A.A,X U&&H6'RPAM#NW?7O:^Q\(95:&,C#*UAH4G0O66;.7^$AUH8:0?4%
MI2)2CSH/Y3CGRZ@*+UCS"<!V04>HBW32F^.X)/O#Y62VPE\F+TDHYNW0J^=:
M^0J2/LQ8<A@#^X' ]H9>V%#Z!0WTS6#1J;6T:?N8Q3.QH7WZS>@:;"9F!5_G
M)TGX.?;V8HW\7<R\H\]C?8%MLS%PEN^$5HBYNRO<8/P/_4JZ%U ^1.<9?. <
M,$SM43W='=SFWZ8(/?R8/:/'\ X"UN=NR!$Z$M7I?22<YE?%&_0J.]!)>W7)
MS=!0"TJA_DF8:D-,%0(=.+<[(PB.6':@E%T?XANS$A;:V>L8EVX]W'/0YSX*
MN/Q?;TPV&\9FS0O^?R7GN6 Z;+Z-O\V]%+Q<MRM3N1Z!IC[(-(!=^<946$--
M4Q"#";#?Z-M(TD5%+,(/U$]NR)M5K=?_R1] 0(-$A;LI(I_!DZ60<GFVQ+:I
M^@30CO;,"*U4U4;#,=>54/]\O->H-,'5IGDQWAU:BI=6QN4=!2M.[8XG#YLI
M#1)RR)$[!J09C 5"]\S?==[C> *D!L=MTNBUP9;]-6E?];B4)_NYQ='I&ZQ9
MQ>XXAK42X9/M>W$X4\X^A#UME')V$QHC)?-2!] 7P_H#Y?^A$#S-_]?+9/]]
M2*<:XZ'HY%,7$@^FI/0]#J'TJ3?1+95J,21.IT,G-'#VMA(<!2<8@C854HW9
M.7R:8AB0=!4LV?QJEX]SK^M;/3[:W,ON">(2H]OB8(/(QJJDC>I^BJ-?#14
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M06R@_X!IRTM1KI9IBX;4X?OUV0:CS]4:^_JSJ5;AN6QJ_;ZO:3#0_FQDY Y
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M]YX]^YY[S[[FFNQ09ZDK $ZCNX9W 71T ( ![06@H@ W]<">;@" B0G@&@
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M/D _Z#RH9N85T$WNI:UJ5RK35IWM&K*RVJ_,N\E=_E@)N3"R(16?F?'&\FQ
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M#QUIY247AD3RFS6-06QDSK04GQ*MU<<31%!:0^/7(%]>JIP_F%#>+@"T*GL
M:T0[%J71];'>OL&+FE81F2EL0_F!;SWSF1;7J^$R+Y-$LHXUB0ZP ;E6]D@M
M52J@=.[W#A5 N (BY=;32//OUG(JH(SE=X$F*DF"/=UFV_/@RWXLC2$$!1_[
MJEGZAN[K',%'@$@V"JLQ5FG%.N$ZY(P7XW)2")%)8;&W]$U,[=<O_F/&FM]$
MGA8T?X+7K"E8,5C_LHB]VGYV^N+*JAK0B&) X02G=@"K1S!BGX:()F )DI-(
MAO)B"3GKI^>-M"4!.J)UAO\=BWR6!VO2S$MG;^=!A?SS^17!"3_>-!"OEG[D
M=Y=>AF<A>']-/4M1J2+288\HK*M8Z2YD=VO&JA_'=BM7"@H?6=7<-&]3/5:B
MP)O)$1)?M9SB=6@^@!\QKZZ?#-X:WY[>5LX6>/(8UR_T?&"[\V+YJ=-B4=+8
M";3[2\1C*F#>UH_#CB2*2TG#YG2G&?7?4/*\W T7RW1R\HB>G^^7AWB[I+V)
MLLY7.,IY5=EL2F2G=(WWNW^ZM1II@3JLD6_7GN3PY,$M;+-P2]_),!BXG/ X
MFCOHFXA2PD3"CR Y/PY3N3*-AYO7K8V>.CADF#^=;FELF9YVNA\X?5*TJR&]
M*C<;@<_! 3$FV'H;W&;"G[?:(K]-IMTFS*7%+B47I2"7'O?^=-.,?Y/RHXUW
M1827W*(5":<@,R@_PT0N3(B-79ZN%99W_/@6<U=3K30$PC_7D.0,O*ZN!L].
M97)>A-P7U@MZ<-]BRB,;O[=_ U_U/7)D<D!Z?Q,_26YI=B?*DIZ,MHIZY%^8
M.(R4?C N6VL<7\F.\ "I;*.9#3HTRE@ TOF;&0G',QT@K(4<T@MMFA3"QG$*
MHC(V;R0(+?EBJ^>?DPR<"Y[-#[L2DF5N=8GAL;A7KL#-/W +.E2EUZN.7H'3
MW1;IC;Z&'L9PGAWH+S-0/O!;&:;Z,W0*CJ[@[T::9,=7>IQ:0I__BKR=@31I
M$,")*?P,! B]<YI9:I[')Y,1)!CV )]12\[7X0 [W\,)_TEU<A;/25;9PTBC
M3\=#RLRJS V.SJ4+A3ZS9E<[IYBM4^K0UU+,KS3U2%HR N-CYCBMLJ'=B=;'
M;&(W4048%D^BQM,ET2G?VJ;!(<5^WQ7.R$R=3Y<5JA:O0N3R5"$-*ZO*1]I0
M2<HH\ ))#@6?']0G1'PF7</V-'SI_T+P/0=WT%68Y#-.\ZE[>-FDZ>."5G-T
M<I$Z_#$9CO!=3BCX/M/SEH/)&"6K:H'-+_/QB? +W0@(Q/+M[S[@1 ,5A.T\
M>ED?Y-?NK:H)EEYZO/7XZOYPB4Y8N%R$7FCM1&3]I8>UNR/_T<_R0J339 3$
M%(UX >0$>O@EY0M7C34KH0P_?/^6:J*8>\BVQ3S$>CS<&2U^D:MMH0M;VFI*
MUP'>N2]HTRC?;)FI.M4_)YZ-V4X6OO,^]R11#\K22R-]JF0X">3T!3R#&NG0
M9$L]O75O8V/-$YE?)/SE<IR3]L(Y/<ZK94'<B2_Z =9+5$ 5,Z:<'^-4ZI7G
MUE"H_X%0T)G(GL,UW^=2UQ 5V.Z:"!N.>13:J.#M:N"<SC\S#%$?DE<+?U+>
M'=BS,)WNJ[J;I@#GVTE<ND!NIEP@Y. S<O N-5A*.5_+V9+(4J%>SLC7@X_3
MF^JY<U6^T<BQ4E\?[Y$V3&V9%;@N&[:,5P$G4@&&>](GZA60FRB2"LCZ#+NB
MY_U,E]V]<E\JX/6GH7[-&!XS$,";QTP/\#]M,.K8__B@E?X83RL#STD\TS W
MT^167@(50-36DXPSC2_) ^1!('9/=[Y^O9S*>+,Q?IXK1BRP_[DB(S0*UJX%
M<XN OP"QV'4[*E>#F\-7W?CSXG]8X!.]H/?XANTVSD2Y9%X054BH"V4E+AT9
M3RA+R4I,^EQJC&")Z6XR%FR(??PURF"0OK:CZ3HJ.E9,[0K<>GFC]>*3@$</
MM>J,'[I*D3^+SR>!TA'Y+;6M"H69#5$)5^'/55C_[X\]'2<<(W!^'<]24Z$\
MA(FV1JTT71A:F]]LPF<I<)!U*-Q'_.HXK]7C%V_X+AGVWC3EG<^V3%*XL2GI
M4HQ0,';&\5-8Z*B 2WZ)!7BV;U3 :*4TK6I$W?:T4D746+\ZE/YD]>@/%7#&
M_@9[VSFA_C#OI,%?\VS7]=W$6B*/B<R4;A /K9@0]X3M:>OV< P^T84/G<8O
MSV4L#)BA%+,5P_&CCX57A<+"5JPD=P2([)!'Y!R=*UY+-P@ORG_EQ61_+M8I
MX/;,6!B\FE5Y*2>(!?/A09.SV*7X8;4]4&L ,^_ZH8C_EK4ILB<][JB"[WV+
MQCO_4O)\Y68[L)XIL72;U@J8E6M?IC!FSSQ$8'^J7FWC39,P!K^1WV7UCRS?
M62;(:%<TD@2QXH."Y;J5S1XWZ9\J?WWYXI>.66^M'V54]%MJ]TC"<NUN+H[8
MB6R-\T']UASB0ZTTYJ_+&7GVR-VX)E'=8S@;ZG8K7U$OHA[SFRA/.,(7$R)0
MRRPD(&+B!G%(S)+H7?'%^(;9#<<[:4[LG,/&KG&,-WO"=\"> 7=9GGQ_I#&8
MG2D+W&VUK"7%[2R6E6[V4R3$:63O@I/X)D6B3K2TB=<+UB[,3"O** LPKN(E
M#/L:YM-U_57O6SRP6G(N+&Q^([+(SWOWJ+(7'T4 P4G\M MD_Y0*8".9!?B$
M?"% 1^['AGO/+2WFUKX1)\\;I#6<=YIBUBX_@.%OD;.A.J3[!.?/)"?R>P@$
M(@F?VZ[74)ZJ1U;*:!$],)A*GJ]XU!'W!*?9Y%7D>7GE7RA/IZH&/B>!&4N4
MUKV\#(3<W%/\+RJ@+R=$;6OT%P7868:DS=Y\Q[HM2CFW^1&JS(E/"U&'F!-<
MU8S(91. (67S#_DQUA]FP644UE0JX/1P.?>(:SDAM4,EHZ?S&L[4JZQG^]8V
M:Q53ZS8YA0I8>4>Y1##!78(JDT)F9$/VN)%:&7.VR.8<A9*?;7&-#?G!=].=
M&NJ>%S,='Z4SR4+,R"^AU\'+^-7OY-(;%2#=Q [\R6;<H4I='GK+[Z?&/:MX
MQ5?3<X5+/4RS6@N<=XT.4KX"!5QK JJ*V&\'E,0&'Q_:3S0'@T(HV.#B*4R3
MSA=R$ZRF@D:S0?'PCU$YP+FG2<Y]0#>E'LD+,(YTD';5.QR(&=8N5$&Z!I'&
M">Y*O")D.LX5%Z\.\UU14:!;N)1I^,[?0."7--[:8?1/P3F/O+C80Z)ERX2R
M7;B/[X?7KA)1P5*75:NE+M* -A&X\@8H"N4G;&QVP[Z/=#%^JWG[K'/#<<$S
M+U.^@;G?LV*TN+]7/'.8R:(%PLR\ ;YVK"-]I6O&TE5=2DIS#HG4? 8%BCVM
M>FID:(\=(5S;T1&N)7_^,P>YRJ7\^8:Q@+)H]2IL'K+U4@(W\G;M= M^!SZZ
M1Y"::8_8BQ>M=BWKXJ@N)V2@#B1VEFR&?:[S.K?HT6Y?&_%BO,U(1?CFSA2M
M<QK!\<="K]S"9> S<3=$KDWO5&:?L&F&NS49[O;^K%ZR7RC4BA%BY[S.!G@T
ML&[Z&]I0N)4O/A;"<?:WO^ST^R]V@UY!;.2Y2^]9#>+F,E][C8W\&.2(KL@>
M;YO$%SRT'7251N*LMUQF1OK>F/L8D4W7C=%^&-VOI/NT5.6CC,CGEK9BA]8[
MEIY_O8>[]>I/C7WD2M7 5OT4SVI)Y!'Q*42BZ9_^;I<0@NT94'[DH]S$-"T0
MOAP6X!.FM98VI=?.6DP%L'XZL2%PT,RJ<)N=!:DG_*E:?I4>C671$,U/+7\X
M;\D.+M_W&50NR!6:%[\9S^!SD5M^Y=-P$*BB0%"'DV"\6M_IX(Z")9M1 =7*
MKR8%+ETT8:CZ!BZ-?\,I+'Q+@('K]2V&A"-P3HKB3Q5-9E,YR*2SJE4HQ5-U
MZZM%J&/B1\Z2*P4JFR@J8"=&$G/$T1:I#G0? G9.$*YY[AEX5;MOUBQYR2R!
MTZ:J>YA01RKX[F<PTKD@?#BA'-NT&ENQVN(6R7W0>5*:'.(NO278\OY$YKLI
MPQA:TU,4<+Z/^;Q [[/U2S00"*', ]E]0@H82!<)N2[YW#.+TVBU6K8F#A45
M(=410/R4P 0KQ:Y!;%W\$[P)]H1C-K03;U4SV6R,-KDO'-;3N"#M=P._;84<
MGY4/8F!L"UM:46IB7*R]^;!=MHPO0(5)3<OEV]06T._[2U&MG*/Y]&KKI659
M;YZMIO**U$&_N52CJBG$RJ>3]*><7[>\T'Z\"Y=_L#-4L?4D?XLH<LK$7^3J
MJZRFL'&P&^.:VJWI;J:1-'CRUV07UC@Z TB_?X]$@?[";^QRG6\)\<[OQM8X
M8.SNH7;HH2RFK,$+)?+I.L.E-$RZ_.!&)<GH9GN[KU(),0+:N<Q+!3PU?:5S
M >?>2;:[,X&YD2PS=R^O^$C!8%Q@R?Y#%-+?FEWC=1"RKJR[ 7;2^[);X_=<
M3T)BY+FCFL-9QP'[9+O/)33Z Q@-KN#'GTK4GZA(9W.0"#Z-*=*C<[8$%PG=
MW-I/!PJ2.B9WE=5H^)1C>R\T5V4?<B?XQV;QDP$KLS\'IRAJ\ 539-.*9")%
M SHT V2&B(4[>WX=",94@PQE0A&_ L5:;:^60&^_1US:K)3NAS)2NA1_ ;\[
MUA)O0'P;JQ&4.<2/9E7!.]_5GM=GCAJ>6] 5X+Z+V\Q$ZC-?3 ,!.TB@Z/9U
M2W+-GAJ:9^'9_IP#%>!@_-FPP7.61"&_+B:WH@@<99([QV6$9S!&$^VM,Z'>
M)/S;(=>W(]P:=>"V!9V-I5FX*2U'?*$C0%XH/\1_JCGLZTBA(QAF.5;Y=3U2
MS+H:H9=MN)*GI>\CMD(O %BE5]NS+P9B[R/FW5')E=4K!2]%S\ED=-@2&Q?T
M^3Z&.6WT=+H=KW!I%&DX@0;#Q"'%6;Q'?CNWB&=GH0/3>3GQ$,//G96$&;L8
MGXW\1:-Y6SNFLX^?_SA+7& *>]Q4]XGUAT1+I0S:F]T?W.]4/@Y==CVM$RZW
M5R_A!F]IM9W-"UZ<FNY=+^B,%#6=@:V4']4)OF,). 4><?C!<CD6I#CE6Q;_
M+>+KJZ_:IYE:"VF!#=K:U<=0^)=Y1"!A>>^<<,.]*:?N1BH6MHBU%?S-*S;*
M0ABPIIL"_]B/"J]M 5GPC=D["%$!D@\24&(60G:GZZ.O[8KX I@9L!QPZ'+!
M][@N4V19YQ+G>*O(MH95@6K<;F79N^WT$>[OPZ_*O[4SK+VVW+P8Z94'YWWL
M",M&/W3=V1HW,BT,S?,D_WKZ=BV]:E\5(VX,:[^F(\ =1*R@_Y/\>WN$(%$E
MBNW+DZPK^4P%_#IPX$BF51J'B%Y$E4H\4?FI;6U)67RP"=#4 "ZF:.B*G^?F
M$"\T>!+0H.K-WE3OHX:$AI$38,Y^2#@>1L@IVQ91Q446D"[:TC!^2'#"HBE/
MH+3A9>&0<%7\I3[_XFK.669ZY;4G!S),<I>[G:!5YX>LWM]Y3UYW]WJV3!HP
M>^HY__'D #2LBG&F J3TQH [VBA1,M,PHBB/](ZP2#Q-LB=D$5VWEFONQI7_
M\@?[3EB,PD66-B*R6A6VHNCD+8W=DZK#3;X)W%07D![6@76RSY^)[K'^G)"7
M$%R<=5*WZN( KLM*30&N?"O8!T%H$/7D)^C$+@3T"5B7&G<C4A+/A8/%>?LX
MQW8:C]40,&@].C$[3PSIVP=_%<SY;G 89I/(1K(E?VJ5]-!1)L!H##$R.[>H
MM.#:TZ"%;JDLWRLY@:]DR\R;7.@E7O1IA<'KJ "/Y1C'2P0$48=0A*+AAX]/
M;:1OC[2':U.8L2MX+;D_-%G<7SZN\!S&<5KZE3^<+?VV\L,MHP/0X)[>(JG2
M*+J9-/("N)+2105TY. :-U^@ 0%4@._KF=_-Z?H\/C)?N3CYW)R? ];236]*
MHT"SDOC'N*.=>BP5T$6CVR\^>>;%;,"_L,V^-<[V=+;I8A&Y,,+.H&*)Y4ER
MSI_ZXXZA0X%>B6@0E-$CC!"YYNH)DB'\D79R2S<IO9O!T/].4!78.:OSM/'.
M)8Z1^C*S_7>>\9VKU<@I*4O'X4#'(^-'TB=B1H:?I L&-WL+D@3K>X'(' ="
M>=&6"=I8,])(]5N5@N$-\ZW&H"\WT\7!3A<^/>_C27%HZ!\*!=7Z841Q1?AW
M$S7&\%=4  ?F#Q<JR!^W]&C.L6/)H>WFEO2(6.7/PK2V]E_AZN27Y!<P)RJ
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M%_NU!#K9=Q$1%A_AF-H9F!KAVTQ[4/ZGN;FQE1ZW 7WV->Y>QRWJD#+S55_
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M>OSD@[O[!$\ER-T2U^ZZC4=,5.6,R2B+S,F*6/$$!0U65<AX?WO4&?=(E-H
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MW>O!X+YEJ2G^EB2]ZH::J*4_]E=P#R%<GVY\$E]KO['_2WV#ERF)!*!GP(G
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M@3=.I->>D*$FB;^&SB(!8D-N8/E \4K/>HY4C&PAF(S25Z.;Y"E'FK[]='*
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M@\;V8]XTOJR3?ZV13/[P8[/RS>66==YX2]3H?#,(U=8&2.K'F\CE!"&JE\W
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MK"%PH-4'XO34+@3N6_&ZH@]7J7]?)0'8-"LT2 "#L^0+P#7ZH#?[MF0AOTF
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MH"3[!(3Y6,G\MT4/LRT28-^6!+A]N$I#B)5KOX $V.:PG9, N$N##P9AR4@
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MYW+ I8D\Z*CP[_C<I)W)'F/S7V.-_9+=/MR4&N*WLAQB?_?</&Y19]A @&I
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M0A"_!1'6;=M#U*$9F*GN29I^XEOETVC!R#SJ!'"9I)YJ'YIEOTM.PGMBA4X
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MGG/:&F.G2Y'3;Y>0KW]< KH._#DLWL]'-ZUH7*?!VL,3]K;,H>I(LO(G(3/
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MG'?_?)-LF%E[C9DYU_K,QLH^FSE;!ERXIV>@!Z"B @#N4GX 9RC +=T0#U<
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MB.XBLIT!/LMW@]/SS@!BE@WR1"X;E#]TM()PA^T\!#13 C\#=&KB[MN0RO:
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MY4#((98K08=/!<"D^"G0J5&PO?$YE[KJ#[E 9CM[CA3CHDCSU$=>(L4$Y3-
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MYTEQ)FD.<NX#Z@WPX6G=&N32!R7/(]N9W!#9)RGKZ[I1?&8M+>]*2PO$4D(
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MW%G\D]Y3MH;-$M?JRZ\DEZ.L:1]CM]" LQ$PK=A?U-\NY,8;.E%TO$O*UQ+
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M(ENQ/A =Y"3Q.IY]^&4UQ+<QJ&KAXB5775^VAWQN6<1[),09P%V8N4-+&2.
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M1D0 6# D2$<E$SYKLX1L85&(6E>X[!QTPR%Y!FM]FEM<O-GLM5A;-J_OYN3
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MZH9*BH0Q5XHB9&2\9.L(!DY&Z!W'DV!581V&9',=E="=I*I,G#2^&BN-NX?
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M*>A61"[>HLH8.Z2[FMHK^*;#Q044RA]-NQJV)B?['74IU3#'>(:@J]1H.V5
M+ON)<%U2_;">5R4+CT"3DMM%DIC$0&ZY_8L'@QT+82[/ M>?-[X_I[8)$ ;
M>Q&S+Y7FC/%2_8WX)Z+D#O %?()LA 0)2-#0">YT2I*Y* (FTK=Y+I$96P@0
M/ 6&=&&*^'0/'Y2=PWM;YI<6A =1 2Y(Z_6I&S,NF6M/BNXG,EYN)Y%B$0ZR
MS#AK0P0//MHDJ5OKQN1%@D8F^R4;FQO,WNX5C:]V;5^WZW5<!'#K[<VAK\O
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M$=E_:R9'D&2//Z(Q+*L.7"/?/?7+D/E-T=6&H8T?'BN\PNJAXD=S_*/<.R!
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M<UUS8:!U%JD$=JY]N.(1V2<3X-EC4#R0&]-[[^ EI[NI7YIU]9:(P.3NTS/
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MQRS9"OV7)<>S'-/F+\V'QT"F^^&%QNG [<U1(I(L,X8YAL*3ZT< #CECYB.
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MY3RMU:Y[;N;[(/G-P^"->YWW5#HX[A,$=2^)GU[O*DQ@WC1NV@ZS9:'P$8\
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MO\F>/)OJOFEWC;3]XDB\<0OD#,V<V- ?IN;\ GWHUFEB]]*!*?OTY0+F$.9
MP($LN90R.5].5=@(O!'[ [S.'Q_].B-#P.)JNG+.;D[HF\<6:.&%-\:5, BI
M$#>+FD>&' &8X5?USMUI4XS$U=S]:243LM7FJ1!^,L'XRL;FW%E$DP:#U=^O
MC5OC6GV%06EN7RJW5\JG !,A1^5=5@3_X7X[A!4FOA!_#GAZ@VS@E>>*+4WX
M)77QR^J]>8Z[0$'&!$) C=V'*KN!9@!'YD>DY(%EGZZ&."TG5\UH%X5I"\_;
MD["-.I1XXMP3BC$Q>G[EO8?=R_C[I"25HMD!L$-U^'3B!YEX&%O@X7XS@FC<
M'PJ_/"XI+5(6M]YB-$,.<AL^P>NCS'?G\N+G78BM_PIN+AQ^G:*RT60K6@;.
ME%KG?OM-^&U)<8^#KKKZZLDE(%9Z8?LMA!S(&!^N5 WJI.EYG*HW&S#@3#P)
MR^"1*4RX#<ZJ_@YRP+Q-,:3*4-CND<2GK6;6'MDLO?"0IKNUQOYVZ'_XU/C"
M$:!)0X-EM99>7*@>XV>6#HLBCU'S!"UCT3K]:7U#S%;4]G.Z$JZ-G2X9UV-U
MGUX)!\"&J=(6%Z2; R/2$[M5M H@IYS!WL\>WN5#?0><1.H?8,BOC@ ?;A0>
M 9ZK'@'H@M UP8[/C_XY+?%?6'OOJ":?:%WXI2@B37HG""A=BO2N*$4$%$20
M%NF=@+0 H2N](Z (!$0$:0'IO3>ITIN4T$L@H48(X?([YY9U[CGWGO/=]?TQ
M_[RSLC+OO'L_^WEF]NP1KQZ$]G:?ZX;"Q JQQ6^"'HQKAVO"$\EN3520U07K
MD!!)_LX\$&KE4]0M#52\'I=*DS9F9[[-+ZZZ.G7"G-T2J5E3D![&UEC?$W@@
M0=".;<3?#D#N7@'TIF^@MX?'+^[+6K^2?@$2+53F_VO=JU-]!MH[NW@-CSR<
MWU;BTUAM:;+1B"6M4>RJ7;P7U7,C2!!/.<UDREUQ!1CV>)S5[8+SKH!*1+S(
M6\R#=([4^ZX,-H=M[?=:7#_3$5R*"8:_>!66E'F*4,(L=>L2P23CQ_$TE^I[
MXSOD_4X0<KV%A07QV"0VT>*^F;[^^9"DY(<&+>R.YMPMHWLVT\+?8JNH$X?B
MW^6-&GZT#[+2G9OO!J,3G2]@V>SCK14QR]*SQ,F7)>K9!4/M+LT-HR0_<<I8
M^')KU)2T8<N=%NG['>#[.\R6R8O(Q<?B#$:V!EY]6QKMF\3+TT%@3I@+-F:%
MBM $]V@"=V/=&*=>-59U!=3\$7K00>84\PF%3+;M_6@=92,N4#M4112:%T.]
MW7(7JXOQ65G\D ^M?8VY_V7UWH1P-6N ,7J19BIMR5ZK.&!II[R3DF[O;C!9
MY@N2J9.X FC$D\EJ=BW-<0AW?>/O-0T$MVH*>3)GDD&C=2X)>P@S8D3DINXJ
M2GZ%I%,WCC%0?EJ2W<Y@RG/7I-@IIO+>^QH?Z?#9KT[O1$UL29.B F9EMR-A
M)G9E4*61U<U(W#VDL$ZO89CI;Y><=-0[\8*Y]0K;=P6A;6*QM&-<^OL8%5"^
MM5WTAH(Z\@])1XK#':?T^W].YK>.YT6IEP8;4ME_4XYZKUM9U9?+[(ZU&"G=
MF1KI+I5?AN'E,:#3>V41#UKO#3@*-<2A)FJ5;0_CQFYXA=.;(25Z18;5@*/C
M:9AF(8@,"NDRSLQ81J=W6X\)0S;N?L^>8Y7]0SP,+ D%VO8ZDR?M9@"79-W,
MW<Q#= #NMG;.;:^[,CDW0[8UPQ8S*1X0Y-RTH_,Z'T?S2T4#C.P_)H(MT_[_
MQW'5^()J877N&^TY!!K,%%,MEMC)"RE[.*V=$M?H?DKGXOTPC^X?/$K./^X2
MJ%)E^0*6+5EZNHL]?GCZOUX7>M@((TQ$=Y;TRO?Z8NV5$2K)SB>N*Y]F*]3C
MC. 2607$7B@5BBG<RVO2Z1KCOKP4F\T&[\EF&+[9Z.'%IL5QLXOC\4'@?,-9
MMV]$ITBPMS*#R[=JK!EF[-'*YO"E@+#4HSNOG>7V?1D/I#RZI3O/7\/1,<B>
M+RN0&]!0,+N#X6G/F[3#/4<+:]L9M3N)HC=]V0QGEJC_N;&5 IJ!43!<WKT8
M(GL=X?Q;U4FFNMJ!7FUT*^I7RL0+DE$P:0N#/9P4QD\5X?E![2./)=)35VB$
MZ\&?->ME>*E?5)OL@;DZVE\=&Y.#]3V&1^K-#4E6:*"R9V<'U(I#K84(A#-.
M$EO [.K-@((+<?;G?(KLIJ /]TEW8U^Y"-FSJ-TU4+]7!]P&/HJZ9OZNH^U^
M63,A<7%",[/ LR/?M;.*F7.LR2W=.G\<5@2>GW5=8U[7Z%4^H%9A6?](0^7X
MPF/(=F8GP[48@&LWAA\^Q+EI_!0I,. Q\$<%/?T]HU[BR' J7P^6>Y40'W;]
M(]8;%?/P9P8NG4O-=F\<,UQS:88*S)Y"X]J@9M;@(<W2&W^&]P+I@//_5PM1
MDV'N<7!@S6<$2+@5^49DOK'IL;VL(VM(YQW+X-N4R8>(,OK(Y ^)9U:UN?T_
MB:O)RXL1F3RW845^&9)H)S[.'XKV1-TM$C@?M&Z[",4( OO=[EW1RMT0\K&T
M6\/B,4=OD:VRMI<-5X ].+)6_ KH2$2GP;TLC?Y"?G2[.Z]3">B\\>TUO@2F
M@FQ;/^#O86.N +*'71F&\Y+?C-)DF[8_\K\/A7/5J<;Z>2PV(\<ZQG[=0I7^
M-K!\401LW0 "'RFC9"^@4!765@:H2&>K]4X/Z?W4T/@Z@J$ >C3OZ3[:I^N/
MA0(WTNG-<;-_[LTIHYSA=1T.':4C4$?++$:M.1^KWIF^R#7YAJNR/+9OO>]%
MCE_*I5.;#5JZ[0J8\WG,<2^[0_B%\;!5O%$9&W'&W43-#Q-LD"U[HAVF+-Y'
M JF>%JDVLL0@/W]^WNWS*<8/QX*Z9-@@'?1ZM$OM>([&'>M, 7)*$]ZCLM!@
MYK!>MA?Z"I['W4K1P'//(6*]WRK4[]O:<)<.@U0$*CV^Y_J%.;<ZO(@!Q1\E
MMSMV,Y<YJB7%P2>ZQQ($1T%[ZU< I[8AOL/G"CA7F!XS\P!+X8?!A\2307N\
M05= WE  =R:1"@7X2]B$-\I4I"L(L(?3*# 68>7-(K5<"N<'*)\5TXG?U1ZH
MN\-$U%ZVY#K!O_1W_+X[S=^?\#^%_:A:]B$@2!Q.W[K\&<2"HT8V#B"(.B$^
MN9H2<:[C9FH\AS$6XD4W*>6FY^$52WMW5R$W=M,X1+'9W)$S@\F=;+3?BM88
MR-G>9KZ-OF3 &**DT:#VLW$'X]ZXJD_5MS*+YYL7G+A^9HH*Z+Y<;-0EPIEC
M+3!L#Z'<76DLG;$0$Y/W'V/7R%&\912 GV)SD_=H+[$ISS-Z];<DA'6Z[+ '
M:-ZN.I1ACYSQ8G]!I615/T^BJ<KPS56VT9\:]6W#K-?484N6B# 1URP_2I(.
MU5V>[A0A@7KHH6O"<E0YLDK#&;?%_",:%V[#Y30__\'R C4W=<0TEQ&A010M
MH)TP8_1P&F:)1]DVVNE+<4QOZ)+L8:ZTN.8Z+\A+[,#\FVS[MFX.E5S8BG3G
M!>26 P=1V+/Y7'O]=@\;R.8P[$=I_M%7EW5<SSROC"WG,6>\(*\QEAG=VB6W
M6(FD,%%W@"@\3ML.JMG9X-N\X$G2(I-P__6CF8,)_S8WTI3FT=L UVC@:(D-
M]P"MWJ5>48\Q"!OP^<XH5?OZC-;8M'.#7$:S=%&6L/QBH)%DK'@6QX/U*G"0
MX_A0L%4Q/X-U_>LES[2:_/3P@$XNZG/8?FID4N4&P_"[=RJ]^582G^B X:I&
M;7G"ZUAD<1.N[?H1R)(M."D<4O#,N?%?<?GO:40<QSL123WO>DL!K40/E,I;
M%:5JIK^L]LPC/!=C)R0^@Q2 0CG3&3+%;7CQA"4T!R5/L$6%*.6^4TB4Z5?K
M/$H\RTPTE?;UK8_79K4,P%K@6O5? S<'F;O^&5Z2$1S'P+2Y*E'8+I@"_]L0
M7#D2!=,F>1^HL%W^B,E;2[XX:CU6UD9O_8F1@GMFQD4,$Y.E6Y#<$2023-I$
M@1'4"5#NFK.F'?SU6CXMBL,^QDHHMFT9$SM*$H>CO/QR!=A> 03:H.A .@?1
MDLH?-G7Q#IG47+$8;HX\^I-7E:KD+D)=7(7](V\%#\^ZX>7P> F3;1$E)IPZ
MAL?AKE#-R ]?44[+0 ,#(H"<P'02OF=QH;+K6A,H@(U!O)FCC?!W>1.#4O1+
M> 9<I/=> 573':W$VI>IEY4N_J4/7;3N[/V48J4(JTI(+_5?CVMOJ8E'PXK%
M!6\<+SR<:GF.?7G!CI/'OD/O&#=/CL1(T@%_S^OB-U2>+:]$;V87++8T&J5Q
MTHA27P>N90*4"@TYYRD].AT5@@E"]KX_OD#<@@FB_TSE>9Z&;S@-^#Q_2E82
MW947'ZUROV6W,Y@.4&]V4Z:1V 5A'RMH!8[>K9>S&?/-5[ML,6&OWXT]S:&*
M45[.;#B+.KD"WE\!#AB;(_ .&5N@=4FN%JW0S+*;#&'3+WD0=> 4B$/RDDIO
MDIR#'KTY+Z1=H;+CNK?)J70RUX:"6>7[J>-HX?!P_?@0/2&KUH/[NZ;3>RHT
MTTB?;FVE[9J% :2+J_7(XF%L(8FYNPI#(.U.P_3>!>;( *M5N -V0B]^/4W<
MKDB]59["G&9)-3A4#Z]'UL$I'3BX+\OP8MC?)T//$>$*K$4[+$PU LS&6G;"
MK =FL:*L!9((3,MB@.YI+?I/3;:6IATL_#E'H+]UC[N9,H[VU)YS*E#&Z#GA
M'SB'8X'#CLHMTAQ*_V5\,W(I.*@JL!AM933)JH=>Z[>A#TVE+M+VB.+A/A!;
M;Z %_VB+3<J<7COHZ6UHN*SPK/-\^@92"O'<Y#R6C9/:YZX.\"J!J6'G5X)H
MGE)%>@8\4&31FTF3]O[BZM9DQ^XW2C+YAJB4N>BWQE@W6XDHNT'=";>D>%AF
M=E;S%L'Q_[&(^/^EO5_VT/K'J3MF9"59M5FRC6P+'2M-NUU$9E])?-$9/),Y
M &=RB&,*4#8.R("7$@'<V@%*\I]?$X[_8NIAV^,AFJ8?BNSFX]AXF:S%,*>G
M-0G/[T ^U*$IL *GCF+/3IOPBB#MWDN?+S@GQ&^<TX7>LTY4AGDVP7$&&%/F
MYQMKOIU]XDKR@S[("=1TR;T@=UJFU9.MC [JS&)S6GPX,:Y=Z<O -"#8=_CK
M"O#BCA<=WG/3H==L&WF&Q-,Y<BA/>'Z ][P>5>6W98J;;>!0.JOVO0+B6KI!
M*"WT"4Z]<H]7?9)12WS5?I*LN]5! 2(:L."Q;89)=MS"#FHSZGS[4>O/48"^
M E9!P?A[X,5M<^;F] MUG:?)_EK%#B7[>M(RAH>;3RS?8^JLB8+=M/WR81B,
M?H\2 =J[6:FDIL(4]O0G>K_4]_N-:'4/%R?:Y_V"O+\J&@L&FH*-[A2X;W9_
M51)%ZX8KT>/T?F)ZBA&.YB(3QS$N.E.'N\,5C3&&IK]J3F=(R9[H6(FA.G[\
MR<@C.KC=4XFAC"IT,DZ(<$9P?]$;TR-I#-$QIJ\GMUR:8;S515FWF<N,.XP/
M KW!T35A-V ^95HE#L9'W1#[:>L9UI<E 4FY:81B? *#/K(\%$5U!MVFV!"[
M0JQ)-ZC*+L:3W>=5Y83G'VGU#(;XPZ<&_H5KEFZWKM5K7$60NR91*1 89RB)
M#&*TYZ"L^=F$H6BOB7G15#N^<I?]S/1/73Q/!Z':ADS_L@]7R_,OG1SWJS%+
M8?@[B]BS+@H;))D@RN-%DQ,R/5WZ3@F?L,OWIZ]#;PB-?1K/I'D8+-:.#3/
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M "\/4;UQ>+D/<2[=2.0?9E]];3&17=#\#DZM)+ZU2-+<./JV?,(K0&>J&U'
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ML]OCD%UP<FNET+4N@72!(FF@KKL]I^9T+%V1]"(EHY+8*+.$E#;E^TK.?M$
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M_SOI.WFW<U*2G9H1@R)8_NRDPB'TJN[T:;]4RMM5U$O5QD'+HZ>53*NQ'AG
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M]/0N](V5%T2HA]5[JKU]YWH 5T!5>KRG%CB8Y7LMSZ]RQ]-PF5O]"],OZ76
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MS*Y&@F*^#POZPVF9S+63^N''!M24^KX*RCF(2F%GH9(7O7:$*N\WG1WI[+:
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MSDUQ2;Q'37&MBTW7+N[WXHV@4$%VU O,P+]W"/0_9[8;H9*;BYA%&'^+^X.
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MT!9H=!8L7#F*@RLE/9I'H4\VTXL_L;@Q-UPL-.A!2SISRIK2)7WA6]N65A,
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M\C ]3-,IBW3M]37[ZJ2N#%"(;PMMND1B0AX/8/2XW[X^_<PA/VVO9/"?Y?D
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M7.)M6LHUP<W@=3WPVU=WHID%CR;JKV<!8?^16+[D\>]@8NGKWBL' G>YC8H
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M&/;DKC,^X]\4)O<Q4AL)A'5]SX V#"+=K:K[F,4 [=.E-X15/8@/Y<PWO.=
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M:B$I!%T%"4<PN2[MK 3MV.V8SO4K1GH[&G?([9D^>EJ?SYY\F#=U@[A\!HA
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M&Z/^LOM^L31V\.YS\4AM,52DO_=5/'B;G]PROBM1/>KI6:;KE'C;B7= GP_
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M?")K%U2!&H P!_)T+M3NQ5[!(3N)!E(DX)??#E6C7P12W43@9>U]PMV=*6"
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M]<BW=.F+SU11.<EBP0N_9=C][^?B;G8%WL9WJ_U <D)ZQ<71 QK%C?2+<UT
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M\NO_(+-_ JM6(&5)(=X"%F@1HR":%I%J[T"C+KS5F[V\N4Z;E,EQO8^HR#,
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M_>,M.4CY&W\'_Z_VWCNJJ6[K%]X4#4U!.E("TJ4)2$="4:H0Q4(3HH)"0$!
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M0G6B>1X$7;$FC2=:!Z(O1JKG411RA\^_N%;W\OE 8Z2OW$;<UL/]4CUA)]H
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M@ZN\G69Q'R( @-X*F/-7*^.YKSSHIT]/E'#)#1[YD9]N=>&OS[^]<#G^VO&
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M)>%5\?&9=W;ZX'">#>]P)!]%"5\?"^M <HS0.DO>>PZM!6GP7JI8UU'U!54
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M9C; PQ>#Y$=(M[\/8S6NKD=+[+SRYNR-!,1]RW0)X1 %W3NDPO8#@.L N'<
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M<^WJU;<$?WE_2_BG=\J5MT1_<J+*=Z1_L_G;N&6DJJ6%1R,'7T='3S\7+W\
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MU@!P<0, /K<Y!/@&_C'W6Y'!U[T+ "W "+ !W  /( B( 9+ #4 !N FH =J
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MTO8[/!?_$<K2?P9H<;/_KVH-#(*MU(&XL!)A!.=96,[@C)79I(#1J!9L/:I
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M9!,AWWU[D+*TPP)*[56&3G/S!%.!H=_PE7D#?@X@A?])F#+NS"/B.8/*#@J
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MK[(H2Z9_F"@TH=NRVL:LE$^3GHOS4A\K-<Y44V-761M-DNI]V=GQU/@F;T7
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MN,<"ZO+&VP^?R#<F<7SCJF6U;AUA"JYX]%%8@DK"G?CK*@^)2FZ^0+1ZH-Q
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MDK_I+I/O(\XP03=DOQ#AQR+ZC,\?49M# T2HV1H3)(PYRP0]5K@+IVEM#!]
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M#ILLL@?(:O]%Y8U] E^HB& M8]]"2>BY*'93$<H_-&$ AD*5^CAV?EC'BZ/
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M/!4?E.$_V8V7-&2/3YLB34E-I!:;BIZ#G\>![;*>E4N9EKQ?S[13.?[4LKX
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M,+*6+_+L):4$\Y  .^5^ C[> I]%OF%,1<MB?GR!IS-!C_)9&#6J1<<A#$Y
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MCNKCZ#4?OL,<L"4+9IC:%\86E.!V)NC&($^\>&#!A=-"\7;G3=FP#!T/H8F
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MZ5Y+]G WA359C[UQ"6XORY9G9Z"0,(SBO/7-'MX14">9[K2QG'*7[B)-^BI
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M2AW=/;9<E*<& > S)YH41?/]VJ($<>P9Q9@8E>H5%\ 0FLLB\BO5@T>GOL>
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M,:>FH=UD-JTPI4WJ(CC2R6_G T/FBU'SV2\T429#>""(6B^.0DH .?V__0&
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MRM .]4VW"V-;MLD/^?JKJZZE*N:Y*R3N8U-SK>BDHZS#Z>3'\$<SHP/K-\[
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MR@%TBCHZ$PS9#;8S<!+2=SOBV41N8(K-9TZDC1,UP$Z#Z))MJ!OK"J9BU.]
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M@FL$6U9+H#%@'DAW9\'5$&,4>:$[3&12W7$)R+&>^68A-L288&NT:S6YO^5
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MU3O'&&&^M'%5Y=24@ONH'^^/6N_])'7PN!OG"8!K_9<D50>2JT<TJN?[ZHZ
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M,WW74MU&I^<'3Y/;6F_XU G@6RJUDL'6<'["JW*K)*!"^]$@:[^H6>9+3:Z
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M[)!SO^0KMQ:UW@=5630K,R0@"<@'D1+>DNC*?;1#7=JR2]\5N*3UHY!53M]
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MR'$A+$4:KOB#"E\4?_@@\W?G\;%XRI[<B8H%N?_BVULI(I\>QBDW:]_S^PV
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ML#3PZ'5480.[;&R>$@S<U:7QB@ZPIC(>/?>0CI43L8_R7,A2CN748FMO"$.
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MSK*"6O8-XVZ:^#4<6XD#42/=0;LW"][3D-7Z?;E6H;\MW+"@D)T8T 6<2 "
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M;MD"0PT#9WP1Z&Y9]4;P/\EZU:6;[QII)SY OH3RN,O_):SV'890@SY)1G]
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M>Q\Q#<RS.F!,_[IAL#.;<,@IV_?EWVA9XNQ+3]8?$TI2++[ZOX4=4[3+3'3
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MIS@OMC$0*F+EJ19PR'R>U7Q*VYJ</^Q5#8OLFZ3GV9#&^[NR4E(BO,3&&\C
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M-R;3KLIK9<VH^'ZUSDP5XU-9_8+GCT*1B(PK>Z?!<,-N\E5%*B\VFFV*=H\
MN@:S<PD?%I%KG@P=L[8A?2W5S:G\7'H?[;0ML%1=+KCM\VCJ<$,E^)UOI( I
MZS'!6%@;;L3C\3W,_ @G,Q*ZB;,H,QZQ3'M0:6!>F,F1)PON&RW0L?I&<WK)
MR'=E"EH5ZGTV'B*WSI&_VA'M<_6R439N\'%0N_,XT)P[/ET+EIROS<[+\]XF
M;GM%,O7D%\^6ZH9U5BKT*ZAY;^?>Z0/&ISP!/_@3D@(E//&P*];K'6SVSVEY
MN/X*W>SPIG)K26=/2L!4BX*T1*:\LE/+9 OK>_^Z@*>[ ?*/,L,.E'ZL*XS9
M]**="H(@Q?R#4]5\NV.?&%(['6]7N>;!%3O1&?B,=!%!:I?Y]79E[9,AMYB*
M:O=GSM$B=2Y%;MZ:[^7T^R%V VX=16)R9I?K9($F8=*3M7;%#D/ T=[+T>,(
MOC. CX* _@HPIO<2CA9,4$O9A01_3XET43#X<+%RNOM^W9:RHW<G.[([PG+1
MMVVFX8=S\_/GO5$_ORU\GDH;QBMMZ2[S.W))+XT6_++.VY^*LRY:]?>_TB7O
M\JX0:CFL>X,4GC G]YNA,AX4(>*(VGD_@FFN3AZ"-/JQY:W<)56G#1/D]TQR
MK\<[6%>@'.O%^<S*$?IA2.HMT.XR"A855@UE@VO-UL,KQ;/Z3]0'=.[ZD8[]
MND:\<+O-2*"I['X#JJXGB#_A1VH=G"\XW5AZ7RO_I9&G%2PB\KR6_JT)5K 7
M.]YF.I@GB7%GP&0Z\C@>284,<8PI%MU+8HPCE=N4TMDK%.[&B747.U^Z)^]?
M@<SIE27E)=&8"3KN_2(J)$8#'LI%C::XW',B43!H%Q_'H9PH=NU1OVW63Z7M
M;:_^55-*_(/H\9K5<&-XL](6Y5@D,U$D,UFP%F_RS"JN;$G)$;0IBN.W\\]9
M[W@.5/\<<E7$+^<)E_O+CVO\T;=R99F22T$)*)8#3ZTPL;*4U;RNVT19$WF%
M&LR3<Y19WC4]=?@.KJ=)4*-!>-:VCH(AJ BUR;J%-!Q7<K*\6C)NWMTC'U4W
M?H&QM0%#@'%6_<X&T90Z&U$%Q?%G7VJK8%5G@%X?5;UL%Y/N^B?34=\EITHL
M.ZD!T6""UR13_S)S-5:!<)XT&3Q55O$P#TTSGCJO0AENU?BG!@+,%A_[@X\J
M$=Z/@]*[=;98:JS]YG35$7VW,/[F__1>Q\%#JF *V"5MTDRLSYW2ND6:$IF7
M=CNOTZS0_\(/ERWK#4BKP!U,B+LG5\!1DT^G"ZDYWG5KQ<B+JXWY<PRA!BEH
MQ^7NB&+)\KV;+H%LLLIZ;FF=4JRR/&>5'=@X\XFZ=.7$F2H_K-G**]:_KIFN
M_\9]"PO\&S4P%T[QO^HJ<8[9Z0(E6@EB@G^C79M1?-\2)#GUY\>&<G1]&]/4
M0QC,2>J[PZ(IO;*2.\9^*\>';:3U1,'A2=@ U=G1 &54N9S&)@_"B[?'1;US
MZE"8ZQU*A[\W+YE@_#36-FR$>L8SOH?9Z*#,W7:B4,<=[N.(<]Z\<P80$RW?
MT6;/M>S/&!KI&-2^&B(TZ,'Q.==GUS,YEQ=XN.YTJE9T!@AG4<2B=HNB-NN?
MH/;V&8GG4"-T!O!83B\(WV4BB,Z/$R03#Z3@;/4;HOS:FFYU^K4;L[QMH&MX
M:H8G?OQ:BC#+B,]>C;_=J0$YIR@\Q, O@#*S][/K?H0/!<F4HOR0ZP/7?K?V
M^F[E.+,E-M-7)A&W:!)>V!B8&^J2L[@<NDO[?3!(=O\G6$34D\$9],LMHR0B
MCTA55ZS_IX25WRQ>5P3);O?EV1G /[W^BD6][;>AGSB4X?5J*]5S,5UE6;OS
MX0RP\JX32..:ZD?PP<W)XO"0&D?X)3)TZ QP&2:)5X]YJGO+!T1*V;(:K9LW
M)VT-VY%N0RB4*E5YT_NMO;BZL/>\ZF9G@'F(*:=;X TDNVV_-?;T2K>_G+#C
M]ZI)[.B\X3>_:T37V2-W=3XIG=J1].6R5M#&6&'0<P@V4*P/1_R!CE$NVDM1
M[J3=2V%,8PWY6#X09*@/*38RMH%L"</3I7&HF$*3;/=#7S-3Z-^@%33PU ^3
MT<LONO!8E$F?T(!GLX!)P52H3^>10,139)O@.-5P-1<(.C6]J3OY5R]T45!V
M$3^^@W![R1BF]([.#R]$0GVBH\V?+TTY/:-\HY\!-CZ+7A)[%:Q.NV^\SCF"
M:;V+68 NR"K:VKD=BN]PB^[R]4>/;\U@FIR+%K9@RSNCY_+WE%Z)\+O'W'(&
MB%L&#M-N/C]2MA\E+O/X/N_E(V4M.]&:YC:/\E#U+7,KB$47('"SL\K>]&7]
M$FXD=C9_O>.)'4[;%K&L4E!J<@?E"FGRU=WAW!R76H2KZXX.C)<#XWLY(0G0
MP3=G )J\#8J%].E9D;SSN)J-C!_+]V25ZZ7_Q!'WK!C?!O#"L,AI;ON*V49X
MP+G0-(B>1UZ BU=1UVU(T,3N"'SMY4D7?9<NJB=!@6JL$%JL-L_4WC6-_E;_
M5,4E>FUH1&IQ[\E4:!?>AZ4']S']JW0 9]:E08=_"[BA%A-NB6DW(3#H"4IB
MYQV:5\L'TXB26O:L?4WNYCCH(#FEASR]8Q3_-40H46D8ER#ZAVE2X][./%\W
MV'BH6$A5.^RJH?H?9CT^)HJE5\TD$EL*TV3@.$^!P-^W>E,9A?]]=+V*S!#E
M3B_F8EPA[7[BG:H8BV8P79Q;:%\WB7]%#@E*I*MB5M,Z3M4$C%=/U7>6!$B0
M&7'3ETV.ZMBI/#5(0K6P+"[V#!!5R2RKQ84\;6RIPKG.KJ"X(;21DT"ZE(A!
MXC!, <]XE!N<5KJCL:?=!SG:+V+S/OVA'%-M"$GP3*^8_.H52K)GIM\WM"_R
M#/^'.H-Y ?KT\3\O$L>X F>G5I\:T<Q)]7V8F"6V:5H8F7,(@GD\$2JOR&%K
M>_FTQ]QV6M)[1P7,9!H;MM10M]7&T^F:YYT6'!%R_0^DK-;7QE[A446'H> 4
M]#^CI*#U6E=T>+FT%5KP:\N+QB.I;RA^FTKYFSQ^AFDFAV(FV1%H^3R#M>4'
M=?6EC-AEDFD&]?9X?R!5$AGSCLQ3HX)\N=P\FZR"2QD&<7LTNOOCM_VJ(P-;
M8+SX&O7XGQ,T1?]@H7='3M?FMAD*F8:%]J>ZA3QYI3[0CR42U.H",D,1OQGI
MW)7P :?PS\CT9.XMR^R.X(ZL^!SGA^]FQ5F_)G"("VCCA$T.H\?_R)OLTR_?
M5MV;;F.8LG^#PMNB;F&<M_=#OOV?&\ZQRU0%25HA4S_R5,'1G%&]_-*6\N^C
M/#$Y"/WO\S@T_P;J.@-X[=&*7>7/ $U1J6> F8Q$H,)Y+/P+\>GUJ<D9X#N.
MM'P& (O(UY5H,]2<S@"N#:(GMF);&.] 6D;WW7,N-[I^!MAZ8H'0LR4Q'7_A
M^F/0]PQP75>8^H+J\^(H \Y;NN5):T#[,J2_'2P0)9174TQ'-P)8B<7OM(DM
M_E?5;I5'5'ZKU3@#J$B;69X2>3)"F+!"QOEX1DL>B1*1WO_^M[894'J8\&'K
M7DBD+U_$E.5FM)^P?RVN=K=;/1=RS67>>2C+:=%Q3'BPF]0^8GIU0ME +J!=
MBMPDRWY_T&,JI0FL6@9VJ,_3'ZXVK!,IWYA%6:7Y6@55&M:(FZ$T!^<MBC51
M4B8*1ORWIR;>#8K=?7N5;FX[>>"DJ<KF;O5A\NG-C[E'UMUM'YI2M!7>A(3=
MMJB(# @NP5FF5AR[\9NXB'$MG+Z>B.]_3,:5)?2Y!?-]^8O!PN>HJLB-\C_V
ML4I=VUT5OJH I!Y][)4K,$6P4*?ZH\5+N)_G H'4#*.9)TGNC](G#="NSITR
MBBRKV9<>_]%WPW:ZU#73K%:@.<_(JFBEU_FS2(([=HYA?F5ZK%&;*(M6YV9>
MTWRB?HE94X)0)@=FL<S*! ]*5H%K.69FC-*Y_K@T-M92W#T+";_F.+\P-#D>
M$B(7Y-1W_6IW%EA6+MCP;\_B.5NCV_^ )>8MP6WOC%TP?Z5)6U4ZEDM-H+5:
M?(WUBF4LLK?,S WX])A'K"*E!M5.Q/X&\45SI-1_$$V&LAM0].@OJ<O86]O!
M]_3HR%/SKY\#L]G>2/XS%GBH[5)_Z&RD@'"S6D;(9Y2> :PUL-_I;D'(ZW37
M6<JY/SF@&QHA@?-1D,S/?KTO#S1^IMM/VA>+)__E():I!DE_\..RD9&5[>OL
MF)KRF"LW"!V[_FJMN3OPGV52)A;9SIX\1*G/&B-**4VI[W:FP X5=26Q&[<9
M\HB5>L0^X@P@@-D1);6= 6S58_PH9N>>^9J=E6:/I)O4(,Y_U8<>&T4SG0$^
ME,B>>WJ7-NB#>>SROK$NSQE@3I-DQ"C3\HPV2CD#O!@X7ZA!(%U3C.9!5#B6
MI58S1A[^/@/8P<HFJHN.FY3M9IK]_S76PA9N-Z7BHL,GMNP[2^GT+[CW+UN!
MM7U[-[N;]O%WF%F"-%0MXK9T'8.R5VD?4K).W[W!Q7XDAK",GNMYLOV./L3F
M+NQ%>\&8K 1.YF[1/,1D2PUB*/(/^<)'5]G\!9C3T!('6;X_43[P+2S+<$;"
M-H7NIN@SV\9^$3%D@@>E<(?=/=R4Q97:99X!T-GKEU;)!L)S&>SDRY:7K-4^
M-:76%:Y:5N:OYO_@$E7OSVY0D3;X'56H\T(XR@/V/W_N]G^YX1P]=6!\0E[
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M='#?\BI  %#.S;WCI@QJ?&U]8C<GP<4"E*?3^_J%/WMP2L[+9L3[G?MU.VW
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MW$8NC!G_MZ_R'"+ 5_T,X)%+<EI(02>.1@Q<8S9]6;9 >S- 3?T*.W8C'R>
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M]8M\K>3F$"IS?;'IZQ>IQYN6I7*&-^WB>J]4GY9L[7%/Z:\%_G=&\LG>_\=
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MR;EW.-$R+,&,G]%B5(6/NO>H"$+])9K)Q(&.$_Y7"_Z4#AH4".AL)6^,EJ9
MU*W-Y88T#E:G\.:M3EN6GP/5<E2[(90VGJD% Q5$JMLVI-0UYZDV6H!4Y&EB
M@0'I'!@KI!1Z"=MDK?J@W6F:^"_KNI_:8V6^M@?RI_4'L[/>Q1*4NLTN3><J
M;R_A9"S05T),KY$Y\QHJ$[)]];E9,K$XM%6QL1YT_6:5@?ME]/N^"F>=I4(V
M^@_'J!])JY_#W(4'DGR";R/VQ];:.#Y]IET=C(0<7 P@\HK[:-1YM)K-HS8.
M0!M3K#*_^_'H)+2 QIMO97(&?+W>D_4RP6$^0U#?NT@5ZZV<\6DH]=81K9P5
M[T5/ 7&!#EVI,;U^*6> GP8OSP#U[8%TG0O'D9O(,X#4&6 01%'&(^C>2K]W
MZU-!K0GH4WY$GT?O/6JB=7L7$B^97DY5QR-2'.7^99Q(N4E5)"V?WAMLM4OJ
M&IOIY@\+42OSK11T=O6QWGXAQ\;IRX"[Z@*ET@/[[66"C1^_CWI6P1-HCMC.
M3YD,+)<I?W=B:,(YFSE,<!9>&>(=@I9B_N7YW3?4;;#C.E%N*JZA:37QU)=H
M=OMDR-JQNDV"51-EQO>B+1-MQ&U^(:T@LV_?!$B55]]QJ;@[A0@PCZ%07J!C
MN_TN)YT!6+UAB)&.20:NYKZ?:%RO]/?//KWS+K*#%N;NY=MMKW(2P(Y@H)VH
M;SOY,CJ,<X6VY$HQ30E0]>Z@0Y#&CKR4=J^HB$I'ZYCEUV9:,L&&2+T]?K+L
MMBY3,,JDW9EXNT2=;L7XMH9*IMAKXB+:6"%IKHZO_@=O[Q76U/K]^\;E4I92
MH@+2B8KTIO02R1(4! 2D=R(B70S=(($LE=ZRE*:T+(000HMT42!"@"Q 0'H5
M2"(B31+ $" D)[_]G(NS]SEG[__%?O9-[N;SS#G'&-_Q_;QYYWA[?>T3'SF=
MSA@O"GU)\H9$V:@3[?)KD%T>D!51#J >?9R!/$GXA6X/]FA7Y@!D+\(X "\Z
M^K#XUH'-6QM6^5+&$D.-BCJ&BREN0%M$>CJ@[#/<&/V^PY2EY2_[=F!?L&7A
MP_PRW<XEB@VMS07;-E,< %G*,Y:"S9();FISQU\(.OR<ZN,=H64OEWVZZE7@
M5H!6R)4_#L*+M/101GT/ZO.KD]ZN.MJ'8!1B;?P3_]D*ML_0#M3^3/:/CT'+
M+', ?,OL;/2=QSJ487V<LRZY)@_>/I?E[(9QBZP7%7[=SG/V6[B#I[RE:O?]
MMQL/%+OOP=O(DF%G\=/7(Y"9T'HH2RB?\9II2>< /DU[&3)[Z2*4)T3T12;>
M[(O1)2:4(I+^"RWF;I2)#W)BB!0LIK#E.B>N?ODU!-KBK9KW6(M8H[!FU0IQ
MX +$SC^'"TO)#9M.IQM*$XCD>B&<1:32/<Q9]8(B]WOHQHP8LG)XLZR:^Z[9
MXAWV !W[8YZ,OAAZ.L;RRO)/*7*)S(!&D1\D>==(NI_FJNU"O28:]#I-3^51
M^( HG!JJ-^)':U:DX"@WGM?0]0)(YZU5CSF _^SZ85XF$T[$+RW5[_=N"ZP%
M5W@@'M&77OC0_6>[,158"CYY\0;-"*W6N*+T3/AX\1F%_[<I5MGO;5P0:T%M
M12S:A)%IG1H8!$J[VR%?HVNT>A/?'NA<ZEJ)3-+$ZDHO3,W>YFI0F@?LC?\B
M -[5+98D2PFD69L4#2HR\J-"9YW//=3_?D7/R.]X\X9D/!15?5/[J>5Y)<4C
M4=M$2#EAN072XMR[/<L!W&;:T J72>E1ZH#UI0NJ+$L*1 3^D=@*O4^WZGQ1
M:E6Q-F>=^7;])8DQ=%[;RIC!_GGD,%:GTNQ]C KT#XD1Q@R7\9.*NV9-!:7
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M=O9=D@_TE+&>;\8KO*)35/4X]@Q%R0$Q&?PA5U4ZWG$E:B+NWO^6<8HGJ!R
MJ)&LR;(J<).A8<J6G2R#-_VKY^,/5-2I-KA?>0?8'_ J+.Q)AIG*Q7UOH^UG
M>J8(R]=''G?E)=$G%6S$;&,)+L7C2:=S""55^]46D.Y_2M[A[%"Z.]"QP361
M!)KA"TCCSEU3Z=:4!7OC3HGD:["\ZOYWCS4P:92BD(M%,F8GY3<;/NBAGEP;
MDA0*>/#.17+4EK57$/A8+H\2(QVX^O)[@:MH^ZM!99%7YE*I_D_"7=^DJO2\
MBH!.W,.>O9>H="_3()(J'KG6I=!][KEMPF7A<A]1C"CFK?E5Y'-XNY<R*+V'
M6C^3-M/^6/>\NTA&+T7)HD5&,*UG(O>1Z94.UU:#YFK'HG5'G,X*-_NM6FX[
M1?P_QU?RM,:/@!JQ?>ISU11"4N=9%B\MA /(;(^CQ!1N3NG,A^QMR=]]5B:.
M2F%95@^U$(EL\5%JKMRD=JVI2VU([MM$\,9@NKLKR^L21;(L<:?=-*R8JKC\
M3L^W9J76HED\?@285-YQR"P8"A\K^WU^LM/%U"YK0L&Q9R)3Z?KWP@,%3'LY
M(\,9>:MNSNSP/W/BN?2W_(;P!V&Y&'W6WG34WIJ.YZK01=<N]5Y41L1:6!<N
M^(E[P@89>38=9;1/9)\8_7;>S+><%-H0_*1EB?;W1@ILI:5I'#*"OP V'T+<
M'/)TJZO@O=K=3U(:D+']$.G=.A7FT?X.GU53M^K8-^&M7CW:K-=FLQ7J(NZB
MY%&_7V6Q.%9;\^U(?>7YK"D;9K_72= Q-/XOG+OT?_(SV%@22T33=D)K:1;8
MI8Z%>KG<(&V=6CX*7!Q8CW4J66*? Z7I2M\:.MGW,'FDM14]@, 6_ZX1LG1!
M>'DYI<^UV5<!^^B47UUV(X/IB&$U[4$@AZ?([V;08IK_4D+WKI_'DJ<B[(J"
MQ[".QMA#8G?.<;GPG7[3^&',G0C3L6]%U'A7;I1.L,^Q)Z#-JJM=1\"9HV6A
M3G7QY*S.R_#TGL-:TK-O$]M&EYC$(Q\3VE0Q,.G1=NVY=3>1Y+U"*-]BD%O[
MAY!)PGP(3(W07+>U%VQ9^3A^5R1W):QW4)=TI.8FI#C^O'90\H:T^43\*/;G
M</G7VZ**\G[Y5SWF6@_%N!#.M#'+J)?6A"?R%:XO0(@QCQU?8$J(O";)&C"<
MS^[=N[L6,T_QZS,LDHB]5EEB%U'0%/NNVCA_XL=$WU29 ?06D'EE:8L42YY'
M"7X-) B<;KXJ=\"Z'$,_JPAVC8G0B-EQ+^P9Q])>=@:ZD%3RO533OF)E,^?-
MCN:X)M\C_,Z$0TZ]9.K.D0MYRT(QH.F[HWY(,RYDO/3@XR&,R9_\&>?K4 ^^
M2[M>0"3IE1)?9=D8YXACQ=->](P/L>O^R4X(^+9;B2O/%5;^\P"[#-S2/C)C
M=R%%R\?*/M!MDLDT4JJ(%;.0YM/SZBNI-/B<^["@X[N.+W4/=:(-/KKU7_V@
MFZJUE[4NDK?X<^[GQMVV MX1,U#>RNQ/?HL)[);BKG=]SM8(+S[<MF#J7N<K
MK*JNDYTY?IQE0FLE0LI%3IE=_+&BG[![MYX"=\]L^-<6SI*RR-E.P)N +*3G
M.OD=,[RS!J\+.&!%)\KL,B4=%1S*C@E,LUX#4!9"D8P79S[XI:W.S_SXYRC+
MZI^@\\CJSM'FKT9+]N-J$]&"LYXF:N,#/^=BA)FU;O:E3ACQ]#R,>#9&CU&L
MK]>/**AG7U@5LX9<&FJ\B](J55'SS_83_8R_1K2DE&8.TH6OO:]2)S366H1U
M#D^[@7JVN86?42++-.?RZWEF&UUG,7@KCBT1/[4(ICN6/(NK69I?.TQC6E(J
M<+$^9<,_QD6U]K.Z):Z\O-4M\>>51&%'P''AJ1?8=/*FG-@<>DJCYH:\W;7T
MG+@*\?/A[EYN2W$C^^K/].25J<"R)SRA'7>\=U9Z%H$/Q6X_ZDOB =H+)L:0
MSGA?^T5OHDP(W[WEFU(<.Q!<@N_0UYE=+P$Q3W'OZC2W>(N#=;GZ%.4_H8WF
MLXHU6/.2IW^OET\P$EOKE7\UN8=//KQ"#&^861N29+1&P'UN$;(,"V,3IYK%
MHM[XZDJ.DQY*:O]!OCQX-E4M*/)2%<7W;1"W]_FKBCO*2HE_2TNLW8E!I4#-
M;-[V\0*[1?7(--=R!7MX>W4RS788CKV ^6,R2STE;#BR*)CB4.J4"1Z72L[!
M.530] +NEUK9[X#F#!EGCZL@#YA-:"GXN&4+5* . PO!LNXR RD2'6;F8]HX
M70G+V.K)EM%V$_)&6\J\3TQEX-,XS )I<THW^RM/XM.=S7WE8?T?MMF,HMI!
M_E2LZ$#H1L!BY+HL(\=7+J_V:APJ"7E'_0P"5J)YZ5^ZH]=#VJ0210^:IC&G
M]\A+\Z2$4K/"EZBPML>^IKQN>Z$S[;>#M*:;\<;%(F*$KS"FS,A6%Q4U!_R3
MCNZRR8B7S>^%G(N7"FR1OD+#IC:;[2)N4U G1R*U.JQOA&\6']:5D4/LXJ1/
M3_X\09A0^;5Q/4YU:+)H/Q\$[)V5Y>N,#'MM$#\(3,G!36) Y+&:?"T/D=E,
M%]Q1^M?T%RL-0<I,B37TLNEM\K#WJ["14[Y_#\ C4L-<,EIU!F@OOPV&US"*
MU6N]??]ZFZ\FR%] 5J0JJ4CI_D)H/SH%J^[.%9_X,7Y$95".J_;P7,T3(-"M
M@PT]?7IUG^1U"C%CR!M];T*T\6+K-$^;AZU<L0]8%;?.QLZLN_VLJK<*D1W*
M>R.'ACT)B8T+OD1KN%OEVFDDZK"@:*I6=^5M,]F47WXP3A\C+VIFYJ_F5_1@
M9)5P@G6UESE$D?;LOE?K?"IGM,Q9EP+N>_ZB^MF_M(BRL]O +2'<,4PD!9\X
M2,NZ5RWN2+?M<2BS2SQ;#\E!\@<B6WE80JN4Q_7>/"E@,_K%==+ 9%3KU*]M
MIEFG" (R#E-;-%0M"( W25V\F&/1(NZ5BED,GGOEMNA)]*W4+BF-$%EWE'U%
MFQ*_P(BDK1V]NX?=NJZ](HSOH _-3>=\*Y4H7X )(>M<*Y0_H=Z2>._7"VLL
MM":M.7_O6I;Y:Y#0!,>GU&LI]#ENIX7E022T!<Q2>JGUD1HLY6K3C UR[B-M
MQ3A5/+*+CP-X=$/&--]N'&%),^P5H<U;ZK)D#G4S$([!N(5!<9&LL8'5'J^3
M7YJ<2A!_3&XW>QK-RMZ_6NS]>?#[./716_N57'"(PE?U0"6M(KNY+7N\_BSL
M9Y_UO/*/>&C^\0VP2)^/=V*O+R(FA[QJ=XX]VO>MS>J1JH).F=+DFN\;-D2R
M%)A) B;T3(;:Y*%OX A9['/QH]!FT":0_I1JTC*!L"=[FG0=?G.*O\'4I10.
MMM!:&B_$1'@$SM4]W[7!FLEN)7XJM*#+O4J/Y1,)77<S_8<Q_@)2GSZXT[[_
M1P75HB:H>^]ZY"O&NQ^8,[.67U\UX0:M)'TE:B$!5'5^A,*A<6B(2MQ='?M"
M[]VBWS="]\57'!1(.EW6SHE@:T'I4AM!A2\]=M_Z?.&D37^[#-K[SUI!X\V0
M]4%&-0V6Q@&$0&:BMRV9YRMGU@X)?5!^EC(=FZC6/.2U8=QD=6';DX;-]&^=
MT.8WF&+ Y0Q4--W[?W._@W_"SE2XK3)X\-C9+<^J6-&G3-&$QU[0M":P6Q.Q
M+JR %>WO143'5JO:[)ATW]U0H$%(:7IU$*)SS_WW\EJ4!90NYEF7'6D2OJX?
M#7MICTLF/E#Z@K4#>14;O"S$B8A#.I*U7R%)D"U!FB67)AM;>T<$63),]!,,
M%#Y/O!Z@&;3OIH:+JED;D_M(WE*'CK=GFNZ,]7T/+_##^DN^M0Q@O;$E6ZV)
M?XSOR*<&^(E:N+1K^8IKZT\(44IE-]<MBO"B;;+;M^=&8.\Y@,!V'6J=%%WF
M14/=-;*%W@>QB_Y@Q+7(^O<6+I)WI4]>[_5EEB"TQ9O7[&V$$VL5PB?RP9)^
M6XIZ^'G0C W[#/;(!7&=2:>!J(1TQ,WE8%2R@7TO-\[*0,G@_+F/ 8>K"5&B
M3<RR,?\O(5M7WYM.JK#FH]M=*+R774&#GDLB)6%RCJF?J.^$ J==4N/7-7+/
MAB5K&]2'[^>:7>T@^0_.WT+RP0_VT+07:>T0*AO0W[#)0%^@4%6J$H,.3I\$
M)K@LG Y+RKMBUV<"LJL);$ZH[;>U#<^EPNO\86,HIJ+ZUF[@D3B<QW(4#()A
M@Z$2G9?=%Y'=H(IUP @6#KW=\C4DEAKW>/3:X[>M[<H^I8%V_;^[M92W:OR[
M,QMPF-E$T">^X1U6'H@J*GU.?'_D:F;N4#BE=>G0RV#8@O6R8718%7D]3I2-
M<FQ_1.%S,M3'I7ZBR0MP^WYC&E';1K" 6A4^4?KR?A!A>0##.TVBD,4&>1(C
M2T6[.S7Y[4!#!"+D+PZ@A< 2RNY[.I(N0Z #46Q2E(K;= \ZY7!KN'#9ZC2=
MF@3;M#)8W=QU=;=^:16T1D:=_C'>4ARHW;1=X3H#CG#^,5,4;4EL\K;,*Y%>
MT_-^1[/#VP:US7T(\=3>4AKRK&@K_,*UQLPR%(OO4./A:Y6W+HC6Y+AF!<N3
M1+!F_EBO_T&BZ,"]0X9< >[LK\ VXZJ8NJC,BGIMW"16TA%QR_?DK)$JLNL2
M\M'2LWCQ?(I:$EN F=(I^=?Z-!UQA2Z24@>&OC7S*XG<9QCX-9-'>(,,\F?_
M5$LGDR:T_1P#[6T<36509WK;C'2PDZM;H:SM/(@;ULJVF&%]#V=WG;!_X/,=
M8<-SK,&Z0%T8!FNCLJ*(R#G'BT"@T?7!\+D8'0-'3+\-$"K\['.CAX[(W(_"
MSV5)W7(3TI=;\+_R68) ]MET:AD5S\<>1C:A4W^R7$N9+8QIXI) YU7F\R=M
M=+47%,N6M'$S&B$MRE4SHN['X=:L);^NZ\0BU66L.;8P0'W[<9/[2[G$E3!U
MOGL,84V^#P48 ]NHZZ)!01.K5LK#M0JUE_54??_ B-W4%2JOA?P;GPNZK?)<
M_W0@Q3E)WU$2+97]I?HU79[/=V)2!0_*';6KSA@*+[H:8JG>M[)GW_,@5,]E
MO.L!S:'*@?BE+!,SB&*_4=[U87WX7\U^ZH4$V,PN+>]O6=&P/>A3G?I,'5+?
M(H .#CO&6[<%AL#VOAK/QXS_VA;8N%@K7?8//-GBY9R5H<NX_/-U_MT_AU2+
MAR:;V-- N@"L^Z "I-=_/;O+Y]W0SD2:'=:NJ';$Y+RI,Q8*M+U:98<3$7DX
MB1'M]W?*--C[JE1OG]!J,^CW47NT%K7;Q+5JK[E\J6FDPOTUB%?FEW$Y0F;&
M\S#[=LCL"XC[Z=:O>*6"3@E:+PK279YYD8R9B67S)E?SYXP71+7C#+3HIS,+
M%=5JM4;V1(C("^'X<PV$$+/L4\7WR<*%OFIOP\O4HR%NW5[CM7]5*\J>+6J?
M\#M.A,68.AJI@_["/<=-13[D )[837$ K;(A0F-KC6YUN'B_Z37YDO]A&]-]
M#H &$V$)Q]3ZT3@ EN N(Y%^U7B,8MI\_)H5AH?FO.+M+[[#!%4N?C5? 8N\
M$D&3D47TX?P=#Z;XHGM7W/+0%>(!A#3".T&%HC0DP1WESKH7EBN[U^]!=PVQ
MHG6^"M5FFJ.DER;B!_IA4;)[!](^P?>#;T"^2]M@C_611ZC6+A8.^5";E15W
MY_]_5>4ZT_Y/T'=GK@?V;T];99_%T!O6[>9]Z6;)O&)9NQ_9YX_/BX3]A ,$
MBTX\^^LZ=%@ROF+W[HKYKI6I0:WZ3_7BVB6VQ+$J[9DQFH^VH'4O8]W=4C5X
M[>WN'<:?&G^OLN%=&=$]MAP F@-P1&IV+.9-LOT9JHSHUH_"L*.H&+=Y0^ E
MKFTP6EK=.U84/'8%W8@?_Y!1\*1[/C\=W0S%E&UM-+BD0))M'D/4R\EN%A4A
MO,<I$>K91LX951_$5#:+UQT<V';I1YW;7[AH_OS2%HCF")F91*[_LS%#9>.F
M,_78S<<\W:D<0$V,^]K6"@=0H;1QB$!]0XEHT>;3D)NGD]E8;XC,_L=E75:M
M,WT<?9 $YUZY];';AY5V) EB%7EX%9I6$8[_M?L1?[V( QC0Y<;_U^X9#J":
M97XP3@8R%9 ID.5B*,U#?5Z>(CPQE[G=!97^S\9/\79A^G9W7CSW@CFOLV@*
M/J5@NM<MY'FV)%N)B8PUW#B\..%>N*%9QWR@7&@(N["XH)YH8XA[27_L[]FJ
M(OMH4,1,Q/1&8-R#Z&K17[C;BV'KTUIJ.5\[MX4_3>AM= L(?^HU%FOA36HH
M\K),S<UO["6IE@XE%1UZT]^EE;IO=GN1SE$5O:F"AYCC/ [@/O1WEACW'66R
M[(\_(/T'"4 H>YBK]SR;LQ&U"[?)@X/R8UKX- ,. &4D!>_Z1> O%SBUFM"I
M]$,YBAIB%"S<UO)N^C)=);PCJ;@2_GB(<'NP(<C%8_=\X7*1[+//-('H%QY_
M]U@WGRV:F'9S>>U5M?+!WMYKTU,+J4L'B3_8]?I]$&X(SH3[MZNB^S(\X5:.
MN'Q;K@)4949/?TP;# XG*RGN#$1Z26'TB>=E6;7(+@)RYXW$(N2[QW$98<]S
MZ4#X8/NT^['_.,P_Z]CF!P<@@?PV:<8F?(,4V4RBLY"T,/DT([[_S/[0!CTK
MD:7E)B<C?5 ))?ITYT^PM,^,BX?X+&W(A=F-EP$%J+[*9@DXIOW=&$*X9FWD
M.'_YZ]7/4:C3-A3>6CN);:$@::D6&O8+A;E8(9&"?5$LR]?(ZP8'VWS .-G;
M?\M3- \JL[#=#S2C8(97GKYZCCEHL5GV FG3%DO"DGN&"<)^<+!.1!Y&U^:,
M#5!)K1F,&<^^5^SAJ8@/3,/!?-,R_Q@/)7:WUT/R030HA"DGD'NDRS)^=]Q(
M\)<R(-T[SB4$>!KS^]BE=\??7DIBBR-,Z&#^FM[C7#GT=]?;M W*[8_]%.!I
M3]>VL<BO5K\@ NY(_S4\63EXNYC*[05QO@7W+XOY,M<4S>V=L<;-MS^WQ<1-
M&A-(YO@HRX*"IK@"9!E<F2)U]^BDD> (5B],VLQJK(*NFXD@GDP.2F>D16>3
M[E_-Y7.0/>H?=]CHC*FY6\I:CAYA\:PKDS?Q,.6ZP9#\7VQH.WH:Q+J8#:)]
MVV;*H$"[=[FH] AXU#0D(GSH+ P]MB=GAAQE\"\=C_L@-TP.4-VP \-X)>0,
M\08',%6 8T8=B:[WMH-J?M0=7%^?=BYU>64LY""Z9_OLV1BA0&\QL[Y)>?ZI
M$IJRM!1/VL<F_RH<W/">[Z@75I*=E/>=I^W5,^#Z/X '7/W(I:W^T&EU7#M6
MYN\?'C-Z3]W9^Z?\52.!/#U>?U!\9.LNRM:86WA.Z,RV%+7=!:I>Z8N+#9'N
M4/Y5PIN[,V?;2G1U9R_BXD1,Z-9&F8UW'?::WC7LM*J>49\V.3(X?@6[VOP%
M+''^@<6/#V:51U-_7Z/B3<;W*(3Z=XC!,\G?K=5GB&8?]AT)O*!OK4(#FA2^
M,=O&])Y F%*H#=UL&]:=7J;V)K@$&8W^%XD>7QN#\W28AK_]"_3_L<:]2]@R
M/[* \S#LF(84FW2O&Q\R>K'&4T9BM!V/J^+Y&0C7B-]'RN#^E@L-NL4Q5]55
MM\:(&H%/'3L8.##L5"%N3Z.]I3,P'9OP3Z=JT 3RE+AYW=-7.Y9W:E>X/.J$
M&D/(TX@I"$^J!_[%^Z=H%;K&85_@&X<7>8*R_3\L0%Y#UY_VZGW!RO+=.*4P
MT4=5\J8Y0%OP)YEVS!5Z(X5GZSS=I!<J8B071'*D.Z=MSU$<4\!NCU'8WJ-:
M=>*A5%F_^DRDU<7^!_7CM1FO!E=N,]('TS\>_*Q;/?YXZCEQA1GD<E=+/] N
M,W_7&AI4ON0Z=#3V5/GC;87R_*.E3QZ\Q$X)6H5]UX+ZB\,*^QSO23U]-Y<B
M/SDOAOIUDJ,MJI7D4]WFW#-AFZ"_LOECO"P9:Y$)N5I7MOG?&94.I@^-1(**
M@:/(2TE+_.V&<124*//M@4IDL5ROOORVAY>7A\Y\',1B?&O*<LC>H?V5A)1!
MGUC=S^]IHF^2=92%34X95\@+VFGA[-*SPZ,[6C*<=HK0'_\P_6E5GCM22%E4
M)?\\1=X<3(-C-4ISOKVQXH&*I-=Q %MS+H@;LD>?K34%[?.2!,\8:^)3\7JV
M96>LS4$S2YO*1Z>9)QDZ-+>A=) PPI\N5_0.OD^YE!52XO"J-Q*A2!;]F:<?
M.7)FUN;41\WFCA8,17D>_LO*V\>EJ4/>E/4$/!(FUAL7@[N_-L!$:$\5A!]9
MY(TY/NSPL=+] Z9HPS(ZO'E\12^;)/FKZ\.!V4E?^!N;9+A_@8A=ANQMOX.>
MRE8^K[ 4C'YYV[IWPX"V_XM/;1&4>OA2IW(WI/A_8OM>TULS$+JTC:X2->8+
MJJK=D@DM^1GB.AY.ZG6;')T/+F/"B.*.4ZUU0?E7PU7WCC7ZUG\^X#G?/3F;
M[\MLG[_VR=<U3NQ!V$&>)F_^<BB-N4&AYY*3B+;/V4'-5<9%B&^)B@JF=GDO
MT\)A#6D?CUY!_D51U5/86EP=MX(\@LPAJ>CD/>4AGQ[VM1=4U)9436"$Q1CZ
M#]85ICU9-;A/YH[FK7R@!AQ")B5IH7D"[E6^Q.-#(F.!VE;3<R+'9#)+7H!I
M^ DL1G2IL3(0!7=ZZ';K/1W-S(/<&*;//"+,5_9WW:;N/O)]%"_[4<EAU0NK
MWO8O^\KC"K4.MU3/P3G'X /O/]K<V5\3')S[0:- EKC-D3\'T"U"KZ;J;NI2
M:IT'OG1JKEU >#-M@\-T9AXP\Y=OZ!A"I'X<(L0^Y[-5F%&G*CZ&]D;W^M*:
MWPV,46Q6@%B;9,(<V)"X>'4Y8$F0V#QULWC@_'Z)S9NI*(W/MUWC"ESXYNR)
MMQ^O^UN:EF%QKZ97<&##IPX>-$]]2L>W]I532 O__5[H]S-[_^W V1-,*PZ
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M'C(,?#RM#V(JD+:JN?)_ZLQQ#3CNR&D=<J9=E0;S9*9[DRUAY^#.W6Z=F+K
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M6\5!BZN+()KF_AY/"N\9QSX>%4R,-BECLT(AU&:Y<+LYDJXSSP SL5T>=--
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M=)::]Y>0Y*0O>NTJ#VY$B[N=9&_([:?BH<:$5W?#^_52FD,-/E&_^B_M!3]
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M/G:"H4M6(8>BSJ< "] _V=5&/@)2,#M;)\A66:1Z"97_$<+ O/DXBLVHW:>
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M#>0<&O1YC-_HSV&CFX/32BG->#^QN_T&/?9CCTF!P8UBT>KP=[]W-E<Y+?S
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M(&%:NFG+M Z(Q^5;4$=!8UW_@G0.Q7^F9M>^*T!]^QTR"R*W[,B27>85N5-
M=3Z_,J^9UK=,0ZB/4&E25=)9I=RO&F(XN5++9+)TJRF3_O>#1&J9WN7-559*
MCI=%91[,;H]'YBL]>IOWD"2JT'^8'KBC_'VC=>V7&9N"V>GI>25<!#X"UZ<"
M>X%?,1_+))B5/9=H=H?+=ZDV?>7"@6V#%-"?T]O#A-@J6N ,0:^ '?.(LPUJ
M7]!857OKF2YE4CLR]5TZ&IJEE^,&V5;G[$DZGA%=:;>^2A6ZWA]>YIB)XJ:I
MI'/<RB4;F4K$Y!N97H<.16M\, J<"(SR=\0O1X2J,ZL$$@-,X=;J>DF*AE!H
M74YZ<PDNN6A#QJD$_5V[4S>[]S5N:0-(4SZS4*'6%E++X&X=1U?;1E3-,D2R
M/,X*W0!>47SW$TOO#E3])J'/$52W!UC4SM(3V&AG\L#XDQ1(R-LO?#V#YC$F
MEW.(PR_5_"3"";?Y=Z)6@K4LK2Y\_H5HU2Q<*-H[#%PL98OMH0V+:Y;-'*Y0
M>S(J$V9,*3^DTR))ZL_U/*]VM8Q'8;++^>2GR#0/KUIW,D\$511O(C>)'8GL
M[?CS5Z(YPZN&5D@TM$H\"M!MKJ(A_H/MF=X!E7<YGPCZ--WK%"Z#>A3[T)Z)
M641BW))^I9(6(ITRC#<0#Y;?1X5_#<9W^<1*G7&7$>EV(10*0(332E6TZ90/
M0R5YFIJ9-];K;C'2V[3=0I7I@]CO=SPPVYYSJW.'<PM[HV2>SAOM5SY@.UH+
M#';>A: R?9^1%Z"O*XNX*GUS%'T>9MV=]1"K/8M[@N*:**F=3*R=1"G>"B]Q
M]^/JVQNZD/[OML_:.]433OY'YIO_^5^_!-5?3(4(,*2ISKTF<K1(*L>M%JKZ
M<QBDQK(ZZ$3U)Y5OI20CI\I,Y5[NG*?K?-^9PU)$D*QS44Q%2$B"G[:>$V6H
MB+0UA9]&IE;H66/%:R>*VCH5=JJL=+[TH<25^\UKOOP,G[G@![M<[@NS(CQ.
M"JXW&HP([U_YNBG5M:]\4[^%I*,4[3^-5/Q,)&WBHS3UX_+##S9&,\U[3P%2
MP+:V[<O+P*]C Q&6(7*[:2:\4/P)!69,)=;R>/R'NML>QDGK#K%3"&8XUKB2
M[_[,69BY1S5.?!38873?,JQA?0ZX_?ALO*4!8?;M>/_G#'CC'4@^)N6;;6?(
M>"YV C99/2D716*[J':$&:C:Q'RY4,"BU-]K+\MP4&,?,7WO&7]@IHL)V/+&
M8$)]WI:O6-W"C_4A9+"3?6I>.'1V,LF=_X8&[?>>)ZR7_[6D(*E30&CY+($E
MJ.J)R.CA:_(B99]?5* 6E(?Q^WR&F24H^[C:J'BK*A.%\H6.TRY,>+PL'/.=
M5D&'X'#P3+@J(G1)$8HH)XL>CMHG([Z*U36W-!NA^(19'X_+<9E#M>K?'YD$
M'C^P/S1?H:4=X/H747Y?<$S;467:2&^[@9H8V2C*6=SW:YSR[ \CL\Q:9;_S
M#CF'KL[GG7-<L@-DW*\EV&+"%-;$5-0D?V7A&L9^)?YO%S+^/E*ZLEKZ..!M
MP)&SKNBAJ(:GRZ+KF"IZI72EH5X'.X7\Q)OK-O_MTPL5(?R&RO7*04EEA2M*
M]BBGD@W'1"6[6B[[6NMJAXU)E/:ROO4%Z^N)E?.^XM>*0G3^ H<@6]MNS[ 4
M6./ %K,!OAM_CIMH,^)H7Z@(<\H73D(1I ^8YJE/996^$4[:F5PO\%29B0X*
M46BX8 Z@\][W%I>YO*>E2&D*%2*%2M>G8@@,'<*Q<#"$_CVX^-IPTU![J0-N
M3NFO]Y-R;@L6D*Y'4_(=IKGU3LA\B_QK54TE*\IQ'IVP;%',&RU08SE-V_F0
M0+.G#"_K[7#2+S$L)[6M."',R@:&)!GS?"ZK9;I@FG65"GF*9IBCH"@2T5E/
ML+PER$26<MCMBUZ7",Z]<X8,M?=H2O*;Q#2HAH*>FY1T<9;Z28'PC.@\.Z)W
M^+RB/?#9F#^)6;V2^''U.MZQ=W7T/'P5R)F&GR20Z]Y^L(?.ZY@_^H*T"S_:
M4Z(D6;1<&X]V\+AQ$-&19PP.0#)G?F07L:U:!5LX@VUV2)3XY;!LV$WZ%9A.
M([,2YY=] 8IRG8%QB#YC6)(R)0?@OU-8F+?NGAL]W%2_YS WM+]SVY&G5!ID
M.]XC$G^!EFXUU4*_80P^, +%)^BF>!WTB"1HP'3&VF-5\-31$/LD?137,P*I
M6>^5EV;^WOR8T*V\@*E/&OH,?J"0=8FFM<D"-/@1?KK"J7K=_F3*,$C07LK)
MY@7*SCI1&&S5)N.4]Z;#U#;7+;@DM&BG\1#(.-_&.O=O2CA#NTP/ATDST:>
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M<,[Q* H"*KU(CM)#D]Y"<M0#" A([T1 I$D7"1*(1ZK4(UVJ2 D]=*1&NH"
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M+P'@=29=8/K3>6DCAZS'E8/92>),\24@KA^C4DHH(V])[8%'+])$^43FENF
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MY:$5FT%U\<$THX.H J+_+V,\VV=5- <Z8"T.<QAZKDM-A<9"SPU0<]L=KG3
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MVX2AWYA?'E/]86T3U?S'DE9),X^S#TVM*.Q;MM..W)T(Z9;>Z73Q70[5J0M
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M*1O9_#!83K!O.85!9+O'H'@]*$.07$3<PM(!2^M$=[Q*,G[=<)KB[;2&7.3
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M+8,P9MH76,/6 '*19Z *@T^@")"\<0>Q&NEU[QYGFD,$)FJ:6&XRC^G\@?2
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M13?5(^>?G>0I99P!J)CK0:][@/=4!\#;KB\9@(D$SW4Z&P/P;9[8<.;K\PS
MEFE&X0"&RF%+AR#O,@#UGB0F!L H](2FGH3Y900^O8RE/P9/IJ* U'=Y4%H&
MZ,Q@*$6)"0S1922:?ATB3+U&&;H03>N+#@0!D<1Q\XEB@S33,?2\A.,$%5+J
MX*RTXA]P^%DXPN;M"&*Q2;_(.6X@,OG+'H63$_+#/<@?9VU=')>$F"BZ99">
MXVPEK+'8K/4; 3G5;:F4?<HD''2'Q/?L*5IHC1W'YR>3DR+!^QRWI-!J(X<6
M/:PT/ ^5[^IMEJ4EU1T\?4ONI_51KV'IS/JG8*HLA?4#8@0LV/XWAC4,^L<F
M0CRWFRZ!&4>S8%AA:08D];@P=JYV]:P3TXQ?.6;-KA6^#OF?6<TNA9XFJTDS
M15GX%LOFV9$,V99)&ANK?%)(NV2O<6M) R,KE%;HLO&FDK?QM:0;M.DPZ=.F
M"2(B$VH Y="H[1$*CZ.R9'9*='M2G&KX:ZQC>_ ?5Y^ZJ$L/!,W<\S1D3ZPU
MT!ADNWGY1?<$A$63($GPC$N^)^/U<:IP'BF(7*H%UHUT8]B@+C"]WAU2%JY[
M%KE]1G)Y^BQYFFT3WC4)U"8<RFK-_3,6NOKNP\^?CD,5F_>[5DU\BZ%*EZ#8
MKJ#,P(1R;IO8B?7YD,F:Y="VO;&DO!5IOYRD9YK%1-T+)X*4<5QV!K-F[YT6
M"7%R.KTU=^V0V#F5P<, /#V\5\P27_[.C21U^50J[/HKK#'\4V7R^T(ENJFN
M+M61=$;&SI/T<!BASNOZ\N3:'M. S55^UZ8"89ZI::/F^O%MN&;1D-1.YD#W
MB=*&@(5\KNKLE\SQS6M&X:'[0R=EYR_'#A ;/VD@H]C_S/'7;!;_M6DJFV^T
M;_*PV=Q(-.OD&+_+1-R-=9),(_*RF0&M\.VL I9)FY:9:M5.SL:4A.-,W:OA
MT?!I =*[IN/K^D,3J-@DK[&DZ[1T!J!+)6P.>)7>?1;S^?/)/;:2'DO9C8)1
M@I7'ZIU"TX?Y;'NS?[-9W U0.;J=_/+B5.^4!1)(,'Z,RE]E-IZN*FM?MLB3
MX.FT .. I1>A4%G2;D^%1H)ER=;:IT')??V^@AB/K*6Z RF].Z67QWOTRV75
M'<N0:HM$.QK/K@FMO?/FHE,W"4N L,!5IAJ//*2:>5[#;AH2MP8X0%JR]!<1
MYSR6C/Z,GV1%)'=S6GS]- JAA 4K9*6%H;212\J)QX4;F.^U@H;<!TA\#A>*
M'R(SU%)X/B[)(2#?>ZUEL%\AQ]$(O\_,?>W9GIG\H]39PA^[=.;F4Q#5[!.%
MG:BV;T+:C45(^VI!HA$BWWS#/GA/B_#HBHTWWE79U5V$-D_E/!H[-*F4;8LP
M+=-[5O\3>P&7]X _M?<15?:=:VE*G^3]\NA7FP0YE)CM3'^ 3>A/V2$NVJ^2
MY>*&"""V4R62@VJ(=S*,$XHPY,;.I%Y:"G[:S-%;+?/D1J8_+2N^#\*QO>FQ
M_^6CC,VUC @"EZ+%>[QQF*1-QJ3R$@- D<5LOR&P2O=-0=&%40?9NU0Q0H?V
M'>(T3E-F^>U3D ZA6F!*1Q"[<'WBFBKXT6C8SL5IH^_Z,\!'C5,J,-?/V7*J
M\UJ2D0LL0^4#;'L58^:5QI;ET1"(MW%@0:G&49[XFG8 7I;[_<@B_>6"PLJ/
M3I%:_,60)%3LT%Z2F;8R7F,JW;M/L5\1[:*L.! T##EZ]Q.C4)G8=\I]VO]#
MQF_-@*T &I\N@^S2Q"Q5N[!3#(G[_XX\-\D/F,867&UZB_V"X0K=,MGE$%;_
MVW!?!BY-B&0W:VJ=FATW,'@[<GLR%!9FF&K*(P ZL49W%F3MR5W'&_]HOT.:
M";Q9;HUR9)$0@(_/6GL/F][>6PC*DN]X*JDN9PDNJ?W. &@MBX@.@OXF8C95
M0V16JX+YCYC=?%WW1JI6V4#H?;]*X;ARDS\JW4N*'8&O>D>82Q-@2?X@9X=W
ML;&QZT>X6HH,>!NZ!+SDXJM[F70&%;A%;IW<SNBE71:8+T[ <G[!Z'PN>"<Y
M!"<@DESJE?/XYZ4T<Z32J3TZ>M;$F9EN1Q]&A%_NYL<]JXOVX>BVP&!LJHTM
MZCO;7Y=J]C]NQA*[#G,<"@>IP -YTN>XD!P^F:/K6.(3<X'1%+#64 @(Q2N@
MXJY1L6CQQ<..&B O'!]Z7"  :E2P?E0LT$(%B>WP[H/Q$!;JOT/N$A!3ZC69
M8SX(-4HEH;B6@K&J?VE91.'M5H1X>H:7WYOF-"++L\+4_W&4E;[;W-;V=G/#
M/S2?9]9DWN%D2CIU3&JRBTBV%G[JA?>.T%)\LE9M,_2QI/I9AN=3X_[^O=Q&
M2U^:WE"#R\43-9C>;;FJH%;@I17@S+':M8Z[D4CPL)@9VD?#SB#]YLX^:$LA
MK [6G^[5F\%KRYM<+L"GQ>UA<II,]'S5" %0]+H[+Q*':G^T:RZ-L'D5<'_W
M&PA4:U.//9CSE[C7[*UP)9D[H^36V%66^DQ0#M4,;3]=:8,V?)9185:U^'38
MS (9 >X:W%7O"[X8DNLY4PH-S/9\FJFM-B@MUE^Q'")DZN0B]2%EU++:YK&Y
M@[XJ]P<MA\']_PZI2F8  FI_9.'5=W:([#W /Q&W_FZ+G-D_Q,0"K\K*R.ZB
M&8 877!,[^JT(>G1&Z%Z1]65#[2BJG83_&ZSG1X!R3X24:)#S@\1RZQ&1<:>
M)Y7Y?LG^#=0:$!MA?Y+B_CQ]A9D_\]RP4F5TQ5B6:,<D2 =AU*X*ZZYX14"9
MP2E5JB!G?O./C<^Z;:;RQAH]@:8Y8Z0 ;67J-,9[=Z:8@-F.)]7V8L[1E;VN
MK1<H$@/>CXKU&X+)\@FA_#.+>J34Z$!4#$<%Q;W'QKBYS>/ AU]9K3"2NZS2
M'>GA3T\.FN98<;)/>] P6-!6'=5K"<DDD7\XD$SF'I#NFY[*F(D@5N[JT&9?
M/R[5"LG"NBD<!J$]#*K\EALV-&C9N,-$:'CWCN@8D?DHZ3^(C:-I^B75,\JF
MF$96I!P#SY1O0N?-4_;M<=*^4]VGR;6)LKE2N"HE-[3I!!*K^U>\A^O%K.+-
M%S+MZLN?/[@V.5\/38XPS_U*S+N+9"-]QF;T\O.2AVUC+0B@F%=K^I;0CL'Z
MKZW6/1YDA\EJX_V>)5=/">LI[/A1G9'(,"3UI#30W?P,C*:\M7?,RD;+?Q6\
M*<R2/I4XX?^#[Z(%\VOFU__\R='U9] _PI>6N:E7(UL:_^L2YU=!B/1S%.&S
MWT&A9;A1:*<W?!:DQV?U21"LD=M$:*'XK&]9A%' AYP3Y3]%>0U-(JM3L\_]
MO"2L"TY6^KI<GVU+3E%5:/J5D)CV-FUZ5-X$B(9=[\'\@)L*W43QCP_Z\X<8
M_2-Q"0U\NGU(E:V)HPN"'T*%&  W2J(U4:3T>IQ/S?35RR\2MW?=<AVNU2:G
M0*7,.SU<HZ#]>9Y96N^>P7[H[[O2OM749O\^:$,2I\!C]'-#W%J'CS?,Y#1*
M*BW#QT!O9G3:&YN+3B1'^);":8K0;&"55TW.]'M)J2^'OX0B+^VNZ]P"ZG^P
MV=IH*JRE*AZGGEI35=*PNA(BLN-%CT;1];K34A+GK?(3OU8QS0LR+9QBDA&5
MW9HY.%==E 6T\WU'SP[UU@;/YZWOU)#DQ[%1O3*1MS"N<92?U@Q I,23]B8J
M^]O]+W/?73' WLXN%_J1]1E]OX(I@?^M_I<"U2NQ^?/J#@W^W,7V7,318=^Z
MI-=X(&IF=E&!4V)E1/CI&3=&I&]W_$+/F6*N"J<D/$/JGMUK4H'MF2?(N0[=
M<"K $[Y6Q+=< \[P]I?UE8[\PO_MJ[!FWWB':;4@])LW!>EX[CO,$=OL(DUB
MRWAOWSOVK=RY*^#TG/BM5?\R@_,?:H7RV(-Q(80ZA6Y7G^G<%:LB\?:?-O'/
M.MCR1*[!MJVOB&DLSEDEB04V\.P@L^:+3NWQ\NQ8/)3-:P$8SR6L#&ENS$M1
M-[WFYZVQM/8'AJ77342>&WJ5 5C9,3)]*O[[#8WE17<?4Q067XP6N(_:NE52
M: JN-HMCQQ;N(4\F!\/.U XT:\7]JZXFK!VFCO]=%R[( /1TGYP/+.UEFW[[
MN,M87%-&[\&Y;TOGOM;ZQA+E@=G?2P,?*YF591F%?B?"TA12G-/=*L6+K,?>
MECZU-RK=]2UMU-T^2_M!5%8&X!43OK0Y3O[#S9X"M9:W#(#ET.<[A 7'J!!_
M_I]*5I>#SDG\]4?(%*990^)6BG/&[8;\S6FG^JA8Z5?N <XG.CKL>YZ]="E[
M!N#:P&4S4&/]L=$I^NE&?QAOQP=XL\WB(/T-YM'BI4]JC_E2!=GG^U#'#,"-
MSJ_4NS1/8FE<4WWT[:57YN/"& CQ/=M$, X@^Y];V\]$79<A ^ W#R9K4S@C
M*KR..$Q(X03F18HGWN;='25!T[N.$F14TN[[;+'D@UJF.:>N\%_MG.+%U?->
M.??*N4L/YP^S,-A64 ,\U%W53QR862;E4-E+W^%#D[=4"$TK+_..$A+IB2<J
M,(DX4F'J1U?%]#4V-OQT[)!&,U?K\DY0YQC4ZIO"?JQ,<>*PSU@^6Y@&2.UB
MIC8OOU;CK=%JZNW-9P6EU3[J)[T-'Z$^LYV5$6'E/CDUJ' =>G&YCWJ#SM .
MC78X\?;G@LO\3R/1(UO;:]] ^W?W^K>W!Y&>2>Z7>J\FN5[2-U!,,$]RYTIW
MYRM)=^=ZFV1A)/K6!CSO)\?+^A+K2K0#Z5P19V>ZG<)[^176(OJ*&B]++$I
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M4PP"GIB1=E_F::;B4[C[-?2 SP=#*HYW?-K_>3X<;-?B1N(3PLCG:UDK;3,
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M@ !G\BX$F%"V4X%@"W<9+8UUAJ(+/QP]Z!!<19(WZ]89 *(7 [!]YJM+GE^
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MDW;ZB#ZZV#C9E!]>X@WFU97P?<8 Q*A4ZS]PAI@2K=]%_4-4C:EJ&C/Q4XV
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M5H+K.>W\4]@WF-.,A2DRU<DR]U[2.T3+==M!,%E S'(S!'A!K6V^\*7HF'/
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M?#%Q(P3S)Q1LG=S!^^<43!L7MYG+"I52)^[$[$3FHN;D"ZGEO@X![VUF!_Z
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M0UF09BGBX'0-LO_N'& K(PRUZZP_![AT4F3?M3Z*[ZC;KH^+)/;>3^"<#$R
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MV16^8<:\BC7]_+^QS,:8'WH]] >H1FI;X#-YJ!,$@#LMQN5RP.2)ZR^\;E\
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MC(LF@^*29PPATX;]$;&ULO5N*VF"&N']>N'NZ-WQA:MC:(IT<3?7S"=8JG?
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MFG75%FIS=O<<T/C&;78'23P:WOL?Q+U75%-K%"Z*VX)TD5ZCTKOT8B!;V8"
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M.0%-Q"8T:V5T$"ZI['T?(6";7+SK9\-'>^=V!Q=GQW+>R\.?V/Y^,=0"2 L
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MOMR=\6A=ZVE,E\NN$,AH/+B#R2IK[>CQI%_=K<:&II;T];:V?$DW_3!K#;<
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M*)GO"K3M5%76<R9P6R1W'+QSG,#!] )SF#<=#MP.[FP1XMT#JAJ'![:<T[W
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M34HAJY1!XWR8=XJ4<U-;EDM4'J;S4,?JO]:^X"1L_9\= 1+B,(]B&3$-5Z>
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M^593A#(6L%;V[+=IY$P8OGH,TB5ZR26EDR.X!]%R_:H%?3HK"<AK%(@[U,E
M),H?5>!@]YBRHOM@Y.=]=>IXAL<@XD36X[<*HYF25NE "K&0EU;[OST27PX#
MM$Q8Y\9$NFLD3.C/&/9CGMEL?3FO@:\269;.?O$D$0?@*!ZQ><AJX%?4=X??
M)L#3874FI\DCX3W4GOV/TYLNJ$N;72N'J1OG* *#_B:O]BK&[+X,)"$]&R]"
M,-Q9DPUE#ZT[.'.BVTLB/$->F:?*Q*B:P6ZG/6S!SBA GJF8_U,P;$S+8!QJ
M)#T/<MX5\MNQ(2:-X/[/FC(XV**W@$8!$U2D)3._"BJ MJ0MD;ST;[K2C%><
MX:> /&OJV-3J^ _]$]+Y\TFYID.5V6X]D-V[%?=__,VL"!+'W^MFKI]>OF;W
M[V->H>C"N.#5F <'DRN6;XQLUU8M3!7W\ L?8*/$?YIC&;R]'Q'\FS3,N6^2
MII;*-5W!5%[] 6I.;B=)"![G$6_G1=FP3@8_I>[?P$>YR]/%?4S+BE\X'H-.
MO09R:+P4XG9.$ 4;WZ%%@Z<R[A&%"!XEU6T4IM\#VIG*5M_2''*\\I.[+-R-
MGG\;FM/6R.3(SWLKWB4*_[1Y#E"^:(+/Y5;8^:B761Y5B87K/DC6#M*Q:EM-
M,/XQB)"-,-P?($=(D,$B&ZOZRF\\]&]D0?G[5>&0_EK1)VT<OW)G\\<UD$P$
MEUDF!&FA7MX;HA-67'CJZ_O4R=;#R,/_#POKG*2"69S*;/EZ,LVZ  QV@T]@
M'D>/Y_5&B.>N&-)^=^\X]$HY+)!T]^U,L+P [%[;3_6V':1A>DA'?04RJS4F
MQP.=OO' 6\M6<V_1D;G.ZU^L&NR]4J_BYVXQ7A@3^2U$?O^=/>3YM2QJE.2C
M%6\=V7'8Z$@18O3WB5Y[%6<*1P*O\(?[PX)U^3>Z9G5_=DX.73]$FJ@.!P2'
M!=BA>:X+E[_J>NA#IEE3?Q2HH%JM*FXE(WI?J-G]YY 14ZFA%&<N<V99A(J=
MB?]TJ'CI*UBJ"D$*Z5^<71O=D-5$C<EX4*]FYU#UOG0MZ&R_Q@%_+*_',YSV
MZENCRR%B%9SUSLRMJ6Q\"[,NH?.%A+Y,LF0-.(:*BZR[4(JWZ%I3!R*R0FS>
MI:5<PCA9!R59CQNY*;16VQB9SI,::[C^)[5X<MG0'E=YTFW0JF/[FBG(5/Z>
M<)KP2-<12KG.H! _ZVQ*_K[\%BO_3\='^HVNNNB5-W:%%VUCZT6V_]DCW%]_
MCQN,#;G,$C62WV!._5.K4S-6U#V O]HY34U-"/BX3X8K9?*(5^52U$./FGCY
MC,4R*FZJL"<%S-MX("##.>=(C"Z(Z?2$7O0JN#K:(<V:MFV*@%#-:L*%\['"
M11,[#41!0/^+FR*2R#_G-?VW=X<L]1>APQCA?!LW!\3TSOT(T:G^M1ZM_ON0
ML1Y9^Q.G>VCE+#[FM&2]%EABLU#QU'<@?WXN2-=W7OYVT&%?'Z10CL?]0R6&
M#[AYJ\FT8/D[G!^ VB5\K,3I6#&/,@('@/DI51T7=PO)']'R%$6/J4V#+&'!
M0&"((K+_VS?(+\S/+]137\LF^T%/$#+(5\'4+\A/'ZDDT*E^MRA+[+U'FKS[
M8R.^S+\S_YQ92U:?]RY]E^LSI%%D&HRL8]E,EE@D&V<@+=\I3'HJ6'M;196S
M_Y*?+V=6+)M1J&VD/<!O;)[F73P5OW'A?ULV@"-B$=9L&XUQXST%(&TF"9?Q
MJ*5>Q 79F6T"US\.3K=+OX\$D6>#<S3TEOB1%N?6)O:W8#OM6H\TQ5\P#PJ5
MB)[QRI<$EN;I.<*&MKI5%GQX<75_UM!,V8SZCGF_@3KY?096MCD@R?=%,/SH
MY'>V<4G[KC2%YRQ36WIY+_5K/],)01^#KE69H?*?>*U9]O1QW5;ZU)=6("/@
MN"F:L1[7[?K=M1#L+6?C,L)KXP?((7:$5HY!\]D'?@U "TU>_2K:J!S8ZIU_
MV$A=PU[)*9[S?OZT%%]JM^ X$A+NO^7A=ZW1,3&O_ <NY>JWUEQDI.QPP!G$
M;:7/+@+<(]OD6U$U%D[C@1DW-C33'!K#9=.^IZD=&:%\21V"J!Q$Y$?7E?4L
MU^N2B0([04IW K1; 8(-/U!YUSACXP%.Q*7X!AYGG*FKOBHG_B!:0]3P1RMU
MY%/7_XNB,-39O?D=TZF;??"9F?\(J*&N&")KYN4.PL9#3,.[F@XT#=:.0101
M4H^<!2V5%/CG,<@XVSSFZCH-_IK_:HT8X38RG SXRK"#9->Z12VSN1-\ <M!
M$PRL[&V&\'K^\G:EF06NQB!26=*\UVQ_6VM^\?\X^!'BJFT;> QZE*QS&%;-
MM66E\T^-2\+3=QV3$5-Z8;O@7=G6>@9P\]0?UVZ*G0J6:;J!IV\#=5[_JU$6
MP@$MOX.--F8>#.F%\<2(^ 3T45,/*@CCZ"OQX8%ND22BZ,Y]=K3FT4@$JQ-4
ML4+PL(!E*;/ATTW9UH1IM')H0,@EP&=\&--)>+'\EB;"2:"?,R+,1*_8"J$,
M]KH]^,VS7 V>33&M;VEO6J ',N3=WK]O)^# ?C*]+Q "VY<92B8/CD'<SN6-
M+,BKZN;4/>QW>407QWST_WW]" ,:/HGO+\F49O*"[RTMVWBSFY(OP]V)QR"7
MEU K()EJ,6@3LQK1FY(NFS#@;E&94F)_K^\6S]G>&SK%X]ZEZ:;VN-DR,ZM5
ML2XSM4B+J**BI*PA:'(P3!+F#0.N0#H1"9I:3;FXE\'X<^NYX5E3ZNW0LW[1
MG^<@_K(>'OS87=_^OFID=Q_UP/:MY8,"<<'Y].P;5\L&=E</P:%O4.D]]J=6
M]:'0TDNT!ZO=PT'&7-M>T^^R!NN !9HMZRS>MVA38!/+R7"L]K)]Q<<OD7Y*
M>&7 &7_%_=4WVR?<RQ=ROIU 2.2B0J*[VUPKY"T_N P3NZJF^\'U_L>@<8C0
MR\*S*]1&J:>>\M.DDA&6X.KE]QL+DX>1UNRI%Q QORA$R E&Q.F:597<.>GX
MHMF%8 ]8?Y58Z'O$%)6J>M/BWQ:HAI!+I+ZV?!J\X4'(LJEO1,!"V":X#*YX
MM&1\OK1$5,E&3J/0L<#8O%S7ZGO)"ZEUC1+B,D\],^T8]/1TDB.AX/Q78<-W
MH64^<0C)P*&')P[ZGA9DDDF=SZ=*Y'RL=AB,42+P8O+%HXX,-.R6(A,WOW&@
M*NH-'Q\H_^(%J\/M>#ZOQ\4S[BXSKY_QNB-G.%E=K?+LV^'G^UEEEDFG_RK^
MX[K=CT_[UU@<7=*_GL^&,FIQ>K^!AOWF+^AI[_VV3O, 7/9#FG58$<1;3M3H
M;DUL9OD"#9I(16R?M9D]!G4A5FI$D;;7A_R4IDT"SM5>DOGI^.I;X1Y"2?:R
MR34]7I O70G7]52B<RQ[VLN@*N(1Y?#2N+/U_.%\WS<T?!^[(CD0/&WI4,J3
MY'K5C,<B(?,@/<D#[ZPQ2L\CCVR/D6NXF$FHH*XL\9 >PJ73A*9ZJY9@[7_#
M5/_5/OU2"@Y=>K^\1R">,$Y6NL(?+71+\DW&GQFYCL['(,0K@">DIX6%B>MV
M4Y/L$["G/%JWR2N7,S/]OBO2\6[D X&7RO]CAWS=X=HW# =YPWE]"!O T&5B
MR4U[TB8WQY[W'8.FCQYPS$?P 6&>Q3W"LWS/HE<>2MT@CC2"PKE+DIYM_G$5
M%' ,VJ2\5%=-.0U2_C]Z!@UF@XX8LWSG&.0!GLON82E-:-AM0V517?(,+NH'
M=2X-"JK&_D/+$N6L[\"_[\'GO-]\W2K=W!29L+5H'@]>&!JIF%_X$IY_(Y,P
M<[W$V+Q#/'67!O>B7]7P\?U=I6AIY.!4;>J8V4@_!HWAN[R!-DH*/)U26]U\
M_ENUSC%(V,QI])^])&X?=,N338.1>4_ME@>#1<8917%'[4XV5_*BKF56C+/$
M/ O"R]=:6K),$A/C'Q6$K3U+LR_-3.Q7^J"CM'?O6WT;_^?NM"!$D^_[,65^
M!]FL>-D&(V5^1_"N_D5._VA=]D_PBJ@ESDR5??S:/.KBV9+_-K]23;)(<DLS
MDGW#??I_V>^9SHXZIYXQDVTI-=TZ&&\8V+M<B_3?1WB$9RR.B=T_[?^DP;JW
M4,N$&$:/0D.@=\&IYH(9*Z5/81VR;:,=P^,J.>6]6+Y>G;ZIVBVE?XY!+Q)B
M-<+D&/IJA#"EAK7JB93F1NW!KP3R90;O_B)MD/F 7 ;8DMZ66U*@D$Y=PNVX
M0O.N4NNN3,GO@UQ#9THDX1<FHYT4C>@YSI*!>%%F$)?:T;N:P=0]R?^?5XS\
MGPZA!ULN7JK[#&[,_K2%HW;D^$)Z_6+J%H%$<N,TX/LTY"VCX07F4Y"S29.,
M'P5I$OQ"7L5%5)EAZE[4MF@W.U*AOW2;%$8\,(.J5!;7HA(MNDN>%1V#H%M[
M58[%BX3RP;D!']6,%G.FQKX#K0,7Z?*G.6NJ9RKV9,"=,@^TI6%6B/?#]M^2
M;7'>8]'K.X&Y4QZ_<,9""E8#^)7RKFCT'?\$<*\^U=17?7KFVJ!?@)_2WTZ.
M(Q(D?8&N-1W77/D_^@7K[E6F&6Q6LZW@YBG;[?[2= >V#X3 _=AY,'C#"N?P
M3G?2YU:5>&VTL;6WL1K.(I]2PIFQ+KRB;:9LS)\8D.'@/9N0\[]LFHX"[\A3
M(WB389PAN^?OE'5<K+U= QB0,^'9%"E-L>3&(M75/Z>6TU;N%=R%?72<:IM3
M;;I W)2^$+ #Y]5>4AZ^\FVOTM+>)<Q(L^4#P=G8IRI$J'ASV>=6EFZ&^D$:
MB2[MI5!M0@47-T=.ZOM0BVZ0GYM'H6)/<&"I*9?,$P_0M[/&*JFS1D9;<-Z\
MT0*9J]U6B<QN5;S0]I8)K[@:*V0MQC',H[E *\%+%O4XX:X"S41 ,$W+\G5U
M4HD]_,_7BDSG*++%A7(S\W>Z;Y(VAI6UA]D,F>$PUFON7=J =&<%(\WQL7A;
M7I?\#9M"BV"D1;F(V#C>V$Q(?EAE6"WJ_<K5=DM3OJF<_ZM#@T<]&1+F= GT
M:68]<?G]#%2"^1ZM5H+ZW0GFZ.  2"M/<ZCKW>=.S\00?"E?>7L1/ RQ]W8H
MO&%^V/-C4&SPJQ4\D=_9*W"W;G)WWU=EQKYQ4EU,PU1W]Q"SX=?WQ81\#(I6
M[:%6JS39OUTGW'U)GF^I%LD5);2=C/_T^"/CKI,0:BNZQX8U%,,C&NV3X4U1
MA//JVKT=P_/:RI'&N]VJ;!3,<<;6@M+C:1F7JEM+AL)]WW?D@A=V&4)]K',X
MNB #^=]7PZSQ&5WB)V(4C%??DAJT#.L>20"?AUX!U#YU"%,-XR+ ['>=UQ>J
M0O7=L_M%Y-D0UC)='FP)=BT%<"3+G(8\)L_:QOO&YBG?AG9C$F.;JM4S<N%C
M>#>++YI'=B3HOC2FN\7 -/_188Q'\F?_EE(1[<_7 ,X==N#;O$V_E8^D.PFK
MZ#=NN%T\M:X@4&50,^9>^_;Y6X<9G)G*._EA@21W$8ZS+<H60'"]HV-IWZ&>
M+?TQ^N:1%EO5&MBC3T+?8K\^9$TM@IE%:*%_;J[X_K%[:Y)P@F9)GIHNNO*&
M-X4EL373ZE)8OF'3^L%QD1OL/-'H+&) XX@-\:QKCYFQ&?<EM]<3QG\T<NFE
M#NA[4'$*M-C7 4[R;]T\LMU<XXMROK54RBOL#08]T="=+)O.Y%"(6.*VB9'A
MB^YY8"W?,EHC;_E.=[3$0@JEY%0;,F57[?'4B/342T\S_?M4NMGPD*\[_2^:
MW X;/LY\9B?*1W*--+^=$UHD;-0Q2#ID2T+"U\0>: ^ICAAD^\>3ZL*&F#YX
MK#-05^AS!"=!P$.XA1[IO!+#2F"AMVEZNNF@J=S=C]_A+^(G43.^(Q?@G-@R
MRD6G.I2D[9/I8<C[YC9WK\[E>SJMF1[1_:KJBIYB3CX#9E6>L8,?-H8#\]\9
M=82!_]K\=AA=8ILEY)Q-?*ZV7:,^>7G.Q6)B]!!YD'H,BC2$GD7?HFJL=V,
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M8(8"C]*7P\&#5H8DNHXTHP,H(^=0C2&F8 ,@N]1;TP9!34$94D:ZCD%")-\
MWTJ4G\GH?@ZL@:%S(R8N^0RA&5: VB)7LI*^^'4NR@#.B;T>AP9Z4C9\@XHK
MJJ)Q#^L^0MP1?!DV51:XZ;HYZ:!7&60%T=;9!-J!]L?);@TEB)S!2?YZ7:':
MV;)>RP27O02GL>?RQ=E*GAS3\LJ5S<3#0X8GX%V!%@%(-,3RCV;8?$@-FYOX
M"2'4"=L6NDX#W:!\&2[H4R!,Q&Y7R0[YKGWUMB#.S7O?UR/4RV1^P4QL1VH5
M=8OQ&&%=B_ICA_>2FK4*>9Y&&.MD\:1<SP@;3\ J*=X-NMJ7._-A]O#YW\'K
MNGXHLP<O-!(#F+QVS%CB-_:%?02FZT)>@H\:&9==Y.*(>WX?=UG_+LH=@Z:N
MJ!-@]![>(Z;),<@DGI6 H/J'_F>U6 ;_# E[@J!&UT7=)A_4T6I65OL20[@-
M>Q 7@L.'PN]1L21B3%51SP%JWQGB0&5.L1HIW)C>SF ]/'VK'6Q4.TZPDC#.
M>S#UI'J;.$!\O_OR$)+TL>-R#\U%3[V0]$5-DEO!3JFZ75\9_129%QX6I'_W
M"51!L!9P4G%FC7%:D5W:C6<5;9,5A.0GCSY/@/4%O0TRW#:MB>V70T1O?16J
M7LC*G9/=GP*?9",I5PB6_[_'O#&^J:D(J@U\0:N+=68*[4G70:F1$9^PKZ @
M:DWT+V1JK LG#30>0N1#+JI3>Y,ISNX]1Y-0V3$CPM2^MEE)Q:!G#=ILYM<-
MO>V95DSL_,S^4O&+\^!74&G_D=?Z)Y(^>WDP;-]Z.AEUYQ1HB1GH5+M&'P!H
M%0E(K]NUC&NB8:ZJX#82Y?*VET&IR)6N,?R(6:D\/%O9#QQ?GM)]]:=YDKQ%
ME.6WQ/JG1EIR(:U36YI',BO8^2 69]TQB$..<9M9J']W)75NZ> .LR[B-)I[
MG&$8#B;51+V)^.2B1+-KIR97[=,V0F%\C40QM 0-%J?A)["5^Z 9<Z$ZL=KK
M2.7=LSU(C%)#^261B1>['(#BOO' 1T>N[ !;27\1_@ A)V6MW/74[B_"7',K
M.&.5ANN54 1VF3IY#?7\RY+U4:]XQZ5*_J-5XW[Z5;*C1-X /E,)>NF=+',
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ME?906A<3K["^4F'9NH;K/UN-^/&QQTB]J0VS>)_>QN+YQ$SMX+Y9ROI,I%J
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M/L#W6P@Z;:Y4#)=$P'W/2ZH&^T]=M:D1GV3>?Z:\3,W G<59^*@O?ZLN0KG
M2P<4!I'S&R7N>Q@6-SN#O-YDS2\U&>[$8^AR$;-0%?:4[962HW"\U'>G$/\
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M($IF<Z\S\C9MTX<?E<B2=TR5].HX/7Z1.D/RCKA82R5Y.]A&KDZ?>GYGZR)
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MY^1Y&I4_)IO$(.*&1;K+#1GT9,>\8$8(2_B>@=$W!S&MC*+'<.,"N^<]#0+
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MD!4/0^6I30:]+18[#5FLY-RPV *OIL?0Q'J.J%YQ61RN\K>W":B26B^MA.*
M<EN)"';963_7(SN0Q#Z[!@;WQZP"V?01&U;1G\9URH:*P7.6;L&R5OE-M=WN
M\@A(J6M 4W BP7J^3W6':>@^_'-+4\)1:"6'.%JRQU&(Y<[,EWP\UT%Y7XMA
MUEE9JV9+Z5*Z[K[OA1(A)LE;[1$)TKT(248;=^/K=SZS)P;PTB.X966FQ$#=
MC@+1498&7Z2GO15=&[].K1M7;8X7*.HBS7DA4LN7 ))0,]FXB* %GL?;3(UW
M%M:64C"!,S(&7S2\N2\!M_T\:9[]Q90T;E@).;1NM:$<EQH=BK 03O?W%=M%
M(P,CZWZV^S6)FO&.:"(V'4E"FU<%@QKU G6;H&@I8$T51QB,"C)Q*\PO)X8_
MD<U?@6!Z'!X:"9V8\HSP#M\,_P!#=/\_IBDP7S,^.UG0KVN?DN*_.V^QH!_H
M*^:73 .=MP3?/_G,"/AUQ#WS\ZVJC=VC:#8&*N.N1TAEYE==T[IU+R-#Q'[
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MLEZ>\7@Z%["3@MS&ZO]_K5KY/PVII_MOT >8 %[Y^9YRYQ 79H[5*@[$ 5/
M/$?FYVKMA!HL\,1M@21*1/;URJ/NDGTK%ZU)(>CL9+AQ&),.CS#1.7>,9JN+
ML[:ID&/E3*\']GD]EB*R6N;BAXW$)K/W2H;*!Q:&F(GWYV;S(S+6&OC$09*Y
MC?C8:H(%9[F<!INQ489Y0?SP5Q((B]1-@*K/I&3\.K)+R-6K L4<;N-62"IB
M^,8E<LTJ\&<[5BKF"-50&['2AV+J<,2=$UTZ=N*M1[B>$51;6P\(G*^_WJ/Z
MP;H6;D5!? N[UN)<(%PUUBO^A\4Z543O6OH:B=IN<KX%T^OP1,0'_*8MNRE_
MR5!F/5-MA!H2-&A,SH#QS873PKJQ 8^WY4_ #< =VT $*=A0:M>.GR1#5+OO
M:%G?W8MR(1@FR]+1#Q@O(_P<#'DW[8ST$YT93S^0+P%W+ZY5:#.(YHO@N$5Q
MTZ?2^1KIRNS!14,C.6LM^?JZ\G,+8C4A2\('\U8F8W*--FH%FV-@\BT=V*;N
MP+'9.7OX<E'=[.XY8:Y+D#(,9FI8X=J<#_SY@!@8M><8QC:PPM"HJB[RI6E2
MQ7?U?+>M-,;[J158$[%U3;(#6'T)<%FQ@?I:SH@C"S=@C*0H; HGR3:O*B^Q
MSG7.WZIKTH+V+6>O4Q"2TT#4_V Q#+B(XV-1-D"*H5FB3QJP"6CLEL[?)UZD
M7,4<7Z/< %))0_&:\-%!R-,W<R?W0Z^U_*]GG[#@!NW=)P2F$WV26P79]N(S
M182DAU5 7SQ@3K<F:EX"TB7A(6LJ$V^6N2:0QNLV1/-8CY)XK3K"?G3#DKEU
MI\4O^2;&V,6:24(1E3>0^_?18Q[&'S)SOR%V(_9?35M+M JF[/C88O.BN:Y'
MO8>8]CELOT1CVDS*N4J4&R$3[PLLRY[YP]+T0.?\>0>2_YV:X>GB#9\"W@CG
MI(P#J:OEK&MB8"SD)VZXL3N&U9"T-_/MF^8^^K2P>4Z;&K$YFR]-!U\^?.2_
M[O$K=;R2FU0?_<2.!J>R$N7;\C+:/14O].^ -IVE@[#H>.+KB\PW914?O#.L
MLD5W)EV[=;^X8J*>AS*9)TTW'*E^[H*.__](- H(MEH+KMT@Z1/E&>:EON6J
M7&DL@YKDEH\V7M']GGY*=)>(;MK2TD@MP.VIU'UK#6_DMVK^! HC#?C>S5SV
M:K]SX4N \>H.?EO1<V=14P\G70LV[SJ6+N?_7#@R'I!44%3OM::OK@^K0:DS
M<*%FZ9F+HL@:R4D&_*O#_$X?1AMR:W*],KB%)[]\63"K)!Q;8KIU%],HP\BL
M&A<E>Z+<"@X95GOQ^W^1WYB5YI3N8P)5'S.Q*<6A:9F#E-&L7,PZ$=583[0M
MC@O5>'N/^3;])Y>F61;K.^)G46?S.#'SZ)6+!V>RWCLMB(@5!CQ1;4$1RZ9W
M,SCIW.I4PB,PTZR]+K='J\"F?=$<KDT3Z=]Y-E%@2%C97%L]"@42#;C=TE<=
MH[%%C"5Q(YSH[JLK<%5\<)Z'Z+*^\-^6D978^E[$&U"O,_MQU,4RJY_7)8#6
M_.A?LN3_<=M1R/K.P+D!V>,BF2('53B)N"@,]0Y;98A7N]7:DJT]@WS5@&IH
MJT,U9J'-QQN7N(PCMG5G0X%(R.&(8P5$.;/J!(-^D,DJUB+A\>JT4'J5<A\_
MRC- 0#&O31VJY,E$\H$9E PRL,89>.-H(3J[Q&)KNCCT=**K$5++.]]J+1 A
MTF,U@31A,):#Z&5YSVW.C\@>09#BX67A\U?XZK5.9G8\V23QE5/&P/>.+P%1
M*/HN#E+A\N30P#RL&W;3M8MI6NT19"9=VT^VB'D[_ '1)5&.O2&AO>5!GNED
MJ(Q"C.R%E:)F-,+='Z[O:P_$\_!<L(:*$%9BRXA:)E&COC8K5")30Z+$6_;:
M7-JBE8HM(6]9N6@BOAGY8PV,DSA_?L=MC?N<9#A13T0]/\$]>6$G6%27%_G@
M* W!8_>Z3:=IJ1W^^J2Q 4B[?29[:+A52:$KNG@/6RTH:K[8WS4D[)]TDD H
M)C6)4& ]@2JQB^.GSA4$!T84J/%N(7IY>(F%<$<X&4B,B:HZ]B1I=SP/?9#]
M1_F75:[5$,Z64]C^CG@W*J$K.UP 6HZ-DJ0=@;(I4;Y_/U3^6 C.F[+4,LR1
MVE46HXD;VIA"?ER522\^KGHTT/82K2SI1A7KDXGG"@E2X[H3?S)>0Q^$3GMI
M<YC27I&NRYBT<^H)^ZV-!>XNG5.'!EV\"P>2UE>S^VO^@B+0)[G N,8A<,RR
MPM110HZ*!%&[&S0?N8F]!'!"@>!DJ1UWCR'S24WXTEI7D;_ <E29CG_Q-JC-
MHQ:Q8F$->TYRQVG300O0')YW"2=.[_L,NICH5#"2)7:,_:_G(C<U<3[D<!:4
M9TRY>K.*R& 5LXQL":T6C[_7L<AT]L<XM%G/=*9R:II.EX[<WJ@81'/G:+=I
M=(3W2K8);_DH\WI7>,I.@J( V3AF5/TW'G[/^4+F/.N8U>^$UX5W9SY-KA/?
M 4C^9$^&6(,X(?34E<)&9MDZW&.F+62_^EF (:!*.0F7 ,I# PBE'N8T$ ^;
M8[OY8X#^\!*P>S,9/=C@Q>6094.HO%NOM3*%?[:L@U<K+0K7/TY!HN=\0WA#
M%CQW3H-L6]M\P=G9R$M N^^)^4GY3,?U2ECW$JIVK>8]V##=]K\6XI4[&T7,
M20G6#24#*X12-;EMUM0MYYMT%\5LZ"0P=B?$PW)=CZ5.?X@:S0S[U\N9]TGQ
M$3N^%3]M%MWGG+.H]:)"Y$K+G&%5W*KJ'BGRA3]^3SW1AEK1EY11))W/MULZ
M_M"7N/5+FS0?^NA? C;IA5+#YXI8&Q@B@(2 2\#.(7Z?V35+63"J***+"C7=
M^!1>BZFBZDOY-W>V)R$D8>$'C["[>]I^_]>@639&@:KG>DO*"U61(8O74G'0
MA(VG?1QV]$DOM 07-7(FB[5X)I'@'0/^X@)=YLTO:THM3@=KB4QY 2\-0/_@
M!,M=,E[/ZT[A S_;'*T9KA&#0U.28*N[GG/9./-_49Y@&@HFD(=W2C+\7J@/
MR61UC %B)]W4<"4MF X886_Y7'V&S%6Q#&]IKIWA'[<?[]"$=_O*7Y@;=G:Y
MJXQ<)%1H._Y94:>7&GPB14O,?TAK)NR2KU3@2#0C,.8[VI5:YHX6\M&EE.@/
MY<)OQF7QT5B]3"HS0^B;K9WUL9GDJ90HXLP\P$M3D<9I5B(:VFSP],;<@P7W
MQ[!5#'@N!J?=*T42EH2?O[#:X$Q"]8#G_F"SDQLN7/J?+"QU?[:#'N(D$U7X
M/I%$>_X'6><9U.3VA?L</8@T$>DU-GJ)2H=(CG(  0'IG0A("8AT"1#(4>GU
M2%5:1$J,]-Z))!3IT@442!"0GE!BA"3<G'L_W?E_RDQF,K/ROFNOY_?L/7LM
MDB[%6=?1C]MF#F$8_J3^=?EFNY.@>M'?[7'_YN9'J5'QLD.=2F4XWMZ)G+ ^
MX6Y'2^Y_4HH5], -<KU1D;QOK-#1$7:AB<5Q/5,8_Z69*AG+]52YO;S//\?L
MT [C\Y,QF;FF,"5KH*/:[@1(=Q_X MB"CN]4/ .P>D5/[)9MDPQ)RY3$V?0=
MOQJGTL3_=L'9:O#^L=!+M&OOPKU%AUJGN?N1KP*H:D-DXP<WR.*DV,[DM]>1
MH_!<_$,;Y9]Z.)]F 6,U@M.=U1T5360D'97OI5FMS1OFB\L@T!AV)UF4[BNY
M=]9C'+;*$LW'Y>9/LZ$SR\^\[_- (3"SW/6=Z)+HK\Q@P,IG@#]?,SU^!++G
M:328ZK9A5D^6WDTG)P^XR)+$U_.&_3_ EDD3# F2&;Y0]._Z%N<BO?%_&%=I
M?U';B-_O7&S@K\[ ^J1)-L4/ 5-) E')9'P?J&2<R_V:33GO/T&<+2QOISZV
M8:S/ %9D^SA?*(^%PZ&N\M!!9_)Y!]/)PK#/R]IM\PEHL4N\MSY4(?0,-1;1
M3>8OC6EWLM:>)0_K]F%7\I<O=OXWC"R5&24/XS.21>>JCU;4$OKT=O0$D!VA
M2"S!L+:UI.O1"[KE-@4%NX43;@8/LYP!$B!/4((HMDW]OP^NSX1NZ[?-E_UN
M/>$64!Y!_H,R5-(DBE5GVYFO7N(?JWL#\O V)&K42-:PPP<J;\C9N6A\BGK>
MA5(NCOM0'#&KC+NO06N.U73\I0KKM]W5AS56-81(#G79ZI(:&)>^T#$0@C^R
MYU[GM5/MGPOQ"^#;IS((V<G&0OW1FX=76Z@H<M!=R,"20M[U^$%AT@.J??FX
MT 7'R%TYBG"!UAM7QK\G/ '^%,'8KWNR-<:9POWS,SY''YGJ*?VYT*GAO$!1
MNR=PT=KMR +MDI_4T@52!U>-)Z7>I"]<-EI>1G6!:+FO$=W&O]UK=J;Z(&W+
MU#N[4_XTOJ2[^&CD$U:.;^^ 3>=RSK?^^4_@E'S!$]O? Z=_69X!4A_NHFE>
MOAMG *'G\9,!OVA]9X!O6,8ZY!9V96X_L1W:LT]5X(5#^GX%P(/. ,0Y'#05
MR;*S>XPQ?7N-["0R'M=]S=%;(5?J<GO5-!-']E1.G756V*I5SXMG\=REY9"!
M7[O?M-U]>OH)5?/XFH(S.!U,8%PMJ"53AK<LBI.'-A*=<NF]U_+[*[<&OL?>
MW#+\:&02^./0BDRKGRKBE]TN;[%HJ6GSQT<"U<\ /7W(!E!OS?PO!GO^J1X<
MU<< 3BMV\IS>@V= 4I8Y$(X4XQ?%\!)]LE1N.?"R_5>?"TOR]JK^[/ R56=N
MQRGKA8/QH:G]#5V/2EBN+=+^R)I(*TD""Q.<)%CYC<+C.0A [@T-"3C=G24!
M9U-Q;#]=-K+^837 98 GOL+#M&QK*IF2)7]?:+W1RUC4>DAGUW:<S5$_S[:A
MJ;IPREG'F\YTV:_ 6$__A A( M8'N<C=&R%)>4%JL"+I))/,>D08%?RCL?$I
MJC%D%8E;Y+ZEQ)MD U]D.5P'<NFG@$CYA_I\>*BXQ]'/FQG$ =NT\=^KFX2^
MW]8(Z0L!$KP\9KP%$R.!8KIO"-X:5A7_X.FF=ISM1=?TVB8KTN&=)D8JX>%E
MQI<^#LI8O=N*T.02EG;HL'F5A!8XL@A;S^XL>5*S\2R%H7\&\%M.;!?LQRY"
M**W4 4)D:3=IH ^YX+\ZT)O.M=3_4F./!EE%)KG(DI62@Q)TMD;+?6SJ930U
M7%MS!FOVS+CO(,RX UC/_Q#ZK 4?R8S1\)7IFWJV)U30(=7SF'S9OR+501EZ
M ]=K8M5KBP'&A7X<C3#RJ^E)^]_&_\:]T-_JW\*8W_GSG@&V,D6$D+^2@,<G
MN8Q<WA.FTKWZ+#Z^ZWAZM=<Y!79ZEUH\>7? K1/%<\S_>D9GJZ'27+X64)MV
M*X@GD!9UQ&9,-US%V#N33;G4_1S2+/6')X*UE7*]&ICE5)3[#.!2=@8H WHB
M>XJ0_"IT,THHO5GG#YC64G(90G="YR;<BU@>S[70H_/^!)G:R74&N.C@BYRO
M)'_S:0?%-XV?VZSXH*#WKA%EW_@R[,5QI+_VBDZ1L*(#V)JPP6N+)\I[V*6@
MA3.(DB9#*ME.';<97^!(G\Q83GUYKC<S(?F-3$.LJ6?X*!>DKZL]T6MI(BO;
M[^M[.K'6U5ZZ^K/;:VUC $K58)(+A_^I&L*9^H($6I5#")"\>FOB7*1FP++$
M*E9S*M"+)^GT81M<X)=9GHF-RO21H@-+LM47U0Z(LNF<BF^'N*-)4:3H<#B*
M8BIZ(ATEH=%R?8B:?I6Q/'(G99G50/1E[P11+E7+^EW9SE:?^;,TJ9@: _XX
MC$_K4SVM+'E]?MDA^:1ROS<3!9AI2F"!:+++>'.>[\<=BL^H=_0+QA>@*':E
M:UD8LO(O1 #B:[8 )*;O6)/F*-[4%I)Z7RU\G)">PA"G8GNP8JK<L6> RVN9
MA%_QR_@<2A'W;.==&-$_4==IJIHAT1-.%.56&X>2EM"J:Z5S<0N+!PPAPG*)
MSKW5:L-/-/D,ZJO\P.<&O7;"'K_[H7F/ VG:QII#[QL>6O09P6DZ<G!PR=:Q
M:YZ1D%%!TZW6]MMH"Y7IC1F;<B_+/[2.O>)BA:<07[(D10HR?MWP#RW="!VL
M'E.B<Z>KUC!?:P\,N?*=>[YEY0S0A_R3,8%D[59BC& %P;;:S@@-TBR*B$R!
M7@ +5U+C]6O)H+B:&E6((%7YT\)RS HUT3O4_ETK-;R:&FDZTW3WSI;Q8NI]
MR@F.".W$$QGI6*,QA?&@A_A8Y9WTY ,PIZ;R4^>'$KJ]0C0=@:Z'$DJ%6AJ<
M^-OX58]L*PI/EO)#-;DJ$=5W&%RV5N@U,;%@SO)4S?XJS8F";I:(+.)".[5$
M--B7I%+=_HU>P]2[^\S@_1<9'"#B?@*T+GW7^%04KCC"3-3C<4%X0Z^$L&.-
M"(*'+!'KA?'.$RAA(KTPG&- (*)K(V;*,M,Y_91]:Z.O6S[]44=J):)">#5I
M#[I1(ZZ3MDP&U&I"@20OB74V S#^<8"=DV,<M%?CH8F178J)F,UYY6'T_2+5
M"3NOXP3=\R]#WM'+MO3: X\"A-/GOM4>UY*I8J6K^Y8PE2J9(5K'YC[D]>^.
M_T""7L009@QA2<%>NX$DUI4%52R>.QYYB:$V3P4]]#VMLF3P[(HZ,%V?+1%.
MDVI/I;6(Q.Y$7\YWS,>1G7QL;?.R7L,N+J3N[NZC0M6W=33(^O[]J+\E+A 1
MOS%>PM4P?),R^U"6#-V7)]Y^C&LU*EM2Q&I)2P.^*LE^"ZVOU&&%F4(/7SQX
M#+L?%^B2#7EY&3/4(3VH!#U]3G$QQE ]F,3S1_08E@?IM4^50^V:!Z\Z7V*,
MXYE.J/NJ#U1,1Q2>9!S>_YJ(9:/=O[P=/%JR-,AI[@R)5STM=,3E]?*L[80Z
M2Q"O/VF)=,Q'_=PO$>3W<#)?P;(,@'HG,8D$6G7Z)<^O#X9TEL^G#M7$I?A.
M63SCX(^-Y?1CNROWJ/>^@Z'IY<-@(\NRU*J11@P(QNHG*>R+ICH3:7.^P"DH
M331R)15)8<+.2\/H!4CS>'^7SD9/-"=Y@=I ''B5Z13GJUT51ACOJ8EK+]#R
M3WSZ%)3!4K38+R&+G0N!<MST*".+?G4P=FM8\'&P:H%^AAB+X3F(H#0)(#P<
M/^/ZQOU@[N7@[3. 3987YW]W[XZ<GTH:9?UN\_JGQP+O=KOJM%7/(A SJ*6:
M=3?E/8CK1:^;G)+=T/&-Z%HT:Q6V<Z]D>4^*^GT%R,?,RGO(E1G(/P$(UB:F
M"SOMQY[K%D"(=$UW @GCZK9DEA^H!GYFGG)U1KYSV,RI^[X,23@:9_OJXR+=
M_&569K])7MO1N_&#%V-RZG%'D?A(K8M@E$IKGI,A9&<$FZA<P"@4BU::OE7K
MY'IQ?=Y3*K2<8.CJZ^YCT3/.&V::;3@ZFQ65;?\71C!I4#92<E3N$7JO"KH7
M-7BSI3VIJ\/O"X.SFQ<A14TD#Q/]7T9?HLF2BNI6H8G RS3#<JH9SH5_XNEZ
MQW23B9=EJR/<C>?OE,?-+2Q[3:*;M(Z[RF8M[=.@]9:&IB+O,\!DY[[V4&NP
MS(CRSK:HKM)04*6DTS-MT80"V$1Q?(D$3+NYK4SQFE&!O]:,![M5B5QF"G0$
M5[!EJD(0E!W\T"\?>09PI+@8_&)2#*OIDC?R'&3E#91D!OFZ?NC0T$4N2B>?
M_Z0\/W >/(J!(YGZA#K>C].Y-GLM,M:XK-'/G6@;UVLQSF?Q+:IBG7WBX2O:
MCQ.AJ=Y Z10)6?(N&+RY=GPP,J0<9"27)IW4BN(J< W8U2=M6-U)<9YV3-%4
MF33WFO2R*7N%(^R'RQJL?Y@,\-_/T_2G:I%05%=NJM3+'RO;83%IO>FOBO@
MJ^5_W>1^6!!:/5YL0"M "2)W)%",FKK2#>3>5PB4/L!+?L7@"CT#9/70!,X
M];[DQ3. =306^@7X$/G[MICN&<#]F<@98&:,[_# _]<)<@5S!BA5_@6B^%';
M"#5Q$%(8<A=)V.=Q6?QJ3.X@,($3!^$:#5TKO4/-9?#5?((D"=BX("HQ+/W%
M7J2!1W5UPH<@T)YBR%?^C:XT-48@\5NR8$'4!0U!_ABT7')\L(/]NM(MK$H
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M;'30?HQO+:3EE^WK#;H$0F4<(4D:5ESIOM&WIO%MBO7-.K4]^\"(.J+_Q^3
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M6WI!IPZA,(R&D;G1G7AIA:9GQGF&Q]3O1];$2]*KK50,09K/E6J9(F==G#1
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M*^-A\SYC&)2&/9H@B)!;YQ@&\HQ//Y&;UF:]T86H@\A-Y#S_O\@MEV>(_#,
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M)2$T\58>][.=))P^/-Y-'+E=CS?EK^/#$&\%XC].;]CR)_29=K%;,^W$NS,
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M_"OO!&"#A5)0+[I2L9(9]QZU:XFU54PIWM,UB6U >>9\I8HHAE+?IMR:>M#
MJ.35RRQQ%> QD+\ %?!00]]L6KI<#9SO-&2=U:%K#Q)RJYIJDR%B#[$NGB&-
ML!C6>K=+=J+DN)NT&^S^<L\S^RFJF?%>HQ'1U?6]*7!>_)$P27K@6E+E4\]'
MP2B74/M2_:=V$0]JMRUJ?Q;CWX;,GR(^#+OMV$=..#4S.$7:55^\KGS FY8E
M<V1W8);;I9JE-^*_ZYLU_2$+-[?WY 1P'NY%*)[78'%&TFT6#,NW*\MAE?A-
M_ZJ-O*7L6?D>J$ 7<$NXYKVDN>6;TJ@1;J=H[76+F:; L<-")<>ZW*J:]%]6
MDQ'/Z"Y:ZC_EAH%:!@&V6'E.UWE"9;^2TV"0[K\;'DQ8!VQG#7'\"C;/@_D?
M5I&+/E!$HWI7KR57OQBXIV:6/JKK^*INZO)O\K>W&$41AF"H9KV31!#P^WTR
M[)7B82&/L?P9Y -HXVQ_[3G$..1TER3#E]P076Q.64ZH/C+5).DM#K\//#^H
M6DP$\BVZ739N7/33VRTJ_6"AU\<_2O4)3Y5^8X2X\?9>A3?MB_&YLH82ZSZS
M&=OX]'+-3PK=_0Z;4>&0/NB%-J Z>2&5EA&CX;NK!H>\G>HQX<=\NCMPKUSD
MOOIB?Z'VC\W)+^K'WQX^4&@WG4SUMK1YG Q)@LRC^CPND75V!^FW: ,]+M6C
M<40D#V*R^&)SYRGGAOV^M:Q*_V7^(WJ^Y,WQ#Z875(-4I4W?O2Y1&WJU'7_7
M9&?.73&BX4Y7JA-F I--N*1['2V<4%;@7EWJ I%F#I)+%8;#]O[ :@^&I<@J
M(^SS8,[=- G\*6CNU[X5BH1:CFUM?-5[XJI9LS;!1L?L;C#(>/PXB/X7LELL
MPBH-\<<X2YTUCKP MUK91@+G38A!'#T>HJT-;93"M8RJ"N@<#-4G=9DBJ%=8
M4_RTVE!M2GK".!GC(>[:$=AI8MW4%96J#LP;:>L1$3OH7J4]LR^2I.ME!6A_
MQ!A^#]^T+1^:CVM_VDZLR4MQL\E@N5#R-VOC5E0O]3^RBL=J9?G:ZSYI:L#B
M=4<4'<O3[_:MN.)GA]6K6E6*+M9<3CMS][BI'B4>_ZYB'&/"&U=]4Y.B\1O%
MXE)C5XSO^52EV!XI77)D\I&5!$.9$E^I$]\U7>NTX *+Q4M=21N*MAR[,RT_
MF:ZB8=,RT[2@8K9WI[.E>7+59**9.S!?Z,*"V_=C^/5>\VL1?@ZE8B(5:O8J
MEA:3&+,M56N;7^\)\D)76F7]C<H_03%,L:Z,NY3^LK#7Z\[: I>(7W(X>2:_
MK1YM30\WNE78;Q("[]=E4M2+E+@=3R75QI4FECC47#ZGB]4RLU_6,K/#UJ[T
MU>Y:T)'+<#'FZZ9E,8O(%5Q<GD%]5)EVL\H&^03P$JMU>GLD@@@5,O?+T?DT
MW?_F8JDW 7C62$^WKK5M GL=?0+P<5D*$$9-ISSUN"'A$:3(Z= [>B'G,NJZ
M2YJVW::\]VD=4?N*F5VSQVNK*8XSE&8H)RN-AM"F9 B\Z4F+['N[*,1C\[DG
M]DM8RBCZ["0Z:_5"U:;UY\E^*UZH[JBLQ<"VD#_Q0,)QIF(</X[:9I6P37R.
MYGP"..L]TI)%61\X 9#KXG+I4HT?_0S82/M2;6_F4EP[>:0)N1#J/')5T05T
M<42KR5)"=L%H=7A?C81U;+%TDH!,[U5)ZQ4MY R5PG.@1YOR+?G%_;"0^0M]
MQ0OA%40&A+!\%+8 "GJ!]Q'-H2X^^OGLDS/:--K8OL3*7O0'.<ZY?W'*2PE/
MT5EQ3&9)(WJ+6WP3YO?]#FL%X.JT8ATV +^ZJ#:ZOZG7\CRBEF:,]2H'QPZ9
MCZB> "QTA#_9DP8:%$@31V^E!>87LNAW@I0-(C+L&M;*$WNJC"6;_6_"BR92
MJJO1HLZFJ@5?YXH7&=$9C\;2BCA]%%_*)@^UE<9Y]KKI>]A-J<' W?>03?MN
M9BCLQOTZ6I9EO&I2UJJE4Q6O:91>LP!K>YM\P.#ZKU?_#2R9K;@'RZ<1"]!&
MG5[<W'K_&Z>;<$>TUEX,PR3JU!"+@Y9:.J U$,/P]9;A"MY=OCTM8HCAABP%
M>$AVSAPJO?H9SG39GR!MT>23Z@N$>]N#D;%A@=SVAJ()R0W]JT<N:1H<FLR9
MBHF98NW,[9Y4O_W13%D)-5W8?3_+EX>V+OIP?BA/#LV]\%.UMN_OYXP[M! 2
M-!9WGA%(KB0:Q$804%)P,$6[GL!WT4\G_\Y\<&O)DKGW4WYS43_571E8UWCY
MEG:ZN1=F\\!E2UM@S#OBSPEDF6BP5\S(/N.B?XYCFOPI%-ZZCQ"(#\@,O&%Y
M;J''W\ E\T?FYE0*9D3!"$W64AC-,IW(:]H<[#$?>;(?53[M7*#UY/7_OJ;/
M<0@Z 9Q91\QGL,8@+2"&QJ\D$ ,7#VEVTS:XD*2?'!>_;$3K+&6^)Q%F:H4+
M))%$1([8P M5Y2#6B"KZ(RT9GZ.^>%M3*4H?U8UX+0&4^+?13>NCJ;W<1[WE
MR<%JP?8->8MU7ZYT:(54MHWW]P>9VL;QW!)T;'F,:GU#9,8K?1MD[5WP>V8/
MQ2.O>ZXM1@$WI*$]\O-Q@/^VE3M[.&6&V64ALP .Z:/R6^]. ,4'FW^+-OJU
M3$0D(O=>(V_\+9H.\Q@\>&L+^9FV_)QE]P<_S:87>*3& B#C ![)^)DWI/,?
M3P#/V2_B<ZW+D_>2WU]A<$P\!RG?[N3XH;;[-__7_^9W_R 7,P1#J#DA<V%4
M!\I>RF'T'?\B".46!^$$@#?U\J0N("_2LF>V9&>J,N.M(7%-KR*L^/$R&S,Q
M>^9-K86R.FH+8S\?45V9Y;E?2Z\<W$6SQA-Q/1L3@8L(>Q^2N;F^Z?S,)^;!
MQC0ADF&$O*C.DR$:!RN2&O)EU8?>\A;>D<]8C? WW]*:;Z0^;=&&W:FPCDV%
M>B=7ZCU.:,RZC>2>N+W_S_Y0WX\W\Z:2:<[?1]?N1Z6;RN$>LIJ^G@">35B;
MJ:5X"::G> F)]*D(>HF@_QWNIYO?2A?]^_^R4PBK K*2NMQPDZ%$LXI@%\I)
MDZLP.DGVI<+*=%?BQ!X[UKD<;K4WM,5P7N#%+EWO2I*,6/,$S<.O>1&>[OR(
M$=_>^(E4)$G,W:>$?KY;K T\<P*(&IJ5H3@$.#1&4B\$9V.K[2+L\ZPS3@!
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M-')JT$ ?+DI&[9XF9PQ .!A! I(<_?,RQ_[8>-T?V'&MVT/?_1"7)[/=C".
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M/VG#VKE>\ W"-: ?)U'R\K4'+2V+WR[P.DSO:?J\;:CB_OA[K_WRE>5R&F2
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MU5+_[>46\:AW703K Q+:\9E(-3+D-#R_>1"E;"_:-LI5$ZWJX7;]M,7\D&V
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M#?/AWT<[JOGZ9VFE\LFK7\%:1'<.XZ] *R G0H(79-7\B:+5WZPQ&%W)G;S
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M_I107)_L-?9L E+D2LXM&@=Q16S?K8V+\YOX."5;EFSNH9&2=0+ YLU%E1.
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M[MS&_$A\214LTNHK5I0\^7F)BVQQ DANJ@Q<Y@WHDNT<9_VU-?\DO\)MR4_
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M?3YZOVN>]AXHRYTL%WHVV^I=ZL%\R)'F0F*+ZQNZ=^00\5?\4P5XGK'F#P'
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M4%15I!I*@YEL<!VX2WM)66X;Q"_N]&6+7L!03@\YQ>;DPN*Z_$K@'K8NSH[
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M6[\+V)1DE^JT.ZHH@6>(@!24(9Y-O?.#[/6*#?(D K+HA%U]%Q):S,<I-,8
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M%N\:1R77&"B@B+I$@-6W[6&HX(= K<?:'L2N%1"@>@V>C; GWR]*U3#5"9D
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M5F&U,1Z4:&\V[9AZ(>TCY7 &R_%4PCM&.PX_]]"Y54Q%-LBF[W_M3D"!T18
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M@@EI:F9",I0862=LJ-X4<+E[7L+V!^Q1=S!5="_XS]7#>PE1^X0:[[:7$Z
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M+9KT5$CYD7.64-K8<L_WY<9<>6_'U#.AOS8&Q9YUN%__%VN>;?^2I)-Q57I
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M5B,.]$(J"HQ;AC06T+PF(Q5!]Z(FPX2,\R3\W_<)_@')\@$3LM1;S(145RU
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MRT%BN-3,N:+[._WTTQL=XZ4&*'X-]?D"N)=)GT5MVGJ$#EH0=[_SO\S/QA[
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M*O(P'-@S ? *#(V[ !XTH@F8W42%GQ[ U\ 4T)2XN!)B6E^A=B/H8$95IQ&
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M8]Z!F5_M:-9N^X2I5/?<YI29:]*1%B#N"Y:362:D,!KHA%$SYO\ '5X+;H5
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M#A(R<E)HXNH[,UP$][T8&<[$XSMB[1Q!BG1 ((,KS#0<UVTNSIW2S%3(Q71
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MZ/]=Q9Y)^!VGK"^!T0$,K2T"8X^ 48@5H69/VG"C'4-IS;@)&W0 ;I(.^##
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MP95)$F](DKUTP"5=IZ6K*KU<L$;Y<Y9?1<<;(B0,T-^]M7F'%^<6!$B7XBJ
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M95/S6P_O^U^D3MJVAX)X$4O;H-ES-#Y^!N]$D#\31[)6*7'D<%( )8+$M;,
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M0 IZNZUZ&@MI7<K_8MEC,R0#R>$]G;MT8MB@J0\+G*>YCAM7!"G8W3'*VE\
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M0B6P)O,I*Y<)JF4I59S('A=?%=)<K3\K4N.)F8-%RIO,VZ3NGDFK,?N#MQ5
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MM1_5;.W'WP-A?L1]4PWU#J;:A$=T@)4G6FXN)PF9?:UHSO;YSANYA2?/;"5
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M07ZT1&XB$*V'D707-R1DW9ASF6Y?#76I7#T&<\C(F\A35 R>0]&GE]'];)"
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M6E8G#Y8;O)OT@:8W,KM0Z?]-C/]_O)QF3_U/"[].T@)89P[I%R,UF<4=;M0
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M, -=GX8_(U-W#[:R6P0?.ZE/'=>E2I5"Y0;W]-+CB_#@&5&DF&V@]IS-_JW
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M4(%MHH5&QZO6K\U^7F1067[57YE(9C34 PJXL4&S?$O9VY5L$-<Z0VD7L"X
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MU=.G&<6<YM32KY:4;)7\(,-=L.J-Z6>9T:O!C?UJOY3G6>A2(902D+VM2H\
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MT?ZL,>:56O;E?S@H@8[YCQT\W'9GBSZR0;6R_<3Y7=H$$$0IZEWD XJH? 8
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M,C;Z&^YCO?IZDA]A/'P']C:/'C>U'G%PYW<O9A$;Y(Z>=:9]:09JZ4\C]3\
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M#,0;<B6*4,(1=14A<F1+6>G'70&J5T'QK>=,[$Z !3D%=P'G<<X43[\]%QK
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M3XKO2P=MSMD+_/,$>;?=_L%54Z+)J-ANJT+D(2L'JMPF6>]:H%(BP/E;E^P
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MBI#6^KU'#36YR!OZB7KFR.P[$"O1.L%/U/F7YH6*!MT]6X-.6S7WM@FY(OW
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M'5J#<:D>8LY]-'_T'2UQ$S7"XVM5V7%+JT)Z(KC*Z$U9J9:I.CJC3;S#?^S
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MP"8?OT\4JO1JH=)HSZO"6\&ZKGU.)L](U0%BJ2Z0A.#7''ZQ_U#\>)*(QJS
M?,OCVPH\LQ**@1S;MNG5&:$_TA&%K.=3-,C__"(?Y#7!!W<C#\&QM2P2.]+3
M%"V^/CNIV33%>5?OEY<C)F$AW.7Z"B?14= YZJU1GL=3"F->0M57>5S+G?V1
M@@N9Y',BNU&-VCLW..Y[_$DJ9>FP]C^K!Y#Z+"=I2D"$H^:8&$O5Z!U2I14M
MCK=%V\^8)\]3 ^ZL*?-D9GB_2?=.W187->R_W!T[.:>S_Z#E[].U&&%[#RY
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M_/3M<?/6PVYZ/\4EHQB5;+)R^V;=?$OT+WW[3]?W9XPR:/=6AR!>PI(DKTO
M!O;%65Q(QE<46M3]Q=D@'\\Q^KZD]4C1K()U@X91JX4+C?78Y^3ENKOOW5KI
M;J/ 7*[R)>?<SJD2P[I<@V/2!=/EK NF%TG__I_[9Q%P'_8?M RM"B.[$VF[
M+W:N"1H,8B%43N (K0/6D67JD@HY 9.8.482[(6N\*%LWR_? A#Q/7,E3CY0
M-KGQ)+@)(VN]G$#GE@+7T'W>G84S) DG1$_*C^Y?5O2TG[OR*-,O*(=GK9$Z
MI3B&:%%RDE5R>NIJH]+^O.8QA[IBWX9&[?W?938MSK(AG/NN*79H1$O_W="2
M;ZLA3CJRPJXN3ZOTE6+<A]7'^>N^S _*RQC?LZD9#7^$92GB[KD-MJU)]H\G
M8/G0T15J#6M%2;KJ%+-^&+]O7;N(03]=:0[6=:_6Y8KGD^3@"E\^I=M1GW]/
M:7@1RT-_^77>E/GG$:4NG.S;<H]Y->?G(P W'[6S=QWT13FI:L\CTU/OZ+V3
M:0G9P&M:Y>/E/#0U#7\,?RE:FGW),,4?##SX=R?*0^S#@QB&]O.B<N^2U1,9
MAD"FK+ _!#+GSC[8T"4F)9/)T#BT9@C)CY"(9.L1VR[DIIS&Z./(!1(;E)9
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M#)NB]Q--W&Y9?S0_K2"NY,AF5V7#$[^$GJ2-=A_K/OEWO]QJS\I5765&<0R
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MEGPP?A]--'P-G:BE?>_@:S3_/;PZ@-<Z?XJYKNVUCLECS8O92W9&;YM\MJ7
M*.6"=]MH>MA]XY5ST4(Z ^#-%E26O>\9E6MPP6?0M2A<5 2-(Z4'#("V[ CJ
M.L483#S[I?=(0[,V, 95H]JCBM)G>;\H!]FAE"L%MAIGTK(%5Q0$V E2'\\
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MS>;[!J;6W6T+B53(/H+X!0M3K)-EV1C!PX4""\6==7&9K)]&<OS,>/7VVE'
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MWQ#3?3SQFFC9;8-\I7%K$\'2IE8,K3:*<;A*S/] C+$=\PD<HV21%+#]S&7
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M2V;K[;.:Y>_=0_(=<X(T4W!UG4](>P.D@*3-1VAYM8S+SKS-5B*.\_SB^ZI
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MO_4R@\/;[F[CB:!']$!58W,U'G))R#^KQ8SV+O'5J"+H[<_F$?M-BN&?ZE/
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MS9T>19OD9FVVMLZ_3=X)]MX)]AFN.T;X-5SV&R45TAT) [&QC$;J^A9J.ML
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ML7?S[7+?FX\$#N1TWB/>VTN9KX;+^7'UOD0!%MW>N]0F8<ZW:]T^4^\6F5;
MIIIIGO -"5L3L(\?4L6[5AU43?SJU9(R\,OXF2,GDP52IE7[O<-H27^5N!)X
M])0RJ:!&J34\FE^T6]B8^O>_0N^7KDB7EW?R=Y)_<CDXS2S,]OUPG%UP>%BJ
M_G6P]3MI^-SG-/T;:B_*^OYS"G@L,\3KPIJ.9DW?O*>*MLA+)VB:RMSS2_<5
MO&<.ZS;W41NS!\IXP[!U#:['$:> -US,4M)$/@='H>IM:-R[#%86LM0RPAZY
MG;BBQ._]:A'(3!U\B9"TYK ;7W"6&DEJ(7PED( T25?B316O"-TIM=LC4KK<
MUQ_-;A4*/64KI 7OIY&A?^\-_44&=] *XQ:<M;X]\=OK<N.IV2:"ZFH0_7)#
M+[V0LU"FHYZQ>!PP<%OBZ?6#Q7=XI/#\G;S:2\X%XFP)^>!Y8[.QM9B]) +'
MRUP4T6MQMZ!'@BDIG>#!7?80&J^OQ:3ZG .U3HDW8IA)8^K <PN.>C=F%CQS
M NT9T:62^<KQ-S(46BU+O#M6Q=/<8XC6*BHAI4*'X:S*MK*+K.8?8_(UXMK]
M=<-,;D7=;"+$E<O?EDPLYYE+S&3](OP6R[/"ZSU3[0&K\%G8WK!<W7$+W-E[
M^)T)F%8(#>*"!X-UA, .Q4\>UG@Z7Z5*D%%VY-6NK_^#L_>,:K+[OD7C:T5
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M:&OP1\N5.?+!5%4$7?VVC7V=#(T[3:JR;81P.B.)_+6[0RK=0+?,GD%OX&A
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M27U&XX?B4'+23(_JCR:3-XE+67TVGG0:K6[S5,H:D7D[8QQ>L-*P'RTV\?7
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M ,<6Y*IGB\PKT T*ZW)6[+$T)U:ULW(@OYQ<Z<9*^BG)%_P0='!YA+'#4YV
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M1'@,D17F2 ?$K- 13.T^%A0#N89PCA67O+_4T\;<3!#NP5PF8[NMZF+_L1C
M8;CU"!I;^]\7^2?^:$>><K3H5&R' HGL)_Y9]D4V6\1-TLT@#_1O"!,YX$\/
M84S:1O1[8YM>EE?9EFF:96*$ U:9<NF?B'NVH\HM%V QU_N],N"/$!86:HI
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M0)DW'F/';*-:K M@/8]'[^0>D!",6*+]H[^G$L+Y5 @206WYP24P1S#7IE5
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MF^AYNOL;EH=OX1,<'J.QY2A]-T<P[X8N?.&WW6LEAE?-V>],12SN7S<_C.2
MT;FDPY\*W!G@QC<;]=T&X?/6_&G"JK3)'YO_C;WWCFIR"]\%<XY'45I$0#I1
M>D>:( (YR@$$A$CO1$2$T(M @$ L%*E1I"A5J4* T&L@TJ5+ETZ"2)>$$@*$
M9#@S<^?^9N[,G7OO6O>_NU;6^K*^E?7EW7N_^WF?9^]OO^^IQ/*_JS? 4_4*
M%\CMW)HN%>,)XK4 2DF)]J)&AO6@LG_&!U?3R=GLSWU:-<U'*2&W:21J T)Q
M\F 7B'A "<=L'H&<QYZ#^2@0JTDYZL>U4[GL(H\IKH8&09TR,_NAGW;W1'*,
ML(HC8@MON_8XM<]2,[^C8_L#-%0N[T]UN5!F.9S@O3GE]BH&SU>&5+GU,OP-
M]E*>-'C)0O[# DX:<OD7AB+1N^UQCE.72<AM9&G$-S W#N]M33VG=SV90('S
M(64\(A2_0%964.U*J,J-1*JC51<=<($BY079(5*05N$GRJ&1EKE/YT+)0YJE
M0]3$@WO$8A16[JO?@J#Z-V3EIJM:&PB=UGMJ)CI(JV%FX5_D+D;D*@P*Z\T8
MLM^S;2E8&SFM$^79.^7ID0?&I3+<+U9_]:7PM_'MEJ@VM=Z:'[_!R\O(_UT'
MG'K3SI\WW4$'S"!7H%2970&$P,3L"N%VS+F1*X2E5W0 7B"2JO =JP$ZA1"X
M7F#%\S?I )):35/-W&=WWLR(W1V^B'[2X")R]'6'_%7JW14,VWZ2 GYW&]&@
M59"?0@#756MT;D%.G=GC&JKZ]V6\0D&-)5?.O7HLKVZ5,AY7-LX3W?6H\WZB
M<8A9Q-[/+*_?HN1\CD,'N8@7$4,@HMD(10BU4WX>J$K/LL!/H!1)JT3Y-L%S
M&VH:7M(XX7HFQ(B: NK3ZK!RC^7@R-QSQWE-$X*S]X*O'&B:2J=,:0B-MX=\
M7G2<<T\;=S\93M>*"G3AC$8''\=PP34/(HE'/4DR)&"'1EL:3#NNAGE+P%#@
M?ML]%68PFW.::U)_C4R#1M>H+QSAGU!"D!S/YM&-%BSSN_IE\WN,!?\SAS=?
MQSJ?K'[;N,_FY^YA:YBFF/"IN;?HI,[KXQX=0+W60F/4/#>][RP&Z2I/D3K:
M)I701LW<<O@H:%+#RD]HM?L"0HZR2Y#&O4%>QF#_**'(XQUK0I %5,4)'%X
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M[<_;<:[\V^]BH70 "Y#$1VXG!G?[<%,,>LU\+L*",G*C'C8[]!06+=A OL!
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M KK6AM*2@'OD/O$O\V%VY1FV.?QHUM\8+SR@\#')(L-I/GWR5ZF3I"5<QIY
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MP4=PD .G0*=Z"J\@6_"" KS*5+*!]&@?=, HHN [PBDX[/F;@N/'+P#X^TD
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M&50@;YPIXU:%*$!:GS?K.:+CWJ!&EBC"XMO%Q!;R"THN"40 =3,!*?JR$9>
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MY-\$"@^3I9,N?[KR?Y\DQ\[D2<I:<<0PN(:K>RE>/:J]04N0F//Y>LXWO8Q
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MO17B#K0XMU^^= .+'#C9#G=QE4A3N7$(6J.>,EZ6^Z^D%?.DS2PJ>>1RK$<
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M10Z_YB"RR:L5<RZVCUYY5WS(5O2RLL>.*\>'6W5,IRMNSNKTY'^9Z13+]*N
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MKJZO:G(OR' X4*[15%LL[:-1 A_OM:_1!KJC<-VU1\_],!B7W;/]H_TO+\Q
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M#^PX$$@QT=\QY"&EDC8NN3$YG@:V;3>S9HXZT8-J4V C):JAC">R\HX,#L,
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M=GG2TAFE;+_"C>:]S1/LTJ!A8LRQZ+%0F5'4S52&O$E80WR;HG]C46;R=NF
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MOM2'294TLFQG9\\'[BX;:^8=01_TWOKNK)\O*D:L^#XHDYE_URC_-2'#0^E
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M1=7G5(#A.U$QU:R_!C;3CI*M-AP'D8<&O\%(<B>?>,5Q-44%982<7.*84?C
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M_I,STHC9D32!6#3##%L9;J,"/EXB/^^#C>6#?YE1 =ET)&WI"P_8SQOD7"H
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M/%+*9!A>V=IW:[J";/*P+*CH[X)F#.P3N7%"34F!^Q[=,H;2"?Y#.5_B#[\
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MMZ%J1 @&]@[=++S_  EEF 29W&POZ9J>CX]N5U&PJWQWY0>.U"F.#UP_:>K
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MJ')=OZN( 2_Q.>S5&#+EK;S_N1@CRY%13;0LU7?TS&^=&_VE+:*^["/QM=R
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MV_<+U$>+6PTI"E6W=XZ>B$D9/3P,D)2$QV=D8VO?F!(\+%I-5OCZ$;24P5%
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M<T""@LVNSDB#I=K4QD+J*)+P O17R!O2/T07&UG"5!JAH@M2YG('=!QQW%I
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M8NNW>#[)=D_U(.T=I(QO^UF].!"S$K'-U<L*G"A>%4A.&P 3-)&GZDZ[F L
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MRS;&?=Q-,R0K1AGR[ S!NI9T?.@_=T1)_(IS^RGT,/5_KJ*#+#E':_V&GQ1
MXQ)F:I+M0T6UP-VH"P#TW@4 =4\Y)X^2N"]BB:Q\Y\P-K_UK7D7FSSY-2K.[
MWL*<3URF[Q"R-'.>>EXV],>R]JC^)P4W-5Z7X__^U__>O<L,2'B+V;F'S?E
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MU2_1TR(6:97)"AF%IU8F<\=:/AGT\G*7U!-WQDVFN^9![,B>%X P8^3*S 4
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M$GL&1U_BO6V=^NT/6.AL1&8$Z]*^@)V1LVKK4!*$XD%]1D-CGZ"B!Y^'&1'
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M; .ML!:/>>5DWDLN,R;W^B9DN:79B_*RS@M$-='.F4(ES*3H+"<E%$1O/ /
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M1UN  C9=&0 IY>48&GP92X,=<A_NTR]N4DQ)X!,8#5U=CWWW);_TS3(L 2'
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M&O+85<>427RI2ZQT675Z45T\\\7:73B$W@EG(KAM-G"8KPM[*BEZGNFO^[K
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MQ5_?$V9[]?^QAYG=]@>9J^/RU *TFG<P0,&,<LIP'GIOH%_!7]WX+G@96$5
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MUZ#C7Z[3;KPIWE@:KR\E%]U&Q\%5-SU'O$WH4@*JN3H1!7S%M7?\#L%"T&Q
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M)A-EXM9J$:<T!X?@+2IF["CI>FFCORBE9K!UX(?FI!$"%F30 SZ-D>^TQ!=
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MB?0>D!S[PWF(R C/X\"ZB:HC.RT[01I 7__>A?[$?V-'+VVJV0^6C'.-R#1
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M4H3&' 66XI*MI7OR#P2QZ>$P$]>(&$/_4T!4#7"P,$PR;&;>8O0%&KFVJ3%
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MMT$N#>>9\@I^7<D?@AZAV]X&MT"C]L@W-V%809?KXE'AA 38<NW(FP/+O5/
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M%IK$T_Q:RF[A@5J_1#54X!VK?L$O1L/?=#W/-:RYX?,@*XW2@R1['@G\%.A
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M!WH=SD(8)*5^UY* A0UVWB2_)ZS8$\??4SG=<]FPQ^'283DL?:C3L1+<?KR
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M(N;,IE:9/(JO5-"G^+Q0"Y#=C_AWG%NE&@:SSAZJ&/L@&!PV;:D_9'MZEKA
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M=$ZK3Y%\K+>L\O[;OS4ZW%.<SNS%XCY53TUCVU*3[Q>M@6]G9QI_L$4^0 H
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MZ5)_$J0MPT@121XFTK]W8P)%89L>O8U_QK.3+GZ&*6ZBR![O1R@\<O*]O;/
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MCRNDXUI>WNE87" FQ]LY<WJC,JWSA@8I;+W4&R<RN^X7;?Z2W')V$U9B,U-
M5CV3I!B0![V)*_V-;#;N#D(8 F<W)GHV[V;5T2[[ F^%OB\K[*QO9<[F\<A5
MTP1!_2G%*L2,1'Y!<?O*HH,8>5?@!D%7D,A[+:JW_2S^(/X=7/%M!?=,C^FW
M0\J77$_QY@_%1H$]SAF@RED/(ZWE!DDM#A^@54!25$17&#R(,$8=^["QZS">
MG-TBV?YSIW[>OBKIMPBIZ2+'IY'=2A=&.QG#>9PTET62OW@4 !<EUW!V1]$
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M;) U+EN;2=KQ/4J&T="D0D_+K:B0(.W>HQ=6==#I9OA@.8;D< 'B5R'GR32
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MI]TRL.+MG8ZYQL8VWU?C1ZZ_[T7W;>3RP+)Z6G)LTN1XK'/4@@3-#TWRF6@
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M8P>(.%D&9/$34#*!V-]GDNTO10S(9@4#$F&+(V3AM@UQK@P(31$XC=CO-61
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M/K)GV_7SA3/Y,2CJUNY#>N6- >J5^?@7-4 L\KPO9BI1'1=-\L !!31CBL-
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MP-2,+[8(H9TZ0(G%0>)O:&]P0V2L/%(@&HLHF7]ORY6>NFH1)]MIF*V;_K-
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M$37$OME#0T*%7>V;<[EV2(EO0[8E=E+BSPC.\MX(HS<SE"[REYIWTMYOM@C
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M0NDX"C3UPUTB$0$)Z/+V/8S'+K^(.5Y$R#4VPS:/CWYO1L0?(5SC\WVXQZ-
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M#A036LL"\.X2)8XU.DZH>EQ^/0N0P_9?/=. ^/ &<LS=@UBL0*Q(4,!*/"Q
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MCWZ_A4TU=/MB7M[%=@L2[/E0OZERO.:D0FZ&I/L!?F/@Y98^)#J;BXU11^-
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M?;NO-6,':J^7B?#52E%]5%2P(%619B-7V1\ZL8"'LC#![A)M0DK)@D3_"IN
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M?_BD \%2CGUI8">U=RX'KP^>UH'R$3\)[5U.@K/3 %-!M9DN(8U74D>%)D;
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MBKY#\M[3#6A**!I(LK3A,\%J,)6:+BXN5L;9"-MZN6V5<TF;C:Z'INZ$*M
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MMDDJ_4QA;PB!:C7$&/"Z%WW]8)?)DGC<K:"A1ABQ C+!;A,ABQ2M)^-RNC0
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M *>#L2Q1>81D <F?-:4&3+]@1D1_@8)"HJ_I^"'XZK3<*TN9.#403LI8IY;
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M7^XV*OO8W=^SOB]C $GO\8+[5JO6.M@_15TKO]NIZ.H5[5_;&%B[O>9(%B:
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M<(\,E5<G70Q"Q+V '1Y4T9K2QV)_ X]*5$+TQQ9#1U<GK/77/']\H0,"UNF
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M$(1\#.XAHH.'#KB&Z;8&AJO1 20K!*$)C+M-FZ/-$B*BVV97$!V8GW1 M<;
M$; Z,",B^PBM(5--!Z#H #T$+VR@/>&0E6K<^=OOK A##G/)FF2W"]$]WG2
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MZ;H.ME5L5X/T<)>#(Q U<I)5X="H,L,<!J!>G!XWG*/VL1%*UZPH+$_IM5:
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ME P;SGJ3/X\YN$V5R*;%[.G$1(Z"<U=CBW08B%0-STVKMB8_RO+ 20Z_N.I
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M2%V@(%4Z9U#ESG&X3"P]6?UWJ3*8*CA\V**YMWM]*N[U[S?)E_3OE+?4.M3
MR"/\4RM2J36'< $LE9G!E(-:,=H^7JA9;XA2'$LW\O514-ACLY]VF^%KQS$]
MZ+3!AL9HBC]7]#PNTC$H2$LAGQDK&%FE5ND?_#F=["!2Y4F%9VSKH!L(A?6X
MC58E7D[MK:# :]6-+O6E_\3/O)IQ;S=SV^.^M>[[L\O=4!;[Q@=4T?PL-Q2[
M_=SN4W%DM$AW5%I4H59N%%;@LL-5(?2S&I42?[\4NL%65_6LNF ZX<8X?><2
MFW0'KAT1D H8[(A4 -9DG0/\BXZG'TD3.-SNI/&$D MR.^WQ?G?V,BAY5'W>
MD/]E6INOUP'KY;_+-ADGF=72,QQ@@SK?GZ,?ZBY(F6:3$*R>'LOK24?:&E/(
MN".Z[2<Y,!=<:/#:,/FAQJ<=N$* $Z4)*EZN4^K<';C_U=4NW"C[@AG;?E^!
M@%D4#B.[Y*;:Z9Y_^WIP_P.]:5SA6*L@NH7>*[(:[#R1X@I=#LQB<&\1)Z*<
MZYO57G7T@1K!6DZ;(U:F >!IJT-0MMY4@L8(E6NC%@'$H[Y6U_B1MYI"VIK&
M)'GF6H<#12^;HR[\<IY1__/CU0.QDQ2YP4>,!QR&P*^F&?Y'BKT;=^(MRZU8
M4^J\B-L8B78[>6>8)8^ ;KRODU3$\81U8!.P>N&:+$-3&I>7B%ODI-!OTV2?
MPY0$$W(LNE13.NH483UV"_Q_"0^ :(#%=="TLP@4Y# T1?=WH_B$_B:(5U7@
MTIO]$8MLY.)0"%C]U==+&W_!SL#C$OEF[6WOL!8%S0NRS65;R%RYZYZC0Z3*
M9H2<'E]_W;3J$,=7XQT7BEJTB-A.>*3S!%(A:[(R.R1R_@B]7D;OLGJRD"*Z
MB[Q_1+&!__Y/8FLC*60NEC.5:?AS2K6R'V'!K#(^$$1\1WH-G^>N-]"74+T+
M-W#)HC/3N3?=JZR]*$N*='.EFEJD-8FAW"7ZM,F$P]BA>4C;'_&8J#%GPA4'
MO9FRU?[]&FZK%ZCA9J_^/%2=A$C[T%?YLUG0TRPVQ0$GM;05&H!'SP>YG#FJ
MI]MS7 KIZ)GZGP?/>L@V==#B5VMV2ED)!*?147B8=9GZ6]$X_7&'28M&4 ?F
MIDP3E\?E_$C<6G6(^8Y/ +OMQQDU@I&[5;^K'?VZ?REJ-5VFN(PY4(_90^ E
MBF)Q V5Q07!!="*?5V=N,'I:]]9D9M*(ZT%7H9<(#6 5R$E-]$,'&4\R$@24
MK?VP\P^K-P,-@HP?\7)V318.60 3U$NPNM]O-:=OVG,\6]/* (_"M@7 [&4E
MHSTT !^$!<%$UB/=P^UH_,"P*C/CF/\BY6IGFCF,ULRP?9!D%>&4JG4R)9PT
MVM>A=$T#DRMRK2$;IOC$^HKF^@\CZA0(0V2'K9-ZZZT:Q<-4O=2TEN^M'#V:
MAO%3[1Y1.8=.P&W0-8\L!H]YG= ATE/E_@,R^C:]9XS8!7,C;SL#[BWFJ([^
ME-OONY]8F;39.F()WD(<AJ7JMS_E-$\T,J/I :^NW;T0#P/X"'T['WI;A_,=
M'A#_S?-"X Z4$ED5J2YKH?+Q5C;X]9C]:1WM[NG!+('D,ERIBKGUYBAV\&O!
M$QK@MA,ZBLN(($[<A]GJUC]B33%I*4][EK9ZD"G0MO(J2=$S1(C+H5_MNM:=
MS%Z< ,_=A,DIH1W^1C6)EU0SPLR&81OOS=?2?KK&X>T>$-Z^I!>O*[E98)-M
M=O*A;)P^I!26T$)J#[WG2B$E1==%ILMPY=C=6VRTN^>,F:2/1_\ 74( 25!L
M:(<4TS0,TH:X4WG&FH "N]D>_#QF>S=9]S"E'C,N*];KT#IVQ-4@T-C:DND2
MONS@!8G#51@3DC9M/&1YP.-6*T++)?':+_[M_"<BP)X77PGJEI3$S=]=^G[O
M%PD=\8ASZON[-%,BJ=G*12I$&JT>3/]**Q/($))+#X-+<D;9:@73NZ-U1:55
M;C4,I?T'K[Q265S,5U3Y,.G-/QSF+]I,#-L,Y.]&W>RZJ-.%9AW5D9F(EJW2
M>3NI_18I>T[>RDA\WTM\)+R6-+;#<U&4I(49GU@V^(T/1&>3.GM-*:D:O9!H
MY5:37!?W,O'219,'FZQ5:JYDP>FZF1)EN7QJ]&</;P6GQ0,GS[['P>(N)'"E
M?HA@_YQSK^ATU_R1GX*5)A(-TI#*#[G^VI-ZE1#+(:[BK-IQ.<%C[L7!ZZ+A
ME6!&U=L1+/+G8P./*!-XDA;+:Y!36HG0^-:J6>R:A>EP#9+9V315$H-R!O-6
MY \2&T,2BO_,.:4F!?^"'4B4B4O9?-R<@.W+=2CK_VRV>X[X<$W=/6JC[]&G
MI"5Y66'-=U')T?[ #4EFKJ!?[HG24PBQZS$_<(5%]9;V3"WBNFPWM2#7M=@C
M'F:(5B]HCB;FG#YZ7+#Q7Q3HF0V/9+AK%&F L.#36!2=#-$:DVWU[XC'M57[
M0 0#B-4C%*:T4R%?UWJ=AY^3YD@T@&CGO@?]Y G"WCLC\('1^?U@H"HR>W7<
MXE2J@\J>+83,ICP$H5YBB!N(T,@P,,:D]>B<7PZF\S3[*E >@)*\0'U;NTB\
M/F[2>COEJ"))F(ZO#E0&_&FDVAJIA]^$?0G;V(>LG.Z,=!ME@/A._A58%\+D
M9_EF91_ 4'F8G973V3-#ZK4& A$R54<<(_$MG>P.U(7X0&Y)=63Q9']^#O58
M' K3:N4:LVL2B -+T+UJ&&DV_TLIS^$5_B@N[I/S$6[-#%)J1TIU0NQG%!LL
M+'U<=;(XR4%='O:"9)-2HI0?UN>^?T1N?+#6A2T?DNE?D%CA=C.%&_$Q#=U6
ME\7K:3C:.+B^17Z31?R#_/+_4<H#5$!,('D/8Z<2B/ZD7$*9J?07,C/65<.D
MNC9N7'4*R2BT/5&Q'#VB!.^+N*;$=-G3EN#Q8Y' WK"CEI[?/ T6H'A7[+K/
MZYB"!O>W<Y+VHCI'\Z9U]KMJWN7W]>"'L('(SH4;-2!6N#UAI:V5,-D5Z+G6
MZ3\P]J&NM$JZ;F3GQL_!?D;P6Y/(.E\Y$64'1^HK'&/?=Y>OIIV#IL<9S?$S
MY)03/HKQXB!/A_L0\^+#7Q*RNG<*>M)<T-" -W7OD"-U_UQD9,J*!2;!8B;F
MB?MU"PNG!ZH5]=5G?A(!T(J#H9ZAF.EW[1(\KA+Z4LW&A>W]Z.F_ZJO538R;
MZH%SEQX8]Y7;T5UI86R2@O5Z*74G<JXB?]$ 2;YDY-.? U["*_AJE<U1C+A)
M_]E X*D?,)Y7@*#:LG3=8,F,P)OK5;@P*VT?CU/WB=;D?WXK8;\[(S@P6M%H
MO4TM_<[]1G[X];?/+9^UH/P:$S8"2T<61A\H>?SH0:^ .6;T@KTM3@XK3P [
MDS$@J8/I]ULC%+;]4V]D2-_<]>M"IF/5U]6NFZJWUH_6,)AJWFNL\8UY9J=@
MK:'_^:&HP]6QR"@<BJTQP%<R$:VKA1*1UU+25+& )!<;'GD1W<_7OBL!I,O+
M2V",FX'UOPQ:$W=/K6EV!HW8]BI\?265RL#J![SW')[LD*)]3<I):_=3HU3Y
MF9]4W[S#G!U'9?<H4;9E5D=VI']:DJKG<KP>J/\Q$+ 7\V<)Y2<YOVFE:HJQ
MG6T$N_C4G"Y0.7NBX# 2U)4@AB46HDN<&[O3&%-#PKT^K$J,B?IV6A2$!RFQ
ML"\SN=1=B(2]?69'M!^S;[1H:5V97/:;RF>2GQ5X 35@2.75$?,\!1_7K;D@
M(I%M-VD 9U<H&"_9A*_K\E\9V"U=#'3H'8XG^KI\^OU;]&=$I71@W!SHISM&
MN$<(?1A[R=Z@:]'Y==%09C['=^V6P#1-RJ2_/[CG9&FIA_%5WZ-95:>@CB+Y
MM]WI20BS:9"%H?/Q1IYUQKL&RANR+,'&N=9D9]6N-A\!=0-EJG[I"FP@<8']
MBH5.D>#,/8:]OP,Q0] #TBM-V?\-4\T G:,V)!(*#&.#<-  CA0N[//<%\I"
MBYJW=-38(1EZKZ1I@#R]^Q6=CI^!@O?:8NB2J"8-2IAX98M!@<YTAR!LHV?K
M1:'X4O!-MW'1F?G$D9DYRPJ=@*+]R@9J,H6[WC,E%'%C=19I(AWSKNM&)O-%
M$_=H/,EHYZI!2N<>")&7FY>?JR/$?@<7HP1;JOTH&W.5S\PFY@$+7XQT!0O=
MWT7?+ICQY^1>OI-[-2_1.-'(^Q@>7[F3C=/-VQST<=8R+#30]4K/6!'IG3=(
MV)U?^P(W(&6@R8K#J<^O>93.YHM+7!EI2PO+?+Y]C2OVC*%'%N?0,,Z=Q3S
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MKJP\G4]?XIZ)K,@\WF%"OZ!H!*T?6)]/1E7GCCH)-CGEATZQ'-A_^"\,^7)
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M$Y=V5A);V3?@Z.0(Q@,4%(!<E#I%:*S[QKH+UH:W&+TC?@MR^]\D20;'O],
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MWN2PP,_(01WF80S0VU:+5I9I=0JBS1?;K!)[ "NX"PD=*+$YTL<4F6C*31I
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MW87ZLK;[2HM^?+DU1KQ+1>RIT;I'Q_=IH[@)A?R:M>@:N_W]$P@D&CKJ)1N
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M8E>EX5!Z[B65_C2!6JNI^2=]:<=?(?64R@%59Z-;.'U _N=\B YKJ/YN(PW
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MW;_5HQ694UQG/P*"6BJC2</G\[ /V/9+F065BDE]+FH69IL5AV5!-$ 4]8^
MJ,%H3W)M(_^PNVZ V)WLX76=%>0.NG3;8C+9'S>LCLY#Y]?JZ& 5\W5,PC$Z
MU?.?>)2/]TQ(>><"", ?*_LGBNHCL;S73>YD&F@A @/$L]E.:J^2B@\4W8M,
MOB%U@CX2$W'5R_(?U,Y!8!VGWL<6'T>=_<RH?!%Z3MD([.ZERO 9R<ON<I?9
M%:4\6!R4'PXZ1.8IL;(:QCG*LVF-&V2,JJ;KLJ3/CY2\,RI;W>SSMMD[FFT8
MI'8OTJO=)98N+R3XY\\XIP7\!5>"N<\W>W6ZJ,(_%P:JI!HG3M\.'=ZM5PV
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M+:,JA"QDOH\5&S0]I(HN<C)1U:'-L+H7J6YIU$0-@^$5<O>S5A;*6W]I"Y
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M'*+S]P;V+-TH*O'/@EG,Z&RR,XYM,@DDK!VNW4_<8+R45ZE>Q55XIYX7!\2
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M-^+UGK;[ Q TP-L N_- +6M$A&!*+0M@+LQD:'S_/>\">I,*6?[ _N%Q[%6
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M, :S+)Y^&;N. E,NVY&EJ>JO:DYDB<JPQ/57+$TPB>U#H:=*P9>_P\$"L+.
M35R>L@#!E\L=])K7"S5@IXN?S_]0B?W;%R:!TF]G2RI_!%R_$'KZICH@0*1\
MP<4]247EF;Q-HS>U5FJ-TWOG+!-95,/\#^J_>ZF?^FXA*:X47F[OI81.,DA/
MY$[=/OH(_.% H=Y&[!"Y68 J[SVJ/4/4.4J)+1[93@.P0?L7[K?T1JLQ+NBO
M  %1ZU9;<(9FD^_5+NP^99KK!^1[*R)1N^*9OM-O5>P+>MUO4 >;4UL9HSS<
MTNXKU$O,3VE+(Z=+F5UAO1<15#9'1 4.-2;QT0:<\Y)83:]/25;ZZ&$>(0H+
MRWBYR:^=GX%.9PN)O:U4\EEI5__XD^:A/%@*)A?VW^"37?D0& G"V0"G._96
MAG>TEN>-U-&3QUU ^B)N!62\,JC69KAHL^Y8Q-/5^3F;P?PN4R6W5J_>I:#A
M.R]MY 5*EBI4I FC5NG0K0#Q6<(&M')I <:9$.OAO:W5R?A%XOLX%)W$Y,//
MH0B>=[(L)G^!#D"5P7?("LC1W36[<J*I*=J'E6_YY3D_T]^_/2H%TF_APSQK
M#KIADG_J_4>Z^DUKA%T+,Y1E*RP7GU#$?E:ZW K5^:)H6.6JRA[079ZV5E>J
M7GF8QZ-S>T3[PW*&T+W$IRMO(T>S"&WS64#M Y6]-QE.M:XR&RAZ6&>@F$"1
MCXNWRPC9B(C%+9 P%5U<EKH9O)3T[\/W<_/G/I"^( K>7K*1"[]6YGO^*:OL
M,1M46*%,A:\FQ4QT97*[HDA_A#PKTZ%#%U-,!^EXMUZ(]7$8HP&*W'M[(@HE
MR:CA6M\<+PMQZ\GL1F?N+-C1=W8DF?G;5.,,)F%[D7>?FHWZ!%*+[O.NF_6'
M6=(A67MMX$7_M)%=="IO<46ZPH=/1S+&AE:>UR-_5,7E-[5\$7/]ICXWILO[
M-N[V=2V[MA[]KS*9!GKZCJ6M?3PI5FNLFN9U29;*+8B6YAWH ID99Q2D1G3!
M+#(^BTSOF,6:E7Q>=JE>+Y$G/>6;F=YXQ#V!^SPSS!15;&#=04C(]UY<0_\-
M34ZW;2T-S=.8]+0:JZJC'NN5NOBA!D9DXTQGGXS5<KTYZ;K3:)V%]+N9W*$1
M$WMZ+DEY2E5!*3F6IS8EQ7!OK0B<."W4D\*OJ#,7:R_@\TT'M4;5!/]SCBW1
M'\:?$$,5=TE[UUY,UI[2G4Q+O_$C2?7FO.F(/_3EI9M:8G=T\_8<_,ZC"B%T
M0OY0,^Q6QX1+?BYD>M^'!'>C:IY,''Y8_KT^9Z OTC%AU&D?53*7U'C:GY9>
M/;&O/8-0@H_2 #OSF!X&YS]JTD"%WF= ?6J=R.[P^OK4A'H0JA18EG.G=O_M
M,H?G1X.$;Q^PT9<#L6YIAR-8P1O_DD\O&I8__V?G\YGW("[04AX-0.=^KP&W
MUSM\S?)",5';,A!\$X#>37]J_BC^7<S^![?\W%D^OJ+CUB#JN14'>I-BS4L]
MYMX<W6O7'_3TB.^6W]P:6W->6#[V3GE;-TY%GPH00\.+C!1P12K%S*EX=:54
MJ>(AR=@'TW")SJ&6-:R%H5F8>N!&T.S7;5,UGK&WLC%LAI:!&W<T$ACVU4;_
M=&V10\KTC E[T>25*]%%<9VC7:-!AUL=A F^.9]XI(4515ZN'V\N9QLS(.GA
M@?A8*BC@LZ<.FA^2TBG1'DYU+=,/55,FJ];CBJ)V?4H%_1PS9FL[JMR[:P=N
MK6ML:?9?.0F?Y.4"+*/$EV,+7W"^Q=]>IB(BW9Q*:Z]L#W(%HN1@1A#+[IKJ
M7TEIEE%P<?LT=0/GH.*IKTD$KYAXPO2\2  WXVS(U9SL]XHT $_K"\I3L)5#
M\E0A"+BJ\/7B7;?>AW_])7C!O;.5>T+%J'1F(T-%0G7P5Q23QY?XBV_=DIZ,
MFLI<RE1]H/"GT0.B_7L+UVF[O*;8I_DWEGFBI2SI8.3 *VCQ0J+]T8%H1[[3
M:-X5/<EWVB;\S/GWN-:$M$>U_$!ZS8P8#N %HHO>R-OWOR1+K09JW@2&LR5I
M]"IG1^UZR'U78";96'XH2'NY@1&RP.GD6)#&%G1GAXO4OX&BB)F@;D]QKYA!
M3RE82V8<>\!,*NOF90V2AJ06_\+.]&2M2S"=UKA/#/)I[H_:-)C4LXN7;J3.
M73_7WLME^6$$/QK5]>1*!"+Z^W*NWG6KL6ES7W1Y3'F?F__T&["E[*\'_F[<
M-XO-6&RRF2\'Z6IKR2#6 E%5R0[M4-8D]YO$""/\-<S\7NV5',7\OK2'^VEO
M>J!6<7FL',:BD'OOU)K:LL(+>9DR\>'B614QF9U+)?IE_A7R>B3^;\D6-J/3
M,D%[Z NQ#T[>6'=0F>U37^:E/2^*&W0T&#7ZCAG0-36=M"3QB]DQ"^V.GB:3
M%#9NLB$X'""GH5N2"6U0X"/P6"_N6>,)'V*;!C@',P79!C$[OZQ\SQ126;$6
M>Q8-16,A0+<^B;;#1VT7?C]_^O^]F\X?V%L1R\[8)A$*9U)[0$R\>.KPOEDZ
MN*P@*N41!5%J*TH&Y>;W4HPS=EM\"C>9?DK9!4YXE)DY;;<M;=GA(4%<(D)3
MQ:Q>JKE I/S\XRN#!:4&56:5!"@7SM1N68(#-WQQS;63N<N\''A^^[M2#-W'
MIM+/=FN7\$\D!C9?>2;'1_6$FIDUD-D@4SW<=XEA*XRWB7O=?HAB2&:/S=T)
MLGX%^,&,N(^K&S58X_3I2M^-3D),A"7DUK$O[C(F]O+*<Q D5R.'/4Y4E=_9
MVZDCA<41'1T+NP@;E7N4N-8LG;A*5DX>>6%5RCO@8:X'?F3>"%'YBSN'/20E
MR>I(-5NAL9:]13O>*+WEOA=S\?9_49V4![#V2VKGVEV_!9E3"F1C& ^Q>KL2
M8=R7&U*MGRG9?_J!9XPKSS6]+Y1$I32+V5T:=ZQP.]5 .//[-.3(D-?C/?<R
MKZ2UDRK!EN5-?0=&7U'8WR5)2!M(:R0-((%R!$9ZE<9A&.EQ)DFY'XO4Q(>+
MVXNPDCX3;YMX\@QG.K?J[3-?\6MM&MC]F+ 'SALF4EC-UHM.?OPG5QU? L!H
MX_]15R\Y(7,+M6+Q!.-R.LVD>G/_#5?;6B_ZZ'S"B1_%CY\,CECD +;UDCF]
M2 (2[>!97ATB#8!I,F(,@3D#&6'NSI)\VFFGX&[PQ?;"#6[9D)O9+_%_)4N$
M!9FWVJWKE#LO\,]<*I/;@,\N:BX(47]CKC9<Y]%:47!&5N8?M5A5LVZ9=6@M
M8FVW1?58=)G97[B*S\)XLS&4G/LY/" &[Q34]IHLZT#%3$S,M,NO4_BP&'13
M#%ZTZO_("CW[YYP5VC*XY]-6.$B_IX&_28:GW+D4EDRJD8OHW&#N5IW*?60U
MP:*W?4I^3]JC7DDFO9JC=L+J0!VHN"E="/5"TDDS/3Z@H\L_77[Q*ME6M2 ]
M:KVN3C0J.!A3S(-N=BAP&L(5YI9"G'M^SLWXTP NH4N0E0B66QZ[RJ)Q:<)"
MKZI.=-0YW;BTC5\M3L<Y-F#6)2JO#NFJV9AMV#J7R.8)X'3FX"GVKMY4TQ3$
MY*3FJ??F3#B\=)/ 7I<<Z%KL9%&06IY7Z"QG&%5VQ*!V>GFWK )Q'YQFZ=+D
M]"IGP63Y:;X&)SN5/XM?[UV10KW>38\L/H1@OT2:@4M>C*E+GN8(S,)U7]SX
M_7\#%8-@T?>OE]EGI,F\^S0 J/_]/;D;\"7PP.FK]Y?0&/#9%1?H*B#;-<_J
M)6,;#+[V\-8E@Y%_QNO_/R%-2E:$N3$N);Z+\0#[3]\E(US% =<X]4)*\OW-
M:>J-1Q0%<L!SP^!L.(;BCDHD+\+:=:@,NDN,,7>X[]6,B"-V5+3R_KX_D<HG
MERZO]-JWA(>.8NQ^S5W.=TE.[6W=' WPG,CUN:1!PS9MJ-D*-V&BK1"L..XP
MM-7GY,=U*SBM=QG*OT3) 3'$Q DPF\)%MRSGF_V-30B'>R/DBY1"J@RD$T-
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MBPP5AB]9>A*U<=?VJ<V?\J;Y8@\XMCL&$&IJ[S5B EKL%K!*;+43+J^.C!1
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M+=ZS2@<P_('MXU&N ^@D&N;:U=4(14@/'; ><FRH:48@(S32:&<6\39H%SH
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M)V9LTP&NY?-NQT/4QT10*'[$Y:YRY+62QL7K(<>O[.MB5J@(R\@#MH_WSFQ
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M>,7)U/KQI"FJ^6"AGLS:V1?14&O+5MQ :-;D,!9\-"WMJ:#E)EHV,5MKJUO
M:&:"+QYK*9;OZQ]PGU^XM +"6V6D[Q9,;K/.-M(!FWV.GN3KZ*W+* PJX1/C
M<NHB<Q_?=UISW$3Q#?D5F5\2*3TZ9G\V=^2T_@HGJO=;F=?R?-^N/PH*,346
M'D@?'9JEC2(69Y S1W#OQ6O.!_^0,_ @J4XZX,H&NMF">-/%T.,@S@V7-+A"
M1OZ0996L6R]-B/B>TC8I[2+3GQ:%$W4]7M#2^4H6S1G%?*&\QD%+ENYV-"@8
M8I?LBNR<TD=2)81U.GI$>;C,67G_U!SLC2*WA<O=[,^897-W4O0GF^IJ3A S
M&8BP[FI(B0+E^?;_C@[E%QT0W$H']+RGV-$!%:?(1#7-OHK.QX&.0%:0MB@Z
M8,RI<)]U:)2F"PI&;+!&TP'[B;\&D:?\+@52T[VQ2IPY$";[XL0CH;=;_X%Q
M=LIRT $=[&CX0_Q"9.M-XE:CX[7#N-K2)D%7+Y2984U+\*,F->O&.K\[!NF7
M;QKW\0B6;]WOD^+2\HPLC?B!7]=UQQ:-Y4>4RBN9WAI5UXG1&C"9L2L+BMJK
M)39U9/.3L%%2\5R+UR4'JS)5H-B/.5_^4&0R[8P91[%_C#ED<!JL(6WC.0]U
M2B^/%+,--.C'YO"F.U!9Z8#P46H"YN\JPAY# 2L!Z  "%4X''(BYT0%/^Q&T
MFZ?%[@]P&4/^0)-"#!>2..F ?W[=I0-6_-:_:W>*AW\_3<?R(,&_W&!B? MQ
M8O3EQ'Y& K=#.NU+*5E=41BKL@]^@J"V%)K/KJ*<<Y4RBE2+U=.NUKV;LE"6
M[;GSR2@>9JZIL'Y%-\S8VCSGPE,O D?SN.C&TL:T;O-1;B^JQ&E::LDC4Z#C
MR/<?/1P8&[$;BXE:PU?("\$A\7V5QN!YX^:!5WX^H!,(DWHJGT%7-W-X*LOU
M=.]<R^3B>:D81+!"-^46]F",6A8D2([Y :I@;=<$P\RPX4LT(92GQJC,;>MU
MK1/]"F-8@N4X&!J81^9L\SDN<P=_UX[POH3V-E$WOV?IQ-3)EU\XAPW?>5MZ
M1:LU,":MMMAM[JENK%[5N\)+.GHHD_:#E!<[G8YY!AETP),*J/+"N>:[.'!]
M9-#'6:M(VD1_2QJ%][6$<9DL8RK/U--\>+5X^YLQB2\'OGJ7!8NL=T6DBZSN
M9,G^M5KME2E)=Z/<PAS\IB8&"<!\?V#J%]JO7(8+H#LND2 17BA^K#E+#%C"
M?'WZ8B5.TTB'R!!C,S*B'VB&3=59G<X#.=3NNDFO6@J;59G+)2XWF*;L<)FG
MF")VUO+R[UM.ZQ4S5L;YFT\<.LG==]C(2QF./A:'L2\Q7+$S.1Q>B2W%RO7E
MC?96BUB*WWA_4)ZYHG'F\^OJM_R<D>_\K#/-W?U2'*W=DPZ\_1RL;=@-<H^C
M3IR"9I18J"D8>XM'2X8?'*V63@4^]ZS#L6I[C+P8'8!_@K8D1Z@TD2XBT6NL
MJ2-\?3#+T6=5&7KI&N=6%IK3?;Y</1#0LW@ZNOSN;6J!XV>-"SI]0 Y&S\Y'
M 43]Y>(&%7%MA^4Q@[WXJFH" =&;S0!C32=7X[4$/E1S-,3?QA+WP:Y2,:5:
M<=576\/-XG+3K"4IBAP57KGIX]V&X2PW.L3M(V(]Y+^,EE>@@4:[Y[ (+LAB
M?3:$&!?1A;X"ER>Z4>X<MR:V\@V#^;-!9&][SS('N5<QZX]:Y+#?!R-G\+>&
M9DU2TE[6!3Y5--*K3V07^=HBQ[(M/C+V@VC)7=UFT&%X,)16G05UM"C25#)B
MUP^#O$[WUY@CQ&BJ3U12=;X0!8:T(ZIC5<\M-VMFT0&NBY5NPMUVVQ)X];$*
MDS!VJF4MEY;MASZCZT^]2@6X#(QQ^:'MX[$XT_P+ZGEW#Q(H3,XT1LY2VN^8
M)43$J7H6S",_6F+%-CT*-#T6/:OX=%29!(J8)SO*U0\Y<J &#G)SUM)92@X,
M%<;#.JEC8L=9L0<NUUW?EE%<>7!D6^ZN5HZRDD72M78PI=QK[?[N_49E%:E8
M?&8.'S.Q9F* QK.7<2S_NIG5C_6&>[E+S*\&\2AA_;:A;"L1F;>N)I^[(B;O
M6ZW$MNMB<97DET$W9=87/6Y5[-FSX81'RPJ=#-8]Z "BEMM,TA)T4X>$/@@F
MRG7\;F:_^(&(/^>!^]PL\77.T4@GE627FQNY[>I:ZZ)6/BR"^F;0V[7\^(V]
MM8>9QW6UX%ZB,>-O-Y?!2)_B3?X\3!B[0S*/B\EF(!_\XJ+;Y096;"8=$):?
M-2B!-XW.=A09!6FPJACV$'__<KI5;/6@-S;+/]'UEXY.C:ZADB[Y5,Y?<*3F
MM;+2QD^K\&58 &XE-.ANVS=RF@G9@^B)57"+V,\M&UCB03M\1T1L[:,WYG27
M#$A/>][(.,P\'OXVLK7O8GFH'3VQU3XO:[KO#A=,Q;]KOBZ;[]_@J^#>8;VF
MGO>0F5OM>S37L$X^6@ C9GM)T$(VJ+$-\8P.N HK;;<$+)5U1^YF<Q;']3T
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M!8YILL4VMUN+"[HOIUH\5<E6.[_1?M^0YY]=^*!XV Z<W\V(]2JTMI;1Z[0
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M; 3;#33-@HLB2G4\B\,+/] !YZNI:)I8T"0=  RZ?RK9%HD58\UWET0%GHY
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MJ9KC;+3"[#IM^2>.[X783'C&Y>3IF4]4K*''O8IGV57GRAK7LCI$OF5VB/P
MA*_HY@J-%6MEKQ7KWBXV$'7I8#:,-$][E6+[C ;X\J9,M/] M4:BMSI77/6.
M>=IR96. 340!S#&J_>4/#%/45_JZ,U?#XNN" JN[0?)[ Y#?1__=I%&NT0 ?
M',,'I*EC- !*.Z)6/,0@^Q2[],Z'P('C^*7>$UA(#-Z:J44S+OPBM#@!V=P/
M7)LT=ZMES5-<JK=99_1NU>6'JC,Q_[&;R;)Q^]?5'$D=C-DK-@R98-G7A<L6
MC(!3MJU ZW9%''%>'<@;->7AEYEO\NAT"N.G&+9)LXH#W6DK"0,EFBJ':TIN
M7:\V3-Q,2E8*WB>Z#+&KY=( #>\ %Z_+ $; Y7> ';IP$5CD@_\W>/;_\['^
M[_^=Q_I7^/Y.-HR[\\YQH/&)]##?/="P(L)QY,1]CUKN7).R5TMM.V3Q20=F
M8L?.1S,209_NB<_9C9&3S"%CLA2'Y^-^B9".,9-1E)YHJXSQF.3N2G/EN-\<
M*4A<\HBT;?D^[L_0R:BEAR=B]:K2[EJ*H)GVW]N<0VF;$T5*1B6ZWB4&A=R1
MFT,,NJR1&55I @5"J-J48(L?D),PLP5@JI4'5?LLE09HUZ,!'$C(Z?B3#N)7
MO.WL$)7IDK6M9!+UMJU=9A:2>H?8A#O8QOQ;1#HLT<.6Q<J!Z-P4UEGFW18Y
MT2E^26:O@1OPF%Q+7ADL3[U"VF:+OR)%6SX*Y&\\4%D5*8IV0D=7,:>+.2IZ
M<%G$:DG\(N9BZ(^?/]\LG%#8'Z4!D&]G[$A)^/V]I1*\?ECDY/"J#YVOOAL:
MD?CRJ-Z^0O'<7"P]1RRZL@389?4'C?PYR6TA&NVN=R(FFG_Q#JBX655S )LB
M,WVJY<V'3QUO!,-_T@")H-MH9W#\$E.X(EED$E1)#L./=<X&?B2K!3WT4$NK
MOV,$*W0-;LWNO3TN*^[9M5<;%JCORJ>OH=/64N/*=QA1_#YG[;/UW*7X?I]:
MRG<.#BT_D2[7AT5XDX@:PQ(#:Y2P[N+NLZZ9'7>#PA(#F9@N8..1ZUP!1,7O
M0@^\\)JY?%)(#"$YA0\#&4$NL.B:GTV22;*1'@Y/K*J"0I:1G!97Z@A>[U$Q
MTE9]3?!H?Q^YK!1W=Y^2S77PE%B*OJ1I92.<6*S>ZV,-RL8=E$/"Q^@-?YBL
MK24]B$05Q'YHMDXOF373/U!I)_U.L=,T\"FY/@2\E3Z5Z4?&';D7F*EG(GDJ
M_ZL,/E2AWB31  *7"3G4#A@]^M@-^J@M,Q*V&A9) UP5I $,2^'C=AK@LV?A
M-VB 2EM1&F!23P4DC7XI2>1/WEDCO0@?L&4@]A!8.X%WRE5-<0QVW7<XZMK8
M")+1L@O,]W^K&I9L3&K-CAGAS6H">9)='5FM.>5NF*Y+$,J?F<F=JY(^'O+4
MR" B,)B;F\91'!QFZ3K@I:(;S0T3'Q8V]Q!,6UZ%"J/]G>B;+<9#1-'H@T6F
M3D>E "9^Y),*K_0_#;F^^?;I]M*H"=UIZ\/+6H:)D#&3<>_?/M\+.)7D!JC#
M-$ ,1WB/W9%\:!@-T#'<#B+ONO?0 #8UR6>G%X*R70YV]H6L1Q5<ZDX^9X4&
MT0#1ST]I@&\1;91R*M,&NAI,9NE?$>P 1RHL/FC^K2J-#?)K5D&S+D+<(#M-
MVIW@N":_-BF]_E91O9%=1_ .#<"^7?EX;?.WF%FXD36GO)X,-OW5>C9!G8D]
MWF1\R]3(+<4G1A[(P*_59Y1J>RP2>)K?[*<]1'S<#=V_JYZARM[-XQ#3[^+$
M^=W]EFFPDNG-:>LKTKD*'1:?7U=$\=B*<D.8+@27G7+N=':2:>."'*-+A^HZ
MF5FT8Q$X@G8 $Y_5SNGY3:G:$R2[%<(?MIEH!/I()$Q")-)=5>>RP34SKI,E
M<HBJ&9Y'=@O#/(_W_F1X*(XB=-9YA_1)RHIN(FG!_++K IF!@DXD+=&BS**C
MC4%?'J]$^$Q#*8KWL@ V-"/)_'']CBN&FXLX;^/F79U<B_Q8)N+O)N%JH!@L
ME8;0NAVU3Q1WC@I5081W!6?&REFYFTV2.0GT[5S)4?L/DRD2W*U6+[R8M@(R
MQB3NO6H>E>-NK$#T2CU_([X&'9BL&V99[D/=S^W.M5I%Q""XXHN^LAN)(RJ*
MV%(7?&5KWV VE'*<+( \WHT!+ C3]T,-OFH8IUH^R?FA)"8&GAYZ,X3"7N-(
MM[U+1_K3UD+VX'\3TI51#I(YH4"2"#'U9.-B=7Q&':3RCJ#40$^)J<OTR>SN
MME?AD$.MG/(YHETW\#:9@RE:$LFW))#N7K[QR?5@;@OHU*CG3I$TL'QE=4,P
M&Z15X0I^B&OI+EP1QI:5OBC_ZNFBG.9]W/HMOEXF\BS5W#RAR.--\E@-_$[U
M\"7US[8"3HKS GSW,#P:8.&?Z^-XU636#R79JRT*><-R7[6LJ[HFVAV*/B8^
M5T 5;MD3H/DZROCB&Z$8+'(63KU90KKF @%'A N'\D^HVN&'VP/,SB7@/BNP
MJ_/$G,>C?O?DI>DJX,5D<R(L.*-;5._9I+CL]NQDW9OR@KA%%4-G#_86];SG
MR*C#F;XZ#G8NQ>SA_/\49W^;B_*T@!!:YXB-]^E;O<+ XX>@&VT?[9[="I=4
MP:I+=;R>-\PW+TGL-/I54VII!N+X_.KUEFGG*ZA&[ _E4E.WWF%V"OS]3Y+;
M:+J.Z<D$OQ&L"(TW@,]9G=A3"LFFN#S)#KO+H>QX^I-W;943JIHX%;5K_^"7
M8<#-U"WYP/S[DV)DKPL ?#SNGU,W*5 WCD*PVKSWOU6KG-XR.VZF'+46,TA@
MU,]RK"W1K9"O4[G$^21/06F<TIEF[=H^DK9^5^+IRHWV TK.DTW0'Z9"^/M%
M$:A]VIIB^5*R[_#M%F4,3BK+T])*:D!&PO9>EQ'&[&O&<MEKBX$>*<S+$NW+
M!M\Y+B?U_\&?F$I-""\[6C%I,Q/ 9&8PU<#KI.UBO:&C 2;>EYNCNF$'XGVP
M+AJ@"0]Z>^X#ZRW#NU,[0*?S[3S_I;[2H,R%M/^P2'[5.([XTJ1^EP#K1C-O
M]OK<\BT,3H.\F=5$]8F]3Q=$V;RRBG=]MW2%T".F^5K3_\)T2O!F#)JH7>&7
MFWU#B_N/4B%^H1_E4,D:G?/]K)F4*PTB&5R%FV)3 LMO:IA%?-,5Q,2JI+I-
MOL]#WA:;+G\U* 0V*[]->YUK!3Y)I=YD<O8(([&&CTDM/$U]"K^IJ@W]L57^
M;<4@3H6D],_+?Z 2NU^RY;=2M"H*'WU05_C;4VD(,D6A,T[V>'AFMTP#:! C
M-M8A14P\9(D\X08=0H"E9D.S IA9V'Y; UQCE*@SEC+3K:]V+_G/XI359.T2
MD>]J@?WW7QT]=I3:U*>$O]ZMRG]D>K^CJGW+V66VC :X<>?C-SW2@, Q(!S?
M+7ID?ETOX=5JZU802 U$(+D:P\X,?"'AVN<>YI??=U(4I"8(TK9+$O@G%CN-
MI-+IS77402\JS(HZV.-0L+?MM?<=IK&$?XZDA\(ZX)5+.Q2F&(3X[I@U/BU?
M>%+@_6T=&([IMEO]Z2QJ83YN8&S^X8X8>^&KW[.6D%F1+H;:%UUG- "+:8FY
M2@]):ZFF;.=+TW^BW]OY1ZP6CSV.08,T0)& ^^<_BZK$CZK="-WD2[G:PNU/
M"D(;0ILE.NPW7FZ,Q!N:;.IFGV,2C(S*;!%FZ\HIN6@5&F"Y39T=OX.^U789
MNK"+,.[*4%>9(HMZ!/#-A?A@%XPQ!VY3=:.Z#8>(-RAQ(#CE[MK2B:O7NCM,
M<M=<W>LWGA\2SYI4$+B3=],?0A(I%'FK6332,*0SY\\>]HG"1U([?-/'8XR[
MJLF%LC6TBSG8F45PB/XNSK*7N;N\89H ;#>KX^".C5RC#WGVXGNI;PB7:MN%
MT=)93J* +.%=(+P!\O;65G_I-IKI*,S!B+$K9_<<WI$<4Y_I^'&U*M]9,'!P
M>/#0J;D!PER<2Z!3)$LA%;5F0ZJZS/7&GH;''&G_Q%8/\X2G!'G>7#+N)\9S
M?N@X*),LPT*;8S<,=0),L&R([]DN,,VE*V3A+U".Y?V.I6M$R.3L,&:1APC#
MBHOJ1(_\]<1#W$^%S9(H]CICM][&VEI%1WRP<W1>_V&J[H'">D,?2A1'D"NM
MVS)!FAFC Q6*T^OTOIEMP++G?7.<.$^Y?&Q]LR=*K*0'&N(5NW#KIHMN*.NP
M(.40"0M#LP*#_]2TS+UOP)S =Q>Y'G,"KZG#"Y+OC"TGE2S_6JD9#S5?D7P?
MF/]07TVS44%=$$J^AU,2-#F[E1T3]:^U&YUI^'B]L8[\9G&&-N6R6"JR'3H]
M.2E;XN  SK$1IIYGVV'+"D,L^5]_HOX+-8=4P(XX5LH% H7-,8Z<DKPC_;S\
M)#VCOK2:\FK9>=0:QFEX!IOJ-=UD@F6T,(YT4-@5QNZ*=@'Q5C1 %$0=Y4Q'
MS3V_(!IY3ZQ4/D^Z!ZW])O-[(&;*?S=(]]]N'4/,X#Y!E-AUGR5$I66]60-_
MJ#**\,FLZ=:4*]#UM[Z'J&\6T([FS) 4/K].\%2X#/D.9.5!)WK_1N@:L MC
M@+DF/\W\UKEU64[N9L<]BC>*#XS7%T 7V,5.RC?!,4OW-NM_([HROBX/LUDL
M_%P1ED-,?@RCZY109D\1YKP;S&.^_CE@)?:K4+/B9.&8#5<N!,9''L-F3WC/
M:V.(V:Q^V_:'+:4HKD^C)ENC/?;K!CYA/(YL4T[)?^:HURE\\)E,ZDU.9H>U
M8@Q%_BD8:YZ*I0&Z4)_>'3M&_QWV*4STR%.<!OB4R40#3#]%'_-=AWU'/_^%
M),;!M(4M?=7_[NQJ0VC'-CSN"A84MIJ :\':+Z-7DT*#:8#JK(N>*)H9+7L7
MOA;Z$S8M!Z8HAWN1GH!6:_$D:F_H!84S*_X$:V>D 5:;J9,TP GC;_2Q-$'.
MGU!,CC^ $RXDRW-C=<SF13\/KT6@3Y@_P[8RA4&%L^15&D"ZXW].HY$*(XHN
M[=Y'0F-.$L$?JC<AU=! S.SC?*O8BNF-PU\CFLHZ/B^KR <B&#%#CO2(9WO]
M+)^XF;:&KQV\4:?GHX[Z88W:E'UU"V+06FRG<:FCHT8;&9,@II7Y[CJ^1U#)
M8+;*7EMA4NI;HF?S=^3A&3"^R32%;#U12]'H4(;'^J'P3D5B"L&.M1S>CTO#
M\E?<"QZ?>#M&/:=[A!:YMGJ*G' V2SMS,VC"="3L4 I7M%@"44AUDY/1BQN7
MC$[@;K'7'T]ON_MX$)GFN5N/"TO'%ZQ(=H+>\0K$=U+OM<&?-&CI."4=#5^%
MJ_KPJL]QO^E#_@.]!+WB<*T;Q\C32ZSY"S\=\\0 B.EZD:?4ERE_FJ:$")/=
M=FS<6@NJL_^$XS/*+J&3C$M_UG?3NLDEKVZN7L/AI(B":A,F.XV(H4 <@P+-
M7@Y_7WZ"W];S^-Z<>Q8H?[)G+9P8#,][&" 64'(]M.W.\IOBB D(T:7%2<!V
M1U3?UCM"+WM*+Z"B690/J8)[$Q#2SX6<,4Z<*P)&M>7YV4S!^' VY@;X.SG%
M<JTG^;/,!#)^SD:G:$[72\)+(%:W3'6D,)ZUM/-QAJ;)%8>$.)*2B'1BKI):
M77*&?'.]64:.UTPP4&G?=FYF<Z.6A,8VR>P@9T"X-^B_VH2A,J:5S7IA(EO/
MR KE_5 N+66-"%_6W@=LII\J=(73N_]ZUS 8'H*+UJ:4=1SG*?N+3/[4FQM]
MX?XT4[#5OR)QUZ,E&;'<TOM2)EO70+HH5C=MON+TM+9F;'US%68"NADNM9F9
M<8(,*YNQZA+I-K+*Z8<:UE_Z@!2+*V0>N[:9CR('EY@$ZN;.062_+;34:N_O
M^>'2U]GOU'IT6>V[6NT=A"SMZK-:U(Z_P3;6-43C. V?^SX6T;L5_[Y/C_.U
MSUZYIEY\?&UJO U7C9W S4$;V2DM%'@$H;[RQ=QLDPH;/F-[%_;?<A;T0L^W
M_F!^YLNU5N=;6?6#;D"3MD:W%F:%=RL\CD)Z7^9SOHA)LG!\FJ)@Q'G/-.T#
MG4=,7'HP<XJ!!$JH]L1U2!BI5:N6Q%N@VP;[]!MIP.XR.?2H3Z[$)"Y=.:W4
MP>5)D5+7II !0[>AVY!X\5=R5'@7^@;,PVLNJ(T?UG&99 E=[XC!PLGWU\W5
MI8DUA)<P%UB'4ZCQ"?!"*^U8)1J#'&F 2*/#79CK 6@%-]=[" M9HZ)R<=5O
M,K<6ET2^FF^K3V5.8[W;]JM.S/^LOUB:%8609"@I!'0\F0'/[]USCL%>?9Q#
M R! <Z+7*/'MY+^I2,I'2NHNM>9X"ZH78K<;S-LS$P+&FJZOG2JUH0A3.QP7
MBZ4Q$8A%..#,(V!NE,">5*A1]XIY"WX]BBH3:@:[;6=AJ;V^R"W.U)5Q)__>
ME/J@!T_](]? X)A9B4EF1K@C+!@/0:=JJ&%#/9[9ESF^^%*J\T1.9!G?-JCD
M@E36'^*:\16:\9PW:B*'_'W^#X6%N"_;[MWMCV6TPQP=OM%4O7=K6&XYGSG)
M)J;3+'PH#IG42V#W%;N&*A$R2A)) LZ,^*YWFF%^)VSU'%VCWM DO27VG-3@
MKR6T  FOK-QI@#B[FW8:(4A6R*S5YDJW[=VI+C(DH"3$WO'6G3OG?[)"BFPL
MW?8=Z(KRQA6430?,JN9UH.#W74K\/*6M7-,F*U%=OK.IGK;=Y4I!7SE5ZF]H
MZ;3KU"'X0_B]UF%%P^\:)2/(&BG.JO>Y&L+9<!LK$SP5"+?/,2E.6;Z8?M:H
MK[%()9S(2VD3:;^RERNV_NZ&>6(VPA/IBK_UCJO;7E#5_^=M+G+I!5'N(LYU
MAU^B)-M!\)+QH7K+@TY><;;7QPHGR,(5;N&\$[P=(6'!0>5)7PNM9VTH&:X(
MC]4,)I7^3U]BF_(B@(8=;"Y3@V>BH\40>GJ(=;H]UZ<F;YV#7CF_G)JZF./B
MW_7W>Q5CNJ'+OF2XZ!#^!?;Y*>LM7J]W'7\LGN&$Q_LWQRHJI_M,?Y LGB">
M=10+RIJL?IN8.1K>8:IPM^6G)**=PP([(6TER.WL8DRBQ+;QI#_BR;[IA#]W
M1O:&7-=)09C8::!OI2F#7.?HLW\ ]7^US)_?+LYU8MOLD,7R/$VSO_ZC0Z3_
M6;?PPY84D,3YXV4I);M$VX>.9Y[T-S)?2N7JQQ=$M;_T/O+^_%Q.J"-37$R=
MF^FFG\M8\C/CR%=-?-M]!^ >IK[]N9@37PHR7"HTF,BZPO2N3;T-C\9XT6D4
MPCJ""JS(SZ=:.!F+?9@24DW&\X[4A.+U78:_=+&7R2V=KSUV6FI"_NB5N55P
MXUV/8<^+Q.?ZSI+V"M%1SNP[00[[_1:0P&"/1HKS,NBC+8.W<PPY+!4:@6D(
MG?IXV(B[D#QD#X,[_8>-6-?AAQD<#'=7"*Z3/TN#(M=,14"7/:M/DY,O6&\)
MC(TJ0 2=X"B?0B6QDK'Y2OCZZ.,0$&"P;(.7A^#4^G5CMKQ^B</+CS0CIR;S
M'(VJ1KN7T;N(53#,/SJK^\3?_.=^=6LX!\:^=+41I=L0S.[VQ+11T"A=:>A.
MAT"CHU ]MYII=LTX)7/C:T>H>"Z1847 /==[\G&.$U2D1>/6'?NLUV?A(.Z(
M:&"$RRLA;?JX+ONM24RI8EPJ4M\P5TFD=SRQN(1R?>HG<%WQOP"@"1I=-5HN
MB;(Q.AG3'SUJ%FW5,QY'T7]^LR.[J]RQJ->\3=KNCTE:'.WKF^3T]-PK3E$4
MW\6EN-KP:=F_B-PRN/A_C4N,#*,4GT@8YZZ..US7%.TS\A#J$JU__2_PS](%
MD(10T)(@+_ALLS6!Z6(NLJB7R:+*R>_"K[HV"Z"J6WZ_;'Z,#'WB+KP2[5-"
MUIH0*YB\8[7Q8%R\1<X#&W9GZRY01WKJ-#/*FIF7Y9<W$7*4YALZ:E)EB=+G
MP1H6[U2Z&?ZQ';ZL:Y"S]C:B@L!N[)-=W^]D@?0P/$#M; I\R?A( P2=>FS4
MG089F;?2 &)EI_JU$/YO>D]31AYF?+SXX/#SOXMZ^8'7_M!B2N#KMF4CABS;
M,)YVMLD2>F)KO6Y ]3!-;@5;7.NQ9(T?5IO*$JFOJU5]N/,T7C35HV(&4Q0C
M?GW78;YD/QC?A:TF"XC>2T#<DF>BBT'$=;T243'^&H,92X=,.(UZ9>0I]AGT
MUKMK*KPVN2_<)_7A;=IJP5W$?.&H3NCPL1XE&N0(IJ=VP:O1'<"9.<R+S5V%
M#ZIREXD]D+%1_3818E1YU42+#R[(4X(OZ613#G1[P99!:C%9'O,X0F=D.6FV
M1[^FMIX&>-0P]9&@ZM!Y5G_[E?5H-P[287BQ"/CW;U"W+T<E&/O$5&,Z;KIQ
M&=24F#8:%!9)CGA#7;!2XS^T%E?#_K2-+]9D#IG7.SI6JZ.0Z<I/_I\WZ%4Q
MN)AN4 SP*EFA!%J&8_I8N\ND-_HMR;V*OU,RF"_]@];(]%F\-_;CW?L!*ZW!
MG.'F28.B8YCERD.$48&;O/Z339O%@#6S)QZ:;CN?B)HDR(4.<!<CJTG&A7+B
M19_KY1G]G(:])M9I_3L[3_\O4G[9/OO*P?V7 Q$A/"NNBNPD)@:HH4@_4]R0
MR-N1G$S4ETQ,_[?9T<"PVKIH%D33APMQFT(#R. OU,YN*DF+_); 6(2 ;N/"
M6X/<0V\9NIR\[7&P=W[S.Q9RO6W8ZTKA;4:+RKL_+::N@:H<0Z7_?7UT7_M:
MYJA1#+DU,#4'4B(GNS-V@=,OYW.: RD@\,\SO1WYXE*5T+F/03:]7OLL,_VL
MO0Z]2H+9YR O-02]AZ,!?5$3_^]\4XH"U<%*O^J5):)=?"H?701&E;C;@<7%
M3V&8(+K,UR:IF'/9AJ77Q<#=RM*D![4!.=36R^D!6J8]D8C/-,!7Z]Z7UR[Q
MT;WCS?-)[JB/EG>;QT=>Z(B[5&7W0QH@.E]S3&,LE(G0<_*.J%*ZT33\@1R"
MU&!\YY$Q"ZSG>(] %#*<.+_/>&*8R0>"\KSMNPE7X4Q];8D2J:V"BJA.G.46
M]:4:9>3VC5@%D#!+B8VV\5[;Y.3IY!DK*CV" -8@W$-&M2F[3+8]&$%QCL[>
M"ZMPK&L:C5<6>V5A-*FX>#N+GD_&.?U5Y'>8& Y\M9)=:K3K-6I!I'9*]H?0
MHHR.V]Z)QT[FPN]9Q8R\PEIJ2Q-P-.8GT^P%6-( NS>^:9>10033I&^F7:B)
MM!1MNG'SV+)U# ^38-:C[M6H3VPQ0"D>GO#+N=Y4UT^3)XIDV<WCA)UY'KN.
M^91J#S_E%:%^; C0'++%;/"E['+/V3J9RHYC<_G I N _#>OEM?LUCX%'^!0
MF9A3YI.IXK//J<A^ZF:7\ [\/Z76WFD?2BP5U!]OV!MDF=OU;Q.#N;Q>DRRI
M$=$T %\2.CEZ96F/!H _I\J]2AE?D;M^P*C]HV=E][A\%D7.HX*UT']-5M7W
M[\T=35/U+^ZK'%[S(?1OXBD-0"^)J7MD111=<6F;6C"4=B\BG@]^X96JC(H.
MP)2I#<+C_M:Y"RMR.T>@2OGS(I_!?WAGO") .2++'FZ_#+)GK\WG1,ZW#:<,
M93;77FAO2QL:H!S^E(G5C@L:3#2607)E[5\BW6H21R^](KYM@I^(!XDK%7TP
M*5N3XZ=SU+[QOL3,H.V!4>8:?=)B 3!VD\K;T995!K*;(J,USBO*_8[&SDEQ
MGLI46/(9+BTC?G0PV 5Z7-!T%AP@U)=EO#N\W@[\'F*NLCL'/B"#^/K*@!\]
M: "&DJR_:8!C"JCG&F_6SY(P]?U4:N:O U$-,-B?!K!]-I3N#1M>.0-2KIOI
M6UK5GXF&;2WYJJH^EYL+4P,5%Z<<R#C9,JK )):PEOT>RAX'5#3?>I7?,;K_
M:&SM/(NUV&<.CAD[?U7M&IJ_F(<&?SK\W&1K"POLWY-795B!WPD5(TQ%AC\D
M,EDTXFF !/(-G+A@ERW'9/FTV&Q S;=%[1 '1:.;^C<R)$7V1AU39D]&=78J
M<!FSKM_"=<?MS5@+S%3'USDX>TC(T<DIBSEL0$V3NI5BOU16G5U"O\^X@]VU
M)(QI!\X%;#&4[J*H;X=+R)3#*J(4]9\4\EB_FCKGH78MH< 1-,";Y)GUGS0
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M/Q=--- ;/M@_>4')")>!M>O+>O&0W8@E)$=HIO:X[-+=>9=MK"@K#)=HK-=
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M*QB\>;ZBU62=::5FE(*1M20;/,?V5@O\8M WR*]"_$(G7(#RBIR]E'S&UMG
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M.W([WA*J%GT"N+Q\/&":,\AX[8A;6$P1 0V=[E0H\9SR#U4&H9:SZPQTV=5
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MR'U]--^R*U_Q^X"GYMVX)L\_J8]Z#2-M2L8<V6:\'Z5:T2[O>](!%QVHE>%
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MWY&50I)Q'I(;Z))2 \_H$B1+349;:FOMNCV21B1U9XJ*@=F> S ?.G$GG><
M6F(\?T%T4(9S?G-M8T+H.,?^8ZX^(9L8WLQI'\6[.O+1U,<XH?0*]71;#TFA
M<5F41N^BIVM-WC;J/B(%KL.P&@V;2 >6H( 37&WU<2GO^S_V@M;F6\3C?W!$
M_]?ZX)O+K"H[PROG@(F2^/4[I6']%!#B'&!>OL%-VJ"")Q/2ICVI5FT&#[ P
M/7)S:')VXC'SM+4Y+*4-^:>]2?M72!L"C4Y'Y,/G3F;(T8C)9<_)D1#LQLR_
MLY#^H?!_'O_:ZW)O&:B223CB\-T&L0TBVV=T5X)"9ER7(2V@\DFRV"&L=^]C
M-@=Q'X^X %P:LF&N1-N##7&,2G E]^@ZIKNZ?#>L M.S1.N5[T(@I']ROG7:
M<;U>I/B9B1K=?9-+T;DQA6Z!S_2K6PM0K!W&&S+US$[>6>-9\/)_A\D=@N@:
MVKAPV[D+K$E+C\P-.59T6&8YE@18R*BR_)+"^'9#9'A&]3(A&B*KS+NOL2^*
M78M",1$/NV%W%>R<"$ &HHI9RY]:4X. #QKEX!/F.G<ACSZIK.\S7R1II5;R
M(F=-+6=T*Q4&\PG!4H]31<(XM)D#C181S(6CJ?&B*36%-_PUP!JJ%1&DJ,Y@
M]>1]^%U[LF["Y%F/4=8;OJ4?28G1Q3>-X'M/CY=H=)YVVPBJ%3'?UWR66!B9
M;YSS;+EQ[;?B!3/J**7\(5B;@U(7)A-&S.4I"[!3Q5MNC5<#SP%B:/CA:".F
M+JON"+9\I-#_8V&87/.,&]Q9?TIY_O"' '"E_M>!2R?.>,:46GIV]&Q5=QA!
MA$4L;0MPHN*L OS. :"4YFR1Q^GK=>,P<,3LZP0O:A"A[!R 5.GL&FTBFYP&
M4K_W?P4-UY\#3">$O7?J_VVYO-D[C..?"Z4[(TN(.[SX &I&;UQL'\GDB;0=
M"@R,I\LIU1G2JXN?H"A*8,X$'])U(B.ITD3I_1L=0"8JN_^'DXYY.?R35CN<
M*"TTE2=X1E&M0[L_J5V@M9:0%4*3VFD\BLQM0->&B&P>OAHKKW@KLBN\O%*N
MEOTX>7T<+BE;829<LS[I6 ,I3U<?6 O0N2W]TTZ\I9?NCLX-=K4+5\]:E)PK
M">WN&47HWT47ZM/JQ+U$%^MH>L: UT5)-T*GLV]2&D(!Q"!<;SAUL(!8-S"
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M35KQL# WZ:II:!I&*%$%%^)#7Y>W8?XV0=?A?KM'TH^F#! J+F(W^'Z2BN#
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M?2,.&#&[A@BCD.X!7HH344HIC -L&]TGSQ-_#=<T=;QVL+@3NMX=,%6V(#+
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MWD_\DQX#?>H5A.Y6])"!&[PZJ="<$2%;:DZ?R0%<W*[9J20*2^6-H4]R^?K
M37[@M%-@:.C  @-9';?P8).39=^A*,O&P>Y^6>B#IAJ-^\<R(]/V9B<O-ZMZ
M;Y4F?-*?^;!VGUR.,P' 2JNH8S])F@T*1H'Q^4FZ4X=FWS%]NSM!%JZZLS+/
MH@O3%ZY%ORXTCN-3RQ&HKZDEC$_SG?E.JIS=)%["'K\L9X^/# KRHGK"^]N
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M!::F.#;)!]7L8=)]=WXO3\12/)#]\%?_X2X@]UT\;66P_WCH-6J?];.V/^;
M'1B3A;7_.[IG=C?U-X?4(/./55C0MVY:Z^PJ[82<1+ J*BQ$/?U1UN83D2PX
M,-BC.?*JOZ;QS<(OZH,6F4GFI]8N)@W0&1(IH[CP%F- 8T*1XZT6P-"VAPQR
M:]8J7V8T;%SNM2$N8^,AP[$&5SA[\%!\X^U; &RP0UF&Z?6L*[:0A@SW^;C
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M$EM[61XVWM_I UO#J:PY94;AYP"_4Z9EJWXUN7<RY-XERQV+<<C!!L7[SZ&
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MY!Y'= S?L3*;5T%)L?AP[_2> TI!:RS(JR<.Y%9WO]PS9JR_IEE/&>@372\
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MURI8H@:=&CT!/CK&]*$GR3EG'D0L]8>3'CXB0DS 3/JN;3&NH9Y1K1 +QPE
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M"^X0B];^(\K,&??3;'FB1)A63AX%]Y^ D* Z< _R5#_6<\77@5B#TA9-OS&
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M>#.\[1*$^K&5"<7;6Z/L3, Q>LUG1C4]3ZL^IX8)N.*W0YLRKZ%ZCB]6T%=
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MJ] )"/- 7^\R#3:Y>T7?ZAXGBPV)*IJD/K:,%H1;DWH$*2KAA:D;4X4[3 "
M%M_- \D_PSEGE^V^W#K2@[W^J+%EZIW?C^5_>,(T%P:>*%0\D[WH>;-U%]?J
M(U%GF8"V^1;]J+5WSUV>TERBJ1?CJY+W:M._K6IK1\^ ()%%YM$7L8C=[=?3
MO/A]O33%6FKOP&F_GN34Q25CMT[96-;FM>XL3^CFL'_\]_5\[R@![1NO$G(M
M]B)GCVN/;36%K]<9B(8/'*]%M-'D4Y;Q[GJ^NU+[Q2*DWM50W?!11NCW)QN
MWHE[F:M<-O[\IS.^N?XW:.@"C8,)H*BV?AY?H)>I@V"!:7HP("6P.T=<R?T.
M5X@<[&;M5 -CYYFLY5]L6E%5$>8G*6^ECT%GR$!*@/B&4M8I=R_R)K##K\SU
MBZYAS^X-JQ&Q6ZJ@*=)W)L %5P6#M7+,;=JJ1"# +)X+]63)=-_W[RB%)EZ
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MA1Z[.NYP8-H:$JV<1]9[%^!=R.NN@@!2<;[ZB9RZ=)IN V,V;C890?GY4@O
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MY1/9K<:V[5OQ_K;B1G6IXFB!1YW;W%7NDEO+2<YW$F\G3J3S[GDKA9BMFQ9
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M.2TR]$6&J:]-61D-,EXG&:'T<=6=?3[U%/":*G L22T(E=R=F]9(]_I\![#
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MQ!;97VK6L^0*M R^YMV2;3,TU*<P,H5XGPV;34(=$^9W-!Q/ 2^&(YZ0A3O
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MY'LMH?Z[7G\>=R@[?('5T<T'93UKW77-4+BNJ_;FG>1OT_GO_GDGH))\ZZC
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ME=$;X&Y>[A]S'.GK5MCQX@^U)^(NJ&GP=A[](K[I'@*S=QQ=E>E.O*DU%*0
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M]M.%:8,B&ENEJ9!EBC$NL(2A33M-4[$!O3,_,R=MO@\7J:A-]:][[8"BL,#
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M5R23I$3NFNQ7I/U@2X/O_5*X&T']J 0<L6,OZ!/I\K=269V'$YF6]07W'\R
MGY_T-XL>4?];E']KNBQ"+U+52:TUBU["E"1=4E)$LY;;P8Q[ISJ-UOJAR*V^
MVW(^H5)^RUYM?$O^V>O1T?-R6C._#@[\JP9\-!6U:UW'.\TB!:XN0]!Z RR^
M"TM2H.M-<C:3UZ>K]4J3G8)ZKCS[(A3W]X#BUV[O#Y #/B$&;1GK>DI6"7(V
M,4@3>)*:[38:L6Z>99 C<'4-4BYI@KK=DT:Y24[Y!@2V"J]@N1&\:_CU5B8R
M]W +O  V(>"97ZBU317-_7M<\R92_0<L_2"#]&TJ/<D?;C14JV0(7WKT- G1
M-<$?CGG9"6:->1T)@V6EFA7(A!AXEW('UF,&Q$(\]K00M^8K_R'MQBC^%.NR
M5/OWYL_Z=*B%8#@JIF-1]/Z)H7S[L_?!7I<C2BTXU>-8XPLVS:53XJ5WVPQL
M&Q %MJC^_ZZOC(3:*#T)I2K1T*U_AX(I8?/@BY3ECL-3 *OIT+@*)W?;QS;G
MTLZI\=DWT<9V$C;CGMSQ!+BB84D^*U?)3UMNC(]RK_=M8R#[&PPD\N&";[R;
MSZSV0EX+[J)<3BTHE.R^<MBES?E\F\6;!YGMQ!_)(1OZ_M&M)Z8W2J&L*J\*
M$I,[FY^=8S8J8NG/]'76&%;0$;RYU4C"?<-E8F';4\BVO&J%]B"$?.#R?;+"
MFUHG,D<"L60/RZ)3;%BF'X8.*_WX]A3@#K.V*_3_W.7\? <[)6#4KC8J/FNE
M)5LNB\YZFGXE8A6?5Y-C#&ONE[Y11[_8-[MI8QBT@L@C B.#YN)MH1P<O8I'
M]C8)Z38)@TNQ0\NQ45?X0CFK39-.1'AYK<U=U,<6+YZ("?H8F-J6:@>?'+23
M>+).KDEL)O@0<3RG@/;S$N&U#,$6]2GZ(9*'EF).D//5,!2]/&ZJQPN%-T<,
MSDT5\VT>]F)$2V)J$Y_86S4<J)<:3I=5%VQJ;3L'WAW"1N<2$G,WM[_O?::S
M>5^0Z+X=*&.HQ!#OA(O+EMEIOU_D*MT&U;?_6[:X1C"QU$LXL&^/'^,=O[UD
MFBZO&/?;SFNC[N0AQ?2@DG*WD.I$>A:] .18L6Y%5ZY><D-(V*FHN**^^S$K
MKW\0LY,^!9C4[!2G*Y$\&EUV>F=+YN0<,YWK7E38?O9#&1<N7C3JSU 50PD6
M?BW@_31WOYL,[9"=:]=6ZGX."4@:J)'M.!_QS5$BMC]7;'X)?*-#C\O@1F"S
M-D^#YC]B_+.QM@,S<%@8EWW0T9?_&Y$92CLQH(_EG44Z@:*L45W8J7,+%][-
M@RZN]BE9B8V5>B\ N6%5.K]UB+CS@?X2 GFQFGI!J39A-Q_%WF<!3:LP5RCW
M>F+0-,T"\<&:06=-#JO(TAC,+4P_VCA>?1SSY"353:_B]^CH2#.:5RE;JJO_
MQ9/8&6R?/*9:CQ1V"CC/4 6OQZDO:$U;?I@H$0"=0)$YD5>NFL9TT$"/=Z@6
M9'E!_?3 .L[8X]D<R<3C?O?WQ.8ZDL@'">JU1I^[3L?OR/)H1Z\*A3W<A4"_
MC.<+J/BN$\T.-6O:LR<M;(*PG^^E?:R-Q/&=0R&0UO.Z<NWVVA+\TJU+&NVY
MN$(474:+NW;)9GUPRA\:T]^"F]<"X8Y^8TV*#']E$$\!3#MJ>A-ATB&@ZOIK
M)O5O9+Y'P-?KFH+XS_N91N]/ CZZO++['"U-C2^26:D7!YQY97<I"?KEE7MC
MI'Q0=UY ^48ZX]FJI[:F^8SM0CRXMPK3XQ[4&O;^9OGWZIECJ5/ 7S\9OWN'
M_LOX3@AU P,H?* H;4&*^1X-O' *Z(I;5_TRTLQ*G"XMM(2C_YX[NYZK.!%9
M-]X0254YW_EBUHA]N !Y*^^C6W!KN2-)^V]*>&I@6 H-*>QA[!"SC$I=>IPA
MY^$76!2D7TB+XHA<(*M%H:\N&F3F!*>N#C2=>5F>6-['Z9_ML396_S;)>=9S
M=@/A.6*$V?M(RT*Z<$8@J[W:L!>H+!0QXOM0Q7G0^=5UN#O_3O%XW9"!SOTR
M2D'G<?+]<^[:$A-;:9BZ!).'GZX,#IPO:LG-@;LXPNF!WIR7?C>;9BWL-B]?
M(:MM.!T5[IN5C":F?OX!"X E"G*RFA;HJPYP!]TVZG]Q,JC%8@E[7*"K^?GU
M40/!),SI&-O8WWMH0&9__3_5 WD$WU]-KQ^(WC8!#7L?/V::!U*O;M.9&U#4
MT)&M9A_2\8QRWIM@31];/;>S%_=HS_^:>GJKGGR-UOAXT-[_7[S0E=!A\!I"
M)##<(LK;D#FQQ:.^+E]*=7LDB3)-X7U0OS?-4ALT3D@^26'$"2G>JD1R2=!F
MIN0N=\Q>K\Z<01>[/DOX].[?@/AW2G><ONU>\XC>[M:[#QW[PM9Q)L\!(LJD
MME99,)@5#VV?/59Q]U=#2WOBMNC8RJBMK-*IM;?,Z.PK3#@1A-,F[NB@R\4D
MM51#9>58"0]VU*WA9SL@V1;W+>A;\ F.W1JA#P<CN)^D%I#J6P"+VZ&748.&
M4QH=HB]">XY @ N @RZ_#D&5PF3W:@B]0N_::GXL0YMLW]R!\?1KL7REA]?+
M.">B"%>.E!5<)NGA1-+Y;UYS<W=65_F<026%Y.\G-S*&YPK.@YM.$K/ I/24
MIQ"P7''JF;P;4?%YSJ*H!J+MN**Y2]%&<ZV_E(Y\]*-\\WN?(NY^,^=[LG?N
ME6T7ZQW>O4UMNWN_95QU[74!SRW/Y!1E>4D7))7.!_3<4N#6.Q>=?JW)0-%^
MPS,E"_I,._C,0< WS&2]"S:NR_Y6O=7OQ#O'XF_[9VU9^ WL;$4+9$N5A#[]
M4O5YR0L*)V_'@'F9G?FO%NF&VWYIOA<\?#(2\0EO?,5^=Z)ZHU%J](0A<1LL
MUNEZZ[SMN"BN-5X>[$KGWXHEC]^;FW\# "Z<300( =2ZSR.N3<,;RCTW#SU6
M0#8(%JI4DO'K*7VY;]^@C&P7I4J=.=2-*>IQ_LNU[,)5-L=B-9KB'6$^/KZ/
MY__[-^ZU<R^;QG-$'LUK?=."":Y-5/%SO.7;_XLC.%$CB2S<4M;*BTA"BFI-
M*%AN[C"$VKGO?1^4;M*1N%. =6H:6HR&M&&&H<=AV-[>=.V/B9P-1PQ=:![Z
M9'.Z+U_BF<]$/077 $:= FP:\#\?YQ41DGZYB?EFGK086V^Q%Y+;]E;Q* \$
M<#3+ G+3N$<N#)X]'Y*HCCQN%#D%1#X[V3A @ N.IC^IN']PV_ECQ.S=9BU_
MKBHE) +B]%K=G.8KJB\_/@6\/.;OFM:KH6H.Z]+Q?Y&3U9&U7TX!9Q*#?8LF
MT;R_3@&8;^/:.5@%!<(,0H\WS#W\K9J6VDH(YJ@+B#\%@-;W^2E:C.K-00L/
M+9[0UJ;RC+R/=O,#OZ&?&Y7EN-KDU4K.B):M^$Y4&O);L).^R/WWV;#@N4.C
M$CW.GZ3?885*&[ZTF7\B,;=#;XTJ/YL#UQA80$;36XFT]3V/XWMVSG1!\NQM
M:VDU8^X%6;AOK6%ZU/U,2,7X1G)!ZL+RDS[ZNGQ);8<J);27SY%^I!6-(JX>
M.\:>A(2MDW?I:-0@?:.4-01SO.JH]3U1,1R_NDD'9A09-8KX&?@W(CG_/%W_
MD@744PN+.EI$%3^;0^K-^",5=NW ZFBY/];X '9)9W%ZCYY;<)PX]\A,A8;(
M;<%FC>VXF]3M'4(9-\,TV=@7OE'WI]O/+1^;Y1J+<H8UV""AH\[,UWJ$L1F,
MX)T"QJU4X.J^R +-V%J,+P%+F%LZ+KAE6;\G% !<WJ%I?Y[03>)I%>YJ  [\
MB=/JDW1Y)77_@P/0:%5J4!CGK2(5L=_8<HS"P/>!3(XOP.@_;P25<2]SF+#<
MH2\"NG0,3]+ZTF.L!?IV"L@S@*SB=^A8]*V=LI&E5=0\C?,3R!DZ=;BXO&%.
MYD>(4EG('IF:$T]'I[L05\9&[?2^T35'/7X'?1K5="#.:5_$$".&7M0+I%40
MU.DQ!P-]OG)0P\RU(#%B][^NCE([%@F;)+/$E$C"ZC2<FU %E^F:%-L1>M)N
MI<K]+Z(@BYBFP^$2U65:I_F,I3 MF[1?\=/+=1>?G,/2_/F@%C5P%=N _<%$
M9\DZ =%G!1ZI\Z3X #O B?607$0+"=J9F:JT9N'VEXC?+(9T"K (K%@@]T3/
M,RM^=3>TL0O13510M1N1E7M6W=)""?6W>O-M8-9VKW8)?7YKO3ICQ[ Z&%0]
M245VYPHOAPJ:CY<S)?9+:%OS%XMD'<"V1E#QJ&U-,3>W ?Y^LS*X+EJ/OQM4
MO+\,_%\^/^$!628QCWB'?[OXWK(8$_3NZ$O9^RY"=E<Y!Z8_+U+W/K*^!-R0
M/-M\L"[]]@ZC -,;&I;N"'5-1,L5A\U:_YF\NOY8>>I'G7-^&SRAY()6-![E
M]=WW(T>46L2_CO&^(JD7TU]R707\&\S9^_CL_S  Y<S2'%^K,E66<F9>RV8!
MV@T4<*6?)SU+$*SK+B_7_R=]9\E12:=H)=.Y,$"@&(N>V9QT_+1"")C*^14A
MRX/K$W0@[5>9.^IQ&IO##%V[/&HM4J84+2Q2,^,AFZ+3Q"U!G!I&N>-7LU;Z
MPDW-'J[KI402&1)AFVKGH>/VY7$[L71&_8]C:2:E9S46"V*P>XHD+Y4;M^"U
M:46K(C41S[H#F>D (Z$I?Y2KO&-T#X@+[H2<Q<8K;'S ZY'V!Z7?HE[OQ7W=
MK+SF7K @9VH3M26L:D0[)T%<LY0WH*0)4-!BY]U'/RZBB51\7$,K(4'A63KZ
M%)"/X P3>>')'.AQ^(:.R26;B;&,B?4NI3O573F$G$TS:ZV)BVC9WA3246LT
MB==&W8LH;62H:^!3L,<9.I(3<P1Z7."U?CS]:1(XMN<Z-14LX[]& U6BW;IX
M%'.QZ6K?J,%A3/GEAG2FHV,%G!'X6:2@E=\Z#0G1?2UQ1Y$&,OZ&N-=X+=6<
MOKU+Q]XGY.LY_[G:[PW[&!#.6-V%RG1'J^Q3)35CF>9^Z*M5ICRJ'QPVTX)$
M>[AU7'YF.18Z>&>Q@7)FKJ%5Q@SCO*/U2%S$O.S>98L7,$4[#83U0?U)#NQ:
M=VQ<^Z=(X,L>S^72?4W"JI4EC25-;03%\AB2H%:"29[9]#_T*F\2?O3]OR"0
M%GB^IRWI31ZP]1HE@.C53CN[W*DM2Y:;F]R$+T(,-5B=!+=5X$\/W>\7NQY[
MG*GT8[^WZ'&+A"(_'.FF_FBV!YZ++HWM,F.0,8O4!CCM_3T9*V.OF0C(=G43
M5*:[V;T#(4(B.'=E6[P?'5#RJ,S0@N$/RR;0U^F85VV/[>DRP/CLL$0N=O!L
MZ9.3X:OY)H6@^KP?X0>2E* 3'NH-,&N@KUYEX$GGV]4&+%=HF*Q'@[TXH8+X
M5L\-U2,Q5$R!ZB6O[<@Q&=@JZ2E/- QI%P7Y:=!OYKBH[,:#Z_*V2'M'!5$?
MZU%,<"?ZN-7D[0'WDRH#*5&J(GFZ1^0:&1N;"W^/RB =6,GJ B,IP=D8/9EO
MXZE7RY]>SSH>=D],$%"YR68:FNB=P*8L290<*0+6R72#./^WN];_US9&PG\*
M%_O22UU.@UL_6#ARS X8%&@/W2I)MR\9*E<^U@)2%=-D0_3YYO<._LSDDS6Q
MWX/OG$30)NW@^#\GH-WLH3A2Z3D@^;%/FUO8]>,50\BT9][$NR0?CJ5>H20<
M-6F74.[RZW '633T]U[#OM<ZZ79($^)B#[B)#HRFB+27Q,B Y*-O^GEE5ZHC
MLT-"@B^O/AZO6SG<V97F1/U\84%H>2BL?@KXIP=U=WJG9"<84>Y$M[<[+SEM
MWO#K>:XHZ>#=@I:HV7<_FH31A*^1"[AE5"6'R^ISW;AR@J/^F-ROVC%EM,6C
MEM@0N?O@UMI,&YL!F2]B]8T-Z0^?)2SZWR]B&7^^[P8I@!2QC,'NH07V7*3-
M7<>+QTK'BTPXE"*(8ORZWLG>;@9RRM&%*4821=G6C:EP=Q6*_\1P#UF'07YL
M&8+@B3NP.A%32GU!X2Y:LU[>F$:O79RJ3[KR<\T:TZ8%.:KO0<%J:C-4,^B
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MA8F;]TE\'VUC $A(N_P:ZYGUB:5/V.4Y6+F5Y$DA"1.G(;N(N>)"ER591->
M.2FF79Q/U]6X8C242RS=K00KG[^*$^;*]"Q&#7D[!GG=EJL:./>]0=.W&][U
M>6'V1;8CES-G&<Z6=\WA&'<MLNNYI%FG/1/U[<6&F&:@5=6D5-\[(%74R$WN
M;<IH48KN_<==_TN)HAMGQUYS_@>[SE:< ,3.[G8>_F*.:#G\(BWI\SB<Y].
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M(2/NRC=,A;<=2E/9PIV-,SBA@8:KC@6[>97J<@^1LA3/N /9SP@DF-[( &Q
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M?EI?_S-83U:Q?G8:ZGV2 )5P^7\I7[SKO$5@ .XXG((1/V^2C^@?/#<FOC$
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M1?,Z?$8K:%$P%B+-'DTN6_NE#SD%R-WE>[%7/O[:[(W2]LJ9U]R*A]RRUQN
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M2RZMJPP =.K (:.Y?B=1]\):TA[%^X<YSW2O8J!7 ]"S87\-N8K0FLB"X!B
M,[NAV&^3,NO#)[HB(>YO'@-Q4TDD:FM)L(<G'?N9>F-DJ-SBF+]UZ\L_UF=1
M@YJZ7TY,K$I#\<MT;=34J"(%NGO,[[^%,F]G /YA ,![)\2D@0$PY7QVZ%;1
M0W$['1UV\ /L=J;K+E9V!(1IH,K16A +2%GAS*F>I-?3HCO@:7\0/UQQ3/J%
MZYW0>7]\= O/<\^D)IW!>C5LE'1^PJNB#>V(.+WG4(]WY NB=]B!ID?!.I%W
MO!96BRU23C5OF6-]"5G+-?FTG_OPD\<2QE])P.@&!F .X_B6L"W1,Q&;P.%H
ME&B12Y10F<ZL$?]G3[\J)6&"'YXJ=%F?JI$I-'SN+NCNJH]F4WRP/W>O_FGX
M:4?!S8QC?RAIKAYZ.QSE?1R"B**_"?9^O+?"7D4'8S,P7@U?R$L(H=50T,G<
M19KHWGIS.9($-$Q20TM/-#, 3!7PE:;_I-GG(M,/AX0@9"+S>NOG&("SV(RY
MHKB!4IUIS28M/ DD:\CAG)3DM4Q'#+NE#&"BVJ9!&R=[VI>$>G^OE-I G)0J
ME94=KGDQS<+9^N-<0ROU<BP)A%82T^-"7=@'T;R\F,3D-%'#G!R52Q:=QY;,
M:SYQ<K,@3A/+O@X:WE5,S9]A@@/UI'HH1RO!_QCQE9Z>*9(CI7JHA1V)#?]>
M^F & 1UC /X-C6]$T]J0*]3#;\2,WPW6HSY:L+>FSX$&3@YTM+L_:?56"K"C
M<-18R"D#P+YQ4M>;HX:86ITZH !=PGJPI*>8:?=#3O*Y#,3%%DA3U+^UZJM>
M<%-22C=QQ8(21-03FD[RIV5F<![E\D\N_?N(C<C..K^F5D#N]KA2>"??T9TM
M\_C#9C5; K0E2L3:IZ=,(;ENWB3IR+&DV=BUF@"K?[TK*)T_\('0FBZ7;?/J
M.)TO/5TF=DTPS()WWW3JQU0\@:\/=VB2\I[);IU0$@3Y$W$X$P<FM4:682_2
ME0U<DF>I@N1?Q<X"V\6O_N5<A6N251-[]<G[=QM=.?N_LREWV[<+CY=3)9T=
MS@^2J)[*4ET+.4N-:Z&9%>",/KW0*,\DHUBCWETD%\RCBU]XQ0XMN\5?K#\Z
M2/);6FL/198_/5H)3X%89.5<<<H#7S/^0=/I41$Z]TKWB4.=Y'>0UO_F= 89
MF8BL$6W'_,2T<R&NMBG!CAZ11".WPJ5+W>1:INN:@R]L[R,ONW"Z>J-A29 /
MM!DVP9[M9Y\MO63:AIY[^/O_28%+PVVU#=CUS9U.M%U:EF4CK]'W,V/71W=(
M>%9GJO4'7']#B%37KV=]/_N,$[X0UC8W[,GRRYT$,5UG2*O^JU_>;ZVS\[FH
MF+ 9)B=:0^- ?$:5I+U#IS@KBBBICLA3LX'GX7M;1VDD;@2%=_N1W:P\!D?@
MH+&5^&@T&JX9"(KAO7MD(2A<RY60_R.TS;+3S,6J7#V]U79"!'W1P].#JR:Y
M'CHW8V312&LE9(Q6"W\+0V=Y9W62KWCSZ* U:K6';[?K6;:;%4*NI;M"V.R\
M;EQ<*)]0?%OZK72<JD!;VM6H:NX3+A\SD"H;%DY6G=U5KY3:WC3@%$[^*8H.
M??%76K*>R.?8*JL@/X/:5C6ADUZV"#V=:V_B;Z>:V:?:I_H9QUKIB$L*EZ$_
M5[5N]P+_ 0U33@]/:'/73[$@"A"YLCWR*:T&M[=+QTH*Z8B%+*ZJ.5-OAK5J
M2HR=8M'L5@G2Y:U<S,#;&TE0"T,NTF%G]Z>O[:!6F5".;3D0&YW!'M!DNAMP
MJ..O!]1@]OO?54OG"EJO;]$0UH*M+.+NM& $M*3NK?&I W" :NB6EF24K>9/
MS?#:&&GEO?[WV937^<>F^B>"Y8*1Q2*!GPV:O1XU0PMIP4)%D?=NNH57K-"V
M:5%AV7[HL:K*PX9@B0AN$ZACR+Q/</^TM&R!'\7D4<U0!W,>'4)?X\]HB8:-
M0:_[R48@6#1 ,HU$6S?;L:%;[J%\?X_E2?BS7X4EF?X@K5G)?+RT)R/#KW%T
MG5N!IC1]:MY24=&TV.M0\3. %U9F#G;69WU4FZ-'R_3+1RDL[1N\P(BK=,@8
M$%O^)E^(:+E'B$=P>@<X7/[3\M^(/"-QLYY?*HVESW<WZUG]-2#J-T !.2J[
MN,+S&CIW"B^+\%)BH=-1F[JG5YA<$=<F6!1#^)8_11>"O?D^1+\-UVY^R_;0
M;EQ(.]E0^;$N7PV"Y=F<)WUPS+XKY5SL'B3SZ.D??M1 M>]DU>XPU_E<WNS"
M@Y=R85L*^[\R]B:3#7)#0C^(]3ZDWB=/]2:*D['1\\IRJ;OSW /N4S;RG3=+
M&I_[3-^HX93DQ"WW.*MDWHV:NE<N(3X?>247R)(FM-5$!G?\_Y:2^3^Q 3%&
M_I.D6\7^2(VI6:Q<^UVB -*W)_LU1C)D '7    &<S51@2MTH0U]4/])&'3J
M^/KDF!4"^3Y-PVX6N$=':-6"SC*#ZI:F/Q0D2_&5>%;_!XK$ ("BCCE",]<H
MY?C)=BZOASDM]3VP$_+,%(EN@V!3P%EQB1U Y3\TU;=KO&(&(4B6?)!7BAD8
M'U(';3ADMM0ND'LWZ+IA("-)Y7D\$9JB@_:5'3BAE_ED0&;TN!>+V)_X4;$9
M8!O#IG*DK YV +50#4ZC7U[R]Y"9WYXG3JY?]$3+Y*7/A[A_2'8/6LA5BG5W
MCW:$Q+HX)F2JVK^W%$[X** OS^*=$I^OHOK@J9N^,;Q<+@Z2RCLIK:[H%;'I
MUO:;SN\@1/ D,PQ%R'_X#;X+6J/+U+=1C:0WY7GE<!T*,&]:1Y04*SD4$DH$
M1_)Z5'4?)EW2/O-^!W[)P7,JC-< (=]I/+>:G,#7B1^G<U$Z^9TG*"%QE1(J
MV+F1@>JF/7A#Z\U;D8/K^M2&HLWB1:=C;ZXZD8ZJPUHZXF[_L9<U*S P:,S
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M]LCN0O7^+P8@Q6%ABO;6C"D#$8"P<$2[ W:I4TN8 ?@Q2L(Q *8YG"U7KC(
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M%)*K:O)]XE-=:T/MGJ\&[E(J80YN=C26QCTS/9G6QNN]6?,KJ^:?S.8)T>/
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MH&O"(2^7Q%-'R6'+9G]I> :>@HHDGOD^38>+BNOX'"+ *N;X A,F,'E/&W.
M8_*DV?M*"NIA&I;Y02**-]&A92D5/YPN_UX%V^YEMX!<AIAP:E"\NA+[TM[I
MY]'>A*CV\HQ'BQFDF\E VJ[,D]WJQL1F5;_0D/O*9>,RME\>EQFW.74'4$_E
MUJC*RXY9T>830$?;A<+]*=&3KW05@R7UJ//1/C^-!M]7.K:H%H\]J@ABV!9"
MI1I*"U8M)+6?KSKH;R0QGQM=,WI68W)93?#<A?C/XS:4=/2=,D*6X#CB6@$A
MD<R:TN_Y2@>?)H/E%ZZ1DA%?IGZ#+@Y\["+85YR\F^YPLS8#*!13*O+N?J"@
MJ8%E!UG&#M_W+&K1J.\,E"@/HDONK0NX5W( WHB.CQ-5E1/VOV+_::4CR2MU
M]QS4YH0>4?_R"CIS V!T\G=IP(DWMS1O*LON 87<J\10#I&!6$W\\!)B7UH.
M[B7#HF$)RBM'' _O*NWBCA@71N5K=R!/4-9O$"R1\D'L@6 '/Q-B[@FI"UT'
M(YX?ZQGR1" /W>JSA.AH.' !<<HC[RRE*AI&TQ'%SXD38"I)0%/LW%9=8(;@
M#3U?_FR5E"&M:V%+C1F.<>]_91CZYI5SM3VE'%RT.I[=NFJ=FO-SPRW$>/-N
MBG.*D0?RUP^RQD!CK'*WN\9OM^1!9>\(""SI6^TU4^^G:@)6&=<M*]]@9,=0
MUR1Y_0F9"IK/HM5E.L[$TW%D->8Y$$V%OD**,.^>NT$WE\@FG_2AS*^!+U)\
MWZAR ,=-R^?NL=W&)PJ+5S2CP!)-[;BTNN:8$@:(5KF^>65/"*-5%SOUA7KU
M^:MB$97G3F./FAZ;U6L&6)\=D>FSH,7?.+BQM&AT);T.Y+. *N9/RCF<_OC%
MM<R$Q;C>9^<%@8<SW1\&.N=8?1F)"O&TP+O4O//\I5)-#Y8ZH2NH/E_V "U,
M0-]1(164Q+*/HP[.]%"F@=%*%#63[ XCD@F_T"R0;JS]W(VD8]<9"GY?[D$3
M8N 257#G[(/1%MC:ZLGZ=QLJCDD/6T'N5PN?Z^2E_KUX19_]R1UBSYB<?%)V
MH&$!:?ZPTIU3?+SO>K&<9;'@XC&PE]AFNK2\QUUVFJYF?QRZ:X3\S4:;N/@N
M,2N%W?<5NOCN?JU _!?R#>%P0=.$/NH%,\%B;P-(9+HW[)K(-WG#DV:YWDXK
M:*%=<K@.Q;H=8!Z-!8L3=OEC>XGVVJ?G!,<M32&FC93*ADR)),&D4%4-Q24<
M5N2)$?1*9JV3TWVA;UF>5Z_J_62Y8+&,T5(9DDYYY<;CWT8V+Y;\D%)ID%OM
MJT;>*0[ 9$7)H4N=2O'+O^P3U<YH3X>L#E0GJVN;:D^7R-E/N7I$V*IX$E<C
MO,PJ7.^<7[G#K(YZE&;7BSO& 2SD0#X)?<;%,>RZ^6- )S9;-<A)?YG:.O^U
MQSZ'DUB]I:D,#37(S_>"0HNYRM)2W1B_9#0>P*<D:1G#%K8D1[0^-SU_5G^5
M1$^XU4TLCNHDN5I&C9TGK\OH#Z58Y/C*$"QMTUPVA00W8%7(R<:>%26RM 2E
M2NFU>GF\S-.'IQZ+75'F!:YRP?!Q.=F61RBFA^CL!!:2+WQ3K&G_[:H$3E<P
M.&30>M_+^%D.6<F"?NG@$GN0JY/(-^'.),QK$#^">'*2&21F$5S% ;#/#HD%
MQQ[8JOM6J0I/KK?+416;W%P;:*LAM24S4ZFX?A<7ZZ20YTT-C]]9%9I<>$,;
M6T;PZO9%ZYH'&(9:+\PWI^QEZUHE,Y]0)3M;L5?[U&?><  -G]C M.*TQQS
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MDC>P :6TS:X[!&W.E??:7<=AUA;;7V3J[W$ _]H]<87M,1,[L%%*#*4UQC[
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MFAF(XSLT$&%K0\^Y[G<+XC,SR38+8H;<VJ=I\,V VK:8^(\KJ#LZ' #+N<:
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M LN\8U-('=U1,4[:<BB_D$9""V4_^ZU8E.'\KNMAV+W&TO[#[ZSBZT]$'-/
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M%0S,6V@J^QG\31>FC_BF&O;H^<@,<2FM.KT@H\JL72+BDD$$Z 7W7HT@#G$
M'I6GS$\S3]*;%H#QFK"Z9[T?,5':ANA5AY*XI0Q[2>JIEY]*6HB])3)S]T5^
M9:,'9$0+#>X<IY8-E]]Q2B\=S&DQ4U3;=A99'Y]TW;H_=&5@RZ$L&99!OKG?
M\C'B:=1*1W%ED$$AN*_.9GS1V"]^>JG.UO!_LG+Y?U\N-'?7%@8'F;1/:NN5
MKS@<C2N>:9M#5ZR%)N6]+?)L>'NB-^"C5VC4Q(2M[0@2I_.->A?5V9%E6I?2
M$GJE>5_2007J(M<1(Y%NO%O6>R==1&71LM)(IY#WF9EEZHIP"1/9MXG$41Q
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M$159"Z24B/_*;?\HUV.L$2,XS\XIF[<+-[]I7W_OPW/\90?>GEAM'VKO=8:
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M:O>VR(._5N['XB>#."B^X!X;"J0P*(Q#1WD@I07R%XC6X#Q<O>Z-IBQ):A)
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MW86;,8UK=4=MDMBT$A86=25;MHF.L2#S+;)2><#A*&0BBPO)<G?F Y2VY%H
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MWBG-*6(!=Z<Q^V:KU36,$0X.F)&:0/0I]OI0G[DD9MO7L3@K Z4.EV0K,98
M8:^A[^0+JP^W'$<U'J])K-@SX:L*PZQ,D% NMAXL%O'PLAM.SUW(-\9Z7\>S
MN6;D9L/""+6I,3#MQ)$_& %YXWD!(XBF.35H:M<MQ:]K4\?0)BR5V0=G,8A^
MIP>;E>Z3[F]YH,Y&4X )YX'VKO*Y2DC$LAA 6<5TXY^Z?*M,A<RX=$Y&Q0[?
MKCSAASR(9J87]QX-Y('TMJ_56J5FPE>2N\"%#B>_JDR-E%S3K%^0CU54EN:N
M6O5Z<V1FWQSE?A/9FWL!2?BZSS0)QM22WU0E I-E]%%%.E@ V6&!O E1T#E
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MU"Z0"PUVS,C <WVG_U>D S*0G)$L\&F!)SQ5=K.8K=/$A[=3R XRF3T6$V(
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MQ8TF]3?AO6:XJ_LJ0L1Z\ZEQQ-+R)&92B9$WPOMP*KP#N;"%K!*L=^/N9<;
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MW!^MBE=IB0D!7O!@<.I*'CD ,(8/0Z@I)Z7#M WW#?_C9X1OAI)0* +-L'\
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MO=>-!SNG73W@S?6ZE:120P>KL6SPD[&ZZP: [A8QT216GGU3)/3!CW:+FE#
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MM&."(A!M?5*I#+<1  +4C*3S,-AQ 'KJ6;B$/(YZ&9_XRM2HIW%$,-E3=A4
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MWYZ<HV4U&B][R\TDG%J.S*[L*ZP[IEDG76>%&3>%]7+>T,40/-J?T,V1J%T
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M^$'5E>Z'Y?8G8G((.%B?;V"%:$AH!Y1MZ4]8%IT,6PX2F(@6[0K1-/#*H>4
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MAARSTS.Z'O]):$C^=8=(3\&AJ<6K.2U,Q[-+J^FG:UCF5^)DIZ1A7S$NN.Y
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MJ1TKNP>,X7=F0?6<[1[LRZD'WOSGX?+_^  3]_W7$[,,)- MM,2(''Q%U^A
M O4YLD32RV7ZG>_VH>6%*7/WW[ K!U$DX>.5XG<_AR1$:6N/[W1<9%)8'"'@
MZ!'>SZS]W,TLD<#MZ=>+RU<?@H"42S]:N"Y8#2:-Y\ZX1R><6";RB7R&*TE+
M"!OJ,D+"\7#TM9(V)JJ=4X[M3^F)$$/V5]O9NXE@O8R!BE'T\X.#'?9U=C.&
M8((ABKQ8W'-S88T<9Z<\,4#K*SUT,6@I>T9V:6F[663Q,A5.HE]K'@;<CY56
M6QIBKL$$H\B7;CLG* *AS,Y+J'D:.<,*,PHB<C9<>I^H?+AKYAAO;0F!I;/N
MEI"4VYX"'%E#D(9\T:'O\YV*_NV9[^-G4HV8I[$D7L[G&=Q9GB -(@8[M-\W
MR$]5]=[D"IN/A/.W"BX, ['FH1(3/+&*J];NQJ+FP4>R2W/;#C14P.S]!4CK
MJ<M&VE9%EK#%/L -O""X^;.Q5 PQ(AC>C@$3'8R6?B7 1/;W^1SY&D9HX= $
M_C=<][+59/7%#R!4&"6&/+$8<%UM>B>&;-NXH#^[L#?83LV>K($GKT^-$:T@
MRI*_=3EC5=<JU%\!7&Q5*OZ?ZKXTJHETW3I*VRC8IE4$VXM$0644'+ ;5"Q$
MD5:4M"#0BA 5:4#$B"C(D!0VVJ@($1506HFB&">(##(*A:(F@,H0) S&H(0A
M0B!F(I545;Y*]W?.O6N=>^XZW_?G]/W#NQ84->Z]W_T\]=;S */C,)&IO9?2
M8XW(25FMH^0/$IS$;-FL, 2R%T\>WG+XLO:JOG3<NN,P&&!_(P'EAG>'XJ(L
M?04X^,%.'*3Q&K@:=Z=$^7=H?KX^+ZOO:U"<14G"K:,9Y8TZ2#%7Z^H6A*E-
M?M._.F6-7 3#K1^"PJDI0PQP5.2D2L2W%#HK,'^]]RV&KJ%"J:'Q=$XXXD+*
ML>&5(N!KUUPY4 U>5):0QW.0,LV!#!7EQ,NW3[%!E)Z_N> E,,SLC\5,#M6
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MM"WG6$0R<IPXW&>"D;N: =;G#62@FG) D1A!>L:X!_B(9H)VRX=RM$FME:)
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M!$H-9J/UK[B3Z;'3Y4;P0J2(>),1[DF=K-O&I\4(OS+:K,R(#"J!GSF?B6V
MB]%JWEL&LNT1S#;,0Z(!-$"EP#*FPASP=TBCGY&_X$&K ?PE"*T"32IJ.ZXS
MS$.ONYLVD-Y#FW0(WX8-I(U!\P)[?,C^IH'7VPM2T'C:H4(^:6SL'LIDMX80
MPK!)W$-[Y.F48B&HGFVQ;(_-28*]VAK\GR(-!MVYJ$?W- I-;*13>E\$*NX9
MD>WTQ* !,A096_B0Z6ESGB2H,R-PSE66+",T#[]N^#YV1T&K%1%4"XZ?R#0
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MDN(4>PC17WC[+Q9Y]/1_G4;4Y/8X!=-I;T]%)3M[.#4SE'W0":,B+703>#'
MF=#QDF,?5Y7,^8JV^]E-O?S>NQ4TL&RZA@94M!18&A \L.I;0DCB]P6#S]/5
M3!'T.J;K.:#OWZTH;Z<L!1?E*+Y\LH D(+9_,O_IN,>]U]P19A_N[1#Z6_4V
MW.7!V+)*8 D"^U;]60<:>$'8<Y&UE 3E0086H[1N,AJ#B9V-U=Y9CKF*";UH
MU6R[5)=[/P!:T& ^Q&HYU48#'%;]/Z\)QS!^L+84?&V !L8H%WN.JTINDYX@
M>\P0F=%-=\QZK4@[G8@_=VUWF:]^X3C?[Y\"H@_:0 0;,YDNMJE:@9_^\WT
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M7P]>U"W^!C=NQ.WA<7OP*(ZN#C7'O^"E^5WCQ'F?;P3PTB@/7C7U1]VHH('
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M__;<]SFUTI]18!%%!&^?Y@VU-KYM6W"8S5-+U;"!4 O3)C_T4A5L88O=P^
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MD(,AG':4<;A-VD_?CZ_;Q4&3,Y"S&H(T/BJ[MZV0K(+(&$SE ^1%5<OO_=\
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M0%A?D<1@YU@NK7L6*^ -K^?]U'SK*GC1[\8FC[4^?X)7)P@>BS=?6 M3%]M
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MNO J+3_1&0E)>_AXP2FY,PBJ#;I*I?&(FSJ8%B;:A0RW.>H(<FN=2H_W=O<
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M.(!SFR_XQ)),=,=[X"CJF4M..AK#[-.O8! X\33<\*=SDOB]Y%IQAS0EL:0
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M[_&TEMNBVUA=G7Y&1T*HBU/'$],0Q;@SG%)GX#_IWVTSV(J,ST1VD$&7B!J
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M-6#?HA2S-HT*(#,!0(I],X*WG,H17E[GJ712*8ETR:ELHC+X+O53ZF3.JE\
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MB=CHRWKL \+[ 4(5J!'L;7NMMC0KB@M20?SC@G&YVT-MB5WYI\;3NZ#-(";
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M?$,-NRUPW@0K_+7*&YJHN=X?1@<GPWR'S/WL3GEG7(="'>)15KLDS@,S 2J
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M+-A0,H1HOF<"7 -L6U5"9A:_*(T<(A;-Q5+KSSYMB/S3POSW@@1E'_<E0(T
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M^6<Y(X_CS@,_[M#"?XD7%1H#@A\JKZG"VK&(R<RGHR[VXPV4OC#IPA?32Y_
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MP(_*&7R7"84,1^>=5\'P7WB^K3@LFOPM>U@V!L%,>(V4" #7UE2$G4(J0,G
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ML#%>][:^-,AFF(FT(GD!*'U/^48.YY\ >3:BUTI;\6AZ^GO,)1@3C!+\&04
MK $*':S=7E2JRYMZ6L9/PC[S7@97=YK__F-J*?#S8;SX(IA2#-[</&9\._8Z
MB?68+!B!4J:M+IWS?U/*E"NT5S0-^<P5R+PZ)T/(7X"$?P[#JQ5RLM"!?*#
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MLU<8FIHUCN]\,SNS@2['*U,Q1I$%"QU2+[PH?%"&"VB1WBLPEH,]^MP(\E1
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M3 (U:$X(GJ"O:I(C._K0EK':H\K<"IXIR!]<NP"HG\(&#[Z*':7QXOHQH<M
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MDN!MT(;)0><97\WV6$-\C'^,8/[5^W:V6D4A*^KS-D*%QF2)8=<5@FD#7U\
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M.Q[&431)GQ[@?:ZMZSHOO[2TW:6G.975:#<U-=<W)21OTJ;W))+S;?:-@FP
MV1HELZ(_TZ\_8BEF/?7G\D"1Z#X^ ^Z.^*5\8A$R+6,/CA:Z^L_>GIC_.W08
M/!8L_&?SE^X3@;?D^]1'4^<12!3_C K^\:*"FYEO<+?)K'G!A/.39KH<Q$T
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M+B:W(;LHNV UU^WA>5Q9L9C:6=NV74^6Q,=T3-NY-S/<RRV,M>46:)G(&Y>
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MI'0BV0DD&/6O-#G)E;4@O5D;)=#GL"&O"]<4!;[D(JJ?V,W\@C\_4C2=N\Z
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M UOX\/:]\HZ@)/>O2H_-*>P.6.H6R=+_$%4V[VU< JBA1E*UU7ER$'A?SB5
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M:4FX,?K' 1S6(P2M-PVQH4<<+H\F&PR=I0W9SJ09P.9CGNE$?C 50F2Y>#[
M>$U988<>&VG:Q&[RI[Z!IFCTVU%8P;B0*;BS=L.&[!+08.BORD)G=3^%N5)L
M5%>Z/%CZNUH[)_V+N5\?<F$Q/S>6>,?+:@Q,MZ@GA&7MB==68L>:7B-G&]&+
M!<.^*VE023*K'PMC#CYC<[F@X]_-/[B7K.R<C!H(R#YS[G,M^'+ %S@,RPEV
MK,+U1&,LF"X!R0C>6N)PZMUMB3+*^TL[M--3]4<7Y=Y6U_X^AVN.\(\O*RJP
M:^W4UCCOZGV8LN/N$9OZ/KAI:)WPYY!8+F?8'/O]+BH5B?Y.)!EX-[.U]^X2
ML&#P(OY@H]8N:E(T=IX"[:VJ:5]J1-RF)[E"EX>B3KX2$GX]B><AQ?V'H*]Y
M+:#$XT$L#[AA5$[P$@"[WSJ@^?@2T/D&KP#>)VGM/1]%XDP:T$T^A#/D!XA9
MMLVVG^@J_A+PMO4:X_DBXQ/(R0-QPF^F$MJ=4&Q%CZNXG(&[<DK@'0I,%7N:
M^[&<FU[DC%'%D1W3?B-BMI6$GA7YUE)UQ>/6NX1!/J#&VM>[X"?D7EC$I$++
MO7IY!&#D[39]#/-!5T-92\;[LXLL/MF?:BU/\3C++>&N+9C<*W_A=Z"^;T,6
MYJ/5'/(3T/GS .5)T.&T=(%4[%<E  *Z\@Y$C:]:K=>:#@<)==O9"2W58LNJ
M'Q>?65NRK1$"+P$AQ,1S93C_^![CLTG9=SC!+\VN1S_6)O[8;!$3?KV_^O9Y
MW[U?<0E(_D!FAE=:5!9.[_!AIRS"Q52YW0C._FSMH1J5R7C:;VUB /\TD5:"
M +):*$+QRF9E]VY:*(AZH*PO\EX7U==44H<<.X8V^R^6%99%-YB_N)^,?7 O
MOB>77B?'^+WH9YQ.K"KC2BIH''/AUZOST#:@%*.8UKIHRE-Q#$CG4UP:^;B<
MU9K4^KCA;^S=2\!'M=56>L(R'5%@L\ZC3G!<2_?0&<Y=:BY^T'!A1T9,VO5[
ME.*8YVCJ)Q=R":AZWLE)[YN@BJH4N-F8.:C"2?,B7*A$"77KZK^'C$*KU@AR
MV*D?J]JNS/XJ@G65B\3)R?5$5NZMQOW\X8M"53-BZ?1]+%-!!J-,_[=EGJ.;
M65KU8*P@L:90'RJ FY5,(#"WOI\+,,K9*!U8]:3KG/ ::T%<+9&LX60/) @;
MM\*]0AXE]VR=*[>W[LSU:5WM.!6S:KQ/9X-0\*&%$0W><U1,=O[V+!G]NI.$
M7EN_4(E0HN4D+UEUTO*7[.F^Y/@:K=NF]__7*5B80:+ ):"&.Y\$#87<T@)/
MYC;L7P+BY*[TV![&[1 \][0]10U<[1UP?W[K=[8"L,POS;J\P+\#$MCZ5S"
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MYVAYGS[#H1?Y$3;Z!J  @OB0 -'^0?Z_CGG$ZTT\;,?9-AF:GKQY_W[ B2(
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M-B#4M#+S3H#MD\Y=,BVVV$;G]V2:'Q\Q'M3X3=G;.[YUI(G^JG.MI5'<52-
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M3^WR8]KHAPK,'93X*=^T^5HO"99#,'9K8N-EKW[^>;#]G?SD[$Y/-OTUO7;
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MI<ZQ0Q)  IE2<<C-O.[/@1_$YG9O-B$7Q<?*X,T::/Y4V&+(HTJIE9R:/:(
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M]_:M!-60]])^_2'W"!7XG>=[D"/\)$X%<(O6V4:FT(;X!C'CK2Q:KU%I..6
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M4CV2EA^?-Z'SH-YXG79UDP[8>9/YBS263PS>^P<_5TSQ,DQ;JA[E[>$/$2B
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M,A1T%<G[-T^MBOG=_R,5S-W 38>_\K9F5$#90?;Q'? JGQ@-=CM1H@RJ +]
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MZ'$.HI'98O_>T>#_;_+N75X=%]5X%F EFC[>[K^8PPG!D'G'_M1,#;?&RU*
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M:5^.?'K-_RNBZH[H]]^!+6L^E19)P@61\M',U_O"[U0D +0:0/DY&OA?Q>1
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M_^$R2'EB!,'WBSW]UH-.D?%1E<BVPOJW1YDR(1X)/E3D/8>PS>^=]+"?DH3
M7N65]Y^3[X_6K_$'J?;/J4;-1MHV&W]A>\0(:7<?*?T;)Z1C$07R/L?X$KC?
MUF##D2><3\9N[-C=4Z^5)(Z+(UW=CQHXO0\^0/J:394"V"NU'9KB2 J(4+-Z
ML.42!<!57"+$O,G<<0_@W_1EI0 L3\J,CBULUM:J+=M]%_\^/>=74YN!H'^^
M6"&FXS= !V21T4(*$')"19HO=WC144!>;,&,V'E)]DF^P9]1 +9U6O!<1Q1J
M_Z;\!\5^Q.MWYY^Q6H"/G/]5R,*J7Z)'K?S[]CD-\XPG7$:Y@2(?G?^ 10,^
M%^]" 7XZRG^4W-+'2\A&X+3X]JU5ZBA O;>UV$>VPT))$@T%>.?+O\8ANII,
M? %^@Z0 /$V*4Y"#H>[%U3U-79)<4Z33.06Q!=NVG*^%D)<QD \L]M/O.^L1
ML^><C2?^>(G,P3$/DUL @AKQAR+%6+BLT'XAF=4\T1.RS(VOLX/N[_4$4("3
MFZ[DWIZ#Q XK^X^L,NHQ!9U!Y\3P Z%S\RWH3:TPI%>]QH,'LB@(KP+CTV&C
MBO8;J@S%EB[DT(U[#^ +K>?6PO]O\S,4> \LO:_&LM>/@;P([>1OP.?$0O9&
M=@0<* !TV?@LYM1P#HX\-Q!_S@>I*BZ8!C["&Y^];YV(/%[8?6#^WYM]0WL8
MT7H^*&3\(PSUN&:A-6ICF0."?4C2:3N?C:9>#ZL'!Z=RUS!D:_U>\*."SCN$
M8Q'X+C\JY5\MDV0'.X:54<E0<WANQ4GN#?+QY?Y579(,!>@N/U_DHC?S*T+.
M2L@!PU/NXF"S;O%-R-_PP7S;W+E0' 3DEI>C^Z2AH=]>P<_HC"Y^V0LF11(9
MVSM$LJYK)%4TI>BA\3JW6]Y"?J$7TY/H>5@B:BB FE.6UQD[O[FM,QZ!C<YY
M[8(5OZ, [CT4-H O:.N?N:YT2=3!!5!F:@]O'QV^)_(]NS^ "UKVTGO:G F)
MU]'=M$3AQ]0O-)\/3>%CU8OC]4-#99WA,1CFZ+Q_>F,:'/X)-_/\=@N>G"\5
MC:H[:HT,'@^-)@WVDS?$C7(H #8X*/>4K&%_E:0KI<8P>_DY"-=[3CO?G"Z1
MSY<L[T[T(PN1M:.L>O'CHJ=2R +APLUQ<_0]B*+025[=-G0'=5@TWOD'=G.4
M'S*OZ'L?(I9?2+YFC[EJ<MZ=S)Z/'O)&3VI'"]+P(!%Z]89];6;XBP'HM7@*
MT/28M*W^>!5.-(;QH2A 2@S.*TY"<Z.QZ>KS4KRI0[SQJ11)LIFO86%+_-61
M8NN;;:,I1\$PD#9XQ@)9IQ)B"3-CO:,:8TBDQ7O=[_\%%7Q&/.>D:YZ0?>^0
M?6[9;C+[B/=9<I'E]-;ZLG7_3<A..DN;MH]IWV0Y2;]I8^:?8^'5#O]+INIC
MIS+ICV(D&CR>:E=YFI5SB+C\P2,G/K@BNYE&4Z5QN:Q?P+'#O]YT-#7A[ZQ6
M6Y6(8UWPEF$UFG![%:>JS/*YN67,W%!A2_3O*ZG';4< 8^@SE"&)N\R]M2FJ
M?O!Q3V/-]$;@.[$Q39ZM&G;UIPA%I4<:7M I].:I0C"X_HU>!HJ@O_=)\OOI
M9Y;^$\52II1="C"L?$:#K,)EZS :%WVN6<LAM4IF/KXK-"Y<$$_<T_B/[EC^
M!X0:2P%>@]O.&B&N1>=3W-AY WZZ:N2,;!;%@=Z@VLZ:8:JEI(/1?_3C:+#<
MZA36(@6_>I#Y>S@P%I((.CDRH@"&/>>]W%3E_3_IQ>X8^4HI_M2.D-Q- 6A>
MY'*,5ON'GJE8A3HP%(&\A9.VYWXE?44K*&KD9?OS8SH?G[,67Q(7<641A&$<
M[N6YC5>H*W!5;/78RNF=.,ANK"GS8^I'W!7A*TK4^**:8M]YH/MX_(^<A_J2
MV820@;N!'L;2V3?J+^-4_1/S='/1A,I/6AD+^8?3$O*5!F(9YAQNI?YA7D@G
M6P%AL7[ 1Q^9K<Y/'J< 5\C<^N()F2;NRG_;A&4-:.VM.3V[!GO>R4-<.;5P
MAT$R5C7Q#Y)+7:E^77R]DK%.2S7L;[9!6R)KSRTK6_-<,&X[6'[YN>K]O%EA
MT>-]]9B8=L5TBXKFWSC$+VO2@I'6SIDC^0JHJ@A%X"6&I&EO>I=?A _P.9Q,
M[/QS2ZQ.O5S*8QQK!')?KWE.+7L=SK$W'EZ#0@%3J^X&3%RR%8A[&J6OT./@
M;^VNA-LB*HV=2W_N! 5GW-WM8U _<MFQ1TLF(!@ZI=Q<S(FA5>B*O[*5)4PL
MOFYP*%)%RTZQ(7]($N](=B%B%ZY#C?%[9L1 K(=!3ZIX=;Z'C]^FON=?5 )1
M2WL/7MR[-#\3>#V;RT^>L!)+8'W=\!7J@E\PR=2<\K!0;A=O5 I7$KFS[_S2
M-\7^W/C59FX9%).@/W^/RM<;RO:%W.T]RS1<Y JN>3UA!'\P]=.A[DK0AF?"
MODL/SL=&1S,^23UR-;*3[%;U$NI, 2X.$?D)E5BA)*AM&(&U.[ 3/.H?)B,8
M;YU7WAGTG.;Q\ZW%K0#5ZKO(Z6_"2"_:J"=N%=Z!NNC5X[D':!8Q4[VBN<9=
MLW]VDI/9_B-A5=$>B!OR6!$<#S\4=;<_T18/#0L";QF7K9_8_YDBW%LR:4F:
M%%%5K/A2)?K&+"/4\E8<U=WO*K452<6QU&D6.$B,I$[@BGZ[J0#J \RU[9\3
M?P/-)#$*4&.M30%&A2MG-L]9MW.8KM$$Y#DJZHC#XT>@L2ZVX\XEUVSE3Y^M
M^IG+](;8N2TM_.GI5../ODE1 '1R ?V$?'P%8@\R>&[6K+G^M]FUE/%_0_;^
MI6!7T-WD<Z72_OVA"&,Y"VBD<@8M07D*?<*#JS#">8P@'+A'[0:V)(ZQ ZGE
MK=8^=?5EY<N*G8Z);";NGXYTH2?>9E":I2I^G%#,5$\6UV/TRU%5:T\6,\.!
MJ2@7MM4D]QZ(N]?Q[4GP(4L,!?AKV,X@;[.U/P;NO.XO?F77^FI^!0M3=R^7
MJ/+R!:7?X>JD I0<B1\'QO#W9XG/(:/\.6>^AXK0IQFM5MRW''\F+9; MBAQ
MKWQ#7TT[!/SGF)#<Q]HIF_RE4Z(M\U'\@?-UM7Y9+;G[-I']OWFC>*,'&!("
MO])J?B(Y$I'N! 3Y^E5Q)7A=U,9,<4UXFGC+JQ(OV;)OI*ZZ^D!:ED-#*#5.
M$DS$@# <$!"ZVK:_A/O%$*A.[-.MW5P]].V1/CHA_@X5G'DRR:,4&I*I^7E*
M8FM_I>-S@G6_J)BU0!(3VG6)WF)U4P,,,[97(X_.\TVIRN-/%A[AS_8Q8=\W
MKO4Y17Q3TN(JJM:]*P#ZUOYLH1\F ZGS'XX=:O#SURR/C1I);\?RK!QK'?0"
M85/:,-LU.!-9B9ALD*:!7_E=7"[G4S\ZZ%EK^(JZHJ)2CTKXM1LOO5-:-B$)
MV0M3):;@^W$M=1/^WS<[%# ;*A$7TV0%&E/?S2BDO8X2A,\S4YW(:D.C3A]
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MEI\*D3F)%#W^,E4_0)(EI.'LHY ^=5W5<[-E_.SQOW520,O=J"(.DAT%B(R
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MJEYZDZZ TQ+4:5=*CQ[T(.EA$%Y<\;!]JK E\]3]K\94EL1#\19_1TG\)9<
M*M_Q**&?YK2G$MK^0KVN/+-@"16#Z$SP[!=J"%ZF(0H/0H= XF'"O]PP6[5V
M5CII/QS>.7.G//R);KZX2OLZ*2@/5"4'QW",0J(9EB@ LY5 H,S<=W</MY</
MG9V B$PA@'I/47/:*1QJ2 '<41P?43+BK$;6#\[0J^S2Z[^]J-5/(5=0IQ9K
M&1AI?#N']M]FRJ[6'34S?34Z@K?5^E\ ,AK<+;T!6:!X]9N]ITKJ'WQ]GX/_
M,/6+ESN=:MFSJ+XY[4UX[_SRE91OA 9/QR(XD8>#T/_&'WPCW9U=SB++>C.
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MS4\K",ZRF;\L8*"=",=6L8,9:RP[%G@CL>-;1B='^_ENE;<AE_I]#?-VKN@
MG 01Z#4Y,G?F+N1H<K/6!=(Q19M#3V+F'CRP#.XX\HL@ 5G& SZ,[&!/LXO3
M?IX5&#@#^EZHOX\SQ<34O2L2UV,FX0O!;$-\O8DDMI9SJ;+H;1 $]?*'_LF!
M9O1-$#X6_7!6A<NI>-PA[]ZSVE/$3K2%.8>8GW5+2=5<5#SOJU1M4H+K?A-C
M!&NC@;CP2;*P?Z-8^E@V;6$C:^1*]#'1L@[TD]LW8Z01M].'O0?7".()<%#
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M[@_/E[H431;UIXU4A ;-I 1 +*[?VF]S1(^X%6.L+^YM"M6XFS[YKF9A7)E
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M\W)FZMDUOL;^0[L"7#CEL1P27L<L:=%MWGS0HY.P]'+"R'HT4>2-XC;+$:G
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MF\O</O-Y79_[NJ_KOJ[W==_70!^ESP#<YPR,#0 &!@ P K\ .@[0U0]PNPD
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MG1V]]/2\^Z6!_&N:,4WG!4)"$\W(2P]@MW282$M0$<I^ CI!45HX1)5Y,#Z
MUS:<8R5$)V!T9 ::X#=U!F_6<@K90GQEK%8>Z'^?[X=1G,K'74E' F-]%TF:
MF$'CP8QNX_VC'(+A;B7L07K/CB?9,AZ0KN9/VYA81[-2G]:"YL\JD#N;<-]I
MBB6R5KIPZFNB]IB'V!3+R'YEKFU71O3*2SH@S3.#W*7"=H\N[PJ@Y_.W+M*!
MU&@"C(I 4?E^D'&S,'ZW>A9">O$LIWVQRRO;+C]I#3EQBPE#LJE!WY+1"ZX.
M&$D&VH(F&=?+V 3L:;,?=N +WWXAQCG7:X5X=K XNKUX\I3[+)(G@*O%08!
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M4,<R3E3.M#V &<+<UD:+R"T(B8'@,P3%,^5E=F5I?J)GT[6L)9+//?F:(/1
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M$WR#SON;!%[/+/1\81(M8A+(5'PB4=<RS8_)Z1[Z 0:W B]6IW)68DE'Z^C
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MJT*I4/X ;+/9CK2#(&@S]BA:C.V6&4F!BY)$!]AA*\)OZ, "J:"-)H+\I$G
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MD@[$8J&QW=J7<B&18_=8(I\Q$6IS(6%O$;&F=%KU9L61SA'?O]HUSZ/?BUD
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M!1\D%Y1DF49@4X$.6^)8'"&<ZD0>T^0@[KW<Q)]<+#'\A_9"!7@V710OP95
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M5Z6]3(I'*Z!--UF7@GJ7[\V]T;+]K/\MU<>'OJGZ[ADC;02RU:T 'OK<BV&
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M2?MJCY^7'GV8?;L>6V%%SW!N_:$9\5\H?YD$UVB-R3QA0PWEK:1KV/139/R
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M"*29[ 9:"OG[*4G\[COI"[3^^,@1Z#YLVCB2P:SS,&\/7*0/P(;Q'H/:".3
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M*_C&[HN.&G_S'Y:B17G K^YM(XQ^=+])RA%' 85$LY'@WMG$9L:Z >>_JE1
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MC,!40%N_*BD Q R2I7,#B*:C[%C-!"?&R<#5X-S===VE&?(R=!3&BL,A"8L
M=<Q_ :U!B("*+$,QQ;P5_TP30GG[^QO@;^((^@.6*1(#V$XO!H@X 0;ZK<);
MT\Q/B",TQ5DW4NX<Y+$C^U?B"/SDFQL>:K[A@FO*I@^AE?%G]$ (6[.K[=9
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M&'ZJ.!2/FY9\>"%92'!I9=GX18W)S1OM7$]+B8L=25FV]_:!S/K->>8@W P
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M"]8*F\ALQU8@5YX3UN*P,D9RHC QAJU":[G[,=G!Z9.O,BYT'7++&M$G[J\
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M!V8^Q-57VL,8C-S_R7)Q^J*JGB[TU,>HA?,)'H,6,QSOA)[YL+LK'V"-#YB
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M(JJO')Q=0SE3_2E]*[A9[*.ZD>C7[K*B%/D1^Y*>Z'GU<&2(G.;U]P%GWKI
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MO?6*>9:\[_&VPEDG!C_,EVW] 7K!<3E_6_-__ 8 6.X.B'P-NJ4Q([L#PD>
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M<D-];'U69[&M[[&C1AT-1=DS?W$!-G5N0.'3Y)X**WJG:ZK=E.55.>R4JW1
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MOV79OQOV+[OF '. _A_$0/LP,3 P,#$ST8CY!/-?.L%VXA_$]I^(XQ_$]9=
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MLE]O4'(X0J#S5.^RBN&#YHZI_N/8N9UG59A?)3H^/SS+V.ROA\:GN]911JB
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MO\6&^!2\_87&+*M +29^\9-I#%B/"M#<$K7J28BN&L&VHY^\#WQO+JK[\HV
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MT9Z.+P693<)]0:BTE2OL*^)^EUJ^+HW*3:N=N[2($?OP+9ZR%W^5(D7P)CK
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MO2D%??^C- SC@?IA]0;&N)H?=_"%[4AYBW]M&.9=09W3%#S/F,XS\21?7]^
MD:MW0$(3.Q8#-0E?J1;:Y-EH\\S=R?5G'31FNJSI]A3[KC0W@C[&\([2WM$
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MWJI#L^ WE8,:ZUB&Y.''I8_C<^9S,J?HCI\1HZG 4!<MFUT? 9-+D '&!E1
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M[G0%&GG20A^[4RV3%O/N8H&KPXL2__0]2U,W?NC\&2 ?!0_=^J5&JQCK['O
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MX/X7EO.O<TJME 7KFDF-GUX\U!US$+LXEW5C)),P^??O*:C 9QP-CQ-9[*E
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M+Z,NG[NL-!G_FUEZ+9T*-,O'&M<?]+6* $P\=/N0[:TOV963_>*L186S !,
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M^[*1P5'80#1-JQC^Q8N_J2#U0 @B]6;!/UPB3.(9^S5%=LHBN-([BJ*R204
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MQ_(J,!<AJ!-?&HPNL9BVJHD;]%3(^ZDI%\)B,9I*5W:EYRZ7O3)@;JLYA?P
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MYI09Q%YZ4(%A@*.=Y:2V2;]HGJ^#Y7_(%@K<&#X'J>#?YB#>(3G9:Y4*@D[
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M*[-*U5Y1> EZ6J)>T+DS$^==LO;6G+P^"R]H_=:-%QY@J_.9+?U<^#^7C8?
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M??-[+<=^SKCR4N:(5/RL2]),ZJ,'1C+CQY#:.C*(-@F$,Q5X!5>IQT6D!Y1
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ML(XE)1Z4$]^>+9]R,_G@?O0FO&1H/6MW725S<%1NP.LN75WGZ@=UP6Z/3_^
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M&?[73PB)00R$?C\A_NI(R6+%:8%TSRYE&C\1!8X6XI?<1Q -G%O?R@8L!R(
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MLC2KOL4U2XR.01P=%X'^+8"PU;UV-D#5 *OER5;T3?W@J ;(M'1;53M(BVH
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M'6(-C$5G:IKO'LA]-S$8%Q39HBQ ;IC7I#2,;1UM4RI)KM%7/"=LJ61CE>?
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M0RUHW=G.4YNG[?YS1,@&]53,EV>J9QW]<MV-[RHZ$S\3L>W_&O])<*= <]*
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M16><Q(-GJF"0H"O"0]\9]9>6%G]\VOOTFJA!@T+:!M4="04T+QFH,A&[S$*
MF>T]ML!"@*+>A#E/3@Y5P"+!^-_#^I_"'(OG2PV,''L3GUS28U/4XWA+L/AC
MDN9=V]=^TEEGV[\_6#A5V^?\&BOTT.;E#(Q_<)L*X_M0"S8F#/E(XCNY?Y2
MN3E(9_M7.[W[HIN7ASAJQXOP3Q:T[::LQ,Y '5=KC'5.K VD)]FIQ1G*2M]-
MVE^V?W\];_R))1UXZ<+3,;N8B+?H1OQ?/5P)!YU? +I > (L.)4P$=U&.70K
M0A$)0F9$IL\95XXP"'5$SAG//9R]N3?O_W1R3*CNW<*7 .0UDR#DFCP(FU4$
M3%8V-7#@8YDON"W^[?S)0 V _@H=^=RL$GI'(K[$YP -Q;>(,XH R(FZ7W4:
M%BEY$#EILF_65KB8//UTHKQ/<>)3Z'11D7F?T5,V9^NHNC/!(Q.\L8'],]Z
M/))GN^[/5P!JVJ/$1%PT)>8\!J%#;;,DN2:^K8Q-6D/LWJRX>R:L%S-2?EU>
MM/*GPLRS!@/R-D'R&#_0C6QIHX)$CAO=&_J<F$_/EGIU/\01L\ A.'9JO2"!
M1&A@(MCI5N1QNC26H\JE7?L2=:%#Y-S78[<.WC1#Q HBW_)O?MT>,.Q"PV'9
MV?H%$Z69F[UWJ%P4]K<30$2-!B@VR;XRS=V__R@)VW4/NC0<@&F0J^^]IL:R
M]0ZM0S=D9$$\&!G*47)R]+K%K1]]?*D9D4,6P9DOA\N?[=O->F(^F.?QQN#[
MR"$A1451 [Z+%H.Q.W*BXTUN[01.(@7H>KF8RQ1<I([BA2R:YM5>XRKN38Y;
MYU?V^6<J9WM<PEDBH* 25(2M0+?VCG%>I27ATRRN&3^XTS4<:-H18I>_:-J'
MB=Y1QTW@HB!V,'SB%1&^M3(^X&##=^DXDN^ B#W/D?V!=P(!85*\TDYCFM*L
M)^9\XEMR%[DW?'A4<VE?E.\J[IC =\\-/?5O=)7P"3JRJ/]I!GA(NTQ<=$5=
MNZKN%A/A2$,M<RSWH@6'A_E8MD.5-6H@Q]3I&.CMA'RK^T2/_84LE3IRHL_.
MYX@)AZ"A:DNB.C#Q"KTBZ]L#$?.!M6MFP_@#D#+]!'C6CI^)P)6\6%LNGFYY
MPI[D5[H^R&?W.B@NJ:EK)!*Q7!)@^O5L-\$[WY">:ZPCI'CD/I=;K+3B-*O4
M!.N7WU4;)(<F$Q;ZW1XE;X#%IM7'+>N;Q(NO7'5G/RTA.!!I/);D/0;44A!)
M4:J%Y,A-H7G5I5E>F<Y<;&8?JXEIXPX)OPQ.GFG^E,3]&&'LET7G]8<,-Z*
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M"-^V2B-E"=TF:^>VY7 2^B?!6!&*)&0X'@DL\ ? LRY>J00>=J GCXL! Y^
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M;#,Z[U,XGK4O]OME]D>-N=]7[(4Y;+_;?VH^.E%(L=B:TPV6D("B-0$YOKZ
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M0$<&%+0EE<>.A\?L[LK_L3IL((U'/JR0/Q/%Z7[QSLGZ@W@H2-IW#;\:H=2
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MW<?#<$OW/?C:O,5\?4UW5T<O\C5GENY],]'6R>M+%X(@WC?_ U!6\BR&Y&6
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MPC9E1989VVV8 /GR[S;[U0RTA/-B9BU[H.C)P<N0C/_E=R!< @IV?[81<R;
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M[Y@ W@;2GA!N#"+#&_'T?+B[V? ERC,0GD>3&=39B9@][ETZ<O7]J,#@2G5
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M!H1R?E)ZF4#<ELM5@2I0BEZ%, .^ DN[BX>2S:^WC@>O(+CQLY=Z,*1MXW]
MVP_QOXW_(1$"^8BF<Z:-FZWI!.P.9+7=6R]G3_ZDD?*<:(^[Y)*60V8JW]FG
ME,0A=TV& J@3:801JBT+@6X%2!R0(_SRU$!XA.AX#$R@7/YC.;=^:_6WSY^;
MRA)-#F;?[5QJDWF:JFRBUH%$'R*?B(R1;?9]_[W _:</ EF5B%%$GW!?%7[[
MG&NR> ?F/N1*K^M$,5]R<R"+V('?@EZ/QDG6\>PHR*1*<2%'U[CWM)W-,./7
MC94I+[M0<^!MK::I9)"AKCJDJ)G'9F#HY.+!3@7-,^2CN4ZN0/.=)A]5S\S.
M.P7%@/ :_QIL89!J13,$Q<DI3?C=ZX@]\[[)L;E=3&"OZ([:Q!L^+NWZC0YI
M9D=F]@>->P7>^,!/MZ-Q@IZDE9F)E*:19UC.'W<[%,/+4KS]Y(13TWHD3624
M3;02D?U_(0Y)^'^C_IY W$2'"PK(6A#D6U[,90)BN$',+Q="'">ER6-SWQJ6
M!E3^P916I!@P3Y(S(_([)%F,.QR<AIA2?#!\S4R-"5"IKDR@37Y]_-?+?M<^
M0(N HORHOS#$KGT@8CT^8L8X>?G '[CW"/+=GDG"J[+D)DWQVXMI^EW"^F4\
MVD(,-2HW!!8[")5T#E\S!F + 4I^T)EZ +1M@A(TR0(>ER9#27"^EVMKBVR5
M=X4HNI1\OG7HD/#%PD!C(3%678G"W^7WNV%O+O_Z% CMEH!0&CR5 0'P0 &(
M-D%)]_3O LS^539H"$'_=BGL5_O4A27\)D2YWZ6#*/[=M"&FHA@VOG;H!QQD
M\?@#/$\9T70F)[KH>S]C&(QA#+G]-R.RG,?_<I7Y;R_, C(!B"_MJ &-'R6_
M!3V*SYT0LC[JGGW5>^/AO<U+B]#S*Q'L(ON0N'"-A;L)JX>OVE0'+[0\P7ZP
M+,4T7*;Q3;S?2U$C'WV1-2L2$-J#^*%WL[(\ZA" +-N^TV"[H]?W]]$4/A+;
M0S7X$!O!B?&2\/[XTER Q/%$Z]>$1"/WY0Z5 ]+T<W]LP?]_B,+DU[ 4NZT-
M3JD7_>7#B95A]PN+1-J1-=%*'J@//6&5^P4^.1;SH+Z_U__%.>1?]90%2)TJ
M$Q"1B1$)R),)N4(^8KZD?;X/</Q)#%3][YX WVI?]1^M=FJF7:*J,;K0ZN1#
MY/@8M"C*VV9@J%)[>BS%7;7GC=#.*_</G@*$QI\_P-VLK SJ85]T=["Z$7I*
M<C]'7L$Q?MT)0!VXGY_W.[OZB 'EL8V82*P @P\E:PS>( 3HMYRHL)GLTM+P
MJADU$3,<,!AK#WQ4$R&\CNLU"QNP]/5HPG.Z#I+*W_<7)SGL>ULU_$-2-ZJ]
M?FU_$'MQSU_TI;*G)S.X:%8D/&U?V^2)9CP?:'JIU__0ZX:BHN1\[;*$H5'A
MY47'&*-#HK:^V<<:IK8A*0]^G:0-AW2>C68G8YH17U?;='A)$O%>N/F4KI="
M1UYGN>8^,<BW-:::Z\FZR2NUZ>["54%O]@A_'<>.RJ['E)QHPK&#O6?>=:L5
M:0Q,'[VU-.GB')JVXGUA]NO^I.N&?GP(N^Y_SH))J<,E23<>H?:O218,65G]
MJ" .GJ^,&]@A'4'4C=@U1<KD<?OV%VL.IGD7^*CR-!>0CSPR*1N'EG$]]F/3
M*$;6N]<I;HDS+.G<5"_WQ[TJLA\F:/6^EG/KOT]P;T"NM$.%GL$XA.[!;+L/
M8_67[K7O5_/CW6,SI]RB\.E*NT)6:6WH4ZU/!<8^CZZ+K6:TUK6#2H3/M@WC
M;+6<!''T@9VY+V8UG&+[W!H:S=R18A?EG*2/<>4XBDGT__A]A0_;-&^]V1!B
MTN@AQ$#Q>S$NL#T_CHV \LUOW%P=[E?>,9&.O:==T_;4(B8Z*;8ZK_4DKG_N
MOT;_?SMJD:WX4ER]6:3("BJW;9QGC7?W/(?E">]A]]K5*KWRTW&S-@87CO%_
M9'V#<\H*//1C$XW-L;+]X6M1=N7*%<_7%_2V'?$T$.$NB(C:5I G! # #\M?
MRRQH6WT3*_V/@O%DAPE8Z'U8F)U(GY9YWC"8)IKJOC;O_2YIOZU\F;)RZRX.
MX3[G5\;B\^MGHH!5LZ#-VR^R_<5)!^,+;=^_7(\+?MF@I9QO(IDL;]7?W;<B
M;+5;;Q;9,_OKX^SI20P>_RO_XB!FS=C_Y2 C\TBG@JLV'\73/V(OE"4J[?NT
MK6+-T GR$#_+A<7?K8 D2]O75(]6!1]395#AC5C>-<VNW?,G!(<=VIP=.,TT
M7WO+=9[:+QUJ_GA6?@!NC^5"13=@2W*;S#A1E>>J>M1B3Y@8%[L?S7;)#=-=
M.E-]G..Y1%A=]O]T?<O ?VKYY_\]_L\Y6+?V<?S?8!S_]_AGZO3?J7S_EV,%
MOYMV!]0C:-O/-#%DR.AGK^:NA)X>6.W,EW9ZHK%T$=7^"!T6J'TQ*FCX^QAE
M6+[#1,!%UB#QA'[2_1M)UXTN&.WO6P/,[6S96I=#+.T.(':-H&K.I5C[8=]&
M&U1=.E3%7=K!B7U?$^,[F \EI+MU1\E=P336W)8"L->JHOO6S!-]L<J+[/TY
MAZWD9/,;'X,67=RH[*8ZI6X"F2W42TCMVO&)-W'$;\T);PT/U_/-U@?KBO:9
MVQD5TOQ Q4RW%)NCI9/GCG8RV@VC4([O=,D?PKE>JS2P!6E>8"LVMY-A MPR
MI+V,\&\0M]_VF(;T:T*(U.U%=5A%-S'XR3?3"^8NA;DL+LY8)@0=NGG *',[
MU@U8VY0/\8B"\>YM925045$=C#VG&N"EM&FJ(3'C]G&OSJYG/ZY]@T"$G2T1
M'CO.7BOU>A3EW<PXVEOV^7RO<[J'UESBP76>FB<KRJ_9*:HL<Y<M(W&+!TC\
MG=V3WV"R XML<^=\+<.U$ 0S(1L(#8>L/]-V&SHO8BH?L<1O]D*I% B(!>Y?
M_A6S7+HVH.HJMFBQ/=&/Q<X\R]\;/$$\9S-RZHN_TRN$FR!NNFF[)7N/\0QX
MV?GQXE8/"/[TPKGAF\$OOR%M^OL>7!%0*NOMDM\1I_[%*35R%LCD%I'O\C]
M=B#@XG&O>K4$B:;B;DMC< WCHIO6X@Y<@IZL%<:P6%]^8)_E<["4N-S$N\W-
M-1O5T4P1T5Y+.-+!_6E>+.RXC/[UU:#+@0&%W7P]IZVEKL].[-;[L']M_Q?6
MO*S:GZWC CJB_NKL6IY$4P4)DYU34:Y&S^=[[S:_>Q1_IRJ3]U16[=[3]#R\
M,Q/8?:TH+GTR5OOFO5!!+DJ!6:;K@-I,I18%YV-D8NX8&YP=J,>V/_A+L"Y/
M5I7B'IHYZ#WQ[>9@T]AA,G]R4O[X82V!GWL*3"0_3.\KR,A\L]\O:MD%R"I9
M+_(P(7U/\BI&#GI^=:48.Z;Y/+OEF3GWR4S/VHZ/C _Q]WOU\35*Q;)BX-:-
MI$R?(L<]DNT%KR\DC,H?:GNQCZ6O^^]9OW"U,MK?@\#+XOIVCJ'2OUAF>\AI
MM_3@1?;NE]>M]LOF'S!IRU3#-(U)??&WS1X!@YLT0C1>/?.J:O&\330>1_+?
M.C89MAUV2H[5+4H^C 2QS/'P,?E!G+\2 ;?;VLVWXKDT,AKIDVQBSZ<>V\'R
M1?Y1[N@7MGL&_#,Z1\ :4E-]6IK+F#)9.RP^0-I4N>F>1MN!V,@+7[4FDO;#
M(*-V.Y3W0_)(PIO[=]CW3^WVW>W:!WFMWZ1'-(R[3FR[A#I9)CE>.OBN@6IV
MI]>/=_97/QA57;7DSD+W(4J90,31@;;SY-:,TI.-T6%^%K)?5.=%5D<R_"ZP
MO>\^]V<%G?\W(% ^ENS1;,8"<JA/D7,C;JF:J>\5^39JQ/E!L+C%7OCMN(LJ
MRY#Y57B(C@Q-ATQZS-B-X[-"GMO=\;*HT422]XJNM]Q/R9I?><JC/[J';>NV
M\R/ H^%<-)^\CASP1/. R.<%OE0[4>L!([Z@?14LU,Q'*DO:R"]Y0%:5AR#M
M'!@PL:O(G88D<BH(V$ZT;J].=7#=MELH3^O1+O[1+RP&-U"/FQD2)'0\/$+K
M4E[#2]>*EM,I@CQ2L:9O#';$%^YF>U>@PT<>#*X-N'$\?^+]S4&;LLI'3=(5
M);OXI3E$7:5>-+&"7]@L#?B?%<YKP,/7?I0'^&YR'V\=O6D:G2H@],BW]!T'
M?*^NR&7+SE[T *;TM:#A9YKG3<?M,5EG?[315:W:T>4+=8+D^% M]UQN1*-(
MRZM2Y_17MB:)3E=:'U3T/*C,4]?I8^GYL]4Y(=.68@GI!V?LR-P+-@_2;]9\
MKTIO-!*9$;ZIQ6/,VD?6%2FSA!/B^4%D:]HIY-C>OLS^LA_6"<Z5GM).CPB!
M4E5:(K/_0'JII;8P 7Z&"+B-(GZB-4/F;??M8JE5AZ@YI]AAK:11EI.M>L+K
M.]_!05?%0.R:S@\8N \[J2LQ8H!ZC2GSKO?)L<HBCR5V3AU^>#]5FL1F0RGX
M?S5=S-:"YT>+@'MN("=A^UR'M3]>('(^>SKY-'^V4=([86G'51(6LB[4HJ/'
M#C"LR?988(]"^J=[6M=)G 6)'=@[<JPEOXVW8!QA_2/94B0Y6]G69MAPY?.1
MD,-&8M=+5?;6 ]M,%N3;X(2<NFV8+]0<S,1%3"S@Y\Y/1)!Z$"SPV8 >..D0
MO+4&R^9O0%)L%EIZ23*L<2UZF6#P?+A=FB]5^?)Q#6?7MIY S3/_"R4?SGB1
M]V/SW)/AY,)[_$GI)2G)KND.<6KBUND1 .]%9,=K';C_GK[U SE6J!FCM!\1
M%N9^ N+QNJ]MD7MG=V7R7LMZM-O0:'_/E_^9:J[_H%P=5S\^/'CV?3\3<.T2
M'78EISKIB4T;T58K>K/3])D RVD'T'(Y"6V$L!IVPY+,GZ4K,Y34BD9Q7'G?
M)$ZJ7GR=^S7( $IK5"&:+I3P5B>.1Z3L\4D9$U=X:?:X4Z'^&)4)Y#M"AO(^
M?)(WC@ ZDYJ:,]03 A^;EB9,<'<7PW[>.<0$?*^8@X,SV 5D@#<I99()Q*%9
MY_>(IR@H#D4S@0Z3U\)1RO&;R-O3C"AY/!WO?PF3/P2>F,@-CT_-1V5MR*+Z
M5MI?'ZC47Y0N-AO0 &A+()][7AMYDO!M*0>'OS!PI)AO=#KGRKMAQ&#RE?G!
M(HP!/S@YB>?XBH)1VD&G"?H13-9L4]- GF=0H^2^MS_M3\#N(8H8A\D2SR8@
MF.%6=W@ YI2<@%3K:ZO[<.$=Z^@DX*W*LO&0>FWN!%84[H)E]]_V9>FX7FZM
MYV@UK>&H(I#HO#]@^? WB_!W-UIN,^KMU/&DI1KB>"!#YJ!HA_!T365D_&C:
MSMW7FE66^ (EX@*0>RDB),I+LBQQ, :M#:9J?<Q*M B-EZ=T4!0/-C&!LUD;
M2D.._)V,WN.#V-+E1<M,FD-WEM.; 3O-#7YUGA\1BED2*X;Z>^=E #3>DG@^
MFM36A!#$W&("0J!\2YAG[E4WW^8BBC??QVK9!U>5N%M]R8ARFP<OG M=*</%
MZ8>[7'WVG..*;J^]*^=T8T%ONR7AY7*SV1[_H_1B?R1QF<.%"8Q4AX@4%XD,
M+R94'BG1>-OLX_'DGB[,#].$U]F&Z3J'@%!8+Q.(M0P@=5#TP7.D9ZW',]1)
MA7.R%TNL+\++KAY)(#HJ55PVS"&UB0VV8TBC" GX;#(3F.+L(N&*X3>[8L:.
M@VTY\]X,-=(@3>KNC](6L4,ECJM7#*2Q8X$H*;$+;,V)3*#=V(B.462DM:#?
M64[=PJ\D\C$!1 <3>/4647P9L)QD:^7=,<L$^. >FN,[4('MJHLV<XV':I-W
M'1Q?^& [;<_#8_02W34XY1&)GY8^Q@0&U\,9:<1,WFRGK<TF_-D2.%ZVEO+!
MFRL]IS#C%Q(V+=NPPNB=J!D*G"R00M8GA-5X>F;7$OE4 DN:#FR$"!Y^:F+_
MY-","YO0?O$<1I_E9R90WOD,F<_HK%.-^G$YPCT[G9.WFO19-%\B/ :MRC([
MSL:0^DJS!CU>@)LMV^'#=VZZA.M8-#NVJ3IH$1RO<)B9!X^]/US'!0W'^]OH
MJ#]OWP36,V[PVCOCR-E](R/O6!G;FQEJ/],!SSH8&#D!XY_SUE ,TS+*=1L.
M32L]Y^'JM6^E-:]!J$1J#V#/(OMN6\UA6BSY+(;T>;QR!S9B+UVT:4SAZ=F9
M+':U@TI=&?4&=[B>B@,VU"X*%H2\C:-M ANQ3O7Q+Z3FH1L<]9H"LI9_WD@9
M4U.0I>T,U#[1!.?S9YW4+(Q69$?%GQ]84A"\WSUTS> ..5^]@_WK(Y76<_<8
M1\!OI/CZRL\OP=*6Z@?IOD_';Z\6GDW]4:TVV@$^1/ P/NGL&4 +H=LECH/Y
M+T]U$,5]VRE+W8$;/9QR.<9"VWCN,!R#J?5%*,&%? )L*+LM>;B,"8B56Z0T
MKWY[&\5]:M-6W3&RW\JX5+[M^YD5P5'AU?H-GX\ '?-'V@ 7I3$[45#:6 ET
M%>CY?C+CF*^'A4P*>4L2_>_H<32S"6S,& P,IVJ[':?X<G'S-^=[HZ;DQB-?
M&%U.R(FRJMHH\3FI+;]6$'AH#K["6\T$BLV80&8:XZ:6HE<Q>)?2V[:IG*0#
MPY=ZI91<W;-ZBG?PHT<[_E6 $4/O)V+](Q-8VXL(PY:F0)X+6L/9&"JSQXR^
M(VR'?E0.!')58ET&E4,1WA>ZF4!]'BMEIG%,LI=VC9 NWV)SZ79I_^*-FI"?
M0\IL #7P3L#\)'QDM6V9@ ]Y,,;Q]AYE6?#;:TW!95&DO4R*T$S*2HIX$]\E
M='T=' J^A1,=X,6Y<S\S]E;[^>]-IJHUJ)PRH[%_"!XR\%&,,:(I8D>>F9!*
MF$"."X(WP?$YSX7R%WO/&#,!-\)DZ/N456 5 <J&IG>FDQ^W^ 80A8H5RB+M
M$W@M[E>'6GG.&J";-'.,>XP;^%B.F-0#7M*#4^-;K:AE861!QGL/_%J=!I63
MTKQ5'\LQ.7&[A%*RX9L2H?329H+P\!W;YQNC[B$ZO#='=&')=O"*0;RKHIB_
M!5B84VJ2"][\>JV^JM/]0-*!2,P0$S"R/J@S%W /D8=_BVM>!JUAV\NJ<#*K
M:F;<$'(NGI?]+LDOH9\Q<]] 3[9P9[$\93]HX4I@ @^5YVR^Y?G4WNTQTU"G
M#MB>/=8Z5M#QOJTL:95WH:G@&Z,+<DU8A X7\FY2[WID1H,PR'W$L</AT,_$
MXX?97@?W!,(OUDF#KQ#;_;7)BO]/>]\5U=0?K7DH2J_26Q105$"DHY1@H8D(
MZA]06D1Z;R)!0H(HO0D(*"@!19%FI!<QH2,=*=(A) +2$Y082)MXYV7NFEFW
MS,.LN6O=AYVGG)S\SMG[V]_W*WNG!N"/6;U9G[+/+!Z6,I?WLM7;N@-$5^SY
MD5QHR-\,8-:%T@4Y!E?Q$X_ 2;<?ZY8I]FQZ/:JO]?&2L@0O:[G;J* X!TG:
M\5O=KI!W(QTTB3LVO?%P;W;>])'![1-FD&X+T0/1<OH(LIYC:Q+GMQV&39L<
M1KUUDMFMX=+*,BUY;EF@Q!'U0?'H5=>^XW]WT;\WB*  ,-#D;YX7K0*D*HX[
MYGV-F1_EH%+&1K8Y[O,/LR>*V<,E?T+!TSR]<CKI"$&J/-$I@L_GK6F@2FK_
M=*/ZP(HU:[7$7'-.3EC[PN.AR-4D!G $(%<M2Z^,&9TEZW#]R$C@KO5I-(Y0
MR4H20=XK-WKM]UL).]*; 5!#OWE,4&5#U\-]ZIQGG( \G9660!MS#SV]<$6Y
M5S(Q+ ?KE! &T#= YJ"W:C$ FIXUY*,M^1<%X;0X XLFI*T6B",CCF;[**IO
MJZ)-OC2=_FR?G06T_9AB7L6G2PEB -].,Z%=K)0!]'Y@VX;,/J%;_2W!QI=]
MD'S  .A<S,RB:.;  *KCUQB A:KRZE(R",0 _!#"5*.I!R"F$J7WCZ*J\O4'
M4%O1EP5.R9LZ#N;:F?16L"JOJY&5K*F9LG[T'FDD3;&N2 #M_9]8$Z+^/:L4
MF\H<G=0H8HL9RUGS4X-+U>!>Y9%XH_/6<7!MK_K1UNO?++W'/4SJ%SJ4+^,-
M%9HNOS74K&XZDA:MR7S(D@P@2[N( 4S#!6@GFU'RY$8"._D/"4+@Z!;@<=PA
M"L13P>Z!M]1_+=RIO%10:I^0Y[(2P7_CFS&HHOY FR+!O/?DW^YBJ(#;#."&
MS=3X4G5O[S(1T88AI)/C\8CD5ITDV7:W7PN.M.F="S^0R]FT2O4>@O(J:+J7
M?@.%LZ9%^6(.0^-CP'<6QA1]%.\EQN0J8H&+67Z$*[VDV3_;)_$9R1C1![D^
MS'?'.\?3)"XY5*)1HJY& ?_<5.Q=L/[HMZ_[[T>VD_C6)4+Y.!/S6#TFZC_;
M_(*NE!0^"/E3V?#"->V+;5Y4AL]IMGI:&EP)T?&5?/)==Z3:RW)H$/UDQ%VP
MNN"'/9D_^F_.<AG>T8["="%%!K 9">B3Q+36^TR?N[BQIW6ATX+]^D:I; H@
M4 ]WH ]>K%K:8@"4F^0GV)[&,\[@.R^WA) Q8SW7&S20D0KWBQY]-53>1_T;
M 2C"PO10-?C((6);+1JGEH01TT[Y3.3#)N'2;6J=;OR4S;<_GI-ZE,56_2<G
MSY-]ZW0&<$_@R2'Z<9CX8_IDT2:7I,Z>=N<(FSE'?TUE0?K8H^?'T]\:"@P>
MHK8.*#;P(9=3Z"DCS@6GC4/M]F'*\6P+15^+J\TUP1$ML<;NIC)9W-G),]_
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M9MJ9>_SHL\\UZ8\_"=*7H::;G7EHL;%SK2"5V]Y!?@+3#J!]S_GC0G$C>MQ
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M-JC5EU 5Q%.&G3*WWC<A9Z[<1I,%*!90)%8W\1Q7_:1[%%0V?O2/&'8@X)P
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MN'2H-S4]\7]]EO+@" 5Q]TH9["'!Y74(\NSF]88DTBM95*3&*Y"3U&$87?:
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M$?R_P>)^APC2C>*R-O?\*7[T;0Z/'M#J3\TAX)$LC(UB#!TAE9,=B1J_>N#
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M2)27^@MV^/V:#T&+]UC)2NB1SI&9[-Y"85II/2;-(8U><"JAS&GCMAGOK<'
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M ]F'L-M)/U)_MM.L+EU2UF@KV^W!&._C/S]4EM( N!^]<VDOA $((3:_4QB
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MZNYJJOXO:_6R*P0U.F)_A,K-U$J9/]E6@L2H? 3PXW =HM?6+K'7K/9SRLF
M0.T*/[_4\.D\=7/1]O4&DYOIE7[[^(ZQQ:'E-/F :QY-G[.&%][G2#J[/^MY
M-ZT!*SF6Q8DEX=#G&4!")(SI<$A:& -@+6( /QY1(BS& WX'G!LQKU.Y5QVO
MIW NM%O>IB(+6&,K/,TFWBNG),=->%B/^U.;;6,E-N;7&RO,GJ7(Z1R;W1/,
MA3I%*\1X&PJ08D;#K1RM/@6<6KO6(FCIISB@5>A8Y+WRU;8MK-FXU]9@"OVW
ML29[;N/-RM'!=[(R1^WL),Y>PL;JR6.T#4PHTC [<@C>#RE%'S(ZFW$M?C-2
M)T)8RUJX>22+RT*A\#S\YW/6\T9$Z0]LTPP@2)OPC89$S3D(,2-'=:64Y+D5
M1+%X'EF@SP ^_ I+GZRB\+]_CZG-2QA^8YT[OEC@GXU4VN;7_WW0B9]%1R:0
MC,F[Q*BNW$=3VY+XJP76]1QBI*S(VI@;UTQC%1L3(B)L>A_O%7+2SHS6&2IU
M.FCG)?Q6=J\=__WS%N>)5-=;>CTB IW-/_8-1H]6_56,1P#RWP1JUE$!D;UK
MTO*GPYZEY'BH_TYRK]*-&U-"C9]XH_UVKW41U1)^[XJ2HVX3>JI!+]TJ'"W]
M+OY1'XR3EB,;R/7$@"7I*E3[282/H29VK6-(##\\$7@_T==,O_J#0?PX[$E#
M5]HJ>,LRGQ8VL0\Z"I,F!S=*512 ^*">P]*A5ZW5S15XN%DS*S3# 6Q4H88?
M#O,?)M4C2RX*!'HV[@O;3<+P9Z!YO-Y<L:$I-4O7[&S./<X?,G*</^3,M%@.
MMO[#G!HV@ ?SP3QI":W.;R _T4I65RPG';R2%;T<HW)B2@MDNRN$19:G>$LR
M7U6P*B\$@-UW9R'8GGI$".%8SR?9L\3:E>OT?U(Y%G[=R[UPW/-F#R$T<OE2
MMS\903(@-Q(5>D@N6K1WK;9B%4<RG>ZVK=KE".[L-9GCXG4,&G.Y A\=:P+@
MSWPB!LI]<A_EGT@+7$Z_5S5Y-5F:8]ZS<A[1VXK9:=PK^U\DS\NS>4FCX??,
M5IE2,YO.5<$ 3@2!$%-\^G_/;J.?T.J- $3'&,&>>FI1JF$)A^"[.BAZU&5G
MT*,D(=U224UB?[[(HPSA#IFI[04#J%;K,":/UB&&?]@6%G)E\NCSDI9!OUQ3
M)!?54_^L0P)&.7Z])O+@^5%$L\Y%CC'852EGZXYG0^Y3*F&D1$G\^5JYSY/_
M5!R;8JFQT*,ET&K^ME?H:"%+5[RK1+N\PQGXV$V#SXL#!X/ZJ9=!'+6BJ)=&
MFO!V.46B;E?4D@A5#3/V>QMT*R3L9-6/[*NC\^JG;!-->"M6LG^I*;#GL 'V
M*/HDLC:A&Y2Q>'I4^M+D@P$!?F^"QO.6W/!7(_KT0^/,CI]P$^/FD*^&+$4"
M.4:<\*Z+NUU!"0Y>&>^)E6C) &^#)#_9[.NPYP_O++QR,GF-#60+NGQA]3-*
M#-%N0+T2M#QD>CB"$YF=7,AIK9V;Z2NM25I-XS+OE"Z==:(6-[SR>@<O_OE(
M![F\(-;9>7@=;I7[,DBTCHLV76R<" :.^-IPK.8Q<RO.!T.@-Q.0-_,TU]5H
MQ>Z5D12#0;$';-].SB[=Y7N /D*KH+I@ZM[7$C)PR&FM+_+*!0/29X1//3U8
M/ZU3I9BAP&LIV(9E'6SJ\4%+T[+A"E V4C8BQ>CH1-T'F+I.L>*(C\KXN][I
MG=[#JY>U'[_M%PLZ'?GBP"9+_Y':]@F*/#0,GS9-M,MXI*4F4N(G/7P;)F[^
MA%/I9CSOV[CP-1G!MG. 4><#"Z&WF5<46)F,Z<F$$.09A&"CQ@K3(J17+W^!
M=#QL.+1.U 8;HE2W1=WNGK#ZK 0=9W&,O"?-AKC0YZ*SC?"RGDOIM'O2.2N0
MSC7^S-]:R?[U+2T9H/"^<A')1MTE@5! DIQ\0_27,R+_PATAGJ0*J^"^*>8N
M>^88K3<WO>((;@(=E]!KO]_,SK8+8;$JGR=+=S9*[>QNGWDP9]JR]'HQZO+[
MZVNO=H;]*M\D WL!9GC=MAD[_+7)UJ#EM=LM9XH*;M4I,.64)#,7<*)2X:>I
M0K24UJ@U"#FH]Y'XDWT+C2O3&P_3?.\P@$<S[[@YZCPO_K;<)2OMMO-=)N'H
M4=O^%F$*_>V!16QA6;V@GS0-7Q15?P +H3* 3219E(,!*(P>16Q%OX$V=K@H
M$3GBSJ%/K*/U")-5KP+NM\ _Y'4<_:5.+PW)$FK\ #KU2-AO=_9@#=N[-4+X
M@[4K^[!!YVN:4$+>CKOWW,5*IEQ(.GA6^#0A;,,JFL\8E(41,0+@D^)+H'UD
MBASON%M+EO):GF5+(:[GILQIG2L-TKG'_9T"YE_>TN6/_.B'5P0W.L"TIJ1Q
MK41,''L(K>GT6.CM(2LD<><-9+\ O@N.]R,9M6;@,3'AB&0P%^P*UO"HM^KN
MOO<;\Y)FSSO_]&J81SRWOW>^)+@T'Z#^HJ7@:>]YC22CN6U!//"Y$-([!G!I
M8;)U!&TT3J^5%1A/IGFCV&CY:#'H$^Q21X$:&[00]WV#/HM;M8O2C7A:.2;F
M)"FL\U46[O"G__^ZY (UC?89\V/9@/FD7<00A\ZJ\&;[OW7<4%M]^)%4I A5
M$X_@A:PW-%S4KA,<S,L:S-8T"?TE'*OG?DOG$YO*!>KFSO_\H>')^FCE2^.E
MW[4'IA]L\M@N:7=WI8C<1%W_W,S]=CZ?B#P&LZ3EMWJ]0Z?@1L2@CO;5V96Z
M#G&ORI VDL,2#Q78'VK_7!(T$'A+M2 \+,-&1Z]F6$^^%;K^?4O8IO@)M;*_
M3>;#!A\L@0'P[Y&9.1-\N$8_<HD!?/W-@L4(@[VL9W+IV$T,IY'J3[38Q-L@
M#?W(>NBI!OX+TB>%#[Z%+6E$<5- I)"I\"\\V.>SO5T,0,S!K].L</O=Y'U,
M.EV@ICV6J^GR7$/J*]V1Z52BB\?_=J-]#)&#Y#Q13 :6V(WX?/W\C@R_R;,7
M]OWU:>GH]?2";>P%&J['>/HH2]^6L9$9$=4ED(QI6$I?6E[KA"*O$0R?)O\R
M>'F'^FE)M7L9%)FN*:+0M',IY-"" ,%FQ-(YR*X/!+@[5YV&15%!)6PC+9EF
M=H;/W;<N=63<L@ 7RDG3DAF [\C1.4NO98%$G8NRK;NK%K+I566."FCUYESE
M<'9\:F&(,XBJL;1=SP!,F.Q,^1## "2*!"8VE-/($6_)*9V+[*-::F)+")]-
M.S&;2Y'AJP:+#XA%]@@-8]D_0J\'60RMM6>8Z&E-%>%H;YP]58S]>Q1$YJCT
M]EF<_H5W-_M;_0-5%?7HFQSL2%NYG!7T1:)VXW8DY1KY6.=%^UV8OH>7CW;'
MF?ZSK7Z1,*ZMZ2X.6CTKQMI('6;02*XBC'3)L;YZ8U'NJ-&N^').=M#=@#^8
MJ^-K^8VC(9D0+7@?I*8QT8A]XW W">87X1I=MM0I6U5<'>E^IV@!'=!SY\V%
MA__TL"P_^F4,LJ3:$=<ZEQ+D> MLR5GM6M*Y8M:2#5'/G_57)<YJV4G?_2?C
MQ9$M:WDTJ(F62.>&00@KI1ET(;^I%K[<FGAOX:OB=AL:ER"J_==*SI^]] PO
MJ[PKD(3A_RV0C.:<-.#"V095^]Y\_$4OZXQ@?/I5\*(I\*O]9RB7Z,%R,7T(
MV2#>WAGVAJI K'K5HC@F=E7C")NAT]Q\M[QI+R9WJ/""%LN*D0R:W$T!44-'
MC60VI+"3OYWO6U[^7J;0%Z#Z;F)5=OW8+]Y^V^K&)C:54@Y2/,;02)C^54X'
MD:3# ,318'*:-LUS^)^FV%FER,?YY^[[N(<;B\FSW/GV\ =_,#=RM 7XA4H%
M[5G  AC /4-+!F!1@HIC -@"\-Y9\AP=$P#^[3CU4SQ#2QDC @5UN4B.+RBT
M3/[>_*R7?^NJW\DN5:F\LQ)Q1^*#N7K=(+KPKPP @+D1CETEBA7@>09X^L*C
M$D\F3ENH)%<(:[RF^]\4#(6V:;'L_\OD -P=/B['/457A-UO)>PFP\_Z&/$2
M/%K%*G,C9DO,MQS..W_O';3J?1@\EL, W#,A[_?W,-W6,QS+0=U,9YR'XKMU
M'Y4XQ$V$7!WP,[C9W2#*V60?-QQ\837&X.UR1"=HNF Y+_L1S'&9 0CY?L/2
M4+<G559G.UN#=X5."1S?5@%_@3BN@R6,A#8C2(<Z<7@K83IIY6GPW-R&V-B
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M8 "];&5A9'K1D*PV ,!D<M$W,(B"%0 " L-#K8S/B5RU=Q"A_4)N20_0  H
MX.H>%FQN;73EN =30P.1,'(EX/]*>V._CS$L8W)91 3XKR4V]^#0</(D+Y-I
M)0\R\V0Z@4S[1X4''[_'DFE.-[]CFH+JF XE3Y!,GSBFO7^GI7^K\SNM=TQ[
M! 1ZD.GC.0=[!'@<TV@R?2<RPI-,4UXDTTF1OIY19'J$3(O[1P3XDFG\<=L
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M';N7=V?V O8.?Z7B>?$O]M7WNP_L#I8/HPBTA(='9XZ:B&;$;Z0 $HDT!1@
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MT])^!OT1ZU3=DD=C(6_V\./9'EWWNIV^RT=9<*%P5%;!\XHY.6K8,-EY=7S
M/K8]J"G&X&4#^I::]^(ZKBZ\=?N\QK(;;;<H?O!X?*KNW[9<I879.T4">-?Y
M=_4D@'-U[T#V'H>T%V;N<4MZ\.N2./OI+! GM^03E86-0ZCTF_VFJ/:LM*::
MW&CG"V FNM*(]37.87$T6_]!2Y$Z,K9@C#\IY5FJ!A_/MICTD_O^;&^]G[:+
MZ2ZU.6-=[N&,%S)^I>YJ$)5772AS.Z$CRFAL44KIROIDN+R3=C!O$>:,>%3N
MJ<QK$PRV-F<5](0FL*@%[X0VN<X8;2T$9"^SR":"6=BR/K?W\BNO+X,Z=3UO
M)(*_B@=H7:+OBAKMA3%V_&KCP&X4%KU&.L.:'1*%-.K7#F$GW[VSEFJJI+-D
MI0;7 ;2,]SZ)[RH#EH:<@-U]XE]L]&?QA!;1W'MN]BBE0(UXMU/OQ"P["?!"
MX:\6<]>T!)$ >IX]1/%<M4'[K.LA^%%67=M6W7Z1V]%,D<L,HD4J%R]WJ$ P
MQ/L]@T5UN(CCZY_A%^9K'EP+_P27BIA[(<(3B>'.5([N0R<S3)U8O+3Q5B<,
M>I%L74H+B'A=B>&=(]'QN?Y498L$V\@A)],;SZ?P+C.K0T=E;(FAJ8/WPW]^
MX;7X+$S[I#L/;[QGC'^-[9BR@5(18IQUM]!VC7RH.X$J<G13SHS5EZ(D'-]R
M7FB[=/E\B:B]<2XX#.I('B8"2SOW)?]0AR"&W8I33NLM/-=MDJF_U]P2?<]4
M&JE<HS?G92H0ITE!J]X7(_,_]PJ_Z=?'X@;CCIM:>\GX>FS__+,?0^'1-75'
M=K9"(B/*^*W 7'6A09>AOE-'L_F2!36?>[JL!&Z-O2*+O'CBE_'1?1+@NXQ-
M3&B"WIEUP=;/E-)4-7EPQSPOYE2S?8$U_TYMG&2;;7_U2<" _'<[*.[7AR(6
M?$8IWEH/AWJ_Q0=#6HXLMK4,[SC:U"5;O^;.,>;_)E6]'L3WJD"13U);?KKN
MKE3^4;+N:0(7CB>SQ6:^/Y'L->JW&/P4IOBK[6S':YZT%'PW/HL6V^Y;1'^A
M5'(7;N;GOQM,1SLQ8FD(<))SM,5Z(8F\?6&#B.@^,I P<47:(L\<W4-]'XME
M)@%?\TL1*TPJJR._*]PBE #1(KXH)CHCCKJ@+Q\0*@=H5\O_Z9WQ/Y<_"+],
MNVMY+,-\^+6C$FT0EG-%K-L!-S!EL]W6G2:5EJ74,[&$>)FQM_#9HC5].7UN
MW!B[C9%,)IZ%02QP=HE($E"W0YZ4O.-TM*(ARB.#GY!S]E5G*8O>2M$#;!2!
M:^THJ"/K>25A?>T'"B^91<@G ;=TFY*)>=_LJ!38<R6N!)1 O]]4@==D"!1E
MNCU:?ES@9^;H7(<R^''@<+IF>^D<>3<%9T/\LQ(.HC; .+_YXDZSP;(?V\Z^
M!S55VOHO?'$ST]+!.B6MSPK,#E&*%BK.^0]2RS0HJUV)?9#:S:S#,\3A_GE&
M^G 46UOKO%^K$;-]^$?I77/=TX'5EG.//C)D,56+OGFM-_7$]6,-:F$K0UL0
MQV^,?7YK 7%K1AGG4EK1>S.Z_$=#I2]+N9N,>*;:6SO'KS,JKLH>RI=@KLV^
M(G9*ARQP2[P41DX05ME9S$@4])OA''-O4'.HJ48ZZT>K?,RTN6.\_*@WY3&-
MUP=(I*J:R!PKN/9O>%JJI\68!$B:8[>)Z'X.Q$IDO$NEBPT&LJ\9E%R\)P%[
M1 +,ZOB 78?3)7$,_UXF+ R1 -=6VCWD6$L$CK[^IE1[J#G&V>&#H+ Y=K=P
M2E^F]?NKED9D,.^,KSU35=P3"L-NI_'96#F<3G=B@+]7XX *E%5E=%TU@"4G
MN_;]&U6FGT'A%,JK:/:O/YZW@?';"^ XZ[4V25QY6ALE?FES-"*ZSMP K:FR
MHYJK63^BI$QM?W*DE..USU?7@7?M3.JB<;J/CE(# \2/'A,@?I[/5V("VAY%
M5_@^"E<^XQH\]NL7F\YGX%Y"?O:S#R8TYV@I6B=;IO:B<%E)+3>QCAU-R_$[
M9[25YF^DN15$WA/52YHY\=UG).#6C#S+Y[@36*/@4-JRWV&EB_6?(;;?:.6?
M\1404_\7Q'&_[C>+^6]FT,_^C9/@=%E='=@E2+):DTY6FA?6!<4\VG_'Y7QM
M[?#D@D5?3\NU5_FG?O;4#%51>N8!XT6QGV*^3_9W@1.X!_ 7%CIB68?:^%=5
M9TZ,R$EF+..8&R?K1OWR,B CCT7-%E]+'HFP6J@,$K_-L(WI2L*:R8$2-K)"
M+A%N0X9'FXTO9F I@>+IS(*Z/7FJ1N+M#_O$<PF!SD7VU\(<$'1>VVUR<*KF
M!R=3)[?GJ6;=AC?L_"-9Q(<FK4#B&Q&P[%#8SY O"WK"]F,\Z=J>)7C*SL8F
M<H@:H753S+CV\O#TMX81IU<V0L_R[UPN%<\!J.Y*1;8%'34J'TZT2&&7K=+L
M\SH+9+,7,C1_.8R59*H1^VM_+F=MT'ZV-:27?M7PR^K%N7?SIRF'7/$D8,Y>
MF_'& KU*2E4=O]:S-[D!!A9-]8_Z QZ)7CV5X1D5I"C_\H49-^#52*#%@3M)
M ,>.ZFB+6H5LJ;? EI_<9A&O:[Y"VQFW;)N%D.P'$;14 J%2"[U;=^S4)I.R
MJV;P#1;\<$FL,;J7UPU7.)BRH/K&U_K#QBGTA=>]7/6+Z M>'W@@2AR\*C\0
M#-]Q06AP"H('#L6BNG3Y7V$S*ZLGNUF>5?RX=WUL\O$KW[&!7I7*SAO^JE(5
MZ:@O MWM_"QS8*N_;+6CBY W482"_G;4(8=RT-')I%:'WVV0:+-V\ *YZ/+;
M+\C+U..G!F0."5W3Y;RI EWVAAHAVK5(P/<!;=K=$<A.&Z8MC 3<;D54X2UW
M1A&%A3=Y20#5%ADFZF&%Q\E1\M!A*FX%@;(8)F2A/B ^*221 +*>3_67_BA)
MW0/_-HRN_5'925QB=S>2OAN[],OX-<Y_AG%\OND=CO%C;F3,#2??_7=VZ=P<
MXFWV-I,V<?YOYOBV^R?DG![9XY]B;T\*TSO!+#KX[#IO&DUU\B5^Q[403S8<
MVA94A^+*#^XEF,(;Q$E &07]4A-DZE&'9C=ZBP=FUS'#,GH*BTQ%S0N.[?+W
ML\F@LV^5ED]8+7U$/U3B+<N9S>BM[95F\;.89YJ)ZMJ*RPLM4W!T@8L\6G>X
M^7(CLQU=X'A!3[RP!LDN:R%T2>.;#^6:YG8TRD<.Y("?E&-P6@NU7U.<(0'>
MYV6K9%T;<G\\IF-?+&6M2TBG8C'5!LQC#.&)AT;P\P,M-@M!C"L'8'2K7)?:
M051:^%O96*[)AZ?>O7M[^X@J1R/K2)0CT'B2'C&-*(U[7WF9M@4VM; <%RN(
MSY&A1>N*)U\:*5!_ELVD^#'W]<=%L1LI; R.I:]..MCJF:AK6RX$916!\%$8
MDSIA5GR.H):5#R;WO'ROJ$.WV/V,3?'S9P(SWR?ZVH-$YG!05<)57&3\G",)
MF*SLG#G[-HGYQ@=N>51R^-1MW<$:0]DLKL>7'8RB\Q,_ASZ]0E41?(G2ZQ49
M#;/ZSC+"I0[/XR'=C9?+T^$63ZX^SRK_)J_&MWG$P,B5- A6>M6<Z7$V_RPT
MY+W_ .VX,%N;*DQN7GHL!%;NP'>SZWNH!5>+ZK"SV??N+$4O$\L)-_/>)B,0
MCYBXU[M" ZOZ,92O19)#8L9GM5P[%UH<Y]XOU4TA#7>_/NH'H\G4)B*W->-=
MW'G2E)&W((+5]9!4S;ZB9,]H[/C%X>IZ<ZMK=\VC?$-"QQM^;'3V=/@(7^M5
M%Z!L>-<_(=E!5,<6W]&EGH!]V'S_09=_+:G3+-XT]\O:I?29'QF+3EK?+HA?
MJ^:+J^#N2V"=UJ.=#/\#SG#:B2T@4V?H\= ]8?S%%D]R<$%_LQDQ@6A4,9%N
M&ZP-) %R?1'3C3'>O!\6^RV=N@DJ6>W@ ^EB, G OGA- A;J0*MU=@\0G5<)
MK"2@Y!.6!)  AC1AHI8SY%:L%$P2DSR%FF?&Y243'/<$BZ\3.T=%6@]UCZ:T
M^\],!6YDI2]H.0HR Q%_PU=_RUS[X\]6=64'(L"@U<@F\^2T%D%7' <Z;0[%
M,O6-/\#:;J2L><3F6;,O*.F$3'M;MB=U_FLA2U/DX 4" 0^9+W2PF&SL*-)J
M:&:%:X^VV&"JM?2Q]>BA2Y,1:+](N2#KNZ_JMJ<^PZNKZSW)0<L [2#BM=.X
M&I0B9_5@_%#-N@G'@@JY\:R2AB^B<_57@,P+L?C%UU+9[2+9[5Q;7/.(UR];
M(%3I'#V!6]4$8PQ=4)"Q67/BF!S5O?209/\&VHL+C^V:+M.>Q"E9C>T4TT^[
M_'"8329HJ%1L!ZI8<+S?MG=\#Y)=KU#64?_^\4E8 3: 8Z\0%XN<VVEXD]P9
MLW5G5XY/,D%9CMVW0FU/J.SYU(;5K'BLNY:XJ6"'HG@5G\F%% WQ&[-HTQ9K
MFMO)'3%":1BIL8<R7XIK5MFO=IYZ9SO=<.5V4''D%UYYHTUCKCEN1"TD0V9C
MBV -8,?2%JAQSQK3E;>85FH_*_N%">9]?=:HM'_V<#EER3O?E?*SIQ8+BYZ.
M]]P6VH(5=L\%UY@ =RH(@SWJB'IEH+*9Q71W$NKX3:]67]-0K/E\L#,O8QN?
MH@&K$>]?/'\JMG\=)9S:$H"!W$&PY6 Z/TRB#V46L(B4""GQX:KSJK@T:-U4
M:VW_N^H<.]FG4==.[X?>@/XI'A.J_EM@T2<D3=Z>,V*_$.EPMK7S?4$8GJ_U
MU4)[ ;H'4X<<EO=ZBL[P:7"$.C[P5\Q^("X0;%*%PL>HK7>3 $,E$G":KYP$
MB-EA4!ONQP@/=X_8K>--AG//D6>?@&=G_UIS2)<#9Y2WD,7H,R,V&-@V5>K'
M?7E554W7L7M97]I//*C^O6?/*_5K=/TB?$0GOX,_.R9ET*I'[,W*/'P*CD</
M;STW;= 5>QI%_#Q0=1'AT_33(\]KGUMY7\S6/2]"@')<1^I%X+L-J :BW8!L
M5$R(A?Z:8A+P;&_W@?T-S=!BCR^?!4]@0J[\,/,UE0Q8GS0N@8L<E;0)$V("
MKL!X7#0GAEJ*&[QZ,+.]VU'[B#5W\XF?LYO+)Y9YN58@%PA+9+$9D+T:<F<(
M5;@8FWXTV<ML.5;*VQM%] X,NYWDG%F16#:5'M!V4$9HSBI)E7J!N_W?N)0#
M9R("Z949$7=( #.T:[(XM:Z0PD_084)%F-K^RT%1<3 YR*,(4CWM\9E9^!%'
MQP23B^K7*7ISR-?-_KFE>QB_9CDJ_*,/;4JX*YK:D?%7<,\+$9RYDQXLJ;FO
MM,=>&0BX%H)SX\.$+FV\XX@==SF)K8-R$/GP09BHC.]81*>@P[!5SM+,K'V
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MJI-N94Y1/3W]]GPDNE+ \8'9NXY-IX-_ <1L__:%['[5416"'+@H(KXN5Y&
ME?#119M55'T6.<#Y8'$HL%M\)%O0\C*.X2^G1PB5^J,S?_XR%MB%.NQW$QE.
MDL?[QTW'3M2_.F=:1B-H8K-^ZCB5$XU.('#=V\9?$%@3Z&XQ%[' ;KL%.?B2
M0 9PM\^1@+_?;V38J5(>30I#/N^^+2<:<Q&A!Q>X4T\CS^_K_5?^#PH9KZL&
MZ]7',Y*G)((M1H-3Q-:+6,;@)PXD,I!.:)?92RC'VU]XX[1TC3QEOCI]Q[W-
M:EG+QVUUHIC@5MAO![1I.XQ@MA_#K/W>+]Z_Z7X;[IK]\]6G3B:VKP.TMV,'
M$0UJ[P,DYY"I8R2@NXT'Y^^0E!<2()16MBH/[8L9,NIYO1]2RTHO$N@/&LE.
M_4IF,19FX8156X_"]IOB!)0<KW_R5.G4#Z;+.?W\7:Z/Y:WO;)S9&>79Z9&5
M+HQ'\6T@@@Z.27,I&=MKFF7=&"+-X:(]?EN2]F2V1)2-R$\Z7MIL%Q*@)RQ'
MB,%^*R !75E4<"5L59$PEK-(Y-5(1%H_:T.B;U3468?6IINYHQ+GBMQOEC4K
M,-FXBS,$M4\S.N&E#@T,L5O6..[BA1LZ[IUY#J,U3R95GF56/+\C&X#Q>>[G
M89C#>_%]I6)\$[? +1<+',L"1CA=VV8>D8S@:J/W$^:0"3^4<<%"?:/&Y'5V
M!F<<9:IWZWOZF'*G3C[(+OWL_\'RYZMSQJ^)/42V86TVC,SUX0MX9@PX"1+8
MN+W9HH^\/G9P?[PF_>5=Y=GK1>Z=M<"E]M=-[(J@G=80%)LN!]X14\7GX2(Y
M#+WLK!K95 NK66J B9\>S+5+&7UC.1&SX^[\@!.T;91X>,)WAID,A(N3X(:R
MQ9@3VJYJZ>&%MJN\-27U#YX][@X2E]-0?')[Z:KS@\$RYI:[7Y$6>&-LP^%[
M)7RI_7C]0[@!II_S.N.+ZU%C#5Y#$Y$& JSM5!*F#$;9Z">!D6Y=#XN"=43_
M/WE&Y7=4TG8F=M"%"3=:G]R!2'" 9K8HC['UR9;?>&GHOQ+JHH<+B+X[=_9#
M6!9&&P>]8'E\\M0)Q0X(-\P>\7N3 R[LDT82\/WE 6INLW4!S %7&XR0$X;%
M@AEA;;!OJWPZ56O:D9_%KSW1K*6\3_=-X7!TRO+_ISH'DTC&RF&$,G"/G'!3
M\'-88L511;C8U0@Y!O-3HYFY;VB<=6<B1KC$G)CRJ32BM+ZI<AFW#NH)4>/$
M]D+&X79(V!:1;8O/8+X?#-=K2!I'CUG[&BU]7X]SU&X(H\]VC989%3TU=%E5
M"@#3-&:@/(^LK5IQ#[(2X%#:1/B9A9NZLV1F'TG<#ZRA, R4,9LP7Q9)G)FP
M$G4^1>GV"M@]X$L%<,4GX*SCI;@'Q2E$ 7Q)=_ODRQ]GYBM?[,J<JN>/JLTT
MRIE>,"P2?=,Q9%97JYA]DJD\_FH;&QY13CB-[\(&M1]8]\DDI6%) %K5TCPX
M3+PY2)G5(VSZX6*FUFODD[]^.?F_?]_U_RQP,@CA-Z.ZD['8?(9A[N:0L4/!
MT[<)%E39''6:#T[%I*>'',,J'"U! ;S!2P*,;V' !':R\I^R#H?B)7^A#Y&I
M0A0X[TR4STV#[MP9MK&3HQMUTP:&9WFS1_-MB$.1W PTP;'WM_#A_;=(P(\J
M^!42T/Y-F)#ES-.)PDMD)>CRP[;U<#;%:.2=R0<S&3>X=FP+,I%,N=O*_B?$
M4T6H*C[0487H"=NO3LH6(AV.\JQ?-8P$_*+]&3AO;QW\(_A]^GBW+AAOC(%.
M*K188*K5NF.".M?X!6]8#=9ML?R8X1Z6-<S[NNG1R!PSC.X7SXEV.Y=_F6M<
M, QJ3 A]U*VJRS,<(0=,-%17K!S45X\N97%B.R6>N9U(F3.5V.=*;9C/>3>1
MT:F"\\J:EPI*1TP2S^+RUFL7F*.@;6,JZD%!=8614Q=2-T\CRS-/ER=)_;#U
MRE0VR9_FCTYO6&+. >W.KE<L2"&%X!Q#*HP_E-]NR6RI,"O:UZDGV*H%^-U0
M>??NEC'HE$+T0P'/OIBC$"@= $V:Y+3$*T*37[5SZ/,D>?U4N_HA\_]P]YY1
M34;;NG 0!)'>I4@0$%2:2%-:0*2)B*#T$I$:$$(G:" (TIN @( 4*8*TB)30
M)$@5$9$.H28(2$\H(4" &_?>YSO[[+W'N>?><[\[QO?]>'\PQF*]Z\U:ZYG/
M,]><<WV-.XITQ9MJ,57 ['-]).KRF<5Q)>U !KCKSW7Y/.Y)6[#%Q%S7AZG*
MW$)_!U%SV4BVKZ*H%*5O6Z*,"S=O?J5QS)O<_^(QWXQF,()6N"D;]H\$3M6!
M6-V44 ]L=![U2/+(W=_1^&9\]\V,EX^NZ/+PE7QF(^Q^AP<=-B3-M^0W]W!G
M1H;4\R#?H$"%F=&9CK-,DL/?^T43;Y<MOIF_]B(44&7^_U4'&OK_O@/M;X_J
M'"YC@QZ_-3^LS1('-W<J<>-P^#KD(.6-\#+2Y*K0+(8?71485\!+$"-'0D!N
M'&Y-2J$*P3S8N61E#"G;IB&2'BE=\/;.X.6L&KW2\_T9KZH8'WO\6HB%3O+8
MD, +6^RDG?FYV-IC<=OQ+><1?RF9KJ8[YD24KUY7IMGJ]8P'8OH'6DV)?>9H
M1R["?D?.6?4+L/TV<V7M'[G^3'>!G)#Q9-L5GG;W_3?=\>?2K])A8/JL[-4J
MCG[Y+,57_H^</]T%_(7"_J=QIP<#_ZGU[RD^.089;:N? BC_*MK-3X:> J#J
M?T)Y)M3_,L(=1"RX5KP#'6[(J2Y%L$W/*35,$M&/K^LZ_J)&8U9-F[:S7N1K
M,]Z&Q/ ;DXY+#<M^SP)&=\%1(7?6W'$>/K@+8BU-L=X<=]+=^H7S)13M;C?(
MOD"E)EY%.]KZ8A%)+08+ ^$AUX9W<P+!G[.-1VK1W"ML8,Q,OPBWDW5INZU&
MIO@B\ZJ*E-WQ*_.>.68_3I+]PAR5S0J/<M"(PA6X<8F==F 1F!XYZ\!W7=BB
M" C!BFK<[=Q('@I5?UWP__\#%<H\38&4_FR&2[F.]0F+:6,W!PWDJML /OIJ
M$? ]BBJ:*L<&OO3G')+GGQJ(SA7.VKRH+J7T!1_7=72O2B3VJK2/U(*S#P^3
M6' #\CYI'!^H2=K##UO@E6+Z<:Y-^?'WQCBBWYND2$:;1HM$:L^'L=P^A\PD
M^Q^IPCWPNI%PB7<DRAKM ++!@=@\5@AFHSY)X:4R;=G9HK4K+T1?,IA/\_!G
MW1RXM=Q -XIFKD.RDE*_'(84XI!,+.?<,P0=C J.FU2&G]+$B]"ZMID]>7%A
MX^O9Z-YN(V,;5 >2QPZV]@434E=*@C["I^T-O*EQ;6K/;ZSW2RZ\5"]WU6RR
MT4+@QJ=<N=A5U[_.\S\'1/U3B'>HFM6_!9TMU1"K_^(9ZCT%..364!;&L'F:
M>=G)/P9  "3^%J*GSHSX6[_DL?'=XK_N4X&_2PD>:=I;^4LD'J4SQA<++8<3
MB)7@S\%\,)J]760?"Z:0N#\2(@ZCZP:=KX-&4DAPO)N'7WI@ZBG 4VIN\GU]
MDVYR0,5YY,YM\TN$'YIJI&I_^_MO7^>N3&VJQUUJ&^]V@/QXZ?GN"JK,S'S.
M'/EUXQ0P_VIN35WB6!ZY' 0NY ^]=7&-$$C4/JX:6"^#F^E&T%%6+"H"::N[
MGJN;O(P8OJKDN?.Y&M4*.X:0)!8VM'!Y[7-,)-3#GP@L;\.81^M$%G2*>ZTO
MHO<ZZDU9_E:<XYLV"32$E[9Q^_!C&A?-'GCIV;1U6*=)STC7?<67F)JFL4'S
MH7TR,Y&BDA^1O/XWJH90[YP"<*CP4X#+%C=<A\ =,P^*Z"4HX?C!]S!=<\2-
MF<2D$ENYU*O-+7(TS!>JK[=7D=DBD/>/7U'F;(-EWCQ! <H'BJZ DJW+(!M.
M8LGY=Q?TAS<P>K\<(RX'B;W:2@ ]%_F5J%CEGD:HZUE_BN96Z =VYC(.7AX#
MU5E-F1/.=H?+03ZNWE!<BL7MN[Q.20_QF3C[4>\6%^:D+P#-(--ZR4UYH!T4
M+H7-8ZS/%*7&47VT56?2RRP09K#(8^_G\)!VPI0Q"OF^<J5>?7:ERKIG5A%Z
M9H753A=[[-LY/.!5/SCQFSLLJ(_+>7HJDXV5PN"=;-)X^P :RED2/87')7!Q
M\1>;_L1/8[@6U%A&1PK,TT# #8U)J*W,CPL86K1U9 0Z=Z #?NJMJ?.138;5
MKT .W]:;/8M,+84H59:L6NE4GHO<_#8OK,>N;>9TJ3!%R4S'R<E+4YYJX)^S
MBO_9V/PUA09Q;>_XD?DV\B]_ 4>5ZGS0[*K>/!U0:O>0:XW#2 45->'1+4^I
M"E6T:GNX7WR!N;;* [GD!G;.4(;'@N7JK\<>M(7ORM?51V@7BRZ6@8!HSR0,
MJAU1NP83)3G<'Y,$59_=PB#JL)%J)X%_@FDDE@4?NMQ<5=Y)LCE.IB EZ"Q9
ME*2$98D*G.4GF%7C^(-<(A[J? KS5DV=,1"%L,J5U[!=JU+\A:)6=5G<PJS-
M>Y.H"'TV^,46.[LH[P0#W8.:N%N6]272&T<H2^&^G/Y%:!NCQ"1E>V2BJ1!8
M>_BC1L)2)63IMSKGE[J=@N^^J\SJ]SSCRX.N9C+SVEZLG/!R7UQYA-Q#S5 H
M#3+YR%F.(5TR3'IKLF<VL:E^JV1VXU=(]=7I_*$AD_&1O.B(/S]3WI^#6^ 1
M"%:#4XJN-:(B2QO%H%DQA\YCTI0]Y[GN%ZR\\C;3< ;[1LBK*R:2*W ^7NI9
MX'K4$= 5<:8%4@X;)&L[(' S#XW<K\HGG#'GNY_G.:0K(GI5HE<^"@XYF@2*
M>M?YVB 3JD .3J3J*M<34;QSC'3U<=D8!ATM+<^;;1AEG(R2-^=I5BUZ7;.3
MWB85IOFU:IQH74>R#"8P&(^%L)%YH8PDI]I>(2 K4]@*WNU./QNK52<IW34;
MXBL]^L">^FVX!O#AH'90:S:A66^D5:8/_VN%;R_Q4[TY#WX6;"'/;6ZL*2K[
MS3XYT;'#1O>K;8EX[A7JH2M(("G\R(#D@AV/]D^XL64X[J\23#O+CV9UR[*-
MSAJ^$_G@KEH?E&F?ZE7TZ.3#I<=4M*D]Z-KEB%;@6E9E0G=>E1LQZV*%4A.Q
MLG"2(4Z-CU[3,06['RGR^ 8;7_,U^S=GA5ZQV/^SU38B,"S4)\\SN0WKA.N,
MPZTKIBW4*S"(R$KN)3W)M+#LJ.G?S08"U\)LOWJ43=Q<KB _+(8M+"RW0UE_
MHV)*70^1H2V:SR'^@K?[.#.R&$0>;]\X-[^MS <@'OX;I[Y&63*-<SMW3@&;
M%*Y<SW5@#B[+P]ML'10@]O\D[)PGE^>?09N"YB-!.]:@37K*3._]M8T6\* R
M;Y^&TN80</SH#[ 1'$[.4VB ^ L"]9H]A>ARCQZBCBBVO+>)+$.Q&0[W*#;#
MHGP[];_2JO/+*:!E= ^1>:C+AOA:2'7"16E:.$PA*\2!_O8_QDSI.-^>%*C4
M;NM[PET[]A'&+LN9]3(C@UT3V'?M3??OB5L.0AI<]RU>7?>-)4%/>)%M0"#/
M-Y(W?MF(Y(2EAYT"7@YW\Z4MN/'0'Z])*51I O!W,BYKTJE;(IM:51'MZ"2L
M;K1TR)4.>^]Y:XOT99,DD^@^^G.KO:\!Z1Y8Q5*:]#9 *EA("W'$-0/Q[65I
M+X<H+&:I/(?2Y]%/B]7!MR7DP2YU3DS"'W4/3N:G=F[\<J1>VPI%GZ^5"0/3
MP]7F\YA6E9Y5)12+EC/M[:[)#\M]W_[Z?14 4D$#'C,RC_[V7P8!_!K\H"^S
MF'*0H6BL!:8$(PAD"$K6>YI<)>HT[7!92^_"W6_T&,=K^D)9NVX "A;CN#]7
MP5PZE'A.!/%;Y,M\KY_*/A[O=6X.FMZ0" \%K-/O<BTS'.D'U\Q#.] "$S"/
MS3JT(#]#,+!C:5<XN[PT_IUHP^1VD7=1U0_6G.JW5V]R4FW^4T1EK3H'V;B)
ML#<7*^\!U08SD6HZE#XX?5CY:1?\B5'_O"'CSX'%;L>$P6X&X>M._M=D?R#^
M+WK+C=S(;126^AY.H40O$=U9YIW'ZI*6[LWR&T9+1ZCD;GC)P=O4I=L17M%<
M(?TI!OK@$O+A. .A!NL4U8V,:!7%FQ6<&+8BW9X8Q,L%<5QE89PR?5W?RP7T
MG.?W9*$9EQ9+0KW'CI=\V/C5&/_I^U-9!H^\PCGRL3%IX4B8S'(*B#@F#-S&
M+WX/<8[PO%]< 9\X!6C%9/AX_9YK"4@4>#?=ZDEF?8_V-@W(?W#C+!Q]=.:D
MOREJ_0C?>@)EGSR.ZE8^'L]&>"Q)YKE$"J_0J!0F+X0PIFS: .<V;DU(K%[>
MK;A^$V%_?]NJ9@CW=- 9-KX^L]*AO3Q#GIM_M6KUQW$O]+]%2;2(+RECK\/O
M8U'QK0Q)48=*,3U)>Y6^CX:M[WYN;!XI";/5F)'?\KA80\,68V_R8]ZQBME]
M168RB1A*JB,8]/ \ R:VTL_ %7Y6^J$:4"/%0=]4^R3U/@+P^;RZ ?.G@#[U
MW-20GT.P;U ,-38AK^.*WW,6@1QQ\UQ;<&?"I>$I TO)3F(EIP.\:EBA-MS]
MG=&5MZ^^2_P\N:!)> ]BO1\B8D=B7KYS)'?.O)T8^'$Z+F&EMCK7W#8;_CU4
M+J=E09YJ-6T)7,O2Q03&@CJ(HWXL#*NMDF.;GH75-77#?E/9O\)T&4,&?=*_
M;D>+G+>,_2"Z8=QW?A=SA7K!'S_]#/RBA0&WP6]$"(RIJ@4"D]A)30N/\/U[
MD86E!FJOB34S'4Z25T6*;B]=C&&OGYC'-&<R^><Q[1I%MTH3ECN1@K#;AQU?
MK&2B]ZR=:J.Z[;B:<Y>(#.X7+O%(T&$V1%%FK^X!D@UNE E<.9J[;ZPA^%])
M_/U/(A+@A:> LXS'>=(GBO!+<:8_GSJ/P,VQ,5:K/\8F#?I\/8_,<)RV\]SM
M1>&++F(7H^4N/T.OC^+-QN=9OLQ0MQN?LWX0*0-ZV/3RC+2,Z,'[X"^L3>';
ME^P;=)+#]]U'^6*[3&)+5RLQU;_[@'8PO?GL?>$I,&@%G0W4OBSU-.C+'R?E
M4M0&Q1(PN&.W.J"\<!X@RRZ4(PFX9K7TX7U]VG/?P ]&-$TOFB"S&!7G<R+L
M[<4Y;;TV N-#X!K@!A7!'9>1*+T+N@CG:"*YO[-:@7I#/]S=>1V4;I'\F JK
M<2-Q@X+]Z<%J8L?OB@BOYVKI.OA!D0]^$P5O*=]'JC:A8_BT2NK3/UG&;%A=
MZ3ZP?>\.H1V_G6M\Z](;\W?DZ^$+]T*$WI)U/N,O_H@A.K,B(]:W[!MY^(<A
M#JI5S8H'F0 7E:!NBO:56$+RP+!2Z*?@<[:G@':5!88$)4,\\4.!S:I9*\?(
M^T\&Y=F5M[!GL$*RKR487WZ]4+"N\L9\J/8!7<\I@&/*"G__PY$.# 8S H_[
MLT2/#?9A,^7[KSTO=V]T'"KXZ"J6P]H#7>QE)LK=8)':/^/ESF_U<V_KY3.Z
M[CEJ(VS.\\XL9$*M^TU5%?_B%=^9*?!]/U?Y\5CWEUH76WL]]JLS7P7Y>/)^
M0=:[YK-D6$(1+N@X8A:QIF!M]M(@5)7Z/2E$HI]:KW'DUU%P_#BCO>,+WM0?
MUJ],IVDN7^ 6,)<[DB%?(>BV@_C@7$.JEKB+!@]'C3HJ_=\/R8C46,AG&FY&
M;VO1AW$&\*:Z!R6)RR84,2ZOQVXCV?[B3%/]LRX[YPYM\W_2E0W^+4[^P)RR
MZ'Z< K+$3P'>Z../R&]-?_$'_ >O 8#K\,,I@$:6THS"1;V,CM'_UNSOW 8_
MZ5:+.4T>T.$&R)SB)T;4.+JQ#HI5D"K?@Q)=*/+4GP0^!3SISJ08_&KS1?'_
M0J,8BIH**E\]!<CM)@J? I)UJ,D2IP!]W??&VEP;>=E_V*N@UM%#&%TG@KV5
M==KUA+.V>D2A8<]6PB1VP*3ANO4T@S5)VDK)JS*TC^TB$]R\-&0PCV]/!G,-
M&LTGTQ8-!_MCCZ_M?!DVS!\(\G46X_'NE>Y+=:6NA7+HW':$]_>'9)KW &G'
M%R)V0V0;28XGU#_)@).K8QR&0RV67(NC>RT?@F_8LC]V[81<_IIKFH!*8Z=J
MO@"@_@U]$:)(4.H$1SP3CVX!8RWA7#B) ="&%>?W=>*4>(I\K[_903+;@?'^
M*8!OEV^)3--Z+:[=3&+!LO9Y$D>2W(:/JZS!Q>3CA:?;8V8N0+'OO_*R VZV
M5:6$WLJ+YNLN*2#=/US0Q\^< F*1F?#:8?G)C7>9^]X-"IW5.F>6Q:69Z0"Y
M$DM&9\DJI#B7(S4X5WTCGKFPA%2#=7Y78B0=YUMJH>(VJ.LD5=PS692(7:!S
MZOM$;Z7ZIDU%LS\XG )$B_/(%R@0FRID 2T(P_1TSC)G@S^C;%6TA^'&@>^G
M.R!G:[TE9BXJKS@$7>R,YZS-Y@P])XEK1OS/78!_JHW]S3EUX@YR!QXH0^/S
MB+?60(>V"D&FSY#_(C/Q#+I8YC]V#.[W^*>\C5 UJY06%$YF0WP>&&%W#<P,
MBWHP*CQF^-KJ!<50,.D:3]*D& AX]GO0Q#9GT6LP:AZP7*@*/.%WP.J23P$P
M"O2>"_8]!;SZ33WCBCQ_"HB<(!F? D"S5R@8 K0Y!?Q2WCKA(=O@T=UJX@]&
MR%>?^P=YE,Q>5%^!^DV5T]N_U>9LYI.(7D#L^=YIV_C"?/W93SJ/_]WR,=UY
M0%5#+)C7_9D0J0>;%PMFAJHJJ6Y##GM>%K4T#CM" & %:;^]@)F/C^G9E1YL
MRH:Y]5#8$3MDK%4Q; %;G-&=%/W [DI-XPC9OVSNR[O)MB$1?>53@*M]KBG]
M=G2!\RVGRUH<8/O!?R]U]=\T77__P"&$G<Y9+D(ZJH E/H275(Q?VNGP'1#+
MJX#=->C+4=1Y=7;'9-G(W&.*%I LXL^\<$&L LY"$,MQ7W"55N>SA+N2(L[B
MXE1RC'JL*LE\%]\R"<NG(HF1O(L/\J[$BCFDFSR252!>_+NTES18TLG];.SR
M<4RN&&7L&[2?S?ZQW!6%2-3^;7PAIJ> ?_"!_A%"_U$M:9S]CR[0M;\V^G>U
MM$MU6(QI]3M&U0W$Y-*3M&3B3GC7AB&!39P%'G?'5*Y(WR%Z;#='I/"><TT<
M%[UQ)>F'U%MI]=B5W3+EJ@P($A+XS/.=.]-&Q(C1V:ZZ[T_T%A->F.F8T=QX
MI2<4S^JNG.P3IX]9OL]=ZVH>8:FM+U[FME+5,\_3R1+-=PKH EUP$[Q*T'EW
M_*%J[@ !:=XNC OY.B9_(&)J_%);@&I8S7W#:((.M]R=%SO')@\ZG\0]K87?
M:A^3S9YP&);2.%*]*X*JXPC.25R^I#G];4/ E^MQ7];!0V(B22X0S[) %ZUZ
MR:M&(:VE-2#;]_H33\E??;>/O@D%4/_R*71-N04XJCLL/*(CGZ502R!>SBA8
MY^L4J:23W]_0J#_.<3 2/#U5_WMPO.^V'/_RTR1%9B;X+'.:>32DOK+Q2)S=
MX;K7-TB35]RROI9V0?V*WZ>CS-UB3F/P@Q#1/[/CD\?:HE]%TNVH_/!;G;N!
M$/']!C+GO>5,%]3GY\[G=SMZNM[=;)E*OCLN +)A, )_'\@%"W_8,(YP!=*2
M2FQ;4T[VM>J,6*WZ13>?7=/DC0]5+,-^/<])'2JQRQX+( Q,]IB->K9(^RWA
MT?%^4&8+)-E@SRB:+Z9AK(X[2#3P1O?W[0+I>9[^QZ2VB7<ZP8G_YGG_?]DC
M^W<=_YU+]N]QLPWAFG2@[/%';%$6I$%=[*)[V7$!Z-=*W9_W&QU+CTFD57*W
M<6V JEG(82>2E/Z6T(=.0^5=Y1C$$^#!6;(EI;=^Q&Y?L4EZ6["$-N>C_TZY
MF;^0A_]24MYX^5^1C8(8"%,*>/RE2@X=!4$XX/=(F03AA05H9Z7X75)J!<E7
M9[#.P%I"@DFYPR!%7F=HW?-">D--NHZ800R+3#PK & ^I8 ')Z)_8=5O4+[O
MB],IX+V:=-8T]0D'.O84L&O98OSG%(FBU])&$.V!!/!)G%(L"&_^[A2PW50V
M:.Y(-XS^E!&OL$4AJ<,*8 ZWH;6FKZ,*<5<5Z+&1O&(&'B:KL\)]YT4?1^,T
M DIIXA?$/D>VB!,IU"@UF#*?U>&=B$,X&AE0T?9/57/_%ZLF_1]ST!05%X2J
M\A!#C]/((,(4CJ4#R;YJAL_ ;QQXZ"CJG0*&*\+D8VA>%" 4M-N[MF49%ON\
MDS(CGC?A92=,N->5AX[=.#FM4ZQJ@G#73%]"OIG'>Z9L!'KO&FM;AOY3>N%_
MI7;<O]<JV+'\%X>XY:.(?S3Z *Y_%OPG[O^JFL \J%:7G*.(^K.T8OXXTKI\
MZD9#!H';?I@_[Q<_R7#G^C86]_@\,6\BZD03P8U8]P4?WU@QQ8W^XZ[X8/!8
M/:T@]MI_6D+V?_;@!Q*4K#)B6^7@BB1_YL8R&$)K]*F_AXM)MG;S<Y7R9 C1
M O?"Y9[R5?=/&Q_#X'6\7X1V\LY1[+ [D)X4LM"A+C>RM\7FC@E 5T&XE;CY
MN#8KGP>[V/L+A,#[G&C>.!IDN\Y,7'&^M6KX#-FY]3+@%,"&E&<R8X(^PJ-B
MY'F=4@W'Y1%" ^>_98M%%Q%Z.;I7>:Y]#=(6"J.J!$6"F':1$79L*/Q)ZN71
M$0/Y_4 >U#:]-%3:.:TX-^@M@'=6U_DFP#<4  "PO&GE.!GV)2D1'4@2)23S
MMEQQ@EV%/)-8]\Z&(.]XY5./)X9*4E[2]L/2--\<$V^.]YHS+4M0?^2N"C_A
M6\"Q'+.#R:\)B%/ C;T]6^>U4P &//$LBBA4ISPP^>N(9VH_.&\  T?+0?MK
M N10;UTXJ;;',H^<87U6+S;EMR(?@*V+AJWEZW^2ZK79NT2T)1V1D7J,*2*%
M,J9.C[TTN=#S<Y@IVV;";0M8#38I6CZ!V^!6"5]5%):BU]SL;%9$[[[2YVRZ
M7,,BZY@67H57C60*Z\LS)UUZ-T-"8!=; @\O[T?52?0=:YE^'I:IFF]VE?;<
M<FG.,;$(T8W[GD.NZ7@ZV4 [8Q=.84&G "8IK,PA-5GC%-#AC0.>:"+;9$B.
M6Q0@V]4Y$4)@98)/ =WEAP^KZ!;HNI%T9 ;\--]R_!YO[11#S$D?M::3VK"^
MK([7BR<Z(I?XT]L)O?DLRXDRDWDX,J;RQYL\>K(G)JV6S:;?.5>@14Z;,T&X
M1T0\(\W<U>E\Y^,WTRQ-WB#RC<#N4\"A"((5A,]H/04LF![)8N>FLHE^J=U6
M)0ET\7O6MNYF0W['TON&C3^WWEI)U<P8\B5?;*82@RXR:GUZ]0'5"/T 5\))
MJ73-7AS:FQ$+:!C:4]%#>HB[SLJ)WA#R>U)%+6WZH@.@$P3X29='^5 #F,%)
MZ"F \L)I6!2% [O_RN."A:V9D+X0Y&SJ\="D7T-["4_&5KL1)$V%=\MWLDPC
MFA6'(8W>DNQ5%ZBWE]_1G$0::P#?*F?$1\9Y9O!%1:IZVWON:#W]- ,3MTBP
MLG2T*(CGK@/4?/T=^]DR4Z-7R(PG05T2';ZP/=P6HCZJ< EZ>0U"@!D]0*5)
M.0@9>,W"99.N,@@Y\P*:EGG[@XL)4Q9@WJ \9E40#28J\7$PL/.CUG8/%"*@
MG&5PMK^CD0IK6?&#5"AF]N#VAN1%^%;W'*!5F/R0</FUH 1Z:.X1_C (XQ*W
MOH[ F59@>B6ATIEE$(0;^W5V3<;0HDC%"?IK@2+F<F>BUJ,(P]KX\38UOCES
M_%;24\_-.B;KAWKF;<]&OVY+UZF4O[F@?[:P>ZH@2_&;"DMV97"0C7@'. K5
MRL)77URU9H@SXEQ[*(I)+*H_!3B'TM@F:T%IE[??:?_@K)&57O_>E>#//2LT
MM.7?MR$\9UR79S:\$&O=?&')+&OF\MRB?#3S(U"&V)"N"O]%)CT^O[^O!,0Y
M%'2].4VJSL##N+=MPV10 WB!K$!PB?6 2^!%<#ES<7N5Y@](,15:[I6_Q\T3
MQ+*$/J,:TJ]LS(L\%9LIC*;58+C6NCU58]M:1T!J?R;MS<^Q=?VI ,Y2"#GA
M&Y<_RLXCF3>1MI<;FH8<(Q2SI7I\,#]\J*A=1-D;U^# (^G?=BP$[HA ;C32
MC8\N2GI3I@6$=>\54@Y(5>T3KNFIYTHC5@Q5/+$4T!%5T5@0'/V76ZE,"5QG
M]$)^*H[A>;,1_Y0-^+M'Q4(V=C^:K<J)K>7]S2_5?1\3KP)=>Z?X!6,-GU^&
M[7>QG"=1M@!NOR,XI'N:%-[^3#U_>!IB]DD3ZNO@1\P(*-B!OZ1_MXUT9#EW
M;;[H?L1'0L-9- D"I4?\!.+H3OB36"F6GPF('YIE/P7D@SI9R$J"ERABCF*Y
MKE!O(T_.5SO@@!BC$RX$62*/"JY!X"'*$$NF**^,'I."YZFLAY@?'CV:R;MF
MU/S68YF7EWPPBG9&Q!TRIS[_L$K9S= 22+W7Y_[1Q;DH&>'(<\D&JHD;%\Z7
MY:=TS@/TD2MNK4\H%,T-&=;D#AO  I/@VN6N@ZM\"F,YY6#+E4#F]!AO@$FY
M<.?"=]G^SQ8B^9A 5J\B:H+X":_* N*8#1T-)!G,(0AE1Z> $WHCRE G:TZX
MH\B24,I0\5O$<2)X D09J73+EOA&+O0PSGPJ21'T.7YSX>;-HVSLW$8:/@Z'
MBJO=8B!9=\FY/=M\M\3O'C"(G#>?Y->;:TD_J_E21_7CC^NWA,Q1#^A>_PLD
M<*4(X71\QC'5'^QK(%"(E=!X^9_:K0Y'YC!JDT]9Q!]SW>,!7GWR[#::^%,
M&#:DY^BZI&/O$-HKK'Q=M5R$.HS)6Y#A^#-<9 '(9UC 0DW6K:Y)Z3DRNC\*
M_C*^S^:F&!%6V6FLR9D:9-3 Y9.M)W+9J(_"&YBR<8+56#5H5QZ#](8_,NI9
MY(?@2D@('\&I5L*WZO)B9X92'--W;?5>MG1+>%J#ONBT=?^E\S2#)/<C4;<0
MWF%T=3'A'IYT_M#=O3GG_&&;>L//]G)BL/2RL74FVX;]N>J7";2/;FQ=>M-
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M]?234!6W'H)97IG;K""Z9M ?O'[1S#76VDUGTC/DQW'>MR=<A-^&3\U5%EB
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M]Y%3 "2)$7Z;X)PTWPR,.B268X?%8Z12K5L'LV8\A8>MKJ;K\_PXJZ=[O1K
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M7KDL>0KH#*1.W_1Y/MXU*SR.?H)@=95;R67'/U5&Q9 +Y(]D:$E6)W.61QK
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M9[=%+@FZR;/?;K39V,9[O]#@0S/2Q5.X[B 8GTUJ;L<$=C2VJ&$;=^,0+*>
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M:<=&(06IN[1C=!52 ^Y$J(%:F/*?;A%MD97';F-*CXZ$TAR*OY-&OM4H;BR
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MKRX")S "[6*>JAK=S@YS<1[SL;E":#+;X.4YSA%MG?>K(>B6XC);_$-K![O
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MIYWKTG??*E>AWD='8+=/>K( -DJ0K5%=0G01-BN!+%E 6P&;5(LY1>=2VE-
M=#'R1"/A"AW&*,6]?"."=FULY4T-]LK[V"_E($89",703]FK,+A64:13D-Z6
ME/^W7W ZE 7$YS./E?WS3Q;P%,("A(VDV/%XR":!!1B'@NF'+,GO8[KM;X\E
M".F^?#-2U=F;_M9MCW<R%=4EC!!F]X;'$D*28W>FS)!&T2,=2"B%^]F2@J++
M-92@5R>4, ,X]6A5&<FE2>K3/%#>F0+G%[7_^'@^W36&]+_EMXQ2.,.QLRE'
M%VJ^SK9EI(M=PRNZ#;'E ;)DS?Q%+6>AJ =C 7SF_2_OQI]E=&JK;QQ/BA23
MY=R91MRD>2)N4NV(@[ROU@R5[E!%^R#\^K:>OMXECDM_1 5P7A$Z7P.W\A+7
M3:\4?K[1'NRB U8$X+!5%E")L"&A^U <GM!C+>;DF([ O<J\5$_!%=P+^^C7
MI5^QYVH_!MP^\^T L!LG]R8 ,Y9%QU+=R6_9^@6:C.9=0RK0 T@B93YXQA-)
M\TNDV0C_5F/HK;$QX89@UX\-1D_-CW:<F$_DG4?F_8/D.:4TG]][<>Y;<,%F
M^M?96EBOMLN;,*^K9SA__:V&N8F<K>5F1&B &7*8XI7_?&@1*$[T&.%6X"EN
MOZ\C5N+Q'X3QP8(H604GX?B<_H_NW&/6_RH1K?UH)F:KZ*81W]3&M=0K2<G!
M'26>Z:@RU!\+  Y=#=BD:T]R,ZXU89@O#4);X::K02Q =M:1!51EWF8!(T68
MH,)V>:UX>_G_,/'AU9_W_R*Y?W'@V,8,&R^VT#AY%*&'NL'L$ 7O<92BJP?I
MV9:=:)IP[2#C5'(E<ABZ>:&%_8_N)J0P@''(#W>F13[>DA&/<V>F]5GF2>6;
M"-WZGZV^>8,P80%R9+P*[<@CU/;[E<7EW;YNZ"9*ZBC[#J2)+."J?;AA\G][
MF><L %980Y**(LWV'/UAX3I'@TAZ_F&J-(WX9'\-U32+7DDY\PC>H'7L^,+C
M8SH]8<%0"1;088&XDRM*=9H3&J>;E\!A'?:9B0]7$>:GV;HJ6"MW^.N(M/#^
MYUJ/%-2N#W?TGN'\#8L)09;.'F4>03QT:+6RF$1*TRVR!LU(M:55=BK1^ZHW
M1*;@#SCNG"?^MET. D^(TQ>H,GC4]V10@N&11A(D::,.)*:<S^.IM>6EF[#;
MH-=F9'/I\)-0;>$]U?_UOL'*"#85I%,8>9!5P3P6L&009@K]%\>,N(1[$-?)
MO9@YG],C&Z8DY'NB_&_TEU +S6'G4[CK6RW):L!>JK-M,7+,^>S(^MD33=23
MA$\/VM"K$\ON#;OS. ?8S+8-) H(.VH"=\LDTWH;<.]SRMD(3+_MNG_T["TG
M,]]'MX3EN#[Q?1)>5[C^,W4 T/U?D7O5_C\%S^7SPI=]W'IGA+.\^^%OW;Y7
MZY<*9Y]OUUE9LX,*;#M=[$8>'M\>4+%.-VEK#"^P)2LOQ*2F<5>J0<2I*GWB
MEI%K+, -&K,7%+^CR##O=MNZ,4*'/)B,5@T*D]GU]M/Y1% 3[@_\;+#(N2U?
MYW!^_<B/=;Q#C-@=>R/)F _?/*7'*F 9>*7*^Q\]GJ0=?*/5NQ"9')/\<G>G
M#'[]#Q[;FP*BUMB.U<(D++UA]]Y>JL<]2T'Y//9QC+MT=TW!4L>@[.*<!E.:
MA"PI<Z8KC2HAS D&WD9U8P'->BN;,MK1A+O?NM/K=I$&K:7E%H/Y*!?L[NF]
M!4;BOPT[Q!+M\$^O3!37AMM$A735.+I;_'53?=2?@EMA)9MOFY]"349"7[#]
MY(E_Z='E1=?_O3LN5.>Z90:$OCF\F02BY%*#,+/PPAD^Y'DL7MQ.%IN!%S]/
M__@SOTGU6 !OP9'&!2&.,IH)ZO-A\BPC0AFRS6G- ES1NUHI41"*XM^:A))/
MF)K4.CPF$5T#3@E@ ;S.FK\B//\$5@>GOIK1L3EG)^;PW,CUO&'=&+)?!K8Z
M2BI&C544HI;.^N]Q+&N\%@*_AQ?%U0VFB#"EQV2&]%7P$A5BKM(CH0,7K%\2
M/W>X<D8FWN*<DM=&:FY=3B&K4R(G-2M@UV(ZD+QVVZ]=HI_@"CZ>(O*K]N7;
MEB&4Q@QEO'B*T>#%/>475NYL'JU:=[Z_.XU%KK_:]=W1X%B$O%?ZKSY]"O<C
MKI$IV:2&O[MLM3B4U6LPQ'L=?MRV_(H7^,!&$L_8]C_2X;I9N_W_ )$C?T%D
MX2^(?,!@Y_)R^499 )Y7;;$IO[+U'G]1(/F$ZTC%K\PO20M[V.,V;8T:0>"&
MABAQ>>%.JO2\9$4JND[[>)@'YY+N?Y=FV=5F'N:=;&J(0HK 333-_/G /3,Z
M'X9V+.Z/WW!T,%8P[U8[9VC5Z,@MJ7,\PGCO2]MUMH>.@X_>(F&Z8/L],YBG
MI;B']4T)_08R=N0+I:]K^TW-Q IBT3L^+\ MQW <\^X:'"18.^P@W+L3(M1V
M<!H')SJ/(T^9DOF)%\C@I^L;6:;UT8IQ&7H5S<:WDXY(TZJ/9?1.ERONH EO
M6(" J&5=/6F_KI"H7PT#8S.)LY.N3N2(-H>'>_Y,>]Q,Y-R?!N?>&D;(D48I
M3HR"-F%X&3ZS=Y9JN8,YZGWH/349),#VW?GL$:K_T*U9^TSIO>]"@ND9<L#<
M.4BAKG:L_^#1)?F2Q:RHPIJBS\U?FC[DG(Z_4! A//;R_(GD%D$C\#E/+:Q
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M,ULU*6E3_*@!^=0N<[)%450Y8;*V_YZG=W"$_?EVA0.'.DX<X= /]S9OGSU
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M0"%.W-NS2$)1-OJ7,^Z;#9>U>K^@ ATL'QH/;+)5_"!%FUI6B @<8<I\]Z"
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M$SFU,Y_=@5URQ_)@YZ[AH5M4P/8)DMH$?3H+,'6H)W;%Q_*D+:05N2Z7!LS
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M^'UY#P4>6<@A,89O2.&EK)1L1[EX\J,_[BL==W7BTOHX"U-$7*6'DE$1Q/)
M7,LKI!-1;&I-LVK7K8.1GS_-^28&8UTJ6V>^4.]3GY1.O+S?\2D=7* OQE1K
MI'BU@B/M#M:Z:14CKA?9$ G6W\HEG@G'--2;R!U+/[\HF" JQ7&1;(++GE\O
MOPEIAD4D(_=6/'KMB1$EHW>J)Q9M4Q8Q\!):@RHAVI;NO."?,>'2*VQ,WSX,
M.PF/X&0@X.< 4#FAU\U^J1XH =.BA[/-9YN1-*GO6T&D2UR?L;_!6P3Y+^[>
M& =X! O@#>1?B"[Q.T<>>0%:[L5,Q;6 &2)J1-:16.SKF2U )ZYKQOWB<RS
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MF.6'3SN^NGG#JG6@U]QC^^6/3_Q?YCTM.S=\&O=&$/^"?I4B94$Q;B<*T+D
M_V9#7DG3H82.ZE[7'=1(I@R=45,QS\.8ZG#;^_@7%?,>NF,YDACMSG2AHC^@
MHD>/]!3I'X%WMT)X=,U)!7D)7W'7^F4I/]XMAJI*9T?D[K><2#BY#S2GNLQ_
M4REN#!7\L#JNL7L,%HD20OB169<S*NMK*+!HY<6W]B.ACPIKB!WGLKYW,CYQ
M!:8G/N%8BRDNLM#H&6X2;]LN)Q6KOH\G_1;'W XX;MY<OR"01.2%NYE5UZ2
M]\*?=+5<=MG[O.K.J3O?C0WEFS8&2Z=I#N:EU556=][>BKDM\/V<8SPM^,27
M!W>T?J3E%@N/Q/9Q4$7;&G848UVSJRF.DK)XC.N#(T4"[^KY#D^:B924G./T
MM'S<K5-Z@[@3P5G$A-7U59A*7&W5!Z%:K/FJ8AZ]LVFV3S!]4?.B+,,^[*;,
M?2A&SVW1MH&[_:&ST#<A[NSQ Y*H\P'"<6E0>ST1&!]3N/[K9)^GNFNQ.NNB
M3&,=+O6DJ/FRADX*,Q0P%$G(3R0XD47?!+T,PK%QQE"^U6Z&F!^,=>PA\]Y?
M/U>OZ4YVR8Q\SK-QE;T+F!NRQ906=N,"="7A[GI)XPO@8. //LTBC@.*OCZ.
M)9T2#,TX?]Y:;IO^BZ(3>=-&YKEN$T3",.U+']()RS_EKSP&II_S[;P]8)+>
M-WS#QHMH1$^"*'^*;[P.M_'^H'^':T3][?GX',D'.E+H7:'%,47YEV)^T"Q-
METO75^/H0TK0F7SD@C76]06S!G>7"4!F: 62E XE.0-0MKP)VF7,E$9]0[IL
M@O+0%>N2GMWT/:PTQB/+&?.Y1,:=N]!*V8C*82&**%.J[DZ<VP'\S)D;-JC1
M>K(< BVCL?Y2QJ/EX(,;4+AE3/) 7J<<S&(%>IK\IEIX+G]@8LU^>_9"!3((
M*S5C#6@C_/)!= 32"RS$QN/A*;AF[$Z$*F)T;TUIK(>Q76^:W.K.E]GQCD^.
M.GI])PES^YE]0S80&D?1P6P-Q$TJN&F1+M>ZD1?.ALP2!3P]]<5:W#<NAGQY
M7]#W.GI. _5"B!=?",A&J',$PHNRAWVTPGP(?S/9KN&%4L8XGUO;P%K=F^$N
MZ?@)-T2P3T)!Q8'[JIV!RU0N4E<X]4Q+GN$@J29AQ,DFXDYY7=( F>#4]<D^
M1<8R9E!V=[:?5,;A1M?WK&K](W;$80/9N5*J..&DTPW" R&/: $.!T9C")H$
MNW6)J]N#H8DX7>[@"CBB(.W*7NW M*6."Y@ZWBFE["KBBJQL7\H*!)A-.WS-
M0Q61 6[(HMF-G]G\7JN+_'=/V(U^?SI2:JKY.:(^=9=XYFY44L.>2)!<MN=+
MR)O4R##;#XXE#W#%H >;H+_E2UWZK54 KBK8JN?R<Z.%O9:A@\>KC"RO9M\$
M?;ZO3WI'+%MDID*;L0QAM:V4JF#H&V+$)FCI\I;:L+=!LP[T=UD:4R'L\[*1
MR#EYOTU05DKM9_=MD7+97%.R__YB !:%_'<-\SO9% 8(F:OZ.S=!S=!Q,WER
M&$I$874DQ3]O.7#XX[B^*;/+9/G0Z9JS/-@[GXYDHR-T=4@ #(K 0R[TJA4B
M*V=2WO996"0Q^G6_Y=R+J'\5*G:'4SI8]9,P T<M)]F&MZ-#TZ0I=MELL\;B
MN[=-8XI&SWX^TZ+1[Z189F@\7+-S.*1)G6+)%+2D>6&W.M2BQ>AI7PC?X?H_
M W<2B%\LOQ7<RODT<N"5_C6S\I>.R JGBP[HMZUC;TIYDYU9JJN8Y A2V.=C
M1H68:?DC(WJ-DPU5%OK+=%E*2<L8NIFX!ZYLAM3FD^DS/M(NAEA_E9QB6_3%
M$A&]6.W-6\\9+(\1FW&%?LS2M>PQ.G;4T#WNT\RUEU:?LT>& [PZXS(3DO*#
MM]H+=>K+,OF^ZLO!K&?R+ <Q\F0WK6B1K98$?J+E=>>>C4S4K&>]U#PP]_(
M9P*H\]XGA@9@5:YXE<-#:.'4@8PL7X92JEN>:_+NQA@?OIK$F6L%*X<;GV8&
MG\1RT 4-Z1ZD5!B8'M0_KS9\?Z%08<E<JKXV(,%$^DZ _QT%JV?2B9V^+RPT
M(W6MLNBJ)LG7!OUT/&0O1NU?\/S!':)W4HVC_._H;EG:235M/JX1+4V520FW
MV@0]O^?V$G)WJSQ[V>XD&0 =,2I)%;C$7^@/0A3^,^SN_#^'W5=^US&LM# T
M (.(V3*(I0Z_7X>MIZ&GPVD> -'#MP(WM]M3-T'9I3U<65N['43!HJ"42W'K
MNF (RQVZ\H2 =0T-4MA*#X7^H.@B5]\#0_#>75(U'T-?7:Q19AL);H(XF;T,
M$]&-B@V>P!/*JZXK0ANK2;@FO>9(N=R#OTJ+4_3E-.>YBM#/BBNZP[%[= T=
M/(K.L$(EZ[VEGA4A:IF?<J_<*]^Y!.+D!!\)5(:IP!FT-'HE"2;N)JX?Q]"
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M,RD3J[CP^0MU72A6,KQ _)VN3M0MD-9)/==T_9.#&&\R.H2XDRU/W]\BR3/
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M@W1'/X4(ZUKEP6U:)!6TDQH",3;6R#LC+5A'#RGFTNEWQR-P"=H.Q8^\&A
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MR\\08#K2%=%3^)E1G3JJ:!3R/;\N+#\PUU:]I#?*EB!M*LZU76)N9GV4F_
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M8Z+U%GS=+Z#DS,,??GA2>^"6_7-Y*4'3'JV85!"01D/O)<J]1+:C7$O/><I
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M=!6#?M$U4!'NZ"A(1D@EY/K>N<C1QXNZORZ;TM]]&H\424MWGS%YQ-*<0]Y
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MR ;^+<!Y-W I1A)8^D85HGC*5\]DN.1+U<D"ZHH(A;>EHD_Y]">3*W?(L,J
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M&TL/<+0!G!F+M,8'<*6P6)WXBO,38M=8"LQ"0T8-#KD,/<M]*B((>\9_O-3
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MC7? E,2'5XD6[1_T:EF.I?TF,J+T5:85?34.#O&@?0KH+M $LFC2YR\,JAE
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M   <    8VLP,# Q.#(T,CDS+3(P,C0Q,C,Q7V<W+FIP9^RY=U23W;HO^H8
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M27]T^S?Z=?$OG4&X!_^M[S^:%U0& !J_*;*Y\V]];A1/TY(, +RS_]8G7@H
M<(K>FH?_A1_N/_;R+X_(Q]-=_H] _TG_KQ/^&_0OY\G_V>Z?XA$^]_?K$_XC
M-_<@_Z#P$.%0RKOQ%);[]T;\?[SP/[Z'K)7G-<\0ST#*"FN*E?D$>E'4'>CA
M\Y=7\PG\SY3X?[CLW]'?=DTAC@HRP.DB#[ .<P+0[4& FH,1@#H64T8@_]3;
M!7IKX,_+LT&L_VWW?Q'D?]V5*OO/5ZB/UU_K]*TN"[N'AT3\/?;G60(T  ,
M!S@!/D ($ .D 3E "5 'M !=P  X#U@ EP$[P!EP![R! " $B 300#R0 F0
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M$^IFZE[J<6HL-8Z:3,-,<X)&AD:3QH3&EL:+)I(FA2:?IHJFB::/9I)FE89
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MUDPVY2%Q<I![B19'PER'3F7>4\4G1K=4ZI"(5U]LNP2;VAT>-!NF<_'(FF@
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M2([G4RLF 5_O);UW-SJPZU&=@<+*BVMR\"X#* ;0ETBXAZ].0(O?.0:ZZ]O
M>Z5S.O7%8&/ZLJT\.U9T-J)Z,)"',9/ZXJ@ARCE6*_8CAK'31WH+A;T:Y:SC
MMOF.JZDC)3J@WLTJY-+@K;LOUZ7\/#QR::-KZZ0(TJ!<6911#YGO)4[U;7/.
MXTW\CZF+ ]$AN3%O:=FCQ=EA]^)6V+D=K[H##,!!'ID!A;-Y5RR(PW350?5Q
M^3G8(QE;/*'(-88VQTNPM!@A[\'0?UHY.>>=5,[K2<2L$>$F&-C9,KVU6.H
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M#A/\)I%LY*%%.)EZP:]%B'H$GLKC4+*MWMR\/ZW@.^;QZ$/@KLI%H>O$)F=
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MR;L^_%,!NY.9S\WKO@4!1]^M3G+994>\DVI5@>SNDS@B*>5KQ2(,*63OLX#
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MB.8%TV$C6ZMGCMU-TLB8&$W.NN<H?>O\DHGVXW>W]W\[P)?N07,L1CBV_XI
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M?".>7Z-)4/61.F#L;'=P,TJ2[(DI06 ,+$,,8#4^]D*6-YQZSKRS]+MZ_;E
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MCQS/X'["!!0ZR7ST;E;<,*?\W(@,@?_.7;!\<@Z,9GQG:=]\:M#V^3^0@UK
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MO8CZ]JRVL?;YMJ#$IJ2[[ZKP<A)Y'J/)3\;['F(+H-,Y4\)^L*2LA0ZT9%>
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M>"8PTZAWB,58&J=8+V^X,H&.Y:\LTCYVF G,#J&.QU\G.1+"_<QW?><)+%G
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MW.'A.0#9GS;>&MPM309ULU!5I!=S"PF8;543;C9_*"1*P1)FF"P6!"X8Z!^
MC/A8W 8J.@!1?(*20;V_=8+K[=H"L<B-=@3&5*SK\*(%X_//T=[.)847.Y&F
M77SGM9\VFBNOA00V_B(3]$SZO*#+VQ-L R@/,CR.H4;N5#%M'JGR5VO\[%!%
MS:5,*&9-:'&+O;K&>^SL52YM%IURFR5$+;.5L##U1!3#$KVQT)6&.,;PHL?@
MPPYY.D7U^D4B)K5X#?74/F;:9NY!]4MT!:_<D/7/?5\O7G;$U"'3M9D&IBB6
MT&'DS]Z['?:!J]DD7&7Q.U+$R^E7?AI+V..F8K^2LX60'>&G<D&?H\C<M(U]
MD%87@SWM )14Q#R6QF*C80[6$G4KL6R0.U,8??H ]._\51.&AW :G%IH"?'\
MLI47^?R%=]CYJOC-.9$?Y(F=Z:=CN,$@R4?ZN1N5!2TL!*I>S!!CF)28J/I:
M4S.V%>[<###F;)$9/E1 BT6%,:/%$4PVUKXAC/S90,'9$+$.[0KT]4::<$%0
MB)K]DFG+1-_[)_46?I*GB8=4'[[>B\ENN7!XYJ:N7'3D+JBOF8:)\]$*-B[T
MHKV5.&PNUYCB>&G9F"/&^?I?B(I_$LDT0EI2K@@^BH4[_D"J\X?&#3V_[PY>
MDR*C2%_J]P#3C53PN>YU'XJ&Y R3Z*I.[P7R+('[])@>D>-S;U]8W"'?$X0W
M87U:J6>( 8G;_+<SKM_E'SDQFQ'Q9'+9!9V^ "%U]<QS/*?#8C&G4=DLKZ17
MER5B?1[E8CO'YTG"F:Y#:L79%ZUCT\/!)WPDT2\NM%\$199UGV.(B>!A_!=I
MVQ,48@\-3_M@$NX5Z*=S' [WL(AS#-.Z_Z'A8;U"ZVSF<LA'V,LW^2?; -VR
M>52JE,W$Z@'HVGCME[60IE!<<UWN;K@O)2]<5>HF*GXTZ!FGH<ID^>_W  O$
M)%)8=]I1S&C!"2Q,&B7^E6([)Z7SU;X#2XM9#9T3FO:L+\#>X".HIA<'K=DI
MF)I_'D!W<>%X #.J1C=$" T;;KQWY![<>MSY:B?M71Z'\0M3DN&T@/R0["\/
M%9<X[:^\K%A@=_ !$!3%!%H8 =+8G/Q-;+&-5E- L=!;%-Y>M,@>EQ_S+<R8
M.%,P)^SF77YNIU1EV!U(Z/7C<ACK\B'&']>--3"A9?; X;NE#64 G"#]XW80
M8K!T9D#F)4J*^7J]0:O63_']_MA+R8QBCBV=/[T7_(?2"DF""&IIQ#(EF+-T
MR>9ZK[F@Z?6ZL1J-XKFI@?6%E'E)Z<#[,Y,N+)")0"TN;4?0PU(A!!*2 'XH
MS=V2O>UWV5F#=SFW$UOI0A1+C8PUJPL^D5%T.C2Q]$OF^"+N%< %B9$%S,BO
M<-*D&4< *NHJP8U44U<KQ5]>_;(24*F^^$A?.#!;OEG_)5JC&X:-BL%QF5"B
MN!DWZ6K,^U1G*P'OR9/:/I$ONAK5%#NSG<U5DXMX9#>EE2;.[=C$A29_*YBZ
M:W5L%BTQMM%AQO_")R2JW!N^'=HVK8]P_F!YSZ IT+(CF[_.P,1+[QI[_B]L
MG\?_=HRQ\ZG$JZ !$8N189@TT;ON=Y'5&UKHV<_5YM,V.F1&/7?=O[X1JSJ%
MTV]-AKN?/280!KK4[[.E@S,#PN@:1H#5'@Q(W]@:JA5;SBU+_38K:#12Y9OM
M7.U5HRV1X??&_T+S!G2<]\P1M\1ZYAH(B1(A<_6"XZ*PI<ES7".J'9I1Y2@1
MZ_2J1I>S2E7KST2V(;CPK)XY'J/*3X_L/FR(LN%R:V-@[EU\G_,E]JO4?]IW
MOCS9(5#DQ01WIO7BP'3-@1#MZJKO$TAE)Q?\NXQIPG#YYFQ,WY)LRM"KO7?_
MM+W%/Q*]#5'/B*9.#S?A=(I^ 9\EYY:NIJ6/W]%%R@G?SG8>NY\K4WG514-E
M<6?H<()5LK0\O2!INMM5#>BBN/ 3[=L;G:NY\!AIYKOX2Y_<(R/#_9O,SQ)Z
MBC1B,A(6_2WOQ=%E(1)$\FP^J&-8%7L TK;*HU@XKONA:\+X'@U*^*_$M$NA
M:N.@1QA&^\5:"%$S\CP_K+<<+49!"GW.;G-9V\Z)_%@]PQ=H^-49W^QZ>QI+
M@.NC!TX%2RJ7@D![\ 5#8B(2*KAL [RTC+"\UT$/FE/ -C:-@S<^\BP.>%Y1
MV?2;KMML-]])JC6I5=W/P\B@'E \\'E^SGTC*X^ TGF;\:WJJX;2>G*-CM4:
M2TU0IU?K'V2%]%2#G]"?@&W_>(9+3)LV&:(U)S.\R <@-M2$'DL945XUN"/-
M!L!\AV=,;(*5IKVO#=ZM\F-EZZ;-^@KV\,VLIO0G6P4-R#3L?!I"R$ =HPQL
M6%F= "P]QK>Z.*=1=[^;9E/NWE\C;9IV'+D[)3D:G:YT!!&XK#(6X@)FQ4%(
M4OYYEB,L6*I0/!(,[I1?K+1@F\BT>*_J;S\A$?JPH]PM5]*H*B8H2YV:SU.R
MX B588Y"!-""5"L!%,*8IAN'%BF?OV$LE=\N75^.<-W1_##(DW%"H/>XF,)<
M^^,'_44<7""(]5\YXH ;4OG ]I-57VZ/&I@%DU\\P\4O>E7[/7\R<R$EI_F6
M<IU=8,^=7GX"W.1&#B$1C80EA*+8OQJ]G&2\AR*3U#Q:L9NM,SHF\G[MI?Q?
M0BC14,-_RZT<:=)+!-T"GJT?T(Z*G8JX.50K\CB)Y.S-]7WST%>W1D6A'9VU
M#^$NQ0S"9!^"$R.#&177>"A'VTB D,>A1^FZR=^&7-2W]RPZ-^W7#[?D[U23
MG6O/^)$H*D]Q;IFMJ4*VH'L/]G081G01 C%.A]3\H&CL)-T25_)BQ>E)A$&0
MF6>#$X+HB\:FS];]J!SDL*1'/0>2+ON]GO#C U"C*0M=N09$YH0!$ZH#PX@$
M2TY+MKV0AF^+K]2(Q^J>U5K.T4FD__IQ[V*WI[S-*\6;1YX([-Y"*"^''H#$
M8'>QDULLLM8<Q2BB+E/AX]J5AO9CA&LK\!&U]V]R-*1(-Q2GI,3MK66[E"H?
M@4$<^MN6].L'('&HO"LPUH_1&_M6"UF.L%VQ!J[V7F@;R3%K;LG64\AZWKZ_
M52UGS/T52HGM_IB[NXX+ %3*4-.4[X19%:I&\M8]+GS;!520G^:%L9_\[$(<
M:\AMV3PD2F3QQ93,8V:?"OTA^AD1'LN[_ZM>49\P<I_GY&C$F(T0V!' C2FH
MYGWXX4!A-2/4,B!NW+S)\7#WZ[A?#W???N;NH4US<_6*R.DS/"^E0>7'[NFO
M!GI/DMX7Q&!. O:"V\Y#A'3UN?Y5<V&15--<T^NS,OP?HS6;<)M .I7W ,0.
M7/CN,(;6K$#AF8HI,B.-MR"D4V$AQC%RRA4ITX^3=NP<OCZ$1P-%9&0_D>1F
MEF=.9^0+ 8B%=N(W$G^!ETBBMN-UFKW%@]@]+<O4%$E_,[=EMO4";HSD"H*'
M*;7,%!VI\0_AU;<+S]W=M%;]GFDA9ZE-2#WGD6$N-2AYIZ6[+Q2+9X@ )L_1
M7(#'<Y1@KR6*I)@F,> [.18^)K794>58=]9"_R<06S2(O;WB=PO1(1#F!),;
M0%(^'X#XO2>D5?.NU;L?'RP%7)GK'*U"_8-NB44!O>=.<<F5U]AN^P&3M-4Y
MRA@K-L4]HQ?GB&>7O%@-G/'!B7<T)KFWY$=.V96BK(6,P^P&!_&IYDN:%-T^
MJY3SQ%2,DCEM=0F?&Q8/E4@LS!]R;LB-3/%?^F(]9R&:+O4CMUR6P*5#ZX,&
M/RWC#DTQ+@-=(>2H!]#3]%O#'?KW/+4-);JE(49-0\A MLU<)CE^[_&AH$K?
M:XDU%4;GGH$+R_^"3ZAD 6FUJ+1>*+ASG*%"3@.N8,O%-:63F^E3VG@1:\4I
M=PD.9>&;$FS)]].?3-K=*".DB2( $;Q(6W\>^:EMOPA=R^MP2A$W<T2_O>*H
MF)C==?^9-U:O*P:>W(Z&\OF\U; !RLI,2ABW)KH\[EU5<]IS:J A"; C>,Q0
M."I#8?K#K+DLGOYJ[-+KO&*VF4>'0R=G(7]AF5&(9*@PPW>_5"N\L0 R2$;$
M,7D[#D NSU:VTU$Q=EE6G.XM+58-/WY8'NG_& K-GZ<AR/QQ- @Y/V[!BD^;
MZIEK@)1J0%@N70E[O5E_MWM0=6T8=!@$.@):_YL559;21)A3$+#6]!JRMWDW
M*N7A]J95&5&A+#9$S&VFI.AV:EW6K4<!O3(T,Z$M0[0S58,D1[7/8?F$%,-E
M]#:MFMB+X/G<G&L#V/N$QQ>5.Y%<\AS7.2?6ZE^YN-]QB0N-YK>Z!K;9S\&H
MH41L:',QM$F\ *H^L_>\Y.F+P10(>-8A_)&1;*R@?+JL5D+0T\K!G431P[CH
M6DD M@!.LL^7*>B'"!H$[Y=5NCAB&UT%A\G"N^K9-<M+_L$*A.[^$U>^G!;K
MOL87*?5_VG(1G40I^!EV%*J*M@4&(^@HTL2&F<X2HG6481;L=NO>3[YR2 79
M9".Q[!DCR2R.)6OBN:_$*5,PV+/K&%04\5OA=3JDY[Q98N../.WI(I8:7.&5
MX^WK=#V65/5&4*??S&CUM)LH*-70QVF28;ZGQ; &8L(":5\)^3 @DAH)?"M?
M[Y!SU^;MA-)()GZ!G'TU"VL2O*A9%V..0!O],0.Y<I]Y"%,)K=<QQI3X/,^'
M$P?8'6NIK/2\L$=K.F^ZR$NMI$-X.SH[592:;ZK:8XPOE[S&-?ZO7+3\/1&B
MP5)Q8(;8!/0$PQV(4\RCKG1H%JZ2VN=6ZH#211+1+O^'J9HY;GN;GS4#[EQS
M-+U\IO^TU;S0IG >I=IMVP]+A_5VB:(5Z @"A,/5>S?U>9'WG-!(CN///A9#
MC]7S29LS4LLK\J/JE[,"V"C18GO*7O9SQX#!<L]<8@Q3!@7I$SE_-"?4'J=*
M3YKT0ZH)4Q2>4GFU$C/D?N6"Z4R!;P=O<Z(_T6J00@QOX)-('Q^BIZTYND.C
MT!,NKIA4"J1J)]AV9B^B%%I:LSGO;EI?;+Q4/A X\W: '9?RKR<[_X\"/ICZ
M#U!+ P04    "  ;B&Y:UY"1DZ%G  #^>P  '    &-K,# P,3@R-#(Y,RTR
M,#(T,3(S,5]G."YJ<&?LNWD\E&_?-WZ.P=@G^Q:C$%FS9QTE6]+8E6((V;)D
MG3(,RKZ%HLA2MD1)MI),]J2R1O:M0LB,=9CM-_I>Z_>^K_N^[OMY7J_?/\]A
M#J^/\]@_Z_MSG(/ZE3H+'#IK9&H$@$ @ND.@" "@SH$(GL'! 5J*BGY!"BYN
M_E?<%5S]?151+@&*2@HG% $=."K Q=7'/5CLBKN'EY^NU/H;K)28EYNNE+V:
M^0GS  -W3R^3FX'NUC?/V[C>]''5=)."Z[&SZ*"T4+X!ON[!+F(HWVM^05HH
MW:._9]>BT0>/%8_JZ02Z7=6R.F/TEQZTOW2/_F4O86%A"F$J"OZ!'HI*FIJ:
MBB>4%965Y6D]Y(-N^ 6[H.3]@L3_,L$9]R#70*^ 8"]_/[&#OUVN^(<$ZQX-
M"?%RT[KJ<E7MBIN;FOP5%Q4W>24E-Q=Y%S<5)7DW%14W#36ED\I7E:X<_<OR
M;JY_6ST@)/#:[[7=7!7=K[G[NOL%!]&XH72P9S=7K4 O#\_@H#]6/W4M^/]L
M^]>\#L9K77/Q\] ]BI)W<[_J$G(MF-:H^$?K7PC:.C2N,C,SZRC^PPX4_\2
MOSRA\91&_4T"!^+XFQ3=_6BB"Z/)B#H''#5$>5T% '-S0 8  "8 %',?H*-1
M(. OA3K/=L'4P !I884P,CUG2%,; & S.>?EYT]W" !\_8(#K8Q/BUVXZ" &
M^4P;R0PP DH X.(:%&!N;61S,(.IH8%8$*T3\$]E9^2/-8;D32S$Q(#_6>%T
M#0@,IFW2@D:KN-$.3Z-OT^AK8<$!!\]Q-)KGBL\!34=_0 ?2-DBC!0YHCS]H
MN=]]_J#U#V@W7S\W&GVPYP W7[<#NH-&)X2&N--H\#D:'1?JY1Y&HX=IM,2U
M$%\O&DTX&.OK[A($ /1L!\^#W5T]:?0)&LT6:&-E0*-U:*QE\_@'^LH_T,'N
MJ."#0QGX!]SX+54Q:=?C8C2E.2EFXAYVS3TX6-Z")CB70#<Q W_? !>_&P#P
MQYE_%ZX#WHK1F*RNI*FN+J^LH/0/C/HO&__-<B#;/ZA-R]\R _%]_/NS_ZR?
M_V, .+E-X\V=OS^[\@  &F,!0&#\[\\DB@  2I-;0]\_G(?O0%_^P8B\W%T5
M#ACZM_+?=O@WRC^LIW PW=_8(W;F#^L3.^";J_\U_Y! L2":W;B+R?]9B?_7
M __S?<A9N5]U#W3WHXVPHVF9EY\'3=Q^;EZ_O9J7W[\2XO]RV)_*'WI-*]PE
M%( 'J0 <ZN,!P&L? 7IN5@!\N8#6 OJ;W,XQVP$'EF</6_Q#[W\7T'^<E2[]
MX%>0E\?O<096-F*N(8&A?[0=F"7  +  4( '$ 1$ 7% &I 'E $-0!O0!PR!
MLP "L $N DZ *^ )^ *!0!B !J*!." 9N /< W*!0J $J "> R^!1J 9: 6Z
M@%Z@'_@"3 "SP'=@!< !.P"1%N8@('80-T@0! -)@F1!RJ"3(#V0(>@<R IT
M$>0,\@#Y@4) :- M4#(H$Y0+>@2J -6 7H-:03V@ = 8: ZT#-H [=.!Z=CH
M>.A$Z([1*=*=I#M%9T9G0^=(YT%WG>XFW6VZ-+K[=(_IJN@:Z%KI>NF^T,W2
MK=!M@P$P*Y@/? 0L#SX)-@ CP [@J^! <"0X"9P-?@Q^#FX"=X.'P+/@5? >
M/2,]-[T8O3R]-KT)O2V]*_UU^DCZ%/I<^B?T#?0=]$/T<_0X>@H#.\-A!ED&
M+093A@L,'@QA#'$,V0QE#/4,G0Q?&+XS[# R,O(Q2C%J,)HP7F3T9@QG3&',
M9ZQF?,<XP+C N V!0 0ALA!=" +B @F&Q$$>0*H@6,@@Y#N$P,3*!&-29C)B
M<F#R8XIARF9ZRM3"-,BTR$1D/L0LR:S%C&!V8[[!G,Y<PMS$W,?\G9G(PLDB
MQ:++8L/BS1+-<I_E.4LGRR3+)BLKZU%6359+5B_6*-;[K"]8W[/.L>ZQ<;')
ML!FP768+84MC*V=[QS;&MLG.SGZ,79_=@3V8/8V]@KV=?9J=P,'-H<!ARN'&
M@>'(XVC@&.3X!66&2D)/09V@-Z'9T%IH'W3U$/.A8X<,#KD<BCR4=^CUH=%#
MVYS<G$J<"$Y?SA3.IYP]G$M<$*YC7(9<;ERWN8JYVKD6N,'<XMP&W*[<M[A+
MN#NYO_,P\DCQF/)X\R3S/./YS(/CY>)5Y;7C1?'F\;[EG>4#\QWC,^6[QI?.
M]Y)OA&^?7X3_%+\[?R+_<_Y!_ET!80%] 7>!)(%J@2\"^X)B@H:"/H(9@HV"
M4T+T0C)"ED)A0@5"G4*KPCS"VL*NPDG"+X7'#],=ECEL=3C\</'ACX>W141%
MC$4"1!Z(M(NLBO*)ZHMZB]X5;1%=AG'#]&!>L+LP+.RG&*_8*;%K8O?%.L1P
M1PX?,3D2<N31D<]'B$>ECMH>C3E:?71*G$7\I/A5\;OB;>(X"9B$N01:HE)B
M7))9\J2DIV2.9+?D[C&I8_;'XH\U'EN2$I RE;HI52DU*<TN#9>^+OU8>O@X
MX_&3QWV.YQ_OEZ&349/QE,F3Z9.EDU67]9+-EQV08Y#3E/.3>RPW*L\F?TH^
M5+Y2?DZ!3^&<0HQ"H\(O10E%!\4,Q6Y%R@FU$]=.E)R84.)2.JL4H]2DM*$L
MH^RJG*<\K,*N8J2"47FE@E>55757+5#]JL:M9JX6K]:F1E;74 ]4?ZZ^K"&A
MX:SQ4&/T),])BY,I)]]K,FB>UL1H-FON::EK!6N]U%K7EM?VT7ZJO:0CI>.N
M4Z*SH'M4UT7WD>ZLGIB>LUZ1WBS\"-P%_A@^KR^N[Z9?IK]XZO@I[U-5IWZ=
M/G$Z\'3]Z5T#+8,(@W=GP&>,SR2=^6S(96AKF&LX;734R,.HT@AGK&8<;OS.
MA,'$S"3#9-14Q-35M,(4=U;C;,39#C,V,VNS7+/Y<S+G L\UF=.9GS7/,I\\
M+WG>[WPC D"8(K(04Q92%M<MWE@R6EI8YEG^L%*R0EMU6W-;(ZV?6N_8G+9)
MMYFPE;8-L6VS@]I=MJNPV[4_8Y]I/WM!\4+$A=Z+0A>]+KYR@#C8.90Y;%\R
MO'3OTO?+:I?C+H\X2CFB''N<A)RN.;U%0I$NR%IG!F=[YZ?.)!>$RV.7[2NF
M5QY>P;D:N.:XKKCIN]UU6W;7=<]T7[RJ>S7SZI*'KD>6Q[(GW#/;<]7+P"O7
M"^]MXEWHO>N#\"GWH5ZSOU;MR^3K[/O:C\O/QZ_#7]0?Y3\0(!L0%S![7>OZ
MO>NX0+/ LB!0D&/0JV >&ICZ&"(=$ALR%ZH7FA=*"+,+JT5QHOQ0'V_(W$B\
ML7C3Z&9I.'VX:W@;^@@Z&CT7<2KB420H\DID&T8<<QOS/<HXZDDT2[1/]*>8
M$S&9,5NW[&\UW1:Y'75[(=8XMC*.(RXP;C1>.[XP@3[!*^%SHDKB@T1*DEO2
MA^03R=G)I!37E ^I2JGW4ZEI5],^IZNG%]QAO.-W9R0#GO$DDS/S9N9"EGE6
MPUVQNTEWM^XA[_5DJV87YK#DA.3,WC]W_]4#B0=W'I!R/7._Y)W.JWYX^&'B
MP]U\M_S! OV"YX4BA<F%^T5>15\?&3]J>'SL<78Q8W%H\8\2NY+NTI.E%65"
M9<EEY'*_\MDG5D\Z*C0J*IX>?II>25<94KE<=;FJ_]F99Z^>RS]_5,U7G?P"
M>!'RXF>-<\W(2[.7;;4G:Y_72=8]K.>N3VH -=QHP#5Z-LZ^NOAJX/79UVU-
MVDWU;Q3>E#<?:<Y[R_LVO86EY78+%7L3N_TNX-UJJT?K0ANR;:+]0OMPAV7'
MYTZSSO==1EWMW:>ZL>]UWS?W:/6\_G#R0V.O>F_#1[6/]9_4/M5_5O_<T*?1
M]ZI?L[]I0&>@91 ^V#IT9JAKV'2X]\OY+P,CMB-?1R^/SGYU^[HT=FT,/QXZ
M3IR(FF283)HZ-)4]?7CZ\<SQF>I9]=FW<V?F/LY;ST\LN"ZL? OZ1OI^^P?[
MC^Q%V&+%DO)2\[+1<O_/2S^_KP2L$%?CUCC7'OZ2_E6WKK_^$7<!]QT?B*=N
MI&P*;I9OJ6ZU;5ML3^_X[A!WDPB"A"=[)_>Z]^WW%XEA) CI/ODXN8EB1IFD
M^E*IU G   #3T1U\:(6>]F%@8F"@IV=@@4 8F=A8V-A865A9V3FX#K%S<'*P
MLA[B.\3)S</+R\L&Y1?@XQ'@XN'E.9@$!*:-H6=@9F!@YF%G9>?Y'Q?J.X"3
M"11)QPD&'07H.$%@3A"U X#1, T#Z'?Y*Z !T='VR AA8F9AI76H/P30@<!@
M.GKPP:YIK1&T=H">DX'KB-(I1FY+%\C1ZSS*T1F/F,1/U[3R6@W@)%2N!,8P
ML_#Q"P@*21Z3DCXNHZJFKG%24\O@C*&1L8GI66L;6SM[&M!RI26!'IY>WD'!
M(:%AJ!LW;]V.C8M/2$S*S+I[+SOG_H/<Q\4EI67E3RJ>OJRMJV]H?/6ZJ:V]
MH[.K^WW/A\&AX2\CHU_'QN?F%[Y]_[&XM/P3O[&YM;VS2]C;/S@7" "#_EK^
MTW-QTLY%1T\/IH<<G M$%W;0@9.>X8@2(]<I2XC+=>ZCRM%,/*<S'M6T,HNK
M6.%XKP0.L/!)J,Y)X@^.]OMD_][!8OY7)_O;P?Y^KG& #0RB"0_,"< !LO7C
M)&G@OZZ$-Q26C 5%'I3V'"P*$JMC784ZO6N#+RW(UZ4DATM6=0G*_PH[[N9L
M\MZN=4%&5QJ\)B2[F>N+F-=8C24ZHL5PI]%71R/E4)ANE1ZO"L\6B?N7IRXJ
M?+=]J'3533#P7>KK#3>(>'GQ!!5H-95O/K4 YT(AV^ 0=,@"NW5[;MUX:/FQ
M'+_,5O_#@?=)/X(GC>;33M^CC]7IAXS;V'<[G:0",>E+38I)S?:N<["X%B5"
M<A'!Z.JM#E'Q?E_;JM4QE1^^KKMM:]<R;= E,?8_JDOU>-!6N-VNZO@FQ52=
MX^$[:ZQV\9\;,W)\*MAL!T8)CA<OFJS:;!=Q="61[N(BL8H=ZRE4X+ \*8AX
MD5 \)Z<EE:*X&OQ,A<)UR_=P]OP/9WHOB<I8_:=%TN\$>+>DUIB:I*+U&"E]
M#6%4@+/YTH+9Q6:/\F1%GN71"K6N*G<54\%7]PJAS';@F$#>Z_JPH %DGI#_
MFF85"49^@_$T%^UMTU,@Y%4@14XN-W'$L/7Z\MA]&/KP+E/\<H_ >^O,=S?M
MGZW <#;0> ?CUBF5[L$EH;V+:E2 8!QBSEZ<IDU66#(:U+B?\N[$>+R SM;)
M(U$ 43EI+]F W'A-/E( -=1-!0Y%BA)JY^*BBR+RGRW@&<IZ\RT0KXQ>&.DS
M]$HSA#G[T=]1]GE'T<*T6BC6P6.U.JQ)\OC1]GS_#B&;3W../E8QJDGVLK'W
M^;I8?MF_8V\5+1:#%:O:?Z<"B5COU*!YCU79Z_P=4!:2,8[\MB6];&H2M3]X
M\I%0R8QOPZF=&\P69@\T0O=X5W["DC -H;=P#BNMTY !':5Y>**>WI?@)_Z^
M)'A1F^0KLXB'9MI!C4<NX(0?28'IHR+@AC>0[^"I]AAA'>V*Z9].#'A8^YJU
M^5LB[^>L^4O^QZQ"91/%X=V"'">^'KZU77U'[W /7HK"(KR $"5DPY,*Q CN
MN.3VIN:F8QGE!*.%U4;[3P)L0^8G-+^+JHO]@C6_ WO)@?:E#-%?B'"T"'[T
MW;J(=^]3M,^PG@3Z9,ZY3).U9G.M3T\N.,IEW/D1:.K9C-70>0*!'5]Q"G]*
MT][SJ@@I&SQ_/(47M=XQP[;U)JZQ"?\V-8$/(^OK=4C#AC[M0H6@(+@4B*@V
M1 N7T$;8;:6&MPX2WA@35!;(B+:;P7EJS[Q94>,3B+UXX7;>T/$/'5RO)E_K
M_'AK/^^Q]GT.SC)),#;%><2'K"=%2N//WQ-M+%\J$&J<.7KA_9M,KT0J8,?4
M)R#A_(OEA EDJ,X^@?()6W_L%M&P?9Y5. )FATM/;M;0FEAQ$AQ]M/%\=:RV
MIH9D,G&I@,-8S(T;![L5,M8BC;Y*F/-?2!_OZYAA/M)/<HUP+5GVZ(2[IYE=
M#SI!IYIIVU9D:\'CS,8"D+T?MUCT4Z3'(GMG7JZV*+_$(Q,PGGU0!Z2I_&*"
M[[9T]?-'4?E5$[UW!CIZ8\#N85SZH(3T!0B)QV=NL3U?N]T:Y?>!.*\V\KK8
M?)ZGH7\*,B8GGII?]LH#_F9.0MADDNT:$P2(BO P1&N4T;AEW0P/>;Q$D6LA
M6"\\DYU[]JW'2R.EO-:NMO%^?I6>5=CC%IL7FI(F+ C>?L(0A46^U!/)UVR*
M6V@K9",YXJ$=XV?;5;WFOA87"-]WXKG[Z;6IN[YDBI],X 4+R-=@^X^%O'!?
MLN+<]]W;:,TRE'#'M#(A?5Y$0=X9I6W4,!7B BYRW<G$?+D3QN8KX2L1*R#5
M%SQ#.)Z)*G3(:Z,($T3P4 ?\CX+G^]WQ#"77>\IE7E8HC$E\>[D@_=;X21&T
MT;,Z!3[WC;72NY_@WUY(WW)D)5(S9NQY/88]CS<FXCAX5=3/%*[QH7<C)?[\
M(F\BKGWA>2K>8&=BL#[5V!P_&AW21SCE)[K2'BEALE:U5ISTT_:&1$K#+!4X
M?B0!> [E >W:\N)Y9TB\_.U7M-<YO:@ FTY0)5J^IIG(WIWVK,KX:[L?:_-Q
MG3*3GZTMSBPQ^L]$PBDLUH_@';X^K4Z,!/_YF42'3_EOZ[<K"8$\V<)O+A:E
MN>B=DDO@N]!U=N,"AS1X]8/L>^S5PG%X^TS=;OLR&E$T-N.E<G&ZI^RGP_FR
M:(5KSXM9'#2 6=R'4[NM0 SD>3_(D,?B_[@BF3"M3L%+:NDQ5(!=E7C'87R]
MN^'$V:<!9]7J!U_T^3%7OUDJ@A9&,M/0- ,5\)CAD4I$P^84I9"I0B=#9%=Z
MGI=&7^#UES/IM+AC(E>DSBS8>K0YC\)<2N_SA#)@36\ICC8=MBP\?(=#GZ0!
M^S@Z$6P!^9Z^.D8T15GO"!*"\/9S4IT^(D;=73LWI[;74LMWT"^?8P\/'#W3
M(V;U*@@V'<A3J<"L"2XFIV&<J4#"PBPR=EO>;$&Q Q:7Y22H:!P;G%<6(XP:
M/VV-#H\;#0%]=16/A&I6#PI6^3XOB[OH.Y]]X?S2]!FV]Q$V!86Q#D703U3@
M:_$LLKTO>88?Z[52*(Q2,<2;=^:DK[LV9-G4FH[S^B3'M)IQ@,0B;:<PK4;-
M\#*"_3ML[71J\9A!F9<ZC%,UV>>2M@TS#Z=<8*RAY3L:<JE^35/"CT@H93"2
MF9R'F2V&UXD6+XSY!7\2MDGJFE)+N%;ZVNQ&]C3_A8=&5>T?A6NZ+]#BUZS#
M3E[80BJ*=%'+\/.#V?4$I+!J19U9^%)SP^O&A*F<0J]5RLT8(Z/OU[.2R"^:
MZN-V^.+F!19C6[8"G[C#+;P-+85B+7CUWP'.+, >-X4E%3?3 >/$7@5+Q0<O
MU^>E0U="FZ9&\NCXP_,\LVTR3J== $D'0MRDZM&5Q.#(@0(1<K,.PVPZ'8E_
MH#Z='Y4[_L,\DC*MJVXR<SY)]B+X]/<HAD3,K*2I(9#Y ;IB:-M8TU#GY<2*
MFKV1ATX58E"8+A=!C$3!Q2./1 ZV,.!'2=S*"W-V#\)1+9JXEN12$7OSUS79
M,#'#)PX=B^'2UILF#\$%$:DWG^VFKF+<X!/.: M"HD\$I'U&F"#3;EZ#YWU;
MDG/BZZ0A^Q//RV)R*CM7OEH@UGFBC%8CLX;Y[5Y,G\9-GLEJ6V _G"2(&!8"
M-I%15*#._A;62QYB-T)BOWX#\WAYMZQ];=?._UH.%[W]L1.S2I;-;/<.WT*R
MD'@(&461[\)FN"E,)-^A$'.I5JV=ZK GGI&2C;79X9=6S!*RI5+J]%_X*YPD
M6)RM";@>A5BNL^CVY^KDDKO^I.TI (A&62M4S;;$/GH=HYV05Q58Y Z/+H+V
M8,9JYSQB*$<H@TC>K!W,D)H/,FX\OCW?X'3#R*_Y)K[E)Y?EO-+5,?</;_!L
MWI9@8]E$QNW"V-'\N#!+'*2S.F5&2$\0A3V7MM%&?*?>:,]:=DZD1/MHK%CP
MQC?H)D1,R4.G@IXR;L 6BJ^R-*HQ*F9) H";@(QF'?%2<L)SB88XTWDJ8"_;
MQ2K5O\T#VNLA*A@(T1PZK#EX@H>_GV2R]NO=>9 >"?K>OI?"CDM!LC5;XC:[
M"^#X] YH/!**OCB;+.P#%T!Q_#!QF$85)ZG7OW(S]HWO47Q!9^HF=E@=?MV;
M-1GU_!'*(_%88I>0)H_RBRVQ[2)H'-;97&KN6 4^:!Z:1#F,(L[#.IZ=]]4;
M'[7!0U->]D^Z8T,K)#(DJH_*B:';06>CUS86VV:28+7Q47J:D?TO2(&XM;+7
M3R8)BQ812K^"7=&N"8[G#].!)K+%T[:)W/[^O%6R/$HE2M)M)=Z\QOTLN5%Z
M<J_(+R(A:$UR1@B,BZ3:O^:GHZNVUG6K&&6ING"M*;OX:)PG.D;95<_3X^1R
M1H\8+%YXKCL1[J)(1YA!$%+G\J1G"8VSE967Y*]VJ5\=J":]EJ!\"OK</Z;_
MSHV/\XY):@*YX3ELP;Z]D'")"C"1D+/13S!NA8>\@I:Q?AOH=?&/I]_L^#E^
M_7S]E0=-\Q6ODI^A^>?7"5)^Z3@ID\%MLYFD\=C8LD3?N?MU/8GW6OHS)3^T
M3*4\CS)Y)9E\8@&F%HXD<2^VAD6"R94M:H1P&UGUZD<H_W8MVXYWOSYF7# \
M?%^WU7-S/1KIB>8EV$/;%&-;H+AD1\,J1U38V5MF0H_J#S7W"L5.\@?Q0 0G
M7I%]L$707L7QS39.M"*Y2<U?%$7L$H430G"[G;EJ;^O+4W0@01+R_M=Y HH=
M)E4]/[VX;[8&9%YD@K"G2Z9WP&N5T6?P_ FJF''[!?7H!=XXM>1NAQBS('()
MG=C&YF&SP+G31WGS>I%34<P":L13U_UYAQ79\!(#)]N-C\;9B=X6K6?U4E<V
MX$%X^ V<#N)2/6L+?9IRG6 !F=^-B91%\7>-P'$Y:$="_4+UK0.8/T]4:TRJ
M\]7Z 5^;.B$C?%'A:!P\OV8CX+V@)2L?7.T:Y5-3=P=V7&IA^PLVU>.5/X]/
M(;-:A)39E^HBOEJG2SUR^(E)K2C@^_NIM-.,/9\1JXXCA;X1W\EEX\+I<K\0
MZB<F$$_Z#.R>@#?,VC#U]K>;P43Z%63M=/VC%3ZL@$OML(YR"Q?EPX/2[/GY
M&V?/5?'[BP9<XW[UDE04P[P%)4C.1&TKQL/JH%U0CI7^/8<?]^:H ,?$E%$'
M7XR!9^G\>\IRV\/K&Z/+L*^^N7B_U&:C[_97/EKXLRX)/Y?Y J 15(!^01CM
M3CPO-F<_[U0<*P)9%VWY^C@)D/Y_]?^_6BU(KM:3\\;2ZX$(\5T.JOV79I:'
MOD+5?W KRP4ZM?*4%*T0&]'AHQI4 ,I$+J0"2Q@DB0=)!?!)P!8VE0KPR4<R
MD51&==S#RZ:]L\>O71IG56-XB;(:TSDV#Q+C[F/I3L))PV<?"_$,HM40A%/H
M<Y>Z9,[*3#Q2"+W;^6J*V+>5FA&Y^8&X]Y-E%($AAD=^'B^M:6S&U[^=>NWN
M*M*5B%ZZ>$'YH3#:[03]S4/LELB)2SM7[$[KF)8Q&MP3;\^Y8?UC;PRV-!FY
MNUNXCIZZ4<21-RNUYEY*"L/OIC3+N\X]<S7+:Q]:]5H_:O$(.'/TLD:O5/[.
M;9:\4;[5,/#&:,OH1P?,VB>BNA=WW8B>_,N7]^YT#5Y:TJBIL5H[8F6(-?^U
MEF[O.IP[1 7B;T?V48$M>#6%19&6]W8"$;R&Z'+8VNLY9 (6IL=-4)G#)C[;
MKA3Q7K%T]#NN.I&0?R7I@ZF+].!CU]TDE12<[,\/_Y<DU_P<-@XVS-M)>T50
M5R7.51O,X>?%,;>)QV]_.#J6/]'X;?'7@L@2^,M!;]E/(?[C9G-&T4\=EYL*
M.[!,R^.I)<\8.DM'&GT/OWA?SI96NE'%)'9K\*T,-@\Y3J2<KYQ?)Z<ZY%#N
MO@4BB52@W88D2 4>U\Q6DV#C-,E_6-;AQKNV(KE*WZ2WZ2GTD\[ON#A\#XXX
M+5O,=&U-\7O-1'ZYX,HMY$>UR$>85@[,-S?"6RK@E.M!B0_2AU4-6R+AD=.B
MPE]T3A%E"3\7#5[G]EWN7\M"OGP5_:%)]V%RP-?NR]V'D].(3\!+0K*;QS%>
M/JEF.X^'X)XJ3WM@;9Y60ZV![<*%LNC],[G)7"JI/0'X,I,^_[.E%92^)J-Z
MFJ/9_!*I@BK3M?-/;!Q7FTD0'RX>\3]BTC(0(H&;Y[EK],Y8AOQ=-P)X!_G)
MRSN/>4D%WF$AZ",X^>SRN636WDLSAY8;5'XJ.WKGV!?X5!E&6^JD<3] _@(]
M3-D2V/E7(LS]R&NF!( R$=[ 9O4X>$Z3,(6KML)A)C"UE+$@#_BXTBXZ^4EY
MM\'HA^[SVTO;BU([:81S538D"YRS<\ I/$-9$!7 2%.!N#L$,RI@:-R*(5B,
M8_ ?@"UOF=+8[992#_\;7M=%OI1V^,AI''J%^F8D:&=W^- I>LY1-;\H%NG'
M43HSW52 F0K,J1-*<;V=;;NKBZV-]J-P#RI00 4\Z\+1P6MO=(W/;B5)%]']
MWZ@MJC54X&Z--V;G'#\5,+-KZ:U.E<-\EW,H)&?1,J+!+T70ETL'*KBY.9].
MXH*VP7E:)%#E71J80R%O9//#K5\-ES3&?>8SR;TH^.&XE 3=U\5!K/[*/#)&
M'5,'[T:"%%.>M6B4Q?N&57BKX[U6YE8$Z8\S?.N7GNSG0B6((FX"&^N$0%@,
M?*F40 NB "T+$MI7V=$DQVXI?OU%!3HU'.")V]!##5C>9BOY+<ZNHQOG;O-.
MC.JYK"R?IP*Q4D1C*C#0#B4=VZ("%.-GT#&/3N0A19T(/*:5!@*]"5V+;3>S
M"WV]GLBG\-TNV3'5IJLY>JMW(6,\2B_UJ4-#CL]SK[!<W]73X;+OG:91EXJ[
M?MK>)9]2"WVUGHSDWD+2$D>.^CYA5/P:[&N3SM'PPI=&$CE>(<A[@<J![6\!
MU+UJ$O?"W+W&U;X;.%U%M86YY-0SWM45:A\AEOQTAKYSI$+%7T7I9.34^Y5/
M-T=3(YE0X5TS].MZ?)=[;KC,Y:4>TQ4.27X\:>B7\.2-8,;=0SPA5KJ5?'T[
MCW *C^9FXH2^WYOZ\B,?S[4F%VSJ<ALVHZQR+Z_PSO-NNY4X*UD&K*]B'!7
M50=C>+O5RP/4GCGX\IL.R%>1IA"634FN;,GL335R8#HS-X"IASY*7[>X?5].
M3[@_>.W8V+?,Z;9Q[0NYU_AE$GCXQ$ /:3\.]S:E4C#^BJPH:,? DM9H^TSB
M2%-JYVINR&,HZ]F>""V^R8;/PMRXDEN"SL;B:3Y?=>!X5\1H"T_?PMA61)C^
MD'/]Z^8\Q&CP8MWPT30ZXJX^J>*H<F]!4<6ZOL@4[T>T!GXG!X]XIP5)WD+
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ML&J/OGH:OPQ/^W?WYD .).)^H#7&<PP14WF@@)QH)%!-+[ROL*.BYW*0@D&
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MG6GTV9F 4ADRNWTI9FAV]N >JW/.Q4P-3AM>A*.-.4(CM7HG8Y723FL^]"?
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M?G-&?19)1YP.22ZJE\8%'+JE!QO."?Y1^^P_=R#<_ZT/BCOP/P!02P,$%
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M-=E&FKUYCGN)] *=,B9I[Y/)0@28_Z9Q.\^:]:UR!?07H\4I&P?CJ"D1Y["
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M4OLF:YN=S/ N:UR".0UHRQR"Y$VK]SR\)/.6A VS$;?"WY"@]Y3;S9X#M]
M &X[6%*%%B0;&I$8(C,IP?J!SPLV*([<WUIOO#S#EQ@^5$QVW@\E>\WBZ->:
M.0<H E]<<X1'37,QPZ6;87GX;_A;!<5$[QZ=1\;*!1>M.J</=@_0?W9=-*W^
M.I?!C.^09%IP$V9SXUAQH<$F#\>\J9H/A!EA:YVL1X?5(Q&5MP>K+@5*#TFV
M:-Z[00^^A6Q5H[@6G SZ%[EX=H(J3D:V-<M7WO:L-GG0)H!3SPR,OL3MR*-C
MFOPX93%9T_M5+?_>=/V1&D6>I/'*#WW&+8=AT M^Y<L6%3><5\,@K\%CTPL.
M4C;J9^I[#E<F:\PFA6L]//0*TU',)S_K)W2D2:, /3FZE[;-?[BTG-Z;/RHG
M%AL\W-C:_CM3L+"]QJ+N_%2?S^*U"Y^I/L#_-YI4/#N*PJ+(EZ0K"=I]2"OB
MD!'!LDS@_H#G+8&+JRRSGJV]?WH/.A$YYLIDQ?8?<U&DBP-^K7/J<=U:=95)
MF\]T')T_U")^<[SK#+#WYF27-?(<OE7MNW.T;TH\QFQ,'3V '1$RDU1)_B3'
M^^5U$";RW.&:H8;;H$:Z,*-#D1-]%$A]$=:S(K<,/?WA'+6O69:(B==QGT6S
M3-?4]'Q=;4!'Y3>2M'XS\QZD]#)Y? SCT%WY0[=8?]PY?I+E0#OPG5'H$IC7
M[5%_FU/L'_;VXA] GNMYGM$4,I86R6%:SL*-G,A(7G/2+81D,Q$:O:VC)\)H
M:QZJ+%#/=B7J#\M6=TMKOWYP2I_$S\6+C8W0T0 ,I#M1[\\R-H>ID@3:+#R2
M(@=VMBGRW<IAC3AA'A<;Y;C:6.UHPU0AQ!/C"^460MVMVX;A6ZJ*$32@^F#S
ME10ZRGY$!UP T]^6(BYF,<W50R\)I%XK4OH4U_SB*MOHH7;0[":]&8D_ Q/X
M:;76>C-6<-/?J%0BI-A/LQ<K*_)&K*]%HG O'W\RV6-:6Y]*)UVTGC97?CT7
M^\<TME^MKO[&R[-&I[:\6P@Q*W*H]=4R\ZK%6JJ)3SVD'1Q+U1BBF!(M"/MY
M[J7P:P-Z[BB76J)BA&J:V-;;5RB_<0O//AG;.G-)];USE+>@4$2_ OI$4&D=
M?X[]]L0O6UG)EZ)>O1>):0%'F6?4U@Q0M(DE >-#EVOOE\5Y5#QCO&0;8/]:
M,B7GG=J@:PXS<2NN=&I="Q&>;^DND%*BH159_=[[]]U8X%$0OYX2W4/@WAG&
M/'>H4N3MJP:*SYKW42M29Y.B:<#LMP%#?Z(S8:^IQ%2:Y'0EM8#Q#/,-;+/<
MA"X3HA5QFBPPOZG=%0QZK6.+++36N^QZIK0H9K,[53G>2ITMF1E[S7T&;C*+
MXR2/C;%Z<:U8>W[W\KJ8(^BO?77+3!,XIQ5]^DRK3F)0:>)[#H8738]'F0;"
M*RPP'WH7QY;G\^LOG/AAW'%CLST-D$B(1A[&U!5!A70LB,@N5 6J!<H*5ZJL
M! O8CUQV4&_P*,C\VOZ"J[3UW4NVP'[3-ZF^K:(LQ][(R!S65)QE%9+)1=Z]
MI+=R[87Z.SKC57I/3JW-CGB19!L9G>'G"#Z8C#%)$G&^@A@5Z8HV%(Q4NZKZ
MRVR12V'@\_7&EZP[>ZO8.[N.[VYH[WP7.Z"N61]W[*#.4.C)5@1(#))HBL1+
M-=E\7&V6$'[^0O#"B/R8RWP*Y6-_4<O+&6FZ->50]W"RQ)Q7!)@#H44="L!4
MA9:A: #SH^EBU8P=<M3/WZ&?.[,>5,Q<>F%U5S]@-GVBBM*$0*TVLQ.I"65N
MPF.H3ZXU6EVY235K9\=2L-Z^B3E.L?2Z8+QT)=R6B&K5!3?5-)$T(E05N:8F
MO=D.\S^P_^BZ1J^5REA[I]5QV,-(6S4CZ9'G=.XB6 *N2+@F/4]E)K'"MBW'
M=80(C4GB/5]A>O=MKVSG1L)+<W'7V[DJ@^J>'R\ZT#LSCB&=H#'X:M1FYB>8
MHR4-B PD/;@_4A5C"P^:G50U+KYJ+G/N+NF+FTJ5G)ST]@==3^SNC_O$Z91B
M%Z]<J&N 199VUWD/W;DIR=HK\?9L3AYXI:M=5TN2&"B7B<[M254@%AA$GSCY
M&%GF(0>)_=73_Z*3CT=EW4*G2^W\U5[MZ6D+"O+GXX(%F8A='),[M+R@\ZJ.
M8YF;G6@%)%9>+:<P?[44D?S[M5(8;"3^UL-O_<&;79#>4(M]"S*J>!598Q@.
MURP&MZ/BQK-RLL_%=5$YRV]]'YZUS)/H@\TG/)SU>.HW%0W-_@C.RP"S-TGD
MK1PFICD3/,X.WQEYWQ/B>.8#RPT_K)#K?85Q&?H,QKP;L[A(71:RKU1'#C\Q
M,9I0[WE&.NW.\%R-ZQG?J(L?4W*ZBO(=65+>/P[\WNR^30.4%K6*+GYNXKW^
MG\[O_[<@'W2AV)!N1Y.8V-+/<+TACTU_YCDO-L.=,[41HA7./7]MGO%J0M^>
M_>$L2;]Q26Z9,V*:X?B3GU?"#!ZA16I.+X5Q'O$(2I97ZIN'# BJ?.7*U_7X
M&0PO"Y>OY-\-!?X10?[_@<ET8^R"9U? <A;@SS=S)2"M[HF_YFIB55'KRW,+
MXC?X@*K_I3G_,E*P69R,F6/(><<9T2RY!N:0JDF9GO, WZMITKASG:5$YD&5
M O/?X.6<T94W]QG[D,0^&B"$65FF&-. B+%W-*!KY43=>Y%/J@W!<U"*=!6.
MJ@&]8WH=I$8#VC4HSVA +HJD2.6U=J8!(KE4(<R\QK$H#3AQY*QA,'DJ5%8?
M@(_3 +894C8U$=F!(9NXHBB>2>23CO$SN[Y4J1-6<K]+ ^;]=_/XZ/Y *2K(
M+J]#31K 0P,(:OE(4@.8D$U500[BR)DG;EZJ0@,2QH=.QJI"G&^WGHF @QSS
M8-&=%G:JHQ]GEM8M,KY-&NM:IO_T!L*!R%G?1/?\S[' Q?\"$N?KF>IGF;.*
MXFNZ7-^(H$2*?_%J!O&Q&V-;L.+D^2K>4X.2B4Z/52ZE CC^C8:GI)&J2>-V
MKVN?ZB*ECJ[U/L^0[^48M_NI$G9-'\Y]9*DGC\5"Q-SM!(>:;+7)-C<JFDBA
M^TGSJ VNFFPG6.HT5W2_OWY*!59(VU"Z>9EHLE=6.-MW:K_+IG##4_4HZ&/&
M;IIVUV#A@_,ZF>?BCY8:UP<3M%Z\,3\ZGAGO?K.G_O5S[.S%_VK"_PG/4R]?
MJ6R\="'LY\\7@)B1VO(T]_%G70'*==(%<D@[F$M'$[T>+Y8)&:Z^6/ V0LB'
MWS(58%0;A0UUB3UH;=A+__FMU<O77D?YQXO;,?RY3ZRZSVT""[.)VN/MT&_C
M<1(0<1BR+1F6W9:5^,$QST@\6U7W%,JP<71S[GJ.?_7\A\J+?XVY-)0T]]0F
M#.+=S-Y/KQ]N4F_5%A[L\5GT'AYT@&.H],=H'= G=_&+M0U$Q=@MKPNQ@U41
M45UXU<B$[TV!3]Y)-CL;/#-OX]/Q;>GZ(&.^>BV=2IC&CO)9I,$=CHNH_'"Z
ML>=^:!"Y8:8]*W(7Y%8;Y1ZTH&Q85[;1%<]X+C'TTD$;& \AH+#9I0:3+;H*
ME2350Q_)3&_\EU@'"TE9[1'_2\A+'<YY@_I\@.F_P /I+&V8G96M0ZS:Y:T%
MAOMGC"1W^0X7$/*/80;#A&:,]_ROS24B7'W)UD2!X/I9J?#TEO[I;]VB@.\C
M_I]#],G1^PUD&>^Y,X,2Y$*"^DCX7SN+_9+SQLLB>EOX>R'T=M6BA:JNDIX5
M!K/*%>_#.&]RYL$-2?3[&>0K<V0*W0DU5K@(OVFHC:WJTSTR@K(AYDS4%N1>
M-#ZK9<KU/&/ M E]1O9J#W:.4)43$] OCS89*G'@FK2:+/M%B/=[)/9RMZQH
M]Y'DARRO7&J*;-:CO[[S?>ZM#>.;^O-_B+D=J:[3.@,>_G_+JD6^6QM5*W*[
M#?WZ69AOU8XB[]<ZR0^SK'QB%$*/N.6*1Q?H^2DX#F^:S4LU+4;J+>QI=KG'
MY^X8MPLT*%/42&SBO,UU:02^@A;#+A^LK\KU-*/SU+$_($USN<6_L]R)&A:_
MH!4/8+WS^Q[C\V0/_R^A68H":X/D.T@>UIB->_&U\1<FRB/BLP,C-+N 3:@%
M-F]"ST.M*B!@U>N*XV4YG@B?&=BW+HZ0Y5*3T]SXMN1VX7:^)Y<,A2,?T7\$
M_/CH9D$L5&F*>=+^JV:R%TE,!_0BO)V^0WT\1R!J39FY<4>GEE?;.5?\6O&*
MUM]C\ )UD094.*$._=T.3_WC<)B+G'*DM@[BTK$/+<-3W,@IA(L*-QF&5,5N
MXN6NJG^$IEB?D;CZVP<B.< H1!*9Q6$W0^:P"=5);)0'M8--LH4N^<.&PT+,
MZA:6+<F4Z*L>?6OPG\Z+_#]6P)4T8%/;N1"F;(.)'^OSLO_4YUIH6%6;[==[
MVNLG4GVX,BT5GH;;9@_ $+%:-.!8U*N3!E!$K)$[:J#_5@,$(BMHP"OJ!?@U
M\@/W7 J$=!>A2-)Z;'1^1*+GE$1"RL++>YH+R^C9:V[-;B=DK7E"MROS",63
M?!,_3 -2BD<IG,2:@U8,![I)WGL>PP=+7%NX)]"AU?G3S$TI*.ZEZ9B::671
MXCW.Q[L?.0Z;9.9Q[9"X'!5RRJS\@Q9=G>@VJO"PM'RI:P5]]NA?S"]P^TZ(
MUU3\UQ).LN,')#518YZ1REX*_BN<],__<S3@WRM>:B$GX@BX3FAT3;,\)%9<
M(Z[+!^J6Y)U7Y9Y4>=VJ&=J@M7A/B^T)W<QD\1+ZO_;.JSE.VEL/>?L47 7I
MG+CE6>:89EYUZ9=F*PTP6'&A7V61Y?.XKX+R-?Z/@\G_A//]'%I#@]=!V<CJ
MFA0'N*MK(<689-$6A^9Q,=]/_AV'85D+M!#)<_T28_LDFT>_1B8T4<3%P &P
M1PURLOX.1;=KW3H1/=6-?YX3D%56"K^D>ND;KDQPWK_&A,:A)[5-B>(H$JYC
M'#1AISA">7Q9HB(59SQ66E+*:E3P6*USP4'?02JJ54P#E/SW(UW=L^8#LJ]"
M)KA]ALWH4[M4\^M#VV++=L498U^>OV[3A(#8/5+@/E\VAN"5PCWU%@32E=<G
M:A- ,3KNTA]\BWOR;99862TGIH,^A-U"7924#;#M2Q20J88)4'@+YIH+2"+M
M&-Y-BM[<:I/]'*LB?Y_*5)4*EJ7U,M<;R[/W=>K"O[0ZSKY4OOY;96_/D1S8
M>B@3\67TRV#5#P^U/?=5->W]VNOY2ZNCCY:0%N?Y>*G=91='(UQZLY.:#M-'
M2!^\.I'<NB!*,-G[HQM"=MA_FX-<LVP69:PZ&%E5T\;JJ!KRE*=FZP7'0V?^
M[=%9I AF81'LC#JDCF%VI]UGY-[8Z_/=ISO!&4B,CM5GLGHO:U_@P^HA#^>Z
MV"%9M!1W<9\$0Z(2Q/S9.;K?8]7PP2.D)70->H:B?>:ME6)2?)4*W^??_1?L
M ]X&W#AXXR\AL28W($FTZ!SKPL7@+R.A+)XXJ@D+@(S%N*+H8(IS#W5/CWIM
M.Y#X:OK\OG460)33[W/0W=*4\OE-WU:^:8UB0FB1#><S4%_MR ;[<_O37832
M_*!2I]>>9@8W[,,XE*_\"G],H0$<NK(0C?>("S#8W7MW$P@, 3K<XYL2Y1(K
M)KHSA.U.XZN]UG#] 7DZ +'>=IV-[E5+O1@C']U*C;C2H!J$VRV8/:?8W;?4
M-48TLX:[EVUL_5RO@-U')4:ATMB_>OO>@W#]+XAQC!B2(-ELXK"WX>=%?F>S
MNM0O]#*&R*^AU+WRHJL9_?%4[,7_!@[P7,:G(%="4H4U^=YV%]>:#PUPMK.<
MP(E*:P=QM_=V_CKUT?ZV*&6>?T=C ST+Y7=%">NH><U]9\4B)Z:%ALK.$1<Q
M,?X>TI9^VE9<!G3&SG_R+[^^8"7ZA$,7Y0(;ZE,#,;J/I;HQWDX,89[SN"XJ
M\F3PF_*RA(AO(Q&- __"ME %!Y$N2<QOJ1?(7E#28V'5VKM94A_F6.-XGYX^
M&S#X0XGUVZW\U7FP^H'9&3JU=7O_3P^&*T-!/0$7;')W,YH"VO<AY) "N"68
MRZ%B1,1"8&BMW++GZ\]#N,:0=(_"?(U\^;.GL]_$_HQ]CXW](V%V'R-7_4,6
MZI(54'BA)\C>/?!"0M%P6]GUW=.QY!_[#VJBAO>IQT6?PP1G8Y#E85AA!M.C
M\ &6([=FV>,,S.(Y5+77<2MF]\97^DVW?_LFZ%_ _5)WGI6>[!I3=X$Y.*YJ
MRL:".'6<$UF2Q+FV@XWS,"D]NV)3<^.W@P-]O).C!-K4Q*V%#"&(ZEXF17>Y
MEWH>F9 ;T7B]>>-?%\8V_+OE5;E/:R0)%_\JYR@W**Y^0]_H*E$FM\N#46VZ
M)M"&B0:)9)J-[>$BIR5)I^W.:PC@HS[,E4(,,5%_<+K/2QUVC$\G@C23?,(3
M/EJLGDDHL8:%&U6.;$C;Q,G59;@\LTN,5V:BR UC)[/4\=,H]-]@EBOP,O.!
M1GT^BPRE$_%#O[Q+ ]*.,JD]J<C5T>(5EG\1^OYI]Z6:S[4>]B\NBPMNW_58
MN-8F$*^K:];"=1MWGPDM,Z9S@P0Q(@5&^ZF$SO[E*,LT648ZVR8I]NA[HER6
MM;\;7+DNWJ[O2+:[AI"_%OVZ3'4R^T2E;88J,)^/>W:&SB)0<[W?>SCVU[_<
MQ?\K./LY)T/F[HH+''^N%K'99B4_-U)XJ7JDJ<;)VE<XY5XLW[0EH6)XX"C
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M8S2@ QDYS4Y:C!]'2!-S8N9$BFVL>)BK3;1$,F-NR[#T?WF5 T._.4DZ,V@
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M\F!F\T#,NF?A-\<I0L4VL,_S5@-;NGU!QZ@O?P<9\2)1G-VMNV@E$B>%;YO
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M/X(W-$^F[;.;6S1V9B<06L5X'/UO\< $JA=)98.L>S+3@%0D^ZKBL8)A#G4
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M^7JM>CF\NO245'Q=PXCX2->]ZWB=PJE*7/[5=5L3;PRQ01>$'#@@H"BB-C2
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MA!]@7ST81J*!4Y8#8PN,GD<F$V9H;VX_ESD O;^8_E<?7"I)HZ*!JE[ HW<
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M49OMT])N;>#P9Z@V3/C>3,@.K&1?4=DV>.).=T'O?._/1':YIA,L3%7D3JF
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M3./KG^N;*FIPH=F)1)//L*!7UK.K"<@'ESH[Y]UB;()1S1#$9? K)*OGN):
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M+.!_5B.,R&>?TBBI_^YA#0,48"B3_*B  MT?S@2^?I=3JAW/OX9T%WCY]#I
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M\5M#C:&)?+@JUB^]QVA7T<8F HZ/CTG#CBY<5-!TA9-.?EA8=\M><<J$JAZ
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M+>TH7D[EB*JXJ56+64B1_,Q\.78@;DKSSP6P?SFCLBQ=*$(-D@G5YTA*97
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M8[$9UZWOMJSJ;8GZM9/@2]8ZK%0#HOHKK9L?X:GZ5,M<JKY5POI]DF/F4.-
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M>T7@Z>,M"VWIJ\^\0Y.3,XE*4I]?JS&'Q:G$WD[*:C;"7+,527@:AP,"Y^G
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MY#4GQ:O_RT7@_S42N\Q_ %!+ P04    "  ;B&Y:CI]^(MOO  #*I0D '0
M &-K,# P,3@R-#(Y,RTR,#(T,3(S,5]L86(N>&ULW+U[<]PXEB?Z_WP*W-X_
M;G6$T,4'^.J8F0W9EGNUX;)T95?W3#@V,O"4V9W*5)&9*JL__07XR&2F,DD
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MQ%D!VH_B_ -V]K32V.I_5[]M\R>\5.K]3AKV1:Z,?/4+:?,?_J#S9'W3(S>
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M.;TA-I7<RBC2(C";<60B;M=(,GK/?*%_7J\^\[7A >7@I8F7KJ0%/U_=&)Q
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M1A+/SH3=V;()>&[O*\,0)6'&("&9-#!\&D*<^ (2)N*$I2E+,J/R9@>C3VP
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M$H9Q#",?(U4W)%$E0S*8XC# )&/89\@X?.L,L8D5WIZJ6H&;BBX@BC#X"9<
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M/K77XNXH3M"/:T J=X?VDU3F/K3WB7KBT-[[^)BR^[S(>?DA:/O&-=\A#M-
MT)3#+"("HNIO2(20LQB%1&0T],U;H)RF-?%*K8F"#S!HPX5LKNS/P-2_7!T+
M;[9D3\@]O&:- ;"I33\:",O:\P8?@F4]^5[)S.K%GQ[J%>K!]\ITNMY[_RMV
M=E8=#5LW'GEXQ*MGY<C,-QO.WN/'?(.7BTQUZY1H0E\$4F6QF$'"$P230$BV
ML.]C812I,$AQ8L6UIZ^*7U%<?C<S,881TS,VG.)@IL,Z$#2T+\"..FC(NS-
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M&OH4<HPRB%*/P#3,$.0LS!*>93'74UR3<3BQQMO7('A1$FHF<_+LU$QL3+H
M?'93\D7)B"DJ5DT&Z6O;D&?Y^]>P((?@=68_#A(:83UV"GW=_+Z2"NM[_B@-
M5*HV[GN^\)@74(QBB"+59I41%;F>!5!@+_.B 'DD1L:&9#_-J>,A6HK@<4=2
M'0';2CJ**_ 3EIJW?4#S(&\"JX$-Z@XL,^UX6)!OC]J>MGM8+(Q4=_#8V:LC
M8+*S8?4$-C)G!X:<W[+5D_&DD:OYJIV]>[G:Y%59K?R)?^%T6U1A5%<_Z'++
M./LHA5&:?5M_0C?B"A<J&;R4]"O5O;\5$(*'L2\"B)"'( IC#G&:I5 >SZ,
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M9U[?ZDX5O*OR_4(O]&+L(8BH+U4:)P1B3%+HAW&6R?\+F:<5U7TPZM1Z2WW
MY297)X,F_J5R?YKD4AZBT*^BK&4SU$-V8AD5O7HAQHB"5_NQ9BMV]8+];J&K
ME[^TZ#K*UY_Q ]?N,EH_/O'W?GMU Q09@[ZAC1C]W[6E!&9?]2#S9LT^#]FU
M:^[9C#%?,\]#I@^:=Q[]:HSABBN/O?+--R7?JEC!QHE?WE2U/]A"&JV,"Q)#
M)#)/VK H@P0'\MA-18B\, UYJ%7,T(+VU-L"7NYS.B_ 0U,U\*DJ,*Q^7@<
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M><(<\X>J%9<DS#=5)+Y)&L)IH8=-SM'R&B[&LZ(Z33GHE<K*%CT]XFP6::]
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M1$*S,D<+VN]PY ]R\&W@[-_F$X,$V_HV^(Q+%3"3U&42P0#%]TLO,(.B-_'
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M8-5F(J CW=1+:E;E8B+TL78PNL=N>[>*]2]7_+1-[0-+DIQ$28*H#(3RVL(
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M:\W?TFE JLX^3D/W.&V$=\NV:[6XPC*__[TY>TK\4/B$8H0QE4IO$88RRO4
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M%,5!@GA&,,*,YHA@R5#,B<@%"W% 0=V=>ZE-_>%M"'HE1:O&+?UHF2D 9Q@
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M ; :&A&3@06T)O9\5$9%FY-6V9GCQG#C8' X%QM ?/:AV'!@NB9B6ZQB.RZ
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MP&IF0$X#%DS[*QXJQ7/7PNHGS8BW6/W)V_'B70ZC!C8VX0 XLC\!A&<U2>&
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M+B5I[_^O[MN:([>5--_G5_!IQXX09GD!27 V8B+4:O49S7:W%"W9&UX_5(
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M75]_N?[Z8)!*T(D3(+M@K/0&"0?. 4W+-6+:HMG,3>BD,W^Z0I^XG1D,O2_
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M_D!_-#&"?Q3KLKQ,RZJ0?L?"#S(:I")&+(V)] -<BD@:>RA*.0FP"-R8@OR
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M/ (50YPG-;'J*\+.$66]&4=0P/04W0X,,"TW10#>1GU0.%O]TL\3FK<Q^J#
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M9;4="8(?<Q@G6')ZM<QH$N_\T*C(>7+]+T<^P&CQU4&"X6#QJ0=A-I_Z.!^
M\X8[GTD*-!&9+27!>$D0>"'Y)#FH-?X+W3,D?*&6&<0_?9E\_PT_^+<BB_*'
MA5 6 KFWW%(XN]%]M0\_X<\.>#8<3+!$\XQD6U[(%H98SW!S<>:RTGN1?7NU
MNU3?5NK!-/XRF2:8HB&Y6LY/XST%WX7PZB=^^^:G^$$D?AV.TM6_SM/)10U=
MS2<5)+=4"Y+[ZR_(=8;I%-*'I58>9&[!V1S-*RQ^LH;&#\;C2S\Z@V^3Z7S
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MER:#BP^\2_3SNM3=^ZQZ#>L>)W//WG6W.1JLKW0-(F\U%P[#4\91[S*;0$+
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MM&#1J8L< TII-2FW@VBZ:6)6TRCX8V^9=JKR>)B<9KRA[G!42QD-V)]')12
M2B4Q3#"JQ)@6>4JE?C\9R8 I]NB,]]U*,O=*9K^$H]0=JBJIH@%0W6I%L*A\
MNMV)0#L>&&=END_Q!(TLPP71,91!A1B-$6!K'W*/D--W/6P=C6\P3S7$WP"2
M#E):W!CYT:D?IJ/Q6_]MB$?J+0X'*7-(&H_O9%4D4GM17A)P8JRRVC'KZ]_
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MPW7"/3.#F\0Y$A0W1 :MB(^E< [WBPV6:KK^A'C_*.,!6OH]'E\(;%45TD)
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M1%_US4L_&FP<LHL]^12_26MFC.,$I+%$"F6(CY(2*Z4%!@%CNKU[4SV7J.T
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M@V-TF1;%TX?'^U:#/_:Q]2S5UL17,E?EC?%PV<T?(?=VLBB<A7&\DZ>\B35
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M]Z>[&V5SZ[+ZWBB4-> '9RQEY:D(L^@<1MQM7E)+?.)"!^ULA-H%H]M3U^[
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M>4XDEP2)5,D2SY$U%QQX126$[';"S&.K-E$CU0UPJ@F[,?3PC0PYD5*2N!W
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M8!X_7+<JT<%9Q8PAB99-8J(A&*=%PE \GN48.=2>Q?T43?WF\9MY,KZ;CIK
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M9T++E0H0;H(25 5I?.V4\=Y$;P?;UW5ST8]&&X#PU1X\&*?E)KSE-W^"Z<7
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MYSRU@BC[_[?W9LUM'4NZZ/O]+W5OS</+B: ERLT^-LE#TM['3X@:*;1!0!L
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M=Y98Q4N_3S2GKM]'AR,#[D#E5 F\J^'LSR_3&,_&<$['V?P5;\EZR3B5"*<
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M;Y>VUG%I+ 41,9>K4)6W>4Q/1,D1R;&E$(FVZQFP[FL]@Z6P6M>ED!\LXUK
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MS(/.&#:8!X^Q["0OI!-N/NC[6,%]TS](:MDNI2W(F[%(SFA/@B$(*ZH0YX1
M&$;!B"3BDQ:,4U5-X731N5KUO4Q5?.BTALR/MH>NAK,_OTQC/!L#@7$V7PB$
MF^!<3LJD4F9U28IR+VA$B9'1*"YB/17539GZH)UN*MQ#!T.FECWTF(L<K?&1
M KT)1PPGJ)1PEBHP 3+/=1).,M=)G%)!$4@-J-Q?"54_[)]<7Y_>7/YV]>D_
M3JY/3WZ^.CW]]?3\IL!K_?:%RSW![\% H7?UG^YG *?9###HAN-'"(X#&)PX
M/_'_OA_.%GDMSV^2UN6\#YN=W5RN2IE"QH2$K,52>L:5Q:4KPO:CL-R[^=-W
M7WUD]M/#JS\]WGW9:(-0$#)KG'(!+V'(<8D1)K#YA/#&A>(6;$\:^[TVZ1!A
MFU^].U!>CP?G;#H??)K<YR,?9#Y_R.\'BV>O/&N6A*@0Y8+" 4" $T,PHE0$
M$P@Q&)LFX(,/O (>_.D%=)N^7<O3=A>:GA04>\^PN8K?[J?^*_@0)[?@-F8G
M8I6EY4N44E91;#S2D@?$;4I($PC)1'*4*ZZ,$26PU)B@?@!61N>3KA70(ZI>
M>TF#$_!'O]OIGS=?X]1^B_?SH9^=C?WR&5)9(21C!DF>\T2EL<@2X9"APG&B
ME?16-G7!FG^V/^!TI.M)IX*O("!<8\-?@AP(01)SWB'/2*[R27DPG%)(!>45
M!$#$F]+W(=OHJ>7-ML-SK[A:*H#8Y73B8PRS+R#2:YL%"#\)]WD*45SXHGF"
M%9>"!8><HKE)?(ZKM;=@YFG@S'JM3>E,E]U4U>&['XZ 2:?JJ/I6XM/%K[^>
MW>1 _OKD_/.GB_.;L_.?3\\_G9U>%[B::+!ZN?N)?5DI=$D!H>/=</Z8'3T.
MN3!E.+Z-8S^,LY<<Z^<(,@9PT8SEB#D-P)$.SCUM TJ)>Y :0*=X[L->!!YJ
MRGZ9Y&#ZU2<>+7T@F+' !(IB49[#(S*<1N1"\K!/(X:?%&9[/27]FJSNL+)J
MPPKHH>?@\&8XSZ;W;!SRB]R]'2TBG2"5IT9*Y'RN.[!<(LN)0=D 21:EQ<H7
M" 37?KQ?[)30Z*2D>&O#Q[^&\Z^+ZI7L;7X=?KN9G(*TY@]/R:S6,9<[RW@<
M-;"F:'Z9H"A Y"R9-2[%1I9W7^1L)ZN_>+   +;!J: V:KE/^#*9WL7IIZ_#
MF$[_COX^^X,7*0U]G"Y#VZ"2Y-%#:&L%1SQ1@8S$%@GIL!,1)V)<JSN%G9^N
M"$<E-;_N=J&L&BH(_]Y9]E>/J%Q)C15!$5,*G)C<LTY:E+3%.M&0HBD].6LS
M-?W>+A0\_PH+OA;[].GBIZN3G^(XIN%\MGR47PX:$D8[%ZU&,0J+N.84:68=
MDC00%WC49#5OIZ%AVOS-RKREEJI=9X *R;D6V #I/JOF%JSHC9W>QOE/D_']
M;. ]]@KKB&24#G:6B,BRW(I6.^DU!,[2F%:8V?#!RLQ+0<"4D'#5MTAGYY\N
M?CV].?F_5]%/0'JCX6+=2?H206MV= W?N0<H/IR-X;^)-_;OG!HVG\R_QM.4
MXN)F[<U?%;A[ZHRF<C=6QQ%;H7NNYP^MN:G W,A(I$#"<8&XR!?Y A.$M0]8
M8,,2*WV]LX6<@^M-U\KVK8Y.YEMU-."<8Z=X0!$$ P<!D\@X29 0EF+!/&?:
M%99( ;+[/;-+(>Q=*>J1]5E!2-&$Y<QI+OK]!58;/?^[.!M G.\-PQ$%E^!8
M(L"KPQ*C(+$R+EAG?.D\ND/H[==OZ!.T133X0=!Z/LEG6'Z$@Z@O%VN,9W$0
MM<*4&(J"R@*VX#L9$QCR)#FF=,*2EVY6T9;6?BMU^D3IP9K[( B%'WX"RB F
MO +E KE?!\8KH5/B2(8\OH/"CM1"<Q1\U%H(0^UJCM%1\/F>TGYK8/I$YX%:
MJV<J<Q-F/WW-]1MGX\]+2N$?/28TY$J>1W5#H/*7'2\*+XACDE@4>.Z52D5"
M+K$\+2=$GC#!MOA+=6$6^BVAZ1/47>GY@UCB"PB0I\\_&M\NKG&6ES #+[R,
M45KD74X_##(@;?.-G>'.6Z$9MJ6OU ^EN=]A)'T"N9@FJT7NXYWC/?!V\0WB
MS\6CV4#;)"S3N;=%+C:1N7E\,N#.:^&(4<2'U"C+X6",KJ.NWRD>QT7CP=II
MC[O)W(Z.=6V;BSPGXYR6-$FOSHQ8HIEP\X]T<+&Z'V-'N"DEE@B2+,@H! HV
MBP=D$L%(.4X93TQ'7SJ/M\.;TG?^Q<_3R>RE22RC0D=L!$J<:L0=A_VH2-Z>
M(7HPVIK)TA=)VRFJ]WYS'URLFJZ"6JC@F'S'S=+RCF\73W1V.GU83O"<#8AV
MVCLX\I..$7Q7&\#@*X4\!8\6)Q9DL[*P0P"VF;R>&SP71,4NP!5248WHR]MU
M^;/EW=6;C@CC\)0(L+YE0NZC/>"8A.2$1")8@C@.$FG")2+&N."\%#Z6#CFZ
MX*/?B_9CXOG82O\8P,\79-/O,:>NGW@_O;>CV>)_@=:A=;E1WS#.!IQ$%P.U
MB!'.$??*("NL1(J%J%Q0$):5]G!*T=[O'7V_ "^OW!I!?39>%'?-GB][@=W/
M\7L<3;[E+*X!#B91!5&=U@DCSG%$#L(Y1"3Q0EJBN:5=@W<'C?U>U1\3I"65
M52,8GY\>WGA,S\\0B>A@O6,HQN 0%S0@RTQ"RBLGP:6BIO@%_)XD]CRH_+CV
MLI2J:D0B[#/PX.</N?_[/,_C^O?]\'&/$4I,,"$@S!AX,4(XY")VP%GDP=$D
M(RF=V=6<NIZ'=!\1?V445"/T?IY,PE_#T0B8.@/EC6]SEL"RRAIVD[8A@@@E
M!6]#V(B,4!9Y&:2BWA)WA/NCS?3U/,[ZB/ KI:0J 9C%-B""!6QA\U I\SPK
MX9&53J (9CQ()I..G=\D+2AI!"K]0X!J;\$7>TPY'#[/=[FOHR/-O,:$)214
M4HA;B/N=<QR")>VH,M@E4?K9;AL]]29&EKCM/E@#]:3N-$G3  ^2)18("A#=
M@)G%.6$N#S2)@DKFI%&V=,__4BDVO60U%GU0.5 ?%2/MU>8YC_,!93)PX@)*
M+#((J95'1B>#I#:,)DU(8IW'G&])JC<SL2C"#M##QT@Q.(? V>;\BI(I!>\6
M[2"%8#OA1T@94-$:EMNFNUS2SI6+R#KLD;=1.:^-LQ\I9>!YZ9=BRX?'2FZA
M,98Q@$O)('[E)GJD7<(H!&"<.6%B9%WQN4I,O8D"^Z!AU>J4D7T%0=PS(R?W
M\Z^3Z7#^L&A>HHAEG$/P()3*U=<I(,U%0"$"!P('1DGI=];UE%0"G\/4O D\
M[65>)7*6;4FL58:'1)"G)!=YPY9RU"N4@/X0,('XMG2IQB9:*D'/ 7K>"9T6
M0J\ /$!UG,V'?M$W=_KPU&T&$Q6\CRCE-I#<8X* +7#=")5"..4]+7UNK26D
M-MBTT?&JFWRPP&MILK$HU7PMG24O$>RQ\" .P?)T'&<I,I9)) DQ7$:LPRIX
M&C;9V/#!2NZ$2H"DN'QKP<JBG'<=+U$GHJU!SB29+[<,LBPZY/,D,D%,Q%2U
MPLJ&#U9RN5,<*R7D6\%IM,[-^^6Y:0TS.#JJ-.*8LMP\%%P]$$!NB>:8<DGY
MXJFQ6PFJQ/!TXQ(?K($*X/3^CG/UDNJIJO#D+A_'@R 9<W#@@FEEP!_PAAR!
M/<,=ID(PB[4JG1JP+XV5N$2'PV-R1%U5@,5M^>0>*^>80#A$,-+:<^2LQ$CJ
MR*7$1M%0.DX[,,/_J$:M#+X*R;\6AVHS.^>3^?6]^Z_HYS>3T[^_#1]+_ ;)
M8J?RJ$&Z&#7NK$"&. V>0& DO^TH15IY6OM24HD+5@Q@QU-+_=A;QV$(VO'D
M,?+>XCRJVR+'E4,::X^#%<JD4!AX;5'7_9O;L5%WJ$(J.#A_&T^CG]R.A_^]
M< 6>RE1NOMKYOR;WHW!V]\WZ^7.M\[+*&:)DE])BSC7.DJ6PNS3($4D%#G"(
M41E7^N*\':65M/0H?N >06]5-Q"]_NVGZ]/_\]OI^<WI[WF 2X%'XDU+EGLB
M;D1TH0=BL$VS^.][H/;T^V)\R--[H ^*NMSFW%"G<OL6B8Q5!JQ4U#F+0!LC
M"F_=3;0</-[V[;K+&6&,$H<51C9YBCCL,(A<)(!=.\R8#<JZTA4YZ^CH>:)H
M">V_&TA[J+@K..]6>8#_['$@IK,<$TN0I#G>Q9X@'6@$3U%Y B+CGI?.Q-Q
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M'][9QZ>E<EGRC3[06Z9H6ZWN([:>-7QQ/P<;#^?X^+:@*=V\:F^IHVUUN5-
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M'MK/1]@MF-X]A4Q5B<F-;U?JK7Y^7Q]N#?NUJ.1F.#_8O7ZS5&^%\"V5\D8
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M,6P=G>>3^9+4,O?]S;]2R?7_@7K>(K_N+?KR+_(OSL[B__I__G]02P,$%
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MXW_Q9G1Y&E,&/#:^A;Z9W); SLG#AVZ!9*9L>+GCK#5</B471CQ8!T5^)NL
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MBD3'.1__KRB7B5=]]_,:!$[;  U"9VA"T@0Q\R;N['/O83*#?ZA*)9>K!'8
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M"U^P2)O8-&*3_,FRS_JD ?;THN:(,C&4CK!+&B<4F=*C+BT]=<[=/IOB)E9
M^(G? !78A2D*&/3Z; !JP7=3=[^P;7<KH8 '.S/EWH+IE8A;7;QYL;-XN^D?
M$?$A4H*R;AP@5CZ\6/$T-BWJ,?_*'80QMS%=;-3.](69$$KY_8+DP;&Y-!S;
MCDLJ&$Z1-$2E3<MKSQ_<":$.7$]"4@GX68E)@EU)7(?R&\Q_TFRX5#ZU"%09
M3:LO5G<-E!]*K\OK]L+Y-"^KZ!RKF-=G/[3;6%H:8HOO,Z2M;"JP@\2:\^A(
M#%#<071ULAW" WV#7=HE86I\E']T,KVE>!.1>@1W3\TQ*JF13[K\9&/XJU*6
MO^ED@M.U/IRQ!]+]$S45+?Q4AHCDUZ &*V$):)-Z=RE86R(DX=Q_ZS+?B7-;
M<15PZ:$CR ; @N"Q8]O"@,A4!JQ[P6M0H+CMU/E52H37)4CZJ,7A#81N(6N%
MR1(JS2>T1W1@EX0\T%>>5<7I4,0NZ<7=002[)45S!U[CNWPD>HOX.-IMAFF?
M<;_=:CJ##NSM-WX#6^)4XNH[:%_#+)X4:[ K^O5GE]?>I01V*AZZ-YFKJ2F3
M'42KS#VY\/(MTT!PBIIX,U2:AK2_O2S( XJ&(,DGEVH.VGV*\W*B,OCDQ,4N
MW-BNC-7?@EB])2UP0I#3U<M2GZ; [!?*@]-7.%+/5MT]?DL]0RW-$"Y";GI8
M94+(!X]]T7-^&^;6DD8;R_$\0;I;CI<)%PM&6OEXYB%<<PY_<XGM9]]$8ONK
MVM?OZ$LBZ7JVIEL;R9\73W/2T!$OA:NJQZ[LB$?A71Y<.]5D#BW<@*A- <31
MWJ_8)TWXF.ET_,9#Y(?OG[YXC7'/ D8I@&CDE\/Q4<:])TS*W;]'&F,_H)S@
MN[Z%(Z/;\&JELK4I8?G2":@O/"9Z8E]3N/Y1+NO.%NUCL4SL<O&+'>!6#<_T
M.#NGDQRJ1E20!VRBZ2LA=+!5B&/?831%<UT?M!L@.5W/!$BOK31=B&"/PU9+
M;%&W,88FZ%\U:-IG+%AJ' 44-PX9_7N4>U*7OGZ E@[T)VS43%(&5,BDP!DF
M<VT<8>5D-#868?9_U> IZ%)2D1Q/\>8=AC/1_T!W--,+6".YTM-$$^*?LIL>
ML.1!6+W5>>[E5(!%PYG#PZ(M'."@B>NLLOE&*7MCY/8&3_!JE0K9S-N?A>/=
ME#)NSH&%KH]+NF^N5LV_037HD)7XWX%O =;2F*04^[J4(FVYXPU-YZXDJ6P@
M9?WM%<,VBJ2*G>;K]D:5ZL3P$$E"G@M.MTCG,NG$!(JN:N/0 SRKTW].4E:N
M!*T(QEHJ003\ZX_4]8 9/56T9+Q<_X6SCV!B0<[ X=NN!Y)6=].\G55KJL@F
MAL*EI;$>B-Q](1@G8^S#<X4]ZO DDY:+07.LY:,L-<%6+'M UA4T+4FNN\/?
MF1OPA$&_9T5?ST8-(^#X/81CYN&YS[S5; [H3,>?.^!N;B7D 4R+<X-MB.2-
M#(-JS?'MEI+=1%Q+7^BU<#>E@-Q]G%QMX0J^A*.S.3^_W?/SI #3=QW"OE)[
MR16X*/0X,(GRBKK 7SO;%AV+97N<JU8%9B+]:7TNB\.XN,\(ID#/=XUO'3J[
M.YI@,-*6&#8M:#.$&C2>!T,B&ESCW8:K!+T@OAUW\^V4:_D@58NLH',G@_3:
M=R( 8J,Y-IKC/C7'<1Z=J[&.?E/E*"]7JSQ6:6B^(9L!#_.P*KO3G;NSZ>U@
M\>0G8\A=9\586-V'71?Y!1-FE3..2B\ ."-*9HQ =)1#-N%<O(?/#6\_\<R[
M\)=HV:9E?=C'GOL'.B<K]*L$0XWN$V4'_ZR3"7-H5/18=/?LWR62_1L"15*Z
M60Z0.T)92JG3H4$N !<>9J"D35+#.;*T [NFDG$V=EN9E*YM2_D8'U5C.QI^
MXT-U<#\U$*4S&',XY,3 <G'F),VO!B[UWFKY1B8P_*KR3!TM0HIA)F  .->M
M'O0%5#VXJL$C\_'80C@R_P=X%C <[YV[6T*,'[Z!/'OY<"EE1Q-"X##=J1&F
MX"Y\7RTZ_NU&Q M/LHM64E,LT&;^\' ;EY"ZSAM#P47WIF$+X9!%4#& R"-J
M3=+CI-TQIK>B1LF_#X=KV2GY].QHY^#MT?[9_O'!471Z=O+[\)R*"O9/3]\.
M#_9_>7L479Q$KM[@Z# Z/3H[APL^)\/X8O?QNF08O_OY(L?L;8&ES!2K,)E*
ML*<X_MM;MI[F8*P3VMU]\%YUF9O$[5:-*5S02*YI2K#_:6]1*11Q@'65 :N1
M<9ZF1-2/ ]N)4_<H3 L;5J@4;&GEF_KC>1N(B%_LY]\01&2M=MG^DF1@E4_X
MR'!,<P8<3W!D$X-8B4Z*L '9+4\,1EL!S!D[LDH13(0FAL"N@CPC%1 2L#5/
MMP=!C*R-PPZPA$OAGZTW.]*N5+6 B U]5R900W3ER]B@]4!<G1,SK@91FJL,
MVXOI!+&"-#XSJEW>5D54<CF(GC[:V_I E$OG!LVM:'BVSZ\;2_F<C]^YWV[[
M&.38E&"7<*',HIX1?1>.G0&X?7%2 ;R4W/+6DP:&.BR/=8(=S3Z7(.#9;01]
MXZP?]X /T )?7H'5*I[1L NV0A J\_GXK3#&&#V+*@LI-T!'J1YOTV6N"M@S
M&(N91\;K<A$T'ON$'(?+!.ZS\KC+).B>HDD; ;V5@)ZYE,V8."%#U=/0@H)#
MTO@/O9H'I KA$A4QNXQJ"^^WEEE=4"DEEZ$R*ZAS(SZMT6H;4?KJ1>E"2 =Z
M89%8*U@F#?R2D#R2QV-*2R+%33Q5$5U%/Z"FZE[N<9E(R&ZL^W'MI6@C,9W3
ML<^*06X*3K+ Z3A*75,-U#V\SF1YA<:<4T^+2LRE23QS+=?CY1(3Z1I7:R]
M&S5TDU"]SU(F0[O,/VA"%$Q*)6W@&UB" "J$8D0*1<#8,:[0@W)YE)T/H@9C
M+")I'V^-<=U RUU="<C7%3@9]'X<"M)$<^\8&J*KE4+F;_$^$HP/WE"&C0$+
M5U;O\9/(RP&S2['!KL/@R2"90+@/=G&CTT'<;,00OB-J^)/A[9N]LC9[I5\!
MHUPNBQ+7O+OPMP=3H\?1$:7 <5^XV]&5]^>SR!$_J\\Y;5Q2>$V%&AS^@!6C
MYE-1+FL8=B%Z[A"U%&XW\MW0XZ.88J([/GN+\JFA=FJO&;GS]XRJW6R8Q?_]
M(\BLC'1J]*5VE.X>"X9F2ZC"=Y:2IOQZ-OP2'9WO4Y%NY.+.<D%I.:XY)7]F
M3D( )_RLJ%QA0%Y0T%[O7*FYJR1M%4H'F<0"_6IK/F(I?#7]$L20&X%9J< 8
ML Z91*<;_&.8@DOGDL46&F6N;TR<9]C+@XY;IJ42T2'$6D\M^Z:#;'N57GP3
M^:C-]E^;[;^/]O%'@V8"^FV<)4NBK,9\&N' IJIT- ;7ZX@O1/FZ$8H5!%!E
ML5VUAQG/E]C[Z"N .9%B8Z'<4>MAZC'$_WHOHQ-J?S!NU07!MP,/DL#0GJ6M
M95"-YF&^V1.MV0(SUH,.:V/*A3(FZ[VG27)3=-%DV-!O:M*DU!F'K!???5/^
MVP6 ?!;\X:S2:2NV)$@Y=(9-Z4*VHM(86M#'IN8"PM&^"RSL/1H]V]F+3C&S
MOZ6P-=F8^Y(ABG"[I\4:8MNZQ(37/I8!0"$KD1#)<$UVL[PY=OV;JG3L-EX/
MI,_GTA"%6(JQEL,G(C5@3>"A2C-;KOB(3-T)BJ!K]MEE6;B[B<SJ$'CK"<$[
M^N^#HU-F\KW;UEN+;78=4-L+]UD-,A](^(J+?8B[S/8$&3UWHM37('UU:6N,
MXC,2^)9:("#);B%J@W98$;/*]6(";XC#$QJV(;=M\-)2/EB*%E@@,EM $OKC
M"]M#+Z!]PU63$"$!E]18=,4E=FT<8[]8AFHLU/T8Q^+'^NXZ &4(G$?4E.OV
MI,&#C(7U4'0WU0@3^%JPUIAK<>/$!7$Y _+L:)JH&PXU=KDCRW";7(Z(>SHO
MNU-UV&YTG%="9XZMK6A*>H4*<\WX-DS?$-TR?A/WE.4#F]X((TUK+N&XE E6
M,R(>ZI""4JD6$]])ET[J6>F[='HFLO!*)U".M\C'U+F$N)EK872GCP;3,0#"
M@06"<PG3LAV,;D"O=\Z'^"&<[FI1]GG\!M+JI=CY5E/Q:JG]%J+2%UBK"N&
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MX*!'(WG>(B*WDG0IMG>$ERLPA.>^>K2%FW>)8W+#)'"0M!XGY:'. T-5@?!
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MF&93T0!+/N@B= BZW-8>_M ?1#]\_^3IZ_XNNHXZ*Y4&5(%PHM'(O0+;1L2
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M),7^5>FG*B^6SLY8/V4/[1/Z;U!+ P04    "  ;B&Y:$P5_&<PB  #Z60$
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MYRZO4S1P'\&H\I<WM6,*!F!!A5TL$Y \L6<\L:-D<P_1=.CE4IQA..3R$6D
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M.!T;+Y9%Z\I/]]+LD7U9]_]02P,$%     @ &XAN6NAVN%<B"   <"L  !4
M  !G<FDM,C R-#$P:U]E>#,Q,BYH=&WM6FUOV[86_GY_!6^*VR6 [5A^21HG
M#> F[F:L-RD<!]L^7=#2D4U$$C52LN/]^ON0E-]B>W.7=G."%6@2F8?DX3D/
MG_.0UL4HBZ/+BQ'QX/)?%_\NE]FU]/.8DHSYBGA& <NU2(;LIX#T RN7"ZLK
MF4Z5&(XR5JO6FNPGJ1[$F+OV3&017<[&N3AVSQ?'=I*+@0RFEQ>!&#,1O#\0
MX>G@M$F\T3AY5V^<A,TSKQJ>G'FG?DB<GWC5_WD'Z ISUT=GTXC>'\0B*8_(
MS-]J--/L?"*";-3RJM7_'*S:<36$:293-,(NH\>LS",Q3%K6>UB'$FLMS'T9
M2=5Z4[7_SDU+.>2QB*:M[_HB)LUN:,)Z,N;)=R7-$UW6I$3H#+7XC=PD]G'B
MO#O%.)%(:.:M5S,N=AY'8B R5O<JM8MC8S];X]I*ESSV$4U2?Y/+5YU>O_NQ
M>]7N=V]OV.?[WMU]^Z;/^K>L=_^I<\>\.B][C4-^Q-HWU\QK!L73ZO+V<&'W
M-]>='NO_T&%WG:O[7K??Q6HZ/U_]T+[YOL/:5WUV^Y%Y9_5&:?_7TKYC[>O;
MS_W.]4J&]MYO1-["JEZMF6C;9+1[']HWG;OR[<^?.K_,\E"K5FM?O!IPCKI<
MZ_6M5]K8N-)NB7TBGB3$?J0HFI:83RH3X91E(YZ]?=-\=[YU>4^Y+.5! &8N
M1Q1FK?K)C-U$$F#QK;+W+OWV]+9YD5YEMHB_?O;5L'C52M.$H<M&?$Q,T5C0
M!#4M&PG-VDF2\XCU*)4J8S)A'Z6*F5<M_\A"J6!#;$I<,4)$ W9-/L4#4B#M
MDBEZ#29#]GVORSX(66+=Q*\@?6>O(7VUO4O?!ZZ1 60HGK*'1$XB"H94<EE4
M+GV!A N)A&S!#%PDC"=3EB>9R@DK@)"QF@8IXRS&DQ+(?,A]?*28C%&+,^GL
MU@P2)%YKKJ;&).8/9)$Q'U/CLP#.8,K("B+,80Q\H2" 8):@.SP) )W)2/@C
MIG/S8]%_0HJ*0<P"8J$C*"4CNB8B&V&!.B7?.FC&3>&:#+#,,;H%;#!=#H.%
MX':^?SD8K+\<#!(+18(L&\ LLEH" &&.9K74+A(P"^ E,(Y(_"@WS +D+*6P
M!-0)%4U9BL0;S!HL1]$"E 4>]).I@?M F(%+QB*/8  D2L#%3J>M/S[7(Q9&
M<J)G,%4T%#I3'!-Q\Z'S&UZ6EM"F9\ZL>?M:.*^Q=WCKKR3G[9MW->_T7!>(
M*E2#X0@9A@*/-FU=QA59@"#A8A"1+60$5 XBH4?&W)C%X$?#D>8Y$-J/I,[1
MSS"GDI%#2JJD3P$^UNP0P @(2'/9[SSZ(YX,B;5!2KT\@H45_\U#.K)=K?@W
M3^Y1&"F6.(2:\9EAKB7@.B 97W:>*%R9*,1$LX*]#&=8F*K_#%75;.P11'&:
MVA>,GE3./!.':])0V\B6+6E_#*62J;8^S_7N74S9&Q!@4<SD"JG,%08 .8V%
MMI0'*TKL.$9(+\ARF7 51=SBK*BD"ZR4"C(VC0+$"5^TC$1@[S]T/M B$%P)
MLP#AZKTM 8D9*=>F!MMMJ6W!M@0I-<&A#(1L.J4< /?SB!M>Q[*L$XM:CAY.
M&2P+&OPU(&,(ZD5_"IY!M?N%X\$>X;C>6,?QSH2U!N?=J6YG5&,GC$5@P,JU
M3+CA=*X!=",K#8*Y"F9H KX%'XA(9%-3W3=-:_:6!9[%E-L6*Z9+LM26CL=B
M06FN4F!:6S7B^U(%U@$K4(>40&3@-&M:*#5[QIA ?#OX8F^)%.S]:@#L[Q&
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M6^Y;H#%M?6>TD'?511<^ *_DV7J7K>^7K?QT;[P>VS=M_P]02P,$%     @
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M.<Z-CID4@\Y3\#Y]/H<^GM-D( 5@SNG[!Y&$'8.$57P02SZ#@X>\@P<7.TQ
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M %!+ 0(4 Q0    ( !N(;EKFF32'MUP# *\P&P 9              "  0
M  !C:S P,#$X,C0R.3,M,C R-#$R,S$N:'1M4$L! A0#%     @ &XAN6H2N
M;8'F$@  #ML  !D              ( ![EP# &-K,# P,3@R-#(Y,RTR,#(T
M,3(S,2YX<V102P$"% ,4    "  ;B&Y:+!S\J<08  !*[0  '0
M    @ $+< , 8VLP,# Q.#(T,CDS+3(P,C0Q,C,Q7V-A;"YX;6Q02P$"% ,4
M    "  ;B&Y:'R+H??=8  !MT , '0              @ $*B0, 8VLP,# Q
M.#(T,CDS+3(P,C0Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  ;B&Y:E833-P:Z
M P#NL@0 '               @ $\X@, 8VLP,# Q.#(T,CDS+3(P,C0Q,C,Q
M7V<Q+FIP9U!+ 0(4 Q0    ( !N(;EJ_T"#TPZ<  'BM   =
M  "  7R<!P!C:S P,#$X,C0R.3,M,C R-#$R,S%?9S$P+FIP9U!+ 0(4 Q0
M   ( !N(;EKW/U__,'\  +*&   =              "  7I$" !C:S P,#$X
M,C0R.3,M,C R-#$R,S%?9S$Q+FIP9U!+ 0(4 Q0    ( !N(;EJP$JLHYXH(
M />@"  =              "  >7#" !C:S P,#$X,C0R.3,M,C R-#$R,S%?
M9S$R+FIP9U!+ 0(4 Q0    ( !N(;EI]?<+QM*$! +01 @ =
M  "  0=/$0!C:S P,#$X,C0R.3,M,C R-#$R,S%?9S$S+FIP9U!+ 0(4 Q0
M   ( !N(;EJ$^?0A=P$# ',4 P =              "  ?;P$@!C:S P,#$X
M,C0R.3,M,C R-#$R,S%?9S$T+FIP9U!+ 0(4 Q0    ( !N(;EK!G'3@,-L
M /+S   =              "  :CR%0!C:S P,#$X,C0R.3,M,C R-#$R,S%?
M9S$U+FIP9U!+ 0(4 Q0    ( !N(;EH^H_*:K(0! -&N 0 =
M  "  1/.%@!C:S P,#$X,C0R.3,M,C R-#$R,S%?9S$V+FIP9U!+ 0(4 Q0
M   ( !N(;EJ"^\G561(. #HY#P <              "  ?I2& !C:S P,#$X
M,C0R.3,M,C R-#$R,S%?9S(N:G!G4$L! A0#%     @ &XAN6G0XNF 6&0(
M;TD" !P              ( !C64F &-K,# P,3@R-#(Y,RTR,#(T,3(S,5]G
M,RYJ<&=02P$"% ,4    "  ;B&Y:=X&R%ZJ^  "-)P$ '
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M,C R-#$R,S%?9S@N:G!G4$L! A0#%     @ &XAN6DCP/A02C@  'YD  !P
M             ( !/-LL &-K,# P,3@R-#(Y,RTR,#(T,3(S,5]G.2YJ<&=0
M2P$"% ,4    "  ;B&Y:CI]^(MOO  #*I0D '0              @ &(:2T
M8VLP,# Q.#(T,CDS+3(P,C0Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  ;B&Y:
MAA)(?K66  "_[P8 '0              @ &>62X 8VLP,# Q.#(T,CDS+3(P
M,C0Q,C,Q7W!R92YX;6Q02P$"% ,4    "  ;B&Y: V.9:PXQ  !-00$ %
M            @ &.\"X 9W)I+3(P,C0Q,&M?97@Q.2YH=&U02P$"% ,4
M"  ;B&Y:@,"QHI #  !)"P  %0              @ '.(2\ 9W)I+3(P,C0Q
M,&M?97@R,S$N:'1M4$L! A0#%     @ &XAN6A,%?QG,(@  ^ED! !0
M         ( !D24O &=R:2TR,#(T,3!K7V5X,S$N:'1M4$L! A0#%     @
M&XAN6J# <9DX"   LRL  !4              ( !CT@O &=R:2TR,#(T,3!K
M7V5X,S$Q+FAT;5!+ 0(4 Q0    ( !N(;EKH=KA7(@@  ' K   5
M      "  ?I0+P!G<FDM,C R-#$P:U]E>#,Q,BYH=&U02P$"% ,4    "  ;
MB&Y:RCUGWY4%   :&   %0              @ %/62\ 9W)I+3(P,C0Q,&M?
M97@S,C$N:'1M4$L! A0#%     @ &XAN6D?PW/2"!0  >A<  !4
M     ( !%U\O &=R:2TR,#(T,3!K7V5X,S(R+FAT;5!+ 0(4 Q0    ( !N(
M;EH0\_%@P14  +IK   5              "  <QD+P!G<FDM,C R-#$P:U]E
>>#0R."YH=&U02P4&     !X '@!W"   P'HO

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>ck0001824293-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001824293="http://www.vallon-pharma.com/20241231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001824293-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2025-03-11</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-09</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-06-14</startDate>
            <endDate>2024-06-14</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-21</startDate>
            <endDate>2025-02-21</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-20</startDate>
            <endDate>2024-05-20</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-21</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-20</startDate>
            <endDate>2024-12-20</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-26</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-03</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesBCommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD2WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesDWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-10-21</startDate>
            <endDate>2024-10-21</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:October2024PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PriorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-21</startDate>
            <endDate>2024-10-21</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ck0001824293:PeripheralEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:GRIOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:GRIOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-13</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-14</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-09</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-21</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedAndSeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PriorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:June2024PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesD1CommonWarrantsSeriesD2CommonWarrantsAndPAWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInAugust2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMarch2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInSeptember2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029OneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInOctober2029TwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:GRIOperationsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:GRIOperationsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ck0001824293:AardvarkTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-22</startDate>
            <endDate>2023-08-22</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ck0001824293:StateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">ck0001824293:LocalTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="closing">
        <measure>ck0001824293:closing</measure>
    </unit>
    <unit id="year">
        <measure>ck0001824293:year</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-34">0001824293</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-35">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-36">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-37">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-31" decimals="4" id="f-257" unitRef="number">0.0333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-32" decimals="4" id="f-258" unitRef="number">0.1429</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-33" decimals="4" id="f-259" unitRef="number">0.0769</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-34" decimals="4" id="f-260" unitRef="number">0.0588</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-34" decimals="4" id="f-665" unitRef="number">0.0588</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">GRI BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">2223 Avenida de la Playa</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">#208</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">400-1170</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">GRI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-27">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-28">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-29">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-30">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-31" unitRef="usd">1500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-32" unitRef="shares">525358</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-33">&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-38">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the critical importance of maintaining the trust and confidence of patients, business partners and employees toward our business and are committed to protecting the confidentiality, integrity and availability of our business operations and systems. Our Board is actively involved in oversight of our risk management activities, and cybersecurity represents an important element of our overall approach to risk management. In general, we seek to address cybersecurity risks through a comprehensive approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cybersecurity Risk Management and Strategy; Effect of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We face risks related to cybersecurity such as unauthorized access, cybersecurity attacks and other security incidents, including as perpetrated by hackers and unintentional damage or disruption to hardware and software systems, loss of data, and misappropriation of confidential information. To identify and assess material risks from cybersecurity threats, we maintain a cybersecurity program to ensure our systems are effective and prepared for information security risks, including regular oversight of our programs for security monitoring for internal and external threats to ensure the confidentiality and integrity of our information assets. We consider risks from cybersecurity threats alongside other company risks as part of our overall risk assessment process. As discussed in more detail under &#x201c;Cybersecurity Governance&#x201d; below, our Board provides oversight of our cybersecurity risk management and strategy processes, which are led by our Chief Financial Officer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To provide for the availability of critical data and systems, maintain regulatory compliance, manage our material risks from cybersecurity threats, and protect against and respond to cybersecurity incidents, we undertake the following activities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;monitor emerging data protection laws and implement changes to our processes that are designed to comply with such laws;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;through our policies, practices and contracts (as applicable), require employees, as well as third parties that provide services on our behalf, to treat confidential information and data with care;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;employ technical safeguards that are designed to protect our information systems from cybersecurity threats, including firewalls, intrusion prevention and detection systems, anti-malware functionality and access controls; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;provide training for our employees regarding cybersecurity threats as a means to equip them with effective tools to address cybersecurity threats, and to communicate our evolving information security policies, standards, processes and practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our incident response plan coordinates the activities we take to prepare for, detect, respond to and recover from cybersecurity incidents, which include processes to triage, assess severity for, escalate, contain, investigate and remediate the incident, as well as to comply with potentially applicable legal obligations and mitigate damage to our business and reputation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our processes also address cybersecurity threat risks associated with our use of third-party service providers who have access to employee data or our systems. In addition, cybersecurity considerations affect the selection and oversight of our third-party service providers.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;We describe whether and how risks from identified cybersecurity threats, including as a result of any previous cybersecurity incidents, have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition, in Item 1A. under the heading &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;We may be unable to adequately protect our internal information systems, or those used by our CROs, clinical sites, or other contractors or consultants upon which we rely,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;from cyberattacks, compromises, cybersecurity incidents, or other disruptions, which could result in the compromise of sensitive or proprietary information, lead to operational or service interruption, harm our reputation,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;and subject us to litigation, fines and other significant financial and legal exposure, and other adverse consequences,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x201d; which disclosures are incorporated by reference herein.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the last three fiscal years, we have not experienced any material cybersecurity incidents and the expenses we have incurred from cybersecurity incidents were immaterial. This includes penalties and settlements, of which there were none.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-39">In general, we seek to address cybersecurity risks through a comprehensive approach that is focused on preserving the confidentiality, security and availability of the information that we collect and store by identifying, preventing and mitigating cybersecurity threats and effectively responding to cybersecurity incidents when they occur.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-42">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-43">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-44">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity is an important part of our risk management processes and an area of focus for our Board and management. Our Board is responsible for the oversight of risks from cybersecurity threats. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our Board receives periodic updates from management about our cybersecurity threat risk management and strategy processes. Additionally, upon detection of a cybersecurity threat, our Board receives an update from management of our cybersecurity threat risk management and strategy processes, as well as the steps management has taken to respond to such identified cybersecurity threat. Our Board also receive prompt and timely information regarding any cybersecurity incident that meets establishing reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, is managed by our Chief Financial Officer and supported by consultants with experience in managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs as needed. As discussed above, the Chief Financial Officer reports to our Board about material cybersecurity threat risks.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-45">Cybersecurity is an important part of our risk management processes and an area of focus for our Board and management. Our Board is responsible for the oversight of risks from cybersecurity threats.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-47">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our Board receives periodic updates from management about our cybersecurity threat risk management and strategy processes. Additionally, upon detection of a cybersecurity threat, our Board receives an update from management of our cybersecurity threat risk management and strategy processes, as well as the steps management has taken to respond to such identified cybersecurity threat. Our Board also receive prompt and timely information regarding any cybersecurity incident that meets establishing reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-46">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Our Board receives periodic updates from management about our cybersecurity threat risk management and strategy processes. Additionally, upon detection of a cybersecurity threat, our Board receives an update from management of our cybersecurity threat risk management and strategy processes, as well as the steps management has taken to respond to such identified cybersecurity threat. Our Board also receive prompt and timely information regarding any cybersecurity incident that meets establishing reporting thresholds, as well as ongoing updates regarding any such incident until it has been addressed&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-50">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, is managed by our Chief Financial Officer and supported by consultants with experience in managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs as needed. As discussed above, the Chief Financial Officer reports to our Board about material cybersecurity threat risks.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-49">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, is managed by our Chief Financial Officer and supported by consultants with experience in managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs as needed.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-48">Our cybersecurity risk management and strategy processes, which are discussed in greater detail above, is managed by our Chief Financial Officer and supported by consultants with experience in managing information security, developing cybersecurity strategy, implementing effective information and cybersecurity programs as needed.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-51">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-52">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-4" id="f-53">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-54">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-55">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-56">false</ecd:NonRule10b51ArrTrmntdFlag>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-5" decimals="INF" id="f-57" unitRef="shares">809</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c-6" decimals="INF" id="f-58" unitRef="shares">164</us-gaap:ConversionOfStockSharesConverted1>
    <ck0001824293:ConversionOfStockAdditionalSharesConverted contextRef="c-6" decimals="INF" id="f-59" unitRef="shares">656</ck0001824293:ConversionOfStockAdditionalSharesConverted>
    <dei:AuditorName contextRef="c-1" id="f-60">Sadler, Gibb &amp; Associates LLC</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-61">Draper, Utah</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-62">3627</dei:AuditorFirmId>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-63">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-64" unitRef="usd">5028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-3" id="f-65" unitRef="usd">1808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-66" unitRef="usd">587000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-8" decimals="-3" id="f-67" unitRef="usd">1126000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-68" unitRef="usd">5615000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-8" decimals="-3" id="f-69" unitRef="usd">2934000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-70" unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-71" unitRef="usd">8000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-72" unitRef="usd">120000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-8" decimals="-3" id="f-73" unitRef="usd">14000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-74" unitRef="usd">5739000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-8" decimals="-3" id="f-75" unitRef="usd">2956000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-76" unitRef="usd">897000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-3" id="f-77" unitRef="usd">1410000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-78" unitRef="usd">691000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-79" unitRef="usd">1270000</us-gaap:AccruedLiabilitiesCurrent>
    <ck0001824293:WarrantLiabilityCurrent contextRef="c-7" decimals="-3" id="f-80" unitRef="usd">0</ck0001824293:WarrantLiabilityCurrent>
    <ck0001824293:WarrantLiabilityCurrent contextRef="c-8" decimals="-3" id="f-81" unitRef="usd">3000</ck0001824293:WarrantLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-82" unitRef="usd">48000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-8" decimals="-3" id="f-83" unitRef="usd">14000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-84" unitRef="usd">1636000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-85" unitRef="usd">2697000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-86" unitRef="usd">71000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-87" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-88" unitRef="usd">1707000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-8" decimals="-3" id="f-89" unitRef="usd">2697000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-90" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-8" id="f-91" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-92"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-93"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-94" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="INF" id="f-95" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-96" unitRef="shares">525485</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="INF" id="f-97" unitRef="shares">525485</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-98" unitRef="shares">2909</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="INF" id="f-99" unitRef="shares">2909</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-8" decimals="-3" id="f-101" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-7" decimals="-3" id="f-102" unitRef="usd">43772000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-8" decimals="-3" id="f-103" unitRef="usd">31792000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-104" unitRef="usd">-39740000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-3" id="f-105" unitRef="usd">-31533000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-106" unitRef="usd">4032000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-107" unitRef="usd">259000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-108" unitRef="usd">5739000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-8" decimals="-3" id="f-109" unitRef="usd">2956000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">3768000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-9" decimals="-3" id="f-111" unitRef="usd">3232000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-112" unitRef="usd">4467000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-9" decimals="-3" id="f-113" unitRef="usd">8155000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-114" unitRef="usd">8235000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-9" decimals="-3" id="f-115" unitRef="usd">11387000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">-8235000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-9" decimals="-3" id="f-117" unitRef="usd">-11387000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-118" unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-9" decimals="-3" id="f-119" unitRef="usd">250000</us-gaap:OtherNonoperatingIncomeExpense>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">3000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-9" decimals="-3" id="f-121" unitRef="usd">182000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">25000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-9" decimals="-3" id="f-123" unitRef="usd">-2082000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">-8207000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-125" unitRef="usd">-13037000</us-gaap:NetIncomeLoss>
    <us-gaap:RedeemablePreferredStockDividends contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">1911000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:RedeemablePreferredStockDividends contextRef="c-9" decimals="-3" id="f-127" unitRef="usd">0</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-128" unitRef="usd">-10118000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-9" decimals="-3" id="f-129" unitRef="usd">-13037000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-130"
      unitRef="usdPerShare">-55.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-131"
      unitRef="usdPerShare">-55.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-9"
      decimals="2"
      id="f-132"
      unitRef="usdPerShare">-5018.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-9"
      decimals="2"
      id="f-133"
      unitRef="usdPerShare">-5018.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-134" unitRef="shares">183278</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-135" unitRef="shares">183278</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-9" decimals="0" id="f-136" unitRef="shares">2598</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-9" decimals="0" id="f-137" unitRef="shares">2598</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-138"
      unitRef="shares">646</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-139" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-140" unitRef="usd">16871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-141" unitRef="usd">-18496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-142" unitRef="usd">-1625000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-143" unitRef="usd">388000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-9" decimals="-3" id="f-144" unitRef="usd">388000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-15"
      decimals="INF"
      id="f-145"
      unitRef="shares">106</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-14" decimals="-3" id="f-146" unitRef="usd">532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-9" decimals="-3" id="f-147" unitRef="usd">532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c-15"
      decimals="INF"
      id="f-148"
      unitRef="shares">1028</ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise>
    <ck0001824293:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-14" decimals="-3" id="f-149" unitRef="usd">12000</ck0001824293:StockIssuedDuringPeriodValueWarrantExercises>
    <ck0001824293:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-9" decimals="-3" id="f-150" unitRef="usd">12000</ck0001824293:StockIssuedDuringPeriodValueWarrantExercises>
    <ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing
      contextRef="c-15"
      decimals="INF"
      id="f-151"
      unitRef="shares">785</ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing contextRef="c-14" decimals="-3" id="f-152" unitRef="usd">11721000</ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing contextRef="c-9" decimals="-3" id="f-153" unitRef="usd">11721000</ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt
      contextRef="c-15"
      decimals="INF"
      id="f-154"
      unitRef="shares">35</ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt contextRef="c-14" decimals="-3" id="f-155" unitRef="usd">3333000</ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt contextRef="c-9" decimals="-3" id="f-156" unitRef="usd">3333000</ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses
      contextRef="c-15"
      decimals="INF"
      id="f-157"
      unitRef="shares">19</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses contextRef="c-14" decimals="-3" id="f-158" unitRef="usd">1875000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses contextRef="c-9" decimals="-3" id="f-159" unitRef="usd">1875000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization
      contextRef="c-15"
      decimals="INF"
      id="f-160"
      unitRef="shares">290</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-14" decimals="-3" id="f-161" unitRef="usd">-2940000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-9" decimals="-3" id="f-162" unitRef="usd">-2940000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization>
    <us-gaap:NetIncomeLoss contextRef="c-16" decimals="-3" id="f-163" unitRef="usd">-13037000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-164" unitRef="usd">-13037000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-165"
      unitRef="shares">2909</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-166" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-167" unitRef="usd">31792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-168" unitRef="usd">-31533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-169" unitRef="usd">259000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-170" unitRef="usd">148000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">148000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment
      contextRef="c-21"
      decimals="INF"
      id="f-172"
      unitRef="shares">12</ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment>
    <ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c-21"
      decimals="INF"
      id="f-173"
      unitRef="shares">191946</ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise>
    <ck0001824293:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-20" decimals="-3" id="f-174" unitRef="usd">666000</ck0001824293:StockIssuedDuringPeriodValueWarrantExercises>
    <ck0001824293:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">666000</ck0001824293:StockIssuedDuringPeriodValueWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-21"
      decimals="INF"
      id="f-176"
      unitRef="shares">330642</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-177" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-20" decimals="-3" id="f-178" unitRef="usd">11166000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">11166000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-180" unitRef="usd">-8207000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">-8207000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-23"
      decimals="INF"
      id="f-182"
      unitRef="shares">525485</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-183" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-184" unitRef="usd">43772000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-185" unitRef="usd">-39740000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-186" unitRef="usd">4032000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">-8207000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-9" decimals="-3" id="f-188" unitRef="usd">-13037000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-189" unitRef="usd">4000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-9" decimals="-3" id="f-190" unitRef="usd">4000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-9" decimals="-3" id="f-192" unitRef="usd">2104000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">148000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-9" decimals="-3" id="f-194" unitRef="usd">388000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-195" unitRef="usd">-3000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-9" decimals="-3" id="f-196" unitRef="usd">-182000</us-gaap:FairValueAdjustmentOfWarrants>
    <ck0001824293:OperatingLeaseRightOfUseAssetPeriodicAddition contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">105000</ck0001824293:OperatingLeaseRightOfUseAssetPeriodicAddition>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-9" decimals="-3" id="f-198" unitRef="usd">53000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">-313000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-9" decimals="-3" id="f-200" unitRef="usd">547000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">-387000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-9" decimals="-3" id="f-202" unitRef="usd">2159000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-479000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-9" decimals="-3" id="f-204" unitRef="usd">125000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">105000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-9" decimals="-3" id="f-206" unitRef="usd">-57000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">-8611000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-9" decimals="-3" id="f-208" unitRef="usd">-8990000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-9" decimals="-3" id="f-210" unitRef="usd">8000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-9" decimals="-3" id="f-212" unitRef="usd">-8000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ck0001824293:ProceedsFromAdvancesFromEmployees contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">0</ck0001824293:ProceedsFromAdvancesFromEmployees>
    <ck0001824293:ProceedsFromAdvancesFromEmployees contextRef="c-9" decimals="-3" id="f-214" unitRef="usd">190000</ck0001824293:ProceedsFromAdvancesFromEmployees>
    <ck0001824293:RepaymentOfAdvancesFromEmployees contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">0</ck0001824293:RepaymentOfAdvancesFromEmployees>
    <ck0001824293:RepaymentOfAdvancesFromEmployees contextRef="c-9" decimals="-3" id="f-216" unitRef="usd">195000</ck0001824293:RepaymentOfAdvancesFromEmployees>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-9" decimals="-3" id="f-218" unitRef="usd">1250000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-26" decimals="-3" id="f-219" unitRef="usd">9499000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-27" decimals="-3" id="f-220" unitRef="usd">12250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-28" decimals="-3" id="f-221" unitRef="usd">3604000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-29" decimals="-3" id="f-222" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">762000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-9" decimals="-3" id="f-224" unitRef="usd">12000</us-gaap:ProceedsFromWarrantExercises>
    <ck0001824293:PaymentForFractionalSharesReverseStockSplit contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">1000</ck0001824293:PaymentForFractionalSharesReverseStockSplit>
    <ck0001824293:PaymentForFractionalSharesReverseStockSplit contextRef="c-9" decimals="-3" id="f-226" unitRef="usd">0</ck0001824293:PaymentForFractionalSharesReverseStockSplit>
    <ck0001824293:CashAcquiredInReverseRecapitalization contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">0</ck0001824293:CashAcquiredInReverseRecapitalization>
    <ck0001824293:CashAcquiredInReverseRecapitalization contextRef="c-9" decimals="-3" id="f-228" unitRef="usd">941000</ck0001824293:CashAcquiredInReverseRecapitalization>
    <ck0001824293:PaymentOfReverseRecapitalizationCosts contextRef="c-1" decimals="-3" id="f-229" unitRef="usd">0</ck0001824293:PaymentOfReverseRecapitalizationCosts>
    <ck0001824293:PaymentOfReverseRecapitalizationCosts contextRef="c-9" decimals="-3" id="f-230" unitRef="usd">2984000</ck0001824293:PaymentOfReverseRecapitalizationCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">2033000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-9" decimals="-3" id="f-232" unitRef="usd">517000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-9" decimals="-3" id="f-234" unitRef="usd">150000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">11831000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-9" decimals="-3" id="f-236" unitRef="usd">10797000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">3220000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-9" decimals="-3" id="f-238" unitRef="usd">1799000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-239" unitRef="usd">1808000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-240" unitRef="usd">9000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-241" unitRef="usd">5028000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-3" id="f-242" unitRef="usd">1808000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ck0001824293:StockIssuedForRepaymentOfNotesPayable contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">0</ck0001824293:StockIssuedForRepaymentOfNotesPayable>
    <ck0001824293:StockIssuedForRepaymentOfNotesPayable contextRef="c-9" decimals="-3" id="f-244" unitRef="usd">3333000</ck0001824293:StockIssuedForRepaymentOfNotesPayable>
    <ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">0</ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants>
    <ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants contextRef="c-9" decimals="-3" id="f-246" unitRef="usd">532000</ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants>
    <ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">0</ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization>
    <ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization contextRef="c-9" decimals="-3" id="f-248" unitRef="usd">3881000</ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization>
    <ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">0</ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid>
    <ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid contextRef="c-9" decimals="-3" id="f-250" unitRef="usd">226000</ck0001824293:DebtIssuanceCostsAndFinancingCostsIncurredButNotYetPaid>
    <ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">0</ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts>
    <ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts contextRef="c-9" decimals="-3" id="f-252" unitRef="usd">1875000</ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts>
    <ck0001824293:WarrantsIssued contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">287000</ck0001824293:WarrantsIssued>
    <ck0001824293:WarrantsIssued contextRef="c-9" decimals="-3" id="f-254" unitRef="usd">18000</ck0001824293:WarrantsIssued>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-255">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. The Company&#x2019;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#x2019;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT I) cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#x2019;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T (dNKT) cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reverse Merger with Vallon Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, pursuant to an Agreement and Plan of Merger, dated as of December 13, 2022, as amended on February 17, 2023 (the Merger Agreement), by and among the Company, GRI Bio Operations, Inc., formerly known as GRI Bio, Inc. (GRI Operations), and Vallon Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Merger Sub), Merger Sub was merged with and into GRI Operations (the Merger), with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company (Note 4). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and amended its bylaws to change its name from &#x201c;Vallon Pharmaceuticals, Inc.&#x201d; to &#x201c;GRI Bio, Inc.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Splits&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger, and immediately prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of its common stock, par value $0.0001(Common Stock), at a ratio of one-for thirty (the April 2023 Reverse Stock Split). On January 29, 2024, the Company effected a reverse stock split of its common stock at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 14, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split). On February 21, 2025, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seventeen (the February 2025 Reverse Stock Split and together with the April 2023 Reverse Stock Split, the January 2024 Reverse Stock Split and the June 2024 Reverse Stock Split, the Reverse Stock Splits).Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, GRI Operations. All Common Stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio (as defined below) and the Reverse Stock Splits for all periods presented, to the extent applicable.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-30"
      decimals="INF"
      id="f-256"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c-1" id="f-261">LIQUIDITY&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $39,740 in accumulated deficit through December&#160;31, 2024. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of December&#160;31, 2024, the Company had cash of approximately $5,028. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, the Company, GRI Operations and Altium Growth Fund, LP (Altium) entered into a Securities Purchase Agreement, dated December 13, 2022 (the Equity SPA), pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes (as defined below) in return for the issuance of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of GRI Operations common stock (GRI Operations Common Stock) immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued 4,387 shares of GRI Operations Common Stock (the Initial Shares) to Altium and 17,549 shares of GRI Operations Common Stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 164 shares of the Company&#x2019;s Common Stock and the Additional Shares converted into an aggregate of 656 shares of the Company&#x2019;s Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Company&#x2019;s Common Stock issued in exchange for the Additional Shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2024, the Company entered into a securities purchase agreement (the Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering, (i) 1,495 shares (the February 2024 Shares) of Common Stock, (ii) 21,131 pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock, and (iv) 22,631 Series B-2 common warrants (the Series B-2 Common Warrants, and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of 22,631 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Annual Report on Form 10-K for the year ended December 31, 2024 (Annual Report) as the &#x201c;February 2024 Warrants.&#x201d; The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $243.10 (less $0.0221 for each February Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The February 2024 Pre-Funded Warrants have been exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 and expires on February 6, 2029. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 and expires on August 6, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the securities pursuant to the Purchase Agreement, the exercise price of the Series A-1 Warrants was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants. As of December&#160;31, 2024, all of the Series A-1 Warrants have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp;amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0&#160;million shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company has sold 325,618 shares of Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3,605 of gross proceeds and net proceeds of $3,467, after deducting commissions to the sales agent and other ATM Offering related expenses. On December 20, 2024, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $322, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3,605 that were sold under the ATM Offering through December&#160;31, 2024, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering (the June 2024 Offering), (i) 3,529 shares (the June 2024 Shares) of Common Stock, (ii) 125,047 pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of 125,047 shares of Common Stock, (iii) 128,577 Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of 128,577 shares of Common Stock, and (iv) 128,577 Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants) exercisable for an aggregate of 128,577 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Annual Report as the &#x201c;June 2024 Warrants.&#x201d; The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $31.11 (less $0.0017 for each June 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2024 Pre-Funded Warrants have been exercised in full. Each Series C-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 and expires on September 6, 2029. Each Series C-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 and expires on March 6, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wainwright acted as the exclusive placement agent for the June 2024 Offering. Pursuant to an engagement agreement (the June 2024 Engagement Agreement) with Wainwright, dated as of May 3, 2024, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,002 shares of Common Stock (the June 2024 PA Warrants)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The June 2024 PA Warrants have an exercise price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$38.89&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share, will expire on June 26, 2029 and are exercisable beginning after September 6, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 21, 2024, the Company entered into letter agreements (the Repricing Letter Agreements) with certain holders (the Holders) of its issued and outstanding Series B Common Warrants to purchase an aggregate of 44,842 shares of its Common Stock, offering these Holders the opportunity to exercise all of their Series B Common Warrants for cash at a reduced exercise price equal to $17.00 per share. In addition, these Holders received new unregistered Series D-1 Warrants (the Series Common D-1 Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock and new unregistered Series D-2 Common Warrants (the Series D-2 Common Warrants and, together with the Series D-1 Common Warrants, the Series D Common Warrants) exercisable for up to an aggregate of 44,839 shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $17.00 per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We refer to this transaction as the &#x201c;Warrant Repricing Transaction.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pursuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $25,000 and non-accountable expenses of $10,000. The Company has also issued to Wainwright or its designees warrants to purchase up to an aggregate of 3,140 shares of Common Stock (the October 2024 PA Warrants). The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $21.25 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross proceeds to the Company from the exercise of the Series B Common Warrants were $762 prior to deducting placement agent fees and offering expenses of $154. The issuance under the Repricing Letter Agreements represented $1,911 in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the second quarter of 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#x2019;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-262" unitRef="usd">-39740000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-263" unitRef="usd">5028000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-35" decimals="-3" id="f-264" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-36"
      decimals="INF"
      id="f-265"
      unitRef="shares">4387</us-gaap:CommonStockSharesIssued>
    <ck0001824293:CommonStockHeldIntoEscrowAccount
      contextRef="c-30"
      decimals="INF"
      id="f-266"
      unitRef="shares">17549</ck0001824293:CommonStockHeldIntoEscrowAccount>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-31" decimals="-3" id="f-267" unitRef="usd">11704000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-31" decimals="-3" id="f-268" unitRef="usd">546000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c-6" decimals="INF" id="f-269" unitRef="shares">164</us-gaap:ConversionOfStockSharesConverted1>
    <ck0001824293:ConversionOfStockAdditionalSharesConverted contextRef="c-6" decimals="INF" id="f-270" unitRef="shares">656</ck0001824293:ConversionOfStockAdditionalSharesConverted>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-37"
      decimals="INF"
      id="f-271"
      unitRef="shares">1495</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-38"
      decimals="INF"
      id="f-272"
      unitRef="shares">21131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-38"
      decimals="INF"
      id="f-273"
      unitRef="shares">21131</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-274"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-39"
      decimals="INF"
      id="f-275"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-276"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-40"
      decimals="INF"
      id="f-277"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-37" decimals="-3" id="f-278" unitRef="usd">4389000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-37" decimals="-3" id="f-279" unitRef="usd">1110000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-41"
      decimals="INF"
      id="f-280"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-38"
      decimals="INF"
      id="f-281"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-39"
      decimals="INF"
      id="f-282"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-40"
      decimals="INF"
      id="f-283"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-41"
      decimals="INF"
      id="f-284"
      unitRef="usdPerShare">243.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-42"
      decimals="INF"
      id="f-285"
      unitRef="usdPerShare">0.0221</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-43"
      decimals="INF"
      id="f-286"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-43"
      decimals="INF"
      id="f-287"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-44"
      decimals="INF"
      id="f-288"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-44"
      decimals="INF"
      id="f-289"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-45"
      decimals="INF"
      id="f-290"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-46" decimals="-5" id="f-291" unitRef="usd">10000000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <ck0001824293:SaleOfStockAgentCompensationPercentage contextRef="c-46" decimals="3" id="f-292" unitRef="number">0.030</ck0001824293:SaleOfStockAgentCompensationPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-47"
      decimals="INF"
      id="f-293"
      unitRef="shares">325618</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-48"
      decimals="2"
      id="f-294"
      unitRef="usdPerShare">11.07</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-47" decimals="-3" id="f-295" unitRef="usd">3605000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-47" decimals="-3" id="f-296" unitRef="usd">3467000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-49" decimals="-3" id="f-297" unitRef="usd">322000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-47" decimals="-3" id="f-298" unitRef="usd">3605000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-50"
      decimals="INF"
      id="f-299"
      unitRef="shares">3529</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-51"
      decimals="INF"
      id="f-300"
      unitRef="shares">125047</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-51"
      decimals="INF"
      id="f-301"
      unitRef="shares">125047</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-51"
      decimals="INF"
      id="f-302"
      unitRef="shares">125047</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-52"
      decimals="INF"
      id="f-303"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-52"
      decimals="INF"
      id="f-304"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-53"
      decimals="INF"
      id="f-305"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-53"
      decimals="INF"
      id="f-306"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-50" decimals="-3" id="f-307" unitRef="usd">3172000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-50" decimals="-3" id="f-308" unitRef="usd">1057000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-54"
      decimals="INF"
      id="f-309"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-51"
      decimals="INF"
      id="f-310"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-52"
      decimals="INF"
      id="f-311"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-53"
      decimals="INF"
      id="f-312"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-54"
      decimals="INF"
      id="f-313"
      unitRef="usdPerShare">31.11</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-55"
      decimals="INF"
      id="f-314"
      unitRef="usdPerShare">0.0017</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-56"
      decimals="INF"
      id="f-315"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-54"
      decimals="INF"
      id="f-316"
      unitRef="usdPerShare">31.11</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-57"
      decimals="INF"
      id="f-317"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-57"
      decimals="INF"
      id="f-318"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-58"
      decimals="INF"
      id="f-319"
      unitRef="shares">9002</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-58"
      decimals="2"
      id="f-320"
      unitRef="usdPerShare">38.89</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-59"
      decimals="INF"
      id="f-321"
      unitRef="shares">44842</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-59"
      decimals="2"
      id="f-322"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-60"
      decimals="INF"
      id="f-323"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-61"
      decimals="INF"
      id="f-324"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-62"
      decimals="2"
      id="f-325"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds
      contextRef="c-63"
      decimals="INF"
      id="f-326"
      unitRef="number">0.070</ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds
      contextRef="c-63"
      decimals="INF"
      id="f-327"
      unitRef="number">0.010</ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockReimbursementOfAccountableExpenses contextRef="c-63" decimals="-3" id="f-328" unitRef="usd">25000</ck0001824293:SaleOfStockReimbursementOfAccountableExpenses>
    <ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses contextRef="c-63" decimals="-3" id="f-329" unitRef="usd">10000</ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-64"
      decimals="INF"
      id="f-330"
      unitRef="shares">3140</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-64"
      decimals="2"
      id="f-331"
      unitRef="usdPerShare">21.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-65" decimals="-3" id="f-332" unitRef="usd">762000</us-gaap:ProceedsFromWarrantExercises>
    <ck0001824293:ClassOfWarrantOrRightOfferingCost contextRef="c-65" decimals="-3" id="f-333" unitRef="usd">154000</ck0001824293:ClassOfWarrantOrRightOfferingCost>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-63" decimals="-3" id="f-334" unitRef="usd">1911000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-335">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in this Annual Report to &#x201c;authoritative guidance&#x201d; is meant to refer to accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly-owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of December&#160;31, 2024 and 2023 included investment in money market funds.&#160;The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $4,521 and $1,217 at December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Pricing inputs that are generally unobservable inputs and not corroborated by market data.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At December&#160;31, 2024, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the statement of operations for the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost. The Company commences depreciation when the asset is placed in service. Computers and peripheral equipment are depreciated on a straight-line method over useful lives of three years.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to use, or control the use of, identified property, plant, or equipment for a period of time in exchange for consideration. Lease right-of-use (ROU) assets and lease liabilities recognized in the accompanying balance sheet represent the right to use an underlying asset for the lease term and an obligation to make lease payments arising from the lease respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the lease commencement date, the Company recognizes an ROU asset and a lease liability for its operating leases, except its short-term operating leases with original lease terms of twelve months or less. The ROU asset is initially measured at cost, which primarily comprises the initial amount of the lease liability plus any lease prepayments. The lease liability is initially measured at the present value of the lease payments not yet paid, discounted using an estimate of the Company&#x2019;s incremental borrowing rate for a collateralized loan with a similar amount and terms as the underlying lease in a similar economic environment. That discount rate is used because the interest rate implicit in the Company&#x2019;s lease contracts is typically not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease modifications that grant the right to use an existing leased asset for an additional period of time are not accounted for as separate contracts; however, the lease term, classification, discount rate, and measurement of the remaining consideration due under the contract are reassessed upon execution of such modifications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the May 2022 Warrants (Note 10) in accordance with ASC 815-40, and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the accompanying consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with changes in fair value recognized in the accompanying consolidated statements of operations in the period of change. The derivative liabilities will ultimately be converted into the Common Stock when the warrants are exercised, or will be extinguished upon expiry of the warrant term. Upon exercise, the intrinsic value of the shares issued is transferred to stockholders&#x2019; equity. The difference between the intrinsic value of the stock issued and the fair value of the warrant is recorded as gain or loss on the exchange in the accompanying consolidated statements of operations in the period of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's Common Stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;As the Company had a net loss in each of the years ended December&#160;31, 2024 and 2023, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;359,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;359,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2024-03). The amendments in ASU 2024-03 require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, for all public entities. Early adoption is permitted. Management is currently evaluating the impact of this update on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2023-09). The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. Management is currently evaluating the impact of this update on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, FASB issued ASU 2023-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2023-06)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendments in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2023-06 represent changes to clarify or improve disclosure and presentation requirements of a variety of topics in the Codification and align those requirements with the SEC&#x2019;s regulation. For entities subject to the Security and Exchange Commission&#x2019;s (SEC) existing disclosure requirements, the effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. Management is currently evaluating the impact of this update and its effective dates but does not expect the update to have a material effect on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-336">References in this Annual Report to &#x201c;authoritative guidance&#x201d; is meant to refer to accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-337">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly-owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-338">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-339">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are highly-liquid investments that are readily convertible into cash with original maturities of three months or less when purchased and as of December&#160;31, 2024 and 2023 included investment in money market funds.&#160;The Company maintains its cash and cash equivalent balances at domestic financial institutions. Bank deposits with US banks are insured up to $250 by the Federal Deposits Insurance Corporation. The Company had an uninsured cash balances of $4,521 and $1,217 at December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashFDICInsuredAmount contextRef="c-7" decimals="-3" id="f-340" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:CashUninsuredAmount contextRef="c-7" decimals="-3" id="f-341" unitRef="usd">4521000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount contextRef="c-8" decimals="-3" id="f-342" unitRef="usd">1217000</us-gaap:CashUninsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-343">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Pricing inputs that are generally unobservable inputs and not corroborated by market data.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At December&#160;31, 2024, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the statement of operations for the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-344">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;Property and equipment are stated at cost. The Company commences depreciation when the asset is placed in service. Computers and peripheral equipment are depreciated on a straight-line method over useful lives of three years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-66" id="f-345">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-67" id="f-346">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-347">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to use, or control the use of, identified property, plant, or equipment for a period of time in exchange for consideration. Lease right-of-use (ROU) assets and lease liabilities recognized in the accompanying balance sheet represent the right to use an underlying asset for the lease term and an obligation to make lease payments arising from the lease respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the lease commencement date, the Company recognizes an ROU asset and a lease liability for its operating leases, except its short-term operating leases with original lease terms of twelve months or less. The ROU asset is initially measured at cost, which primarily comprises the initial amount of the lease liability plus any lease prepayments. The lease liability is initially measured at the present value of the lease payments not yet paid, discounted using an estimate of the Company&#x2019;s incremental borrowing rate for a collateralized loan with a similar amount and terms as the underlying lease in a similar economic environment. That discount rate is used because the interest rate implicit in the Company&#x2019;s lease contracts is typically not readily determinable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease modifications that grant the right to use an existing leased asset for an additional period of time are not accounted for as separate contracts; however, the lease term, classification, discount rate, and measurement of the remaining consideration due under the contract are reassessed upon execution of such modifications.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense for operating leases is recognized on a straight-line basis over the term of the lease and is included in operating expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-348">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrant Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the May 2022 Warrants (Note 10) in accordance with ASC 815-40, and concluded that a provision in the warrants related to the reduction of the exercise price in certain circumstances precludes the warrants from being accounted for as components of equity. As the warrants meet the definition of a derivative as contemplated in ASC 815, the warrants are recorded as derivative liabilities on the accompanying consolidated balance sheets and measured at fair value at inception and at each reporting date in accordance with ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with changes in fair value recognized in the accompanying consolidated statements of operations in the period of change. The derivative liabilities will ultimately be converted into the Common Stock when the warrants are exercised, or will be extinguished upon expiry of the warrant term. Upon exercise, the intrinsic value of the shares issued is transferred to stockholders&#x2019; equity. The difference between the intrinsic value of the stock issued and the fair value of the warrant is recorded as gain or loss on the exchange in the accompanying consolidated statements of operations in the period of exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-349">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel costs associated with research and development activities, including third-party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. The Company accrues for costs incurred by external service providers, including contract research organizations and clinical investigators, based on its estimates of service performed and costs incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-350">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes expense for employee and non-employee stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 718). ASC 718 requires that such transactions be accounted for using a fair value-based method. The estimated fair value of the options is amortized over the vesting period, based on the fair value of the options on the date granted, and is calculated using the Black-Scholes option-pricing model. The Company accounts for forfeitures as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of options and shares issued under the employee stock purchase plan requires the input of subjective assumptions, including the estimated fair value of the Company's Common Stock, the expected life of the options, stock price volatility, the risk-free interest rate and expected dividends. The assumptions used in the Company's Black-Scholes option-pricing model represent management's best estimates and involve a number of variables, uncertainties and assumptions and the application of management's judgment, as they are inherently subjective.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-351">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are accounted for under the asset and liability method. The Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of the Company's assets and liabilities and the expected &lt;/span&gt;&lt;/div&gt;benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes, if any, applied during the period in which temporary differences are expected to be settled, is reflected in the Company's financial statements in the period of enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on the weight of the evidence, it is more likely than not that some, or all, of the deferred tax assets will not be realized. As of December&#160;31, 2024 and 2023, the Company concluded that a full valuation allowance was necessary for all of its net deferred tax assets. The Company had no amounts recorded for uncertain tax positions, interest or penalties in the accompanying consolidated financial statements.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-352">&lt;div style="margin-bottom:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#160;As the Company had a net loss in each of the years ended December&#160;31, 2024 and 2023, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;359,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;359,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-68" decimals="0" id="f-354" unitRef="shares">142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-69" decimals="0" id="f-355" unitRef="shares">142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-70" decimals="0" id="f-356" unitRef="shares">359406</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-71" decimals="0" id="f-357" unitRef="shares">1359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-358" unitRef="shares">359548</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-9" decimals="0" id="f-359" unitRef="shares">1501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-360">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers the applicability and impact of all ASUs. ASUs not discussed below were assessed and determined to be either not applicable or are expected to have minimal impact on the financial statements.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2024-03). The amendments in ASU 2024-03 require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, for all public entities. Early adoption is permitted. Management is currently evaluating the impact of this update on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASU 2023-09). The amendments in ASU 2023-09 are intended to enhance the transparency and decision usefulness of income tax disclosures through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for annual periods beginning after December 15, 2024 for public entities, with early adoption permitted. Management is currently evaluating the impact of this update on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, FASB issued ASU 2023-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disclosure Improvements: Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2023-06)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendments in&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2023-06 represent changes to clarify or improve disclosure and presentation requirements of a variety of topics in the Codification and align those requirements with the SEC&#x2019;s regulation. For entities subject to the Security and Exchange Commission&#x2019;s (SEC) existing disclosure requirements, the effective date for each amendment will be the date on which the SEC&#x2019;s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Garamond',serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all entities, if by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. Management is currently evaluating the impact of this update and its effective dates but does not expect the update to have a material effect on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-361">MERGER WITH VALLON.&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into GRI Operations, with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#x201c;Vallon Pharmaceuticals, Inc.&#x201d; to &#x201c;GRI Bio, Inc.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Effective Time:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Each share of GRI Operations Common Stock outstanding immediately prior to the Effective Time, including any shares of GRI Operations Common Stock issued pursuant to the Equity SPA, automatically converted solely into the right to receive a number of shares of the Company&#x2019;s Common Stock equal to 0.0374 (the Exchange Ratio).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Each option to purchase shares of GRI Operations Common Stock (each, a GRI Operations Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the GRI Operations Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#x2019;s Common Stock, and the Company assumed the GRI Operations Plan and each such GRI Operations Option in accordance with the terms of the GRI Operations Plan (the Assumed Options). The number of shares of Common Stock subject to each Assumed Option was determined by multiplying (i) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Common Stock. The per share exercise price for the Common Stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Each warrant to purchase shares of GRI Operations Common Stock (the GRI Operations Warrants) outstanding immediately prior to the Effective Time was assumed by the Company and converted into a warrant to purchase shares of Common Stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Common Stock; (ii) the number of shares of Common Stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Common Stock; and (iii) the per share exercise price for shares of Common Stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of GRI Operations Common Stock subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Bridge Warrants (Note 9) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of 272 shares of the Company&#x2019;s Common Stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants and have an initial exercise price equal to $22,787.31 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;All rights with respect to GRI Operations restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#x2019;s Common Stock. The term, exercisability, vesting schedule and other provisions of the GRI Operations restricted stock awards otherwise remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI Operations was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i) the equity holders of GRI Operations immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately 85% of the outstanding shares of the Company&#x2019;s Common Stock and the Company&#x2019;s stockholders immediately prior to the Merger owned approximately 15% of the outstanding shares of the Company&#x2019;s Common Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ii) GRI Operations held the majority (4 out of 5) of board seats of the combined company, and (iii) GRI Operations&#x2019; management held the majority of key positions in the management of the combined company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net liabilities assumed in the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;April 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepaid and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total net liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plus: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total net liabilities assumed plus transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;In addition to the transaction costs noted above, at the Effective Time, 19 shares of the Common Stock were issued to GRI Operations&#x2019; financial advisor for services related to the Merger.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <ck0001824293:CommonStockExchangeRatio contextRef="c-72" decimals="4" id="f-362" unitRef="number">0.0374</ck0001824293:CommonStockExchangeRatio>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-73"
      decimals="INF"
      id="f-363"
      unitRef="shares">272</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-73"
      decimals="INF"
      id="f-364"
      unitRef="usdPerShare">22787.31</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:CommonStockOwnershipPercentage contextRef="c-74" decimals="2" id="f-365" unitRef="number">0.85</ck0001824293:CommonStockOwnershipPercentage>
    <ck0001824293:CommonStockOwnershipPercentage contextRef="c-75" decimals="2" id="f-366" unitRef="number">0.15</ck0001824293:CommonStockOwnershipPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-367">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net liabilities assumed in the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;April 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Prepaid and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total net liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Plus: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total net liabilities assumed plus transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-72" decimals="-3" id="f-368" unitRef="usd">941000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-72" decimals="-3" id="f-369" unitRef="usd">310000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses contextRef="c-72" decimals="-3" id="f-370" unitRef="usd">4190000</ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-72" decimals="-3" id="f-371" unitRef="usd">-2939000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-72" decimals="-3" id="f-372" unitRef="usd">2984000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts contextRef="c-72" decimals="-3" id="f-373" unitRef="usd">-5923000</ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses
      contextRef="c-31"
      decimals="INF"
      id="f-374"
      unitRef="shares">19</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-375">FAIR VALUE MEASUREMENTS.&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the year ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.902%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.902%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes is the fair value of the Level 3 liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Warrant Liability &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;166.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.26&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-376">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.902%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.902%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <ck0001824293:WarrantLiabilityFairValueDisclosure contextRef="c-76" decimals="-3" id="f-377" unitRef="usd">0</ck0001824293:WarrantLiabilityFairValueDisclosure>
    <ck0001824293:WarrantLiabilityFairValueDisclosure contextRef="c-77" decimals="-3" id="f-378" unitRef="usd">0</ck0001824293:WarrantLiabilityFairValueDisclosure>
    <ck0001824293:WarrantLiabilityFairValueDisclosure contextRef="c-78" decimals="-3" id="f-379" unitRef="usd">0</ck0001824293:WarrantLiabilityFairValueDisclosure>
    <ck0001824293:WarrantLiabilityFairValueDisclosure contextRef="c-79" decimals="-3" id="f-380" unitRef="usd">0</ck0001824293:WarrantLiabilityFairValueDisclosure>
    <ck0001824293:WarrantLiabilityFairValueDisclosure contextRef="c-80" decimals="-3" id="f-381" unitRef="usd">0</ck0001824293:WarrantLiabilityFairValueDisclosure>
    <ck0001824293:WarrantLiabilityFairValueDisclosure contextRef="c-81" decimals="-3" id="f-382" unitRef="usd">3000</ck0001824293:WarrantLiabilityFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-383">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes is the fair value of the Level 3 liability:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Warrant Liability &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4.6pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Balance as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-82" decimals="-3" id="f-384" unitRef="usd">3000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-385" unitRef="usd">3000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-83" decimals="-3" id="f-386" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-387">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model was used to estimate the fair value of the warrants with the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;166.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.26&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;156.3&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.65&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants, and the Placement Agent Warrants with the following weighted-average assumptions:&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.1&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.92&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the Series D-1 Common Warrants, the Series D-2 Common Warrants, and the October 2024 PA Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.4&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.16&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-84" decimals="3" id="f-388" unitRef="number">1.660</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-85" decimals="1" id="f-389" unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-86"
      decimals="INF"
      id="f-390"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-87" decimals="4" id="f-391" unitRef="number">0.0426</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-392">PROPERTY AND EQUIPMENT.&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $4 in each of the years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-393">&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-67" decimals="-3" id="f-394" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-88" decimals="-3" id="f-395" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-89" decimals="-3" id="f-396" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-90" decimals="-3" id="f-397" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="-3" id="f-398" unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-8" decimals="-3" id="f-399" unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-400" unitRef="usd">30000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-401" unitRef="usd">26000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-402" unitRef="usd">4000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-3" id="f-403" unitRef="usd">8000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-9" decimals="-3" id="f-404" unitRef="usd">4000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-405" unitRef="usd">4000</us-gaap:Depreciation>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-406">LEASES.&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office facilities under an operating lease agreement. The lease agreement requires fixed monthly rental payments as well as payments for variable monthly utilities and operating costs throughout the lease term. The Company evaluates renewal options at lease inception on an ongoing basis and includes renewal options that it is reasonably certain to exercise in its expected &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;lease terms when classifying leases and measuring lease liabilities. Lease agreements generally do not require material variable lease payments, residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the operating lease assets and liabilities recognized on the Company's consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.916%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.919%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance Sheet Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments are due as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs were $62 and $59 for each of the years ended December&#160;31, 2024 and 2023, respectively. Operating lease costs are included within selling, general and administrative expenses on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities were $59 and $58 for the years ended December&#160;31, 2024 and 2023, respectively. This amount is included in operating activities in the consolidated statements of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <ck0001824293:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-407">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the operating lease assets and liabilities recognized on the Company's consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.761%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.916%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.919%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Balance Sheet Line Item&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ck0001824293:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-408" unitRef="usd">120000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-8" decimals="-3" id="f-409" unitRef="usd">14000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-410" unitRef="usd">48000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-8" decimals="-3" id="f-411" unitRef="usd">14000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-412" unitRef="usd">71000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-8" decimals="-3" id="f-413" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-414" unitRef="usd">119000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-8" decimals="-3" id="f-415" unitRef="usd">14000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-416">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments are due as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-7" decimals="-3" id="f-417" unitRef="usd">60000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-7" decimals="-3" id="f-418" unitRef="usd">62000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-7" decimals="-3" id="f-419" unitRef="usd">15000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-7" decimals="-3" id="f-420" unitRef="usd">137000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-7" decimals="-3" id="f-421" unitRef="usd">18000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-422" unitRef="usd">119000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-423" unitRef="usd">62000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-9" decimals="-3" id="f-424" unitRef="usd">59000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-425" unitRef="usd">59000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-9" decimals="-3" id="f-426" unitRef="usd">58000</us-gaap:OperatingLeasePayments>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-427">ACCRUED EXPENSES.&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;337&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consisted of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accrued expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;342&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&#160;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;337&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-7" decimals="-3" id="f-429" unitRef="usd">342000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-8" decimals="-3" id="f-430" unitRef="usd">93000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-7" decimals="-3" id="f-431" unitRef="usd">12000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-8" decimals="-3" id="f-432" unitRef="usd">441000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-433" unitRef="usd">337000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-434" unitRef="usd">736000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-435" unitRef="usd">691000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-8" decimals="-3" id="f-436" unitRef="usd">1270000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-437">PROMISSORY NOTES.&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bridge Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, GRI Operations entered into a Securities Purchase Agreement, dated as of December 13, 2022 (Bridge SPA), with Altium, pursuant to which GRI Operations issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $3,333, in exchange for an aggregate purchase price of $2,500. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Bridge Notes were issued in two closings: (i) the first closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on December 14, 2022; and (ii) the second closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#x2019;s assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, upon the funding of each tranche, Altium received warrants to purchase an aggregate of 809 shares of the Common Stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $2,057.51 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants were freely tradable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $1,250 of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $679 and $571, respectively. The $1,250 of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $718 and $532, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered into the Equity SPA (Note 10) pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations&#x2019; Common Stock immediately prior to the consummation of the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants, and have an initial exercise price equal to $22,787.31 per share subject to adjustments for splits and recapitalization events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred debt issuance costs of $294 of which $90 was incurred during the year ended December&#160;31, 2023 related to its issuance of debt under the Bridge SPA. Interest expense stemming from amortization of debt discounts and issuance costs was $2,104 for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-91" decimals="-3" id="f-438" unitRef="usd">3333000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-92" decimals="-3" id="f-439" unitRef="usd">2500000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <ck0001824293:DebtInstrumentNumberOfClosings
      contextRef="c-92"
      decimals="INF"
      id="f-440"
      unitRef="closing">2</ck0001824293:DebtInstrumentNumberOfClosings>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-93" decimals="-3" id="f-441" unitRef="usd">1667000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-94" decimals="-3" id="f-442" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-95" decimals="-3" id="f-443" unitRef="usd">1667000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-96" decimals="-3" id="f-444" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c-5" decimals="INF" id="f-445" unitRef="shares">809</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-5"
      decimals="INF"
      id="f-446"
      unitRef="usdPerShare">2057.51</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-5" id="f-447">P60M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-94" decimals="-3" id="f-448" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-97" decimals="-3" id="f-449" unitRef="usd">679000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-98" decimals="-3" id="f-450" unitRef="usd">571000</us-gaap:ProceedsFromNotesPayable>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-96" decimals="-3" id="f-451" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-99" decimals="-3" id="f-452" unitRef="usd">718000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-100" decimals="-3" id="f-453" unitRef="usd">532000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-35" decimals="-3" id="f-454" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-101"
      decimals="INF"
      id="f-455"
      unitRef="usdPerShare">22787.31</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-102" decimals="-3" id="f-456" unitRef="usd">294000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-103" decimals="-3" id="f-457" unitRef="usd">90000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-9" decimals="-3" id="f-458" unitRef="usd">2104000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-459">STOCKHOLDERS EQUITY.&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered the Equity SPA pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations Common Stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued the Initial Shares to Altium and the Additional Shares into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 164 shares of the Common Stock and the Additional Shares converted into an aggregate of 656 shares of the Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Common Stock issued in exchange for the Additional Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;February 2024 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell (i) 1,495 February 2024 Shares, (ii) 21,131 February 2024 Pre-Funded Warrants exercisable for an aggregate of 21,131 shares of Common Stock, (iii) 22,631 Series B-1 Common Warrants exercisable for an aggregate of 22,631 shares of Common Stock and (iv) 22,631 Series B-2 Common Warrants exercisable for an aggregate of 22,631 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $243.10 (less $0.0221 for each February 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The February 2024 Pre-Funded Warrants have been exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 and expires on February 6, 2029. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $243.10 and expires on August 6, 2026. The February 2024 Warrants were classified as equity and the allocated fair value of $4,279 is included in additional paid in capital. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the amount paid for the February 2024 Pre-Funded Warrants approximates their fair value. The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;156.3&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.65&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants issued in connection with the Merger was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants. All of the Series A-1 Warrants have been exercised in full.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;May 2024 At The Market Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company has sold 325,618 shares of Common Stock in the ATM Offering at a weighted-average price of $11.07 per share, raising $3,605 of gross proceeds and net proceeds of $3,467, after deducting commissions to the sales agent and other ATM Offering related expenses. On December 20, 2024, we filed a prospectus supplement to our registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that we may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $322, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $3,605 that were sold under the ATM Offering through December 20, 2024, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;June 2024 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company issued and sold, in the June 2024 Offering, (i) 3,529 June 2024 Shares, (ii) 125,047 June 2024 Pre-Funded Warrants exercisable for an aggregate of 125,047 shares of Common Stock, (iii) 128,577 Series C-1 Common Warrants exercisable for an aggregate of 128,577 shares of Common Stock, and (iv) 128,577 Series C-2 Common Warrants, exercisable for an aggregate of 128,577 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $31.11 (less $0.0017 for each June 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2024 Pre-Funded Warrants have been exercised in full. Each Series C-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 and expires on September 6, 2029. Each Series C-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $31.11 and expires on March 6, 2026. The June 2024 Pre-Funded Warrants and the Series C Common Warrants were classified as equity and the allocated fair value of $2,908 is included in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the June 2024 Engagement Agreement, the Company, in connection with the June 2024 Offering, issued to Wainwright, or its designees, June 2024 PA Warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,001 shares of Common Stock&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The June 2024 PA Warrants have an exercise price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$38.89&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share and will expire on June 26, 2029. The June 2024 PA Warrants were classified as equity and the fair value of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$229 is included in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the amount paid for the June 2024 Pre-Funded Warrants approximates their fair value. The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants, and the Placement Agent Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;159.1&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.92&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;October 2024 Repricing Letter Agreement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 21, 2024, the Company entered into the Repricing Letter Agreements with certain Holders of its issued and outstanding Series B Common Warrants to purchase an aggregate of 44,842 shares of its Common Stock, offering these Holders the opportunity to exercise all of their Series B Common Warrants for cash at a reduced exercise price equal to $17.00 per share. In addition, these Holders received new unregistered Series D-1 Common Warrants exercisable for up to an aggregate of 44,839 shares of Common Stock and new unregistered Series D-2 Common Warrants exercisable for up to an aggregate of 44,839 shares of Common Stock. The Series D Common Warrants are immediately exercisable and have an exercise price of $17.00 per share. The Series D-1 Common Warrants expire on October 22, 2029, and the Series D-2 Common Warrants expire on April 22, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Wainwright acted as the exclusive placement agent for the Warrant Repricing Transaction pu&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rsuant to an engagement agreement between the Company and Wainwright dated as of October 21, 2024. As compensation for such placement agent services, the Company agreed to pay Wainwright an aggregate cash fee equal to 7.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, plus a management fee equal to 1.0% of the gross proceeds received by the Company from the Warrant Repricing Transaction, and reimbursement for accountable expenses of $25,000 and non-accountable expenses of $10,000. The Company has also issued to Wainwright or its designees the October 2024 PA Warrants to purchase up to an aggregate of 3,140 shares of Common Stock. The October 2024 PA Warrants are immediately exercisable, expire on October 22, 2029, and have an exercise price of $21.25 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net proceeds to the Company from the exercise of the Series B Common Warrants were $609 after deducting placement agent fees and offering expenses of $154. The issuance under the Repricing Letter Agreements represented $1,911 in additional value provided to the investors, which was recorded as a deemed dividend to common stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:8pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the Series D-1 Common Warrants, the Series D-2 Common Warrants, and the October 2024 PA Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;174.4&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.16&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had the following warrants outstanding to purchase common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$464,100.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$43,548.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$94,970.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$38.8875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;September 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$21.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-35" decimals="-3" id="f-460" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-31" decimals="-3" id="f-461" unitRef="usd">11704000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-31" decimals="-3" id="f-462" unitRef="usd">546000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ConversionOfStockSharesConverted1 contextRef="c-6" decimals="INF" id="f-463" unitRef="shares">164</us-gaap:ConversionOfStockSharesConverted1>
    <ck0001824293:ConversionOfStockAdditionalSharesConverted contextRef="c-6" decimals="INF" id="f-464" unitRef="shares">656</ck0001824293:ConversionOfStockAdditionalSharesConverted>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-37"
      decimals="INF"
      id="f-465"
      unitRef="shares">1495</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-38"
      decimals="INF"
      id="f-466"
      unitRef="shares">21131</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-38"
      decimals="INF"
      id="f-467"
      unitRef="shares">21131</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-39"
      decimals="INF"
      id="f-468"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-39"
      decimals="INF"
      id="f-469"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-470"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-40"
      decimals="INF"
      id="f-471"
      unitRef="shares">22631</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-37" decimals="-3" id="f-472" unitRef="usd">4389000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-37" decimals="-3" id="f-473" unitRef="usd">1110000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-41"
      decimals="INF"
      id="f-474"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-38"
      decimals="INF"
      id="f-475"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-39"
      decimals="INF"
      id="f-476"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-40"
      decimals="INF"
      id="f-477"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-41"
      decimals="INF"
      id="f-478"
      unitRef="usdPerShare">243.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-42"
      decimals="INF"
      id="f-479"
      unitRef="usdPerShare">0.0221</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-43"
      decimals="INF"
      id="f-480"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-43"
      decimals="INF"
      id="f-481"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-44"
      decimals="INF"
      id="f-482"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-44"
      decimals="INF"
      id="f-483"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-104" decimals="-3" id="f-484" unitRef="usd">4279000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-105" decimals="3" id="f-485" unitRef="number">1.563</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-106" decimals="2" id="f-486" unitRef="year">1.63</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-107"
      decimals="INF"
      id="f-487"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-108" decimals="4" id="f-488" unitRef="number">0.0465</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-45"
      decimals="INF"
      id="f-489"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-46" decimals="-5" id="f-490" unitRef="usd">10000000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <ck0001824293:SaleOfStockAgentCompensationPercentage contextRef="c-46" decimals="3" id="f-491" unitRef="number">0.030</ck0001824293:SaleOfStockAgentCompensationPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-47"
      decimals="INF"
      id="f-492"
      unitRef="shares">325618</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-48"
      decimals="2"
      id="f-493"
      unitRef="usdPerShare">11.07</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-109" decimals="-3" id="f-494" unitRef="usd">3605000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-47" decimals="-3" id="f-495" unitRef="usd">3467000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-49" decimals="-3" id="f-496" unitRef="usd">322000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-109" decimals="-3" id="f-497" unitRef="usd">3605000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-50"
      decimals="INF"
      id="f-498"
      unitRef="shares">3529</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-51"
      decimals="INF"
      id="f-499"
      unitRef="shares">125047</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-51"
      decimals="INF"
      id="f-500"
      unitRef="shares">125047</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-52"
      decimals="INF"
      id="f-501"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-52"
      decimals="INF"
      id="f-502"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-53"
      decimals="INF"
      id="f-503"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-53"
      decimals="INF"
      id="f-504"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-50" decimals="-3" id="f-505" unitRef="usd">3172000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-50" decimals="-3" id="f-506" unitRef="usd">1057000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-54"
      decimals="INF"
      id="f-507"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-51"
      decimals="INF"
      id="f-508"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-52"
      decimals="INF"
      id="f-509"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-53"
      decimals="INF"
      id="f-510"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-54"
      decimals="INF"
      id="f-511"
      unitRef="usdPerShare">31.11</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-55"
      decimals="INF"
      id="f-512"
      unitRef="usdPerShare">0.0017</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-56"
      decimals="INF"
      id="f-513"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-56"
      decimals="INF"
      id="f-514"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-57"
      decimals="INF"
      id="f-515"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-57"
      decimals="INF"
      id="f-516"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-110" decimals="-3" id="f-517" unitRef="usd">2908000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-111"
      decimals="INF"
      id="f-518"
      unitRef="shares">9001</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-111"
      decimals="INF"
      id="f-519"
      unitRef="usdPerShare">38.89</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-112" decimals="-3" id="f-520" unitRef="usd">229000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-113" decimals="3" id="f-521" unitRef="number">1.591</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-114" decimals="2" id="f-522" unitRef="year">1.65</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-115"
      decimals="INF"
      id="f-523"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-116" decimals="4" id="f-524" unitRef="number">0.0492</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-117"
      decimals="INF"
      id="f-525"
      unitRef="shares">44842</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-117"
      decimals="INF"
      id="f-526"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-60"
      decimals="INF"
      id="f-527"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-61"
      decimals="INF"
      id="f-528"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-62"
      decimals="INF"
      id="f-529"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds
      contextRef="c-63"
      decimals="INF"
      id="f-530"
      unitRef="number">0.070</ck0001824293:SaleOfStockAggregateCashFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds
      contextRef="c-63"
      decimals="INF"
      id="f-531"
      unitRef="number">0.010</ck0001824293:SaleOfStockManagementFeePercentageOfGrossProceeds>
    <ck0001824293:SaleOfStockReimbursementOfAccountableExpenses contextRef="c-63" decimals="-3" id="f-532" unitRef="usd">25000</ck0001824293:SaleOfStockReimbursementOfAccountableExpenses>
    <ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses contextRef="c-63" decimals="-3" id="f-533" unitRef="usd">10000</ck0001824293:SaleOfStockReimbursementOfNonAccountableExpenses>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-118"
      decimals="INF"
      id="f-534"
      unitRef="shares">3140</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-118"
      decimals="INF"
      id="f-535"
      unitRef="usdPerShare">21.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:ProceedsFromWarrantExercisesNetOfOfferingExpense contextRef="c-65" decimals="-3" id="f-536" unitRef="usd">609000</ck0001824293:ProceedsFromWarrantExercisesNetOfOfferingExpense>
    <ck0001824293:ClassOfWarrantOrRightOfferingCost contextRef="c-65" decimals="-3" id="f-537" unitRef="usd">154000</ck0001824293:ClassOfWarrantOrRightOfferingCost>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-63" decimals="-3" id="f-538" unitRef="usd">1911000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-119" decimals="3" id="f-539" unitRef="number">1.744</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-120" decimals="2" id="f-540" unitRef="year">1.65</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-121"
      decimals="INF"
      id="f-541"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-122" decimals="4" id="f-542" unitRef="number">0.0416</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-543">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had the following warrants outstanding to purchase common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$464,100.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;March 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;April 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$43,548.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$94,970.33&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;210&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$243.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,002&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$38.8875&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;June 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;128,577&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$31.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;September 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,839&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$17.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,140&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$21.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;October 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-123"
      decimals="INF"
      id="f-544"
      unitRef="shares">210</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-123"
      decimals="INF"
      id="f-545"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-124"
      decimals="INF"
      id="f-546"
      unitRef="shares">9</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-124"
      decimals="INF"
      id="f-547"
      unitRef="usdPerShare">464100</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-125"
      decimals="INF"
      id="f-548"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-125"
      decimals="INF"
      id="f-549"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-126"
      decimals="INF"
      id="f-550"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-126"
      decimals="INF"
      id="f-551"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-127"
      decimals="INF"
      id="f-552"
      unitRef="shares">16</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-127"
      decimals="INF"
      id="f-553"
      unitRef="usdPerShare">43548.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-128"
      decimals="INF"
      id="f-554"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-128"
      decimals="INF"
      id="f-555"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-129"
      decimals="INF"
      id="f-556"
      unitRef="shares">3</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-129"
      decimals="INF"
      id="f-557"
      unitRef="usdPerShare">94970.33</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-130"
      decimals="INF"
      id="f-558"
      unitRef="shares">210</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-130"
      decimals="INF"
      id="f-559"
      unitRef="usdPerShare">243.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-131"
      decimals="INF"
      id="f-560"
      unitRef="shares">9002</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-131"
      decimals="INF"
      id="f-561"
      unitRef="usdPerShare">38.8875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-132"
      decimals="INF"
      id="f-562"
      unitRef="shares">128577</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-132"
      decimals="INF"
      id="f-563"
      unitRef="usdPerShare">31.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-133"
      decimals="INF"
      id="f-564"
      unitRef="shares">44839</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-133"
      decimals="INF"
      id="f-565"
      unitRef="usdPerShare">17.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-134"
      decimals="INF"
      id="f-566"
      unitRef="shares">3140</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-134"
      decimals="INF"
      id="f-567"
      unitRef="usdPerShare">21.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-568">STOCK BASED COMPENSATION.&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI Operations adopted the GRI Operations Plan, which provided GRI Operations with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Upon completion of the Merger, the Company assumed the GRI Operations Plan and 57 outstanding and unexercised options issued thereunder, and ceased granting awards under the GRI Operations Plan. As of December&#160;31, 2024, no options remain outstanding under the GRI Operations Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated 2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;amp;R 2018 Plan). The A&amp;amp;R 2018 Plan had previously been approved by the Company&#x2019;s board of directors, subject to stockholder approval. The A&amp;amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving an amendment to the A&amp;amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by 109 shares to 140 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company&#x2019;s Common Stock&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for issuance as awards under the A&amp;amp;R 2018 Plan, (ii) to extend the term of the A&amp;amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#x201c;repricing&#x201d; of an award without further approval by the stockholders of Company and (iv) to revise the limits on awards to non-employee directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The A&amp;amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;amp;R 2018 Plan generally have a contractual life of up to 10 years. As of December&#160;31, 2024, awards granted under the A&amp;amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of 142 shares of the Company's Common Stock were outstanding and 256 shares of the Company&#x2019;s Common Stock were reserved for issuance under the A&amp;amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;amp;R 2018 Plan may be increased pursuant to the A&amp;amp;R 2018 Plan&#x2019;s &#x201c;evergreen&#x201d; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#x2019;s Common Stock outstanding on the final day of the immediately preceding calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to equity-based awards issued under the GRI Operations Plan and the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and nine months ended December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;388&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;388&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the year ended December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,376.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,376.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,475.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.57&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,376.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, all of the outstanding and exercisable stock options were out of the money and therefore had no intrinsic value. At December&#160;31, 2024, the unrecognized compensation cost related to unvested stock options expected to vest was $240. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of two years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 141 stock options to employees and non-employees during the year ended December&#160;31, 2023. The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;129.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value of common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,298.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No equity-based awards were granted during the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option valuation methods, including Black-Scholes, require the input of subjective assumptions, which are discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected term of options is determined using the "simplified" method, as prescribed in SEC's SAB No. 107, Share Based Payment (SAB No. 107), whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company's lack of sufficient historical data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected volatility is based on a weighted average of the Company's historical volatility and the volatilities of similar entities within the Company's industry which were commensurate with the expected term assumption as described in SAB No. 107.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The risk-free interest rate is based on the interest rate payable on US Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The expected dividend yield is 0% because the Company has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-135"
      decimals="INF"
      id="f-569"
      unitRef="shares">57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-136"
      decimals="INF"
      id="f-570"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-137"
      decimals="INF"
      id="f-571"
      unitRef="shares">109</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-138"
      decimals="INF"
      id="f-572"
      unitRef="shares">140</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-139" id="f-573">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-140"
      decimals="INF"
      id="f-574"
      unitRef="shares">142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-140"
      decimals="INF"
      id="f-575"
      unitRef="shares">256</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum contextRef="c-140" decimals="2" id="f-576" unitRef="number">0.04</ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-577">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to equity-based awards issued under the GRI Operations Plan and the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and nine months ended December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.316%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;388&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;148&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;388&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-141" decimals="-3" id="f-578" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-142" decimals="-3" id="f-579" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-143" decimals="-3" id="f-580" unitRef="usd">148000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-144" decimals="-3" id="f-581" unitRef="usd">388000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-582" unitRef="usd">148000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-9" decimals="-3" id="f-583" unitRef="usd">388000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-584">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the year ended December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,376.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,376.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,475.38&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.57&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;142&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,376.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-8" decimals="INF" id="f-585" unitRef="shares">142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-8"
      decimals="2"
      id="f-586"
      unitRef="usdPerShare">4376.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-9" id="f-587">P9Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-588" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-589" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-590" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-7" decimals="INF" id="f-591" unitRef="shares">142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-592"
      unitRef="usdPerShare">4376.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-593">P8Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-7" decimals="INF" id="f-594" unitRef="shares">62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-595"
      unitRef="usdPerShare">5475.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-596">P8Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-7" decimals="INF" id="f-597" unitRef="shares">142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-598"
      unitRef="usdPerShare">4376.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-599">P8Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-7" decimals="-3" id="f-600" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-7" decimals="-3" id="f-601" unitRef="usd">240000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-145" id="f-602">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-9" decimals="INF" id="f-603" unitRef="shares">141</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-604">The Black-Scholes option-pricing model was used to estimate the grant date fair value of each stock option grant at the time of grant using the following weighted-average assumptions:&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.873%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;For the Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;129.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5.84&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Fair value of common stock on grant date&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,298.42&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-146" decimals="4" id="f-605" unitRef="number">1.2954</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-146" id="f-606">P5Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-146" decimals="4" id="f-607" unitRef="number">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-146" decimals="4" id="f-608" unitRef="number">0.0434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="c-147"
      decimals="2"
      id="f-609"
      unitRef="usdPerShare">3298.42</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="c-1" decimals="INF" id="f-610" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-145" decimals="4" id="f-611" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AssetAcquisitionTextBlock contextRef="c-1" id="f-612">ASSET PURCHASE AGREEMENT.&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 22, 2023, the Company entered into Asset Purchase Agreement (the Aardvark Agreement) with Aardvark Therapeutics, Inc. (Aardvark), pursuant to which Aardvark agreed to purchase (i) the Company&#x2019;s license agreement with Medice Arzneimittel P&#x171;tter GmbH &amp;amp; Co. KG, dated January 6, 2020, (ii) certain patents related to the Company&#x2019;s ADAIR product candidate, and (iii) files (of contract manufacturing and FDA correspondence) for a formulation described in IND No. 133072, ADAIR for the Treatment of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ADHD and Narcolepsy, filed with the United States Food and Drug Administration. Under the terms of the Aardvark Agreement, the Company received an upfront cash payment of $250, which was recognized as other income. The Company is also eligible to receive potential additional milestone payments contingent upon Aardvark achieving certain future ADAIR regulatory and sales milestones. Other than the upfront payment, the Company does not anticipate the receipt of any milestone payments from Aardvark in the near term, which potential milestone payments may or may not be achieved, paid or received in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-148" decimals="-3" id="f-613" unitRef="usd">250000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-614">COMMITMENTS AND CONTINGENCIES.&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with each of its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Separation and Release Agreement&lt;/span&gt;&lt;/div&gt;In connection with the resignation of David Baker, the Company&#x2019;s former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#x2019;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ck0001824293:COBRABenefitsPaymentPeriod contextRef="c-149" id="f-615">P18M</ck0001824293:COBRABenefitsPaymentPeriod>
    <ck0001824293:PercentageOfTargetBonus
      contextRef="c-149"
      decimals="INF"
      id="f-616"
      unitRef="number">1.50</ck0001824293:PercentageOfTargetBonus>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-617">INCOME TAX.&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected income tax benefit at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;State and local taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-deductible items and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accruals and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2024 and 2023. The Company increased its valuation allowance by approximately $2,163 for the&#160;year ended December&#160;31, 2024. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had federal, state and local net operating loss carryforwards of $52,369, $58,254, and $5,563, respectively; $46,245 of the federal net operating loss carryforwards do not expire and the remaining $6,124 begin to expire in 2029. The state losses also begin to expire in 2029. The local net operating losses begin to expire in 2024. Under the provisions of Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (IRC), these net operating losses, credit carryforwards and other tax attributes may be subject to limitation based on previous significant changes in ownership and upon future significant changes in ownership of the Company, as defined by the IRC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the provisions of Sections&#160;382 and 383 of the IRC, certain substantial changes in the Company&#x2019;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the US federal jurisdiction as well as California, Pennsylvania and Philadelphia. The tax years 2021 to 2024 remain open to examination by the major jurisdictions in which the Company is subject to tax. Fiscal years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early years, which have been carried forward and may be audited in subsequent years when utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2024 and 2023, the Company had no unrecognized income tax benefits that would affect the Company&#x2019;s effective tax rate if recognized. The Company would recognize both accrued interest and penalties related to unrecognized benefits in income tax expense. The Company&#x2019;s uncertain tax positions yet to be determined would be related to years that remain subject to examination by relevant tax authorities. Since the Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-618">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) at the US federal statutory income tax rate and the income tax provision in the financial statements is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Expected income tax benefit at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;State and local taxes, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-deductible items and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(12.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-619" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-9" decimals="INF" id="f-620" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-621" unitRef="number">0.077</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-9" decimals="3" id="f-622" unitRef="number">0.084</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="3" id="f-623" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-9" decimals="3" id="f-624" unitRef="number">-0.121</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-625" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-9" decimals="3" id="f-626" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-627" unitRef="number">-0.264</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-9" decimals="3" id="f-628" unitRef="number">-0.184</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-1" decimals="3" id="f-629" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c-9" decimals="3" id="f-630" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-631" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-9" decimals="3" id="f-632" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-633">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal components of the Company&#x2019;s deferred tax assets and liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Federal and state net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Share based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Accruals and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Capitalized research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Depreciation - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amortization - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,684&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Less: valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(16,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(14,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-634" unitRef="usd">14537000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-8" decimals="-3" id="f-635" unitRef="usd">12848000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-7" decimals="-3" id="f-636" unitRef="usd">200000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-8" decimals="-3" id="f-637" unitRef="usd">166000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-7" decimals="-3" id="f-638" unitRef="usd">94000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-8" decimals="-3" id="f-639" unitRef="usd">255000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-7" decimals="-3" id="f-640" unitRef="usd">1846000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-8" decimals="-3" id="f-641" unitRef="usd">1099000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-7" decimals="-3" id="f-642" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-8" decimals="-3" id="f-643" unitRef="usd">153000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-644" unitRef="usd">2000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c-8" decimals="-3" id="f-645" unitRef="usd">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-7" decimals="-3" id="f-646" unitRef="usd">5000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-8" decimals="-3" id="f-647" unitRef="usd">0</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-648" unitRef="usd">16684000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-8" decimals="-3" id="f-649" unitRef="usd">14521000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-650" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-8" decimals="-3" id="f-651" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-652" unitRef="usd">16684000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-3" id="f-653" unitRef="usd">14521000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-7" decimals="-3" id="f-654" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-8" decimals="-3" id="f-655" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-3" id="f-656" unitRef="usd">2163000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-150" decimals="-3" id="f-657" unitRef="usd">52369000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-151" decimals="-3" id="f-658" unitRef="usd">58254000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-152" decimals="-3" id="f-659" unitRef="usd">5563000</us-gaap:OperatingLossCarryforwards>
    <ck0001824293:OperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-150" decimals="-3" id="f-660" unitRef="usd">46245000</ck0001824293:OperatingLossCarryforwardsNotSubjectToExpiration>
    <ck0001824293:OperatingLossCarryforwardsSubjectToExpiration contextRef="c-150" decimals="-3" id="f-661" unitRef="usd">6124000</ck0001824293:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-8" decimals="-3" id="f-662" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-7" decimals="-3" id="f-663" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-664">SUBSEQUENT EVENTS.&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recapitalization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 21, 2025, the Company effected the February 2025 Reverse Stock Split. Stockholders&#x2019; equity and all references to share and per share amounts in the accompanying financial statements have been retroactively adjusted to reflect the one-for-seventeen reverse stock split for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
